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Plenary Lectures
Monday 4 June 2012
PL-01. Course, causes and developments in
drug treatment of schizophrenia
jPL-01-001jCourse, causes and developments in the treatment
of schizophrenia
H.-J. Mo¨ller. Ludwig-Maximilians-University, Deptartment of Psychiatry,
Munich, Germany
According to recent long-term studies is schizophrenia a chronic
disorder with a high risk of poor outcome in terms of symptoms and
social functioning and possibly also progressive brain alterations. The
relapse rate is high and each relapse can induce further aggravations,
both in psychosocial as well as in neurobiological terms. Thus acute
and long-term treatment with the highest degree of eﬀectiveness
should be provided to the patients in acute and long-term treatment. It
is of special interest that some schizophrenia susceptibility genes and
chromosomal abnormalities, particularly examined for early onset
populations, are associated with premorbid neurodevelopmental ab-
normalities. Recent MRI imaging studies on patients at risk for
schizophrenia showed a speciﬁc pattern of brain alterations which is
predictive for the development of a full-blown psychosis. In addition
to neurodevelopmental disorder, a neuroprogressive brain disorder is
increasingly being hypothesized to explain a further decline es-
pecially in the poor outcome subgroup of schizophrenic patients.
Results from genetic research, especially recently from the genome-
wide association studies hint at disturbances of neurodevelopment/
neuroplasticity as well as immunological and glutamatergic processes
as part of the complex aetiopathogenesis. The relevance of im-
munological processes is especially supported by results indicating
immunological parameter alterations in patients suﬀering from
schizophrenia and especially by the positive outcome of double-blind,
randomised add-on studies using the COX-2 inhibitor Celecoxib as
add-on to neuroleptic treatment (risperidone, amisulpride). Support
for the glutamatergic hypothesis comes primarily from animal models
and recently also from the positive outcome of double-blind, rando-
mised trials on new dopaminergic compounds. This glutamatergic
approach in the drug treatment seems to be a very promising one,
although it currently seems that these compounds are more eﬀective
in the treatment of negative symptoms/cognitive symptoms and not
so much in positive symptoms.
PL-02. Addiction: From molecules to neuronal
circuits
jPL-02-001jAddiction : From molecules to neuronal circuits
N. Volkow. National Inst. on Drug Abuse, National Institutes of Health,
Bethesda, USA
Addiction is a disorder that involves complex interactions between
genes, development and the social environment. Studies employing
neuroimaging technology paired with behavioral measurements, and
more recently genetics, have led to remarkable progress in elucidating
neurochemical and functional changes that occur in the brains of ad-
dicted subjects. Although large and rapid increases in dopamine have
been linked with the rewarding properties of drugs, the addicted
state, in striking contrast, is marked by signiﬁcant decreases in brain
dopamine D2 receptor mediated signaling. Such decreases are asso-
ciated with dysfunction of prefrontal regions including orbitofrontal
cortex, cingulate gyrus and dorsolateral prefrontal cortex and im-
paired striato frontal connectivity. In addiction, disturbances in sal-
ience attribution result in enhanced value given to drugs and drug-
related stimuli at the expense of other reinforcers and promote
inﬂexible behaviors. Dysfunction in inhibitory control systems, by
decreasing the addict’s ability to refrain from seeking and consuming
drugs, ultimately results in the compulsive drug intake that char-
acterizes the disease. Discovery of such disruptions in the ﬁne balance
that normally exists between brain circuits underling reward, motiv-
ation, memory and self-control have important implications for de-
signing multi-pronged interventions for the prevention and treatment
of addictive disorders.
Tuesday 5 June 2012
PL-03. Depressing tales of adult neurogenesis :
A hard look at the evidence
jPL-03-001jDepressing tales of adult neurogenesis : A hard
look at the evidence
P. Rakic. Yale University School of Medicine, Department of
Neurobiology, New Haven, USA
The idea that the beneﬁcial eﬀect of antidepressants in humans
acts by enhancing neurogenesis of granule cells in the dentate gyrus
of the hippocampus was based on the work in young adult mice,
where neurogenesis is robust and is increased by antidepressant
treatment. However, it is not clear if this correlation in mice can
be extrapolated to humans. I will present evidence, from our and
many other laboratories, that the eﬀect of various drugs including
antidepressants on the turnover (e.g. genesis and death) of granule
cells in control mice and in models of depression such as ‘‘forced
helplessness’’ is a side eﬀect that is unlikely related to the depression
and its treatment in humans. Our strategy has been to compare
neurogenesis in developing, young, adult and aged rodents, non-
human primates and humans, to learn not only from their
similarities, but also from their diﬀerences. These diﬀerences include
how changes in the timing and sequence of gene expression aﬀect
molecular and cellular events to produce both quantitative and
qualitative changes. Use of various proliferation markers, indicates
that the magnitude and timing of neurogenesis in non-human
primates is very diﬀerent from the high neuronal turnover in
various vertebrates including rodents. More speciﬁcally, division
of neural stem cells in primates last almost two days and maturation
of the newborn granule cells requires a minimum of 6 months,
which is incompatible with the pharmacodynamics of antide-
pressants in humans, some of which can act within hours or days
after exposure. I will also discuss possible molecular pathways
implicated in limiting neurogenesis in adult primates and discuss
the advantages of this limitation. It is hoped that a better under-
standing of the evolutionary diﬀerences, such as genetically con-
trolled decrease in adult neurogenesis, will allow for insight into
its role on brain homeostasis, as well as potential of neural stem
cells in replacement therapy of human-speciﬁc neuropsychiatric
disorders.
PL-04. Psychopharmacology and Cognition
jPL-04-001jPsychopharmacology and cognition
B.J. Sahakian. University of Cambridge, School of Clinical Medicine,
United Kingdom
Psychiatric disorders are disorders of neurocognition. Many psy-
chiatric disorders, such as schizophrenia and attention deﬁcit hyper-
activity disorder, are of neurodevelopmental origin with an onset or
prodromal stage in childhood or adolescence. Cognitive manifesta-
tions include : attentional biases ; aberrant learning ; dysfunctional re-
ward systems ; and lack of top down cognitive control by prefrontal
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cortex. Recent neuroscience and mental health policy has emphasized
the importance of successful and resilient neurodevelopment.
(Beddington et al., 2008 ; Sahakian et al., 2010 ; Collins et al., 2011).
Therefore biomarkers, including cognitive, genetic and neuroimaging
ones, are needed for prevention, early detection and for assessing the
eﬃcacy of treatments. Policy has also emphasized the importance of
novel approaches to drug development for psychiatric disorders. For
instance, targets for treatment may become closely related to genetics
and neurobiology (e.g. impulsivity, episodic memory) rather than di-
agnostic categories (e.g. schizophrenia, ADHD) (see Sahakian et al.,
2010 ; Sahakian 2011, Insel and Cuthbert 2010). A treatment which
reduces impulsive behaviour, for example, might also do so whether
an individual has a diagnosis of mania, ADHD or substance abuse,
and treatment of episodic memory problems might prove useful for
improving cognition and functional outcome in both mild
Alzheimer’s disease and ﬁrst-episode schizophrenia (Sahakian et al.,
2010 ; Sahakian 2011). It is now recognised that cognitive problems
may impair performance of everyday functioning of patients with
mental health disorders and prove the biggest barrier to rehabilitation
and return to paid employment (Beddington et al., 2008). Therefore
cognitive enhancing drugs are needed to treat cognitive impairment
associated with debilitating neuropsychiatric disorders. Such treat-
ments will improve the quality of life and wellbeing for patients and
their families and reduce the ﬁnancial burden on society (Beddington
et al., 2008). Pharmacological treatments may prove most eﬀective
when used in combination with cognitive ones, such as cognitive be-
havioural therapy or cognitive training.
Policy of full disclosure : Beddington J, Cooper CL, Field J,
Goswami U, Huppert FA, Jenkins R, Jones HS, Kirkwood TBL,
Sahakian BJ, & Thomas SM (2008). The mental wealth of nations.
Nature, 455, 1057–1060 Collins PY, Patel V, Joestl SS, March D,
Insel TR, Daar AS, Bordin IA, Costello EJ, Durkin M., Fairburn C,
Glass RI, Hall W, Huang Y, Hyman SE, Jamison K Kaaya S, Kapur S,
Kleinman A, Ogunniyi A, Otero-Ojeda A, Poo M-M, Ravindranath V,
Sahakian BJ, Saxena S, Singer PA, Stein DJ, Anderson W, Dhansay
MA, Ewart W, Phillips A, Shurin S, & Walport M (2011) Grand chal-
lenges in global mental health. Nature, 475, 27–30. Insel T & Cuthbert
B (2010) Research Domain Criteria (RDoC) : Toward a New
Classiﬁcation Framework for Research on Mental Disorders. Am J
Psychiatry 167 : 7 Sahakian BJ, Malloch G, Kennard C (2010) A UK
strategy for mental health and wellbeing. Lancet, 375, 1854–1855.
Sahakian BJ (2011) Beneﬁts and Opportunities In Brain Waves Module
1 : Neuroscience, society and policy. The Royal Society. http ://roy-
alsociety.org/uploadedFiles/Royal_Society_Content/policy/pub-
lications/2011/4294974932.pdf Professor Barbara Sahakian consults
for Cambridge Cognition. She has consulted for Novartis, Shire,
GlaxoSmithKline, Lilly, Boehringer-Ingelheim and Hoﬀmann-La
Roche. She holds a grant funded by Johnson and Johnson. She has also
received honoraria for Grand Rounds in Psychiatry at Massachusetts
General Hospital (CME credits) (Boston, 27 April 2007) and Grand
Rounds in Psychiatry at the UT Health Science Center at San Antonio
(CME credits) (2011) and for speaking at the International Conference
on Cognitive Dysfunction in Schizophrenia and Mood Disorders :
clinical aspects, mechanisms and therapy (Brescia, 17–19 January
2007). She was on the Medical Research Council Neurosciences and
Mental Health Board (2010) and on the Science Co-ordination Team
for the Foresight Project on Mental Capital and Wellbeing, 2008
(Oﬃce of Science, The Department of Innovation, Universities and
Skills). She was on Panel LS5 for the European Research Council. As
an Associate Editor, she also receives an honorarium from the Journal
of Psychological Medicine.
Wednesday 6 June 2012
PL-05. CNS Drug development at present
jPL-05-001jA role for academic institutions in CNS drug
discovery
J. Conn. Vanderbilt Center for Neuroscience, Drug Discovery, Nashville,
USA
Despite tremendous progress in furthering our understanding in
biology, chemistry, and related disciplines, academic scientists often
fail to perform studies needed to more fully validate potential new
drug targets and allow basic science discoveries to be most useful in
supporting full drug discovery eﬀorts in industry settings. Likewise,
ﬁscal pressures make it increasingly diﬃcult for companies to invest
signiﬁcant resources in early exploratory basic science projects where
potential therapeutic utility and drugability of a new target remains
highly speculative. This is especially true for CNS disorders andmany
companies have deprioritized CNS drug discovery in recent years.
For the CNS drug discovery and development to be maximally eﬀec-
tive in translating new basic science discoveries into breakthrough
new therapeutic agents, it will be important for scientists in academic
and other non proﬁt settings to increase eﬀorts to critically evaluate
novel hypotheses related to new drug targets and provide data nee-
ded to allow translation of advances in basic science to drug discovery
programs. The Vanderbilt Center for Neuroscience Drug Discovery
(VCNDD) represents a new model in which fully integrated drug
discovery research has been implemented in an academic setting.
These eﬀorts are now yielding a steady pipeline of drug candidates
that are advancing into clinical development. These include new ap-
proaches for schizophrenia, Fragile X syndrome, Parkinson’s disease,
and depression. Importantly, each of these eﬀorts represents a novel
approach that has potential to fundamentally impact the standard of
patient care. Also, in each case, these eﬀorts have provided critical
validation of the druggability of new targets and have provided the
data sets that have enabled multiple companies to invest in indepen-
dent eﬀorts focused on innovative targets that have emerged from
basic research.
Policy of full disclosure : Dr. Conn receives research funding that
includes salary support from NIH, Michael J. Fox Foundation, Seaside
Therapeutics, and Janssen Pharmaceutica. Dr. Conn serves as a con-
sultant for Millipore Inc, Seaside Therapeutics, Michael J. Fox
Foundation, and Karuna Pharmaceuticals.
PL-06. Rational pharmacotherapies of major
depressive disorder
jPL-06-001jRational pharmacotherapies of major depressive
disorder
S. Kasper. Medical University of Vienna, Department of Psychiatry and
P, Austria
Depression is one of the most thoroughly evaluated diseases in
psychiatry with regard to diagnosis and treatment possibilities. Early
treatment should be achieved and watchful waiting, which is for in-
stance not done in the treatment of high blood pressure or diabetes,
has not demonstrated to be a rational approach based on neurobiolo-
gical considerations. Like in other diseases, it is apparent that an un-
treated illness may result in biological damage i.e. in depression in a
reduced volume size of the hippocampus. Interestingly, the course of
illness shows that life events are less important in the later stages of
the illness, which can be interpreted that the disease has approached a
speciﬁc neurobiologically determined course. The introduction of the
group of selective serotonin reuptake inhibitors (SSRI) marked a rev-
olution in the treatment of depression, since it was possible to
treat patients eﬀectively with a considerably lower side eﬀect proﬁle
than compared to tricyclic antidepressants. More patients could be
reached with this approach and a possible association between usage
of SSRIs and the reduction of the suicide rates in countries like
Sweden, Austria and Hungary have been discussed. Dual reuptake
inhibitors eﬀecting both the serotonergic and the noradrenergic
pathways and the dopaminergic noradrenergic medication bupropion
have been introduced in the ﬁeld with speciﬁc characteristics of
treatment goals like pain, somatic symptoms or drive. The recently
introduced antidepressant agomelatin demonstrates a novel and
unique mechanism of action with a combination of melatonergic
agonistic and serotonergic antagonistic activity exhibiting a more
distinct inﬂuence on the circadian rhythm compared to other cur-
rently available antidepressants. Deep brain stimulation and vagus
nerve stimulation for treatment refractory depressed patients yield
promising ﬁrst results, although need further substantiation. More
thorough characterisation of the underlying pathophysiology of
depression including molecular biological variables and brain
imaging characterizations will hopefully result in further insight
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into of the understanding of the illness and yield rational decisions for
the treatment of depression.
Policy of full disclosure : Siegfried Kasper received grants/
research support, consulting fees and honoraria within the last
three years from AstraZeneca, Bristol-Myers Squibb, CSC,
Eli Lilly, GlaxoSmithKline, Janssen, Lundbeck, Merck Sharp and
Dome (MSD), Novartis, Organon, Pierre Fabre, Pﬁzer, Schwabe,
Sepracor, Servier, Wyeth.
PL-07. Drugs for Alzheimer’s disease
jPL-07-001jDrugs for Alzheimer’s disease
B. Winblad. Stockholm, Sweden
Alzheimer disease (AD) is the most common cause of dementia in
advanced age. Currently available medications improve AD symp-
toms, and development of disease-modifying drugs is a very active
area of research, which includes cholinergic, glutamate inhibitor
(NMDA receptor antagonist), anti-amyloid compounds, drugs tar-
geting tau-protein or mitochondria, neurotrophins, and other thera-
peutic approaches. The amyloid cascade hypothesis dominates
current drug development strategies. Identiﬁcation of eﬀective dis-
ease-modifying drugs will beneﬁt from understanding the interplay
between mechanisms causing neurodegeneration in AD. Combined
therapy could me a more eﬀective strategy to halt AD progression.
Solving methodological problems in clinical trials on AD – including
use of standardized diagnostic criteria able to identify homogeneous
group of patients, appropriate treatment duration and measures
of disease-modifying eﬀects – will help ﬁnding a cure for AD. The
lecture will summarize current treatment possibilities for AD, as
well as the main ﬁndings for new, and less new drugs with novel
therapeutic use in AD, focusing mainly on compounds in the human
testing phase.
Thursday 7 June 2012
PL-08. The crisis in drug discovery. What can
we do to get it right?
jPL-08-001jThe crisis in drug discovery. What can we do to get
it right?
A. Carlsson. Go¨teborg, Sweden
In Sweden we have recently been reminded of the serious waning
of the drug R&D by the closing down of one of the main research units
of AstraZeneca in So¨derta¨lje, only a few years following upon the
closing down of its subsidiary Draco in Lund, Sweden. Less than a
decade ago Pharmacia, the other Swedish Big Pharma, was devoured
by Pﬁzer. Thus the drug R&D debacle has hit Sweden probably
more than any other country. Nevertheless, the global aspect needs to
be considered in the ﬁrst place, and work to identify its causes is
underway. Perhaps especially illuminating is an article by Swimney
and Anthony (Nature Reviews, Drug Discovery, Vol. 10, July 2011,
p. 507), who examined the discovery process behind all drugs ap-
proved by FDA during 1999 through 2008. It is concluded that the
pharmaceutical industry has unfortunately concentrated its resources
on in-vitro strategies full of pitfalls, i.e. High-Throughput Screening
and the like, resulting in a fatally high attrition rate. This shocking
outcome needs to be examined further. Should we place most of
the blame on the pharmaceutical industry? This is by no means
certain. If we look back on the golden half-century of drug R&D
starting in the 1940s, preclinical academic research as well as import-
ant clinical feedback seem to have been the main driving forces. How
come that they apparently have stopped working? The present wave-
trough in drug R&D is most unfortunate for millions of sick people as
well as for biomedical research as a whole. Moreover, it is paradoxical,
given the enormous technical and other scientiﬁc advances made
during the past century. There is an urgent need for the identiﬁcation
of its causes and for further action. Presumably reversal to a balanced
and well integrated use of in-vivo and in-vitro techniques will be
required.
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Symposia
Monday 4 June 2012
S-01. Dopamine receptors, noradrenergic
mechanisms and D2 containing
heteromers as targets for antipsychotic
drugs
jS-01-001jAntipsychotics – are we targeting the right system
but the wrong end
S. Kapur. Institute of Psychiatry, London, United Kingdom
Objective : Antipsychotics were discovered by serendipity nearly 60
years ago. Since then eﬀorts to make antispychotics that avoid the
dopamine system entirely have not been successful. This raises the
question why dopamine blockade is essential for antipsychotic action.
Despite several studies looking for an increase in dopamine D2
receptors – the data remains equivocal.
Methods : We have recently completed a meta-analysis of all the
available neuroimaging studies (44 studies with 618 patients) of the
dopamine system and ﬁnd only weak evidence for an increase in D2
receptor numbers – a ﬁnding that was driven by a few studies using
butyrophenone tracers in previously treated patients.
Results : This raises the possibility of whether an increase in D2
receptors is missed as this increase is restricted to the High states of
the D2 receptor, a state that can be missed by the standard antagonist
radioligands. Therefore, using 11C-PHNO, a ligand that can image the
high states of the D2 receptor and D3 receptors we have examined
patients with schizophrenia – and ﬁnd no evidence of an increase in
D2/3 receptors – though treatment seems to induce an upregulation
of the D3 subtype. The most striking ﬁnding in the meta-analysis is an
increase in the presynaptic uptake of 18F-Dopa, suggestive of in-
creased synthesis capacity (eﬀect size 0.79). More recent data suggests
that it is not the level of D2 blockade (provided it is in the suﬃcient
range) that determines antipsychotic response – but, the level of pre-
synaptic DA synthesis capacity.
Conclusion : Thus, it seems, that for the last sixty years the anti-
psychotics have been blocking dopamine transmission by focussing
on the wrong end of the DA synapse. The implications of this view for
further antipsychotic development will be presented.
jS-01-002jDopamine, D1 receptors and noradrenergic
mechanisms in the modes of action of antipsychotic
drugs
T. Svensson1, C. Bjo¨rkholm2, K. Jardemark2, M. Marcus2, S. Nyberg3,
B. Schilstro¨m2. 1Karolinska Institutet, Physiology and Pharmacology,
Stockholm, Sweden ; 2Karolinska Institutet, Stockholm, Sweden ;
3AstraZeneca R&D, So¨derta¨lje, Sweden
Objective : Recent clinical data show, using in vivo imaging techni-
ques, a reduced cortical DA release in schizophrenia (SZ), contrasting
the previously observed enhanced striatal DA release that correlates
with psychosis. The reduced prefrontal DA release is thought to gen-
erate impaired cognition by means of insuﬃcient D1-R signaling, as
e.g. D1-R stimulation can reverse the working memory deﬁcit induced
by ketamine, a psychotomimetic NMDA-R antagonist. Both clozapine
and quetiapine, which are eﬀective atypical antipsychotics at low D2-
R occupancies, may improve working memory in SZ. The present
work aimed to elucidate the role of noradrenergic mechanisms and
D1-Rs in their mode of action.
Methods : Experiments were performed in rats using electro-
physiological intracellular recording in pyramidal cells in a prefrontal
cortical slice preparation to assess NMDA-R function, microdialysis in
freely moving animals to assess regional monoamine eﬄux in brain,
and behavioral methodologies, including the conditioned avoidance
response (CAR) test to assess antipsychotic activity, the 8-arm radial
maze to study working memory (WM) and a catalepsy test to assess
extrapyramidal side eﬀects (EPS).
Results : Since the clinical eﬀects of quetiapine are partly mediated
by its metabolite norquetiapine, which is not formed in rodents
and qualitatively diﬀers from quetiapine only by its potent NET
inhibitory action, we compared the behavioral and neurobiological
eﬀects of clozapine and a combination of quetiapine and the selective
NET inhibitor reboxetine with those of raclopride, a typical D2-R
antagonist. In contrast to raclopride, both clozapine and the com-
bination of quetiapine and reboxetine eﬀectively suppressed CAR at
low D2 occupancy levels, markedly and selectively enhanced DA
outﬂow in the medial prefrontal cortex (mPFC) and, via D1-R acti-
vation, facilitated NMDA-R mediated transmission in this region,
an eﬀect that was able to reverse the WM impairment induced by
the selective NMDA-R antagonist MK-801. The eﬀects of clozapine
could largely be mimicked by a combination of raclopride with
idazoxan, an alpha2R antagonist, and those of quetiapine plus NET
inhibition by a combination of raclopride and the NET inhibitor
reboxetine.
Conclusion : The results clearly implicate brain noradrenergic
mechanisms in the modes of action of clozapine and quetiapine.
Blockage of presynaptic alpha2-R on NE terminals may release both
NE and its precursor DA and, moreover, the increased extracellular
NE concentration may elevate cortical DA levels as both transmitters
compete for the same transporter, thus producing D1-R activation in
the mPFC. A recent meta-analysis (Hecht & Landy 2011) provides
further support for he utility of noradrenergic targets in antipsychotic
therapy.
jS-01-003jPutative D2 receptor containing heteromers in the
ventral striatum and their relevance for treatment of
schizophrenia
K. Fuxe1, D. Borroto-Escuela1, W. Romero Fernandez1, F. Ciruela2,
A. Tarakanov3, L. Ferraro4, S. Tanganelli5, L. Agnati6, M. Perez Alea7.
1Karolinska Institutet, Stockholm, Sweden ; 2University of Barcelona,
Spain ; 3Russian Academy of Sciences, St. Petersburg, Russia ; 4University
of Ferrara, Italy ; 5University of Ferrara, Italy ; 6 IRCCS Lido Venice, Italy ;
7Asthon University, Birmingham, United Kingdom
Objective : Our working hypothesis is that one or several of the po-
tential D2R containing heteromers in the ventral striatum especially
A2AR-D2R, D2R-5-HT2AR and NTS1-D2R heteromers may be targets
for typical and atypical antipsychotic drugs. The activation of the
A2AR, 5-HT2AR and NTS1 protomers of the respective heteromers
should result in anti-schizophrenic actions in view of their anta-
gonistic receptor-receptor interactions within ventral striatal D2R
heteromers.
Methods : We have used in situ PLA, FRET/BRET, coimmunopre-
cipitation, biochemical binding, receptor autoradiography, dual-
probe microdialysis and behavioural measurements.
Results : The A2AR-D2R heteromer has been indicated through
biochemical-biophysical methods. On the basis of the existence of the
antagonistic A2AR–D2R interactions, A2AR agonists were proposed
to be atypical antipsychotic drugs. A2AR agonists counteract the D2R-
induced reduction of the glutamate drive from the mediodorsal thal-
amic nucleus to the prefrontal cortex via their reduction of D2R sig-
naling in the nucleus accumbens. There may also exist extrasynaptic
A2AR–D2R–mGluR5 receptor mosaics located on the dendritic spines
of the local circuits of the ventral and dorsal striato-pallidal GABA
neurons. Behavioral evidence indicates that the A2AR agonist
CGS21680 and the mGluR5 agonist CHPG synergize in counteracting
phencylidine-induced motor activity. Furthermore, we demonstrated
that the D2LR and the 5-HT2AR form stable and speciﬁc heteromers
in mammalian cells. Costimulation of D2LR and 5-HT2AR within
the heteromer led to inhibition of the D2LR functioning, thus sug-
gesting the existence of a 5-HT2AR-mediated D2LR trans-inhibition
4
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phenomenon. Also, antagonistic NTS1-D2 receptor interactions in
postulated NTS1–D2R heteromers in the ventral striatum have been
repeatedly proposed to be the molecular mechanism involved in the
postulated antipsychotic eﬀects of neurotensin.
Conclusion : D2R heteromers may be disrupted or dysfunctional in
schizophrenia leading to removal of the brake on D2R signaling in the
striato-pallidal GABA circuits.Receptor-receptor interaction between
cortical NA and DA receptors in potential heteromers should also be
considered as targets for antipsychotics.
jS-01-004jThe DA receptor-transporter complexes and
increased D2 receptor dimerization : Relevance for
schizophrenia
F. Liu1, M. Wang2, P. J. Fletcher2, S. Kapur3, P. Seeman2. 1Addiction
and Mental Health, Toronto, Canada ; 2Toronto, Canada ; 3London, United
Kingdom
Objective : All antipsychotics work via dopamine D2 receptors
(D2Rs), suggesting a critical role for D2Rs in psychosis ; however,
there is little evidence for a change in receptor number or pharmaco-
logical nature of D2Rs. Recent data suggest that D2Rs form dimers
in-vitro and in-vivo, and we hypothesized that schizophrenia, as well
as preclinical models of schizophrenia, would demonstrate altered
dimerization of D2Rs, even though the overall number of D2Rs was
unaltered.
Methods :We measured the expression of D2Rs dimers and mono-
mers in patients with schizophrenia using Western blots, and then in
striatal tissue from rats exhibiting the amphetamine-induced sensi-
tized state (AISS). We further examined the interaction between D2Rs
and the dopamine transporter (DAT) by co-immunoprecipitation, and
measured the expression of dopamine D2High receptors with ligand
binding assays in rat striatum slices with or without acute ampheta-
mine pre-treatment.
Results : We observed signiﬁcantly enhanced expression of D2Rs
dimers (277.7¡33.6%) and decreased expression of D2Rs monomers
in post-mortem striatal tissue of schizophrenia patients. We found
that amphetamine facilitated D2Rs dimerization in both the striatum
of AISS rats and in rat striatal neurons. Furthermore, amphetamine-
induced D2Rs dimerization may be associated with the D2R-DAT
protein-protein interaction as an interfering peptide that disrupts the
D2R-DAT coupling, blocked amphetamine-induced up-regulation of
D2Rs dimerization.
Conclusion : Given the fact that amphetamine induces psychosis
and that the AISS rat is a widely accepted animal model of psychosis,
our data suggest that D2R dimerization may be important in the pa-
thophysiology of schizophrenia and may be a promising new target
for novel antipsychotic drugs.
S-02. Management of treatment-resistant major
depression
jS-02-001jTRD: Pharmacotherapeutic strategies for adults with
major depressive disorder
G.I. Papakostas. Massachusetts General Hospital, Boston, Ma, USA
Objective : Major depressive disorder can, often, be chronic,
recurrent, and associated with signiﬁcant disability, morbidity, and
mortality. Numerous pharmacologic and non-pharmacologic treat-
ment options exist for the treatment of major depressive disorder,
with full and sustained symptomatic remission being the goal of
treatment. However, it has been estimated than as many as half of all
patients may not experience a remission of their depressive episode
despite a treatment trial of adequate dose (in the case of drug therapy)
and duration, while a signiﬁcant burden of (subsyndromal) depress-
ive symptoms may persist among those patients who do achieve
remission of their depression. Thus, in most cases, subsequent treat-
ment approaches are required to help achieve full and sustained
symptomatic remission. The progressive increase in recognition of the
prevalence and burden of TRD, has sparked a rapid growth of re-
search in this treatment area, with a number of novel therapeutic op-
tions emerging. Ultimately, these approaches combined may help
improve the standard of care for major depressive disorder. The goal
of the symposium is to review the prevalence and burden of
treatment-resistant major depressive disorder (TRD), and to review
novel as well as established therapeutic strategies for TRD.
Methods : Literature will be searched for randomized, double-
blind, placebo-controlled trials of pharmacologic interventions
for TRD.
Results : Numerous studies are found and discussed.
Conclusion : Numerous studies support the use of various inter-
ventions for TRD. Their evidence-base, relative eﬃcacy, tolerability,
and safety are discussed.
Policy of full disclosure : Dr. Papakostas has served as a consultant
for Abbott Laboratories, AstraZeneca PLC, Brainsway Ltd, Bristol-
Myers Squibb Company, Cephalon Inc., Dey Pharma, L.P., Eli Lilly
Co., GlaxoSmithKline, Evotec AG, Inﬂabloc Pharmaceuticals,
Jazz Pharmaceuticals, Otsuka Pharmaceuticals, PAMLAB LLC,
Pﬁzer Inc., Pierre Fabre Laboratories, Ridge Diagnostics (formerly
known as Precision Human Biolaboratories), Shire Pharmaceuticals,
Theracos, Inc., and Wyeth, Inc. Dr. Papakostas has received honoraria
from Abbott Laboratories, Astra Zeneca PLC, Bristol-Myers Squibb
Company, Brainsway Ltd, Cephalon Inc., Dey Pharma, L.P., Eli Lilly
Co., Evotec AG, GlaxoSmithKline, Inﬂabloc Pharmaceuticals,
Jazz Pharmaceuticals, Lundbeck, Otsuka Pharmaceuticals, PAMLAB
LLC, Pﬁzer, Pierre Fabre Laboratories, Ridge Diagnostics, Shire
Pharmaceuticals, Theracos, Inc., Titan Pharmaceuticals, and Wyeth
Inc. Dr. Papakostas has received research support from AstraZeneca
PLC, Bristol-Myers Squibb Company, Forest Pharmaceuticals, the
National Institute of Mental Health, PAMLAB LLC, Pﬁzer Inc.,
and Ridge Diagnostics (formerly known as Precision Human
Biolaboratories). Dr. Papakostas has served (not currently) on the
speaker’s bureau for BristolMyersSquibb Co and Pﬁzer, Inc.
jS-02-002jPharmacotherapeutic strategies for adults with
bipolar depression
M. Bauer. Univ. Hosp. Carl Gustav Carus, Technische Universita¨t
Dresden, Germany
Objective : The burden of depression represents the most debilitating
dimension for the majority of patients with bipolar disorder and
dominates the long-term course of the illness. The purpose of this
presentation is to review the evidence base of the available treatment
options for bipolar depression assigned to two frequent clinical sce-
narios A and B.
Methods : The evidence is largely based on a systematic literature
search. All relevant randomized controlled trials were critically eval-
uated.
Results : Scenario A : if a patient with bipolar depression is cur-
rently not being treated with a mood stabilizing agent (de novo de-
pression), then quetiapine or alternatively olanzapine are an option,
carbamazepine and lamotrigine can be considered. Antidepressants
are an option for short-term use, but whether they are administered as
mono- or combination treatment with mood stabilizing agents is still
controversial. Most clinicians prefer to use antidepressants in combi-
nation with an antimanic substance. Scenario B : If a patient is already
treated with a mood stabilizing agent (breakthrough depression) once
adherence has been conﬁrmed and the dose has been adjusted, la-
motrigine is an option in patients on lithium. There is no evidence for
further eﬀects of antidepressants in cases where a patient is already
receiving a mood stabilizer, however, an additional antidepressant is
preferred by most clinicians.
Conclusion : Overall, the evidence from treatment trials in bipolar
depression is relatively sparse compared with the number of con-
trolled trials in unipolar depression and as such the choice of treat-
ment is governed by a multitude of factors. While clinical trials
provide evidence on the eﬃcacy of a certain intervention in a speciﬁc
population, they cannot necessarily determine which intervention
will be optimal for a given patient in a given speciﬁc situation. They
can however inform the choice of intervention and in particular pre-
vent clinicians from choosing interventions that have been shown to
be ineﬀective.
Policy of full disclosure : Grant/Research Support from The
Stanley Medical Research Institute, NARSAD and the European
Commission (FP7). Consultant for AstraZeneca, Lilly, Servier,
Lundbeck, Bristol-Myers Squibb and Otsuka. Speaker Honoraria from
AstraZeneca, Lilly, GlaxoSmithKline, Lundbeck, Bristol-Myers
Squibb and Otsuka.
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jS-02-003jSomatic therapies – Brain stimulation methods
M.S. George. Medical Universiry of South Carolina, Charleston, SC, USA
Objective : This talk overviews recent advances using Brain
Stimulation therapies for treating medication or treatment resistant
depression.
Methods : A literature review shows that these methods range from
relatively non-invasive (e.g. transcranial direct current stimulation
(tDCS) and prefrontal transcranial magnetic stimulation (TMS)), to
more invasive (electroconvulsive therapy (ECT) and vagus nerve
stimulation (VNS)) to very invasive (deep brain stimulation (DBS) and
epidural cortical stimulation (EPCS)).
Results : To date, tDCS studies in acute depression are mixed. TMS
is now US FDA approved and a recent NIH pivotal study (OPT-TMS)
provides class I level of evidence in treating acute depression. The
level of treatment resistance aﬀects TMS response rates. New work
involves accelerated TMS over 3 days, or for use in suicidal crisis. ECT
continues to be the most eﬀective treatment for acute depression.
New advances in ECT pulse width (ultrabrief unilateral ECT) are
showing promise with similar eﬃcacy but less toxicity than older
methods. We will show data on 17 patients treated with a new direc-
tional form of ECT called FEAST. VNS does not have class I level
evidence of eﬀectiveness in acute depression but two longitudinal
studies in either Europe or the US showed similar long-term beneﬁt
in TRD patients followed over several years. The onset of action
is slow (months) but appears durable. DBS controlled trials are
underway with preliminary promise in patients who have failed
to respond to many of the above interventions. There are at least 4
diﬀerent brain regions being targeted by diﬀerent groups. While pre-
liminary results are promising, DBS remains an investigational tech-
nique without convincing class I evidence of either acute or chronic
eﬀects.
Conclusion : Clinicians are now beginning to oﬀer the brain
stimulation methods in a staged approach, similar to cancer manage-
ment, starting with less invasive methods and then gradually
advancing.
jS-02-004jTreatment of adolescent depression : Some
substantive issues
J.K. Buitelaar. St. Radboud and Karakter Child and Adolescent Psychiatry,
Nijmegen, Netherlands
Objective : The objective of this presentation is to discuss the chal-
lenges in treating pediatric depression, and balance medication and
psychological approaches to treatment.
Methods : Narrative review of the results of key clinical trials with
medication and psychological interventions in child and adolescent
depression, based on PubMed search and consultation of authoritat-
ive reviews.
Results : More severe depressive episodes will generally require
treatment with antidepressants. Depressed children and adolescents
treated with SSRIs have a relatively good response rate (40%–70%),
but the placebo response rate is also high (30%–60%). With the ex-
ception of the ﬂuoxetine studies (e.g., Emslie et al., 1997), signiﬁcant
diﬀerences between SSRIs and placebo were, due to the high placebo
response, only found in depressed adolescents but not in depressed
children (Bridge et al., 2007). The TADS compared ﬂuoxetine, cogni-
tive behaviour therapy (CBT), and their combination (TADS, 2004). In
adolescents with moderate to severe depression, treatment with
ﬂuoxetine alone or in combination with CBT accelerates the response.
Adding CBT to medication also enhances the safety of medication.
Taking beneﬁts and harms into account, combined treatment appears
superior to either monotherapy as a treatment for major depression in
adolescents (TADS, 2007). Results of the TORDIA studyshow that
depressed adolescents who have failed to respond to an adequate trial
with a SSRI, a switch to another antidepressant plus CBT resulted in a
better response than a switch to another antidepressant without ad-
ditional psychotherapy (Brent et al., 2007). Fluoxetine was shown to
normalize brain activity in multiple brain regions, including the
frontal, temporal, and limbic cortices after 8 weeks of treatment (Tao
et al., 2012).
Conclusion : Though a reasonable percentage of depressed adoles-
cents respond to treatment, remission rates are rather low in short-
term trials. Treatment should be continued after remission for at least
6–9 months. Most patients recover after 2–4 years, but in the mean-
time, another 50% of these show already recurrence.
Policy of full disclosure : Jan K Buitelaar has been in the past 3 years
a consultant to / member of advisory board of / and/or speaker for
Janssen Cilag BV, Eli Lilly, Bristol-Myer Squibb, Shering Plough, UCB,
Shire, Novartis and Servier. He is not an employee of any of these
companies, and not a stock shareholder of any of these companies.
He has no other ﬁnancial or material support, including expert testi-
mony, patents, royalties.
S-03. Cocaine-induced changes in glutamate
neuroplasticity in developing and
mature neuronal circuits
jS-03-001jCocaine-induced changes in glutamate
neuroplasticity in developing and mature
mesolimbic circuits
C. Bellone1, T. Yuan2, M. Mameli3, C. Lu¨scher2. 1University of Geneva,
Dept. Basic Neuroscience, Switzerland ; 2University of Geneva,
Switzerland ; 3 Institut du Fer a Moulin, Paris, France
Objective : As in many parts of the central nervous system of the
mouse, glutamatergic synapses onto dopamine (DA) neurons in the
ventral tegmental area (VTA) mature postnatally. We have recently
demonstrated that at birth many AMPARs lack GluA2 and most
NMDARs contain the GluN2B subunit. Within two weeks these re-
ceptors are replaced with GluA2- and GluN2A- containing AMPARs
and NMDARs respectively. Here we now show that a single injection
of cocaine triggers not only the redistribution of AMPARs, but also
rearrange NMDARs.
Methods : In order to test our hypothesis, we use in vitro whole-cell
patch-clamp recording in VTA acute slices from neonatal and juvenile
mice.
Results : After the drug exposure the synapses express GluN2B
containing NMDARs along with GluA2-lacking AMPARs, as if ad-
dictive drugs reopen a developmentally critical period. Both during
the development and after single cocaine exposure, mGluR1 acti-
vation drives the insertion of NMDARs (mGluR1-LTPNMDA). This
is associated with an overall increase in NMDAR-EPSCs (mGluR1-
LTPNMDA) and involves PLC, Ca2+ release from the internal stores
as well as PKC activity. Moreover, we identify the Shank3/Homer
interaction as an important player in the mGluR1-LTPNMDA.
Conclusion : While we are only beginning to understand the re-
percussions of drug-evoked receptor redistribution, the striking re-
semblance with the processes occurring during early postnatal
development brings a new, exciting perspective that may help us to
understand both normal development and the development of ad-
diction.
jS-03-002jCocaine experience modulates synaptic transmission
in the habenula complex
M. Mameli1, M. Maroteaux1. 1 Institut du Fer a Moulin, Batiment
INSERM, 75005 Paris, France
Objective : Goal directed actions, aimed to obtain a reward, motivate
our behaviors and inﬂuence our decisions. Midbrain dopamine neu-
rons activity and therefore dopamine release are enhanced by external
cues predicting a reward. Lateral habenula (LHb) neurons play a
central role in this regulation since they instruct dopamine neurons
during reward learning. Addictive subtances induce an abnormal in-
crease in dopamine neurons and recent theories posit that addiction
develops by hijacking the reward system promoting strong associ-
ation between drug and context. Given the critical importance of LHb
neurons in tuning dopamine neurons ﬁring and participating to cue-
reward association we tested whether synaptic trasnmission and
plasticity at glutamatergic synapses in this nuclei are sensitive to drug
exposure.
Results : We have used patch clamp recordings and identify pecu-
liar biophysical properties of AMPA receptors that suggest that such
proteins lack the subunit GluA2. Cocaine experience strenghtens ex-
citatory transmission and alters synaptic plasticity in treated animals
compared to saline injected ones.
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Conclusion : These result suggest that cocaine exposure alters the
synaptic inputs onto LHb neurons, which in turn could explain some
of the mechanisms during drug-context association occurring in the
reward circuit.
jS-03-003jNeuroplastic changes following repeated exposure to
cocaine during adolescence : Focus on the
glutamatergic system
F. Fumagalli1, L. Caﬃno2, G. Giannotti2, G. Racagni2. 1University of
Milan, Dept of Antidrug Policies, Italy ; 2University of Milan, Italy
Objective : To investigate changes in glutamate receptors expression
and phosphorylation following repeated exposure to cocaine during
adolescence.
Methods : We therefore treated male rats from post-natal day
(PND) 28 to PND 42 with saline or cocaine (20 mg/kg). Animals were
sacriﬁced 3 days (PND 45) after the end of treatment or at adulthood
(PND 90) and the brain regions of interest (prefrontal cortex and
nucleus accumbens) were removed. Analyses were carried out by
Western blots.
Results : No major changes were found in the phosphorylation or
expression of the main subunits of NMDA receptors in the prefrontal
cortex of PND 45-old rats with only a slight reduction in the major
AMPA subunit, i.e. GluR1 ; conversely, in nucleus accumbens, we
found increased phosphorylation, but not expression, of NR1, NR2B
and GluR1. At adulthood, we primarily found a signiﬁcant reduction
in GluR1 expression and phosphorylation in the prefrontal cortex
with no major changes in the nucleus accumbens. Additionally, when
we challenged the animals with an acute stress to evaluate whether
exposure to cocaine during adolescence had altered the response of
the glutamatergic system to the stress itself, we found a dysregulated
response in the phosphorylation of the main glutamatergic subunits,
i.e. the NR-1 NMDA subunit and the GluR-1 AMPA subunit.
Conclusion : Our results suggest 1) an early activation of the glu-
tamate system in nucleus accumbens ; 2) a persistent eﬀect of the ex-
posure to cocaine during adolescence on GluR-1 subunit, which
persists into adulthood 3) a dynamic role of glutamatergic receptors
following adolescential exposure to cocaine which is not limited to
changes at the steady state level of these receptors.
jS-03-004jCorticostriatal glutamate dysregulation in an animal
model of cocaine addiction and relapse
R. See. University of South Carolina, Department of Neurosciences,
Charleston, South Carolina, USA
Objective : Cocaine-induced changes in corticostriatal glutamate
regulation have been implicated in cocaine seeking after prolonged
cocaine self-administration in rats. Here, we examined changes in
striatal glutamate release in rats with a history of daily cocaine intake.
Based on evidence for normalization of glutamatergic function by the
cysteine prodrug, N-acetylcysteine (NAC), further experiments tested
whether repeated NAC administration would produce lasting reduc-
tions in cocaine-seeking.
Methods : Male rats self-administered intravenous cocaine during
daily sessions, followed by daily extinction (no reinforcement) or ab-
stinence (alternate environment) sessions. To assess glutamate release
in the dorsal striatum, in vivo microdialysis procedures were used in
awake animals to collect samples that were then analyzed by HPLC-
EC. For assessment of chronic NAC eﬀects, rats received daily injec-
tions of saline, 60, or 100 mg/kg NAC (IP). Subsequently, rats were
tested for cocaine-seeking via conditioned cue-induced, cue+cocaine-
primed, and context induced cocaine seeking.
Results : Rats with a history of chronic cocaine self-administration
showed enhanced striatal glutamate eﬄux under both context in-
duced conditions and after acute injection of cocaine. Chronic NAC
administration blunted cocaine-seeking under multiple experimental
protocols. Speciﬁcally, NAC attenuated responding during cue and
cue+cocaine-primed reinstatement tests following extinction, and
context, cue, and cue+cocaine tests of drug seeking following absti-
nence. Reduction of cocaine seeking by NAC persisted well after
treatment was discontinued, particularly when the high dose was
combined with extinction trials.
Conclusion :Dysregulation of striatal glutamate release likely plays
a key role in persistent cocaine seeking following abstinence. The
ﬁnding that NAC reduced cocaine-seeking after treatment was dis-
continued supports recent preclinical and clinical evidence that NAC
may serve as an eﬀective treatment for inhibiting relapse in cocaine
addicts.
S-04. Insights for personalized medicine in
psychiatry
jS-04-001jComplex regulation of gene expression in brain
C. Wahlestedt. The Scripps Research Institute, Jupiter, USA
Objective : This lecture will present our view on how gene expression
is dynamically regulated by protein and RNAmechanisms in contexts
of diﬀerent epigenetic states and psychiatric disorders.
Methods :We have conducted a wide variety of transcriptomic and
epigenetic experiments over a number of years.
Results : Rather than a ﬁxed hierarchy with one or very few master
regulators at the top, the picture that emerges is that of a recurrent
network in which multiple transcription factors mutually coordinate
their activity in conjunction with the actions of regulatory RNAs.
Much of the mammalian genome is transcribed into small or long
non-coding RNAs of diﬀerent categories and diﬀerent modes of
function. MicroRNAs as well as long noncoding RNAs appear to
control the expression and function of most conventional genes and
pathways.
Conclusion : In the decade since the ﬁrst publications on the entire
human genome, the number and general architecture of conventional
genes has remained remarkably stable. By contrast, surprising chan-
ges have come from noncoding regions and from studies on epigen-
etic phenomena, and their interplay with known gene function, which
have created an entirely new paradigm for all aspects of genome-
related research.
jS-04-002jGene x environment interactions in the prediction of
response to antidepressant treatment
E. Binder. Max-Planck Inst of Psychiatry, Munich, Germany
Objective : High hopes have been held for the ﬁeld of pharmacoge-
netics in the prediction of antidepressant response, but so far no as-
sociations could be consistently replicated. As for the development of
psychiatric disorders per se, treatment response is likely not only
moderated by main genetic eﬀects but also environmental factors and
gene x environment interactions.
Methods : This presentation will focus on early life trauma and
present molecular genetic data, including gene x environment inter-
action data, epigenetic data and gene expression data in human
pharmacogenetic trials.
Results : Several lines of evidence are presented suggesting the
importance of gene x environment interactions in predicting response
to antidepressant treatments. First, a number of genetic polymorph-
isms, including polymorphisms within the serotonin transporter gene
and the stress hormone system genes CRHR1 and FKBP5, have been
shown to interact with early trauma to predict mood disorders. The
same polymorphisms have also been shown to predict response to
antidepressant treatment. Second, gene x environment interactions
lead to highly diﬀerent biological disturbances in mood disorders.
This will be illustrated with FKBP5 polymorphisms as an example, for
which we could show allele-speciﬁc epigenetic changes following
exposure to early trauma. These are accompanied by distinct system-
wide molecular changes, suggesting that diﬀerent pathways need to
be targeted to elicit antidepressant response depending on both, the
FKBP5 genotype and exposure to early trauma. Finally, preliminary
data supporting the importance of early trauma x gene interaction in
the overall and diﬀerential prediction of response antidepressant to
current antidepressant treatments (medication vs. cognitive beha-
vioral therapy) will be presented.
Conclusion : Diﬀerent combinations of environmental and genetic
risk factors likely lead to biologically distinct subsets of mood dis-
orders that could show preferentially response to certain treatment
types. This can be related to the prediction of response to currently
used antidepressant therapies but may also aid in the identiﬁcation of
novel antidepressant targets.
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jS-04-003jPersonalized medicine and the management of TRD
C. Nemeroﬀ. University of Miami, USA
Although there are several eﬀective pharmacotherapeutic and
psychotherapeutic treatments for major depression, a large majority
of patients do not obtain remission after an adequate monotherapy
trial with one of these modalities. There is increasing evidence that
biologically distinct subtypes of major depression, so-called endo-
phenotypes, are to a large extent responsible for this current unfortu-
nate state of treatment outcomes in depression and related mood and
anxiety disorders. One subtype of depression that has repeatedly been
shown to exhibit a lower than expected rate of treatment response
to antidepressants is patients with major depression and a history
of child abuse and neglect. This presentation will summarize the evi-
dence that such patients represent a neurobiologically distinct sub-
group as revealed by structural magnetic resonance imaging (MRI)
and functional brain imaging (PET and fMRI) ﬁndings, alterations
in neuroendocrine and immune function and a distinct pattern
of distribution of several genetic polymorphisms (CRHR1, FKBP5,
PAC1, BDNF) that mediate gene-environment interaction. In addition,
unique symptom proﬁles of this patient group including cognitive
impairment will be described. Taken together these data support the
development of novel treatment strategies based on this subgroup-
speciﬁc pathophysiology for optimal personalized management of a
sizeable percentage of the treatment refractory depressed population.
Policy of full disclosure : Research/Grants : National Institutes of
Health (NIH), Agency for Healthcare Research and Quality (AHRQ)
Speakers Bureau : None Consulting : Xhale, Takeda, SK Pharma, Shire,
Roche, Lilly Stockholder : CeNeRx BioPharma, NovaDel Pharma, Inc.,
PharmaNeuroBoost, Revaax Pharma, Xhale Other Financial Interests :
CeNeRx BioPharma, PharmaNeuroBoost Patents : Method and de-
vices for transdermal delivery of lithium (US 6,375,990B1) Method of
assessing antidepressant drug therapy via transport inhibition of
monoamine neurotransmitters by ex vivo assay (US 7,148,027B2)
Compounds, Compositions, Methods of Synthesis and Methods of
Treatment Scientiﬁc Advisory Boards : American Foundation for
Suicide Prevention (AFSP), CeNeRx BioPharma, National Alliance for
Research on Schizophrenia and Depression (NARSAD), NovaDel
Pharma (2012), Inc., Xhale, PharmaNeuroBoost, Anxiety Disorders
Association of America (ADAA), Skyland Trail, AstraZeneca
Pharmaceuticals (2009) Board of Directors : AFSP, NovaDel Pharma
(1/12/2012), Inc., Mt. Cook Pharma (2010), Skyland Trail Income
sources or equity of $10,000 or more : AstraZeneca Pharmaceuticals,
PharmaNeuroBoost, CeNeRx BioPharma, NovaDel Pharma, Reevax
Pharma, American Psychiatric Publishing, Xhale.
jS-04-004jPharmacogenetics of alcohol reward and therapeutic
response to naltrexone
M. Heilig1, A. Thorsell1. 1Linko¨ping Health Univ, Linko¨ping, Sweden
Objective : Mu-opioid (OPRM1) receptors are key to rewarding
properties of alcohol, and the target for the approved alcoholism
medication naltrexone. Functional 118ApG variation at the OPRM1
locus was suggested to represent a genetic vulnerability factor for al-
cohol and heroin addiction, and to moderate therapeutic eﬃcacy of
naltrexone, but these ﬁndings remain controversial.
Methods : We ﬁrst examined alcohol responses, consumption
and eﬃcacy of naltexone in a functionally equivalent rhesus OPRM1
77CpGmodel. Next, DA release in response to alcohol was examined
using PET and [11C]raclopride displacement in social drinkers re-
cruited by OPRM1 118 genotype. Finally, the causal role of the
human OPRM1 118ApG SNP was isolated from other polymorph-
isms using humanized mouse lines carrying the respective OPRM1
118 variant.
Results : In rhesus macaques, male OPRM1 77G carriers displayed
markedly elevated psychomotor stimulation in response to alcohol,
accompanied by increased alcohol consumption and preference.
These observations suggested an enhanced dopamine (DA) response
to alcohol in minor allele carriers. Accordingly, in male social drin-
kers, striatal DA response to alcohol was restricted to carriers of the
OPRM1 118G allele. In humanized mice, alcohol-induced DA-release
in the Nc Accumbens in response to alcohol was markedly greater in
male 118GG than male 118AA mice. Male, but not female 118GG mice
also consumed higher amounts of alcohol than 118AA mice of the
corresponding sex, in particular at higher alcohol concentrations.
Conclusion : These studies collectively establish that the functional
OPRM1 118G variant is suﬃcient to confer greater alcohol-induced
DA-release and consumption. These ﬁndings are consistent with a role
of this variant to predispose human carriers to endorphin-dependent
alcoholism, but also to render patients more responsive to opiod
antagonist treatment.
S-05. Mechanism of PTSD: From genes
and epigenetics to neurocircuits and
endophenotype
jS-05-001jSearching for epigenetic biomarkers in PTSD
S. Morinobu1, M. Fuchikami2, S. Okada1, S. Yamawaki1, I. Liberzon3,
A. King3, J. Seng3. 1Hiroshima University, Japan ; 2Yale University,
New Haven, USA ; 3University of Michigan, Ann Arbor, USA
Objective : The development of posttraumatic stress disorder (PTSD),
follows exposure to a traumatic/highly stressful event. Since it is well
known that stress exposure changes the mRNA levels of genes in the
rodent brain, it is conceivable that changes in gene expression medi-
ated by alterations in the DNA methylation in the brain are involved
in the pathophysiology of PTSD. In this context, it is hypothesized that
the DNA methylation status may be a potent diagnostic biomarker in
PTSD.
Methods :We examined the methylation proﬁle of 35 CpGs located
in one CpG island (799 bp), covering the exon 1 of the serotonin
transporter (5-HTT) gene using genomic DNA from peripheral
blood of 173 patients with PTSD and48 healthy controls. Methylation
rate at each CpG unit was measured using a MassARRY1 system
(SEQUENOM).
Results :Two-dimensional hierarchical cluster analysis (diagnosisr
methylation rate) of all CpG units did not yield correct diagnostic
classiﬁcation to healthy controls and patients groups. The methylation
rates of 6 CpG units out of 35 CpG units were signiﬁcantly diﬀerent in
patients having current PTSD diagnosis and the methylation rates of
5 CpG units were signiﬁcantly diﬀerent in patients with having life-
time PTSD diagnosis as compared to healthy controls. Among these,
two CpGs units were common to the lifetime and the current PTSD
diagnosis groups. In addition, we will present the results from the
analyses of the methylation status of one CpG island at the promoter
of the exon 1 of the brain-derived neurotrophic factor gene.
Conclusion : These ﬁndings suggest the possibility that the methyl-
ation rate of a certain CpG at the promoter of the 5-HTT gene may be a
diagnostic biomarker in PTSD.
jS-05-002jGenetic approaches to understanding posttraumatic
stress disorder
K. Ressler. Emory University, Atlanta, USA
Objective : Posttraumatic Stress Disorder (PTSD) is an anxiety dis-
order which can develop as a result of exposure to a traumatic event
and is associated with signiﬁcant functional impairment. Family and
twin studies have found that risk for PTSD is associated with an
underlying genetic vulnerability and that more than 30% of the vari-
ance associated with PTSD is related to a heritable component.
Results : Using a fear conditioning model to conceptualize the
neurobiology of PTSD, three primary neuronal systems have been
investigated – the hypothalamic-pituitary-adrenal axis, the locus
coeruleus-noradrenergic system, and neurocircuitry interconnecting
the limbic system and frontal cortex. The majority of the initial in-
vestigations into main eﬀects of candidate genes hypothesized to be
associated with PTSD risk have been negative, but studies examining
the interaction of genetic polymorphisms with speciﬁc environments
in predicting PTSD have produced several positive results which have
increased our understanding of the determinants of risk and resilience
in the aftermath of trauma. Promising avenues of inquiry into the role
of epigenetic modiﬁcation have also been proposed to explain the
enduring impact of environmental exposures which occur during key,
often early, developmental periods on gene expression. Studies of
PTSD endophenotypes, which are heritable biomarkers associated
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with a circumscribed trait within the more complex psychiatric dis-
order, may be more directly amenable to analysis of the underlying
genetics and neural pathways and have provided promising targets
for elucidating the neurobiology of PTSD.
Conclusion : Knowledge of the genetic underpinnings and neuro-
nal pathways involved in the etiology and maintenance of PTSD will
allow for improved targeting of primary prevention amongst vulner-
able individuals or populations, as well as timely, targeted treatment
interventions. This article is part of a Special Issue entitled ’PTSD’.
jS-05-003jStress, emotion and cognition : Lessons from
studying PTSD neurocircuitry
I. Liberzon. University of Michigan, Ann Arbor, USA
Objective : Functional neuroimaging studies identiﬁed abnormalities
in amygdala, Anterior Cingulate Cortex, Medial Prefrontal Cortex
and insula in Post-traumatic stress disorder. Our presentation will
describe recent studies and state of the art knowledge of neuro-
circuitry involved in PTSD vulnerability, neurophysiology and
symptom formation.
Methods : The original conceptualization linked Amygdala
and mPFC abnormalities to abnormal fear learning and expression,
however more recent models examine the potential contribution of
these regions to processes of emotional regulation, memory recall and
reinstatement and contextual modulation. fMRI studies using these
methods in PTSD will be discussed.
Results : In addition, novel analytical approaches to fMRI data
allow for study of connectivity among various brain regions both
during resting state and during speciﬁc tasks, providing additional
information about the status of functional networks of brain regions.
Initial ﬁndings of functional network abnormalities in PTSD are
emerging, and they oﬀer additional insights into abnormal brain
processes potentially contributing to PTSD pathophysiology and
symptom formation.
Conclusion : Together, these novel and more complex models
of information processing in PTSD allow for more nuanced under-
standing of PTSD pathophysiology and symptom formation, as well
identifying potentially more sensitive endophenotypic endpoints for
treatment studies. Finally, recent integration of genetic and neuro-
imaging approaches oﬀers a new and powerful tool to further de-
scribe intermediate phenotype (endophenotype) in PTSD, and to
better identify the speciﬁc contribution of genetic vulnerability or
resilience in PTSD development.
jS-05-004j Intrinsic network abnormalities in PTSD
R. Lanius1, J. Daniels1, P.C. Williamson1, A.C. McFarlane1,
K.A. Moores2, C.R. Clark3, M. Shaw4. 1London, Canada ; 2Millswood,
Australia ; 3Adelaide, South Australia, Australia ; 4Heidelberg, Germany
Objective : Previous neuroimaging studies in healthy controls have
shown the existence of a ‘‘default mode network’’ of correlated brain
regions active during rest. These regions include the posterior cingu-
late, anterior cingulate and medial prefrontal cortex, and lateral
parietal areas. The current studies examined (1) the nature of the ab-
normalities in the default network in chronic PTSD related to early life
trauma ; (2) whether default network connectivity could predict PTSD
symptomatology in an acutely traumatized sample ; and (3) the pat-
tern of default network connectivity during rest versus a working
memory task in PTSD.
Methods : Patients with acute and chronic posttraumatic stress
disorder (PTSD) related to early-life trauma and healthy controls
underwent a 5.5-minute functional magnetic resonance imaging scan
with their eyes closed. Areas of the brain whose activity positively and
negatively correlated with that of the PCC/precuneus were assessed
in both groups. In addition, a working memory task and psychophy-
siologic interaction analyses with the posterior cingulate cortex and
the medial prefrontal cortex as seed regions during ﬁxation in patients
with chronic PTSD and healthy controls were conducted.
Results : In healthy controls, activity in the posterior cingulate
seed region was found to positively correlate with other regions of the
default network. This correlation was signiﬁcantly altered in the
chronic PTSD group. Altered connectivity between the posterior
cingulate and brain regions associated with the task positive network
were observed in chronic PTSD during a working memory task.
Results in the acutely traumatized sample suggest that resting state
connectivity of the PCC with the right amygdala predicts future PTSD
symptoms.
Conclusion : These results suggest that the integrity of the default
network is compromised in acute and chronic PTSD and that the ex-
tent of the deﬁcit reﬂects clinical measures of PTSD.
Track: Basic
S-06. The glutamate synapse and its
regulation: An opportunity for novel
pharmacologic approaches in
mood/anxiety disorders
jS-06-001jTargeting glutamate clearance in the development
of treatments anxiety and depression : Focus on
EAATS
G. Sanacora. Yale University, Nerw Haven, USA
Objective : There is increasing evidence suggesting altered regulation
of glutamate neurotransmission contributes to the pathophysiology
of major mood and anxiety disorders. Recent reports demonstrating
the antidepressant-like eﬀects of several glutamatergic agents has
further spurred interest in gaining a greater understanding of the role
of glutamate in mood disorders. In a parallel line of research several
postmortem studies have demonstrated marked glial cell pathology
and altered levels of excitatory amino acid transport (EAAT) ex-
pression associated with several neuropsychiatric disorders. As glial
cells are primarily responsible for the clearance and metabolism
of glutamate in the brain there is strong motivation to understand the
interaction between glial cells, glutamate neurotransmission and
psychiatric disorders.
Methods : The rodent chronic unpredictable stress (CUS) model
was employed to investigate the eﬀects of stress on glial cell function
and glutamate cycling. Additional studies using drugs such as
riluzole and ceftriaxone, shown to alter glial cell clearance of gluta-
mate were used to investigate potential antidepressant-like eﬀects
in the CUS model. Molecular, cellular and physiological measures
were made to determine the eﬀects of stress and the drugs on glial
cell markers, metabolism and glutamate/glutamine cycling.
Dihydrokainic acid (DHK) an EAAT blocker, was used to speciﬁcally
investigate the role of glutamate uptake in relation to the eﬀects of
stress and antidepressant actions. Lastly, studies using GLT-1
(EAAT2) knockout mice were performed to further evaluate the
eﬀects of glutamate clearance. Clinical trials evaluating the eﬃcacy
of these drugs will be discussed.
Results : CUS resulted in reduced levels of GLT-1 protein in the
pre-and infra-limbic brain regions and reduced levels of glutamate/
glutamine cycling. Riluzole and ceftriaxone both produced anti-
depressant-like eﬀects in several rodent models that could be atte-
nuated with DHK. The drugs also had a reduced antidepressant-like
eﬀect in heterozygous GLT-1 knockout mice.
Conclusion : Similar to previous ﬁndings form postmortem studies
of depressed patients the ﬁndings suggest CUS produces changes
in glial cells and glutamate transporters. Drugs targeting glutamate
transporter activity appear to have antidepressant-like eﬀects in
rodent models and possibly in clinical trials.
jS-06-002jModulating the NMDA receptor complex in
developing therapeutics for bipolar disorder and
major depressive disorder
C. Zarate. NIH/NIMH, Bethesda, USA
Objective : Current treatments are generally unsuccessful for a
number of patients with severe and recurrent mood disorders.
Reasons for this lack of better therapeutics include our limited
understanding of the neurobiological basis of mood disorders, and of
the mechanism of action of existing eﬀective medications. A key
limitation of existing therapeutics is that they are associated with a
signiﬁcant lag of onset of action. Pharmacological strategies that
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rapidly reverse depressive symptoms including suicidal ideation
would have an enormous impact on public health. Several converging
lines of evidence suggest that dysfunction of the glutamatergic
system—particularly the N-methyl-D-aspartate (NMDA) receptor
complex—may play an important role in the pathophysiology of
major depression. Therefore, testing the eﬃcacy of NMDA receptor
modulators and subunit modulators could yield an improved
knowledge of the neurobiological processes involved in these com-
plex illnesses, and lead to the development of radically improved
treatments.
Methods : Several trials examining drugs that aﬀect the NMDA
receptor complex have been conducted to date at NIH in major
depressive disorder (MDD) and bipolar depression (1 double-blind
placebo-controlled study with memantine, 1 with ketamine followed
by continuation therapy with riluzole, 3 controlled studies with the
NMDA antagonist ketamine, and 1 with a selective NR2B antagonist).
In addition, we have obtained biomarker data with including per-
ipheral and electrophysiological and neuroimaging measures such as
magnetoencephalography (MEG), neuroimaging (positron emission
tomography [PET], magnetic resonance spectroscopy [MRS]) looking
for peripheral and neural signals of antidepressant response toNMDA
antagonists.
Results : In the three controlled studies with ketamine, a rapid
antidepressant response was found. In the ﬁrst study in MDD, we
found an onset of antidepressant action within 110 minutes. The eﬀect
size for the drug diﬀerence was very large (d=1.46) after 24 hours and
large (d=0.68) after 1 week. In two BPD studies, we found an anti-
depressant response within 40 minutes ; this improvement remained
signiﬁcant through most of the week for up to 3–5 days. In the latter
controlled study, we found signiﬁcant anti-suicidal eﬀects within
4 minutes lasting 3 days. An antidepressant signal was also found
with an oral selective NR2B antagonist in TRD. The use-dependent
NMDA antagonist memantine was not found to have signiﬁcant
antidepressant eﬀects. With regards to biomarkers predicting anti-
depressant response, we found that increases in slow wave activity
(SWA, a putative marker of synaptic plasticity) and gamma power
cortical activity correlated with decreases in depressive symptoms
following ketamine infusion. Furthermore, pregenual anterior cingu-
late cortical activity in response to an emotional and cognitive task
predicted antidepressant improvement to ketamine.
Conclusion : Modulating the glutamatergic system, particularly
at the NMDA receptor complex appears to be important to the
mechanism of immediate antidepressant and anti-suicidal response.
Electrophysiological and neuroimaging studies are yielding import-
ant insights into the neural correlates of rapid antidepressant action.
jS-06-003jTargeting glutamate release as a testing ground for
compounds with antidepressant/anxiolytic action
M. Popoli. University Milano, Italy
Objective : Stressful life events impact on memory and cognition and
are known to precipitate mood/anxiety disorders. It is increasingly
recognized that stress and its neurochemical and endocrine mediators
induce changes in glutamate synapses morphology and transmission.
Methods : We showed previously that unpredictable footshock
(FS)-stress induces enhancement of depolarization-dependent gluta-
mate release from synaptosomes of prefrontal and frontal cortex
(P/FC), due to a rapid increase of corticosterone (CORT) levels, ac-
tivation of glucocorticoid receptor and presynaptic SNARE complexes
accumulation. Intriguingly, chronic pretreatments with several anti-
depressants, with distinct primary mechanisms, completely abolish
the increase of glutamate release induced by FS-stress. Patch-clamp
recordings of prefrontal cortex pyramidal neurons revealed that FS-
stress induces changes in paired-pulse facilitation (PPF) and its cal-
cium-dependence consistent with an increase in glutamate release.
Chronic desipramine, as observed for glutamate release, completely
prevented the changes in PPF and calcium-dependence. However,
desipramine does not block the increase of the size of the readily re-
leasable pool (RRP) of vesicles induced by FS-stress (measured as
hypertonic sucrose-induced glutamate release), suggesting that the
dampening action of the antidepressant does not aﬀect the RRP size.
Results : Overall, our results show a novel eﬀect of antidepressants
that could be related to their therapeutic action in mood/anxiety dis-
orders. Chronic treatments with benzodiazepines and antipsychotic
drugs have been performed before the stress protocol, to understand
whether this dampening eﬀect of antidepressants is shared by other
psychiatric drugs.
Conclusion : We are currently testing if measurement of stress-
induced glutamate release can be used as a test to assay the pre-
venting action of antidepresants in stress response. Understanding
the action of traditional drugs on glutamate transmission could be
of great help in developing compounds that may work directly at this
level.
jS-06-004jMetabotropic glutamate receptors as therapeutic
targets for anxiety and depression : Focus on
mGluR7
J. Cryan. University College Cork, Ireland
Growing evidence suggests that the glutamatergic system may be
a relevant therapeutic target for stress-related disorders such as de-
pression, anxiety, and cognitive dysfunction. Metabotropic glutamate
(mGlu) receptors are poised to participate in a wide variety of func-
tions of the CNS. The presynaptic mGlu(7) receptor shows the highest
evolutionary conservation within the family and it is thought to
regulate neurotransmitter release. The mGlu(7) receptor is also the
most widely distributed of the presynaptic mGlu receptors and is
present at a broad range of synapses that are postulated to be critical
for both normal CNS function and a range of psychiatric and neuro-
logical disorders. A growing body of evidence suggests that the
mGlu(7) receptor is a key player in shaping synaptic responses at
glutamatergic synapses as well as being a key regulator of inhibitory
GABAergic transmission. The development of selective pharmaco-
logical and genetic tools has allowed for the unravelling of mGlu(7)
receptor function in a host of physiological and behavioural processes.
Knockout mice and siRNA knockdown has pointed to a role of the
mGlu(7) receptor in anxiety, extinction of fear and aversion learning,
spatial memory and the hormonal response to stress. In addition,
these studies are largely supported by pharmacological manipulation
of mGlu(7) receptor although controversies exist and better in vivo
selective ligands are necessary. Finally, selective antidepressant
drugs and models of depression have alterations in hippocampal
mGlu(7) expression which may contribute to their behavioural eﬀects.
Together, these data suggest that the mGlu(7) receptor is an important
regulator of glutamatergic function and modelates behaviours rel-
evant to depression, anxiety and cognition. Thus this receptor re-
presents an innovative therapeutic target for stress-related disorders
at the interface of cognition and emotion.
Policy of full disclosure : None.
S-07. Suicide: Pathophysiology,
psychopharmacology and biomarkers
jS-07-001jSuicide : Social, psychological, biological and
genetic risk factors
W. Bunney. Univ of California, Irvine, USA
Objective : Suicide represents a major public health problem with an
estimated 1 million deaths per year worldwide. The international
magnitude of the problem of suicide, including social, psychological,
biological and genetic risk factors will be reviewed. The critical com-
ponent of psychological pain in suicide will be discussed. Speciﬁc
biological markers that could predict suicide will be reviewed.
Protective factors for suicide will be presented.
Methods : Postmortem brain tissue from depressed patients who
died from suicide compared to depressed patients who died from
other causes was analyzed by microarrays and ﬁndings were con-
ﬁrmed by qPCR.
Results : The expression of a family of genes, metallothioneins (M1,
M2), was signiﬁcantly decreased in brains of depressed patients who
died from suicide in contrast to depressed patients who died from
other causes.
Conclusion : Metallothioneins are modulated by cortisol and pro-
vide neuroprotection against the high cortisol levels consistently re-
ported in mood disorders. Thus, neuroprotection may be signiﬁcantly
decreased in suicide victims. Metallothioneins are highly expressed in
blood and could serve as biomarkers of suicide.
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jS-07-002jGenetic associations and gene-environment
interactions between candidate genes related to
stress-response and stressful life events, in severe
suicide attempts.
D. Wasserman1, M. Sokolowski2, Y. Ben-Efraim2, J. Wasserman2.
1Karolinska Institutet, National Prevention of Suicide, Stockholm, Sweden ;
2NASP, Stockholm, Sweden
Objective : Suicidal behavior (SB) is a major burden in most nations
world-wide and a major public health concern, asy1 million people
commit suicide (SC) each year and 10–20 times more perform suicide
attempts (SA). The causes of why certain people engage in SB are
complex, involving both environmental and genetic factors, and in-
teractions in-between. The aim of this study is to elucidate the inter-
action of certain genes with exposure to physical and sexual abuse
amongst the young (GrE).
Methods : We performed GrE studies taking into consideration
life timing of trauma and gender concerning the corticotrophin
releasing hormone receptor 1 (CRHR1) gene, a major and systemic
stress-modulator of the neuroendocrine hypothalamic-pituitary-
adrenal (HPA) axis. We assessed exposures to rape and/or physical
assault (PA, below or over age of 18) or other lifetime stressful life
events (SLEs) in male and females, by using a family-based design
(n=660 trios) complemented by case-control analysis, in relation to
the outcome of severe lifetime SA in the oﬀspring.
Results : We observed CRHR1 GrE among predominantly
female SA between 5-SNP rs7209436 and PA below 18 years of age
and a male-speciﬁc GrE between 3k-SNP rs16940665 and adulthood
PA exposure, both sharing the SA characteristic of aggression. A third
male-speciﬁc CRHR1 GrE was among depressed SA, between SNP
rs4792887 and cumulative lifetime SLEs. Furthermore, excessive stress
has the potential to induce unfavorable side-eﬀects in a variety of
brain-functions, by interactions of the HPA axis with other neuro-
systems, and we will further report about the results from our
ongoing studies concerning such aspects as well.
Conclusion : We conclude that SA showed diﬀerences in their
GrEs, concordant with a complex SB-aetiology, and that knowledge
of speciﬁc GrEs might become helpful for focused prevention and
intervention eﬀorts in the future.
jS-07-003jThe pharmacogenetics of suicidal adverse reactions
to SSRI medications in children and adolescents
A. Apter1, S. Kroneberg2, A. Frisch2, A. Weizmann2, D. Wasserman2.
1University of Tel Aviv, Sackler School of Medicine, Petah Tikva, USA ;
2University of Tel Aviv, Petah Tikva, USA
Objective : Depression is a common disorder in adolescents with
serious morbidity and even mortality if not treated. SSRI medications
are commonly used for such treatment but only about 55–60% of de-
pressed subjects respond to treatment and 5% show severe side eﬀects
in including suicidal behavior and ideation.
Methods : Consecutive admissions (n=121) to a Child and
Adolescent Psychiatry outpatient were assessed and diagnosed by
DSM-IV-TR criteria. The following assessment instruments were
used : The Schedule for Aﬀective Disorders and Schizophrenia for
school aged children, Present and Lifetime, Screen for Child Anxiety
and Related Emotional Disorders, Children s Depression Inventory ;
Suicidal Ideation Questionnaire, Clinical Global Impression Scale,
SSRI Side Eﬀect Proﬁle Inventory. Genetic polymorphisms of several
genes relevant to the pharmacokinetic and dynamic properties
of SSRI were determined-5HTT, MAO-A, BDNF, TPH2, 5HT2c,
5HT2a, 5HT1b, FKBP5, CHHR1, CRHR2, GR, TBX19, CYP2C19,
CYP2D6.
Results : 5HTT : Children with the ll allele responded in 75% of
cases, ls in 56% of cases and ss in 40% (p<0.05). TPH2 gg allele
together with ll showed and 80% response whereas tg/tt together
with ll had an 80% response (p=.01) ; 5-HTR1B Children with cc had
a 57.1% incidence of motor activation vs. 15.9% with gg (p<0.05) ;
Children with cc had 28.5% psychological activation vs. 4.5% with
gg (p<0.05) FKBP5 rs 136070 cc showed 82.1% remission vs. 33.3%
remission with tt. CRHR1 rs4792887 ct vs. Ct showed signiﬁcant
increase suicidal ideation after treatment.
Conclusion : These preliminary ﬁndings are encouraging and
provide the basis for further investigations in the ﬁeld.
jS-07-004jNoradrenergic and serotonergic pathways and the
stress diathesis model of suicidal behavior
J. Mann1, V. Arango1, R. Parsey1, M. Oquendo1, H. Glafalvy1.
1Columbia University, NY State Psychiatric Institute, New York, USA
Objective : To map the state of the noradrenergic and serotonergic
neurotransmitter systems in suicide and nonfatal suicide attempts
and link to identiﬁed components of psychopathology associated with
suicidal behavior.
Methods : Postmortem brain autoreadiography was employed to
map changes in pre and post-synaptic receptors in the serotonergic
and noradreneregic neurotransmitter systems in suicides. PET in vivo
imaging was used to map serotonin receptors and the transporter in
brain in nonfatal suicide attempters with major depression compared
with nonattempter major depression and healthy volunteers. Findings
are related to clinical components of the stress diathesis model we
have proposed for suicidal behavior.
Results : Noradrenergic deﬁciencies are related to lethality and
probability of suicidal behavior and to its lethality. These deﬁcits are
correlated with hopelessness and depression. Serotonergic deﬁcits are
found in suicides in the brainstem nuclei, ventromedical prefrontal
cortex and anterior cingulate. More recently we have conformed
some of these ﬁndings in living survivors of suicide attempts. Genetic
and epigenetic causal factors have been identiﬁed for some of these
ﬁndings.
Conclusion : The identiﬁcation in nonfatal suicide attempters of
biological abnormalities also found in suicides suggests that brain
scanning may be a potential screening tool for those at risk for suicide.
Treatment and prevention strategies using these ﬁndings as bio-
markers of risk oﬀer an alternative method for outcome indices in
medication and psychotherapy trials.
Policy of full disclosure : Dr. Mann has past unrelated imaging
grants from GSK and Novartis.
S-08. The neurobiology of compulsivity and
OCD: From basic science to clinical
practice
jS-08-001jSymptomatology and pharmacotherapy of obsessive-
compulsive disorder
D. Stein. University of Cape Town, Department of Psychiatry, Capetown,
South Africa
Objective : Obsessive-compulsive disorder is an important neu-
ropsychiatric disorder associated with signiﬁcant morbidity. This
presentation aims to review key questions about the symptomatology
and nosology of obsessive-compulsive disorder, as well as current
work on the pharmacotherapy of this disorder.
Methods : A number of systematic reviews have recently been un-
dertaken of both diagnostic issues and pharmacotherapy approaches
in obsessive-compulsive disorder ; this presentation draws from this
work, highlighting key questions for the ﬁeld, and summarizing rel-
evant data.
Results : There is growing acceptance in the ﬁeld of the construct of
‘‘obsessive-compulsive related disorders’’, although there continues
to be debate about its optimal boundaries. There is good evidence for
the eﬃcacy of serotonin reuptake inhibitors (SRIs) as ﬁrst line agents,
some evidence for the eﬃcacy of antipsychotic agents as augmenting
agents in individuals refractory to SRIs, and ongoing interest in a
range of other drug classes.
Conclusion : While there have been advances in diagnosis and
treatment of obsessive-compulsive disorder, further work to delineate
the underlying psychobiology of this disorder is needed to continue to
progress the ﬁeld.
Policy of full disclosure : Dr. Stein has received research
grants and/or consultancy honoraria from Abbott, Astrazeneca,
Eli-Lilly, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson & Johnson,
Lundbeck, Orion, Pﬁzer, Pharmacia, Roche, Servier, Solvay,
Sumitomo, Takeda, Tikvah, and Wyeth.
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jS-08-002jUnraveling neural mechanisms of compulsivity
using the signal attenuation rat model
D. Joel. Tel Aviv University, Department of Psychology, Israel
Objective : Obsessive-compulsive disorder (OCD) is a psychiatric
disorder aﬀecting 1–3% of the population. The orbitofrontal cortex,
the striatum and the dopaminergic and serotonergic systems
have been implicated in the pathophysiology of OCD, yet the ways
in which these neural systems interact to produce obsessions and
compulsions in patients is currently unknown. Data obtained using
pharmacological manipulations, lesions, inactivation and electrical
stimulation in the signal attenuation rat model of OCD suggest
speciﬁc ways in which these neural systems interact to produce com-
pulsive behaviors.
Methods : The signal attenuation model is a theory-driven rodent
model of OCD which builds on the assumption that compulsive
behaviors result from a deﬁcient signaling that a response was eﬀec-
tive in producing an outcome.
Results : Work in this model found that lesions to the orbitofrontal
cortex decrease striatal serotonin and dopamine content and increase
compulsive lever-pressing, and that this increase is blocked by intra-
striatal administration of a selective serotonin reuptake inhibitor.
Lesions to the subthalamic nucleus similarly decrease striatal sero-
tonin and dopamine and increase compulsive lever-pressing.
Consistent with these ﬁndings, high frequency stimulation of the
subthalamic nucleus, which exerts an anti-compulsive eﬀect in OCD
patients and in the signal attenuation model, increases dopamine
content in the striatum.
Conclusion : Taken together, these results suggest that alterations
in striatal serotonin and/or dopamine may provide a ﬁnal common
pathway by which diﬀerent brain pathologies may lead to compulsive
behaviors.
jS-08-003jThe translational neuroscience of OCD
T. Robbins. University of Cambridge, Dept. Experimental Psychology,
United Kingdom
Objective : Obsessive-compulsive disorder entails a tendency com-
pulsively to perform repetitive acts and has traditionally been as-
sociated with anxiety states and obsessions, putatively reﬂecting
pathology in the orbitofrontal cortex, striatum and amygdala. We
have been searching for endophenotypic markers in the disorder that
can also be related to these brain systems on the basis of studies with
human neuroimaging and animal models.
Methods : A major candidate has been cognitive inﬂexibility, for
example, in reversal learning and extra-dimensional set-shifting
(a core component of the Wisconsin Card Sorting Test), previously
shown in studies with monkeys and rodents to depend on distinct
cortico-striatal loops involving the orbitofrontal and lateral prefrontal
cortex. We used a human fMRI paradigm previously shown to sep-
arate these regions according to the BOLD responses during reversal
and extra-dimensional set-shifting as well as parallel behavioural
paradigms in rodents and monkeys.
Results : We demonstrated hypoactivity of the orbitofrontal
network during reversal learning in an obsessive-compulsive group
and in their ﬁrst degree relatives without clinical symptoms. Parallel
work with marmoset monkeys showed reversal learning to depend on
5-HT modulated functions of the orbitofrontal cortex and dopamine-
modulated functions of the ventromedial striatum. Stop-signal reac-
tion time performance was similarly impaired in patients with
obsessive-compulsive disorder and their ﬁrst-degree relatives, and
was also shown to involve orbitofrontal and lateral frontal-striatal
circuits in rodents. Finally, the balance of competing neural systems
mediating action-outcome learning and stimulus-response habit
learning was shifted towards the latter in obsessive-compulsive dis-
order, based on performance of a human associative learning para-
digm inspired by neuropsychological experiments on associative
learning in rodents.
Conclusion : These results (obtained with appetitive paradigms
that do not elicit anxiety) are discussed in terms of contributory
neurobehavioural mechanisms underlying obsessive-compulsive
disorder. They may also be relevant to changing perceptions of its
aetiology and nosological status.
Policy of full disclosure : Cambridge Cognition (consultancy and
royalties) (CANTAB) Consultancy and research grants from E. Lilly,
Lundbeck and GlaxoSmithKline. This research was funded by a
Programme Grant from the Wellcome Trust. The BCNI is funded by
a joint grant from the MRC and the Wellcome Trust.
jS-08-004jAnimal models of obsessive-compulsive disorder :
What deep brain stimulation may tell us about
pathophysiology
A. Grace1, S. Ewing2. 1University of Pittsburgh, Pittsburgh, PA, USA ;
2University of Pittsburgh, Department of Neuroscience, Pittsburgh, PA,
USA
Objective : OCD patients exhibit hyperactivity in the orbitofrontal
cortex (OFC), and eﬀective treatments normalize OFC activity.
Moreover, intractable OCD is responsive to deep brain stimulation
(DBS) of the ventral striatum (VS). Therefore, we evaluated animal
models of OCD, and examined the neuronal alterations produced
by continuous DBS of the VS target used in OCD treatment in
humans.
Methods : Two models of OCD were evaluated ; the clomipramine
model (15 mg/kg twice/day between postnatal days 9 and 16) and
the quinpirole model (0.5 mg/kg twice/week for 7 weeks). Rats were
evaluated for compulsive behavior and VTA DA neuron activity. DBS
was administered to the VS site for 5 days continuously (130 Hz,
100 usec and 100 uA bilaterally), and local ﬁeld potentials recorded.
Results : In our hands, the clomipramine model failed to show re-
sults consistent with OCD. Quinpirole treated rats showed signiﬁcant
perseveration and compulsive lever pressing, and increased VTA DA
neuron population activity. DBS in control rats increased gamma
power bilaterally in the VS, but decreased coherence between the VS
and the prelimbic PFC, and between the VS and the thalamus. In
contrast, there was an increase in coherence between the OFC and the
thalamus, and the OFC bilaterally.
Conclusion : These data suggest that DBS induces acute increases
in power in cortical regions, but over time this change undergoes
compensation and is replaced with changes in coherence. Changes in
coherence is likely to reﬂect alterations in information processing.
Thus increased coherence between the OFC and its aﬀerent structures
would improve signal processing, potentially enabling the OFC to
eﬀectively devalue stimuli that are no longer relevant for behavior ; a
function impaired in OCD. In contrast, decreased coherence in the
prelimbic PFC and ventral striatum may reﬂect improved extinction.
Whether DBS has diﬀerent eﬀects on power and coherence in animal
models of OCD is currently being evaluated.
Policy of full disclosure : Johnson & Johnson, Lundbeck, Pﬁzer,
GalaxoSmithKlein, Merk, Takeda, Dainippon Sumitomo, Otsuka.
S-09. Neuropeptides and mental diseases
jS-09-001jRole of orexin/hypocretin in panic and other stress
disorders
A. Shekhar1, P.L. Johnson1, W.A. Truitt1, A. Molosh1.
1Raymond E. Houk, Indiana University School, USA
Objective : Panic disorder (PD) is a severe anxiety disorder charac-
terized by recurrent panic attacks aﬀecting about 2–5% of the popu-
lation and resulting in severe disability in about a third of those
subjects. We recently identiﬁed that orexin (hypocretin) neurons are
one of the key regulators of a coordinated panic response and that
patients with panic but not depression symptoms do indeed have
high levels of orexin in their cerebrospinal ﬂuid. Panic patients also
have enhanced vulnerability to conditioned fears, avoidance and
phobias. The present study was conducted to elucidate the mech-
anisms of these long term consequence of panic disorder utilizing
preclinical model system.
Methods : Utilizing chronic disinhibition of orexinergic neurons in
the perifornical/dorsomedial hypothalamus (PeF/DMH, we tested
the eﬀects on disrupted network functions on induction of 1) chronic
anxiety states ; 2) enhanced fear conditioning ; and 3) delayed extinc-
tion of conditioned fear. We measured behavioral, molecular and
electrophysiological endpoints, utilizing pharmacological and gene
silencing experiments in both whole animal and slice preparations.
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Results : Chronic disinhibition of ORX neurons in the DMH/PeF
inducing molecular and network changes in the bed nucleus of the
stria terminalis (BNST) to decrease GABAergic and to enhance gluta-
matergic neurotransmission in order to induce a chronic anxiety-like
phenotype. Hyperactivation of orexin system enhanced acquisition
and expression of conditioned fears seen in panic-prone rats, and re-
sulted in excitation and reduced inhibition in the central nucleus of
the amygdala (CeA), thus facilitating neuronal plasticity in the CeA.
Conclusion : These results provide a mechanistic model to under-
stand the pathophysiology of PD and its disabling consequences and
provide insight into the functional network electrophysiology as well
as basic cellular and molecular changes within key limbic circuits.
Finally, at the translational level, these results provide novel insights
into the persistent and hard to extinguish nature of agoraphobia and
anticipatory anxiety in patients with panic disorder.
Policy of full disclosure : Supported by the US National Institute of
Mental Health grant, R01 MH052619.
jS-09-002jCRH1 Receptor antagonists – Back on the map
F. Holsboer. Max-Planck-Institut, fu¨r Psychiatrie, Munich, Germany
Objective : Strong evidence emerged from basic and clinical research
that many of the signs and symptoms prevalent in depression are
mediated by CRH via CRHR1 receptors. Key ﬁndings were behavioral
changes in animals that were chronically stressed, received centrally
CRH or were overexpressing transgenically CRH. The CRHR1 sub-
type was among other techniques identiﬁed by conditional CRHR1
gene deletions. Clinical support for targeting the CRH/CRHR1 sys-
tem came from enhanced CRH concentrations in the brains and cer-
ebral spinal ﬂuids of depressed patients, neuroendocrine and sleep-
EEG studies and a ﬁrst open label trial with R121919, a nonpeptide
CRHR1 antagonist. All major pharmaceutical companies developed
CRHR1 antagonists and compared them with current standard com-
pounds and placebo. Without exception all so far reported controlled
trials yielded negative results, i.e. the test drugs were equal to placebo
and comparators were superior. The reason was that in the absence of
laboratory tests identifying patient subgroups where CRH hyper-
activity accounts for the clinical condition, a speciﬁc intervention such
as CRHR1 blockade will be inferior to a current unspeciﬁc anti-
depressant.
Methods : We developed a genetest allowing to accumulate poten-
tial CRH hypersecretors. In addition, we observed in transgenic mice
overexpressing CRH a disinhibiton of REM-like sleep. REM-
disinhibition was associated with beneﬁcial response to CRHR1
antagonist treatment among severely depressed patients. Therefore
we argue that a genetest combined with sleep-EEG analysis will
identify potential CRHR1 antagonist responders.
jS-09-003jDuplications of the neuropeptide receptor gene
VIPR2 confer signiﬁcant risk for schizophrenia
J. Sebat. Chief, Beyster Center for Genomics of Neuropsychiatric, La Jolla,
USA
Rare copy number variants (CNVs) have a prominent role in the
aetiology of schizophrenia and other neuropsychiatric disorders.
Substantial risk for schizophrenia is conferred by large (>500-kilo-
base) CNVs at several loci, including microdeletions at 1q21.1 (ref. 2),
3q29 (ref. 3), 15q13.3 (ref. 2) and 22q11.2 (ref. 4) and microduplication
at 16p11.2 (ref. 5). However, these CNVs collectively account for a
small fraction (2–4%) of cases, and the relevant genes and neuro-
biological mechanisms are not well understood. Here we performed
a large two-stage genome-wide scan of rare CNVs and report the
signiﬁcant association of copy number gains at chromosome 7q36.3
with schizophrenia. Microduplications with variable breakpoints
occurred within a 362-kilobase region and were detected in 29 of 8,290
(0.35%) patients versus 2 of 7,431 (0.03%) controls in the combined
sample. All duplications overlapped or were located within 89 kilo-
bases upstream of the vasoactive intestinal peptide receptor gene
VIPR2. VIPR2 transcription and cyclic-AMP signalling were signiﬁ-
cantly increased in cultured lymphocytes from patients with micro-
duplications of 7q36.3. These ﬁndings implicate altered vasoactive
intestinal peptide signalling in the pathogenesis of schizophrenia and
indicate the VPAC2 receptor as a potential target for the development
of new antipsychotic drugs.
jS-09-004jGalanin and galanin receptors in depression – focus
on the human brain
T. Ho¨kfelt1, E. Le Maı¨tre2, S. Barde2, E. Kuteeva2, M. Palkovits3,
S.-O. O¨gren2. 1Karolinska Institutet, Department of Neuroscience,
Stockholm, Sweden ; 2Karolinska Institutet, Stockholm, Sweden ;
3Semmelweis University & HAS, Budapest, Hungary
Objective : Galanin is a 29 (30 in humans) neuropeptide that is ex-
pressed in many regions of the rodent brain, including locus coeruleus
(LC) and dorsal raphe nucleus (DRN), where it in rat coexists with
noradrenaline and serotonin, respectively. There is evidence from
animal experiments that galanin is involved in mood regulation, in
fact also from human genetic studies. Animal experiments suggest
that a galanin antagonist should have antidepressant actions. The aim
of this work is to reveal to what extent distribution of the galanin
system in the human brain is similar to that reported in rodents.
Methods : We have used riboprobes and in situ hybridization to
localize galanin and its receptor (GalR1–3) mRNAs in LC and DRN.
Some other markers like transcripts for tyrosine hydroxylase, trypto-
phan hydroxylase 2, vesicular glutamate transporters and nitric oxide
synthase were also analysed.
Results : In the human post mortem brain LC galanin and GalR3,
but not GalR1 and -R2 could be detected. In the DRN galanin was not
found in areas harbouring serotonin neurons, but GalR3-positive and
serotonin neurons overlapped.
Conclusion : These ﬁndings indicate that the galanin system ex-
hibits considerable species diﬀerences, which should be taken into
account in work aiming at development of novel antidepressants. Our
results based on analysis of the human post mortem brain, and on
animal experiments, suggest that antagonists at the GalR3, but not the
GalR1, receptor would be potential antidepressants. In fact, such an-
tagonists have been generated.
S-10. Putative abnormalities in Orexin and
GABA metabolism in panic disorder
jS-10-001jOrexin and psychiatric symptoms in suicide
attempters
L. Brundin1, L. Tra¨skman-Bendz2. 1Lund University, Psychoimmunology
Unit, Sweden ; 2Lund University, Sweden
Objective : The orexins (hypocretins) are hypothalamic peptides in-
itially discovered to be involved in the regulation of sleep, appetite
and state of arousal. We analyzed orexin levels in the cerebrospinal
ﬂuid (CSF) of patients who were hospitalized after a suicide attempt.
Methods :At the day of the lumbar puncture, psychiatric symptoms
were carefully rated using the Comprehensive Psychopathological
Rating Scale (CPRS) as well as the Suicide Assessment Scale (SUAS),
and the patients underwent a thorough diagnostic interview.
Results : We found that suicide attempters with a diagnosis of
Major Depressive Disorder had signiﬁcantly lower levels of orexin in
the CSF than patients with adjustment disorder and dysthymia.
Furthermore, we found that orexin levels increased signiﬁcantly dur-
ing the ﬁrst year after the suicide attempt, together with an improve-
ment of the scores on the SUAS. We also found that low CSF-orexin
levels were related to pronounced symptoms of inertia and reduced
motor activity in suicidal patients.
Conclusion : The lower the orexin levels, the higher were ratings of
overall illness, as observed by a specialist in psychiatry. Interestingly,
depressed patients with anxiety display signiﬁcantly higher orexin
levels than patients without such symptoms. Thus, high vs. low levels
of orexin might be coupled to diﬀerent spectrums of psychiatric
symptoms.
jS-10-002jGABA imaging ﬁndings in panic disorder measured
by 1H MRS
U. Dydak1, Z. Long2, Y.-W. Shin3, M. Dzemidzic4, A. Goddard4.
1Purdue University, West Lafayette, USA ; 2School of Health Sciences,
West Lafayette, USA ; 3Department of Psychiatry, Seoul, Republic of
Korea ; 4 Indiana Univ. School of Med., Indianapolis, USA
Objective : Several 1H Magnetic Resonance Spectroscopy (MRS)
studies found decreased levels of the inhibitory neurotransmitter
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y-aminobutyric acid (GABA) in cortical regions of unmedicated
patients with panic disorder (PD). Furthermore it has been suggested
that a positive family history of PD may play a role in cortical GABA
changes in PDpatients. This talkwill reviewpublished 1H-MRSGABA
ﬁndings in PD and present data from a recent study investigating
the inﬂuence of family history on GABA levels in unmedicated PD
patients.
Methods : A GABA-editing MRS technique was used for GABA
detection in anterior cingulate cortex (ACC) and occipital cortex
(OCC) in ﬁve family history-positive (FHP) patients, six family his-
tory-negative (FHN) patients and 11 matched controls.
Results : While no signiﬁcant diﬀerence in GABA levels, expressed
as the ratio of GABA over total Creatine (tCr), were found between the
groups in either brain region, ACC GABA/tCr levels had a numerical
trend to be lower in FHP patients versus controls. A signiﬁcant cor-
relation was found between OCC GABA/tCr levels and the trails B
test scores (a test of visual attention) (r=0.8, p<0.05) in this patient
group. Interestingly, the correlations between prescan state anxiety
scores and GABA/tCr levels seem to be opposite for ACC and OCC,
as well as for FHP and FHN patient groups : a positive correlation
is found for FHN patients in ACC (r=0.95, p<0.01) and for FHP
patients in OCC (r=0.52, trend only) ; however, a negative correlation
was seen for FHN patients in OCC (r=x0.88, p<0.01) and for FHP
patients in ACC (r=x0.62, trend only).
Conclusion : Our results agree with previous reports on GABA
deﬁcits in PD patients. Decreased GABA in family history-positive
patients suggests a unique GABAergic mechanism in these patients.
jS-10-003jResting-state functional connectivity in panic
disorder
Y.-W. Shin1, M. Dzemidzic2, U. Dydak3, A. Goddard4, Z. Long5.
1Ulsan University, Seoul, Republic of Korea ; 2Department of Neurology,
Indianapolis, USA ; 3Department of Radiology, Indianapolis, USA ;
4Department of Psychiatry, Indianapolis, USA ; 5School of Health Sciences,
West Lafayette, USA
Objective : Decreased GABA concentration in the anterior cingulate
cortex (ACC) has been reported in panic disorder. A recent study
showing the increased GABA concentration in the ACC was posi-
tively correlated with negative blood oxygen level dependent re-
sponse in the area has made it necessary to investigate a resting-state
functional connectivity of the ACC in panic disorder.
Methods : The functional connectivity maps with seed ROI located
in the ACCwere identiﬁed in the patients with panic disorder (N=11)
and age- and sex- matched normal control subjects (N=11). The cor-
relation was investigated between the index of functional connectivity
in the area showing group diﬀerences and the GABA concentration
around the seed ROI volume.
Results : The patients with panic disorder showed increased func-
tional connectivity between ACC and precuneus compared to control
subjects with family-wise error corrected at q<0.05. The functional
connectivity between the ACC and precuneus had a negative corre-
lation with GABA concentration in the ACC.
Conclusion : Increased functional connectivity in the resting-state
default mode network including the ACC and precuneus might play
an important role in the pathophysiology of panic disorder.
jS-10-004jClinical studies of Orexin (ORX) and GABA
function in panic anxiety : Translational
implications.
A. Goddard1, P. Johnson1, U. Dydak2, Y.-W. Shin3, Z. Long2,
C. Medlock1, L. Brundin4, A. Shekhar1. 1 Indiana University,
Indianapolis, USA ; 2Purdue University, West Lafayette, USA ; 3Ulsan
University, Seoul, Republic of Korea ; 4Lund University, Sweden
Objective : PD is a signiﬁcant public health problem as it is a common
psychiatric condition with a lifetime prevalence of up to 4% in
the general community. It is a chronic illness, which can profoundly
aﬀect functioning and quality of life. Despite improvements in diag-
nosis and treatment over the last few decades, the pathophysiology
of PD and mechanisms of eﬀective treatments remain unclear. The
present work evaluates the role of GABA-ORX interaction in human
panic.
Methods : As mentioned by other symposium speakers, perturba-
tions in GABA (MRS measures) and neuropeptide/ORX function
(CSF ORX) may contribute to a panic vulnerability state, which may
be reﬂected in variations in resting-state fcMRI parameters. A series of
recent preclinical and clinical studies (Johnson, Truitt et al., 2010),
has led us to hypothesize that PD is associated with speciﬁc cortical
and subcortical GABA deﬁcits that result in disruption of normal
inhibitory regulation of ORX neurons. This disruption promotes
excessive ORX release, sympathetic activation, and vulnerability to
spontaneous or lactate-induced panic.
Results : Follow-up animal and human work within our anxiety
research team has identiﬁed evidence of ORX neuronal hyperactivity
in association with CO2-induced anxiety. Furthermore, other inves-
tigators have reported ORX metabolic abnormalities at rest in patients
with chronic PTSD, another anxiety disorder with pathophysiologic
similarities to PD (Strawn et al., 2010).
Conclusion : Our collaborative research eﬀort has implications for
elucidating key ORX-GABA interactions that contribute to human
panic states, as well as for deﬁning the therapeutic mechanisms of
actions of known eﬀective antipanic therapies (e.g. benzodiazepines,
SSRIs, CBT), and novel panicolytics (e.g. ORX1 receptors antagonists).
Policy of full disclosure : Pﬁzer-Consultant, Janssen-Independent
grant awardee, Astra-Zeneca-Independent grant awardee.
RS-01. Neuroimaging applications in
neuropsychopharmacologyCINP Asia
Regional Committee
jRS-01-001j Imaging evaluation of drug target molecule :
translational perspective from animal model
and human brain
T. Suhara. National Institute of Japan, Radiological Sciences, Chiba, Japan
Positron emission tomography (PET) techniques have enabled
the visualization of transporter protein and functions. In the ﬁeld of
neuropsychopharmacology, monoamine transporters such as sero-
tonin transporter and norepinephrine transporter (NET) are the major
target of antidepressants and eﬄux transporters such as P-glyco-
protein is a major component of blood brain barrier. The serotonin
transporter occupancy has been used as a reliable index for thera-
peutic drug monitoring. Previous PET studies on antidepressants
have suggested over that 80% of occupancy provides the desired
therapeutic eﬀects. On the other hand, the NET occupancy by anti-
depressants in human brain has not been reported because of a lack
of suitable radioligands for NET. (S,S)-[18F]FMeNER-D2 was recently
developed as a radioligand for the measurement of NET binding with
PET. The mean NET occupancies by nortriptyline doses were 16.4%
at 10 mg, 33.2% at 25 mg, and 41.1% at 75 mg, respectively. The
mean plasma concentration of nortriptyline was 0 ng/ml at 10 mg,
23.7 ng/ml at 25 mg, and 50.5 ng/ml at 75 mg. Estimated ED50 (50%
eﬀective dose) was 76.8 mg of administration dose and 59.8 ng/ml
of plasma concentration.
jRS-01-002jDrug-receptor occupancy study in predicting
proper dose of psychotropic drugs with PK-PD
modeling
E. Kim1, O. Howes2, S. Kapur2, J.S. Kwon1. 1Seoul National University,
Republic of Korea ; 2 Institute of Psychiatry, London, United Kingdom
Objective : To predict proper dose of antipsychotic drugs in terms
of receptor occupancy, it is necessary to determine the relationship
between plasma drug concentration and receptor occupancy.
Typically, most studies of antipsychotic drugs have applied the Emax
model alone to characterize the relationship. However, a limitation of
this approach is that it does not account for the discrepancy between
the time courses of plasma drug concentration and receptor oc-
cupancy by antipsychotic drugs. This prompts the necessity of com-
bined pharmacokinetic-pharmacodynamic (PK-PD) modeling for
the reliable analysis of the concentration-occupancy relationship.
We will introduce PK-PD modeling in the concentration-occupancy
analysis and compare it with conventional approach (Emax model
alone).
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Methods : We measured dopamine receptor occupancy using
[11C]raclopride PET and plasma concentration of aripiprazole at a
number of time points after the administration of aripiprazole. We
built the PK-PD model and simulated the time eﬀect on the concen-
tration-occupancy relationship.
Results : The hysteresis characteristics were observed in the
concentration-occupancy relationship and the value of EC50 was
diﬀerent according to the analysis approach (EC50=11.1 ng/ml
(95%CI=10.1y12.1) from Emax model alone ; EC50=8.63 ng/ml
(95%CI=7.75y9.51) from PK-PD model).
Conclusion : This ﬁnding suggests that PK-PDmodeling is required
to obtain reliable results in study about the antipsychotic concen-
tration-occupancy relationship.
jRS-01-003jAssociation of brain serotonin transporter (SERT)
availability and brain-derived neurotrophic factor
in models of SERT genotypes in human subjects :
a new insight for the development of
antidepressant
Y.-H. Chou. Taipei Veterans General Hospit, Taiwan
Objective : The S-allele of functional polymorphisms of the serotonin
transporter (SERT) gene has been demonstrated to have lower trans-
criptional activity compared with the L-allele, which shows low ex-
pression of SERT in the brain. However, this ﬁnding cannot be
consistently replicated in vivo. Importantly, the frequency of poly-
morphism is diﬀerent from Asian and Caucasian. The aim of this
study was to determine the availability of SERT based on SERT
genotype in an Asian population. We also examined the relationship
between brain-derived neurotrophic factor (BDNF) and the avail-
ability of SERT.
Methods : Sixty-two healthy subjects were recruited. Each subject
underwent single photon emission computed tomography (SPECT)
with 123I-ADAM for imaging SERT in the brain. The speciﬁc uptake
ratio (SUR) was measured and venous blood was drawn when the
subject underwent SPECT to evaluate plasma BDNF levels and SERT
genotype. All subjects expressed SERT genotypes that were consistent
with a bi-allelic model, and 26 subjects had SERT genotypes that were
consistent with a tri-allelic model.
Results : No diﬀerences in SUR were detected in the midbrain,
putamen, caudate and thalamus based on the SERT genotype using
the bi-allelic and tri-allelic models. Interestingly, linear regression
revealed a positive correlation between plasma BDNF and SERT
availability. In particular, this relationship was observed in homo-
zygous S-allele expression and a genotype with low functional ex-
pression (SaSa/SaLg) in the bi-allelic and tri-allelic models of SERT
genotypes, respectively.
Conclusion : This ﬁnding might explain why the SS genotype
of SERT did not increase the risk of MDD in Asian populations and
implicate an important role of BDNF in the patients, who has the SS
genotype of the SERT gene.
jRS-01-004jA two-year follow-up study on the functional
connectivity abnormality in ﬁrst-episode
drug-naive schizophrenia in a Chinese population
T. Li. Chengdu, China
Objective : By ﬁrst episode of illness and prior to treatment, diﬀusion
tensor imaging (DTI) studies conﬁrm patients with schizophrenia
have lower regional white matter fractional anisotropy (FA) measures
than typically developing controls. However, it is not clear whether
antipsychotic drugs ameliorate or worsen microstructural changes in
white matter systems during the very early phase of treatment. To
explore longitudinal alterations in white matter (WM) microstructure
in antipsychotic-naı¨ve patients with ﬁrst-episode schizophrenia dur-
ing the very early phase of treatment.
Methods : High-resolution diﬀusion tensor imaging (DTI) was ob-
tained from 35 ﬁrst-episode drug-naı¨ve patients with schizophrenia
and 22 controls at baseline and 6 weeks later, respectively. The
patients received standard antipsychotic treatment during the 6-week
period. The diﬀerences in Positive and Negative Syndrome Scale
(PANSS) scores and Global Assessment of Functioning (GAF) scores
between baseline and 6 weeks later were evaluated and expressed as a
6-week/baseline ratio. In addition a 6 week ‘diﬀerence map’ was
generated from the follow-up image minus the baseline DTI image.
The FA diﬀerence maps in cases and controls were compared and
potential correlations between FA changes and changes in PANSS,
outcome scores and antipsychotic drug dosages were explored.
Results : Compared to healthy controls, there was a signiﬁcant de-
crease in absolute FA in WM around the bilateral anterior cingulate
gyrus and right anterior corona radiata of frontal lobe in ﬁrst episode
drug-naive patients with schizophrenia following 6 weeks treatment.
The change in FA did not correlate with change in clinical symptoms
or the dosages of antipsychotic medication.
Conclusion : During the early phase of treatment, there is an acute
reduction in white matter FA which may due to the eﬀects of anti-
psychotic medications. However, it is not possible to entirely exclude
the eﬀects of underlying progression of illness.
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S-11. Mental health and the immune system
jS-11-001jAntidepressants as anti-inﬂammatory agents in the
treatment of depression : Fact or ﬁction?
B. Leonard. National University of Ireland, Galway, Ireland
Objective : There is substantial evidence that chronic low grade
inﬂammation plays a vital role in the psychopathology of depression.
As antidepressants attenuate depressive symptoms, do they do so by
attenuating the inﬂammatory status?
Methods : A search of the published literature clearly indicates
that the pro-inﬂammatory cytokines, IL-6 and TNF-alpha are consist-
ently raised in the sera of depressed patients. The response of these
markers to eﬀective antidepressant treatment was assessed.
Results : The eﬀects of antidepressants on the pro-inﬂammatory
cytokines in the sera was inconsistent, dual action antidepressants
being most eﬀective. Evidence from some studies show that the cyto-
kine concentration in the frontal cortex increases despite the reduction
in the sera associated with the therapeutic response. Concurrent ad-
ministration of ibruprofen was shown to block the antidepressant
response but to reduce the cortical inﬂammatory cytokines.
Conclusion : The hypothesis that eﬀective antidepressant treat-
ment is associated with a reduction in brain inﬂammation requires
further evaluation. The previously reported enhancement of the anti-
depressant response by NSAID’s also needs reconsideration.
jS-11-002jThe role of tryptophan catabolites in the
pathogenesis of depression : Lessons from
interferon-alpha
C. Raison. Emory University, Atlanta, USA
Objective : To assess the possibility that activation of the body’s
inﬂammatory response system promotes depression and related
behavioral symptoms in part via indoleamine 2,3-dioxygenase (IDO)
induced production of kynurenine and its metabolites.
Methods : Recent data are reviewed that support a role for IDO
in the development of depression in response to chronic immune
activation provided by treatment with the cytokine interferon (IFN)-
alpha.
Results : While it has long been known that inﬂammatory stimuli
activate IDO, it was presumed that IDO contributed to depression
primarily by reducing the availability of serotonin precursors.
More recent ﬁndings suggest that marked increases in CNS levels of
kynurenine and its metabolites quinolinic acid and kynurenic acid
may be more directly involved in depressive pathogenesis.
Conclusion : Recent ﬁndings using IFN-alpha as a model system
support long-forgotten ﬁndings from early psychiatric research that
kynurenine and its metabolites may be relevant to the pathogenesis
of depression. Agents that impact kynurenine production and/or
metabolism may hold therapeutic promise for the treatment of de-
pression.
Policy of full disclosure : Work presented here was funded by
the National Institute of Mental Health. In the previous 12 months
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Dr. Raison has served as a consultant to Brystol Myers Squibb and
Pamlab and has developed and presented disease state promotional
material for Pamlab.
jS-11-003jThe immune system and the kynurenine pathway in
schizophrenia : Pathophysiological and therapeutic
aspects
M. Schwarz1, A.-M. Myint1, M. Riedel1, N. Mueller1. 1Ludwig-
Maximilians University, Munich, Germany
Objective : The paradigm of a disturbed dopaminergic neuro-
transmission being a key-feature in the neurobiology of schizophrenia
has more and more been replaced by more complex hypotheses
including the interaction between distinct neurotransmitter systems
and the immune system. One highly intriguing functional link is
represented by the kynurenine pathway of the tryptophan metab-
olism.
Methods : This presentation will sum up results of several studies.
Results : The immune response in schizophrenia seems to be a
two-sided sword : There are data clearly indicating an enhanced acti-
vation of the T-helper2-like immune system associated with more
pronounced positive symptoms, which ﬁt with the ﬁndings of an en-
hanced production of the NMDA and alpha7nACh receptor antag-
onist kynurenic acid. On the other hand there are data showing that
the immune system is clearly activated, characterised by an enhanced
production of pro-inﬂammatory cytokines. This pro-inﬂammatory
state is associated with the activation of the enzyme indoleamine
2,3-dioxygenase (IDO) resulting in an increased production of neuro-
toxic kynurenine metabolites including 3-hydroxykynurenine. The
immunological eﬀects of antipsychotics partly reverse the immune
imbalance and there is evidence for their modulating eﬀect on the
kynurenine pathway as well.
Conclusion : Substances acting directly on the kynurenine metab-
olism, are still in early stages of development, while anti-inﬂamma-
tory drugs acting indirectly on this metabolism are discussed as
therapeutic or preventive agents in schizophrenia. Most of the current
data are related to COX-2 inhibitors, which have been tested in animal
experiments and in clinical trials, pointing to favourable eﬀects in
schizophrenia.
Policy of full disclosure : The author is involved in two patents on
kynurenine metabolites as biomarkers for psychiatric disorders.
jS-11-004jOxidative and immune biomarkers as targets for the
development of novel therapies
M. Berk. University of Melbourne, Swanston Centre, Geelong, Australia
Objective : There is abundant evidence that inﬂammatory and oxi-
dative processes play a role in mood disorders. There is evidence
of increased inﬂammatory activity in mood disorders, including ele-
vations in cytokines.
Methods : The brain is the most metabolically active tissue,
and disruptions in mitochondrial energy generation are now well
described in mood disorders. Administration of pro-inﬂammatory
cytokines is amongst the best models of depression. The consequences
of inﬂammatory and oxidative stress include lipid peroxidation,
DNA fragmentation protein carbonylation and an increased vulner-
ability to apoptosis. Inﬂammatory and oxidative stress leads to de-
creased BDNF and other trophic factors. Established antidepressants
and mood stabilisers including lithium and valproate have a role in
ameliorating oxidative stress, and additionally alter immune markers.
N-acetyl cysteine (NAC) is a precursor of glutathione, has anti-
inﬂammatory properties and has been shown to reverse animal
models of oxidative stress.
Results : Clinical data shows a signiﬁcant beneﬁt of NAC on
measures of depression, quality of life and functioning Equally,
inﬂammation provide some novel therapeutic targets, which are
clinically accessible, including statins, aspirin and NSAIDS.
Conclusion : There is data that these agents may reduce risk for
mood disorders. Such biomarker data have the potential to lead to
the development of novel therapies for mood disorders outside of
traditional monoamine targets.
Policy of full disclosure : Grant/Research support : Stanley
Medical Research Foundation, MBF, NHMRC, BeyondBlue, Geelong
Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo
SmithKline, Organon, Novartis, Mayne Pharma, Servier. Speaker :
AstraZeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline,
Janssen Cilag, Lundbeck, Pﬁzer, Sanoﬁ Synthelabo, Servier, Solvay,
Wyeth. Consultant : AstraZeneca, Bristol Myers Squibb, Eli Lilly,
Glaxo SmithKline, Janssen Cilag, Lundbeck, Servier.
S-12. Oxidative stress, and the development of
mental disorders
jS-12-001jMood disorders and mitochondrial dysfunction
T. Young. University of Toronto, Canada
Mood disorders present an enormous burden of illness and many
patients do not respond to available treatments. While we continue to
focus on neurocognitive changes and cellular loss and damage in
speciﬁc brain regions, the exact etiology remains uncertain. Genome
wide association studies support multiple genes of small eﬀect which
confer increased for these illnesses. Continued progress on studying
post-mortem brain tissue and blood cells from patients have demon-
strated new possibilities for biological causes of these disorders.
Evidence from a number of investigators has shown that oxidative
stress and damage is increased in patients with bipolar disorder
which may be related to abnormalities within the electron transport
chain. Build up of oxidative metabolites may lead to cellular damage
and loss. Studies from animal models and patients suggest that
treatment with mood stabilizers may reduce oxidative damage and
ultimately prevent cellular damage and loss. Oxidative stress has long
been held as a mechanism in other neurodegenerative disorders in-
cluding Parkinsonism. Of particular interest is the relation of oxidi-
zation to dopamine metabolism which may be important in the
mechanism of action of mood stabilizing drugs. These ﬁndings help to
broaden yet focus the search for the speciﬁc causes of mood disorders,
lead to the development of biomarkers and make way for novel
eﬀective treatments.
jS-12-002jLong term consequences of brain oxidative-stress
during early postnatal life
M. Behrens. Salk Institute, La Jolla, CA, USA
Objective : Through its involvement in the generation of gamma os-
cillatory activity, the fast-spiking parvalbumin-positive (PV+) neu-
ronal system is essential for shaping neuronal circuits during
postnatal brain development. Discrete functional disruptions in this
GABAergic system are expected to alter the excitatory/inhibitory
balance in brain and to produce cognitive deﬁciencies, as those ob-
served in schizophrenia. We have studied the postnatal develop-
mental periods in which a redox imbalance produced by NMDA
receptor antagonists leads to a permanent alteration of the PV+
neuronal system in the rodent cortex.
Methods : Our studies encompass molecular determinations, slice
electrophysiological recordings, and in vivo EEG recordings of mice
exposed to ketamine during the perinatal period. These data is then
used in computer simulation studies of prefrontal cortex function.
Results : Our work has shown that repetitive exposure of rodents
to ketamine during the perinatal period increases brain levels of IL-6
and activates the superoxide-producing enzyme NADPH oxidase
(Nox2). This, in turn, produces a lasting redox imbalance that leads
a permanent loss of PV and GAD67 expression in PV+ neurons, to a
decreased response of the interneurons to excitatory transmission and
to a diminished inhibitory drive to pyramidal neurons. At the systems
level, it leads to pronounced alterations in auditory evoked related
potentials, with decreased stimulus-induced gamma oscillatory ac-
tivity, and a shift in the evoked gamma/beta ratio. Computational
simulations that incorporate the reductions in PV and GAD67 ob-
served in the mouse model lead to networks showing a diminished
gamma-band oscillatory activity in response to stimuli, and to a re-
duced evoked gamma/beta ratio as observed in vivo.
Conclusion : Our data suggest that a period of oxidative-stress,
caused by activation of the IL-6/Nox2 pathway during early life,
may alter the normal development of PV+ neurons leading to the
alterations in gamma oscillatory activity observed in schizophrenia
patients.
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jS-12-003jOxidative stress in prefrontal cortical parvalbumin
interneurons in the neonatal ventral hippocampal
lesion model of schizophrenia
P. O’Donnell1, P. Piantadosi1, J.H. Cabungcal2, K. Do2. 1University of
Maryland, Baltimore, Md, USA ; 2University of Lausanne, Switzerland
Objective : Prefrontal cortical interneurons are aﬀected in a variety
of rodent models of schizophrenia, including the neonatal ventral
hippocampal lesion (NVHL) and genetic models. Together with post-
mortem studies showing altered markers related to GABA trans-
mission in the prefrontal cortex (PFC) of schizophrenia patients, these
ﬁndings suggest inhibitory interneurons in the PFC may become
aﬀected by many genetic and environmental factors during develop-
ment. As there is increasing evidence of redox dysregulation in
schizophrenia, we tested whether NVHL rats exhibit signs of oxidat-
ive stress in PFC interneurons and whether antioxidant treatment
improves outcome.
Methods : Sprague-Dawley rats received a bilateral injection
of ibotenic acid (lesion) or vehicle (sham) in the ventral hippocampus
at postnatal day (P) 6–7. Some rats received the antioxidant N-acetyl-
cysteine (NAC) between P5 and P56. Rats were euthanized and par-
valbumin (PV) cell counts were assessed with unbiased stereology ;
additional rats were tested for prepulse inhibition deﬁcits and elec-
trophysiological measures.
Results : Juvenile rats with a NVHL, but not sham controls, ex-
hibited high levels of the oxidative stress marker 8-oxo-DG but
no diﬀerences in PV staining. Most PV neurons exhibited 8-oxo-DG
staining, indicating this cell type is susceptible to oxidative damage.
At P61, we observed a marked reduction in parvalbumin labeling in
untreated NVHL PFC. NAC treatment reversed the deﬁcit in PV cells
as well as the PPI deﬁcits in NVHL rats.
Conclusion : The data indicate that a neonatal hippocampal lesion
has deleterious eﬀects on PFC development, yielding PV interneurons
with oxidative damage during the pre-pubertal stage and a loss of PV
labeling and behavioral deﬁcits in the adult stage, which are reversed
with antioxidant treatment. This suggests that PFC interneurons can
present oxidative stress in rodent models of schizophrenia, and this
could be the mechanism that renders them into a reduced level of
activity, eventually causing cognitive and other deﬁcits associated
with the disease.
jS-12-004jRedox dysregulation, inhibitory-excitatory
imbalance and myelination impairment in
schizophrenia
K. Do1, J.-H. Cabungcal2, P. Conus2, J.M. das Neves Duarte3,
R. Gruetter3, A. Kulak2, A. Monin2, P. Steullet2, M. Cuenod2.
1Lausanne University Hospital, Dept of Psychiatry, Prilly-Lausanne,
Switzerland ; 2Lausanne University Hospital, Prilly-Lausanne,
Switzerland ; 3Ecole Polytech. Fed. Lausanne, Switzerland
Objective : Glutathione (GSH), a major cellular redox regulator and
antioxidant, is decreased in chronic schizophrenia (SZ) patients.
Polymorphisms of key GSH-synthesizing enzyme genes, glutamate-
cysteine ligase catalytic and modiﬁer (GCLM) subunits, are associated
with SZ. GSH dysregulation was investigated now in early psychosis
patients (EP). Impaired GSH synthesis of genetic origin, when com-
bined with environmental risk factors generating oxidative stress,
may play a critical role in inducing connectivity anomalies, a hy-
pothesis tested in GCLM-/- mice (70% lower GSH).
Methods : In EP, GSH genes were genotyped and their expression
assessed in ﬁbroblasts. In GCLM-/- mice hippocampus (HP) and an-
terior cingulate cortex (ACC), morphology (oxidative stress, parval-
bumin immunohistochemistry of inhibitory interneurons [PVI],
myelin), electrophysiology (oscillations and synchronization), neuro-
chemical proﬁle (1H-MRS at 14.1Tesla) were assessed, as well as
behavior. A dopamine uptake inhibitor was used to model the impact
of environmental factors.
Results : In EP ﬁbroblast, mRNA decrease of GSH genes, observed
in chronic SZ, is conﬁrmed in EP, demonstrating that redox dysregu-
lation is not due to chronicity or treatment. Moreover, mRNA de-
crease of xCT, the exchanger Glu/Cyt, absent in chronic SZ, appears
in EP. GCLM-/- mice show morphological, physiological and beha-
vioral phenotypes similar to patients, including elevated oxidative
stress, impairment of PVI and b/c-oscillations in ventral HP. In ACC,
PVI formation is delayed. PVI are vulnerable to insults applied during
development but not in adulthood. Myelination is impaired.
Neurochemical proﬁle reveals increased Gln, Glu, Gln/Glu at peri-
pubertal age, as in EP. N-acetyl-cysteine, a GSH precursor and anti-
oxidant, reverses PVI and neurochemical anomalies.
Conclusion : Redox dysregulation is a critical SZ risk factor. In
GSH deﬁcit models, it leads to region and time selective oxidative
stress, Glu anomalies and impairment of structural and functional
integrity.
S-13. Molecular mechanisms and prophylaxis
in PTSD, contributions from prospective
and longitudinal studies
jS-13-001jBiological correlates of PTSD: From endocrinology
to molecular biology
R. Yehuda. New York, USA
Objective : Many endocrine and glucocorticoid alterations have been
examined with PTSD, prompting an interest in molecular biology.
Epigenetic and molecular mechanisms that may inﬂuence glucocorti-
coid alteration in PTSD. This study examined cytosine methylation of
the 1F exon on the human GR gene (NR3C1) and gene expression of
the GR related genes in order to determine the relevance of these
measures to PTSD risk, pathophysiology, or recovery.
Methods : Cytosine methylation of the GR gene along with other
neuroendocrine measures (cortisol, glucocorticoid receptor sensi-
tivity, and neuropeptide Y) were measured over time in association
with symptom change following prolonged exposure psychotherapy.
We will present data from 16 patients, all combat veterans, obtained
prior to treatment, at treatment end, and at follow-up.
Results : At treatment end, 50% of patients no longer met diag-
nostic critieria for PTSD. Treatment response was signiﬁcantly
predicted by cytosine methylation of the GR gene. Cytosine methyl-
ation, in turn, predicted neuroendocrine changes in urinary cortisol
excretion (which was signiﬁcantly elevated) and plasma neuropeptide
Y (also elevated) in responders compared to non-responders.
Conclusion : This is the ﬁrst study examining gene methylation and
expression cross-sectionally in PTSD in association with treatment. It
is also the ﬁrst to provide an indication that molecular mechanisms
associated with GR activity are involved in PTSD risk, pathophysiol-
ogy, and resilience. We conclude that the molecular biology of the GR
should be further examined as it may be a potential target for PTSD
prevention and treatment.
jS-13-002jTrue prospective studies in military cohorts ; central
and peripheral regulation of combat stress
E. Vermetten1, M. van Zuiden1, E. Geuze1, G. van Wingen2,
A. Rademaker1, A. Kavelaars3, G. Fernandez4, C. Heijnen1. 1UMC
Utrecht/Military Mental Health, Netherlands ; 2AMC Amsterdam,
Netherlands ; 3UMC Utrecht, Netherlands ; 4Donders Neuroscience Center,
Nijmegen, Netherlands
Objective : The course of central and peripheral regulation of severe
stress can provide information on preexisting vulnerability factors as
well as neuronal responsivity to severe stress. Prospective studies can
be informative in understanding trajectories of resiliency as well as
disease.
Methods : We conducted a large epidemiological study in
which functional stress-related biological parameters were used in
association with predicting PTSD symptoms prior to and on two
separate time points within the ﬁrst year after deployment. We also
looked at neural responsivity to salient stimuli with fMRI in similar
time course.
Results : Before military deployment, GR number in PBMCs was
signiﬁcantly higher in a group that, after deployment, developed
PTSD symptoms relative to matched comparison subjects. This was
maintained at 1 and 6 months after deployment. Also FKBP5 and
GILZ mRNA expression contributed as a predictor for PTSD symp-
toms in the total cohort. Amygdala reactivity to salient stimuli was
correlated to high threat perception during deployment, in compari-
son to a group that was not deployed during the same time period.
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This normalized in the ﬁrst year after deployment. Yet, we observed
persistent changes in amygdala-dACC connectivity.
Conclusion : The results from this study have enhanced our ability
to understand biological concomitants of vulnerability and resilience.
Preexisting high GR number in PBMCs as well as FKBP5 and GILZ
mRNA expression are vulnerability factors for subsequent develop-
ment of PTSD symptoms. Central regulation of combat stress at the
level of the amygdala appeared highly plastic and adaptive to en-
vironmental demands. We speculate that a normalization failure may
underlie the pathophysiology of PTSD which is presumably related to
preexisting vulnerabilities.
jS-13-003jHydrocortisone in the golden hours and PTSD
trajectory – Clinical and animal studies
J. Zohar. Tel Hashomer, Israel
Objective : Animal studies and anecdotal human case reports point
out the importance of adaptive response of the HPA axis in response
to traumatic events. Along these lines, it is possible that the adminis-
tration of cortisol immediately after exposure (in the ‘‘golden hours’’)
to a trauma might alter the trajectory of trauma exposure by promot-
ing recovery. A series of studies using a well-validated animal model
for PTSD demonstrated a greater susceptibility to experimentally in-
duced PTSD-like behavioral changes in rats with hypoactive/reactive
vs. hyperactive/reactive HPA axis, i.e., Lewis strain vs. Fischer strain.
Exogenous administration of cortisol to Lewis rats prior to the stressor
signiﬁcantly reduced this diﬀerence. Further animal studies examined
the eﬀect of a single intervention with high-dose corticosterone im-
mediately after exposure to a stressor. A signiﬁcant reduction in the
incidence of PTSD-like behaviors and improved resilience to sub-
sequent trauma was observed.
Methods :We conducted a double blind, placebo-controlled clinical
pilot study, in which patients were randomly assigned to one of two
treatment groups : placebo or hydrocortisone treatment (100–140 mg
iv, injected 1.5–5.5 hours following the traumatic event).
Results : Results based on 2-week and 3-month follow-up support a
potential therapeutic role for administration of hydrocortisone in the
‘‘golden hours’’.
Conclusion : Potential interventions, once explored in a systematic
way in an animal model can then, via a process of translational re-
search, be implemented into the clinical arena. Early intervention
after psychological trauma is an area which may speciﬁcally beneﬁt
from translational research. Changing the focus from treatment once
PTSD is already established to secondary prevention of PTSD in the
‘‘window of opportunity’’ – the ﬁrst few hours after exposure to a
traumatic event – has opened the door to new exciting possibilities in
PTSD research and treatment.
Policy of full disclosure : Prof. Zohar has received research fund-
ing from Lundbeck, Servier and Pﬁzer, and has been a speaker/
consultant for Lundbeck, Servier, Pﬁzer, Abbott, Pierre Fabre, BMS
and Roche.
jS-13-004jProspective study of risk and resilience factors for
posttraumatic stress in police oﬃcers
C. Marmar. New York, USA
Objective : Results will be presented on a prospective longitudinal
study of risk and resilience for PTSD symptoms in 400 police academy
recruits, assessed during academy training and followed during the
ﬁrst 7 years of police service.
Methods : Utilizing Latent Growth Mixture Modeling (LGMM) we
have established three symptom trajectories, highly resilient, initially
distressed with gradual improvement and increasing distress.
Results : We will present ﬁndings on the relations of the following
predictors ascertained during academy training to the three PTSD
symptom trajectories : I.Q., family histories of anxiety, depression,
alcohol and drug abuse, neuroticism, personal histories of childhood
or adolescent traumatic exposure, levels of awakening cortisol, fear-
potentiated acoustic startle, MHPG and cortisol responses to a critical
incident video challenge, sleep quality as measured by actigraphy,
and candidate polymorphisms including serotonin transporter
(SLC6A4), adrenergic pathway genes, (ADRB1, ADRB2, ADRA2C),
brain derived neurotrophic factor gene (BDNF), genes for several
critical components of the HPA axis such as the glucocorticoid re-
ceptor (NR3C1), CRH receptor 1 (CRHR1), and FK506 binding protein
5 (FKBP5) and Catechol-O-methyltransferase (COMT). Mulivariate
models of risk and resilience will be presented utilizing a multinomial
logistic regression nested in the unconditional LGMM.
S-14. Pharmacogenomics and personalised
medicine in psychiatry: Prospects for
clinical implementation
jS-14-001jGenomics of response and side eﬀects of
antipsychotics
D. Rujescu. University of Munich, Dept. of Psychiatry, Germany
Objective : A major drawback of the therapy with antipsychotics
is the lack of eﬃcacy and the occurrence of extrapyramidal symptoms
(EPS) in some patients that can both limit therapy and compliance.
Thus, the availability of a predictive tool for response to anti-
psychotics is desirable.
Methods : To search for genes associated with response to anti-
psychotics or EPS, a hypothesis free approach was used including
animal models, neuronal cell cultures, and diﬀerential gene ex-
pression analyses. Immunohistochemical analyses were performed in
rats that received an agent mimicking aspects of psychosis (MK-801),
haloperidol, a combination of these agents, or saline. Genes diﬀeren-
tially expressed between the diﬀerent groups had been genotyped
in one hundred four patients with acute psychosis (schizophrenia,
schizoaﬀective, brief psychotic, and substance-induced psychotic
disorder) treated with haloperidol for up to 28 days. Diagnosis was
established by applying the SCID I and II interview. Patients were
assessed at baseline and on days 3, 7, 14, 21 and 28. Improvement and
response were measured by using the Positive and Negative
Syndrome Scale.
Results : Furthermore, genome wide studies were performed for
parkinsonism, dyskinesia and akathisia.
Conclusion : Dan Rujescu will present novel data on this ongoing
genetic study on response to haloperidol and discuss that in the con-
text of the literatur.
jS-14-002jPharmacogenetics of antidepressant therapies
A. Serretti. University of Bologna, Italy
Objective : The response to antidepressant treatment is still un-
satisfactory : about 40–50% of depressed patients do not respond to
ﬁrst antidepressant and about 60% do not reach remission at all.
Evidence suggests that genetic factors contribute for about 50% of
the antidepressant response therefore the knowledge of the patient
genetic proﬁle may lead to an individualized therapy in the next
years.
Results : Several gene variants have been reported in association
with short term antidepressant response. A growing number of
evidence has been reported for the functional polymorphism in the
upstream regulatory region of the serotonin transporter gene
(5-HTTLPR), particularly l allele has been associated with a better
response in Caucasian. A signiﬁcant number of replication ﬁndings
are present in literature also for 5-HT2a, 5-HT1a, BDNF, COMT,
MAOA, NET, Gbeta3, FKBP5, Pgp, TPH, ACE and GSK-3b variants,
although an high number of failure of replication is reported for
these genes. Furthermore new candidate genes have been recently
identify through the genome-wide scan approach and multi-sites
projects like STAR*D and GENDEP. Among these the more promising
are GRIK4, GRIK2 and DTNBP1. A pathway analysis performed by
us on the large STAR*D and STEPBD databases yielded promising
results.
Conclusion : Until now genetics was not able to predict the overall
response to antidepressant. However there are increasing evidences
of a genetic modulation on treatment response, both directly and
through a modulation or an interaction with clinical variables that
could inﬂuence the response to antidepressant, like personality and
social modulators.
Policy of full disclosure : Dr. Serretti is or has been consultant/
speaker for : Abbott, Astra Zeneca, Clinical Data, Boheringer, Bristol
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Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Lundbeck, Pﬁzer,
Sanoﬁ, Servier.
jS-14-003jPharmacogenomics of nicotine addiction
B. Lerer1, L. Greenbaum1, K. Sarner1, A. Rigbi1. 1Hadassah-Hebrew
Univ Med Ctr, Jerusalem, Israel
Nicotine dependence (ND) is a complex, multifactorial phenotype,
in which both genetic and environmental factors are involved. The
heritability of ND is estimated at more than 50%. Due to their
prominent biological relevance, brain nicotinic acetylcholine receptor
(nAChR) – encoding genes are among the most widely studied can-
didate genes for ND. Traditionally, much attention has been paid
to two nAChR genes, encoding the alpha4- and beta2-subunits re-
spectively. However, the focus has shifted substantially in the last
few years with the discovery of the major contribution of the chro-
mosome 15q24 nAChR gene loci, CHRNA5-CHRNA3-CHRNB4, to
several smoking phenotypes as well as to substance abuse in general.
At least three common independent ND risk variants located within
these loci are associated with several ND-related phenotypes, each
with a small eﬀect size. The association results are robustly supported
by multiple replications in various populations. Less clear, however,
is their association with smoking cessation in pharmacogenetic trials.
One of the ND associated SNPs, rs16969968, changes an amino acid
in the CHRNA5 protein, and thus alters the electrophysiological
properties of the nicotinic receptor. Other associated SNPs may in-
ﬂuence receptor expression level. Many interesting questions are
currently emerging, such as the possible inﬂuence of rare variants
within the loci on the phenotype, relation of ND genetic risk variants
to lung cancer susceptibility and interaction with other genes and
environmental factors. On the other hand, functional biological
understanding of the novel genetics ﬁndings is relatively limited
and translational approaches are needed (for example, in transgenic
mouse models), exploration of the interaction of these gene variants
with environmental factors and their role in cognitive processes
inﬂuenced by nicotine. Findings may have important implications
for the neurobiological understanding of addiction, as well as for
the development of pharmaceutical agents to aid in nicotine with-
drawal.
jS-14-004jThe role of leptin in the pharmacogenomics of
obesity
M.-L. Wong. John Curtin Institute, ANU, Canberra, Australia
Objective : Pharmacogenomics is based on the premise that genomic
heterogeneity will be reﬂected in treatment heterogeneity. Common
and complex disorders such as obesity are the outcome of genetic and
environmental factors. Each person has diﬀerent contributions of
genetics and environmental to their body weight. In obesity, 3 to 5%
of cases are due to genes of major eﬀect. In those situations the eﬀect of
a genetic mutation overrides environmental eﬀects. Such is the case
with functional mutations of the leptin gene. Leptin is an adipokine
that is synthesized principally by white fat and for which there are
receptors in the brain. It send a satiety signal to the central nervous
system by activating anorectic pathways, mediated by POMC and
MC4-R, and by suppressing oxeregenic pathways, mediated by NPY
and AgRP. Leptin is also a trophic factor for the maturation of the
reproductive system.
Methods : We have studied a Turkish family with a Mendelian re-
cessive missense mutation in the leptin gene that results in the same
truncated and non-functional molecule as that found in the ob/ob
mouse. Those patients were morbidly obese and hypogonadic, with a
body mass index (BMI) of 50.
Results : Treatment with recombinant human leptin, while not
generally eﬀective for obesity, had a major eﬀect in those patients and
drastically reduced their weight and brought about normalization of
reproductive function.
Conclusion : Our results show that indeed genetic heterogeneity
is the basis of treatment heterogeneity in the therapeutics of
obesity.
S-15. Oxytocin in normal and abnormal
psychology: Promises and caveats
jS-15-001jOxytocin increases the salience of social agents :
Evidence from psychopathology
S. Shamay-Tsoory. University of Haifa, Israel
Objective : Recent classes of theories explaining the role of oxytocin in
social behavior have focused mainly on prosocial positive behaviors
such as trust, generosity and empathy. A plausible hypothesis sug-
gested here is that oxytocin has a general eﬀect on increasing the
salience of social agents, and therefore administration of oxytocin may
provoke a wide range of emotions and behaviors related to social be-
havior. To show that oxytocin is involved mainly in increasing the
salience of social agents we conducted two experiments that ex-
amined the eﬀects of oxytocin on competitive as well as collaborative
behaviors.
Methods : In the ﬁrst experiment we investigated the inﬂuence of a
single intranasal administration of oxytocin on cooperative behavior.
Cooperation was assessed using a computerized drawing task (a co-
ordinated Etch a Sketch game) which required participants to work
together in coordination with each other. In the second experiment
participants played a game of chance with another (fake) participant
who won more money (envy manipulation), lost more money (scha-
denfreude manipulation) or won/lost equal amounts of money.
Results : In the ﬁrst experiment we demonstrate that the adminis-
tration of oxytocin improves subject’s accuracy in the cooperation task
when completing the task in the couple condition, as compared to the
performance of the same subjects subsequent to the administration of
placebo. In the second experiment, oxytocin, compared with placebo,
had an eﬀect of increasing envy ratings during unequal monetary
gains conditions involving relative loss and increased ratings of
gloating during relative gain conditions.
Conclusion : It is concluded that rather than being involved solely
in positive prosocial behaviors (as believed so far), the oxytocinergic
system probably plays a key role in a wider range of social emotion-
related behaviors.
jS-15-002jOxytocin modulates cooperation and competition
within and between groups
C. de Dreu. University of Amsterdam, Netherlands
Objective : Examines the possibility that hypothalamic release
(or infusion) of the neuropeptide oxytocin modulates the regulation
of cooperation and conﬂict among humans.
Methods : Reviews research programs focusing on eﬀects of
intranasal administration of oxytocin (v.s placebo) in healthy volun-
teers.
Results : First, oxytocin enables social categorization of others
into in-group versus out-group. Second, oxytocin dampens amygdala
activity and enables the development of trust. Third, and ﬁnally,
oxytocin up-regulates neural circuitries (e.g., inferior frontal gyrus,
ventromedial prefrontal cortex, caudate nucleus) involved in empathy
and other-concern.
Conclusion : Consistent with an evolutionary perspective on
the functionality of cooperation, oxytocin-motivated cooperation is
mostly parochial—it motivates (i) in-group favoritism, (ii) cooperation
towards in-group but not out-group members, and (iii) defense-mo-
tivated non-cooperation towards threatening outsiders. In addition to
its well-known role in reproduction and pair-bond formation, oxyto-
cin’s primary functions include in-group ‘‘ tend-and-defend.’’
jS-15-003jOxytocin treatment in schizophrenia reduces
psychotic symptoms and improves theory of mind
and social perception
C. Pedersen1, S. Rau1, K. Salimi1, C. Gibson1, J. Leserman1, D. Penn1.
1University of North Carolina, Chapel Hill, USA
Objective : Because oxytocin (OT) has prosocial and antipsychotic-
like eﬀects in animals and recent human studies, we hypothesized
that a trial of OT treatment would reduce social cognition deﬁcits as
well as psychotic symptoms in schizophrenia.
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Methods : A double blind study compared twice daily intranasal
OT (24 IU/dose, N=14) vs. placebo (N=11) for 14 days on social
cognition tests, PANSS scores and Paranoia Scale self-ratings.
Subjects’ symptoms (PANSS>60) and psychotropic medications were
stable for>1 month prior to starting the treatment trial and medica-
tions were unchanged during the trial.
Results : From baseline to treatment day 14, the OT group : 1) sig-
niﬁcantly increased accuracy in recognition of 2nd and 3rd order false
belief on the Bru¨ne Theory of Mind Task ; 2) trended toward greater
accuracy in recognizing deception on the Bru¨ne Task and more
trustworthy ratings of faces on the Trustworthiness Task. Also, mean
scores on PANSS social items (suspiciousness, hostility, social with-
drawal [passive/apathetic, active], uncooperativeness) declined
dramatically. There were signiﬁcant reductions in PANSS total, posi-
tive, negative and general subscale scores, the individual suspicious-
ness and anxiety item scores as well as Paranoia Scale scores. In the
placebo group, only PANSS suspiciousness and anxiety item scores
declined signiﬁcantly. ANCOVAs controlling for baseline revealed
that the OT group vs. placebo group had signiﬁcantly greater declines
in PANSS total scores and trends toward greater declines in PANSS
mean social item and positive subscale scores.
Conclusion : Enhancement of social cognition suggests that OT
treatment may improve social dysfunction, which responds poorly
to antipsychotic medications and is the major cause of disability in
schizophrenia. OT may augment antipsychotic eﬃcacy and should be
tested as a monotherapy for schizophrenia. Our results indicate that
OT may play an important role in the pathophysiology of psychotic
symptoms in schizophrenia and associated social cognition and social
function deﬁcits.
jS-15-004jDoes oxytocin have a role in borderline personality
disorder?
M. Bru¨ne1, A. Ebert1. 1Ruhr-University Bochum, Germany
Objective : Oxytocin (OT) is an evolutionarily conserved nonapeptide
which attenuates fear responses, improves empathy, exerts major
eﬀects on pair-bonding and attachment, and has the potential to im-
prove trust and reciprocity. With regard to borderline personality
disorder (BPD), a recent study reported that stress reactivity im-
proved upon administration of OT, whereas another study demon-
strated that trust and cooperation decreased in patients with BPD as a
function of anxious-ambivalent attachment. Accordingly, we sought
to examine interpersonal perception and the processing of threat in
BPD under OT compared to placebo.
Methods : Twenty patients with BPD and 20 matched healthy
controls received OT versus placebo in a randomized controlled
double-blind trial. Threat processing was examined using a dot probe
task. Interpersonal perception was assessed using the Interpersonal
Perception Task.
Results : Preliminary analyses show that patients with BPD process
social stimuli diﬀferently compared to controls.
Conclusion : OT may have diﬀerential eﬀects depending onn per-
sonality variable, and does not unequivocally act in a ‘‘prosocial ’’
manner.
S-16. Alpha7 nicotinic acetylcholine receptors
in dementia and other brain disorders :
From bench to bedside
jS-16-001jAlpha 7 nicotinic acetylcholine receptor crosstalk
with the lipid microenvironment in health and
disease
F. Barrantes. National Science & Technology, Res. Council (CONICET),
Bahı´a Blanca, Argentina
The homomeric alpha7-subtype of nicotinic acetylcholine receptors
(AChR) is one of the pentameric ligand-gated ion channels that
mediate fast synaptic transmission. It is broadly distributed in the
central nervous system, where it plays important roles in synaptic
signaling, neurite outgrowth, synaptic plasticity, learning, memory
formation and neuroprotection, and constitutes an important target for
the treatment of cognitive deﬁcits in schizophrenia and Alzheimer’s
disease (AD). The alpha7 AChR is highly expressed in brain regions
relevant to cognitive and memory processing. The alpha7 AChR
subunit gene (CHRNA7) is located in the highly duplicated 15q13–q14
region implicated in several neuropsychiatric diseases, including
schizophrenia and bipolar aﬀective disorder. Postmortem brains
show decreased amounts of AChRs in AD patients ; the most vulner-
able neurons appear to be those expressing high levels of alpha7
AChR. In cortical neurons, alpha7 AChRs are expressed post-
synaptically at over 70% of synapses, where they may regulate glu-
tamate receptor traﬃcking. There is increasing evidence showing a
misregulation of lipid, and in particular cholesterol metabolism in the
development of AD. Since cholesterol aﬀects the AChR protein at
multiple levels (distribution in the membrane, degree of aggregation,
endocytosis, association with the cytoskeleton, traﬃcking, single-
channel conductance) we have speculated that some of the neuro-
logical correlates of AD might be partly associated with abnormal
crosstalk between the receptor protein and the sterol in this synapto-
pathy (see e.g. Barrantes, Valles and Borroni, FEBS Lett. 584 (2010)
1856–1863).
jS-16-002jAlpha7 nicotinic receptors as important targets
for neuroprotective mechanisms in new drug targets
for Alzheimer’s disease
A. Nordberg1, A. Lilja2, R. Ni2, L. Voytenko2, P.-G. Gillberg2,
A. Marutle2. 1Karolinska Institutet, Div. Alzheimer Neurobiology,
Stockholm, Sweden ; 2Karolinska Institutet, Stockholm, Sweden
Objective : The neuronal acetylcholine receptors (nAChRs) play
an important role in cognitive processes in brain regulating and
modulating several neurotransmitters. The nAChRs also seem to be
involved in pathological processes as amyloid (Ab) toxicity in
Alzheimer´s disease (AD).
Methods : Fibrillar Ab was measured using 3H-PIB binding, astro-
cytes using 3H-Deprenyl and 131-I-Bungarotoxin in AD autopsy brain
tissue.Fibrillar and oligomeric and its interactions with Ab and with
a7 nAChRs and a7 nicotinic agonists were characterized in PC cells.
Results : Binding studies showed a signiﬁcant negative correlation
between regional 3H-nicotine binding (a4b2 nAChRs) and deposition
of ﬁbrillar (Ab (3H-PIB binding) in autopsy AD brains (Kadir et al.,
2011). Fibrillar Abmay at least partly exert its toxic eﬀect by forming a
complex and blockade of a7 nAChRs while oligomeric Ab may in-
stead act as ligand activating a7 nAChRs (Lilja et al., 2011). The a7
nAChR agonist JN403 as well as the partial a7 nAChR agonist var-
enicline but not the a4 nAChR agonist cytosine induced an increase in
the 3H-PIB binding in AD autopsy brain tissue homogenates as a sign
for interaction and release of Ab from preformed complex Ab/nAChR
compex (Ni et al., submitted). The a7 nAChRs are also found in astro-
cytes and thereby also related to neuroinﬂammatory processes in AD.
Conclusion : Activation of a7nAChRs might be a promising strat-
egy to prevent Ab toxicty and obtain neuroprotective eﬀects in early
stages of AD. Kadir A et al., Brain 2011 ;134 : 301–317. Lilja AM et al.,
J Alzheimers Dis 2011 ;23 : 335–347.
jS-16-003jNeuronal circuits and mechanisms involved in the
cognitive enhancing properties of a7 nicotinic
acetylcholine receptor (nAChR) modulators
J. Mikkelsen1, M.S. Thomsen2, K. Alexander3, M. Pershing4, D. Bortz4,
R. Schwarcz5, J.P. Bruno4. 1Center Integrated Molecular, Brain Imaging,
Copenhagen, Denmark ; 2Neurobiology Research Unit, University Hospital
Copenhagen, Copenhagen O, Denmark ; 3Dept Psych Neuroscience,
The Ohio State University, Columbus, USA ; 4Dept Psychol Neurosci,
The Ohio State University, Columbus, USA ; 5Maryland Psych Res Ctr,
University of Maryland, Baltimore, USA
Objective : Alpha7 nicotinic acetylcholine receptor (nAChR) selective
agonists have been reported to exhibit pro-cognitive eﬀects in patients
with schizophrenia (SCZ). We have carried out behavioural, bio-
chemical and neuroanatomical studies in the rat to investigate the
neuronal systems and mechanisms involved in this eﬀect.
Methods : Systemic administration of kynurenine (KYN, 100 mg/
kg, ip), the precursor of kynurenic acid (KYNA, an endogenous,
astrocyte-derived, antagonist of a7nAChR whose levels are increased
in the brains of schizophrenics), produced selective deﬁcits in the initial
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reversal and extra-dimensional shift stages of an attentional set-
shifting task. These deﬁcits mirror the performance of patients with
SCZ in such tasks.
Results : Pre-treatment with the a7nAChR agonist SSR180711
(3 mg/kg, ip) returned the performance of KYN-treated rats back
to control levels. Performance in this task is highly dependent on
increases in glutamatergic and cholinergic transmission within the
prefrontal cortex (PFC). However, the mechanisms within the PFC
through which these a7nAChR modulators work to enhance per-
formance are poorly deﬁned. Systemic administrations of a number of
a7 nAChR agonists produce an increase in c-Fos activation in the
prelimbic region of the PFC as well as in cholinergic cells of the basal
forebrain projecting directly to the PFC. This increase in gene ex-
pression is mediated via the cholinergic neurons in the basal fore-
brain, because a selective lesion of the cholinergic input to the PFC
eliminates c-Fos induction after administration of an a7nAChR
agonist. Furthermore, intra-PFC infusion of SSR180771 led to a dose-
dependent increase in local extracellular glutamate as measured by a
microelectrode array.
Conclusion : The a7 nAChR-dependent increases in prefrontal
acetylcholine and glutamate may be critical components of the pro-
cognitive eﬀects of SSR180711 in KYN-treated rats. These data further
support the potential value of the a7nAChR as a therapeutic target
for the development of drugs to treat the cognitive deﬁcits associated
with SCZ.
jS-16-004jAlpha7 nicotinic acetylcholine receptors as a
potential target for imaging of brain disorders
with positron emission tomography
P. Brust1, G.M. Knudsen2, J.D. Mikkelsen2, A. Ettrup2, W. Deuther-
Conrad1, D. Peters3. 1Helmholtz-Zentrum Dresden, Leipzig, Germany ;
2University of Copenhagen, Denmark ; 3NeuroSearch A/S, Ballerup,
Denmark
S-17. Neurodevelopmental bases for progress
in pharmacotherapy in autism spectrum
disorders
jS-17-001jNeurophysiological biomarker of impaired social
interaction in ASD
K. Yui1, M. Koshiba2, S. Nakamura2. 1Ashiya University, Japan ; 2Tokyo
University of Agricultur, Koganei, Japan
Objective : The core symptoms of Autism spectrum disorders (ASD)
(i.e., impaired social interactions ; communication, and restricted and
repetitive patterns of interests and behavior) can be attributed to the
impaired delivery of aﬀerent signals To understand neuropathologi-
cal underpinnings of ASD, it is important to specify clear biomarkers
of neurobiological abnormalities. Our original integrated multivariate
analysis of the neuropsychological cues may be useful in diagnosis for
ASD. Furthermore, we tried arachidonic acid as supplementation
since this has neuronal signal transduction eﬀect.
Methods : The core symptoms of Autism spectrum disorders (ASD)
(i.e., impaired social interactions ; communication, and restricted and
repetitive patterns of interests and behavior) can be attributed to the
impaired delivery of aﬀerent signals To understand neuropathologi-
cal underpinnings of ASD, it is important to specify clear biomarkers
of neurobiological abnormalities. Our original integrated multivariate
analysis of the neuropsychological cues may be useful in diagnosis for
ASD. Furthermore, we tried arachidonic acid as supplementation
since this has neuronal signal transduction eﬀect.
Results : The 7 individuals with ASD exhibited increases of pre-
frontal EEG b spectrum power and the standard deviation of the
head surface temperature based on IRS in response to unfamiliar
male approach, which reﬂect heightened central nervous system
arousal. While, plasma prolactin and cortisol levels didn’t increase.
Our supplementation regimen improved the repetitive and stereo-
typed interests and behavior, and the impaired communication
(Yui K). Improvement of neurophysiological function by ARA re-
mains to be clariﬁed.
Conclusion : The neurophysiological responses to unfamiliar adults
may reﬂect functional vulnerability of the limbic system relevant
to relevant to social cognition. Altered signal transduction might
contribute to pathophysiology of impaired social interaction in
individuals with ASD.
jS-17-002jThe predictive value of multiparameter image of
whole-brain structures in autism spectrum disorders
C. Ecker. Section of Brain Maturation, Institute of Psychiatry, London,
United Kingdom
Objective : The objective of this research was therefore to characterize
the complex and subtle structural pattern of gray matter abnormalities
in adults with ASD on the basis of multiple morphometric parameters,
and to disentangle spatially distributed patterns of regional diﬀer-
ences with potentially diﬀerent neuropathological underpinning.
Furthermore, we aimed to examine the predictive value of individual
morphometric parameters for group membership (i.e. diagnostic
value).
Methods : Structural MRI data was collected on 20 well-character-
ized male adults with ASD, and 20 age/IQ matched healthy controls.
All individuals with ASD met algorithm cut-oﬀs for ASD on both
the ADI & ADOS. For each participant, a set of 5 morphological
parameters including both volumetric and geometric features were
obtained at each spatial location on the cortical surface (i.e. vertex)
was obtained using FreeSurfer software. This set of measures was
then used to (1) discriminate between individuals with ASD and
controls using a Support Vector Machine analytical approach, and to
(2) ﬁnd a spatially distributed pattern of regions with maximal dis-
criminative power.
Results : SVM achieved good separation between ASD and control
group and was able to identify individuals with ASD at a sensitivity
and speciﬁcity of up to 90% and 80% respectively using cortical
thickness. In addition, SVM revealed spatially distributed, indepen-
dent patterns of regions with maximal discriminative power for each
of the ﬁve morphometric features describing brain volume and geo-
metry. For all parameters, the left hemisphere provided higher
classiﬁcation values than the right hemisphere.
Conclusion : Our results conﬁrm the hypothesis that the neuro-
anatomy of ASD is truly multi-dimensional. These diﬀerences also
provided signiﬁcant predictive power for group membership, and
could thus be used as a potential biomarker for ASD. The spatial
patterns detected using SVM may also help further exploration of the
speciﬁc genetic and neuropathological underpinnings of ASD, and
provide new insights into the most likely multi-factorial aetiology of
the condition.
jS-17-003jNeurobiological marker in ASD
R.L. Davis. Neuroinﬂammation Research, Laboratory, Tulsa, USA
Objective : We are particularly interested in mercury-induced eﬀects
on neuroimmune signaling given that mercury exposure and neuro-
inﬂammation are both implicated in autism. Thus, our studies are
focused on the hypothesis that environmental triggers of autism are
mediated through disruption of neuroimmune signaling.
Methods : We utilized the prairie vole as an animal model. Prairie
voles have been used extensively to study the physiological and
neurochemical underpinnings of social behaviors. Prairie voles are
highly social and there social behaviors are remarkably similar to
those of humans. However, their preference for social proximity is
quite sensitive to exposure to environmental toxins. Adult prairie
voles were chronically exposed to 60 ppm HgCl2 in drinking water
for 10 weeks. Mercury was therefore used as a tool to induce a male-
speciﬁc change in social behavior as a model for autism-like behavior.
Following mercury exposure, social behavior was assessed ; then
brain tissue was collected and cytokine/chemokine protein ex-
pression measured in select brain regions by ELISA.
Results : Following chronic mercury exposure, these normally
highly social animals avoided strangers and displayed social with-
drawal. Importantly, these social deﬁcits were more prevalent in male
voles than they were in females. Additionally, chronic mercury ex-
posure resulted in a male-speciﬁc, increase in TNFb protein ex-
pression in the cerebellum and hippocampus ; whereas, chemokine
(CCL2 and CXCL10) expression was not aﬀected by mercury
exposure.
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Conclusion : Further investigation is expected to more fully
deﬁne the brain regions, cell types and immune factors involved in
the altered neuroimmune signaling. Together, these ﬁndings are ex-
pected to lend insight into the role of altered neuroimmune signaling
in autism.
jS-17-004jDisrupted Cortical Connectivity as a Neural
Signature of Autism Spectrum Disorders
R.K. Kana. UAB Civitan International Research, Center, CIRC 235G,
Birmingham, USA
Objective : The main objective of this set of studies is to characterize
the brain structure, function, and connectivity in autism spectrum
disorders.
Methods : Functional MRI and Diﬀusion Tensor data were collected
from several participants (adults and children) with autism spectrum
disorders. The tasks mainly focused on theory-of-mind, emotion rec-
ognition, action understanding, and resting state.
Results : In addition to decreased engagement of critical brain areas
in autism, such as the mirror neuron system, theory-of-mind network,
and cortical midline structures, we found disrupted connectivity
across several brain areas. Functional and anatomical under-
connectivity were found primarily in long-distance connections, and
overconnectivity was found in short-distance or local connections,
especially in frontal and in relatively posterior brain areas.
Conclusion : Overall, the results of these studies point to
disrupted cortical connectivity as a characteristic feature of the brain
in autism.
S-18. Fatigue syndrome in psychiatry. Novel
understanding and treatments
jS-18-001jThe psychiatrist confronted with a chronic fatigue/
ﬁbromyalgia patient
S. Kasper. Medical University of Vienna, Department of Psychiatry,
Austria
Objective : Fibromyalgia/chronic fatigue patients are usually treated
by rheumatologists and/or neurologists but since there is frequently
comorbid depression and anxiety, psychiatrists are likely to be con-
fronted with patients suﬀering from ﬁbromyalgia. However, the
patients do not want to be a ‘‘psychiatric case’’ and therefore a
neurobiological approach has been reported to be most successful.
The symptoms associated with ﬁbromyalgia/chronic fatigue vary
from person to person but there is one common syndrome – they ache
all over, demonstrate fatigue and have diﬃculties concentrating. The
pain can be a deep ache, a stabbing or burning pain or a tingling
sensation. Pain can be mild at times but in other moments so severe
that it becomes unbearable. In addition to pain, patients report fati-
gue, headaches, poor sleep, depressed mood, and irregular bowel
habits, which are all also symptoms of depression.
Methods : For a formal diagnosis of ﬁbromyalgia the ACR
(American College of Rheumatology) criteria require the patient to
have widespread pain for at least 3 months together with tenderness
in at least 11 of 18 speciﬁc tender points.Treatment of ﬁbromyalgia
requires a comprehensive approach involving education, aerobic ex-
ercise, physiotherapy and cognitive behavioural therapy in addition
to pharmacotherapy.
Results : The most eﬀective drugs available (or will shortly be
available) for the treatment for ﬁbromyalgia are amitriptyline, the
selective serotonin-noraepinephrine reuptake inhibitors (SNRIs), mil-
nacipran and duloxetine and the anti-epileptic, pregabalin, are all well
known to psychiatrists.
Conclusion : Improvement in pain severity is a key element of re-
sponse to a treatment programme but reduction of other symptoms of
the Fibromyalgia Inventory Questionnaire including fatigue, poor
concentration, stiﬀness, anxiety and depression are also essential in-
dicators of the patient’s improvement.
Policy of full disclosure : Siegfried Kasper received grants/
research support, consulting fees and honoraria within the last
three years from AstraZeneca, Bristol-Myers Squibb, CSC, Eli Lilly,
GlaxoSmithKline, Janssen, Lundbeck, Merck Sharp and Dome (MSD),
Novartis, Organon, Pierre Fabre, Pﬁzer, Schwabe, Sepracor, Servier,
Wyeth.
jS-18-002jTreating CFS – it may not be rocket science, but at
least it works
S. Wessely. Academic Department of Psychological Medicine, London,
United Kingdom
Chronic fatigue syndrome (CFS) has an undeserved reputation for
being diﬃcult or impossible to treat, which allows a wide variety of
unorthodox and sometimes unscrupulous treatments to ﬂourish at the
literal and metaphorical expense of patients. However, a long pro-
gramme of work over two decades, culminating in the recent Lancet
multi centre large PACE trial, now provides compelling evidence that
neither nihilism nor opportunism is necessary. There are now two
rehabilitative treatments that are both safe and eﬀective. Neither are
perfect, but then not much in medicine is. Both can be recommended
now to patients as the best currently available options. I shall review
the evidence for both, and show how non expert practitioners can use
basic CBT principles in clinical practice.
jS-18-003jThe concept of ‘Mental Fatigue’ in a broader
dimensional context
C. Tamminga. USA
Psychiatric nosology is being encouraged these days to become
dimensional in its organization and to consider cognitive and aﬀective
disease symptoms as altered and pathological dimensions of normal
brain functions. The NIMH has designed and discussed a system call
the RDoCs approach, a system that will encourage a biological con-
nection and formulation for all diseases of the brain. The RDoCs ap-
proach has already generated a set of dimensions of function, along
with a unique anatomy, physiology and potential pharmacology for
the dimensions. Along this continuum of function and dysfunction,
the task for any single syndrome is to ﬁt its primary symptoms into
the deﬁned dimensions. For a syndrome like ‘‘Mental Fatigue’’ this
is a most useful and clarifying exercise. In this talk, I will suggest a
framework for deﬁning the intermediate phenotypes of mental fatigue
in dimensional constructs. It will suggest its relationships to other
psychiatric disease constructs and to behavioral aspects of medical
disease diagnoses. These relationships might suggest new formula-
tions for pathophysiology and certainly for treatments.
jS-18-004jEﬀect of the dopamine stabilizer OSU 6162 on
mental fatigue in neurological patients
A. Carlsson. Go¨teborg, Sweden
Objective : The (-)-enantiomer of OSU6162 is a phenylpiperidine
derivative characterized as a dopamine stabilizer, given its aﬃnity for
dopamine D2 receptors leading to mixed activating and inhibitory
eﬀects on behavior. More recently this compound has also been found
to be a partial agonist on a number of serotonergic receptors, which
further contributes to its behaviorally stabilizing properties. Early
clinical studies have shown beneﬁcial actions in patients with
Parkinson’s disease, Huntington’s disease, schizophrenia, and metal
fantigue. The present report deals with the actions of this agent in
patients with mental fatigue of long duration following upon stroke
or traumatic brain injury (TBI).
Methods : OSU6162 was given orally for four weeks in doses in-
creasing from 15 to 45 mg b.i.d. to twelve patients suﬀering from
mental fatigue, following upon stroke (N=6) or TBI (N=6). OSU6162
was compared with placebo using a double-blind, randomized cross-
over design. Patients included were well rehabilitated physically with
no gross impairment in cognitive functions other than those related to
the mental fatigue.
Results : OSU6162 caused a remarkable improvement in mental
stamina, as evaluated by a self assessment scale on mental fatigue.
Statistical signiﬁcance was reached on the primary end-point (Mental
Fatigue Scale). Principal component analysis demonstrated an overall
positive treatment eﬀect in seven of 12 patients. Beneﬁcial responses
were seen already during the ﬁrst few days of active drug treatment.
Increasing dosage caused no further improvement. Side eﬀects
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consisted of short-lasting mild nausea and attenuated appetite. These
side eﬀects disappeared upon dose reduction.
Conclusion : OSU6162 oﬀers promise as a candidate for treatment
of mental fatigue after a stroke or TBI and deserves to be tested in
other brain disorders accompanied by fatigue.
Policy of full disclosure : A.C. is a co-inventor in patent applica-
tions for OSU6162
S-19. Recent advances in research on
serotonergic hallucinogens: Implications
for treatment of schizophrenia
jS-19-001jHallucinogenic signaling in a GPCR heterocomplex
J. Gonza´lez Maeso. Mount Sinai School of Medicine, Department
of Psychiatry, New York, USA
Objective : Traditionally, G protein-coupled receptors (GPCRs) were
thought to function as monomeric units. However, over the past few
years, GPCRs have been shown to be located in close molecular
proximity at the plasma membrane in living mammalian cells, im-
plying the existence of dimers or even higher-order oligomers. The
neurotransmitters serotonin and glutamate both have been the target
of considerable attention regarding psychosis and antipsychotic drug
development. Atypical antipsychotics, such as clozapine, olanzapine
and risperidone, all have in common a high aﬃnity to block the
function of the 5-HT2A receptor. The psychoactive eﬀects of halluci-
nogenic 5-HT2A receptor agonists, such as lysergic acid diethylamide
(LSD) and psilocybin, share several features with schizophrenia, in-
cluding perceptual disturbances and alterations in cognition and
mood. A new class of potential antipsychotic drugs acting as agonists
at metabotropic glutamate 2/3 (mGlu2/3) receptors has recently re-
ceived attention in preclinical and clinical studies.
Methods : We used biophysical assays to characterize the oligo-
merization of 5-HT2A and mGlu2 receptors, and mouse behavior
models to determine the molecular mechanisms contributing to anti-
psychotic eﬃcacy.
Results :We found that 5-HT2A and mGlu2 receptors form a GPCR
heterocomplex in tissue culture and mouse frontal cortex. Our results
suggest that the 5-HT2A-mGlu2 receptor heterocomplex is necessary
for the cellular and behavioral responses induced by hallucinogenic
and antipsychotic drugs.
Conclusion : These observations provide a mechanistic insight into
antipsychotic action.
jS-19-002jComparing serotonergic and glutamatergic
hallucinogens in animal and human models related
to psychotic disorders
M. Geyer. University California San Diego, La Jolla, CA, USA
Objective : Both glutamatergic and serotonergic hallucinogens are
used as model psychoses in humans and animals. Recent studies
suggest that both drug classes increase levels of synaptic glutamate,
suggesting some overlap in their pharmacological eﬀects despite
diﬀering primary mechanisms of action. Here we compare the beha-
vioral proﬁles of these drug classes in measures related to psychotic
disorders.
Methods : Startle habituation and prepulse inhibition (PPI) have
been measured in both schizophrenia and psychotic bipolar patients
and in parallel animal models after administration of hallucinogens.
Similarly, these psychiatric groups have been examined in terms of
patterns of exploratory locomotor responses to a novel environment
using methods that parallel rodent studies of the eﬀects of glutama-
tergic and serotonergic hallucinogens.
Results : First-break, never-medicated schizophrenic patients have
deﬁcient PPI and habituation of startle, operational measures of
the gating abnormalities related to cognitive disorganization in psy-
choses. Similarly, manic bipolar disorder patients exhibit deﬁcient
gating. Both hallucinogenic serotonergic agonists and psychotomi-
metic glutamatergic antagonists disrupt homologous measures of
PPI and habituation of startle in rodents. These eﬀects are insensitive
to dopamine antagonists, but are blocked by 5-HT2A antagonists and
some atypical antipsychotics. In motor activity paradigms, manic
bipolar patients exhibit hyperactivity in a novel environment, while
schizophrenia patients instead exhibit normal initial levels of activity
but reduced rates of habituation over time. In rodents similarly tested
for locomotor activity, serotonergic hallucinogens produce an ex-
aggerated neophobia response characterized by initial reductions in
exploratory behavior only in novel environments, while glutamatergic
antagonists exhibit motor hyperactivity in both novel.
Conclusion : Thus, across behavioral paradigms in rodents, there
are both similarities and diﬀerences in the proﬁles exhibited by sero-
tonergic and glutamatergic hallucinogens. Further explication of the
neurobiological substrates of these similarities and diﬀerences are
likely to help elucidate the domains of overlap and diﬀerentiation
between the syndromes of schizophrenia and bipolar mania.
Policy of full disclosure : Work supported by the U.S. National
Institute on Drug Abuse and the National Institute of Mental Health.
jS-19-003jSuppression of slow cortical oscillations by
hallucinogens : Relationship to schizophrenia
F. Artigas1, M. Riga2, P. Celada2. 1CSIC, Depart. of Neurochemistry and,
Barcelona, Spain ; 2CSIC-IDIBAPS, CIBERSAM, Barcelona, Spain
Objective : Psychotomimetic drugs, such as non-competitive NMDA
receptor antagonists and serotonergic hallucinogens are used as
animal models of schizophrenia. However, their neurobiological
basis of action is poorly known. Our objectives are 1) to characterize
the actions of hallucinogenic drugs (the NMDA receptor antagonist
phencyclidine –PCP- and 5-HT2A receptor agonists) on neuronal ac-
tivity in prefrotnal cortex, and 2) to examine the potential reversal of
these actions by antipsychotic drugs.
Methods : Electrophysiological recordings in the medial prefrontal
cortex of anesthetized rats and mice : single unit extracellular record-
ings of identiﬁed pyramidal neurons and local ﬁeld potential record-
ings.
Results : The non-competitve NMDA receptor antagonist
phencyclidine (PCP) and the preferential 5-HT2A agonist DOI share
the ability to disrupt prefrontal cortex (PFC) activity in anesthetized
rodents. These drugs markedly increase the discharge of y40% of
pyramidal neurons and decrease that of y30%, reducing also slow
cortical oscillations (SCO ;<4 Hz) to which neuronal discharge is
temporally coupled. Interestingly, these eﬀects are reversed by the
subsequent treatment with haloperidol and clozapine, acting also via
diﬀerent pharmacological mechanisms. In line with these observa-
tions, the 5-HT1A/2A receptor agonist 5-methoxy-N,N-dimethyl-
tryptamine (5-MeO-DMT), natural component of the Amazonian
beverage Ayahuasca, evokes similar changes in PFC and other cortical
areas (V1 and S1). The reduction of SCO induced by 5-MeO-DMT is
also reversed by antipsychotic drugs (haloperidol, risperidone, clo-
zapine) and by the mGluR2/3 agonist LY379268.
Conclusion : The disruption of PFC function is a common action
of hallucinogens, irrespectively of their primary site of action (NMDA
or 5-HT receptors). These drugs evoke a chaotic PFC activity, charac-
terized by a randomly occurring discharge imbalance, which may
account for the perceptual and cognitive changes induced by these
drugs. The reversal by antipsychotic drugs with diﬀerent mechanisms
of action reinforces their relationship with schizophrenia symptoms.
jS-19-004jNeurophysiological studies of psilocybin-induced
hallucinations : role of 5-HT2A receptors
F. X. Vollenweider1, A. Schmidt2, M. Kometer2. 1University of Zurich,
Switzerland ; 2University Hospital of Zurich, Switzerland
Objective : Serotonergic hallucinogens such as psilocybin produce
positive-like symptoms and perceptual disturbances including visual
hallucinations and deﬁcits in visual contour processing that are
reminiscent to that observed in some patients in early or acute stages
of schizophrenia. However, the neurophysiological mechanisms and
5-HT receptor sites that mediate these visual perceptual alterations
remain largely unknown.
Methods : To further elucidate the role of 5-HT2A receptors in
visual processing, we performed a double-blind placebo-controlled
randomized trial in healthy human subjects (n=20) to assess the ef-
fects of psilocybin (215 mg/kg p.o.), on prestimulus and subsequent
visual stimulus-induced parieto-occipital alpha oscillations and
S-19. Recent advances in research on serotonergic hallucinogens: Implications for treatment of
schizophrenia 23
Downloaded from https://academic.oup.com/ijnp/article-abstract/15/Supplement_1/1/650920
by University of Groningen user
on 13 March 2018
early visual-evoked potentials and to determine whether these
psilocybin-induced eﬀects are (II) reversed by the preferential 5-HT2A
antagonist ketanserin (50 mg p.o.) or the partial 5-HT1A agonist
buspirone.
Results : Analysis of the visual-evoked potentials revealed that
psilocybin selectively increased the medial P1 potential, whereas
ketanserin selectively decreased the medial P1 potential. The sub-
sequent N170 potential was strongly decreased over the lateral oc-
cipital cortex by psilocybin and associated with the appearance
of visual hallucinations and audiovisual synesthesia, both of which
were completely blocked by the 5-HT2A antagonist ketanserin. A
correlational analysis showed that the decease the N170 potential
correlated with the intensity of psilocybin-induced subjective altera-
tions in visual perceptions. In contrast to this, the partial 5-HT1A
agonist buspirone did only moderately reduced psilocybin-induced
visual disturbances and partially reversed the reduction in the N170
potential.
Conclusion : The present results show that 5-HT2A rather than
5-HT1A receptor stimulation is the key mechanism for the generation
of visual hallucinations and audiovisual synesthesia in psilocybin
states and suggests that such a mechanism may also be responsible
for the visual disturbances observed in early schizophrenia and/or
Parkinson’s disease.
S-20. The translocator protein (18 KDa) as a
novel target in neurology and psychiatry
jS-20-001jTranslocator protein 18 KDa ligands as novel
anxiolytics without benzodiazepine like side eﬀects
R. Rupprecht. Medizinische Einrichtungen des, Bezirks Oberpfalz GmbH,
Regensburg, Germany
Objective :The translocator protein 18 KDa (TSPO)mediates the trans-
port of cholesterol from the outer to the inner side of the mitochon-
drial membrane. TSPO ligands oﬀer a broad spectrum of diagnostic
and therapeutic possibilities.
Methods : We assessed GABAergic neurotransmission by means
of slice studies with the selective TSPO ligand XBD173. Moreover, we
studied the eﬀects of XBD173 on behavioral anxiety paradigms in rats
and humans.
Results : XBD173 stimulated neurosteroidogenesis and enhanced
GABAergic neurotransmission in slices of the mouse prefrontal
cortex. Moreover, XBD173 displayed antipanic activity in rats and
in humans employing the CCK-4 challenge paradigm. In contrast to
alprazolam there was no sedation and no induction of withdrawal
symptoms.
Conclusion : TSPO ligans may oﬀer therapeutic potential as anxio-
lytics but also for other indications such as pain and neurodegenera-
tive disorders.
Policy of full disclosure : The studies with XBD173 were sponsered
by Novartis, Switherland. Rainer Rupprecht has been a consultant for
Novartis and Gru¨nenthal.
jS-20-002jStructure and function of the translocator protein
(18-kDa) in steroid and neurosteroid biosynthesis
V. Papadopoulos. Montreal, Canada
Objective : Translocator protein (18-kDa ; TSPO) is the product of a
gene family that is evolutionarily conserved from bacteria to humans
and expressed in most mammalian tissues. Among all tissues TSPO is
expressed at the highest levels in those with the ability to synthesize
steroids. Subsequently, TSPO was shown to be primarily localized to
mitochondria and to be associated with cholesterol import into mito-
chondria, a key function in steroidogenesis. Indeed, cholesterol
transfer from the outer mitochondrial membrane (OMM) to the inner
mitochondrial membrane (IMM) is the rate-limiting and hormone-
sensitive step in the regulation of steroid biosynthesis.
Methods : Using cellular, molecular, biochemical, biophysical and
genetic methods we demonstrated that TSPO binds with high aﬃnity
to cholesterol, identiﬁed a cholesterol recognition amino acid con-
sensus and investigated the mechanism underlying TSPO-mediated
cholesterol import.
Results : Our studied demonstrated that the transfer of cholesterol
into OMM occurs through a protein complex termed the transduceo-
some which is composed both of cytosolic proteins and the OMM
proteins TSPO and voltage-dependent anion channel (VDAC). Steroid
production is proposed to be initiated at this complex by the mi-
tochondrial-targeted Steroidogenic Acute Regulatory protein (STAR)
which acts on the OMM to facilitate cholesterol transfer to the IMM
through the assistance of TSPO. Further studies demonstrated photo-
activatable cholesterol binding to two native cholesterol binding-
protein mitochondrial complexes of 66- and 800-kDa. STAR was
found to mobilize cholesterol from the 800-kDa complex and induce
cholesterol metabolism to pregnenolone, the precursor of all steroids.
Immunoblot and mass spectrometry analyses revealed that this com-
plex contains the OMM TSPO and VDAC and IMM proteins, includ-
ing CYP11A1, the enzyme metabolizing cholesterol to pregnenolone.
We then demonstrated that the 800-kDa complex contains CYP11A1
activity.
Conclusion : These results identify a bioactive, TSPO-anchored
multimeric protein complex spanning the OMM and IMM that is
responsible for the cholesterol import, segregation, targeting, and
metabolism to steroids and neurosteroids.
jS-20-003jUsing PET to explore the role of the translocator
pattern in human brain diseases
D. Nutt1, D. Owen1, C. Parker1, N. Kalk1, A. Lingford-Hughes1.
1London, United Kingdom
Objective : The TSPO is a cholesterol transporter located in the outer
membrane of the mitochondrion. When activated it enhances choles-
terol conversion to pregnenolone and then on to allopregnenolone
and other neurosteroids. The original ligands for this site were
Ro5–4864 and PK11195, both of which were available in tritiated
versions.
Methods : Subsequently PK11195 was labeled with C-11 and used
in a number of PET studies revealing, for instance, increased bind-
ing in the brains of patients with MS and in brain stem nuclei with
neuritis. However PK11195 has limitations as a tracer due to high non-
speciﬁc binding and poor modeling characteristics. For these reasons,
more speciﬁc and selective tracers have been developed including the
PBR series such as PBR28 and PBR111, which are amenable to C-11
and F-18 radiolabeling, respectively, and may provide the ability for
more widespread use.
Results : Recent research on these compounds has revealed intri-
guing diﬀerences in binding of the PBR radiotracers in humans, where
humans are able to be distinguished into three sub-populations, (1)
those exhibiting high aﬃnity binding, (2) those exhibiting low aﬃnity
binding and (3) those exhibiting both binding characteristics, i.e. high
and low aﬃnity. This polymorphism shows marked diﬀerences in
frequency between those of Caucasian and Chinese origins, and these
turned out to be due to genetic variants produced by a single amino-
acid mutation within the TSPO, which can now be measured in peri-
pheral white cells.
Conclusion : Measuring individual genotypes may oﬀer a way
to optimize the use of PET TSPO tracers for diagnostic purposes,
enable patient stratiﬁcation and may also explain why it may be dif-
ﬁcult to demonstrate eﬃcacy of drugs targeted at the TSPO binding
site, since in Caucasians many patients will have low levels of drug
binding.
jS-20-004jPeripheral nerve regeneration : Therapeutic
perspectives for TSPO ligands
M. Schumacher. Paris, France
Objective : We investigate the potential therapeutic beneﬁts of trans-
locator protein (TSPO) drug ligands for neuroprotection, axonal
regeneration, neuroinﬂammatory responses and neuropathic pain
symptoms. TSPO expression is strongly upregulated in response to
nerve injury, primarily in Schwann cells and macrophages, but also in
neurons. Importantly, TSPO levels only return to low control values
when nerve regeneration is completed, strongly supporting a role in
regenerative processes. The mechanisms of action of TSPO ligands
involve the regulation of mitochondrial activity and function and the
stimulation of steroid biosynthesis.
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Methods : Experimental models : freeze injury or transection of the
rat sciatic nerve, crush injury of the rat facial nerve, neuropathic pain
symptoms induced by the chemotherapeutic agent vincristine.
Treatment : chronic treatment with etifoxine. Eﬃcacy endpoint mea-
sures : axonal regeneration, inﬂammatory responses, functional re-
covery, neuropathic pain symptoms, analysis of steroids in nervous
tissues by gas chromatography/mass spectrometry.
Results : Treatment with the benzoxazine etifoxine, which binds
to TSPO and GABAA receptors, resulted in a 2-fold acceleration in
axonal regeneration after sciatic nerve injury and in a marked im-
provement of both the rate and quality of functional recovery.
Walking track test, automated grid walk assay and nerve pinch test
showed that the recovery of both motor and sensory functions was
accelerated and improved. Treatment with etifoxine also strongly
reduced the number of macrophages and blunted the production of
inﬂammatory cytokines. This eﬀect appeared earlier in the proximal
stump than in the part of the injured nerve distal to the lesion site.
Importantly, etifoxine has been shown to reduce mechanical and
thermal pain induced by the chemotherapeutic agent vincristine.
Thus, TSPO ligands are also promising agents for reducing neuro-
pathic pain symptoms.
Conclusion : Etifoxine, an already clinically approved drug for the
treatment of anxiety disorders, and TSPO ligands in general, oﬀers
promise for the treatment of peripheral nerve injuries and axonal
neuropathies.
S-21. From gene to drug response:
Multi-method approach to the
pharmacogenomics of response to
antidepressants
jS-21-001jMulti-method approaches to pharmacogenomics in
animal models
M. Popoli. University Milano, Italy
Objective : Preclinical research in rodent models may contribute to
the identiﬁcation of genomic determinants of response to drugs.
Diﬀerent techniques, from transcriptomics and proteomics to the
more recent epigenetic methods can be employed to reach this objec-
tive. Aim of this presentation will be to draw from diﬀerent animal
studies a number of converging, validated genes and pathways that
may inform human pharmacogenetic studies.
Methods : Results from a number of diﬀerent studies will be dis-
cussed : (1) Transcriptomics of the Flinders Sensitive Line (FSL) gen-
etic model of depression (2) Synaptoproteomics of FSL subjected to
early-life stress (gene x environment model) (3) Synaptoproteomics of
the Learned Helplessness (LH) model (4) Epigenetic analysis of
transgenic mice carrying the BDNF Val66Met human mutation (5)
Analysis of microRNAs (miRs) involved in the action of anti-
depressants.
Results : A common ﬁnding of the FSL and LH models studies was
that energy metabolism and cellular remodeling pathways are in-
volved in both the depressive-like phenotype and in the response
to antidepressants. A number of interesting biomarkers was regulated
in opposite directions by stress and antidepressants in both models.
Results with the BDNF Val66Met mice have been obtained both from
candidate gene studies and from a genome-wide ChIP-Seq study.
Bioinformatic analysis of genes with epigenetic changes in their pro-
moters revealed the involvement of networks related to lipid metab-
olism, small molecule biochemistry, cell death, cellular development
functions, among others. In addition, consistent changes in epigenetic
tags and in expression have been found in select splice variants
of BDNF transcripts.
Conclusion : Overall, the results obtained in the diﬀerent
rodent studies allowed to select a number of genes and pathways
that may be involved in pathophysiology as well as in response
to drug treatments. Converging results from diﬀerent studies and
models will be implemented to inform human pharmacogenetic
research.
jS-21-002jTranscriptomic and epigenetic correlates of
antidepressant response
G. Turecki1, F. Mamdani2, J.P. Lpez2, M. Berlim2, A. Labbe2. 1McGill
University, Department of Psychiatry, Montreal, Canada ; 2McGill
University, Montreal, Canada
Objective : There is signiﬁcant variability in antidepressant treatment
outcome, with approximately 30–40% of patients with major de-
pressive disorder (MDD) not presenting with adequate response even
following several trials. To identify potential gene expression and
epigenetic biomarkers of response we investigated peripheral
gene expression patterns of response to antidepressant treatment in
MDD.
Methods : We used Aﬀymetrix HG-U133 Plus2 microarrays in
blood samples from untreated individuals with MDD (N=63) ascer-
tained at a community outpatient clinic, pre- and post eight-week
treatment with citalopram and used a regression model to assess the
impact of gene expression diﬀerences on antidepressant response.
We carried out technical validation of signiﬁcant probesets by
qRT-PCR and conducted CNS follow-up of the most signiﬁcant result
in post-mortem brain samples from MDD and control individuals.
We investigated epigenetic mechanisms that could explain diﬀerential
expression of selected genes.
Results : A total of 32 probesests were diﬀerentially expressed ac-
cording to response to citalopram treatment following FDR correction.
Interferon Regulatory Factor 7 (IRF7) was the most signiﬁcant diﬀer-
entially expressed gene and its expression was upregulated by cita-
lopram treatment in individuals who responded to treatment.
Consistent results were found in postmortem brain tissue of MDD
subjects and epigenetic mechanisms seem to play a relevant role.
Conclusion : These ﬁndings are promising and support studies in-
vestigating genomic factors associated with antidepressant response.
jS-21-003jAntidepressants and emotional processing
C. Harmer. University of Oxford, Psychiatry, United Kingdom
Objective : The neurochemical actions of antidepressant drug treat-
ment are relatively well understood but there has been little work
on how these changes become translated into the clinical eﬀects
on mood and psychological processes seen in the treatment of
depression.
Methods : A recent series of studies suggests that antidepressants
aﬀect key psychological processes important in depression early in
treatment and before therapeutic eﬀects are seen. This has been
investigated using behavioural and fMRI test batteries in healthy
volunteers and acutely depressed patients.
Results : Antidepressant treatments have been observed to bias
emotional processing towards positive vs. negative valenced infor-
mation. This increase in positive bias could therefore provide a plat-
form for subsequent cognitive restructuring and learning which
contributes to later improvements in depression. Consistent with
this, we have also found that changes in emotional bias in depressed
patients with a single dose of an antidepressant predicted therapeutic
response after 6 weeks of treatment. fMRI studies further suggest
modulation of amygdala and extra-striate responses to emotional
stimuli, indicating drug-modulation of attentional processing.
Conclusion : These results challenge long held assumptions that
the delay in antidepressant drug action results solely from the
need for neurophysiological processes to be completed. Rather,
the role of psychological mechanisms may be important in anti-
depressant drug response as patients learn to re-evaluate themselves
and their emotional context in the light of new processing biases.
Such an approach may therefore help us to understand how drug
treatments are working, how we might be able to improve treatment
approaches and also may provide biomarkers for early candidate
selection.
Policy of full disclosure : Advisory board and shareholder in
P1vital Ltd. Received consultancy from Eli-Lilly, Servier and P1vital.
Company director of Oxford Psychologists Ltd. Research work has
been funded by the Medical Research Council.
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jS-21-004jGenomic search for predictors of antidepressant
response : a NEWMEDS consortium study.
K. Tansey. King’s College London, United Kingdom
Objective :Major depressive disorder is a severe debilitating disorder
with antidepressants established as the initial step in treatment ;
however the eﬀectiveness of any particular antidepressant in an in-
dividual is not predictable. The current study is the largest anti-
depressant pharmacogenomic study to date investigating genetic
predictors of response to treatment with antidepressants.
Methods : The academic and industrial partners of the NEWMEDS
consortium compiled a sample of over 2000 cases ofmoderate to severe
depression with prospective outcome data for up to 12 weeks treat-
ment. Individuals were given either a serotonin reuptake inhibiting
(SRI) or norepinephrine reuptake inhibiting (NRI) antidepressant. The
primary aim of the study was to obtain genetic predictors of anti-
depressant response thus power analyses and interpretation of results
focused on detecting clinically signiﬁcant eﬀect for genetic markers. In
1790 individuals with high quality genotyping information, four gen-
ome-wide linear regressions tested the associations of half million
geneticmarkerswith percentage change in depression severity overall,
with SRI, with NRI and with diﬀerential response to SRI and NRI.
Results : None of the more than half million genetic markers sig-
niﬁcantly predicted response to antidepressants overall, SRI, NRI or
diﬀerential response to SRI and NRI. Pathway analysis in ALIGATOR
revealed no biological pathways that were signiﬁcantly overrep-
resented in the results. Ameta-analysis undertaken with another large
sample (STAR*D) detected no signiﬁcant associations. Polygenic scor-
ing found no convergence among multiple associations in NEWMEDS
and STAR*D. Machine learning algorithms suggest that genetic infor-
mation can meaningfully contribute to prediction of treatment out-
come and predict approximately 3% of the variance in outcome.
Conclusion : The absence of pharmacogenetic associations with
clinically meaningful eﬀect suggests that genetic information is not
ready to inform personalization of treatment for depression in the
near future. Complex prediction algorithms allowing for non-additive
eﬀects may be able in the future to aid in the prediction of anti-
depressant response.
S-22. ECT: Research and practice update
jS-22-001jWhat we now know about ECT mechanisms of
action
T. Bolwig. Copenhagen University Hospital, Denmark
Objective : To review the existing literature in search of a hypothesis
for the working action of ECT.
Methods : The presentation has focused on hypotheses based on
reproducible empirical data, and attemps to link clinical and para-
clinical ﬁndings with the wealth of ﬁndings relevant for ECT emerg-
ing from animal studies conducted primarily during the last four
decades.
Results : Especially three hypotheses have proven useful from a
heuristic point of view : The Generalized Seizure Theory points to
therapeutic eﬃcacy being toally dependent on the elicitation of brain
ctivity corresponding to a grand mal seizure. The neuroendocrine
theory enounces that ECT works by restoring neuroendocrine dys-
function associated with melancholic depression. The Combined
Anatomical-Ictal Theory enounces thar seizure activity in th limbic
system induces neurotrophic eﬀects crucial for the therapeutic eﬃcacy
of ECT.
Conclusion : Generalization of seizures (grand mal) is necessary for
therapeutic eﬀect of ECT. Among the theories to explain this eﬀect the
neuroendocrine theory, at the present time has the strongest foun-
dation among the existing theories to explain the working action of
ECT.
jS-22-002jLatest NIMH supported ECT data – eﬃcacy and
safety
C. Kellner. Mount Sinai School of Medicine, New York, USA
Objective : To review recent eﬃcacy and safety data from recent
NIMH-supported multicenter clinical trials.
Methods : In this presentation, we review data from multicenter
ECT clinical trials conducted under the auspices of the National
Institute of Mental health (NIMH) in the USA in recent years.
Results : Studies from the Consortium for Research in ECT (CORE)
and Columbia group (Opt-ECT trial) will be presented. Topics cov-
ered will include eﬃcacy of acute ECT, eﬃcacy of continuation ECT,
comparative eﬃcacy of electrode placements (BT, BF, RUL) and eﬃ-
cacy/safety of antidepressant-augmented ECT, in adult and geriatric
cohorts.
Conclusion : ECT remains the most eﬀective treatment modality for
severe depression ; reﬁnements in treatment technique have made
ECT even safer and more tolerable for patients.
jS-22-003j Impact of ECTAS on UK ECT
C. Freeman. Royal Edinburgh Hospital, Department of Psychiatry,
Edingburg, United Kingdom
Objective : To improve the practice, training and outcomes for ECT
in England Wales and Eire.
Methods : Repeated cycles of audit and accreditation of ECT clinics
in all 3 countries over a 10 year period rating clinics and staﬀ practice
on 3 levels of standards : Type 1, type 2 and type 3. Regular training
courses for Psychiatrists, anaesthetists and nurses and an active email
list serve and advice network. the development of competencies for all
types and level of staﬀ.
Results :Over 80% of clinics have enrolled. The most mature clinics
have now been through 3 three year cycles. Results show a steady
increase in the number of standards met and a progression from type
3 to 2 and type 2 to one. In other words clinics are doing better even
when standards have regularly been raised.
Conclusion : Detailed and regular accreditation is possible, wel-
comed by staﬀ, and has improved standards and outcomes. The status
of ECT has improved and in particular ECT nursing staﬀ are now seen
as highly skilled and specialized nurses.
jS-22-004jCognitive eﬀects of ECT
D. McLoughlin1, M. Semkovska1, R. Dunne1, M. Noone1. 1Trinity
College Dublin, Ireland
Objective : Concerns about cognitive side-eﬀects following ECT for
depression limit its use. We sought to quantify ECT-associated cog-
nitive changes, specify their pattern and progression and explore the
eﬀects of electrode placement.
Methods : We performed a series of meta-analyses to quantify
changes in cognitive performance as measured using standardised
tests after completing a course of ECT.
Results : Cognitive deﬁcits were mainly limited to the ﬁrst three
days after completing an ECT course. During this period right uni-
lateral (RUL) ECT was associated with signiﬁcantly smaller deﬁcits
than bitemporal (BT) ECT. However, after three days there were no
signiﬁcant diﬀerences between BT and RUL ECT and after 15 days all
levels of functioning were restored to at least baseline with many
signiﬁcantly improving beyond this. Meta-analyses of trials compar-
ing bifrontal (BF) ECT to BT or RUL ECT found BF ECT to be no more
eﬀective than BT or RUL ECT with only modest beneﬁts on visual
recall compared to RUL ECT. It was not possible to meta-analyse
autobiographical amnesia outcomes due to lack of use of standardised
measures ; and signiﬁcant publication bias was found, favouring re-
porting of larger percentage loss. To address this we have validated a
new scoring system for the Columbia Autobiographical Memory
Interview – Short Form (CAMI-SF), the most commonly used such
instrument in ECT studies, and have obtained normative data for re-
trieval consistency of its semantic, episodic-extended and episodic-
speciﬁc components for both healthy controls and depressed persons.
On initial assessment, depressed patients produced less episodic-
speciﬁc memories than controls. Both groups showed equivalent
amounts of consistency loss over a two-month interval on all compo-
nents.
Conclusion : The majority of cognitive abnormalities associated
with ECT appear to be transient and function improves over time.
Research quantifying retrograde amnesia following ECT for de-
pression needs to control for normal loss in consistency over time and
contribution of persisting depressive symptoms.
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S-23. Deﬁning the neurobiological basis of
cognitive impairment in schizophrenia
through translational research
jS-23-001jSerotonergic-glutamateric-dopaminergic
interactions : The basis for the cognitive enhancing
eﬀects of atypical antipsychotic drugs in
schizoprenia and NMDA receptor antagonist animal
models
H. Meltzer1, H.Y. Meltzer2. 1Vanderbilt University Med Sch, Nashville,
USA ; 2Northwestern Feinberg School, Chicago, IL, USA
Objective : to identify contribution of various serotonin (5-HT),
dopamine (DA) and glutamate (Glu) receptors to the ability of atypi-
cal antipsychotic drugs APD) to reverse or prevent the enduring
deﬁcit in novel object recognition (NOR) in female rats treated with
phencyclidine (PCP), an NMDA receptor non-competitive antagonist,
which has been considered to provide the best model of the cognitive
deﬁcit in SCH.
Methods : The administration of PCP, 2 mg/kg ip for 7 days,
followed by a 7 day washout period, to groups of 8 rats produced
a deﬁcit in NOR that lasted for many months. Various APDs, speciﬁc
5-HT, DA and Glu receptor agonists and antagonists were given along
with PCP, or acutely or for 7 days following the PCP washout period.
The eﬀect of treatments on the discrimination index (novel-familiar/
novel+familiar) during the retention period, which is 0.4–0.5 in con-
trol rats was assessed.
Results : Atypical APDs which are potent 5-HT2A inverse agonists
with less potency for D2 receptors, e.g. lurasidone, as well as amisul-
pride, a D2/D3/.5-HT7 antagonist reversed the deﬁcit in NOR
produced by subchronic PCP. Stepholidine A, a putative atypical
APD, with D1 and 5-HT1A agonist properties was also eﬀective.
Haloperidol (HAL), a D2 antagonist, did not. By means of selective
agonists and antagonists, it was possible to establish that D1 agonism,
5-HT1A partial agonism, 5-HT2A inverse agonism, 5-HT7 antagon-
ism, and mGluR2/3 agonism can positively impact the eﬀects of
subchronic PCP. Some, but not all of these mechanisms, also pre-
vented the eﬀect of subchronic PCP to impair NOR or produce an
enduring reversal of the eﬀects of PCP.
Conclusion : A variety of 5-HT, DA and glutamate mechanisms
can be shown to ameliorate the deﬁcit in a behavior analogous to
declarative memory in PCP-treated rodents. The translational value
of these ﬁndings will be discussed.
Policy of full disclosure : Grant support from Dainippon
Sumitomo ; Masakuni Horiguchi is an employee of Dainippon
Sumitomo.
jS-23-002jEﬀects of antipsychotic and antidepressant drugs,
alone and in combination, on cortical dopaminergic
and glutamatergic transmission and cognitive
impairment in schizophrenia
T. Svensson1, C. Bjo¨rkholm2, K. Jardemark2, M. Marcus2,
B. Schilstro¨m2. 1Karolinska Institutet, Physiology and Pharmacology,
Stockholm, Sweden ; 2Karolinska Institutet, Stockholm, Sweden
Objective : Clinical studies indicate that both atypical antipsychotic
drugs and a combination of conventional antipsychotic and anti-
depressant drugs may enhance neurocognition in schizophrenia. A
reduced cortical dopamine release as well as impaired glutamatergic
transmission in prefrontal cortical areas have also been proposed in
this disease, which may underlie certain aspects of the cognitive
impairment.The present studies aimed to elucidate the eﬀects of
atypical antipsychotic drugs such as clozapine aswell as a combination
of moderate doses of other antipsychotic drugs and conventional
antidepressants on cortical dopaminergic and glutamatergic trans-
mission, including both NMDA- and AMPA receptor functioning.
Methods : Experiments were performed in rats, using electro-
physiological intracellular recording in pyramidal cells in a prefrontal
cortical slice preparation, microdialysis in freely moving animals to
assess regional monoamine eﬄux in brain, and behavioral methodol-
ogies, including the conditioned avoidance response (CAR) test to
assess antipsychotic activity, the 8-arm radial maze to study working
memory function and a sensitive catalepsy test to estimate extra-
pyramidal side eﬀect liability.
Results : Clozapine and a combination of suboptimal doses/
concentrations of other antipsychotic drugs and conventional anti-
depressants, i.e. reboxetine or SSRI :s, that caused a suﬃcient sup-
pression of CAR to indicate an eﬀective antipsychotic action, in
parallel markedly increased prefrontal cortical dopamine outﬂow and
also generated a signiﬁcant potentiation of NMDA receptor-mediated
transmission in this region. In the case of clozapine these eﬀects were
found to be associated with a reversal of impaired working memory
induced by MK-801, a selective NMDA receptor antagonist, and to
be mediated via dopamine D1 receptors which are coupled to the
NMDA receptors. None of the drugs except clozapine was able to
achieve these ends when given alone in the same doses/concentra-
tions. Importantly, the combination of low concentrations of anti-
psychotic and antidepressant drugs also facilitated prefrontal cortical
AMPA receptor-induced currents in pyramidal neurons.
Conclusion : These results propose that clozapine as well as a
combination of antidepressants and other antipsychotic drugs
may improve neurocognition in schizophrenia by means of activation
of prefrontal dopamine release, D1 receptors and an associated
potentiation of glutamatergic NMDA receptor-mediated transmission
in this brain region. The concomitant AMPA receptor facilitation may
indicate a relatively rapid onset antidepressant eﬀect as well.
jS-23-003jTranslational biomarkers of NMDA dysfunction in
schizophrenia : Mechanisms and opportunities
D.C. Javitt. New York University Sch Med, Nashville, USA
Objective : Deﬁcits in NMDA receptor function represent a core fea-
ture of schizophrenia and a primary target for new drug develop-
ment. A key challenge is development of compounds to augment
NMDA neurotransmission, and development of measures that can be
used in preclinical studies to guide translational drug development.
Deﬁcits in auditory sensory event-related potentials (ERP) including
N1, mismatch negativity (MMN) and auditory steady-state response
(ASSR) have become increasingly well documented over recent years.
These studies evaluate generators of auditory ERP in animal models,
and their relation to underlying NMDA function.
Methods : ERP were recording in both primates and rodents. In
primates, ERP were recorded using multichannel electrodes im-
planted into primary auditory cortex. Laminar proﬁle of response was
analyzed as well as response to the NMDAR antagonist ketamine. In
rodents, eﬀects were measured both of NMDA receptor antagonists
and genetic manipulations relative to NMDA function.
Results : In primates, generators of N1, MMN, and ASSR were lo-
calized to discrete layers of primary auditory cortex, reﬂecting diﬀer-
ential function. Moreover, ketamine decreased N1 generation, while
increasing ASSR, suggesting diﬀerential underlying circuit mechan-
isms. In rodents, serine racemase and selective PV/NMDA KO led to
selective modulations of N1 and ASSR generation, and increased
sensitivity to ketamine.
Conclusion : These ﬁndings validate neurophysiological measures,
including N1, MMN and ASSR as indices of NMDA receptor dys-
function in both schizophrenia and in underlying primate and rodent
models, and suggest their use as translational measures in early stage
drug development processes.
Policy of full disclosure : Funded by NIMH, NIDA.
jS-23-004jEﬀect of clozapine and ketanserin on S-ketamine-
induced brain activation and psychotic symptoms in
healthy humans
F.X. Vollenweider1, D. Andel2, M. Kometer2, E. Seifritz2, A. Schmidt2.
1University of Zurich, Switzerland ; 2University Hospital of Zurich,
Switzerland
Objective : NMDR antagonist such S-ketamine induces positive-like
symptoms and cognitive impairments of schizophrenia in healthy
S-23. Deﬁning the neurobiological basis of cognitive impairment in schizophrenia through translational
research 27
Downloaded from https://academic.oup.com/ijnp/article-abstract/15/Supplement_1/1/650920
by University of Groningen user
on 13 March 2018
subjects. In animals, NMDAR antagonists disrupt sensory gating (PPI)
comparable to that observed in schizophrenia, a ﬁnding that is re-
versed by atypical 5-HT2A/D2/3 and 5-HT2A antagonists, but not by
typical antipsychotics. Similarly, previous work in humans suggests
that clozapine but not haloperidol partially ameliorates ketamine-
induced symptoms. Here, we examined the functional network
underlying S-ketamine-induced psychotic symptoms and whether
clozapine and ketanserin reverse such symptoms, and if so, where
these changes would be expressed.
Methods : S-ketamine-induced psychotic symptoms (OAV) and
alterations in regional brain activity were assessed using H215O-
PET. Twenty male subjects were tested (double-blind, randomized) :
10 receiving placebo, S-ketamine (0.006 mg/kg/min), clozapine
(30 mg po), and S-ketamine plus clozapine ; the other 10 receiving
ketanserin (50 mg po) as pretreatment.
Results : S-ketamine produced positive symptoms and cognitive
disturbances that were diﬀerentially associated with increased brain
activity in an extended neural network including prefrontal regions,
anterior cingultate, putamen, thalamus and the temporomedial and
insular cortex. Reduced activity was found in parietal and occipital
cortex regions, and cerebellum (p<0.00001). Pretreatment with clo-
zapine (30 mg) moderately reduced some of the S-ketamine induced
symptoms and partially reversed the S-ketamine-induced alterations
in anterior cingulate, insula, temporomedial cortex, and cerebelllum.
Moreover, clozapine reduced brain activity in left hippocampus and
bilaterally in parahippocampus and increased the activity in pons and
orbitofrontal cortex. Pretreatment with ketanserin (50 mg) partially
reversed S-ketamine-induced mania-like symptoms and alterations
the left insula, putamen, anterior cingulate, cerebellum, and pons.
Conclusion : The present ﬁndings suggest that a disruption of
NMDAR- but not of 5-HT2AR- mediated neurotransmission within
fronto-temporal-striato-thalamic pathways mainly contributes to
ketamine-induced psychotic symptoms.
S-24. Cytokines and psychiatric illness
jS-24-001j Inﬂammation-induced depression : Evidence and
mechanisms
R. Dantzer. MD Anderson Cancer Center, Department of Symptom
Research, Houston, Texas, USA
Exposure to pathogenic micro-organisms triggers an episode of
sickness behavior. The development of sickness behavior is triggered
by the proinﬂammatory cytokines that are produced by activated cells
of the innate immune system when they sense speciﬁc pathogen-
associated molecular patterns via toll-like receptors. These cytokines
include mainly interleukin (IL)-1 (IL-1a and IL-1b), IL-6, and tumor
necrosis factor alpha (TNF-a). The same cytokines are produced in the
brain by macrophage-like cells including microglia in response to
peripherally produced cytokines. Brain cytokines ultimately act on
neurons to alter body metabolism and behavior. In the same way as
inﬂammation normally resolves and leaves room for repair mech-
anisms, sickness behavior is normally followed by recovery. How-
ever, when the peripheral immune responses is too intense or lasts too
long, the behavioral response to cytokines can become maladaptive
and culminate in an episode of depression. The mechanisms of tran-
sition from sickness to depression have been studied both in the
clinics in patients receiving chronic cytokine immunotherapy for the
treatment of chemotherapy-resistant tumors or hepatitis C virus, and
at the bench, in animal models of inﬂammation-induced depression.
The transition from sickness to depression is mediated by activation
of the tryptophan-degrading enzyme, indoleamine 2,3 dioxygenase
(IDO), which is the ﬁrst and rate-limiting enzyme of the kynurenine
metabolic pathway. Kynurenine is further metabolized in neurotoxic
compounds including 3-hydroxy kynurenine and quinolinic acid. In-
hibition of IDO by pharmacological or genetic means abrogates
the development of depression but does not aﬀect sickness in re-
sponse to inﬂammation. In contrast inhibition of the cytokine re-
sponse abrogates both sickness and depression. The way this research
ultimately impacts on our understanding of the occurrence and
treatment of non-speciﬁc symptoms in physically ill patients will be
discussed.
Policy of full disclosure : Funded by NIH Honorarium from
Janssen Consultancy with Lundbeck Laboratories.
jS-24-002j Inﬂammation as a cause of suicidality?
L. Brundin1, S. Erhardt2, L. Tra¨skman-Bendz2. 1Lund University,
Psychoimmunology Unit, Sweden ; 2Lund University, Sweden
Objective : There is accumulating evidence that the immune system is
involved in the pathophysiology of depression. Depressed patients
display elevated levels of proinﬂammatory cytokines in the blood,
and patients treated with interferons for other disorders often develop
depression. It is currently not known whether inﬂammation gives rise
to speciﬁc psychiatric symptoms. Suicidality is a comparatively well-
deﬁned phenomenon, present in some depressive patients but not
others, which we hypothesized to be associated with inﬂammation.
Methods : In 2009, we found increased IL-6 in the cerebrospinal
ﬂuid (CSF) of suicide attempters, and that cytokine levels were related
to severity of depression. In a subsequent study, we compared suicide
attempters to non-suicidal depressive patients as well as healthy
controls. We found that suicide attempters displayed higher plasma
levels of IL-6 and TNF-a, than both depressed- and healthy controls.
Results : In a recent study we measured quinolinic acid (QUIN), a
metabolite produced when the kynurenine pathway is induced by
inﬂammation, in the CSF of suicide attempters. QUIN is an agonist of
the NMDA receptor and thus an interesting link between the immune
system and glutamate neurotransmission. We found increased QUIN
in suicide attempters compared to healthy controls, and there was a
correlation with the degree of suicidal intent as well as with IL-6 levels
in CSF.
Conclusion : Our studies provide evidence of both central and
peripheral inﬂammation in suicide attempters. There were positive
correlations between inﬂammatory factors and both depressive and
suicidal symptoms. QUIN, aﬀecting glutamate neurotransmission
might be a key player in the symptom generation.
jS-24-003jNeuroinﬂammation in psychotic disorders
G. Engberg. Karolinska Institutet, Stockholm, Sweden
Objective : Accumulating evidence suggests that psychotic disorders
are associated with brain inﬂammatory processes. However, direct
evidence for a central immune activation in schizophrenia is relatively
sparse. Several studies have shown that brain kynurenic acid (KYNA),
a neuroactive compound blocking the glycine site of the NMDA re-
ceptor and the alpha7nicotinic receptor, is elevated in schizophrenia.
In the past few years it has become evident that CSF KYNA serves as a
biological marker of brain immune activation. The present study was
undertaken in order to investigate concentrations of cytokines in the
CSF of psychotic patients.
Methods : Cytokines were analyzed by an electrochemi-
luminescence biosensor assay (Meso Scale Discovery, Gaithersburg,
MD, USA). Also the relationship between cytokines and KYNA was
studied in in vitro settings.
Results : The pro-inﬂammatory cytokine interleukin (IL)-1beta is
markedly elevated in the CSF of ﬁrst-episode patients with schizo-
phrenia (mean 6.5¡0.7 pg/ml) as compared to healthy volunteers
(0.8¡0.04 pg/ml). Furthermore, in olanzapine-medicated patients
with chronic schizophrenia we found that CSF IL-6 is elevated
(3.2¡0.4 pg/ml¡ ) compared to healthy volunteers (1.8¡0.2 pg/ml).
Also in patients with bipolar disorder CSF KYNA and IL-1beta are
elevated. In this regard, levels of KYNA correlate to life-time occur-
rence of psychotic episode, while CSF IL-1beta levels correlate to the
occurrence of recent symptoms of mania. In vitro studies utilizing
human astrocytes show that the rate limiting enzymes of the kynur-
enine pathway of tryptophan degradation, IDO and TDO, are induced
by administration of IL-1beta, resulting in increased KYNA formation.
These ﬁndings may rationally link together the elevation of KYNA
and IL-1beta seen in patients with schizophrenia or bipolar disorder.
Conclusion : Present results provide direct evidence for brain im-
mune activation in these disorders.
jS-24-004jCytokines in psychiatric disorders : Therapeutic
approaches
N. Mu¨ller. Ludwig-Maximilian University, Mu¨nchen, Germany
Proinﬂammatory cytokines, such as IL-6, IL-1 and TNF- appear to be
elevated at least in the peripheral blood of depressed patients. Thus
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the activity of IDO, a key enzyme of the tryptophane/kynurenine
metabolism, may be enhanced in depressed patients through these
cytokines. Although IL-6 does not directly act on IDO, its elevated
levels in serum may contribute to IDO activation within the CNS by
the stimulatory eﬀect on PGE2, which acts as cofactor in the activation
of IDO. This ﬁts with a report on the correlation of increased in vitro
IL-6 production with decreased tryptophan levels in depressed
patients. In schizophrenia, however, a role for an inﬂammatory pro-
cess has been postulated. A prenatal immune challenge during the
second trimenon of pregnancy might be crucial. Due to the increase
of proinﬂammatory cytokines and PGE2 in at least a subgroup of
psychiatric patients, antiinﬂammatory treatment would be expected
to show advantagous eﬀects. Cyclo-oxygenase-2 inhibitors have been
evaluated in major depression. We were able to demonstrate a stat-
istically signiﬁcant therapeutic eﬀect of the COX-2 inhibitor on de-
pressive symptoms in a randomized double blind pilot add-on study
using the selective COX-2 inhibitor celecoxib in MD. Another rando-
mized double-blind study in ﬁfty depressed patients suﬀering from
MD also showed an statistically signiﬁcant better outcome of the
COX-2 inhibitor celecoxib plus ﬂuoxetine compared to ﬂuoxetine
alone. Further therapeutic strategies based on immune-modulatory
eﬀects will be discussed, too. Due to the signs of inﬂammation and the
increase of PGE2 in some schizophrenic patients, antiinﬂammatory
treatment would be expected to show also advantagous eﬀects in
schizophrenia. COX-2 inhibition reduces not only the levels of proin-
ﬂammatory cytokines, COX-2 inhibition has also an impact to the
glutamatergic neurotransmission and inﬂuences the tryptophan/
kynurenine metabolism : all three components seem to be involved
in the pathophysiology of schizophrenia. In the meantime, several
studies with the COX-2 inhibitor celecoxib have been performed in
schizophrenia. Short term studies of the COX-2 inhibitor celecoxib
show a therapeutic eﬀect mainly in early stages of schizophrenia, the
pertaining studies will be discussed. However, other immune-based
therapeutic approaches including the use of antibiotics and antiviral
agents have been studied and will be outlined. Further therapeutic
strategies based on immune-modulatory eﬀects will be discussed, too.
S-25. Genetic and non-genetic risk factors
in translational models of psychiatric
disorders
jS-25-001jMice mutant for genes associated with
schizophrenia : Eﬀects of exposure to biological and
psychosocial adversities over developmental
trajectory
J. Waddington1, L. Desbonnet1, C. O’Leary1, E. Petit1, C. O’Tuathaigh1.
1Royal College of Surgeons, Dublin, Ireland
Objective : As molecular genetic ﬁndings in schizophrenia advance,
they are now being complemented by a new generation of epidemio-
logical studies that implicate also both biological and psychosocial
adversities acting across its developmental trajectory. This highlights
a need for more incisive models of gene environment interactions that
are rooted in these genetic and environmental ﬁndings. Thus, we have
studied a series of such environmental adversities in mice mutant for
two genes bearing diﬀerent relationships to schizophrenia : neur-
egulin-1 (NRG1) and catechol-O-methyltransferase (COMT).
Methods : Mice mutant for NRG1 were subjected to one of three
environmental adversities : intrauterine compromise via maternal
immune activation with Poly I :C ; adolescent psychosocial stress via
repeated social defeat ; and adult, subchronic exposure to the psy-
chotomimetic phencyclidine (PCP). COMT mutants were subjected to
adolescent vs. adult, subchronic exposure to the psychotomimetic D9-
tetrahydrocannabinol (THC). Phenotypic evaluations included etho-
logical assesment, exploratory activity, prepulse inhibition, cognition,
social behaviour and magnetic resonance imaging.
Results : Eﬀects of genetic mutation on the functional consequences
of each environmental adversity were characterised. For example,
eﬀects of maternal immune activation with Poly I :C were altered in
NRG1 mutants eﬀects of acute PCP were attenuated in NRG1 mutants
given subchronic vehicle but heightened in NRG1 mutants given
subchronic PCP ; the eﬀects of adolescent THC were heightened in
COMT mutants while no such eﬀects of adult THC were evident.
Conclusion : The present ﬁndings indicate that for a series of both
biological and psychosocial environmental factors, resultant pheno-
type may be determined by their interaction with psychosis-related
genes operating across the developmental trajectory of schizophrenia
at critical time points.
Policy of full disclosure : The authors’ studies are supported by
Science Foundation Ireland and the Health Research Board.
jS-25-002j Infectious and immune factors modulate
neurobehavioral abnormalities in DISC1 mice
M. Pletnikov1. 1 Johns Hopkins University, USA
Objective : Although infections contribute to schizophrenia, the
mechanisms whereby microbes aﬀect neurodevelopment remain
unclear. Interaction between microbial and genetic factors may be re-
sponsible for the disease in predisposed individuals. We studied the
neurobehavioral eﬀects of prenatal immune activation or early post-
natal parasitic infection in control and mutant DISC1 mice to model
human conditions of gene-environment interactions in schizophrenia.
Methods : We evaluated neurobehavioral schizophrenia-like
alterations in mice exposed to early or late postnatal infection with
Toxoplasma gondii (T. gondii), a pathogen associated with schizo-
phrenia. In a diﬀerent animal model, control and mutant DISC1 mice
were challenged with immune activation with Poly I :C at embryonic
day 9. Gene expression proﬁles, brain pathology, neurochemical
alterations and behavioral abnormalities were examined in adult mice
in both models.
Results : Early but not late infection with T. gondii produced loco-
motor hyperactivity and stimulants-induced impaired pre-pulse
inhibition of the acoustic startle in male but not female mice. Sex-
dependent eﬀects of the parasitic infection were also present in ab-
normal gene expression in the cortex and cysts distribution in the
brain although no diﬀerences in antibody titres were seen between
sexes. Prenatal interaction produced abnormal aﬀective and social
behaviors and associated smaller amygdala and periaqueductal gray
matter, and decreased density of spines on dendrites of hippocampal
granule cells. Mutant DISC1 modulated Poly I :C-induced secretion
of cytokines in fetal brains, and levels of endogenous mouse DISC1
and GSK-3b.
Conclusions : The present data suggest the timing of infection and
sex of the host could play major roles in modulating schizophrenia-
like neurobehavioral changes in mice. In addition, genetic predis-
position to schizophrenia may modulate behavioral consequences of
immune activation produced by microbes in utero. The present mouse
models may facilitate a better understanding of the contribution of
microbes to schizophrenia and related conditions.
jS-25-003j Identifying interactions between genes and early
environment in the mouse
V. Carola. EMBL, Mouse Biology Programme, Santa Lucia Foundation,
Rome, Italy
Objective :Much of the impact of genes on mood disorders is likely to
depend on interactions between genes and the environment. Such
interactions would lead to the expression of environmental eﬀects
only in the presence of a permissive genetic background. Human
studies have demonstrated interactions between genes and life
stressful events in the modulation of mood disorders. Research in this
ﬁeld can take advantages of animal models where the manipulation of
the genetic and environmental components is easy to perform. During
the past years in our laboratory we have been establishing mouse
models of the interaction between genes and early environment in the
modulation of anxiety and depression-like behavior.
Methods : In parallel experiments, we exposed mice carrying
targeted mutations in selected genes (5HTT ; BDNF ; and 5HT1A re-
ceptor) to diﬀerent maternal environment (‘‘high’’ vs. ‘‘ low’’ levels
of maternal care) during early development. The eﬀect of the gene-by-
early environment interaction (GrE) was evaluated using behavioral
tests in adult mice. To identify the molecular substrates of the
GrE, brains of these mice were all processed by HPLC, In Situ
Hybridization, and autoradiography techniques.
Results : For 5HTT mutation, we clearly observed GrE eﬀect
with heterozygous 5-HTT knockout mice exposed to ‘‘ low’’ maternal
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care showing the highest level of anxiety and depression-like
behavior among the experimental groups. A more complex GrE
was observed for BDNFmutation, with a greater eﬀect of the maternal
care observed in heterozygous BDNF knockout mice than in wild
type mice. For 5HT1A mutation, GrE eﬀect was observed on social
anxiety, with 5HT1A knockout mice being more responsive to
augmented levels of maternal care than controls. Finally we iden-
tiﬁed several neural substrates of the environmental, gene, and GrE
eﬀect.
Conclusion : Mouse models of gene-environment interactions are
a useful tool to expand the knowledge on the behavioral features
and molecular mechanisms implicated in mood disorders.
jS-25-004jAdvanced paternal age : Modelling non-genetic risk
factors in psychiatry
D. Eyles1, C. Foldi2, T. Burne2, J. McGrath2. 1Queensland Brain
Institute, Brisbane, Australia ; 2Brisbane, Australia
Objective : Advanced paternal age (APA) is associated with an in-
creased risk of neurodevelopmental disorders, such as schizophrenia
and autism. We have developed a mouse model to explore the
neurobiological correlates of APA. In this presentation the eﬀects
of APA on brain morphology and behaviour with relevance to
neuropsychiatric disorders will be discussed.
Methods : We investigated structure-function relationships in
the adult oﬀspring of young (3 month-old, Control) and old
(12–24 month-old, APA) C57Bl/6J sires. Mice underwent a beha-
vioural test battery comprising tests for locomotion, anxiety, explo-
ration, learned helplessness, social behaviour, avoidance learning,
prepulse inhibition (PPI) of the acoustic startle response and amphe-
tamine (AMPH)-induced locomotion. Brains of these mice were
examined ex vivo using a 16.4T animal MRI scanner.
Results : We ﬁnd no evidence of behavioural phenotypes that are
commonly associated with models of schizophrenia, such as increased
amphetamine-mediated hyperlocomotion or PPI deﬁcits. Social be-
haviour was also unaltered, suggesting that the APA mouse model
does not recapitulate classical features of ASD. However, APA ap-
pears to produce a robust anxiogenic phenotype that is increased with
the age of the APA sire (APA ‘‘dose’’). Regarding the brain structural
phenotype, we have shown that the trajectory of cortical development
is altered in male APA mice, such that the cortex is smaller at birth
(F1,17=5.48, p=.03) and larger in adulthood (F1,17=7.61, p=0.01). In
addition, the corpus callosum was signiﬁcantly smaller in adult APA
mice (F1,79=5.14, p=0.03).
Conclusion : The APA mouse produces a robust anxiety-like
phenotype that is directly related to increasing sire age. Although this
behavioural phenotype would not appear to obediently map on to the
neuropsychiatric conditions in which APA is implicated, structural
and functional changes in corpus callosum have been consistently
reported in both autism and schizophrenia. These studies have clari-
ﬁed APA ‘‘dose’’ as a possible explanation for the variable phenotype
reported in other APA animal models and suggest the eﬀects of APA
in oﬀspring may require sire age to reach a critical threshold rather
than exist as a continuous variable. Studies are ongoing regarding the
molecular features of this model.
S-26. Emerging opportunities to treat
psychiatric disorders with muscarinic
receptor agonists
jS-26-001jMuscarinic receptors in schizophrenia : Are they a
marker for a distinct pathophysiology?
E. Scarr1, B. Dean2. 1University of Melbourne, Australia ; 2Mental Health
Research Institut, Melbourne, Australia
Objective :Decreased levels of muscarinic receptors have been widely
reported to occur in the brains of people with schizophrenia. Studies
have identiﬁed that cortical muscarinic M1 receptors are altered,
whilst in the hippocampus the M4 receptors are decreased. We re-
cently discovered that the decreases in M1 receptors did not occur
in everyone with schizophrenia but are restricted to a small portion
of subjects, who have large deﬁcits. This raised the question of
whether this subgroup has unique neurochemical deﬁcits compared
to people with schizophrenia who do not have the deﬁcit in M1
receptors.
Methods : RNA was extracted from Brodmann’s area 9 from
15 non-psychiatric controls and 30 subjects with schizophrenia, half
of who had low muscarinic M1 receptor levels. cDNA was generated
from all samples and run on Aﬀymetrix Human Exon 1.0 ST micro-
arrays. Using JMP Genomics, the quality control probes were
checked and principle component analyses carried out prior to the
data being analysed using an ANOVA. Genes with signiﬁcantly
diﬀerent expression proﬁles were inputted into Ingenuity Pathway
Analysis.
Results : 487 genes were diﬀerentially expressed. 157 were uniquely
diﬀerent between controls and schizophrenia with normal levels of
M1 receptors and a further 330 between controls and schizophrenia
with low levels of M1 receptors. Pathway analyses revealed that like
other microarray studies, many of our transcripts were involved in
metabolic processes. A number of pathways have been identiﬁed
which diﬀerentiate between the three groups in the study including
control of cell cycle and tyrosine metabolism.
Conclusion : This microarray study reveals a number of pathways
that are changed in both groups with schizophrenia compared to
controls. However, it also identiﬁes pathways that are changed in only
one group of subjects with schizophrenia, supporting the concept that
people with schizophrenia who have low levels of M1 receptors may
have a distinct pathophysiology.
Policy of full disclosure : Elizabeth Scarr is an Australian Research
Council Future Fellow. Brian Dean is a National Health and Medical
Research Council Senior Research Fellow. This project was funded by
the NHMRC project grant (566967).
jS-26-002jThe role of muscarinic receptors in the
pathophysiology of major depressive disorder,
bipolar disorder and suicide
B. Dean1, W.J. Jeon2, A. Gibbons2, S. Boer3, S. Jusva3, E. Scarr4.
1Mental Health Research Institut, Kenneth Myer Building, Victoria,
Australia ; 2Molecular Psychiatry Lab., University of Melbourne,
Australia ; 3Rebecca L. Cooper Research Lab, Parkville, Australia ;
4Department of Psychiatry, University of Melbourne, Australia
Objective :Dysfunction of muscarinic receptors (CHRM) has been im-
plicated in the pathology of bipolar disorder (BPD), major depressive
disorder (MDD) and suicide. However, there is conﬂicting evidence
regarding which CHRM is aﬀected by the pathophysiology of these
disorders. This lead us to undertake a systematic radioligand binding
analysis of several CHRM antagonists in postmortem cortical tissue
from subjects with BPD, MDD and age/sex matched controls, as well
as individuals who did or did not commit suicide, to gain some in-
sight into which CHRMs may be altered in the cortex of subjects with
diﬀerent mood disorders.
Methods : We used the muscarinic receptor selective radioligands
[3H]pirenzepine, [3H]AFDX-384 and [3H]4-DAMP to CHRM1/
CHRM4, CHRM2/CHRM4 and CHRM3, respectively. Radioligand
binding was measured in postmortem tissue obtained from
Brodmann’s area (BA) 10, 46 and 40 in mood disorders and BA 9 from
subjects analysed for eﬀects of suicide.
Results : [3H]AFDX-384 binding was decreased in BA 46 in both
BPD (p<0.01) and MDD (p<0.05). [3H]4-DAMP binding was de-
creased in BA 10 in BPD (p<0.05) but not MDD (p<0.05). [3H]AFDX-
384 and [3H]4-DAMP binding were unaltered in any other cortical
region examined for either disorder (p<0.05). [3H]pirenzepine bind-
ing was not signiﬁcantly altered in either disorder in any region
(p<0.05). Unlike some studies, our data showed no diﬀerence in any
radioligand binding in subjects who had died by suicide.
Conclusion : Our data is consistent with previously published
data implicating a role for CHRM2 receptors in the pathology of
bipolar and major depressive disorder but provides no evidence to
suggest muscarinic receptor density varies with suicide. The demon-
stration of a novel association between decreased CHRM3 receptor
expression and bipolar disorder suggests bipolar and major de-
pressive disorder diﬀer in the underlying nature of their cholinergic
dysfunction.
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jS-26-003jGenetic variation in Cholinergic-Muscarinic-2
Receptor gene modulates Muscarinic2-Receptor
binding in vivo and accounts for reduced binding in
bipolar disorder
D. Cannon1, F.J. McMahon2, W.C. Drevets3. 1National University of
Ireland, Department of Psychiatry, Galway, Ireland ; 2Mood & Anxiety
Disorders Prog, NIMH, Bethesda, USA ; 3Laureate Institute for Brain,
Oklahoma University College Medicine, Tulsa, USA
Objective : Genetic variation in the cholinergic muscarinic-2 (M2) re-
ceptor gene (CHRM2) has been associated with the risk for develop-
ing depression. We previously reported that M2-receptor distribution
volume (VT) was reduced in depressed subjects with bipolar disorder
(BD) relative to depressed subjects with major depressive disorder
(MDD) and healthy controls (HCs). In this study, we investigated the
eﬀects of six single-nucleotide polymorphisms (SNPs) for CHRM2 on
M2-receptor binding to test the hypotheses that genetic variation in
CHRM2 inﬂuences M2-receptor binding and that a CHRM2 poly-
morphism underlies the deﬁcits in M2-receptor VT observed in BD.
Methods : The M2-receptor VT was measured using positron
emission tomography and [18F]FP-TZTP in unmedicated, depressed
subjects with BD (n=16) or MDD (n=24) and HCs (n=25), and the
eﬀect of genotype on VT was assessed.
Results : In the controls, one SNP (with identiﬁer rs324650, in
which the ancestral allele adenine (A) is replaced with one or two
copies of thymine (T), showed a signiﬁcant allelic eﬀect on VT in the
pregenual and subgenual anterior cingulate cortices in the direction
AA<AT<TT. In contrast, in BD subjects with the TT genotype, VT
was signiﬁcantly lower than in BD subjects with the AT genotype in
these regions. The BD subjects homozygous for the T –allele also
showed markedly lower VT (by 27 to 37% across regions) than HCs of
the same genotype. Post hoc analyses suggested that T homozygosity
was associated with a more severe illness course, as manifested by
lower socioeconomic function, poorer spatial recognition memory and
a greater likelihood of having attempted suicide.
Conclusion : These data represent novel preliminary evidence that
reduced M2-receptor VT in BD is associated with genetic variation
within CHRM2. The diﬀerential impact of the M2-receptor poly-
morphism at rs324650 in the BD and HC samples suggests interactive
eﬀects with an unidentiﬁed vulnerability factor for BD.
jS-26-004jPotential roles for allosteric Muscarinic receptor
modulators for the treatment of psychiatric and
neurologic disorders
C. Jones. Vanderbilt University, Vanderbilt Program in Drug Dis,
Nashville, USA
Objective : Preclinical and early proof-of-concept clinical studies have
revealed that activators of speciﬁc muscarinic acetylcholine receptor
(mAChR) subtypes are eﬃcacious in animal models predictive of an-
tipsychotic-like activity and cognitive enhancement, as well as in the
treatment of the symptoms associated with schizophrenia and
Alzheimer’s disease. More recently, our group and others have used
an innovative strategy to identify highly subtype selective ligands that
act at allosteric sites on mAChRs, which are less highly conserved
than the orthosteric site, including allosteric agonists and positive
allosteric modulators (PAMs).
Methods : A combination of medicinal chemistry, HTS and chem-
informatic approaches were used to identify subtype selective
mAChR allosteric agonists and/or PAMs. In vitro studies using cal-
cium mobilization assays were used in parallel to generate functional
eﬃcacy and potency data for all allosteric modulators and the
pharmacokinetic properties of each ligand were determined in a rat
plasma-brain-level study using LC/MS detection of drug levels after
systemic dosing. In vivo eﬃcacy was evaluated in several rodent
models predictive of antipsychotic-like activity and enhancement of
aﬀective and/or cognitive functions.
Results : Here we report the pharmacologic characterization
of several subtype selective mAChR activators, including the M1
allosteric agonist VU0184670 andM1 PAM BQCA. These M1 allosteric
ligands modulate numerous behavioral and physiologic parameters
consistent with enhancement of cognition, including stimulation
of NMDA receptors and/or spontaneous excitatory postsynaptic
currents in medial prefrontal cortex pyramidal cells and reversal of
disruptions in learning and memory paradigms in rodents. We
have also identiﬁed highly selective M4 PAMs, as represented by
VU0152100, which are also eﬃcacious in preclinical models of anti-
psychotic-like activity and in reversal of disruptions in hippocampal
memory tasks.
Conclusion : Collectively, these allosteric mAChR activators are
serving as key tools for further understanding the relative roles of the
diﬀerent mAChR subtypes in the observed eﬃcacy of nonselective
mAChR agonists in vivo.
S-27. Advances in translational research in
serotonin neurobiology: Implications
for mood disorders
jS-27-001jMolecular target of seratonin
neurotransmission – implication in therapeutics
of mood disorders
X. Li. Birmingham, USA
Serotonin is a neurotransmitter with broad functions in brain
development, neuronal activity, and behaviors ; and serotonin is the
prominent drug target in mood disorders. The multiple actions of
serotonin are mediated by diverse serotonin receptor subtypes and
associated signaling pathways. However, the key signaling compo-
nents that mediate speciﬁc function of serotonin neurotransmission
have not been fully identiﬁed. This presentation will provide evidence
from biochemical, pharmacological, and animal behavioral studies
showing that brain glycogen synthase kinase-3 (GSK3) is an important
component in serotonin signal transduction. GSK3 is a protein kinase
which abnormal activity is association with mood disorders. Several
classes of mood-modulating drugs, such as lithium, antidepressants,
and atypical antipsychotics, regulate GSK3 by inhibiting its activity in
brain, which reinforces the importance of GSK3 as a potential thera-
peutic target in mood disorders. In animal studies, brain serotonin
regulates the activation states of GSK3, mainly through serotonin 1A
and 2A receptors. In return, GSK3 directly interacts with serotonin
receptors in a highly selective manner, with a prominent eﬀect on
modulating serotonin 1B receptor activity. Therefore, GSK3 acts as
an intermediate modulator in the serotonin neurotransmission sys-
tem, and balanced GSK3 activity is essential for serotonin-regulated
brain activity and behaviors. With this prominent relationship be-
tween serotonin neurotransmission and GSK3, drugs targeting GSK3
may elicit mood stabilizing eﬀects by normalizing brain serotonin
activity.
jS-27-002jRole of the serotonin receptor adaptor protein p11
in depression
P. Svenningsson. Stockholm, Sweden
Objective : The molecular mechanisms underlying depression and
therapeutic eﬃcacy of antidepressants remain largely unknown. This
presentation will introduce the possible role of p11 in depression and
its treatment.
Methods : Using yeast two hybrid and co-immunoprecipitation
experiments, p11 (S100A10, annexin II light chain) was found as an
adaptor to 5-HT1B and 5-HT4 receptors. To study the functional role
of p11, subsequent studies have used histological, molecular biologi-
cal, biochemical, electrophysiological and behavioral approaches.
Results : A pronounced reduction of p11 has been found both in
post-mortem human tissue from depressed individuals or suicide
victims and in a rodent model of depression. Conversely, p11 is in-
creased in rodent brains by antidepressants or electroconvulsive
therapy. The expression of p11 is also controlled by L-DOPA and
BDNF. p11 knockout mice exhibit a depression-like phenotype,
abnormal emotional processing and have reduced or paradoxical be-
havioral, neurogenic and neurochemical responses to antidepressants
as well as 5-HT1B and 5-HT4 receptor agonists. Viral or transgenic
overexpression of p11 recapitulates certain behaviors on mood and
anxiety seen after antidepressant treatment in mice. While p11 is
wide-spread in the brain, there is some enrichment in populations of
interneurons. In addition to serving as an adaptor protein to 5-HT
receptors, p11 interacts with ion channels (incl. ASIC-1, TASK-1,
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TRPV5/6), intracellular enzymes (incl phospholipase A2, PCTAIRE-1,
tPA and cathepsin B) as well as its principal partner annexin 2.
Conclusion : The inducible protein p11 may contribute to certain
aspects of depression symptomatology and mediate antidepressant
actions.
Policy of full disclosure : Swedish Research Council Servier
Dainippon Sumitumo.
jS-27-003jContribution of animal models to the understanding
of epigenetic mechanisms in aﬀective disorders and
resilience
K.P. Lesch. Wuerzburg, Germany
Objective : Adverse childhood experiences are associated with in-
creased risk for psychiatric diseases later in life, especially anxiety
disorders and depression. Several studies indicate that whether a in-
dividual develops disorders of emotion regulation following early-life
stress is inﬂuenced by variation of the serotonin transporter gene
(5-HTT).
Methods : Multimodal fMRI in humans suggested that life stress
interacts with the 5-HTT genotype to inﬂuence amygdala and hippo-
campal resting activation. There are also compelling data from non-
human primates. In rhesus monkeys (Macaca mulatta), maternal
separation during the ﬁrst months of life results in deﬁcient social
adaptation and peer interaction.
Results : These deﬁciencies are related to brain serotonin system
function, based on testing for interactions between early life stress and
5-HTT. In addition to main eﬀects of 5-HTT genotype and early stress
to variation in serotonergic function in later life, 5-HTT also interacts
with deleterious early rearing experience to inﬂuence attentional and
emotional resources, stress reactivity, and alcohol preference and de-
pendence. However, the molecular mechanisms by which stress in-
creases disease risk in adulthood are not known, but may include
epigenetic programming of gene expression. Various gene-by-
environment interaction (GrE) paradigms in the mouse allow in-
vestigations of the molecular mechanisms underlying epigenetic
programming by early adverse environment in an animal model
amenable to genetic manipulation. Using these GrE paradigms it was
shown that prenatal stress or dominant/subordinate social interaction
on anxiety-related behavior is modulated by inactivation of 5-HTT.
Conclusion : These ﬁndings suggest that the molecular mechanisms
involved in these GrE models are relevant to the etiology of disease
in humans.
jS-27-004jMolecular imaging of serotonin vulnerability in
mood disorders
G. Smith. Baltimore, USA
Objective : Findings from studies of animal models (including
amyloid transgenic mice) can be translated into testable hypotheses in
humans using molecular imaging methods. Studies of the functional
neuroanatomy of geriatric depression have shown elevated glucose
metabolism in cortico-cortico networks that include regions of the
‘default network’. Citalopram treatment decreased metabolism in a
subcortical-limbic-frontal network that was associated with improve-
ment in aﬀect (depression and anxiety), while decreases in a medial
temporal-parietal-frontal network was associated with improvement
in cognition (verbal memory and verbal ﬂuency). Having identiﬁed
the functional neuroanatomy, the next step is to examine the under-
lying pathophysiology.
Methods : Molecular imaging studies using high resolution PET
(HRRT) and well-established radiotracers have focused on the role of
the serotonin transporter (5-HTT) and beta-amyloid deposition (Ab)
as mechanisms underlying aﬀective and cognitive network dysfunc-
tion, respectively, in geriatric depression.
Results : Lower 5-HTT concentrations in patients than controls were
observed in cortical (including precuneus and posterior cingulate),
limbic (parahippocampal gyrus) and subcortical (striatum, thalamus,
midbrain [raphe] regions. Signiﬁcant correlations between 5-HTT oc-
cupancy by citalopram and improvement of depressive symptoms
were observed in these regions, as well the anterior cingulate (BA 24).
Ab overlaps with the regions in the cognitive network and is asso-
ciated with less improvement in cognition by citalopram. The spatial
covariance pattern of 5-HTT degeneration and Ab was uncovered in
the anterior cingulate, medial frontal, orbitofrontal cortices, posterior
cingulate, precuneus, hippocampus/parahippocampal gyrus.
Conclusion : Serotonin degeneration associated with Ab is observed
in amyloid transgenic mice, aswell as in human neuroimaging studies.
This may represent a neurobiological basis for the association between
late life depression and vulnerability to cognitive decline, aswell as the
increased risk of cognitive decline associated with neuropsychiatric
symptoms (depression, agitation, anxiety) in mild cognitive impair-
ment. These data may have implications for identifying subjects at risk
and for identifying therapeutic targets for early intervention.
S-28. Novel targets for antipsychotic
medication development
jS-28-001jEﬃcacy of selective GABA A alpha 5 positive and
negative allosteric modulators in the MAM model
of schizophrenia.
A. Grace1, K. Gill2, J. Cook3. 1University of Pittsburgh, Pittsburgh, PA,
USA ; 2University of Pittsburgh, Department of Neuroscience, Pittsburgh,
PA, USA ; 3University of Wisconsin Madiso, Madison, WI, USA
Objective : Using the MAM developmental disruption rat model of
schizophrenia, we examined the eﬃcacy of novel GABA A allosteric
modulators in reversing the hyperdopaminergic state thought to un-
derly psychotic symptoms in schizophrenia in humans. Our studies
showed that this model demonstrated parvalbumin GABAergic in-
terneuron loss in the hippocampus leading to hippocampal hyper-
activity and increased dopamine neuron population activity and
hyper-responsivity to amphetamine. Therefore, we used drugs that
targeted the GABA A alpha 5 receptor, which is selectively con-
centrated in the hippocampus.
Methods :Methylazoxymethanol acetate (MAM) was administered
at 20 mg/kg i.p. to pregnant rats at gestational day 17, and the oﬀ-
spring studied as adults. Recordings of dopamine neuron population
activity (active neurons per electrode track) and locomotor response
to amphetamine (0.5 mg/kg i.p.) was evaluated.
Results : MAM treated rats exhibited signiﬁcant elevations in
the number of DA neurons ﬁring in the ventral tegmental area and
hyper-responsivity to amphetamine. The alpha 5 positive allosteric
modulator SH-053–20F-R-CH3 and the negative modulator selectively
attenuated ventral hippocampal excitability in controls, and reversed
the increased DA neuron population activity and response to am-
phetamine to control levels without signiﬁcantly aﬀecting controls.
Interestingly, the negative allosteric modulator Ro4938581 increased
DA neuron population activity in controls, but decreased it in MAM
to control levels.
Conclusion : Unlike D2 antagonist antipsychotic drugs, manipu-
lation of the GABA A apha 5 receptor appeared to restore the hyper-
reactive DA system in the MAM rat to control levels. The fact that this
worked with both the positive and negative modulator suggests that
the important point is not increasing inhibition, but restoring balance
within a disrupted interneuron network. By attacking schizophrenia
at the site of disruption is likely to be a more eﬀective treatment for
schizophrenia than is dopamine blockade, which works at least 5 sy-
napses downstream from the site of pathology.
Policy of full disclosure : Johnson & Johnson, Lundbeck, Galaxo
Smith Klein, Otsuka, Takeda.
jS-28-002jTranslational pharmacodynamics of
phosphodiesterase 10A (PDE10A) inhibitors for
treatment of schizophrenia
J. Nielsen1, B. Steiniger-Brach1. 1H. Lundbeck A/S, Copenhagen,
Denmark
Objective : Phosphodiesterase 10A (PDE10A) is a dominant phospho-
diesterase in striatal Medium Spiny Neurons. Inhibition of PDE10A
leads to an increase of cAMP in these neurons and negatively mod-
ulates dopamine D2 receptor signalling in the striatum. Preclinical
evidence suggests that PDE10A inhibitors are anti-psychotic, pro-
cognitive and hold potential for treatment of negative symptoms.
PDE10A inhibitors are currently being evaluated in clinical settings
for the treatment of schizophrenia.
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Methods : A novel PDE10A in vivo binding ligand was developed
and validated. Rodents were dosed with selective PDE10A inhibitors
and were tested in schizophrenia relevant assays. The occupancy of
the PDE10A enzyme was monitored by in vivo binding.
Results : PDE10A inhibitors were eﬃcacious in a number of in vivo
assays relevant for schizophrenia including assays for positive and
cognitive symptoms as well as motor side eﬀect assays. The dynamic
occupancy range overlaps between diﬀerent eﬃcacy assays although
some diﬀerences are reported in this study. For most in vivo assays,
relatively low PDE10A occupancy is needed, and in cognition assays
as little as 15% occupancy has signiﬁcant eﬀect. Diﬀerent selective
PDE10A inhibitors had similar occupancies at eﬃcacious doses in
these assays.
Conclusion : The data supports the potential of PDE10A inhibitors
as a drug target for treatment of schizophrenia across symptoms do-
mains and provide a basis for selecting doses in clinical trials through
evaluation of PDE10A occupancy with PET.
Policy of full disclosure : All authors are employees of
H. Lundbeck A/S.
jS-28-003jThe glycine reuptake inhibitor (GRI) bitopertin :
Going beyond antipsychotics towards a
non-dopaminergic treatment for schizophrenia
D. Umbricht1, M. Martin-Facklam1, E. Wasef1, E. Dorﬂinger1,
A. Bausch1, K. Yoo1, L. Santarelli1. 1F. Hoﬀman – La Roche Ltd, Basel,
Switzerland
Objective : Deﬁcient NMDA receptor signaling is considered a lead-
ing hypothesis in the pathophysiology of schizophrenia, including
negative symptoms. Targeting the co-agonist glycine site of the
NMDA receptor oﬀers a safe approach to enhance NMDA receptor
function. The eﬀects of the glycine reuptake inhibitor (GRI) bitopertin
(RG1678) on negative symptoms of schizophrenia were investigated
in a phase II proof-of-concept study.
Methods : 323 clinically stable patients with predominant negative
symptoms were randomized to 8 weeks of treatment with three doses
of bitopertin (10 mg, 30 mg, 60 mg) or placebo once daily in combi-
nation with a stable antipsychotic treatment. Eﬃcacy parameters in-
cluded the PANSS negative symptom factor score (NSFS) ; proportion
of responders (o20% improvement in NSFS) ; Clinical Global
Impression – Improvement in Negative Symptoms (CGI-I-N), and
Personal and Social Performance (PSP) scale.
Results : In the per protocol population (231 patients) the NSFS
showed a signiﬁcantly greater decrease from baseline (delta=25%) in
the 10 mg and 30 mg groups versus placebo (delta=19%) (10 mg,
p=0.049 ; 30 mg, p=0.034). The response rate was signiﬁcantly higher
for 10 mg group versus placebo (65% vs. 43%, p=0.013). Diﬀerences
in CGI-I-N were signiﬁcant for the 10 mg dose group (p=0.025).
There was a trend towards functional improvement (PSP score) in the
10 mg dose group (p=0.072). The largest eﬀect sizes for the 10 and
30 mg were observed for NSFS items N1 (x0.32, x0.27), N2 (x0.37,
x0.65 N4 (x0.39,x0.41) and G16 (x0.37,x0.36).
Conclusion : Bitopertin 10mg demonstrated a consistent reduction
in negative symptoms, accompanied by the emergence of a positive
trend on personal and social functioning. Bitopertin may exert its
greatest eﬀect on key negative symptoms that include emotional
withdrawal and apathetic/social withdrawal. These results support
glycine reuptake inhibition and enhancement of NMDA signaling as a
therapeutic approach for negative symptoms in patients with schizo-
phrenia.
Policy of full disclosure : All authors are employees of
F. Hoﬀmann – La Roche, Ltd.
jS-28-004jModulation of glutamate function via mGlu5
receptor : Potential novel antipsychotic target?
S. Parmentier-Batteur1, J.H. Uslaner2, K. Menzel2, B.A. Mattson2,
J.A. O’Brien2, B.C. Magliaro2, N. Lambeng3, H. Faure´3, T.M.
Williams4, P.H. Hutson5. 1Merck, Inc., 770 Sumneytown, West Point,
USA ; 2Merck & Co., Inc., West Point, USA ; 3Addex Pharmaceuticals,
Geneva, Switzerland ; 4West Point, USA ; 5Landsdale, USA
Objective : An emerging hypothesis regarding the neurobiological
cause of schizophrenia suggests that the disease is due to altered
glutamate neurotransmission in general and reduced NMDA receptor
function in particular. For this reason, pharmacological approaches
are being pursued to normalize glutamate or enhance NMDA recep-
tor function. Direct approaches to increase NMDA receptor function
are limited by the risk of seizures and neurotoxicity. As a result,
indirect NMDA modulation has received recent attention. Ad-
ministration of high doses of the NMDA receptor co-agonists glycine,
D-alanine, and D-serine improve positive and negative symptoms,
as well as cognitive deﬁcits in schizophrenic patients (Heresco-Levy
et al., 2002 ; Tsai et al., 2006). A promising, alternative strategy
to indirect NMDA facilitation is to activate metabotropic glutamate
5 receptors (mGlu5). We have focused on developing positive
allosteric modulators (PAM), rather than agonists, in the hope that
we might achieve subtype selectivity and have a reduced risk of tox-
icity through excessive mGlu5 activation.
Methods : Selective mGlu5 PAMs are active in various rodent
models predictive of eﬃcacy on positive, negative, and cognitive
symptoms. Although these ﬁndings with mGlu5 receptor PAMs are
exciting, little is known regarding the side-eﬀect liability of these
compounds.
Results : We described structurally novel mGlu5 PAMs which are
selective for mGlu5 receptors and exhibit anti-psychotic like activity.
We demonstrated the potential for neurotoxicity in rats and wild-type
mice but not in mice lacking the expression of mGlu5.
Conclusion : This study reveals for the ﬁrst time that activation of
mGlu5 with selective allosteric modulators can result in mechanism-
based neurotoxicity. It is not yet clear that these eﬀects will be seen
with all PAMs and a detailed analysis of the pharmacological control
of mGluR5 activation by a variety of mGlu5 receptor PAM may be an
important step towards the ﬁnding of new generation antipsychotics.
Policy of full disclosure : Employee of Merck & Co., Inc.
S-29. Molecular and genetic substrates
underpinning diagnosis of major
depression
jS-29-001jMolecular evidence for BDNF- and GABA-related
dysfunctions in the Major Depression
E. Sibille. University of Pittsburgh, Department of Psychiatry, USA
Objective : (1) To investigate primary evidence in support of low
brain-derived neurotrophic factor (BDNF) and reduced GABA func-
tion in the postmortem brain of subjects with depression and matched
controls. (2) To test causal links between BDNF levels and expression
of markers of GABA interneuron subtypes, using mice with gen-
etically altered and reduced BDNF function (BDNF-HZ and BDNF-
IV-KO). (3) To focus on corticolimbic regions (amygdala and anterior
cingulated cortex).
Methods : Large-scale quantiﬁcation of gene expression proﬁles in
depressed and control human subjects (n=y50/group ; amygdala
LBNC nuclei and subgenual anterior cingulated cortex), followed
by quantitative PCR (qPCR) and selected Western blot validations.
qPCR in BDNF-HZ and BDNF-IV-KO rodent samples (amygdala
BLA nuclei and pre-cingulate cortex) assessed the degree of BDNF-
dependency on target genes.
Results : BDNF, or its receptor TRKB, were downregulated in de-
pressed subjects. Robust downregulations were also observed for
gene transcripts coding for GABA interneuron-related peptides that
are known to be BDNF-dependent, including somatostatin (SST), ta-
chykinin (TAC1), neuropeptide Y (NPY) and cortistatin (CORT).
Changes extended to GABA markers (GAD1) that display low or no
BDNF dependency. Notable regional (amygdala/cingulate cortex)
and gender diﬀerence were observed. Out of all clinical and demo-
graphic factors investigated, only age further aﬀected transcript levels
of our genes of interest.
Conclusion : We provide both direct (low RNA/protein) and in-
direct (low BDNF-dependent gene pattern) evidence for reduced
BDNF function in the amygdala and cingulate cortex of MDD sub-
jects. Supporting studies in mutant mouse models suggest a complex
mechanism of upstream BDNF-dependent and independent causal
factors, thus partly linking the neurotrophic and GABA hypotheses
of depression. Notably, the most consistently ﬁndings identiﬁed
reduced markers of GABA interneuron subtypes that target the
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dendritic compartment of excitatory pyramidal cells SST, NPY
and CORT). Together the results suggest a common BDNF/GABA-
related pathology in MDD with gender- and brain region-speciﬁc
features.
jS-29-002j Identifying diﬀerentially methylated regions
in depression and suicide by next generation
sequencing
G. Turecki1, C. Nagy2, M. Suderman2, M. Szyf2, N. Mechawar2,
C. Ernst2. 1McGill University, Department of Psychiatry, Montreal,
Canada ; 2McGill University, Montreal, Canada
Objective : Suicide is a complex and heterogeneous phenomenon. We
have recently described a molecular subphenotype characterized
by extreme low expression of astrocytic genes. In this study, we
investigated the potential role of genomic DNA methylation in this
subphenotype.
Methods : Prefrontal brain samples from 184 subjects were screened
using a combination of techniques to identify extreme low expressors
(ELE). Of these, 21 (11.4%) suicides were ELE and were matched to 21
psychiatrically-unaﬀected controls according to gender, age, PMI and
pH. Genomic DNA was sheared and methylated regions were iso-
lated using methylated binding domain-2 (MBD) protein. Libraries
were made using the Illumina ChIP-Seq library preparation protocol
and each library used one lane of Illumina GAIIx, 36 base pair single
read sequencing. Using the DESeq software, a negative binomial test
was implemented to obtain DMRs between suicides and controls. The
most signiﬁcant results were validated by EpiTyper.
Results : A total of y250 million reads were produced per group
and were used to assess diﬀerentially methylated regions (DMRs).
Reads were trimmed, duplicates removed and the resulting data was
mapped to the human genome (hg19) using BWA. The genome was
tiled using overlapping 500 bp windows at every 250 bp and reads
were counted for each 500 bp interval. 989 DMRs passed multiple
corrections using FDR.
Conclusion : These results point to a large number of genomic
DMRs that may play a role in the neurobiology of suicides. Several of
these DMRs may help explain the ELE phenotype. Studies using
functional models will be useful to characterize these ﬁndings.
jS-29-003jRole of MicroRNAs in depression : Evidence from
animal and human postmortem brain studies
Y. Dwivedi. University of Illinois, Chicago, USA
Objective : microRNAs (miRNAs) are newly discovered gene
expression regulators that have recently been implicated in a variety
of human diseases, including neuropsychiatric diseases. The present
study was undertaken to examine whether the miRNA regulatory
network is altered in depression.
Methods : Expression of miRNAs was measured in prefrontal
cortex of depressed and well-matched non-psychiatric control sub-
jects using multiplex RT-PCR plates. Levels of dicer, drosha, DGCR8
mRNA, and several pri-miRs were determined by qPCR. In addition,
miRNAs were measured in frontal cortex of learned helpless (LH),
non-learned helpless (NLH) and tested control (TC) rats.
Results : miRNA expression was globally down-regulated in
depressed suicide subjects and was accompanied by a signiﬁcant
decrease in inter-individual variability. Using individual tests of
statistical signiﬁcance, 21 miRNAs were signiﬁcantly decreased.
In addition, a set of 29 miRNAs, whose expression was not pairwise
correlated in the normal controls, showed a high degree of co-
regulation across individuals in the depressed group. Changes
in some of the miRNAs were inversely correlated with target gene
expression. Levels of dicer, drosha, DGCR8 mRNA and several
pri-miRs were not signiﬁcantly altered. NLH rats showed a robust
adaptive miRNA response to inescapable shock whereas LH rats
showed a markedly blunted response. One set of 12 miRNAs showed
particularly large, signiﬁcant down-regulation in NLH rats relative
to tested controls. These were encoded at a few shared polycistronic
loci, suggesting that the down-regulation was coordinately controlled
at the level of transcription. We also identiﬁed a core miRNA co-
expression module consisting of 36 miRNAs that were highly
correlated with each other across individuals of the LH group but not
in the NLH or TC groups.
Conclusion : These ﬁndings show that miRNAs contribute sub-
stantially to a reorganization of gene expression networks that occur
in depression. miRNA proﬁling may assist in identifying factors that
correlate with diagnosis, prognosis or response to treatment.
jS-29-004jGenome-wide and candidate gene studies for
neuroticism
D. Rujescu. University of Munich, Dept. of Psychiatry, Germany
Objective : The risk of suicide-related behavior is supposed to be de-
termined by a complex interplay of sociocultural factors, psychiatric
history, personality traits, and genetic vulnerability. This view is
supported by adoption and family studies indicating that suicidal acts
have a genetic contribution that is independent of the heritability of
Axis I and II psychopathology. There is strong evidence for a herita-
bility of suicidal behaviour as shown by family, twin- and adoption
studies. Several studies suggest heritability between 45 and 55%.
There is no doubt that suicidal behavior is not caused by any single
gene but it is a disease with complex genetic features.
Methods : Personality traits could be an intermediate phenotype of
suicidal behavior, which is a trait that reﬂects a tendency toward
negative mood states, and has been linked to internalizing depressive
conditions.
Results : Neuroticism is one example of such an intermediate
phenotype of suicidal behavior and has been linked to internalizing
depressive conditions.
Conclusion : Dan Rujescu will present genome-wide and candidate
gene studies on neuroticism, demonstrating a genetic approach for
discovering potentially important pathogenic pathways for which
clinically powerful (bio)markers may eventually be developed.
S-30. Dosing of antidepressants and anti-
psychotics : Are we doing right?
jS-30-001jCentral D2-occupancy and optimal dosing – does it
apply for atypical antipsychotics?
L. Farde. Karolinska Institute, Stockholm, Sweden
Objective : ‘Receptor occupancy’ is deﬁned as the fraction (%) of a
receptor population that is occupied by an unlabelled drug. Positron
Emission Tomography (PET) measurements of receptor occupancy
have since the 1980’s been extensively been applied for the study of
antipsychotic drug binding. Of particular interest is that patients with
acute extrapyramidal syndromes (EPS) had high D2-occupancy when
compared with patients having no side eﬀects. Based on these ob-
servations we suggested a PET-deﬁned occupancy interval of 70–80%
as optimal for clinical treatment with classical antipsychotics. Careful
clinical titration to a dose which is lower than that which induces EPS
is the proposed strategy to optimize individual treatment. PET-stu-
dies of receptor occupancy have more recently been implemented in
the development of the new generation of antipsychotic drugs. The
aim of the present presentation is to review the literature over the last
25 years.g.
Methods : [11C]raclopride is the most widely used radioligand for
estiamation of antipsychotic drug induced D2-dopamine receptor oc-
cupancy. For comparative purposes, the present survey is limited to
[11C]raclopride data.
Results : The prototype atypical antipsychotic clozapine is the
major lead to identify new mechanisms, Several studies have shown
that patients responding to a wide dose range of clozapine had low
(20–67%) D2 receptor occupancy. More recent data indicate that op-
timal dosing with second generation antipsychotics such as risper-
idone or olanzapine correspond to an occupancy level within the
60–80% interval for typical antipsychotics.
Conclusion : The concept ‘atypical antpsychotic’ was coined
for clozapine in the 1970’s and has since then been widened to more
recently developed antipsychotics. However, PET-studies of anti-
psychotic drug induced occupancy do not conﬁrm that all second
generation antipsychotics show eﬃcacy at the same low occupancy
as clozapine. These observations indicate that clozapine may act at
targets other than the D2 dopamine receptor.
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Policy of full disclosure : Employee and share-holder of
AstraZeneca, Sweden.
jS-30-003jPlasma concentration based dosing of antipsychotics
and antidepressants
C. Hiemke. University of Mainz, Germany
Objective : Psychotropic drug concentrations in blood resulting are
highly variable between individual patients due to variability in drug
metabolism or adherence to the medication. In 1971, it was reported
for nortriptyline that drug concentrations in blood correlate well with
clinical amelioration. Animal studies have shown that antidepressant
and antipsychotic drug concentrations in the brain correlate much
better with drug concentrations in plasma than with the dose. Plasma
concentration based dosing, i.e. therapeutic drug monitoring (TDM),
is therefore superior to symptom based dosing to attain maximal
clinical eﬀectiveness.
Methods : To promote an appropriate use of TDM the TDM ex-
pert group of the Association of Neuropsychoparmacology and
Pharmacopsychiatry (AGNP) updated their guidelines for TDM in
psychiatry.
Results : Evidence-based ‘‘therapeutic reference ranges’’ and
‘‘dose related reference ranges’’ were elaborated after intensive
literature research and intensive discussions for 30 antipsychotic and
26 antidepressant drugs. A ‘‘laboratory alert level ’’ was newly in-
troduced above which the laboratory should immediately inform the
treating physician. Recommendations are also given when TDM
should be supported with pharmacogenetic tests. Supportive infor-
mation such as substrate, inhibitor or inducer properties of medica-
tions is provided for the interpretative service.
Conclusion : This presentation will show how to use the updated
guidelines to improve outcomes of psychopharmacotherapy of many
patients, especially in case of pharmacokinetic problems.
Policy of full disclosure : Dr. Hiemke has served served on the
speakers’ bureau of AstraZeneca, Bristol-Myers Squibb, Eli Lilly,
Janssen Cilag, Pﬁzer, Servier, and Wyeth. He is managing director of
the psiac company.
jS-30-004jDosing of antipsychotics and antidepressants :
Guidance from PET imaging
G. Gru¨nder1, C. Hiemke2, M. Paulzen1, T. Veselinovic1, I. Vernaleken1.
1RWTH Aachen University, Germany ; 2Mainz, Germany
Objective : Rational pharmacotherapy is based on the assumption
that the wanted and unwanted clinical eﬀects of a speciﬁc psycho-
tropic drug are directly related to its occupancy of the molecular
target. Here we show that positron emission tomography (PET) of
drug targets in the brain (neuroreceptors and transporters) allows for
establishment of these relationships, thereby providing guidance for
clinical dosing regimens.
Methods : Associations between brain target occupancy, plasma
concentrations, and clinical eﬀects and side eﬀects will be discussed
for the most commonly used antidepressant and antipsychotic drugs.
It will also be demonstrated that PET studies unmasked some tra-
ditional dosing strategies as wrong and potentially harmful.
Results : Research over the past two decades has clearly established
relationships between target engagement of the most commonly pre-
scribed antidepressants (especially selective serotonin reuptake
inhibitors) and antipsychotics and clinically useful doses of these
drugs. This is especially true for the class of antipsychotics. However,
it will be demonstrated that the recommended doses of haloperidol
(and some other ﬁrst-generation antipsychotics) are still too high
based on PET studies. In addition, some newer antidepressants (e.g.,
bupropion) exemplify that questions related to rational dosing di-
rectly allude to problems of mechanism of action.
Conclusion :Nuclear imaging with PET is one of the most powerful
tools to determine and validate rational drug doses and the respective
plasma concentrations. In the future, PET studies on the relation-
ship between brain target engagement and plasma levels should
complement the development of every psychotropic drug. This will
allow for the establishment of TDM services and, consequently,
for rational dosing right from the introduction of a new drug to the
market.
Policy of full disclosure : Dr. Gru¨nder has served as a consultant
for Astra Zeneca, Bristol-Myers Squibb, Cheplapharm, Eli Lilly,
Johnson & Johnson, Lundbeck, Otsuka, and Servier. He has served on
the speakers’ bureau of Astra Zeneca, Bristol-Myers Squibb, Eli Lilly,
Janssen Cilag, Otsuka, Pﬁzer, Servier, and Wyeth. He has received
grant support from Alkermes, Bristol-Myers Squibb, Eli Lilly, and
Johnson & Johnson. He is co-founder of Pharma-Image – Molecular
Imaging Technologies GmbH, Du¨sseldorf, Germany. Dr. Hiemke has
served as a consultant for Servier. He has received grant support from
Pﬁzer and Sanoﬁ-Aventis and served on the speakers’ bureau of
AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen Cilag, Pﬁzer,
Servier, and Wyeth. Dr. Paulzen declares no conﬂicts of interest.
Dr. Veselinovic has received grant support from Bristol-Myers
Squibb. Dr. Vernaleken has served on the speakers’ bureau of Bristol-
Myers Squibb, Eli Lilly, and GlaxoSmithKline.
S-31. Lithium and novel targets in bipolar
disorders
jS-31-001j Interfering with the activating eﬀect of calbindin
D28k on inositol mono-phosphatase activity to
mimic lithium’s inhibitory eﬀect on the enzyme
at a diﬀerent site of action
G. Agam1, L. Toker2, Y. Bersudsky3, I. Plaschkes4, V. Chalifa-Caspi5,
G. Berry6, D. Moechars7, R. Belmaker8. 1Beer-Sheva, Israel ; 2Faculty
of Health Sciences ; 3Psychiatry Research Unit ; 45National Institute
for Biotechnology in the Negev (NIBN) ; 55National Institute for
Biotechnology in the Negev (NIBN), Beer-Sheva, Israel ; 6Metabolism
Program Division of Genetics ; 7 Johnson & Johnson Pharmaceutical
Research and Development, Beerse, Belgium ; 8Beer Sheva, Israel
Objective : Clinical eﬃcacy of lithium (Li) is characterized by a lag
in onset of 1–3 weeks suggesting that the therapeutic eﬀect requires
reprogramming of gene expression. Previous studies have shown
alteration in gene expression following mood stabilizing drug treat-
ment in a variety of genes, including genes involved in inositol
metabolism. Inositol-monophosphatase (IMPase)-1 is inhibited by
therapeutically-relevant Li concentrations in an uncompetitive
manner, possibly resulting in decreased inositol, subsequent down
regulation of the phosphatidylinositol (PI) cycle and dampening of
assumed hyperactive neurotransmission through this pathway (the
‘‘ inositol depletion’’ hypothesis). Li was also shown to down-regulate
the expression of sodium myo-inositol co-transporter (SMIT)1, re-
sponsible for the uptake of myo-inositol from extracellular ﬂuid. Both
IMPA1 and SMIT1 homozygote knockout (KO) mice exhibit Li-like
behavior in the forced-swim test (FST) and the pilocarpine-induced
seizures paradigm. We aimed to identify gene networks and path-
ways aﬀected in homozygote IMPA1 and SMIT1 knockout mice and
in Li-treated mice compared with wild-type (WT) untreated mice.
Methods : Male, 2 month old, IMPA1 KO, SMIT1 KO and their lit-
termate WTmice were used. Mice received powdered food. Li-treated
WTmice received powdered food supplemented with 0.2% Li for ﬁve
days, followed by 0.4% Li for another 10 days. DNA microarray
analysis was performed using the Aﬃmetrix platform. Results were
analyzed using the software Ingenuity Pathway Analysis (IPA), GSEA
and DAVID.
Results : We show that Oxidative Phosphorylation and
Mitochondrial Function are the only signiﬁcant pathways aﬀected in
the frontal cortex of SMIT1 and IMPA1 knockout mice and Li-treated
mice. To verify this result the interrelationship between Li treatment
and a pharmacological intervention in mitochondrial function by
chronic mild treatment with rotenone, an inhibitor of the oxidative
phosphorylation complex I, was studied behaviorally in bipolar
disorder-related animal models. As hypothesized based on the
microarray results, Li and rotenone counteracted each other’s eﬀects
both in the FST model of depression-like despair behavior and in
the amphetamine-induced hyperlocomotion model of manic-like
behavior.
Conclusion : Our results corroborate previous ﬁnding in bipolar
patients suggesting that improvement of mitochondrial dysfunction
might underlie the therapeutic eﬀect of Li, support the inositol de-
pletion hypothesis of the molecular mechanism of mood stabilization
and suggest that a consequent end point is amelioration of aberrant
mitochondrial function in patients by its up-regulation.
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jS-31-002jLithium is a gold standard in bipolar illness.
Is it indicated for other conditions?
M. Alda. Dalhousie University, Halifax, Canada
Objective : Lithium is established as a ﬁrst-line long term treatment
of bipolar disorder, but it may be beneﬁcial in other conditions as
well. In this presentation I will review the eﬀects of lithium based on
published evidence and present data from two large datasets.
Methods : First we studied risk factors for completed and attempted
suicide in 737 families of probands with bipolar disorder in Nova
Scotia and Sardinia. In the second study we examined lithium use
and prevalence of neurodegenerative conditions in the Province of
Nova Scotia. Speciﬁcally, we linked population databases containing
data on persons diagnosed with Alzheimer’s disease, multi-infarct
dementia, Parkinson’s disease and stroke with prescription database
of individuals older than 65 years.
Results : Published evidence suggests that lithium can be beneﬁcial
in major depression, aggressive behaviour, prevention of suicide,
and cluster headaches among others ; it is also being investigated
for neuroprotective eﬀects in neurodegenerative conditions such as
amyotrophic lateral sclerosis or Alzheimer’s disease. In the family
study, the risk of suicide was signiﬁcantly reduced in those subjects
who showed partial or full stabilization on lithium. In the population
study, rates of all studied conditions were signiﬁcantly elevated
in those with bipolar disorder not on lithium (n=1173) compared
with control subjects. History of at least one prescription of lithium
(n=797) was associated with moderate reduction of the risk of
Alzheimer’s disease and chronic stroke, but not the other diagnoses.
Conclusion : In addition to prevention of manic and depressive
episodes in bipolar disorder, lithium appears beneﬁcial in a range of
conditions. The most intriguing are its antisuicidal and neuroprotec-
tive eﬀects. Interestingly, the prevention of suicide may be indepen-
dent of the mood-stabilizing properties. However, it remains to be
determined if the neuroprotective eﬀects of lithium are at the core of
its prophylactic action in bipolar disorder.
jS-31-003jNeurocognition as a lithium target in bipolar
disorder
J. Rybakowski. Poznan Univ Med Sciences, Department of Adult
Psychiatry, Poland
Objective : The aim of this study is to assess the performance on
neuropsychological tests in patients with bipolar illness receiving
long-term lithium prophylaxis compared to matched healthy control
subjects, and to relate the cognitive performance to the functional
Val66Met brain derived neurotrophic factor (BDNF) gene poly-
morphism, BDNF serum level and the quality of lithium prophylaxis.
Methods : Patients with bipolar mood disorder on long-term (5–25
years) lithium treatment were genotyped for Val66Met BDNF gene
polymorphism. The Wisconsin Card Sorting Test (WCST) was com-
pared in 30 lithium treated-patients, among which 7 were lithium
non-responders (NR), with 30 age-and gender matched healthy con-
trol subjects. Also, four tests from the CANTAB battery (Spatial
Working Memory, Spatial Span, Stockings of Cambridge and Rapid
Visual Information Processing) and BDNF serum lithium levels
were compared between 60 lithium-treated patients, 13 of which were
excellent lithium responders (ER) and 84 healthy control subjects.
Results : The patients with Met allele of BDNF polymorphism
showed signiﬁcantly better response to lithium prophylaxis suggest-
ing that lithium could be more eﬀective in subjects with lower activity
of BDNF system. NR performed worse on WCST compared to
matched healthy subjects, signiﬁcantly so on perseverative errors
(WCST-P) and conceptual responses (WCST-%conc). The perform-
ance on CANTAB tests was signiﬁcantly worse in lithium-treated
patients as a group, compared with matched healthy control subjects.
However, the results of ER as well as serum BDNF lithium level were
not diﬀerent from those of the healthy persons.
Conclusion : Favorable response to lithium may be connected with
preservation or even augmentation of cognitive functions. In ER after
many years of successful lithium prophylaxis, the performance on
neuropsychological tests and BDNF serum level was not diﬀerent
from that of matched healthy control subjects. ER may constitute a
speciﬁc group of bipolar patients in which long-term lithium admin-
istration can produce complete normality.
jS-31-004jThe Consortium on Lithium Genetics (ConLiGen) :
Genome-wide association studies of lithium
response phenotypes in bipolar disorder
T. Schulze1, U. Boer1. 1University of Goettingen, Germany
Objective : Lithium remains a mainstay in the long-term treatment of
BD. Response to lithium is variable. About 30% of patients treated
with lithium have fewer illness episodes over time, while about 20%
have no response. Data from pharmacogenetic studies of lithium are
comparatively sparse, and these studies have generally employed
small sample sizes and varying deﬁnitions of response. Genetic mar-
kers of lithium response would be valuable for treatment planning
and could provide insights into the biological mechanism of lithium
action. To put that idea into practice, the international Consortium on
Lithium Genetics (www.ConLiGen.org) was established.
Methods : ConLiGen has now collected over 1400 lithium-treated
bipolar disorder (BD) patients. All patients have been characterized
for lithium response with an 11-point treatment response scale (‘‘Alda
Scale’’, Grof et al., 2002). The Alda Scale assesses clinical improve-
ment attributable to lithium, taking into account the history and fre-
quency of episodes, duration of treatment, medication adherence, and
concurrent treatment. Phenotype deﬁnitions were developed by con-
sensus within ConLiGen. The whole sample has been genotyped
using Illumina arrays to perform a genome-wide association study
(GWAS) of lithium response.
Results : Inter-rater reliability of lithium response assessment was
good, with kappa values>0.7. Given a responder rate of 35%, the
ConLiGen sample has>80% power to detect a common allele that
confers a genotype relative risk of response of 1.5, at genome-wide
signiﬁcance. At the time of abstract submission (12/2011) genotyping
has been completed, and preliminary quality control data indicates
excellent call rates. (>99% of samples have a call rate>98%) GWAS
completion is expected for 04/2012.
Conclusion : Genetic ﬁndings from ConLiGen could have import-
ant implications for treatment planning and for developing new drugs
that mimic the action of lithium but are better tolerated and more
eﬀective.
S-32. Novel NMDA amino acids for the
pathophysiology and treatment of
mental disorders
jS-32-001jNovel mechanism of regulation of N-methyl-
D-aspartate neurotransmission for CNS disorders
G. Tsai. Harbor-UCLA Med CTR, Torrance, USA
Objective : D-amino acid oxidase activator (DAAOA, or named G72)
is a primate speciﬁc regulator of DAAO. Both DAAO and DAAOA are
strong susceptibility genes for schizophrenia. DAAO metabolizes
D-serine, which is a potent coagonist at the ‘‘glycine’’ site of NMDA
receptor (see ﬁgure). To date, trials of NMDA-enhancing agents,
including glycine, D-serine, D-alanine, and sarcosine (a glycine
transporter I inhibitor), reveal beneﬁcial eﬃcacy for the symptoms of
schizophrenia. In addition, benzoate is a DAAO inhibitor which can
elevate synaptic concentration of D-serine.
Methods :We explored the eﬀect of benzoate on prepulse inhibition
(PPI) and forced swimming test (FST) in rodent and examined the
eﬃcacy and safety of add-on treatment of benzoate for schizophrenia
by a randomized, double-blind, placebo-controlled trial. We also de-
termine whether G72 can serve as a biomarker for schizophrenia.
Results : Benzoate can reverse ketamine-induced deﬁcit in PPI and
reduce the duration of immobility in FST. Benzoate treatment pro-
duces substantial improvement in the scores of PANSS, SANS, QOL,
CGI and HAMD as well as 3 cognitive domains of MATRICS battery
(processing speed, verbal learning, and visual learning). The ex-
pression of plasma G72 protein in schizophrenia was signiﬁcantly
higher than in healthy controls. G72 protein expression is similar
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between drug-free vs. medicated schizophrenia patients. PANSS-
negative score showed a negative correlation with G72 levels.
The logistic regression analysis suggests that plasma G72 protein
can be a diagnostic biomarker for schizophrenia (OR=6.90, 95%
CI=3.45x13.85). The ROC curve showed that a cut-oﬀ level of
1.48 pg/ml of plasma G72 protein can reach 85% sensitivity and a 91%
speciﬁcity for separating schizophrenia from control (AUC=0.89).
Conclusion : Taken together the animal and human ﬁndings, DAA-
DAAO-DAAOA is an novel NMDA pathway that can be exploited for
the diagnosis and treatment of schizophrenia.
Policy of full disclosure : Dr. Tsai is the inventor for US patents
6228875, 6667297, 6420351, 6974821, 2010/0189818 for the use of
NMDA agents in CNS disorders.
jS-32-002jGlyT-1 and DAAO inhibitors as potential
therapeutic drugs for schizophrenia
K. Hashimoto. Chiba University, Japan
Objective : Accumulating evidence suggests that the glycine modu-
latory site on N-methyl-D-aspartate (NMDA) receptor is a potential
therapeutic target for schizophrenia. Increasing synaptic levels of
glycine by inhibition of glycine transporter-1 (GlyT-1) on glial cells
will lead to enhanced NMDA receptor activation. In contrast, D-
serine, an endogenous co-agonist for the glycine modulatory site on
NMDA receptor, is metabolized by D-amino acid oxidase (DAAO)
which may decrease oral bioavailability of D-serine. In this study,
we examined the eﬀects of GlyT-1 inhibitors and a combination of
D-serine with a DAAO inhibitor on animal models of schizophrenia.
Methods : The eﬀects of GlyT-1 inhibitor NFPS on cognitive deﬁcits
in mice after repeated administration of NMDA receptor antagonist
phencyclidine (PCP) were examined. Furthermore, we measured the
levels of GlyT-1 protein and amino acids in the frontal cortex and
hippocampus of mice treated with PCP. The eﬀects of D-serine with or
without a potent DAAO inhibitor 5-chloro-benzo[d]isoxazol-3-ol
(CBIO) on prepulse inhibition (PPI) deﬁcits in mice after adminis-
tration of NMDA receptor antagonist dizocilpine were examined.
Moreover, the extracellular levels of D-serine in the brain were
measured using in vivo microdialysis method.
Results : Cognitive deﬁcits in mice after the repeated administration
of PCP were signiﬁcantly improved by subsequent subchronic ad-
ministration of NFPS and D-serine. Repeated administration of PCP
signiﬁcantly increased the levels of GlyT-1 protein in the hippo-
campus, but not frontal cortex. Furthermore, we found that co-
administration of CBIO increased the oral bioavailability of D-serine
in mice, and that co-administration of CBIO signiﬁcantly enhanced
the eﬃcacy of D-serine in attenuating dizocilpine-induced PPI deﬁcits
in mice.
Conclusion : These ﬁndings suggest that GlyT-1 inhibitors and a
combination with D-serine plus a DAAO inhibitor would be new ap-
proaches for the treatment of schizophrenia.
jS-32-003jTreatment of NMDA agonist, glycine transporter I
Inhibitor and D-Amino acid oxidase inhibitor for
mental disorders
H.-Y. Lane. China Medical University, Taichung, Taiwan
Objective : Enhancement of NMDA neurotransmission has been
proposed as a potential treatment of schizophrenia and other mental
disorders. Several studies targeted at the glycine site of the NMDA
receptor using full agonists (glycine, D-serine, D-alanine) or the
partial agonist D-cycloserine. Another strategy to improve NMDA
neurotransmission is increasing the synaptic glycine level by blocking
the glycine transporter-1 (GlyT-1). The third strategy is increasing
synaptic concentrations of D-serine and D-alanine by inhibiting
D-amino acid oxidase (DAAO).
Methods : N-methylglycine (sarcosine), exiting in human tissues
(including blood, muscle, brain) and many foods, is the prototype
GlyT-1 inhibitor. Sodium benzoate, a legal food additive, is an in-
hibitor of DAAO. We conducted several studies.
Results : A pilot clinical trial demonstrated that sarcosine adjuvant
therapy improved positive and negative symptoms in patients with
chronically stable schizophrenia. More recent studies further suggest
that add-on sarcosine, superior to D-serine, can beneﬁt the negative
symptoms in both acutely ill and chronically stable patients, and that
sarcosine can be used as monotherapy in acute psychosis. Sarcosine
also improves life quality and functioning. Our study also showed
that sarcosine was more eﬃcacious than a commonly used anti-
depressant, citalopram (a selective serotonin reuptake inhibitor), in
the treatment of major depressive disorder. The sarcosine-treated
patients improved more in global functioning and were more likely
to be remitters. Sarcosine monotherapy also beneﬁted drug-naı¨ve
patients with obsessive compulsive disorder. In a double-blind,
placebo-controlled trial, 6-week, 1-g/day sodium benzoate adjunctive
therapy signiﬁcantly and safely improved positive, negative, general,
and cognitive symptoms in patients with chronic schizophrenia.
Conclusion : These ﬁndings indicate that enhancing NMDA func-
tion via inhibiting GlyT-1 or DAAO can improve symptoms of schizo-
phrenia or other mental disorders and can be a novel mechanism for
drug development.
jS-32-004jD-Serine, glia-synapse interaction and schizophrenia
T. Nishikawa. Tokyo Medical and Dental University, Japan
Objective : An endogenous coagonist for the N-methyl-D-aspartate
(NMDA) type glutamate receptor (NMDA receptor), D-serine, and its
metabolic pathways in the brain could be dysregulated in and the
suitable targets for the development of a novel pharmacotherapy for
schizophrenia, because (1) NMDA receptor antagonists cause positive
and negative symptoms indistinguishable from those of schizo-
phrenia and (2) D-serine has been reported to ameliorate these
symptoms in schizophrenic patients as well as their animal models.
To obtain further insight into these possibilities, we have investigated
the molecular and cellular mechanisms underlying the D-serine
metabolism and signaling.
Methods : A molecular cloning, quantitative analysis of various
amino acids by high-performance liquid chromatography, in vivo
microdialysis, and single nucleotide polymorphism genotyping tech-
nique were applied to the present animal and human studies that
have been approved by the ethics committees of the Tokyo Medical
and Dental University and National Center of Neurology and
Psychiatry.
Results : In the rodent brains, the selective destruction or activity
manipulations of the neurons and glia resulted in the changes in the
tissue and extracellular contents of D-serine in a diﬀerent ways from
those observed in classical neurotransmitters, and a local application
of agents acting at the a-amino-3-hydroxyl-5-methyl-4-isoxazole-pro-
pionate type glutamate receptor and the GABAA receptor. Moreover,
we have isolated a gene, D-serine-modulator-1, which encodes the
protein inﬂuencing the intra- and extracellular D-serine contents
when expressed in the Xenopus oocytes and its association studies are
in progress.
Conclusion : These ﬁndings suggest that brain D-serine might par-
ticipate in glia-glutamate synapse communication linked with the
glutamate-GABA interaction, which could malfunction in a group of
schizophrenia. The molecules composing these systems might be the
new candidate targets for the D-serine modulating anti-schizophrenic
agents.
Thursday 7 June 2012
S-33. Do psychotropics aﬀect brain structure?
Linking animal models, imaging and
clinical studies
jS-33-001jContrasting eﬀects of antipsychotics and lithium on
the brain : In-vivo MRI and ex-vivo conﬁrmation
S. Kapur. Institute of Psychiatry, London, United Kingdom
It has long been a matter of controversy whether psychotropic drugs,
particularly antipsychotics and lithium, have an eﬀect on ‘brain struc-
ture’. To address this issue, we implemented a model in rats com-
bining serial in vivo MRI, ex vivo MRI and post-mortem analysis with
clinically relevant drug doses. Haloperidol (HAL, 2 mg/kg/d), olan-
zapine (OLZ, 10 mg/kg/d) or vehicle (b-hydroxypropylcyclodextrin,
S-33. Do psychotropics aﬀect brain structure? Linking animal models, imaging and clinical studies 37
Downloaded from https://academic.oup.com/ijnp/article-abstract/15/Supplement_1/1/650920
by University of Groningen user
on 13 March 2018
20% w/v, acidiﬁed by ascorbic acid, to pH 6) was continuously ad-
ministered to rats for 8 weeks (wks). In a second group, HAL (0.5,
2 mg/kg/d) or lithium chloride (LiCl, 2 mMeq./kg/d) was adminis-
tered for 8 wks followed by an equivalent wash out period (16 wks
total). Drugs were given subcutaneously via osmotic mini-pumps.
Serial MRI scans were obtained, and after the terminal scan the ani-
mals were perfused, ex vivo MRI scans acquired and brain tissue
processed for post-mortem analysis. Region of interest (ROI) volume
analyses were performed onMR images and post-mortem brain tissue
by 2 independent raters blinded to treatment group. Chronic (8 wks)
HAL and OLZ treatment resulted in decreased whole brain and cor-
tical volume, the magnitude of this eﬀect being smaller in OLZ-treated
animals. Chronic HAL, but not OLZ, increased striatal volume in
vivo. In contrast, chronic LiCl (8 wks) increased whole brain and
cortical volume in vivo. The drug eﬀects tended to reverse with the
washout, with the exception that LiCl-treated animals retained greater
whole brain volume. These data were conﬁrmed by ex vivo MRI and
all MRI data were conﬁrmed post-mortem using unbiased stereology.
Thus, chronic treatment with APD and LiCl has contrasting eﬀects on
rat brain structure, though some of these eﬀects appear to be revers-
ible. The cellular basis of these changes is currently under investi-
gation. The ﬁndings provide the ﬁrst systematic MRI-post-mortem
study of these drugs and provide a basis for understanding some of
the clinical studies with MRI.
Policy of full disclosure : $ There is no ex vivo MRI data for
animals who were ON then OFF drug for 8 weeks. We only conﬁrmed
the data post-mortem $ We have no data on drug withdrawal for
Olanzapine.
jS-33-002jAntipsychotic medications and progressive brain
tissue loss in schizophrenia
N. Andreasen. University of Iowa, Department of Psychiatry, Iowa City,
USA
Objective : Studies comparing brain volume measurements in pa-
tients at the time of onset with healthy normal volunteers have in-
dicated that the patients have smaller mean volumes in many regions,
particularly frontal cortex. Furthermore, longitudinal studies have
shown that the mean diﬀerences in brain volumes continue to prog-
ress over time and that these diﬀerences have functional signiﬁcance,
in that they are related to cognitive impairments. The focus of scien-
tiﬁc attention is now on determining why the tissue loss occurs and
why it continues to progress. The loss is very likely due to multiple
factors : genes and their expression, environmental factors such as
substance abuse, eﬀects of treatment, and eﬀects of the course of the
disease. This presentation examines two of these factors : treatment
eﬀects and disease progression as measured by number and duration
of relapse.
Methods : We studied 202 patients drawn from the Iowa
Longitudinal Study of First Episode Schizophrenia (ILS) for whomwe
have adequate sMR data (N=661 scans, an average of 3/subject) ob-
tained at regular intervals over an average time period of seven years.
Because we obtained clinical follow-up data at six-month intervals,
we were able to obtain measures of treatment intensity using dose-
years and of relapse number and duration and relate them to sMR
measures.
Results : Both antipsychotic treatment intensity and relapse dur-
ation were independently and signiﬁcantly related to progressive
brain tissue loss. However, the tissue types and regions aﬀected were
somewhat diﬀerent.
Conclusion : Thus, paradoxically, two factors appear to account for
the brain changes that occur after the onset of schizophrenia : relapse
duration and intensity of antipsychotic treatment. Determining how
to balance the impact of these factors poses a major clinical and
scientiﬁc challenge.
Policy of full disclosure : Funding sources : research grants from
NIMH and Janssen Scientiﬁc Aﬀairs.
jS-33-003jDrugs, stress and inﬂammation : Explaining
progressive brain changes in schizophrenia
C. Pantelis. University of Melbourne, Australia
Objective : In schizophrenia the view since the 1980’s was that
brain pathology begins during foetal development and is static. This
suggested that identiﬁcation of abnormalities in patients with estab-
lished disorder would provide markers relevant to early identiﬁcation
of at-risk individuals. However, the available neuroimaging evidence
in early illness stages does not support such a notion. Rather, the
evidence indicates that there is neuroprogression in psychotic dis-
orders (Pantelis et al., Schizophr Bull, 2005). Such progressive change
is also consistent with the clinical picture of psychosis. Thus, clinical
deterioration is often observed over the ﬁrst few years of the illness.
While progressive brain changes over the initial phase of illness are
consistent with the clinical deterioration, there is a continuing debate
about their validity, and the nature of the underlying neuropathology.
Criticism has been levelled at the methods, the possibility of artefact,
the impact of therapeutic as well as illicit drugs, diagnostic hetero-
geneity, and the inﬂuence of factors like stress and HPA-axis function.
Recent evidence has investigated these factors.
Methods : Our group has undertaken a series of longitudinal ima-
ging studies across the stages of illness from pre-psychosis onset and
has examined some of these potential confounds.
Results : I will present the ﬁndings from our series of studies
investigating progressive brain changes in psychosis from before ill-
ness onset and examine confounds that may explain these changes
(esp. cannabis, stress and the eﬀects of medication).
Conclusion : Progressive brain changes begin from before
illness onset and are most apparent over the ﬁrst few years of illness.
Factors such as drug use, the impact of stress and medication need
to be taken into account in understanding these changes. I will also
discuss the possible role of neuroinﬂammation and how this may be
examined.
Policy of full disclosure : The studies were funded by National
Health and Medical Research Council (NHMRC) of Australia and
Australian Research Council (ARC). Additional support was pro-
vided by University of Melbourne, Melbourne Health, Jack Brockhoﬀ
Foundation, Ian Potter Foundation, AE Rowden White Foundation,
Ramaciotti Foundation, Pratt Foundation, Woods Family Trust,
Rebecca L Cooper Medical Research Foundation, Australian
Computing & Communications Institute, Wellcome Trust, NARSAD,
Stanley Foundation. The PET study was funded by Janssen-Cilag.
jS-33-004jLithium eﬀects on brain gray matter volumes
P.F. Renshaw1, T.-S. Kim1. 1University of Utah, Salt Lake city, UT, USA
Objective : The monovalent cation lithium remains one of the ﬁrst-
line mood stabilizing agents for the treatment of bipolar disorder (BD)
in both the acute and maintenance phases. A substantial amount of
preclinical and clinical evidence suggests that lithium may exert
neuroprotective and/or neurotrophic eﬀects in response to a range of
insults. This presentation will provide an overview of the evidence in
support of neuroprotective and/or neurotrophic eﬀects of lithium on
the brain and suggest clinically related research directions for future
studies.
Methods : The authors review animal and cellular studies that ex-
plore the eﬀects of lithium on neurons and structural neuroimaging
studies that investigate the relationship between lithium use and
brain gray matter (GM) volume in BD patients.
Results : A number of preclinical studies have demonstrated
that lithium increases the neuroprotective proteins, bcl-2 and brain-
derived neurotrophic factor ; inhibits glycogen synthase kinase 3b ac-
tivity to regulate phosphorylated tau and b-catenin ; and protects
brain cells from glutamate-induced, N-methyl-D-aspartate receptor-
mediated apoptosis. Several structural neuroimaging studies have
supported the neuroprotective and potentially neuroregenerative
eﬀects of lithium in BD patients. Recent meta-analyses have also
suggested that lithium use in BD patients may be associated with
volume increments not only in total GM but also in hippocampus and
amygdala. Longitudinal neuroimaging studies have corroborated the
lithium-induced increase in GM volume of BD, especially in the pre-
frontal cortex. Interestingly, these neurotrophic eﬀects have also been
associated with positive clinical response to treatment in BD.
Conclusion : Preclinical and clinical studies suggest that lithium
may have neuroprotective and/or neurotrophic eﬀects and its use
in BD patients may be related to volumetric increase of GM. Future
studies will be needed to investigate possible lithium eﬀects on the
GM volume of speciﬁc brain regions related to cognitive and
emotional symptoms in BD patients.
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Policy of full disclosure : Professor Renshaw is a consultant to
Kyowa Hakko and Ridge Diagnostics. Dr. Kim has no ﬁnancial con-
ﬂict of interest.
S-34. Molecular imaging biomarkers in major
CNS diseases and drug development
jS-34-001jTranslational prediction and validation of imaging
biomarkers
T. Suhara. National Institute of Japan, Radiological Sciences, Chiba, Japan
Alzheimer’s disease is featured at a molecular level by depositions of
self-aggregating molecules, as represented by amyloid b peptides
(Ab) and tau proteins. Mutagenesis and multiplication of the genes
encoding Ab, tau and other pathogenic initiators may accelerate the
incipient process Ab and tau protein. Requirements for a side-by-side
comparison of PET-detectable Ab lesions in AD patients and amyloid
precursor protein (APP) transgenic mice has revealed that these
amyloid ligands preferentially bind to an N-terminally truncated,
modiﬁed Ab subspecies dubbed AbN3pE. A genetic deﬁciency of an
Ab-degrading enzyme, neprilysin, has given rise to selective over-
production of AbN3pE, enhanced amyloid PET signals and aug-
mented cognitive deterioration in APP transgenics, supporting the
notion that AbN3pE is a major constituent of binding sites for radi-
oligands and disrupts neuronal integrities. Multi-tracer, multi-scan
PET study is also of pivotal importance using PET ligand for translo-
cator protein (TSPO) for capturing glial activation. Neuroimaging
biomarkers would also promote bidirectional translational research
between clinical and preclinical levels, since they serve as common
indices shared by humans and animal models and thus ease ex-
trapolation of pathobiological information in a reciprocal manner.
jS-34-002jAmyloid imaging : A boost for drug development
K. van Laere. Leuven, Belgium
Since the ﬁrst human imaging trials with 11C-PIB less than a decade
ago, large eﬀorts by industry and academia have resulted in a boost
of speciﬁc and clinically applicable 18F-labeled radiotracers for
beta-amyloid. This was led both by clinical demand for early and
diﬀerential diagnostic tools for in vivo assessment of amyloidosis
in Alzheimer’s disease and other forms of dementia, as well as the
commercial drive for a biomarker for objective quantitative assess-
ment of disease burden in anti-amyloid trials. Early 2012, at least ﬁve
18F-labeled amyloid ligands are in phase II or III clinical trials, and
three are expected to obtain FDA approval in the course of 2012–2013 :
18F-ﬂutemetamol, 18F-ﬂorbetaben and 18F-ﬂorbetapir. 18F-AZD4694
and 18F-MK3328 are two more recent compounds, currently in phase
II trials. Despite some diﬀerences in dynamic range, all these ligands
allow excellent separation of amyloid positive scans versus controls.
Neuropathology correlations have shown the robustness of in vivo
amyloid imaging. Whereas aspeciﬁc uptake in white matter is seen for
all the above ligands, this does not seem to hamper high diagnostic
accuracy in binary scan classiﬁcation under clinical conditions either
by visual read or simpliﬁed semiquantiﬁcation. Ongoing multicenter
eﬀorts are showing that amyloid imaging in MCI has especially a very
high negative predictive value for AD conversion. Regarding normal
aging, a small proportion of elderly healthy individuals have positive
amyloid scans and the signiﬁcance of this ﬁnding is currently inves-
tigated in longitudinal studies. Amyloid PET is highly discriminative
in frontotemporal dementia, while elevated tracer binding is observed
in many Lewy body dementia patients. Although the ﬁrst results
of clinical trials using imaging show only modest eﬃcacy of anti-
amyloid therapies, the large scale availability of 18F-labeled imaging
compounds will certainly contribute to further drug development
and especially allow widespread clinical application in the very near
future.
jS-34-003j Imaging biomarkers in substance abuse
G. Gru¨nder1, L. Rademacher1, K. Spreckelmeyer1, M. Paulzen1,
S. Prinz1, I. Vernaleken1. 1RWTH Aachen University, Germany
Objective : Functional imaging has been increasingly used in the
past decade for the characterization of patients with substance abuse
disorders in order to gain insight in the neurobiology of these diseases
and to enhance the development of drugs to treat them. Here we will
review the current knowledge.
Methods : The available PET studies especially on the function
dopamine systems in substance abuse will be reviewed, with a focus
on alcohol and nicotine dependence and special emphasis on own
studies in those patient groups. FMRI studies will be discussed
where relevant for the interpretation and understanding of the PET
studies.
Results : Irrespective of the abused drug, dopamine D2 receptors
seem to be down-regulated and presynaptic dopamine function is
apparently reduced in substance abuse disorders. Furthermore, the
interaction between dopamine and other neurotransmitter systems,
such as the opioidergic, seems to be dysregulated in a speciﬁc manner.
FMRI studies demonstrate that the response of the reward system to
drug-related cues is increased, while processing of cues not related to
drug-use is diminished.
Conclusion : Substance abuse disorders irrespective of the abused
drug share in common similar molecular imaging biomarkers, which
can be used both for characterization of these disorders and for
evaluation of anticraving drugs. Furthermore, functional magnetic
resonance imaging can complement PET imaging, thereby providing
information a single modality is unable to deliver.
Policy of full disclosure : Dr. Gru¨nder has served as a consultant
for Astra Zeneca, Bristol-Myers Squibb, Cheplapharm, Eli Lilly,
Johnson & Johnson, Lundbeck, Otsuka, and Servier. He has served on
the speakers’ bureau of Astra Zeneca, Bristol-Myers Squibb, Eli Lilly,
Janssen Cilag, Otsuka, Pﬁzer, Servier, and Wyeth. He has received
grant support from Alkermes, Bristol-Myers Squibb, Eli Lilly, and
Johnson & Johnson. He is co-founder of Pharma-Image – Molecular
Imaging Technologies GmbH, Du¨sseldorf, Germany. Dr. Vernaleken
has served on the speakers’ bureau of Bristol-Myers Squibb, Eli Lilly,
and GlaxoSmithKline. The other authors declare no conﬂicts of
interest.
jS-34-004jNovel PET biomarkers for dementia and psychosis
and target engagement : Cannabinoids, metabotropic
glutamate, glycine and beyond
D.F. Wong1, H. Kuwabara2, Y. Zhou2, E. Borroni1, R. Waterhouse1,
J. Brasic1, A. Rahmim1, W. Mathews1, A. Horti1, R. Dannals1.
1Baltimore, USA ; 2 Johns Hopkins University, Baltimore, USA
Objective : There are challenges associated with the development of
new drugs, especially in neuropsychiatry, particularly in industry
sponsored research. This is despite the continuing morbidity and
challenges in treatment of schizophrenia and the exponential increase
expected in dementia related disorders. There clearly is a need to meet
these increasing public health needs. It has been suggested by some
leaders in the drug development ﬁeld that much of the eﬀort should
be placed on early human development (such as Phase I equivalent)
and late preclinical discovery to try to select the most viable candi-
dates early. Thus, the increasingly limited resources for CNS drug
development should be focused with the greatest eﬃciency.
Fortunately, several areas continue to appear to be great opportunities
for therapeutic target methods.
Methods : In this presentation, we will present a number of novel
potential biomarkers, both in imaging and related CSF and plasma
levels, to aid in such drug development. Speciﬁc topics will include
successful non-human primate and human target engagement
dosing and mechanism of action studies for CB1 and CB2 cannabi-
noids, and metabotropic glutamate (mGluR5, mGluR2,3, GlyT1,
PDE4, PDE10 and others). In the last few years, through successful
collaborations between academia and industry, several new PET
radioligands have been developed from novel structures and rapidly
accelerated for dose ranging occupancy and correlation with early
eﬃcacy studies.
Results : Studies from our preclinical human research in glutamate
mGluR, glycine, two [18F] amyloid radioligands and CB1 and CB2
cannabinoids will be presented.
Conclusion : The focus of this presentation will concentrate on this
novel information.
Policy of full disclosure : Amgen – consulting Funded Research
Avid Biotie GE Intracellular Johnson and Johnson Lilly Lundbeck
Merck Orexigen Otsuka Roche Sanoﬁ-Aventis.
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S-35. Advances in understanding the causes
and treatment of major depressive
disorders
jS-35-001jThe role of tumour necrosis factor in the
pathophysiology of major depressive disorder,
bipolar disorder and schizophrenia
A. Gibbons. Mental Health Research Inst, Parkville, Australia
Objective : Altered plasma levels of pro-inﬂammatory cytokines have
been reported in individuals with mood disorders and schizophrenia.
Elevated protein levels of the transmembrane form of the pro-
inﬂammatory cytokine tumour necrosis factor (tmTNF) were recently
reported in the dorsolateral prefrontal cortex (DLPFC) but not the
anterior cingulate (ACC) from subjects with major depressive dis-
order (MDD). By contrast, levels of the soluble form of TNF (sTNF)
were not changed in either region. These ﬁndings have been extended
by measuring cortical tmTNF and sTNF levels in bipolar disorder
(BPD) and schizophrenia.
Methods : Experiments were performed on DLPFC and ACC
obtained post-mortem from 10 subjects with BPD, 10 subjects with
MDD and 10 matched controls and from 19 subjects with schizo-
phrenia and 20 matched controls. Western blotting was used to
measure the protein levels of tmTNF and sTNF in BPD and schizo-
phrenia. TNF mRNA levels were measured using qPCR. Surrogate
protein markers of glial (GFAP), microglial (CD11b) and pre- and
post-synaptic neuronal (synaptophysin and PSD-95) cell type and
IL-1B protein were measured using western blotting.
Results : tmTNF protein levels were increased in the ACC but not
the DLPFC in BPD (p<0.05). sTNF levels were unchanged in both
regions compared to controls and TNF mRNA levels were also un-
altered. There was no evidence of gliosis or apoptosis or of a broader
cytokine response, indicated by unaltered cell-type marker and IL1B
protein levels respectively, to suggest the increase in tmTNF is re-
ﬂective of a pro-inﬂammatory response. Levels of tmTNF and sTNF
protein or TNFmRNAwere not signiﬁcantly altered in schizophrenia.
Conclusion : Regionally speciﬁc increases in cortical tmTNF levels
contribute to the pathophysiology of BPD and MDD but not schizo-
phrenia. These elevated tmTNF levels are not consistent with a pro-
inﬂammatory response, suggesting TNF’s non-inﬂammatory signal-
ing pathways are likely to be aﬀected in the CNS of individuals with
mood disorders.
jS-35-002jThe neuroanatomy of melancholy : An update circa
2012
J. Soares. University of Texas-Houston, Department of Psychiatry, USA
Mood disorders such as unipolar depression and bipolar disorder
present brain abnormalities in key fronto-limbic brain circuits in-
volved in emotional modulation. Over the past two decades a sub-
stantial number of neuroimaging studies have been completed and
despite sometimes conﬂicting results, there is considerable evidence
to support the fronto-limbic dysregulation hypothesis. Our presen-
tation will review the anatomical and functional studies that focused
on patients with major depression to summarize the status of knowl-
edge in this maturing ﬁeld. We will discuss a model where key ab-
normalities in the anterior cingulate, amygdala and hippocampus,
as well as circuits that interconnect these regions, may be key steps
involved in pathophysiology of these serious mental illnesses.
Policy of full disclosure : None.
jS-35-003jAnimal models of depression : Relevance to drug
discovery
T. Norman. University of Melbourne, Department of Psychiatry,
Heidelberg, Australia
Objective : This paper reviews some traditional as well as innovative
approaches to the use of pre-clinical models for drug discovery.
Conclusion : Major depressive disorder is a complex, genetically
inherited set of conditions, the underlying causes of which are far
from completely delineated. Consequently development of pre-
clinical models is doomed to fall far short of the goal of a complete
analogy. Clearly some symptoms of depression cannot be modelled
in animals. Nevertheless, despite these limitations, numerous
‘‘so-called’’ animal models of depression have been developed in the
past. Traditional models have proven useful for the discovery of
newer agents, but there have been some notable (and costly) failures.
More recent approaches to the development of animal models have
taken discoveries from the clinic and using various genetic strategies
have attempted to develop models based on incorporating these
ﬁndings. The utility of this approach for the discovery of truly novel
agents awaits particular studies.
jS-35-004jHow to improve treatment strategies in depression
P. Blier1, P. McGrath2, R. Bergeron3, J. Stewart4. 1Ottawa, Canada ;
2NewYork State Psychiatric Inst, New York, USA ; 3University of Ottawa,
Canada ; 4New York State Psychiatric Inst., USA
Objective : Two prior double-blind studies using mirtazapine com-
binations from treatment initiaion produced greater responses than
antidepressants used in monotherapy, but not in a single-blind trial
using low and/or conventional doses. High doses of escitalopram and
bupropion were investigated based on their synergy between the
serotonin and norepinephrine systems.
Methods : Patients with MDD (n=241 ; minimum MADRS : 22)
in 3 centers were randomized to escalating doses at weekly intervals
of escitalopram (10–40 mg/day), bupropion (150–450 mg/day), or
their combination, according to tolerability and/or achievement
of remission status. Patients were assessed using the HAMD, the
MADRS, and the CGI-severity and -improvement scales. Assess-
ments were done weekly for the ﬁrst 4 weeks and at weeks 6, 8, 10,
and 12.
Results : The sample did not diﬀer at baseline on the demographics
between the 3 groups, although there were diﬀerences between sites.
The overall dropout rates at week 12 were not statistically diﬀerent :
escitalopram-25%, bupropion-35%, and combination-30%. There
were signiﬁcantly more remitters at week 2 in the combination group
vs. both monotherapies based on the HAM-D, MADRS, and CGI-I. At
week 12, there were more remitters on escitalopram (54%) than on
bupropion (33%), but not on the combination (42%) : X2=7.67, df=2,
P=0.02.
Conclusion : Early remission was hastened by the combination.
High doses of escitalopram outperformed optimal doses of bupro-
pion. The combination was not the most eﬀective treatment at study
end in the overall analysis, although further analyses remain to be
carried out to determine the inﬂuence of demographics and dropout
rates.
Policy of full disclosure : Astra Zeneca, Bristol Myers Squibb,
Euthymics, Janssen, Lundbeck, Merck, Pﬁzer, Servier, Takeda,
Valiant.
S-36. Drug targets and novel treatment
strategies in alcohol and drug addiction
jS-36-001jDevelopment of new medications for the treatment
of alcoholism
C. O’Brien. University of Pennsylvania, Department of Psychiatry, USA
Objective : Translate ﬁndings from animal models of alcohol use
disorder to the improved clinical treatment of alcoholism. Develop
personalized treatment by studying genotypes relevant to the en-
dogenous opioid system after animal models pointed the way.
Methods : An animal model of alcohol drinking in monkeys
showed that blocking opioid receptors blocked alcohol self-
administration. Translate to human alcoholics in double blind clinical
trial. Study successful patients using human lab studies of drinking
behavior, check family histories of successful patients, analyze
DNA, search for genetic variants in the endogenous opioid system of
successful v. unsuccessful patients.
Results : Patients randomized to naltrexone reported less craving
for alcohol and less pleasure if they did drink. Successful patients
had strongly positive family history of alcoholism & more pre-
treatment craving. Those with an allelic variant of the gene for the m
opioid receptor had a high probability of success if randomized to
naltrexone. Another opioid receptor antagonist, nalmephene, was
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also found to reduce heavy drinking in clinical trials in the U.S. and
Europe.
Conclusion : Alcohol produces reward via several mechanisms
and one important mechanism involves activation of endogenous
opioids. Blocking this eﬀect with an opioid antagonist reduces the
reward from alcohol and makes the patient more responsive to
counseling. Unfortunately, in the U.S., anti-medicine philosophy
dominates and few patients receive the beneﬁts of this treatment.
A recent advance is the introduction of a slow release depot product
that improves compliance and thus improves the success rate of
naltrexone treatment.
Policy of full disclosure : Consultant to Alkermes, producer of
Vivitrol, slow release naltrexone.
jS-36-002jThe role of the GABAB receptor system in
alcoholism and stress : The role of the GABAB
receptor agonist baclofen
G. Addolorato. Catholic University of Rome, Depart. of Internal
Medicine, Italy
Alcoholism and stress share some common neurobiological circuits,
including the GABAergic system. In particular, the GABAB receptor
seems to play an important role. The GABAB receptor agonist baclo-
fen has been studied as a treatment for alcohol-dependent subjects.
Baclofen administration in alcohol-dependent patients was able to
promote abstinence, inducing the remission of withdrawal symptoms,
reducing alcohol craving, and reducing alcohol intake. Baclofen also
reduced anxiety in alcohol-dependent subjects, probably acting on
brain stress circuitry and/or on other neuroendocrine systems.
Baclofen also showed excellent safety and tolerability, even in alcohol-
dependent patients with advanced liver disease (i.e., cirrhosis). Future
studies should investigate which alcoholic subtype may better beneﬁt
of the administration of baclofen in the treatment of alcohol depen-
dence.
jS-36-003j Impact of the stress hormone system as a
pharmacotherapeutic target in the treatment of
alcohol and drug addiction
F. Kiefer. CIMH, Univ. of Heidelberg, Mannheim, Germany
The ability of most drugs to enhance dopamine neurotransmission
particularly within the mesocorticolimbic dopamine (‘‘reward’’) sys-
tem was demonstrated repeatedly. However, the past decade has
placed the dopamine system within a broader context of neuronal
circuitry involved in drug seeking, drug taking, and recovery. Speciﬁc
eﬀects on other receptors symptoms provide particular challenges
given the almost ubiquitous expression of these receptors throughout
the CNS. Additionally, new emphasis on various neuropeptide sys-
tems has re-emerged, including opioid peptides and the stress-related
peptides of the hypothalamus-pituitary-adrenal axis. The stress hor-
mone system serves as a pharmacotherapeutic target in the treatment
of alcohol and drug addiction ; new data based on a GWAS on alcohol
dependence and a pharmacogenomic follow-up study point towards
an involvement of neuroendocrine pathways in relapse-related beha-
vior. Continued research is warranted on the various neurobiological
based components that underlie the transition from drug intake to
addiction to deﬁne drug targets for innovative pharmacological
treatment options.
jS-36-004jADHD in drug addiction : A RCT on the feasibility
of methylphenidate treatment in criminal
amphetamine users
J. Franck1, M. Konstenius2, N. Jayaram-Lindstrom2, B. Philips2,
J. Guterstam2. 1Karolinska Institutet, Centre for Psychiatric Res.,
Stockholm, Sweden ; 2Karolinska Institutet, Stockholm, Sweden
Objective : The present clinical trial was designed to evaluate the
feasibility and eﬃcacy of methylphenidate (MPH) for the treatment of
ADHD in patients with amphetamine dependence and comorbid
ADHD, using relapse to drug use as the primary outcome variable.
Methods : The study was a double-blind, placebo-controlled trial
with parallel groups design. Participants were recruited and assessed
while serving a short (<1.5 yrs) prison sentence in a medium security
prison. The eﬃcacy of OROS MPH(max dose 180 mg/day) was com-
pared with identical placebo (PL) in currently abstinent adult males.
Fifty-four treatment-seeking patients fulﬁlling DSM-IV criteria for
amphetamine dependence and ADHDwere randomized to MPH/PL.
The medication started 14 days before release from prison and con-
tinued at an outpatient facility with twice weekly visits and
supervised urine drug screening. ADHD-symptoms, other psychiatric
symptoms and relapse to criminality were also monitored. All
patients participated in a relapse prevention training programme on
a weekly basis.
Results : The mean age was 42.3 years (SD 10.5). All had i.v. am-
phetamine use and the mean debut age was 18 years, mean length
of use 19.6 years (SD 11). The participants had been incarcerated on
11.3 occasions (SD 8.2). The most frequent axis-II diagnoses were
antisocial (50%), obsessive-compulsive (23%) and borderline person-
ality disorder (18%). Forty-four percent had prior alcohol de-
pendence, 19% other substance use disorders and 13% anxiety
syndromes. The average retention in treatment was 11.3 weeks (Cl
8.7–13.8). Twenty-four percent (n=12) of the participants completed
all 24 weeks of treatment. Retention in treatment was signiﬁcantly
higher in the MPH group. No unexpected adverse events were de-
tected using the maximum dose of MPH.
Conclusion : This clinical trial demonstrates the feasibility and
safety of studying long-acting MPH in convicted patients with ADHD
and comorbid amphetamine dependence.
Policy of full disclosure : The study was supported by grants
from the Stockholm County Council and the Swedish Research
Council.
S-37. Stress and vulnerability – antecedents to
psychopathology and implications for
eﬀective treatment
jS-37-001jEarly life adverse experience, 5-HT2 receptors and
long term epigenetic modiﬁcations : Implications for
aﬀective vulnerability
V. Vaidya1, M. Benekareddy2, D. Suri2, K. Vadodaria2, A. Nair2. 1Tata
Inst. Fundamental Research, Dept of Biological Sciences, Colaba, Mumbai,
India ; 2Tata Inst. Fundamental Research, Colaba, Mumbai, India
Objective : Prefrontal serotonin 5-HT2 receptors have been linked to
the pathogenesis and treatment of aﬀective disorders, yet their func-
tion in psychiatric vulnerability is not known.We examined the eﬀects
of 5-HT2 receptors in a rat model of early life stress, and addressed
whether postnatal 5-HT2 receptor blockade would prevent the
consequences of early stress on anxiety, hippocampal neurogenesis
and dysregulated gene expression.
Methods : Control and maternally separated animals received
treatment with the 5-HT2 receptor agonist DOI and eﬀects on gene
expression and behavior were assessed. Control and maternally se-
parated litters received treatment with the 5-HT2 receptor antagonist,
ketanserin, and were examined for eﬀects on adult anxiety, stress-
induced gene expression responses, transcriptional changes and hip-
pocampal neurogenesis.
Results : Stimulation of 5-HT2 receptors potentiated head shake
behavior and heightened transcriptional changes in maternally sepa-
rated animals, indicating enhanced 5-HT2 receptor responses.
Treatment with ketanserin during postnatal life blocked the eﬀects
of maternal separation on anxiety, perturbed gene expression and
hippocampal neurogenesis. Ketanserin treatment also normalized the
changes in serotonin type 2A receptor messenger RNA expression
during postnatal life and in genes associated with G-protein signaling
in adulthood.
Conclusion : Animals with an early stress history of maternal sep-
aration exhibited exaggerated 5-HT2 receptor mediated responses.
Postnatal treatment with the 5-HT2 receptors receptor antagonist,
ketanserin, blocked speciﬁc consequences of maternal separation, in-
cluding anxiety behavior, changes in hippocampal neurogeensis and
dysregulated gene expression in the prefrontal cortex and hippo-
campus. Our results suggest that enhanced 5-HT2 receptor function
may contribute to the emergence of anxiety behavior and perturbed
stress responses following early life stress.
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jS-37-002jSocial isolation stress in a genetic rat model of
depression : Eﬀects of physical activity as an
intervention
E. A˚berg1, A. Mattsson2, L. Graae2, M. Gomez Galan2, S. Nikkou
Aski2, T. Femenia Canto2, A. Sierakowiak3, P. Damberg2,
M. Lindskog2, S. Brene´4. 1Karolinska Institutet, Stockholm, Sweden ;
2Karolinska Institutet, Stockholm, Sweden ; 3Karolinska Institutet, Dept. of
Neurobiology, Solna, Sweden ; 4Karolinska Institutet, Department of
Neurobiology, Huddinge, Stockholm, Sweden
Objective : There is evidence from both pre-clinical and clinical
studies that physical activity can have an antidepressant eﬀect.
Moreover from rodent studies it is well known that social isolation
by itself is a stress factor, which is likely to impact the aﬀective state.
In this study our aim was to test how Flinders Sensitive Line
rats (FSL), which is a rodent genetic model of depression, re-
spond to single-housing in cages with or without access to running
wheels.
Methods : The single housed male FSL rats, runners, were allowed
free access to a running wheel during 5 weeks whereas controls,
non-runners, had no access. We analyzed eﬀects of running on
hippocampal size using volumetric 3-D in vivo Magnetic Resonance
Imaging, 9.4 Tesla, long-term potentiation (LTP) induction in CA1 in
hippocampal slices, and spine density in dentate gyrus. Levels of
glutamate receptor and transporters were analyzed in hippocampus
from rats with or without access to running wheels.
Results : Wheel running increased the size of hippocampus and
number of spines in dentate gyrus compared to the non-running
controls. Moreover, levels of the AMPA receptor subunit GluR2 and
the glutamate transporter GLAST were increased in hippocampus
after running. LTP, could not be induced in non-running FSL rats but
was induced in the group of runners.
Conclusion : Physical activity can induce both structural and func-
tional plasticity. In the FSL model of depression with social isolation
we ﬁnd an enlarged total hippocampal volume, increased dendritic
spine numbers, increased sensitivity to LTP induction, and increased
levels of glutamate receptors and transporters after physical activity.
Thus, we present ﬁndings that are likely to be important for the pro-
tective eﬀects of physical activity on depression.
jS-37-003jRodent models of vulnerability to emotional trauma :
Neural correlates and novel treatment options
N. Singewald1, M. Hauschild2, S. Sartori2, P. Muigg, R. Landgraf3,
K. Hefner4, M. Camp4, I. Neumann5, A. Holmes4, N. Whittle2.
1University of Innsbruck, Dept Pharmacology & Toxico, Austria ;
2University of Innsbruck, Austria ; 3MPI Psychiatry, Munich, Germany ;
4NIAAA, Behav Sci &Genetics, Rockville, USA ; 5University of
Regensburg, Germany
Objective : There are individual diﬀerences in coping with emotional
trauma, including the ability to extinguish learned fear responses,
which is suggested as a biomarker predicting the vulnerability to de-
velop speciﬁc anxiety disorders. Animal models of deﬁcient extinction
could be particularly useful to study underlying mechanisms and
identify novel targets to inhibit pathological fear persistently.
Methods : Diﬀerent pharmacological and non-pharmacological
treatments were investigated for their fear extinction-promoting
eﬀects using classical conditioning/extinction paradigms in rodent
models of impaired extinction, the Wister rat line selectively bred for
high anxiety-related behaviour (HAB) and inbred 129/SvImJ (129S1)
mice. Associated brain neuronal activity changes were assessed by
quantiﬁcation of immediate-early-gene expression.
Results : show that rescue of impaired extinction in HAB rats and
129S1 mice was achieved by neuropeptide S or a-2 adrenoceptor
antagonist treatments. Further testing in 129S1 revealed that SSRIs
and in particular novel treatments targeting the zinc system, histone
acetylation, mGluR7-mediated transmission or deep brain stimulation
rescued the highly impaired fear extinction in this model. Con-
siderable diﬀerences in the eﬃcacy of these treatments to inhibit re-
turn of fear persistently were revealed. In particular we observed that
targeting histone acetylation and zinc systems very eﬃciently pro-
tected against spontaneous recovery and fear renewal in a novel
context. Rescue of impaired extinction was associated with normalis-
ation of aberrant functional brain activity in 129S1. This normalisation
was observed in key regions of fear/extinction circuitries including
the prefrontal cortex, intercalated cell masses of the amygdala and
culminated in attenuation of hyperactivity of the medial subunit of the
central amygdala, the main amygdala output region controlling fear
behaviour.
Conclusion : These studies in psychopathologically relevant animal
models identiﬁed extinction-enhancing treatments that promoted
sustained inhibition of fear and furthermore, revealed important
neural target correlates of such interventions. These ﬁndings should
provide a basis for the development of novel therapeutic adjuncts in
extinction-driven therapy.
Policy of full disclosure : Supported by the Austrian Science Fund
(FWF) SFB-F4410 (NS).
jS-37-004jChronic stress, dysregulation of prefrontal cognitive
function and mechanisms underlying the response
to eﬀective antidepressant treatment
D. Morilak. Univ. Texas Health Science Ctr, San Antonio, USA
Objective : Cognitive ﬂexibility, the ability to modify established
thoughts and behaviors based on changes in the environment, de-
pends upon prefrontal cortical function, and is compromised in many
stress-related psychiatric disorders, e.g., depression. Using rat mod-
els, we address mechanisms by which chronic stress impairs cognitive
ﬂexibility, and by which therapeutic approaches exert beneﬁcial
eﬀects.
Methods : The rat attentional set-shifting test was used as a measure
of prefrontal cognitive ﬂexibility. Prefrontal function was assessed
by fos activation in response to MDT stimulation. Chronic stress
included psychogenic chronic unpredictable stress (CUS) and meta-
bolic chronic intermittent cold stress (CIC). Novel and traditional
therapeutic strategies included monoamine reuptake blockers, anti-
inﬂammatories, and a rat model of cognitive behavioral therapy
(CBT).
Results : CUS impaired cognitive set-shifting and reversal learning,
and attenuated activation of PFC. CIC selectively impaired reversal
learning, related to serotonergic dysfunction in OFC. These deﬁcits
were reversed or prevented by chronic treatment with selective NE or
5-HT reuptake blockers, respectively. Alpha1 adrenergic receptors in
mPFC facilitate set-shifting, and 5-HT2A receptors in OFC facilitate
reversal learning. These mechanisms contribute to eﬀective anti-
depressant response. However, noradrenergic facilitation in mPFC
also contributes to the detrimental eﬀects, as antagonist treatment
during chronic stress protects against the cognitive deﬁcit. Thus a
paradox – how can elevating NE by chronic stress be bad, but elevat-
ing NE by chronic reuptake blockade is good? We hypothesize that
noradrenergic facilitation interacts with other convergent stress-
evoked signaling pathways in PFC, including cytokines, contributing
to the detrimental eﬀect. Finally, preliminary results indicate that a rat
model of CBT has antidepressant eﬃcacy.
Conclusion : Monoaminergic modulation in PFC enhances cogni-
tive ﬂexibility, and contributes to eﬀective antidepressant response.
Approaches that target other convergent pathways may improve
treatment response. Further, behavioral or other strategies that engage
the prefrontal circuitry compromised in depression can induce direct
improvement, or provide an active substrate for monoaminergic fa-
cilitation.
Policy of full disclosure : This work was supported by research
grants from NIH and the Department of Defense (USA). The author
has received funds in the past year from Forest Laboratories for re-
search on a product unrelated to any of the material or data presented
in this talk.
S-38. Neurostimulation therapies: Current
advances and controversies
jS-38-002jTaking deep brain stimulation for major depression
one step deeper – current data and outlook
T. Schlaepfer. University of Bonn, Germany
Objective : Conceptualizations of the underlying neurobiology
of major depression – and consequently the development of novel
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hypothesis-guided treatment approaches – concentrated for a long
time on alterations on monoaminergic or endocrine systems. A more
comprehensive and appropriate treatment might arise from modeling
depression as a dysfunction of speciﬁc brain networks mediating
mood and reward signals. DBS is currently being researched actively
for its putative application in treatment resistant major depression
(TRD). While ﬁrst studies on three diﬀerent targets in TRD (Brodmans
Area cg25, anterior limb of the capsula interna and Nucleus
Accumbens) showed prom-ising eﬀects in comparable patient popu-
lations, only 50–60% of patients responded at a clinically signiﬁcant
level. Furthermore, stimulation intensities ranging from 4–10V and
large electrodes geometries were used ; somewhat undermining target
speciﬁcity.
Methods : Seven patients suﬀering from extremely treatment re-
sistant depression (TRD, mean lengths of current episode 7.6 years)
underwent bilateral DBS electrode implantation in the supero-lateral
medial forebrain bundle slMFB) after Diﬀusion Tensor Imaging (DTI)
based personalized target site deﬁnition.
Results : Montgomery A˚sberg Rating Scale for Depression
(MADRS) scores decreased from a mean of 29.9 (SD 8.0) at baseline
to 12.4 (SD 10.2) after 11 weeks of stimulation, onset of eﬃcacy
was typically observed within two days of start of stimulation and
6 patients reached the response criterion within 7 days. Stimulation
intensity ranged from 1.5 to 2.5V.
Conclusion : These pilot data support the notion that slMFB DBS
might be associated with more rapidly developing and signiﬁcantly
stronger antidepressant eﬀects in patients with TRD.
jS-38-003jDeep Brain Stimulation to the subcallosal cingulate
gyrus for treatment resistant depression : An update
S. Kennedy. University Health Network, Toronto, Canada
Objective : Antidepressant treatments, including pharmacotherapy
and psychotherapy, do not result in remission for the majority of
patients with Major Depressive Disorder. Consequently, the high
prevalence of treatment resistant depression (TRD) results in a high
social and economic burden.
Methods : The emergence of neurostimulation therapies, including
Deep Brain Stimulation (DBS) for TRD is a promising development
that involves the bilateral implantation of electrodes to a neuroana-
tomical site, which receives remote electrical stimulation via a sub-
clavicularly implanted pacemaker. Through the use of neuroimaging,
and other biomarker testing, there is an opportunity to elucidate both
the underlying circuitry of TRD and the mechanism of action of DBS.
Studies on the neurocircuitry of depression support hyperactivity in
the subcallosal cingulate gyrus-Area 25 (SCg25), which is ameliorated
by neuromodulation treatments.
Results : The Neurostimulation team at University Health Network,
University of Toronto has a seven-year experience involving over 30
patients who have received SCg25 DBS, and have been followed up to
6 years. These data support the long-term eﬀectiveness of DBS for
TRD, while highlighting the mortality rate associated with treatment
resistance. Beyond the initial DBS trial to the SCg25, additional
neuroanatomical targets are being explored, including the nucleus
accumbens and internal capsule/ventral striatum, lateral habenula,
and inferior thalamic peduncle.
Conclusion : To date, there are open-label reports on over 100 sub-
jects, demonstrating acute and sustained eﬀectiveness and safety.
However, until published randomized controlled trials establish
eﬃcacy for this invasive treatment, the medical community and the
media need to exercise caution in their enthusiastic endorsement of
this appealing advance in psychiatry.
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jRA-01-001jRegulation of inﬂammation and T cells by
glycogen synthase kinase-3 (GSK3) and
association with depression
E. Beurel. Dept of Psychiatry, Miami, USA
Objective : Accumulating evidence shows that inﬂammation strongly
inﬂuences the development and treatment of depression. Inﬂam-
matory molecules are elevated in many patients with depression,
administration of inﬂammatory cytokines induces depression in sus-
ceptible people, and inﬂammation in rodents causes depressive-like
behaviors and impairs antidepressant therapeutic eﬀects. Glycogen
synthase kinase-3 (GSK3) is a critical regulator of the immune system,
which may contribute to its action in increasing susceptibility to mood
dysregulation. Previously, GSK3 was shown to have important inﬂu-
ences in mood disorders : (a) GSK3 is inhibited by mood stabilizers
and antidepressants, (b) pharmacological or genetic reduction of
GSK3 activity reduces depression-like behaviors in rodents, (c) GSK3
is activated when serotonergic signaling is deﬁcient, (d) brain-derived
neurotrophic factor, that may be deﬁcient in depression, normally
inhibits GSK3, and (e) studies of human blood cells, postmortem
brain, and polymorphisms implicate GSK3 in mood disorders.
Methods : GSK3 activity was increased by using GSK3a/b/21A/
21A/9A/9A knockin mice with serine-to-alanine mutations to
block inhibitory serine-phosphorylation of GSK3 or decreased by ad-
ministration of GSK3 inhibitors (lithium, CHIR99021 and TDZD-8).
Cytokines were measured by ELISA. Activation of the transcription
factor signal transducer and activator of transcription-3 (STAT3) was
assessed by immunoblotting. The learned helplessness paradigm of
depression-like behavior was evaluated in adult male mice.
Results : Inhibition of GSK3 or knockdown of GSK3 inhibited
inﬂammatory cytokine production by astrocytes and microglia and
blocked the inﬂammatory activation of the transcription factor STAT3.
Blocking cytokine production and downregulation of STAT3 by GSK3
inhibition diminished T cell diﬀerentiation towards pathogenic Th17
cells, whereas active GSK3 promoted depressive-like behavior in mice
and increased Th17 cells in mouse brain.
Conclusion : Altogether, these ﬁndings indicate that GSK3 pro-
motes inﬂammatory immune system activation and depression-like
behavior. Activation by dysregulated GSK3 of these immune system
actions may contribute to susceptibility to mood disorders and be
controlled by mood stabilizers.
jRA-01-002jAssociation of nicotine dependence susceptibility
gene, CHRNA5, with Parkinson’s disease age at
onset : Gene and smoking status interaction
L. Greenbaum1, A. Rigbi2, L. Nurit2, R. Cilia3, S. Tesei3, R. Asselta4,
R. Djaldetti5, S. Goldwurm3, B. Lerer2. 1Hadassah-Hebrew University,
Medical Center, Jerusalem, Israel ; 2Biological Psychiatry Laboratory,
Department of Psychiatry, Hadassah – Hebrew University Medical Cen,
Jerusalem, Israel ; 3Parkinson Institute – Instituti Clinici di
Perfezionamento, Milan, Italy ; 4Dipartimento di Biologia e Genetica per le
Scienze Mediche, Universita` degli Studi di Milano, Milan, Italy ;
5Department of Neurology, Rabin Medical Center, Petah Tiqwa, Israel
Objective : Smoking is a well documented environmental factor that
reduces susceptibility to Parkinson’s disease (PD). Several genetic
variants within the nicotinic cholinergic receptor gene cluster,
CHRNA5-CHRNA3-CHRNB4 have been reported to be associated
with nicotine dependence (ND), and this association has been vali-
dated in multiple studies. Due to the inverse correlation between
smoking and PD susceptibility, we investigated whether ND-related
genetic variants are associated with age at onset (AAO) of PD among
smokers.
Methods : We performed a genetic association study in a sample
of 667 Italian PD patients, ages 34–76. 438 had never smoked (NS),
and 239 were current or past smokers (ever smokers, ES). Three
independent SNPs within the CHRNA5-CHRNA3-CHRNB4 gene
cluster (rs588765, rs16969968, rs578776) were analyzed for association
with AAO.
Results : We demonstrated an interaction between the rs588765
SNP and smoking status (NS vs. ES) that was nominally signiﬁcant
in its eﬀect on PD AAO (p=0.04). The rs588765 ND risk allele, C, was
associated with delayed AAO among ES, but had no signiﬁcant eﬀect
among NS. In the ES group, a dominant model of inheritance was
observed : carriers of the CC genotype presented delayed AAO com-
pared to carriers of the CT or TT genotypes.
Conclusion : Our preliminary results suggest that the ND risk
variant, rs588765, has a protective eﬀect in PD, and is associated with
later AAO, but only when the individual was previously exposed to
nicotine. This may be explained by modulation of dopamine trans-
mission by nicotinic cholinergic receptors expressed on dopaminergic
neurons in PD relevant brain regions.
jRA-01-003jOpioid receptors and reward : An fMRI study
with naltrexone
C. McCabe. Neuroscience Building, United Kingdom
Objective : Opiates are known to be involved in facilitating con-
summatory behaviour in animals and humans. Opioid receptors are
highly expressed in neural ‘reward’ areas such as orbitofrontal cortex,
ventral tegmental area and nucleus accumbens. Naltrexone, an opioid
antagonist, can decrease the behaviour-reinforcing eﬀects of primary
rewards and increase the eﬀect of negative experience, such as pain.
The aim of the current experiment was to examine the eﬀects of the
opioid antagonist naltrexone on rewarding and aversive taste pro-
cessing in the human brain.
Methods : We used functional magnetic resonance imaging (fMRI)
to examine the eﬀects of naltrexone on the neural responses to plea-
sant chocolate and aversive sights and tastes of mouldy strawberry in
a within-subjects double-blind crossover design (n=20).
Results : Relative to placebo, naltrexone decreased the neural
activation to the rewarding chocolate stimulus in the vmPFC but in-
creased activation to the aversive strawberry stimulus in the same
region. Results are consistent with studies showing opiates reduce
reward but also how opioid antagonists may enhance the un-
pleasantness of aversive stimuli.
Conclusion : These ﬁndings provide novel insight into the mech-
anism by which opioid antagonists may reduce food intake not only
through eﬀects on reward but also eﬀects on unpleasant food stimuli.
These results have implications for the use of opioids as possible
treatments for disorders of compulsion such as obesity.
jRA-01-004jBDNF-TrkB signaling is involved in the
antidepressant-like eﬀect induced by genetic
deletion of iNOS
S. Joca1, C. Biojone2, P. Casarotto2, K. Montezuma1, F. Cunha2,
F. Guimara˜es2. 1FCFRP-University of Sao Paulo, Ribeira˜o Preto-Sp,
Brazil ; 2FMRP-University of Sao Paulo, Ribeira˜o Preto-Sp, Brazil
Objective : We have recently shown that the pharmacological or
genetic inhibition of the inducible nitric oxide (NO) synthase (iNOS)
isoform evokes antidepressant-like eﬀects. However, the molecular
mechanism underling this eﬀect is still unknown. Brain derived
neurotrophic factor (BDNF) is a neurotrophin implicated in the anti-
depressant eﬀect and it can be modulated by NO in hippocampus
(HPC) and pre-frontal cortex (PFC). Therefore, the aim of this study
was investigate the hypothesis that inhibition of iNOS induces
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antidepressant-like eﬀects associated to increased BDNF signaling in
hippocampus and PFC.
Methods : Male iNOS deﬁcient (KO) and C57BL/6 wild-type (WT)
control mice were submitted to forced swimming test (FST) and their
immobility time was videotaped and scored. Naı¨ve and stressed (FST)
animals were sacriﬁced immediately after FST and their HPC and PFC
were dissected. BDNF and its receptor, TrkB, as well as NOx levels
were measured. Independent groups of KO andWTmice were treated
with k252a, a Trk antagonist, and submitted to FST or to the open ﬁeld
test (OFT).
Results : iNOS KO animals presented a decreased immobility
time in the FST compared to WT controls (t14=3.18 ; p<0.01). KO
animals had increased levels of BDNF in HPC and PFC (genotyper
stress : HPC : F1,32=5.41, p<0.05 ; PFC : F1,28=4.48, p<0.05), which
was not inﬂuenced by FST. iNOS KO mice also had increased levels
of TrkB (t14=3.29 ; p<0.05) and NOx (t6=2.526 ; p<0.05) in PFC. In
the HPC, only TrkB levels were increased (t13=2.182 ; p<0.05).
Systemic injection of K252a reversed the behavioral phenotype of
iNOS KO mice, without changing the behavior of WT mice (drugr
phenotype : F1,18=13.21, p<0.01). No eﬀects were observed in
the OFT.
Conclusion : Our results indicate that there is a diﬀerential inter-
action between NO and BDNF-TrkB signaling in HPC and PFC. This
interaction may be involved in the antidepressant-like phenotype of
iNOS KO mice.
jRA-01-005jMDMA, oxytocin and empathy : Preliminary
results from a placebo controlled study
K. Kuypers1, J. G. Ramaekers1. 1Maastricht University, Netherlands
Objective : Background. The neurobiological mechanism underlying
MDMA-induced prosocial behaviour (PSB) is yet not known. Two
potential mediators of these eﬀects are oxytocin and the serotonin
(5-HT) 1a-receptor as they seem to play a role in facilitation of positive
mood, empathy and social interaction. Moreover, MDMA is known to
increase blood oxytocin levels and the 5-HT1a-receptor is a mediator
of the eﬀects of MDMA and oxytocin. The study aim is to investigate
the roles of oxytocin and the 5-HT1a-receptor in the MDMA-induced
PSB eﬀects.
Methods : Twenty participants will participate in this 4 way-
crossover study (currently N=5). Treatments are MDMA (75 mg,
oral) alone, and in combination with a 5-HT1a antagonist (pindolol,
20mg, oral), Oxytocin (48 IU, intranasal), and placebo. Empathy and
mood are assessed by means of two computer tasks (Reading the
Mind in the Eyes Test and the Multifaceted Empathy test) and a
questionnaire (Proﬁle of Mood States). It is hypothesized that oxytocin
will mimic MDMA-induced prosocial eﬀects and that the 5-HT1A-
receptor is an important mediator of these eﬀects.
Results : Preliminary analyses of both empathy tests did not reveal
statistically signiﬁcant main eﬀects of treatment. Analyses of the
POMS revealed a main eﬀect of treatment on the ‘vigor’ scale
(p=0.032) and a trend on the ‘arousal ’ and ‘elation’ scale. These
‘stimulant ’ eﬀects were caused by the combined treatment and oxy-
tocin. Closer inspection of the data however leads to the suggestion
that an increase in power will lead to signiﬁcant eﬀects (also of
MDMA) on more scales.
Conclusion : The data of the POMS questionnaire suggest that
the three active treatments have ‘stimulant’ eﬀects on diﬀerent
mood states. Inclusion of more subjects will provide more clarity
on the role of oxytocin and the 5-HT1a-receptor in MDMA-induced
PSB.
jRA-01-006j Impact of the genome wide supported NRGN
gene on anterior cingulate morphology in
schizophrenia
K. Ohi1, R. Hashimoto2, Y. Yasuda3, K. Nemoto4, T. Ohnishi5,
M. Fukumoto6, H. Yamamori7, M. Iwase6, H. Kazui8, M. Takeda6.
1Osaka University, Japan ; 2Mol Res Center for Children´s, Mental Dev,
United Grad Sch, Osaka, Japan ; 3Osaka, Japan ; 4Department of
Neuropsychiatry, Institute of Clinical Medicine, Tsukuba, Japan ; 5CNS
Science Department, Scientiﬁc Aﬀairs Division, Tokyo, Japan ;
6Department of Psychiatry, Osaka University Graduate, Japan ; 7Dept of of
Mol Neuropsychiatry, Osaka University Graduate, Japan ; 8Department of
Psychiatry, Osaka University Graduate, Japan
Objective : The rs12807809 single-nucleotide polymorphism in NRGN
is a genetic risk variant with genome-wide signiﬁcance for schizo-
phrenia. The frequency of the T allele of rs12807809 is higher in in-
dividuals with schizophrenia than in those without the disorder.
Reduced immunoreactivity of NRGN, which is expressed exclusively
in the brain, has been observed in Brodmann areas (BA) 9 and 32 of
the prefrontal cortex in postmortem brains from patients with
schizophrenia compared with those in controls.
Methods : Genotype eﬀects of rs12807809 were investigated on gray
matter (GM) and white matter (WM) volumes using magnetic reson-
ance imaging (MRI) with a voxel-based morphometry (VBM) tech-
nique in a sample of 99 Japanese patients with schizophrenia and 263
healthy controls.
Results : Although signiﬁcant genotype-diagnosis interaction either
on GM or WM volume was not observed, there was a trend of geno-
type-diagnosis interaction on GM volume in the left anterior cingulate
cortex (ACC). Thus, the eﬀects of NRGN genotype on GM volume
of patients with schizophrenia and healthy controls were separately
investigated. In patients with schizophrenia, carriers of the risk T
allele had a smaller GM volume in the left ACC (BA32) than did car-
riers of the non-risk C allele. Signiﬁcant genotype eﬀect on other
regions of the GM or WM was not observed for either the patients or
controls.
Conclusion : Our ﬁndings suggest that the genome-wide associated
genetic risk variant in the NRGN gene may be related to a small GM
volume in the ACC in the left hemisphere in patients with schizo-
phrenia.
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jRA-01-007jCircuit-wide eﬀects of deep brain stimulation
for neurological and psychiatric disorders :
A comparison
C. McCracken1, A. Grace2, Z. Kiss1. 1University of Calgary, Canada ;
2University of Pittsburgh, USA
Objective : High-frequency electrical stimulation of speciﬁc brain
structures, commonly known as deep-brain stimulation (DBS), has
attracted substantial attention for treatment of neurological and psy-
chiatric disorders that fail to respond to standard therapies. Here, we
compare and contrast the circuit-level eﬀects of DBS applied to either
the nucleus accumbens (NAC), an eﬀective target for treating OCD
and depression, or the entopeduncular nucleus (EP), the rat homolog
of the internal globus pallidus and a target for treatment of dystonia
and Parkinson’s disease.
Methods : We used simultaneous multi-site local ﬁeld potential
(LFP) recordings in urethane-anesthetized rats to assess the eﬀects of
high-frequency (HF, 130 Hz ; clinically eﬀective), low-frequency (LF,
10–15 Hz ; clinically ineﬀective) and sham DBS delivered to either
NAC or EP. For NAC DBS, LFP activity was recorded from the orbital
and medial prefrontal cortices, mediodorsal thalamus, and the
stimulation site. For EP DBS, we recorded from dorsal striatum, ven-
troanterior thalamus, primary motor cortex, and the stimulation site.
Spontaneous and acute stimulus-induced LFP oscillation power and
coherence were assessed at baseline, and after 30, 60, and 90 minutes
of stimulation.
Results : Compared to LF and sham, HF NAC DBS was associated
with widespread, time-dependent increases in fast (beta/gamma) os-
cillation power, whereas HF EP DBS produced no speciﬁc changes in
spontaneous fast oscillation power. LF NAC DBS produced region
speciﬁc increases in theta band power, and reduced induced gamma
coherence between regions ; LF EP DBS produced no signiﬁcant
changes. Notably, HF DBS of both EP and NAC DBS produced time-
dependent increases in spontaneous and induced beta and gamma
coherence between regions.
Conclusion : These data suggest that enhanced coherent activity
in the beta and gamma bands along cortico-basal-ganglia-thalamic
circuits may represent a common mechanism of action of DBS for
diﬀerent indications. Future studies will continue to dissect general-
ized and disease-speciﬁc therapeutic mechanisms to better optimize
this technology.
jRA-01-008jPsychopharmacological eﬀect of naringin in
unpredictable chronic mild stress model of
depression : Behavioral, biochemical &
neurochemical evidences
A. Kuhad1, M. Singla1, K. Chopra1. 1Panjab University, Chandigarh,
India
Objective : A complex relationship exists among stressful situations,
body’s reaction to stress, and the onset of clinical depression. Chronic
unpredictable stressors can produce a situation similar to clinical
depression and such animal models can be used for the pre-clinical
evaluation of antidepressants. Clinical studies reported neuro-
transmitter alterations, increased MAO activity, nitrodative stress and
inﬂammation in patients with depression. The present study was de-
signed to investigate the eﬀect of naringin on unpredictable chronic
stress-induced behavioral, biochemical and neurochemical alterations
in mice.
Methods : Animals were subjected to diﬀerent stress paradigms
daily for a period of 21 days to induce depressive-like behavior. The
sucrose preference, immobility period, locomotor activity, memory
acquisition and retention were signiﬁcantly altered in stressed mice.
These behavioral deﬁcits were integrated with decreased biogenic
amine (dopamine, norepinephrine and serotonin) levels, increased
nitrodative stress (increased lipid peroxidation & nitrite levels ; de-
creased glutathione levels, superoxide dismutase & catalase activi-
ties), enhanced MAO and inﬂammatory cytokine (TNF-a & IL-1b)
activities.
Results : Chronic treatment with naringin signiﬁcantly and dose-
dependently restored the unpredictable chronic stress-induced beha-
vioral (increased immobility period, reduced sucrose preference),
biochemical (decreased nitrodative stress, MAO and inﬂammatory
cytokine activity), and neurochemical (dopamine, norepinephrine
and serotonin levels) deﬁcits in stressed mice.
Conclusion : The study revealed that naringin exerted anti-
depressant-like eﬀects in behavioral despair paradigm in chronically
stressed mice, speciﬁcally by modulating biogenic amines, MAO,
nitrodative stress and inﬂammation. Thus, naringin may ﬁnd clinical
application in therapeutic armamentarium of stress induced
depression.
jRA-01-009jEstrogen aﬀects neural processing in empathy
task in women. An ultra-highﬁeld 7 tesla
functional MRI study
C. Spindelegger1, G. Kranz2, R. Sladky3, A. Hahn2, J. Troestl3,
A. Hoeﬂich2, C. Lamm4, C. Windischberger3, S. Kasper2,
R. Lanzenberger2. 1Medical University of Vienna, Austria ; 2Medical
University of Vienna, Department of Psychiatry, Austria ; 3Medical
University of Vienna, MR Center of Excellence &, Austria ; 4University of
Vienna, Institute for Clin., Biol., Austria
Objective : Neural mechanisms of empathy, deﬁned as a psychologi-
cal construct of understanding and responding to other peoples’
aﬀective experiences, have gained focus in neuropsychological re-
search. Studies revealed higher empathy scores in females and sug-
gested that neural empathy networks are diﬀerentially modulated by
gender. Furthermore, estrogen has been shown to inﬂuence brain ac-
tivation in memory as well as emotional tasks in women. Following
that, this study with functional magnetic resonance imaging (fMRI)
aims to investigate the relation between estrogen plasma levels and
brain activation during an empathy task.
Methods : 17 healthy female volunteers (26.4¡5.8 years) were
analysed in this 7 Tesla ultra-highﬁeld (Magnetom 7T, Siemens
Medical) fMRI study undergoing an fMRI scan (245 whole brain
volumes, matrix size 128r128pr2r32, TR=1.4 s, TE=23 ms,
FoV=192r192 mm2, 2 mm slice thickness). All subjects performed
an empathy-related task, previously described by Lamm et al.,
Participants were watching video clips of actors who were instructed
to emphasize a painful response to an auditory stimulation, whereas
the participants where informed that they would see patients with a
neurological disease experiencing auditory stimulations as a medical
treatment intervention. Estrogen plasma levels were quantiﬁed by
means of electrochemiluminescence, whereas blood samples were
taken prior to the fMRI scan. Data pre-processing and analysis were
performed in SPM8 based on a random eﬀects model.
Results : Empathy task-related activations were found in the
inferior frontal cortex (IFC), anterior medial cingulate cortex,
supplementary motor area (SMA), anterior insula and amygdala-
hippocampus-complex (T>5.5 ; p<0.05 FDR corrected). Empathy-
related activation showed strong correlations with estrogen plasma
levels in the right IFC, SMA and in the right amygdala-hippocampus-
complex (T>4 ; p<0.001 uncorrected).
Conclusion : Our study revealed activations in the empathy task
that are in line with previously reported ﬁndings. Furthermore,
empathy related activations were associated with estrogen levels in
healthy females, which might provide a neurobiological rationale of
gender diﬀerences in empathy.
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jP-01-001jTreatment adherence pattern in patients aﬀected by
schizophrenia or bipolar disorder that switched from
quetiapine IR to quetiapine XR
L. Degli Esposti1, F. La Tour2, C. Mencacci3, G. Montagnani2,
C. Pasina4, D. Sangiorgi1, E. Spina5. 1CliCon Srl, Ravenna, Italy ;
2AstraZeneca Italy, Medical Department, Basiglio, Italy ; 3Fatebenefratelli
Hospital, Neuroscience Department, Milan, Italy ; 4AstraZeneca Italy,
Market Access, Basiglio, Italy ; 5University of Messina, Pharmacology
Department, Italy
Objective : In patients with schizophrenia and bipolar disorder
(BD), non-adherence to medication can increase the risk of relapse.
The Italian Burden of Illness on Schizophrenia and BD (IBIS) study
aimed to describe pharmaco-utilisation of antipsychotic treatment
in schizophrenia and BD patients. A secondary study objective was
to assess diﬀerences in medication adherence for patients switching
from quetiapine immediate release (QTP-IR) to quetiapine extended
release (QTP-XR). Here we present interim adherence results collected
from administrative databases in 6 of 20 Italian Local Health Units
included in the study.
Methods : Multicentre, retrospective, observational cohort study
(NCT01392482). Data were collected between 1 January 2008 and
31 December 2010. Patients were included for analysis when they
switched from the antipsychotic medication QTP-IR to QTP-XR. Data
were collected 6 months before and 6 months after the switch. A
control group that received QTP-IR was matched to the switching
group based on diagnosis, gender and age, for analysis. Adherence
¡SD was estimated using the Catalan method.
Results : Of 6,817 patients in the study population, 213 switched
medication from QTP-IR to QTP-XR (86 with schizophrenia, 127 with
BD). Overall, there was an increase in adherence to medication
after switching (from 44.2¡24.7% to 62.6¡26.5% [p=0.009]). For
patients with schizophrenia adherence increased from 48.3¡23.5%
to 56.5¡27.0% [p=0.125], and for patients with BD adherence in-
creased from 41.5¡25.3% to 66.7¡25.4% [p=0.036]. In the matched
control group smaller increases in adherence were observed in the
overall interim population, and stratiﬁed by disease : 51.8¡22.5%
to 53.4¡26.4% [p=0.493] in total ; 55.7¡22.2% to 56.6¡25.7%
[p=0.816] in patients with schizophrenia ; 49.2¡22.4% to 51.3¡26.8%
[p=0.479] in patients with BD.
Conclusion : These interim results suggest that adherence im-
proved in patients with schizophrenia and BD after switching from
QTP-IR to QTP-XR.
Policy of full disclosure : The IBIS study was funded by
AstraZeneca and the presenting author received a grant from
AstraZeneca.
jP-01-002jVariability of treatment patterns for patients aﬀected
by schizophrenia and bipolar disorder
L. Degli Esposti1, F. La Tour2, C. Mencacci3, G. Montagnani2,
C. Pasina4, D. Sangiorgi1, E. Spina5. 1CliCon Srl, Ravenna, Italy ;
2AstraZeneca Italy, Medical Department, Basiglio, Italy ; 3Fatebenefratelli
Hospital, Neuroscience Department, Milan, Italy ; 4AstraZeneca Italy,
Market Access, Basiglio, Italy ; 5University of Messina, Pharmacology
Department, Italy
Objective : Schizophrenia and bipolar disorder (BD) are serious psy-
chiatric disorders commonly treated with antipsychotic medications.
Little is known about which combinations of antipsychotics are fre-
quently used in clinical practice. The Italian Burden of Illness on
Schizophrenia and BD (IBIS) study aims to describe the pharmaco-
utilisation of antipsychotic and concomitant medications in patients
with schizophrenia and BD.
Methods : Multicentre, retrospective, observational cohort study
(NCT01392482). Interim data are shown from administrative
databases of 6 of 20 Italian Local Health Units included in the study,
collected between 1 January 2008 and 31 December 2010. Patients
were retrospectively followed for one year from index date (ﬁrst pre-
scription of antipsychotics).
Results : In total, 6,817 patients were included in the study popu-
lation (4,097 with schizophrenia, 2,720 with BD). In patients with
schizophrenia, 65.5% were treated with a single antipsychotic, and
34.5% were prescribed more than one antipsychotic during the study
period. A notable number of schizophrenic patients receiving either
one or multiple antipsychotics, respectively, also received mood
stabilisers (13.5%, 21.3%), antidepressants (15.9%, 17.5%) or both
(5.5%, 15.2%). In patients with BD, 66.7% were prescribed a single
antipsychotic and 33.3% multiple antipsychotics. Concomitant medi-
cations were more frequently prescribed in patients with BD than
with schizophrenia ; BD patients receiving single and multiple anti-
psychotics, respectively, also received mood stabilisers (31.0%,
27.0%), antidepressants (14.8%, 13.6%) or both (34.9%, 48.5%).
Overall, in patients receiving multiple antipsychotics, up to 333 dif-
ferent combinations were used. Of the antipsychotic combinations
reported in the study, 22.7% of schizophrenia patients received the
5 most frequently used combinations for schizophrenia, and 23.4%
of BD patients received the 5 most common combinations for BD.
Conclusion : These interim results show a high level of treatment
variability in schizophrenia and BD patients. Most were treated with a
single antipsychotic, and concomitant treatment with mood stabilisers
and antidepressants was common.
Policy of full disclosure : The IBIS study was funded by
AstraZeneca and the presenting author received a grant from
AstraZeneca.
jP-01-003j Interactions between adenosine-A2A and alpha2
adrenergic receptors and their potential role in
antipsychotic drug response
E. Dremencov1, S. Postma2, B. Westerink3. 1BMC Netherlands,
Groningen, Netherlands ; 2Brains On-Line BV, Groningen, Netherlands ;
3University of Groningen, Netherlands
Objective : The aim of the current study was to investigate potential
interactions between A2A and Alpha2A-adrenergic receptors and
their putative role in antipsychotic drug response.
Methods : Male Wistar rats (300–350 g) were used in the experi-
ments. In-vivo electrophysiology, under propofol (1.2 mg/kg/min,
i.v.) anesthesia, was used to assess the ﬁring activity of norepi-
nephrine neurons in the locus coeruleus (LC). In-vivo microdialysis
(in freely-moving rats) was used to assess dopamine and norepi-
nephrine levels in the nucleus accumbens (NAcc) and prefrontal cor-
tex (PFC). Microdialysis probes were implanted under isoﬂurane
anesthesia, 24 hours prior to the experiment. The levels of catechola-
mines in dialysates were assessed using the high-performance liquid
chromatography (HPLC) and electrochemical detection.
Results : The mean basal ﬁring rate of norepinephrine neurons was
2.87¡1.54 Hz. Selective agonist of A2A receptors, CGS 21680
(0.05–0.5 mg/kg, i.v.), signiﬁcantly and dose-dependently decreased
the ﬁring rate of norepinephrine neurons (to 25% of baseline).
Subsequent administration of the selective antagonist of A2A re-
ceptors, ZM 241385 (0.1–1 mg/kg), partially recovered the ﬁring rate
(to 50% of baseline). Finally, injection of clonidine (0.02 mg/kg)
almost completely (>90%) inhibited norepinephrine neurons in the
LC. Haloperidol (1 mg/kg, s.c) signiﬁcantly increased dopamine
levels in NAcc and PFC ; norepinephrine levels were not altered. Pre-
treatment with ZM 241385 (0.5 mg/kg, i.p., 40 min prior to haloper-
idol administration) resulted in signiﬁcant increase in norepinephrine
levels in the PFC and in potentiation of haloperidol-induced elevation
of dopamine levels in the NAcc (Figure 1).
Conclusion : CGS 21680 inhibits the ﬁring rate of norepinephrine
neurons ; this inhibition is reserved by ZM 241385. ZM 241385
potentiates the eﬀect of haloperidol on dopamine levels in the NAcc
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and norepinephrine levels in the PFC. Antagonists of A2A receptors
may be thus beneﬁcial as adjuncts to antipsychotic drugs.
jP-01-004jMetabolic syndrome in a sample of drug-naive
egyptian patients with psychotic disorders
S. Elghonemy. Ain Shams University, Cairo, Egypt
Objective : The main objective of this study is to determine the rate of
occurrence of metabolic syndrome (MetS) in a sample of drug-naive
patients with psychotic disorders compared with a matched control
group and to identify the signiﬁcant criteria for this diagnosis.
Methods : This study is designed as a preliminary cross-sectional
case–control study. Twenty patients were selected from inpatient
psychiatric units at the Institute of Psychiatry, Ain Shams University,
Cairo, Egypt, with an established diagnosis of acute psychosis or ﬁrst
episode schizophrenia according to ICD-10 classiﬁcation during a
period of 6 months and matched with 20 controls. The case group was
assessed by a semistructured psychiatric interview sheet of the
Institute of Psychiatry, Ain Shams University, and both the groups
were subjected to measurements of (a) waist circumference (WC) and
BMI and (b) laboratory investigations including an oral glucose tol-
erance test (OGTT), HDL and triglycerides, and (c) blood pressure
measurements.
Results : MetS was detected in seven (63.6%) patients with schizo-
phrenia, one (33.3%) patient had acute psychosis, four patients had
unipolar depression, and only one had bipolar aﬀective disorder
compared with 7 (35%) participants in the control group. In addition,
WC, BMI, and OGTT were found to be signiﬁcantly correlated to de-
velopment of MetS in the studied sample.
Conclusion : Drug-naive patients are more likely to develop meta-
bolic changes ; in addition impaired OGTT, increasedWC, and obesity
(BMI430 kg/m2) are signiﬁcant predictors of developing MetS among
patients with psychotic disorders even before starting their anti-
psychotic medications.
jP-01-005jHigh doses of long acting atypical antipsychotics :
Role in a severe mentally illness treatment retention
J.J. Fernandez-Miranda1, V. Carame´s-Garcı´a1, A. Sa´nchez-Garcı´a1.
1SESPA, Gijon, Spain
Objective : To know the retention in treatment of severe mentally ill
patients and the role of long acting atypical antipsychotics, taking into
account high doses tolerability.
Methods : 3-year prospective, observational study of patients un-
dergoing speciﬁc severe mental illness programme (September 2007
to September 2011). (N=319 ; 44.2% of them with schizophrenia).
Assessment included the Clinical Global Impression (CGI) severity
scale, the WHO Disability Assessment Schedule (WHO/DAS), the
Camberwell Assessment of Need (CAN), laboratory tests and weight,
at the beginning and after three years of follow-up. Time in treatment,
reasons of discharge, medications used and hospital admissions were
registered.
Results : CGI at baseline was 5.72+/x0.8 ; After three years 35.7%
of patients continued under treatment (CGI=4.11+/x0.9 ; p<0.01) ;
40.4% were medical discharged (CGI=3.14+/x1.3 ; p<0.001) ;
DAS also decreased in the four areas (self-care and employment
p<0.01 ; family and social p<0.005) and also CAN (p<0.01) ; 8.5%
had moved to other places ; 14.1% were voluntary discharges. There
were signiﬁcant less hospital admissions than during the 18 months
previous treatment (p<0.001). Four patients dead. Time in the
Programme was 23+/x7.1 months. 43% of patients received
risperidone longacting inyectable (RLAI) (109.7+/x19 mg/14 day).
Tolerability was good and there were almost no discharges (4.2%) due
to side eﬀects or to relevant biological parameters alterations or
weight gain.
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Conclusion : Retention of patients with severe mental illness in a
speciﬁc programme was high. And the use of long acting atypical
antipsychotics in patients who had needed high doses (over 75mg/
14 day of RLAI) to get clinical stabilization and better functioning
seemed to be useful in improving treatment adherence, due to their
high tolerability.
jP-01-006jThe eﬀect of clozapine on white matter in
schizophrenia : A diﬀusion imaging and
tractography study
N. Forde1, M. Ahmed2, L. Holleran3, C. Scanlon2, C. McDonald2,
D.M. Cannon2. 1NUI Galway, Ireland ; 2NUI Galway, Clinical
Neuroimaging Lab, Ireland ; 3NUI Galway, Clinical Neuroimaging Lab,
Ireland
Objective : The pathophysiology of schizophrenia has been associated
with structural brain changes and clozapine, an eﬀective antipsychotic
medication has been suggested to have neuroprotective eﬀects in
preclinical studies. However in vivo imaging studies report a decline
in brain volume as a result of long-term clozapine use. Herein we
explicitly test the eﬀect of 6 months of treatment with clozapine on
white matter organization quantiﬁed as fractional anisotropy (FA).
Methods : Twenty-one chronic treatment resistant individuals
with schizophrenia(SZ, 16 male, mean-age=35¡9) and twenty-one
age- and gender-matched controls (HC, 12 male, mean-age=39¡10)
underwent psychiatric clinical assessment and diﬀusion-MR scanning
before and after either six months of treatment with the atypical
antipsychotic clozapine or no treatment, respectively. Analysis of FA
included voxel-based (TBSS) and tractography (ExploreDTI).
Results : The SZ-group improved clinically by an average of
21-points(¡13.53%) on the positive and negative syndrome scale
(PANSS) from baseline (45¡14) to follow up (24¡16). Compared
with baseline, patients treated with clozapine displayed reduced FA
in the genu and body of the corpus callosum, the cingulum bundle,
and anterior superior longitudinal fasciculus (SLF). There were
no signiﬁcant FA changes in the HC group. Tractography detected
reduced mean tract FA in the genu following treatment with clozapine
(DTI : 1.49%, t(19)=2.58, p=0.018 ; CSD :3.13%, t(20)=2.40, p=0.026)
but not in the HC group (DTI : 0.20%, t(19)=0.51, p=0.62 ; CSD :
0.72%, t(20)=0.77, p=0.45).
Conclusion : Patients treated with clozapine for 6 months display
reduced microstructural organization of the commissural ﬁbers,
cingulum bundle and SLF. It remains unclear whether this represents
a side-eﬀect or mechanistic element of clozapine treatment or a
manifestation of illness progression, in which case clozapine does not
reverse or halt microstructural disorganization in schizophrenia.
CSD-based proved more sensitive than did tensor-based tractography
in detecting these changes.
jP-01-007j Involvement of 5-HT2A receptor and
a2-adrenoceptor blockade in the asenapine-induced
elevation of prefrontal cortical monoamine outﬂow
O. Fra˚nberg1, M.M. Marcus1, T.H. Svensson1. 1Karolinska Institutet,
Stockholm, Sweden
Objective : The psychotropic drug asenapine is approved for treat-
ment of schizophrenia and manic or mixed episodes associated with
bipolar I disorder. Asenapine exhibits higher aﬃnity for several 5-HT
receptors and a2-adrenoceptors than for D2 receptors. Noteworthy,
both blockage of 5-HT2A and a2-adrenergic receptors has been shown
to enhance prefrontal dopamine release induced by D2 receptor an-
tagonists. Previous results show that asenapine, both systemically and
locally, increases dopamine, noradrenaline and serotonin release in
the medial prefrontal cortex (mPFC), and that the increased dopamine
release largely depends on an intracortical action.
Methods : Using reverse microdialysis in freely moving rats, we
here assessed the potency of low concentrations of asenapine to cause
a pharmacologically signiﬁcant blockage in vivo of 5-HT2A/2C re-
ceptors and a2-adrenoceptors within the mPFC, and thus its ability to
aﬀect cortical monoamine release by these receptors.
Results : Intracortical administration of DOI, a 5-HT2A/2C receptor
agonist, increased cortical monoamine release, eﬀects that were
antagonized both by asenapine and the selective 5-HT2A antagonist
M100907. Application of clonidine, an a2-adrenoceptor agonist, sig-
niﬁcantly reduced monoamine release in the mPFC. The selective
a2-adrenoceptor antagonist idazoxan blocked, whereas asenapine
partially blocked clonidine-induced cortical dopamine and noradre-
naline decrease. The eﬀects of asenapine and idazoxan on clonidine-
induced serotonin decrease were less pronounced.
Conclusion : Our results propose that low concentrations of asena-
pine in the mPFC exhibit a pharmacologically signiﬁcant 5-HT2A and,
to a weaker extent, a2 receptor antagonistic activity, which may con-
tribute to enhance prefrontal monoamine release in vivo and, sec-
ondarily, its clinical eﬀects in schizophrenia and bipolar disorder.
Policy of full disclosure : This work was supported by the Swedish
Research Council (grant no. 4747), the Karolinska Institutet and sup-
ported in part by a research grant from the Investigator Initiated
Studies Program of an Aﬃliate of Merck Sharp & Dohme Corp. The
opinions expressed in this paper are those of the authors and do not
necessarily represent those of Merck Sharp & Dohme Corp, nor its
Aﬃliates.
jP-01-008jDeﬁned daily dose system as a tool for standardizing
antipsychotic dosages. Reliability in high dose users
P.R. Gargoloﬀ1, D. Gargoloﬀ1, A. Corsico2, F. Rodriguez2, J. Sanchez
Viamonte2. 1City Bell, Argentina ; 2La Plata, Argentina
Objective : There is a report that found the Deﬁned Daily Doses
(DDDs) system as a reliable tool for standardizing antipsychotic doses
in drug utilization research (Nose et al., 2008). However, this study
was based upon a population receiving a wide range of antipsychotic
doses, with few of them being prescribed high doses deﬁned as
1000 mg o more chlorpromazine equivalents (CPZEs) thus limiting
the results. The aim of this study was to establish whether the DDDs
system could be reliably applied to standardize antipsychotic
dosages, focusing in high dose antipsychotic users.
Methods : The study was done in the Neuropsychiatric Hospital
Dr. Alejandro Korn, Argentina. Data was esxtracted from clinical
records on a census day 14th december 2009. The relationship
between antipsychotic doses expressed as DDDs, CPZEs and percen-
tages of the British National Formulary (BNF) maximum re-
commended daily dose were investigated by calculating Spearman’s
rank correlation coeﬃcients. it was approved by an Independent
Ethic Committee.
Results : The study sample were all of the167 inpatients with
schizophrenia receiving>=1000 mg CPZEs. Relationship between
antipsychotic daily doses expressed as multiples of DDDs and
CPZEs revealed a signiﬁcant correlation (Spearman’s rho=0.983,
P<0.001). Similarly, the relationship between antipsychotic daily
doses expressed as multiples of DDDs and percentages of the
BNF maximum recommended daily dose revealed a signiﬁcant
correlation (Spearman’s rho=0.920, P<0.001). We also analyzed both
relationships in the 239 schizophrenic inpatients with low and
medium antipsychotic doses showing similar signiﬁcant positive
correlations.
Conclusion : In conclusion, this study found that the DDD system is
a reliable tool to standardize antipsychotic dosages even in the sub-
population on high dose regimens.
jP-01-009jPrescription patterns in chronic psychiatric
hospitalization : 1995–2009 comparison
P.R. Gargoloﬀ1, D. Gargoloﬀ1, F. Rodriguez2, A. Corsico2,
U. Reckziegel2. 1City Bell, Argentina ; 2La Plata, Argentina
Objective : The aim was to identify changes in prescription patterns
for patients with chronic hospitalization between two diﬀerent peri-
ods in terms of availability of psychotropics, 1995 when clozapine was
the only atypical antipsychotic and 2009 when there was access to a
wider range of these drugs.
Methods : The study was performed at the Alejandro Korn
Hospital, Argentina. All inpatients in the chronic rehabilitation wards
were included on both census days 15–06–1995 and 14–12–2009. Data
was extracted from clinical records. The study was approved by an
Independent Ethics Committee.
Results : The total number of inpatients dropped from 1048 to 648
between 1995 and 2009. Mean age increased from de 52,9 to 58 years
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and male population grew up from 44.2% to 57.2%. The most preva-
lent diagnoses were Schizophrenia and Mental Retardation with 45%
and 28% respectively in 1995, and 40% and 31% in 2009. The length
of hospital stay was above 20 years in almost 30% of the patients
in both census. The mean antipsychotic dose was similar in both
periods, 600 mg chlopromazine equivalents. The proportion in each
census of schizophrenic (89% and 93%) and mental retardation
patients (79% and 80%) receiving antipsychotic agents, was pre-
served. The rate of antipsychotic polypharmacy dropped. However,
in both periods 53% of the patients with schizophrenia were pre-
scribed 3 or 4 psychotropics agents simultaneously. Haloperidol was
the most frequently antipsychotic used in both samples, and was
prescribed to over 30% of the inpatients. The rate of patients with
general clinical medications was higher in 2009 than 1995 (37.1% and
27.1% respectively).
Conclusion : In conclusion, there is an aging of the population of
inpatients and a reversion in the gender distribution with a greater
proportion of males in 2009. There are no signiﬁcant changes in the
overall prescription patterns despite the availability of diﬀerent
atypical antipsychotics in 2009 census.
jP-01-010jEpidemiology of antipsychotic-induced
hyperpolactinemia in psychiatric in-patients
O. Gerasimenko1, E. Starostina1, L. Dzeranova1, G. Kolesnikova1,
G. Kazia1, N. Goncharov1, I. Dedov1. 1Moscow, Russia
Objective : To evaluate prevalence of antipsychotic-induced hyper-
polactinemia (AIH) in psychiatric in-patients.
Methods : Cross-sectional study in 143 psychiatric in-patients
(F :M=65 : 78) treated with antipsychotics, mostly for schizophrenia
(93%). The patients were screened for serum prolactin and macro-
prolactin. Data is shown as median [1, 3 quartile]. Odds ratios (OR) for
AIH with various antipsychotics were calculated, compared to AIH
with haloperidol.
Results : Overall AIH prevalence was 57.0% (F, 72.0% ; M, 43.6%).
Macroprolactin was found in one patient only (2.0%). Prolactin
levels inversely correlated with duration of mental disorder in women
(r=x0,3, p=0.02), but not in men. AIH prevalence in women with
disease duration of<9 yrs was higher (85%) than in women with
disease duration ofo9 yrs (60%, p=0.02). AIH prevalence in men of
19–34 yrs was higher (57%) than in men of 35–45 yrs (28%, p=0.01).
In order of OR for AIH, antipsychotics ranged as follows : 1, risper-
idone (OR=12.5) ; 2, amisulpride (OR=6.3) ; 3, olanzapine (OR=2.2) ;
4, thioridazine (OR=1.4) ; 5, chlorpromazine (OR=1.2) ; 6, clozapine
(OR=1.1) ; 7, triﬂuoperazine (OR=1.0) ; 8, ﬂuphenazine, zuclo-
penthixol, periciazine (OR=0.9 each) ; 9, chlorprothixene (OR=0.8) ;
10, perphenazine (OR=0.6) ; 11, quetiapine and aripiprazole (OR=0.5
each). With risperidone, AIH was most probable both in men and
women (OR=10.3 and 3, respectively). Besides, in men, AIH was
predominantly associated with amisulpride and olanzapine (OR=5.7
each), in women, with sertindole and sulpiride (OR=1.4 each).
Conclusion :AIH found at screening is more than 1.5-fold prevalent
than that diagnosed by referral (39%). In patients with AIH,
measurement of macroprolactin is unnecessary. Men at risk for AIH
belong to a younger age group, women at risk have shorter duration
of mental disorder. The results cannot be fully explained by prefer-
ential use of atypical antipsychotics in the respective age and/or dis-
ease duration groups.
jP-01-011jThyrotoxicosis presenting with capgras delusion-a
case report
A. Ghosh1, J. Yogaratnam1, R. Jacob1. 1 IMH-WH, Singapore, Singapore
Objective : Psychiatric manifestations of hyperthyroidism are usually
anxiety and depression. Psychosis is rare and aﬀects around 1%.
Methods : Single case report.
Results : We present a 54 year old lady with hyperthyroidism who
presented with psychosis as well as Capgras delusions. The symp-
toms resolved with correction of her hyperthyroid status and low
doses of risperidone which was stopped after discharge.
Conclusion : Psychosis can be a rare presentation for patients
with hyperthyroidism and it is important for clinicians to be aware
of this.
jP-01-012jCost minimization analysis comparing paliperidone
palmitate with risperidone long-acting injectable in
Spain
J. Quintero1, B. Gonza´lez2, I. Garcı´a2. 1Hospital Universitario,
Infanta Leonor, Madrid, Spain ; 2 Janssen, Madrid, Spain
Objective : Estimate the savings produced by the use of Paliperidone
Palmitate (PP) instead of Risperidone Long-Acting Injectable (RLAI)
when treating schizophrenia patients, from the perspective of the
Spanish National Health System.
Methods : The cost-minimization analysis used in the SMC (Scottish
Medicine Consortium) evaluation was adapted for the treatment of
patients with schizophrenia in Spain. Only direct costs were included :
(1) medication costs (including oral antipsychotic drug supple-
mentation cost) and (2) cost of administration in the community.
Two diﬀerent time horizons were used : 1 year (to compare initiation
treatment) and 2 years (to compare maintenance treatment). The fol-
lowing assumptions were used for the base-case : (1) 50% of
the patients initiate treatment in hospital and 50% in community ;
(2) 50% of patients initiate treatment from a long-acting injectable
and 50% from an oral antipsychotic ; (3) no reduction in the length of
stay.
Results : PP use could save E648 per patient during the ﬁrst year of
treatment compared to RLAI. From the second year the saving could
be E906 per patient/year also in favour of PP. These savings are
mainly due to (1) lower drug cost of PP vs. RLAI in the community
setting, (2) fewer visits to Community nurses for drug administration.
Sensitivity analyses were done for the main parameters of the model
and conﬁrmed the robustness of the results, even in the most un-
favourable scenarios : if 100% of the patients (1) initiate treatment in
hospital the savings could be E628 per patient/year, (2) initiate treat-
ment from an oral antipsychotic the savings could be E418 per
patient/year. If PP could reduce the length of stay by approximately
one third, as some studies indicate (SMC, Crivera), the savings could
be E1,707 per patient/year.
Conclusion : To treat patients with PP instead of RLAI could be a
cost-saving strategy for the Spanish National Health System.
Policy of full disclosure : This study was supported by Janssen.
jP-01-013j Incidence and time course of extrapyramidal
symptoms : A comparison of oral and long-acting
injectable paliperidone randomized controlled
studies
S. Gopal1, Y. Liu2, L. Alphs3, A. Savitz2, I. Nuamah2, D. Hough2.
1 Janssen Research & Development, Titusville, USA ; 2 Janssen Research &
Development, Titusville, USA ; 3 Janssen Scientiﬁc Aﬀairs LLC, Titusville,
USA
Objective : To compare incidence and time course of extrapyramidal
symptoms-related (EPS) adverse events (AEs) between oral and long-
acting injectable (LAI) paliperidone.
Methods : Analysis included pooled data (safety analysis set ;
n=2256 for non-placebo treated patients) from randomized, double-
blind and controlled paliperidone studies (3 oral [6-wks each] ; 4 LAI
[13-wks each]), and assessed comparable doses (oral : 3–15 mg ; LAI :
25–150 mg eq [US doses 39–234 mg] intramuscularly). We summar-
ized incidence rates and time of onset for EPS-related AEs, categor-
ized by MedDRA EPS group terms as tremor, dystonia, hyperkinesia,
parkinsonism, and dyskinesia. Mean values over time for AIMS
(Abnormal Involuntary Movement Scale ; dyskinesia), BARS (Barnes
Akathisia Rating Scale ; akathisia) and SAS (Simpson Angus Rating
Scale ; parkinsonism) were graphed.
Results : Mean reductions (SD) from baseline to endpoint in EPS
scores were larger for LAI (AIMS : x0.10[1.27] ; BARS : x0.09[1.06] ;
SAS : x0.04[0.20]) vs. oral studies (AIMS : x0.08[1.32] ; BARS :
x0.03[1.24] ; SAS : 0.0[0.23]). These diﬀerences favored LAI for
BARS (P=0.023) and SAS (P<0.0001) but not AIMS (P=0.49). Anti-
cholinergic use (to treat EPS) was lower in LAI (12%) vs. oral studies
(17%). Incidence for all categories of spontaneously reported
EPS-related AEs was highest in the ﬁrst 8 treatment days though
generally lower for LAI than oral. Mean values for EPS scale
scores were comparable (LAI and oral) without evidence of a dose
response ; scores increased between days 8–15 in LAI, but not oral
studies.
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Conclusion : Incidence of spontaneously reported EPS-related AEs
was similar following approximately 90 days exposure with LAI and
40 days of oral paliperidone, at comparable doses.
Policy of full disclosure : All authors are full-time employees of
Johnson & Johnson.
jP-01-014jClinical and sociodemographic characteristics of
140 male patients treated with long-acting
risperidone during period of 4 years
V. Grosic1, P. Kalember2, A. Loncar Vuina3, M. Mihanovic3.
1Psychiatric Hospital St. Ivan, Zagreb, Croatia ; 2Polyclinic ‘‘Neuron ’’,
Zagreb, Croatia ; 3Psychiatric Hospital St. Ivan, Zagreb, Croatia
Objective : Risperidone long-acting injection is momentarily only
long-acting second generation antipsychotic reimbursed in Croatia
and it is registered for treatment of positive and negative symptoms
of schizophrenia. Risperidone long-acting injection (RLAI) has been
shown to improve clinical parameters, to decrease relapse rate and
increase adherence in patients suﬀering from psychotic disorders.
Objective of this poster is to describe demographic and clinical fea-
tures of acute psychiatric ward male patients, who were in everyday
practice clinically estimated as suitable for risperidone long-acting
injection treatment.
Methods : Research included all patients treated with risperidone
long-acting injection, in inpatient and outpatient setting of acute
male ward of Psychiatric Hospital ’’Sveti Ivan’’ in Zagreb, Croatia,
over time period of 4 years. Patients have been diagnosed by criteria
of International Classiﬁcation of Diseases (ICD), 10th revision. Data
were collected by computerized search of digitalized medical records
of Psychiatric Hospital ’’Sveti Ivan’’.
Results : Research sample included 140 male patients, in age range
from 21 to 70 years. Results will be available next month and they will
describe and show patients family status, education, place and con-
ditions of living. They also show diagnoses, earlier antipsychotic
medication and concomitant medication.
Conclusion : Poster data represent overview of our clinical experi-
ence with risperidone long-acting injection in naturalistic setting of
an acute male ward in psychiatric hospital, over period of 4 years.
Presented data describe demographic and clinical features of patients
who were considered to be suitable for risperidone long-acting injec-
tion treatment and who were expected to gain beneﬁt from it.
jP-01-015jEﬀective pharmaceutical care by pharmacists in
psychiatric medication therapy
Y. Hashimoto1, H. Watanabe2, M. Tensho2. 1Kobegakuin university,
Kobe, Japan ; 2Sawa Hospital, Osaka, Japan
Objective : Evaluation in the pharmaceutical care by pharmacists on
physician’s prescriptions for mental illness.
Methods : -Design- Seventeen inpatients with schizophrenia who
are given polypharmacy and/or excessive dose of antipsychotics
are described. Interventions to correct medication-related problems in
these patients are described. -Setting- Inpatients psychiatry service
in Sawa hospital in Japan -Patients- Subjects are inpatients with
chronic antipsychotics therapy. Average age is 49.2 years (SD=15.0,
n=17) and duration of schizophrenia is 26.3 years (SD=13.5, n=17).
Pharmacists monitored the prescriptions and the patient’s outcomes.
If the results end up failing, pharmacists intervene in them actively.
-Interventions- We performed to optimize and/or simplify a formula
in subjects who take polypharmacy and/or excessive dose of anti-
psychotics and to monitor side eﬀects.
Results : Of the 14 patients, the number of antipsychotics (from
3.1 (SD=1.2) to 1.2 (SD=0.4) medications) and dose (from 1775.8 mg
(SD=744.8) to 594.8 mg (SD=320.4) as chlorpromazine equivalent),
were reduced and leaded to monotherapy in 12 patients. Reducing the
dose of antipsychotics is attributed to decreasing the side eﬀects as
well as improving psychotic symptoms.
Conclusion : In the pharmaceutical care, medication-related
problems are prevalent in psychiatric patient, contributing to poly-
pharmacy and/or excessive dose. In this clinical practice, interven-
tions by pharmacists on physician’s prescriptions are performed.
Thereby reducing polypharmacy can lead to decreasing the side ef-
fects as well as improving psychotic symptoms.
jP-01-016jPsychopharmacology and psycopathology of
dopeminergic system
Y. Hayashi. University of Kochi, Kochi City, Japan
Objective : It is well known that psychotropic agents, which block
the dopaminergic system, show remarkable eﬀects in schizophrenia
especially in those cases with positive symptom. Moreover, the equi-
valent amount of psychotropic agents actually works extremely well
in dissociative identity disorder (multiple personality disorder) as
well. There is also a certain amount of medical literature stating that
anti-dopaminergic psychotropic agents are eﬀective in the treatment
of pathological gambling (compulsive gambling).
Methods : I experienced two cases of dissociative (conversion) dis-
orders treated with haloperidol eﬀectively. I introduce it in detail and
consider their pharmacological/biologic bases and psychopathologi-
cal bases as well as schizophrenia.
Results : They can be said that the development of schizophrenia,
dissociative identity disorder (multiple personality disorder), and
pathological gambling (compulsive gambling) somehow involves the
dopaminergic system.
Conclusion : If so, what is the psychopathological feature common
to these pathologies which involve the dopaminergic system in their
development? The objective of this article is to start discussion of the
psychopharmacology (psychobiology) of the dopaminergic system
from this point. Schizophrenia.
jP-01-017jDose of atypical antipsychotic drugs and cognitive
impairments in schizophrenia patients : Aripiprazole
has diﬀerent cognitive proﬁle from other atypical
antipsychotics?
H. Hori1, R. Yoshimura1, A. Katsuki1, A. Sugita1, W. Nakano1,
J. Nakamura1. 1UOEH, Kitakyushu, Japan
Objective : We investigated the eﬀects of the atypical antipsychotics
risperidone, olanzapine, and aripiprazole on cognitive functions in
Japanese patients with schizophrenia from the view point of dosing
schedule.
Methods : We performed a cross-sectional survey. Neurocognitive
functions were evaluated using the Brief Assessment of Cognition
in Schizophrenia, Japanese-language version (BACS-J) in 101 schizo-
phrenia patients who were maintained with the same dose of one of
the three above-named antipsychotics for at least 3 months.
Results : The BACS-J composite score was signiﬁcantly correlated
with the dosage of risperidone and olanzapine. On the other hand, no
correlation was found between the BACS-J composite score and the
dosage of aripiprazole. Moreover, the primary scores of verbal learn-
ing, motor function and attention and processing speed were signiﬁ-
cantly negative correlated with the dose of risperidone. The scores of
verbal learning and motor function were also signiﬁcantly negative
correlated with the dose of olanzapine. No correlation was found be-
tween any scores of the BACS-J and the dose of aripiprazole.
Conclusion : Aripiprazole had a diﬀerent pattern of relationship
between doses and cognitive impairments, which might be due to its
unique pharmacological proﬁle.
jP-01-018jDopamine D2 receptor occupancy with risperidone
long-acting injectable during maintenance treatment
in schizophrenia : A cross-sectional study
S. Ikai1, G. Remington2, T. Suzuki3, T. Tsuboi3, J. Hirano3,
K. Tsunoda4, M. Nishimoto5, K. Watanabe6, R. Kitahata3, M. Mimura3,
H. Uchida3. 1Yamanashi Prefect Kita Hosp, Kofu, Japan ; 2Toronto,
Canada ; 3Tokyo, Japan ; 4Sitama, Japan ; 5Kanagawa, Japan ; 6Kyorin
University, Department of Psychiatry, Tokyo, Japan
Objective : While 65–80% occupancy of dopamine D2 receptors with
antipsychotics has been proposed to achieve optimal therapeutic
response during acute treatment of schizophrenia, it remains unclear
as to whether it is also necessary to maintain D2 receptor occupancy
within this ‘‘safe’’ window for ongoing maintenance treatment.
The data are especially scarce for long-acting antipsychotic
formulations.
Methods : Clinically stable patients with schizophrenia (DSM-IV)
receiving a stable dose of Risperidone Long-acting Injectable (RLAI)
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as antipsychotic monotherapy for at least three months and free of any
psychiatric hospitalization over the past six months were included.
Dopamine D2 receptor occupancy levels at trough were estimated
from plasma concentrations of risperidone plus 9-hydroxyrisperidone
immediately before the intramuscular injection of RLAI, using a one-
site binding model derived from our previous positron emission
tomography data.
Results : 36 patients were included in this study (mean¡SD
age, 49.3¡14.0 years ; mean¡SD dose and interval of injections,
38.2¡11.6 mg and 16.5¡14.0 days, respectively). Mean¡SD D2 re-
ceptor occupancy was 62.1¡15.4% ; 52.8% of the subjects (N=19) did
not demonstrate an occupancy of o65%. On the other hand, 13.9%
(N=5) showed a D2 occupancy as high as over 80% at the estimated
trough.
Conclusion :More than half of patients on RLAI maintained clinical
stability without achieving continuous blockade of dopamine D2
receptors>65% in real-world clinical settings. Results suggest that
sustained dopamine D2 receptor occupancy levels ofo65% may not
be necessary for maintenance treatment with RLAI in schizophrenia.
jP-01-019jPaliperidone in the treatment of hebephrenic type
of schizophrenia
C. Istikoglou1, F. Mouchourtis2, D. Foutsitzis2, P. Kanellos2,
N. Poloniﬁs2, K. Vlachos3, T. Stroumbini2. 1Nea Ionia, Athens, Greece ;
2 ‘‘Konstantopouleio ’’ Hospital, Psychiatric Department, Nea Ionia,
Athens, Greece ; 3 , Nea Ionia, Athens, Greece
Objective : Hebephrenic Schizophrenia is the type of the schizo-
phrenic disorders range with the worst prognosis, given that it is
related to disorganized behavior and residual symptoms, despite the
relative absence of delirious ideas and delusions. Paliperidone (9-OH
Risperidone), a metabolite of risperidone, blocks D2 Dopamine-
receptors and 5HT-2A Serotonin receptors. The aim of the study is
to elevate the eﬀectiveness of Paliperidone for the treatment of
Hebephrenia.
Methods : 20 patients (n=20), 12 male and 8 female were studied in
the inpatient facility and the outpatient setting of the Psychiatric
Department of ‘‘Konstatopouleio ’’ General Hospital, Nea Ionia, dur-
ing the years 2009 and 2011. All patients received Paliperidone, in
monotherapy, at a dose of 9–12 mg. The above patients were given the
PANSS (Positive and Negative Symptoms in Schizophrenia), CGI-S
(Clinical Global Impression of Severity), and QOL (Quality of Life)
Scales before commencing treatment with Paliperidone, and again
after 30 and 45 days of Paliperidone reception commencement. The
age range of the patient sample was 18–31 years.
Results : 16 patients (85%) out of 20 patients (n=20), PANSS scor-
ing reduced. 10 out of 16 patients (n=16) were male and 6 female. On
the remaining 4 patients (15%), PANSS scores remained unchanged
after 30 and 45 days of treatment. This eﬀect urged the change of
medication, or the addition of diﬀerent antipsychotic medication. On
the 16 patients above, CGI-S was reduced from 5 to 3.1, while QoL
Scale scores also improved. Of those patients that interrupted treat-
ment and showed adverse eﬀects, 2 women showed galactorrhoea
with an increase of prolactin, and 2 men showed severe insomnia and
EPS. None of the 20 patients given Paliperidone treatment showed
any cognitive deﬁcits.
Conclusion : Paliperidone is known to be a safe and eﬀective
medication for the treatment of Hebephrenia. The release of long-
action Paliperidone may also prove an eﬀective treatment for this
resistive form of schizophrenia.
jP-01-020jPsycopharmacological treatment of cycloid psychosis
M.J. Jimenez Contreras1, R. Sa´nchez Gonza´lez1. 1Barcelona, Spain
Objective : INTRODUCTION: The concept of cycloid psychosis, per-
tains to particular types of acute, episodic, polymorphic psychotic
disorders, which are, frequently, diagnosed by the formal diagnostic
systems as either brief psychotic disorder, schizophreniform disorder
or psychotic disorder not otherwise speciﬁed. Three overlapping
cycloid subtypes (anxiety-happiness psychosis, confusion psychosis,
and motility psychosis) have been described, representing a valid
clinical construct that can be easily diﬀerentiated from the boundary
disorders on clinical grounds. The favourable prognosis of this
acute psychotic disorder in the long-term, makes it necessary to
emphasize in the importance of the accurate diagnosis and the
appropriate therapeutic approach. OBJECTIVES : To review in the
bibliographic literature the psychopharmacological treatment of
the cycloid psychosis and present a case report that exempliﬁes its
clinical features.
Methods : A bibliographic search is made in PUBMED and CSIC
database including the terms cycloid psychosis, looking for all the
literature that contains scientiﬁc evidence about its pharmacological
treatment. A case report is attached.
Results : – No controlled studies of cycloid psychosis treatment
have been conducted to date ; this being mainly due to the fact that the
disorder remains largely unrecognized in the formal diagnostic
systems.Data on treatment is based on clinical experience, uncon-
trolled studies, and anecdotal case reports. – Controversy in the use of
pharmacological treatment in the acute episode and as a maintenance
therapy. – Antipsychotics seem to be eﬀective in aborting the episode,
as we could see in the case report presented, but their potential to
reduce relapse rates remains unclear. – Other treatments described :
Electroconvulsive therapy, benzodiazepines, lithium and estradiol
substitution.
Conclusion : The treatment with low-doses of atypical antipsy-
chotics is a good alternative in the acute treatment of cycloid
psychosis. – Future studies on the psychopharmacological treatment
of this speciﬁc group of patients would be useful to ensure the ap-
propriate therapeutic approach.
jP-01-021jSimulation of dopamine D2 receptor occupancy by
aripiprazole in steady state : Based on PK-PD
modeling
E. Kim1, B.-H. Kim1, S. N. Kim1, I.-J. Jang1, S.-G. Shin1, J. M. Jeong1,
J. S. Kwon1. 1Seoul National University, Republic of Korea
Objective : Receptor occupancy study has been performed to evaluate
pharmacokinetic proﬁles in antipsychotic drug development. In par-
ticular, dopamine D2 receptor occupancy is a meaningful biomarker
in that it reﬂects the antipsychotic action at the target site in the brain
and predicts both the clinical response to antipsychotic drugs and the
emergence of drug side eﬀects. The importance of measuring dopa-
mine D2 receptor occupancy by a novel antipsychotic drug is further
emphasized by studies showing wide discrepancy between the time
courses of drug concentration in plasma and receptor occupancy in
the brain. While these ﬁndings highlight the value of measuring re-
ceptor occupancy in dose-ﬁnding study, a challenge is the impossi-
bility of obtaining as many receptor occupancy data as would be
necessary to design clinical trials with various dosing strategies. This
raises the necessity of in-silico simulation of dopamine receptor oc-
cupancy by antipsychotic drugs.
Methods : We previously reported a novel methodology using
pharmacokinetic-pharmacodynamic (PK-PD) modeling for the con-
centration-occupancy relationship analysis and estimated parameters
for the PK-PD model after single administration of aripiprazole
(J Cereb Blood Flow Metab. 2011 Dec 21. doi : 10.1038/jcbfm.2011.
180.). Based on the parameter estimates from the PK-PD model, we
simulated dopamine D2 receptor occupancy by aripiprazole in steady
state.
Results : In the case of once-a-day dosing schedule, the simulation
shows that dopamine D2 receptors would be almost fully occupied in
steady state even with 10mg of aripiprazole. In addition, the ﬂuctu-
ation index (=(maximal level-tough level)/trough level) in steady
state was lower than 5% in occupancy while higher than 100% in
plasma concentration. These ﬁndings suggest that aripiprazole is
likely to be given with higher dose and shorter interval than is re-
quired for the treatment of schizophrenia in terms of receptor occu-
pancy.
Conclusion : This study shows in-silico simulation based on the
PK-PD modeling can be useful for exploring appropriate doses for
antipsychotic drugs.
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jP-01-022jAssociation of antipsychotic-induced akathisia with
dopamine D2/3 receptor occupancy in ventral
striatum : A high-resolution PET study with
[11C]raclopride
J.-H. Kim1, Y.-D. Son2, S.-Y. Lee2, Y.-B. Kim2, Z.-H. Cho2. 1Gachon
University, Gil Hospital, Incheon, Republic of Korea ; 2Gachon University,
Neuroscience Research Institut, Incheon, Republic of Korea
Objective : The neurobiological basis of akathisia is not well under-
stood, although the strong aﬀective component suggests that it is of
a central origin. The authors examined the relationship between anti-
psychotic-induced akathisia and dopamine D2/3 receptor occupancy
in striatal subdivisions using high-resolution positron emission tom-
ography (HRRT) with [11C]raclopride to better understand its
underlying neurochemical mechanism.
Methods : Twenty-one schizophrenic patients receiving stable
doses of antipsychotics and 24 age- and gender-matched normal
controls completed 3-Tesla magnetic resonance imaging and HRRT
scans with [11C]raclopride in order to measure D2/3 receptor binding
potential (BPND) in the striatum. The D2/3 receptor BPND was
obtained using Logan graphical analysis with reference region input
and receptor occupancy was calculated as the percentage reduction
of receptor BPND with drug treatment relative to baseline. The data
obtained from age- and gender-matched normal controls were
used as an estimate of the patients’ baseline, as previously proposed.
Antipsychotic-induced akathisia was measured with the Liverpool
University Neuroleptic Side-Eﬀect Rating Scale. The striatum was
divided into 5 anatomic regions of interests (ROIs), including the
ventral striatum (VST), the pre-commissural dorsal caudate
(preDCA), the pre-commissural dorsal putamen (preDPU), the post-
commissural caudate (postCA), and the post-commissural putamen
(postPU). Pearson’s bivariate product-moment correlations were
calculated between akathisia score and D2/3 receptor occupancy
in subregions of the striatum. The strict level of signiﬁcance for
the analysis of 5 ROIs was adjusted as p<0.01 using Bonferroni cor-
rection.
Results : The analysis revealed that akathisia score had signiﬁcant
positive associations with D2/3 occupancy only in the VST (r=0.56,
p=0.009).
Conclusion : These results suggest that akathisia is signiﬁcantly
associated with D2/3 receptor blockade in the limbic subdivision of
the striatum, i.e., VST, which plays a crucial role in the regulation
of aﬀect and motivation.
Policy of full disclosure : This work was supported by the
Korea Science and Engineering Foundation (KOSEF) grant (No. 2010-
0022796).
jP-01-023jPaliperidone ER versus risperidone for
neurocognitive function in patients with
schizophrenia : A randomized, open-label,
controlled trial
S.-W. Kim1, Y.-C. Chung2, Y.-H. Lee1, J.-H. Lee3, S.-Y. Kim1,
K.-Y. Bae1, J.-E. Jang1, J.-M. Kim1, I.-S. Shin1, J.-S. Yoon1. 1Chonnam
N. University Hospital, Gwangju, Republic of Korea ; 2Chonbuk National
University, Jeonju, Republic of Korea ; 3Gwangju City Hospital, Republic
of Korea
Objective : No direct clinical comparison between paliperidone
extended-release (ER) and risperidone regarding cognitive function
has been published. This study aims to determine the eﬀectiveness of
paliperidone ER on cognitive function in patients with schizophrenia
in comparison to risperidone.
Methods : This was a 12-week, randomized, open-label study in
schizophrenia patients who were receiving risperidone. The patients
were randomized to a risperidone-continuation group or a pali-
peridone-switch group. The primary outcome measure was neuro-
cognitive function, which was measured with a computerized battery.
Secondary eﬃcacy measures included the Positive and Negative
Syndrome Scale, Social and Occupational Functioning Scale (SOFAS),
and Calgary Depression Scale for Schizophrenia. Safety measures in-
cluded extrapyramidal symptoms and laboratory measures.
Results : Fifty-eight subjects participated in this trial. The mean
dose at endpoint was 4.9 mg/day for risperidone and 9.0 mg/day
for paliperidone ER. The improvements in the recall following an
interference phase on the verbal learning test were signiﬁcantly
greater in the paliperidone-switch than in the risperidone-
continuation group. In the other six domains of neurocognitive
measures, signiﬁcant diﬀerences of changes were not observed.
Improvements in the SOFAS were signiﬁcantly greater in the pali-
peridone ER-switch group than in the risperidone-continuation
group. In other eﬃcacy outcome measures, no signiﬁcant diﬀerences
were observed between the two drugs. Paliperidone ER had a similar
side eﬀect proﬁle to risperidone, including metabolic problems and
prolactin-related adverse events.
Conclusion : Switching from risperidone to paliperidone ER may
produce additional cognitive and social functional improvements.
Policy of full disclosure : This study was supported in part by
an investigator-initiated grant from Janssen Korea Co. Ltd. Rep-
resentatives of the company were allowed to comment on the report,
but the ﬁnal approval of content was retained by the investigators
exclusively.
jP-01-024jThe eﬀect of paliperidone ER on subjective
well-being and attitudes toward medication among
patients with schizophrenia
S.-W. Kim1, J.-S. Yoon1, Y. S. Kim2, Y.-M. Ahn2, C.-E. Kim3, H.-J. Go4,
I.-S. Chee4, Y.-D. Kim4, J.-H. Lee5, Y.-J. Kwon6, Y.-M. Jae7. 1Chonnam
N. University Hospital, Gwangju, Republic of Korea ; 2Seoul Natl Univ
Hospital, Republic of Korea ; 3 Inha Univ Hospital, Incheon, Republic of
Korea ; 4Daejeon, Republic of Korea ; 5Daegu, Republic of Korea ;
6Cheonan, Republic of Korea ; 7Busan, Republic of Korea
Objective : This study aims to evaluate the subjective well-being and
attitudes toward antipsychotic medication of patients with schizo-
phrenia who had switched to paliperidone extended release (ER).
Methods : A total of 291 patients with schizophrenia treated with
antipsychotics participated in this open-label, 24-week switching
study. The primary outcome measures were the Subjective Well-Being
under Neuroleptic Treatment Scale-short version (SWN-K) and the
Drug Attitude Inventory (DAI).
Results : Data from a total of 243 subjects who received the study
medication and had at least one follow-up assessment without a major
protocol violation were analyzed. Scores on the DAI and SWN-K
showed signiﬁcant improvement between baseline and end-point
measurements beginning during the second week. Scores on the
Krawiecka scale, all ﬁve subscales of the Clinical Global Impression-
Schizophrenia scale, and the Personal and Social Performance scale
were also signiﬁcantly improved at the end point compared with the
baseline. Scores on the DAI and total SWN-K scores were signiﬁcantly
improved in subjects who were previously treated with risperidone
but not in those who were previously treated with other anti-
psychotics.
Conclusion : Paliperidone ER was eﬀective for improving the
subjective well-being and attitudes toward antipsychotic medication
of patients with schizophrenia, particularly those who had been pre-
viously treated with risperidone.
Policy of full disclosure : This study was supported in part by an
investigator-initiated grant from Janssen Korea Co. Ltd. Represen-
tatives of the company were allowed to comment on the report, but
the ﬁnal approval of content was retained by the investigators
exclusively.
jP-01-025jEﬀectiveness of long-acting risperidone for patients
with treatment refractory schizophrenia
H. Kimura1, N. Kanahara1, N. Komasu2, M. Ishige3, K. Muneoka4,
M. Yoshimura5, H. Yamanaka6, T. Suzuki7, H. Watanabe1, Y. Sekine1,
M. Iyo1. 1Chiba University, Japan ; 2Douwakai Chiba Hospital, Japan ;
3Sodegaura Satsukidai Hospital, Chiba, Japan ; 4Gakujukai Kimura
Hospital, Chiba, Japan ; 5Dojinkai Kisarazu Hospital, Chiba, Japan ;
6Chiba PsychiatricMedicalCenter, Japan ; 7Koutokukai Sato Hospital,
Chiba, Japan
Objective : Up to 30–60% of patients with schizophrenia do not
respond suﬃciently to antipsychotics. Treatment-resistant Schizo-
phrenia (TRS) can have several reasons, including early onset,
nonadherence to oral medication regimens, and persistent negative
symptoms known as deﬁcit syndrome. Recently, dopamine super-
sensitivity psychosis (DSP) and tardive dyskinesia (TD), both of which
P-01. Antipsychotics 53
Downloaded from https://academic.oup.com/ijnp/article-abstract/15/Supplement_1/1/650920
by University of Groningen user
on 13 March 2018
could be caused by inappropriate pharmacotherapy, as typiﬁed by
excessive dosages of antipsychotics, have also been presumed rel-
evant to TRS. Several lines of evidence suggest that both DSP and TD
are closely linked to the supersensitivity of dopamine D2 receptors ;
this could be caused by a potent blockade of the receptors by anti-
psychotics. Several studies have reported that risperidone long-acting
injection (RLAI) successfully reduced antipsychotic dosage and ex-
trapyramidal symptoms, as well as relapse rate. Furthermore, some
reports suggested greater improvement in the psychotic symptoms in
RLAI compared to oral medication. We have therefore hypothesized
that RLAI with narrower blood kinetics than oral medication could
provide a continuous optimal blockade of dopamine D2 receptors,
leading to the prevention and/or improvement of the supersensitivity
state of the receptors.
Methods : Here we try to verify RLAI’s eﬀectiveness in a TRS
group, including patients with a background of DSP. This study,
which is in progress as of January 2012, is a naturalistic, one-arm de-
sign with a 12-month observation period of a moderate sample size
(N=150).
Results : Of the 43 TRS patients with 6 months observational period
following RLAI initiation, 25 (58%) were diagnosed as DSP.Following
6 months of RLAI treatment, 17 of these 25 DSP patients (68%) had
responded to RLAI, whereas the 18 patients without a history of DSP
showed insuﬃcient responses, indicating that RLAI is exceedingly
eﬀective in patients with DSP.
Conclusion : Although this is only a progress report, the present
results strongly suggest that RLAI could become an eﬀective treat-
ment strategy for TRS with DSP.
jP-01-026jThese data support results from recent studies
that paliperidone ER is well tolerated and eﬀective
in patients previously unsuccessfully treated with
other antipsychotics
V. Kola. University Hosp. Center Tirana, Albania
Objective : Paliperidone is a second generation antipsychotic medi-
cation approved for the treatment of schizophrenia. It is a useful op-
tion in the treatment of the acute symptoms of schizophrenia and
may also be used in patients previously unsuccessfully treated with
other antipsychotics. The aim of this work was to explore tolerability
and treatment response of ﬂexible doses of paliperidone ER (3, 6, 9,
12 mg/day) in adults suﬀering from resistant paranoid schizophrenia.
Methods : Four patients with resistant paranoid schizophrenia were
included in this study. The patients were male, on the average 39.8
years old, diagnosed according to DSM-IV with schizophrenia from
on the average 15.7 years, which had presented therapeutic resistance
to some antipsychotics (haloperidol, clopixol, rispolepidone, olanza-
pine, clozapine). All subjects were treated with 3–12mg paliperidone
ER, according to the severity of symptoms. Patient’s Positive and
Negative Syndrome Scale (PANSS), Clincal Global Impression-
Severity (CGI-S), Adverse Events (AEs) were assessed at ﬁve time
points : baseline, 1st, 2nd, 3rd, month of treatment. Personal and Social
Performance (PSP) scale was assessed at every three month of treat-
ment.
Results : Three patients completed the four month trial of paliper-
idone ER and one of them interrupted the medication (3mg/day) after
one month because of the noncompliance. One patient started and
ﬁnished the treatment with paliperidone XR 6mg/day, two patients
started the treatment with 9mg/day, but during the last month they
received 12mg/day for better improvement. The PANSS, CGI-S, AEs
and PSP scales indicated that the treatment with paliperidone XR of
three schizophrenic patients was eﬀective and paliperidone did not
produce adverse events. The treatment with this medication was
noneﬀective only for one patient.
Conclusion : These data support results from recent studies that
paliperidone ER is well tolerated and eﬀective in patients previously
unsuccessfully treated with other antipsychotics.
jP-01-027jNovel D2/5-HT6/5-HT7 receptor antagonist with a
broad antipsychotic activity
M. Kolaczkowski1, P. Mierzejewski2, A. Wesolowska3, P. Bienkowski4,
K. Mitka5, J. Jaskowska6, P. Kowalski5, A. Bucki3, M. Marcinkowska3,
M. Pawlowski3. 1 Jagiellonian University, Cracow, Poland ; 2 Institute of
Psychiatry and Neurology, Warsaw, Poland ; 3 Jagiellonian University,
Collegium Medicum, Cracow, Poland ; 4 Institute of Psychiatry and
Neurology, Cracow, Poland ; 5Cracow University of Technology, Poland ;
6Cracow University of Technology, Poland
Objective : 5-HT6 and 5-HT7 receptor antagonism has been associated
with potential procognitive as well as antidepressant and anxiolytic
activity. Therefore, introduction of strong functional antagonism of
those receptors is considered beneﬁcial for the proﬁle of a modern
antipsychotic drug. We designed and synthesized a novel series of
arylsulfonamide derivatives being strong D2/5-HT6/5-HT7 receptor
antagonists, without signiﬁcant anticholinergic and antihistaminergic
eﬀects or hERG channel blockade and tested them in a series of in vivo
models.
Methods : The following animal models were used : $amphetamine
(2.5 mg/kg) and dizocilpine (0.2 mg/kg) induced hyperlocomotion in
mice $apomorphine (0.6 mg/kg) and dizocilpine (1.2 mg/kg) in-
duced strereotypies in rats $DOI (2.5 mg/kg) induced head twitches
in rats $Conditioned avoidance response and passive avoidance in
rats $Prepulse inhibition deﬁcit induced by amphetamine (6.0 mg/
kg) $Tail suspension test in mice $Porsolt’s forced swimm test in
rats$Four-plate test in mice $Vogel’s conﬂict drinking test and elev-
ated plus maze test in rats.
Results : Minimal eﬀective doses of the best compound (in mg/kg)
are as follows : amphetamine and dizocilpine induced hyperlocomo-
tion – 2.5 and 1.25, apomorphine and dizocilpine induced strereo-
typies – 10 and 3, DOI induced head twitches – 1, conditioned
avoidance response – 3, prepulse inhibition deﬁcit induced by am-
phetamine – 30, tail suspension test – 0.156, Porsolt’s forced swimm
test – 0.3, four-plate test – 0.312, Vogel’s conﬂict drinking test and
elevated plusmaze test – 3 and 0.3. Not active in passive avoidance test
up to 30 mg/g.
Conclusion : The most interesting compound displayed a wide an-
tipsychotic activity in a broad range of mice and rat models. At the
same time it proved to have no detrimental eﬀect on cognition as well
as to possess potentially beneﬁcial inﬂuence on aﬀective dimension of
schizophrenia.
Policy of full disclosure : The studies were co-ﬁnanced by Adamed
Pharmaceuticals, Pienkow, Poland and National Centre for Research
and Development, Warsaw, Poland grant no. KB/88/12655/IT1-C/
U/08.
jP-01-028jRabbit syndrome due to olanzapine
G. Kunjithapatham1, C.-H. Jessie Chiu1. 1 Institute of Mental Health,
Singapore, Singapore
Objective : There are very few case reports in the literature on rabbit
syndrome due to olanzapine and other atypical antipsychotic
agents.we describe a patient who developed this syndrome with
olanzapine and it improved with reduction of dose and with intro-
duction of antcholinergics(benzhexol).
Methods : 32 year old lady with learning disablity and bipolar
depression (Severe Depressive disorder with psychotic symptoms).
She developed rabbit syndrome after the dose of olanzapine was
increased to 15 mg. Symptoms improved after the reduction of dosage
to 5 mg and with the introduction of anticholinergic agents.
Results : Patient is currently receiving Olanzapine 5 mg/day and
Mirtazepine 30 mg/day and the extrapyramidal symptoms have
abated.
Conclusion : This case adds on to the existing literature of rabbit
syndrome secondary to use of atypical antipsychotic drugs.
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jP-01-029jAntipsychotic preferences for psychiatrists and their
family members
M. Latas1, T. Stojkovic2, T. Ralic2, S. Milovanovic1, M. Jasovic Gasic1.
1Clinic of Psychiatry, Belgrade, Serbia ; 2Belgrade, Serbia
Objective : We aimed to evaluate which antipsychotic drugs psy-
chiatrists would prefer for themselves, their partners and children in
case of a mental illness.
Methods : The study was conducted among psychiatrists in Serbia
and we have assessed 90 participants : 68 (75.6%) psychiatrists and
22 (24.4%) psychiatric trainees who were asked to complete the
questionnaire about their drug selection in hypothetical situations of
becoming ill with schizophrenia or these conditions occurring in their
partners and children.
Results : In case of schizophrenia, majority of participants reported
that they would take atypical antipsychotic and risperidone was the
ﬁrst choice made by most psychiatrists for themselves (51.1%), their
partners (55.8%) or children (43.3%), followed by clozapine (12.2%),
haloperidol (10.0%) and olanzapine (10.0%). The preferred doses
were slightly lower than the recommended ones (Risperidone 2.8 mg,
Clozapine 181.8 mg, Haloperidol 5 mg, Olanzapine 11.7 mg). All the
preferences were similar, regardless the respondent was specialists
in psychiatry or psychiatric trainee.
Conclusion : Most psychiatrists would take or administer atypical
antipsychotics as the ﬁrst choice for themselves, their partners or
children. These preferences are mostly in accordance with current
treatment guidelines, but there is still room to narrow the gap between
guideline recommendations and psychiatrists’ medication choices in
personally meaningful situations.
jP-01-031jDopamine D2 antagonist-induced striatal gene
expression requires activation of mGlu5 receptors
by cortical aﬀerents
D. Levesque1, J. Maheux1, E. Tirrota2, E. Borrelli2, C. Rouillard3,
P.-P. Rompre´4. 1University of Montreal, Faculty of Pharmacy, Canada ;
2 Irvine University, Irvine, California, USA ; 3Laval University, Quebec,
Canada ; 4University of Montreal, Faculty of Medicine, Canada
Objective : Antipsychotic drugs are used to alleviate schizophrenia
symptoms. Despite the fact that all antipsychotic drugs interact with
dopamine D2 receptors, the exact mechanism that explains their ac-
tivity still remains elusive. Here we explored the relationship between
glutamate, adenosine and dopamine receptors in the modulation of
the transcription factor Nur77 (NGFI-B, NR4A1) in the striatum, an
important brain structure involved in antipsychotic drug eﬀects.
Methods : We performed eticlopride (ETI ; D2 antagonist) treat-
ments in transgenic mice with a genetic deletion of the postsynaptic
dopamine D2L receptor isoform, as well as in rats bearing an ibotenic
acid-induced cortical lesion. Additionally, groups of mice receiving an
acute injection of vehicle, MPEP (mGluR5 antagonist), SCH58261
(A2A antagonist), ETI or compound combinations have been
investigated. Organotypic cultures of striatal slices exposed to these
drugs were also performed.
Results : ETI was still able to strongly induced Nur77 mRNA levels
in the striatum of D2L receptor knockout mice, while cortical lesions
strongly attenuated ETI-induced Nur77 expression in the striatum.
Systemic blockade of mGluR5 and A2A receptors strongly reduced
ETI-induced Nur77 mRNA levels in the striatum, whereas MPEP or
SCH58261 alone remained inactive. On the other hand, mGluR5 ago-
nists can directly modulate Nur77 expression in striatal organotypic
cultures. Furthermore, blockade of glutamate reuptake in organotypic
striatal slices strongly activated Nur77 transcription that can be abol-
ished by an mGluR5 antagonist. Interestingly, D2 agonist or antag-
onist cannot modulate Nur77 expression by themselves in the striatal
slices.
Conclusion : These observations indicate that modulation of
the transcription factor Nur77 in striatal cells following dopamine
D2 antagonists (antipsychotic drugs) is mediated, at least in part,
by an interaction of the drug with presynaptic dopamine D2S
receptors located on corticostriatal aﬀerents and subsequent acti-
vation of postsynaptic mGluR5/A2A receptors in striatal cells. JM
holds a studentship from the Canadian Institute for Health Research
(CIHR).
jP-01-032jRole of the transcription factor NUR77 in
haloperidol-induced hyperprolactinemia
D. Levesque1, X. Giner1, C. Rouillard2. 1University of Montreal, Faculty
of Pharmacy, Canada ; 2Laval University, Faculty of Medicine, Quebec,
Canada
Objective : Antipsychotic drugs are used to treat schizophrenia
symptoms. But, they are known to cause various motor and endocrine
side eﬀects and have a limited eﬀectiveness. The main characteristic of
antipsychotic drugs is to interact, and act as antagonists, with the
dopamine D2 receptors. In lactotrope cells of the anterior pituitary,
activation of D2 receptors inhibits prolactin (PRL) secretion and syn-
thesis. Accordingly, antipsychotic drugs increase PRL transcription
and induce hyperprolactinemia. However, the molecular mechanism
leading to the hyperprolactinemia remains elusive. Previous works
from our laboratory suggest that the transcription factor Nur77
(Nr4a1) is associated with motor side eﬀects induced by antipsychotic
drugs (Levesque and Rouillard, TiNS, 2007).
Methods : In the present study, we measured pituitary Nur77
and PRL mRNA levels using quantitative RT-PCR assays, and
serum PRL levels were evaluated by ELISA, in wild type FHH and
Nur77 knockout (-/-) rats (FHH-Nr4a1m1Mcwi, nonsense mutation
Y130stop) treated with vehicle or haloperidol. Electrophoretic gel
mobility shift assays (EMSA) were performed to identify transcription
factor binding to the PRL promoter.
Results : We report that Nur77 is expressed in basal conditions in
the anterior pituitary and that Nur77 mRNA levels are signiﬁcantly
up-regulated by haloperidol. Interestingly, in Nur77 knockout (-/-)
rats, basal pituitary PRL mRNA levels are elevated, but haloperidol is
unable to increase PRL transcription, as compared to their littermates.
Consequently, haloperidol-induced serum PRL levels are strongly
reduced in Nur77 (-/-) rats. In silico analysis reveals numerous puta-
tive Nur77 responsive elements (NBRE) in the PRL promoter and
electrophoretic gel mobility shift assays (EMSA) indicate that Nur77
can bind to the PRL promoter.
Conclusion : Taken together, these results indicate that Nur77
regulates PRL transcription and secretion following the adminis-
tration of a typical antipsychotic drug.
jP-01-033jRegulating oligodendrocyte regeneration and
development in vitro : A new feature of atypical
antipsychotic drugs?
X.-M. Li1, Y. Zhang1, H. Zhang1, J. Wang1, J. Kong2, L. Wang1.
1University of Manitoba, Winnipeg, Canada ; 2University of Manitoba,
Department of Human Anatomy, Winnipeg, Canada
Objective :Neuroimaging and microarray studies have indicated that
oligodendrocyte and myelin abnormalities are important pathological
changes of schizophrenia. Antipsychotic drugs (APDs) are eﬀective in
treatment of schizophrenia ; but the underlying mechanism remains
unknown. Our previous studies suggested that quetiapine, an atypi-
cal antipsychotic drug, promoted neural progenitor cells to diﬀeren-
tiate into oligodendrocyte lineage cells and alleviated CPZ-induced
demyelinating pathology. In this project, we further investigated the
eﬀect of diﬀerent antipsychotic drugs on the oligodendrocyte in vitro.
Methods :Awell established oligodendrocyte-lineage cell line, CG4
cells were used to exam the eﬀect of three antipsychotic drugs : halo-
peridol, quetiapine and olanzapine. Antipsychotics showed no eﬀects
on proliferation of CG4 cells evaluated by CCK-8 proliferation assay.
However, all of the drugs promoted diﬀerentiation of CG4 cells into
mature oligodendrocytes when it was evaluated by the expression of
CNPase, a maker of mature oligodendrocyte. Further to investigate
the mechanism of antipsychotic drugs, we found the expression
of oligodendrocyte transcription factor 1 (olig1) and 2 (olig2) were
distinctly regulated by the drugs.
Results : The expression of olig2 was up-regulated by the all the
drugs tested and olig1 was only increased by quetiapine and olanza-
pine, but not by haloperidol. These data suggested that olig1 and olig2
may play a key role in the regulation process of APDs on oligoden-
drocyte development and there may be some diﬀerences between the
action of typical and atypical antipsychotics.
Conclusion : Our results indicate APDs have eﬀects to promote the
diﬀerentiation of CG4 oligodendrocyte cell line in vitro and oligo-
dendrocyte/myelin may be a novel target for APDs.
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Policy of full disclosure : Dr. Xin-Min Li accepted research grant
from Astrazeneca Canada and Pﬁzer Canada.
jP-01-034jPreventing and treating olanzapine-induced obesity
with betahistine : A chronic animal model study
J. Lian1, X.-F. Huang2, N. Pai3, C. Deng4. 132.326, Wollongong,
Australia ; 232.305, IHMRI, Wollongong, Australia ; 328.G07A, Graduate
School of Medicine, Wollongong, Australia ; 432.331, IHMRI, Wollongong,
Australia
Objective : Olanzapine, an atypical antipsychotic drug, is widely
prescribed to treat schizophrenia, but induces serious weight gain/
obesity side-eﬀects. Antipsychotic drugs antagonistic aﬃnity for his-
tamine H1 receptors is the main indicator of weight gain side-eﬀects.
This study aimed to investigate whether chronic treatment with
betahistine (H1 receptor agonist/H3 receptor antagonist) could pre-
vent/treat olanzapine-induced weight gain at diﬀerent stages of
treatment.
Methods : Female Sprague-Dawley rats were administered under 5
conditions (n=12) : (1) Rats were treated with vehicle (control) during
whole experimental period ; (2) ‘‘Obesity treatment group’’ : 5 weeks
olanzapine treatment (1 mg/kg, t.i.d.), followed by 6 weeks co-
administration of olanzapine with betahistine (9.6 mg/kg, t.i.d.) ;
(3) ‘‘Obesity prevention group’’ : 3.5 weeks olanzapine treatment,
followed by 2.5 weeks withdrawed, then co-administration of olan-
zapine and betahistine (4.8 mg/kg, t.i.d.) was introduced ; (4) Sole
olanzapine treatment following the same time course as Group 3 ;
(5) Rats were treated solely with betahistine (4.8 mg/kg, t.i.d.) during
weeks 7–11.
Results : Compared to controls, olanzapine treatment increased
body weight (p<0.001), food intake (p<0.01), inguinal fat mass
(p<0.05) and liver weight (p<0.01). On the other hand, the ‘‘obesity
treatment group’’ had lower weight gain (p<0.001), food intake and
inguinal fat (p<0.05) than the sole olanzapine treatment group.
The ‘‘Obesity prevention group’’ also showed signiﬁcantly decreased
weight gain (p<0.05), compared to the olanzapine group.
Conclusion : This study revealed that chronic co-treatment of
olanzapine and betahistine is eﬀective at reducing olanzapine-
induced obesity side-eﬀects. These results provide support for further
clinical trials to improve of olanzapine-induced obesity side-eﬀects
using betahistine co-treatment.
jP-01-035j Insulin resistance, obesity and metabolic syndrome
in psychiatric patients
I.I. Lieber1, A. Epelbaum2, D.M. Epelbaum2. 1Buenos Aires, Argentina ;
2Argentina, Argentina
Objective : The treatment with certain antipsychotics, antide-
pressants, stabilizers of mood, in patients with schizophrenia, uni-
polar or bipolar disorder, can contribute to produce dismetabolism
and to conﬁgure a metabolic syndrome with a coronary and brain
vascular risk. Nutritional, carbohydrate metabolic disorders such as
functional hypoglycemia, resistance to insuline, hiperinsulinism,
diabetes, obesity can accompany, induce, aggravate the development
of neuropsychiatric alterations. The objective is to prevent obesity,
insulin resistance, that are determinant factors in metabolic syndrome,
therefore the goal of recovery needs to combine the concept of general
medical health with that of the healthy mind. When there is hiper-
insulism it creates insulin resistance, obesity, there are more adi-
pocites, liberation of free fatty acids, adipokinines, inﬂammatory
cytokines, and these intervene in the metabolic disbalance producing
a pro-atherogenic, prothrombotic state, endothelial disfunction, which
are all present in the metabolic syndrome. Obesity is also associated
with a state of inﬂammation and immune response characterized with
elevation of reactive protein C, adipoquinines TNF alfa a mediator to
insulin resistance.
Methods : We implemented a program with aerobic exercice, re-
striction of calories, reﬁned sugars, ﬂour, and a balanced diet with the
addition of nutritional supplements, because food controls insulin, it
can reduce oxidative stress, inﬂammation and prevent development
of metabolic syndrome.
Results : We obtained a regulation in all parameters that were
altered in the metabolic syndrome in the psychiatric patients and in
ratio TGL/HDL, that is an indirect marker of the levels of inﬂam-
mation and insulin.
Conclusion : We give importance to excercise and the nutritional
factors that regulate insulin/glucagon axis, to prevent functional
hypoglycemia, hyperinsulinism, insulin resistance obesity, diabetes,
inﬂammation which conduce to metabolic syndrome. In patients with
mental illness that are taking antipsychotics, antidepressants and
stabilizers of mood it is necessary to elevate the metabolic monitoring
in the care and in the management of cardiac and brain risk factors to
prevent premature death.
jP-01-036jClozapine induces diﬀerentiation of human
preadipocytes via the aryl hydrocarbone receptor
C. Luckhaus1, B. Kappel2, K. Hemmrich3, K. Fehsel1. 1Heinrich-Heine-
University, Du¨sseldorf, Germany ; 2University of Aachen, Department of
Plastic Surgery, Germany ; 3University of Aachen, Germany
Objective : Among the pleiotropic pharmacology of clozapine is
the undesirable eﬀect of preadipocyte diﬀerentiation, which can be
antagonized by green tea extract (EGCG) in vitro. As this drug eﬀect
diﬀers from fat cell hypertrophic changes seen under olanzapine, we
hypothesize that an unshared molecular mechanism of clozapine
should be responsible. The chemical structure of clozapine resembling
a chlorinated polycyclic aromatic hydrocarbon led us to study the
involvement of the aryl hydorcarbon receptor (AhR).
Methods : Human preadipocytes obtained as a by-product of
abdominal plastic surgery were isolated and cultured in vitro. Cell
diﬀerentiation was studied by histochemistry 14 days after the ad-
dition of hormones and clozapine vs. hormones and other neuroleptic
compounds. EGCG and alpha-naphtoﬂavin (alpha-NF) were used as
antagonists. AhR activity was studied by luciferase reporter gene
assay and by RT-PCR of target gene CYP1A1.
Results : Unlike olanzapine and other atypical neuroleptics, cloza-
pine addition signiﬁcantly increased preadipocyte diﬀerentiation
by up to 60%. This eﬀect was fully antagonized by either EGCG or
alpha-NF. Clozapine speciﬁcally increased both AhR promoter ac-
tivity and transcription of target gene Cyp1A1.
Conclusion : Our study indicates that clozapine induced pre-
adipocyte diﬀerentiation is mediated by AhR activation. This
mechanism may be unique to clozapine, as it diﬀers from fat cell hy-
pertrophy eﬀected by olanzapine and other neuroleptic compounds.
AhR mediated eﬀects by clozapine may have further relevance at the
CNS and stem cell level, and could possibly account for some com-
ponents of its complex pharmacology.
jP-01-037jUse oﬀ label of antipsychotic medication – a 6 month
descriptive study of the antipsychotic use in the ﬁrst
visits in our center for mental health
M. Malo Lopez1, E. Gorgues Queralt2, A. Espelt3, P. Bonet i Dalmau2.
1Barcelona, Spain ; 2Althaia, Division of Mental Health, Manresa
(Barcelona), Spain ; 3Psychobiologist Department, Health Science,
Barcelona, Spain
Objective : To evaluate the characteristics of the ﬁrst 100 new patients
and to determine the use of antipsychotic in our Center for Mental
Health between July and December 2011 and to determine the
characteristics of the patients that were prescribed the use of anti-
psychotic.
Methods : Subjects : The population study were a hundred patients
that were ﬁrst time visited in the Center for Mental Health between
July and December 2011. Procedure : This is a cross-sectional
study – Independent variable were sex and age. Patients were diag-
nosed according to DSM’s criteria-IV of Unipolar disorder, Bipolar
aﬀective disorder /Psychotic disorders /Substance use disorder / or
comorbidity among axis II.
Results : From the selected sample of 100 patients 40 were male and
60 were female. The 24% were treated with antipsychotic in the ﬁrst
visit. The 86% of the selected sample were diagnosed Unipolar
Depression or/and Anxiety disorders and only a 6% of Psychotic
disorder and 7% of substances abuse disorder. The range of age in
which more patients were treated with neuroleptics was between 17th
and 35th years old (27.6% of patient between these ages were treated
with antipsychotic). The 37.5% of the patients that were treated with
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antipsychotic had diagnosis of personality disorders. To be men aged
between 17th-35th years old were the main variables associated to be
prescribed the use of antipsychotic [IC95% (24,8–55,2) p-value 0,002].
Conclusion : From our selected hundred patients visited from the
ﬁrst time in our Adults Center for Mental Health 24 were treated with
antipsychotic in spite of the fact that only 6% of these patients were
diagnosed of Psychotic disorder. The use of low-dose of typical anti-
psychotics in the treatment of personality disorders are useful not
only to improve symptoms of psychotic type (cognitive dysfunction,
perceptual, anxiety and paranoid ideation) but also the depressive
spirit, the impulsiveness and the anger.
jP-01-038jMental health rehabilitation unit : The role of
clozapine
M. Martı´n1, F. Pastoriza1, N. Ribas1, B. Garcı´a1, R.M. Del Valle1,
O. Orejas1. 1Parc de Salut Mar, Barcelona, Spain
Objective : To analyse the prescription of clozapine in a sample of
37 patients admitted to the mental health rehabilitation unit.
Methods : This is a transversal study. All patients admitted for
psychiatric rehabilitation treatment from the 01/01/2010 to the
31/12/2011 were included. Data about socio-demographical status,
information about the admission and clinical situation were obtained.
We then compared the patients who received treatment with cloza-
pine with the ones who did not.
Results : The sample was composed by 37 patients (78.4% men ;
mean age : 36+10 years). The majority of them were single (89.2%).
All of them were Spanish. Only the 5.4% of them were working and
the most represented group (73%) were receiving a disabillity allow-
ance. In the 70.27% of the cases schizophrenia was the diagnose
motivating the admission. The 378% of all patients had a comorbid
substance use disorder. Within the 26 patients with the diagnose of
schizophrenia, 9 (34.61%) did receive clozapine during the admission.
We compared the two groups (clozapine group vs. non-clozapine
group) and obtained the following results : there were no signiﬁcant
diﬀerences between the groups in terms of sex, civil state or working
state. Instead, it seemed that in the clozapine group the patients were
older, had a major number of previous hospital admissions, had a
larger trajectory of their disease and had more often committed sui-
cide attempts.
Conclusion : Patients requiring treatment with clozapine had a
major number of hospital admissions and had more often committed
suicide attempts, suggesting a more severe course of the disorder.
They were older as the non-clozapine group. This last may be related
with the fact that clozapine is delayed in its use among treatment-
resistant patients [2]. It’s worth highlighting that only 3461% of the
schizophrenic patients in the rehabilitation unit received clozapine.
This could mean that clozapine is underprescribed.
jP-01-039jHow to conduct clinical bioequivalence trials with
higher-dose quetiapine fumarate or pramipexole
hydrochloride hydrate safely in healthy subjects
S. Matsuki1, K. Ogawa2, K. Natori2, T. Matsui2, K. Matsuguma1,
A. Tanaka1, A. Watanabe1, T. Higuchi1, S. Irie1. 1Kyushu Clinical
Pharmacology, Research Clinic, Fukuoka, Japan ; 2Towa Pharmaceutical
Co., Ltd., Osaka, Japan
Objective : The aims were (1) to determine the maximum tolerated
doses (MTD) of quetiapine and pramipexole when given to healthy
Japanese male subjects in gradually increasing single doses and (2) to
evaluate the availability of this exploratory method for further bio-
equivalence trials.
Methods : This study was approved by Kyushu Clinical
Pharmacology Research Clinic Institutional Review Board, and all
subjects gave their written informed consent. In the quetiapine group,
18 participants received 25 mg in the ﬁrst stage. In the second stage,
they were divided into three groups of six subjects each and desig-
nated to receive either 50 mg, 75 mg or 100 mg depending on the
severity of the symptoms in the ﬁrst stage. In the pramipexole group,
18 participants received 0.125 mg and then received either 0.25 mg,
0.375 mg, or 0.5 mg in the same manner as the quetiapine group.
Results : In the group receiving 75 mg of quetiapine, three mild
adverse events (AEs) and seven moderate AEs (e.g., nightmare and
syncope) were reported from all six subjects. In the group receiving
0.5 mg of pramipexole, three mild and ﬁve moderate AEs were
reported from ﬁve subjects. In both groups, although no severe or
serious AEs were reported, we judged that doses equal to or greater
than 75 mg and 0.5 mg of quetiapine and pramipexole, respectively,
were not tolerated well in healthy subjects. The maximum concen-
tration of the drug in each subject was not always correlated with
severity of the AEs.
Conclusion : Doses of quetiapine 75 mg and higher and doses of
pramipexole 0.5 mg and higher were not tolerated well in healthy
subjects. Determining the MTD of psychotropic agents in bioequiva-
lence trials was safely achieved by giving the agents gradually
increasing doses based on severity of symptoms in the ﬁrst stage and
by carefully observing subjects in small groups (n=6).
jP-01-040jAntipsychotic-like properties of zolpidem in the rat
P. Mierzejewski1, M. Kolaczkowski2, A. Jastrzebska1, I. Korkosz1,
A. Wesolowska3, A. Korkosz1, A. Scinska1, P. Bienkowski1. 1 Institute
of Psychiatry, Warsaw, Poland ; 2 Jagiellonian University, Krakow, Poland ;
3 Jagiellonian University, Cracow, Poland
Objective : Preclinical and clinical studies support the assumption
that positive GABA-A receptor modulators may possess antipsychotic
properties. Our preliminary research showed that selective alpha1
GABA-A receptor agonist, zolpidem, but not benzodiazepines, can
produce neuroleptic-like cataleptogenic responses in the rat. The aim
of the present study was to investigate a potential antipsychotic pro-
ﬁle of zolpidem in a series of preclinical models of psychosis.
Methods : All experiments were conducted on drug-naive male
Wistar rats. Zolpidem and comparator drugs (diazepam, midazolam,
zaleplone, haloperidol, olanzapine) were tested in the following
models : $hyperlocomotion induced by amphetamine (1.0 mg/kg)
and dizocilpine (0.3 mg/kg) $apomorphine (0.6 mg/kg)-induced
stereotypies $dizocilpine (1.2 mg/kg)-induced stereotypies $DOI
(2.5 mg/kg)-induced head twitches $pre-pulse inhibition (PPI) deﬁ-
cits induced by amphetamine (6.0 mg/kg) or dizocilpine (0.6 mg/kg)
$conditioned avoidance response (CAR).
Results : Low doses of zolpidem (0.3–3.0 mg/kg, i.p.) inhibited
hyperlocomotion induced by amphetamine or dizocilpine. Higher
doses of the drug (3.0–10.0 mg/kg) reversed apomorphine- and
dizocilpine-induced stereotypies as well as DOI-induced head twit-
ches. Zolpidem (3.0–10.0 mg/kg) also reversed PPI deﬁcits produced
by amphetamine and inhibited CAR.
Conclusion : Zolpidem produced dose-dependent antipsychotic
eﬀects in several preclinical models of psychosis. Its eﬃcacy was
comparable to haloperidol and olanzapine and was superior to less
selective GABA-A positive modulators (diazepam, midazolam, zale-
plone).
jP-01-041jOne-year open-label study of the cognitive eﬃcacy
of blonanserin in antipsychotic-naı¨ve ﬁrst-episode
schizophrenia
S. Miyamoto1, T. Tenjin1, N. Miyake1, K. Ojima1, Y. Ninomiya1,
R. Kitajima1, S. Ogino1, Y. Kaneda2, T. Sumiyoshi3, N. Yamaguchi1.
1St. Marianna Univ. Sch. Med., Kawasaki, Japan ; 2 Iwaki Clinic, Anan,
Japan ; 3University of Toyama, Japan
Objective : Cognitive impairment, a core feature of schizophrenia, has
been established as an important symptom domain associated with
long-term outcome. The purpose of this study was to evaluate the
long-term eﬀects of blonanserin, a novel second-generation anti-
psychotic drug developed in Japan in 2008, on cognitive function in
ﬁrst-episode schizophrenia.
Methods : Twenty-four antipsychotic-naı¨ve patients with ﬁrst-
episode schizophrenia participated in the study. Blonanserin
(2–24 mg/day) was given in an open label design for one year. The
Brief Assessment of Cognition in Schizophrenia (BACS-J) was ad-
ministered as the primary outcome measure at baseline, 24, and
52 weeks. Clinical evaluation included the Positive and Negative
Syndrome Scale (PANSS), the Schizophrenia Quality of Life Scale
(SQLS-J), and the Clinical Global Impression-Severity of Illness Scale
(CGI-S). This study protocol was approved by the bioethics committee
of St. Marianna University School of Medicine, and written informed
consent was received from all participants.
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Results : Thirteen patients (6 males and 7 females ; mean age,
28.2¡5.6 years) completed the study. The mean daily dose of blo-
nanserin was 4.2¡3.0 mg/day at 52 weeks. One patient used antic-
holinergics (biperiden dose : 2 mg/day) at endpoint. At the 52-week
endpoint, signiﬁcant improvements were shown in letter ﬂuency,
executive function, and composite score, as measured by the BACS-J
compared with baseline (p<0.05). In addition, the psychosocial con-
dition score (p<0.01) and motivation/energy score (p<0.05) on the
SQLS-J, and all items on the PANSS (p<0.01) and CGI-S (p<0.01)
signiﬁcantly improved after 52 weeks treatment.
Conclusion : These results suggest that blonanserin has a beneﬁcial
eﬀect on some types of cognitive function associated with prefrontal
cortical function in patients with antipsychotic-naı¨ve ﬁrst-episode
schizophrenia. However, the conclusions that can be drawn are lim-
ited by the small sample size and the lack of control groups to exclude
the possibility of retest eﬀects.
Policy of full disclosure : Dr. Miyamoto has served as a consultant
for Dainippon Sumitomo Pharmaceutical. He has received advisory
board honoraria from Chugai Pharmaceutical. No other authors have
any conﬂicts of interest with any commercial or other associations in
connection with this study.
jP-01-042jCaregiver burden of patients with psychotic
disorders
R. Molina Ramos1, M. S. Sanchez2, M. Lliteras3, B. Hernandez3,
C. Castillo2, M. Millan4, C. Chada2, D. Giner2, H. Arnillas2, M. Gili5.
1Hospital Comarcal de Manacor, Spain ; 2Mallorca, Spain ; 3Hospital de
Manacor, Mallorca, Spain ; 4Hospital son Llatzer, Mallorca, Spain ;
5Universidad Islas Baleares, Mallorca, Spain
Objective : To evaluate the presence of caregiver burden in psychotic
outpatients who are treated in Mental Health Clinics and to know
clinical features associated with the presence of burden.
Methods : Cross-sectional study conducted in naturalistic type of
Mental Health Outpatient Clinics in Balearic Islands (Spain) belong to
hospitals in Majorca (Hospital de Manacor and Hospital son Llatzer)
and Menorca (Hospital Mateu Orﬁla). We used the Zarit Scale for
assessing caregiver burden.
Results : We obtained a ﬁnal sample of 77 caregivers. The mean
score on the Zarit scale was 39 (+17.11) Patients with psychotic dis-
orders assessed were male (62%) with a mean age of 43 years (+14.4)
with a diagnosis of more than 5 years evolution (72.7%) schizophrenia
was the most frequent diagnosis (55%) and risperidone long-acting
injection (RLAI) the most widely used antipsychotic (55.8%).
Conclusion : 1. The patients on maintenance monotherapy with
RLAI showed better adherence rates and more insight, evaluated by
their psychiatrists. 2. 78% of patients receiving antipsychotic medi-
cation injections were satisﬁed with the treatment. 3. Patients with
RLAI given in deltoid were satisﬁed in 65.7%.
jP-01-043jDopamine D2 receptor occupancy and remission in
schizophrenia : Analysis of the catie data
S. Moriguchi1, R. Bies2, G. Remington3, T. Suzuki4, D. Mamo3,
M. Mimura1, B. Pollock3, H. Uchida1. 1Keio University School of Med,
Tokyo, Japan ; 2 Indiana University Sch. of Med, Division of Clinical
Pharmacol, Indianapolis, USA ; 3University of Toronto, Department of
Psychiatry, Canada ; 4 Inokashira Hospital, Tokyo, Japan
Objective : In treating schizophrenia, it has been established that
65–80% occupancy of dopamine D2 receptors optimizes therapeutic
eﬃcacy while minimizing risks of extrapyramidal symptoms and
cognitive impairment. However, it is unclear as to whether it is
necessary to keep D2 receptor occupancy within this therapeutic
window to maintain clinical response.
Methods : The dataset from phase1 of the Clinical Antipsychotic
Trials in Intervention Eﬀectiveness (CATIE) trial was used. Patients
receiving risperidone, olanzapine, or ziprasidone were included in the
present analysis if they fulﬁlled the following deﬁnition of remission :
a score of f3 on 8 speciﬁc Positive and Negative Syndrome Scale
(PANSS) items (i.e. P1, P2, P3, N1, N4, N6, G5, and G9) at baseline
and months 1, 2, and 6. These criteria follow the deﬁnition proposed
by Andreasen et al., (2005). Peak and trough D2 receptor occupancy
levels at month 6 and endpoint were estimated from plasma
antipsychotic concentrations using population pharmacokinetic
analysis and our D2 prediction model.
Results : 30 subjects (15 men ; mean¡SD age=41.5¡11.8 years ;
risperidone, N=12, olanzapine, N=12, and ziprasidone N=6 ;
mean¡SD duration of follow-up 495.5¡78.1 days) fulﬁlled inclusion
criteria. Peak and trough D2 receptor occupancy levels at month 6
were 70.3¡9.8% and 60.5¡20.2% (mean¡SD), respectively ; among
these individuals, 46.7% (N=14) did not achieve continuous blockade
of o65% (i.e. trough D2 occupancy of <65%). 25 of these subjects
completed phase 1 with improvement ; of these, 52.0% (N=14)
did not achieve continuous blockade of o65% at endpoint. No sig-
niﬁcant diﬀerence was found in peak or trough D2 occupancy be-
tween those who successfully completed phase 1 and those who
did not.
Conclusion : Approximately half of patients who maintained re-
mission did not achieve continuous blockade of D2 receptor occu-
pancy o65%. Results suggest that sustained D2 receptor occupancy
over 65% is not always necessary for the maintenance treatment of
schizophrenia.
Policy of full disclosure :Data used in the preparation of this article
were obtained from the limited access datasets distributed from the
NIH-supported ‘‘Clinical Antipsychotic Trials of Intervention
Eﬀectiveness in Schizophrenia’’ (CATIE-Sz). This is a multisite, clini-
cal trial of persons with schizophrenia comparing the eﬀectiveness of
randomly assigned medication treatment. The study was supported
by NIMH Contract #N01MH90001 to the University of North Carolina
at Chapel Hill. The ClinicalTrials.gov identiﬁer is NCT00014001. The
version of the dataset used was 1.0. This study was also supported by
grant R01MH064173 from the National Institute of Mental Health and
was ancillary to Clinical Antipsychotic Trials of Intervention
Eﬀectiveness, N01MH90001, from the National Institute of Mental
Health.
jP-01-044jA comparison of the pharmacotherapy of japanese
mental disorders between inpatients and outpatients
receiving home visit nursing service
D. Nakamura1, O. Takashio1, M. Tani1, H. Shimizu1, S. Hasegawa1,
Y. Takayama1, T. Ohno1, N. Akashi1, A. Inamoto1, N. Kato1.
1Showa University, Kawasaki, Japan
Objective : Japan’s rapidly aging population has become a top medi-
cal issue. Similarly, Japanese mental disorders face the problem of
aging. In contrast, the Ministry of Health, Labor and Welfare plan to
reduce long hospitalization of Japanese mental disorders to improve
their quality of life and restrain increases in medical expenses. One
of the plans is home visit nursing service. The purpose of this study
was to examine the pharmacotherapy of Japanese mental disorders
between inpatients and outpatients receiving home visit nursing
service.
Methods : We conduct a survey of prescription and demographics
from inpatient’s medical records dated 30th September 2009 and
outpatient’s dated 31st May 2011 at Showa University Karasuyama
Hospital. This study was approved by the Medical Ethics Committee
of Showa University School of Medicine.
Results : As a result, one hundred ﬁfty-seven inpatients and sixty-
eight outpatients (almost chronic schizophrenia) had similar out-
comes and demographics. As they grew older, they hadmore physical
diseases (r=0.43, p<0.0001) and took lower amount of antipsychotics
(r=x0.34, p<0.0001) (Pearson product-moment correlation co-
eﬃcient). Outpatients had more physical diseases for their age than
inpatients because outpatient’s illnesses were more out of control.
Both patients had diabetes mellitus, hyperlipidemia, bone fracture,
diﬃculty swallowing and others, that could have inﬂuenced the
pharmacotherapy for rapidly aging mental disorders.
Conclusion : In conclusion, these results indicate that aging out-
patients were not healthier than inpatients. Various physical diseases
they had will aﬀect selection of drug by psychiatrists materially.
Psychiatrists in an aging society, like Japan, should realize the
necessity of managerial support for their illness and be more careful
when prescribe for aging outpatients.
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jP-01-045jA case series on the use of atypical long acting
injectables as ﬁrst-line antipsychotic treatment :
Who beneﬁts and how?
N.R. Nik Jaafar1, H. Zakaria2, M. Midin2, C. YS3. 1University
Kebangsaan Malaysia, Kuala Lumpur, Malaysia ; 2University Kebangsaan
Malaysia, UKM Medical Centre, Kuala Lumpur, Malaysia ; 3Universiti
Sains Isla Malaysia, Kuala Lumpur, Malaysia
Objective : The use of long acting injectables (LAI) antipsychotics
is mainly reserved as the second line treatment when all eﬀorts to
ensure patients’ adherence to regular oral medication failed. We aim
to describe the common clinical features of patients with schizo-
phrenia who beneﬁted from the use of LAI early in the course of
illness.
Methods : We report four patients with ﬁrst presentation of
schizophrenia, all of whom were started with atypical antipsychotic
LAI without prior history of oral antipsychotic. In all of the cases,
the treating doctors independently did not use short acting
major tranquilizers in the acute phase of psychosis because the
patients were not agitated but remained adamant in refusing oral
medications.
Results : We observed the four patients shared common clinical
features of prominent delusion rather than hallucination amidst other
psychotic symptoms, obstinate refusal of oral medication but without
agitation, with good pre-morbid functioning and very poor insight.
Interestingly, following the remission of the acute psychotic phase, all
showed marked improvement in their insight and had better than
expected therapeutic alliance.
Conclusion : We conclude that LAI may be used as the ﬁrst line
antipsychotic treatment in the acute psychotic phase in patients who
are non-agitated but have prominent symptom of delusions with poor
insight. LAI may improve the doctor-patient therapeutic alliance due
to its minimal side eﬀects and by ways of increasing the patients’
sense of control and allowing psychoeducation to take place when the
patient is ready.
jP-01-046jSexual dysfunction and changes in satisfaction with
switch to aripiprazole
M. Nishimoto1, T. Ishigaki1, Y. Koyama1, K. Nishimoto1, K. Funaki2,
Y. Matsunaga1, Y. Akao1. 1Toyoko Keiai Hospital, Kawasaki, Japan ;
2Tokyo, Japan
Objective : This study looked into the usefulness of switching to
aripiprazole in schizophrenic patients who experienced sexual dys-
function with antipsychotic treatment. In addition, changes in the
levels of satisfaction with medication were also examined.
Methods : Patients with schizophrenia receiving treatment at
our hospital and taking an antipsychotic drug were surveyed about
their subjective perception of frequency and severity of side eﬀects
on a self-completed questionnaire, and the level of satisfaction with
their medication, using the DAI-10 (Drug Attitude Inventory-10).
Of them, for patients who checked one of the items concerning
sexual dysfunction, attending physicians engaged in SDM (shared
decision making), and those for whom it was judged reasonable
to switch to aripiprazole and who agreed to switch became the
subjects of this study. Prolactin levels were measured upon switch-
ing, and again after the completion of the switch, along with the
self-completed questionnaire survey and evaluation using the
DAI-10.
Results : Seven patients had their medication switched to ar-
ipiprazole. As a result of this switch, they showed resolution or im-
provement of sexual dysfunction, and improvements in prolactin
levels (from 154.4¡94.0 to 65.5¡50.1). Improvements in DAI-10 were
also seen. No deterioration of psychotic symptoms was observed after
the switch.
Conclusion : One of the risks for the development of sexual dys-
function is increases in prolactin levels, and the improvement in pro-
lactin levels associated with a switch to aripiprazole was considered
to have resulted in the improvements in sexual dysfunction. This in
turn was considered to improve the level of patient satisfaction with
medication. These ﬁndings suggested that a switch to aripiprazole
may be useful in patients who experience sexual dysfunction with
antipsychotic treatment.
jP-01-047jMechanisms underlying the modulation of
antipsychotic-induced extrapyramidal motor
disorders by antidepressants
Y. Ohno1, A. Tatara1, M. Sato1, T. Sugiuchi1, A. Masui1, Y. Mizuguchi1,
J. Imaki1, M. Sasa2, S. Shimizu1. 1Osaka Univ. Pharm. Sci., Japan ;
2Nagisa Clinic, Osaka, Japan
Objective : Antipsychotic drugs are widely used not only for schizo-
phrenia, but also for mood disorders such as bipolar disease and de-
pression. To evaluate the interactions between antipsychotics and
antidepressants in modulating the extrapyramidal motor functions,
we examined the eﬀects of various antidepressants on haloperidol
(HAL)-induced bradykinesia and catalepsy in mice and rats.
Methods : Male ddY mice or SD rats were used. Animals were ﬁrst
given valious antidepressants and then treatred with HAL. The pole-
test and catalepsy-test were performed 30 min after HAL injection to
evaluate extrapyramidal disorders. Various 5-HT receptor antagonists
were also examined in conbination with antidepressants.
Results : The selective serotonin reuptake inhibitors (SSRIs),
ﬂuoxetine and paroxetine, and the tricyclic antidepressant (TCA)
clomipramine signiﬁcantly potentiated HAL-induced bradykinesia
and catalepsy in a dose-dependent manner. The 5-HT stimulant 5-
hydroxytryptophan also enhanced HAL-induced extrapyramidal side
eﬀects (EPS). However, a noradrenergic and speciﬁc serotonergic an-
tidepressant mirtazapine failed to augment, but rather attenuated EPS
induction. Treatment of animals with ritanserin (5-HT2A/2C antag-
onist), ondansetron (5-HT3 antagonist), and SB-258585 (5-HT6 antag-
onist) signiﬁcantly antagonized the EPS augmentation by ﬂuoxetine.
Intrastriatal injection of ritanserin or SB-258585, but not ondansetron,
also attenuated the EPS induction. In addition, both BRL-44408
(alpha2A antagonist) and JP-1302 (alpha2C antagonist) signiﬁcantly
ameliorated HAL-induced EPS.
Conclusion : The present study suggests that SSRIs augment anti-
psychotic-induced EPS by activating 5-HT2A/2C, 5-HT3 and 5-HT6
receptors. In addition, mirtazapine seems to be superior to SSRIs or
TCAs in combined therapy for mood disorders with antipsychotics in
terms of EPS induction. This is probably due to its alpha2 antagonistic
actions.
jP-01-048jPattern of clozapine use among patients in a
nigerian neuropsychiatric hospital
T. Ojo1, O. Abayomi. 1Neuropsychiatric Hospital, Abeokuta, Nigeria
Objective : Previous studies on the prescription patterns of psycho-
tropic medications have highlighted the use of Clozapine in the
treatment of persons with Schizophrenia. Little is known about the
prescription pattern of Clozapine in Nigeria. This study examined the
prescription pattern of Clozapine in a Nigerian Neuropsychiatric
Hospital.
Methods : A complete list of patients that had been on Clozapine in
the past year was retrieved from the pharmacy register of a Nigerian
Hospital. Information on pattern of Clozapine use was obtained from
Casenotes using a standardized data collection form.
Results : A total of 39 patients had received Clozapine in the past
year. Mean age was 43.3 years (SD=13). Majority were males (51.3%),
unmarried (66.7%) and unemployed (64.1%). About 8 (20.5%) had
comorbid substance use disorder. Most (81.2%) reported side eﬀects
related to clozapine use. Hypersalivation (46.2%) was the commonest
reported side eﬀect followed by drowsiness (41%), urinary problems
(17.8) and constipation (12.8%). Clozapine discontinuation occurred
among 64.8% of the subjects. Reasons for discontinuing included ﬁ-
nancial constraints (36.4%) and low White Blood Cell count (22.7%).
Conclusion : This study highlighted the pattern of Clozapine pre-
scription in an understudied population. Further research on factors
inﬂuencing its prescription is required.
jP-01-049jNeuroleptic malignant syndrome and catatonia
spectrum disorders in a colombian psychiatric unit
G.F. Oviedo1, J. Vengoechea2. 1Clı´nica de la Paz, Bogota´, Colombia ;
2Clı´nica de la Paz, Pontiﬁcia Universidad Javeria, Bogota´, Colombia
Objective : Our objective is to describe the clinical features associated
in these patients related to treatment response and course of illness in
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patients with NMS secondary to both typical and atypical anti-
psychotic agents as well as the description of 3 cases of catatonia with
diﬀerent patterns of outcome.
Methods : Case Series and Literature Review.
Results : We have recently diagnosed 5 cases of NMS in the psy-
chiatric hospital and 3 cases of catatonia in the context of aﬀective and
psychotic disorders. A retrospective medical chart review of the cases
was made along with the literature review. We found a positive re-
sponse to a benzodiazepine trial in half of the cases.
Conclusion : The pathopsysiology of Neuroleptic Malignant
Syndrome (NMS) and Catatonia remains enigmatic due to its unpre-
dictable an often sudden emergence, and the absence of established
vulnerability markers. In both conditions a variety of mechanisms
have been proposed to account for the clinical characteristics includ-
ing reduced central dopamine transmission, sympathetic nervous
system dysregulation, disordered muscle metabolism, adrenal gland
secondary dysfunction and altered central GABAergic function. Since
its initial description by Kahlbaum over a century ago, catatonia has
been associated with psychiatric, neurologic, and medical disorders.
Contemporary authors view catatonia as a syndrome of motor signs in
association with disorders of mood, behavior or thought.
jP-01-050jDiﬀerential eﬀects of aripiprazole and haloperidol
on dopamine markers in the arcuate nucleus and
prolactin levels in male rats
B. Pan1, K. Weston-Green2, M. De Santis2, C. Deng2. 1University of
Wollongong, Fairy Meadow, Australia ; 2School of Health Sciences,
IHMRI, Wollongong, Australia
Objective : Aripiprazole is a new antipsychotic drug with a high
aﬃnity for dopamine D2 receptors but reduced risks for inducing
extrapyramidal (EPS) and hyperprolactinaemia (HPL) side-eﬀects.
Our previous study (Han et al., 2009, International Journal of
Neuropsychopharmacology 12 : 941–952) showed that aripiprazole
selectively reduced the expression of tyrosine hydroxylase (TH ; a
rate-limiting enzyme for the synthesis of dopamine) in the ventral
tegmental area (VTA) but not the substantia nigra (SN), suggesting
a selective reduction of dopamine synthesis in the VTA but not
SN. However haloperidol aﬀected on both nuclei. Since the tuber-
oinfundibular dopamine neurons in the arcuate nucleus (Arc) modu-
late prolactin secretion, this study investigated the eﬀects of
aripiprazole on the expression of dopamine markers in the Arc and
plasma prolactin levels following short and long-term treatment. As a
comparison, the eﬀects of haloperidol on these measurements were
also examined.
Methods :Male Sprague Dawley rats were treated with aripiprazole
(0.75mg/kg, t.i.d.), haloperidol (0.1mg/kg, t.i.d) or control (vehicle)
for 1-week or 10-weeks (n=6/group). Protein levels of TH, phospho-
TH (pTH) and dopamine transporter (DAT) in the Arc, as well as
plasma prolactin levels, were examined.
Results : Compared to controls, haloperidol signiﬁcantly increased
TH levels (p<0.01) after both short- and long-term treatment,
and pTH and DAT after long-term treatment (p<0.05) ; however,
aripiprazole had no signiﬁcant eﬀect on these dopamine markers in
the Arc. Consistently, haloperidol (p<0.01), not aripiprazole, signiﬁ-
cantly increased plasma prolactin levels.
Conclusion : Aripiprazole and haloperidol have diﬀerent eﬀects on
the expressions of dopamine markers in the Arc and prolactin levels.
These results support the selective eﬀects of aripiprazole on dopamine
synthesis in diﬀerent dopamine pathways as a possible mechanism
for the long-term eﬃcacy of aripiprazole with low EPS and HPL side-
eﬀects liability.
jP-01-051jMetabolic syndrome in patients with schizophrenia
treated with antipsychotics : Attitudes from
psychiatrists
J.M. Pelayo-Tera´n1, Y. Zapico-Merayo2, A.R. Alonso-Fernandez2,
J. Martı´nez-Dı´ez3. 1Arriondas, Spain ; 2Hospital El Bierzo, Ponferrada,
Spain ; 3AGC Salud Mental de Arriondas, Spain
Objective : to evaluate the prevalence of metabolic syndrome in
patients with schizophrenia and to investigate the consequent actions
implemented in the Mental Health Services (MHS).
Methods : This was part of a longitudinal research focused in
physical health of patients treated with antipsychotic medication,
performed in two outpatient clinics. 147 patients (84 males) with a
DSM-IV diagnosis of schizophrenia (n=111), schizoaﬀective disorder
(n=18) or related psychoses (n=18) were included. Metabolic syn-
drome was deﬁned according to NCEP-III criteria. Actions im-
plemented after the evaluation of the patients were assessed with
medical records and a structured questionnaire. Associated factors
and actions were included in a logistic regression model.
Results : 52.7% of the patients fulﬁlled metabolic syndrome criteria.
BMI was associated to all the metabolic factors (p<0.001), time of
antipsychotic medication was associated with metabolic syndrome,
abdominal perimeter and triglycerides. Tobacco use was associated to
glycaemia and HDL and gender was related to glycaemia. The model
for metabolic syndrome (X2=30.040 ; R2 : 0.225 ; p<0.001) included
gender, age, BMI and tobacco. Only 23 patients (15.4%) were receiv-
ing treatment for any metabolic factor. In patients with metabolic
syndrome, 50% were intensiﬁed in the monitoring, 45.5% were re-
ferred to the GP and 3.9% received pharmacological treatment.
Remission to GP (X2=29.584 ; R2 : 0.189 ; p<0.001) only included glu-
cose, triglycerides and HDL levels and polymedication as indepen-
dent predictor factors. Interestingly, two fold diﬀerences between the
Mental Health Services were observed in the rate of implemented ac-
tions.
Conclusion :Metabolic syndrome was highly prevalent and related
to male gender, tobacco and BMI. Actions implemented appear to be
conservative and unequal. Glucose, triglycerides and HDL levels
were the factors implied in more actions. There is a need of im-
plementation of standard procedures in MHS in order to reduce the
impact on cardiovascular risk and the diﬀerences between services.
jP-01-052jEarly response to antipsychotic treatment as clinical
marker of subsequent response in ﬁrst episode
schizophrenia patients
R. Prikryl1, M. Vrzalova2, L. Ustohal2, H. Prikrylova Kucerova2,
E. Ceskova2, M. Vecerova1, T. Kasparek2. 1University Hospital, Brno,
Czech Republic ; 2CEITEC-MU, Masaryk University, Brno, Czech
Republic ;
Objective : The time-course of response to antipsychotic treatment has
important implications for management of acute treatment of patients
suﬀered from schizophrenia. In recent studies it has been shown that
some patients with long-term schizophrenia have demonstrated a
response to antipsychotic treatment within 2 weeks of initiating
treatment. Early improvement of schizophrenic symptomatology has
been associated with later response to antipsychotic treatment.
However it is still unknown whether the predictive pattern of early
response seen in patients with long-term schizophrenia exists for
patients with ﬁrst-episode psychosis as well. The aim of the study was
to investigate whether early response in the second week can predict
response in the fourth week of antipsychotic treatment in a population
of the ﬁrst episode schizophrenia patients.
Methods : First episode schizophrenia male patients were rated
by PANSS in four consecutive weeks during monotherapy with
risperidone. Response rates in particular weeks were calculated.
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Responders were characterized by 20% decrease of total PANSS score
at least.
Results : Fourteen patiens were included to the study, average age
was 24 years and average duration of schizophrenia was 4,4 months.
71% of patients were assessed as responders (N=10) and 29% of
them as nonresponders (N=4). In the second week of therapy later
responders reached higher decrease of total PANSS score (about 43%)
in relation to nonresponders (about 22%).
Conclusion : First episode schizophrenia patients are characterized
by the high reactivity to antipsychotic therapy. The most prominent
improvement of schizophrenic symptomatology occurs during ﬁrst
two weeks of treatment. Early response in the second week predicts
consecutive response in the fourth week of the therapy.
Acknowledgement : This work was supported by the project
‘‘CEITEC – Central European Institute of Technology’’ (CZ.1.05/
1.1.00/02.0068) from European Regional Development Fund.
jP-01-053jClozapine induced rash : Case report of successful
desensitisation
K. Raju1, R. Singh2, J. Darroch3, J. Southern2. 114 Cotterill Drive,
Warrington, United Kingdom ; 2Chester, United Kingdom ; 314 Cotterill
Drive, Liverpool, United Kingdom
Objective : Clozapine is the drug of choice for patients with treat-
ment-resistant schizophrenia. However a minority of them have been
unable to continue with Clozapine due to side-eﬀects, for example
rash. This report looks at the use of graded desensitization in a patient
who developed cutaneous reactions to Clozapine.
Methods : This report describes the management of a patient with
treatment resistant-schizophrenia, mild learning disabilities and epi-
lepsy, following a cutaneous reaction to Clozapine. Having been
maintained on Clopixol depot until 4 years ago, he required a change
in antipsychotics following a relapse of psychotic symptoms. He was
then treated unsuccessfully with various anti-psychotics, before
starting Clozapine, to which he showed a good response. Unfortu-
nately he developed an eczematous rash on two separate occasions
when the drug was introduced. Again he was tried on other anti-
psychotics, to which he also developed a rash. He was then put on a
graded desensitization regimen of liquid Clozapine.
Results : Graded desensitization, using incremental increases in
drug dose, allowed maintenance treatment with therapeutic doses of
Clozapine to be achieved in the absence of cutaneous hypersensitivity
reactions. The patient’s previously treatment-resistant psychotic
symptoms were improved by this method.
Conclusion : We should be aware of possibilities for the manage-
ment of both the common and uncommon side-eﬀects associated with
Clozapine, as the result might vastly improve the patients’ quality of
life. Desensitisation regimens can be an eﬀective means of overcoming
drug hypersensitivity but should be used with great caution,
especially when patients exhibit delayed-type hypersensitivity reac-
tions (as here).
jP-01-054jPsychotic episode in epilepsy-treatment modality
D. Ravanic1, S. Djukic Dejanovic1, M. Pantovic2, B. Radmanovic1,
M. Ilic2, V. Janjic1, D. Petrovic1, M. Jovanovic1, D. Djokovic1. 1Clinical
Centre Kragujevac, Serbia ; 2Medical Faculty Kragujevac, Serbia
Objective : The aim of this study was to compare parallel eﬀects of
risperidone and closapine in treatment of psychotic episode in veri-
ﬁed Grand-mall epilepsy. Due to changes in organic substrate, psy-
chosis is not rare comorbidity in epilepsy. There were no consensus
about treatment options. It is known that antipsychotics lower seizure
threshold, cause EEG abnormalities and put the patients in the risk for
additional seizures.
Methods : The total of 85 adult patients of both gender (39 females)
with clinically and EEG conﬁrmed Grand-mall epilepsy developed
psychotic episode. The psychotic state was evaluated using BPRS
scale. Subject were treated either with risperidone (n=43)
5.7¡.1.4 mg per day or with clozapine (n=42) 106.2¡29.8 mg per
day, orally. Results. The total BPRS scores in risperidone group at
baseline, in 1st, 2nd and 3rd week were 134.1¡41.3, 98.4¡28.7,
88.9¡21.9, and 78.3¡14.8, respectively (p<0.05).
Results : The total BPRS scores in risperidone group at baseline, in
1st, 2nd and 3rd week were 134.1¡41.3, 98.4¡28.7, 88.9¡21.9, and
78.3¡14.8, respectively (p<0.05). The total BPRS scores in clozapine
group at baseline, in 1st, 2nd and 3rd week were 138.3¡33.7,
109.1¡33.1, 97.3¡22.8, and 90.7¡21.4, respectively (p<0.05).
Conclusion : Our results showed that risperidone is more eﬀective
and comfortable drug than clozapine in the treatment of psychotic
episodes in epilepsy.
jP-01-055jAripiprazole in the treatment of ﬁrst episode of
psychosis in a patient with hypogonadism due to
hyperprolactinemia
E. Rizos1, M. Peppa1, E. Tsigkaropoulou1, C. Zompola1, I. Xelioti1,
A. Filippopoulou1, L. Lykouras1. 1Univ. Athens, Medical School., Greece
Objective : Aripiprazole is a new atypical antipsychotic with dopa-
minergic agonistic activity at a low dose. Dopamine is a prolactin-
inhibiting factor and dopamine imbalance has been implicated in the
pathophysiology of psychotic disorders. We investigated the probable
relatioship between hyperpralactinemia and the development of
psychotic symptoms and the role of aripiprazole medication, in a
single case.
Methods : We present the case of a patient with hypogonadism
secondary to chronic, untreated hyperprolactinemia who developed
acute psychotic symptoms and the beneﬁcial role of aripiprazolemedi-
cation on both psychotic symptoms and on serum prolactin levels.
Results : Psychotic symptoms resolved soon after treatment with
aripiprazole in conjunction with cabergoline, with a concomitant de-
crease in serum prolactin levels.
Conclusion : This is an interesting case indicating the beneﬁcial role
of aripiprazole treatment and also illustrating a complicated relation-
ship among hypogonadism secondary to prolactinoma and dopamine
and psychosis.
jP-01-056jThe eﬀect of the atypical antipsychotics on cognitive
deﬁcit in schizophrenia
I. Sacuiu1, V. Chirita2, A. Burlea3, R. Chirita2. 1Clinical Hospital Socola,
Lasi, Romania ; 2Clinical Hospital Socola, Gr.T. Popa University, Lasi,
Romania ; 3UMF Gr T Popa, Lasi, Romania
Objective :While the typical antipsychotics do not improve cognition
and may even alter memory due to their prevalent antimuscarinic and
antidopaminergic features, recent studies show that atypical anti-
psychotics cause improvements in learning, processing speed, speech
ﬂuency and motor abilities. Objectives : The study aimed at deﬁning
the cognitive deﬁcit in schizophrenia and the inﬂuence of the atypical
antipsychotics on it. Another objective was to compare the neurocog-
nitive eﬀects of olanzapine, quetiapine, risperidone, ziprasidone,
clozapine and sertindole.
Methods : The study was of the observational prospective type,
lasting for 52 weeks was made on 7 groups of 20 patients each, ac-
cording to the type of the antipsychotic used in therapy : olanzapine,
quetiapine, risperidone, aripiprazole, ziprasidone, clozapine and
sertindole. The CATIE (Clinical Antipsychotic Trials of Intervention
Eﬀectiveness) and BACS (Brief Assessment of Cognition in
Schizophrenia) test batteries have been applied.
Results : After 40 weeks, corresponding V10, every antipsychotic
drug improved the compound score of the CATIE and BACS neuro-
cognitive battery comparing to the moment of the inclusion in the
study (Vi). There was a positive correlation : the patients who dis-
played a cognitive improvement at the V10 moment, also displayed
beneﬁts in the social and occupational ﬁelds, which suggests a func-
tional relevance for the improvement of cognition.
Conclusion : There is an important cognitive deﬁcit in the majority
of the schizophrenic patients. Olanzapine, quetiapine, risperidone,
aripiprazole, ziprasidone, clozapine and sertindole have displayed
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jP-01-057jRelapses in psychotic disorders treated with oral
paliperidone : A 12-month follow-up
R. Sanchez Gonzalez1, M.J. Jimenez Contreras1. 1Parc de Salut
Mar – INAD, Sta. Coloma Gramenet, Spain
Objective : Describe and compare the relapse rate at 12 months in
a sample of patients with psychotic disorders treated with oral
Paliperidone versus other antipsychotics.
Methods : Descriptive observational study comparing two histori-
cal cohorts. Patients were recruited over a period of two years Sample
of patients with psychotic disorder, mainly schizophrenia. We in-
cluded patients aged o18 years, diagnosis of psychotic disorder
and relapse situation that requires hospitalization. Subjects that in
the observation period did not present psychotic symptoms are ex-
cluded.
Results : 200 patients were included, all the patients were hospita-
lized at the time of inclusion in the study. Homogeneous groups
in terms of size, demographic (except for sex) and clinical character-
istics. 73% had a diagnosis of schizophrenia and 7.5% had other di-
agnoses with transitory psychotic symptoms. 23% of patients treated
with oral paliperidone relapse and were readmitted at 12 months after
discharge, compared to 50% in the group of patients taking other
antipsychotics (p<0.05). Both groups showed a non statistically
signiﬁcant diﬀerence (p=0.809) in the number of total days of hospi-
talization since admission : case 35.46 days (SD 31.2), controls
34.27 days (SD 37.9). There was no diﬀerences regarding the use
of adjunctive BZD (cases=47%, controls=45%, p=0.77) and/or bi-
periden (cases=17%, controls=27%, p=0.088). The mean dose of
oral paliperidone at discharge was 10 mg/day (SD 4.41, range 3–24.
Conclusion :Due to the study design, no causal relationships can be
established. However, data suggest that patients treated with oral
paliperidone have fewer relapses and readmissions at 12 months fol-
low-up than patients treated with other antipsychotic treatment.
These results could be associated with favorable side-eﬀect proﬁle and
a lower treatment discontinuation rate.
jP-01-058jSwitching from olanzapine to ziprasidone : A
twelve-week, open-label, multicenter study
evaluating the eﬀectiveness and safety of
ziprasidone in patients with schizophrenia
T. Si1, Y.P. Duan2, Y. Su3, W. Dang4, H. Deng5, M. Tao6, T. Liu7,
H. Chen8. 1Peking University, Beijing, China ; 2Peking University,
Institute of Mental Health, Beijing, China ; 3Peking University, Insitute of
Mental Health, Beijing, China ; 4Peking University, Institute of Mental
Health, Beijing, China ; 5Sichuan University, Beijing, China ; 6Zhejiang
Chinese Medical Unive, Hangzhou, China ; 7Shenzhen Kangning Hospital,
Shen Zhen, China ; 8Wuhan Mental Health Center, China
Objective : To evaluate the eﬀects and safety of switching from olan-
zapine to ziprasidone, due to inadequate response or intolerance to
olanzapine.
Methods : Totally, 120 subjects with schizophrenia who were either
suboptimal eﬃcacy or poor tolerability to olanzapine treatment (dose
range 10–20 mg/day) foro8 weeks were enrolled in a 12-week, open-
label, ﬂexible-dose ziprasidone trial. Olanzapine was tapered and
discontinued over the course of 2 weeks, while ziprasidone was
titrated up and dosed at 40–80 mg b.i.d. The primary endpoint was
the improvement in Positive and Negative Syndrome Scale (PANSS)
total score from baseline. The second endpoint were the change in
lipid proﬁle, fasting glucose, glycosylated hemoglobin (HbA1c) and
serum prolactin level in 8 weeks of treatment from baseline.
Results : The intent-to-treat population was 100, and 86 patients
completed 12 weeks trial. At week 12, there was a statistically sig-
niﬁcant decrease in PANSS total score, with a mean change from
baseline was 65% ¡26% using the LOCF analysis. The CDSS total
score and each items, except item 3, Self-depreciation, decreased sig-
niﬁcantly from baseline. There were signiﬁcant decreases in levels of
total cholesterol. The ﬁnding replicate the results of some earlier stu-
dies (Rsossi et al., 2008 ; Grootens et al., 2011)[1, 2]. Adverse eﬀect of
ziprasidone is transitory and mild, including insomnia, somnolence,
and nausea. There were no signiﬁcant changes in the QTc interval.
Conclusion : Subjects switching from olanzapine to ziprasidone
showed a signiﬁcant improvement in clinical symptoms and quality
of life, and decrease in total cholesterol levels, regardless of their
metabolic status and disease severity at baseline. Ziprasidone with a
comparatively neural metabolic proﬁle and the comparable eﬃcacy
relative to other atypical antipsychics may be an important alternative
for patients experiencing no-response or lack of tolerability with
olanzapine treatment.
jP-01-059jResearch of olanzapine : Comparison research
of a tablet and a sustained release drug
T. Tamura1, T. Owashi1. 1Showa Univ.Fujigaoka Hospital, Yokohama,
Japan
Objective : Lack of insight of the patients with bipolar disorder an-
d/or schizophrenia is common. Therefore, maintenance management
of medicinal use is important. There are many patients who do not
take drugs. Changing the form of medication maymake those patients
feel the medicinal using easier, We aimed to evaluate the adherence at
maintenance pharmacological management by changing a tablet of
olanzapine into a sustained release olanzapine.
Methods : This is a prospective study in Japan. Subjects were the
patients with schizophrenia and/or bipolar disorder diagnosed by
DSM-IV or ICD-10 who were taking olanzapine. Olanzapine were
changed into an equivalent amount of sustained release drugs from
the tablet. The patients who had changed to the sustained release drug
were assessed 2 times by DAI-10 ; one month and two months later.
The patients who started the sustained release drug newly were ex-
cluded.
Results : The patient who changed from the tablet to the sustained
release drug showed good adherence assessed by DAI-10. We found
better adherence at two months. Conclusions : Adherence of the
patient having changed into the sustained release drug from the tablet
of olanzapine was quite good.
Conclusion : Our ﬁndings showed the possibility that the change of
the form of medication would improve the patients adherence even
in the same drug. That is very important for continuation of a patient’s
medicine. We expect that changing into a sustained release drug
would decrease the reduction of relapse.
jP-01-060jClinical interventions to counteract antipsychotic
polypharmacy : A systematic review
H. Tani1, H. Uchida2, T. Suzuki3, Y. Fujii4, N. Nagai4, C. Tsutsumi5,
K. Funaki6, K. Watanabe7, M. Mimura2. 1Yamanashi Pref. KITA
Hospital, Asahi-Machi, Japan ; 2Department of Neuropsychiatry, Keio
University, Tokyo, Japan ; 3Department of Psychiatry, Inokashira Hospital,
Tokyo, Japan ; 4Yamanashi Pref. KITA Hospital, Japan ; 5Department of
Psychiatry, Komagino Hospital, Tokyo, Japan ; 6Department of Psychiatry,
Toyoko Keiai Hospital, Kanagawa, Japan ; 7Department of
Neuropsychiatry, Kyorin University, Tokyo, Japan
Objective : While pros and cons of antipsychotic polypharmacy have
been frequently discussed, it still remains unclear as to how to
counteract this common but controversial practice. The objective of
this study was to synthesize the evidence on trials to reduce anti-
psychotic polypharmacy in schizophrenia.
Methods : A PubMED search was performed to identify two types
of clinical trials : studies that systematically switched antipsychotic
polypharmacy to monotherapy in research settings, and studies
that intervened physicians’ prescribing behaviours in clinical
settings (last search : Dec 2011). The following search terms were
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used : (‘‘antipsychotic ’’ or ‘‘antipsychotics’’) AND (‘‘polypharmacy’’
or ‘‘polytherapy’’). Cross-referencing of the identiﬁed articles was
also performed.
Results : The literature identiﬁed only two clinical trials (one ran-
domized controlled trial and one open-label trial) that systematically
converted polypharmacy to monotherapy ; in both of them, approxi-
mately two thirds of the subjects successfully completed the switch
(40/58, 69.0% ; and 34/44, 77.3%, respectively). Those who experi-
enced clinical worsening following the switch were mostly managed
by going back to the previous antipsychotics. We also identiﬁed 13
relevant articles that examined impacts of interventions, including
educational sessions, to have physicians, when possible, refrain from
the use of antipsychotic polypharmacy for the treatment of schizo-
phrenia. A modest intervention with educational approach alone was
eﬀective in 3 of 5 articles (60%). On the other hand, a more assertive
intervention that directly cautioned physicians on the use of multiple
antipsychotics was eﬀective in 9 of 11 articles (82%).
Conclusion : Switching from polypharmacy to monotherapy seems
feasible in a majority of patients with schizophrenia. Assertive inter-
ventions, rather than educational approach alone, appear more useful
to practically reduce the use of antipsychotic polypharmacy in clinical
settings. In light of the paucity of the data, further investigations are
needed on this prevailing but controversial issue.
jP-01-061jLate-onset angioedema probably induced by
risperidone in an elderly woman with schizophrenia
E. Theochari1, D. Kontis2, A. Retziou1, K. Ouzonidou1, M. Fiste3,
E. Neroutsos1. 1General Hospital of Elefsina, Greece ; 2Psychiatric
Hospital of Attica, Dafni, Athens, Greece ; 3Psychiatric Hospital of Athens,
Dromokaitio, Greece
Objective : Angioneurotic oedema is a rare adverse reaction which
mainly involves oedema of the deep dermal and subcutaneous tis-
sues. Few case reports have established its association with the use of
speciﬁc antipsychotics such as risperidone, clozapine, ziprasidone,
droperidol and chlorpromazine. The aim of this study is to present a
case of angiooedema in an elderly woman with psychosis possibly
induced by risperidone.
Methods : We reviewed the patient’s case notes and the relevant
literature.
Results : The patient is a 69 years old Greek woman who was hos-
pitalized due to a psychotic relapse. Her symptoms included ideas of
reference, persecutory delusions, passivity phenomena, visual and
auditory hallucinations. She was diagnosed with schizophrenia
of paranoid type according to DSM-IV-TR criteria. During her hospi-
talization she was administered antipsychotic treatment with oral
risperidone which was titrated up to 3mg daily. Psychotic symptoms
improved and she was discharged from the ward. Eight months later
she presented at the emergency department of the hospital suﬀering
from oedema of face and lower extremities. These symptoms were not
better accounted by any other medical condition (e.g. systemic infec-
tion, cardiovascular or respiratory disease). At that time she was not
receiving any other drug treatment except risperidone and had no
known history of allergy. Therefore, risperidone was considered
responsible for her symptoms and was discontinued. She initially re-
ceived treatment with cetirizine followed by low dose of hydroxyzine.
The swelling subdued over a period of two weeks. Laboratory tests
were within normal limits, but measurement of complement pathway
activity was not performed.
Conclusion : We conclude that our patient developed late-
onset risperidone-induced angioneurotic oedema. To our knowledge
there is no previous report in the literature about angioneurotic
oedema occurring within months of risperidone onset. Further
studies are needed to delineate the mechanism of this kind of allergic
reaction.
jP-01-062jAripiprazol (abilify) application by schizophrenia
patients’ therapy and aﬀective disorders
E. Valzdorf. Irkutsk, Russia
Objective : 25 patients were examined stationary. According to epi-
sodes clinic patients were divided into 6 groups. The 1st- of schizo-
phrenia patients with aﬀective delusive episodes included 5 people.
The 2nd- with aﬀective hallucinate episodes included 3. The 3rd- with
hallucinate delusive episodes included 3. The 4th- with primary ma-
niacal episode included 3. The 5th- with bipolar aﬀective disorder,
current maniacal episode included 7. And the 6th- with bipolar
aﬀective disorder, mixed episode included 4.
Methods : Clinic-psychopathological method.
Results : the therapy of atypical neuroleptic- abilify was being made
to schizophrenia patients with productive psychotic for the 1st,
2nd and 3rd groups. The dose started from 15 mg a day with gradual
dose increasing in 1–2 days to 30 mg a day intake. At the same time
these patients took the dose of haloperidol – decanoat. The dose was
5 mg intramuscularly once four weeks altogether with such prep-
aration as tsicllodol. Also these patients depending on emotional
condition in episode took amitriptillin 50 mg a day or vellacsin 50 mg
a day and litiya carbonate 0,9 g a day. The improvement of these
patients was noticed the 5th week therapy. ‘‘Voice’’ intensity and
its frequency were decreased, hallucinate ideas became less actual.
The expression of negative disorders of some patients was also
decreased. The patients with bipolar aﬀective disorder, current
maniacal episode and with primary maniacal episode took abilify in
dose 30 mg a day. The improvement of primary patients was the
3rd week, but the improvement of secondary patients was the
5th treatment. The mood became much better, statements and be-
haviour was regulated.
Conclusion : The improvement of patients with bipolar aﬀective
disorder, current maniacal episode was the 3rd week abilify treat-
ment together. The improvement of schizophrenia patients with
productive psychotic symtomatology was caused by abilify after
5 weeks treatment conducting with traditional neuroleptic. Abilify
decreased the expression of negative symptoms of some schizo-
phrenia patients.
jP-01-063jEﬀect of chronic antipsychotic drug treatment on the
rodent cerebral cortex : Linking ex vivo
neuroimaging ﬁndings with post-mortem
neuropathology
A. Vernon1, W. Chege1, W. Crum1, S. Natesan1, M. Modo1, J. Cooper1,
S. Williams1, S. Kapur1. 1 Institute of Psychiatry, Kings College London,
United Kingdom
Objective : To identify the locus of volume decreases in the rat
neocortex due to chronic haloperidol treatment and provide prelimi-
nary evidence for the mechanisms underlying this eﬀect. Background :
Antipsychotic drugs (APD) may aﬀect brain structure directly in
Schizophrenia patients (Ho et al., 2011). Indeed, pre-clinical studies
suggest chronic haloperidol treatment results in a decreased total
volume of the neocortex, which is reversible upon drug withdrawal
(Vernon et al., 2012). However, the location of volume changes
within the neocortex and the mechanisms underlying this eﬀect
are not fully elucidated. We now report preliminary results of auto-
mated MR image analysis and post-mortem studies to address these
issues.
Methods : Male Sprague-dawley rats were treated chronically (8
weeks) with placebo (n=8) or haloperidol (2 mg/kg/day s.c. n=8).
MRI scans were acquired ex vivo after cessation of treatment. Brain
volume diﬀerences between treatment groups were analysed using a
hypothesis-free deformation-based morphometry (DBM) analysis
(Vernon et al., 2011). Volumetric diﬀerences in the neocortex ident-
iﬁed by DBMwere investigated post-mortem from nissl stained tissue
sections (40 mm thick, 1/12 series) using unbiased stereology
(Cavalieri probe) to validate the DBM-led approach.
Results : DBM analysis identiﬁed local tissue volume decreases in
the neocortex, most prominently in the medial prefrontal cortex
(mPFC) of haloperidol-treated animals (p<0.05 uncorrected). Post-
mortem analysis conﬁrmed signiﬁcant decreases in the thickness of
the prelimbic (PrL) region of the mPFC and in the volume of the an-
terior cingulate cortex (ACC), but not in the thickness of the primary
motor, sensorimotor or visual cortices. Preliminary analysis of neu-
ronal number in the ACC revealed no signiﬁcant diﬀerences between
vehicle and haloperidol-treated groups.
Conclusion : Chronic haloperidol treatment induces volumetric
decreases in the mPFC of the rat neocortex, which is potentially not




by University of Groningen user
on 13 March 2018
jP-01-064jMedication adherence in schizophrenia and
potential risk factors associated with non adherence
in South West Ethiopia
N.T. Wabe1, K. Abebe1. 1Pharmacy Department, Jimma University,
Ethiopia
Objective : Non-adherence behavior is a signiﬁcant issue in the
management of psychotic disorders, for it is major cause of psychotic
relapse and is strongly inﬂuenced by many factors. Medication ad-
herence to antipsychotic drugs is detrimental to the perceived out-
come of treatment. The objective of this study is to evaluate adherence
rate to antipsychotic medications and identify the potential risk fac-
tors associated with non adherence.
Methods : A cross-sectional study was conducted on 336 patients
using patients self report and pharmacy reﬁll record where by both
qualitative and quantitative methods of data collection was used. The
self report involved the structured patient interview after verbal in-
formed consent was obtained. Data were analyzed using SPSS for
windows version 16.0. Chi-square test was used to observe the as-
sociation of variables with adherence.
Results : The adherence rate of patients (n=336) is found to be
57.5% based on their reﬁll records, compliant ﬁll rate. On the basis of
patients self-report for their pattern of drug use, 52.1% participants
said that they had never missed their doses, while 32.1% participants
missed daily doses sometimes, 4.7% missed only time of taking, and
5.9% missed both time of taking daily dose sometimes. The most
common reasons for missing dose were forgetfulness (36.2%) and
being busy (21.0%). Pill burden, side eﬀects of medications, exposure
for social drugs have statistically signiﬁcant negative association but,
increased duration of maintenance medication is found to enhance
rate of adherence.
Conclusion : Large proportion of the study patients failed to reﬁll
their medications properly which indicates the severity of the prob-
lem and calls due consideration in planning appropriate strategies to
improve the existing conditions.
jP-01-065jEﬀects of an adjunct nicotinic a7 receptor agonist to
the atypical antipsychotic risperidone in animal
models of antipsychotic activity and extrapyramidal
side eﬀect liability
M.-L. Wadenberg1, A. Khan2, S. Babu Koritala2. 1Linnaeus University,
Kalmar, Sweden ; 2University of Sko¨vde, Sweden
Objective : Cognitive impairment is debilitating in schizophrenia
(SCH). Eﬀects of adjunct treatment with cholinergic nicotinic a7
receptor agonists to antipsychotics (APDs) for cognitive improvement
in SCH are under investigation in clinical studies with some positive
reports. However, changes in retained antipsychotic eﬃcacy of the
simultaneously given APD, as well as changes in extrapyramidal side
eﬀect (EPS) liability, following adjunct nicotinic s7 agonist treatment
are, to the best of our knowledge, not well known. Therefore, we here
investigated, experimentally, the eﬀects of adjunct treatment with the
selective nicotinic a7 receptor agonist PHA 543, 613 (1 mg/kg) to the
atypical APD risperidone (0.2 or 0.8 mg/kg) in animal models of an-
tipsychotic activity and EPS liability, in rats.
Methods : The conditioned avoidance response (CAR) test was
used for assessment of antipsychotic activity. Assessment of EPS
liability was performed using the catalepsy test. Statistical evaluation
was performed by means of non-parametric statistics.
Results : CAR : Risperidone produced a dose-dependent, signiﬁcant
antipsychotic-like suppression of CAR. Compared with risperidone
0.2 mg/kg alone, pretreatment with PHA 543, 613 (1 mg/kg) showed
a strong tendency to reverse risperidone 0.2 mg/kg – induced sup-
pression of CAR that was close to statistical signiﬁcance. PHA 543, 613
alone had no eﬀects on CAR. Catalepsy : Compared with vehicle
treated controls, risperidone (0.2 mg/kg) signiﬁcantly increased cata-
lepsy scores. Pretreatment with PHA 543 613 further enhanced ris-
peridone-induced increase in catalepsy scores. Also PHA 543 613
alone signiﬁcantly increased catalepsy scores. The diﬀerence in cata-
lepsy scores between risperidone alone and combined PHA 543 613/
risperidone treatment groups was close to statistical signiﬁcance.
Conclusion : The data suggest that adjunct nicotinic a7 agonist
treatment for cognitive impairment in SCH may come with a risk of
reduced antipsychotic eﬃcacy and an increase in EPS liability, at least
when given with a low dose of the atypical APD risperidone.
jP-01-066jChanges in metabolic parameters and Framingham
cardiovascular risk scores after in-hospital
antipsychotic treatment – preliminary results
A. Wysokinski1, M. Kowman1, I. Kloszewska1. 1Lodz, Poland
Objective : The objective of this study was to assess changes in the
prevalence of metabolic syndrome (MetS) and cardiovascular risk
scores after in-hospital treatment with antipsychotics.
Methods : 31 subjects (F 18/M 13 ; mean age 36.5 years) with
schizophrenia were assessed on admission and at discharge. Height,
weight, waist circumference, blood pressure, plasma lipids and
glucose were measured. Smoking, illness duration, hospital stay
duration, number and doses of antipsychotics, concomitant use of
antihypertensives, antidiabetics or hypolipidemics were registered.
International Diabetes Federation deﬁnition of MetS was used.
Cardiovascular risk scores were calculated using the Framingham
Heart Study algorithms.
Results : Mean illness duration was 126.9 months, mean hospital
stay was 51.9 days. 25 patients (80.6%) were taking more than 1 anti-
psychotic. The majority of subjects (90.3%) were taking second gen-
eration antipsychotics. Overweight, obesity, abdominal obesity, lipid
abnormalities and hypertension was were found in 13 (41.9%), 14
(45.1%), 24 (77.4%), 24 (77.4%) and 16 (51.6%) patients, respectively.
At discharge metabolic parameters did not improve, while triglycer-
ide levels increased (P=0.003). MetS prevalence increased from
41.94% to 61.29% (P=0.029). Number of MetS criteria met increased
(P<0.001). The rate of abdominal obesity (P<0.001), raised TGA
(P<0.001), raised FPG (P=0.005) and reduced HDL (P<0.001) in-
creased. No diﬀerences in age, sex, tobacco smoking, duration of
hospital stay and schizophrenia, number and type of antipsychotics
between subjects with or without MetS were found. Cardiovascular
risk scores did not increase at discharge.
Conclusion : Between admission and discharge the prevalence of
MetS, number of MetS criteria met, the rate of abdominal obesity,
raised TGA, raised FPG and reduced HDL increased. Metabolic
parameters did not improve during hospital stay, while triglyceride
levels increased. No increase of cardiovascular risk scores was found.
The majority of patients had abnormal body weight, abdominal
obesity and untreated hyperlipidemia.
jP-01-067jAnimal model of treatment-resistant schizophrenia
K. Yamada1, D. Ibi2, T. Nabeshima3, A. Sawa4, T. Nagai5. 1Nagoya
Univ. Grad. Sch. Med., Japan ; 2Nagoya Univ. Grad. Sch. Med, Dept.
Neuropsychopharmcology, Japan ; 3Meijo Univ. Grad. Sch. Pharm. Sci.,
Dept. Chem. Pharmacology, Nagoya, Japan ; 4 Johns Hopkins Uni. Sch.
Med., Department of Psychiatry, Baltimore, USA ; 5Nagoya Univ. Grad.
Sch. Med., Dept. of Neuropsychopharmacology, Japan
Objective : Animal models are invaluable for the screening of novel
compounds for mental disorders such as schizophrenia. In most of the
animal models, ﬁrst generation antipsychotic drugs such as haloper-
idol are eﬀective in reducing spontaneous and drug-induced hyper-
activity but have little eﬀect on behavioral changes related to negative
symptoms and cognitive dysfunctions. In contrast, second generation
antipsychotic drugs such as clozapine are reported to be eﬀective in
ameliorating most of the behavioral abnormalities, although one-ﬁfth
to two-third of patients are considered treatment resistant and show
persistent psychotic and other symptoms despite the optimal use of
antipsychotic medications. To identify compounds that may be more
eﬀective than existing antipsychotic medications in ameliorating
the negative symptoms and cognitive dysfunctions in schizophrenia,
animal models for antipsychotic drug-resistant schizophrenia are
needed.
Methods : Transgenic mice expressing a dominant-negative
N-terminal human DISC1 under the expression control of CaMKII
promoter (DN-DISC1 mice) were injected with polyI :C during the
neonatal stage, and their behavioral phenotypes were examined in
adulthood.
Results : PolyI :C-treated DN-DISC1 mice exhibited the deﬁcits of
short-term memory, object recognition memory, social interaction,
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hippocampus-dependent fear memory, and augmentation of MK801-
induced hyperactivity after puberty, although polyI :C treatment or
DN-DISC1 expression by itself has negligible eﬀect on wild-type mice.
Cognitive impairment in this model was ameliorated by repeated
administration of clozapine, but not haloperidol. Both antipsychotic
drugs suppressed the enhancement of MK801-induced hyperactivity
in the model but have no eﬀects on deﬁcits of short-term memory and
hippocampus-dependent fear memory, or impairment of social inter-
actions.
Conclusion : These results suggest that adult DN-DISC1 mice with
neonatal polyI :C treatment may be useful for the screening of poten-
tial antipsychotic compounds that could be more eﬀective in ameli-
orating social and cognitive impairments in treatment-resistant
schizophrenia.
jP-01-068j Impact of switching to second-generation
antipsychotics on the treatment of long-term
inpatients with schizophrenia
Y. Yamawaki1, A. Yoshino2, M. Sawa2, R. Jin-nin3, K. Tamai2,
T. Adachi2, E. Yukutake2, S. Toki3, T. Oyamada2, T. Takahashi2,
H. Akagi4. 1Hiroshima International Univ., Japan ; 2Mihara Hospital,
Japan ; 3Hiroshima University, Department of Psychiatry, Japan ;
4Hiroshima International Univ., Department of Pharmacy, Kure, Japan
Objective : The purpose of this study is to investigate the impact of
switching from the ﬁrst generation antipsychotics (FGAs) to the se-
cond generation antipsychotics (SGAs) on clinical eﬃcacy and ad-
verse eﬀect in the treatment for long-term inpatients with
schizophrenia.
Methods : Eighty ﬁve patients with schizophrenia diagnosed by
DSM-IV were selected among inpatients hospitalized for at least
12 years. Eﬃcacy on Brief Psychiatric Rating Scale (BPRS) and adverse
eﬀect on Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS)
have been evaluated and analyzed with these patients’ characteristics
and the proﬁles of prescribed drugs including antipsychotics, anti-
parkinsonian agents and mood stabilizer.
Results : After switching to SGAs, the scores of BPRS and DIEPSS
were signiﬁcantly decreased, and the number of prescribed anti-
psychotics and antiparkinsonian agents was signiﬁcantly decreased
although the total Chlorpromazine-equivalent dose of antipsychotics
has been unaltered for 12 years of inpatient duration.
Conclusion : These results suggested that switching to SGAs from
FGAs in the treatment for long-term inpatients with schizophrenia
brought a better outcome in both clinical eﬃcacy and safety, and
possible prevention of polypharmacy.
jP-01-069jNo association between hormonal abnormality and
sexual dysfunction in Japanese schizophrenia
patients treated with antipsychotics
N. Yasui-Furukori1, K. Hashimoto1, A. Fujii1, N. Sugawara1,
S. Tsuchimine1, M. Saito1, S. Kaneko1. 1Hirosaki, Japan
Objective : Although sexual dysfunction is believed to be caused by
hormonal abnormalities, few reports have studied sexual dysfunction
and its association with hormonal abnormalities in Asian populations
with schizophrenia.
Methods : We employed a cross-sectional, case-control survey de-
sign to collect data from 191 (108 men) Japanese schizophrenia out-
patients treated with antipsychotics and 182 (49 men) healthy subjects.
Sexual dysfunction was evaluated using the Udvalg for Kliniske
Undersøgelser (UKU) Side Eﬀect Rating Scale. We measured plasma
concentrations of prolactin in both genders and testosterone in men
and estradiol in women.
Results : Multiple regression analyses revealed the following ﬁnd-
ings : the number of antipsychotics correlated with diminished sexual
desire (standardized beta=0.241, p<0.05) ; the dose of antipsychotics
correlated with gynecomastia (standardized beta=0.277, p<0.01),
increased sexual desire (standardized beta=0.229, p<0.05), and
ejaculatory dysfunction (standardized beta=0.248, p<0.05) ; and
the dose of antipsychotics correlated with menorrhagia in women
(standardized beta=0.284, p< 0.05). However, neither plasma con-
centrations of prolactin, testosterone nor estradiol correlated with
sexual dysfunction.
Conclusion : The present study demonstrated that an association
between sex hormone abnormalities and sexual dysfunction is un-
likely but that the dose or number of antipsychotics is associated with
some sexual dysfunction.
jP-01-070jEﬀectiveness of prn medications in psychiatric
patients : A systematic review
K. Yoshida1, T. Suzuki2, H. Uchida3, S. Nio3, R. Kitahata3, T. Tsuboi3,
M. Tada3, Y. Mizuno4, K. Watanabe5, M. Mimura3. 1Ohizumi Hospital,
Tokyo, Japan ; 2 Inokashira Hospital, Department of Psychiatry, Tokyo,
Japan ; 3Department of Neuropsychiatry, Keio University, Tokyo, Japan ;
4Department of Psychiatry, Kawasaki Municipal Hospital, Kanagawa
Prefecture, Japan ; 5Department of Psychiatry, Kyorin University, Tokyo,
Japan
Objective : The use of ‘‘pro re nata (prn)’’ medications to manage
patients’ perturbed behaviors such as agitation and aggression is
widespread in psychiatric clinical practice. However, it is unclear
which psychotropic drugs are more eﬀective and tolerable than
others. The aim of this study was to synthesize the evidence on prn
medications in psychiatric patients.
Methods : A MEDLINE search was performed to identify studies
published in English between 1966 and December 2011. The following
search terms were used : (‘‘prn’’ or ‘‘p.r.n’’ or ‘‘pro re nata’’ or ‘‘as
needed’’ or ‘‘as required’’ or ‘‘stat* med*’’ or ‘‘as necessary’’) and
(psychiatr* or mental* or antipsychotic* or psychotropic*). Cross-
referencing of the identiﬁed articles was also performed.
Results : The literature search identiﬁed 13 studies that assessed
epidemiological usage of prn medications and 13 retrospective studies
that evaluated the eﬀectiveness/safety as well as reasons for prn ad-
ministrations. Patients studied were all inpatients, and the reasons
for prn administration were commonly acute behavioral dyscontrol.
On the other hand, diagnoses and outcome measures to assess
eﬀectiveness/safety varied and inadequately described. Medications
under study included antipsychotics, mood stabilizers and benzo-
diazepines. On the whole, most studies reported that prn medications
were eﬀective in psychiatric inpatients. However, only three pro-
spective studies were identiﬁed to evaluate the eﬀectiveness/safety
of prn medications ; furthermore, all of them included solely a
child/adolescent population. One was a preliminary double-blind
study of diphenhydramine in a child population (N=21). Another
was concerned about child/adolescent patients for subjective per-
ceptions of prn medications (N=42). The other was a post-hoc
analysis of the data from clinical records of 338 child/adolescent
patients.
Conclusion : Our ﬁndings indicate that there has been only
equivocal evidence to guide a choice of prn medications for psychi-
atric patients. Further clinical trials needed to investigate the eﬀec-
tiveness and safety of prn medications in various psychiatric
disorders.
jP-01-071jNot only dopamine D2 receptors involved in
peony-glycyrrhiza decoction, an herbal preparation
against antipsychotic-associated hyperprolactinemia
Z.-J. Zhang1, D. Wang1. 1The University of Hong Kong, Hong Kong
SAR, China
Objective : Hyperprolactinemia (hyperPRL) is a frequent com-
plication of antipsychotic treatment. Clinical studies have
demonstrated the eﬀectiveness of an herbal preparation called Peony-
Glycyrrhiza Decoction (PGD) in alleviating antipsychotic-induced
hyperPRL.
Methods : In the present study, we further examined the pharma-
cological action of PGD on prolactin (PRL) secretion using in vitro and
in vivo models, with speciﬁc attention to the role of dopaminergic
mediators and other sexual hormones.
Results : Treatment with PGD at 1 mg/ml and 5 mg/ml for 24 and
36 hrs signiﬁcantly suppressed PRL secretion in MMQ cells, a model
of hyperPRL derived from pituitary adenoma cells. PGD also sup-
pressed PRL synthesis by MMQ cells in a dose-dependent manner.
These suppressive eﬀects were completely abolished by pretreatment
with 10 microM haloperidol, a dopamine D2 receptor antagonist.
consistent with a D2-action, PGD did not aﬀect PRL secretion and
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synthesis in rat pituitary lactotropic tumor-derived GH3 cells that lack
the D2 receptor expression but signiﬁcantly increased the expression
of the D2 receptors and dopamine transporters (DAT) in PC12 cells. In
a rat model of hyperPRL, produced by repeated injection of dopamine
blocker metoclopramide (MCP), chronic PGD (2.5–10 g/kg daily) for
14 days signiﬁcantly reduced elevated serum PRL. The reduction in
magnitude was similar to that elicited by 0.6 mg/kg bromocriptine
(BMT), a dopamine D2 receptor agonist currently used for treatment
of hyperPRL. Neither PGD nor BMT altered serum estradiol, but PGD
reversed MCP-induced decrease in serum progesterone to control
level, whereas BMT did not.
Conclusion : These results indicate that the anti-hyperPRL eﬀects of
PGD are associated not only with D2 receptor and DAT modulation,
but also with a normalization of other sexual hormone dysfunction.
This experimental evidence supports clinical use of PGD as an eﬀec-
tive treatment of antipsychotic-induced hyperPRL.
jP-01-072jEﬀects of chronic oral treatment with aripiprazole on
the expression NMDA receptor subunits and
binding sites in rat brain
M. Zink1, N. Peselmann1, T. Ferbert1, A. Schmitt1, P. Gass1,
P. Gebicke-Haerter1. 1CIMH, Mannheim, Germany
Objective : The glutamatergic theory of schizophrenia proposes a
dysfunction of ionotropic N-Methyl-D-aspartate receptors (NMDA-
R). Several therapeutic strategies address NMDA-R function and
eﬀects of antipsychotic agents on NMDA-R expression have been
described. Within the second generation antipsychotics, the partial
dopaminergic and serotonergic agonist aripiprazole (APZ) was able to
counteract behavioural eﬀects of NMDA-R antagonists. We intended
to investigate the eﬀects of APZ on NMDA-R subunit expression and
binding.
Methods : Male, wildtype Sprague-Dawley rats were treated for
4 weeks or 4 months with APZ in daily oral doses of 10 and 40 mg
per kg body weight. Gene expression of the NMDA-R subunits NR1,
NR2A, NR2B, NR2C and NR2D was assessed by semiquantitative
radioactive in situ-hybridization, and in parallel receptor binding
using 3H-MK-801 receptor autoradiography.
Results : Increased expression levels of NR1 (4 weeks), NR2A
(4 weeks), NR2C (4 weeks and 4 months) and NR2D (4 months) were
observed in several hippocampal and cortical brain regions. The par-
allel reduced expression of NR2B mRNAs (4 months) resulted in a
relative increase of the NR2A/NR2B ratio. Marked diﬀerences be-
tween speciﬁc brain regions, the doses of APZ and the time points
of assessment became obvious. On the receptor level, increased MK-
801-binding was found after 4 weeks in the 40 mg-group and after
4 months in the 10 mg-group.
Conclusion : The eﬀects of APZ converge in enhanced NMDA-
receptor expression and a shift of subunit-composition towards adult-
type receptors. Our results conﬁrm regulatory connections between
dopaminergic, serotonergic and glutamatergic neurotransmission. In
consequence, APZ treatment may counteract a glutamatergic deﬁcit
state with positive consequences on cognitive and negative symptoms
of schizophrenia.
jP-01-073jNew onset metabolic syndrome among patients
receiving clozapine
A. Avasthi1, S. Grover1, N. Nebhinani1, S. Chakrabarti1. 1PGIMER,
Chandigarh, India
Objective : To study the prevalence of metabolic syndrome in
patients receiving clozapine and prospectively evaluate the incidence
of new onset metabolic syndrome after 3 months of therapy with
clozapine.
Methods : For this study, 53 patients who were considered for
clozapine therapy were evaluated for the presence of metabolic
syndrome as deﬁned by modiﬁed National Cholesterol Education
Program Adult Treatment Panel III (NCEP ATP-III) criteria. These
patients were prospectively followed after 3 months for change in
metabolic syndrome status.
Results : Slightly more than one third of the patients had metabolic
syndrome prior to starting clozapine. Another one sixth of the patients
who did not have metabolic syndrome prior to starting clozapine
developed metabolic syndrome after receiving clozapine for a dur-
ation of 3 months.
Conclusion : Clozapine contributes to the metabolic disturbances.
jP-01-074jCourse of negative symptoms in ﬁrst-episode
psychosis on aripiprazole vs. other antipsychotics
during a two years follow-up
D. Berge1, A. Mane1, P. Salgado1, P.C. Garnier2, L.M. Martin1,
A. Merino1, A. Bulbena1. 1 INAD/PSMar, Barcelona, Spain ; 2 INAD/
PSMar, CSMA Sant Martı´ Sud, Barcelona, Spain
Objective : Severeal lines of evidence indicate that early intervention
with appropriate pharmacological treatment can contribute to im-
prove the course and outcome of the illness (Linszen et al., Br J Psych
Suppl 1998). Aripiprazole is an atypical antipsychotic that appears
to be well tolerated and it has a low propensity for causing extra-
pyramidal symptoms which can cause secondary negative symptoms
(5). The present prospective naturalistic study sets out to investigate
changes in overall functionallity, total symptomatology and, more
speciﬁcally, negative symptomatology with aripiprazol and other se-
cond generation antipsychotics (SGA) in ﬁrst episode patients during
two-years of follow-up period.
Methods : Subjects with a ﬁrst episode of psychosis were assessed
and followed according to the ﬁrst episode program of the centre
(INAD). From the total sample of 130 recruited subjects, 42 completed
the two years follow-up*. During the follow up period, patients were
clinically assessed using PANSS scale (amongst others). Antipsychotic
treatment was prescribed by specialized psychiatrists according to
clinical criteria. In this naturalistic study we studied the association of
antipsychotic treatment (aripiprazole vs. other SGA) at 2nd year of the
follow up period and change in negative symptoms during the follow-
up period.
Results : Patients on aripiprazole at 2nd year in comparison to the
beginning of the follow-up period had a signiﬁcant higher decrease of
negative symptoms : Ari : 3.09 (SD : 4.0) ; Others : x0.79 (SD : 5.3),
p=0.044. There were no other signiﬁcant diﬀerences in changes in
positive symptoms or general functioning between groups.
Conclusion : Aripiprazole seems to improve negative symptoms
more than other second generation antipsychotics without signiﬁcant
risk of increasing positive symptoms or worsening functioning.
Important limitations of this study include that patients were not
randomly assigned and that aripiprazole seems to be chosen by psy-
chiatrists for those patients showing more negative symptoms. * Four
patients included in another study were excluded from this analysis.
Policy of full disclosure : Travel expenses and congress attendance
were facilitated by Otsuka.
jP-01-075jQuetiapine prevents oligodendrocyte and myelin
losses and promotes maturation of oligodendrocyte
progenitors in the hippocampus of global cerebral
ischemia mice
X. Bi1, X.-M. Li2, Y. Zhang3. 1Shanghai Changhai Hospital, China ;
2Department of Psychiatry, University of Manitoba, Winnipeg, Canada ;
3Department of Psychiatry, University of Saskatchewan, Saskatoon,
Canada
Objective : White matter impairment is the feature of vascular de-
pression. Antipsychotic quetiapine has been shown enhancing the
therapeutic eﬀects of antidepressants on vascular depression, but
the mechanism remains unknown. In this study, we will try to ﬁnd the
white matter protective eﬀects of quetiapine in vascular depression
mice model in order to clarify the mechanism of eﬀects of quetiapine
on vascular depression.
Methods : Mice were assigned to receive a sham or global cerebral
ischemia surgery, which generated four treatment groups : Sham
(sham+saline), QTP (sham+quetiapine), GCI (GCI+saline) and
G+Q (GCI+quetiapine). GCI was induced by bilateral common
carotid arteries occlusion (BCCAO). Immunohistochemistry staining
was used for pathological study. Myeline damage was observed by
MBP staining. Loss and proliferation of Oligodendrocyts were ob-
served by GST-pi, O4, NG2 and BrdU staining.
Results : we found that two weeks of treatment with quetiapine
prior to bilateral carotid artery occlusion and reperfusion, an animal
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model of vascular depression resulted in reduced myelin breakdown
down and oligodendrocyte loss compared to placebo treated mice
on postoperative day (POD) 7. For late stage of recovery (POD40),
quetiapine treatment resulted in enhanced oligodendrocyte matu-
ration relative to placebo.
Conclusion : The results suggest that quetiapine is a potential
intervention for oligodendrocyte damage and may contribute its
antidepressant eﬀects through white matter protection in vascular
depression.
Policy of full disclosure : Xin-Min Li has received funding from
AstraZeneca. Other authors have no conﬂict.
jP-01-076jPaliperidone palmitate treatment in schizophrenia
A. Chinchilla1, M. Vega1, M. Garcı´a1, C. Parro1, G. Martı´nez1,
C. Centelles1. 1Hospital Ramo´n y Cajal, Madrid, Spain
Objective : Treatment with Paliperidone Palmitate, see its eﬀective-
ness, tolerability and adherence in schizophrenia, an experience with
17 patients.
Methods : In 17 schizophrenic patients (DSM-IV-Tr) who were
being treated with other antipsychotics, previous treatment was dis-
continued in case of intolerance or insuﬃcient response, and changed
to Paliperidone Palmitate (75–150 mg/month) the follow-up per-
formed was for 2 months. We used as a measure of eﬃcacy, the
PANNS and the ICG. We evaluated potential side eﬀects reported
by patients, evaluating tolerance and eﬀectiveness of treatment.
Antiparkinsonian drugs were only used in 3 patients during the ﬁrst
week, mainly due to presence of extrapyramidal symptomatology due
to previous antipsychotic treatments.
Results : The mean baseline measurement on day 0 in the PANSS
was 76 and the mean CGI was 4.5. The study is still carrying on
since Paliperidone Palmitate was marketed in Spain in early
November 2011, therefore we can not present at this time deﬁnitive
data, except baseline scores. So far the impression is good, both
in eﬃciency and in tolerance. We will give deﬁnitive results at the
end of the study.
Conclusion : If the preliminarily data obtained are conﬁrmed at the
end of the follow up period we believe that Paliperidone Palmitate
should occupy a prominent place in the treatment of schizophrenia.
We also believe that will facilitate treatment adherence so necessary
in these patients prone to abandonment and non-compliance.
jP-01-077jDose translation of aripiprazole between human and
animal studies
Y.-H. Chou. Taipei Veterans General Hospit, Taiwan
Objective : Aripiprazole is a newly developed antipsychotic which
has a unique pharmacological proﬁle of D2 receptor partial agonistic
eﬀect. As it has been approved for the treatment of schizophrenia,
a growing body of studies has applied this compound to animal study
with its novelty. To determine a suitable dose for animal study we
compared the plasma concentration of aripiprazole and its metabolite
in schizophrenic patients and rats.
Methods : Plasma concentration of aripiprazole was measured in
25 schizophrenic patients who were stably treated with aripiprazol at
least six months and 12 SD rats that treated with aripiprazole 21 days.
Plasma concentration of aripiprazole and metabolite was measures by
LC-MS-MS. The dose range for schizophrenic patients was 10–30 mg
per day and corresponding dose for rats that was estimated by using
the body surface area (BSA) normalization method.
Results : The average oral dose of aripiprazole was
0.20¡0.08 mg/kg in human and a low dose (1.92¡0.05 g) and high
dose group (3.78¡0) in rats. The average plasma concentration of
aripiprazole and metabolite, opc14857 was 334.62¡205.35 ng/mL
and 90.55¡70.23 ng/mL in human and 3.00¡2.57 ng/mL and
0.92¡0.52 ng/mL in low dose group and 9.83¡6.62 ng/mL and i1.
84¡0.58 ng/mL in high dose group n rats. The ratio of aripirazole and
oral dose was 1736.38¡839.82 in human and 1.58¡1.37 in low dose
group and 2.6¡1.75 in high dose group in rats.
Conclusion : Our results demonstrated that by using the BAS
normalization method the oral dose for animal studies was ten times
high compared with human study. However, the plasma concen-
tration is one hundred times lower in animal. We advocate that a dose
translation between human and animal studies in aripiprazole should
be cautious.
jP-01-078jA ﬂexible-dose study of paliperidone ER in
non-acute patients with schizophrenia previously
unsuccessfully treated with other oral antipsychotics
in the Asia Paciﬁc region
W.S.D. Chung. Tai Po Hospital, CUHK, Hong Kong, Hong Kong SAR,
China
Objective : To explore tolerability, safety, and treatment response
of ﬂexible doses of paliperidone ER in adult Asian patients with non-
acute schizophrenia, previously unsuccessfully treated with other oral
antipsychotics.
Methods : Non-acute schizophrenia patients, who were unsuccess-
fully treated due to lack of eﬃcacy, tolerability or safety issues, lack
of compliance and/or other reasons, are transitioned to Pali-ER.
The subjects were prescribed ﬂexible dose Pali-ER 3–12 mg/day for
6 months.
Results : Data from 984 patients from 5 Asian countries were ana-
lysed. Data evaluated in two groups : Group A (switched due to lack
of eﬃcacy) n=424 ; Group B (switched due to tolerability or safety
issues, lack of compliance or other reasons) n=560. 53% of Group A
patients achieved more than 50% PANSS improvement from baseline
to endpoint. Dosage distribution : 46% of Group A patients required
Pali-ER 9–12 mg/day at end point ; 58% patients in Group B required
6 mg/day at end point. There was an increase in the proportion of
patients in both Group A (16%)and Group B (31%) achieving CGI-S
categories of mildly ill or less at endpoint when compared to baseline.
43% and 73% more patients from Group A and Group B respectively
at endpoint reported good to very good in terms of treatment satis-
faction compared to baseline. 37% more patients from Group A and
35% more patients from Group B reached the PSP-deﬁned categories
of mild to no diﬃculties when compared to baseline. Visual analog
scale shows that quality of sleep and drowsiness improved signiﬁ-
cantly (p<0.0001) from baseline in both groups.
Conclusion : Flexibly dosed paliperidone ER treatment for up to
6 months shows improvements in non-acute schizophrenic patients
who had an unsatisfactory outcome with previous antipsychotics, in-
cluding PANSS, CGI-S, PSP, drowsiness and sleep quality.
Policy of full disclosure : The author has received research funding
from Janssen, a division of Johnson & Johnson (HK) Ltd.
jP-01-079jOral vs. long-acting antipsychotics in a crisis
resolution/home treatment team
D. Corcoles1, M.A. Malagon1, P. Alvaro1, A. Martinez1, S. Castillo1,
S. Gasque1, M.T. Nascimento1, R. Cortizo1, C. Garnier1, L.M. Martin1,
A. Bulbena1. 1 INAD, Barcelona, Spain
Objective : To describe the diﬀerences between schizophenic patients
with oral vs. long-acting antipsychotic in a Crisis Resolution/Home
Treatment (CRHT) Team in Barcelona.
Methods :We evaluated consecutive visits in a CRHT during 2 years
in patients with psychotic disorder. A descriptive, observational and
cross-linked study conducted in 163 patients. We collected demo-
graphic and clinical variables including the Global Assessment of
Functioning scale (GAF), the Clinical Global Impression scale (CGI),
the Severity of Psychiatric Illness scale (SPI), the aggressive behaviour
and violence scale (AVAT), the Scale Unawareness of Mental Disorder
(SUMD), the World Health Organization Disability Assessment
Schedule (WHODAS), and the Positive and Negative Syndrome Scale
(PANSS). The sample was divided on two groups, use of oral or long-
acting antipsychotic.
Results : There are no clinical diﬀerences on most of the clinical
scales. The results only showed diﬀerences in GAF scale (mean 37.6
SD 13.9 in oral treatment vs. 46.3 (32.5) in long-acting treatment).
There are also diﬀerences in ‘known psychiatric background’ (75.0%
vs. 97.3%) (oral vs. long-acting), ‘Legally incapacitated’ (17.5% vs.
40.5%), ‘Previous hospital admission’ (60.3% vs. 83,8%), ‘Previous
non-compliance treatment’ (73.6% vs. 97.3%), ‘Hospitalisation de-
cision’ (46.8% vs. 21.6%).
Conclusion : The results show that the decision to give a long-acting
antipsychotic treatment is poorly correlated to clinical variables of
P-01. Antipsychotics 67
Downloaded from https://academic.oup.com/ijnp/article-abstract/15/Supplement_1/1/650920
by University of Groningen user
on 13 March 2018
patients, being more important previous history referring to poor
outcome in adherence to treatment. We also observe that patients with
long.term treatment are admitted less frequently than those receiving
oral treatment.
P-02. Addictive Disorders
jP-02-001jRegulation of CB1 receptor protein and mTOR
signaling in the cerebral cortex of cocaine addicts
and cocaine-treated mice
M. A´lvaro-Bartolome´1, J.A. Garcı´a-Sevilla1. 1 IUNICS, Palma de
Mallorca, Spain
Objective : Endocannabinoids, CB1 receptors and dopamine D2
receptors interact to induce the eﬀects of the psychostimulant cocaine.
This study assessed the status of CB1 receptor protein and its down-
stream partner the mammalian target of rapamycin (mTOR, a serine/
threonine kinase) in brains of cocaine addicts and cocaine-treated
mice.
Methods : Postmortem prefrontal cortex (PFC/BA 9) was collected
from cocaine addicts (5M/4F ; 35¡47 yr ; 28¡7 PMD) and healthy
matched controls (5M/4F ; 40¡4 yr ; 27¡7 PMD). Toxicology at
autopsy (blood and hair) revealed long-term abuse of cocaine
only. CD1 mice were treated (i.p.) with saline/vehicle (n=7/5),
cocaine (acute : 20 mg/kg, 2 h, n=5 ; chronic : 20 mg/kg, 7 days, n=8)
or WIN55, 212–2 (CB1 agonist, acute : 8 mg/kg, 1 h, n=5 ; chronic :
1–8 mg/kg, 5 days, n=5). CB1 protein (total homogenate and sub-
cellular fractions) and p-mTOR/mTOR ratio (kinase activation in total
homogenate) were quantiﬁed by Western blot analysis with speciﬁc
antibodies.
Results : Cortical CB1 receptor protein was reduced in long-term
cocaine addicts (44¡9%, p=0.03) compared to matched controls.
Chronic cocaine in mice also reduced cortical CB1 receptor protein
(44¡8%, p=0.01). CB1 protein (chronic cocaine ; human and mouse
cortex) was reduced in membranes (10–31%) and augmented in
cytosol (11–23%), indicating receptor internalization. Acute WIN55,
212–2 and acute cocaine activated cortical mTOR kinase (140% and
70%, respectively). In contrast, chronic WIN55, 212–2 and chronic
cocaine did not induce mTOR activation (induction of receptor toler-
ance). Similarly, mTOR was not signiﬁcantly activated in PFC/BA9 of
long-term cocaine addicts (22¡10%, p>0.05).
Conclusion : Cortical CB1 receptor protein is downregulated after
chronic exposure to cocaine in humans and mice, which indicates the
participation of endocannabinoids in cocaine addiction. In line with
this novel ﬁnding, the signaling of CB1 receptors involving the ac-
tivation of mTOR was dampened after chronic cocaine in human and
mouse brains.
Policy of full disclosure : Supported by SAF2011–29918 (MEC-
FEDER, Spain) and RETICS RD06/001/003 (MSC-FEDER, Spain).
jP-02-002jSubstance use disorders, psychiatric comorbidity,
social vulnerability and long term outcome ;
a ﬁve year follow-up
S. Bjo¨rstad1, K.W. Nilsson1, S. Hodgins2, C. A˚slund1. 1Centrum fo¨r
Klinisk Forskning, Va¨stera˚s, Sweden ; 2Department of Forensic Mental,
Health Science, Institute, London, United Kingdom
Objective : Although substance use disorders (SUD) among adoles-
cents are poorly understood, it is well known that SUD in teenagers
are associated with comorbid mental disorders and other adverse
conditions in adult life. The aim of the study was to identify risk fac-
tors in early adolescence associated with presence of SUD ﬁve years
later.
Methods : A representative sample of 180 adolescents, who had
consulted a clinic for substance misuse problems, and their parents,
were assessed at ﬁrst contact with the clinic. The 180 adolescents and
their 251 parents completed questionnaires and diagnostic interviews
measuring psychopathology, substance use, maltreatment, victimiza-
tion, criminality and poverty. Follow-up measurements took place
ﬁve years from baseline including 147 participants from the original
sample.
Results : Increased odds for presenting with SUD at ﬁve follow-up
were shown for females with baseline experience of victimization by
peers, sexual abuse, mothers with alcohol use disorder, fathers with
drug use disorder and treatment for SUD. Male reports of baseline
violent criminality and treatment for SUD elevated the odds for drug
use disorder at follow up. Adjusting for baseline SUD, the odds in-
creased among both males and females to present the same disorder
ﬁve years later.
Conclusion : SUDwere shown to be persistent over time. Treatment
displayed no eﬀect. Female SUD are shown to be aﬀected largely by
social context rather than individual factors. This was not shown for
males.
jP-02-003jDiagnosis of psychotic disorders in tirana psychiaric
emergency in the context of substance use
I. Braho1, L. Sinani2, A. Kazaferi2, E. Sotiri2, Z. Halla2, M. Kulla2,
F. Elezi2. 1QSUT, Tirana, Albania ; 2QSUT ‘‘Nene Tereza ’’, Tirana,
Albania
Objective : For patients, who actively use substances and manifest
psychotic symptoms, remains a challenge to deﬁne whether psychotic
symptoms are due to a primary psychotic disorder or caused by sub-
stance use. Therefore it is most important the clariﬁcation of the nat-
ure of psychosis in such patients, especially during ﬁrst psychotic
episode. This clariﬁcation impacts the plan to their further treatment.
Methods : Patients (males and females) aged over 16 years old
presenting to the Emergency of Psychiatry and hospitalized during
the period January 2008–December 2011 are included, diagnosed with
psychotic disorders according to DSM-IV.
Results : Data gained from this study indicate the percentage
of cases diagnosed with primary psychotic disorders and how many
emergency admissions are not psychotic or psychotic disorders
caused by the use of substances. Diagnostic agreement was generally
low (k=0.32). Percentage of patients diagnosed with primary psy-
chotic disorders is higher than those diagnosed with psychotic dis-
orders caused by substances, and are treated with antipsychotics
(p<0.001).
Conclusion : Clinicians in Psychiatric Urgency seem to have a
tendency to attribute the psychotic symptoms rather to a primary
psychotic disorder than to a concurrent substance abuse. This is a fact,
which shows the importance of psychotic symptoms. The diagnosis
implies with the management of psychosis signiﬁcantly in the future,
so it is important to improve diagnostic techniques in psychiatric
emergencies.
jP-02-004jPreliminary study about the vulnerability to drug
consumption associated with human single
nucleotide polymorphisms of CNR1, FAAH
and COMT genes
K.-M. Bu¨hler1, E. Huertas2, V. Echeverry-Alzate2, J.A. Lopez-
Moreno2. 1University Complutense Madrid, Spain ; 2University
Complutense Madrid, Fac. Psychology, Spain
Objective :Genetic variants, such as single nucleotide polymorphisms
(SNPs), inﬂuence the vulnerability to addictive behavior. SNPs present
in the cannabinnoid receptor 1 gene (CNR1) and the fatty acid amide
hydrolase enzyme (FAAH) have been repeatedly associated with
marijuana and alcohol abuse, whereas other SNPs in the dopaminergic
D2 receptor D2 (DRD2) and the catechol-o-methyltransferase enzyme
(COMT) have been related to cocaine and nicotine addiction. In this
work we have tried to examine the association between several SNPs
of the cannabinoid and catecholaminergic systems with self-reported
drug consumption.
Methods : For this, DNA samples from voluntary students from the
Complutense University of Madrid (Spain) were sequenced and their
drug consumption habits were assessed. Moreover, participants
were asked to complete valence ratings of drug-related and non-drug-
related pictures.
Results : The results showed a signiﬁcant association between ﬁve
analyzed SNPs and drug consumption. Valence of drug-related pic-
tures was much more positive within drug consuming participants.
For example, tobacco smokers rated tobacco images signiﬁcant more
pleasant than ex-smoker or non-smoker.
Conclusion : Here, we provide preliminary evidences for the as-
sociation of SNPs present in the cannabionid and catecholaminergic
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system with drug consumption. In addition, it is very robust the eﬀect
that drug consuming people show higher emotional preference for
drug-related stimuli than non-drug consuming people.
jP-02-005jPatological gambling in patients under treatment
for Parkinson disease
I.M. Castillo Garcia1, L.P. del Nido Varo1, I. Martines Gras1,
E. Verdura1, E. Soria Garcia-Rosel1, J.C. Vazquel Caubet1, G. Ponce1,
M.A. Jimenez Arriero1. 1Hospital 12 de Octubre, Madrid, Spain
Objective : The prevalence of Pathological Gambling (PG) is higher
among patients with Parkinson Disease (PD) than within general
population. (1). This fact could be related to the pharmacological
treatment´s used in PD. This work aims to be a review about epi-
demiological, clinical and neurobiological features implied in PG
in PD.
Methods : we looked trough Medline for articles published after to
2007 regarding PG in PD. Furthermore, we will present two cases of
PD in which PG is developed.
Results : Prevalence of Impulse Control Disorders (ICD) in PD
is assessed in 4–14%, this includes compulsive shopping (5.7%), PG
(5%), compulsive eating (4.3%) and hipersexuality (3.6%)(ref). The
most important risk factors for the development of PG in PD are
treatment with dopaminergic agonists and L-dopa used, followed by
early onset of PD, long course PD and either familiar or personal his-
tory of Adictive Disorders (AD) (2). It seems that the neurobiological
mechanism of PG in PD has to do with the cortico- striatal pathways,
changes in the phasic secretion of dopamine and over stimulation of
D2 receptor, D3 senzitancion and long- term plastic changes as a result
of the former. Management of PG in PD is complex ; an early diag-
nosis, psicoeducation and behavior measures are of great importance.
As to the pharmacological strategies, lowering doses of dopa agonists
with augmentation of L-Dopa, switching for another dopa agonist,
treatment cessation and use of other drugs (such as antipsychotics,
SSRI, mood stabilizers, amantadine, or zonisamide might be
helpful (3).
Conclusion : 1. The relationship between PG and PD seems to be
mediated by PD´s pharmachological treatment rather than PD itself.
2. A subpopulation of patients with PD could have subclinical features
that make them prone to the development of PG.
jP-02-007jMaladaptive schemas and coping strategies of
substance dependents
B. Haciomeroglu1, A. Cinar2, M. Ak2, B. Garip2, E. Congologlu2,
L. Sutcigil3. 1Gazi University, Ankara, Turkey ; 2Gulhane School of
Medicine, Department of Psychiatry, Ankara, Turkey ; 3Gulhane School of
Medicine, Ankara, Turkey
Objective : Substance dependence is a prevalent and chronic
behavioral health problem. The aim of this study was to evaluate the
substance dependents in terms of their maladaptive schemas and
coping strategies.
Methods : Thirty one male patients (M=24.12¡4.44) who were di-
agnosed with substance dependence according to DSM-IV criteria and
hospitalized for detoxiﬁcation, participated in the study. Subjects
were screened for HIV, HBV and HCV markers. Schemas and coping
strategies of substance dependents were evaluated using Young
Schema Scale and COPE. Socio-demographic properties, kind of sub-
stance use, frequency and duration of substance use were obtained via
socio-demographic information form. Moreover, each participant was
evaluated through SCID-I and patients with any comorbid psychiatric
disorder were excluded from the study. The control group composed
of 31 male subjects (23.32¡2.85) without any psychiatric disorders
and was evaluated through the same procedure.
Results : MONOVA results revealed that in terms of
schemas, substance dependents scored signiﬁcantly higher than con-
trol group in abandonment/instability, mistrust/abuse, defective-
ness/shame, social isolation/alienation, dependence/incompetence,
enmeshment/undeveloped self, failure, insuﬃcient self-control/self-
discipline, subjugation, self-sacriﬁce, approval-seeking/recognition-
seeking, negativity/pessimism, emotional inhibition, unrelenting
standards/hypercriticalness, punitiveness. In terms of coping strate-
gies, substance dependents scored signiﬁcantly lower than control
group in positive reinterpretation and growth, seeking social support
for instrumental reasons, active coping, turning to religion, seeking
social support for emotional reasons, and scored signiﬁcantly higher
than control group in alcohol-drug disengagement.
Conclusion : These ﬁndings support the importance of early mala-
daptive schemas which might be underlying the dependency problem
and prevent the person to deal with the problem with more active and
problem focused coping strategies. Therefore, in cognitive-based
psychotherapeutic approaches for patients with substance depen-
dence, it would be eﬀective to focus on maladaptive schemas and
coping strategies as part of the treatment procedure.
jP-02-008jSuppression of alcohol-dependence using
high-dose baclofen : A two-year observational study
of 100 patients
R. de Beaurepaire. CHS Paul Guiraud, Service IV 94G11, Villejuif Cedex,
France
Objective : Evaluate alcohol-dependence suppression by baclofen in
a large cohort of patients.
Methods : Patients with treatment-resistant alcohol dependence
seeking baclofen treatment were treated with escalating doses of
baclofen and observed for 24 months. A hundred treatment-compliant
patients were included in this observational and compassion-
motivated study. Alcohol consumption and craving for alcohol were
assessed before treatment and at 3, 6, 12 and 24 months. Assessments
were based on patients’ statements. The outcome measure was the
WHO criteria (‘‘at low risk’’, ‘‘at risk’’, ‘‘at high risk’’).
Results : 92% of patients reported that they experienced an eﬀort-
less craving-suppressing eﬀect of baclofen. While all patients were
rated ‘‘at high risk’’ at baseline, approximately half of them were
rated ‘‘at low risk’’ at 3, 6, 12 and 24 months. The low rate of relapse
after 6 months was remarkable. The average maximal dose of baclofen
taken was 147 mg/day. Signiﬁcant relationships were found between
the amount of alcohol taken before treatment and the maximal dose
of baclofen required, and between the existence of a mental disorder
and a lesser eﬀect of baclofen. Side-eﬀects were common, but always
benign.
Conclusion : Baclofen produces an eﬀortless decrease or sup-
pression of alcohol craving in almost all patients when it is prescribed
with no superior limit of dose. Potential limitations in the eﬀective-
ness of baclofen include the coexistence of a mental disorder, the
concomitant use of other psychotropic drugs, a lack of real motivation
in patients to stop drinking, and an impossibility to reach the optimal
dose of baclofen because of a limited capacity of certain patients to
tolerate undesirable side-eﬀects.
jP-02-009jThe alpha-2-adrenoceptor agonist guanfacine
signiﬁcantly decrease voluntary ethanol intake
in wistar rats
I. Fredriksson1, E. Nystro¨m1, E. Nylander1, L. Khemiri1,
P. Steensland1. 1Karolinska Institutet, Stockholm, Sweden
Objective : Alcohol use disorder (AUD) is a chronic relapse disease.
However, only three medications, with limited clinical eﬃcacy, are
available. Thus, new eﬀective medications are needed. High rates of
cravings, even after long periods of abstinence, in combination with
decreased cognitive functions including impaired decision making
and impulse control often lead to relapse in drinking. It has been
suggested that increased release of noradrenalin during abstinence
contributes to the impaired impulse control. Thus, enhancement of
cognitive function through inhibition of the noradrenalin system may
serve as novel treatment strategy for AUD. Recent studies show
that the FDA-approved ADHD-medication guanfacine (an alpha-
2-adrenoceptor agonist) attenuate reinstatement of alcohol seeking in
rats. Here we evaluated the eﬀects of guanfacine, on voluntary ethanol
intake in Wistar rats following long-term voluntary ethanol con-
sumption.
Methods : Wistar rats were given intermittent-access to 20%
ethanol (three 24-hour-ethanol-sessions per week ; Mon, Wed and Fri)
for at least three months before treatment. Acute guanfacine treatment
(0, 0.3 and 0.6 mg/kg) was given to rats voluntarily consuming low
(1.9¡0.2 mg/kg/24 hr ; n=7) or high (4.3¡0.2 mg/kg/24 hr ; n=11)
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amounts of ethanol. Repeated guanfacine treatment (0 and
0.6 mg/kg/day over 5 consecutive drinking sessions) were given to a
group of rats consuming high amounts of ethanol (4.3¡0.2 mg/kg/
24 hr ; n=12). All injections were given 30 minutes before the ethanol-
drinking-session started. Thus, the rats had undergone 23 hours of
abstinence at the time of treatment.
Results : Acute and repeated guanfacine treatment selectively
decreased ethanol intake in high, but not low, ethanol consuming rats.
The repeated guanfacine treatment indicating that no tolerance to
guanfacine’s ability to decrease ethanol intake develops over time.
Moreover, there was no post-treatment rebound increase in ethanol
consumption.
Conclusion : The present study gives further support for the
hypothesis that the cognitive enhancer guanfacine may serve as a
novel treatment for AUD.
jP-02-010jAnterior cingulate (AC) glutamate, cravings for
alcohol and depressive symptoms
M. Frye1, J. Baruth1, J. Port1, A. McKean1, D.-S. Choi1, V. Karpyak1,
J. Biernacka1, J. Geske1, L. Gunderson1, D. Mrazek1. 1Mayo Clinic,
Rochester, Minnesota, USA
Objective : Converging evidence indicates acute disruption in gluta-
matergic neurotransmission is associated with symptoms of alcohol
intoxication and withdrawal. We wanted to evaluate the relationship
between AC glutamate and cravings for alcohol and depressive
symptoms.
Methods : 14 subjects (mean age=43.0¡13.0 ; 8 females and
6 males) with alcohol dependance admitted to residential treatment
have enrolled in the study. Single-voxel 2D J-resolved PRESS H-MRS
of the AC was measured y5 days from last drink and reported as
Glx/creatine (Glx/Cr). Cravings for alcohol were measured by the
Penn Alcohol Craving Scale (PACS) and self report symptoms
of depression were rated with the Patient Health Questionnaire
(PHQ 2).
Results : Inverse correlations were found between Glx/Cr
and PHQ-2 (r=x0.62, p=0.019) and Glx/Cr and PACS (r=x0.51,
p=0.066) indicating depressed mood, anhedonia, and alcohol craving
were associated with decreased AC glutamate. When subjects were
divided into both depressed (PHQ 2 o3) vs. non-depressed (PHQ
2<3) and high-craving (split at median) vs. low-craving groups,
GLX/Cr was signiﬁcantly reduced in depressed and high-craving
groups.
Conclusion : Alcohol craving and depressive symptoms during
early abstinence may be associated with a glutamate deﬁcit in the AC.
Our ﬁndings are in contrast to previous clinical studies which may be
related to diﬀerent methodology including the length of early absti-
nence period. As this sample is 5 days from last drink we conclude
that the acute withdrawal period has passed and our data captures a
period of relative glutamate deﬁcit prior to normalization.
Policy of full disclosure : Disclosure Declaration Mark A. Frye,
M.D. 2012 Grant Support Pﬁzer, National Alliance for Schizophrenia
and Depression (NARSAD), National Institute of Mental Health
(NIMH), National Institute of Alcohol Abuse and Alcoholism
(NIAAA), Mayo Foundation Speakers’ Bureau NONE Financial
Interest/Stock ownership/Royalties NONE.
jP-02-011jSulforaphane as a therapeutic drug for
methamphetamine abuse
Y. Fujita1, H. Chen1, J. Wu1, J. Zhang1, T. Ishima1, M. Iyo1,
K. Hashimoto1. 1Chiba University, Japan
Objective : Accumulating evidence suggests a role of oxidative stress
in the pathophysiology of substance abuse. Sulforaphane (SFN),
found in cruciferous vegetables, is a potent antioxidant. It is, therefore,
of interest to determine whether SFN can attenuate behavioral and
neuropathological changes in mice after administration of psychosti-
mulant methamphetamine (METH).
Methods : The eﬀects of SFN on acute hyperlocomotion and the
development of behavioral sensitization induced by the adminis-
tration of METH were examined in male Balb/c mice. Levels of
dopamine (DA) and its major metabolite 3,4-dihydroxyphenyl acetic
acid (DOPAC) in the striatum were measured. In addition,
immunohistochemistry for DA transporter (DAT) and MAC1 (micro-
glia activation) was also performed.
Results : Pretreatment with SFN (1, 3, and 10 mg/kg) elicited a dose
dependent attenuation of acute hyperlocomotion in mice after a single
administration of METH (3 mg/kg). The development of behavioral
sensitization after repeated administrations of METH (3 mg/kg/day,
once daily for 5 days) was signiﬁcantly reduced by pretreatment with
SFN (10 mg/kg). In addition, the lowering of DA levels and DOPAC
as well as DAT immunoreactivity in the striatum after repeated
administration of METH was signiﬁcantly attenuated by both pre-
treatment and the subsequent administration of SFN (10 mg/kg).
Furthermore, SFN (10 mg/kg) signiﬁcantly reduced microglial acti-
vation in the striatum after repeated exposure to METH.
Conclusion : These results suggest that SFN could be a potential
therapeutic drug for the treatment of METH abuse since it is a safe for
human consumption.
jP-02-012jA study on the eﬀectiveness of electroacupuncture as
adjunctive treatment among methadone maintenance
therapy clients in University of Malaya Medical
Center, Kuala Lumpur, Malaysia
S.I. Hasan1, R. Abd Rashid2, M. Ahmad Zahari2, C.G. Ng1,
A.H. Sulaiman1, F. Ibrahim1, N. Robson1, R. Abdul Kadir1,
M. Mustafa1, M.H. Habil1, W.A. Irnee Wan Hussin3. 1University of
Malaya, Kuala Lumpur, Malaysia ; 2University of Malaya, Center of
Addiction Sciences, Kuala Lumpur, Malaysia ; 3Kuala Lumpur, Malaysia
Objective : To investigate the role of acupuncture as an adjunct
treatment for opiate dependant individuals.
Methods : Prospective, open-labelled, parallel, randomized-control
trial will be conducted in the University of Malaya Medical Centre
from Feb 2012 till December 2013. One hundred and twenty subjects
who fulﬁlled Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition criteria for the opiate dependence receiving metha-
done maintenance therapy were randomly assigned into two groups.
Subject will receive the methadone based on the National Guidelines
of Malaysian Ministry of Health. Treatment group will receive elec-
troacupuncture stimulation at 1.1+80 Hz while control group will
receive Sham acupuncture for 30 minutes per session as followed :
ﬁrst week (ﬁve times per week), second week (two times per week)
and third week to following weeks until one year (once a week).
Outcome assessment will use structured questionnaires such as
Opiate Treatment Index (OTI) to measure drug use, HIV risk-taking
behaviours, social functioning, criminality, health status and psycho-
logical functioning. The World Health Organization Quality of
Life – BREF (WHOQoL-BREF) will use to measure physical health,
psychological health, social relationships, and environment. In ad-
dition, Clinical Opiate Withdrawal Scales (COWS) will use to measure
the withdrawal syndrome in opiate dependence individuals.
Results : From this study, we expected to come out with acupunc-
ture group has better results of outcomes measures as compare to
control group.
Conclusion : The result of this study suggests that acupuncture add
on treatment on top of methadone therapy potentially have additional
advantage in reducing withdrawal intensity and better outcomes for
overall.
Policy of full disclosure : This study was supported by High
Impact Research Grant under The Ministry of Higher Education of
Malaysia.
jP-02-013jChanges in serotonergic modulation of neuronal
activity in the nucleus accumbens following
repeated methamphetamine administrations in rats
K. Ishihara1, N. Takahashi1, N. Komoto1. 1Hiroshima International
Univ., Kure, Japan
Objective : Electrophysiological studies were performed to determine
whether or not serotonergic modulation on neuronal activities (in-
cluding synapses) in the nucleus accumbens (NAcc) was aﬀected after
repeated methamphetamine (MAP) administrations.
Methods : Rats (age range : 5–8 weeks) were administered with
either MAP (5 mg/kg ; i.p.) or an equal volume of saline once daily for
5 days. Brain slices containing NAcc (thickness : 400 micro-m) were
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prepared 5days after the ﬁnal injection of MAP or saline. Population
spikes (PS) induced by local stimulation of NAcc were recorded with
a glass microelectrode placed in the same nucleus. All agents with
the same dose (10 microM) tested were applied via a bath perfusion
system.
Results : Compared with the saline-treated group, PS inhibition by
5-HT was signiﬁcantly attenuated in the MAP-treated group 5 days
after treatment. Although administration with 8-OH-DPAT (a
5-HT1A receptor agonist) suppressed PS, the inhibition rate was not
signiﬁcantly aﬀected by repeated MAP treatment. In addition, alpha-
methyl-5-HT (a 5-HT2 receptor agonist)-induced inhibition was
slightly reversed without signiﬁcance in the MAP group. However,
signiﬁcant diﬀerent eﬀects on PS with m-chlorophenylbiganide
(5-HT3 receptor agonist) and RS-67333 (a 5-HT4 receptor agonist)
were observed in the MAP group (vs. saline group). EMD 386088
(a 5-HT6 receptor agonist) did not aﬀect PS in both groups.
Interestingly, although slight (about 10%) enhancement eﬀect on
PS was noted in the saline group, AS 19 (a 5-HT7 receptor agonist)
signiﬁcantly enhanced PS in the MAP group.
Conclusion : In fact, 5-HT-induced inhibition of PS in NAcc was
attenuated 5 days after termination of repeated MAP treatment : an
eﬀect probably due to enhancement of the excitatory modulation via
the 5-HT7 receptor.
jP-02-014jDextromethorphan induced bipolar disorder
R. Jacob1, J.N. Nicholapillai1. 1 Institute of Mental Health, Singapore,
Singapore
Objective : There are very few case reports in the literature linking
dextromethorphan inducing bipolar disorder We describe a patient
who developed recurrent episodes of mania following sustained
dextromethorphan use and which resolved after cessation of its use.
Methods : The patient is a 42 year old male, who had a history of
heroin, subutex and midazolam use in the past but completely stop-
ped its use in 2008. He started consuming dextromethorphan tablets
about 30 tablets a day (450 mg daily) since May 2011 2 to 3 times
a week. He did not consume any other illicit drugs or alcohol. He
started exhibiting symptoms of mania 2 to 3 weeks after starting
dextromethorphan which required inpatient admission for a week.
Symptoms resolved after a few days of admission. He had a second
admission on 17th June 2011 after he restarted dextromethorphan use
after discharge. He exhibited short lived manic symptoms which set-
tled after 1 week of admission. This was followed again by a third
episode of mania which occurred in September 2011 which lasted for
2 weeks and required inpatient admission. There was no past history
of either manic or depressive episodes prior to onset of use of
dextromethorphan or any signiﬁcant family history.
Results : All these 3 episodes of mania occurred after heavy con-
sumption of dextromethorphan use and resolved with cessation
of use.
Conclusion : This report adds to the existing sparse literature about
dextromethorphan inducing manic episodes.
jP-02-015jSequence variation in Gata4 gene is associated
with alcohol dependence
V. Karpyak1, S. Winham1, J. Biernacka1, J. Cunningham1,
O. Abulseoud1, D. Hall-Flavin1, L. Loukianova1, T. Schneekloth1,
M. Frye1, D. Mrazek1, J. Heit. 1Mayo Clinic, Rochester, MN, USA
Objective : Recent studies suggested that an intronic SNP
(rs13273672) in the GATA4 gene encoding GATA-binding protein 4 is
associated with alcohol dependence (Treutlein et al., 2010) and relapse
following treatment with acamprosate (Kiefer et al., 2011). To replicate
this ﬁnding and further explore potential associations between
alcohol dependence and sequence variation in GATA4 gene we
investigated the association of alcohol dependence with this SNP
as well as 10 haplotype tagging SNPs in the GATA4 gene.
Methods : GATA4 SNPs were genotyped in 816 alcohol dependent
cases and compared with the same SNPs 1248 controls previously
genotyped as part of a genome-wide association study. When mul-
tiple SNPs in a gene are associated with a trait, a gene-level test may
be a powerful approach for detecting association with variation in the
gene. We therefore performed a global test for association of alcohol
dependence with variation in the GATA4 gene using principle com-
ponents analysis involving the 11 genotyped GATA4 SNPs.
Results : Our analyses did not provide signiﬁcant evidence for
association of alcohol dependence with SNP rs13273672. However,
nominal evidence of association (p<0.05) was obtained for ﬁve of the
other ten GATA4 SNPs, including rs10112596, rs809204, rs804283,
rs6601604, and rs12550668. Signiﬁcant evidence of association be-
tween GATA4 and alcohol dependence was observed at the gene-
level (p=0.009).
Conclusion : Our ﬁndings do support potential role of GATA4
variation but not rs13273672 SNP in alcohol dependence. Further
studies are needed to identify the potentially causal variant(s) and
the functional mechanism contributing to this association. As part of
the ongoing work of our NIAAA-funded alcoholism research center
(Mayo Clinic Center for Individualized Treatment of Alcohol
Dependence) we will investigate the association of these SNPs with
response to acamprosate treatment.
jP-02-016j Inﬂuence of betaxolol(BTX) on the
methamphetamine(MAP) dependence mice
B.J. Kim1, P.H. Kim1. 1Presbyterian Medical Center, Jeonju, Republic of
Korea
Objective : We investigated the eﬀect of BTX in MAP.
Methods : Animal mice were used in conditioned place preference
test.Statistical analysis : one-way ANOVA/Kruskal-Wallis test.
Results : The repeated administration of BTX (5 mg/kg,i.p) 30 min
prior to the exposure to MAP signiﬁcantly reduced the development
of MAP-induced CPP. When BTX was administered 24 h prior to the
CPP testing session,it also signiﬁcantly attenuated CPP, but not
changed locomotor activity.In the drug-priming reinstatement study,
the extinguished CPP was reinstated by MAP (0.125 mg/kg,s.c.) in-
jection & this was signiﬁcantly attenuated by BTX.
Conclusion : BTX has a therapeutic and preventive eﬀect on
the development,expression & drug-priming reinstatement of MAP
induced CPP.
jP-02-017jAnxiety-like response to methamphetamine in adult
mice is not altered by prenatal exposure to modaﬁnil
J. Kucerova1, P. Amchova2, A. Machalova3, J. Pistovcakova2,
A. Sulcova3. 1Masaryk University Kame, Brno, Czech Republic ; 2Masaryk
University, Faculty of Medicine, Brno, Czech Republic ; 3Masaryk
University, CEITEC, Brno, Czech Republic
Objective : Methamphetamine (MET) is a commonly abused psy-
chostimulant drug. Modaﬁnil (MDF), a drug registered for treatment
of narcolepsy, is often consumed by young fertile generation for its
stimulatory properties, and thus it is important to assess its beha-
vioural toxicity in oﬀspring. This study investigated inﬂuence of pre-
natal exposure to MDF and MET on anxiety-like measures after acute
and chronic administration of MET in adult mouse males using elev-
ated plus maze.
Methods : Pregnant female mice were given nine daily doses
of saline (SAL, 10 ml/kg/day), MET (2.5 mg/kg/day) or MDF
(50 mg/kg/day). Eﬀects of the same treatment doses were evaluated
in adult male oﬀspring in six experimental groups : SAL or MET
treated oﬀspring with prenatal exposure to SAL, MET and MDF.
Anxiety was assessed as % of entries and time spent in open and
closed arms in the elevated plus maze on : Day 1 – naı¨ve mice (no drug
dose, baseline conditions), Day 8 – acute dose of SAL or MET,
Day 15 – challenge dose after one week of repeated SAL or MET ad-
ministration.
Results : At baseline conditions on the Day 1, prenatal treatment
with MDF increased % of entries and time spent in the closed arms
compared to SAL prenatal administration (but did not signiﬁcantly
aﬀect behaviour in the open arms). Prenatal administration of MET
did not alter anxiety-like behaviour compared to prenatally naı¨ve
animals. Anxiety-like response to acute dose (Day 8) or chronic treat-
ment (Day 15) of MET in the elevated plus maze was not altered
by diﬀerent prenatal exposures (SAL compared to MET and MDF).
Conclusion : We can conclude that prenatal treatment with
MDF increases anxiety at baseline conditions. However, there were
observed no diﬀerences in reactivity to postnatal administration of
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either drug (MET or MDF). Modaﬁnil provoked behavioural toxicity
although not linked to methamphetamine abuse.
Policy of full disclosure : Supported by Masaryk University
Student Grant for Speciﬁc Research : MUNI/A/0852/2010 and
CEITEC CZ.1.05/1.1.00/02.0068 from European Regional Develop-
ment Fund.
jP-02-018jAre delerium tremens and alcohol-related seizures in
inpatients admitted for alcohol detoxiﬁcation related
to daily alcohol consumption and breath alcohol
content on admission?
P.S. Kundi. Warrington, United Kingdom
Objective : The primary aim of this study was to investigate whether
daily alcohol consumption and Breath Alcohol Content (BrAC) aﬀect
the incidence of Delirium Tremens and Alcohol-related seizures in
patients admitted for alcohol detoxiﬁcation.
Methods : The study comprised of a cross-sectional survey in
which data was collected from 100 consecutive inpatients admitted for
alcohol detoxiﬁcation in the unit in 2010. Data was collected from the
clinical records of the patients and we looked at demographics, daily
alcohol consumption, Breath Alcohol Content at admission and cur-
rent episodes and past history of delirium tremens and alcohol-
related ﬁts.
Results :We noticed that 14 patients experienced Delirium Tremens
and 10 patients experienced alcohol-related ﬁts during their current
admission whilst 56 patients had a past history of Delirium Tremens
and 40 had a past history of alcohol-related ﬁts. 2 patients experienced
both Delirium Tremens and ﬁts. All these patients had a daily con-
sumption of alcohol higher than 30 units of alcohol. 86% (12/14) of the
patients who developed Delirium Tremens and 90% (9/10) of patients
who had alcohol-related ﬁts had a Breath Alcohol Content of more
than 1.00 at admission.
Conclusion : Daily alcohol usage and Breath Alcohol Content
at admission could be related to a risk of developing Delirium
Tremens and Alcohol-related ﬁts during the detoxiﬁcation process.
This can aid in identifying high risk patients and help reduce their
morbidity.
jP-02-019jCortisol levels and MDMA-induced memory
impairment
K. Kuypers1, R. de la Torre2, M. Farre2, J.G. Ramaekers1. 1Maastricht
University, Netherlands ; 2 IMIM Hospital del Mar, Barcelona, Spain
Objective : Ecstasy use is commonly linked with memory deﬁcits in
abstinent ecstasy users. Similar impairments are being found during
ecstasy intoxication after single doses of MDMA. The concordance of
memory impairments during intoxication and abstinence suggests
a similar neuropharmacological mechanism underlying acute and
chronic memory impairments. The mechanism underlying this im-
pairment is to date not known. We hypothesized that cortisol might
play an important role in this mechanism as cortisol, implicated in the
regulation of memory performance, can be brought out of balance
by stressors like MDMA. In the present study we aimed to block the
MDMA-induced acute memory defect by giving participants a cor-
tisol synthesis inhibitor (Metyrapone1) together with a single dose of
MDMA.
Methods : Seventeen polydrug MDMA users entered this placebo
controlled within subject study with four treatment conditions. The
treatments consisted of MDMA (75 mg) and Metyrapone1 (750 mg),
alone and in combination, and double placebo. Pretreatment with
Metyrapone or Placebo occured 1 h prior to MDMA or Placebo
administration. Memory performance was tested at peak drug con-
centrations by means of several memory tests. Cortisol levels were
determined in blood ; this served as a control measure to see whether
manipulations were eﬀective.
Results : Main ﬁndings indicated that whereas treatment with
Metyrapone blocked the expected MDMA-induced increase in cor-
tisol levels in blood, it did not prevent the MDMA-induced memory
deﬁcit from happening.
Conclusion :We therefore conclude that MDMA-induced increases
in cortisol concentrations are not responsible for impairing memory
performance while intoxicated with MDMA.
jP-02-021jCocaine reverses naltrexone-induced reduction in
operant ethanol self-administration
J.A. Lopez-Moreno1, V. Echverry-Alzate2, K. Bu¨hler2, E. Gine´3,
A. Santos4, P. Olmos5. 1Complutense University, Pozuelo Alarcon,
Madrid, Spain ; 2Complutense University, Department of Psychobiology,
Pozuelo Alarcon, Madrid, Spain ; 3Complutense University, Department of
Biochemistry, Pozuelo Alarcon, Madrid, Spain ; 4Complutense University,
Department of Biochemistry, Madrid, Spain ; 5 (1) Complutense University,
(2)CIEMAT Avda. Complutense 22, Pozuelo Alarcon, Madrid, Spain
Objective : Naltrexone is a clinically approved medication for
alcoholism. We aimed to investigate the eﬃcacy of naltrexone when
there is an interaction with cocaine and their associations with im-
mediate-early gene expression in the prefrontal cortex.
Methods : Using rats, we designed the experiments to maximise
their predictive validity in humans. We used chronic operant ethanol
self-administration and treatments (p.o.) prescribed for alcoholism.
We performed real-time PCR analysis to determine gene expression
levels.
Results : Only the highest dose of naltrexone (10 mg/kg) reduced
ethanol intake. Cocaine increased ethanol self-administration dose-
dependently (2.5, 10, 20 mg/kg) and reverted the naltrexone-induced
reduction. Naltrexone failed to prevent cocaine-induced increase
in locomotor activity observed in these animals. Ethanol caused a re-
duction in C-fos gene expression and an overexpression of the COX-2
and Homer1a genes in the rat prefrontal cortex. Neither the sup-
pressive eﬀects of naltrexone nor the cocaine-induced increase
of ethanol self-administration were related to the genetic changes
observed.
Conclusion : Chronic ethanol self-administration is prevented by
naltrexone, but cocaine fully reverses this eﬀect. This suggests that
cocaine may overcome the eﬃcacy of naltrexone as a treatment for
alcoholism. The ethanol-induced reduction in C-fos gene expression
in the prefrontal cortex reveals an abnormal activity of these neurons,
which may be relevant for compulsive drinking of ethanol, the regu-
lation of behaviour and the control of reward-related areas.
jP-02-022jModiﬁcation of prepulse inhibition of the startle
reﬂex during detoxiﬁcation treatment in alcohol
dependent males
M. Marin1, P. Curivil1, R. Jurado1, I. Martinez-Gras1, G. Ponce1,
G. Rubio1. 1Hospital 12 de Octubre, Madrid, Spain
Objective : Prepulse inhibition (PPI) of the startle reﬂex refers to the
ability of innocuous sensory events to reduce startle reﬂex and it has
been described as an operational measure of sensorimotor gating. It
has been reported that alcoholic withdrawing patients show a sig-
niﬁcantly decreased PPI, which reaches its lowest point on the ﬁrst
and third day of abstinence and increases progressively after the ﬁrst
week. The aim of this study was to explore modiﬁcations in PPI levels
during alcohol withdrawal syndrome and detoxiﬁcation treatment in
alcohol dependent males.
Methods : 15 male patients, aged 18 to 55 years, who met DSM-IV
criteria for alcohol dependence, were recruited through the
Outpatient Alcohol Unit at the Hospital 12 de Octubre, Madrid.
Patients were detoxiﬁed for a period of 10–14 days using benzodia-
zepines and/or anticonvulsants. They underwent testing for PPI at
baseline and after detoxiﬁcation had concluded.
Results : At baseline, patients exhibited remarkably low levels
of PPI. After 10–14 days of detoxiﬁcation treatment, PPI percentage
signiﬁcantly increased, speciﬁcally at both 30-ms (p<0.001) and
60-ms (p<0.05) prepulse-to-pulse interval. At 120-ms prepulse-
to-pulse interval, no signiﬁcant diﬀerences between baseline and post-
detoxiﬁcation were found.
Conclusion : These data suggest that sensory information proces-
sing could be damaged in withdrawing alcohol dependent patients,
probably due to neurotoxicity of alcohol over CNS.
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jP-02-023jMethadone maintenance treatment in patients with
dual diagnosis : Diﬀerential characteristics in
response to the dose of methadone
R. Martinez Riera1, G. Mateu-Codina1, L. Diaz Digon1, C. Castillo
Buenaventura1, J. Roig Llesuy1, G. Vallecillo Sanchez1, L. Morro
Fernandez1, M. Torrens Melich1. 1Parc de Salut Mar, Barcelona, Spain
Objective : To describe a sample of dual diagnosed patients who
were included in a methadone maintenance program at the time
of discharge of a brief dual diagnosis unit. More speciﬁcally we
try to ﬁnd distinguishing characteristics between patients treated
with standard therapeutic doses (SD ; from 60 mg/day) and those
treated with low doses of methadone (LD ; less than 60 mg/day).
Methods : Data on demographic, family, and clinical factors were
gathered among subjects admitted to our dual diagnosis unit between
September 2007 and September 2011, all of them meeting DSM-IV
criteria of any non-substance related Axis I or II disorder and co-
morbid substance use disorder (SUD). Statistical analysis was per-
formed by using SPSS program.
Results : $From the whole sample (N=134), age 38.7¡7.6, most of
them (68.7%) were male. Mean length of stay were 20.8¡20.6.
$Distribution of non-SUD diagnosis were as follows : psychotic dis-
orders (40.3%), personality disorders (39.5%), depressive disorders
(8.2%), bipolar disorders (6%) and adjustment disorders (6%). In our
sample, most common comorbid SUD (except opioid use disorder)
were cocaine (64.2%) and alcohol (32.1%). $Comparing to LD group
(N=86 ; 64.2%), we found that SD group (N=48 ; 35.8%) had more
prevalence of sedatives SUD, sedatives treatment both at admission
and at discharge, and antipsychotic treatment at admission. $In ad-
dition, we also observed an early onset of consumption of sedatives,
heroine and nicotine and, in turn, an earlier onset of problematic use
of alcohol, sedatives, heroine, cannabis and nicotine. It also aimed to
lower consumption of cocaine and heroin in the last 30 days prior
to current admission.
Conclusion : Patients treated with standard therapeutic doses of
methadone showed higher prevalence of sedatives SUD and a more
severe proﬁle of substance use in respect with those patients treated
with suboptimal methadone dosis.
jP-02-024jSuicide in personality disorders with substance use
disorders comorbid
R. Martinez Riera1, G.-A. Mateu Codina1, L. Diaz Digon1, C. Castillo
Buenaventura1, J. Roig Llesuy1, G. Vallecillo Sanchez1, L. Morro
Fernandez1, M. Torrens Melich1. 1Parc de Salut Mar, Barcelona, Spain
Objective : To analyze diﬀerences between patients admitted
for suicidal ideation and those who join for other reasons, within
the group of patients with Personality Disorders and Substance
Use Disorders(SUD)comorbid admitted to a brief dual diagnosis
unit.
Methods : Total of patients admitted to our dual pathology unit
between September 2007 and December 2011 and who met DSM-IV
criteria for diagnosis of Personality Disorder and comorbid SUD were
included. Data on demographic, family, and clinical factors were col-
lected.
Results : From the whole sample (N=250), age 38.58¡8.8,
most of them (64.4%) were male. The main drugs of abuse were
alcohol (47%), cocaine (26.9%) and cannabis (10%). Comparing to
non-suicidal ideation group (N=163 ; 65.2%), we found that suicidal
ideation group (N=87 ; 34.8%) had more prevalence of females
(47.1% vs. 29.4% ; p=0.008), higher rates of taking a drug treatment
regularly during the 6 months previous to hospital admission (32.4%
vs. 18.9% ; p=0.038), had more previous history of suicide attempts
(91.2% vs. 64% ; p<0.001) and more prevalence of comorbid Opioids
Use Disorder (37.9% vs. 19.6% ; p=0.002). This group received more
antidepressive drugs (64.4% vs. 41.7% ; p=0.001). Non-suicidal
ideation group had more patients admitted involuntarily (35.6% vs.
9.2% ; p<0.001), more previous history of physical aggression (75.3%
vs. 58% ; p=0.038), higher prevalence of comorbid diagnosis of
Psychosis (23.3% vs. 3.4% ; p<0.001), Antisocial Personality Disorder
(22.1% vs. 6.9% ; p=0.002), Amphetamines Use Disorder (9.2% vs.
0% ; p=0.002) and Cannabis Use Disorder (36.2% vs. 21.8% ; p=0.02).
This group showed a tendency to receive more antipsychotic drugs
(70.6% vs. 58.6 ; p=0.068).
Conclusion : Sex, type of SUD and comorbidity with other axis I
disorders, could distinguish Personality Disorders if they are or not
admitted for suicidal ideation.
jP-02-025jEﬃcacy of antidepressant in concurrent primary or
substance-induced depression and alcohol use
disorders : A systematic review and meta-analysis
D. Martinez Sanvisens1, C. Castillo1, F. Fonseca1, J. Mestre1, M. Farre´
Albadalejo1, M. Torrens Me`lich1. 1Parc Salut Mar, Barcelona, Spain
Objective : Antidepressants (AD) are commonly used in alcohol de-
pendence to treat comorbid depression and for the potential action
of these drugs on the underlying mechanisms of alcohol addiction.
Two previous systematic reviews (1,2) evaluating the eﬃcacy of AD
in the treatment of concurrent depression and alcohol use disorder
(AUD), did not support the use of AD in this dual disorder, but most
of the studies included did not diﬀerentiate between Primary (PD)
and Substance-Induced Depression (SID) Objective : To evaluate the
eﬃcacy of antidepressants in the treatment of concurrent PD or SID
and AUD.
Methods : Included studies have to be randomized placebo-
controlled (RCT) evaluating eﬃcacy of antidepressants in PD or SID
and AUD, from 1960 to December 2011. Studies should include out-
comemeasures of depressive symptoms (Hamilton Depression Rating
Scale) and alcohol consumption (self-report). Eligible studies will be
identiﬁed from available systematic reviews, from searches in elec-
tronic databases (Pub Med). Two independent researchers selected
the trials that scored>3 on Jadad scale.
Results : Only 6 RCT diﬀerentiate between PD and SID. No study
evaluates the eﬃcacy of the AD on SID. Five RCT show outcome
measures in depressive symptoms (3 using Selective Serotonin
Reuptake Inhibitors (SSRI) and 2 other AD). Data analysis show that
other antidepressants no SSRI are eﬀective to improve depressive
symptoms (OR :2.70, [95% CI : 1.07–6.84]). Four RCT provide data
from alcohol use (2 with SSRI and 2 other AD). Data analysis show
that antidepressive treatment are not eﬀective to reduce alcohol con-
sumption.
Conclusion : Although limitations in comparing diﬀerent RCT
(diﬀerent DSM criteria, antidepressant drug, dose use and status
consumption at baseline..) the analysis show eﬃcacy in treat de-
pressive symptoms in concurrent PD and AUD with non-SSRI anti-
depressants. As in previous studies antidepressants were not eﬀective
to treat alcohol use.
Policy of full disclosure : Financial support by Fondo de
Investigacio´n Sanitaria, Instituto Carlos III (RD06/0001/1009).
jP-02-026jSynthetic cannabinoids : Psychoactive eﬀects and
diﬀusion in the web
G. Martinotti1, E. Chillemi2, F. Vellante2, M. Di Giannantonio3,
I. Gualtieri1. 1Psychiatry, Rome, Italy ; 2Rome, Italy ; 3Psychiatry, Chieti,
Italy
Objective : A new generation of synthetic cannabinoids, readily
available on the web and in smart shops under the brand names of
‘‘Spice, ’’ ‘‘Aroma,’’ or ‘‘Dream’’, has recently come on the market.
Compared to THC, ‘‘spice’’ products possesses approximately a four-
fold higher aﬃnity for the cannabinoid CB1 receptor and a 10-fold
higher aﬃnity for the CB2 receptor. Spice blends better satisfy users’
expectations, in that their psychoactive eﬀects are perceived to be
even stronger than cannabis. They produce psychoactive reinforce-
ment, are highly attractive, perceived as safe drugs and not easily
detectable in urine and blood samples.
Methods : The study focused on quantifying the existence of web-
sites related to synthetic cannabinoid products and aimed at dividing
their positions towards drug use in tree main categories : Anti Drugs,
Pro Drugs and Harm Reduction Approach.
Results : A web mapping developed through the most well-





existence of 61 main websites that shared information about the
‘‘Spice’’ : 43 (70.5%) were Pro Drugs, 13 (21.3%) were Anti Drugs and
5 (8.2%) were Harm Reduction Approach.
Conclusion : Although the internet provides a wide range of infor-
mation about the side eﬀect of the ‘‘Spice’’ and many Countries have
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banned it, there is still an high number of Pro Drugs websites that
actively promotes to consume it. Very limited information is available
on the safety of Spice ingredients in humans and the occurrence of
serious health damage in abusers is highly probable, as is the likeli-
hood of prompting the development of psychotic symptoms and full
psychotic episodes.
jP-02-027jAssociation between risk-taking behavior and
voluntary alcohol intake in male outbred wistar rats
S. Momeni1, E. Roman1. 1Uppsala University, Sweden
Objective : Risk assessment and risk taking versus inhibitory control
are evolutionary conserved behaviors of survival value implicated in
the multifaceted construct of impulsivity. When maladaptive, im-
pulsivity is associated with drug-taking behavior. Previous studies
have shown that locomotor activity in a novel environment is useful
for identifying individuals at risk for excessive intake of drugs of
abuse. In this study we focus on individual diﬀerences in risk-taking
behavior in a novel environment. We hypothesize that high risk-
taking (HRT) animals are prone to higher alcohol intake compared to
low risk-taking (LRT) animals.
Methods : Thirty adult male outbred Wistar rats were tested in the
open ﬁeld test. Based on the percentage duration of time spent in the
central part of the open ﬁeld, animals were divided into HRT or LRT.
For further behavioral proﬁling the multivariate concentric square
ﬁeld
TM
(MCSF) test was used, which includes a variety of zones in-
cluding sheltered, open and elevated areas, exploratory incentives,
areas with diﬀerent illumination, and wall-enclosed corridors. The
rats then had access to 20% alcohol using a two-bottle free-choice
paradigm, with intermittent 24 h access three times per week for ﬁve
weeks.
Results : The results revealed that HRT animals displayed a higher
risk-taking behavior also in the MCSF compared to the LRT animals.
Moreover, HRT rats showed faster acquisition of alcohol intake, ac-
companied by higher alcohol preference. Furthermore, risk-taking
behavior as deﬁned in the open ﬁeld test correlated with alcohol pre-
ference during the acquisition period.
Conclusion : While previous studies have focused on the associ-
ation between locomotor activity and intake or sensitivity to drugs of
abuse, we here demonstrate an association between individual dif-
ferences in risk-taking behavior, of relevance for impulsivity, and
voluntary alcohol intake and preference. The results demonstrate that
screening of individual diﬀerences is a useful strategy in identifying
subgroups of individuals at risk for excessive alcohol intake.
jP-02-028jOverexpression of Shati in the nucleus accumbens
aﬀects the abnormal behavior induced by
methamphetamine in mice
A. Nitta1, Y. Ishikawa1, N. Iegaki1, S.-I. Miuramatsu2, T. Nabeshima3,
Y. Furukawa-Hibi3, K. Uno1, Y. Miyamoto1. 1University of Toyama,
Japan ; 2Tochigi, Japan ; 3Nagoya, Japan
Objective : The abuse of methamphetamine (Meth) has signiﬁcantly
psychiatric and medical consequences, including dependence, psy-
chosis and even death. A novel molecule shati has been identiﬁed
from the nucleus accumbens (NAc) of mice treated with Meth using
the polymerase chain reaction-select complementary DNA subtrac-
tion method. In vivo and vitro studies, shati regulates Meth-induced
dopamine (DA) release. However, it is not clear which brain regions
are involved with the function of shati. In this study, we over-
expressed shati in the NAc or dorsal striatum (dS) of mice speciﬁcally
using adenoassociated virus vectors.
Methods : we overexpressed shati in the NAc or dorsal striatum
(dS) of mice speciﬁcally using adenoassociated virus vectors.
Results : Overexpression of shati only in the NAc suppressed
Meth-induced hyperlocomotion, sensitization and place preference in
mice. Moreover, in vivo microdialysis method revealed that over-
expression of shati in the NAc inhibits Meth-induced increase of DA
release.
Conclusion : These results indicate that shati in the NAc, but
not in the dS, plays an important suppressive role in the establish-
ment of Meth-induced dependence by mediating extracellular DA
levels.
jP-02-029jAssociation between the fyn kinase gene and
patients with methamphetamine psychosis
Y. Okahisa1, S. Sakamoto1, M. Kodama1, M. Takaki1, Y. Mizuki1,
H. Ujike1, Y. Uchitomi1. 1Okayama University Hospital, Japan
Objective : Dysfunction of the N-methyl-D-aspartate (NMDA) re-
ceptor has been considered to underlie the pathophysiology of psy-
chiatric disorder including schizophrenia and substance-induced
psychoses. We previously reported the signiﬁcant associations
between methamphetamine psychosis and several genes, e.g. the
dysbindine gene, the G72 gene, the serine rasemase gene and the
GRIN1 and 2B genes, those are involved in the glutamatergic signal-
ing and NMDA receptor functions. Fyn kinase is a member of the Src
family of tyrosine kinases and mediates phosphorylation of glutama-
tergic NMDA receptor subunits. Previous studies showed that Fyn
is involved in the pathophysiologies of neuropsychiatric disorders,
such as schizophrenia, alcoholism, epilepsy and Alzheimer’s disease.
The FYN gene is localized in the 6q21, which was found in the region
linked to neuropsychiatric disorders. Therefore, we investigated the
association between the FYN gene and methamphetamine psychosis.
Methods : Subjects were comprised of 220 patients and 293 age- and
gender-matched healthy controls. We genotyped three polymorph-
isms, rs706895, rs3730353 and rs6916861, in the FYN gene.
Results : There were no signiﬁcant diﬀerences in genotypic or allelic
distribution of any polymorphism in the FYN gene between the
two groups. Clinical phenotypes of methamphetamine dependence,
e.g. age of ﬁrst consumption, latency from the ﬁrst consumption to
onset of psychosis, complication of spontaneous relapse of psychosis,
and poly-substance abuse status, did not signiﬁcantly associate
with any polymorphism. The three SNPs, rs706895, rs3730353 and
rs6916861, showed linkage disequilibrium with each other. We then
analyzed the 2- and 3-loci haplotype distribution, but no signiﬁcant
diﬀerence was found between patients with methamphetamine de-
pendence and control subjects.
Conclusion : This study suggested that the FYN gene is unlikely to
play a major role in methamphetamine dependence liability and/or
the development of methamphetamine induced psychosis, at least in a
Japanese population.
jP-02-030jAﬀective disorders of adolescent opiate addicts
D. Petrovic1, S. Djukic Dejanovic1, G. Mihajlovic1, M. Jovanovic1,
B. Radmanovic1. 1Clinical Centre Kragujevac, Serbia
Objective : Research and evaluation of aﬀective disorders of
adolescent opiate addicts is the main goal of this paper. Aﬀective
disorders are considered to be the causes of determination to abuse
drugs in adolescence.
Methods : Our sample consisted of 60 subjects Assessment of de-
pression of opiate drug users group and the control group was done
by using the following Depression scale : Hamilton Depression Rating
Scale (HAMD). Scale for the Assessment of neurotic/endogenous
depression-Newcastle (NERS). Self-assessment scale for depression
(Zunge) Montgomery-Asberg Depression Rating Scale (MMPI).
Results : If we analyze the scale for the assessment of depression
in opiate addicts we come to the following results. According to
Becks scale, 55% of respondents expressed marked depression,
while 35% had moderate signs of acute depression. In relation to the
distribution of ﬁndings in the control group, the diﬀerence is of
high statistical signiﬁcance (X2=199.274, p<0.001). According to
Montgomery-Asbergj scale 58.3% were estimated as medium de-
pression, and 15% as marked depression. Distribution ﬁndings to
strong points on the Montgomery-Asberg scale between a group of
opiate addicts and control groups were also statistically signiﬁcant
(X2=116.444 ; p<0.001). According to MMPI scale, higher levels of
depression manifested itself in 56.6% of opiate addicts. Compared
to values in the control group, the diﬀerence is conﬁrmed as highly
signiﬁcant (t=11.42 ; p<0.001).
Conclusion : There is a statistically signiﬁcant correlation between
aﬀective disorders and opiate dependence. Under all experimental
scales used in the research, opiate addicts exhibited marked de-
pression as compared to the control group, signiﬁcantly higher scores
of depression (p<0.01) in 93.3% of respondents were found and
according to the Newcastle scale, in 78.3% of cases, it was a none-
ndogenous depression. According to Zunge scale depression 63.3%
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meets the criteria for hospitalization. Opiate dependence regarding
the degree of depression best discriminate against Hamilton and
Montgomery-Asberg scale.
jP-02-031jHow empathetic are cocaine users? A social
neuroscience approach
K. Preller1, L.M. Hulka1, D. Jenni1, M. Vonmoos1, I. Dziobek2,
B.B. Quednow1. 1University of Zurich, Switzerland ; 2Max-Planck-
Institute for Human Development, Berlin, Germany
Objective : Although it was proposed that social cognition might
play a crucial role in the development and treatment of drug depen-
dence, studies investigating social cognition in drug users are scarce.
Chronic cocaine users display neurochemical and functional altera-
tions in brain areas involved in social cognition (e.g., the medial
prefrontal cortex and the ventral striatum). Therefore, we investigated
mentalizing and empathy abilities in dependent and occasional
cocaine users by means of video-based and photorealistic stimuli of
every-day situations.
Methods : Seventy occasional cocaine users, 37 dependent
cocaine users and 70 drug-naı¨ve control participants completed
the Multifaceted Empathy Test (MET) and the Movie for the
Assessment of Social Cognition (MASC). The MET assesses cognitive
and emotional empathy by the judgement of emotional pictures.
The MASC requires watching a short ﬁlm and answering 45 questions
about the actors’ mental states (Theory-of-Mind, TOM).
Results :Dependent cocaine users performed signiﬁcantly worse on
the cognitive empathy scale of the MET than occasional users and
controls. In the MASC, dependent cocaine users made more mistakes
than occasional users and controls primarily because of exaggerated
perspective taking. Furthermore, lifetime cocaine use was signiﬁ-
cantly correlated with test performance in the MASC. No signiﬁcant
diﬀerences were found between control subjects and occasional co-
caine users.
Conclusion : These results indicate that dependent cocaine users
show impairments in speciﬁc mentalizing abilities. Cognitive empa-
thy seems to be aﬀected more strongly than emotional empathy.
Furthermore, cocaine users mademore errors with regard to excessive
TOM, indicating that they tried to take the perspective of others but
failed. These alterations appear to be associated with the extent
of cocaine consumption. Occasional cocaine users do not show sig-
niﬁcant impairments, but the dose-response correlation reﬂects that
the performance lies on a drug-induced continuum. Impairments in
social functioning in cocaine users should be considered and targeted
in therapy.
jP-02-032jTo assess prevalence of chronic pain among subjects
with alcohol dependence syndrome. To study the
relationship of alcohol use and its eﬀect on pain
J. Rohilla1, G. Desai1, P. Chand1. 1NIMHANS, Bangalore, India
Objective : To assess prevalence of chronic pain among subjects with
alcohol dependence syndrome. To study the relationship of alcohol
use and its eﬀect on pain.
Methods : Patients attending outpatient services of Center for
Addiction Medicine in National Institute of Mental Health and
Neurosciences, Bangalore, India who fulﬁlled the diagnostic criteria
for alcohol dependence syndrome were screened for chronic pain.
Patients having chronic pain were interviewed after obtaining in-
formed consents by following instruments – Semi structured pro-
forma to collect details on demography, pain related details and
questions on relationship of alcohol and pain, Brief pain inventory
and Severity of Alcohol Dependence Questionnaire (SADQ-C). This
study was approved by the institution ethics committee.
Results : Chronic pain was prevalent in 18.2% of subjects with al-
cohol dependence syndrome with 49% of them reporting pain to be of
severe intensity. Use of other substances (nicotine, benzodiazepines,
opioids and inhalants) were found in 96.3% with nicotine use being
most common. Use of alcohol to manage pain in last month was re-
ported by 75% of patients while 62% reported pain as a reason to
continue to use alcohol. Only 34% of patients were currently receiving
treatment for chronic pain and 62% expressed interest in receiving
treatment.
Conclusion : Chronic severe pain was prevalent in subjects with
alcohol dependence syndrome attending an outpatient service.
Signiﬁcant number of them were using alcohol for pain relief and
reporting it to be reason to continue to use alcohol. Few patients were
taking treatment for pain while larger number expressed interest for
eﬀective treatment. Eﬀorts should be made to better address the pain
problems in this patient population.
jP-02-033jBlockade of ventral midbrain NMDA receptors
prevents neurotensin-induced sensitization to
amphetamine
P.-P. Rompre1, D. Levesque2. 1Universite´ de Montre´al, Montreal,
Canada ; 2Universite´ de Montre´al, Faculty of Pharmacy, Montreal, Canada
Objective : Previous studies have shown that neurotensin, an en-
dogenous neuropeptide that modulates limbic neurotransmission,
plays a key role in the development of sensitization to amphetamine-
induced locomotor activity. In this study, we tested the hypothesis
that neurotensin acts within the ventral midbrain to initiate amphe-
tamine sensitization and that this eﬀect is dependent upon activation
of local NMDA receptors.
Methods : Experiments were performed on adult male Long-Evans
rats implanted with bilateral cannulae above the ventral midbrain.
During a ﬁrst initiation period, locomotor activity (ambulatory, non-
ambulatory and vertical movements) was measured in diﬀerent
groups of habituated rats on three occasions, every second day (day 1,
3 and 5), for two hours after bilateral ventral midbrain injections of
vehicle (0.5 ul/side), D-Tyr[11]neurotensin (1.5 nmol/side), RS-CPP
(40 or 120 pmol/side), Ro04–5595 (200 or 1200 pmol/side), RS-CPP
(40 or 120 pmol/side)+neurotensin (1.5 nmol/side) or Ro04–5595
(200 or 1200 pmol/side)+neurotensin (1.5 nmol/side). Five days after
the third injection, on day 10, locomotor responses to a single injection
of amphetamine sulfate (0.75 mg/kg, ip) were measured in all the
animals.
Results : Results show that amphetamine induced signiﬁcantly
stronger locomotor responses (ambulatory, non-ambulatory and ver-
tical activity) in neurotensin pre-exposed animals than in controls
(vehicle pre-exposed). This amphetamine sensitization eﬀect was
prevented by the preferred GluN2A,2B subunit antagonist, RS-CPP,
but not the selective GluN2B antagonist, Ro04–5595 ; the latter rather
slightly enhanced the eﬀect of neurotensin.
Conclusion : These results demonstrate that i) ventral midbrain
neurotensin induces glutamate release to initiate neural changes that
subserve sensitization to the behavioral eﬀects of amphetamine and
ii) this sensitization eﬀect most likely results from activation of ventral
midbrain NMDA receptors that are composed of GluN2A subunits.
Supported by Canadian Institutes for Health Research(CIHR,
Canada).
jP-02-034j Impulsivity in Internet addiction : A comparison
with pathological gambling and healthy controls
J.M. Seol1, J.-S. Choi1, H.W. Lee1, J.-Y. Lee1, H.Y. Jung1. 1SMG-SNU
Boramae Medical Center, Seoul, Republic of Korea
Objective : he present study investigated trait impulsivity in
Internet addiction compared with pathological gambling from the
perspective of considering Internet addiction as an impulse control
disorder.
Methods : Twenty-seven patients with Internet addiction (age,
24.78¡4.37 years), 27 patients with pathological gambling (age,
25.67¡3.97 years), and 27 healthy controls (age, 25.33¡2.79 years)
were enrolled in this study. All patients were treatment-seeking, and
only male subjects were enrolled. Trait impulsivity was measured by
Barratt Impulsiveness Scale-11 and severities of Internet addiction
and pathological gambling were Young’s Internet Addiction Test and
South Oaks Gambling Screen, respectively. Beck Depression
Inventory and Beck Anxiety Inventory were also administered to all
subjects.
Results : We found that the Internet addiction group showed in-
creased level of trait impulsivity, which was comparable to that in
patients with pathological gambling. In addition, severity of Internet
addiction was positively correlated with level of trait impulsivity in
patients with Internet addiction.
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Conclusion : These results provide the evidence that Internet ad-
diction is conceptualized as an impulse control disorder and trait
impulsivity could be a vulnerability marker for developing Internet
addiction.
jP-02-035jEvent-related potentials P300 in patients with
alcohol dependence and pathological gambling
K. Shin1, E. Park2, Y.-S. Choi1. 1St. Andrew´s Hospital, Icheon, Republic of
Korea ; 2 Incheon St. Mary Hospital, Republic of Korea
Objective : This study was designed to evaluate the auditory and
visual event-related potential P300 in the patients with alcohol de-
pendence & pathological gambling.
Methods : Subjects were composed of patients with alcohol depen-
dence (N=24), pathological gambling (N=24) and normal control
(N=24). Topographic auditory & visual event-related potential P300
was measured by ‘‘Oddball paradigm’’, which was known as a stan-
dard method, and was determined by a conventional method, Global
Field Power method.
Results : In patients with alcohol dependence and pathological
gambling, the amplitude of auditory & visual event-related potential
P300 was signiﬁcantly smaller than normal control (p<0.01). The
Auditory P300 between alcohol dependence and pathological gam-
bling had no signiﬁcant diﬀerences in the amplitude and latency. In
patients with pathological gambling, the latency of visual P300 was
signiﬁcantly later in Fz, Cz, Pz than patients with alcohol dependence
(p<0.01).
Conclusion : It suggests that patients with alcohol dependence
and pathological gambling have brain dysfunction in some neuro-
physiological aspects. In patients with pathological gambling, the
latency of visual P300 was signiﬁcantly later in Fz, Cz, Pz than patients
with alcohol dependence, and this result suggest that patients with
pathological gambling may have more impairment in cognitive func-
tion than patients with alcohol dependence.
jP-02-036jOveruse and abuse of diphenoxylate hydrochloride
three case report
R. Sidana1, A. Sidana1, N. Chadha1. 1TCSM Psychiatric Hospital,
Sriganganagar, India
Objective : diphenoxylate hydrochloride is an opiate derivative used
for treatment of acute diarrhea to be relative safe and with low abuse
potential.in last few years we have come across young adults taking
heavy doses of diphenoxylate hydrochloride and physically depen-
dent on it.
Methods : we report 3 cases where the subjects were taking
>100 tablets of diphenoxylate hydrochloride per day.
Results : we report 3 cases where the subjects were taking
>100 tablets of diphenoxylate hydrochloride per day.all of them
started taking the drug when they were trying to stop opiates 2
of them were using multiple substance of abuse.surprisingly the
withdrawal symptoms were mild in spite of heavy doses.yawning,
watering eyes,legs pain,sleep disturbance,none of them presented
with diarrhea.
Conclusion : implication of the study and review of literature will
be discussed in detail.
jP-02-037j (-)-OSU6162 potentiates amphetamine-mediated
eﬀects in habituated but not in novel environments
A. Sierakowiak1, A. Bonito-Oliva2, S. Ferre´3, L. Olson2, A. Carlsson4,
G. Fisone2, S. Brene´5. 1Karolinska Institutet, Dept. of Neurobiology,
Solna, Sweden ; 2Karolinska Institutet, Neuroscience, Stockholm, Sweden ;
3National Institute of Health, NIDA, Baltimore, MD, USA ; 4Go¨teborgs
Universitet, Inst. of Neuroscience and Physiology, Go¨teborg, Sweden ;
5Karolinska Institutet, NVS, Stockholm, Sweden
Objective : (-)-OSU6162 is a substance belonging to a new class
of drugs, termed ‘‘dopamine stabilizing drugs’’. (-)-OSU6162 binds
with low aﬃnity to the dopamine D2 receptor and causes diﬀerent
behavioral responses when administered in novel compared to habi-
tuated environments. Here we characterized the environmental im-
pact on the interaction of (-)-OSU6162 and amphetamine.
Methods : The locomotor response to (-)-OSU6162 or amphetamine
themselves and the combination of the two were measured in animals
given the drugs in habituated or novel environments. Immuno-
histochemistry and in situ hybridization was used as to analyze levels
of protein and mRNA, respectively, of the immediate early gene
c-fos in rats and mice after administration of (-)-OSU6162 and
amphetamine.
Results : The behavioral studies showed that (-)-OSU6162 increased
locomotion in animals habituated to their home cages, but not in
animals given the drugs in a novel environment. (-)-OSU6162
caused a dose dependent increase of c-fos mRNA in striatum and
nucleus accumbens in habituated animals, with a more homogenous
induction compared to amphetamine, which was strongest in
medial parts. Protein levels of c-Fos were elevated in medium spiny
dopamine D1-receptor neurons of the dorso-lateral striatum after
(-)-OSU6162 itself and even more elevated in the group receiving
(-)-OSU6162 thirty minutes prior to amphetamine in their home
cages.
Conclusion : Locomotion tests in rats given (-)-OSU6162 in com-
bination with amphetamine show that (-)-OSU6162 attenuates
amphetamine-mediated locomotion in a novel environment, but has
an opposite eﬀect in habituated animals. The c-Fos expression
indicated that (-)-OSU6162 has an impact on D1-receptor medium
spiny neurons in habituated animals, even though the eﬀect is most
likely not directly mediated via D1 receptors as no binding aﬃnity has
been reported for (-)-OSU6162 on D1-receptors.
jP-02-038jThe dopamine stabilizer (-)-OSU6162 attenuates
voluntary ethanol intake and ethanol-induced
dopamine output in the nucleus accumbens
P. Steensland1, I. Fredriksson1, S. Holst1, K. Feltmann1, J. Franck1,
B. Schilstro¨m1, A. Carlsson2. 1Karolinska Institutet, Stockholm, Sweden ;
2Sahlgrenska Academy, University, Gothenburg, Sweden
Objective : New medications for alcohol use disorder (AUD) are
needed. ‘‘Dopamine stabilizers ’’ is a new class of compounds
characterized by the ability to suppress, stimulate, or show no eﬀect
on dopamine activity depending on the prevailing dopaminergic
tone. Thus, they may be hypothesized to normalize dysregulated
dopamine activity induced by, for example, long-term alcohol con-
sumption.
Methods : The eﬀects of acute and repeated treatment of the dopa-
mine stabilizer (-)-OSU6162 (OSU6162) was evaluated in rats given
intermittent-access to 20% ethanol for at least three months before
treatment. OSU6162’s eﬀect on ethanol seeking, using the operant self-
administration paradigm, was also evaluated. Furthermore, we stud-
ied the interaction of OSU6162 with ethanol on dopamine output and
metabolism in awake rats, using microdialysis.
Results : OSU6162-treatment selectively decreased voluntary etha-
nol consumption and preference without decreasing intake of water
or a salty solution. The eﬀect on ethanol intake was more pronounced
in rats voluntarily consuming high compared to moderate amounts of
ethanol. There was no tolerance development to OSU6162’s ability to
decrease ethanol intake during repeated OSU6162 treatment and no
rebound increase in ethanol intake after the treatment was terminated.
We found that pretreatment with OSU6162 blunted the ethanol-
induced dopamine output in the nucleus accumbens.
Conclusion : These results highlight OSU6162’s ability to stabilize
dopamine activity depending on the prevailing dopaminergic tone
and indicate that OSU6162 might decrease ethanol intake by attenu-
ating the acute rewarding properties of ethanol. The present study is
to our knowledge the ﬁrst indicating that OSU6162 may serve as a
novel medication for AUD.
jP-02-039j Inﬂuence of GIRK channel inhibition on relapse
risk in Japanese alcohol-dependent inpatients
N. Sugaya1, Y. Ogai2, Y. Kakibuchi3, E. Senoo4, K. Ikeda5. 1Tokyo,
Japan ; 2University of Tsukuba, Ibaraki, Japan ; 3Narimasu Kousei
Hospital, Tokyo, Japan ; 4 IPMCP, Ibaraki, Japan ; 5TMIMS, Tokyo, Japan
Objective : We examined the inﬂuence of G-protein-activated
inwardly rectifying K+ (GIRK) channel inhibition on relapse risk in
Japanese alcohol-dependent inpatients.
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Methods : The participants included 11 patients who received GIRK
inhibition treatment and 39 patients who did not receive GIRK inhi-
bition treatment. The participants answered a questionnaire, includ-
ing the Alcohol Relapse Risk Scale (ARRS) and a questionnaire about
their experiences of stressful events 2 weeks after hospitalization
(time 1) and completed follow-up questionnaires 45–60 days after the
ﬁrst rating (time 2).
Results : A signiﬁcant interaction was found between group and
time on positive expectancy for alcohol scores on the ARRS (F=5.93,
p=0.02). The simple main eﬀect test showed that the scores at time
1 in the GIRK inhibition treatment group were higher than in the
non-GIRK inhibition treatment group (p=0.03). The scores at time 1
were higher than that at time 2 only in the GIRK inhibition treatment
group (p=0.004). Signiﬁcant main eﬀects of time were found on total
ARRS score (F=5.10, p=0.03) and stimulus-induced vulnerability
score on the ARRS (F=7.28, p=0.01), and these scores at time 1 were
higher than at time 2. No signiﬁcant interaction was found between
group and time, with no main eﬀect of either factor on the experience
of stressful events.
Conclusion : The results of the present study suggest that GIRK
inhibition treatment may improve the positive expectancy for alcohol,
a component of relapse risk. However, the lower positive expectancy
scores in patients who did not receive GIRK inhibition treatment
at time 1 may be responsible for the lack of changes in positive
expectancy scores. Although this result should be interpreted with
caution, the present study suggests that the eﬀects of GIRK inhibition
treatment should be investigated further in future studies.
jP-02-041jUsage of xenon for relief of acute abstinent
syndrome in the treatment of drugs addiction
B. Tsygankov. Mos State Medical Stom University, Moscow, Russia
Objective : The purpose of this study was to evaluate the clinical
eﬃciency and safety of xenon therapy in the treatment of patients with
opium dependence during abstinent syndrome. In the treatment of
80 patients with opium dependence was included inhalation of xenon
via anesthetic machine «Drager» «Fabius» (Germany) in a ratio of
Xe : O2=4 : 4 l/min.
Methods : Assessment of the severity of abstinent syndrome
and the eﬀectiveness of the therapy was conducted using clinical-
psychopathological method based on a specially designed scales
daily during 15 days. During each treatment session was monitored
ECG, blood pressure, dynamics of consciousness change, time to
reach the desired level of anesthesia, duration of rest after anesthesia.
Therapy sessions were held 3–4 times in the 1st day, 2 times dur-
ing the 2nd day and once in the next 3 days. The whole course re-
quired 9–10 sessions of 40 minutes. The average time to reach the
desired level of anesthesia coincided with clinical improvement of
the patient.
Results : The clinical study showed that Xenon has analgesic eﬀect
and reduces the aﬀective, astenic and behavioral disorders of patients
with opium dependence. Xenon inhalations does not aﬀect hemo-
dynamics and respiration, therefore, is safe. The therapy that included
course of Xenon inhalations was more successful for patients with
opium abstinence syndrome, than therapy without this course. When
repeating inhalation the tolerance to Xenon does not increase, like for
other analgesics and psychotropic drugs, but decreases.
Conclusion : This phenomena authentically matches the clinical
improvement of patient’s condition and may be used as a test for
severity of opium abstinent syndrome. Usage of Xenon inhalations for
patients with opium dependence allows to relief faster the manifes-
tation of disease and reduce attraction for the drug.
jP-02-042j Inﬂuence of the family on the inclination to use
alcohol, toxic and narcotic substances in teenagers
E. Valzdorf. Irkutsk, Russia
Objective : 50 reports of the Commission of forensic psychiatric
experts over the period from January 2004 to December 2006 were
analyzed. The forensic psychiatric examination was carried out on
an outpatient basis. The analysis showed that the ﬁfty examined
teenagers included 46 male and 4 female teenagers aged between
15 and 18.
Methods : The research is based on the statistical method along
with the analysis of data of forensic psychological – psychiatric and
forensic psychiatric examinations.
Results : The research revealed the following factors leading to
consumption of alcohol, toxic and narcotic substances : group 1(14
persons), – a one-parent family, where the child was raised by one
parent who did not abuse alcohol, group 2 (14 persons) – a one- parent
family in which the parent abused alcohol, group 3 (5 persons) –
teenagers who do not have parents and close relatives, group 4
(4 persons) – families with both parents abusing alcohol. At the same
time 12 of 50 individuals had secure families (they were brought up
by both parents who did not abuse alcohol). In group 1, 4 teenagers
used alcohol, 5 – inhaled vapors of toxic substances, 2 – used drugs.
In group 2, 3 individuals used alcohol, 4 – inhaled vapors of toxic
substances, 2 – used drugs. In group 3 all teenagers used alcohol. In
group 4 one person used alcohol, 1 – used drugs. However, even
among the individuals who were brought up in secure families still
there were 3 inclined to alcohol abuse and 2 – to drug abuse.
Conclusion : the teenagers raised in the families with one parent
no matter if he/she abused alcohol or not, are more inclined to con-
sumption of alcohol, drugs and other toxic substances. It should also
be noted that the family security is not an absolute indicator for the
absence of inclination to commit criminally punishable acts and abuse
alcohol and narcotic substances.
jP-02-043jNaltrexone eﬀectiveness in alcohol dependence with
comorbid cluster B personality disorders
D. Vasile1, O. Vasiliu1, M. Blandu1, D.G. Ojog1. 1Military Emergency
Hospital, Bucharest, Romania
Objective : To evaluate the eﬃcacy and tolerability of naltrexone use
in patients with dual diagnosis- alcohol dependence and cluster B
personality disorder.
Methods : A group of 32 patients, 19 male and 13 female, mean age
35.7, admitted in our department for alcohol dependence, were also
diagnosed with cluster B personality disorders (antisocial n=9, bor-
derline n=10, histrionic n=10, narcissistic n=3) according to the
DSM IV TR criteria. Patients presented a documented history of al-
cohol dependence of at least 2 years prior to the baseline evaluation,
with no more than one hospitalization for speciﬁc treatment in the last
24 months. The diagnosis of personality disorder was based upon
Structured Clinical Interview for DSM IV Disorder (SCID –II) and
clinical psychiatric evaluation. Patients received naltrexone
50 mg/day, single dose daily, after the initial detoxiﬁcation period
(mean duration 8.5 days). Patients were monitored using every
4 weeks for 6 months Inventory of Drug Taking Situations- alcohol
focused version (IDTS), Global Assessment of Functioning (GAF) and
Clinical Global Impressions –Severity and Improvement (CGI-S/I).
Results : At week 24, patients had an overall improved IDTS
score (x49.1 points to baseline, p<0.01), with greater improvements
observed in areas like ‘‘physical discomfort ’’ (p=.0422) and ‘‘ testing
personal control ’’ (p=.0324). GAF values increased in the treatment
group with 28.5 points, compared to baseline. CGI-I decreased from
a mean value of 4.8 to 1.2 at week 24. A number of 7 patients dis-
continued treatment due to adverse events (vomiting, nausea, ab-
dominal pains, n=4) or non-compliance (n=3). Mild and moderate
adverse events were reported in 12 patients, especially gastro-
intestinal discomfort and anxiety.
Conclusion : Naltrexone is a good therapeutic option in alcohol
dependent patients with cluster B personality disorder, because of
its eﬃcacy and low rate of adverse events. Naltrexone decreased sig-
niﬁcantly alcohol consumption in situations of ‘‘physical discomfort ’’
and testing of personal control.
jP-02-044jPathological gambling and maintenance of attention
E.J. Verdura Vizcaino1, P. Ferna´ndez Navarro2, G. Rubio Valladolid1,
I. Martinez Gras1, L. Del Nido1, I. Castillo1, G. Ponce1, C. Blanco3.
1Hospital 12 de Octubre de Madrid, Madrid, Spain ; 2Carlos III Institute of
Health, Madrid, Spain ; 3Columbia University, NYSPI, New York, USA
Objective : Pathological Gambling (PG) is a persistent and recurrent
maladaptive pattern of gambling behavior characterized by increased
preoccupation with gambling activities, loss of control and continued
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gambling despite problems in social or occupational functioning.
In the study of addiction, attentional bias (AB) refers to the obser-
vation that substance-related cues tend to capture the attention of
experienced substance users. This concept is based on Robinson and
Berridge’s incentive-sensitization theory, which suggests that the
substance and its associated cues increase their motivational incentive
and salience with each new administration. In this study we sought to
assess AB at the level of maintenance of attention in a sample of
Pathological Gamblers (PGRs). We build on prior work by using the
Visual Probe Task (VPT), previously used to assess individuals with
substance use disorders.
Methods : PGRs (n=23) were recruited from two 12-step programs
for PGRs in Madrid (Spain). The comparison group of healthy
volunteers (non-gamblers ; NG) (n=21) was recruited through ad-
vertisements. The procedure for the Visual Probe Task was based on
that of Lubman (Lubman et al., 2000).
Results : The reaction time of individuals with PGwhen the dot was
in the same location as the gambling-related cue was signiﬁcantly
lower than the reaction time when the dot and the gambling-related
cue were in diﬀerent locations, indicating the presence of AB
(t=x3.9, df=22, p=0.001). By contrast, in the group of healthy vo-
lunteers, reaction times did not diﬀer signiﬁcantly (t=x0.5, df=20,
p=0.6). The reaction times were signiﬁcantly slower in individuals
with PG than in healthy volunteers.
Conclusion : Our ﬁnding that PGRs have AB for gambling-related
cues is consistent with prior studies that have shown AB at early
attentional process, but extend them by assessing maintenance of
attention.
jP-02-045jMorphine excites dopamine neurons(da) in ventral
tegmental area(vta) : The gating role of prefrontal
cortex(pfc)
X. Zhen. Soochow University, Suzhou, China
Objective : We studied the gating role of PFC in morphine-excited
DA neurons in VTA.
Methods : use of in vivo single unit recording techniques and
microdylysis to study how PFC regulates VTADA neurons in rats in
response to morphine.
Results : We found that morphine markedly increased DA cell
activity. The eﬀect of morphine can be reversed and prevented by
naloxone, suggesting that the eﬀect is associated with the activation
of mu opiate receptor. Lesion of PFC by tetradotoxin produced no
signiﬁcant inﬂuence on basal DA cell activity in naı¨ve rats. However,
PFC lesion abolished the morphine’s eﬀects on DA cells, accordingly,
the morphine – stimulated DA content in NAc was also abolished.
This indicates that the PFC is critical in mediating the morphine’s
excitation on DA neurons and that the PFC might play a gating role
in morphine’s eﬀect on DA cells. Interestingly, in rats pretreated with
morphine 24 hours before morphine challenge, the gating role of
PFC disappeared. It thus appeared that morphine -enhanced DA
neuronal ﬁring is independent of the function of PFC in rats that
previously exposed to morphine. Furthermore, we found that mor-
phine inhibited PFC pyramidal neurons in all recorded cells in naı¨ve
rats. Whereas only 46% (7 in 15) recorded pyramidal neurons was
inhibited by morphine challenge in rats that were previously exposed
to morphine.
Conclusion : our data provided evidences that the PFC play a gat-
ing role in acute morphine’s eﬀect on DA neurons, The underling
mechanism may attribute to morphine – inhibited PFC pyramidal
neurons which leads to the reduced output. However, single mor-
phine pretreatment resulted in loss of the gating eﬀect of PFC, which
may associated with the single morphine-induced dysinhibition on
PFC neurons.
P-03. Bipolar Disorders
jP-03-001jAssociation of metabolic syndrome and clinical
outcome among patients with bipolar disorder
Y.M. Bai. Taipei Veterans General, Hospital, Taiwan
Objective : Bipolar disorder is with high prevalence of metabolic
syndrome, ranged from 32% to 50%. However, the inﬂuence of
metabolic syndrome for clinical outcome is not clear. This
study evaluated the association of metabolic syndrome for clinical
outcome among symptomatically stable outpatients with bipolar
disorder.
Methods : The patients aged between 18 to 65 years with DSM-IV
diagnosis of bipolar disorder and with clinical global severity less
than 3 were enrolled. Metabolic syndrome was surveyed and clinical
symptoms, side eﬀects, insight, function, life quality, and cognitive
executive function were assessed.
Results : The study enrolled 84 patients with 71.4% of female, and
average age of 43.9¡12.2 years old. The prevalence of metabolic
syndrome was 34.5%. The patients with metabolic syndrome tended
to have elder age (48.5¡11.5 vs. 41.5¡11.9, p=0.084), education years
less than 12 years (75.9% vs. 56.4%, p=0.098), higher frequency of
ﬁrst episode with manic episode (55.6% vs. 33.3%, p=0.092), more
hospitalization times (4.2¡3.8 vs. 2.8¡3.5, p=0.067),more extra-
pyramidal side eﬀect by Simpson and Angus rating scale (4.03¡5.5
vs. 2.0¡3.9, p =0.076), poorer insight by Schedule Assessment of
Insight (15.7¡5.1 vs. 19.1¡3.7, p=0.006), poorer quality of mental
health (41.6¡11.1 vs. 35.2¡12.4, p=0.023), and poorer executive
function of Wisconsin card sorting test percent of conceptual level
response (29.0¡11.3 vs. 38.2¡12.6, p=0.014).
Conclusion : The prevalence of metabolic syndrome was high to
one third, and associated with poorer clinical outcomes, including
more hospitalizations, more side eﬀects, poorer insight, poorer quality
of mental health and poorer cognitive executive function. Monitoring
metabolic syndrome is important for patients with bipolar disorder.
Policy of full disclosure : The study was sponsored by Taiwan
National Science council (NSC 99–2628-B-075–004 -MY3), there is no
ﬁnical conﬂict of interest.
jP-03-002jCorrelation among impulsivity, temperament,
character and neurocognitive performance in
euthymic bipolar patients
D. Bordalejo1, O. Boullosa2, E. Hadid2, L. Herbst3, M. Puricelli1,
E. Romero2, L. Tannenhaus2, A. Vieitez2, G. Vazquez4. 1Cinep, Buenos
Aires, Argentina ; 2Cinep, Universidad de Palermo, Buenos Aires,
Argentina ; 3Hospital Borda, Buenos Aires, Argentina ; 4Universidad de
Palermo, Buenos Aires, Argentina
Objective : To investigate the prevalence of clinical impulsivity and
its correlation with personality traits, aﬀective temperaments and
neuropsychological performance in bipolar disorder outpatients com-
pared with healthy controls.
Methods : A sample of 63 adult (aged o18–65 years) outpatients
who fulﬁlled DSM-IV-TR criteria by SCID-I interview for bipolar dis-
order were included. All bipolar patients fulﬁlled clinical criteria for
euthymia [YMRS ratings <6 and HAM-D ratings <8] and also did
not meet criteria for DSM-IV mood episodes for at least 8 weeks before
entry to the sudy. Healthy controls (N 40) did not meet criteria for any
axis I (SCID-I). Strict exclussion criteria were used. All subjects com-
pleted a standard neurocognitive battery and personality traits were
determined by the Temperament and Character Inventory.
Impulsivity was assessed using the BIS-11. Aﬀective temperaments
were evaluated using the TEMPS-A Buenos Aires.
Results : Euthymic bipolar disorders subjects demonstrate signiﬁ-
cant diﬀerences on the Barratt Impulsivity Scale (BIS-11) subitems
and total scores compared with healthy controls. However, there
were no statistical diﬀerences in impulsivity scores between both
subgroups of patients (bipolar I vs. II). We found a positive correlation
between impulsivity scores and sensation seeking and a negative
correlation with self-directedness, measured by TCI. Euthymic
bipolar disorder individuals displayed signiﬁcant higher scores
on cyclothymic temperament and demonstrated impaired neu-
ropsychological functioning across almost all domains, mainly
executive function, attention and memory tasks, compared with
healthy controls.
Conclusion : Preliminary results show that trait-like impulsivity
was substantially higher in subjects with bipolar disorder than in
healthy comparison subjects, regardless of symptoms. Within subjects
with bipolar disorder during euthymia, high impulsivity scores were
associated with speciﬁc personality traits, cyclothymic and anxious
temperament and generalized impairment on neuropsychological
functioning.
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jP-03-003jThe risk of insulin resistance and type 2 diabetes
mellitus in bipolar disorder
C. Calkin1, M. Ruzickova1, C. Slaney1, J. Garnham1, M. Alda1.
1Dalhousie University, Halifax, Canada
Objective : Patients with bipolar disorder (BD) have up to a three
times increased risk of type 2 diabetes mellitus (T2D). The prevalence
of insulin resistance (IR) in BD, however, has not been systematically
studied. The possible links between aberrant glucose metabolism and
BD include treatment, lifestyle, neuroendocrine and neurotransmitter
dysfunctions, and genetic predisposition. This study aims to establish
the rate of IR in patients with BD and examine the correlates of
abnormal glucose metabolism with the course and outcome of BD,
including response to treatment and medical outcomes. We hypothe-
size that subjects with co-morbid T2D/IR will have a more refractory
form of BD than those without T2D/IR, as well as poorer response to
treatment.
Methods : Patients for this study are being recruited from
The Maritime Bipolar Registry and Mood Disorders Clinic, reﬂecting
primary and tertiary samples of BD respectively. The diagnosis of T2D
is determined according to two measures of fasting plasma glucose
(FPG) and OGTT if still equivocal. Fasting serum insulin and FPG is
used to determine HOMA-IR to quantify insulin resistance in those
with normal FPG.
Results : To date, 64 subjects have been included in the study ;
with diagnoses of BD I, II and NOS and age range of 24–85 years. Only
50% of all patients had euglycemia, 29.7% have IR and 20.3% T2D. In
a preliminary analysis, patients with T2D had signiﬁcantly higher
rates of psychosis during mood episodes than euglycemic patients
(p=0.04).
Conclusion : In agreement with previously reported increased rates
of T2D in BD, our preliminary results showed an increased proportion
of T2D in BD. In addition, only half of bipolar patients had eu-
glycemia ; the rest of the sample showed some abnormality in glucose
metabolism. Our completed study will look at the correlates of ab-
normalities in glucose metabolism, various clinical characteristics,
prognosis and outcome.
Policy of full disclosure : Capital District Research Fund.
jP-03-004jBipolar disorders in emergency departments in
Latin-America : Prevalence and associated
comorbidity
R. Castilla-Puentes1, R. Secin2, R. Galeno3, A. Grau-Martinez4,
J. Ospina-Duque5, A. Camacho6, W. Castilla-Puentes7, S. Castilla-
Puentes8, J. Tellez-Vargas9, C. Leon-Andrade10. 1Temple University,
Philadelphia, USA ; 2Hospital Angeles del Pedregal, Mexico City, Mexico ;
3 Instituto de Neurociencias, Mendoza, Argentina ; 4Hospital Jose´ Horwitz,
Santiago de Chile, Chile ; 5Universidad de Antioquia, Medellin, Colombia ;
6University of Califonia, San Diego, USA ; 7Hospital Regional de
Duitama, INSA-Colombia, Colombia ; 8Hospital Regional de Duitama,
Hospital de Yopal, Colombia ; 9Psiquiatria Biologica, Bogota, Colombia ;
10Hospital Metropolitano, Quito, Ecuador
Objective : To investigate prevalence rates of BPD and associated
comorbidity in ED in Latin American countries.
Methods : To identify patients with BPD, we used a combination
of DSM IV-criteria interview and the Mood Disorder Question-
naire (MDQ). We analyzed data from patients from hospitals
in Argentina, Brazil, Chile, Colombia, and Mexico and described
the demographic and comorbidity between BPD and non-BPD
patients.
Results : The estimate was based on a total of 1,535 patients, mean
age 37 years, with response rates of 83.0%. Prevalence of BPD ranges
from 3.8–6.0%. Compared to non-BPD patients, BPD patients were
more likely to be obese (39.7% vs. 26.9%) and to report a diagnosis of
asthma (16.7% vs. 9%), thyroid problems (12.8% vs. 5.8%) and sei-
zures (23.1% vs. 3.0%), all pf0.05. BPD patients versus those without
BPD were also diﬀerentiated in their psychiatric comorbidity as fol-
lows : higher rate of alcohol abuse (30.8% vs. 10.0%), ADHD (50.0%
vs. 12%), depression (81.6% vs. 45.7%), OCD (20.1% vs. 3.0%), panic
disorders (23.1% vs. 12.3%) and other anxiety disorders (82.1% vs.
41.8%). Compared to non-BPD, suicidal plans and attempts were
also signiﬁcant higher in the bipolar group (11.5% vs. 2.8% and 10.3%
vs. 1.8% respectively). Multivariate analysis identiﬁed ADHD,
anxiety, depression, alcohol abuse, and last month suicide plan and
attempts to be independently associated with BPD.
Conclusion : Our data suggest that the prevalence of BPD is elev-
ated among ED patients in Latin American countries. BPD patients
in ED are likely to have complex psychiatric, and medical histories,
which will be necessary to take into account when evaluate and
design ED-initiated interventions.
Policy of full disclosure : Dr. Castilla-Puentes is currently working
as Global Medical Safety Physician with Johnson & Johnson,
Pharmaceutical Research and Development.
jP-03-005jThe HCL-32 is a usefull tool in diﬀerentiating
bipolar disorder from borderline personality
disorder
M. Cetkovich1, J.C. Marengo2, P. Lopez2, D. Cardona1, J. Bustin2,
F. Doria Medina3. 1 INECO, Buenos Aires, Argentina ; 2 INECO, Favaloro
University, Buenos Aires, Argentina ; 3Favaloro University, Buenos Aires,
Argentina
Objective : The selection of an adequate treatment strategy depends
on an accurate diagnosis. A complex challenge in clinical practice
is the diﬀerential diagnosis between bipolar disorder (BD) and
borderline personality disorder (BPD). Previous studies suggest that
phenomenologically, hypomania in BD is dissimilar to aﬀective in-
stability in BPD. Hence, a tool that discriminates hypomania form
aﬀective instability could aid in this diﬃcult diﬀerential diagnosis.
The HCL-32 is a ten minutes self administrated scale for the screening
of hypomania. The aim of this study is to determine the usefulness of
the HCL-32 in diﬀerentiating BD from BPD patients.
Methods : Patients with a diagnosis of BPD (n=20) and BD (n=33)
were assessed using the HCL-32. The diagnosis of BPD or BD was
established by two clinicians with a vast experience in these disorders
and blinded to the results of the HCL-32. Both groups were compared
using one way ANCOVA, controlling for anxiety trait and depression.
All statistical analyses were performed using the SPSS 17.0 software
package.
Results : Non signiﬁcant statistical diﬀerences were found in
demographic variables between the two groups. The group of patients
with BD scored higher on the HCL-32, even when controlling for
anxiety and depression (ps<0.001).
Conclusion : These results suggests that HCL-32 could be a very
useful instrument helping to diﬀerentiate BPD patients from BD
patients.
jP-03-006jUtility of the INECO frontal screening (IFS) for the
detection of executive dysfunction in patients with
bipolar disorder
M. Cetkovich1, S. Baez1, H. Urquina2, E. Gleichgerrcht1, A. Perez1, A.
Lischinsky3, M. Roca3, F. Manes3, T. Torralva3. 1 INECO, Buenos Aires,
Argentina ; 2Favaloro University, Buenos Aires, Argentina ; 3 INECO,
Favaloro University, Buenos Aires, Argentina
Objective : Bipolar Disorder (BD) patients present not only changes
of mood, but also cognitive deﬁcits, even during euthymic periods.
These cognitive deﬁcits include important executive functioning
failures. The detection of executive dysfunction usually requires the
administration of an extensive neuropsycological battery, because
there are few screening tests speciﬁcally designed to assess executive
functions. The INECO Frontal Screening (IFS) is as solid and brief
tool, which has proved useful for the assessment of the executive
functions in patients with dementia. The aim of this study was to
assess the utility of the IFS to detect executive dysfunction in BD
patients.
Methods : A total of 46 subjects, 20 of which were diagnosed with
BD, and 26 of which were healthy controls, were assessed with
classical executive tests and the IFS. The cutoﬀ score was established
by the analysis of the ROC curve (Receiver Operating Characteristics).
Results : The IFS total score was signiﬁcantly lower in patients
(M=24.40) compared with controls (M=26/30). A cutoﬀ of 26/30
points on the IFS was associated with a sensitivity of 73% and speci-
ﬁcity of 68.4%. Also, the IFS total score correlated with performance
on classical executive tests (Phonological ﬂuency task >r=0.03
<TMT-B : r=0.69, p=0.00 ; digits backwards span r=0.63, p=0.00 ;
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letters and number sequence : r=0.48, p=0.001 ; arithmetic : r=0.49,
p=0.001).
Conclusion : The IFS is a solid and useful tool for the detection of
executive dysfunction in BD patients.
jP-03-007jAltered feedback-related negativity in bipolar
patients performing probabilistic reward learning
H.-S. Cho1, V. Ryu2, R. Ha1, S. Lee1, T. Kim1. 1Yonsei University,
Gwangju-Gyeonggido, Republic of Korea ; 2Konyang University, Daejon,
Republic of Korea
Objective : Bipolar patients have the manic symptoms of grandiosity,
increased goal-directed activity and excessive involvement in
pleasurable activity indicating reward learning and behaviors.
Feedback-related negativity (FRN) is elicited by positive feedback and
appears as relatively more positive ERP deﬂection. We investigated if
bipolar patients show impairments in adjusting behavior during and
to examine the feedback-related negativity during reward learning
process using probabilistic reward task.
Methods : We recruited 20 manic and 15 euthymic patients, and
26 healthy controls. We recorded the FRN to reward feedback while
performing a probabilistic reward task. This task was designed to
facilitate to make the response bias with signal-detection theory,
which was consisted with three blocks.
Results : In response bias analysis, repeated measures ANOVA re-
vealed the main eﬀect of block (p=0.04) and interaction of response
bias and group (p=0.05). In FRN amplitude analysis, repeated
measures ANOVA revealed the main eﬀect of block (p=0.05). While
FRN amplitudes were not diﬀerent between block 1 and 3 in healthy
controls (p=0.90), FRN amplitudes in block 3 were more negative
than that in block 1 in bipolar patients (p=0.01).
Conclusion : Bipolar patients appeared to have the impaired
acquisition of response bias and reduced FRN amplitude toward the
more frequently rewarded stimuli. These results suggest that bipolar
patients might have the dysfunctional reward learning over time and
are related to the reduced electrophysiological activity during reward
learning process.
Policy of full disclosure : This study was supported by grant
A101915 from the Korea Healthcare Technology R & D Project,
Ministry of Health & Welfare, Republic of Korea.
jP-03-008j Impaired cognition in bipolar I disorder : Searching
for a biological substrate
Y.-H. Chou1, S.-J. Wang1, J.-F. Lirng1. 1Taipei Veterans General Hospital,
Taiwan
Objective : It has been proposed that cognitive deﬁcit could be found
in bipolar I disorder (BDI) patients across diﬀerent mood state. The
goal of this study was designed to replicate precious ﬁndings in cog-
nitive deﬁcit in euthymic BDI patients and further explore the possible
underlying substrates.
Methods : Thirty-three age, education matched healthy controls
(HC) and twenty-three euthymic BDI patients who met the criteria of
DSM-IV-TR were recruited. The deﬁnition of euthymia was that
Montgomery-Asberg Depression Rating Scale (MADRS) scores less
than 10 and Young Mania Rating Scale (YMRS) scores less than
7 within an 8-week consecutive period. Single photon emission
tomography (SPECT) with radiotracer 123I-ADAM was used for the
image of brain serotonin transporter (SERT). Speciﬁc uptake ratio
(SUR) was determined for the measured outcome. Ten ml venous
blood was drawn when subject underwent SPECT for the measure-
ment of brain derived neurotrophic factor (BDNF).
Results : we found that SERT binding in both the midbrain and
striatal regions was decreased in patients than that in HC. However,
BDNF was not diﬀerent in both groups. There was no correlation of
SERT binding and BDNF. Although there were statistic signiﬁcantly
diﬀerent in several sub-items of facial memory and Wisconsin Card
Sorting Test (WCST) between patients and HC, the overall deﬁcit in
cognition were not signiﬁcantly correlated with SERT binding and/or
BDNF.
Conclusion : we replicated previous ﬁndings which showed
the deﬁcit of cognition in BDI patients. However, the underlying
substrates of cognitive deﬁcit may be beyond SERT and BDNF.
jP-03-009jThe change of cholsterol level and impulsiveness
after pharmacotherapy in patients with bipolar
disorder
M.Y. Chung1, S.H. Kang2. 1Seoul Veterans Hospital, Republic of Korea ;
2Seoul National University Hospital, Republic of Korea
Objective :Many Studies supported signiﬁcant relationships between
low cholesterol levels and impulsiveness, aggression and mood. In
this study, we investigated the association between total cholesterol
levels and impulsiveness, and evaluated correlation between diﬀer-
ences of total cholesterol level after pharmacologic treatments and
changes of impulsiveness in patients with bipolar disorder.
Methods : Forty patients with bipolar disorder and 40 healthy
normal controls were selected. They were evaluated twice with
Korean version of Young Mania Rating Scale (K-YMRS), Clinical
Global Impression Scale-severity (CGI-S) and Barratt Impulsiveness
Scale (BIS) at admission (pretreatment) and after 6 weeks of treatment
(post-treatment). The pretreatment and post-treatment serum total
cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL) and
high density lipoprotein (HDL) levels in the BD were measured, and
were compared to those of healthy normal controls.
Results : Posttreatment YMRS scores were signiﬁcantly lower than
pretreatment YMRS scores in the patients group. The TC levels were
signiﬁcantly higher in posttreatment patients group than pretreat-
ment group. Posttreatment BIS scores were signiﬁcantly lower than
pretreatment group. But it is found to be no correlation between TC
levels and BIS scores after pharmacotherapy.
Conclusion : Our results supported earlier reports of signiﬁcant
increase in the cholesterol levels when BD patients were treated with
pharmacotherapy for 6 weeks. Although the results in our study are
statistically signiﬁcant, their clinical signiﬁcance requires further
examination in longer-term studies and with larger subjects. Key
words : Total Cholesterol, Barratt Impulsiveness Scale, Bipolar dis-
order.
jP-03-010jBipolar disorder and clarithromycin : More than
a single manic episode
J. Cuevas1, M. Planella1, L. Baladon1, A. Min˜ambres1, M. Fuste1,
M. Ban˜uelos1, A. Iglesias1, M.J. Rodriguez1. 1Parc Sanitari Sant Joan de
Deu, Barcelona, Spain
Objective : To describe the onset of a Bipolar Disorder after being
on treatment with clarithromycin.
Methods : Systematic search of the literature of MEDLINE,
EMBASE, and the Cochrane Library. No references about bipolar
disorders which break out after starting treatment with clari-
thromycin, were found.
Results : A 47-year-old woman with no previous psychiatry or
substance abuse history, was brought to emergency department
because of behavioral disturbances and manic symptoms. One week
before the onset of the illness, the patient had an upper digestive
haemorrhage due to a perforated ulcer. Infection by H pylori was
conﬁrmed, so she started taking clarithromycin, amoxicillin, and
omeprazole 4 days after starting this treatment, she suddenly devel-
oped insomnia, hiperactivity, grandious delusions, irritability, press-
ure speech, tangenciale thinking and increased energy level. She was
admitted in inpatient psychiatry service Clarithromycin was dis-
continued and Olanzapine 20 mg/day was administered from the
beginning. One week after the admission the manic symptoms still
persisted, so Divalproex sodium 2000 mg/day was added. Troughout
the next days an improvement was noted, and manic and psychotic
symptoms gradually dissipated, though expansive mood still per-
sisted. She was discharged after three weeks of hospital stay. One
month later, in the follow-up consultation, the patient still had
hypomanic symptoms. She was diagnosed as Bipolar I Disorder,
Single Manic Episode, Severe With Psychotic Features.
Conclusion : This patient developed an acute manic psychosis
within a 4-day period. There was no evidence of infection, substance
abuse, or hypoglycemia to account for her symptoms. The psychosis
began approximately 3 days after the initiation of triple therapy with
clarithromycin, amoxicillin, and omeprazole for H pylori peptic ulcer
disease. In the reported Clarithromycin-induced manic episodes, a
complete resolution of symptoms in 24 to 36 hours after ﬁnishing
treatment is described [3]. Because of the severity and duration of the
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aﬀective symptoms and the family psychiatry history, the patient was
ﬁnally diagnosed as bipolar disorder.
jP-03-011jAttitudes of investigators and staﬀ toward placebo
response in a global bipolar depression trial
D. Daniel1, A. Loebel2, J. Cucchiaro3, J. Dries4. 1United BioSource
Corporation, Mclean, Virginia, USA ; 2Sunovion, Marlborough,
Massachusetts, USA ; 3United BioSource Corporation, Marlborough, MA,
USA ; 4United BioSource Corporation, Wayne, PA, USA
Objective : Attitudes of clinical trials investigators and site staﬀ were
explored with respect to their ability to inﬂuence placebo response.
Methods : 165 clinical trialists from the US, Central Europe, India
and Japan attending regional industry sponsored investigators’
meetings for a double blind, placebo controlled, bipolar depression
trial were queried regarding their ability to inﬂuence placebo re-
sponse. Associations among responses were evaluated using the chi-
square test statistic.
Results : 69.3% (n=109) had previously received training to reduce
placebo response. 66.2% (n=100) indicated they could inﬂuence
the magnitude of placebo response in a clinical trial ‘‘markedly or
moderately’’, whereas 33.8% (n=51) responded ‘‘slightly’’ or ‘‘not at
all ’’. 75.5% (n=117) disagreed with the notion that ‘‘My role in a
clinical trial includes ensuring that subjects improve clinically ’’,
whereas 24.5% (n=38) agreed. 62.9% (n=95) disagreed that ‘‘ It is
unethical to continue subjects in a clinical trial who are not improv-
ing’’, whereas 37.1% (n=56) agreed. Increased exposure to placebo
response training was associated with : 1) increased conﬁdence that
the individual respondent’s (p<0.01) or the site staﬀ’s (p<0.01) be-
havior can inﬂuence the magnitude of placebo response in a clinical
trial ; and 2) disagreement with the notions that the respondent’s role
in a clinical trial includes ensuring that patients improve clinically
(p<0.001) or that it is unethical to continue subjects in a clinical trial
who are not improving (p<0.05).
Conclusion : A high level of agreement was reported on the im-
portance of placebo response and the ability to inﬂuence it in clinical
trials. While the majority disagreed with the notion that clinical trials
patients should improve clinically, a signiﬁcant minority agreed.
Increased exposure to placebo response training was associated with
increased conﬁdence in the ability to modulate placebo response and
diminished belief that patients should improve during clinical trial
participation. Further research should investigate which approaches
to placebo response minimization are most eﬀective.
Policy of full disclosure : David Daniel and Jean Dries are em-
ployees of United BioSource Corporation (UBC). UBC provided rater
training to the investigators and provided funding for the statistical
analyses. Antony Loebel and Josephine Cucchiaro are employees of
Sunovion. Sunovion conducted the clinical trials noted in the abstract.
jP-03-012jPhenotype deﬁnition and clinical correlates of
antidepressant-induced mania
M. Frye1, S. McElroy2, M. Chauhan3, S. Kung4, K. Harper4, B. Sutor4,
C. Galardy4, S. Crow5, L. Seymour4, I. Johnson4, J. Geske4. 1Mayo
Clinic, Rochester, Minnesota, USA ; 2Lindner Center of HOPE, Mason,
USA ; 3Mayo Clinic Health System, Austin, USA ; 4Mayo Clinic,
Rochester, USA ; 5University of Minnesota, Minneapolis, USA
Objective : Although a random eﬀects meta-analysis showed weak
evidence of association of the S allele with antidepressant induced
mania (AIM+) status, a test of heterogeneity indicated signiﬁcant
diﬀerences in estimated genetic eﬀects. It is likely that phenotypic
variability is a source of heterogeneity. The purpose of this study was
to rigorously deﬁne the AIM+ phenotype and subsequently attempt
replication of previous association of AIM+with variation in the
serotonin transporter gene SLC6A4.
Methods : Subjects with bipolar I or II disorder, conﬁrmed by
structured diagnostic interview, enrolled in the Mayo Clinic Bipolar
Disorder Biobank. The medical record was reviewed by a psychiatrist
with at least 10 years clinical experience. AIM+was deﬁned as within
60 days of starting or changing dose of antidepressant treatment.
Each AIM+ case was matched to two separate AIM- controls match-
ing, in hierarchical order, on gender, SSRI antidepressant, I vs.
II subtype, and age.
Results : 518 (95.7% Caucasian) subjects completed enrollment with
12.1% (n=63) meeting criteria for a history of AIM+. The majority
were female (60.7%), Bipolar I (88.5%) with onset of AIM+ at start
(85.3%) of SSRI (68%) treatment with rapid cycling present only 28%
of the time. In comparison AIMx (n=122), AIM+ patients had a
higher rate of past history of attention deﬁcit disorder, both as chil-
dren (20 vs. 10%, p=0.056) and adults (25.4 vs. 11.6%, p=0.018).
Preliminary data on genetic variation of candidate genes will be
presented.
Conclusion : This early analysis emphasizes the importance of
phenotype assessment prior to genomic analysis. Identifying a genetic
variation associated with SSRI induced mania or may have high
clinical translational value in individualizing treatment for bipolar
depression.
Policy of full disclosure : Disclosure Declaration Mark A. Frye,
M.D. 2012 Grant Support Pﬁzer, National Alliance for Schizophrenia
and Depression (NARSAD), National Institute of Mental
Health (NIMH), National Institute of Alcohol Abuse and Alcoholism
(NIAAA), Mayo Foundation Speakers’ Bureau NONE Financial
Interest/Stock ownership/Royalties NONE.
jP-03-013jNeurological side eﬀects due to GSK-3 inhibition
by chronic lithium or transgenesis can be prevented
by blocking NFAT/FAS pathway
R. Gomez-Sintes1, J.J. Lucas2. 1CBM, Madrid, Spain ; 2CBMSO, CSIC/
UAM/CiberNed, Madrid, Spain
Objective : Despite lithium’s eﬃcacy for treatment of bipolar dis-
order, its clinical use is often curtailed by its side eﬀects. Lithium
inhibits, among other enzymes, glycogen synthase kinase-3 (GSK-3)
and this has been postulated to contribute to its therapeutic eﬃcacy
but also to its neurological toxicity. GSK-3 inhibition has been shown
to result in increased apoptosis through extrinsic pathway. We rea-
soned that this may relate to the well documented side eﬀects of
lithium therapy and that understanding the underlying molecular
mechanisms might help to apply treatments based on GSK-3 in-
hibitors. Here we aim to genetically dissect whether GSK-3 inhibition
induces toxicity in a NFAT/Fas-dependent manner.
Methods : We have combined pharmacological and genetic
sustained GSK-3 inhibition with two diﬀerent approaches to block
NFAT/Fas signalling : 1) Cyclosporine A (CsA) or 2) lpr mice,
Fas-deﬁcient.
Results : GSK-3 activity was inhibited by chronic lithium (Gomez-
Sintes and Lucas, 2010) or by a conditional transgenic mouse
expressing a dominant negative form of GSK-3 (Tet/DN-GSK-3 mice ;
Gomez-Sintes et al., 2007). In good agreement with the common
neurological side eﬀects of lithium therapy, lithium treated mice and
Tet/DN-GSK-3 transgenic mice showed subtle motor deﬁcits and
neuronal apoptosis. We now demonstrate that NFAT/Fas signaling
mediates both neuronal apoptosis and motor deﬁcits induced by de-
creased GSK-3 activity (induced by two diﬀerent approaches) as these
are absent when NFAT nuclear translocation is prevented by CsA
administration or when the experiments were conducted on Fas-
deﬁcient lpr mice.
Conclusion : Motor side eﬀects and neuronal apoptosis induced
by decreased GSK-3 activity are attenuated by blocking NFAT/Fas
signalling. These ﬁndings may enable development of combined
therapies not only to counteract the drawbacks of lithium treatment
for mood disorders but also to extend the potential of GSK-3
inhibitors.
jP-03-014jCompatability of pharmacotherapy for Korean
bipolar disorder patients to treatement guidelines
T.H. Ha1, S. Lee1, S.Y. Lee1, J.H. Baek1, Y.S. Park1, J.S. Chang1, K. Ha1.
1Seoul National University, Bundang Hospital, Seongnam-Si, Republic of
Korea
Objective : The aim of the current study was to investigate the overall
pattern of pharmacotherapy for patients with bipolar disorders
in Korea and to compare the pattern to treatment guidelines pro-
posed.
Methods : We retrospectively reviewed the medical records of
1,527 patients with bipolar disorders from ten hospitals. The daily
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prescription of subjects who admitted to inpatient units or visited the
outpatient clinic between January 1st, 2009 and December 31st, 2009
were analyzed.
Results : The study sample includes 480 manic inpatients, 328
depressive inpatients, and 719 outpatients on the maintenance ther-
apy. In the management of acute manic episodes, 83.3% of patients
were treated with a combination treatment of mood stabilizer (s) (MS)
and antipsychotic (s), followed by atypical antipsychotics (AAPs)
only strategy (12.3%), and MS monotherapy (3.1%). The initially
chosen mood stabilizer was valproic acid followed by lithium and
determined by institution characteristics. The concordance rate of
naturalistic treatments for manic inpatient with the Canadian
Network for Mood and Anxiety Treatments (CANMAT) guideline
was 55.2%, while the concordance rate with the Korean Society
for Depression and Bipolar disorder (KSDB) guideline was 76.0%.
In the management of acute depressive episodes, 26.4% of patients
were treated with antidepressant. Also, 29.3% were treated with
lamotrigine. Other 29.3% were treated with MS(s) (excluding lamo-
trigine) and AAP. In bipolar depression, treatments for only 28.3%
of subjects were concordant with the CANMAT guideline, while
75.1% were concordant with the KSDB guideline. In the maintenance
treatment, 50.3% of patients were treated with MS (including lamo-
trigine) and AAP. Antidepressant combination strategy was used in
22.8% of subjects, followed by MS only (18.4%) and AP only (6.3%)
strategy.
Conclusion : Results suggest that treatment strategy for acute
mania has been relatively well established, while that for acute bipolar
depression has not been standardized yet. More consensus on treat-
ment for bipolar depression is warranted.
jP-03-015jThe relation of ‘bright side’ and ‘dark side’
hypomania to psychological functioning, sleep and
physical activity in young adults
E. Holsboer-Trachsler1, M. Gerber2, U. Pu¨hse2, S. Brand1. 1Psychiatric
University Clinics, Basel, Switzerland ; 2 Institute of Exercise/Health,
University of Basel, Switzerland
Objective : No research has yet focused on hypomanic states in early
adulthood. The aim of the present study was therefore to assess hy-
pomania in a large non-clinical sample of young adults, to diﬀeren-
tiate between favorable (bright side) and unfavorable (dark side)
hypomanic stages, and to relate hypomanic stages with sleep and
physical activity.
Methods : A total of 862 participants (university students ; 74.1%
females ; mean age : M=24.67 ; SD=5.91) took part in the study. They
completed a series of validated self-report questionnaires assessing
hypomania (HCL-32), psychological functioning, sleep and physical
activity.
Results : Based on the HCL-32, 81% of the participants
were categorized as currently not being in a hypomanic state ;
19% of the participants were categorized as currently being in
a hypomanic state. Of those, 57.6% were classiﬁed as ‘‘active/
elated’’ (‘bright side’), whereas 42.4% were classiﬁed as ‘‘ irritable/
risk-taking’’ (‘dark side’). Compared to non-hypomanic par-
ticipants and the ‘bright side’ group, ‘dark side’ hypomanic
participants reported more depressive symptoms, sleep disturbances,
somatic complaints, perceived stress, negative coping strategies,
and lower self-eﬃcacy. By contrast, ‘bright side’ hypomanic par-
ticipants had lower stress scores, more positive self-instructions, and
higher levels of exploration, self-eﬃcacy, and physical activity.
Compared to the dark side hypomania, the bright side hypomania
was associated with more goal-oriented and structured physical
activity.
Conclusion : Among a non-clinical sample of young adults
hypomania was frequently reported (19%). The present results
underscore the notion of a continuity between a moderate mood
state and both favorable (‘bright side’) and unfavorable (‘dark side’)
hypomanic states. Moreover, ‘bright ’ and ‘dark side’ hypomania
diﬀer with respect to psychological functioning and sleep. Our
results suggest that ‘restlessness/overactivity’, a core symptom of
hypomania, might be observed only in the dark side hypomania,
whereas in bright side hypomania, amount of activity was related to
more goal-oriented physical activity.
jP-03-016jSerotonin transporter gene expression in bipolar
disorder : A preliminary study in malaysia
N.J. Suﬀee1, Z. Zainal2, S. Kanagasundram2, G. Kaur3, A. Zain4,
E. Gavin Reynolds2, G. Gurdeep Singh1. 1Pusat Perubatan Universiti,
Malaya, Petaling Jaya, Malaysia ; 2University Malaya, Dept of
Psychological Medicine, Kuala Lumpur, Malaysia ; 3 Institute of Public
Health, Ministry of Health, Kuala Lumpur, Malaysia ; 4University
Malaya, Department of Pharmacology, Kuala Lumpur, Malaysia
Objective : To analyze the relative SERT expression in bipolar dis-
order patients prior to and after being treated with olanzapine and
valproate for 8 weeks. Relative SERT expressions were determined at
weeks 0, 4 and 8 among patients and compared with healthy age, sex
and ethnicity matched controls.
Methods : We compared 17 bipolar patients with 16 age, sex and
ethnicity matched healthy controls in a prospective study. Patients
were treated with olanzapine with the dose ranged between
10–20 mg/day and valproate at 20 mg/kg body weight and Young
Mania Rating Scale (YMRS) was used to assess symptomatology in
patients at weeks 0, 4 and 8. Blood samples were taken at weeks 0, 4
and 8 for the bipolar group and once for the control group for analysis
of relative SERT expression.
Results : After 1 blood sample could not be analyzed, 1 patient re-
lapsed and 2 defaulted, all the remaining 12 patients who completed
the study responded to the treatment of olanzapine and valproate as
they had more than 50% decrease in YMRS score both at weeks 4
and 8 (p<0.05). Relative SERT expression of bipolar group prior to
starting treatment was 0.065 and signiﬁcantly lower than relative
SERT expression in the control group (p<0.05). After 8 weeks of
treatment, relative SERT expression of patients increased compared
to week 0.
Conclusion : Relative SERT expression of bipolar group prior to
starting treatment was statistically lower than relative SERT ex-
pression in the control group. After 8 weeks of treatment, all patients
who completed the study responded to treatment with olanzapine
and valproate as measured by more than 50% decrease in YMRS score
and there was up-regulation of SERT expression compared to week 0.
jP-03-017jLong-term safety and eﬃcacy of olanzapine in the
treatment of japanese patients with bipolar I
disorder, depressed
H. Katagiri1, M. Tohen2, D. Patrick McDonnell3, S. Fujikoshi1,
M. Case3, S. Kanba4, M. Takahashi1, J.-C. Gomez3. 1Eli Lilly Japan
K.K., Kobe, Japan ; 2University of Texas Health, Science Center at San
Antonio, USA ; 3Eli Lilly and Company, Indianapolis, USA ; 4University
of Kyushu Graduate, School of Medical Sciences, Fukuoka, Japan
Objective : Long-term safety and eﬃcacy of olanzapine (OLZ) up to
48 weeks was evaluated in Japanese patients with bipolar depression.
Methods : An integrated analysis was performed on results from 2
studies of OLZ-treated Japanese patients with bipolar I disorder,
depressed (N=165). Study 1 was a global study and it included a
double-blind placebo (PBO)-controlled treatment period and an open-
label extension treatment period. Randomized patients received blin-
ded OLZ (5–20 mg/day) or PBO for 6 weeks, and then continued into
the open-label extension period with OLZ for 18 weeks. Study 2 was
an open-label long-term treatment study conducted only in Japan.
Patients who had completed Study 1 (both Pre-OLZ/Pre-PBO groups)
received OLZ for an additional 24 weeks, and newly recruited pa-
tients received OLZ for 48 weeks (New-OLZ). Safety was assessed by
treatment-emergent adverse events (TEAEs) and changes in weight/
glucose/lipids. Eﬃcacy was evaluated by the rates of remission
(Montgomery-A˚sberg Depression Rating Scale (MADRS) score f12)
and emergence of mania (Young Mania Rating Scale scoreo15).
Results : Completion rate was 43.0% and the mean daily dose
of OLZ was 7.79 mg/day. Common TEAEs were weight increased
(47.9%), somnolence (37.0%), nasopharyngitis (23.6%) and increased
appetite (21.8%). Most TEAEs were mild or moderate in severity.
Mean changes in safety parameters were +3.54 kg (weight),
+3.4 mg/dL (fasting glucose),+8.2 mg/dL (fasting total cholesterol),
and +35.1 mg/dL (fasting triglycerides). Weight gains o7% body
weight were observed in 53.9% of patients. Remission rates were
79.8% (Pre-OLZ), 90.2% (Pre-PBO), 85.0% (New-OLZ). Emergence of
mania was not observed in any patient.
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Conclusion : Long-term safety, consistent with OLZ’s known
proﬁle including weight/glucose/lipid increases, and sustained
eﬃcacy were shown in OLZ-treated Japanese patients with bipolar
depression.
Policy of full disclosure : The studies were funded by Eli Lilly
and Company and/or Eli Lilly Japan. Drs. Katagiri and Takahashi,
and Mr. Fujikoshi are employees of Eli Lilly Japan. Dr. Tohen was an
employee of Eli Lilly and Company (up to 2008). He has served as
consultant for Eli Lilly and Company and has received honoraria from
Eli Lilly and Company. His spouse is a current employee of Eli Lilly
and Company. Drs. McDonnell and Gomez, and Mr. Case are em-
ployees of Eli Lilly and Company. Dr. Kanba has received grant/
research support from Eli Lilly Japan ; is an advisory board mem-
ber for Eli Lilly Japan and has also received honoraria from Eli Lilly
Japan.
jP-03-018jCognitive impairments proﬁle in euthymic bipolar 1
disorder and their relation to functional recovery
A. Khalil1, T. Okasha2, A. Eissa2, G. Abdel Razek2, T. Qassem2,
K. Ghazi2. 1Cairo, Egypt ; 2Ain Shams University, Cairo, Egypt
Objective : To demonstrate the range of neuropsychological deﬁcits in
the various cognitive domains in euthymic patients with bipolar I
depending on the previous clinical state, to compare that to control
and to correlate these cognitive deﬁcits with illness characteristics and
proﬁle.
Methods : A case control, study included 60 subjects they were or-
ganized into two major groups, one stratiﬁed random sample of 30
patients in the euthymic phase of bipolar I disorder and one control
group. The patients group diagnosed using Structured Clinical
Interview for DSM-IV (SCID-I) and the euthymic state determined
using Young Mania Rating Scale (YMRS) and Hamilton Rating Scale
for Depression (HRSD) and we used WIMS & WMSR for cognitive
assessment.
Results : Euthymic patients with bipolar I performed poorer than
controls on tests of intelligence, attention, memory and executive
functions Performance on most domains of WAIS was associated with
age of onset of illness and the number of depressive episodes. These
diﬀerences were with statistical signiﬁcance with residual symptoms
not reaching clinical signiﬁcance.
Conclusion : We conclude that cognitive deﬁcits associated with
euthymia in bipolar disorder are considered both a consequence of the
disorder, determinant of outcome in recovery and could be trait
markers for bipolar 1 disorder.
jP-03-019jEﬀect of lithium and valproate on brain activation
patterns in FMRI within a working memory
paradigm of bipolar patients
C. Lopez-Jaramillo. Universidad de Antioquia, Medellin, Colombia
Objective : We seek to identify diﬀerences and identify the role of
treatment in neurofunctional response in patients with Bipolar
Disorder type I, compared to controls, speciﬁcally while challenged
with working memory tasks.
Methods : Thirty-three euthymic patients with Bipolar Disorder
type I and 10 controls were evaluated in a cross-sectional study ; 13 of
them were on treatment with Lithium, 9 on Valproic Acid and 10
without treatment for at least 2 months prior to the study. Correlation
between functional Magnetic Resonance (fMRI) BOLD signal and
working memory processes.
Results : There were no signiﬁcant diﬀerences between the groups
in demographic or clinical variables except for YMRS score. Patients
and controls demonstrated signiﬁcantly diﬀerent patterns of brain
activation in anterior cingulated (p : 0.05) during working memory
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task. There were no diﬀerences in the angular gyrus, fronto-orbital
cortex and frontal lobe. There were no diﬀerence in activation patterns
in fMRI between patients treated with Valproic Acid or Lithium and
patients without pharmacologic treatment.
Conclusion : There are statistically signiﬁcant diﬀerences in the
anterior cingulate BOLD (Blood oxygen level dependent) signal be-
tween patients with Type I Bipolar Disorder compared to controls.
There were no other diﬀerences in the studied regions. Treatment
with Valproic Acid and Lithium didn’t play a role in those diﬀerences.
jP-03-020jA multinational observational study of compliance
associated with bipolar disorder : Results of the
BALANCE study (bipolar longitudinal compliance)
D. Mcdonnell1, A. Kutzelnigg2, Y. Dyachkova2, T. Treuer3, L. Botezat4,
E. Kulja5, C.-K. Chen6, M.G. Pujol-Luna7, Y.-C. Shin8, J. Salburg2,
M. Kopeinig9. 1Eli Lilly and Company, Little Island, Co, Cork, Ireland ;
2Eli Lilly Austria, Vienna, Austria ; 3Lilly Hungaria Kft., Budapest,
Hungary ; 4Cabinet Medical Individual, Bucharest, Romania ; 5Szabolcs-
Szatmar-Bereg County, Admin Psychiatric Hosp., Nagyka´llo´, Hungary ;
6Chang Gung Memorial Hospital, Department of Psychiatry, Taoyuan,
Taiwan ; 7Hospital Angeles Metropolitano, Mexico City, Mexico ;
8Kangbuk Samsung Hospital, Department of Psychiatry, Seoul, Republic of
Korea ; 9Facharzt fu¨r Psychiatrie und Psychotherapeutische Medizin,
Vienna, Austria
Objective : BALANCE study was conducted to explore factors as-
sociated with better compliance from diverse practice settings in
patients receiving treatment for Bipolar Disorder up to 24 months.
Methods : Adult outpatients, receiving olanzapine (mono- or com-
bination therapy) for at least 4 weeks and stable, Clinical Global
Impression Severity f3, were enrolled. Observations were recorded
at baseline and 3, 6, 9, 12, 18, 24 months. Compliance to each medi-
cation regimen prescribed by treating psychiatrist was assessed by
investigators using a single-item measure as noncompliant (<20%),
low (20–59%), medium (60–79%), high (80–100%). Baseline and post-
baseline factors including socio-demographics, disease severity, atti-
tude toward medication, olanzapine mono vs. combination therapy,
insight into illness, strength of the patient-physician relationship were
used to predict the likelihood of high compliance utilizing generalized
estimating equations repeated measures logistic regression model.
Other data analyzed included quality of life, tolerability, functional
status, and relapse.
Results : A total of 891 eligible patients were recruited into the
study from Austria (239), Hungary (167), Korea (145), Mexico (61),
Romania (180), Taiwan (99), of whom 73% completed the 24 months
observation period and demonstrated high compliance (o80% in
67%–80% of patients visit-wise). Results identiﬁed high baseline
compliance as a strong predictor of later compliance (OR=6.9, 95%
CI : 5.0–9.5, p<0.001), high compliance associated with higher life
satisfaction (p=0.002), better insights into illness (p<0.001), lesser
work impairment (p=0.007) and shorter hospital stay (p=0.002).
Compliance also varied by country (p<0.001) and length of post-
baseline treatment regimen (p=0.014).
Conclusion : Compliance to therapy in bipolar disorder was gen-
erally high and associated with baseline severity, insights into illness,
work impairment and satisfaction with life.
Policy of full disclosure : Dr. David McDonnell is a full-time em-
ployee of Eli Lilly and Company.
jP-03-021jNeurocysticercosis and bipolar disorder.
A case report
I. Michopoulos1, R. Gournellis2, X. Geronikola-Trapali3,
D. Plachouras4, C. Zopmola2, P. Kavagka2, A. Kaparoudaki5,
M. Papadopoulou6, L. Lykouras2. 1University of Athens, Medical,
Greece ; 2University of Athens, Medical, School, 2nd Department of Psy.,
Greece ; 3University of Athens, Medical, School, Nc. Medicine Department,
Greece ; 4University of Athens, Medical, School, 4th Department of Int.,
Greece ; 5Greek Center of Mental Health, and Research, Athens, Greece ;
6Neurological Department, Ygeia, s Melathron, Athens, Greece
Objective : Cerebral cysticercosis is caused by neuronal infection
by the pork tapeworm Taenia solium. In aﬀected patients, psychiatric
disorders, mainly depression and cognitive decline are highly
prevalent.
Methods : We present the case of a 65 year-old woman with mani-
festations of bipolar disorder since 15 years with history of neuro-
cysticercosis.
Results : She was initially diagnosed as suﬀering from depression-
like symptoms 15 years ago and she was treated successfully for
cysticercosis infection. Afterwards, she was retired due to her
emotional and cognitive problems. During hospitalization she pre-
sented episodes characterized by elevated mood, hyperactivity and
progressive development of psychomotor agitation and aggression
(YMRS 18), followed after a short period of time by progressive de-
velopment of psychomotor retardation, withdrawal, very poor speech
and hypersomnia and dysphoric mood (HRSD 21). She was well
oriented without memory dysfunction in clinical assessment (MMSE
26, 3-MS 89). The comprehensive neuropsychological evaluation by
the use of Cambridge Neuropsychological Test Automated Battery
has shown executive deﬁcits. The MRI revealed brain atrophy and
subcortical white matter lesions characteristic of cysticercosis infec-
tion, whereas, Tc99m -HMPAO (CERETEC) SPECT i.v adu. 20 mCu
revealed normal diﬀusion in the cerebral cortex. The patient’s symp-
toms were substantially ameliorated by olanzapine (20 mg/day) and
valproic (500 mg/day) administration.
Conclusion : In our patient’s case neurocysticercosis was linked
with manifestations of bipolar disorder which was substantially
ameliorated by valproic and olanzapine combination.
jP-03-022jReduced inferior frontal gyrus activation during
emotion inhibition in young people at increased
genetic risk for bipolar disorder
P. Mitchell1, G. Roberts1, M. Green1, M. Breakspear2, A. Frankland1,
C. McCormack1, A. Wright1, F. Levy1, R. Lenroot1, H. Chan1.
1University of New South Wales, Randwick, Australia ; 2QIMR, Brisbane,
Australia
Objective : There is growing interest in structural and functional brain
imaging of young people at increased genetic risk for bipolar disorder
as a means of identifying potential endophenotypes for this condition.
Dysfunctional neural mechanisms for the cognitive control of emotion
are postulated in the genetic predisposition to bipolar disorder, with
aberrant activity in fronto-cortical, striatal, and limbic networks pre-
viously reported in subjects with established bipolar disorder during
inhibitory and emotion processing tasks. We investigated functional
brain activity during inhibition of emotional material in young people
at increased genetic risk for bipolar disorder, using a facial-emotion
go/no-go task during functional magnetic resonance imaging.
Methods : Data from 47 genetically high-risk individuals aged
18–30 years with at least one ﬁrst-degree relative with bipolar disorder
were compared with 49 controls (within the same age range but
without a family history of bipolar disorder or other severe mental
illness).
Results : Behavioural performance of all participants on the aﬀect-
ive go/no-go task exceeded 75% accuracy. Whole brain corrected
analyses revealed a highly speciﬁc and signiﬁcant lack of recruitment
of the inferior frontal gyrus when inhibiting fearful faces in the at-risk
participants compared to controls (p=0.011, FWE corrected).
Conclusion : This impaired inhibitory function of the inferior fron-
tal cortex may represent a trait marker of vulnerability to bipolar
disorder. These ﬁndings further implicate dysregulated cortical and
sub-cortical brain networks as a neurocognitive endophenotype for
bipolar disorder and add to the growing evidence for pre-existing
functional and structural disturbances in those at high genetic risk for
bipolar disorder.
jP-03-023j Increase of serum brain-derived neurotrophic factor
levels in two cases of treatment-resistant mood
disorder remitted by lamotrigine augmentation
K. Nemoto1, K. Mihara2, A. Nakamura2, G. Nagai2, S. Kagawa2,
T. Suzuki2, T. Kondo2. 1University of the Ryukyus, Nishihara, Okinawa,
Japan ; 2University of the ryukyus, the Department of Nishihara, Okinawa,
Japan
Objective : Introduction We showed that lamotrigine (LTG) augmen-
tation was eﬀective for treatment-resistant mood disorder (TRMD).
Animal studies reported that brain-derived neurotrophic factor
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(BDNF) was an essential mediator for the antidepressant eﬀects of
LTG. We report two cases of TRMD remitted by the treatment of LTG
augmentation, together with their BDNF levels increments.
Methods : Case reports Case A The patient was a 56-year-old
female. She had ﬁrst depressive episode at the age of 54. Her de-
pressive symptoms showed no response to several antidepressants
with enough doses and durations. Because she became hypomanic
with mirtazapine treatment, the drug was withdrawn. Her hypo-
manic symptoms disappeared with valproate (VPA) treatment.
However, she became gradually depressed again. The dose of VPA
was increased up to 600 mg/day with some response. LTGwas added
to VPA at her MADRS score of 15. On the 8th week (LTG 75 mg/day),
her MADRS score became 0. Her serum BDNF levels before and after
8-week LTG were 21.1 and 43.0 ng/mL. Case B The patient was a
67-year-old female. She had had ﬁrst depressive episode at the age
of 60. She had been remitted with ﬂuvoxamine treatment. Because
she became hypomanic at age of 67, the drug was withdrawn. Her
hypomanic symptoms disappeared with VPA treatment. However,
she became agitatedly depressed without any response to some anti-
psychotics. LTG was coadministered to VPA (800 smg/day) at her
MADRS score of 20. On 8th week (LTG 75 mg/day), her MADRS
score became 2. Her serum BDNF levels before and after 8-week LTG
were 23.1 and 37.1 ng/mL.
Conclusion : These cases suggest that LTG shows antidepressant
eﬀects through BDNF increment in the treatment of TRMD.
jP-03-024jSuccessful switching to olanzapine from
polypharmacy in a bipolar II disorder patient with
suicidal ideations : A seven-year follow-up study
H. Ono1, T. Yuka2, E. Tsujimoto2, R. Taketani2, A. Maruyama3.
1Kwansei Gakuin University, Nishinomiya, Japan ; 2Kwansei Gakuin
University, Graduate School of Humanities, Nishinomiya, Japan ;
3Maruyama Clinic, Sanda, Japan
Objective : Pharmacological treatment of patients with bipolar II
disorder in Japan is characterized by polypharmacy. We report on a
seven-year follow-up of a patient with bipolar II disorder, whose
medication was switched to olanzapine from polypharmacy. The ob-
jective of this case report is to focus attention on the signiﬁcance
of avoiding unnecessary and potentially harmful polypharmacy,
and to demonstrate the eﬀectiveness of olanzapine in bipolar II
disorder.
Methods : A case report. This case study was conducted with the
written informed consent of the patient. This study was approved by
the ethical committee of Kwansei Gakuin University.
Results : The patient was a 30’s woman with bipolar II disorder.
Before her visit to our hospital, she had been treated with 2 anti-
anxiety agents (alprazolam, diazepam), 10 hypnotic drugs (triazolam,
estazolam, lormetazepam, ﬂurazepam, zolpidem, brotizolam, nitra-
zepam, ﬂunitrazepam, rilmazafone), one antidepressant (paroxetine)
and 2 antipsychotics (risperidone, chlorpromazine) for about
6 months. Her condition had gotten worse as a result of the poly-
pharmacy. She had quit her company job and attempted suicides.
At the ﬁrst visit to our hospital, she showed mixed episodes and
amnesia. Her medication was switched to olanzapine and ﬂuni-
trazepam. After 3 months of switching the medication, she became
able to sleep, and her mood became stable. After 2 years, she found a
new job. At the 7-year follow up, she was in good condition and was
not suﬀering from any severe side eﬀects.
Conclusion : This study suggested that polypharmacy caused
mood instability, and that olanzapine was eﬀective as a maintenance
therapy for bipolar II disorder.
Policy of full disclosure : This study was partly supported by
Grants-in-Aid for Scientiﬁc Research of Japan (22530776).
jP-03-025jNonlinear techniques as an approach for
understanding mood regulation in bipolar disorder
A. Ortiz1, K. Bradler2, J. Garnham1, C. Slaney1, M. Alda1. 1Dalhousie
University, Halifax, Canada ; 2McGill University, Montreal, Canada
Objective : 1. To analyze if mood regulation in bipolar disorder (BD)
subjects is essentially diﬀerent from the one in healthy controls (HC).
2. To determine if entropy levels diﬀer between HC and BD.
Methods : 30 HC and 30 euthymic BD patients (age- and sex-
matched) rated their mood, anxiety, energy levels and sleep daily,
twice a day, during 3 months, via a paper-based visual analog scale.
We analyzed the data using methods suitable for the study of stoch-
astic processes (time series analysis).
Results : HC showed low ﬂuctuations (high variability) in their
mood, anxiety, and energy levels. The diﬀerences between morning
and evening ratings were not statistically diﬀerent (D=1.0, p>0.05).
The autocorrelation analysis showed a strong weekly periodicity in
70% of the HC sample. In contrast, BD patients showed less varia-
bility in their mood, anxiety and energy levels. All diﬀerent entropy
levels were signiﬁcantly higher in the HC group compared to BD
patients (all p<0.01).
Conclusion : Mood ﬂuctuates even in the absence of stimuli in
healthy subjects, resulting in higher entropy levels. Our results sug-
gest that the mechanisms of mood regulation in HC and BD patients
may be essentially diﬀerent. This understanding is a prerequisite for
the development of protocols related to episode prediction.
jP-03-026jUse of videotape recording of manic episodes to
enhance adherence to pharmacological treatment
in the maintenance phase of bipolar disorder
F. Mun˜oz1, G.F. Oviedo1. 1Clı´nica de la Paz, Bogota´, Colombia
Objective : Our aim in this presentation is to describe the impact of
showing a group of patients in a remission phase of the acute episode
the characteristics of their previous manic episode videotaped, in
order to overcome denial and to improve pharmacological adherence
and non pharmacological recommendations during de follow-up
period.
Methods : Case Series.
Results : Videotaping of manic episodes had a positive impact on
latter pharmacological treatment in a group of patients with bipolar
disoders.
Conclusion : In the treatment of Bipolar Disorder (BD) high fre-
quencies for poor adherence of patients in maintenance phase of
pharmacological treatment regimens is well known. Denial of severity
of illness is one of the predictors of non adherence.
jP-03-027jBipolar depression : Quetiapine XR short time
eﬀectiveness
S. Porcelli1, B. Beatrice2, A. Serretti2, D. De Ronchi1. 1Bologna, Italy ;
2 Institute of Psychiatry, University of Bologna, Italy
Objective : Quetiapine (QTP) has been shown to be eﬀective as an
acute treatment in patients with bipolar depression. Nonetheless, the
time of onset of QTP antidepressive action as well as its minimum
eﬀective dose have not been clariﬁed. We aimed to evaluate the short-
term eﬃcacy of QTP XR in bipolar depression. We also compared the
diﬀerent eﬃcacy and side eﬀect proﬁle of 300 mg and 600 mg/day
dosages.
Methods : 31 acutely depressed patients were recruited ; 14 were
treated with QTP XR 300 mg/day and 17 with 600 mg/day. Assess-
ment was performed with Hamilton Depression Scale (HAMD),
Hamilton Anxiety Scale (HAMA), Dosage Record and Treatment
Emergent Symptom Scale (DOTES), HAMD clusters ‘‘Core’’, ‘‘Psy-
chic anxiety’’, ‘‘Somatic anxiety’’, ‘‘Activity’’, ‘‘Delusion’’.
Results :QTP XRwas eﬀective since the ﬁrst three days of treatment
in reducing all the eﬃcacy measures except for somatic anxiety. The
comparison of 300 and 600 mg dosages did not show any signiﬁcant
diﬀerence in terms of eﬃcacy, despite a clear trend was observed fa-
voring the 600 mg group. The incidence of hypotension was signiﬁ-
cantly higher in patients taking QTP 600 mg (p=0.004).
Conclusion : Our results suggest that QTP XR is eﬀective against
depressive symptomatology within the ﬁrst days of treatment.
Further, there is not a signiﬁcant advantage for the 600 mg dose in
comparison with the 300 mg one. The clinical eﬀect seems to be not
associated with sedation, suggesting that it may be due to the mol-
ecular drug eﬀect. Nevertheless, further studies focusing on the ﬁrst
days of treatment are needed in order to conﬁrm our ﬁndings.
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jP-03-028jA pooled analysis of the eﬀects of asenapine on the
persistent negative symptoms of schizophrenia
S. Potkin1, P. Phiri2, J. Zhao2, L. Alphs3, R. Buchanan4, A. Szegedi2,
J. Panagides5, P. Cazorla6. 1University of California, Irvine, USA ;
2Merck, Whitehouse Station, NJ, USA ; 3Pﬁzer Inc, (at the time of this re-
search), Ann Arbor, MI, USA ; 4Maryland Psych. Res. Center, University
of Maryland, Baltimore, USA ; 5Schering-Plough, (at the time of this re-
search), Summit, USA ; 6Merck, (at the time of this research), Whitehouse
Station, NJ, USA
Objective : Asenapine and olanzapine reduced persistent negative
symptoms (PNS) of schizophrenia, in a study population that also
met criteria for predominant negative symptoms, in 2 double-blind,
randomized 26-week core and subsequent 26-week extension studies ;
superiority of asenapine over olanzapine was observed in one ex-
tension study. Post-hoc analyses of pooled data of the 2 core and 2
extension studies were conducted in order to further compare the
long-term eﬃcacy of asenapine and olanzapine in the treatment of
negative symptoms in a population whose symptoms were both per-
sistent and predominant.
Methods : Core study participants were randomized to asenapine
(5 or 10 mg BID) or olanzapine (5–20 mg QD) ; extension participants
continued existing treatment. Mixed model for repeated measures
analyses, on the pooled intent-to-treat populations for patients enter-
ing the core or extension studies, assessed between-group diﬀerences
on change from core study baseline in the 16-item Negative
Symptoms Assessment (NSA-16) total score at weeks 26 and 52.
Results : Of 949 participants treated with asenapine or olanzapine
(n=485 and 464, respectively), 613 (n=277 and 336) completed the
core studies and 412 (n=170 and 242) completed the extensions.
Between-group diﬀerences in least squares mean ¡ SE NSA-16
total score change from core study baseline for asenapine versus
olanzapine were not signiﬁcant at week 26 (core participants,x11.1¡
0.6 vs. x11.2¡0.6, P=0.9457 ; extension participants, x13.1¡0.7 vs.
x12.2¡0.6, P=0.3710) but were signiﬁcantly greater with asenapine
versus olanzapine at week 52 (core participants, x14.6¡0.8 vs.
x12.6¡0.7, P=0.0497 ; extension participants, x16.5¡0.9 vs.
x13.6¡0.7, P=0.0083).
Conclusion : Asenapine and olanzapine reduced PNS in these post-
hoc analyses, with statistical superiority of asenapine observed at
week 52. These results should be interpreted in view of the fact that a
large portion of participants did not enter the extension studies.
Policy of full disclosure : Potential conﬂicts of interest : In the past
12 months, Dr Potkin has been a consultant or on the speakers
or advisory boards for or has received honoraria or grant/research
support from the following : Alzheimer’s Association, Baxter, Baylor
College of Medicine, Bioline, Bristol-Myers Squibb, Cephalon,
Ceregene, Cortex, Eisai, Eli Lilly, Forest Laboratories, Genentech,
International Society for CNS Clinical Trials and Methodology
(ISCTM), Janssen Pharmaceutical, Lundbeck, Merck, National
Institute on Alcohol Abuse and Alcoholism (NIAAA), National
Institute of Biomedical Imagine and Bioengineering (NIBIB), National
Institutes of Health/National Center for Research Resources (NIH/
NCRR), Novartis, Organon, Otsuka, Pﬁzer, Roche, Shire Development
Inc, Solvay Pharmaceuticals, Sunovion, Takeda Global R&D, Takeda
Pharmaceutical, University of California San Francisco, University of
California San Diego, University of Southern California.
jP-03-029jThe pharmacogenomics of bipolar disorder – acute
and longitudinal treatment aspects : A systematic
review
M. Budde1, D. Degner1, J. Brockmo¨ller1, T. Schulze1. 1Goettingen,
Germany
Objective : Pharmacotherapy constitutes a mainstay in the treatment
of both acute episodes and in maintenance therapy of bipolar disorder
(BD). For more than two decades, there have been attempts to clarify
the genetic basis of mechanisms of drug action, aiming at the possi-
bility to oﬀer a more personalized medicine. Here we compile the
current state of pharmacogenomics of BD.
Methods : First, we decided to focus on the pharmacogenetics of
ﬁrst line treatments for BD on the basis of international guidelines. We
focused on drugs recommended as monotherapies. PubMed was
searched for articles published until using the search terms ‘‘bipolar
disorder’’ or ‘‘manic-depressive illness’’ cross-referenced with drugs
in question. We also manually reviewed reference lists of the ident-
iﬁed publications. From these, we selected case-control-association
studies, with the case-control-status being the drug response or the
occurrence of adverse events.
Results : As regards response, we 28, with the following break-
down : lithium (25), lamotrigine (1), divalproex (1), olanzapine (1). As
regards adverse events, our search algorithm yielded one study on
divalproex. Most of the pharmacogenetic research in BD is about
lithium, while there are only few case-control-association-studies
concerning the other ﬁrst line treatments. The candidate genes studied
for lithium included 5-HT2A, 5-HT2C 5, HTTLPR, AP-2b, BCR,
BDNF, COMT, DAT1, DGKH, DRD1, DRD2, DRD3, DRD4, FYN, Gb3,
GABRA1, GR, GRIA2, GRIN2B, GRK3, GSK3-b, HTR2A, IMPA1,
IMPA2, INPP1, MAO-A, MARCKS, NR1D1, NTRK2, ODZ4, SDC2,
SERTPE, SV2B, and XBP1.
Conclusion : There is a striking lack of replicated ﬁndings. For only
two genes, the 5-HTTLPR and the BDNF gene, positive ﬁndings could
be replicated in a second study. Also, most studies included very
small samples, with the majority totaling less than 200 subjects. Future
pharmacogenomic research should be based on larger samples, uni-
ﬁed, exact criteria for response and adverse events, integrate knowl-
edge from biochemical pathways, and also include pharmacokinetic
aspects.
jP-03-030jNeurotrophin levels and the eﬃcacy of single
ketamine infusion in bipolar depression resistant
to antidepressants
M. Skibinska1, A. Permoda-Osip2, R. Adamski2, A. Bartkowska-
Sniatkowska3, M. Chlopocka-Wozniak2, J. Rybakowski2. 1University
of Medical Sciences, Dept. of Adult Psychiatry, Poznan, Poland ;
2University of Medical Sciences, Department of Adult Psychiatry, Poznan,
Poland ; 3University of Medical Sciences, Department of Anaesthesiology,
Poznan, Poland
Objective : In our previous study performed on 10 patients, we ob-
served an antidepressant eﬀect of single intravenous dose of keta-
mine, as an addition to mood stabilizing drugs in patients with
bipolar depression resistant to treatment with antidepressants. We
also found an increase of serum brain derived neurotrophic factor
(BDNF) in ketamine responders. The aim of this study was to inves-
tigate serum levels of three neurotrophins : BDNF, neurotrophin 4
(NTF4) and glial-derived neurotrophic factor (GDNF) in relation to
ketamine eﬃcacy, in larger group of patients.
Methods : The study comprised 25 patients (4 male, 21 female),
aged 27–67 years, with bipolar depression, receiving mood-stabilizing
medications. They were resistant to treatment with antidepressants
which were discontinued for at least 7 days before single intravenous
ketamine infusion (0.5 mg/kg body weight) between 8:00–8:45 h.
Psychometric assessment was done using 17-item Hamilton
Depression Rating Scale (HDRS). Response to ketamine was deﬁned
as 50% reduction of HDRS after one week, compared to baseline.
Serum BDNF, NTF4 and GDNF levels were estimated by the ELISA
method.
Results : The mean intensity of depression before ketamine infusion
was 21+4 points on HDRS, reduced to 12+7 points after one week.
There were 16 ketamine responders and 9 ketamine non-responders.
In ketamine responders, the increase of BDNF after one week was not
signiﬁcant, however, in such patients a reduction of GDNF serum
level (statistical trend p=0.07) was found. In ketamine non-
responders, a signiﬁcant reduction of BDNF level was observed. No
relationship between serum levels of NTF4 and response to ketamine
was found.
Conclusion : The results of present study conﬁrm an antidepressant
eﬀect of ketamine infusion as an add-on to mood-stabilizing drugs in
bipolar depression resistant to antidepressant treatment. They may
also indicate a possible involvement of such neurotrophins as BDNF
and GDNF in this eﬀect.
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jP-03-031jElevated levels of circulating inﬂammatory cytokines
in euthymic individuals with bipolar disorder
J. Soczynska1, S. Kennedy2, M. Li2, H. Woldeyohannes2, R. McIntyre2.
1University of Toronto, Canada ; 2University of Toronto, University
Health Network, Canada
Objective : To test the hypothesis that euthymic individuals
with bipolar disorder (BD) exhibit abnormalities in pro- and anti-
inﬂammatory cytokines.
Methods : Prospectively veriﬁed euthymic individuals (N=45,
mean age=41.02+9.89) with DSM-IV-TR-deﬁned BD-I/II as well as
healthy volunteers (N=29, mean age=45.36+12.15) were enrolled.
Inﬂammatory cytokines [granulocyte-macrophage colony-stimulating
factor (GM-CSF), interleukin (IL) 1b (IL-1b), IL-2, IL-4, IL-5, IL-6, IL-8,
IL-10, tumor necrosis factor b (TNF-a) and interferon c (IFN-c)] were
measured in plasma with an ultrasensitive 10-plex bead-based im-
munoassay for Luminex. The Mann-Whitney U Tests and multiple
logistic regression were used to compare levels of inﬂammatory
cytokines between euthymic individuals with BD and healthy volun-
teers.
Results : Both pro-inﬂammatory (GM-CSF, IL-1b, IL-2, IL-5, IL-6,
IL-8, TNFa, INFc) and anti-inﬂammatory cytokines (IL-4 and IL-10)
were elevated in euthymic individuals with BD as compared to heal-
thy volunteers (all p<0.01). A multiple logistic regression revealed
that a model containing GM-CSF, IL-2, IL-6, TNFa, IL-4 and IL-10
signiﬁcantly predicted BD (Model Nagelkerke R2=0.806 ; p<0.001).
Moreover, TNFa was the strongest independent predictor of BD in
this model (odds ratio=1.883 95% CI : 1.28–2.76 ; p=0.001).
Conclusion : Bipolar disorder is marked by elevated levels of
inﬂammatory cytokines that persist into euthymia. These results
suggest that the inﬂammatory cytokine network is salient to the
pathophysiology of BD and may constitute a viable target for novel
treatment development.
Policy of full disclosure : Eli Lilly Fellowship Received travel funds
from Janssen.
jP-03-032jHypermethylation of serotonin transporter gene in
bipolar disorder detected by epigenome analysis of
discordant monozygotic twins
H. Sugawara1, K. Iwamoto2, M. Bundo2, N. Adati3, I. Kusumi4,
Y. Okazaki5, J. Ishigooka6, T. Kojima3, T. Kato7. 1Tokyo Womens
Medical Uni., Japan ; 2The University of Tokyo, Japan ; 3Hamamatsu,
Japan ; 4Sapporo, Japan ; 5Tokyo, Japan ; 6Tokyo Women´s Medical
University, Japan ; 7Wako, Japan
Objective : Bipolar disorder (BD) is a severe mental disorder charac-
terized by recurrent episodes of mania and depression. Although high
concordance rate of BD in monozygotic (MZ) twins supports the
contribution of genetic factor in BD, importantly, it is not 100%.
Because MZ twins have been regarded as having identical genomes,
these facts suggest the importance of environmental or epigenetic
factor for the onset of mental disorders.
Methods : We performed promoter-wide DNA methylation
analysis of lymphoblastoid cell lines (LCLs) derived from two pairs
of monozygotic twins discordant for BD. Promoter-wide DNA
methylation proﬁles of the twins were examined by Aﬀymetrix
GeneChip Human Promoter 1.0R tilling arrays after methylated DNA
was enriched using MBD2b and MBD3L1 conjugated beads. Fully
unmethylated DNA obtained by whole genome ampliﬁcation was
used as a reference. To rule out the possible discordance of copy
number variation (CNV) between twins, we performed CNV analysis.
Results : We found the copy number proﬁles were nearly identical
between the twin pairs except for immunoglobulin-related regions.
Three genes showing distinct diﬀerence of DNAmethylation between
one of the two pairs were obtained as candidate regions. Among
them, hypermethylation of SLC6A4, encoding serotonin transporter
(HTT), in the bipolar twin was conﬁrmed by bisulﬁte sequencing.
Promoter hypermethylation of SLC6A4 in LCLs of BD patients was
conﬁrmed in a case-control analysis. DNA methylation of SLC6A4
was signiﬁcantly correlated with its mRNA expression level in in-
dividuals with the S/S genotype of serotonin transporter-linked pro-
moter region (HTTLPR), and mRNA expression level was lower in BD
patients carrying the S/S genotype. DNAmethylation of the same site
was also higher in the postmortem brains of BD patients.
Conclusion : This is the ﬁrst study to report the role of epigenetic
modiﬁcation of SLC6A4 in BD using an unbiased approach, which
provides a new insight to elucidate the pathophysiolosy of mood
disorder.
jP-03-033j ‘‘Paper-and-pencil ’’ cognitive tests results in
euthymic bipolar patients treated with lithium
A. Suwalska1, G. Liczbinska2, W. Palys3, K. Jaracz4, K. Go´rna4,
J. Pniewska4, J. Rybakowski3. 1University of Medical Sciences, Poznan,
Poland ; 2Adam Mickiewicz University, Institute of Anthropology, Poznan,
Poland ; 3University of Medical Sciences, Dept. of Adult Psychiatry,
Poznan, Poland ; 4University of Medical Sciences, Dept. of Nursing,
Poznan, Poland
Objective : Cognitive deﬁcits in bipolar patients may persist during
remission. In our previous study using Cambridge Neuropsy-
chological Testing Automated Battery (CANTAB) euthymic bipolar
patients treated with lithium showed poorer performance on several
neuropsychological tests than healthy controls and the quality of the
response to prophylactic lithium treatment inﬂuenced the cognitive
performance (Rybakowski and Suwalska, 2010). The aim of the study
was to assess frontal lobe cognitive functions in euthymic bipolar
patients treated with lithium.
Methods : Fifty-six patients with bipolar disorder in remission
lasting for at least 4 months (21 male, 35 female ; mean age 52.6¡10.0)
and 77 healthy controls (22 male, 65 female ; mean age 51.6¡13.6)
entered the study. Duration of illness was at least 5 years and
prophylactic treatment lasted for at least 2 years. Sixteen patients were
excellent litium ELRs, deﬁned as having had no aﬀective episodes on
lithium monotherapy. For the neuropsychological assessment, the
following tests were used : the Trail Making Test (TMT), the Stroop
test, the verbal ﬂuency test, including semantic (categories : animals,
fruit and vegetables) and phonemic ﬂuency tasks (letters F, A, S).
Results : Bipolar patients performed signiﬁcantly worse than
healthy controls on semantic and phonemic verbal ﬂuency, TMTA&B
and Stroop test part B, whereas the results of excellent lithium re-
sponders did not diﬀer from those of healthy people. Bipolar men
performed signiﬁcantly worse than bipolar women on semantic
ﬂuency test and Stroop test part B. Whilst bipolar women had worse
results than healthy control women only in TMT A and TMTB, bipolar
men performed poorer than healthy men on all tests.
Conclusion : Our results point to the presence of cognitive deﬁcits
in euthymic bipolar patients, protective eﬀect of lithium in excellent
lithium responders and gender-associated diﬀerences in the severity
of neuropsychological dysfunctions. Rybakowski JK, Suwalska
A (2010) Excellent lithium responders have normal cognitive func-
tions and plasma BDNF levels. International Journal of
Neuropsychopharmacology 13, 617–622.
jP-03-034j Increased trans-membrane tumour necrosis factor
in the anterior cingulate cortex of subjects with
bipolar disorder
N. Tawadros1, A. Gibbons1, E. Scarr2, B. Dean1. 1Melbourne University,
(MHRI), Vic, Australia ; 2Melbourne University, Department of
Psychiatry, Vic, Australia
Objective :Altered inﬂammatory signalling has been implicated in the
pathophysiology of mood disorders and schizophrenia. We recently
reported a 2.4-fold increase in the expression of a trans-membrane
form of the pro-inﬂammatory cytokine, tumour necrosis factor
(tmTNF) in Brodmann’s area (BA) 46 but not BA24 of the frontal
cortex from subjects with major depressive disorder (MDD). The ex-
pression of soluble TNF (sTNF) was not altered in these subjects. We
have examined TNF expression in the frontal cortex of subjects with
bipolar disorder (BPD) and schizophrenia.
Methods :Western blotting was used to measure tmTNF and sTNF
levels in post-mortem tissue from BA24 and BA46 from 10 subjects
with BPD and 10 matched controls and from 20 subjects with schizo-
phrenia and 20 matched controls.
Results : tmTNF was increased in BA24 (CON) (mean ratio of
internal control ¡ SEM)=2.77¡1.03 vs. BPD=7.15¡1.75 ; p<0.05),
but not BA46 (CON=0.89¡0.10 vs. BPD=1.84¡0.47 ; p>0.05) from
subjects with bipolar disorder. There was no change in the level of
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tmTNF in BA24 (CON=2.62¡0.55 vs. SCZ=2.00¡0.38 ; p>0.05) or
BA46 (CON=0.80¡0.07 vs. SCZ=1.02¡0.171 ; p>0.05) from subjects
with schizophrenia compared to controls. Levels of sTNF were not
changed in either BA24 or BA46 from subjects with BPD or schizo-
phrenia compared to controls.
Conclusion : Our data further supports a role for tmTNF in the
pathophysiology of mood disorders but not schizophrenia. Further-
more, abnormal tmTNF expression is localised to diﬀerent cortical
regions in BPD compared to MDD. Contrasting studies in the per-
iphery, our data from the CNS does not support the involvement of
sTNF-mediated, pro-inﬂammatory pathways in the pathophysiology
of mood disorders.
jP-03-035jMolecular conformational changes in microglia
and diﬀerentiated monocitic cells induced by
therapeutic concentrations of lithium
H. Tomita1, Y. Zhiqian1, C. Ono1. 1Tohoku University, Sendai, Japan
Objective : Lithium (Li), a direct inhibitor of glycogen synthase kinase
3 (GSK-3), is a commonly prescribed mood stabilizer in the treatment
of bipolar disorder. Li aﬀects various types of immune cells, which
play pivotal roles in the innate immune systems in both brain and
peripheral tissues. Evidence suggests that GSK-3 regulates microglial
migration and inﬂammation, and also mediates diﬀerentiation and
activation of proinﬂammatory monocyte-derived dendritic cells
(MoDCs).
Methods : Microarray gene expression proﬁles of resident diﬀer-
entiated monocytic cells (mouse microglia, mouse microglia and
macrophage-like cell line, human MoDCs and monocyte-derived
macrophages) along with undiﬀerentiated mouse and human mono-
cytes were evaluated using Illunima microarrays, and post promi-
nently induced and suppressed molecules were validated using
Q-RT-PCR and western blotting. Eﬀects of GSK-3 inhibitors on the
molecules were also evaluated.
Results : We found several molecules prominently induced by the
therapeutic concentration of Li and GSK-3 inhibitors in the resident
diﬀerentiated monocytic cells (mouse microglia, mouse microglia and
macrophage-like cell line, human MoDCs and monocyte-derived
macrophages), but not in undiﬀerentiated mouse and human mono-
cytes.
Conclusion : The ﬁndings indicate the mechanisms of lithium-
induced functional changes in microglia and diﬀerentiated monocytic
cells, and their possible involvements in the neuroprotective and
mood stabilizing eﬀects of Li treatment.
jP-03-036jBipolar disorder in patients with suicidal behavior
F.A. Vasquez1, C. Salirosas1, Y. Nicolas1, S. Falconı´1, V. Vite1.
1National Institut of Mental Health, Lima, Peru
Objective : to study prevalence of bipolar disorder (BD) in patients
with suicidal behavior assisted at National Institute of Mental Health
in a three-year period (2008–2010).
Methods : A prospective study using clinical assessment in
ambulatory suicidal patients searching diagnostic criteria DSM IV-TR
for BD.
Results : Over a sample of 1300 patients with suicidal behavior,
92 of them (7.1%) were diagnosed as Bipolar : 25 males (27.2%) and
67 females (72.8%), being 70% of them aged less than 33 years old. For
Bipolar I : 71 patients (77.2%), Bipolar II : 21 patients (22.8%). There
were 38 patients with bipolar depresive state (41.3%), 36 for mixed
episodes (39.1%), 12 of them for pure manic episode (13%) and other
6 considered rapid cycling patients (6.5%). Psychotic features were
found in 43 patients (47%). Most important co-morbidities were : ex-
cessive smoking in 25%, abuse of alcohol and other substances in 31%
and BPD in 24%. Regarding suicidal behavior : it was found suicidal
ideation in 35.8%, suicide attempt in 59.8%, and complete suicide in
4(4.4%). About suicide attempters, near half of them diagnosed as
bipolar depressive episode, 47% as mixed episode and 3.6% as manic
episode. Almost 75% of patients were in an inadequate treatment.
Among 4 patients who completed suicide : 3 females/1 male, 2 of
them diagnosed as mixed bipolar with psychotic features.
Conclusion : According the trial, prevalence of BD amongst
suicidal patients is not too infrequent, being predominant in young
female, mostly bipolar depression and mixed states, worsening
in case of comorbidity with substances abuse and BPD, and also
under inadequate approach ; being author´s advise an early and better
identiﬁcation of BD for its adequate treatment and eﬀective suicide
prevention.
jP-03-037jSolar activity and mood episodes in bipolar disorder
J. Villarroel1, F. Ivanovic-Zuvic1, L. Risco1. 1Universidad de Chile,
Santiago, Chile
Objective : Some authors have been linked solar cycles with changes
in human social evolution, proposing that exposure to solar activity
can inﬂuence diﬀerent aspects of human behavior. Currently there
have been developed researches about the inﬂuence of the solar cyclic
activity on various aspects of human health. Bipolar disorder is a
psychiatric illness with cyclical developments. There are few and
limited studies that have focused on the relationship between solar
activity and epidemiology of bipolar disorder. The aim of this study is
to evaluate the possible relationship between solar activity and the
annual incidence of mood episodes, depressive or manic, in bipolar
disorder.
Methods : Retrospective review of hospital admissions by psychi-
atric diagnoses in the country of Chile between 2001 and 2008, of
which 3973 cases were due to depresive or manic episodes in patients
with bipolar disorder.
Results : We found a signiﬁcant inversely relation between the
incidence of hospital admissions by depressive episodes and the
intensity of solar activity (p<0.001, F 128.54), and no relation between
the incidence of manic episodes and intensity of solar activity during
the same period, in bipolar disorders.
Conclusion : We conclude that the exposure to solar cyclic activity
can inﬂuence the occurrence of depressive episodes in bipolar dis-
order.
jP-03-038jAssessing the relationship between history of
suicide attempts and cognitive dysfunction in
bipolar aﬀective disorder
M.I. Vrabie1, V. Marinescu2, D. Enache3, R. Vuta4. 1Bucharest,
Romania ; 2Al. Obregia Hospital, UMF Carol Davila, Bucharest, Romania ;
3Al. Obregia Hospital, Bucharest, Romania ; 4Emergency County Hospital,
Ploiesti, Romania
Objective : The objective of this study is assessing relationship be-
tween history of suicide attempts and cognitive impairment in bipolar
disorder.
Methods : We examined 60 bipolar (depressive, manic/hipomanic,
mixt, euthymic) patients (according to DSMIVTR). The comparison
group consisted of 20 healthy subjects without history of neurologi-
cal/psychiatric disorder. The cognitive battery included standardized
test of IQ, attention, working memory, visual memory, verbal memory
and executive functioning. Demographic data (gender, age, years of
education, socioeconomic status and current employment) were sys-
tematically obtained. Data about psychiatric history, past and current
treatment, history of psychosis, duration of illness, age of onset and
family history were collected. We analyzed statistically these data and
assessed the relationships between history of suicide and cognitive
deﬁcits in bipolar patients from this study.
Results : Suicidality among bipolar patients seems to be associated
with executive dysfunction, especially when highly lethal attempts
are made. Depressed patients with a history of high lethality suicide
attempts have lower performance on task of executive functioning
compared to depressed patients without past history of attempts
and patients with a history of low lethality suicide attempts.
Neurocognitive function didn’t diﬀer between bipolar individuals
with a history of nonviolent suicide attempts versus bipolars without
history of suicide attempts. There are no signiﬁcant diﬀerences of
cognitive dysfunction between patients with violent versus non-
violent attempts. It seems that diﬃculties with response inhibition are
associated with an increased rate of suicide attempts. Euthymic,
manic, depressed and mixt-episode bipolar patients with past of sui-
cide attempts also have more impulsive response when compared to
bipolar individuals without a history of suicide attempts. Both bipolar
disorder attempters and healthy controls exhibit impairments on
88 Poster Sessions, Monday 4 June 2012 – Wednesday 6 June 2012
Downloaded from https://academic.oup.com/ijnp/article-abstract/15/Supplement_1/1/650920
by University of Groningen user
on 13 March 2018
cognitive tasks assessing working memory, psychomotor speed and
impulsivity.
Conclusion : Clearly, suicidality among bipolar disorder patients
is a signiﬁcant public health concern worthy of further extensive
examination.
jP-03-039jAssessment of cognitive function across the diﬀerent
phases of bipolar aﬀective disorder
M.I. Vrabie1, I. Miclutia2, V. Marinescu3, C. Popescu4. 1Bucharest,
Romania ; 2UMF Iuliu Hatieganu, Emergency County Hospital, Cluj-
Napoca, Romania ; 3Al. Obregia Hospital, UMF Carol Davila, Bucharest,
Romania ; 4Emergency County Hospital, Cluj-Napoca, Romania
Objective : The objective of this study is identifying speciﬁc domains
of cognitive dysfunction for diﬀerent phases of bipolar disorder.
Methods : We examined 60 bipolar (depressive : Hamilton
Depression Rating Scale HAMD score>=17, manic/hippomanic :
Young Mania Rating Scale YMRS score>=12, euthymic : 6 month of
remission, HAMD score<=8, YMRS score<=6) patients (according
to DSMIVTR). All the patients were free of psychotic symptoms at
the moment of neurocognitive evaluation. The comparison group
consisted of 20 healthy subjects without history of neurological/
psychiatric disorder. The cognitive battery included standardized test
of IQ, attention, working memory, visual memory, verbal memory
and executive functioning. Demographic data (gender, age, years of
education, socioeconomic status and current employment) were sys-
tematically obtained. Data about psychiatric history, past and current
treatment, history of psychosis, duration of illness, age of onset and
family history were collected. We analyzed statistically these data and
identiﬁed speciﬁc domains of cognitive dysfunction for diﬀerent
phases of bipolar disorder.
Results : Cognitive deﬁcits involving executive functioning (work-
ing memory, executive control, verbal ﬂuency, mental manipulation
and cognitive ﬂexibility), verbal learning and memory and attention
are evident across all phases of illness and persist during euthymic
phase too. Sustained attention (vigilance) is impaired in bipolar pa-
tients regardless of whether they are studied during periods of mania
or depression (not remitted completely during euthymia). In addition,
selective attention deﬁcits during acute episodes don’t normalize
during euthymia. Depressed patients have the lowest verbal ﬂuency
and were particularly impaired in domains as aﬀective processing.
Performances on task that tapes domains of verbal learning and
memory, and sustained attention were particularly impaired in manic
patients.
Conclusion : Bipolar patients exhibit widespread neurocognitive
dysfunctions during their lives. There are persistent cognitive deﬁcits
over the course of bipolar disorder and speciﬁc cognitive impairment
of each phase of the illness.
jP-03-040j Identifying and assessing the risk factors for
cognitive impairment in bipolar aﬀective disorder
M.I. Vrabie1, I. Miclutia2, V. Marinescu3, C. Popescu4. 1Bucharest,
Romania ; 2UMF Iuliu Hatieganu, Emergency County Hospital, Cluj-
Napoca, Romania ; 3Al. Obregia Hospital, UMF Carol Davila, Bucharest,
Romania ; 4Emergency County Hospital, Cluj-Napoca, Romania
Objective : The objective of this study is identifying and assessing the
risk factors for cognitive impairment in bipolar disorder.
Methods : We examined 60 bipolar (depressive, manic/hipomanic,
euthymic) patients (according to DSMIVTR). The cognitive battery
included standardized test of IQ, executive functioning, working
memory, attention, visual and verbal memory. Demographic data
(gender, age, years of education, socioeconomic status and current
employment) were systematically obtained. Data about psychiatric
history, past and current treatment, psychosis history, illness
duration, age of onset and family history were collected. We analyzed
statistically these data and assessed the relationships between cogni-
tive deﬁcits and clinical and demographic variables in bipolar
patients.
Results : Cognitive deﬁcits are more frequent in bipolar
patients with more severe course of illness, as indicated by : longer
durations of mood disturbance (negatively correlated with executive
function, psychomotor speed, attention, concentration and verbal
memory-associated with a higher number of past manic episodes too),
younger age at onset, history of multiple and frequent episodes (with
manic episodes impacting neuropsychological impairment most ex-
tensively ; attention and executive function deteriorated by the recur-
rence of episodes) and higher number of hospitalization (negatively
correlated with visual and verbal memory, verbal ﬂuency, spatial
memory, psychomotor speed and executive function). Other risk fac-
tors are : pharmacological treatments, individual response, familial
risk factors (positive family history for mood disorders negatively
inﬂuences cognition), rapid cycling and seasonality, too. There’s as
well a speciﬁc relationship between executive functioning and ad-
mission for mania and between cognitive performance on several
tasks and admission for depressive episodes. Females performed
better on tests for verbal memory. Besides depressive and manic
symptoms, anxiety and psychosis history negatively inﬂuence cog-
nition too.
Conclusion : We evidentiated several risk factors that may inﬂu-
ence cognitive function in bipolar disorder but there’s a growing
need for further clariﬁcation regarding the magnitude, clinical
relevance and confounding variables of cognitive deﬁcits in bipolar
individuals.
jP-03-041jEﬀects of asenapine in bipolar I patients
experiencing manic episodes with depressive
symptoms : Results from post-hoc analyses
E. Weiller1, J.-M. Azorin2, C. Sapin1, K. Hansen1. 1Lundbeck, Issy Les
Moulineaux, France ; 2Hospital Ste. Marguerite, Marseille, France
Objective : Asenapine demonstrated superiority over placebo in
bipolar I disorder patients experiencing acute manic or mixed epi-
sodes in two 3-week, randomised, placebo-and olanzapine-controlled
trials(1,2), and comparable eﬃcacy to olanzapine in a 9-week non-
inferiority double-blind extension trial(3). We assessed the eﬀects of
asenapine on manic and depressive symptoms in patients experienc-
ing manic episodes with depressive symptoms.
Methods : 977 patients were randomised in the original trials to
ﬂexible-dose asenapine (10 or 5 mg twice daily), placebo, or olanza-
pine (5–20 mg once daily) for 3 weeks. In the intent-to-treat popu-
lation, 295 patients had a mixed episode (placebo : 66, olanzpine : 122 ;
asenapine : 107). Of these, 102 patients (olanzapine : 56 ; asenapine : 46)
entered the 9-week extension study. Pooled data were analysed
through analysis of covariance with treatment and centre as factors
and baseline value as covariate on observed cases.
Results : Decreases in YMRS and MADRS total scores were signiﬁ-
cantly greater with asenapine (YMRS :x15.0 ; MADRS :x8.2) versus
placebo (YMRS : x11.5 ; MADRS : x4.5) at week 3 ; diﬀerences be-
tween olanzapine (YMRS : x13.3 ; MADRS : x6.5) and placebo were
not statistically diﬀerent. The eﬀect of asenapine on manic and de-
pressive symptoms was maintained over the extension trial (week 12,
YMRS : x22.4 ; MADRS : x11.9) ; non-statistically diﬀerent from
olanzapine (YMRS : x20.2 ; MADRS : x7.9). At week 3, asenapine
was signiﬁcantly superior to placebo in improving ‘inability to feel ’,
’elevated mood, ‘sexual interest’, ‘ language/thought disorders’,
‘reduced appetite ’ and ‘inner tension’ ; asenapine was signiﬁcantly
superior to olanzapine in improving ‘inner tension’. At week 12,
asenapine was signiﬁcantly superior to olanzapine in improving
‘disruptive/aggressive behaviour’, ‘appearance’ and ‘inability to
feel ’.
Conclusion : In these post-hoc analyses, asenapine had signiﬁcantly
better treatment eﬀects on both manic and depressive symptoms than
placebo, and more pronounced eﬀects than olanzapine in some
symptom domains.
Reference
1. J. Aﬀect. Disord. 2010, 122, 27 2&3. Bipolar. Disord. 2009, 11,
673&815.
Policy of full disclosure : Emmanuelle Weiller is employed by
H. Lundbeck A/S.
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jP-03-042j Increased expression of cortical selenium binding
protein 1 in subjects with schizophrenia but not
mood disorders
T. Money1, M. Udawela2, J. Neo2, G. Perera3, E. Scarr2, B. Dean4,
I.P. Everall2. 1University of Melbourne, Victoria, Australia ; 2Viktoria,
Australia ; 3Victoria, Australia ; 4Mental Health Research Institut,
Kenneth Myer Building, Victoria, Australia
Objective : We previously reported a signiﬁcant upregulation of
selenium binding protein 1 (SELENBP1) in three diﬀerent cohorts of
subjects with schizophrenia1,2,3. We also found a signiﬁcant increase
in SELENBP1 in the blood of a separate cohort1. In this study we
aimed to (i) measure the expression of SELENBP1 in mood disorders
(ii) measure the expression of SELENBP1 in subjects with schizo-
phrenia in three diﬀerent cortical regions to determine whether the
increase in SELENBP1 is widespread and (iii) measure the eﬀect of
exogenous selenium on the expression of SELENBP1 in SH-SY5Y
cells.
Methods : Using qPCR we measured SELENBP1 mRNA in
Brodmann’s area (BA) 9 from 10 subjects with major depressive
disorder, 10 subjects with bipolar disorder and 10 matched non-
psychiatric controls. We also measured SELENBP1 mRNA in BA 8, 9
and 44 from 30 subjects with schizophrenia and 30 non-psychiatric
controls. SH-SY5Y cells were treated with vehicle or 175 mg/L sel-
enium for one hour before RNA was extracted and SELENBP1 ex-
pression measured using qPCR.
Results : There was no signiﬁcant diﬀerence in SELENBP1
expression in subjects with mood disorders compared to controls
(p=0.655). There were signiﬁcant diﬀerences in SELENBP1 ex-
pression between subjects with schizophrenia and control subjects in
BA8 (p<0.0001), BA9 (p=0.036) and BA44 (p<0.0001). There was
no signiﬁcant eﬀect of selenium treatment on the expression of
SELENBP1 in SH-SY5Y cells (p=0.200).
Conclusion : The increase in SELENBP1 expression in schizo-
phrenia extends our previous ﬁndings, demonstrating that the change
is widespread throughout the cortex. These results suggest that the
increase in SELENBP1 is involved in the pathophysiology of schizo-
phrenia, but not in mood disorders. Treatment with selenium had
no signiﬁcant eﬀect on expression of SELENBP1, indicating that the
increased expression of SELENBP1 in the brain may not be an acute
response to increased selenium.
Policy of full disclosure : The authors declare no conﬂict of interest.
P-04. Anxiety Disorders
jP-04-001jPrenatal exposure to modaﬁnil alters anxiety-like
responses in adult mice
P. Amchova1, J. Kucerova2, A. Machalova2, J. Pistovcakova3,
A. Sulcova4. 1Masaryk University, Brno, Czech Republic ; 2Masaryk
University, Faculty of Medicine, CEITEC, Brno, Czech Republic ;
3Masaryk University, Faculty of Medicine, Brno, Czech Republic ;
4Masaryk University, CEITEC, Brno, Czech Republic
Objective : Modaﬁnil (MDF), a psychostimulant drug currently
indicated for treatment of narcolepsy, is often consumed by young
generation in fertile age and thus there is an increasing importance
to assess possible developmental behavioural toxicity. This study in-
vestigated inﬂuence of chronic prenatal exposure to MDF on anxiety-
like measures in adult mouse males.
Methods : Pregnant female mice were given nine doses of saline
(SAL, 10 ml/kg/day) or MDF (50 mg/kg/day). The same drug dos-
age regimen was used in their adult male oﬀspring. Thus, there were
four experimental groups : SAL andMDF oﬀspring from SALmothers
and SAL and MDF oﬀspring from MDF mothers. Anxiety was as-
sessed as % of entries to open and closed arms in the elevated plus
maze on : Day 1 – naı¨ve mice, Day 8 – acute dose of SAL or MDF, Day
15 – one week repeated administration.
Results : Prenatal treatment with MDF increased % of entries to
closed arms compared to SAL prenatal administration (but did not
signiﬁcantly alter % of entries to open arms). In prenatally naı¨ve mice
neither acute nor chronic MDF treatment induced changes in anxiety-
like behaviour compared to SAL treatment. However, in oﬀspring
of MDF treated mothers acute MDF dose signiﬁcantly decreased %
of entries to open arms and chronic MDF treatment signiﬁcantly
increased % of entries to closed arms compared to the prenatally
naı¨ve controls.
Conclusion : We can conclude that MDF did not alter anxiety in
prenatally naı¨ve mice but there was observed partial increase in
anxiety-like behaviour induced by combination of prenatal and post-
natal MDF treatment.
Policy of full disclosure : This work was supported by Masaryk
University Student grant for speciﬁc research : MUNI/A/0852/2010
and Central European Institute of Technology CZ.1.05/1.1.00/02.0068
from European Regional Development Fund.
jP-04-002jEnsemble classiﬁers operating on multimodal
random subsample fMRI-data for robust
between-subject classiﬁcation in SAD
A. Holik1, G. Dorﬀner1, H. Heinzl1, C. Windischberger1,
R. Lanzenberger1. 1Medical University of Vienna, Austria
Objective : Subject-level classiﬁcation of functional imaging data in
populations of controls and patients is typically complicated by the
combined eﬀects of high intra-class and low inter-class variation in
imaging data with high dimensionality. To facilitate classiﬁcation
we propose combining task-speciﬁc derived modalities including
(1) estimates of activation, (2) spatial autocorrelation of activation,
(3) functional connectivity and (4) spectral density in a region of in-
terest-based (ROI) approach adherent to the Automatic Anatomical
Labelling (AAL) atlasing framework. Functional data from 72 subjects
(47 controls, 25 patients) performing a facial emotion discrimination
task in two diﬀerent scanning environments regarding scanner-
hardware, stimulus-design and acquisition parameters was available
for validating our approach.
Methods : Prior to data-aggregation principal component analysis
(PCA) was applied to check for components related to scanning-
environment within each isolated modality. Components displaying
clear separation of both datasets were selectively excluded from
back-projection into original feature-space. Subsequent to data-
aggregation, random forest feature ranking was performed on the
resulting 7389 features. Ensemble classiﬁers were built from nine
leave one out cross-validated (LOOCV) linear discriminant analysis
(LDA) base-learners operating on random feature-partitions of
size=12, thus eﬀectively including only the 108 most informative
features.
Results : Averaged performances of 100 ensembles gave an overall
accuracy of 86.03¡2.08%, a sensitivity of 79.48¡4.61% and a speci-
ﬁcity of 89.51¡1.90% (mean¡SD). Pooled votes from all ensembles
gave 8 misclassiﬁcations with an overall accuracy of 88.89%, a sensi-
tivity of 84.00% and a speciﬁcity of 91.49%.
Conclusion : Our results indicate that even simple base-learners
oﬀer high potential for robust subject-level classiﬁcation of multi-
modal fMRI data when ensembled so as to capture a maximum of
informative features from the data at hand.
jP-04-003jAn investigation of attention process in chronic
fatigue syndrome : Health-threat related attentional
bias and the role of attentional control
R. Hou1, R. Moss-Morris2, A. Risdale3, P. Jeevaratnam3, K. Mogg3,
B. Bradley1, R. Peveler1. 1University of Southampton, United Kingdom ;
2King’s College London, United Kingdom ; 3Southampton, United
Kingdom
Objective : Attentional bias is an important psychological mechanism
that has been extensively explored within literature for anxiety and
more recently for chronic pain. Cognitive behavioural models of
chronic fatigue syndrome (CFS) and chronic pain suggest an overlap
in the mechanisms of these two conditions. The current study in-
vestigated attentional bias towards health-threat stimuli in in-
dividuals with CFS and in healthy controls, and also examined
whether individuals with CFS have impaired executive attention, and
whether this was related to attentional bias.
Methods : 27 participant with CFS and 35 healthy controls com-
pleted a Visual Probe Task measuring attentional bias towards health-
threat stimuli, and an Attention Network Test measuring alerting,
orienting and executive attention. Participants also completed a series
of standard self-report measures.
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Results : When compared to the control group, the CFS group
showed a signiﬁcantly slower reaction time, and a trend of greater
attentional bias towards threat-words than pictures. The CFS group
was signiﬁcantly impaired on executive attention compared to con-
trols. Post-hoc analyses indicated that CFS individuals with poor
executive attention showed a threat-word bias when compared to
controls and CFS individuals with good executive attention.
Conclusion : This was the ﬁrst study to investigate attention pro-
cesses using a combined experimental paradigm and report an inter-
esting relationship between attentional bias and executive attention in
CFS. The study demonstrated that attentional biases in individuals
with CFS are dependent on their capacity to voluntarily control their
attention, which suggests that adding attentional control strategies to
current intervention models may be beneﬁcial for CFS.
jP-04-004jHuman translocator protein (18 kDa) and its genetic
variation in relation to stress sensitivity in patients
with atopic dermatitis
M. Kaga1, K. Nakamura2, S. Kawana3, M. Yoshii4, Y. Nakamoto4.
1Nippon Med. School, Dept. Dermatology, Tokyo, Japan ; 2Hamamatsu
Univ., Shizuoka, Japan ; 3Nippon Med. Sch., Tokyo, Japan ; 4Tokyo
Metropol Inst. Medical Science, Japan
Objective : Expression of the translocator protein (18 kDa) (TSPO),
formerly known as the peripheral-type benzodiazepine receptor, is
correlated with trait anxiety in normal human subjects (Nakamura
et al., 2002). Many dermatological diseases become more serious
under stressful conditions, but their relations to individual’s sensi-
tivity to stress are not well understood.
Methods : To address this issue, we examined patients with atopic
dermatitis (AD) for their expression and genomic variation of TSPO as
well as their levels of anxiety using the STAI scores.
Results : The AD patients (30 males, 22 females) showed higher
STAI scores, especially trait anxiety in males (p<0.001), compared to
healthy subjects. The expression of platelet TSPO was signiﬁcantly
higher in males (p<0.001) and females (p<0.05) compared to their
normal controls (86 males, 70 females). A single-nucleotide poly-
morphism (SNP) of the human TSPO gene at exon 4 (485G>A) lead-
ing to an amino acid substitution of TSPO (Arg162His), which is
associated with anxiety disorders (Nakamura et al., 2006), showed
a signiﬁcantly (p<0.05) diﬀerent frequency distribution in the AD
patients compared to normal subjects : a lower frequency of G/G
(44.2%) and a higher frequency of G/A (50%). The severity of AD
(SCORAD) was signiﬁcantly (p<0.05) correlated with TSPO ex-
pression in male G/A patients.
Conclusion : The results suggest that the 485G>A SNP of the TSPO
gene and the amino acid substitution of TSPO may be related to the
sensitivity to stress and the pathogenesis of AD.
jP-04-005jThe long-term eﬃcacy of escitalopram for the
treatment of korean panic disorder patients : A
prospective, open-labeled, multi-center trial
B. Kim1, K.-W. Choi2, J.-M. Woo2, Y.-R. Kim2, S.-H. Lee2, S.-Y. Lee2,
E.-J. Kim2, S.-K. Chung2, E.-H. Kang2, J.-H. Lee2, B.-H. Yu1. 1Samsung
Medical Center, Seoul, Republic of Korea ; 2Seoul, Republic of Korea
Objective : Objective The purpose of this study was to examine the
long-term eﬃcacy of escitalopram for the treatment of Korean panic
disorder (PD) patients.
Methods : The study subjects were 119 adult PD patients
(18–70 years old) from 6 university hospitals in South Korea (Samsung
Medical Center, Seoul Paik Hospital, Ilsan Paik Hospital, Wonkwang
University Hospital, Ewha Womans University Mokdong Hospital,
and Chonbuk National University Hospital). The structured clinical
interview for the DSM-IV (SCID-IV) was administered to all subjects
by experienced psychiatrists. The primary outcome measures were
improvement on the Panic Disorder Severity Scale (PDSS) and the
remission rate of panic disorder. Secondary outcome measures
included improvement on the Sheehan Disability Scale (SDS). All
Patients were assessed on the Hamilton Rating Scales for Depression
(HAM-D), PDSS, and SDS at baseline and 4, 12 and 24 weeks after
beginning treatment. We used the LOCF method. Repeated measure
ANOVA was used to test for the improvement on the PDSS and SDS.
Results : Among 119 PD patients, 87 patients (73.1%) had attained
a remission state during the 24 weeks of escitalopram treatment.
The mean dose of escitalopram was 11.65¡3.83 mg/day. At the
LOCF week 24 evaluation, a signiﬁcant diﬀerence in PDSS total score
was observed. (ITT :-11.16¡6.51, p-value <0.0001) (t=18.71). In the
post-hoc analysis, we found a continuous signiﬁcant improvement on
the PDSS total score at baseline, week 4, week 12 and week 24.
We found a continuous signiﬁcant improvement on the 3 domains
of SDS (work, social relationship, and responsibilities at home
and with family) at baseline, week 4, week 12, and week 24.
(p-value<0.0001).
Conclusion : This study suggests that long term eﬃcacy of escita-
lopram measured by the PDSS and SDS is high in the Korean PD
patients.
jP-04-006jClinical characteristics of obsessive compulsive
disorder with schizophrenia
M.-S. Koo1, C.-H. Kim2. 1Kwandong University, Goyang, Republic of
Korea ; 2Yonsei University, Seoul, Republic of Korea
Objective : We investigated the prevalence of obsessive compulsive
disorder (OCD) among patients with schizophrenia. We also in-
vestigated the diﬀerences in the psychotic symptoms and suicidality
between patients with schizophrenia who did or did not have OC
symptoms.
Methods : Seventy-one subjects with the DSM-IV diagnosis of
schizophrenia were evaluated by the Structured Clinical Interview for
DSM-IV Axis I disorders, the Yale-Brown Obsessive-compulsive Scale
and the Positive and Negative Syndrome Scale.
Results : The OCD patients with schizophrenia were 20 (28.2%)
among 71 subjects. The 20 subjects with OCD had signiﬁcantly more
severe negative and total psychotic symptoms evaluated with PANSS
than subjects without OCD. The schizophrenia with OCD had sig-
niﬁcant higher recent suicidal attempt rate than the subjects without
OCD.
Conclusion : The results of this study suggest the possibility that
OCD symptoms in schizophrenia may be related to negative symp-
toms and the OC symptoms may be related to the impulsivity ex-
pressed as suicidal attempts.
jP-04-007jNon-verbal memory dysfunction in checking type
obsessive-compulsive disorder
M.-S. Koo1, H.S. Lee2, H.S. Suh3. 1Kwandong University, Goyang,
Republic of Korea ; 2Yonsei University, Seoul, Republic of Korea ; 3Cha
University, School of Medicine, Seoul, Republic of Korea
Objective : The purpose of this study is to examine the role of memory
dysfunction in obsessive-compulsive disorder (OCD). Especially we
tested the memory function of checking type of obsessive compulsive
disorder compare to that of cleaning type and that of normal controls.
Methods : Subjects were 16 patients aged 18–45 years who met the
diagnostic criteria of obsessive compulsive disorder and 8 normal
controls. Informed consent was done. 16 OCD patients was divided
into two groups, 8 ‘checking’ type and 8 ‘cleaning’ type patients by
evaluation of Yale-Brown Obsessive compulsive scale and Maudsley
Obsessive compulsive inventory. All patients were tested memory
functions by Rey-Osterrich comlex ﬁgure test (RCFT) for non-verbal
memory function, Hopkins verbal learning test (HVLT) for verbal
memory function, Wisconsin card sorting test (WCST) and evaluated
depression and anxiety by Beck Depression Inventory (BDI) and
Taylor Anxiety scale.
Results : The Reyimmediate and Reydelayed memory test scores
were signiﬁcantly lower (P<0.05) in checking types than in cleaning
types and normal controls (student t-test). There were no signiﬁcant
diﬀerences of Reycopy test scores, and verbal memory test (HVLT)
scores, BDI and Taylor Anxiety scale scores in checking, cleaning type
groups and normal controls.
Conclusion : The non-verbal memory function of checking type
OCD patients were signiﬁcantly decreased than other OCD patients
and normal controls. This non-verbal memory dysfunction is not re-
lated to depression and anxiety. This results suggest that checking
symptoms development of OCD is related to non-verbal memory
dysfunctions.
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jP-04-008jCaudate asymmetry in obesessive compulsive
disorder : A voxel based morphometry study
M. Nakataki1, S. Sumitani1, H. Kubo1, T. Ohmori1. 1The University of
Tokushima, Japan
Objective : Obsessive-compulsive disorder (OCD) is a common neu-
ropsychiatric disorder, characterized by persistent intrusive thoughts
(obsessions), repetitive actions (compulsions) and excessive anxiety.
Numerous functional neuroimaging studies have suggested that OCD
patients had a neurobiological abnormality in the orbitofrontal-
cingulated-striatal-thalamic circuits. Voxel-based morphometry
(VBM) is a fully automated and unbiased whole-brain method, which
assesses regional diﬀerences between subjects in gray matter (GM).
Several VBM studies have been conducted for OCD, showing volume
alterations in these regions, although the ﬁndings were not entirely
consistent. The application of high magnetic ﬁeld MRI with increased
signal-to-noise ratio would improve the ability to detect subtle
abnormalities for VBM study, whereas there is only one study using
3-Tesla MRI on OCD study. The aim of this study is to contribute to
the validation of morphometric ﬁndings using high magnetic ﬁeld
equipment.
Methods : Thirty-one patients diagnosed with OCD according to
DSM-IV criteria and 31 age- and gender-mached healthy controls
were participated in this study. T1-weighted three dimensional
spoiled gradient echo (SPGR) images were acquired via 3-T MRI
scanner (Signa, GE). MR images were spatially normalized and seg-
mented using the VBM8 package. Statistical analysis was performed
using statistical parametric mapping software. We compared the GM
volume between two groups.
Results : Compared with healthy controls, OCD patients had a sig-
niﬁcantly lower GM volume in the left caudate, right thalamus, right
medial prefrontal and anterior cingulated cortex (Pf0.05, FWE cor-
rected), on the contrary, signiﬁcantly higher right caudate GM volume
(Pf0.05, FWE corrected).
Conclusion : This is the ﬁrst study that revealed the asymmetry
of caudate volume in OCD patients. Other ﬁndings are consistent
with previous studies reporting abnormality in the orbitofrontal-
cingulated-striatal-thalamic circuits.
jP-04-009jLong-term treatment of panic disorder : Tapering out
clonazepam and paroxetine
A. Nardi1, M. Mochcovitch1, R. Amrein1, R. Freire1, M. Versiani1.
1 Institute of Psychiatry – UFRJ, Rio de Janeiro, Brazil
Objective : We describe the successful tapering out of panic disorder
(PD) patients treated for 3 years with clonazepam or paroxetine or
their combination.
Methods : 94 asymptomatic PD patients after three years of drug
treatment and wishful to leave the medication participated in this
trial. The protocol envisaged a dose discontinuation phase protracted
over 8 weeks and 12 months of follow-up. The dose of clonazepam
was decreased in 2-week intervals by increments of 0.5 mg clonaze-
pam until reaching 1 mg/day followed by weekly dose reduction of
0.25 mg ; or 10 mg paroxetine until reaching 20 mg/day followed by
weekly dose reduction of 5 mg.
Results : The mean dose at staring the tapering out was
1.9¡0.3 mg/day of clonazepam and 38.8¡3.9 of paroxetine. 57.8% of
clonazepam and 18.2% of paroxetine patients were free of the medi-
cation after the 2 months of tapering as the protocol. 19 (26.0%) nee-
ded another 3 months to leave the medication. 9 (12.3%) of this last
group used also mirtazapine or carbamazepine as adjunct therapy
during this period. 3 (4.1%) patients gave up the tapering due to re-
turn of anxiety symptoms. The withdrawal symptoms were mild and
observed in 55 (75.3%) patients. Insomnia, tremor, nausea, sweating,
headache, and subjective anxiety were the main complains. Patients of
the clonazepam group had during the withdrawal period fewer side
eﬀects/withdrawal symptoms than those of the paroxetine or combi-
nation group and signiﬁcantly more patients of the clonazepam group
were drug free, asymptomatic and without AE at the end of the ﬁrst
follow up year.
Conclusion : It is possible to take the clonazepam and paroxetine
slowly out even after a long treatment without any major withdrawal
symptom. The dose should be tapered slowly and some adjunct drug
may be useful for some cases.
jP-04-010jState of vegetative provision of women with
anxiety-depressive disorders co-morbid with
polycystic ovary syndrome
R. Nasyrova1, L. Sotnikova2, M. Netkach2. 1Mental Health Research
Institut, Tomsk, Russia ; 2Siberian State Medical University, Tomsk,
Russia
Objective : We have conducted investigation of vegetative status of
women with polycystic ovary syndrome having anxiety-depressive
symptoms.
Methods :We have examined 50 women of reproductive age (18–45
years) with polycystic ovary syndrome (E 28.2 according ICD-10).
Control group has been entered by 25 practically healthy women
matched in age. Presence of vegetative dystonia syndrome was
identiﬁed with ‘‘Questionnaire for Revealing the Signs of Vegetative
Changes’’ (Veyn A.M., 2003). We rated spectral and time character-
istics of variability of heart rhythm with apparatus-program complex
‘‘VNS-Micro’’ (Neurosoft). Results of the investigation were pro-
cessed with program Statistica (version 8.0).
Results : According to results of testing with questionnaire of
Veyn A.M. (2003) syndrome of vegetative dystonia has been diag-
nosed in 84% of the examined. Investigation of variability of heart
rhythm has demonstrated reduction of current functional state
(TP=1132.6¡112.8 mc2/Hz ; in norm 2393.0¡107.6 mc2/Hz, p<0.01),
excessive activation of sympathetic-adrenal system (ratio LF/HF=
1.93¡0.18 ; in norm 0.72¡0.06 ; p<0.01) and reduction of activity
(tonus) of parasympathetic system of regulation (HF-component=
426.2¡21.8 mc2/Hz ; in norm 984.4¡78.1 mc2/Hz, p<0.01). These
changes are pathogenetic basis of development of reactions of dis-
adaptation that manifest themselves clinically as vegetative dysfunc-
tion syndrome.
Conclusion : Vegetative dysfunction accompanies mental symp-
toms. Disorder of vegetative provision of the activity worsens quality
of life of women with anxiety-depressive disorders co-morbid with
polycystic ovary syndrome, conditions insuﬃcient adaptation and is a
predisposition to development of anxiety-depressive disorders.
Complex investigation of status of vegetative neuroses system allows
rating current functional state of the organism and its adaptive re-
serves, giving prognosis of the disease, developing recommendation
in choice of optimal therapy taking into account background of neu-
rohumoral regulation as well as accomplishing the subsequent control
of conducted treatment.
jP-04-011j Involvement of a polymorphism in the 5-HTT gene
in impulsive response style in Japanese population
M. Nomura1, M. Kaneko2, I. Kusumi3, T. Canli4, T. Koyama3, Y.
Nomura5. 1Kyoto University, Japan ; 2Chiba Institute of Science, Choshi,
Japan ; 3Hokkaido University, Sapporo, Japan ; 4Stony Brook University,
New York, USA ; 5Yokohama College of Pharmacy, Kyoto, Japan
Objective : The biochemical mechanism of the 5-HTTLPR gene is
thought to result in enhanced neural processing of the amygdala,
particularly during presentation of negative adverse environmental
cues. Thus, the S-allele of the 5-HTTLPR gene could relatively increase
neuroticism, anxiety (Kaufman et al., 2004), and emotional regulation
disorders in the context of early and adult life adversity (Caspi et al.,
2003). These observations led to the idea that 5-HTTLPR function does
not directly aﬀect the behavioral regulatory process itself, the single
speciﬁc dimension of cognitive function, but possibly via evaluation
of the potential risk accompanied by particular behavioral outputs.
Methods : The polymorphism of the 5-HTT gene promoter was
analyzed by PCR using lymphocytes from 60 volunteers (34 men, age
29.1¡1.4) gave written informed consent and participated in the ex-
periment. Impulsivity was deﬁned as the number of commission
errors (responding when one should not) made during a Go/No-go
task. Stimuli and Procedure : Participants were required to respond to
target stimuli (three-digit numbers) within 800 ms and inhibit their
response to non-targets.
Results : We identiﬁed that while monetary punishment was given
for impulsive behavior (responses for non-target stimuli), the S/S
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homozygous made fewer commission errors than the L-allele carriers.
Given that the S/S homozygous of the 5-HTTLPR gene could rela-
tively increase neuroticism or anxiety, this result is consistent with our
earlier study showing the positive correlation between a high tend-
ency toward neuroticism and a more inhibited response style in a Go/
No-Go task when it entailed the probability of receiving punishment
(Masui, Kashino, Nomura, 2009).
Conclusion : These results suggest the impulsivity are modulated
by sensitivity to punishment as a function of the 5-HTT genotypes ;
this was clariﬁed in Japanese population that present results lead to
the question that whether this eﬀect could be also intermediated by
various environmental factors including culture.
jP-04-012jDisagreement between adolescent and parent reports
of anxiety symptoms : Who is right?
S. Olofsdotter1, S. Vadlin1, K. Sonnby1, K. Nilsson1. 1Centre for Clinical
Research, Vasteras, Sweden
Objective : It is known that adolescent and parent ratings of ado-
lescent mental health are poorly correlated. In a previous study of
adolescent and parent estimations of anxiety using the Spence
Children’s Anxiety Scale (SCAS), a correlation of 0.41–0.66 was re-
ported. This result, however, says little about whose ratings are most
accurate. The aim of our study was to ; 1) investigate the correlation
between adolescent and parent ratings in a Swedish child- and ado-
lescent psychiatric outpatient population, and 2) to compare these
ratings with a semi-structured diagnostic interview (K-SADS), in this
study regarded as gold standard.
Methods : 275 consecutive patients in a child and adolescent psy-
chiatric outpatient clinic in the county of Vastmanland (adolescents
13–18 years and their parents) completed the SCAS. Cut-oﬀs in each
diagnosis was set to +1 Std. dev. above the mean. Thirty of these
patients and their parents also completed a diagnostic interview
(K-SADS) by a specially trained member of the staﬀ, where the inter-
viewers were blinded for the results from the self-assessments.
Results : Overall, parent ratings indicated lower levels of anxiety in
their adolescents compared to the adolescents’ own ratings. Kappa
correspondences between parent and adolescent ratings ranged
from 0.07–0.19. Preliminary results suggest, that adolescent derived-
compared with interview derived diagnoses, have a high concordance
with the diagnoses Generalized Anxiety Disorder and Social Phobia,
(kappa value 1.0).
Conclusion : This study extends the literature in terms of evaluating
adolescent self-reported anxiety symptoms. Unlike previous studies,
our study demonstrates low concordance between adolescent and
parent ratings with the SCAS, and a very high agreement between
adolescent self-reported anxiety and diagnostic interview.
jP-04-013jRelationship between child and adolescent anxiety
disorders and alcohol use disorders : Synthesis of
evidence and literature review between 1990–2012
R.D. Pattanayak1, R. Sagar2, M. Mehta1. 1A.I.I.M.S., New Delhi, India ;
2A.I.I.M.S., New Delhi, India, Additional Professor, India
Objective : Background : While the research in adult population sug-
gests an association between anxiety disorders and risk for alcohol use
disorders, available studies in youth population have inconsistent and
at times, conﬂicting results. Adolescents may show a relatively
heightened sensitivity to some of positive alcohol eﬀects e.g. social
facilitation. The relationship of early onset anxiety disorders to alcohol
use disorders appears to be complex and perhaps bidirectional.
Objective : The present review was planned in order to examine and
describe the nature of association between early-onset (f18 years)
anxiety disorders and alcohol use disorders.
Methods : Relevant studies from English language literature were
included from PUBMED/MEDLINE, PsychINFO and EMBASE
search between 1990–2012 using key words such as [Anxiety or Panic
or Phobia or Agoraphobia, Shyness], [Alcohol or Substance or Drugs]
and [Youth or Early or Child or Adolescent OR Students]. Inclusion
criteria were as follows (a) studies focusing on children and adoles-
cents or, samples with mean agef18 years (b) reporting the original
data (c) assessing the concurrent/prospective prevalence of (any or
all) anxiety disorders and (any or all) alcohol use disorders as per
DSM/ICD, or standard research instruments. Duplicate study data
from same group of researchers were excluded, with the larger sam-
ple retained.
Results : The evidence and strength of relationship diﬀers across the
spectrum of anxiety disorders and whether the alcohol use is prob-
lematic, non-dependent or dependent, in addition to inﬂuence by a
host of other factors e.g. co morbidity. Several lacunae emerged in the
available literature, which are highlighted. Detailed analysis of the
literature review and strength of evidence will be discussed along
with the limitations and future directions.
Conclusion : The link between child and adolescent anxiety dis-
orders and alcohol use disorders provides several interesting insights
and need more research attention.
jP-04-014jAcute administration of escitalopram exacerbates
contextual fear in the startle paradigm in rat
R. Pettersson1, M. Hagsa¨ter2, J. Na¨slund2, E. Eriksson2. 1Neuroscience
and Physiology, Go¨teborg, Sweden ; 2Neuroscience and Physiology,
Department of Pharmacology, Go¨teborg, Sweden
Objective : Selective reuptake inhibitors (SSRIs) generally display
marked eﬃcacy in treatment of anxiety disorders ; however, during
the ﬁrst weeks of treatment patients frequently experience increased
anxiety. The reason for this paradoxical aﬀect is unknown, but re-
vealing it would probably enhance our insight into the physiological
role of serotonin for the regulation of fear and related emotions.
Animal experiments performed in an attempt to investigate the eﬀect
of short-term SSRI administration on anxiety have shown diverse re-
sults : some have revealed increased anxiety-like behavior, whereas
others have shown the opposite, with an immediate decrease in
anxiety-like behavior after acute SSRI administration. In this study the
eﬀect of acute SSRI administration (escitalopram, 10 mg/kg, 60 min
prior to the test) on the acoustic startle reﬂex in a putative animal
model of anxiety, i.e. contextual conditioned fear, was investigated.
Methods : Startle reactivity was measured following fear con-
ditioning. Furthermore, baseline startle, as well as startle in control
animals that had not undergone fear conditioning, was investigated.
Results : Fear-conditioned animals treated with escitalopram 60
min prior to test exhibited signiﬁcantly greater startle than controls.
No signiﬁcant eﬀect of the drug was seen in non-conditioned animals.
Conclusion : These ﬁndings imply that conditions similar to those
in humans are at hand also in rat, i.e. that short-term SSRI adminis-
tration may exacerbate anxiety. This further supports startle reactivity
as measurement of contextual conditioned fear as a useful animal
model for investigating the mechanisms underlying the inﬂuence of
serotonin on anxiety.
jP-04-015jAssotiation of elevation endocannabinoid plasma
levels with mild cognitive impairment and anxiety
in people with obesity
V. Piotrovskaya1, N. Neznanov2, K. Monosova1. 1State Pavlov Medical
University, St. Petersburg, Russia ; 2State Pavlov Medical Universit,
Bechterev Psychoneurologic, St. Petersburg, Russia
Objective : The endocannabinoid (EC) system has been proposed as
regulator of anxiety, and modulator of cognitive, behavioral responses
to stressful stimuli. (1, 2). Also obesity has an association with anxiety
and depression (3).This study focuses on the eﬀects of EC system
modulation in people with obesity of cognition and emotion (anxiety).
Methods : Aim of this study was to evaluate a possible association
between EC plasma levels, such as anandamide (AEA) and
2-arachidonoylglycerol (2-AG), and mental processes such as, cogni-
tive functions and anxiety in obesity. Methods and results. Study
participants (n=67) were divided into three groups dye to there body
mass index (BMI) : control group BMI f24, 9, (n=21) ; overweight
group, BMIo25–30 (n=27), obese group, BMIo30 (n=19). All sub-
jects were passed through tests : MMSE, HADS, and HARS.
Results : Elevation 2-AG plasma level, was signiﬁcantly associated
with BMI in all groups (0.62, p<0.5 ; 0.62, p<0.5 ; 0, 33, p<0.5). Low
MMSE data were signiﬁcantly associated with elevation AEA plasma
level in control group (x0.44, p<0.5) and elevation 2-AG in obese
group (x0.52, p<0.5). In normal and obese group only elevation of
AEA plasma level was associated with high anxiety (0.61, p<0.5).
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In overweight subjects high anxiety was associated with high 2-AG
plasma level (0.47, p<0.5).
Conclusion : Conclusions. Increased EC plasma levels of AEA or
2-AG are associated with increasing of anxiety and poor cognition up
to the mild cognitive impairment.
jP-04-016jPsychological problems in relatives of patients with
severe mental disorder : Assessment and
intervention
M.A. Ramos1, G. Rolda´n1, I. Salazar1, L. Garrido1. 1Hospital Virgen de
las Nieves, Granada, Spain
Objective : This work has two objectives : 1) to identify the psycho-
logical problems in relatives of patients with severe mental disorder
(SMD), and 2) to show the main components of psychological inter-
vention with relatives.
Methods : Relatives of patients were examined in the Day Hospital
of Mental Health of Granada (Spain). The Spanish versions of ‘‘Beck’s
Anxiety Inventory’’, ‘‘Beck’s Depression Inventory-II ’’ and ‘‘Coping
Strategies Inventory’’ were used. The psychological intervention
consisted of 20 weekly sessions of two hours each one. It included : 1)
psycho education ; 2) elaboration of mourning ; 3) acceptance of life
experiences and commitment to values-based living ; and, 4) skills
training. The sessions followed all of them a similar structure con-
sisting of exercise review, functional analysis, use of metaphors, ex-
periential exercises, and training techniques for emotional regulation
and assertive communication.
Results : Regarding the ﬁrst objective, 48 relatives were evaluated.
64.7% of them had depression and 52.2% anxiety. A high relationship
between these two variables was found (r=0.734, p=0.000). With re-
gard to the second objective, nine relatives participated in a psycho-
logical intervention program. Wilcoxon test showed that for people
participating in the program the level of depression decreased and the
use of strategies focused on problem solving increased (p<0.05).
Although anxiety also decreased as a result of treatment it not reached
a signiﬁcant level. 88% of relatives said that the intervention was
useful, and that they applied what they have learned to their daily
lives. 62.5% of relatives have recovered many valued activities of their
lives.
Conclusion : The presence of psychological problems seems high
prevalent among relatives of patients with SMD. The intervention
program was successful, reducing some psychological problems and
improving some coping strategies in relatives. They reported to have
decreased their distress and have recovered valued activities pre-
viously abandoned because of their implication with the care of the
patient.
jP-04-017jRelationship between attachment styles and
personality traits to wellbeing and stress related
disorders
C. Remedi1, C.A. Soria1, D. Nu´n˜ez1, E. Roldan1. 1 Instituto Henri
Laborit, Co´rdoba, Argentina
Objective : The ﬁve most common worldwide diseases planned for
2020 will have stress as an underlying factor. People with this type of
condition display a reversed role with primary caregivers. Insecure
attachment styles and certain personality traits – neuroticism, have
been associated with anxiety and stress related disorders. Because
personality characteristics have emerged as some of the most robust
predictors of anxiety, it was predicted that the link between attach-
ment and stress response be through personality traits. The objective
is to examine associations between attachment styles and personality
traits to sensitization processes in anxiety development.
Methods : Thirty volunteer participants, 22 female (73.6%), 8 male
(26.6%), aged over 21 years completed the personality assessment
NEO-FFI, Adult Attachment Questionnaire and HARS.
Results : Overall, neuroticism, mediated relationship between in-
secure-resistant attachment and anxiety. Higher scores on neuroticism
predicted higher expression of psychopathology and explained
relationship between insecure-resistant attachment and anxiety dis-
orders. Females score signiﬁcantly higher than males in Neuroticism
and symptoms of anxiety (n :22 ; p<0.001) Anxious attachment
style prevailed. Underlying factors related to attachment reveals low
self-steem, need of approval, fear of rejection, as well as feeling´s ex-
pression and comfort with relationships, respectively, scored higher
(46,17 ; 36,94).
Conclusion : Relationships between attachment style and anxiety
appear as indirect, in that neuroticism fully mediates associations
between insecure attachment and anxiety, predictive of maladjust-
ment. Measurement of personality traits and attachment styles may
lead the ﬁeld toward a model that integrates these two issues as
putative predictors of either anxiety or balanced aﬀect.
jP-04-018jAssessment of allostatic load and stress related
disorders through translational evaluation of
alprazolam on MHPG, cortisol and cognitive
domains
C.A. Soria1, C. Remedi1, D. Nu´n˜ez1, E. Roldan1. 1 Instituto Henri
Laborit, Co´rdoba, Argentina
Objective : To assess impact of Alprazolam on salive MHPG and
cortisol, cognitive functions and parameters of allostatic load in anxi-
ety disorders and stress related disorders.
Methods : Fifty volunteer participants, 13 male (26%) and 37 female
(74%) over 21 years, meeting following criteria : NEO-FFI scoring over
18 points, HARS over 7 points, over 3 parameters of
Seeman – McEwen Allostatic Load Parameters and comorbid anxiety
disorder plus at least a stress related disorder. Evaluations were con-
ducted on days x7, 0, 7, 14, 28, 60 and 90, recieving Alprazolam on
day 0 between 0,75 to 3 mg/day according to clinical status. Salivary
concentrations of Alprazolam were monitored from day 7. Clinical
progression was followed up with HARS, STAI, NEO-FFI, neuro-
psychological test battery (Continuous Performance Test, Digit
Symbol, Digit Span, Verbal Fluency Test, Five Points Test, Revised
Taylor Complex Figure Test, Stroop Test), and parameters of allostatic
load measured through clinical and neurobiochemical trials (salivary
MHPG and cortisol).
Results : Saliva MHPG signiﬁcantly reduced 57.3% from visit 1 to
visit 7 with Alprazolam correlating with descending levels of HARS
and STAI (43.1% and 9.4%, respectively), along with steady decrease
in cortisol (15.4%). Females score signiﬁcantly higher than males in
Neuroticism and symptoms of anxiety (n :37 ; p<0.001) MHPG ap-
peared inﬂuenced by life events. Improvement in executive functions
through modulation of anxiety, stabilization in sustained attention,
interference control and decrease in impulsivity rates.
Conclusion : MHPG appears as useful marker to assess stress re-
sponse. Alprazolan impacts rapidly and steadily on ergotrophic acti-
vation to stress response, lowering anxiety scores and promoting
clinical progression through modulation of response to allostatic load.
jP-04-019jEﬃcacy and tolerability of agomelatine in
generalized anxiety disorder (gad) : A randomised
double-blind, placebo-controlled trial with
escitalopram as validator
D. Stein1, M.S. Ma´rquez2, C. Ho¨schl3, A. Ahokas4, K.S. Oh5,
M. Jarema6, A. Avedisova7, L. Vavrusova8, V. Olivier9. 1University of
Cape Town, Department of Psychiatry, Capetown, South Africa ; 2Buenos
Aires, Argentina ; 3Praha, Czech Republic ; 4Helsinki, Finland ; 5Seoul,
Republic of Korea ; 6Warszawa, Poland ; 7Moscow, Russia ; 8Bratislava,
Slovak Republic ; 9Suresnes, France
Objective : Agomelatine, a MT1/MT2 receptor agonist and 5-HT2C
receptor antagonist, has demonstrated eﬃcacy in GAD. This 12 weeks
multi-centre, randomised, double-blind, parallel group study in
GAD aimed to conﬁrm the superiority of agomelatine (25–50 mg/day)
vs. placebo, using escitalopram (10–20 mg/day) as a validator, on the
Hamilton Anxiety Rating Scale (HAMA) total score.
Methods : 412 patients with a DSM-IV diagnosis of GAD were
randomised to receive agomelatine (139), placebo (131) or escitalo-
pram (142). The HAMA total scores at baseline in the Full Analysis Set
(FAS) (n=409) were respectively : 28.6 ; 28.2 and 28.6.
Results : At last value, the HAMA total score decreased signiﬁ-
cantly more with agomelatine x15.6 (p<0.0001) and with escitalo-
pramx15.6 (p<0.0001) compared to placebox10.6. In patients with
more severe GAD symptoms (HAMA total score>=25 and CGI-
S>=5 at baseline), the between group diﬀerence vs. placebo was 5.61
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for agomelatine (SE=1.49, p<0.001) and 4.08 for escitalopram
(SE=1.50, p=0.007). Signiﬁcant improvement of patients’ functioning
was clearly shown on the Sheehan Disability Scale (SDS) for agome-
latine and escitalopram compared to placebo at the last value with a
SDS work score between group diﬀerence vs. placebo of 1.69 for ago-
melatine and 1.55 for escitalopram (SE=0.35, p<0.0001 for both
comparisons). Similar results were observed on both the SDS social
and family life scores (unplanned analyses). The proportion of
patients reporting at least one Emergent Adverse Event (EAE) was
47.5% with agomelatine, 48.2% with escitalopram and 44.3% with
placebo. Fewer patients discontinued the treatment for EAE with
agomelatine (2.2%) and placebo (3.5%) than with escitalopram
(8.5%). The most commonly reported EAEs were headache, naso-
pharyngitis, diarrhoea, and nausea.
Conclusion : This study conﬁrms that agomelatine is eﬃcacious
and well tolerated in the treatment of GAD.
Policy of full disclosure : Pr. STEIN has received research
grants and/or consultancy honoraria from Abbott, Astrazeneca,
Eli-Lilly, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson &
Johnson, Lundbeck, Orion, Pﬁzer, Pharmacia, Roche, Servier, Solvay,
Sumitomo, Takeda, Tikvah, and Wyeth.
jP-04-020j Internet screening for anxiety disorders : Eﬀects on
treatment-seeking behaviour in a 3-month follow-up
study
M. Van Ameringen1, W. Simpson2, B. Patterson3. 1McMaster
University/St.Josephs, Hamilton, Canada ; 2McMaster University/
St.Josephs, MiNDS Neuroscience Graduate Pg, Hamilton, Canada ;
3McMaster University, Psychiatry/Behav.Neurosciences, Hamilton,
Canada
Objective : The internet is an extensive resource for health infor-
mation and is often used for self-diagnosis of mental health symp-
toms. This may be especially common for sensitive, stigma-prone
mental health issues. Numerous barriers prevent people from seeking
proper mental health treatment, however little is known about the
relationship between internet self-diagnosis and treatment seeking
behaviour.
Methods : A link to the MACSCREEN (a validated, self report
screening tool for anxiety and depression) was posted on our home-
page. Three months after completing the MACSREEN and a variety
of symptom severity scales, respondents were emailed a follow up
questionnaire asking about potential treatment-seeking behaviours.
Results : Of the 494 participants who completed the MACSCREEN,
48 completed the follow-up questionnaire. Prior to completing the
survey, 89.6% had planned to seek further assessment. At 3-month
follow-up, 62% reported seeking treatment. The most common bar-
riers to treatment were fear/lack of desire to take medication (50%),
cost of therapy (27.8%) and lack of impairment (27.8%). Compared to
those who did not complete the follow-up questionnaire, follow-up
participants were more likely to have received previous treatment
(p<0.01). All follow-up participants were assessed as having clini-
cally signiﬁcant diagnoses (p<0.001). Higher scores were found on
the Sheehan Disability Scale (p<0.01), and higher rates of Obsessive
Compulsive Disorder, Generalized Anxiety Disorder and Depression
were assessed in the follow-up participants compared with those who
did not complete the follow-up questionnaire (p<0.05).
Conclusion : Some individuals with anxiety disorders use the in-
ternet for self diagnosis. Completion of a self report screening
measure may have stimulated treatment seeking. Potential use of
medication and cost of therapy appeared to be the largest factors
preventing individuals from seeking help.
Policy of full disclosure : Financial Disclosure, Dr. Michael Van
Ameringen : Grant/Research Support : Janssen-Ortho Inc., NIH
(National Institutes of Health), Pﬁzer Inc. Speakers’ Bureau : Valiant,
GlaxoSmithKline, Lundbeck, Pﬁzer Inc. Advisory Boards : Valiant, Eli
Lilly, Janssen-Ortho Inc., Labo Pharm, Lundbeck, Pﬁzer Inc., Shire
William Simpson and Beth Patterson have no ﬁnancial interests to
disclose.
jP-04-021jMedication algorithm for generalized anxiety
disorder in Korea : Treatment strategies for initial
treatment, long-term treatment and comorbid
conditions
H.-S. Suh1, J.-Y. Lee2, S.-H. Lee3, M.-S. Kim4, J.-C. Yang5, C.-H. Kim6,
B.-H. Yu7. 1Kangnam CHA Hospital, Seoul, Republic of Korea ; 2Kumi
CHA Hospital, Republic of Korea ; 3Bundang CHA Hospital, Sungnam,
Republic of Korea ; 4Sankye Baik Hospital, Seoul, Republic of Korea ;
5Chonbuk National Univ Hospital, Jteonju, Republic of Korea ; 6Severance
Mental Hospital, Kwangju, Republic of Korea ; 7Samsung Hospital, Seoul,
Republic of Korea
Objective : This study investigated the consensus about treatment
strategies for initial treatment, long-term treatment and comorbid
conditions in generalized anxiety disorder (GAD) in Korea.
Methods : The executive committee for Korean medication algor-
ithm project for GAD developed questionnaires about treatment
strategies for patients with GAD based on guidelines or algorithms
and clinical trial studies previously published. Fifty-ﬁve (64%) of 86
experts on a committee reviewing GAD in Korea responded to the
questionnaires.
Results : For initial treatment of GAD, antidepressants mono-
therapy and combination of antidepressants and benzodiazepines
were recommended as the 1st line strategies. Escitalopram, paroxetine
CR and venlafaxine XR were selected as 1st line treatments and
alprazolam, clonazepam and lorazepam were preferred in benzo-
diazepines. For the long-term treatment strategy, venlafaxine XR,
escitalopram, ﬂuoxetine, paroxetine CR, sertraline and buspirone
were selected as 1st line treatment. For the consensus of medication
algorithm in the treatment of GAD, step 1 is the use of the one of a
selective serotonin reuptake inhibitor (SSRI), a serotonin and nora-
drenaline reuptake inhibitor (SNRI) and buspirone for at least 4 to
6 weeks. Step 2, ‘switch from a SSRI to a SNRI or a buspirone or vice
versa’, step 3, ‘augment with atypical antipsychotic or add a benzo-
diazepine or antihistamine’, step 4, ‘switch to another combination
that includes SSRI, SNRI, mirtazapine or tricyclic antidepressant ’,
step 6, ‘re-evaluate the diagnosis ’, and ‘benzodiazepines including
clonazepam and alprazolam can be combined with another drug even
from the initial period’ were recommended as 1st line strategy. The
consensus about treatment strategies in the case of GAD with co-
morbid depression recommended SSRIs and SNRIs as the 1st line
drug treatment. SSRIs and SNRIs and benzodiazepines (e.g. alprazo-
lam, clonazepam) were recommended in GAD patients with other
comorbid anxiety disorders.
Conclusion : These results, which reﬂect the recent studies and
clinical experiences, may provide the guideline about optimal medi-
cation treatment strategies for GAD.
jP-04-022jAnxiolytic eﬀects of Yokukansan, a traditional
japanese medicine, via serotonin 5-HT1A receptors
on anxiety-related behaviors in rats experienced with
aversive stress
T. Yamaguchi1, A. Tsujimatsu2, H. Kumamoto2, T. Izumi2, Y.
Ohmura2, T. Yoshida2, T. Yamamoto1, M. Yoshioka2. 1Nagasaki Intl.
Univ., Sasebo, Japan ; 2Hokkaido Univ., Sapporo, Japan
Objective : Yokukansan, a traditional Japanese medicine (Kampo),
has been reported in the treatment of behavioral and psychological
symptoms of dementia (BPSD) such as aggression, anxiety and de-
pression in patients with Alzheimer’s disease and other forms of se-
nile dementia. In the present study, we investigated the anxiolytic
eﬀects of yokukansan on anxiety-related behaviors in rats that have
experienced aversive stress.
Methods : We used male Wistar/ST rats which received an electri-
cal footshock as aversive stress. Yokukansan at a dose of 1.0 g/kg was
administered orally once a day for 14 or 16 days before behavioral
tests. To evaluate the anxiolytic eﬀects, we used the contextual fear
conditioning (CFC) test and elevated plus maze (EPM) test.
Results : In the CFC test, rats that had experienced footshock
showed signiﬁcant freezing behavior on re-exposure to the box
14 days after footshock stress. Yokukansan signiﬁcantly suppressed
freezing behavior in the CFC test. In the EPM test on the 16th day
after the CFC test, yokukansan signiﬁcantly increased the time
spent in open arms after footshock stress compared to control rats.
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These anxiolytic eﬀects by yokukansan were antagonized by WAY-
100635, a selective 5-HT1A receptor antagonist, in the CFC test, but
not the EPM test. Furthermore, 5-HT1A receptor agonist buspirone
signiﬁcantly suppressed freezing behavior in the CFC test ; however,
buspirone induced no change in the time spent in open arms in the
EPM test.
Conclusion : These ﬁndings suggested that yokukansan has anxio-
lytic eﬀects on anxiety-like behaviors induced by both innate fear and
memory-dependent fear. In particular, yokukansan produced anxio-
lytic eﬀects via 5-HT1A receptors in memory-dependent fear induced
by aversive stress. Furthermore, yokukansan could be useful as a
therapeutic drug for the treatment of anxiety disorders and various
mental disorders that have comorbid anxiety.
jP-04-023jStudy of benzodiazepine reception in C57Bl/6
and Balb/c mice
M. Yarkova1, S. Seredenin1. 1 Institute of Pharmacology, Moscow, Russia
Objective : The decrease of benzodiazepine binding in anxiety states
is proved in a number of clinical and experimental investigations.
In our previous experiments, stress in the ‘‘open-ﬁeld’’ test (OF)
caused reduction of benzodiazepine reception in Balb/c mice. In
C57Bl/6 mice such eﬀect was not observed. In the present research
benzodiazepine reception in inbred mice C57Bl/6 & BALB/c
with diﬀerent OF behavior was studied : (1) anxiety factors aﬀecting
benzodiazepine reception, (2) duration of the anxiety-induced ben-
zodiazepine reception reduction.
Methods : Open ﬁeld, Elevated Plus Maze, Short Immobilization,
Exposure to a predator, Radioligand binding assay.
Results : The level of speciﬁc [N-methyl-3H]-ﬂunitrazepam binding
with P1+P2 membrane fraction of C57Bl/6 and Balb/c mice brain
tissue was studied after tests OF, ‘‘Elevated Plus Maze’’ (EPM), 3 h
immobilization, ‘‘Exposure to a predator’’. Stress-induced decrease of
benzodiazepine reception was registered after test OF, EPM only in
Balb/c mice. After test ‘‘Exposure to a predator ’’ and 3 h im-
mobilization signiﬁcant decrease is obtained for both Balb/c and
C57Bl/6. We found that stress in OF signiﬁcantly changed the level of
speciﬁc [N-methyl-3H]-ﬂunitrazepam binding in Balb/c mice brain
for 1.5 h. The restoration of reception to the control level occurred in
Balb/c mice brain after 8 h and after 24 h in C57Bl/6 mice brain after
the test ‘‘Exposure to a predator ’’.
Conclusion : Thus, the duration of recovery of change in benzo-
diazepine binding depends on the phenotype of stress response, the
strength of stress factors and can serve as an important marker of
anxiety.
jP-04-024jA novel open-ﬁeld stress-induced activation of
GAD67-containing 5-HT neurons in the dorsal raphe
nucleus of rats
M. Yoshioka1, H. Shikanai2, T. Yoshida1, K. Konno1, T. Izumi1, Y.
Ohmura1. 1Hokkaido University, Sapporo, Japan ; 2Hokkaido University,
Graduate School of Medicine, Sapporo, Japan
Objective : The presence of GABA and its synthetic enzyme
glutamic acid decarboxylase (GAD) has been reported in 5-HT
neurons in the dorsal raphe nucleus (DRN). However, neurochemical
and functional properties of the GAD-positive 5-HT neurons remain
unknown.
Methods : In the present study, we characterized GAD67-
expressing 5-HT neurons in the rat DRN and also examined
regional diﬀerences in neuronal responsiveness to emotional
stress.
Results : Mild emotional stress induced by open-ﬁeld
exposure caused c-Fos expression in all three subdivisions of
the DRN, particularly in the DRL. This response was selectively
suppressed in the DRL by potentiation of GABA receptors with
diazepam. In the DRL, the open-ﬁeld stress-induced c-Fos ex-
pression was more prominent in 5-HT/GAD67 neurons than in 5-HT
neurons.
Conclusion : These ﬁndings indicate that 5-HT/GAD67 neurons
constitute a unique neuronal population in the DRN and high re-
sponsiveness to mild emotional stress.
jP-04-025jAnxiety disorders among nursery students
F. Zyberaj1, S. Tomori2, I. BRAHO1, E. Petrela2, F. Elezi2. 1Tirana,
Albania ; 2QSUT Nene Tereza, Tirana, Albania
Objective : Evaluation of anxiety symptoms and panic disorder to
Nursery students. We evaluated anxiety symptoms related to panic
disorders where the signs of anxiety which occurred suddenly and the
dynamic and spontaneous growth of fear seem to be very aggravated
and easily understood.
Methods : The study was conducted on the period March–April
2011 (outside the exam season) that included nursery and master level
students. To identify anxiety disorders, especially panic disorders,
Beck Inventory for Anxiety was used. After completing the question-
naire, which consisted of 21 signs of anxiety all the screened persons
who presented with more than four symptoms were evaluated by
psychiatrists as candidates considered to have panic disorder. DSM IV
criteria where used. The sample chosen in this study consisted of 795
students, 679 females and 116 males. The average age was 20.82¡1.29
years, M=20.82 and SD=2.395. Screening with BAI questionnaire,
students were asked for symptoms they had last month and the day of
completing the questionnaire. The diﬀerences were analyzed with
Chi-square and student test.
Results : Variables with statistical signiﬁcance found in this study
are listed as follows : gender is correlated with the manifestation of
anxiety with statistical signiﬁcance p=0.012, of which 34.27% of the
interviewed females presented slight anxiety, 13.74% moderate anxi-
ety and 6.65% (45 of sample students) had severe anxiety scale with
interval rating scale 26–63. Through linear regression analysis a sig-
niﬁcant statistical relation between age and anxiety rate was found
(p=0.001), with smocking (p=0.04) and consumption of alcohol
(p=0.014).
Conclusion : Anxiety is present to the Nursery students and is re-
lated to the age of the students and is related also to substance use.
P-05. Genetics
jP-05-001jThe ‘‘DGPPN – cohort study’’ – a national
collaboration initiative by the German Association
for Psychiatry and Psychotherapy (DGPPN) for
establishing a large-scale cohort of psychiatric
patients
H. Anderson-Schmidt1, S. Demiroglu2, M. Budde3, U. Heilbronner3,
M. Quade2, T.G. Schulze3, D. Cohort Steering Committee4. 1UMG
Goettingen, Germany ; 2UMG Goettingen, Dept. of Medical Informatics,
Germany ; 3UMG Goettingen, Dept. of Psychiatry, Germany ; 4DGPPN,
Berlin, Germany
Results from genome-wide association studies (GWAS) have
demonstrated the need for even larger samples than studied so far
to comprehensively understand the complex genetic architecture of
mental illness. Little is known about the course of various illnesses
over time as information is usually collected retrospectively, and cri-
teria and methodologies used in various studies are heterogeneous.
Therefore, collaborations between diﬀerent centres collecting the
same information longitudinally are essential to understand the re-
lationship between phenotypes and genotypes better. Ideally, any
large-scale collaborative eﬀort should bring together academic and
non-academic centers. To foster such a research framework, the
DGPPN has committed to establish a prospective national cohort of
patients with major psychiatric disorders. The DGPPN Cohort
Steering Committee (Deckert, J., Grabe, H.-J., Gruber, O., Juckel, G.,
Kircher, T., Reif, A., Rujescu, D., Walter, H., Maier, W., Falkai, P.G.,
Rietschel, M.) will supervise the collection of longitudinal data on a
large national scale in centres spread across Germany, using existing
information and re-recruiting patients to collect additional infor-
mation, focusing on the course of illness over time. The use of uniform
phenotyping, standardised measures, identical consent forms, shared
databases and other resources, while simultaneously ensuring the
highest standards of data protection and quality assurance, makes this
a new and exciting attempt to advance our knowledge of psychiatric
disorders. Another asset to this will be the use of a centralised biobank
structure, achieved by networking already established ‘‘biobanks’’.
This will make it possible to pool already existing data from various
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centres, while meeting the highest data protection standards. By
combining resources, the aim is to have a cohort of 100 000 patients by
2020. This cohort will not be restricted to genetic or other biological
psychiatric research but constitute a valuable resource for research
on epidemiological aspects, quality of care, and socio-demographic
aspects of psychiatric morbidity.
jP-05-002jExpression of Wnt/b-catenin signaling pathway
genes in peripheral blood correlate with negative
symptoms among Individuals with psychosis
C. Bousman1, S.J. Glatt, S.D. Chandler, J. Lohr, W.S. Kremen,
M.T. Tsuang, I. Everall2. 1University of Melbourne, Parkville, Australia ;
2Parkville, Australia
Objective : To correlate blood-based gene expression of the Wnt/
b-catenin signaling pathway with negative and positive symptom se-
verity indices of patients with a history of psychosis (i.e. schizo-
phrenia or bipolar disorder).
Methods : A total of 19 subjects meeting DSM-IV criteria for at least
one episode of psychosis were recruited and assessed using the
Scales for the Assessment of Positive and Negative Symptoms (SAPS/
SANS). Twenty-ﬁve of the most well-characterized genes involved
in the Wnt signaling pathway were selected, based on the Kyoto
Encyclopedia of Genes and Genomes database. Spearman’s correla-
tions were conducted between expression intensities for each of the
25 selected Wnt pathway genes and SANS/SAPS global severity
scores, adjusting for gender, ethnicity, age, education, current smok-
ing (yes/no), and past six-month substance use (yes/no). A
Bonferroni-adjusted alpha threshold of 0.05/50=0.001 was used to
reduce the risk of Type I errors.
Results : Two (DVL2 and GSK3B) of the 25 Wnt signaling pathway
genes examined were correlated with scores on the SANS, however,
only DVL2 remained signiﬁcant after Bonferroni correction. DVL2
(r=x0.70, p=0.0008) showed a negative correlation whereas, GSK3B
(r=0.48, p=0.039) was positively correlated with the SANS ratings.
Post-hoc exploration of the four subscales of the SANS revealed sig-
niﬁcant negative correlations between DVL2 expression and aﬀective
ﬂattening (r=x0.55, p=0.015) and alogia (r=x0.65, p=0.003) se-
verity. GSK3B expression was positively correlated with alogia
(r=0.60, p=0.007) only. None of the 25 gene transcripts examined
were signiﬁcantly correlated with severity scores on the SAPS.
Conclusion : Our ﬁndings suggest that the Wnt signaling pathway
may harbor biomarkers for severity of negative but not positive
symptoms.
Policy of full disclosure : There is no ﬁnancial conﬂict of interest.
jP-05-003jMeta-analysis of COMT Val158/108Met association
ﬁndings in major depression
M. Cislakova1, M. Schmo¨ger1, L. Carlberg1, A. Schosser1. 1Medical
University Vienna, Austria
Objective :Many studies described the association of Val158/108Met
polymorphism of the Catechol-O-Methyltransferase (COMT) Gene
and psychiatric disorders including major depressive disorder
(MDD). The COMT Val158/108Met polymorphism has been inves-
tigated regarding its role in aetiology, course of illness and therapy-
response, although with conﬂicting results. In the present study we
therefore perform a meta-analysis of the current literature.
Methods : To identify studies eligible for meta-analysis, we search
the Pubmed andMedline with the Keywords : ‘‘unipolar depression’’,
‘‘major depression’’, ‘‘depressive disorder’’ and ‘‘aﬀective disorder’’
combined with ‘‘COMT’’, ‘‘polymorphism’’, ‘‘gene’’ and ‘‘allele ’’.
Based on this literature research we aim to identify case-control-
studies published in peer-reviewed journals which provide enough
data to calculate an eﬀect size. Studies are excluded from further
examination if cases were selected by questionnaires assessing
symptoms of depression, if the study didn´t include a control group of
subjects or included bipolar patients. The distribution of genotypes
has to be in Hardy-Weinberg Equilibrium to be considered in this
meta-analysis. In addition, references cited in these studies are re-
viewed to identify further publications not obtained by MEDLINE.
Results : The included case-control studies selected in this manner
will be analysed by random eﬀects meta-analysis.
Conclusion : The results of this meta-analysis on COMT Val158/
108Met polymorphism in MDD will be presented.
jP-05-004jSearch of rare genetic variants of psychotic disorders
in Algerian consanguineous families
A. Dahdouh1, M. Guipponi2, P. Courtet3, F. Bena2, R. Benosman4,
M. Taleb5, N. Perroud2, B. Semaoune6, S. Antonarakis7, A. Malafosse2.
1CHU Oran, Algeria ; 2HUG, Geneva, Switzerland ; 3CHU Montpellier,
France ; 4CHU Tlemcen, Algeria ; 5CHI Vernon, Paris, France ; 6HCA
Alger, Algeria ; 7HUG Geneva, Switzerland
Objective : Several recent studies have reported associations of
schizophrenia (SZP) with rare copy number variations (CNVs), such
as 1q21.1 and 15q13.3 deletions. These CNV results suggest a broader
neuropsychiatric spectrum of phenotypes, and support a ‘‘Common
Diseases – Many Rare Alleles ’’ hypothesis. The majority of these
CNVs are de novo, and we lack information about the phenotypes
associated with such variants when they are transmitted. These
results also suggest that other types of rare mutations could be as-
sociated with psychotic disorders. We are studying four families from
North-West Algeria identiﬁed through patients with psychotic dis-
orders, in order to identify new rare variants responsible for these
disorders.
Methods : We are studying four consanguineous families from
Tlemcen in North-West Algeria with 30 patients with psychotic dis-
orders, in order to identify new rare variants. Information was col-
lected about direct interview (DIGS) and medical records. The Agilent
Human Genome CGH Microarray Kit 44K is used for the genome-
wide DNA copy number variation proﬁling, and the Illumina’s
Genome AnalyzerIIe for exome high-throughput sequencing.
Results : In three families all the aﬀected members analyzed up to
now are schizophrenics and in one bipolar I (BDI) with psychotic
symptoms. Three new CNVs have been identiﬁed, one 1.6 Mb dupli-
cation on chromosome 4q26 and on small 28.8 deletion on chromo-
some 16q23.1 and deletion 21q21.1. Segregation of these new CNVs is
currently analyzed. Sequencing data are not yet available.
Conclusion : This ongoing study of three Algerian families with
SZP and one with BDI allow us to identify two new CNVs. Complete
CNV analysis and exonic sequencing will be presented.
jP-05-005jQuantitative smoking eﬀects diﬀerences in male mu
opioid A118G alleles
E. Domino1, C. Evans1, L. Ni1, S. Guthrie1, R. Koeppe1, J.-K. Zubieta1.
1University of Michigan, Ann Arbor, MI, USA
Objective : The objective of the present study was to provide ad-
ditional support for a role of mu opioid receptors in tobacco smokers.
There are basic and clinical studies indicating that the endogenous mu
opioid system is involved with several substances of abuse.
Methods : After overnight tobacco abstinence, 14 genotyped males
smoked denicotinized (denic) and average nicotine (avnic) containing
tobacco cigarettes in a PET brain imaging study using 11C-raclopride.
Results : Mean decreased dopamine (DA) binding was observed in
the left dorsal caudate (x14 6 11 ; t=3.77), left and right ventral pu-
tamen (x26 3 8 ; t=4.27 ; 28 2 1 ; t=4.25, respectively), and right cau-
date (17 18 1 ; t=3.92). The eﬀects of the A118G genotype on the
binding potentials for these four regions were analyzed after denic
minus avnic tobacco smoking. Carriers of the G allele demonstrated
larger magnitudes of DA release in response to avnic smoking than
those homozygous for the more prevalent AA allele in the right cau-
date and right ventral pallidum (t=3.03 ; p=0.008 and t=3.91 ;
p=0.001). A voxel by voxel whole brain SPM analysis using an inde-
pendent samples t test did not reveal any other diﬀerences between
genotype groups. In addition, the venous plasma cortisol levels of the
volunteers from 8:30 a.m. to 12:00 p.m. were lower in the AG/GG
alleles. Avnic smoking increased plasma cortisol in both groups, but
they were higher in the AA group.
Conclusion : The present results indicate that the mu opioid re-
ceptor function has important tobacco smoking eﬀects.
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jP-05-006j Investigating telomere length and psychological
stress in South African rape victims
S. Hemmings1, S. Malan1, M. Kidd1, L. Martin1, S. Seedat1.
1Stellenbosch University, Tygerberg, South Africa
Objective : Women are at an increased risk of depression and other
mental health problems following rape. Various aetiological factors
for depression, including predisposing genetic factors, have been
identiﬁed. Telomeres are repetitive nucleoprotein structures located
at chromosomal ends that protect them from premature degradation.
Telomeres reduce in length with each cell division, resulting in cellu-
lar senescence and apoptosis. Additional factors, such as oxidative
and psychological stress, can further induce telomere shortening.
Methods : This study performed relative quantiﬁcation of telomeric
repeats with the use of real-time PCR methods to investigate whether
shorter relative leukocyte telomere length (LTL) in a cohort of rape
victims was associated with resilience, the development of trauma-
related major depressive disorder (MDD), as well as the development
of PTSD after three months.
Results : No signiﬁcant associations were observed between rela-
tive LTL and resilience or the development of MDD at either baseline
or after three months in this cohort. However, a signiﬁcant association
was evident between relative LTL and PTSD status.
Conclusion : The signiﬁcant association between relative LTL
and PTSD suggests that shorter relative LTL might have acted as a
predisposing factor to the development of PTSD after a severely
traumatic event. Telomere shortening may be an important marker of
PTSD risk, which has implications for early intervention and timely
treatment.
jP-05-007jEpigenome analysis in neurons of bipolar disorder
and schizophrenia
K. Iwamoto1, M. Bundo2, J. Ueda3, T. Miyauchi3, A. Komori-Kokubo3,
K. Kasai4, T. Kato3. 1Tokyo University, Japan ; 2University of Tokyo,
Grad. Sch. Med, Japan ; 3RIKEN BSI, Tokyo, Japan ; 4University of Tokyo,
Japan
Objective : Epigenetic factors such as cytosine and histone modi-
ﬁcations are involved in long-lasting gene expression change and are
believed to play important roles for the pathophysiology of
major psychiatric diseases. Here we performed comprehensive DNA
methylation analysis using brains of patients with schizophrenia
(N=35), bipolar disorder (N=35) as well as controls (N=35).
Methods : Postmortem brains (prefrontal cortex, BA10) were
obtained from the Stanley Medical Research Institute. We have pre-
viously established a method for the separation of neuronal and
non-neuronal nuclei from the fresh-frozen postmortem brain using
NeuN-based cell sorting. By using this separation method, neuronal
(NeuN+) and non-neuronal (NeuNx) fractions were obtained from
each brain sample. After the enrichment of methylated DNA with
MBD2B protein, DNA methylation proﬁles were obtained with
Aﬀymetrix promoter tiling arrays. Methylated region was identiﬁed
with MAT software.
Results : In both psychiatric diseases, we identiﬁed speciﬁc
DNA methylation diﬀerences compared to control subjects. Rep-
resentative methylation diﬀerences were extensively conﬁrmed by
qPCR analysis.
Conclusion : Some of DNA methylation diﬀerences were only
found in neuronal or non-neuronal nuclei, suggesting the cell-type
speciﬁc DNA methylation changes in patients’ brain. Such DNA
methylation change may contribute to the pathophysiology of psy-
chiatric diseases.
jP-05-008jAssociation between the CLOCK gene and autism
symptoms in a Swedish twin sample
L. Jonsson1, H. Larsson2, A. Zettergren1, L. Westberg1,
H. Anckarsa¨ter1, P. Lichtenstein2, J. Melke1. 1University of Gothenburg,
Sweden ; 2Karolinska Institutet, Stockholm, Sweden
Objective : Autism spectrum disorders (ASDs) are pervasive
developmental disorders that include Autistic disorder, Asperger
syndrome, and pervasive developmental disorder-not otherwise
speciﬁed (PDD-NOS). Many patients with ASD have sleep im-
pairments and timing problems, suggesting disturbances in the
regulation of circadian rhythm as causative factors for these disorders.
Indeed, low levels of melatonin are recurrent biological ﬁndings
and we have previously found association between genes in the
melatonin pathway and ASDs. Melatonin is closely related to the
circadian rhythms, which is mainly regulated in the suprachias-
matic nucleus (SCN) by a set of clock genes. Genetic variation in
the clock genes have previously been investigated in autism
patients showing an association with the clock genes PER1 and
NPAS2. In this study, we have investigated the possible association
of ﬁve circadian clock genes on autism symptoms in a Swedish
twin sample.
Methods : Single nucleotide polymorphisms in ﬁve circadian clock
genes were genotyped in The Child and Adolescent Twin Study in
Sweden (N=1771, 9–12 years old). The measured autism symptoms
were ﬂexibility, language and social interaction. In addition, the
CLOCK gene was screened for mutations in patients with autism
(N=90).
Results : Our results show a signiﬁcant association in girls between
rs1801260, in the 3-UTR, of the CLOCK gene, and the symptom ﬂexi-
bility (p=0.0003), but not with the symptoms language and social
interaction. The mutation screening revealed ﬁve rare, previously not
reported, variants in six diﬀerent patients.
Conclusion : In conclusion, our results support the hypothesis that
clock genes may be involved in autism related disorders. Moreover,
since all symptoms of autism did not show similar associationwith the
investigated clock genes in this study, our ﬁndings also emphasizes
that genetic research may beneﬁt from taking a symptom-speciﬁc
approach to ﬁnding genes associated with autism.
jP-05-009j Involvement of the 5-HT2A receptor gene
polymorphism in trait anxiety, in activity of VLPFC
and in impulsivity : A NIRS study
S. Kajimura1, M. Kaneko2, J. Nomura3, Y. Okuma2, Y. Nomura4,
M. Nomura1. 1Kyoto University, Japan ; 2Chiba Institute of Science,
Japan ; 3 Johns Hopkins University, Washington, D.C., USA ; 4Yokohama
College of Pharmacy, Japan
Objective : A polymorphism of the 5-HT2A receptor gene has been
suggested to underlie the impulsive behavior. However, relations
among this gene polymorphism, impulsivity and activity of brain
(especially ventro-lateral prefrontal cortex, VLPFC) remain unclear.
We examined whether and how this 5-HT2A receptor gene poly-
morphism modulates impulsivity in a reward-punishment Go/No-go
task and related brain activity measured by near infrared spec-
troscopy (NIRS).
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Methods : Participants : Twenty-seven women (age 21.26¡2.91 ; AA
carriers (AA, n=7) and G carriers (AG and GG, n=20)) gave written
informed consent and participated in the experiment. Stimuli and
Procedure : Participants were required to respond to target stimuli
and to inhibit their response to non-target stimuli with either monet-
ary reward or monetary punishment. The Go/No-go task was per-
formed by each participant under two conditions (reward condition
and punishment condition). Hemodynamic responses of the brain
were acquired using NIRS. After the task, participants answered the
STAI questionnaire.
Results : G carriers compared to AA carriers responded slower to
Go stimuli (p<0.05, Fig. 1 (a)) and made more omission errors
(p<0.10) in Go/No-go task. Correspondingly, STAI scores showed
high trait anxiety of the G carriers compared with the AA carriers
(p<0.05, Fig. 1 (b)). Moreover, the AA carriers showed more acti-
vation in the right VLPFC under the risk of punishment (Fig. 1 (c)).
Conclusion : These results suggest that 1) G carriers are more
cautious than AA carriers ; which is consistent with previous study
(e.g., Nomura et al., 2006), and 2) AA carriers have the possibility,
under certain risky conditions, to show decreased function of the
right VLPFC, which might trigger the impulsive behavior. Further
behavioral studies with measurement of 5-HT2A receptor gene poly-
morphisms should be carried out to clarify the complex relation-
ships between personality traits and vulnerability to impulsive
behaviors.
jP-05-010jShared susceptibility of the peroxisome proliferator
activated receptor-gamma gene in altered glucose
levels and psychosis proﬁles in schizophrenia
patients
E.-W. Loh1, S.-W. Kuo2. 1 Institute of Population, Health Sciences, Miaoli
County, Taiwan ; 2Miaoli County, Taiwan
Objective : Glucose and lipid metabolisms are partly regulated by
peroxisome proliferator activated receptor-c(PPAR-c). Schizophrenia
like syndrome may be induced by retinoid toxicity or deﬁciency,
through actions involving retinoid X receptor-a and PPAR-c hetero-
dimers. Interestingly, glucose and lipid abnormality is common in
schizophrenia patients. We hypothesized a role of the PPAR-c gene in
metabolic and psychosis proﬁle in schizophrenia patients.
Methods : Metabolic proﬁle and single nucleotide polymorphisms
(SNPs) of the PPAR-c gene were examined in 394 schizophrenia pa-
tients, and 372 patients rated with Positive and Negative Syndrome
Scale (PANSS).
Results : Associations of multiple SNPs were identiﬁed in HbA1c
and FPG in linear regression models (GLMs). Two single SNPs were
found associated with triglycerides and high density lipoprotein
cholesterol (HDLC). No associations were found in other metabolic
indexes. Haplotypes were formed from 6 SNPs associated with
HbA1c, and further GLMs and permutation tests provided evidences
supporting a role of the PPAR-c gene in psychosis proﬁle. Pro12Ala
(SNP-11, rs1801282), a nonsynonymous variant at exon B, was asso-
ciated HDLC but not HbA1c or FPG. This implicates that PPAR-c
isoform that contains amino acids coded in exon B, either protein or
mRNA, may play a role in the regulation of HDLC. The consistency of
G and A allele in the signiﬁcant haplotypes suggested that 5’UTR and
intron B may consist genetic variations essential to psychosis proﬁle.
Conclusion : Our study suggests a shared susceptibility of the
PPAR-c gene in altered glucose levels and psychosis proﬁle in
schizophrenia patients, possibly by modifying the mechanisms in-
volved.
jP-05-011jCase report of a patient with schizophrenia and
a mutation in the insulin receptor substrate-4 gene
K. Melkersson. Karolinska Institutet, Upplands Va¨sby, Sweden
Objective : This report concerns a 50 year-old female patient, diag-
nosed with paranoid schizophrenia according to the DSM-IV criteria
and on long-term treatment with perphenazine, who participated in a
recent study regarding the insulin receptor substrate-4 (IRS-4) gene
and schizophrenia (Melkersson et al., 2011).
Methods : The patient gave her written informed consent to par-
ticipate in this case report. She was interviewed by a psychiatrist
about her mental and physical health and a venous blood sample was
taken in an EDTA-containing tube and stored at x20 xC until prep-
aration of DNA. Then, DNA-sequencing of the whole IRS-4 gene on
the X-chromosome was performed.
Results : The DNA sequence of the IRS-4 gene from the patient was
compared to the reference sequence of the gene (http://www.
ensembl.org/release 46) and it was found that the patient had what is
referred to as a mutation : the G/A genotype instead of G/G, G/C or
C/C at gene position 107863596, resulting in a change in amino acid
coding from histidine to tyrosine at amino acid position 879.
Conclusion : Since the IRS-4 protein may be involved in neuronal
growth and function in several areas of the brain, it is possible that this
IRS-4 gene mutation underlies this patient’s schizophrenia develop-
ment. It also seems that this patient belongs to the group of schizo-
phrenia patients who have multiple individually rare mutations,
impacting genes in pathways of the brain important for neurodeve-
lopment and/or neurotransmission, thereby contributing to schizo-
phrenia (Walsh et al., 2008). Melkersson K, et al. (2011). The insulin
receptor substrate-4 (IRS-4) gene and schizophrenia : no evidence for a
main genetic factor, however one report of a single schizophrenia
patient with a mutation. Neuroendocrinology Letters 32, 101–108.
Walsh T, et al. (2008). Rare structural variants disrupt multiple genes
in neurodevelopmental pathways in schizophrenia. Science 320,
539–543.
jP-05-012jConvergent functional genomics of schizophrenia :
From comprehensive understanding to genetic risk
prediction
A. Niculescu. Inst. of Psychiatric Research, Indianapolis, USA
Objective : We set out to comprehensively identify candidate genes,
pathways and mechanisms for schizophrenia,expanding upon our
earlier work on identifying genes for schizophrenia and biomarkers
for psychosis, by integrating the available evidence in the ﬁeld to date.
Methods : We have used a translational convergent functional
genomics (CFG) approach to identify and prioritize genes involved in
schizophrenia, by gene-level integration of genome-wide association
study (GWAS) data with other genetic and gene expression studies
in humans and animal models.
Results :Using this polyevidence scoring and pathway analyses, we
identify top genes (DISC1,TCF4, MBP, NRCAM, NCAM1, NDUFV2,
as well as ADCYAP1, BDNF, CNR1, COMT, DRD2, DTNBP1, GAD1,
GRIA1, GRN2B, HTR2A, MOBP, NRG1, RELN, SNAP-25, TNIK),
brain development, myelination, cell adhesion, synaptic long term
potentiation, and glutamate receptor signalling as key to pathophy-
siology and as targets for therapeutic intervention. Overall, the data is
consistent with a model of disrupted connectivity in schizophrenia,
resulting from the eﬀects of neurodevelopmental environmental
stress on a background of genetic vulnerability. In addition, we
show how the top candidate genes identiﬁed by CFG can be used to
generate a polygenic risk prediction score to aid schizophrenia diag-
nostics. We also show, in three independent cohorts, two European-
American (EA) and one African-American (AA), increasing overlap,
reproducibility and consistency of ﬁndings from SNPs to genes, then
genes prioritized by CFG, and ultimately at the level of biological
pathways and mechanisms. Lastly, we compared our top candidate
genes for schizophrenia from this analysis with top candidate genes
for bipolar disorder and anxiety disorders from previous CFG analy-
ses conducted by us, as well as ﬁndings from the ﬁelds of autism and
Alzheimer.
Conclusion : Overall, our work maps the genomic and biological
landscape for schizophrenia, providing leads towards a better
understanding of illness, diagnostics, and therapeutics. It also reveals
the signiﬁcant genetic overlap with other major psychiatric disorder
domains, sugesting the need for improved nosology.
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jP-05-013jNeuropsychological correlates of transcription factor
AP-2b in healthy females
I. Schabram1, T. Eggermann1, K. Zerres1, G. Gru¨nder1, I. Vernaleken1.
1University Hospital Aachen, Germany
Objective : Studies have shown that transcription factors indi-
rectly inﬂuence the catecholamine metabolism. In particular, AP-2b
is associated with the transcription of genes important for the function
of the dopaminergic system. Studies postulated an association of the
AP-2b-polymorphism to behavioural traits and CSF-HVA levels. As
the dopaminergic system is associated with cognitive performance,
this hypothesis-driven investigation focusses on the relationship be-
tween AP-2b, COMT, and cognitive performance.
Methods : 194 healthy, non-smoking females (mean-age 24.01y ;
SD=3.35) are neuropsychologically tested. The Trail-Making-Test
part-B (TMT-B), Stroop, and dsCPT (degraded stimulus Continuous
Performance Task) were performed. Furthermore, blood samples
(5–15 ml) for the genetic characterization (AP-2b & COMT) were
withdrawn.
Results : Homocygotous carriers of the short (4/4) alleles
(M=40.33s, SD=9.01) are signiﬁcantly faster in the TMT-B compared
with the long (5/5) allele carriers (M=50.12s, SD=11.54 ; p<0.0001 ;
Bonferroni corrected). Furthermore, the results show on trend-level
that the 4/4 allele carrier made less mistakes during the dsCPT com-
pared to 5/5 carrier. Additionally, participants with at least one short
AP-2b allele show signiﬁcant eﬀects of COMT on TMT-B perform-
ance. In this group, allele carriers of val/val or val/met perform sig-
niﬁcantly better than met/met carriers (T=2.172, p=.034).
Conclusion : The study followed a hypothesis-driven approach.
The results show that AP-2b has a highly signiﬁcant and clinically
relevant impact on cognitive performance. TMT-B and dsCPT results
point to the same direction (4/4 better than 5/5 carrier). Moreover,
AP-2b seems to interact with COMT on cognitive performance.
Further investigations have to replicate these results and need to
prove whether these results are based on diﬀerences in the dopami-
nergic transmission/turn-over.
jP-05-014jTranscription factor activating protein 2 beta
(tfap2-b) genotype and co-occurring symptoms of
attention deﬁcit hyperactivity disorder and
depression in two samples
K. Sonnby1, K.W. Nilsson1, N. Nordquist2, E. Comasco2, J. Leppert1,
L. Oreland2, R. Sjo¨berg3. 1Centre for Clinical Research, Va¨stera˚s,
Sweden ; 2Uppsala, Sweden ; 3Umea˚, Sweden
Objective : Familial studies of Attention Deﬁcit Hyperactivity
Disorder (ADHD) suggest that there may be a genetically determined
subtype of ADHD, most common among girls, which is characterized
by comorbid depression. Furthermore, variation in the ﬁrst intron
of the Transcription Factor Activating Protein 2 Beta (TFAP2-b) gene
has been shown to inﬂuence monoaminergic neurotransmission in
rodents and several genes of importance for monoaminergic function
have binding sites for the TFAP-2b. The present study examines the
possible role of a functional Variable Number of Tandem Repeats
(VNTR) polymorphism located in intron 1 of the TFAP2-b gene in the
context of co-occurring symptoms of ADHD and depression.
Methods : Symptoms of ADHD and depression were measured by
self-reports in two population-based samples of adolescents (group A,
n=175 and group B N=1506) from Sweden.
Results : There were 6.1 to 7.8% of adolescents who screened posi-
tively for ADHD and depression symptoms. In both samples symp-
toms of depression were more common among girls who screened
positively for ADHD andwho were not carriers of the 9 repeat version
of the TFAP-2b intron 1 VNTR genotype.
Conclusion : The presence of the 9 repeat variant of the TFAP2-b
intron I VNTR appears to protect girls with ADHD symptoms from
developing symptoms of depression.
jP-05-015j Inﬂuence of family and education factors on
the inclination to commit crimes in Soviet times
and today
E. Valzdorf. Irkutsk, Russia
Objective : 35 reports of the Commission of forensic psychiatric
experts over the period March 2010–1, 35 archive acts of outpatient
forensic psychiatric examination that covered the period March
1991–2 were analyzed.
Methods : The statistic, comparative analysis and the method of
random sampling.
Results : The study found out that 20-of 1 were held criminally
responsible under article 131 of the RF Criminal Code-CC, 13–under
article 132, and 2–135. Out of them 14-received incomplete secondary
education, 7 did not receive any education at all, 6-received full sec-
ondary education, 4–incomplete secondary vocational education,
4–higher vocational education and 1-received education in the form of
8 years of special school. 10 patients were brought up in the family in
which either 1 or both parents abused alcohol, 9-were raised and de-
veloped in a one-parent family, 8-did not have parents at all and only
8 were brought up in secure families.The 35-of 2 included 9-that were
held criminally responsible under article 144 of the RSFSR CC,
5–under article 108 ; 4–103, 145 ; 2–under each of articles 117, 206, 246 ;
1 under each of articles 89, 102, 120, 148, 188, 212, 224. In 2 there were
15-with incomplete secondary education, 13-incomplete secondary
vocational education, 5–full secondary education and 2–full second-
ary vocational education.The anamnestic data showed that 18 patients
from 2 were brought up in the family where either one or both parents
abused alcohol, 28 were raised in a two-parent secure family, 4-raised
in a one-parent family and 3 did not have parents.
Conclusion : The study demonstrated clear relationship between
the education level and some family factors aﬀecting the inclination to
commit criminal oﬀences. In Soviet times there were mainly property
crimes and they were committed by individuals whose education by
the time of criminal responsibility was 9 years of secondary school
and who were raised in two-parent families.
jP-05-016jA novel mutation in exon 2 of the MAPT gene
causing frontotemporal dementia
C. Zekanowski1, M. Berdynski2, K. Zielke3, M. Barcikowska2.
1Medical Research Center, Polish Academy of Sciences, Warszawa, Poland ;
2Medical Research Center, Warszawa, Poland ; 3Department of Psychiatry,
105 Military Hospital, Zary, Poland
Objective :Mutations in the microtubule-associated tau (MAPT) gene
are associated clinically with frontotemporal dementia (FTD) with or
without supranuclear palsy, corticobasal syndrome or parkinsonism.
The pathogenic mutations are located mostly in exons 9–13, and in
intron 10. Only two mutations are located in exon 1, coding for
N-terminal part of the tau protein. The aim of the study was to iden-
tify the genetic basis of clinically diagnosed frontotemporal dementia
in a female patient.
Methods : Clinical evaluation of the patient and genetic analysis of
the MAPT.
Results : A novel mutation G55R located in exon 2 of MAPT was
identiﬁed in a female patient with age of onset 51 y. and with a posi-
tive family history for dementia. The mutation is absent in a group of
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45 FTD cases (familial, and some sporadic), as well as in a group of 100
neurologically healthy subjects (>65 y). Three years after the ﬁrst
symptoms developed the patient presented aphasic disturbances and
spatio-visual disturbances with no psychotic symptoms, and no ag-
gressive behaviors. In neurological examination deliberative symp-
toms were observed. Her MMSE score was 10. A brain MRI showed
generalized brain tissue lesions, most pronounced in frontal lobes,
parietal lobes and temporal lobes ; ventricular enlargement. No par-
kinsonism, and no additional clinical symptoms were identiﬁed.
Conclusion :A novel FTD-causing mutation located in exon 2 of the
MAPT gene was identiﬁed. In silico analysis predicted that the mu-
tation is damaging on protein structure and function, and could in-
ﬂuence the ability of tau protein to regulate the dynamic behavior of
microtubules.
jP-05-017jAssociation between polymorphisms in sex steroid
related genes and autism symptoms in a Swedish
population
A. Zettergren1, L. Jonsson1, J. Melke1, H. Anckarsa¨ter1,
P. Lichtenstein2, L. Westberg1. 1Go¨teborg University, Neuroscience and
Physiology, Sweden ; 2Karolinska Institute, Dept. of Medical Epidemiology,
Stockholm, Sweden
Objective : Sex diﬀerences in psychiatric disorders are common,
which is particularly striking in autism that is ﬁve times more preva-
lent in boys. It has been hypothesized that high levels of testosterone
during early development may be a risk factor for autism. This theory
has been supported by several studies showing fetal testosterone le-
vels, as well as indirect measures of prenatal androgenization, to be
associated with autism and autism-related personality traits. Further,
the importance of sex steroid related genes in autism is supported by
studies reporting associations between polymorphisms in genes in-
volved in sex steroid synthesis/metabolism and autism and/or au-
tistic traits. The aim of the present study was to investigate possible
associations between 29 polymorphisms in 8 genes related to sex
steroids and autism symptoms in a general population.
Methods : Subjects used in the study are a subset from The Child
and Adolescent Twin Study in Sweden (CATSS, N=1771). The par-
ents of the subjects were asked to ﬁll out the telephone interview
Autism–Tics, ADHD, and Other Co morbidities inventory (A-TAC).
Factor analyses in CATSS, using A-TAC, have revealed that the three
dimensions of autism symptoms were social interaction, communi-
cation and ﬂexibility. DNA was extracted from saliva samples using
OraGene1 DNA self-collection kit. The polymorphisms were geno-
typed with KASPar1 PCR SNP genotyping system (KBiosciences,
Herts, UK). The genotyping success rate was >95% and all SNPs
were in Hardy-Weinberg equilibrium.
Results : About 14 associations between any of the investigated
polymorphisms and autism dimensions were found at p<0.05.
For two SNPs (in ESR1 and SRD5A2) the associations survivied
Bonferroni correction for multiple testing.
Conclusion : In conclusion, polymorphisms in sex steroid related
genes known to aﬀect gene expression (the polymorphism in ESR1)
and enzymatic activity (the polymorphism in SRD5A2) seem to in-
crease the risk of autism symptoms in boys and girls respectively.
P-06. Pharmacogenetics/Pharmacokinetics
jP-06-001j Inﬂuence of dopamine D3 receptor gene variation on
electroconvulsive therapy response in depression
K. Domschke1, U. Dannlowski2, E. Birsova3, T. Suslow4, C. Konrad5,
H. Kugel2, P. Ohrmann2, J. Bauer2, V. Arolt2, B. Baune6, P. Zwanzger2.
1University of Wuerzburg, Germany ; 2Muenster, Germany ; 3Townsville,
Australia ; 4Leipzig, Germany ; 5Marburg, Germany ; 6Adelaide, Australia
Objective : The pathogenesis of major depression has been linked to
dysfunction of the dopaminergic system, particularly in the meso-
corticolimbic system. In turn, antidepressant medication and electro-
convulsive therapy (ECT) have been shown to enhance dopamine D3
receptor binding in the striatum. Thus, in the present study the in-
ﬂuence of dopamine D3 receptor gene (DRD3) variation on ECT out-
come in treatment-resistant major depression was investigated
applying a combined molecular and imaging genetic approach.
Methods : In a sample of 104 (f=71, m=33) Caucasian patients with
treatment-resistant major depression, ten representative DRD3 gene
variants were analyzed for association with response to electro-
convulsive therapy. Additionally, in two independent samples of de-
pressed patients (N=54) ventral striatum responsiveness to happy
faces was assessed by means of functional magnetic resonance ima-
ging at 3 Tesla.
Results : We observed signiﬁcant association of DRD3 rs3732790,
rs3773679 and rs9817063 SNPs with response (p=0.02x0.03) and re-
mission (p=0.01) after electroconvulsive therapy. The rs3732790 T
allele conferring a better treatment response was additionally found to
be associated with stronger striatal responsiveness to happy facial
expressions (sample 1 : p=0.002 ; sample 2 : p=0.023).
Conclusion : In conclusion, the present data suggests DRD3 gene
variation to impact electroconvulsive therapy response in major de-
pression. Alleles associated with a more favorable response to ECT
were also associated with stronger striatal responsiveness to positive,
emotionally rewarding social cues, suggesting a potential neurobio-
logical underpinning for the beneﬁcial eﬀects of these alleles.
jP-06-002jClinical and pharmacogenetic study on psychotropic
drug induced weight gain and other metabolic
complications in a Swiss psychiatric population
C.B. Eap1, F. Vandenberghe2, E. Choong1, N. Saigi Morgui1,
A.-E. Ambresin3, A. von Gunten2, P. Conus2. 1Psychiatric
Neurosciences, Prilly, Switzerland ; 2Prilly, Switzerland ; 3Lausanne,
Switzerland
Objective : The weight gain-related side-eﬀects of psychotropic drugs
and their consequences on metabolic complications (hypercholester-
olemia, obesity) in a large Swiss cohort of psychiatric patients (n=561)
were studied. Pharmacogenetic factors inﬂuencing these side-eﬀects
were also analyzed.
Methods : A cross-sectional observational study (n=188) was per-
formed in an out-patient psychiatric division with patients having
received for more than one year the following drugs : clozapine,
olanzapine, quetiapine, risperidone, lithium, amisulpride, ar-
ipiprazole and/or valproate. Another longitudinal study consisted of
a follow up of patients being prescribed the same drugs for up to one
year (n=373).
Results : For the cross-sectional study, the mean age was 41 years
(range : 18–69). Weight gain (>=10% of initial weight) following
drug treatment was reported in 43% of these patients. A high preva-
lence of overweight (BMI : 25–30) or obesity (BMI>30) was found in
this cohort (63%). For the longitudinal study, the mean age was 48
years (range : 12–96). An increase in the overweight or obesity preva-
lence was found during treatment in adults (33%, 35%, 46% and 57%,
before, after one, 3 and 12 months of treatment, respectively) and in
children (21%, 29%, 31% and 50%, respectively).
Conclusion : In conclusion, high prevalence of overweight or obes-
ity was found in an out-patient psychiatric population and conﬁrms
drug-induced weight gain complications during long-term treatment.
Results on other clinical factors of the metabolic syndrome as well as
on analyses of genetic factors linked to obesity and metabolic syn-
drome will also be shown. This study supports the recently published
recommendations of monitoring of metabolic side eﬀects during
treatment with atypical antipsychotics and/or mood stabilizers.
Moreover, the clinical and genetic weight gain predictors found in the
present study could help to highlight patients with special health care
management requirements.
jP-06-003jPolymorphism within the promoter of the serotonin
transporter gene and antidepressant eﬃcacy of
SSRI’s, seroquel XR augmentation eﬀect
D. Karlovic1, M. Stefanovic1, J. Culej1, B. Uglesic1, A. Kovak-Muﬁc1,
B. Vidrih1, A. Matosic1, A. Silic´1. 1University Hospital Center SM,
Zagreb, Croatia
Objective : It has been recently reported that the short variant of the
serotonin transporter (5-HTT) gene-linked functional polymorphic
region (5-HTTLPR) inﬂuences the antidepressant response to certain
selective serotonin reuptake inhibitors. We tested the hypothesis
that allelic variation of the 5-HTT promoter could be related to the
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antidepressant response to SSRI’s and/or augmentation with
Seroquel XR which has been suggested as an augmentation therapy
for nonresponders.
Methods : 93 patients with major depression were treated with
SSRI’s or SSRI’s augmented with Seroquel XR (300 mg) for 6 weeks.
The severity of depressive symptoms was weekly assessed with the
Hamilton Rating Scale for Depression. Allelic variation of 5-HTTLPR
in each subject was determined using a polymerase chain reaction-
based technique.
Results : Both homozygotes for the long variant (l/l) of the
5-HTTLPR and heterozygotes (l/s) showed a better response to SSRI’s
than homozygotes for the short variant (s/s). In the group treated
with SSRI’s plus Seroquel XR all the genotypes acted like l/l treated
with SSRI alone.
Conclusion : Seroquel XR augmentation may ameliorate the rate
of response in 5-HTTLPR short variant subjects, thus reducing the
diﬀerence in the response rate among the genotype variants. If
conﬁrmed, these results may improve patient care by helping the
clinician to individualize treatment according to the patient’s genetic
5-HTTLPR pattern.
jP-06-004jEﬀect of trialleic polymorphism in 5-ht transporter
linked polymorphism on remission after selective
serotonin reuptake inhibitor treatment
S.-W. Lim1, H. Kang1, S.H. Kim2, Y. Lee2, J.H. Song2, S. Kim1,
J.S. Beck1, S.Y. Park1, D.K. Kim3. 1Samsung Medical Center, SBRI, Seoul,
Republic of Korea ; 2Samsung Medical Center, Seoul, Republic of Korea ;
3Samsung Medical Center, Sungkyunkwan University, Seoul, Republic
of Korea
Objective : Functional rs25531 polymorphism in 5-HTTLPR (5-HTT
linked polymorphism region) eﬀects on the transcriptional activity of
5-HTT (serotonin transporter) gene by changing the binding aﬃnity
of transcription factor, AP2 and produces trialleic polymorphism in
5-HTT, known as the primary target of selective serotonin reuptake
inhibitors (SSRIs). We hypothesized whether the triallelic poly-
morphism in 5-HTT gene eﬀects on the outcome after SSRI treatment
during 6 weeks in late-life depressed patients.
Methods : Two hundred seventy seven patients with late-life
depression enrolled and entered a 6 week clinical trial with an SSRI,
with documentation of plasma drug concentrations. Patients were
classiﬁed from genomic DNA for 5-HTTLPR polymorphism in the
5-HTT gene using primer ﬂanking the promoter region. Then PCR
products were determined by visualizing on agarose gel for
5-HTTLPR polymorphism, and also processed the sequencing
analysis for rs25531. Remission was deﬁned as the decrease of HAM-
D score>50% and HAM-D<7 score at 6 week after antidepressant
treatment. Genotypic comparison between two groups was analyzed
using Fisher’s exact test in SPSS ver.10.1.
Results : No diﬀerences were any characteristics of subjects such
as age, gender, age of onset, duration of illness between remission
and non-remission group. An association to treatment outcome was
found in the triallelic polymorphisms between 106 remission group
and 171 non-remission (p=0.048, by Fisher’s exact test).
Conclusion : Functional trialleic polymorphism of 5-HTT gene
aﬀect on the outcome to SSRI treatment in late-onset depressed
patients. This is the ﬁrst reports of the association between rs25531
and remission after SSRI treatment in Asian population. These results
underscore the importance of study in evaluation of candidate genetic
marker as predictor of outcome to treatment of late-onset depression.
jP-06-005jEstimation of unbound drug cerebral exposure using
a merging approach of in vitro and in vivo assays
I. Loryan1, B. Jansson2, C. Mackie3, V. Sinha4, A. Van Peer4,
W. Drinkenburg5, M. Hammarlund-Udenaes2. 1Uppsala Universitet,
Sweden ; 2Uppsala Universitet, Pharmacokinetics, Drug Therapy, Sweden ;
3 Janssen Pharmaceutica NV, CRAETe ADME/Tox, Beerse, Belgium ;
4 Janssen Pharmaceutica NV, Neuroscience Discovery, Beerse, Belgium ;
5 Janssen Pharmaceutica NV, Clinical Pharmacology, Beerse, Belgium
Objective : It is openly accepted that the unbound cerebral drug con-
centration is the main pharmacokinetic determinant of CNS activity of
neurotherapeutics. A clinically relevant picture of the extent of brain
drug delivery can be achieved by evaluation of neuropharmacokinetic
parameters : unbound volume of distribution in the brain (Vu, brain),
unbound brain-to-plasma concentration ratio (Kp, uu, brain) and un-
bound extracellular-to-intracellular concentration ratio (Kp, uu, cell).
The goal of this study was to estimate unbound CNS exposure of
thirty compounds according to the Kp, uu, brain methodological ap-
proach established by Hammarlund-Udenaes et al.
Methods : Thirty compounds developed at Janssen R&D covering a
wide range of physicochemical properties and various pharmaco-
logical CNS targets were selected. Vu, brain was measured using the
rat brain slice method. Unbound brain (fu, brain) and plasma (fu,
plasma) fractions were determined using equilibrium dialysis. Brain
partition coeﬃcient was measured in rats and/or mice.
Results : The compounds were distributed in the brain tissue with
Vu,brain 2.9–624 ml.g brain-1, i.e. all compounds showed binding to
brain parenchyma (Vu, brain >0.8 ml.g brain-1). Estimated Kp, uu,
cell was 0.15–24 with 8 of the compounds indicating the ability to
accumulate in the cell (Kp, uu, cell>1). Assessment of Kp, uu, brain
showed that BBB equilibration was 0.02–2.65 showing active eﬄux of
20/30 compounds (Kp, uu, brain <1), dominating passive transport
for 4/30 compounds (Kp, uu, brain B1), and active uptake into the
brain of 6/30 compounds (Kp, uu, brain >1). Among the 8 eﬄuxed
compounds with Kp, uu, brain <0.1 only two were identiﬁed as
P-glycoprotein substrates in vitro.
Conclusion : The brain slice method combined with in vivo brain
partition coeﬃcient measurement is a reliable tool for the assessment
of unbound CNS exposure in early drug discovery stages, increasing
the probabilities of success in early drug discovery stages.
jP-06-006jAssociation between serotonin transporter gene
promoter-region polymorphism and 4- and 12-week
treatment response to sertraline in posttraumatic
stress disorder
M. Margoob1, D. Mushtaq2, A. Ali3, I. Murtaza4, C. Andrade5.
1 Institute of Mental Health and Srinagar, India ; 2 Institute of Mental
Health and Neurosciences-Kashmir, India, Srinagar, Kashmir, India ;
3Department of Biote, Jamia Millia, New Delhi, India ; 4Department of
Biochemistry, University of Agricultural Sci., Srinagar, India ; 5National
Institute of Mental, Health and Neurosciences, Bangalore, India
Objective : We examined the association between serotonin trans-
porter (5HTTLPR) genotype (SS vs. SL vs. LL) and sertraline treatment
outcome in posttraumatic stress disorder (PTSD).
Methods : Outpatients (n=330) with PTSD underwent 5HTTLPR
genotyping. All patients received sertraline (100 mg/day) for
12 weeks. Patients were assessed using the Clinician-Administered
PTSD Scale (CAPS) and other instruments. Patients and rater were
blind to the genotyping results. The primary outcome was completer
sample CAPS improvement at 12 weeks. Response was deﬁned as
>30% improvement in CAPS total score with a CGI-I score of 1 or 2.
Results : The discontinuation rate was 31.5%. Adverse events led to
drop out in 18.1%, 15.3%, and 5.9% of SS, SL, and LL patients, re-
spectively (P=0.038). Among completers, there were 95, 43, and 88
patients with the SS, SL, and LL genotypes, respectively. At endpoint,
CAPS total scores improved by 26% vs. 46%, respectively, in SS and
SL vs. LL patients (P<0.001) ; much of this improvement (15% vs.
31% in SS and SL vs. LL patients, respectively ; P<0.001) was appar-
ent by week 4. The ﬁndings were largely similar for the other outcome
measures. The response rate was 0%, 0%, and 47.7% in the SS, SL, and
LL groups, respectively (P<0.001). Limitations : We administered a
ﬁxed dose of sertraline. For geopolitical reasons, we planned a com-
pleter analysis only.
Conclusion : Relative to the SS and SL 5HTTLPR genotypes, the LL
genotype is associated with greater responsiveness of PTSD to ser-
traline (100 mg/day) and with lower drop out due to adverse events.
jP-06-007jPharmacogenetic analysis in psychiatry : A
descriptive study of a clinical experience with
21 patients
V. Miguel1, P. Sa´nchez1, M. Garcı´a1, I. Dura´n1, A. Iban˜ez1, A. Soto1,
A. Cebollada1, A. Chinchilla1, J. Saiz1. 1Hospital Ramo´n y Cajal,
Madrid, Spain
Objective : To perform a pharmogenetic analysis to 21 psychiatric
patients, with 39 diﬀerent psychiatric drugs.
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Methods : We have conducted a descriptive study of 21 patients
of whom 16 were admitted to the inpatient unit of the Psychiatry
Service at the Hospital Ramon y Cajal in Madrid, and 5 in the psy-
chiatric day hospital in the same center, who underwent the test
Neurofarmagen (AB-Biotics), that search for genetic biomarkers in the
DNA. Molecules were analyzed individually, and in its therapeutic
group, (antidepressants, antipsychotics, anticonvulsants, mood stabi-
lizers, and miscellaneous.
Results : Grouping antidepressants, 9.5% did not associate any
favorable marker to any antidepressant, 28% for one antidepressant,
for two 23.8%, for three 14.3%, for four 19%, and one patient for
seven. The clustering of antipsychotics with potentially favorable
response markers : 33% for one antipsychotic, 28.6% for two anti-
psychotics, 14.3% for three antipsychotics, 1 patient for four anti-
psychotics, 14.3% for six antipsychotics, and one patient for 7
antipsychotics. The Mood Stabilizers group included lithium, and
Valproic Acid, the presence of favorable response markers, for lithium
occurs in 85.7%. The Anticonvulsant drugs : 76.2% had a marker
associated with potentially adverse eﬀects for 8 of the drugs analyzed.
The Miscellaneous group includes : Clobazam, Clonazepam,
Atomoxetine, Methadone, Naloxone, Naltrexone, Pramipexole, and
Pregabalin. There were none positive indicators for any of the group
molecules in 28.6%. For one drug in 57.1%, for two drugs in 9.5%, and
a patient for four drugs.
Conclusion : We decided to change the treatment in 57.1%.
We identiﬁed that 81% were receiving suboptimal treatment. We
evaluated, how many of our patients had received previous treatment
with unfavorable, or insuﬃcient,response 61.9%. Without the test
results of Neurofarmagen, this change presumably would not have
occurred, and in many of these cases, would have been unlikely to
obtain an adequate therapeutic response.
jP-06-008jCytochrome P450 2D6 genetic polymorphisms
of ugandans
J. Miura1, K. Saito1, C. Obua2, C. Abbo2, S. Kaneko3, T. Tateishi3.
1Muroran Institute Tchnology, Japan ; 2Makerere University, Faculty of
Medicine, Kampala, Uganda ; 3Hirosaki University, Graduate School of
Medicine, Japan
Objective : Marked interindividual variation in the cytochrome
P450 (CYP) 2D6 activity has been reported. This variation can be
explained, at least in part, by genetic polymorphisms causing de-
fective, decreased, or increased enzyme activity. Therefore, geno-
typing of CYP2D6 might be useful in expecting individual drug
response to the substrate drugs (e.g. haloperidol, risperidone, parox-
etine, mirtazapine). Therefore, this study investigates the CYP2D6
genetic polymorphisms of Ugandans, which have not been studied
so far.
Methods : Healthy black Ugandans (n=99) were recruited from
among students at Butabika School of Psychiatric Nursing, Uganda.
CYP2D6*2, *3, *4, *5, *6, *7, *8, *10, *11, *12, *17, *35 alleles and gene
duplication were determined by LA-PCR or PCR-RFLP methods.
The CYP2D6*1 allele was assumed when none of the above-
mentioned alleles was found. The protocol of this study was approved
by the ethics committees of Hirosaki University Graduate School of
Medicine and Makerere University Faculty of Medicine.
Results : The allele frequency of CYP2D6*1, *2, *4, *5, *10, *17, *2xN
and *4xN was 20.5%, 40%, 2.5%, 9%, 1.5%, 22%, 4% and 0.5%, re-
spectively. None of CYP2D6*3, *6, *7, *8, *11, *12 or *35 was found. The
genotype frequency of *1/*1, *1/*2, *1/*5, *1/*17, *2/*2, *2/*4, *2/*5,
*2/*10, *2/*17, *4/*17, *5/*5, *5/*10, *5/*17, *17/*17, *2xN/*2, *2xN/
*17 and *4xN/*2 was 5%, 16%, 4%, 10%, 18%, 1%, 4%, 1%, 16%, 4%,
3%, 2%, 2%, 5%, 6%, 2% and 1%, respectively. The frequency of the
subjects with three, two, one and zero functional alleles were 8%,
71%, 18% and 3%, respectively.
Conclusion : When treating Ugandan patients, and probably other
black African and African American patients with CYP2D6 substrate
drugs, genotyping of CYP2D6 might be useful in expecting individual
drug responses. Among a number of variant alleles reported, deter-
mination of the *4, *5, *10, *17 and gene duplication (*2xN) might be
important.
Policy of full disclosure : This study was supported by ‘‘Fund
for the Promotion of International Scientiﬁc Research’’ (Hirosaki,
Japan).
jP-06-009j Integrating clinical and biomarker data to predict
antidepressant treatment outcomes
D. Mrazek1, J. Biernacka1, Y. Ji1, D. Katzelnick1, D. Hall-Flaven1,
M. Drews1, K. Snyder1, M. Skime1, J. Sagen1, R. Weinshilboum1.
1Mayo Clinic, Rochester, USA
Objective : To report the results of the integration of both clinical and
genomic factors designed to predict antidepressant treatment out-
comes.
Methods : A pharmacogenomic probe study of 398 treatment
adherent subjects with major depression was conducted using citalo-
pram or escitalopram over an eight week period of systematically
administered treatment. Blood levels of these medications were
monitored to document adherence to the protocol. Treatment out-
comes were determined to be remission or response using conven-
tional changes in depression rating scores. Clinically relevant
variables included gender, age, age of onset, length of current de-
pressive episode, employment status, educational status, marital
status, family history of mood disorder, and history of suicide
attempts. Genome-wide association analyses identiﬁed a number
of candidate SNPs of interest although none of these associations
reached the traditional level of genome-wide signiﬁcance. The SNPs
with the highest level of association were subsequently studied to
determine their functional signiﬁcance. Variants in the G protein
coupled receptor kinase gene (GRK5) and the riboﬂavin kinase gene
(RFK) were identiﬁed to have diﬀerential function. Multivariate
strategies were used to investigate the contributions of individual
genomic variants to achieving better estimates of the probability of
treatment outcomes.
Results : The integration of clinical variables associated with a
lower probability of achieving a positive antidepressant treatment
outcome, such as unemployment and a history of a suicide attempt,
and carrying at risk SNPs in GRK5 or RFK were explored. This strat-
egy was anticipated to provide better predictions of the probability
of a range of treatment outcomes when compared to either set of
variables alone. A variety of methods of combining these predictive
variables were employed and their relative strengths and weaknesses
were evaluated.
Conclusion : The integration of clinical variables with the presence
of biological variants associated with treatment outcomes provides a
novel strategy for the future development of more individualized
methods of antidepressant treatment.
jP-06-010jCase-control association study for 10 genes in
patients with schizophrenia : Inﬂuence of 5HTR1A
variation rs10042486 on schizophrenia and response
to antipsychotics
C.-U. Pae1, A. Serretti2. 1Bucheon St. Mary´s Hospital, Republic of Korea ;
2University of Bologna, Italy
Objective : The aim of this study is to investigate possible associations
between a set of single-nucleotide polymorphisms (SNPs) within
10 genes with Schizophrenia (SCZ) and response to antipsychotics in
Korean in-patients treated with antipsychotics.
Methods : Two hundred and twenty-one SCZ in-patients and 170
psychiatrically healthy controls were genotyped for 42 SNPs within
ABCB1, ABCB4, TAP2, CLOCK, CPLX1, CPLX2, SYN2, NRG1,
5HTR1A and GPRIN2. Baseline and ﬁnal clinical measures, including
the Positive and Negative Symptoms Scale (PANSS), were recorded.
Results : Rs10042486 within 5HTR1A was associated with both SCZ
and clinical improvement on PANSS total scores as well as on PANSS
positive and PANSS negative scores. The haplotype analyses focusing
on the four, three and two blocks’ haplotypes within 5HTR1A con-
ﬁrmed such ﬁndings as well. We did not observe any signiﬁcant as-
sociation between the remaining genetic variants under investigation
in this study and clinical outcomes.
Conclusion : Our preliminary ﬁndings suggest that rs10042486
within 5HTR1A promoter region could be associated with SCZ and
with clinical improvement on PANSS total, positive and negative
scores in Korean patients with SCZ. However, taking into account the
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jP-06-011jCytochrome P450 2D6 polymorphism and its impact
on decision-making in psychopharmacotherapy :
Finding the right way in an ultrarapid metabolizing
patient
M. Paulzen1, S. Tauber1, A. Kirner-Veselinovic1, G. Gru¨nder1. 1RWTH
Aachen University, Germany
Objective : The cytochrome P450 (CYP) superfamily represents the
most important phase I drug metabolizing enzyme system. Genetic
mutations play an important role in the activity especially of CYP2D6.
Genetic polymorphisms within CYPs aﬀect the metabolism of drugs
as substrates for the particular enzymes, resulting in variations in
plasma levels of the drugs, diﬀerences in drug response, or altered
risk for adverse eﬀects.
Methods :We report the case of a 55-year-old woman from Turkey.
She neither reached therapeutic drug concentrations of diﬀerent
drugs (metabolized via CYP1A2, CYP2D6, and CYP3A4) ‘‘natively’’
nor reached therapeutic plasma levels by pharmacologic blocking of
CYP1A2 or CYP2D6.
Results : Genotyping of the patient revealed an ultrarapid meta-
bolizer status for CYP2D6 with identiﬁcation of the CYP2D6*2XN
allele with at least more than 1 copy of *2 variant in chromosome 22.
For CYP2C19, the allele CYP2C19*1 was identiﬁed, reﬂecting normal
enzyme activity.
Conclusion : Neither daily doses above the approval limit nor the
well-directed use of pharmacokinetic blockade of the cytochrome
system was able to improve clinical response. Only with a therapeutic
regimen that bypasses liver function was partial remission ﬁnally
achieved. Considering the normal activity of CYP2C19 in our patient,
and that very high activity of CYP2D6 can result in increased metab-
olism of the substances via usually negligible metabolic byways, it is
possible that drugs exclusively metabolized by CYP2C19 or other CYP
isoenzymes (like agomelatine) or drugs that have no CYP-related
metabolism such as milnacipran may exert suﬃcient antidepressant
eﬀects.
jP-06-012jPlasma levels and cerebrospinal ﬂuid penetration by
venlafaxine in a patient with a non-fatal overdose
during a suicide attempt
M. Paulzen1, K. Henkel1, A. Reich1, C.-B. Eap2, S. Tauber1. 1RWTH
Aachen University, Germany ; 2De´partement de Psychiatrie, Prilly,
Switzerland
Objective :Newer antidepressants seem to be less toxic thank trizylics
even in suicidal attempts. Very few is known about the penetration of
venlafaxine into the cerebrospinal ﬂuid especially in the case of acute
intoxications.
Methods :We report a case of an acute intoxikation with 15 gramms
of venlafaxine. Due to unclear unconsciousness a lumbar puncture
was done. Therapeutic Drug Monitoring for Venlafaxine in plasma
and csf was done two hours after ingestion. Later on genotyping as
well for the cytochrome P450 2D6 subsystem was done as well as for
the ABCB1 gene expecting inﬂuence on CSF levels of venlafaxine due
individual characteristics in p-gp activity.
Results : TDM revealed plasma levels for venlafaxine (VEN) and
O-desmethylvenlafaxine (DES) of more than 24.000 ng//mL (active
moiety). CSF-Levels for VEN and DES were more than 6.400 ng/mL.
Genetic testing revealed an extensive metabolizer for 2D6 and showed
the constellation of ABCB1 G2677T : GG and C3435T : CT.
Conclusion : This case shows the very high rate of CSF penetration
of venlafaxine with the massive amount of 6.400 ng//mL in the CSF.
This high rate of CSF penetration requires more understanding
of active transporter mechanisms like p-gp clearing venlafaxine
into CSF.
jP-06-013jBiotransformation of alcohol is increased by
systemic administration of methamphetamine
M. Sabova´1, J. Jurica1, O. Zendulka1, M. Machalı´cek1, P. Sˇve´da1,
M. Farkova´1, A. Sˇulcova´1. 1Masaryk University, Brno, Czech Republic
Objective : Methamphetamine (METH) is a central nervous system
stimulant that causes feeling of increased self-conﬁdence, sociability
and energy. Drugs of abuse are often used together with alcohol as it
is the most frequent combination that leads to visit of Emergency
Department in U.S. in 2008. However, the opposite point of view – the
inﬂuence of METH on alcohol metabolism is still poorly understood.
The recent study was focused on the inﬂuence of chronic systemic
administration of METH on the biotransformation of alcohol in the
preclinical study.
Methods : The experiment was carried out on male Wistar albino
rats. Animals were randomly divided into two groups per 10 individ-
uals. Animals from the control group were injected intraperitoneally
with a single dose of saline. The other group was administered with
METH at the dose of 10.0 mg/kg/day. After 10 days the in vivo an-
imal pharmacokinetic experiment was performed. Both groups of
animals were treated with alcohol (ethanol) at the dose of 2.0 g/kg
in 5% glucose solution administered by intragastric probe. Blood
was sampled in the 40th, 120th, 240th and 300th minute after the p.o.
administration of alcohol. The alcohol levels were measured using GC
method. Measured concentrations were statistically analyzed by
ANOVA method with subsequent Fisher post-hoc test.
Results : Taken together our results suggest that repeated pre-
treatment with MET led to the acceleration of alcohol biotransforma-
tion in time points between minutes 0–120 after single acute alcohol
administration.
Conclusion : The present preclinical experiment suggests that
chronic administration of METH increased biotransformation rate
of alcohol in animal model. It is found in humans that with simul-
taneous administration of alcohol and METH, slowdown of METH
p-hydroxylation and N-demethylation occurs. To our best knowledge
the eﬀect of METH on the biotransformation of alcohol has not
been described in the literature available, either in humans or in
animals.
jP-06-014jThe clinical utility of ABCB1 genotyping in
antidepressant treatment
S. Scheuer1, B. Breitenstein1, M. Rosenhagen2, H. Pﬁster2, M. Uhr2,
S. Lucae2, T. Nickel2, M. Ising2, T. Brueckl2.
1HolsboerMaschmeyerNeuroChemie GmbH, Mu¨nchen, Germany ; 2Max
Planck Institute of Psychiatry, Mu¨nchen, Germany
Objective : The gene product of the ABCB1 gene, the P-glycoprotein
(P-gp), functions as a custodian molecule in the blood brain barrier
and regulates the access of most antidepressants into the brain.
Studies showed that ABCB1 polymorphisms predict the response to
antidepressants that are substrates of the P-gp, whereas the response
to non-substrates was not inﬂuenced by ABCB1 polymorphisms (Uhr
et al., 2008). The aim of the present study was to evaluate the clinical
utility of ABCB1 genotyping in clinical depression therapy.
Methods : Data came from 57 depressed inpatients from the
MARS (Munich-Antidepressant-Response-Signature, www.mars-
depression.de) study whose ABCB1 gene test results were im-
plemented into the clinical decision making process. Hamilton scores,
remission rates and duration of hospital stay were documented with
dosage and kind of antidepressant treatment.
Results : The group where ABCB1 genotyping was conducted had
higher remission rates (Chi-square(1)=3.436, p=0.032, one-sided
test) and lower Hamilton sores (t(22.72)=x1.780, p=0.044, one-sided
test) at the time of discharge from hospital as compared to a group
without ABCB1 testing. Among patients with the less favourable
genotype, an increase in dosage was associated with a shorter dur-
ation of hospital stay (rho(24)=x0.364, p=0.034, one-sided test)
whereas other treatment strategies (e.g., switching to a non-substrate)
showed no signiﬁcant associations with treatment outcome.
Conclusion : Results suggest that the treatment of depression can
be optimized by an application of an ABCB1 gene test. Especially
patients carrying the unfavourable ABCB1 genotype that impedes
brain penetrance seem to beneﬁt from an increase in dosage. The ef-
ﬁcacy of speciﬁc ABCB1 genotype-dependent treatment strategies is
currently tested in a controlled prospective clinical study.
Policy of full disclosure : The presenting author is an employee of
HolsboerMaschmeyerNeuroChemie GmbH.
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jP-06-015jLymphoblastoid cell lines as models for
pharmacogenomics
K. Stiebel1, E. Ersfeld1, S. Lucae2, M. Ising2, J. Stingl1. 1University of
Ulm, Germany ; 2Max Planck Institute of, Psychiatry, Munich, Germany
Objective : Drug treatment of depression is characterized by a high
rate of therapy failure, and so far it is not possible to predict the
individual response to a particular antidepressant drug therapy in
individual patients. There is therefore an urgent need for biomarkers
for depression treatment that could be used to tailor the individual
therapy. The aim of this project is to use individual genomic and
transcriptomic information for assessing pharmacogenomic varia-
bility in cytotoxic eﬀects of antidepressant as a surrogate of treatment
response in lymphoblastoid cell lines from patients. Epstein-Barr
virus (EBV) immortalized human lymphoblastoid cell lines (LCL)
are generated from blood cells of patients who have been treated
with antidepressant drugs and characterized for the clinical course
of drug response in the context of the Munich Antidepressant
Response Signature (MARS) study by the Max Planck Institute of
Psychiatry.
Methods :We examined the eﬀects of 3 diﬀerent antidepressants on
cell growth and viability at diﬀerent concentrations. The experiments
were repeated three-times in each cell line.
Results : In 21 cell lines screened so far, between-subject variability
was 2fold higher than within-subject variability. The concentration
ranges leading to 100% inhibition of cell growth were 110 mM, 30 mM,
600 mM for imipramine, paroxetine, mirtazapine, respectively. We
determined the approximate drug concentration that inhibited the cell
growth by 50% (IC50 : imipramine 80 mM, paroxetine 15 mM, mirta-
zapine 300 mM) and tested the correlation between gene expression of
CHL1, a gene that had been previously described to be associated
with paroxetine growth inhibition in cell lines as well as with toxic
eﬀects of antidepressant drugs in patients from the Star*D study.
Basal gene expression of CHL1 was associated with cell growth at
IC50 of imipramine (r=0.54, p=0.017) and mirtazapine (r=0.71,
p=0.002).
Conclusion : Polymorphisms in CHL1 and other gene regions will
be tested as potential prognostic biomarkers in patient cohorts that are
characterized for antidepressant therapy outcome.
jP-06-016jRelationship of DRD2 TAQ1A polymorphism with
perospirone and aripiprazole eﬃcacy in japanese
schizophrenia patients – a randomized controlled
study
Y. Takekita1, M. Kato1, S. Nonen2, M. Wakeno1, S. Sakai1,
G. Okugawa1, J. Azuma3, T. Kinoshita1. 1Kansai Medical University,
Moriguchi-Shi, Osaka, Japan ; 2Hogo Univ. of Health Sciences, Kobe,
Japan ; 3Hyogo Univ. of Health Sciences, Kobe, Japan
Objective : To detect the therapeutic eﬃcacy and tolerability eﬀect by
DRD2 Taq1A polymorphism on perospirone (PER) and aripiprazole
(ARP) in patients with schizophrenia.
Methods : All patients were diagnosed as schizophrenia according
to DSM-IV-TR. The patients who gave the informed consent to this
12-week and ﬂexible-dose trial were randomly assigned to PER
(n=51) or APZ (n=49). The clinical symptoms were evaluated using
the Positive and Negative Syndrome Scale (PANSS) before and every
4 weeks after treatment. The eﬃcacy was assessed by changes from
baseline for PANSS score. Genotyping for DRD2 Taq1A polymorph-
ism was analyzed. The study was approved by the Ethical Review
Board of Kansai Medical University.
Results : The clinical eﬃcacy of PER and ARPwere almost the same.
In the total sample (PER+ARP sample), the signiﬁcant diﬀerence
was not found in the improvement of PANSS total, PANSS positive,
negative and general psychopathology subscales scores between
Taq1A genotype. In subsequent subsymptom analysis, the patients
with A1/A1 allele (n=17) group showed signiﬁcant better reduction
overtime for PANSS–Excited Component (EC) scores (p<0.05) com-
pared to A2 carrier group (n=83). In stratiﬁed analysis by each drug,
a similar signiﬁcant diﬀerence was found in the ARP group only
(A1/A1 allele : n=9, A1/A2 and A2/A2 allele : n=40, p<0.05). When
separated by each genotype groups, no signiﬁcant diﬀerence was ob-
served for improvement of PANSS-EC between two drugs in both
genotype.
Conclusion : Our ﬁndings show that PER and ARP exhibit similar
eﬃcacy in the treatment of Japanese schizophrenia patients in both
genotype. Our data suggest that PANSS-EC signiﬁcantly improves in
A1 homozygote group as compared with A2 carrier group, especially
in ARP treatment group.
Policy of full disclosure : This poster was supported by a grant
from Promotion and Mutual Aid Corporation for Private Schools of
Japan and National scientiﬁc research fund of Japan (No.23791357).
jP-06-017jAssociation study of the neuropeptide Y gene
polymorphism and sertraline antidepressant
response in major depressive disorder
Y. Wang1, C. Wang2. 1Tianjin Anding Hospital, China ; 2Beijing Anding
Hospital, China
Objective : The goal of this study was to elucidate whether the NPY
polymorphisms are associated with the Sertraline antidepressant
response in subjects with MDD.
Methods : In a sample of ﬁfty-six Chinese Han patients with MDD,
6 single nucleotide polymorphisms (SNPs) in NPY gene with minor
allele frequencies >20% were successfully genotyped by ligase de-
tection reaction. MDD patients were evaluated during 12 weeks
of sertraline treatment. The severity of depression was assessed with
the 17-item Hamilton Depression Rating scale (HAMD-17). The re-
sponse to 12 weeks’ treatment with antidepressant was determined by
changes in HAMD-17 score. Genotypes of single SNP associations
with treatment response were analysed by Plink software.
Results : At 12 weeks, 71% of patients treatment with sertraline met
response (decreased score rate of HAMD-17>50%). All SNPs NPY
was not signiﬁcantly associated with antidepressant response.
Conclusion : Response rate was 71% in MDD patients treatment
with Sertraline. We did not ﬁnd that SNPs of NPY gene were asso-
ciated with sertraline treatment response in this sample.
jP-06-018jThe metabolism of levomepromazine by human
cytochrome P450 isoenzymes
J. Wojcikowski1, W.A. Daniel1. 1Polish Academy of Sciences, Krakow,
Poland
Objective : Levomepromazine, a phenothiazine neuroleptic, is used
in psychiatry as a sedative and in the management of schizophrenia. It
is also used in terminal pain control and postoperative analgesia, and
in the control of nausea. The contribution of cytochrome P450 iso-
forms (CYPs) to the metabolism of levomepromazine has not been
studied in humans so far. Therefore, the aim of the present screening
study was to identify CYPs involved in the 5-sulfoxidation and
N-demethylation of levomepromazine in human liver.
Methods : Levomepromazine metabolism was examined in vitro
using cDNA-expressed human CYPs (CYP1A2, CYP2A6, CYP2B6,
CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4) at a
therapeutic concentration of the neuroleptic (10 microM). The amount
of levomepromazine and its metabolites formed by CYPs was assayed
using HPLC with UV detection.
Results : The preference of CYPs for catalyzing levomepromazine
metabolism was as follows (pmol of product/pmol of CYP isoform/
min) : 3A4>1A2>2B6>2D6>2C8>2C19>2A6=2E1>2C9 for 5-
sulfoxidation and 3A4>1A2>2C19>2B6>2C8>2D6>2C9>2A6=
2E1 for N-demethylation. Considering the obtained results and the
relative expression of various CYPs in human liver, it has been esti-
mated that CYP3A4 is the main isoform responsible for levo-
mepromazine 5-sulfoxidation and N-demethylation at a therapeutic
concentration of the drug. Moreover, CYP1A2 contributes to a lesser
degree to 5-sulfoxidation of the neuroleptic. The role of CYP2A6,
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP2E1 in the
catalysis of the reactions studied seems negligible.
Conclusion : The obtained results may have signiﬁcant implications
for the prediction of potential drug-drug interactions involving levo-
mepromazine and CYP3A4. Supported by grant no. 2011/01/B/
NZ4/04859 from the National Science Centre, Krako´w, Poland and
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P-07. Post Traumatic Stress Disorder/
Obsessive-Compulsive Disorders
jP-07-001jOne trauma three outcomes : Case report
B.D. Akcay1, M.A. Cinar2, M. Ak3, L. Sutcigil3. 1Beytepe Military
Hospital, Ankara, Turkey ; 2TAF Rehabilitation Center, Ankara, Turkey ;
3GATA, Department of Psychiatry, Ankara, Turkey
Objective : Same trauma may aﬀect each exposed person diﬀerently.
We want to report diﬀerent representations of the same traumatic
event based on several psychometric measures and cortisol levels.
Methods : Three survivors of same severe combat related trauma
were assessed with CAPS, Mississippi, HAM-A, HAM-D, IES-R,
DES and MMSE. Venous blood was collected to detect serum cortisol
levels. The patients performed computerized version of Wisconsin
Card Sorting Test (WCST) three hours after venous blood collection.
Results : Patient A had no complaints about the traumatic event.
Patient B had sleep disturbance, avoidance and anger. Patient C had
same complaints as Mr. B also reported memory impairment. Patient
A was diagnosed as PTSD in remission and Patients B and C were
diagnosed as PTSD. Patient C had also comorbid TBI. Patients A, B,
and C’s psychometric measurement scores were as follows ; CAPS :
23-129-154 ; Mississippi : 68-117-118 ; HAM-A : 4-15-43 ; HAM-D : 1-19-
20 ; IES-R : 25-85-51 ; DES : 13-51-41 ; MMSE : 30-28-28. Serum cortisol
levels were detected in normal range (6.87 mcg/dL) for Patient A ; and
low (0.71 mcg/dL and 0.41 mcg/dL) for Patients B and C respectively.
Total categories completed in WCST were ; 1.1 and 4 respectively.
Conclusion : We reported three outcomes of the same traumatic
event in several psychometric measures and cortisol levels. These
ﬁndings support HPA axis disturbances levels may be responsible for
the PTSD symptomology. However, WCST scores were found irrel-
evant with cortisol levels and symptom severity. This ﬁnding made
WCST usefulness arguably in PTSD assessment, even one of the major
sites of glucocorticoid receptors is in prefrontal cortex.
jP-07-002jUse of donepezil in the treatment of cognitive
impairments of severe traumatic brain injury
B.D. Akcay1, M.A. Cinar2, A. Balikci3, B. Garip3. 1Beytepe Military
Hospital, Ankara, Turkey ; 2TAF Rehabilitation Center, Ankara, Turkey ;
3GATA, Department of Psychiatry, Ankara, Turkey
Objective : Donepezil is a pro-cholinergic drug that slows down cog-
nitive and functional impairment in patients with Alzheimer’s dis-
ease. Little research has been carried out to study its eﬀect in other
types of neurobehavioral disorders. The purpose of this case was to
report the response to donepezil therapy in patients with neurobeha-
vioral disorders due to traumatic causes.
Methods : Two patients with PTSD and comorbid TBI were as-
sessed with psychometric tools (CAPS, HAM-A, HAM-D andMMSE).
Treatment progress was evaluated with the same tools.
Results : Donepezil was administered to two patients with mild
cognitive impairment due to traumatic brain injury. Following an
average time of six months, the eﬀects exerted on the cognitive,
functional and behavioral areas were evaluated. Patients showed
greatest improvement on 10 mg donepezil. In general, memory, at-
tention, depression, apathy and psychotic traits tended to improve.
Aggressiveness and irritability tended to get worse. The functional
repercussions of these changes were negligible or inexistent.
Conclusion : Although traumatic brain injury (TBI) frequently re-
sults in signiﬁcant handicap, empirical investigations of pharmaco-
logical treatment of the neurobehavioral sequelae of TBI are rare.
These cases presents evidence that supports hypotheses of a choli-
nergic mechanism underlying some neurobehavioral sequelae of
TBI, as well as a cases of the preliminary evidence supporting
the eﬃcacy of cholinergic agents in TBI. Despite numerous methodo-
logical limitations, preliminary evidence exists for the eﬃcacy
of cholinergic agents in ameliorating attention and memory deﬁcits
following TBI. Treatment with donepezil improved cognition and
conduct in patients with neurobehavioral disorders due to post-
traumatic causes. These results will have to be conﬁrmed and ex-
panded by means of controlled studies, and research must continue
into the characteristics of responding patients and the relevance of
their responses.
jP-07-003jCytokine enviroment in PTSD patients of armenian
nationality
L. Hovhannisyan1, D. Avetyan1, G. Mkrtchyan1, S. Sukiasian2,
A. Boyajyan1. 1 Institute of Molecular Biology, Yerevan, Armenia ; 2Stress
Center, Yerevan, Armenia
Objective : Post-traumatic stress disorder (PTSD) is a serious and
debilitating condition triggered by terrifying events. It is proposed
that the inﬂammatory mediators may have a signiﬁcant input in
PTSD-associated neuronal and behavioral changes that resemble
some key features of this disease. Our aim was to evaluate the re-
lationship between the levels of the proinﬂammatory and chemotactic
cytokines IL-1b, IL-6, IL-8, TNF-a, MCP-1 in PTSD patients.
Methods : Patients with chronic PTSD (DSM-IV ; mean age M¡
E42¡4,6), and nontraumatized healthy controls (mean age 39¡3.1)
were examined. Blood levels of cytokines were determined by
ELISA.
Results : Compared to healthy controls, patients with chronic PTSD
had signiﬁcantly higher levels of IL-1b, IL-6, IL-8, TNF-a and MCP-1
(p<0.05). In addition, a signiﬁcant correlation has been observed be-
tween the blood levels of : IL-6 and IL-1b ; IL-8 and IL-1b ; IL-1b and
MCP-1.
Conclusion : PTSD is associated with altered cytokine environment.
Inﬂammatory processes are among pathological processes, which
play a decisive role in PTSD progression.
jP-07-004jMeasuring symptom exaggeration in PTSD using
the MMPI-2 and the PAI symptom validity scales
S.-W. Kong1, K.-S. Choi1. 1Eulji University Hospital, Daejeon, Republic
of Korea
Objective : We investigated whether PTSD patients have a higher
tendency of exaggerating the extent of their psychological symptoms
compared to other psychiatric patients.
Methods : Medical records of patients, who had received psychi-
atric treatment at 4 University hospitals in Korea between January
2009 and December 2010, were retrospectively reviewed. We com-
pared a group of 37 patients diagnosed with PTSD, and another group
of 41 patients diagnosed with Neurotic, stress-related and somato-
form disorders according to the ICD-10. To compare the extent of
malingering in the two groups, we compared the validity scales of
MMPI-2 and PAI. We detected the number of participants feigning
their responses from both groups using various cutoﬀ scores of the
validity indicators.
Results : The PTSD group showed signiﬁcantly higher scores on
F(p=0.001), F(B)(p=0.000), F(P)(p=0.030), F-K(p=0.003) scale of the
MMPI-2 compared to the Other psychiatric patients group. The PTSD
group had a signiﬁcantly higher NIM score (p=0.001) but a lower
PIM score (p=0.020) of the PAI compared to the Other psychiatric
patients group. Using the cutoﬀ scores, the PTSD group showed sig-
niﬁcantly more participants with feigned responding compared to
the Other psychiatric patients group : Fbo75 (p=0.010), F-Ko1
(p=0.005), F-Ko10 (p=0.011) from the MMPI-2, and NIMo80
(p=0.001) from the PAI.
Conclusion : These results suggest that PTSD patients have a tend-
ency of exaggerating symptoms by overreporting their condition on
standardized personality assessments such as the MMPI-2 or PAI,
compared to patients diagnosed with other psychiatric disorders.
Additional research is required to determine the factors inﬂuencing
symptom exaggeration in PTSD.
jP-07-005jEﬀects of stress and corticosterone on glutamate
release : Modiﬁcation of the readily releasable pool
of vesicles in prefrontal and frontal cortex
L. Musazzi1, G. Trreccani1, M. Milanese2, C. Perego1, A. Mallei1,
G. Racagni1, A. Malgaroli3, G. Bonanno2, M. Popoli1. 1University of
Milano, Italy ; 2University of Genova, Italy ; 3Milano, Italy
Objective : Stress and its mediators cause structural changes and
in turn lasting consequences in the brain, which may be associated
with triggering of neuropsychatric disorders. Several studies suggest
a critical role of glutamatergic neurotransmission in the stress
response. In previous studies, we demonstrated that Footshock
106 Poster Sessions, Monday 4 June 2012 – Wednesday 6 June 2012
Downloaded from https://academic.oup.com/ijnp/article-abstract/15/Supplement_1/1/650920
by University of Groningen user
on 13 March 2018
(FS)-stress induces a marked increase of depolarization-evoked
glutamate release from prefrontal and frontal cortex (P/FC) synapto-
somes, via glucocorticoid receptor activation and SNARE complexes
accumulation in synaptic membranes. The increase of glutamate re-
lease was prevented by chronic antidepressants.
Methods : In order to investigate the presynaptic mechanism
whereby acute stress enhances glutamate release in P/FC we per-
formed the following studies : 1. Measurement of release of endo-
genous glutamate evoked by depolarization or hypertonic sucrose
(which mobilizes exclusively the pool of synaptic vesicles ready for
release, RRP) from isolated superfused synaptosomes of P/FC from
FS-stressed rats. Measurement of depolarization-evoked or hyper-
tonic sucrose-evoked release of glutamate from control synaptosomes
incubated in vitro with corticosterone. 2. Analysis of RRP in synapto-
somes by Total Internal Reﬂection Fluorescence Microscopy, which
allows visualization of the synaptic region within about 100 nm from
the membrane. Synaptic vesicles were labeled with FM1–43, and
synaptosomes were incubated in vitro with corticosterone, ¡ selec-
tive inhibitors of glucocorticoid or mineralocorticoid receptors.
3. Patch-clamp recordings in slices of prefrontal cortex from control
PFC slices incubated with corticosterone (¡ selective inhibitors of
glucocorticoid or mineralocorticoid receptors).
Results : The results obtained suggest that the increase of the
RRP size induced by acute stress is promoted by a local action of
corticosterone on (presumably membrane-located) synaptic gluco-
corticoid receptors. However, in vitro incubation with corticosterone
blocks the depolarization-dependent glutamate release, suggesting
that additional mediators released by postsynaptic neuron and/or
glia, are necessary to trigger release.
Conclusion : The combined results of this study give more insight
into the basic mechanisms whereby behavioural stress aﬀects excit-
atory transmission in the forebrain.
jP-07-006jValproate use in post traumatic stress disorder :
Report of 3 cases and literature review
Z. Pablo1, G.F. Oviedo1. 1Clı´nica de la Paz, Bogota´, Colombia
Objective : Our aim is to review the possible implied mechanisms
and appraise the evidence for the use of the anticonvulsivant
Valproate for the treatment of Posttraumatic Stress Disorder.
Methods : Case Series and Literature Review.
Results : Three cases of non-combat related posttraumatic stress
disorder refractory to conventional treatment are treated with
Valproate as an adjunt medication. These patients showed adecuate
response by meassuring outcomes with the Post Traumatic Diagnostic
Scale (Spanish Version) and the Beck Inventory Depression Scale
(Spanish Version).
Conclusion : Anticonvulsivants have been used in clinical practice
for the treatment of Posttraumatic Stress Disorder (PTSD). Several
biologic models have been discussed as contributing signiﬁcantly to
PTSD symptoms with a focus on alterations in noradrenergic and
serotonergic systems and in the endocrine hypothalamus-pituitary-
adrenocortical axis. In addition, kindling has been proposed by sev-
eral investigators to be involved in the pathophysiology of PTSD. This
hypothesis suggests that anticonvulsants may be promising in the
treatment of PTSD, since they are thought to exhibit their eﬃcacy in
part through an antikindling activity. Valproate is an anticonvulsant
with antikindling activity and enhances the inhibitory eﬀect of the
neurotransmitter g-aminobutyric. A systematic investigation of their
eﬀects in the context of the treatment of PTSD is currently lacking
from the literature.
jP-07-007jDRD2 receptor polymorphism carries a higher risk
for PTSD developpment
A. Rady1, A. Elsheshai1, H. Abou El Wafa1, O. Elkholy1, M. Mokhtar1.
1Alexandria, Egypt
Objective : Dopaminergic neurotransmission is implicated in stress
responses. The dopamine D2 receptor gene (DRD2) has been studied
by the authors to assess its possible role as a predictor of those who
are at a higher risk to develop PTSD after major psychological trauma.
Methods : Over one year period 75 children and adolescents
6–18 yrs of age who had been exposed to moderate to severe burns
were recruited from the burn unit at the Alexandria University
Hospital for the study. Patients and their family were interviewed
within the ﬁrst 10 days of exposure. After signing a written consent
form a 2 ml blood sample was obtained for genetic studies of the
TaqA1/A2 polymorphism site of the DRD2 gene. Patients were re-
evaluated three and six months later for assessment of PTSD.
Results : Among the 75 children recruited in the study, 26 died due
to their burn injury, 19 dropped out as parents refused follow up and
30 continued the study follow up visits. Fourteen carried the A1A2
genotype. Of these 11 (78.6%) developed PTSD. Sixteen carried the
A2A2 genotype. Of these only one child (6.3%) developed PTSD. The
results were signiﬁcant at p<0.001 with a relative risk 12.5.
Conclusion : Following exposure to severe stress, the presence of
the Taq A1 allele of the DRD2 gene results in a signiﬁcant increase in
the risk of developing PTSD.
jP-07-008jFacing violence and burnout in health services :
Intervenction and prevention program
M.A. Ramos1, R.M. Gloria1, L. Garrido Mateo1, J.M. Ramos Navas-
Parejo1. 1Hospital Virgen de las Nieves, Granada, Spain
Objective : The aim of this work is to present the experience of a
group psychological intervention program conducted with profes-
sionals from emergency health services.
Methods : Three intervention groups were made (N=39) with
doctors, nurses, guards/drivers, administrative assistants, social
workers and physiotherapists from emergency health services in the
province of Granada. The program had eight weekly sessions of three
hours each one, structured into three modules : 1) prevention and
management of violent situations, 2) coping of burnout, 3) assertive-
ness training. An active-participatory methodology was followed
using modeling, role-playing and homework. After the program, a
questionnaire for evaluating the program was given.
Results : 87.5% of professionals evaluated the program as very
useful for their professional activity, 65.6% reported a high level of
learning and 90,6% showed high levels of satisfaction.
Conclusion : The professionals valued the experience as very useful
and satisfactory, and considered very important to have well struc-
tured coping skill training programs available to professionals work-
ing in health services, in order to help them to face violence in
working environment and burnout.
jP-07-010jBrain-derived neuroptrophic factor, posttraumatic
stress disorder and memory
S. Seedat1, S. Suliman2, D. Stein3. 1University of Stellenbosch, Cape
Town, South Africa ; 2Department of Psychiatry, Stellenbosch University,
Tygerberg, South Africa ; 3 bDepartment of Psychiatry, University of Cape
Town, South Africa
Objective : Brain-Derived Neurotrophic Factor (BDNF) is a neuro-
trophin that helps to support the survival and encourage the growth
and diﬀerentiation of neurons in both the central and peripheral ner-
vous systems. BDNF has been associated with mood disorders and
trauma exposure, but there is less information regarding its associ-
ation with Posttraumatic Stress Disorder (PTSD). The ﬁrst aim of
this paper was thus, to compare BDNF levels in trauma-exposed
adults with and without (i) Acute Stress Disorder (ASD), (ii) PTSD,
or (iii) depression. As BDNF levels have also been associated with
memory, the second aim of this paper was to correlate BDNF levels
with memory.
Methods : We collected blood samples from 37 participants who
had been involved in a motor vehicle accident in the previous 2 weeks
(59.5% male ; mean age : 33.35¡11.54 years). We used clinical and self
report measures to assess for ASD, PTSD and depression, both at the
time of blood collection and 3 months later. Neuropsychological
measures were used to assess for disturbances in auditory, visual and
working memory.
Results :We did not ﬁnd any signiﬁcant diﬀerences in BDNF levels
between those with and without ASD, PTSD or depression at the
baseline visit, as well as in those with PTSD or depression at the
3 month follow-up. Additionally, BDNF levels and memory did not
correlate. We did, however, ﬁnd that those with PTSD 3 months post-
trauma had higher levels of depression than those without PTSD.
P-07. Post Traumatic Stress Disorder/Obsessive-Compulsive Disorders 107
Downloaded from https://academic.oup.com/ijnp/article-abstract/15/Supplement_1/1/650920
by University of Groningen user
on 13 March 2018
Conclusion : Our ﬁndings suggest that in our sample, alterations
in BDNF level could be due to trauma exposure, rather than to a
psychiatric diagnosis. These ﬁndings are, however, limited by the
small sample size.
jP-07-011jEﬀects of recent earthquake on the prescribing
pattern of antidepressant and antipsychotic drugs in
the southern Iitalian province of L’Aquila
G. Triﬁro1, G. Sini2, C. Ferrajolo3, C. Linguiti4, M. Tari4, P. Stratta5,
F. Allegrini5, A. Rossi5. 1University of Messina, Italy ; 2Reggio Emilia,
Italy ; 3Naples, Italy ; 4Caserta, Italy ; 5L’Aquila, Italy
Objective : To assess the eﬀects of earthquake that occurred on April
6, 2009 on the use of antidepressant and antipsychotic drugs in the
province of L’Aquila.
Methods : We conducted a cross-sectional, drug utilization study.
Data sources of this study were the dispensings database of the
Southern Italian Local Health Unit (LHU) of L’Aquila and Caserta. All
the antidepressant and antipsychotic drugs (except for prescriptions
in dementia patients) are reimbursed by Italian National Health
System and therefore are retrieved in such a database. We measured
the monthly prevalence of use of these drugs one year prior and after
the date of earthquake in L’Aquila LHU. We used as control the
LHU of Caserta, as this area was not aﬀected by the earthquake. All
the analyses were stratiﬁed by age groups, gender and drug classes
(Selective Serotonin Reuptake Inhibitors, Tryciclics, and other ADs ;
atypical and typical antipsychotics).
Results : Overall, the monthly prevalence of use of ADs and
APs was higher in L’Aquila than Caserta. With respect to trend over
time, we observed an increase in the use of antidepressants (mostly
N06AA) and antipsychotics in the ﬁrst two months after the earth-
quake in L’Aquila but not in Caserta. This increase was almost two-
fold higher in women older than 75 years. The use of ADs and APs in
general tended to decrease in the summer period in Caserta, while
such a trend was not observed in L’Aquila after the earthquake. After
the ﬁrst two months from the earthquake, the use of ADs and APs is
stabilized at the pre-earthquake levels in L’Aquila.
Conclusion : The earthquake determined a very short term increase
in the use of antidepressants and antipsychotics mostly in older
women of L’Aquila. Long term evaluations of the eﬀects of the
earthquake on mental health in L’Aquila are needed.
jP-07-012jDevelopment of somatoform disorders in
individuals found mentally sane during the
outpatient forensic psychiatric examination
E. Valzdorf. Irkutsk, Russia
Objective : The objective of research is to study the types of somato-
form disorders in individuals that were found mentally sane during
outpatient forensic psychiatric examination. Material and methods
of research. Thirty mentally sane persons (25 males and 5 females
aged between 16 and 55) against whom the criminal cases were
opened underwent outpatient forensic psychiatric examination.
Methods : The research employed comparative, clinical-
psychopathological and statistical methods in combination with
the analysis of data on somatoneurologic condition as well as instru-
ment-psychological research (drawing tests, Rosenzveig tests,
MMPI, incomplete sentence test, Pictogram, Ebbinghaus test, and
Wechsler subtest).
Results : The research revealed 15 persons who during the exam-
ination showed emotional-volitional instability and found 15 patients
to be mentally sane. At the same time 9 of 15 mentally sane patients
exhibited somatoform disorder of vegetative nervous system, 4
patients exhibited other somatoform disorders and 2 patients – a
stable somatoform pain disorder. The 12 of 15 patients with the fea-
tures of emotional-volitional instability exhibited comorbid somato-
form dysfunction of vegetative nervous system and 3 persons – other
comorbid somatoform disorders.
Conclusion : Based on results of the research we can conclude that
the individuals showing emotional-volitional instability exhibited
comorbid somatoform dysfunction of vegetative nervous system
more often, while mentally sane individuals according to clinical
ﬁndings had a stable somatoform pain disorder along with somato-
form dysfunction of vegetative nervous system.
jP-07-013j Impact of mental disorders on commission of
criminally punishable acts by teenagers
E. Valzdorf. Irkutsk, Russia
Objective : The research aims to study the impact of the revealed
mental disorders (or their absence) in teenagers on commission of
homicide or inﬂiction of grave harm to health, causing manslaughter
by negligence. 32 reports of the Commission of the forensic psychi-
atric examination over the past half a year were analyzed. The forensic
psychiatric examination was carried out on an outpatient basis. The
analysis revealed that out of 32 examined teenagers, 30 were males
and 2 – females at the age of 15–18.
Methods : The statistical method along with the analysis of data of
forensic psychological-psychiatric and forensic psychiatric examina-
tions was applied.
Results : The research revealed that 14 individuals were held crim-
inally liable under article 105 of Criminal Code (CC) of the Russian
Federation (RF) (homicide), of them 4 showed light mental retar-
dation, 2 – organic personality disorder against the background of
brain injuries and epilepsy, 1 – socialized conduct disorder, 7 indivi-
duals turned out to be mentally sane ; 18 individuals were held crim-
inally liable under article 111 part 4 of CC of RF (intentional inﬂiction
of grave harm to health, causing manslaughter by negligence) in-
cluding 4 teenagers with light mental retardation, 3 – with organic
personality disorder against the background of brain injuries
and epilepsy, 2 individuals exhibited light cognitive impairment,
1 – emotionally unstable personality disorder, 1 person showed
opioid addiction, and 7 teenagers appeared to be mentally sane.
Conclusion : Thus, the research revealed that according to the re-
ports of the outpatient forensic psychiatric examination of teenagers
aged between 15 and 18 such criminally punishable acts as homicide
and inﬂiction of grave harm to health, causing manslaughter by neg-
ligence, were most often committed by teenagers without psycho-
pathology and by those exhibiting light mental retardation.
jP-07-014jObsessive comuplsive behaviour following
traumatic brain injury
R. Alowesie. Sultan Humanitarian City, Riyadh, Saudi Arabia
Objective : To describe the psychopathology and treatment outcomes
of a patient who exhibited obsessive–compulsive behavior following a
frontotemporal traumatic brain injury.
Methods : Neuropsychological cognitive and personality assess-
ments were conducted. Descriptive psychopathology and treatment
outcome elucidated.
Results : The patient displayed marked obsessive–compulsive be-
havior along with cognitive impairment and personality changes. The
psychopathology of the obsessive compulsive behavior diﬀered from
the classical DSM description and the treatment outcome using dif-
ferent treatment modalities was poor.
Conclusion : The patient presented in this report had both fronto
temporal lobe dysfunction signs and obsessive compulsive behavior.
The etiological signiﬁcance of head injury and frontal lobe involve-
ment in obsessive–compulsive disorder is discussed in the context of
the clinical and therapeutic outcomes.
jP-07-015jCognitive-behavioral group therapy with and
without pharmacotherapy for obsessive-compulsive
disorder
T. Dogan1, Y. Safak1, M.E. Karadere1, M.H. Turkcapar1, S. Orsel1,
B. Yucens1. 1Diskapi Yildirim Beyazit Resea, Ankara, Turkey
Objective : Although cognitive-behavioral group therapy (CBGT)
and pharmacotherapy have proven eﬀective in reducing symptoms
of obsessive-compulsive disorder (OCD), there is no consensus
about which of these forms of treatment is more eﬀective. The aim
of this study is to compare the eﬀectiveness of combined therapy
(CBGT+pharmacotherapy) with psycotherapy alone (CBGT).
Methods : Thirty-six patients with an OCD diagnosis, according to
DSM-IV criteria were recruited into the study. 20 of them randomly
assigned to antidepressant pharmacotherapy plus Cognitive behav-
ioral group therapy and 16 of them were received only CBGT.
The CBGT therapists were blind to patients’ whether taking
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pharmacotherapy or not. CBGT process consists of 14 sessions.
Eﬃcacy of treatments was rated according to the reduction in scores
on the Yale-Brown Obsessive Compulsive Scale (YBOCS), Beck-
Anxiety Inventory (BAI), Beck-Depression Inventory (BDI) and the
Clinical Global Impression Scale (CGI). The trial was performed in
four successive periods from August 2011 to January 2012.
Results : According to end-point analysis both groups did well
in therapy. Patients treated with only CBGT obtained a mean YBOCS
reduction of symptoms of 45%, while those treated with anti-
depressant plus CBGT treatment have 53% reduction. The reduction
rates were found statistically signiﬁcant according to initial scores
(Paired t-test ; CBGT only group (z=x2.81, p=0.002), combined
therapy group (z=x3.07, p=0.001)). There was no signiﬁcant diﬀer-
ence between these two groups at the end of CBGT (Mann-Whitney
U=50.50, p=0.54). Also there was signiﬁcantly reduction for BAI,
BDI and CGI scores.
Conclusion : Cognitive-behavioral group therapy has shown to be
eﬀective in reducing OCD symptoms regardless of antidepressant
treatment. We suppose that CBGT could be an eﬀective treatment
choice for OCD.
jP-07-016jThe use of aripiprazole in serotonin reuptake
inhibitor resistant obsessive-compulsive disorder :
A naturalistic, retrospective case series of 24 patients
A. Hishimoto1, K. Tanaka1, S. Aoyama2. 1Kobe Univ. Grad. Sch. of
Med., Japan ; 2Dept. Psychiatry and Neurology, Hyogo Prefecture Awaji
Hospital, Japan
Objective : We conducted a naturalistic, retrospective chart review
to evaluate the eﬀectiveness and safety of aripiprazole augmentation-
or mono-therapy for the treatment of resistant obsessive-compulsive
disorder (OCD).
Methods : A total of 24 patients diagnosed with OCD according
to DSM-IV-TR criteria and having a history of resistant to treatment
with serotonin reuptake inhibitors (SRIs) were included in the study.
Aripiprazole was started at 3 mg/day and increased to 24 mg/day
at the clinician’s discretion. The patients were assessed with the Yale-
Brown Obsessive Compulsive Scale (Y-BOCS), the Clinical Global
Impressions-Improvement (CGI-I) Scale, and the Global Assessment
of Functioning (GAF) Scale at baseline and at the ﬁnal visit of
aripiprazole treatment. Safety assessments included evaluation of
vital signs, weight, and treatment-emergent side eﬀects. Follow-up
period for a case was one year and a case who discontinued the drug
for less than one year was also counted. Data were collected from
January 2007 to December 2010.
Results : The mean daily dosage of aripiprazole at endpoint was
12.0¡7.2 mg/day. The mean total Y-BOCS score decreased from 27.2
at baseline to 18.0 at endpoint (P<0.0001) and the mean GAF score
increased from 47.1 at baseline to 60.6 at endpoint (P<0.0001). The
mean CGI-I score was 2.4 points (muchyminimally improved).
The observed side eﬀects included weight gain (2 patients), akathisia
(2 patients), mild sedation (2 patients) and insomnia (1 patient).
Conclusion : These results suggest that aripiprazole augmentation-
or mono-therapy can modestly improve the outcome for the treatment
of resistant OCD. Larger, randomized, double-blind studies are
necessary to establish the eﬃcacy and safety.
jP-07-017jClinical predictors of drug response in patients with
obsessive-compulsive disorder
M.-S. Koo1, C.-H. Kim2. 1Kwandong University, Goyang, Republic of
Korea ; 2Yonsei University, Seoul, Republic of Korea
Objective : The aim of this study was to evaluate which clinical vari-
ables might inﬂuence the antiobsessional response to proserotonergic
drugs in a sample of patients with obsessive-compulsive disorder
(OCD).
Methods : Two hundred forthy-nine patients with DSM-IV OCD
underwent mean 13-month treatment with selective serotonin re-
uptake inhibitors. According to treatment response, deﬁned as a re-
duction of the Yale-Brown Obsessive Compulsive Scale total
score>35% and CGI 1 or 2, patients were divided into two groups.
Results : One hundred fourteen patients responded to treatment
and one hundred thirty ﬁve patients did not. Responders had a
signiﬁcant high long duration of treatment, short duration of pre-
treatment medication and higher frequency of drug naı¨ve cases and
lower baseline Y-BOCS scores.
Conclusion : The pre-treatment factors including pre-treatment
period, drug naı¨ve or not and baseline OCD symptoms and the factor
of duration of treatment may inﬂuence drug treatment response in
OCD patients.
jP-07-018jRelationships between plasma ﬂuvoxamine levels
and OCD symptoms in adult patients
D. Marazziti1, S. Baroni1, G. Giannaccini1, A. Piccinni1, G. Massimetti1,
M. Catena-Dell´Osso1. 1University of Pisa, Italy
Objective : Diﬀerent randomized, double-blind, controlled studies
conﬁrm the eﬃcacy of ﬂuvoxamine in obsessive-compulsive disorder
(OCD). An experimentally determined relationship between plasma
levels and the pharmacological eﬀect of ﬂuvoxamine may represent
an useful method in monitoring clinical response and in the identiﬁ-
cation of predictors of response in order to maximize the therapeutic
eﬀectiveness, but the information on this topic is limited. Therefore,
in this study we explored the possible relationship between plasma
ﬂuvoxamine levels and clinical features in OCD patients treated with
this drug for at least 6 months.
Methods : Twenty OCD outpatients of both sexes taking ﬂuvo-
xamine were included in the study. The symptoms severity
was assessed by means of the Y-BOCS. The ﬂuvoxamine plasma
levels were measured by HPLC analysis. All evaluations were
performed after 4 weeks (t1) and six months (2) of ﬂuvoxamine
intake.
Results : The plasma levels of ﬂuvoxamine remained stable at the
two assessment times, with no sex-related diﬀerences. Sixteen (80%)
patients showed a signiﬁcant improvement, but men’s compulsions
ameliorated more than those of women. Signiﬁcant and positive cor-
relations were detected between ﬂuvoxamine plasma levels at t1 and
t2 and the diﬀerence (delta) of the Y-BOCS total score at t1 and
t2. Another signiﬁcant, albeit negative, correlation was measured be-
tween the delta of drug concentrations and that of the compulsion
subscale score.
Conclusion : These ﬁndings underline the potential importance of
evaluating ﬂuvoxamine plasma levels in OCD and their relationships
with speciﬁc symptoms, as well as the inﬂuence of gender on drug
response.
jP-07-019jNeuroanatomical correlates of naturalistic long-term
outcome of OCD treated with selective serotonin
reuptake inhibitors
J. Narayanaswamy1, S. Kalmadi1, A. Cherian1,
G. Venkatasubramanian1, Y.C. Janardhan Reddy1. 1NIMHANS,
Bangalore, India
Objective : The structural imaging studies have reported the in-
volvement of areas in the fronto-subcortical regions as neurobiological
substrates in OCD. We hypothesized that baseline volumes of orbito-
frontal cortex, cingulate cortex, dorsolateral prefrontal cortex, caudate
nucleus and globus pallidus would predict improvement in obses-
sional symptoms in long-term. With this hypothesis we aimed at
elucidating the structural brain predictors of naturalistic outcome in
drug naı¨ve adult subjects with obsessive-compulsive disorder (OCD).
Methods : We examined the brain volumes using optimized Voxel
Based Morphometry (VBM) paradigm and examined their relation-
ship with 2 to 5 year naturalistic outcome in 29 drug naı¨ve OCD
patients. Statistical parametric maps were constructed to examine
correlations between regional gray matter volume in the apriori
hypothesized regions and percentage reduction in YBOCS scores at
the endpoint.
Results : VBM analysis revealed signiﬁcant positive correlation
between the percentage of reduction on Y-BOCS total score and
left anterior cingulate gyrus volume (X=x3, Y=15, Z=22, T=3.31,
uncorrected ‘p’=0.001 ; FWE-corrected ‘p’ [SVC]=0.014).
Conclusion : ACC is a key region implicated in OCD and as we
hypothesized, higher ACC volume at the baseline correlated with
better clinical outcome. To the best of our knowledge, this is the ﬁrst
study to report of imaging predictors of long-term outcome of OCD.
P-07. Post Traumatic Stress Disorder/Obsessive-Compulsive Disorders 109
Downloaded from https://academic.oup.com/ijnp/article-abstract/15/Supplement_1/1/650920
by University of Groningen user
on 13 March 2018
Apriori delineation of such biomarkers can potentially help in ascer-
taining the prognosis and treatment outcome.
jP-07-020jAntiserotonergic second generation antipsychotics
are associated with obsessive-compulsive symptoms
in schizophrenic patients
M. Zink1, F. Schirmbeck1, C. Esslinger1, F. Rausch1, S. Englisch1,
A. Meyer-Lindenberg1. 1CIMH, Mannheim, Germany
Objective : Epidemiological investigations show that up to 30% of
schizophrenic patients suﬀer from obsessive compulsive symptoms
(OCS). The comorbidity is associated with negative impact on the
general prognosis. It has been proposed that antiserotonergic second
generation antipsychotics (SGA) might induce OCS, but investiga-
tions of large samples integrating psychopathology, neuropsychology
and psychopharmacology are missing.
Methods : We stratiﬁed 70 patients with schizophrenia according
to their mode of antipsychotic treatment : clozapine and olanzapine
(group I) compared with aripiprazole and amisulpride (group II). The
groups were matched according to age, sex, educational levels and
severity of the psychotic disorder (PANSS : Positive and Negative
Syndrome Scale). As primary endpoint, we evaluated the OCS-
severity (YBOCS : Yale-Brown-Obsessive-Compulsive Scale) in a
cross-sectional evaluation.
Results : OCS was signiﬁcantly more prevalent and severe in group
I, in which OCS severity correlated with dosage of clozapine and
duration of treatment. Pronounced cognitive deﬁcits in group I were
found in visuo-spatial perception and visual memory (WAIS-R
block design, Rey-Osterrieth Complex Figure Test), impulse inhi-
bition (Go/Nogo-Test), higher perseveration scores (Wisconsin Card
Sorting Test) and reduced set-shift abilities (Trail Making Test B,
Set-shift Task). These cognitive domains also correlated with OCS
severity.
Conclusion : OCS in schizophrenia is associated with anti-
serotonergic SGA treatment, but longitudinal studies have to provide
further evidence for a causal interaction. Before starting treatment
with antiserotonergic SGAs such as clozapine, speciﬁc neurocognitive
domains should be evaluated, that might indicate an increased risk
for second-onset OCS and further allow the early detection of OCS
secondary to antipsychotic treatment in schizophrenia.
Tuesday, 5 June 2012
P-08. Schizophrenia
jP-08-001jD-serine production is modulated by DISC1 and
serine racemase interaction in astrocytes
B. Abazyan1, M.T. Ma1, S. Abazyan1, A. Sawa1, S.H. Solomon
H. Snyder1, M.V. Pletnikov1. 1 JHU, Baltimore, USA
Objective : Disrupted-In-Schizophrenia-1 (DISC1) is a strong can-
didate gene for psychiatric disorders. The majority of studies have
focused on neuronal functions of DISC1. Recent reports have ident-
iﬁed expression of DISC1 in glial cells, including astrocytes. Our study
sought to elucidate roles for DISC1 in astrocytes as abnormal astro-
cytic functions may contribute to psychiatric disease.
Methods : To study the DISC1 functions in astrocytes, we used
a mouse model of GFAP promoter-driven selective and inducible
expression of mutant DISC1 in astrocytes to impact endogenous
DISC1 in a dominant-negative manner. We evaluated the eﬀects
of mutant DISC1 on glutamate uptake, d-serine production, and ex-
pression of the major astrocytic markers in primary astrocytes and the
brain of transgenic mice at diﬀerent time points during postnatal de-
velopment. In addition, GFAP-DISC1 transgenic mice were assessed
in a series of behavioral tests relevant to aspects of schizophrenia.
Results : Astrocytic expression of mutant DISC1 did not produce
gross developmental abnormalities in mice but was associated with
elevated anxiety, mild cognitive deﬁcits and exacerbated responses to
a NMDA antagonist, MK-801. Notably, the eﬀects of MK-801 were
ameliorated by D-serine treatments predominantly in mutant DISC1
mice. Mutant DISC1 had no signiﬁcant eﬀects on glutamate uptake,
levels of GFAP, GLT-1 or connexins in primary astrocytes or the brain
tissue. In contrast, we found signiﬁcantly decreased expression of
endogenous mouse DISC1 and serine racemase (SR), leading to di-
minished levels of D-serine in primary astrocytes derived from
mutant DISC1 newborn mice. Our biochemical experiments suggest
that DISC1 may partner with SR to modulate production of D-serine.
Conclusion : Our results suggest that DISC1 may play an important
role in modulating production of D-serine and resultant NMDA
neurotransmission relevant to the pathophysiology of schizophrenia.
jP-08-002jPredictors of psychiatric hospitalization during
6 months of maintenance treatment with olanzapine
long acting injection
H. Ascher-Svanum1, D. Novick2, J.M. Haro3, J. Bertsch4,
D. McDonnell1, H. Detke1. 1Eli Lilly and Company, Indianapolis, USA ;
2Eli Lilly and Company, Windlesham, Surrey, United Kingdom ; 3Parc
Sanitari Sant Joan de De´u, Universitat de Barcelona, Sant Boi de Llobregat
(BCN), Spain ; 4Parc Sanitari Sant Joan de De´u, CIBERSAM, Sant Boi de
Llobregat (BCN), Spain
Objective : This study aimed to identify the predictors of psychiatric
hospitalization in the maintenance treatment of schizophrenia
patients with olanzapine long acting injection (olanzapine_LAI) and
assess four hospitalization parameters : the prevalence of hospitaliza-
tion, its incidence rate, duration, and the time to ﬁrst hospitalization.
This analysis also compared olanzapine_LAI with pseudo-placebo
(a very low dose of olanzapine_LAI) and with oral olanzapine on the
hospitalization parameters.
Methods : This was a post hoc exploratory analysis of a randomized
double-blind study comparing the safety and eﬃcacy of olanzapine_
LAI (pooled active depot groups : 405 mg/4 weeks, 300 mg/2weeks,
150 mgs/2 weeks) with oral olanzapine and olanzapine_LAI 45 mg/
4 weeks (pseudo-placebo) during 6 months maintenance treatment of
clinically stable outpatients with schizophrenia (n=1064). Within the
olanzapine_LAI group, patients with and without a hospitalization
were compared on baseline characteristics. A logistic regression
model was used to identify the best predictors of hospitalization.
Comparisons between olanzapine_LAI, pseudo-placebo, and oral
olanzapine on hospitalization parameters employed Chi-square,
Wilcoxon-Mann and Whitney tests, and the Kaplan Meier estimator.
Results : Hospitalization was best predicted by suicide threats
at baseline and by prior hospitalization. Compared with pseudo-
placebo, olanzapine_LAI was associated with a signiﬁcantly lower
hospitalization rate (5.2% vs. 11.1%, p=0.009), lower mean number of
hospitalizations (0.07 vs. 0.15, p=0.009), shorter mean hospitalized
duration (1.50 days vs. 2.85 days, p=0.008) and similar median time
to ﬁrst hospitalization among hospitalized patients (35 vs. 60 days,
p=0.476). Olanzapine_LAI did not signiﬁcantly diﬀer from oral
olanzapine on studied hospitalization parameters.
Conclusion : During the 6-month maintenance treatment of
schizophrenia patients with olanzapine_LAI, psychiatric hospitaliza-
tion was best predicted by patients’ suicide threats at baseline and
prior psychiatric hospitalization. Olanzapine_LAI was associated
with a signiﬁcantly lower prevalence and incidence of psychiatric
hospitalization and shorter hospitalized duration compared to pseu-
do-placebo therapy. Olanzapine_LAI did not signiﬁcantly diﬀer on
these hospitalization parameters from oral olanzapine.
Policy of full disclosure : This study was funded by Eli Lilly and
Company. Haya Ascher-Svanum, Diego Novick, David McDonnell
and Holland Detke are employees of Eli Lilly and Company. Josep
Maria Haro has been a consultant for Lilly for this study and has also
been a consultant for Astra-Zeneca and Lundbeck. Jordan Bertsch has
conducted the statistical analysis under a contract of Fundacio´ Sant
Joan de De´u with Eli Lilly and Company.
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jP-08-003jLong-term safety and tolerability of once-monthly
aripiprazole intramuscular depot for maintenance
treatment in schizophrenia
R. Baker1, W. Fleischhacker2, R. Sanchez3, P. Perry1, N. Jin3,
B. Johnson3, R.A. Forbes3, R.D. McQuade3, W.H. Carson3, J.M. Kane4.
1Otsuka Pharma, Princeton, USA ; 2 Innsbruck, Austria ; 3Princeton, USA ;
4Glen Oaks, USA
Objective : To understand the safety and tolerability of aripiprazole
intramuscular depot (ARI-IMD) in maintenance treatment of schizo-
phrenia.
Methods : Subjects were cross-titrated to oral aripiprazole
(10–30 mg/day) over 4–6-weeks (oral conversion phase ; P1followed
by 4–12-week oral aripiprazole (oral aripiprazole stabilization phase ;
P2). Subjects meeting stability criteria (4 weeks) entered an ARI-IMD
stabilization (400 mg/injection) with co-administration of oral
aripiprazole the ﬁrst 2 weeks (P3). Subjects meeting stability criteria
(12 weeks) were randomized (2 : 1) to ARI-IMD or placebo (52-week,
P4). Primary endpoint was time to impending relapse. Safety was
assessed across phases by time of ﬁrst-onset of AEs, changes in
movement disorder rating scales and changes in weight/metabolic
parameters.
Results : The study stopped early because eﬃcacy was demon-
strated by pre-planned interim analysis (after 64 relapses). ARI-IMD
was well tolerated with similar rates of AEs across phases.
Discontinuations due to TEAEs : 3.8% (P1) ; 3.0% (P2) ; 4.9% (P3) ;
7.1% (P4). Most AEs were mild/moderate. Severe AEs were <5.0%,
all phases. AEs>5% were : insomnia (all phases), headache (P1, P3
and P4), anxiety, akathisia, weight increase (P3, P4), injection site
pain (P3) and tremor (P4). Headache, somnolence, nausea had a peak
ﬁrst-onset within 4 weeks of study initiation. EPS-related events were :
P4 : ARI-IMD14.9% vs. placebo 9.7%. Mean baseline weight ranged
80.4–84.8 kg (all phases). Mean baseline weight changes : x0.2 kg
(P1) ; 0.1 kg (P2) ;x0.2 kg (P3) ;x0.2 kg (ARI-IM-depot, P4),x0.4 kg
(placebo, P4). No unusual shifts in laboratory values or fasting meta-
bolic parameters (all phases). Normal-to-high shifts in metabolic
values were low in P4.
Conclusion : No unexpected AEs emerged with ARI-IM-depot.
Similar rates of AEs in P1 and P2 suggest that the switch strategy
was useful. ARI-IMD oﬀers a new option with a diﬀerent risk–beneﬁt
proﬁle than currently available treatments.
Policy of full disclosure : John M. Kane has received honoraria for
lectures and/or consulting from Alkermes, Amgen, BMS, Cephalon,
Esai, Boehringer Ingelheim, Eli Lilly, Intracellular Therapeutics,
Janssen, Johnson and Johnson, Lundbeck, Merck, Novartis, Otsuka,
Pﬁzer, Pierre Fabre, Proteus, Roche, Sunovion and Targacept. He is a
shareholder of MedAvante. Dr. Fleischhacker has received research
grants from Alkermes, Janssen Cilag, Eli Lilly, BMS/Otsuka and
Pﬁzer. He has received honoraria for educational programs from
Janssen, Pﬁzer and AstraZeneca, speaking fees from AstraZeneca,
Pﬁzer, Janssen Cilag, Roche, Lundbeck, BMS/Otsuka and
advisory board honoraria from BMS/Otsuka, Wyeth, Janssen Cilag
Neurosearch, Amgen, Lundbeck, Endo, United Biosource, Targacept,
MedAvante and AstraZeneca. Raymond Sanchez, Pamela Perry,
Na Jin, Brian Johnson, Robert A Forbes, Robert D McQuade, William
H Carson and Ross Baker are all employees of Otsuka Pharmaceutical
Development and Commercialization, Inc.
jP-08-004jEﬀects of microinjections of MK-801 and NMDA
into the inferior colliculus on prepulse inhibition of
the acoustic startle reﬂex in rat
R.C. Barbosa Da Silva1, G. Labbate1, J. Zangrando1, P. Medeiros1,
L. Thomas-Melo1. 1FederalUniversity of Sao Paulo, Santos, Brazil
Objective : Prepulse inhibition (PPI) is the reduction in the startle re-
sponse caused by a low intensity non-startling stimulus (prepulse)
which is presented shortly before the startle stimulus (pulse), and is
an operational measure of sensorimotor gating. PPI may reﬂect the
functioning of a pre attention ﬁltering system protecting the brain
from sensory overload. Deﬁcits in PPI have been observed in several
neuropsychiatric disorders, including schizophrenia and can be
induced in rats by systemic administration of N-methyl-D-aspartate
(NMDA) glutamatergic antagonist. The inferior colliculus (IC) is a
critical part of the auditory pathway mediating acoustic PPI.
The activation of the IC by the acoustic prepulse reduces startle
magnitude. The aim of this study was to investigate the role of
glutamatergic transmission of the IC on the development of acoustic
PPI.
Methods : Male Wistar rats were unilaterally implanted with
stainless steel guide cannula in the IC. Seven days after the surgery,
the animals received unilateral intracollicular microinjections of
the glutamate NMDA receptor antagonist MK-801 (30 mmol/0.5 ml) ;
of the NMDA receptor agonist N-methyl-D-aspartate (NMDA,
30 nmol/0.5 ml) or of physiological saline (0.5 ml). Five minutes later,
the animals were tested to PPI. They were exposed to 4 types of
stimuli : a startle pulse [P-alone : a 120 dB 40-ms broad band burst] and
3 types of prepulses [68, 71 or 77 dB 20-ms broad band burst] pre-
sented 100 ms prior to the startle pulse. During test session, 50 trials
(12 P-alone, 8 NOSTIM, and 10 of each prepulse trial types) were
presented in pseudorandom order. A variable inter-trial interval
averaged 15 s.
Results : The results showed that microinjections of MK-801 into the
IC disrupted PPI while microinjections of NMDA into this structure
did not alter PPI.
Conclusion : We concluded that glutamatergic neurotransmission
of the IC can be involved in the mediation of PPI in rodents.
jP-08-005jNormobaric hyperoxia treatment of schizophrenia
Y. Bersudsky1, Y. Bloch1, Y. Osher1, S. Amar1, A. Azab2, G. Agam2,
R. Belmaker1. 1Beersheva Mental Health Center, Israel ; 2Ben Gurion
University, Beersheva, Israel
Objective : Several studies of normobaric hyperoxia in neurological
conditions have found positive results. The impaired energy metab-
olism due to mitochondrial dysfunction and frontal lobe hypofunction
in schizophrenia might be improved by increasing O2 supply to the
brain. Normobaric hyperoxia may be a potential treatment for
schizophrenia.
Methods : Participants in this study, outpatients suﬀering
from chronic schizophrenia and inhabitants of community-based
psychiatric institutions (hostels), underwent baseline psychiatric/
cognitive assessment and were randomly assigned to either a treat-
ment intervention of oxygen enriched air inhalation (normobaric
hyperoxia of 40% FiO2), or to regular air inhalation (21% FiO2),
through a nasal tube, for four weeks. Patients were given the air/
oxygen inhalations during the night (mainly while sleeping), for at
least 7 hours a night. After completing four weeks of treatment,
patients were switched (crossed-over) to the other treatment inter-
vention.
Results : Fifteen patients completed the entire study. Five ad-
ditional patients completed Phase A only. There was signiﬁcant
improvement in total PANSS score of patients that received oxygen
compared with control group. There were positive eﬀects of oxygen
on memory and attention in neuropsychological performance
tests. The eﬀect size is small despite the statistical signiﬁcance
but the patient group was extremely chronic and severely impaired.
Conclusion : These results are a proof of concept and normobaric
hyperoxia should be studied in patients with milder forms of the ill-
ness and earlier in the course of illness.
jP-08-006jCariprazine in the treatment of acute mania
in bipolar disorder : A double-blind,
placebo-controlled, phase III trial
A. Bose1, A. Starace1, Q. Wang1, E. Diaz1, J. Goodman1, A. Ruth2, G.
Ne´meth3, I. Laszlovszky3. 1Forest Research Institute, New Jersey, USA ;
2Prescott Medical, Communications Group, Chicago, USA ; 3Gedeon
Richter Plc, Budapest, Hungary
Objective : Cariprazine is a D3-preferring dopamine D3/D2
receptor partial agonist antipsychotic in development for the treat-
ment of schizophrenia and bipolar mania. A Phase III clinical trial
(NCT01058096) evaluated the eﬃcacy, safety, and tolerability of car-
iprazine in patients with acute mania associated with bipolar I dis-
order.
Methods : In a 6-week, multicenter, placebo-controlled, parallel-
group, ﬂexible-dose study, patients (18–65 years) with acute mania
and a Young Mania Rating Scale (YMRS) scoreo20 were randomized
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to cariprazine 3–12 mg/day or placebo for 3-week double-blind
treatment. Patients were hospitalized for a 4–7 day wash-out
screening period and at least 14 days of treatment ; a 2-week
safety period followed. Primary eﬃcacy endpoint : YMRS total score
change from baseline to the end of Week 3 analyzed using a mixed-
eﬀects model of repeated measures (MMRM) approach on the
intent-to-treat (ITT) population ; secondary eﬃcacy : Clinical Global
Impressions-Severity (CGI-S). Safety analyses included adverse
events (AEs), laboratory values, ECGs, and extrapyramidal symptom
(EPS) scales.
Results : 312 patients were randomized and received at least 1 dose
of double-blind treatment (placebo, 154 ; cariprazine, 158) ; 69% of
placebo and 68% of cariprazine patients completed the study.
Baseline YMRS scores were similar between groups (placebo, 32.0 ;
cariprazine, 32.8). Improvements were signiﬁcantly greater for
cariprazine 3–12 mg/day versus placebo on YMRS (LSMD, x4.3 ;
P<0.001 ; MMRM) and CGI-S (LSMD, x0.4 ; P<0.01 ; MMRM).
Overall premature discontinuation rates were similar (cariprazine,
32% ; placebo, 31%) ; 10% of cariprazine and 7% of placebo patients
discontinued due to AEs. Treatment-emergent AEs (TEAEs) occurred
in 80% of cariprazine and 63% of placebo patients ; AEs occurring at
o10% and twice the rate of placebo were akathisia, extrapyramidal
disorder, tremor, dyspepsia, and vomiting ; 46% of cariprazine and
12% placebo patients had EPS-related AEs.
Conclusion : Cariprazine was eﬀective in the treatment of acute
mania associated with bipolar I disorder. Cariprazine was safe and
generally well tolerated.
Policy of full disclosure : Supported by funding from Forest
Laboratories, Inc.
jP-08-007jCOMT Val158Met polymorphism and antipsychotic
treatment interaction on cognitive remediation
outcomes in schizophrenia
M. Bosia1, A. Zanoletti2, M. Buonocore1, A. Pirovano2, E. Smeraldi1,
R. Cavallaro1. 1San Raﬀaele Scientiﬁc Institut, Milan, Italy ; 2Vita-Salute
San Raﬀaele University, Milan, Italy
Objective : Cognitive deﬁcits negatively aﬀect recovery in schizo-
phrenia and poorly respond to pharmacotherapy. Cognitive re-
mediation therapy (CRT) is eﬀective in improving cognition in
schizophrenia, but results are still variable and putative predictors of
successful remediation need to be better analyzed in order to optimize
individual outcomes. The COMT Val158Met polymorphism is known
to have a functional eﬀect on the rate of dopamine (DA) degradation
and thus DA availability in the prefrontal cortex (PFC), which may
aﬀect CRT response. Two studies evaluated the eﬀect of COMT
genotype on cognitive improvement following CRT, with contradic-
tory results [1,2]. Among factors aﬀecting CRT outcomes, pharma-
cotherapy appears of major relevance. Antipsychotics could interact
with COMT polymorphism on DA availability, inﬂuencing individual
capacity to recover from deﬁcit. The present study aims to analyze the
possible eﬀect of COMT Val158Met polymorphism and antipsychotic
treatment (clozapine vs. drugs with greater dopaminergic D2 receptor
blockade activity) on CRT outcomes. We hypothesized that anti-
psychotic- induced changes in PFC DA availability may interacts with
COMT genotype.
Methods : 91 clinically stabilized patients with diagnosis of schizo-
phrenia, receiving antipsychotic monotherapy since at least 3 months,
were recruited. Patients attended a CRT program for three
months. Cognitive performances were evaluated, at baseline and after
3 months, with ‘‘Brief Assessment of Cognition in Schizophrenia’’
(BACS).
Results : Analysis conducted by Repeated Measures ANOVA
showed a signiﬁcant interaction (F=4.0212, p=0.0484) between
COMT genotype and pharmacological treatment, on symbol coding
performances change.
Conclusion : The ﬁndings support the hypothesis of an interaction
between Val158Met COMT polymorphism and pharmacotherapy on
dynamic modulation of cognitive functions through CRT. Val/Val
subjects, only when treated with clozapine, show an improvement in
symbol coding, a task related to speed of processing and executive
functioning and currently regarded as a possible endophenotype of
schizophrenia. Clozapine, known to increase prefrontal DA levels,
could recover the genetic disadvantage.
jP-08-008j Increasing of LINE-1 copy number in postmortem
brains of psychiatric disorder patients
M. Bundo1, T. Miyauchi2, A. Komori-Kokubo2, K. Kasai3, T. Kato2,
K. Iwamoto3. 1The University of Tokyo, Japan ; 2RIKEN, BSI, Saitama,
Japan ; 3The University of Tokyo, Grad. Sch. Med, Japan
Objective : Some retrotransposons have the activity of moving
through the genome, resulting in the generation of variations in the
human genome. Recently, it has been shown that one of the well-
characterized retrotranposons, the LINE-1 (long interspersed nuclear
element 1), possess the retrotranspose activity in neural progenitor
cells. Interestingly, copy number of the LINE-1 was higher in brains
compared with other tissues, and that it was diﬀered among brain
sub-regions. These ﬁndings implicate that aberrant LINE-1 activity
might be associated with the pathophysiology of psychiatric diseases
such as schizophrenia. Here, we quantiﬁed the copy number of the
LINE-1 in genomic DNA of two independent postmortem brain
sample sets.
Methods : Samples consist of schizophrenia, bipolar disorder, major
depression and controls. Both of sample sets were obtained from the
Stanley Medical Research Institute. Copy number of the LINE-1 was
determined by real time PCR method, according to the previous re-
port (Coufal et al., Nature 2009). We calculated the relative LINE-1
content of brain/liver in one set. In another set, we separated brain
tissue into neuronal and non-neuronal cell nuclei using NeuN-based
sorting technique, and calculated relative LINE-1 content of neuron/
non-neuron.
Results : There were signiﬁcant increases in relative LINE-1 con-
tents in schizophrenia in two sample sets. Confounding factors such
as age, gender, postmortem interval, and sample pH did not aﬀect the
LINE-1 content in brains.
Conclusion : These results suggest that aberrant retrotranposon
activity in the neural progenitor cells may be associated with the
pathophysiology of schizophrenia.
jP-08-009jEﬀects of ARI-IM-depot on secondary eﬃcacy
outcomes in maintenance treatment of schizophrenia
W.H. Carson1, P. Perry1, R. Sanchez2, N. Jin2, R.A. Forbes2,
R.D. McQuade2, W. Fleischhacker3, R. Baker2, J.M. Kane4. 1Otsuka
Pharma, Princeton, USA ; 2Princeton, USA ; 3 Innsbruck, Austria ; 4Glen
Oaks, USA
Objective : To evaluate secondary eﬃcacy outcomes of once-monthly
aripiprazole intramuscular depot (ARI-IM-depot) as maintenance
treatment for schizophrenia.
Methods : Subjects were cross-titrated to oral aripiprazole
(10–30 mg/day) during a 4–6-week oral conversion phase (Phase 1).
Phase 2 was a 4–12-week oral aripiprazole stabilisation phase.
Subjects meeting stability criteria (4 weeks) entered an IM-depot
stabilisation phase (400 mg/injection) with co-administration of oral
aripiprazole the ﬁrst 2 weeks (Phase 3). Subjects meeting stability cri-
teria (12 weeks) were randomised (2 : 1) to ARI-IM-depot or placebo
(52-week : Phase 4). Secondary eﬃcacy assessments included mean
changes in Personal and Social Performance scale scores (PSP) scale
scores to assess functional outcomes, and Investigator’s Assessment
Questionnaire (IAQ) scores to assess treatment eﬀectiveness.
Results : 710 subjects entered Phase 2, 576 in Phase 3 and 403 in
Phase 4. The study stopped early because eﬃcacy was demonstrated
by pre-planned interim analysis (after 64 relapses). Mean changes in
PSP scale scores (LOCF) showed improvement during the oral (3.0)
and ARI-IM-depot stabilisation (2.6) phases. Mean change in PSP
scores in Phase 4 showed greater functional stability with ARI-IM-
depot (x1.7) than placebo (x6.2 ; p=0.0002 vs. placebo). Mean IAQ
total score remained stable (Phase 2, 31.3 ; Phase 3, 30.6) and mean
change in Phase 4 was +1.3 for ARI-IM-depot vs. +3.8 for placebo
(p<0.0001).
Conclusion : Improvements in symptoms, functioning and overall
response to treatment were achieved during stabilisation and main-
tained in Phase 4. ARI-IM-depot oﬀers a diﬀerent risk–beneﬁt proﬁle
than currently available treatments.
Policy of full disclosure : John M. Kane has received honoraria for
lectures and/or consulting from Alkermes, Amgen, BMS, Cephalon,
Esai, Boehringer Ingelheim, Eli Lilly, Intracellular Therapeutics,
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Janssen, Johnson and Johnson, Lundbeck, Merck, Novartis, Otsuka,
Pﬁzer, Pierre Fabre, Proteus, Roche, Sunovion and Targacept. He is a
shareholder of MedAvante. Dr. Fleischhacker has received research
grants from Alkermes, Janssen Cilag, Eli Lilly, BMS/Otsuka and
Pﬁzer. He has received honoraria for educational programs from
Janssen, Pﬁzer and AstraZeneca, speaking fees from AstraZeneca,
Pﬁzer, Janssen Cilag, Roche, Lundbeck, BMS/Otsuka and advisory
board honoraria from BMS/Otsuka, Wyeth, Janssen Cilag
Neurosearch, Amgen, Lundbeck, Endo, United Biosource, Targacept,
MedAvante and AstraZeneca. Raymond Sanchez, Pamela Perry, Na
Jin, Ross A Baker, Robert A Forbes, Robert D McQuade, William H
Carson are all employees of Otsuka Pharmaceutical Development and
Commercialization, Inc.
jP-08-010jTreatment of schizophrenia : Does gender matter?
E. Ceskova. Masaryk University, Brno, Czech Republic
Objective : There is little information about gender diﬀerences
concerning treatment of schizophrenia. We have used data from the
e-STAR (electronic Schizophrenia Treatment Adherence Registry),
an international, prospective, observational study assessing use of
risperidone long acting injection (RLAI) in patients with schizo-
phrenia or schizoaﬀective disorder. The aim was a comparison be-
tween male and female patients participating in e-STAR in both Czech
and Slovak Republics.
Methods : The e-STAR was designed to evaluate clinical outcome in
patients who have initiated RLAI as part of their continuing therapy
in routine clinical practice. The decision to initiate pts on RLAI and
their clinical management was determined solely by the treating
physician. The demographic, clinical and treatment related data were
collected at baseline and than prospectively for 2 years. We have
focused on gender diﬀerences in demographic and clinical data (hos-
pitalizations, concomitant medication and clinical improvement using
CGI, GAF and PSP).
Results : Totally 868 patients, 488 male and 380 female were
included. At baseline women were signiﬁcantly older than men 42.1
(12.8) respective 34.8 (11.1) women were also signiﬁcantly more fre-
quently diagnosed as schizoaﬀective disorder. Concerning the pro-
portion of pts hospitalized in the retrospective and prospective period
there was no diﬀerence between men and women (including length
of stay). Comparing the concomitant medication at 24 month the male
group used less antidepressants and benzodiazepines than the female
group (controlled for baseline values). The improvement in CGI-S and
PSP scores was similar. However, the improvement in GAF score was
signiﬁcantly higher in men than in women.
Conclusion : The comparable severity of illness is achieved in
women later. In spite of comparable severity women reacted better
in somemeasures of social functioning. The gender diﬀerences should
be more intensively studied and should be taken into consideration in
guidelines. Supported by research grant from Janssen CR and the
project CEITEC (CZ.1.05/1.1.00/02.0068).
jP-08-011jThe role of nitric oxide inhibitors in treatment on
symptom severity and cognitive deﬁcits in
schizophrenia
R. Chirita1, I. Sacuiu1, A. Burlea1, V. Chirita1. 1University of Medicine,
Iasi, Romania
Objective : Alteration of oxidative stress markers has been reported
in many studies, but with inconsistent results. Recently evidences
show that oxidative stress could be involved in the pathophysiology
of schizophrenia. Thus, accumulating evidence indicates that altera-
tions in NO function may be involved in the pathophysiology of
schizophrenia and these original ﬁndings motivate further investiga-
tions of the potential utility of NO modulation as a novel pharmaco-
logical treatment for schizophrenia. Objective : The objective of this
study was to investigate the beneﬁt of L-lysine, an aminoacid that
occurs naturally in food and which interferes with nitric oxide pro-
duction, as a treatment for schizophrenia.
Methods : The study was designed as a duble-blinded, cross-over
study where patients were randomly assigned to initial treatment
with either L-lysine or placebo and screened at baseline, after four
weeks when treatment was crossed over, and after eight weeks, when
treatment was terminated. L-lysine, 6 g/day, was administered to 20
patients with schizophrenia as an add-on treatment to conventional
antipsychotic medication.
Results : The four-week L-lysine treatment caused a signiﬁcant
increased in blood concentration of the amino. The analysis of out-
come measures from the remaining 16 patients showed a signiﬁcant
decrease in symptom severity (measured by PANSS). Furthermore,
the patient’s ability to solve the Wisconsin Card Sorting Task was
signiﬁcantly improved indicating increased problem solving capacity
and cognitive ﬂexibility.
Conclusion : These ﬁndings suggest potential beneﬁcial eﬀects of
nitric oxide inhibitors on symptom severity and cognitive deﬁcits in
patients with schizophrenia.
jP-08-012jPositively biased recognition of emotional valence
in schizophrenia
Y. Choi1, S. Youn2, S.-H. Han3, Y.-W. Shin2. 1Asan Medical Center,
Seoul, Republic of Korea ; 2University of Ulsan, College of Medicine, Seoul,
Republic of Korea ; 3University of Ulsan, College of Medicine, Seoul,
Republic of Korea
Objective : Schizophrenia is characterized by impairments in rec-
ognizing aﬀect. To evaluate aﬀect recognition of patients with
schizophrenia, facial expressions or words have been used in most
previous studies. Few studies have tackled the issue via reading
written sentences, which is another important component of perceiv-
ing social contexts. The present study aimed to evaluate aﬀect recog-
nition of various emotionally valenced sentences in patients with
schizophrenia.
Methods : A 28-item questionnaire was devised based on prelimi-
nary survey consisted of one hundred written sentences with various
emotional valence selected from newspapers and Korean novels. The
questionnaire was administered to both healthy control (N=32) and
patients with schizophrenia (N=9). Participants were asked to rate
the emotional valence of each sentence in a 7-point Likert scale, ran-
ging from 1 (very negative) to 7 (very positive). The independent
samples t-test was conducted to compare the diﬀerence in the means
of two groups.
Results : Of the 28 items, seven showed either statistically signiﬁ-
cant (three items p<0.05) or a trend of group diﬀerences (four items
p<0.10). On all cases showing group diﬀerences, the patients showed
positively biased emotional recognition. For example, the patients re-
sponded more positively to a sentence ‘Yuna Kim became Olympic
gold medalist getting over diﬃcult times’ (6.89¡0.33 versus
6.25¡0.62, p<0.01 in patients and control subjects respectively).
Conclusion : The tendency to recognize emotion more positively
than normal people may inﬂuence on patients with schizophrenia to
overlook negative emotions or exaggerate positive emotions of others,
and consequently, may interfere with successful social interaction.
jP-08-013jNegative symptoms of schizophrenia, antipsychotics
and clinical outcome
D. Degmecic1, T. Bacun2, M. Zˇivkovic3, B. Uglesˇic4, I. Filipcic5,
Zˇ. Vuksˇic6. 1University Hospital Osijek, Croatia ; 2University Hospital
Osijek, School of Medicine, Croatia ; 3Psychiatric Hospital Popovacˇa,
School of Medicine Osijek, Croatia ; 4University Hospital Split, Croatia ;
5University Hospital Zagreb, School of Medicine Zagreb, Croatia ;
6University Hospital Osijek, School of Medicine Osijek, Croatia
Objective : Negative symptoms such as social withdrawal, emotional
blunting, apathy and anhedonia are more subtle in nature, more in-
sidious and more diﬃcult to treat with antipsychotic drugs compared
with positive symptoms in schizophrenia. Nearly one third patients
with schizophrenia have predominant and persistant negative symp-
toms. In schizophrenia the presence of negative symptoms has been
associated with poorer clinical outcome. In this study we correlated
changes in negative symptoms, as measured by scores on the 16-item
Negative symptoms Assessment scale (NSA-16), with changes on the
Global Assessment of Functioning (GAF), and on the Social and
Occupational Functioning Assessment Scale (SOFAS), and with anti-
psychotic used in therapy.
Methods : In the study authors assessed in total 60 patients with
schizophrenia or schizoaﬀective disorder. The patients were treated
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with antipsychotics : olanzapine, quetiapine and risperidone. They
were assessed with 16-item Negative symptoms Assessment scale
(NSA-16), with Global Assessment of Functioning (GAF), and Social
and Occupational Functioning Assessment Scale (SOFAS), at the
baseline, after one month of the treatment and after 3 months of the
treatment. All of the patients were out-treated.
Results : Changes in negative symptoms rated with NSA x16
showed statistically signiﬁcant correlation with changes recorded on
all of the outcomes measured by GAF and SOFAS scales (HI2=4.27,
p<0.05 : HI2=5.69, p<0.05). There were no statistically signiﬁcant
changes between the groups of patient treated with diﬀerent anti-
psychotic drugs (olanzapine, risperidone, quetiapine).
Conclusion : In this study, negative symptoms assessed by NSA-16
showed association with improvements on GAF and SOFAS. We
can conclude from the results of this study that treatments that are
eﬀective in reducing negative symptoms, also reduce the functional
disability associated with these symptoms in patients with schizo-
phrenia.
jP-08-014jComparison of outcomes in patients with early
versus later phase schizophrenia treated with
olanzapine long-acting injection
H. Detke1, C. Correll2, C. Liu3, J. Landry4, P. Feldman5,
D. McDonnell6. 1Eli Lilly and Company, Indianapolis, USA ; 2Zucker
Hillside Hospital, North Shore–Long Island Jewish, Glen Oaks, USA ;
3PharmaNet/i3, Lexington, USA ; 4Eli Lilly Canada Inc., Toronto, ON,
Canada ; 5Eli Lilly and Company, Lilly Research Laboratories, Indianapolis,
USA ; 6Eli Lilly S.A., European SSC Irish Branch, Cork, Ireland
Objective : The present analyses were conducted to compare treat-
ment outcomes for patients initiating olanzapine long-acting injection
(LAI) within 5 years of onset of illness (‘‘Early Phase’’ group) versus
those initiating olanzapine LAI greater than 5 years after illness onset
(‘‘Later Phase’’ group).
Methods : Data were obtained from the 8 studies in the clinical trial
database involving olanzapine LAI (dose range :>45 mg/4 weeks to
300 mg/2 weeks). Outcome measures included rates of and time to
study discontinuation, relapse, remission, and sustained remission, as
well as mean changes from baseline to endpoint in Positive and
Negative Syndrome Scale (PANSS) or Brief Psychiatric Rating Scale
(BPRS) total and subscale scores.
Results : Of the 1879 patients in the analysis, 24.2% were in the
Early Phase group and 75.8% were in the Later Phase group. The
Early Phase group showed a longer median time to discontinuation
(P=0.003), longer time to relapse (P=0.018), and, among patients
not in remission at study initiation (45.8%), a shorter median time to
sustained remission (P=0.012). Rates of remission and sustained re-
mission were also higher for the Early Phase group relative to the
Later Phase group (P<0.001, both measures). The Early Phase group
also showed greater symptom reduction in their mean PANSS total,
negative, positive, and general psychopathology scores, and in their
BPRS total, positive and anxiety/depression scores (P<0.01, all mea-
sures).
Conclusion : Consideration must be given to the post-hoc nature of
this analysis and the fact that these clinical trials were not speciﬁcally
designed to address the issue of treatment timing and clinical out-
comes. Nevertheless, these ﬁndings support the assertion that clinical
outcomes with use of a depot antipsychotic such as olanzapine LAI
are signiﬁcantly improved in patients who begin the depot earlier in
the course of their illness compared with patients who begin the depot
later.
Policy of full disclosure :Dr. Holland Detke is a full-time employee
of Eli Lilly and Company. Research funded by Eli Lilly and Company.
jP-08-015jWithin-drug beneﬁt/risk of olanzapine LAI at 1 and
2 years of treatment
H. Detke1, J. Lauriello2, J. Landry3, S. Watson1, D. McDonnell4.
1Eli Lilly and Company, Indianapolis, USA ; 2University of Missouri,
Dept. of Psychiatry, Columbia, USA ; 3Eli Lilly Canada Inc., Toronto, ON,
Canada ; 4Eli Lilly S.A., European SSC Irish Branch, Cork, Ireland
Objective : Evaluate 1- and 2-year within-drug beneﬁt/risk of olan-
zapine long-acting injection (LAI).
Methods : Subjects were 1192 patients with the opportunity foro2
years Olanzapine LAI treatment for schizophrenia. Frequencies of key
beneﬁts and risks were evaluated versus average duration of those
events for all patients. Next, authors independently rated olanzapine
LAI using the Transparent Uniform Risk/Beneﬁt Overview method
(TURBO), weighting the 2 most medically serious and/or frequent
events versus primary beneﬁt (eﬀectiveness) and an ancillary beneﬁt.
Averaged ratings were placed on a t-score grid from 1–7 (worst bal-
ance to excellent).
Results : The most frequent event was remaining relapse-free (91%
at 1 year ; 88% at 2 years). Mean cumulative days without relapse was
306 at 1 year and 546 at 2 years. Next most frequent was meeting
symptomatic remission criteria at anytime (82% at 1 year ; 84% at
2 years). Incidence ofo7% weight gain was 33% at 1 year and 42% at
2 years ; mean days duration=54¡99 at 1 year and 124¡210 at 2
years. Per-patient post-injection delirium/sedation syndrome (PDSS)
incidence was 0.8% at 1 year and 1.5% at 2 years ; mean duration=0
days at 1 and 2 years. For those with an event (9 patients at 1 year ; 18
at 2 years), mean duration was 2 days at 1 and 2 years. For TURBO
analysis, PDSS and weight gain were selected as key risks ; choice of
ancillary beneﬁt varied. Mean beneﬁt rating was 5 ; mean risk rating
was 2.8 of 7, yielding a beneﬁt/risk balance t-score of 5 (‘‘accept-
able’’).
Conclusion : Olanzapine LAI’s beneﬁt/risk balance was in the
‘‘acceptable’’ range based on TURBO ratings. Quantitative evaluation
showed beneﬁts (such as remission, relapse-free days) outweighed
lower-probability events (PDSS), but higher-probability risks (weight
gain) remained a signiﬁcant clinical concern.
Policy of full disclosure : Dr. Holland C. Detke is a full-time em-
ployee of Eli Lilly and Company. Reported research was funded by Eli
Lilly and Company.
jP-08-016j Inﬂuence of neuroleptic therapy on neurocognitive
functions of schizophrenic patients in remission
J. Dobrovolskaya1, V.L. Malygin, D. Khritinin2, J. Kruchinskaya1.
1Moscow State University of Medicine, Russia ; 21st MSMU, Moscow,
Russia
Objective : Recovery of neurocognitive functions is the key indicators
of remission quality in schizophrenia, because this parameter de-
termines the functional outcome for the patient. Over the last decade
researches pointed out on advantages of atypical antipsychotics on
classic antipsychotics in neurocognitive failure treatment in schizo-
phrenia. However, the obtained results may be related not only to
pharmacological charasterictics of drugs, but also to the methodology
of research and interpretation of the results. We have surveyed 88
patients with symptomatic episode of paranoid schizophrenia, out of
which 43 were under atypical antipsychotics and 45 under classic
antipsychotics therapy. Assessment of neurocognitive disorders was
carried out taking into account the clinical signs of remission. After
the determination of remission, doses of drugs were reduced to a level
where the stimulating eﬀect is higher than sedation.
Methods : We have assessed verbal ﬂuency, audio-verbal memory,
visual memory, performing function and attention. The analysis of
dynamics showed a signiﬁcant improvement of neurocognitive func-
tion after the onset of clinical remission. Indicators of tests of visual
and audio-verbal memory changed insigniﬁcantly throughout the
study in both groups.
Results : For verbal ﬂuency, performing function and attention tests
the results have signiﬁcantly improved in all indicators after the
transfer of patients from therapeutic doses to support doses. While
comparing two groups of drugs it was shown that atypical anti-
psychotics had better eﬀect on verbal ﬂuency, executive functions and
attention before the onset of clinical remission (approximately
six months of therapy). Subsequently, diﬀerences between groups
were smoothed out. After 12 months of remission atypical anti-
psychotics have shown positive eﬀects on verbal associative pro-
ductivity (characteristic of verbal ﬂuency).
Conclusion : However, the signiﬁcance of this improvement re-
mains controversial, since this parameter has no essential eﬀect on
quality of life of the patients.
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jP-08-017jBiological and psychotherapeutic models of of
chronic acoustical hallucinations therapy at a
paranoid schizophrenia
S. Feday1, A. Kim2. 1Kyrgyz Russian University, Bishkek, Kyrgyzistan ;
2Kyrgyz Russian University, Medical Psychology, Psychiatry, Bishkek,
Kyrgyzistan
Objective : To study the clinical and psychological factors causing
synchronization and resistance of acoustical hallucinations at para-
noid schizophrenia for the purpose of optimization of conducted
therapy.
Methods : clinical, the standardized scales according to alarm level
of, depression of Zung, a questionnaire of vital styles an original scale
of understanding of the patient’s frustration.
Results : results of research it has been revealed that patients suf-
fering the paranoid schizophrenia over 5 years (57%), had persistent
synchronization of acoustical hallucinations where according to
clinical and psychopathological level acoustical hallucinations dif-
fered with their stereotype, deﬁning a plot of insane designs. The
prevalence of MPD depended on duration of frustration for less than
3 years replacement 0. 086 (P<0.01), negation 0. 086 (P<0.01) for
more than 3 years, hyper indemniﬁcation 0.183 (P<0.01), and ratio-
nalization 0.279 (P<0.01).
Conclusion : Acoustical hallucinations with a duration over 5 years
with the diagnosis of the paranoid schizophrenia make (57%).
Duration of disease till 3 years and till one year 26% and 17% rela-
tively, probably cause presence, ﬁrst of all, prevalence of analarm
component, as one of basic, deﬁning synchronization and resistance of
acoustical hallucinations. Prevalence of moderate depression of 50%,
easy depression of 32%, it display of personal reaction it promote the
process of activation speciﬁc MPD. At term of disease for less than
3 years there is replacement of 0.086 (P<0.01) and negation of 0.086
(P<0.01). For more than 3 years, hyper indemniﬁcation of 0.183
(P<0.01) and rationalization of 0,279 (P<0.01) become more active,
and more than 5 years the projection of 0,36 (P<0.01) prevails.
Interdependence of aﬀective frustrations and mechanisms of psycho-
logical protection at acoustical hallucinations, are the system for for-
mation of stereotype of clinical and psychopathological frustrations.
jP-08-018jComparision of atypical and typical antipsychotic
on quantitative EEG measures in a glutamatergic
animal model of psychosis
M. Fujakova1, T. Palenicek1, A. Kubesova1, F. Tyls1, J. Horacek1.
1Prague Psychiatric Centre, Czech Republic
Objective : Schizophrenia has been associated with dysfunctional
integration of diﬀerent cortical areas. These abnormalities can be
documented by the changes in quantitative EEG (qEEG). On the other
hand, neuroleptic agents produce beneﬁcial eﬀects on some of the
symptoms of psychosis and induce speciﬁc alternations in qEEG.
While many changes in qEEG have been found in people with
schizophrenia, only limited information is available in animal models.
Many authors describe EEG spectra in animals using 1–4 electrodes,
and no data on coherence exists. Therefore, the aim of this study is to
evaluate the eﬀect of typical and atypical antipsychotic in an NMDA
antagonist’s model of psychosis using qEEG measures.
Methods : Seven days before EEG recording, 14 electrodes were
stereotactically implanted bilaterally in frontal, parietal and temporal
regions. On the day of the experiment, male Wistar rats were treated
with MK 801 mg/kg 0.3 mg/kg i.p. and either clozapine 10 mg/kg
i.p. or haloperidol 0.1 mg/kg s.c.. The signal was recorded homo-
laterally from six electrode pairs, while the animal’s behaviour was
continuously observed. Subsequent power spectral analysis and the
EEG coherences were assessed congruently with the observed passive
behaviour.
Results : In EEG spectral analysis, MK801 caused an increase of the
power in gamma band and a decrease in slow wave bands. In EEG
coherences, a decrease occurred interhemispherally in high beta and
gamma bands and intrahemispherally in theta, delta, alpha and beta
bands. Clozapine restored the MK801-induced slow wave band
changes seen in power spectra. In EEG coherence, alpha and theta
frequency bands were completely restored by haloperidol while
clozapine partially restored most of the changes induced by MK801.
Conclusion : MK801 produced EEG abnormalities that correlate to
its schizophrenia-like potential. Our results show that clozapine might
be more eﬀective in restoring some of these changes.
Policy of full disclosure : This work is supported by grants IGA
MHCR NS-10374–3, NS-10375–3, CNS MEYS 1M0517, MZ0PCP2005
and GACR P303/10/0580.
jP-08-019j Increased 5HT2A receptor binding in frontal cortex
of schizophrenic subjects : Eﬀect of aging and
antipsychotic drug treatment
A. Garcı´a-Bea1, C. Muguruza1, P. Miranda-Azpiazu1, J.L. Moreno2,
A. Umali2, L.F. Callado1, A.M. Gabilondo1, J. Gonza´lez-Maeso3,
J.J. Meana1. 1Department of Pharmacology, University Basque Country,
Leioa, Spain ; 2Department of Psychiatry, Mount Sinai School of Medicine,
New York, USA ; 3Dpt. of Psychiatry, Neurology and Friedman Brain
Institute, New York, USA
Objective : Neuroimaging and postmortem studies have reported
alterations of the 5HT2A receptor (5HT2AR) in brain of schizophrenic
subjects. However, striking diﬀerences have been obtained in relation
to the diﬀerent methodologies and intrinsic confounding factors. The
aim of the present study was to assess the 5HT2AR mRNA (qRT-PCR)
and protein expression (western blot and [3H]ketanserin binding
(10 nM)) in prefrontal brain cortex (BA9) of schizophrenics (n=45)
and matched controls (n=45).
Methods : Displacement curves of [3H]ketanserin binding (2 nM)
by the agonist DOI were performed in order to delineate the high
aﬃnity state of 5HT2AR. Subjects who gave negative results for anti-
psychotic drugs in the postmortem toxicological screening were
considered antipsychotic (AP)free. To control the eﬀect of suicidal
behaviour, suicide victims (n=13) with other psychiatric diagnosis
were also included. Controls were individually matched by gender,
age and postmortem delay.
Results : Decreased 5HT2AR mRNA expression was observed in
APtreated schizophrenics(x37¡9% ; n=9 ; p<0.05) compared to
matched controls, without changes in APfree subjects (n=18). Im-
munodetection of 5HT2AR protein was unchanged. [3H]Ketanserin
binding was increased in APfree schizophrenics (+23¡11% ; n=29 ;
p<0.05), but not in APtreated subjects (n=16) and suicide victims.
Notably, an increase in the fraction of high-aﬃnity sites for DOI
displacing [3H]ketanserin was found in APfree schizophrenics
(12.4¡1.4% vs. 6.2¡0.8% ; p<0.001). [3H]Ketanserin binding corre-
lated negatively with age in schizophrenic, suicide and control sub-
jects. This eﬀect of aging was more pronounced in APtreated
(slope=x7.4¡3.1) than in APfree (slope=x3.6¡2.6) or control
subjects (slope=x2.3¡0.8).
Conclusion : These results suggest that the active conformation
of 5HT2AR is upregulated in schizophrenia, a modulation that tends
to be reversed by chronic treatment with antipsychotic drugs.
Progressive aging makes the identiﬁcation of the upregulation more
diﬃcult in schizophrenic subjects under treatment. The lower ex-
pression of 5HT2AR in older subjects may also underlie an association
between fewer positive symptoms and increased age.
jP-08-020jSocial cognition and functioning in delusional
disorder and schizophrenia. Diﬀerences between
oral and long-term atypical antipsychotics
A Gonza´lez Rodrı´guez1, O. Molina Andreu2, M.L. Imaz Gurrutxaga3,
M. Bernardo Arroyo3, R. Catalan Campos3. 1Hospital Clinic Barcelona,
Spain ; 2Mutua Terrassa, Spain ; 3Department of Psychiatry, Hospital
Clinic, Barcelona, Spain
Objective : Recent research has showed that there is a relationship
among social cognition, neurocognition and psychosocial functioning
in schizophrenia. Little information exists regarding the role of social
cognition in delusional disorder and its assessment as a measure of
treatment eﬃcacy. We aimed to compare functioning and social cog-
nition outcomes in delusional disorder and schizophrenia outpatients
treated with oral or long-term atypical antipsychotics.
Methods : We included 36 outpatients with chronic psychotic dis-
orders. Sociodemographic data, current age, age at onset in years and
age at ﬁrst psychiatric consultation were recorded. GEOPTE scale on
social cognition and neurocognitive perception deﬁcits, and GAF
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scale for global functioning were assessed. The sample was divided
into two groups according to the treatment received : oral vs. long-
term atypical antipsychotics. For comparisons, Mann-Whitney U-test
and Chi-square test were used.
Results : 18 delusional disorder (DD) patients and 18 patients on
schizophrenia were included. Mean age (SD) at onset of illness was
higher in delusional disorder compared to schizophrenia [45(9.65)
years vs. 27.91(9.21) ; p=0.03] and patients with schizophrenia started
follow-up earlier (p<0.001). No statistically signiﬁcant diﬀerences
were found between delusional disorder and schizophrenia patients
attending to educational level, marital status, number of children and
cohabiters. Mean (SD) score in GEOPTE scale was similar in schizo-
phrenia than in DD [34.70(7.65) vs. 30.29(7.20) ; p=0.082]. Patients
receiving oral antipsychotic treatment displayed more deﬁcits in
social cognition compared to those treated with long-acting atypical
antipsychotics, according to GEOPTE scale score [34.43 (8.08) vs. 29.47
(6.02)] but this result was not statistical signiﬁcant. General function-
ing was similar between the two treatment groups.
Conclusion : Social cognition may be an important target in the
pharmacological treatment of DD and schizophrenia. Long-term
atypical antipsychotics could improve social cognition in patients
with chronic psychotic disorder.
jP-08-021jPharmacological characterization and exploration
of novel transcripts of a developmentally regulated
and phencyclidine-inducible gene, SAP97,
in mammalian brains
E. Haramo1, N. Yamamoto1, A. Uezato1, S. Hiraoka1, E. Hiraaki1,
M. Umino1, A. Umino1, A. Kurumaji1, T. Nishikawa1. 1Tokyo Medical
and Dental University, Japan
Objective : Recently accumulated evidence supports that the dis-
turbed N-methyl-D-aspartate (NMDA) receptor-mediated glutamate
neurotransmission is involved in the pathophysiology of schizo-
phrenia. We have explored the transcripts induced by phencyclidine
(PCP), an NMDA receptor antagonist, in the mammalian cerebral
cortex.
Methods : Using diﬀerential screening, and quantitative RT-PCR
methods, we isolated the neocortical transcript that was up-regulated
in the adult but unchanged in infant rats, after a systemic adminis-
tration of PCP. We further examined the expression and character-
ization of SAP97 in both rat and human specimens. All studies were
approved by the ethics committees of the University.
Results : We have identiﬁed the synapse-associated protein-97
(SAP97)/discs large (DLG1) mRNA as a PCP-responsive transcript.
The up-regulation of the SAP97 transcript in the adult neocortex after
the acute PCP injection was mimicked by another NMDA antagonist,
dizocilpine, but not by the indirect dopamine agonists, methamphe-
tamine and cocaine, a selective D1 receptor antagonist SCH23390, a
D2 receptor-preferring antagonist haloperidol and a GABAergic an-
esthetic pentobarbital. The pretreatment with a typical antipsychotic
haloperidol failed to antagonize the increased neocortical SAP97 gene
expression by PCP.
Conclusion : SAP97 gene encodes the synaptic scaﬀolding PDZ
proteins that interact with ionotropic glutamate receptors. By using
single nucleotide polymorphism (SNP) analyses, we have found a
signiﬁcant association between the human SAP97 gene and schizo-
phrenia (Yamamoto et al., 2012 CINP abstract). These ﬁndings to-
gether suggest that SAP97 might be involved in the molecular basis
of the development-dependent onset of the non-dopaminergic symp-
toms seen in schizophrenia and the schizophrenia-like psychosis
induced by NMDA receptor blocking. Currently, we are further
examining the expression of novel splicing variants of SAP97 in the
human brain and their possible functional relationship with the
symptoms.
jP-08-022jThe p250GAP gene is associated with risk for
schizophrenia and schizotypal personality trait
R. Hashimoto1, K. Ohi2, T. Nakazawa3, Y. Yasuda2, H. Yamamori4,
M. Fukumoto2, M. Iwase2, H. Kazui2, T. Yamamoto5, M. Kano3,
M. Takeda2. 1Osaka University, Suita, Japan ; 2Department of Psychiatry,
Osaka University Graduate, Suita, Japan ; 3Department of
Neurophysiology, Graduate School of Medicine, Tokyo, Japan ; 4Dept. of
Mol Neuropsychiatry, Osaka University Graduate, Suita, Japan ; 5Division
of Oncology, Institute of Medical Science, Tokyo, Japan
Objective : Hypo-function of glutamate N-Methyl-d-aspartate
(NMDA) receptor is implicated in the pathophysiology of schizo-
phrenia. p250GAP is a brain-enriched NMDA receptor-interacting
RhoGAP. p250GAP is involved in spine morphology, which has
been shown to be altered in post-mortem brains of schizophrenia.
Schizotypal personality disorder has a strong familial relationship
with schizophrenia. Several susceptibility genes for schizophrenia
have been related to schizotypal traits.
Methods : We ﬁrst investigated the association of eight linkage
disequilibrium-tagging SNPs that cover the p250GAP gene with
schizophrenia in a Japanese sample of 431 schizophrenia patients and
572 controls. We then investigated impact of the risk genetic variant in
the p250GAP gene on schizotypal personality traits in 180 healthy
subjects using the Schizotypal Personality Questionnaire.
Results : We found a signiﬁcant diﬀerence in genotype frequency
between patients and controls in rs2298599 (k2=17.6, p=0.00015).
The minor A/A genotype frequency of rs2298599 was higher in
patients (18%) than in controls (9%) (k2=15.5, p=0.000083).
Moreover, we found that subjects with the risk A/A genotype of
rs2298599 showed higher scores on schizotypal traits (F1,178=4.08,
p=0.045), particularly interpersonal factor (F1,178=5.85, p=0.017),
compared with G allele carriers.
Conclusion : These results suggest that the genetic variation in
the p250GAP might increase susceptibility not only for schizophrenia
but also for schizotypal personality traits. We concluded that the
p250GAP might be a new candidate gene for susceptibility to schizo-
phrenia.
jP-08-023j Inﬂuence of psychiatric comorbidity on
rehospitalization of patients with ﬁrst-episode
schizophrenia
M. Herceg1, V. Jukic2, P. Brecic2. 1Zagreb, Croatia ; 2University
Psychiatric Hospital, Zagreb, Croatia
Objective : The problem of rehospitalization of patients after the ﬁrst
episode of schizophrenia is one of the major problems inﬂuencing the
course and outcome of the treatment as well as treatment expenses.
The aim of the study was to determine the inﬂuence of psychiatric
comorbidity on the one-year rehospitalization rate for ﬁrst-episode
schizophrenia patients.
Methods : The study was conducted at University Psychiatric
Hospital Vrapce among 123 patients with ﬁrst-episode schizophrenia
who were treated between January 1, 2007 and January 1, 2008. The
patients were prospectively followed-up for rehospitalization during
one year after hospital discharge, i.e., until January 1, 2009.
Descriptive statistics was used to describe demographic and clinical
data, whereas time to rehospitalization was analyzed with Kaplan-
Meier survival analysis.
Results : There was a signiﬁcant diﬀerence between the re-
hospitalized and non-rehospitalized patients in the presence of psy-
chiatric comorbidity (p=0.046).
Conclusion : Among other rehospitalization risk factors, the psy-
chiatric comorbidity was found to increase the rehospitalization rate.
Psychiatric comorbidity that showed the greatest inﬂuence on the re-
hospitalization rate was alcohol and opiate abuse.
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jP-08-024jPartial agonism at trace amine-associated receptor 1
(TAAR1) reveals a novel paradigm for
neuropsychiatric therapeutics
M. Hoener1, F. Revel2, J.-L. Moreau2, R. Gainetdinov3, S. Morairty4,
T. Kilduﬀ4, R. Norcross2, J. Canales5, T. Wallace4, M. Caron6,
J. Wettstein2, T.D. Sotnikova7, A. Ferragud5, C. Velazquez-Sanchez5,
K. Groebke-Zbinden2, A. Bradaia8. 1F. Hoﬀmann-La Roche Ltd., Basel,
Switzerland ; 2F. Hoﬀmann-La Roche, Basel, Switzerland ; 3 Italian
Institute of Technology, Genova, Italy ; 4SRI International, Menlo Park,
USA ; 5University of Canterbury, Christchurch, New Zealand ; 6Duke
University Medical Center, Durham, USA ; 7 Italian Institute of
Technology, Genova, Italy ; 8Neuroservice, Aix-en-Provence, France
Objective : Trace amines, endogenous compounds structurally re-
lated to classical biogenic amines, represent endogenous ligands of
the trace amine-associated receptor 1 (TAAR1). Because trace amines
also inﬂuence the activity of other targets, selective ligands are needed
for the functional elucidation of TAAR1. Here we report on the
identiﬁcation and electrophysiological and behavioral characteriza-
tion of the ﬁrst selective and potent TAAR1 partial agonist.
Furthermore, the suitability of TAAR1 as a drug target for various
neuropsychiatric indications will be discussed.
Methods : The TAAR1 partial agonist was evaluated for its binding
aﬃnity and functional activity at rodent and primate TAAR1 re-
ceptors stably expressed in HEK293 cells, for its physicochemical and
pharmacokinetic properties, for its eﬀects on the ﬁring frequency of
monoaminergic neurons ex vivo, and for its properties in vivo using
genetic and pharmacological models of CNS disorders.
Results : The TAAR1 partial agonist shows high aﬃnity for TAAR1,
has potent functional activity with selectivity over other molecular
targets and has good pharmacokinetic properties. In mouse brain
slices, the TAAR1 partial agonist increased the ﬁring frequency of
dopaminergic and serotonergic neurons in Taar1 expressing regions,
the ventral tegmental area and the dorsal raphe nucleus, respectively.
In vivo, examining the consequences of activating TAAR1 selectively
on various behavioral paradigms in rodents andmonkeys, the TAAR1
partial agonist demonstrates antipsychotic-, anxiolytic- and anti-
depressant-like activities. Furthermore, it attenuates drug-taking be-
havior and is highly eﬀective in promoting attention, cognitive
performance and wakefulness.
Conclusion : Using the ﬁrst potent and selective TAAR1 partial
agonist we show that TAAR1 is implicated in a broad range of
relevant physiological, behavioral and cognitive neuropsychiatric
dimensions. Collectively, these data uncover important neuromodu-
latory roles for TAAR1 and demonstrate its therapeutic potential in
psychiatric disorders such as psychosis, depression and substance
abuse.
Policy of full disclosure : F. Revel, J.-L. Moreau, R. Norcross,
J. Wettstein and M. Hoener are employed by F. Hoﬀmann-La Roche.
R. Gainetdinov is supported in part by research grants from
F. Hoﬀmann-La Roche Ltd. and Compagnia di San Paolo Fondazione
(Torino, Italy). J. Canales has no interests to declare. T. Wallace,
S. Morairty and T. Kilduﬀ are supported in part by research grants
from F. Hoﬀmann-La Roche Ltd. M. Caron has received funds for
Sponsored Research Agreements unrelated to this work from Forest
Laboratories, NeuroSearch, Lundbeck USA as well as consulting fees
from Merck and F. Hoﬀmann-La Roche Ltd. An unrestricted gift to
Duke University was provided by Lundbeck USA to support
Neuroscience research in the laboratory of M. Caron.
jP-08-025jSigniﬁcance of elevated brain kynurenic acid
following neonatal inﬂuenza A infection
M. Holtze1, S.B. Powell2, L. Asp3, H. Karlsson3, S. Erhardt4.
1Karolinska Institutet, Stockholm, Sweden ; 2University of California SD,
San Diego, USA ; 3Karolinska Institutet, Dept. of Neuroscience, Stockholm,
Sweden ; 4Karolinska Institutet, Physiology and Pharmacology, Stockholm,
Sweden
Objective : Neonatal virus infection induces the mouse brain
kynurenine pathway, including kynurenic acid (KYNA) – an end-
metabolite that has previously been implicated in schizophrenia
pathophysiology. The objective of the present study was to investigate
the long-term behavioral eﬀect of such neonatal infection, and the link
to elevated KYNA during neurodevelopment.
Methods : Male C57BL/6 mice were i.p injected with the neuro-
tropic inﬂuenza virus A/WSN/33 or vehicle at P3. Another set of
male C57BL/6 mice were i.p injected with L-kynurenine or vehicle at
P7–16. In adult life, horizontal activity was analyzed. Following a
60 min habituation period, D-amphetamine or saline was adminis-
tered i.p., and horizontal activity was recorded for 90 min. Whole
brain KYNA concentrations was analyzed using a HPLC system and a
ﬂuorescence detector.
Results :Administration of D-amphetamine in adult mice increased
horizontal activity in both infected and uninfected mice. Mice infected
with inﬂuenza virus showed a more pronounced increase in hori-
zontal activity. Similarly, D-amphetamine administration to adult
mice increased horizontal activity in both L-kynurenine treated mice
and vehicle controls. The D-amphetamine induced increase in hori-
zontal activity tended to be more pronounced in the L-kynurenine
treated mice. Basal horizontal activity did not diﬀer between infected
and uninfected mice or between L-kynurenine treated mice and ve-
hicle controls. Brain KYNA levels did not diﬀer between the com-
parison groups at time of locomotor assessment.
Conclusion : Present study conﬁrms that a neonatal virus infection
targeting the brain is associated with behavioral disturbances in adult
life. Our results are in line with the enhanced striatal dopamine re-
lease by amphetamine, as observed by brain imaging studies in
patients with schizophrenia. Notably, subchronic elevations of brain
KYNA in adult rats enhance amphetamine-induced increase in brain
dopamine release. The present study adds support to the hypothesis
of brain KYNA as an important mediator in the development of
neuropsychiatric symptoms.
jP-08-026jAssociation study of catechol-O-methyltransferase
gene polymorphisms with schizophrenia and
psychopathological symptoms in Han Chinese
C.-C. Huang1, S.-Y. Huang2, C.-Y. Chen2. 1National Defense Medical
Center, Taipei, Taiwan ; 2Taipei, Taiwan
Objective : Although dysfunction of catechol-O-methyltransferase
(COMT)-mediated dopamine transmission is implicated in the etiol-
ogy of schizophrenia, the human COMT gene has not been associated
consistently with schizophrenia. The purpose of this study was to in-
vestigate whether the COMT gene is associated with the development
of schizophrenia and whether polymorphisms of this gene inﬂuence
psychopathological symptoms in patients with schizophrenia.
Methods : Fourteen polymorphisms of the COMT gene were ana-
lyzed in a case–control study of 876 Han Chinese individuals (434
patients and 442 controls). All participants were screened using a
Chinese version of the modiﬁed Schedule for Aﬀective Disorders and
Schizophrenia—Lifetime Version (SADS-L) and all patients met the
criteria for schizophrenia. Furthermore, pretreatment psychopath-
ology was assessed using the Positive and Negative Syndrome Scale
(PANSS) in a subset of 224 hospitalized schizophrenia patients that
were drug naı¨ve or drug free, to examine the association between
clinical symptomatology and COMT polymorphisms.
Results :No signiﬁcant diﬀerences in allele or genotype frequencies
were observed between schizophrenia patients and controls, for all
variants investigated. Haplotype analysis revealed that three haplo-
type blocks of the COMT gene were not associated with the develop-
ment of schizophrenia. Moreover, these COMT polymorphisms did
not inﬂuence the PANSS scores of schizophrenia patients.
Conclusion : This study suggests that the COMT gene may not
contribute to the risk of schizophrenia and to the psychopathological
symptoms of schizophrenia among Han Chinese.
jP-08-027jRepetitive transcranial magnetic stimulation-
induced cumulative pattern of serum brain-derived
neurotrophic factor as a biomarker of rehabilitation
in patients with chronic schizophrenia : Optimism or
pessimism for psychiatric rehabilitation
T. Hwang. Jeonbuk Provincial Maeumsarang, Hospital, Wanju, Republic
of Korea
Objective : The aim of this study is to investigate the role of serum
Brain-Derived Neurotrophic Factor (sBDNF) as a biomarker of
neuroplasticity for psychiatric rehabilitation through the evaluation of
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the response of sBDNF to the quantiﬁed stimuli applied with repeti-
tive Transcranial Magnetic Stimulation (rTMS).
Methods : Right-handed twenty inpatients, with chronic schizo-
phrenia, on stable medication whose minimum duration of illness was
10 years were recruited. The handedness was assessed using
Edinburgh Handedness Inventory. Consecutive 10 weekday sessions
with 20 Hz rTMS (a total of 20,000 stimuli) were applied over the left
dorsolateral prefrontal cortex at 100% of motor threshold. There was
no change in the medication for at least 2 week before enrollment and
4 weeks thereafter. Primary outcome measure was the change in the
mean concentration of duplicated sBDNF(pg/ml). Clinical severity or
change was measured using the Clinical Global Impression scale
(CGI) and the Positive and Negative Symptom Scale (PANSS).
Results : Eighteen participants (male, 10 ; female, 8) completed the
study and were analyzed. The mean (SD) of chlorpromazine equiva-
lent (CPZE) of antipsychotics were 1,325.69 (761.58)mg. The mean
(SD) of baseline CGI-severity and total PANSS score were 4.61 (0.50)
and 68.44 (6.05), respectively. The diﬀerences from baseline, in the
level of sBDNF, just after the completion of rTMS sessions were stat-
istically signiﬁcant (paired t-test : t=2.245, df=17, p=0.038). At
2 weeks after the completion of rTMS sessions, however, the sig-
niﬁcance in the level of sBDNF was not manifest (t=1.381, df=17,
p=0.185).
Conclusion : The ﬁndings of this study suggest that in patients with
chronic schizophrenia, sBDNF may serve as a biomarker of neuro-
plasticity, but the change pattern of sBDNF might manifest both
positive and negative implications on psychiatric rehabilitation.
jP-08-028jD-neuron-trace amine hypothesis of schizophrenia
K. Ikemoto. Fukushima Med. U. Sch. Med., Japan
Objective : Dopamine (DA) dysfunction, glutamate hypofunction,
neurodevelopmental deﬁcits, and neural stem cell hypofunction
are widely accepted hypotheses for etiology of schizophrenia.
Nevertheless, molecular mechanisms of mesolimbic DA hyperactivity
have not yet been clariﬁed. The author intended to examine whether
mesolimbic DA hyperactivity might be explained by some mech-
anisms, in which D-neurons, i.e., trace-amine-producing neurons, and
trace amine-associated receptor, type 1 (TAAR1) are involved.
Methods : The author’s previous reports on post-mortem brains
of schizophrenia, using immunohistochemistry with antibodies
against amine-related neural substances, such as aromatic L-amino
acid decarboxylase, and literatures on TAAR1 and neural stem cells,
were referred.
Results : In brains of schizophrenia, hypofunction of neural stem
cells in the subventricular zone of lateral ventricle must cause
decrease of D-neurons in the nucleus accumbens and striatum, and
resulting decrease of the amounts of trace amines in the nucleus. The
reduction of trace amine signals to TAAR1 on DA terminals of ventral
tegmental area (VTA) DA neurons may increase the ﬁring frequency
of VTA DA neurons, and leads to increase of DA release in the nucleus
accumbens. DA hyperactivity in the nucleus accumbens and striatum
may inhibit forebrain neural stem cell proliferation, via DA D2 re-
ceptors, and causes additional decrease of D-neurons, which may in-
duce additional hyperactivity of mesolimbic DA system.
Conclusion : The innovate ‘‘D-neuron-trace amine hypothesis ’’
may explain the molecular mechanism of mesolimbic DA hyper-
activity of schizophrenia.
References
1. Bradaia A et al. (2009) The selective antagonist EPPTB reveals
TAAR1-mediated regulatory mechanisms in dopaminergic
neurons of the mesolimbic system. Proc Natl Acad Sci USA 106 :
20081–20086.
2. Revel FG et al. (2011) TAAR1 activation modulates monoaminergic
neurotransmission, preventing hyperdopaminergic and
hypoglutamatergic activity. Proc Natl Acad Sci USA 108 :
8485–8490 The present study was supported by Grant-in-Aid for
Scientiﬁc Research from Japan Society for the Promotion of
Science (C-22591265).
jP-08-029jFinally we are on the begin : Real causes of some
psychotic disorders
N. Ilankovic1, A. Ilankovic1, T. Lakovic2, V. Ilankovic3, S. Ilankovic2.
1 Institute of Psychiatry, Belgrade, Serbia ; 2Medical College M Milankovic,
Belgrade, Serbia ; 3Faculty of Special Education, Belgrade, Serbia
Objective : The detection of possible real etiological factors by some
psychotic disorders is the best opportunity to introduce more etiolo-
gical targeted and more eﬀective therapy of some Schizophrenia-like
and other psychotic disturbances.
Methods : Clinical study with targeted investigations to detect all
possible etiological factors and comorbidity in sample of 100 patients
by acute psychotic disorders. Clinical, biochemical, bacteriological,
virusological, neurophysiological investigations and targeted neuro-
imageing (MRI, MR angiography – arteriography and venography).
Results : The most frequent etiology in our sample of 100 patients
with psychotic future were : psychoactive drugs (29%), respiratory
tract and other infections (25%), endocrine and metabolic dis-
turbances (16%), cerebrovascular disorders (12%), brain disorders
(11%) and neurodevelopmental disorders (7%). Between patients
with infectious/inﬂammatory etiological factors and events involved
in clinical picture acute of psychotic disorders : sinusitis by 5 of
patients, cerebral venous thrombosis 2, tonsillopharyngitis 3, otitis
media 2, dental focuses 3, bronchitis – bronchopneumonia 4, urogen-
ital infection 1, syphilis 1, neuroboreliosis 1, infectious mononucleosis
2, thrombophlebitis cruris 1.
Conclusion : The relative clear etiology or commorbidity by acute
psychotic disorders is the best way to targeted eﬀective therapy and
further prophylaxis of some mental disorders. The recovery can be
very good, the possibility to relapse is very small and the stigmatiza-
tion of mentally ill patients in these cases is practically diminished.
jP-08-030jDisrupted-in-schizophrenia 1 (DISC1) regulates
oligodendrocyte diﬀerentiation
A. Ito1, T. Hattori1, S. Shimizu1, T. Katayama2, M. Tohyama1. 1Osaka
University, Medical School, Suita, Japan ; 2United Graduate School of
Child Development, Suita, Japan
Objective : Multiple lines of evidence obtained by brain imaging,
studies in postmortem brains and genetic association studies, have
implicated oligodendrocytes (OL) and myelin dysfunction in schizo-
phrenia (SZ). We addressed the possibility of glial expression of
DISC1, a key susceptibility gene for major psychiatric disorders in-
cluding SZ. In addition, we clariﬁed the role of DISC1 in OL diﬀer-
entiation.
Methods :Glial expression of DISC1 was examined both in vivo and
in vitro. Eﬀect of manipulating DISC1 expression on OL diﬀeren-
tiation was assessed by using primary culture of oligodendrocyte
precursor cells (OPC).
Results : DISC1 mRNA expression was detected not only in
neurons but also in glial cells and especially abundant in OPC where
DISC1 localized in cell body, nucleus and process. In an in vitro OL
diﬀerentiation system, myelin related markers such as CNPase, MAG
and MBP increased and cells with matured morphology increased
when endogenous DISC1 was knockdowned by RNA interference.
Furthermore, overexpression of truncated DISC1, supposedly by
functioning in a dominant negative fashion, resulted in an increase of
myelin related proteins. On the contrary, both expression of myelin
related proteins and number of cells with matured morphology were
decreased upon overexpression of full length DISC1. We also show a
possible involvement of Sox10 and Nkx2.2, well known transcription
factors regulating the expression of myelin genes, in the regulatory
pathway of OL diﬀerentiation by DISC1.
Conclusion : Mammalian DISC1 endogenously expressed in OL
lineage negatively regulates OL diﬀerentiation by regulating Sox10
and Nkx2.2 expression.
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jP-08-031jEﬀects of zonisamide on tardive dyskinesia : A
preliminary open-label trial
Y. Iwata1, S. Irie2, H. Uchida1, T. Suzuki1, K. Watanabe1, S. Iwashita3,
M. Mimura1. 1Keio University School of Medicine, Tokyo, Japan ;
2Kitasato University, Kanagawa, Japan ; 3Sakuragaoka Memorial Hospital,
Tokyo, Japan
Objective : Once developed, tardive dyskinesia (TD) is a challenging
condition to treat. The recent evidence has demonstrated that zonisa-
mide, an antiepileptic drug indicated for partial-onset seizures, may
also have beneﬁcial eﬀects for ameliorating dyskinesia in Parkinson’s
disease. However, this ﬁnding has not systematically been tested in
patients with TD associated with antipsychotic treatment. The objec-
tive of this study was to examine the eﬃcacy, tolerability, and safety of
zonisamide against TD in these patients.
Methods : In this 4-week open-label study, subjects who suﬀered
TD were given 50–100 mg/day of zonisamide. Severity of TD was
evaluated at the baseline and endpoint, using the Abnormal
Involuntary Movement Scale (AIMS).
Results : Eleven subjects (6 females ; mean ¡ SD age, 75.5¡4.7
years ; schizophrenia [N=6], bipolar aﬀective disorder [N=2], schi-
zoaﬀective disorder [N=1], mental retardation [N=1], mental retar-
dation with epilepsy [N=1]) participated in this study. The AIMS
total score (mean¡ SD) was signiﬁcantly decreased from 24.1¡5.5 to
19.5¡5.9, with 36.4% of the subjects (N=4) demonstrating a >20%
decrease in the AIMS total score.
Conclusion : Treatment with zonisamide was well-tolerated and no
participants dropped out prematurely. Zonisamide may be safe
and eﬀective for the treatment of TD in a subgroup of patients. These
preliminary ﬁndings need to be further explored by larger well-
designed trials.
jP-08-032jOptimal D2 receptor occupancy rate of
antipsychotics for the treatment of dopamine
supersensitivity psychosis and late-onset psychosis
M. Iyo1, S. Tadokoro1, N. Kanahara1, T. Hashimoto1, T. Niitsu1,
H. Watanabe1, K. Okita1, K. Hashimoto2. 1Chiba University School of
Med., Japan ; 2Chiba University, Center for Forensic Mental, Japan
Objective : Our aim is to estimate optimal D2 receptor occupancy
rate of antipsychotics for the treatment of treatment-resistant schizo-
phrenia, especially for patients with dopamine supersensitivity
psychosis.
Methods : Under assumptions that there is an optimal range of the
number of D2 receptors available for dopamine binding, which is
constant under diﬀerent D2 receptor density, we estimated optimal
D2 receptor occupancy with diﬀerent D2 density.
Results : The results showed that the optimal occupancy rate and
optimal plasma level of antipsychotics increase with an increase in the
D2 density, but decrease with a decrease in the D2 density.
Conclusion : Optimal D2 receptor occupancy of antipsychotics may
change with D2 receptor density of each patient with schizophrenia.
Patients with up-regulated D2 density may need higher doses of an-
tipsychotics for the treatment..
jP-08-033jEﬃcacy of aripiprazole-IM-depot for long-term
maintenance treatment of schizophrenia
J. Kane1, R. Sanchez2, P. Perry2, N. Jin2, B. Johnson2, R.A. Forbes2,
R.D. McQuade2, W.H. Carson2, W. Fleischhacker3. 1Zucker Hillside
Hospital, Glen Oaks, USA ; 2Princeton, USA ; 3 Innsbruck, Austria
Objective : To evaluate the eﬃcacy and tolerability of once-monthly
aripiprazole intramuscular depot (ARI-IMD) for maintenance treat-
ment in adult schizophrenia.
Methods : Subjects were cross-titrated to oral aripiprazole
(10–30 mg/day) during a 4–6-week oral conversion phase (Phase 1).
Phase 2 was a 4–12-week oral aripiprazole stabilisation phase.
Subjects meeting stability criteria (4 weeks) entered an ARI-IMD
stabilisation (400 mg/injection) phase with co-administration of oral
aripiprazole for 2 weeks (Phase 3). Subjects meeting stability criteria
(12 weeks) were randomised (2 : 1) to ARI-IMD or placebo (52-week :
Phase 4). Primary endpoint was time to impending relapse. Safety and
tolerability were assessed.
Results : 710 patients entered Phase 2, 576 progressed to Phase 3
and 403 were randomised to Phase 4. The study stopped early because
eﬃcacy was demonstrated by pre-planned interim analysis. Time-to-
impending relapse was signiﬁcantly delayed in ARI-IMD compared
with placebo in interim and ﬁnal analyses (p<0.0001, log-rank test).
Rate of impending relapse was signiﬁcantly lower with ARI-IMD than
placebo at endpoint (10.0%, n=27/269 vs. 39.6%, n=53/134 ; HR :
5.0 ; 95% CI : 3.15–8.02 ; p<0.0001). Improvements in PANSS Total
score were maintained with ARI-IMD, but showed signiﬁcant
worsening with placebo (mean change at Week 52 : ARI-IMD=1.4,
placebo=11.6, p<0.0001). CGI-S scores showed signiﬁcant diﬀer-
ences favouring ARI-IMD (p<0.0001). Most common treatment-
emergent AEs (o5% of aripiprazole-treated patients and greater than
placebo) were insomnia (10.0% vs. 9.0%), tremor (5.9% vs. 1.5%) and
headache (5.9% vs. 5.2%), respectively. Most AEs were mild or
moderate. Incidence of injection site pain in Phase 3 was 5.9%, while
in Phase 4 was 3.0% vs. 3.7% for ARI-IMD compared with placebo.
Conclusion : ARI-IMD signiﬁcantly delayed time to impending re-
lapse compared with placebo and was a well-tolerated maintenance
treatment option in schizophrenia.
Policy of full disclosure : John M. Kane has received honoraria for
lectures and/or consulting from Alkermes, Amgen, BMS, Cephalon,
Esai, Boehringer Ingelheim, Eli Lilly, Intracellular Therapeutics,
Janssen, Johnson and Johnson, Lundbeck, Merck, Novartis, Otsuka,
Pﬁzer, Pierre Fabre, Proteus, Roche, Sunovion and Targacept. He is
a shareholder of MedAvante. Dr. Fleischhacker has received
research grants from Alkermes, Janssen Cilag, Eli Lilly, BMS/Otsuka
and Pﬁzer. He has received honoraria for educational programs
from Janssen, Pﬁzer and AstraZeneca, speaking fees from
AstraZeneca, Pﬁzer, Janssen Cilag, Roche, Lundbeck, BMS/Otsuka
and advisory board honoraria from BMS/Otsuka, Wyeth, Janssen
Cilag Neurosearch, Amgen, Lundbeck, Endo, United Biosource,
Targacept, MedAvante and AstraZeneca. Raymond Sanchez, Pamela
Perry, Na Jin, Brian Johnson, Robert A Forbes, Robert DMcQuade and
William H Carson are all employees of Otsuka Pharmaceutical
Development and Commercialization, Inc.
jsP-08-034jMedication prescribing patterns for patients with
schizophrenia and related psychosis in a university
psychiatric hospital
C.-H. Kim1, J.-G. Chang1, D. Roh1. 1Severance Mental Health Hospital,
Gwangju-Si, Republic of Korea
Objective : Despite multiple therapeutic advances, especially in psy-
chopharmacology, the treatment of schizophrenia has remained a
major challenge. Surveys of prescribing in psychiatric services inter-
nationally have identiﬁed the relatively frequent and consistent use of
antipsychotics polypharmacy (AP) with a prevalence of up to 50% in
some clinical settings. The purpose of this study was to examine
trends in the use of antipsychotic medications in an inpatient unit at a
university mental health hospital in Korea.
Methods : This retrospective study was conducted in Severance
Mental health Hospital (SMH), a part of the unit of psychiatry, Yonsei
University College of Medicine, which is a representative psychiatric
facility oﬀering comprehensive treatment to institutionalized patients
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with severe and persistent mental illness, in Korea. We reviewed
all the psychotropic medications prescribed to inpatients SMH, diag-
nosed as having schizophrenia or schizoaﬀective disorder (DSM-
IV-TR, 4th edition) at time of discharge and 60days after discharge
in the year 2010.
Results : Of the 264 studied patients, 260 cases were treated with
antipsychotics (Mean dose=723 mg¡519) chlorpromazine equiva-
lent) and 47.3% were discharged under AP treatment. The most
prevalent combination of drugs was risperidone plus quetiapine
(N=20). Quetiapine was the most frequently used antipsychotic as
adjuvant treatment (N=64). Fifty-six cases (21.5%) received mood
stabilizer 22 case received anticholinergics, 157cases (60.3%) received
benzodiazepines and 149 cases (57.3%) were prescribed anti-
cholinergics.
Conclusion : Although, the controlled evidence for its eﬃcacy
and safety as a strategy remains inconclusive, AP is a common
pharmacological strategy as it is shown in our study. Because of
severe and patients in SMH, and using low dose quetiapine for sleep
make the ratio of antipsychotic polypharmacy higher. And at some
cases, polypharmacy was only used for short-term period (less than
60 days), the deﬁnition of antipsychotics polypharmacy. Clearly more
controlled research is needed to evaluate the short-term and long-
term eﬀects of antipsychotic polypharmacy.
jP-08-035jCorrelation between the left temporal lobe volume
and the duration of untreated prodromal state in
ultra-high risk for psychosis
S.N. Kim1, J.Y. Hwang2, J.H. Jang2, H.J. Han3, W.H. Jung4,
C.-H. Choi5, J.S. Kwon2. 1Seoul National University, Republic of Korea ;
2Department of Psychiatry, Seoul National University, Republic of Korea ;
3Dept. of Brain and Cog. Sciences, World Class University Program,
Seoul, Republic of Korea ; 4 Interdisciplinary Program in Neuroscience,
Seoul, Republic of Korea ; 5Dep. of Diagnostic Radiology, National Medical
Center, Seoul, Republic of Korea
Objective : A longer duration of untreated psychosis (DUP) in
schizophrenia is well-reported to lead to a poorer clinical outcome, in
relation to smaller gray matter volume in the left planum temporale,
possibly reﬂecting a neurodegenerative process after the onset of
overt psychosis. However, the eﬀect of duration of untreated period of
prodromal syndrome (DUPS) on brain morphometry is not clearly
understood. This study aimed to investigate the relationship between
the DUPS of ultra-high risk group (UHR) and the regional brain
volume.
Methods : DUPS was deﬁned as the duration in months from the
ﬁrst fulﬁlment of UHR criteria to the UHR screening. It was measured
retrospectively by careful interview at the time of screening just before
the MRI scan. The voxel based analysis tested the gray matter volume
diﬀerences between the UHR and the control groups, and the re-
gression analysis was conducted to examine if there was any gray
matter region correlated with DUPS in UHR group with age and
gender as covariates.
Results : The mean DUPS was 23.27 months (standard deviation :
22.45 months) in 34 ultra-high risk subjects. The left superior temporal
lobe volume appeared to be negatively correlated with DUPS at the
level of uncorrected p=0.001, cluster size=100.
Conclusion : These ﬁndings conformed to the previous reports
of DUP in the ﬁrst episode schizophrenia and may reﬂect that
the pathological process of schizophrenia would progress in the left
temporal lobe during the prodromal state, in continuum to the overt
illness course. The results also supported the requirement of the early
detection and treatment of UHR individuals.
jP-08-036jGenome-wide DNA methylation analysis using
peripheral blood samples derived from unmedicated
patients with schizophrenia
M. Kinoshita1, S. Numata2, A. Tajima1, S.-Y. Watanabe1, J.-I. Iga1,
S. Shinji1, I. Imoto1, T. Ohmori1. 1The University of Tokushima, Japan ;
2The University of Tokushima, Institute of Health Bioscience, Japan
Objective : Schizophrenia is a common and complex psychiatric dis-
ease with a lifetime morbidity rate of 0.5–1.0%. The pathophysiology
of schizophrenia still remains unclear. DNA methylation is known to
play a critical role in gene expression without altering DNA sequence.
To gain further insight into the molecular mechanisms underlying
schizophrenia, a genome-wide DNA methylation proﬁling (485,764
CpG dinucleotides) of the human peripheral blood was conducted
(n=47, 24 unmedicated schizophrenia and 23 matched controls).
Methods : For DNA methylation analysis, Inﬁnium1 human-
methylation450 Beadchip was used. Surrogate variable analysis was
used after background and color-balance corrections. False discovery
rate correction was applied at the 0.05 level for multiple testing.
Furthermore, a cluster analysis was performed to determine whether
we could distinguish schizophrenic samples from controls based on
the selected markers.
Results : Signiﬁcant diagnostic diﬀerences in methylation were
observed at 10,747 CpG sites. Of these CpG sites, 9,765 sites (90.9%)
demonstrated higher methylation level in schizophrenia cases com-
pared with controls. According to the CpG content, 28.7% were
located in CpG islands, 17.7% were in CpG shores, and 14.8% were in
CpG shelves. From the genomic distribution, 35.7% were located in
the promoter regions, 32.4% were in gene bodies, and 3% were in
3k-untranslated regions. All the schizophrenic and control samples
were separated into two distinguished groups using a clustering
based on the methylation proﬁles of the 7 selected markers (signiﬁcant
change in absolute mehtylation level>0.2).
Conclusion : This is the ﬁrst genome-wide methylation study using
unmedicated samples with schizophrenia. Although previous studies
have focused on methylation diﬀerences in schizophrenia at CpG sites
within CpG islands around gene promoter regions, we demonstrated
that aberrant DNA methylation in schizophrenia occurred across the
genes. Our results also indicate that DNA methylation proﬁles can be
used as a potential diagnostic biomarker for schizophrenia.
jP-08-037jAripiprazole and valproate for acute schizophrenia
patients
T. Kishimoto1, M. Kou2, Y. Noriyama1, S.-T. Ueda1, Y. Matsuda1,
H. Matsuura1, K. Matsuoka1, T. Morimoto1, S. Nakano1,
T. Shimamoto1. 1Nara Medical University, Japan ; 2Nara Medical
University, Dep. of Psychiatry, Japan
Objective : It is very important to clarify the eﬀect of combind therapy
of aripiprazple (ARP) and valproic acid (VPA) for acute phase of
patients with schizophrenia.
Methods : 38 schizophrenics (F2 on ICD10 criteria), M/F :19/19,
39.8¡15.6 y.o., were treated with ARP 12–30 mg/day and VPA
600–1200 mg/day for 8-week.
Results : The therapy showed the reduction were PANSS 13.8%,
PANSS-EC 21.1% and CGI-S (clinical Global impression severity)
39.1% and the increment of GAF 18.2%. There was no signiﬁcant
changes on EPS, HbA1c, serum lipids, PRL, and body weight.
Conclusion : The combined therapy of ARP and VPA is very eﬀec-
tive and tolerant for acute schizophrenia patients.
jP-08-038jEﬀects of tapering of long-term benzodiazepines on
cognitive function in patients with schizophrenia
receiving a second-generation antipsychotic
R. Kitajima1, S. Miyamoto1, T. Tenjin1, K. Ojima1, S. Ogino1,
N. Miyake1, K. Fujiwara1, Y. Kaneda2, N. Yamaguchi1. 1St.Marianna
Univ. Sch. of Med., Kawasaki City, Kanagawa, Japan ; 2 Iwaki Clinic, Anan
City, Tokushima, Japan
Objective : The high use of long-term benzodiazepines (BZDs) with
second-generation antipsychotics (SGAs) has been identiﬁed as an
important issue in the treatment of schizophrenia in Japan. BZDs can
cause various adverse eﬀects such as dependence and cognitive im-
pairment. The aim of this study was to evaluate the eﬀects of gradual
reduction or discontinuation of daytime BZD use on cognitive func-
tion and quality of life (QOL) in patients with chronic schizophrenia
receiving an SGA.
Methods : Thirty schizophrenic patients who had received an SGA
with concomitant BZDs for at least 3 months were enrolled. Before
and 4 weeks after tapering of daytime BZDs, the Brief Assessment of
Cognition in Schizophrenia Japanese-language version (BACS-J) and
the Schizophrenia Quality of Life Scale Japanese-language version
(SQLS-J) were administered. Other clinical evaluations also included
120 Poster Sessions, Tuesday, 5 June 2012
Downloaded from https://academic.oup.com/ijnp/article-abstract/15/Supplement_1/1/650920
by University of Groningen user
on 13 March 2018
the Positive and Negative Syndrome Scale (PANSS), the Clinical
Global Impression-Severity of Illness Scale (CGI-S) and the Drug
Induced Extrapyramidal Symptoms Scale (DIEPSS). To compare for
practice eﬀects on the BACS-J, 10 patients with chronic schizophrenia
were assessed without tapering BZDs.
Results : BZDs were reduced or discontinued safely in most
patients, and no emergent withdrawal symptoms were observed.
Of 20 patients, 9 (45.0%) successfully discontinued daytime BZD
and remained daytime BZD-free for at least 4 weeks. Signiﬁcant im-
provements were shown in verbal memory, working memory, and
composite score, as measured by the BACS-J without practice eﬀects.
In addition, the motivation/energy score on the SQLS-J, the negative
symptoms and total scores on the PANSS signiﬁcantly improved after
tapering BZDs. There were no signiﬁcant changes in the CGI-S score
or the DIEPSS total score.
Conclusion : Reduction or discontinuation of long-term daytime
use of BZDs may be warranted in patients with schizophrenia treated
with SGAs, as it may improve cognitive function, subjective QOL, and
psychiatric symptoms with no signiﬁcant adverse eﬀects.
Policy of full disclosure : Dr. Miyamoto has served as a consultant
for Dainippon Sumitomo Pharmaceutical. He has received advisory
board honoraria from Chugai Pharmaceutical. No other authors have
any conﬂicts of interest with any commercial or other associations in
connection with this study.
jP-08-039jSubtype-speciﬁc eﬀect of NMDA receptor blockade
on cortical gamma oscillations
B. Kocsis. Harvard Medical School, Boston, USA
Objective : NMDA receptor (NMDA-R) hypofunction is a key
component of the pathomechanism of cognitive impairment in
schizophrenia. NMDA-R antagonists elicit psychotic symptoms in
human and schizophrenia-relevant signs in rodents, including a
strong increase in gamma activity in diﬀerent cortical areas. NMDA-
Rs are composed of several subunits and the major diﬀerences in the
distribution and dynamical properties of NMDA-Rs containing the
NR2A and NR2B subunits indicate that they may play diﬀerent roles
in cortical network activity, and that hypofunction of these receptors
may diﬀerently aﬀect gamma synchrony, critical for a number of
cognitive functions. The goal of the present study was to test this
hypothesis.
Methods : Gamma power were measured in freely behaving rats
before and after administration of NMDA-R antagonists with diﬀer-
ent subunit selectivity.
Results :We found that the strong aberrant gamma activity induced
by NMDA-R blockade primarily depends on NMDA-Rs containing
the NR2A subunit whereas blockade of NR2B/C/D subunit-contain-
ing receptors do not have such eﬀect. We also demonstrate a second
type of gamma enhancement elicited in a state-dependent fashion
during REM sleep by selective blockade of NR2B subunit-containing
NMDA-Rs, at short latency. This pattern was also present after full
NMDA-R blockade but only at a later stage when the aberrant gamma
oscillations and other psychotic-like symptoms ceased and the per-
iodic alternation of sleep-wake states returned.
Conclusion : Alteration of gamma oscillations due to subtype-
speciﬁc changes in NMDA-R function may have serious implications
for the pathomechanism and treatment of cognitive impairment.
Thus, pathologic neuronal synchronization due to NR2A receptor
deﬁciency may contribute to cognitive deﬁcits in schizophrenia where
the number of interneurons co-expressing NR2A and parvalbumin is
selectively reduced. In contrast, the characteristics of the oscillations
induced by NR2B-dependent mechanisms are in agreement with its
demonstrated higher tolerability and the possibility of minimizing
psychotomimetic side eﬀects in therapeutic applications of NMDA
receptor antagonists.
jP-08-040jFirst cases of the treatment with paliperidone ER
in Albania
V. Kola. University Hospital Center Tirana, Albania
Objective : The aim of this work was to explore tolerability and
treatment response of ﬂexible doses of paliperidone ER (3,6,9,12 mg/
day) in adults suﬀering from resistant paranoid schizophrenia.
Methods : Four patients with resistant paranoid schizophrenia were
included in this study. The patients were male, on the average
39.8 years old, diagnosed according to DSM-IV with schizophrenia
from on the average 15.7 years, which had presented therapeutic re-
sistance to some antipsychotics (haloperidol, clopixol, rispolepidone,
olanzapine, clozapine). All subjects were treated with 3–12 mg pali-
peridone ER, according to the severity of symptoms. Patient’s Positive
and Negative Syndrome Scale (PANSS), Clincal Global Impression-
Severity (CGI-S), Adverse Events (AEs) were assessed at ﬁve time
points : baseline, 1st, 2nd, 3rd, month of treatment. Personal and Social
Performance (PSP) scale was assessed at every three month of treat-
ment.
Results : Three patients completed the four month trial of paliper-
idone ER and one of them interrupted the medication (3 mg/day)
after one month because of the noncompliance. One patient started
and ﬁnished the treatment with paliperidone XR 6 mg/day, two
patients started the treatment with 9 mg/day, but during the last
month they received 12 mg/day for better improvement. The PANSS,
CGI-S, AEs and PSP scales indicated that the treatment with paliper-
idone XR of three schizophrenic patients was eﬀective and paliper-
idone did not produce adverse events. The treatment with this
medication was noneﬀective only for one patient.
Conclusion : These data support results from recent studies
that paliperidone ER is well tolerated and eﬀective in patients pre-
viously unsuccessfully treated with other antipsychotics. Backround :
Paliperidone is a second generation antipsychotic medication ap-
proved for the treatment of schizophrenia. It is a useful option in the
treatment of the acute symptoms of schizophrenia and may also be
used in patients previously unsuccessfully treated with other anti-
psychotics.
jP-08-041jAssociation of antipsychotic dose with memory
performance in chronic schizophrenia
D. Kontis1, E. Theochari1, S. Kleisas1, S. Kalogerakou2,
A. Andreopoulou1, E. Tsaltas2. 1Psychiatric Hospital of Attica, Athens,
Greece ; 2Athens University, Eginition Hospital, Psychiatry, Greece
Objective : The examination of the eﬀect of antipsychotic dosage on
cognition and in particular memory in schizophrenia has produced
contradictory ﬁndings. The aim of this study was to investigate the
association of antipsychotic dose with memory performance in
chronic schizophrenia using a cross-sectional design.
Methods : 107 patients (age=42.3 years, SD=10.12, range 18–64)
with chronic schizophrenia from a psychiatric hospital were assessed
with the Cambridge Automated Neuropsychological Test Battery
(CANTAB) in tasks of pattern, spatial recognition and spatial work-
ing memory (PRM, SRM: per cent correct responses and SWM:
between-search errors and strategy score). The Positive and Negative
Syndrome Scale (PANSS) was used to measure symptomatology.
Regression modeling was carried out to assess the eﬀect of anti-
psychotic dose in chlorpromazine equivalents on memory per-
formance, controlling for symptoms (PANSS), age, education and
anticholinergic use.
Results : The patients’ mean antipsychotic dose was 895.55 and their
mean years of education 11.05 (SD=3.46). Increased antipsychotic
dose was signiﬁcantly associated with worse PRM and SRM per-
formance (B=x0.01, C.I.=x0.02,x0.004, t=x3.29, df=93, p=0.001
and B=x0.006, C.I.=x0.01, x0.002, t=x2.66, df=93, p=0.009, re-
spectively). The correlations of antipsychotic dose with SWM mea-
sures SWM were not signiﬁcant. The above results did not change
after adjusting for atypical antipsychotic administration.
Conclusion : In conclusion, antipsychotic dose negatively corre-
lated with recognition memory but not working memory performance
in schizophrenia. Future prospective trials should further clarify the
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jP-08-042jCost-eﬀectiveness of asenapine in the treatment of
schizophrenia and bipolar disorder in Canada
J. Lachaine1, C. Beauchemin2, K. Mathurin2, D. Gilbert3, M. Beillat4,
H. Corson4. 1University of Montreal, Centre-V, Canada ; 2University of
Montreal, Canada ; 3Lundbeck Canada Inc, Montreal, Canada ; 4Lundbeck
SAS, Issy les Moulineaux, France
Objective : Asenapine is a new antipsychotic approved in Canada for
the treatment of schizophrenia and bipolar disorder (SCZ and BPD).
Asenapine has shown a comparable eﬃcacy proﬁle to atypical anti-
psychotics. However, in contrast to most atypical antipsychotics, it
is associated with a favourable (metabolic) proﬁle. The objective
of this study was to assess the economic impact of asenapine com-
pared to atypical antipsychotics in the treatment of SCZ and BPD
in Canada.
Methods : A combined decision tree and Markov model was con-
structed to assess the cost-utility of asenapine compared with atypical
antipsychotics. The decision tree takes into account the occurrence of
extrapyramidal symptoms (EPS), the probability of switching treat-
ment due to EPS, and the probability of gaining weight. The Markov
model comprises the following states : long-term metabolic com-
plications (diabetes, hypertension, CHDs (Coronary heart Disease),
and stroke), fatal stroke, fatal CHD, and death by suicide or other
causes. For SCZ, asenapine was also compared with olanzapine,
quetiapine, ziprazidone and aripiprazole. For BPD, due to limited
data on other antipisychotics, asenapine was compared with olanza-
pine only. Analyses were conducted from both a CanadianMinistry of
Health (MoH) and a societal perspective over a ﬁve-year time horizon
with yearly cycles.
Results : For both indications, asenapine is a dominant strategy
(meaning more eﬀective and less expensive) over olanzapine from
both a MoH and a societal perspective. Compared to quetiapine,
asenapine is also a dominant strategy in SCZ. Furthermore, asenapine
has a favourable economic impact compared to ziprazidone and
aripripazole in SCZ.
Conclusion : This economic evaluation demonstrates that asena-
pine is a cost-eﬀective strategy compared to olanzapine and to most
atypical antipsychotics used in Canada.
Policy of full disclosure : Jean Lachaine received research funds
from Lundbeck. Dominque Gilbert, Maud Beillat and Helene Corson
are employees at Lundbeck.
jP-08-043jGlutamate levels in the associative striatum decrease
with antipsychotic treatment in ﬁrst-episode of
psychosis
P. Leo´n1, M. Azca´rraga1, S. Stephano1, R. Favila1, P. Alvarado-
Alanis1, J. Ramı´rez-Bermu´dez1, A. Graﬀ-Guerrero2, C. de La Fuente-
Sandoval1. 1 INNN, Mexico City, Mexico ; 2CAMH, Toronto, Canada
Objective : Schizophrenia is a mental illness in which both gluta-
matergic and dopaminergic systems are thought to be involved. Using
proton magnetic resonance spectroscopy (1H-MRS), our group
has demonstrated an increase of glutamate levels in the associative-
striatum (dopamine rich-region) of ﬁrst-episode of psychosis (FEP)
subjects. Nevertheless, it is unclear whether this increase persists after
antipsychotic treatment. The aim was to compare glutamate levels
in FEP patients, before and after antipsychotic treatment, with ap-
propriate controls in the associative-striatum and the cerebellar cortex
as a control region (negligible for dopamine).
Methods : Twenty-one antipsychotic-naı¨ve FEP patients (age :
26.1+x8.5, 12-males), and 18 age and gender similar controls
(age : 24.5+x5.1, 8-males) were included. Patients were treated
with risperidone (3.45+x1.27 mg/day) for 4-weeks with doses
adjusted based on clinical judgment (PANSS pre-treatment=
94.7+x13.3 ; post-treatment=57.6+x9.1, p<0.001). Participants
underwent two 1H-MRS studies in a GE-3T scanner (PRESS
TE=30 ms, TR=2000 ms, 128 averages, voxels=8 ml) centred in the
right dorsal caudate and right cerebellar cortex in all subjects.
Concentrations were estimated with LCmodel and corrected for cer-
ebrospinal ﬂuid proportion.
Results : Patients showed higher levels of glutamate during the
antipsychotic-naı¨ve condition versus controls in the associative-
striatum (T=x2.62, p=0.01). After antipsychotic treatment, patients
showed a decrease in glutamate levels (T=2.18, p=0.04) and no
diﬀerences with controls. There were no diﬀerences in glutamate
cerebellar levels between all groups.
Conclusion : Our results indicate an increase of glutamate in the
associative-striatum in FEP patients, showing a decrease after clini-
cally eﬀective antipsychotic treatment. These preliminary results
suggest that higher glutamate levels in the associative striatum can be
reversed with appropriate antipsychotic treatment. Moreover, the lack
of change in the cerebellum suggests that the increase of glutamate in
psychosis is not ubiquitous within the brain and may be associated
with dopamine rich regions.
Policy of full disclosure : This work was supported by an
Investigator-initiated research by JANSSEN to A Graﬀ-Guerrero and
C de la Fuente-Sandoval. P Leo´n-Ortiz, M Azca´rraga, S Stephano,
P Alvarado-Alanis, and J Ramı´rez-Bermu´dez and have no conﬂicts
of interest to disclose. R Favila is an employee of GE Healthcare. C
de la Fuente-Sandoval has received grant support from UC
MEXUS-CONACyT, ICyTDF, professional services compensation
from IMS Health, and speaker compensation from Eli Lilly. A
Graﬀ-Guerrero has received grant support from NIH, CIHR, and
CONACyT, professional services compensation from Abbott
Laboratories and Gedeon Richter Plc, and speaker compensation from
Eli Lilly.
jP-08-044jA splitting mind : Imbalanced internal and external
worlds in schizophrenia
M. Li1, L. Jiang1, W. Deng1, Z. Chen1, Z. He1, Q. Wang1, C. Huang1,
N. Zhang2, T. Li1. 1West China Hospital, Chengdu, Sichuan, China ;
2Department of Psychiatry, University of Massachusetts, Worcester MA,
USA
Objective : Brain dysconnection has been hypothesized to underlie
the pathophysiology of schizophrenia. This study explores the pattern
of functional dysconnections across whole-brain neural networks in a
sample of 121 ﬁrst-episode, treatment-naı¨ve patients with schizo-
phrenia by comparing to 103 healthy controls.
Methods : Resting-state functional connectivity was measured by
using functional magnetic resonance imaging (fMRI). Group inde-
pendent component analysis was applied to resting-state fMRI data to
extract elementary functional clusters of the brain and the connec-
tional relationships between these clusters were then evaluated. In the
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patient group we found 29 abnormal functional connections, includ-
ing 19 hyper-connections and 10 hypo-connections. To interpret these
aberrant functional connections in terms of brain functionalities, we
divided the whole brain into ten functional networks/areas and
ascribed each functional cluster to one of these networks. Changed
connections between functional clusters were thereby interpreted to
abnormal connections between functional networks.
Results : Hyperconnectivity was observed within the default mode
network (DMN) and between the DMN and other cognitive networks,
whereas hypoconnectivity was predominantly associated with sen-
sory networks. The data collectively suggest that information proces-
sing related to the external world (i.e. connectivity involving sensory
networks) is compromised in company with increased connectivity
related to the internal world (i.e. connectivity involving the DMN),
and communications between the internal and external worlds are
impaired in schizophrenia.
Conclusion : These ﬁndings imply distorted sensory perceptions
and undermined coordination between perception and cognitive
functions in the patient, and should provide a new angle to under-
stand several core features of schizophrenia such as sensory proces-
sing deﬁcits and positive symptoms like hallucination.
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jP-08-045jAhi1 gene expression levels in mutant mice are
directly correlated with levels of state anxiety and
threat detection : Translational relevance to
schizophrenia and autism
T. Lifschytz1, A. Lotan1, P. Zozulinsky1, L. Greenbaum1, B. Lerer1.
1Hadassah Medical Center, Jerusalem, Israel
Objective : Schizophrenia is characterized by substantial genetic con-
tribution to its etiology. The Abelson helper integration site (AHI1)
gene was previously shown by our group to be associated with
schizophrenia in humans, with evidence for changes in its expression
as the possible causative mechanism. Association with autism has also
been reported. Therefore, we studied the behavioral consequences of
expression alterations of this gene in various paradigms modeling
diﬀerent facets of schizophrenia, employing mice heterozygous (HET)
for an Ahi1 knockout mutation.
Methods : Open ﬁeld (OFT), elevated plus maze (EPMT), social in-
teraction in pairs (SIIPT) and light dark box (LDT) tests were con-
ducted on HET mice compared to littermates wild type (WT) mice.
Results : A consistent ﬁnding of our experiments was signiﬁcantly
reduced levels of situational anxiety in HET mice compared to WT
mice. In the OFT, HET mice spent signiﬁcantly more time in the arena
center compared to WT mice (p=0.02). In the EPMT, HET mice,
compared to WTmice, spent signiﬁcantly more time in the maze open
arms (p=0.006) and less time in the closed arms (p=0.009). In the
SIIPT, pairs of unfamiliar HET mice spent signiﬁcantly more time in-
teracting with each other than corresponding pairs of unfamiliar WT
mice, in the ﬁrst, anxiety provoking encounter (p=0.01). This ﬁnding
probably reﬂects less anxiety in the HET mice when encountering a
potentially hazardous situation such as an unknown animal. Finally,
in the LDT, HET mice spent signiﬁcantly more time in the open
lightened zone (p=0.02) than WT mice.
Conclusion : Our ﬁndings indicate that reduced expression of the
Ahi1 gene in mice is associated with a decrease in perception of
threatening situations, which may arise from reduced connectivity
between the amygdala and other forebrain areas, including the cortex.
This ﬁnding has been reported in several psychiatric disorders, in-
cluding schizophrenia and autism.
jP-08-046jG72 protein expression in peripheral blood as a
diagnostic biomarker of schizophrenia
C.-H. Lin1, H.-Y. Lane2, G.E. Tsai3. 1Kaohsiung Chang, Gung Memorial,
Kaohsiung City, Taiwan ; 2Taichung City, Taiwan ; 3CA 90509, USA
Objective : To date, there is no peripheral biomarker for schizo-
phrenia. NMDA hypofunction is implicated in the pathophysiology of
schizophrenia. D-serine, a potent NMDA co-agonist, is metabolized
by D-amino acid oxidase (DAAO), which is activated by DAAO acti-
vator (DAOA, or named G72). Theoretically, DAOA overactivation
leads to NMDA hypofunction. This study examined whether periph-
eral G72 protein expression is characteristic of schizophrenia.
Methods : G72 protein level was measured in peripheral plasma in
patients with schizophrenia, patients with bipolar I disorder, and
healthy controls. Receiver operating characteristic (ROC) curve was
conducted to determine the optimal cutoﬀ values of G72 protein level
for schizophrenia patients vs. healthy controls and vs. bipolar
patients.
Results : Among all subjects, the G72 protein level was higher in
schizophrenia (mean=2.726¡1.411, n=119) when compared with
healthy individuals (0.892¡0.415, p<0.001, (n=42), but lower when
compared with bipolar I patients (3.896¡2.103, p=0.001, (n=51). The
optimal cutoﬀ value, 1.564, between schizophrenia and healthy sub-
jects generated a sensitivity of 0.77 and speciﬁcity of 0.98 (area under
curve [AUC] of ROC=0.894). A cutoﬀ of 4.318 diﬀerentiated all
schizophrenia from bipolar I patients with a sensitivity of 0.41 and
speciﬁcity of 0.87 (AUC=0.659).
Conclusion : These ﬁndings provide the ﬁrst peripheral diagnostic
tool for schizophrenia. NMDA hypofunction as evident by over-acti-
vated G72 protein expression may serve as a common pathway for
vulnerability of schizophrenia.
jP-08-047j Inﬂuences of neurocognition and social cognition on
functional outcome in patients with chronically
stable schizophrenia : Mediated by positive,
negative, and depressive symptoms
C.-H. Lin1, Y.-C. Chang2, G.E. Tsai3, H.-Y. Lane4. 1Kaohsiung Chang,
Gung Memorial, Kaohsiung City, Taiwan ; 2Taipei City, Taiwan ;
3Torrance, CA, USA ; 4Taichung City, Taiwan
Objective : The functional outcome of schizophrenia is aﬀected by
multiple factors, among which cognition and clinical symptoms are
regarded as important determinants suggested by previous studies
that link cognition to outcome. The relationship between cognitions
(both neuro- and social- cognitions) and outcome in the existence of
clinical symptoms remains unclear. The current study employed
structural equation modeling to examine more directly whether
clinical symptoms mediate the relationship between cognition and
functional outcome in patients with schizophrenia.
Methods : Three hundred and two patients with chronically
stable schizophrenia received evaluation of cognition (using
MATRICS Consensus Cognitive Battery, including 7 domains cover-
ing neurocognition and social cognition), clinical symptoms (includ-
ing positive, negative and depressive symptoms), and functional
outcome assessed by Global Assessment of Functioning Scale and
Quality of Life Scale.
Results : Structural equation modeling identiﬁed clinical symptoms
as a mediator of the relationship between cognition (including all 7
domains of MATRICS) and functional outcome in schizophrenia. The
relationship between cognition and functional outcome was signiﬁ-
cant in the basic model, but was not signiﬁcant in the mediation model
that included clinical symptoms. The mediation model demonstrated
that the link between cognition and functional outcome was mediated
by clinical symptoms, mainly negative symptoms.
Conclusion : The present study suggests that clinical symptoms
mediate the inﬂuence of neurocognition and social cognition on
functional outcome in schizophrenia. Future studies should also con-
sider the interaction with other potential mediators to increase the
predictive power.
jP-08-048jEﬀect of lurasidone on weight and metabolic
parameters : Results from pooled short-term
placebo-controlled trials in schizophrenia
A. Pikalov1, R. Silva1, J. Cucchiaro1, J. Hsu1, J. Xu1, A. Loebel1.
1Sunovion Pharmaceuticals Inc., Fort Lee, USA
Objective : To evaluate the eﬀect of lurasidone treatment of subjects
with schizophrenia on weight and metabolic parameters.
Methods : Data were pooled from 7 DB, placebo-controlled trials,
including 4 with active comparators, of subjects who met DSM-IV
criteria for schizophrenia with an acute exacerbation. The analysis
sample consisted of subjects treated with lurasidone (dose range,
20–160 mg, total N=1508) ; haloperidol 10 mg (N=72) ; olanzapine
15 mg (N=122) ; risperidone 4 mg (N=65) ; quetiapine XR (N=119) ;
and placebo (N=708).
Results : During 6 weeks of treatment, the mean change in weight,
in kg at LOCF-endpoint, was+0.43 for lurasidone (pooled),+0.02 for
haloperidol, +4.15 for olanzapine, +2.09 for quetiapine-XR, +0.20
for risperidone, and x0.02 for placebo. The proportion of patients
experiencing o7% weight gain was 3.3% for placebo, 4.2% for halo-
peridol, 4.8% for lurasidone, 6.2% for risperidone, 15.3% for quetia-
pine XR, and 34.4% for olanzapine. Median endpoint changes in
lipids were as follows : triglycerides (mg/dL), x4.0 for lurasidone,
x3.0 for haloperidol, +25.0 for olanzapine, +4.0 for risperidone,
+9.5 for quetiapine XR, and x6.0 for placebo ; and total cholesterol
(mg/dL), x5.0 for lurasidone, x8.0 for haloperidol, +9.0 for olan-
zapine, +6.5 for risperidone, +6.0 for quetiapine XR, and x5.0 for
placebo. Median LOCF-endpoint change in glucose (mg/dL) were
similar for combined lurasidone (0.0) and placebo (0.0), and some-
what higher for haloperidol (+2.0), olanzapine (+4.0), risperidone
(+3.0), and quetiapine XR (+3.0).
Conclusion : In these pooled analyses of short-term studies, treat-
ment with lurasidone was associated with minimal increases in
weight and BMI. Decreases in median total cholesterol and triglycer-
ides were also observed.
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Policy of full disclosure : Dr. Pikalov, Silva, Cucchiaro, Hsu, Xu,
and Loebel are full-time employees of Sunovion Pharmaceuticals Inc,
Fort Lee, NJ, USA.
jP-08-049jEﬀectiveness of lurasidone vs. quetiapine XR for
relapse prevention in schizophrenia : A 12-month,
double-blind study
A. Loebel1, J. Cucchiaro1, J. Xu1, K. Sarma1, A. Pikalov1, J. Kane2.
1Sunovion Pharmaceuticals Inc., Fort Lee, USA ; 2LIJ School of Medicine,
Zucker Hillside Hospital, Glen Oaks, USA
Objective : To evaluate the eﬃcacy and safety of lurasidone (LUR) vs.
quetiapine XR (QXR) in preventing relapse in subjects with schizo-
phrenia.
Methods : After completing an initial DB, 6 week trial with LUR
(80 mg ; 160 mg) or QXR (600 mg), subjects received 12 months of DB,
ﬂexible once-daily doses of LUR (40–160 mg) vs. QXR (200–800 mg).
The primary a priori time-to-relapse comparison was between sub-
jects treated with LUR (n=139) and QXR (n=79) who were clinical
responders after acute treatment, using a Cox proportional hazards
model, with a pre-speciﬁed non-inferiority margin for the risk of re-
lapse hazard ratio of 1.93.
Results : LUR was non-inferior to QXR in risk for relapse over the
12 month treatment period (hazard ratio 0.728, 95% CI [0.410, 1.295]).
Risk of relapse in LUR treated subjects was reduced by 27.2% (hazard
ratio 0.728) compared with QXR. The Kaplan-Meier estimate of the
probability of relapse was lower for LUR vs. QXR (0.237 vs. 0.336).
Rates of adverse events o5% in the LUR group were akathisia
(12.6%), headache (10.6%), insomnia (7.9%), anxiety (6.0%), parkin-
sonism (6.0%), and weight increased (6.0%). At 12 months, treatment
with LUR and QXR, respectively, resulted in a mean change in
weight of +0.7 vs. +1.2 kg ; a median change in cholesterol of 0.0
vs. +4.0 mg/dL ; and a median change in triglycerides of x18.0 vs.
x7.0 mg/dL. There were no clinically meaningful changes in other
laboratory or ECG parameters on either drug.
Conclusion : This DB study demonstrated non-inferiority of
lurasidone to QXR in prevention of relapse over a 12 month period,
with a 27.2% reduction in relapse risk compared with QXR.
Lurasidone was associated with minimal adverse eﬀects on weight
and metabolic parameters.
Policy of full disclosure : Dr. Loebel is a full-time employee of
Sunovion Pharmaceuticals Inc, Fort Lee, NJ, USA.
jP-08-050jEﬃcacy of lurasidone in schizophrenia : Factor
analysis of pooled short-term trials
J. Cucchiaro1, R. Silva1, Y. Mao1, A. Pikalov1, A. Loebel1. 1Sunovion
Pharmaceuticals Inc., Fort Lee, USA
Objective : To evaluate the eﬃcacy of lurasidone across ﬁve
previously validated PANSS factors (positive, negative, disorganized
thought, hostility, and depression/anxiety).
Methods :A post-hoc factor analysis was performed on pooled data
from 5 positive six-week, double-blind, placebo-controlled trials of
subjects hospitalized with an acute exacerbation of schizophrenia who
were randomly assigned to ﬁxed, once-daily doses of lurasidone 40 mg
(n=290), 80 mg (n=334), 120 mg (n=290), 160 mg (n=121), or placebo
(n=497). Data were analyzed using a mixed model repeated
measures (MMRM) model with an unstructured covariance matrix.
Eﬀect sizes (ES) were calculated from an ANCOVA analysis (LOCF-
endpoint) as the between-treatment group diﬀerence in LS mean
change scores divided by the pooled standard deviation of the change
scores.
Results : Baseline characteristics were highly similar in the pooled
lurasidone (n=1035 ; mean PANSS total score, 96.1) and placebo
(n=497 ; mean PANSS total score, 96.1) groups. At endpoint, treat-
ment with lurasidone was associated with signiﬁcantly greater
improvement in the PANSS total score compared with placebo (x22.6
vs. x12.8 ; P<0.001 ; ES, 0.42). Signiﬁcantly greater endpoint
improvement (P<0.001 for all comparisons) was observed for
lurasidone versus placebo across all ﬁve PANSS factors. Changes for
lurasidone vs. placebo were x8.4 vs. x6.0 (ES, 0.35) in the PANSS
positive factor ;x5.2 vs.x3.3 (ES, 0.32) in the PANSS negative ;x4.9
vs.x2.8 (ES, 0.40) for disorganized thought ;x2.7 vs.x1.6 (ES, 0.34)
for hostility ; andx3.2 vs.x2.3 (ES, 0.29) on depression/anxiety fac-
tors. Lurasidone160 mg dose was consistently associated with the
highest eﬀect size for each factor.
Conclusion : In this pooled, post hoc factor analysis of placebo-
controlled trials, treatment with lurasidone across the daily dosing
range of 40–160 mg, was eﬀective in improving all 5 PANSS factors,
suggesting eﬃcacy across the full spectrum of symptoms associated
with schizophrenia.
Policy of full disclosure : Drs. Cucchiaro, Silva, Mao, Pikalov, and
Loebel are all full-time employees of Sunovion Pharmaceuticals Inc,
Fort Lee, NJ, USA.
jP-08-051jAn in vitro analysis of disintegration times of
diﬀerent formulations of orally disintegrating
olanzapine
D. Mcdonnell1, D. Hobbs2, J. Karagianis2, T. Treuer3, J. Raskin4.
1Eli Lilly and Company, Little Island, Co, Cork, Ireland ; 2Eli Lilly and
Company, Indianapolis, USA ; 3Eli Lilly and Company, Budapest,
Hungary ; 4Eli Lilly and Company, Toronto, ON, Canada
Objective :Orally disintegrating tablet (ODT) forms of medication are
sometimes used as alternatives to standard oral tablets for patients
who have diﬃculty swallowing, those who need to have ingestion
veriﬁed, and thosewhomay resist other drug product forms (e.g. injec-
tion). ODTs are a tablet or wafer form of medication that disintegrate
in the mouth, aided only by saliva. ODTs can disperse in as little as 1
to 2 seconds or as long as 2 to 3 minutes, depending on the diﬀerent
fast dissolve/disintegration technologies used to manufacture the
tablets. Orally disintegrating olanzapine (ODO) is manufactured by
several diﬀerent companies, using diﬀerent formulations and pro-
cesses. The objective of the study is to investigate diﬀerences in dis-
integration time of these tablets which may potentially impact clinical
parameters such as patient acceptance and adherence to treatment.
Methods : Six types of ODO, along with Risperdal M-Tab as an
external comparator, were evaluated for formulation composition,
manufacturing method, disintegration and dissolution characteristics,
expiration dates, packaging and formulation diﬀerences in compari-
son with the freeze-dried Zydis/Velotab formulation of ODO.
Automated dissolution test equipment, DISTEK DISBA0045 and
DISBA0046 with an Opt-Diss UV ﬁber optic SPEC0088 attachment,
was used to capture the various ODT dissolution rates by measuring
real time release of the active ingredient. Additionally, a high speed
video camera was used to capture disintegration times of ODO pro-
ducts in simulated saliva held at 37 xC.
Results : Time required for initial and complete disintegration, with
95% conﬁdence intervals, will be presented.
Conclusion : The in vitro disintegration test is a proxy for the dis-
integration process in a patient’s mouth. Diﬀerences found in formu-
lation and manufacturing process of ODO may be associated with
diﬀerent disintegration times which may potentially impact their use
in clinical practice.
Policy of full disclosure : Dr. McDonnell is a full-time employee of
Eli Lilly and Company. Research reported was sponsored/funded
by Eli Lilly and Company.
jP-08-052jPatient satisfaction and caregiver burden related to
olanzapine long-acting injection
D. Mcdonnell1, H. Detke2, C. Liu3, R. Moore4. 1Eli Lilly and Company,
Little Island, Co, Cork, Ireland ; 2Eli Lilly and Company, Indianapolis,
USA ; 3PharmaNet/i3, Lexington, USA ; 4PharmaNet/i3, Blue Bell, USA
Objective : To assess patients’ attitudes toward and satisfaction with
olanzapine long-acting injection (LAI) and determine eﬀects on care-
giver burden.
Methods :Data were analyzed from 2 long-term, open-label studies.
Study 1 (N=931) assessed long-term safety up to 6.5 years. Study 2
was a 2-year randomized study comparing the eﬀectiveness of
olanzapine LAI (N=264) and oral olanzapine (N=260). Measures
included the Patient Satisfaction with Medication Questionnaire-
Modiﬁed (PSMQ) in both studies and the Drug Attitude Inventory
(DAI-10) and Burden Assessment Scale (BAS ; a caregiver self-report
measure) in Study 2, with assessments at 6- to 12-month intervals.
Results : In Study 1, 73% of patients were satisﬁed with olanzapine
LAI at ﬁrst assessment, 87% at 6 years, and 73% at patient’s endpoint.
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In Study 2, 75% were satisﬁed at ﬁrst assessment, 88% at 2 years, and
73% at patient’s endpoint (similar to oral-treated patients). On the
DAI-10, >80% of LAI-treated patients endorsed positive statements
at each time point, including 90% stating that ‘‘ the good things about
the medication outweigh the bad’’ at 2 years. On the BAS, caregivers
reported statistically signiﬁcant improvement in their overall burden
at 2 years (p values<0.001).
Conclusion : Results suggest that olanzapine LAI is viewed posi-
tively by patients and caregivers.
Policy of full disclosure : Dr. McDonnell is a full-time employee of
Eli Lilly and Company.
jP-08-053jPolypharmacy to counteract antipsychotic-induced
non-motor side eﬀects : A systematic review
Y. Mizuno1, H. Uchida2, T. Suzuki3, W.W. Fleischhacker4,
M. Mimura2. 1Kawasaki Municipal Hospital, Japan ; 2Keio University,
School of Medicine, Tokyo, Japan ; 3 Inokashira Hospital, Department of
Psychiatry, Tokyo, Japan ; 4Medical University Innsbruck, Department of
Psychiatry, Austria
Objective : In contrast to antipsychotic-induced extrapyramidal side
eﬀects, the data are still limited on concomitant medications to
counteract non-motor side eﬀects in schizophrenia. We therefore
carried out a systematic review to synthesize the evidence on the
management of antipsychotic-induced non-motor adverse eﬀects with
polypharmacy.
Methods : The following terms were included in a systematic search
of EMBASE, MEDLINE, PubMED, PsycINFO and the Cochrane
Library : (schizophrenia and adjunctive) or (schizophrenia and aug-
mentation) or (schizophrenia and combination) or (schizophrenia and
polypharmacy) or (schizophrenia and polytherapy). As a ﬁnal term
for each search, the following adverse eﬀects were added as potential
targets of polypharmacy : diabetes, dyslipidemia, metabolic, obesity,
weight gain, sexual dysfunction, prolactin, hypotension, and sedation
(last search : December 2011). Studies were included if (1) they tar-
geted subjects with a diagnosis of schizophrenia or related psychotic
disorders, and (2) they reported on the reduction of antipsychotic-
related non-motor adverse eﬀects using concomitant medications as a
primary outcome. Cross-referencing of the identiﬁed articles was also
performed.
Results : From the initial list of 2051 articles, 113 studies met
the inclusion criteria. Of these, nine, ﬁve, two, two, and two double-
blind randomized controlled trials (DBRCTs) showed the eﬃcacy
of adjunctive metformin, topiramate, aripiprazole, reboxetine, and
sibutramine to counter metabolic side eﬀects of antipsychotics, re-
spectively. These studies lasted for 6–16 (mean, 11) weeks with the
number of participants of 15–207 (mean, 56). One DBRCT and three
open-label trials demonstrated that concomitant aripiprazole was ef-
ﬁcacious for hyperprolactinemia induced by other antipsychotics.
Sildenaﬁl has been reported to improve sexual dysfunction in one
DBRCT and one open-label trial.
Conclusion : Although additional drug costs, drug interactions,
and side eﬀects of concomitant drugs themselves need to be carefully
taken into account and more studies are indicated, polypharmacy
aiming for the reduction of antipsychotic-induced non-motor adverse
eﬀects may warrant an individualized clinical consideration.
jP-08-054jDescriptive study of antipsychotic drugs use in
psychiatry outpatients
R. Molina Ramos1, M. Millan2, M.S. Sanchez2, C. Castillo2,
M. Lliteras3, D. Giner2, C. Chada4, H. Arnillas2, B. Hernandez5,
M. Gili6. 1Hospital de Manacor, Spain ; 2Hospital son Llatzer, Mallorca,
Spain ; 3Hospital Manacor, Spain ; 4Menorca, Spain ; 5Hospital de
Manacor, Spain ; 6Universidad Islas Baleares, Mallorca, Spain
Objective : The goal of this study is to know in the current real clinical
practice how is the prescription of antipsychotic drugs in outpatients
with psychotic disorders.
Methods : An observational and descriptive cross-sectional study,
with a CRF developed to collect the speciﬁc data which was ad-
ministered during the period from February to May 2011 in 4 diﬀer-
ents Psychiatry Mental Health Clinic of Balearic Island in Spain
(Manacor, Emili Darder, Pere Garau and Menorca) to patients with
psychotic disorders who were prescribed antipsychotic drugs.
Results : The sample obtained were 205 patients with the following
proﬁle : a man (62%) 43.2+11.9 years old, with paranoid schizo-
phrenia (61.1%) over 5 years evolution (77%) with no substance
use disorder (83.7%) and treated with atypical antipsychotics (99.5%
of cases). The 38% of patients had oral more long acting injection
antipsychotic. The patients under 34 years old were the most fre-
quently performed treatment with antipsychotic long-acting injection
(p<0.05). Risperidone, paliperidone and olanzapine were the most
frequent oral antipsychotics used.
Conclusion : 1. The use of oral antipsychotics in combination with
intramuscular antipsychotics is common in current clinical practice,
2. The age group between 25 and 34 years old is having more prob-
lems with adherence to treatment and more frequently receiving
intramuscular antipsychotic medication as long-term outpatient
treatment, 3. Male patients have a percentage of adherence slightly
lower than women and tend to receive more often antipsychotic in-
jectable long-term, 4. 76% of patients had a good compliance and were
satisﬁed with their treatment in both gluteal or deltoid administration.
jP-08-055jBeneﬁts of switching schizophrenic patients from
olanzapine to aripiprazole
M. Moriwaki1, O. Furukawa2, K. Fujita2, N. Iwata1. 1Fujita Health
University, Toyoake, Japan ; 2Okehazama Hospital, Toyoake, Japan
Objective : It is well-known that olanzapine easily cannot be used in
schizophrenic patients with hyperglycemia and is contraindicated for
patients with diabetes in Japan. Aripiprazole has advantages com-
pared to other antipsychotics regarding side-eﬀects. Schizophrenic
patients switching from an agent with an anticholinergic proﬁle to
another could have risk of cholinergic rebound symptoms. Therefore,
longer taper of the anticholinergic agent may be necessary because of
their diﬀerent receptor-aﬃnity proﬁles. The purpose of the present
study was to evaluate if switching could be successful after switching
from olanzapine to aripiprazole concomitantly with diphenhy-
dramine, an antihistaminergic agent.
Methods : Patients, diagnosed with schizophrenia (DSM-IV criteria)
and required a change in olanzapine therapy because of persistent
symptoms and troublesome side-eﬀects, were included for the study.
Aripiprazole was given at a dose of 6 to 12 mg/day in addition to
olanzapine, and then olanzapine was tapered down at a rate not
exceeding 2.5 mg/week and aripiprazole was up-titrated over
switching, after which aripiprazole was maintaned between 6 and
24 mg/day through the evaluation period. Diphenhydramine was
used between 0 and 150 mg/day. Clinical eﬃcacy was assessed with
PANSS, CGI-S, CGI-I and GAF at weeks 4 and 8 after switching.
Continuation rate of aripiprazole use was investigated. Serum fasting
glucose, HbA1C level, and fasting triglyceride were also evaluated.
Results : Of 14 patients, 9 patients (64.3%) successfully completed
the switch and continued aripiprazole treatment to 8-week after
switching. Although 1 patient showed exacerbation in symptoms
caused by rebound, discontinuations due to adverse events of ar-
ipiprazole were not observed.
Conclusion : Switching from olanzapine to aripiprazole generally
resulted in retention of eﬃcacy and improvements in tolerability
across the evaluation period. Most notably, management of rebound
eﬀects by switching was achieved. This would be due to gradual dis-
continuation of the pre-switch medication and concomitant use of
diphenhydramine to avoid rebound symptoms.
Policy of full disclosure : Speakers’ : Otsuka, Eli Lilly, GSK,
Ds-pharma.
jP-08-056jAltered levels of endocannabinoids in postmortem
human brain of schizophrenic subjects
C. Muguruza1, M. Lehtonen2, N. Aaltonen3, J. Arrieta4, B. Morentin4,
J.J. Meana1, L.F. Callado1. 1Department of Pharmacology, University
Basque Country, Leioa, Spain ; 2Dpt. Pharmaceutical Chemistry, Faculty of
Health Sciences, Kuopio, Finland ; 3Dpt. Pharmacology & Toxicology,
Faculty of Health Sciences, Kuopio, Finland ; 4Section of Forensic
Pathology, Basque Inst. of Legal Medicine, Bilbao, Spain
Objective : Numerous studies have implicated the endocannabinoid
(EC) system in the pathophysiology of schizophrenia. Some ECs have
been measured in blood and cerebrospinal ﬂuid of schizophrenic
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subjects but to the date, there is no information about the status of EC
levels in schizophrenics’ brain tissue. The aim of this study was to
evaluate the EC levels in postmortem cerebellum (CB), hippocampus
(HC) and prefrontal cortex (PFC) of schizophrenics and matched
controls. To investigate the eﬀect of the antipsychotic (AP) treatment,
schizophrenics who gave negative results for antipsychotics in the
postmortem toxicologicology were considered AP-free.
Methods : Brains from 19 patients with diagnosis of schizophrenia
(DSM-IV), and 19 controls matched by age, gender and postmortem
delay were used. The ECs were determined in brain homogenates
lipid fraction by quantitative liquid chromatography with
tandem mass spectrometric detection. The levels of the two main ECs,
2-arachidonoylglycerol (2AG) and arachidonoylethanolamide (ana-
ndamide, AEA) were measured.
Results : Increased levels of 2AG were observed in schizophrenics
compared to controls in all brain areas, reaching signiﬁcant
values in HC (2375¡395 vs. 1415¡237 pmol/g ; p=0.04) and PFC
(1230¡233 vs. 519¡89 pmol/g ; p=0.01). 2AG levels remained in-
creased in HC and PFC of AP-free schizophrenics, while reversed
to control values in the HC of AP-treated subjects. AEA levels were
lower in schizophrenics when compared to controls in all brain
areas. This decrease was statistically signiﬁcant in CB (297¡31 vs.
451¡45 pmol/g ; p=0.009) and HC (265¡31 vs. 400¡31 pmol/g ;
p=0.004). When the schizophrenic group was subdivided, a decrease
in AEA levels was found in the PFC of AP-treated schizophrenics
(219¡36 vs. 346¡31 pmol/g ; p=0.02) but not in AP-free subjects
(310¡49 pmol/g).
Conclusion : These results demonstrate that AEA and 2AG levels
are altered in some brain areas in schizophrenia. Moreover, these data
provide further evidence that the chronic antipsychotic treatment is
able to modulate the EC brain levels.
jP-08-057jAripiprazole treatment and plasma levels of
brain-derived neurotrophic factor (BDNF), BDNF
gene Val66Met polymorphism, and catecholamine
metabolites in ﬁrst-episode untreated Japanese
schizophrenia patients
J. Nakamura1, R. Yoshimura2, H. Hori1, A. Ikenouchi-Sugita2,
W. Umene-Nakano2, A. Katsuki2, K. Hayashi2, K. Atake2.
1Kitakyushu, Japan ; 2UOEH, Kitakyushu, Japan
Objective : We investigated the eﬀects of aripiprazole on plasma
levels of brain-derived neurotrophic factor (BDNF) and catecholamine
metabolites in ﬁrst-episode untreated schizophrenia patients.
Methods : The subjects were 50 Japanese ﬁrst-episode untreated
schizophrenia patients who met the DSM-IV-TR criteria and were
treated with aripiprazole monotherapy. Twenty-nine were male and
21 were female. The age was ranged from 21 to 42 yr (mean¡S.D. ;
30.8¡5.3 yr). The plasma levels of catecholamine metabolites were
measured by HPLC-ECD. The plasma BDNF levels were measured by
ELISA. The genotyping (BDNF Val/Met) was determined by direct
sequence around the region. The study was approved by the Ethical
Committee of the UOEH.
Results : Treatment with aripiprazole for 8 weeks signiﬁcantly
increased plasma BDNF levels. It also changed plasma levels of
homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol
(MHPG). A negative correlation was also observed between duration
of psychosis (DUP) and plasma BDNF levels. No correlation
was however observed between plasma BDNF levels and the dose
of aripiprazole. In addition, twelve of 50 patients were longitudinally
measured plasma levels of catecholamine metabolites and BDNF.
Plasma HVA increased at week 2, and decreased at week 8 comparing
with baseline. Plasma MHPG increased at week 8.
Conclusion : To the best of our knowledge, this is the ﬁrst report
showing that aripiprazole increases plasma levels of BDNF and
MHPG in ﬁrst-episode untreated schizophrenia patients, which
might be related to the improvement of negative symptoms
of schizophrenia and cognitive functions. Furthermore, the BDNF
Val66Met polymorphism was independent of the response to
aripiprazole.
jP-08-058jAssessment of subjective well-being and safety in
patients with antipsychotic-naı¨ve ﬁrst-episode
schizophrenia treated with blonanserin : One-year
open-label trial
Y. Ninomiya1, S. Miyamoto1, K. Ojima1, T. Tenjin1, R. Kitajima1,
S. Ogino1, N. Miyake1, Y. Kaneda2, T. Sumiyoshi3, N. Yamaguchi1.
1St. Marianna Univ. Sch. of Med., Kawasaki City, Kanagawa, Japan ;
2 Iwaki Clinic, Department of Psychiatry, Anan City, Tokushima, Japan ;
3University of Toyama, Department of Neuropsychiatry, Toyama City,
Toyama, Japan
Objective : Blonanserin is a novel atypical antipsychotic that exhibits
a potent antagonistic activity at dopamine D2, 3 and serotonin
5-HT2A receptors. The purpose of this study was to assess the sub-
jective well-being and safety in patients with antipsychotic-naı¨ve ﬁrst-
episode schizophrenia treated with blonanserin for one year.
Methods : Twenty-four antipsychotic-naı¨ve patients with ﬁrst-
episode schizophrenia participated in this study. Blonanserin
(2–24 mg/day) was given in an open label design for 12 months.
Psychopathology, subjective well-being, and safety were evaluated at
baseline, 2, 6, and 12 months. Psychopathology was assessed
by Positive and Negative Syndrome Scale (PANSS). Subjective well-
being was evaluated by the Subjective Well-being Under Neuroleptic
Treatment Scale Short form-Japanese version (SWNS-J). Safety as-
sessments included laboratory tests, body weight, Body Mass Index
(BMI), and the Drug Induced Extra-Pyramidal Symptoms Scale
(DIEPSS). This study was approved by the bioethics committee of
St. Marianna University School of Medicine, and written informed
consent was received from all participants.
Results : Thirteen patients (6 males and 7 females ; mean age,
28.2¡5.6 years) completed the study. The mean blonanserin dose was
4.2¡3.0 mg/day at 12 months. Signiﬁcant improvements from base-
line to endpoint were reported for all items on the PANSS (p<0.01)
and SWNS-J (p<0.05). In the laboratory tests, the values of alkaline
phosphatase signiﬁcantly increased from baseline (p<0.05). In ad-
dition, high density lipoprotein cholesterol and fasting blood sugar
signiﬁcantly decreased (p<0.05), but all of these data remained
within the normal range. Although mean body weight and BMI in-
creased from baseline, the rate of weight gain was only 6.1%. There
was no signiﬁcant change in the DIEPSS score.
Conclusion : Blonanserin produced favorable long-term outcomes
and good safety proﬁles in patients with antipsychotic-naı¨ve ﬁrst-
episode schizophrenia. The results suggest that blonanserin may be
useful in the management of ﬁrst-episode schizophrenia.
Policy of full disclosure : Dr. Miyamoto has served as a consultant
for Dainippon Sumitomo Pharmaceutical. He has received advisory
board honoraria from Chugai Pharmaceutical. No other authors have
any conﬂicts of interest with any commercial or other associations in
connection with this study.
jP-08-059jAntidepressant and anxiolytic eﬀects of quetiapine
strongly correlate to neuropeptide Y increase and
corticotropin-releasing hormone decrease in CSF
from schizophrenic patients
A. Mathe´1, G. Nikisch2, T. Liu1, P. Baumann1. 1Karolinska Institutet,
Stockholm, Sweden ; 2Klinikum Fulda, Germany
Objective : NPY and CRH play a role in the CNS physiology/patho-
physiology and in the mechanisms of action of antidepressant/
antipsychotic drugs. Early data showed increased NPY in CSF from
schizophrenic patients and NPY changes by antipsychotics in rodent
brain. In depression, NPY is decreased in CNS from depressed
patients and animal models of depression, chronic stress and PTSD.
Conversely, ECT, lithium and antidepressants increase NPY. In view
of these ﬁndings we investigated if (1) quetiapine, an antipsychotic
eﬃcient also in aﬀective disorders would modify NPY and CRH
in CSF of schizophrenic patients, and (2) the eﬀects on NPY
and CRH will correlate to changes in depression and anxiety,
symptoms that are common both in schizophrenia and aﬀective dis-
orders.
Methods : Twenty-two DSM-IV schizophrenics(age 35.9¡7.4 y ; ill-
ness duration 20.3¡24.8 m), diagnosis conﬁrmed with Structured
Clinical Interview participated. Patients were assessed with PANSS at
baseline and weekly thereafter. Lumbar puncture was performed at
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baseline and after 4 weeks of 600 mg/day quetiapine. NPY-like im-
munoreactivity (-LI) and CRH-LI were determined by RIA.
Results : PANSS total score decreased>20%. Quetiapine treatment
was associated with an NPY-LI increase and CRH-LI decrease
(p´s<0.01). Stepwise multiple regression analysis revealed that D
NPY-LI and D CRH-LI levels and their ratios predicted 63%
(p<0.001) of the D PANSS total score variability ; D NPY-LI 42% of
the D PANSS anxiety items (p<0.05) and D CRH-LI 40% of the
D PANSS depression items (p<0.05).
Conclusion : Quetiapine eﬀects on NPY and CRH correlated
strongly with the decrease in the depression and anxiety PANSS
items. Since psychiatric diagnoses are generally clusters of symptoms
of various durations and there are hardly any pathognomonic signs,
our approach to focus on speciﬁc symptoms, regardless of diagnosis,
would seem to be a more fruitful approach to elucidate the underlying
neurobiology.
jP-08-060jEﬀects of discontinuation of long-term biperiden
use on cognitive function and quality of life in
schizophrenia
S. Ogino1, S. Miyamoto1, K. Ojima1, T. Tenjin1, R. Kitajima1,
N. Miyake1, Y. Kaneda1, H. Kubota1, N. Yamaguchi1. 1St. Marianna
Univ. School of Medicine, Kanagawa, Kawasaki, Japan
Objective : The high use of long-term antiparkinsonian anticholin-
ergic drugs with antipsychotics has been identiﬁed as an important
issue in the treatment of schizophrenia in Japan. The aim of this study
was to evaluate the eﬀects of gradual discontinuation of biperiden, an
anticholinergic drug, on cognitive function and quality of life (QOL)
in schizophrenia.
Methods : Thirty-nine schizophrenic patients who had received one
or two kinds of second-generation antipsychotics (SGAs) with con-
comitant biperiden for at least 3 months were enrolled. Before and
4 weeks after discontinuation of biperiden, the Japanese version of the
Brief Assessment of Cognition in Schizophrenia (BACS-J) and the
Schizophrenia Quality of Life Scale (SQLS-J) were administered.
Clinical evaluation also included the Positive and Negative
Syndrome Scale (PANSS). To compare the practice eﬀect on BACS-J,
10 chronic patients with schizophrenia were assessed without taper-
ing biperiden.
Results : Biperiden was discontinued safely in most patients re-
ceiving an SGA (N=24), and no emergent extrapyramidal symptoms
(EPS) were observed. Signiﬁcant improvements were shown in at-
tention, processing speed, and composite score, as measured by the
BACS-J without practice eﬀect. In addition, the psychosocial condition
score on the SQLS-J and the general psychopathology score on
the PANSS signiﬁcantly improved after biperiden discontinuation.
However, exacerbation in clinical symptoms and emergent EPS were
observed in patients taking more than two kinds of SGAs (N=5).
Conclusion : Discontinuation of long-term biperiden use may be
warranted in patients with schizophrenia treated with a single SGA,
as it may improve cognitive function, subjective QOL, and psychiatric
symptoms with no signiﬁcant adverse eﬀects. However, caution
should be paid when tapering biperiden in patients treated with more
than two kinds of SGAs, since it may worsen psychotic symptoms or
motor function.
jP-08-062jMultiple behavioral deﬁcits reminiscent of
schizophrenia in mice deﬁcient in DISC-M
(disrupted in schizophrenia matsuzawa), a gene
encoding a transcriptional regulator
T. Ohnishi1, A. Watanabe1, K. Yamada1, H. Ohba1, M. Arai2,
T. Ichikawa2, M. Toyoshima1, Y. Iwayama1, M. Miyashita3,
M. Itokawa2, T. Yoshikawa1. 1RIKEN Brain Science Institute, Wako,
Japan ; 2TMIMS, Tokyo, Japan ; 3TIMS, Tokyo, Japan
Objective : We have recently reported a schizophrenic patient
with a de novo mutation, a balanced chromosome translocation
[t (4 ; 13)(p16.1 ; q21.31)]. We attempted to determine the break point
within chromosome 4 and found that it locates at the upstream region
of a gene encoding a putative transcriptional regulator protein,
and we named the gene DISC-M (Disrupted_In_Schizophrenia,
Matsuzawa). However, it remains unknown whether and how the
functional loss of the gene really impacts on the etiology of schizo-
phrenia in the patient.
Methods : To get insights into the question, we analyzed mice
lacking the corresponding gene using multifaceted approaches in the
current study. In addition, we have conducted a comprehensive gene
expression analysis of the brain from the KO mice.
Results : The homozygous mice were born in a mendelian ratio by
the cross between heterozygous mice. Behavioral assessments showed
that they are hyperactive in the open ﬁeld test and other tests, and that
they are highly sensitive to MK801, an NMDA antagonist. In addition,
the mice have a severe impairment in auditory fear conditioning test,
suggesting deﬁcits in learning/memory abilities. In contrast, we have
found abnormalities in neither prepulse inhibition nor social interac-
tion. Of interest, but neurogenesis in hippocampal dentate gyrus of
the young adult mice was signiﬁcantly decreased, although the tissue
architecture seemed to be not diﬀerent from the control mice.
Furthermore, we identiﬁed DISC-M-regulated genes, many of which
are related to neuronal function or development.
Conclusion : In conclusion, some of phenotypes of the mice seem to
be reminiscent of schizophrenia. Since biological functions of the gene
are still largely unknown, further investigation will be needed to re-
veal the mechanism of the abnormalities and the relationship between
schizophrenia and this gene.
jP-08-063jKynurenic acid in cerebrospinal ﬂuid, plasma
and urine of healthy male volunteers
S. Olsson1, M. Samuelsson2, S. Erhardt1. 1Karolinska Institutet,
Stockholm, Sweden ; 2Linko¨pings University, Dept. of Clin. and
Experiment. Med., Linko¨ping, Sweden
Objective : Kynurenic acid (KYNA) is a neuroactive tryptophan end-
metabolite, produced both in peripheral and brain tissues, with poor
blood-brain crossing properties. Its precursor kynurenine however
easily crosses the blood-brain barrier. KYNA is elevated in the brain
and cerebrospinal ﬂuid (CSF) of patients with schizophrenia and
is currently being investigated for its possible role in schizophrenia
pathophysiology. In the present study we compare the levels of
KYNA in CSF, plasma and urine of healthy male volunteers and cor-
relate these levels to putative confounders.
Methods : Plasma (collected at ﬁve time points over 24 hours
starting/ending at 08:00 am), urine (24-hour) and CSF (collected at the
end-point 08:00 am) from 30 healthy male volunteers were analyzed
for KYNA content using HPLC with ﬂuorescence detection.
Results : The mean 24-hour plasma and urine KYNA levels were
positively correlated (r=0.41, p=0.03). No correlations were observed
between CSF and plasma levels of KYNA. A trend towards signiﬁ-
cance was observed between CSF and urine KYNA levels (r=0.33,
p=0.08). We found no correlations between the CSF, plasma or urine
levels of KYNA and age, weight, height, body mass index or coﬀee
consumption. However, there were negative associations between
nicotine use and the urine (r=x0.45, p=0.02) and CSF (r=x0.47,
p=0.01) levels of KYNA.
Conclusion : The plasma and urine levels of KYNA were positively
correlated, while CSF KYNA levels did not correlate to plasma or
urine KYNA content in healthy male volunteers. Interestingly, the use
of nicotine was negatively associated with both CSF and urine levels
of KYNA. In line with this, chronic exposure to nicotine reduces
KYNA content in the rodent brain [1]. Nicotine use might thus be
an important confounding factor in clinical studies investigating
kynurenine metabolism.
1. Zielinska et al. 2009. PMID : 19616570.
jP-08-064jEndogenous kynurenic acid induces a reduction in
parvalbumin immunoreactivity in the rat frontal
cortex
F. Orhan1, M. Kegel1, M. Larsson1, L. Schwieler1, S. Erhardt1.
1Karolinska Institutet, Stockholm, Sweden
Objective : Reduced expression of GABAergic parvalbumin inter-
neurons and GAD67, a GABA synthesizing enzyme, is one of the most
replicated and consistent ﬁndings in schizophrenia. Recent studies
also conﬁrm that kynurenic acid (KYNA), an endogenous antagonist
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of N-methyl-D-aspartate and b7 nicotinic (NMDA) receptors, is elev-
ated in the cerebrospinal ﬂuid and post mortem brain of these
patients. Experimental studies report that blockade of NMDA re-
ceptor with phencyclidine or ketamine leads to similar dysregulations
in GABAergic circuits and are thus, suggested to be a core feature of
the illness.
Methods : The aim of this study was to investigate if pharmaco-
logical sub-chronic elevation of endogenous KYNA levels decreases
brain expression of GAD67 and GABAergic parvalbumin inter-
neurons. For this purpose, western blottingwas used to quantify tissue
levels of GAD67 and parvalbumin proteins in brain tissue. Localiz-
ation of protein changes was visualized by immunohistochemistry.
Results : Rats were treated twice daily (12-h interval) for 6 days
with saline or kynurenine (s.c.), the immediate precursor of KYNA,
in a dose (100 mg/kg) known to induce a 2-fold increase in brain
KYNA levels. Rats with subchronically elevated KYNA levels dis-
played reduced levels of parvalbumin protein in the cingulate and
piriform cortices.
Conclusion : These data suggest that the dysfunction of parvalbu-
min interneurons observed in patients with schizophrenia might be
a direct consequence of elevated levels of KYNA in these patients.
In addition, present results support subchronic elevation of brain
KYNA as a valid animal model of schizophrenia.
jP-08-065jAnhedonia as an inﬂuencing factor to social
functioning and quality of life at patients with
schizophrenia
N. Orlova1, M. Shkliar1. 1Kiev, Ukraine
Objective : study the role of anhedonia in negative aﬀect to social
functioning and quality of life in patients with schizophrenia and
postpsychotic depression.
Methods : scale for anhedonia assessment Snaith-Hamilthon (1995),
GAF (2002), Sheehan Disability Scale (1983).
Results : 205 patients were divided into comparable groups. 115
patients with negative syndrome of paranoid schizophrenia (NSH),
90 patients with postpsychotyc depression (PPD). Men – 63.9%,
women – 36.1%. The average age was 32.85 (¡0.66) years. 58.53%
of patients had anhedonia. NSH group anhedonia observed in 60
patients (52.17%), PPD group – in 60 patients (66.66%). The anhedo-
nia level in all groups reached moderate (22.16¡0.38). In all groups
the disability level reached of severe. NSH-A group the disability level
was signiﬁcant (pf0.05). NSH-A group observed signiﬁcant dis-
turbances of cognitive functioning and ‘‘communication’’ (p<0.05 ;
r=0.329), ‘‘ family life’’ (p<0.01 ; r=0.385) compared with patients
without anhedonia. PPD-A group the cognitive functioning was a
considerable. In the ‘‘communication’’ (p<0.01 ; r=0.428) and
‘‘ family life’’ (p<0.01 ; r=0.598) revealed moderate disturbance, but
these disturbances were signiﬁcant against groups of patients without
anhedonia. In PPD and NSH groups observed a signiﬁcant reduction
of cognitive functions with respect to education and socioeconomic
status. Was heavy cognitive impairment that interferes with activities
in various areas of social and professional activities or teaching. Was
found poor quality of life in patients with anhedonia in all groups of
study. NSH-A group the quality of life was signiﬁcantly (pf0.05 ;
r=x0.282). In patients without anhedonia in all groups was satisfac-
tory quality of life.
Conclusion : anhedonia presence in the clinical picture of schizo-
phrenia makes a favorable foundation for the impairment of cognitive
performance, breach of communication and inability to perform their
household and family responsibilities, and degrades the quality of life
of patients.
jP-08-066jThe psychopharmacology algorithm project at the
Harvard South shore program: An update on
schizophrenia
D. Osser1, M. Jalali-Roudsari2, T. Manschreck3. 1Needham, USA ;
2Harvard Medical School, Fall River, MA, USA ; 3Harvard Medical
School, Lexington, USA
Objective : This is an update of the algorithm for schizophrenia from
the Psychopharmacology Algorithm Project at the Harvard South
Shore Program.
Methods : A literature review was conducted focusing on new data
since the last published versions (1999–2001).
Results : For new-onset schizophrenia, the ﬁrst-line antipsychotics,
recommended with very slight preference, are amisulpride,
aripiprazole, risperidone, or ziprasidone. If the trial of the ﬁrst anti-
psychotic cannot be completed due to intolerance, try another until
one of the four is tolerated and given an adequate trial of 4–6 weeks.
There should be evidence of bioavailability. If there is an unsatisfac-
tory response to this adequate trial, try a second monotherapy with
any antipsychotic. If there is another unsatisfactory response, and at
least one of the ﬁrst two trials was with risperidone, olanzapine, or a
ﬁrst-generation antipsychotic (FGA), then clozapine is recommended
for the third trial. If neither trial was with one of these three possibly
slightly more eﬀective antipsychotics, a third trial prior to clozapine
should occur, using one of these options. If there is an unsatisfactory
response to monotherapy with clozapine (with dose adjusted using
plasma levels), consider adding risperidone, lamotrigine, or electro-
convulsive therapy. If one of these augmentations is unsuccessful,
possible options are to try another, try adding memantine or omega-3-
fatty acid to clozapine, switch from clozapine to another antipsychotic
not yet tried (especially aripiprazole), combine an FGA with mirta-
zapine, or combine risperidone with celecoxib. Finally, combinations
of antipsychotics not including clozapine may be tried.
Conclusion : Though all recent major guidelines for the pharma-
cotherapy of schizophrenia propose that two monotherapy anti-
psychotic trials should occur followed by a trial of clozapine, there is
variation in the manner in which clinicians are encouragned to ac-
complish these steps. The authors argue that the above is an evidence-
supported approach.
Policy of full disclosure : Osser – no ﬁnancial conﬂict of interest
Jalali-Roudsari – no ﬁnancial conﬂict of interest Manschreck – re-
ceived research support from Pﬁzer in the past year.
jP-08-067jRelationship between serum L-serine level and
symptoms of schizophrenia
Y. Ozeki1, M. Sekine2, K. Fujii1, T. Watanabe1, Y. Takano1,
H. Okayasu1, H. Mori3, K. Akiyama1, H. Homma2, K. Shimoda1.
1Dokkyo Medical University, Mibu, Japan ; 2Kitasato University, Tokyo,
Japan ; 3Mori Hospital, Utsunomiya, Japan
Objective : We previously reported a schizophrenia case with low
serum L-serine and L-glutamate levels. This case had a chromosomal
translocation with breakpoints localized to 3q13.12 and 9q21.2. In this
patient, expression of the phosphoserine aminotransferase 1 gene,
which is located adjacent to the breakpoint and encodes an enzyme in
the L-serine synthesis pathway, was reduced. Therefore, we hy-
pothesized that serine metabolism may be related to the symptoms of
schizophrenia. Here, we compared severity of schizophrenia and le-
vels of amino acids that are related to serine metabolism.
Methods : Twenty-nine schizophrenic patients were included in
this study (17 males and 12 females). The mean age of participants
was 59.9 (SD : 9.6) years. Severity of symptoms was assessed using the
Positive and Negative Syndrome Scale (PANSS). Furthermore, cog-
nitive functions were assessed using Japanese-language version of the
Brief Assessment of Cognition for Schizophrenia (BACS-J). Serum
concentrations of L-serine, D-serine, glutamate, and glutamine were
measured by high-performance liquid chromatography.
Results : Multiple regression analysis revealed that the PANSS
positive score was positively correlated with serum L-serine levels
(p<0.01) and L-glutamine levels (p<0.05). The BACS score showed a
tendency for correlation with the serum level of L-glutamate
(p<0.05). These results were corrected by age and sex.
Conclusion : Our results indicate the importance of studying serine
metabolism in schizophrenic symptoms. However, the number of
participants was relatively small, and conﬁrmation of these results in
a larger cohort is required. Furthermore, functions of enzymes within
the serine metabolism should be investigated in order to elucidate the
role of serine metabolism in schizophrenia pathophysiology.
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jP-08-068jDopamine D1 receptor involvement in EGF receptor
transactivation to ERK signaling induced by
clozapine
A. Pereira1, Y. Zhou1, H. Raaijmakers1, S. Sundram1. 1Mental Health
Research Institut, Parkville, Australia
Objective : Treatment of the positive psychotic symptoms of schizo-
phrenia with standard antipsychotic drugs (APDs) is ineﬀective in
about one third of cases. For these treatment resistant patients the
alternative is the APD clozapine which is superior to other agents but
carries serious side-eﬀects. Why clozapine is uniquely eﬀective is un-
known, but we have postulated may involve G-protein coupled re-
ceptor (GPCR) and epidermal growth factor (EGF) receptor (ErbB1)
transactivation signaling to the MAPK-ERK cascade. This was based
upon clozapine-induced initial down-regulation and delayed ErbB1
mediated activation of the cortical and striatal ERK response in-vivo
distinct from other APDs. The GPCR to which clozapine binds to in-
duce EGF receptor (EGFR) phosphorylation is unidentiﬁed and thus
we examined the dopamine D1 receptor (D1R) as a candidate given its
association with dopaminergic transmission in the prefrontal cortex
and regulation of locomotor activity and cognitive function.
Methods : The eﬀects of the selective D1R agonist SKF38393,
antagonist SCH23390 and EGFR inhibitor, AG1478 on clozapine-
mediated EGFR-ERK phosphorylation in CHO-K1 cells stably
expressing the EGFR and transiently transfected with the D1R were
examined to assess GPCR involvement.
Results : Clozapine induced signiﬁcant inhibition of ERK1/2
phosphorylation within 10 minutes of exposure to CHO-K1-EGFR
D1R transfected cells, followed by a delayed maximal increase in ERK
phosphorylation at 90 minutes which normalized by 120 minutes, a
proﬁle similar to that described in cortical neuronal cells. SKF38393
caused reversal of clozapine-induced ERK1/2 inhibition at 10 min-
utes ; SCH23390 plus clozapine elevated ERK1/2 phosphorylation
above clozapine treatment alone at 90 minutes whilst AG1478 dose-
dependently inhibited clozapine-mediated ERK1/2 phosphorylation
seen at 90 minutes. Parallel detection of EGFR (Tyr1068) phosphor-
ylation indicated a time disconnect with ERK phosphorylation.
Conclusion : These data highlight complexity in the clozapine-
induced D1R-EGFR transactivation mechanism that initiates down-
stream ERK eﬀects and advocate disturbed D1R-EGF system signaling
in refractory schizophrenia.
jP-08-069jDoes repetitive transcranial magnetic stimulation
have a positive eﬀect on working memory and
neuronal activation in treatment of negative
symptoms of schizophrenia?
H. Prikrylova Kucerova1, R. Prikryl2, L. Ustohal2. 1Faculty Hospital,
Brno, Czech Republic ; 2Faculty Hospital, CEITEC MU, Brno, Czech
Republic
Objective : Repetitive transcranial magnetic stimulation represents a
promising therapeutic method for inﬂuencing negative symptoms of
schizophrenia, thanks to its unique ability to modulate the neuronal
activity of the cortical cerebral areas and neuronal spheres that are
included in the pathophysiology of schizophrenia.
Methods : The Aim of Study to ﬁnd out whether, under conditions
of a double-blind, placebo coil controlled study, high frequency rTMS
over the left DLPFC would have a positive eﬀect on working memory,
as assessed by means of the Verbal Fluency Test (VFT), an important
parameter of cognitive schizophrenia deﬁcit with simultaneous fMRI
examination of the respective changes of neuronal activation.
Results : The evaluated group included in total 30 patients (males).
Real rTMS group included 19 patients and the sham rTMS group 11
patients. A statistically signiﬁcant increase in the mean VFT score
and statistically signiﬁcant reduction of severity of the negative, gen-
eral and total symptoms of schizophrenia occurred in the real rTMS
group. The rate of positive symptoms of schizophrenia remained un-
changed. A statistically signiﬁcant increase in the mean VFT score
and statistically signiﬁcant reduction of severity of the general and
total symptoms of schizophrenia occurred in the sham rTMS group.
The intensity of the negative symptoms of schizophrenia was not
statistically signiﬁcantly reduced. The rate of positive symptoms of
schizophrenia remained unchanged. Compared to the sham rTMS,
the real rTMS caused a statistically signiﬁcantly higher reduction of
severity of the negative, aﬀective and total symptoms of schizo-
phrenia. On the contrary, no diﬀerence was found with respect to the
positive and common symptoms of schizophrenia.
Conclusion : (1) No positive impact of high frequency rTMS, ad-
ministered over the left DLPFC area, on working memory parameters
and the respective changes of neuronal activation detected by fMRI
was found. (2) rTMS seems to be a very well tolerated neurostimula-
tion method for treatment of negative schizophrenia symptoms from
the point of view of the eﬀect on cognitive functions.
jP-08-070j Impairment of magnocellular pathway in visual
processing among patients with schizophrenia
A. Rady1, A. Elsheshai1, O. Elkholy1, H. Abou El Wafa1, I. Ramadan1.
1Alexandria, Egypt
Objective : Schizophrenia is associated with deﬁcits in higher order
processing of visual information, steady state visual evoked potential
responses recorded over the occipital cortex in patients with schizo-
phrenia suggest a dysfunction of lower level visual pathways, which
was more prominent for magnocellular than parvocellular biased
stimuli. The magnocellular pathway helps in orienting towards sali-
ent stimuli. A magnocellular pathwad deﬁcit could contribute to
higher level visual cognitive deﬁcits in schizophrenia dysfunction of
the magnocellular pathway may also account for other well described
aspects of neurophysiological dysfunction in schizophrenia, for ex-
ample, the magnocellular pathway projects predominantly to dorsal
cortical stream (i.e. parietal lobe), which codes motion perception and
spatial localization. Our work aims at assessing the magnocellular
pathway by VEP.
Methods : 30 schizophrenic patients were recruited randomly from
Alexandria University Hosiptal. They scored 4 or higher on the
Clinical Global Impression Scale for Severity CGI-S. Visual Evoked
Potential VEP was done to them and compared to healthy control
group.
Results : In the right eye the mean P100 was 104.55¡5.62 and
95¡5.27 msec in schizophrenic and healthy control group respect-
ively with statistical signiﬁcant diﬀerence. A ﬁnding that has been
replicated in the left eye where the mean P100 was 105.8¡5.41 and
95.85¡5.4 msec in the same respective groups.
Conclusion : P100 in both right and left eyes are more prolonged in
schizophrenic patients compared to healthy control groups.
jP-08-071jComparison of the eﬀects of quetiapine XR and
IR on cognitive performance and alertness in
patients with schizophrenia – the extra study
M. Riedel1, M. Schmitz2, P. Ka˚re Østergaard3, L. Ferrannini4,
M.A. Franco Martı´n5, V. Alfano6, E. Dencker Vansvik7. 1Vinzenz von
Paul Hospital, Rottweil, Germany ; 2 Institute for Psychosomatic, Medicine,
Vienna, Austria ; 3Private Psychiatrist, Middlefart, Denmark ;
4Department of Mental Health and Addictions ASL3, Genova, Italy ;
5Zamora Hospital, Psychiatric Department, Spain ; 6Parthenope
University, Naples, Italy ; 7AstraZeneca Italy, Basiglio, Italy
Objective : To assess daytime cognitive performance and overall
sedation in patients receiving quetiapine extended release (XR) versus
quetiapine immediate release (IR).
Methods : Phase IV prospective, double-blind, crossover study
(NCT01213836). Patients with stable schizophrenia were treated with
XR or IR before enrolment. Study design comprised 2 stages ; Periods
1 and 2 (10–18 days each). Patients were randomized to 2 groups : XR
once-daily evening dose (Period 1), followed by IR dosed twice-daily
(Period 2) ; IR twice-daily (Period 1), followed by XR once-daily
evening dose (Period 2). Doses corresponded to quetiapine dose be-
fore enrolment (400–750 mg). Assessments from 3 post-dose visits
(o5 days following treatment in each Period), were analysed accord-
ing to quetiapine formulation received. Daytime cognitive perform-
ance was measured by standardized Attentional Composite score,
combining Detection and Identiﬁcation domains of the CogState
Battery Task. Sedation was assessed with the 0–100-point Bond-Lader
VAS and 1–7-point Stanford Sleepiness Scale.
Results : 65 patients were randomised (69.2% male ; mean age
38.6 years) ; 51 included in per protocol analysis. Averaged across
130 Poster Sessions, Tuesday, 5 June 2012
Downloaded from https://academic.oup.com/ijnp/article-abstract/15/Supplement_1/1/650920
by University of Groningen user
on 13 March 2018
3 post-dose assessments, adjusted mean diﬀerence in Attentional
Composite score in XR and IR patients was 0.005 (p=0.907). Patients
receiving XR were more alert than those receiving IR, (Bond-Lader
VAS score, mean [SD] : 23.5 [19.0] vs. 28.6 [21.4]) ; estimated overall
treatment diﬀerence : 5.2 [95% CI : 2.3 ; 8.2] (p<0.0009). Patients re-
ceiving XR also reported feeling less sedated than those on IR
(Stanford Sleepiness Scale, mean [SD] : 2.4 [0.9] vs. 2.6 [1.0]) ; estimated
overall treatment diﬀerence : 0.28 [95% CI : 0.12 ; 0.43] (p<0.0008).
Conclusion : Daytime cognitive performance was similar for the
quetiapine IR and XR treatment groups. XR was associated with less
daytime sedation than IR at approved doses for this indication.
Policy of full disclosure : M. Riedel has received research grants/
support or has served as a consultant for AstraZeneca, Pﬁzer, Otsuka
Pharma, Janssen-Cilag. In the context of investigator initiated trials
M. Riedel has received support from AstraZeneca and Pﬁzer.
jP-08-072j Is it possible to improve the prediction of the
psychotic chronic patients? An extension study after
60 months
S.L. Romero Guillena1, N. Casas Barquero2, F. Gotor Sanchez-
Luengo3, J.L. Velez Noguera4, L. Gutierrez Rojas4. 1U.G.C. Salud
Mental, Sevilla, Spain ; 2U.G.C.S.M Virgen Macarena, Sevilla, Spain ;
3U.G.C. S.M Valme, Sevilla, Spain ; 4Sevilla, Spain
Objective : To evaluate the clinical and functional progression of pa-
tients that having been treated with conventional antipsychotic
medication in a previous comparative study vs. Risperidone Long
Acting Inyectable(RLAI), accepted RLAI as a treatment choice for
their illness.
Methods :We conducted the study with an initial sample consisting
of 26 schizophrenic patients, treated with conventional antipsychotic
treatment in the previous main study, and 14 of them voluntarily ac-
cepted the change to RLAI treatment. During a period of 12 months,
follow-up visits were performed at 3, 6 and 12 months for all patients
included in both treatment groups. The following scales and ques-
tionnaires were used for assessment and measurement : Global Illness
Severity (Global Clinical Impression GCI), Treatment Satisfaction
Scale, Insight (G12 PANSS), Remission Criteria (Andreassen Criteria),
Global Activity Evaluation Scale (GAES). Personal and Social
Performance (PSP). Also the following information was collected :
hospitalization rates, treatment discontinuation and concomitant an-
tipsychotic.
Results : We found statistical diﬀerences among patients treated
with long acting atypical and typical antipsychotic. The RLAI group
showed signiﬁcantly higher remission rates and treatment satisfaction
scores. Also an improvement in patient Insight, GCI, GAES, PSP and
an increase of patients treated with antipsychotic monotherapy was
observed. Regarding hospitalization and treatment discontinuation
rates, no statistical diﬀerences were found in both groups at baseline
and at endpoint.
Conclusion : Clinical and functional improvements observed fol-
lowing treatment with RLAI for one year in patients previously trea-
ted with conventional antipsychotic treatment, were similar to those
showed in the main study, which this study is its extension.
jP-08-073jPhysical condintion, functionality and cognicion in
patients with schizophrenia
S.L. Romero Guillena1, B.O. Plasencia Garcia de Diego2, E. Garcia
Henche2, P. Aguilar Valseca2, P. Vaquero Casado2, L. Gutierrez
Rojas3. 1U.G.C. Salud Mental, Sevilla, Spain ; 2U.G.C. S.M. Virgen
Macarena, Sevilla, Spain ; 3Sevilla, Spain
Objective : To evaluate the association between physical condition,
mental cognition and functionality in patients with schizophrenia.
Methods : We conducted a epidemiological, retrospective and
transversal study including a total sample of 90 patients diagnosed
with schizophrenia, according to CIE 10. Patients were divided into
2 groups regarding the antipsychotic treatment received : conven-
tional (typical) or atypical ones. Physical condition was assessed by
evaluating the anthropometric, biochemical and clinical parameters
and also by the analysis of the presence of metabolic syndrome (de-
ﬁned according to WHO) and cardiovascular risk (as determined by
Framingham and waist/triglycerides scores). Cognitive impairment
was assessed by the Screen for Cognitive Impairment scale in
Psychosis (SCIP) and functionality was evaluated with the Personal
and Social Performance Scale (PSP). Clinical data also included years
in the disease evolution and number of hospital admissions in the
previous year.
Results : The following signiﬁcant correlations were observed, all of
them measured by the Pearson correlation coeﬃcient ; Inverse corre-
lations : PSP endpoint score and SCIP total score, p<0.05. PSP end-
point score and cardiovascular risk (Framingham), p<0.05. PSP
endpoint score and number of hospital admissions, p<0.01. Direct
correlation : SCIP total score and number of hospital admissions,
p<0.05. Cardiovascular risk (Framingham) and disease progression
years, p<0.05. The group of patients treated with atypical anti-
psychotics have better functionality, less deterioration cognitive and
lower cardiovascular risk when compared to those patients treated
with typical antipsychotics.
Conclusion : Lower functionality has been observed in patients
with greater cognitive impairment and it is related to increased cog-
nitive impairment, cardiovascular risk and number of hospital ad-
missions. The group of patients treated with atypical antipsychotics
demonstrated better functionality, less deterioration cognitive and
lower cardiovascular risk when compared to those patients treated
with typical antipsychotics.
jP-08-074jClinical outcome in outpatients with schizophrenia
who switched their antipsychotic treatment due to
suboptimal eﬃcacy : Results from the ETOS study
A. Roussidis1, C. Kalkavoura2, I. Vlachos3, A. Chaidemenos4,
I. Ioannidou5, E. Mellos6, A. Theodorou7. 1AstraZeneca Hellas, Athens,
Greece ; 2Psychiatric Department, Sismanoglio General Hospital, Athens,
Greece ; 3Private Practice, Patras, Greece ; 48th Psychiatric Clinic,
Psychiatric Hospital, Athens, Greece ; 5Private Practive, Nafplio, Greece ;
6Aiginition Hospital-OKANA, Athens, Greece ; 7Private Practice, Athens,
Greece
Objective : Schizophrenia is a chronic, severely disabling illness as-
sociated with poor treatment adherence and frequent treatment
modiﬁcations. The ETOS study aimed to identify the reasons and
evaluate the outcome of switching antipsychotic treatment in out-
patients with schizophrenia.
Methods : ETOS was an observational 18-week study in out-
patients, diagnosed with schizophrenia according to DSM-IV, who
were initiated on a new antipsychotic monotherapy within the pre-
ceding two weeks. A total of 574 patients were enrolled. Ethical ap-
proval was obtained prior to study initiation (NCT00999895).
Results : The ﬁnal analysis included 568 patients, 53% male and
47% female and mean disease duration of 11.7 (¡12.3) years. In total
249 patients (43.8%) switched due to lack of eﬃcacy and 50 patients
(8.8%) switched due to the lack of both tolerability and eﬃcacy.
Patients who switched due to lack of eﬃcacy were mainly (>10%)
switched from aripiprazole (22.1%), risperidone (21.3%), olanzapine
(16.5%) and ziprasidone (12.9%). PANSS and CGI-S scores at baseline
were 92.9 (¡28.2) and 4.1 (¡1.1) respectively. Following treatment
switch, 86.9% of patients who switched due to eﬃcacy reasons ex-
perienced meaningful clinical beneﬁt by achieving a CGI–CB score of
f4 at ﬁnal visit [clinical beneﬁt in all patients was 87.9% (n=499)].
Total PANSS, CGI-I and CGI-S scores were signiﬁcantly improved by
the end of study, showing a mean decrease of 31.69, 0.70 and 1.14
respectively (all p<0.0001). BARS was also signiﬁcantly improved by
the end of the study with a mean change of 9.73 (p<0.0001).
Conclusion : Antipsychotic monotherapy switch due to lack of ef-
ﬁcacy was shown to be beneﬁcial in outpatients with schizophrenia,
associated with signiﬁcantly improved clinical beneﬁt and signiﬁcant
increase of patients’ adherence to treatment in daily clinical practice.
Policy of full disclosure : Andreas Roussidis is an employee of
AstraZeneca Hellas. This study was funded from AZ Hellas.
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jP-08-075jReasons for switching antipsychotic treatment in
outpatients with schizophrenia : Results from the
ETOS study with focus on tolerability
A. Roussidis1, C. Kalkavoura2, T. Mylonaki3, A. Xafenias4,
V. Peritogiannis5, T. Chioutakos3. 1AstraZeneca Hellas, Athens, Greece ;
2Psychiatric Department, Sismanoglio General Hospital, Athens, Greece ;
3Private Practice, Athens, Greece ; 4Private Practice, Thessaloniki,
Greece ; 5Private Practice, Ioannina, Greece
Objective : The ETOS study aimed to identify the reasons and evalu-
ate the outcome of switching antipsychotic treatment in outpatients
with schizophrenia.
Methods : ETOS was an observational 18-week study in out-
patients, diagnosed with schizophrenia according to DSM-IV,
who were initiated on a new antipsychotic monotherapy within the
preceding two weeks. A total of 574 patients were recruited. Ethical
approval was obtained prior to study initiation (NCT00999895).
Results : The ﬁnal analysis included 568 patients. 53% of partici-
pants were male and 47% female. The main reason for switching
antipsychotic treatment was lack of tolerability (n=369, 65.0%), fol-
lowed by lack of eﬃcacy (n=249, 43.8%), while 8.8% of patients
switched due to lack of both tolerability and eﬃcacy. The main toler-
ability reasons (>5%) in descending order of prevalence were weight
gain (40.4%), extrapyramidal symptoms (30.1%), lack of tolerance
(11.4%), hyperprolactinaemia (10.6%), hyperlipidaemia and/or
hyperglycaemia (6.5%). Patients who changed treatment for toler-
ability reasons (n=369) were mainly (>10%) switched from olanza-
pine (37.4%) and risperidone (24.7%). Of those patients switching due
to lack of tolerability, 58.5% were switched to quetiapine/quetiapine
XR, 10.8% to aripiprazole, 9.8% to olanzapine, 6.2% to paliperidone,
5.4% to ziprasidone, followed by other antipsychotics (<5%). A
CGI–CB score off4 was achieved by 89.0% of patients switching due
to tolerability reasons. In patients switching due to weight gain
(n=149), extrapyramidal symptoms (n=111) or hyperprolactinaemia
(n=39), weight, SAS scores and prolactin levels were signiﬁcantly
decreased by 6.85 kg, 11.30 and 62.30 ng/ml respectively (all
p<0.0001).
Conclusion : The ETOS study identiﬁed lack of tolerability to be
the main reason for switching antipsychotic treatment in outpatients
with schizophrenia. Switching to antipsychotic monotherapy was
accompanied by signiﬁcantly improved tolerability for speciﬁc mea-
sures in daily clinical practice.
Policy of full disclosure : This study was funded from AstraZeneca
Hellas. Andreas Roussidis is an employee of AZ Hellas.
jP-08-076jEﬀect of aripiprazole, risperidone and olanzapine,
on the acoustic startle response in recent episodes of
schizophrenia
G. Rubio1, R. Jurado1, I. Morales1, I. Martı´nez-Gras1, G. Ponce1,
R. Rodrı´guez-Jime´nez1, M.-A. Jime´nez-Arriero1. 1Hospital 12 de
Octubre, Madrid, Spain
Objective : Studies have also shown that diﬀerences in the kind of the
antipsychotics inﬂuenced disruption of the sensorimotor gating sys-
tem, including prepulse inhibition of the startle reﬂex (PPI). Atypical
antipsychotics improve PPI more than typical, but little is known
about the eﬀects of aripiprazole on PPI. Aripiprazole, an atypical an-
tipsychotic drug, is a D2 dopamine–receptor partial agonist, but also
has aﬃnity to several serotonin receptors (5-HT1A,2A,2C,7). We hy-
pothesized that patients taking aripiprazole would show greater im-
pairment in PPI than those patients with risperidone or with
olanzapine.
Methods : In the present study we investigated the inﬂuence on
startle response in recent episodes of schizophrenia in 15 patients
taking aripiprazole, 15 taking risperidone and 14 patients with
olanzapine. Participants were on maintenance therapy with only
one antipsychotic drug for 12 weeks. The startle measures used
were prepulse inhibition percentages at 30, 60 and 120 milliseconds
(% PPI-30, % PPI-60 and % PPI-120, respectively), and % habituation.
Results : Aripiprazole improved PPI more than risperidone
and than olanzapine at 30 and 60 milliseconds but not at 120
(p<0.01). Risperidone improved %PPI-60 more than olanzapine
(p<0.01).
Conclusion : Aripiprazole, in subjects with recent episodes of
schizophrenia improved PPI disruption more than risperidone and
olanzapine at early attentional stages. These data suggest the role of
the D2 Dopamine –receptor partial antagonist on sensoriomotor gat-
ing system of patients with schizophrenia.
jP-08-077jFirst-episode psychosis : Factors inﬂuencing relapse
over 1-year follow-up
A. Sabate´1, L. Go´mez2, A. Mane´2, D. Berge´3, P. Salgado3, A. Bulbena3.
1Hospital del Mar, Sant Cugat Del Valle`s, Spain ; 2Hospital del Mar,
INAD, Barcelona, Spain ; 3Hospital del Mar, Barcelona, Spain
Objective : Describe which variables are related with relapse in pa-
tients diagnosed of ﬁrst-episode psychosis over one-year follow-up.
Methods : Consecutive 129 ﬁrst-episode patients treated in Institut
de Neuropsiquiatria i Addicions from Barcelona from 2007 to 2011
were evaluated over 1-year follow up. We assessed sociodemographic
and clinical variables, including cannabis use, duration of untreated
psychosis (DUP), relapses, and several scales (PANSS, SUMD, GAF),
at diﬀerent timepoints : baseline, at 1-month, 6-months and 1-year
follow-up. We performed a multiple regression analysis. Number of
relapses was the dependent variable, and DUP, gender, age, cannabis
use over follow-up, PANSS positive and negative subscale, GAF, and
SUMD at one-month follow-up were the independent variables.
Results : Gender (p=0.014), PANSS positive symptoms at 1-month
follow-up (p=0.027), and cannabis use (p<0.001), are associated with
relapse in our sample.
Conclusion : Male gender, persistent positive symptoms at
one-month follow-up and cannabis use, may predict independently
relapse in ﬁrst- episode psychosis.
jP-08-078jDopamine D2 receptor occupancy and cognition in
schizophrenia : Analysis of the CATIE data
H. Sakurai1, R. Bies2, S. Stroup3, R. Keefe4, T. Rajji2, T. Suzuki5,
D. Mamo2, B. Pollock2, K. Watanabe5, M. Mimura5, H. Uchida5. 1Keio
University, School of Medicine, Tokyo, Japan ; 2Toronto, Canada ; 3New
York, USA ; 4Durham, USA ; 5Tokyo, Japan
Objective : Antipsychotic drugs exert antipsychotic eﬀects by block-
ing dopamine D2 receptors in the treatment of schizophrenia.
However, eﬀects of D2 receptor blockade on neurocognitive function
still remain to be elucidated. The objective of this analysis was to
evaluate impacts of estimated dopamine D2 receptor occupancy with
antipsychotic drugs on several domains of neurocognitive function in
patients with schizophrenia in the Clinical Antipsychotic Trials in
Intervention Eﬀectiveness (CATIE) trial.
Methods : The dataset from the CATIE trial was used in the present
analysis. Data were extracted from 410 subjects who were treated with
risperidone, olanzapine, or ziprasidone, received assessments for
neurocognitive functions (verbal memory, vigilance, processing
speed, reasoning, and working memory) and psychopathology, and
provided plasma samples for the measurement of plasma anti-
psychotic concentrations. D2 receptor occupancy levels on the day of
neurocognitive assessment were estimated from plasma antipsychotic
concentrations, using population pharmacokinetic analysis and our
recently developed model. A multivariate general linear model was
used to examine eﬀects of clinical and demographic characteristics,
including estimated D2 occupancy levels, on neurocognitive func-
tions.
Results : D2 occupancy levels showed signiﬁcant associations with
the vigilance and the summary scores. Neurocognitive functions, in-
cluding vigilance, were especially impaired in subjects who showed
D2 receptor occupancy level of>77%.
Conclusion : These ﬁndings suggest a non-linear relationship be-
tween prescribed antipsychotic doses and overall neurocognitive
function and vigilance, which has an important clinical implication
and may endorse the upper limit of the established antipsychotic
therapeutic window of D2 occupancy (i.e., 80%) from the standpoint
of cognition as well.
Policy of full disclosure : Dr. Bies has received NIH, CAMH, Lilly
and Indiana University based grant funding. Dr. Stroup has received
grants from NIMH and the Foundation for the National Institutes of
Health. He has received consulting income from Janssen and Lilly.
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jP-08-079jPatient-reported outcomes (PROs) with aripiprazole
intramuscular depot (ARI-IMD) for maintenance
treatment in schizophrenia
R. Sanchez1, B. Johnson2, N. Jin2, R.A. Forbes2, W.H. Carson2,
R.D. McQuade2, J.M. Kane3, W. Fleischhacker4. 1Otsuka Pharma,
Princeton, USA ; 2Princeton, USA ; 3Glen Oaks, USA ; 4 Innsbruck,
Austria
Objective : To characterise the adherence proﬁle of ARI-IMD by ex-
amining PROs from long-term treatment.
Methods : Subjects were cross-titrated to oral aripiprazole
(10–30 mg/day) during a 4–6-week oral conversion phase (Phase 1).
Phase 2 was a 4–12-week oral aripiprazole stabilisation phase.
Subjects meeting stability criteria (4 weeks) entered an IMD stabilis-
ation phase (400 mg/injection) with co-administration of oral
aripiprazole the ﬁrst 2 weeks (Phase 3). Subjects meeting stability
criteria (12 weeks) were randomised (2 : 1) to ARI-IMD or placebo
(52-week : Phase 4). Mean changes in PROs were assessed from base-
line to last visit in Phases 2–4 using the DAI, MAQ and PSMQ modi-
ﬁed.
Results : 710 subjects entered Phase 2 (633 were titrated to oral
aripiprazole in Phase 1) ; 576 Phase 3 and 403 Phase 4. The study
stopped early because eﬃcacy was demonstrated by pre-planned
interim analysis. Between Phases 2–4, mean DAI scores remained
similar (Phase 2 : 21.5 ; Phase 3 : 21.4 ; Phase 4 : 21.1 ARI-IM-depot vs.
22.2 placebo) indicating adherence to medication. Mean MAQ
scores=0–1 indicated high adherence behaviour. PSMQ scale scores
at last visit showed subjects had high levels of treatment satisfaction
(Phase 3 : 92.8% ; Phase 4 ARI-IMD: 92.7% ; Phase 4 placebo : 85.0%).
A high percentage of subjects preferred their current medication at
last visit (Phase 3 : 89.1 ; Phase 4 ARI-IMD: 86.2% ; Phase 4 placebo :
85.7%). There were a sustained percentage of subjects reporting less to
no side-eﬀects at last visit (Phase 3 : 86.9% ; Phase 4 ARI-IMD : 88.9% ;
Phase 4 placebo : 89.0%).
Conclusion : ARI-IMD oﬀers a new treatment option for the long-
term management of schizophrenia with the potential to improve
adherence to medication resulting from improved PROs and medi-
cation satisfaction.
Policy of full disclosure : John M. Kane has received honoraria for
lectures and/or consulting from Alkermes, Amgen, BMS, Cephalon,
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A. Schmidt1, A.O. Diaconescu2, K.E. Stephan2, F.X. Vollenweider1.
1University Zurich, Zu¨rich, Switzerland ; 2University Zu¨rich, ETH
Zu¨rich, Switzerland
Objective : Disordered brain connectivity is a central pathophysiolo-
gical hallmark of schizophrenia. The key mechanism for dysconnec-
tivity is thought to be disrupted N-methyl-D-aspartate receptor
(NMDAR)-mediated synaptic plasticity. However, no study has yet
experimentally investigated the contribution of NMDAR-mediated
synaptic plasticity to psychotic symptom formation. The mismatch
negativity (MMN) is an event-related potential (ERP) and has recently
been interpreted as a prediction error (PE) signal during perceptual
learning and has been shown to depend critically on NMDAR-
dependent synaptic plasticity. Speciﬁcally, the NMDAR antagonist
S-ketamine, which induces schizophrenia-like symptoms, reduces the
MMN in healthy subjects comparable to those observed in schizo-
phrenia. The MMN is generated within a neuronal hierarchy, where
each level provides predictions about the state of the level below and
evaluates the discrepancy with the actual inputs from the lower level
(i.e. PE). Within this Bayesian framework, PEs are conveyed via syn-
aptic connections, which will be adjusted during learning and infer-
ence in order to minimize PE at all levels of the hierarchy.
Methods : We combined conventional statistical parametric map-
ping (SPM) with DCM modeling of ERP data to investigate eﬀective
connectivity within the MMN network in order to examine whether
the known reduction of MMN under S-ketamine can be explained by
changes in the plasticity of glutamatergic long-range connections
among hierarchically related auditory areas, and if so, where these
changes would be expressed.
Results : DCM analyses revealed that S-ketamine signiﬁcantly per-
turbed bottom-up eﬀective connectivity, the extent of which predicted
signiﬁcant S-ketamine-induced cognitive impairments.
Conclusion : Based on empirical data, we have described for the ﬁrst
time a pathophysiological mechanism underlying dysfunctional con-
nectivity, which gives rise to speciﬁc symptom formation, namely to
cognitive impairments. Ourmodel-based characterization ofNMDAR-
mediated eﬀects on synaptic plasticity thus connects pharmacological,
physiological and computational approaches in relation to the for-
mation of a speciﬁc psychotic symptom, suggesting high relevance for
pathophysiological theories of schizophrenia.
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jP-08-081jCentral interleukin-6 activation in patients with
chronic schizophrenia
L. Schwieler1, E. Skogh2, M. Samuelsson3, M. Kegel1, S. Erhardt1,
G. Engberg1. 1Karolinska Institutet, Stockholm, Sweden ; 2Linko¨pings
Universitet, Linko¨ping, Sweden ; 3Karolinska Institutet, Linko¨ping,
Sweden
Objective : Accumulating studies during the last decade indicate that
schizophrenia is associated with immunological processes in the
brain. For this reason, studies have been directed towards cytokines,
proteins that directly initiate and control immunological responses.
One of the most frequently reported cytokine in schizophrenia is in-
terleukin (IL)-6, a cytokine involved in brain development, synaptic
plasticity and behavior. The purpose of the present study is to analyze
cytokine concentration in the cerebrospinal ﬂuid (CSF) from well-
characterized patients with respect to antipsychotic treatment and
symptoms.
Methods : CSF cytokine concentrations were analyzed by an elec-
trochemiluminescence biosensor assay (Meso Scale Discovery,
Gaithersburg, MD, USA). Patients were stable, chronically outpatients
with schizophrenia (17 males and 9 females). Diagnosis was based on
clinical interviews by an experienced psychiatrist and the severity of
symptoms was rated with Brief Psychiatric Rating scale (BPRS) and
global assessment of functioning (GAF). All patients were medicated
with olanzapine for at least one month before lumbar puncture. CSF
concentrations of IL-6 from patients were compared with those of 37
healthy age matched volunteers (23 males and 14 females).
Results : Our results show that patients with schizophrenia display
signiﬁcant increased levels of IL-6 in CSF (3.2¡0.4 pg/ml) compared
with healthy volunteers (1.8¡0.2 pg/ml). No correlation between IL-6
and symptoms rated with BPRS or GAF were found. Further, treat-
ment with olanzapine did not inﬂuence IL-6 concentrations as no
correlation between IL-6 and treatment with respect to prescribed
dose, time of treatment or concentration of olanzapine in CSF were
found.
Conclusion : Present data conﬁrm that IL-6 is increased in the brain
of chronic patients with schizophrenia and strengthen the idea that
the disease is associated with brain immune activation. Cytokines, in
particular IL-6 may hence serve as biomarkers of chronic schizo-
phrenia.
jP-08-082jThe enhancing properties of modaﬁnil in
schizophrenia and early psychosis
L. Scoriels1, B. Sahakian1, P. Jones1. 1University of Cambridge, United
Kingdom
Objective : Modaﬁnil is a central nervous system compound that has
vigilance promoting properties as well as beneﬁcial eﬀects on cogni-
tive and emotional functions in the healthy and diseased population.
Our group showed that modaﬁnil improved working memory, plan-
ning abilities, cognitive ﬂexibility and emotional recognition in
chronic schizophrenia and ﬁrst episode psychosis. It is still unclear
how modaﬁnil aﬀects these functions. We aimed at reviewing the
literature that tested the neuropathways of modaﬁnil in diﬀerent
areas of the brain. We also targeted the cognitive and emotional eﬀects
of modaﬁnil in all the studies that tested the compound in patients
with schizophrenia.
Methods : Two systematic reviews were carried out. One reviewed
the neuropathways taken by modaﬁnil and categorised studies
according to the animal models used, the neurotransmitter systems
and the brain regions activated by the compound. The other was a
Cochrane review protocol that aims at meta-analysing the eﬀects of
modaﬁnil in schizophrenia.
Results : Preliminary results from these two reviews show that
modaﬁnil acts mainly by inhibiting the GABAergic system, where as it
activates the glutamatergic, dopaminergic, noradrenergic and sero-
tonergic systems. These patterns of action have been shown particu-
larly in the prefrontal cortex, hippocampus, hypothalamus, thalamus,
striatum and substantia nigra both in animals and humans. These
neuropharmacological eﬀects of modaﬁnil induce improvements in
working memory, ﬂuency, cognitive ﬂexibility and problem solving
in patients with schizophrenia.
Conclusion : These original ﬁndings allow us to better understand
the neuromechanisms of modaﬁnil and although the interaction
between modaﬁnil and antipsychotics – the most commonly pre-
scribed medication in psychosis – has yet to be tested, results from
these two reviews suggest that modaﬁnil may be an adequate adju-
vant treatment for psychosis. It may help patients cope with their
cognitive impairments and improve their functional outcomes and
quality of life.
jP-08-083jCatalytic activity of abzyms in patients with
schizophrenia with tardive dyskinesia
L. Smirnova1, N. Fattakhov2, E. Odintsova3, V. Buneva3, N. Krotenko4,
E. Rudikov1, S. Ivanova5. 1Mental Health Research Institute, Tomsk,
Russia ; 2Siberian State Medical University, Medico-Biological Faculty,
Tomsk, Russia ; 3Chemical Biology and Basic, Medicine SB RASci,
Novosibirsk, Russia ; 4Siberian State Medical Univers, Tomsk, Russia ;
5 Institute of Mental Health, Tomsk, Russia
Objective : Research objective is studying DNase activity of IgG allo-
cated from the serum of patients with paranoid schizophrenia.
Methods : An antibodies of G group was allocated from the blood
of 35 donors, including control group of 15 healthy persons. Patients
with schizophrenia have been divided on 2 groups : 6 patients with
tardive dyskinesia (TD) and 15 patients without TD. All patients were
treated in department of endogenous disorders of Mental Health
Research Institute SB RAMSci, Tomsk. The diagnosis of schizophrenia
was based on criteria the ICD-10. The severity of TD was assessed
using the abnormal involuntary movement scale (AIMS). DNase ac-
tivity deﬁned on level of hydrolysis of DNA plasmids pBluescript,
proteolytic activity deﬁned on level of hydrolysis of myelin basic
protein and its peptides. The concentration of antibodies to DNA de-
ﬁned by the ELISA method.
Results : It was established that IgG of schizophrenic patients has
higher speciﬁc DNase activity (0.392¡0.190 pmol DNA/mg anti-
body/hour), than in healthy persons (0.029¡0.061 pmol DNA/mg
antibody/hour). It has been deﬁned that speciﬁc DNase activity
is own property of antibodies. It has been deﬁned that speciﬁc
DNase activity of antibodies in patients with TD in 2 times higher
(0.740¡0.300 pmol DNA/mg antibody/hour), than in group without
TD (0.300¡0.130 pmol DNA/mg antibody/hour). The level of spe-
ciﬁc DNase activity of antibodies in healthy controls was
0.029¡0.060 pmol DNA/mg antibody/hour. The hydrolysis of my-
elin basic protein by antibodies in group of the patients with TD also
was maximum 58.6%, unlike patients without TD 12.7%. In group of
control hydrolysis level was 1.5%.
Conclusion : High values of the catalytic activity of IgG in patients
with tardive dyskinesia suggest their involvement in the development
of this complication.
jP-08-084jNeurocognitive deﬁcit correction in patients with
schizophrenia
A. Spikina. St Petersburg Medical Academy, Russia
Objective : To study the inﬂuence of neurocognitive training as well
as long-term use of psychopharmacological drugs with serotoninergic
mechanism of action (serdolect, ﬂuvoxamine) on higher cortical
function in patients with schizophrenia and to evaluate their eﬀec-
tiveness in the treatment of schizophrenia.
Methods : For revealing the symptoms of neurocognitive deﬁcits,
we used standard tests such as learning the 10 words (test of Luria),
Benton Test (Benton Visual Retention Test), Stroop Test – Stroop
Color interference Test, Test ‘‘Encryption’’. To assess the attention :
The test for the visual and motor coordination (parts A and B) – Trail
Making Test A & B. To assess executive functions-test ‘‘Mazes’’.
Results : After training the cognitive processes in schizophrenia
patients were obtained by increasing the tempo of the performance,
improving the concentration, the adequacy of long-term thinking and
memory have been identiﬁed trend towards an increase in operational
short-term memory, the maximum improvement falls on visual
memory, and minimal attention to the function. Patients receiving
serdolect and ﬂuvoxamine have shown signiﬁcant improvement in
neurocognitive proﬁle in comparison with the control group, and,
better indicators such as verbal associative productivity, selective
attention, working memory and motor coordination was signiﬁcantly
higher in patients treated with serdolect.
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Conclusion : The neurocognitive training showed itself as an
eﬀective method of correcting neurocognitive deﬁcits. Using drugs
with serotoninergic mechanism showed signiﬁcant improvement
in neurocognitive proﬁle of schizophrenia patients. Serdolect showed
statistically signiﬁcant improvement in the basic neurocognitive
parameters in comparison with Fevarin.
jP-08-085jService delivery improvement project for clozapine
monitoring in assertive outreach team
S. Sreenivas1, S. Davies2. 1NHS, Halifax, United Kingdom ; 2Southwest
Yorkshire PFT, Halifax, United Kingdom
Objective : Clozapine plasma levels are broadly related to daily
dosing. Despite diﬀerent estimates of response thresholds, plasma
levels can be useful in optimizing treatment. It has been observed
that there needs to be a high quality service system, to aid the eﬀective
monitoring of the Clozapine levels in the Assertive Outreach
Team, Halifax. Objectives : (1) To develop additional indications for
Clozapine level monitoring in the Southwest Yorkshire Partnership
Foundation Trust Policy (2007). (2) To develop Clozapine monitoring
from the date of ﬁrst initiation of Clozapine medication.
Methods :Clozapinemonitoring form has been designed. Clozapine
levels collected from the clinical notes/Kings pathology online
system. Communication made with pharmacists of the Southwest
Yorkshire Partnership Foundation Trust and Clozapine monitoring
Policy discussed in Drug and Therapeutics Sub Committee Meeting in
July 2011.
Results : The Policy now Includes additional indications for cloza-
pine level monitoring : ‘‘To monitor concordance with treatment
particularly if there is a history of non-concordance with medication,
which is linked with previous or likely hospital admission. Adherence
can be measured over time with serial Clozapine assays, particularly
when adherence is a critical part of the care plan, for example for
maintenance of mental health that is essential for the patient’s safety,
adherence to a Community Treatment Order or other Section of the
Mental Health Act 1983 (Amended 2007)’’. Clozapine monitoring
form is designed and is available to the AOT.
Conclusion : The current system would help in a longitudinal
analysis of the variation of levels with doses of Clozapine, also giving
an opportunity to determine possible reasons for changes in clozapine
levels. Clozapine levels can help monitor concordance with treatment
for service users with a history of enduring mental illness and low
compliance, including support with adherence to requirements for
Community Treatment Orders. A Clinical Audit Project can be con-
ductedin 1 year to make sure that the policy is being adhered to and
Clozapine monitoring forms are being completed.
jP-08-086jEﬀects of aripiprazole on autonomic nervous system
activity in schizophrenia
A. Suda1, I. Kishida2, M. Fujibayashi3, C. Kawanishi2, Y. Iwamoto2,
T. Furuno2, C. Ishii4, N. Ishii5, N. Sugiyama1, T. Moritani6,
Y. Hirayasu2. 1Numazu Chuo Hospital, Numazu City, Shizuoka, Japan ;
2Department of Psychiatry, Yokohama City University, Yokohama City,
Kanagawa, Japan ; 3The Division of Physical and Health Education,
Neyagawa City, Osaka, Japan ; 4Fujisawa Hospital, Fujisawa City,
Kanagawa, Japan ; 5Fujisawa Hospital, Fujisawa City, Kanagawa, Japan ;
6Graduate School of Human and Environmental Studies, Kyoto City,
Kyoto, Japan
Objective : Schizophrenic patients have been reported to have an in-
creased prevalence of cardiovascular diseases. Although treatment
with second-generation antipsychotics (SGAs) have eﬀects on positive
and negative symptoms of schizophrenia, they also promote weight
gain, may lead to metabolic syndrome that increases the risk of car-
diovascular diseases. On the other hand, aripiprazole displays low
aﬃnity for H1-histaminergic, muscarinic, cholinergic, and adrenergic
receptors. This proﬁle is predictive of low propensity to weight-gain,
metabolic disruption. We reported reduced autonomic nervous sys-
tem (ANS) activity in schizophrenia. In the present study, we sought
to replicate the reported positive association between low ANS ac-
tivity and schizophrenia in a larger number of patients, and we
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investigated the inﬂuence of aripiprazole on ANS activity and com-
pared with other antipsychotic drugs.
Methods : Subjects were 211 Japanese patients with schizophrenia
and 44 healthy controls. All subjects received an explanation of our
study and written informed consent was obtained. ANS activity was
assessed by means of heart-rate variability power spectral analysis,
which enables us to identify separate frequency components, i.e., total
power (TP : overall ANS), low-frequency (LF : sympatho-vagal)
power, and high-frequency (HF : vagal) power, during a resting con-
dition. Statistical analyses were performed using t-tests to determine
the presence of diﬀerences in the ANS activity.
Results : We found signiﬁcantly lower ANS activity in schizo-
phrenic patients than controls (TP ; p<0.001, LF ; p<0.001, HF ;
p<0.001). Patients receiving aripiprazole (n=11) have higher ANS
activity than the other patients (n=196).
Conclusion : Our ﬁndings suggest that schizophrenic patients
possess reduced ANS activity, which might be associated with in-
creased cardiovascular mortality, and aripiprazole have less adverse
eﬀects on ANS activity compared with other antipsychotic drugs.
jP-08-087jPrevalence of metabolic syndrome among
schizophrenia patients treated with monotherapy
atypical antipsychotics in Malaysia
A.H. Sulaiman1, M.A. Said1, M.H. Habil1. 1University of Malaya,
Kuala Lumpur, Malaysia
Objective : The objective of this study was to determine the preva-
lence of metabolic syndrome(MetS), hypertension and diabetes mel-
litus (DM) among schizophrenia patients treated with monotherapy
atypical antipsychotics.
Methods : The study was conducted at 4 mental institutions and
4 general hospitals in Malaysia. 527 patients were screened during
study period and 485 patients fulﬁlled the DSM-IV criteria for
schizophrenia. 325 schizophrenia patients agreed to be interviewed
but only 274 consented for fasting blood investigations and metabolic
syndrome proﬁle. The deﬁnition of MetS was based on Modiﬁed
National Cholesterol Education Program Adult Treatment Panel
(NCEP ATP III) with Asians values for waist circumference.
Results : Out of 325 patients, 186 patients (57.2%) received mono-
therapy atypical antipsychotics. 64/186 on risperidone, 61/186
patients were on olanzapine, 28/186 patients were on paliperidone,
14/186 were on clozapine, 8/186 on aripiprazole, 7/186 on quetiapine
and 4/186 on amisulpride. The prevalence of hypertension and
DM among schizophrenia patients after initiation of monotherapy
antipsychotics was 5.7% (95% CI 1.9–15.4) and 5.7% (95% CI
1.9–15.4) in olanzapine, 7.5% (95% CI 3.0–17.9) and 5.5% (95% CI
1.9–14.9) in risperidone, 7.1% (95% CI 2.0–22.7) and 11.5% (95%
CI 4.0–29.0) in paliperidone, 16.7% (95% CI 3.0–56.4) of DM in que-
tiapine and 14.3% (95% CI 2.6–51.3) of DM in aripiprazole. None of
amisulpride patients developed hypertension and DM. 53.2% of
overall patients had MetS. While 83.3% in clozapine, 66.7% in que-
tiapine, 53.8% in paliperidone, 52.8% in olanzapine, 43.4% in risper-
idone and 14.3% in aripiprazole developed MetS. None of patients on
amisupride has MetS.
Conclusion : The prevalence of MetS was high among schizo-
phrenia patients treated with monotherapy atypical antipsychotics in
Malaysia. Urgent measures are needed to address the issue.
jP-08-088jDeﬁning treatment-resistant schizophrenia and
treatment response : A pragmatic proposal
T. Suzuki1, B. Mulsant2, H. Uchida3, D. Mamo2, K. Tsunoda3,
K. Watanabe3, M. Mimura3, G. Remington2. 1 Inokashira Hospital,
Tokyo, Japan ; 2Centre for Addiction and Mental Health, Toronto, Canada ;
3Keio University, School of Medicine, Tokyo, Japan
Objective : To propose a pragmatic deﬁnition on treatment-resistant
schizophrenia (TRS) and treatment response that was originated from
a critical appraisal of the currently available evidence.
Methods : The authors previously presented comprehensive re-
views on TRS and response status thereafter in TRS. They formed the
basis of our proposal, with an updated literature search.
Results : Previous studies deﬁned TRS with a failure to respond
to adequate trials with antipsychotics. Treatment response has been
deﬁned mainly with improvements in the Positive and Negative
Syndrome Scale (PANSS) or Brief Psychiatric Rating Scale (BPRS).
Other factors were somewhat variable, and the resultant response
rates diﬀered substantially across the TRS studies. Integrating
past evidence and real-world feasibility, we propose that TRS be
deﬁned by o2 failed adequate trials with diﬀerent antipsychotics
(at chlorpromazine equivalent doses of o600 mg/day for o6 con-
secutive weeks) that could be retrospective or preferably include
prospective failure to respond too1 antipsychotic trials. In addition,
our proposed criteria require both a score ofo4 on the Clinical Global
Impression (CGI)–Severity subscale and a score of f49 on the Func-
tional Assessment for Comprehensive Treatment of Schizophrenia
(FACT-Sz) or f50 on the Global Assessment of Functioning (GAF)
scales to deﬁne TRS. Once TRS is established, we propose that sub-
sequent treatment response be deﬁned based on a CGI–Change score
of f2, a o20% decrease on the total PANSS or BPRS scores, and an
increase ofo20 points on the FACT-Sz or GAF.
Conclusion : Deﬁning TRS, although challenging, is highly relevant
given its personal and societal consequences and an agreement is
desirable for the ﬁeld. We propose an adoption of the CGI (global
impression), PANSS/BPRS (classical psychopathology) and GAF/
FACT-Sz (global functioning) for this purpose. These deﬁnitions
should be further tested for reliability/validity and practicality.
jP-08-089jDeﬁciency of schnurri-2, an MHC enhancer binding
protein, induces mild chronic inﬂammation in the
brain and confers molecular, neuronal, and
behavioral phenotypes related to schizophrenia
K. Takao1, K. Kobayashi2, K. Esaki3, S. Furuya3, T. Takagi4,
N. Walton5, N. Hayashi6, H. Suzuki7, M. Matsumoto8, S. Ishii9,
T. Miyakawa10. 1NIPS, Okazaki, Aichi, Japan ; 2Nippon Medical School,
Tokyo, Japan ; 3Kyushu University, Fukuoka, Japan ; 4Aichi Prefectural
Colony, Kasugai, Japan ; 5NIPS, Skokie, USA ; 6Tokyo Institute of
Technology, Japan ; 7Tokyo, Japan ; 8Astellas, Skokie, USA ; 9RIKEN,
Tsukuba, Japan ; 10 Fujita Health University, Toyoake, Japan
Objective : Schnurri-2 (Shn-2), an NF-kB site-binding protein, tightly
binds to the enhancers of major histocompatibility complex (MHC)
class I genes and inﬂammatory cytokines, which have been shown to
harbor common variant single nucleotide polymorphisms associated
with schizophrenia. Although genes related to immunity are im-
plicated in schizophrenia, there has been no study showing that their
mutation or knock-out results in schizophrenia.
Methods :As a course of our large scale screening to identify animal
models of psychiatric disorders, Shn-2 KO mice were subjected to a
comprehensive behavioral test battery.
Results : Here, we show that Shn-2 knockout mice have behavioral
abnormalities that strongly resemble those of schizophrenics. The
mutant brain demonstrated numerous schizophrenia-related pheno-
types, including transcriptome/proteome changes remarkably
similar to those of postmortem schizophrenia patients, decreased
parvalbumin and GAD67 levels, increased theta power on electro-
encephalograms, and a thinner cortex. Dentate gyrus granule cells
failed to mature in Shn-2 knockout mice, a previously proposed
endophenotype of schizophrenia. Shn-2 mice also exhibited mild
chronic inﬂammation of the brain.
Conclusion : These results suggest that genetically-induced
changes in immune system may be a predisposing factor in schizo-
phrenia.
Policy of full disclosure : NW and MM are employees of
Astellas Research Institute of America, a subsidiary of Astellas
Pharmaceuticals, which designs pharmaceuticals for a wide variety
od diseases that may be related to this research.
jP-08-090jEﬀects of chronic exposure of cariprazine on
dopamine receptor subtypes
F. Tarazi1, Y.K. Choi1, N. Adham2, B. Kiss3, I. Gyertya´n4. 1Harvard
Medical School, Belmont, USA ; 2Forest Research Institute, Jersey City,
USA ; 3G. Richter Plc., Budapest, Hungary ; 4Pharmacological and Safety
Research, Budapest, Hungary
Objective : Cariprazine is a dopamine D3-preferring D3/D2 receptor
partial agonist in development for the treatment of schizophrenia and
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bipolar mania. Long-term eﬀects of cariprazine on expression of
dopamine (DA) receptor subtypes in adult rat brain regions were
quantiﬁed to determine regionally selective changes in tissue levels of
DA receptors.
Methods : Rats (n=8) received vehicle control (1 ml/kg/d) or car-
iprazine (0.06, 0.2, or 0.6 mg/kg) administered intraperitoneally for
28 days. Brains were collected and dopamine receptor autoradio-
graphic assays were performed on tissues from multiple regions.
Mean values of nonspeciﬁc binding in each region were subtracted
from the corresponding mean total binding to determine speciﬁc
radioligand binding expressed as fmol bound/mg tissue ; 2-way
analysis of variance (ANOVA) analyzed overall changes across treat-
ments and brain regions.
Results : Repeated treatment with cariprazine failed to alter levels
of DA D1 receptors in all brain regions examined. Cariprazine 0.2 and
0.6 mg/kg dose-dependently increased D2 receptor concentrations
in medial prefrontal cortex (27% and 43%, respectively), nucleus ac-
cumbens (40% and 45%), medial (41% and 53%) and lateral caudate
putamen (52% and 63%) ; 0.06 mg/kg had no eﬀect. Quantiﬁcation
of D3 receptors using [3H]7-OH-DPAT showed that cariprazine 0.06,
0.2, and 0.6 mg/kg increased D3 receptor binding in olfactory tubercle
(27%, 49%, and 67%) and Islands of Calleja (32%, 41%, and 57%) ;
more increases in D3 receptor levels were also detected using the
D3-preferring radioligand [3H]PHNO particularly in nucleus ac-
cumbens. Cariprazine (0.06, 0.2, and 0.6 mg/kg) increased D4 re-
ceptors in hippocampus (38%, 71%, and 98%).
Conclusion : Long-term administration of cariprazine induced
regional and dose-dependent changes in DA receptor subtypes in
diﬀerent rat forebrain regions. Most changes were similar to other
second generation antipsychotics ; only cariprazine, and not any other
antipsychotic agent, increased abundance of forebrain D3 receptors.
These ﬁndings support the unique psychopharmacological properties
of cariprazine.
Policy of full disclosure : Supported by funding from Forest
Laboratories, Inc.
jP-08-091jEﬀect of blonanserin on cognitive function in
antipsychotic-naı¨ve ﬁrst-episode schizophrenia
T. Tenjn1, S. Miyamoto1, N. Miyake1, S. Ogino1, R. Kitajima1,
K. Ojima1, Y. Kaneda2, T. Sumiyoshi3, N. Yamaguchi1. 1St. Marianna
Univ. Sch. of Med., Kawasaki City, Japan ; 2 Iwaki Clinic, Department of
Psychiatry, Anan City, Tokushima, Japan ; 3University of Toyama,
Department of Neuropsychiatry, Toyama City, Japan
Objective : Cognitive impairment is a core feature of schizophrenia
and is present early in the course of the illness. The purpose of this
study was to evaluate the short-term eﬀects of blonanserin, a novel
second-generation antipsychotic drug developed in Japan in 2008, on
cognitive function in ﬁrst-episode schizophrenia.
Methods : Twenty-four antipsychotic-naı¨ve patients with ﬁrst-
episode schizophrenia participated in the study. Blonanserin
(2–24 mg/day) was given in an open label design for 8 weeks. The
Brief Assessment of Cognition in Schizophrenia (BACS-J) was ad-
ministered as the primary outcome measure at baseline and 8 weeks.
Clinical evaluation included the Positive and Negative Syndrome
Scale (PANSS), the Schizophrenia Quality of Life Scale (SQLS-J), and
the Clinical Global Impression-Severity of Illness Scale (CGI-S). To
exclude the possibility of retest eﬀects on the BACS-J, 10 age-matched
patients with chronic schizophrenia treated with blonanserin were
tested at baseline and after an 8-week interval. This study protocol
was approved by the bioethics committee of St. Marianna University
School of Medicine, and written informed consent was received from
all participants.
Results : Twenty ﬁrst-episode patients (10 males and 10 females)
completed the study. The mean daily dose of blonanserin was
7.2¡4.0 mg/day at 8 weeks. At the 8-week endpoint, repeated
measures analysis of covariance revealed a signiﬁcant group-by-time
interaction eﬀect on the letter ﬂuency task due to better performance
in the ﬁrst-episode group, but not in the control group. Main eﬀect of
time or group-by-time interaction eﬀect on the Tower of London task
was not signiﬁcant ; however, the ﬁrst-episode group, but not control
group showed substantial improvement with a moderate eﬀect size.
All items on the PANSS, SQLS-J, and CGI-S signiﬁcantly improved
after 8 weeks of treatment.
Conclusion : These results suggest that blonanserin improves
some types of cognitive function associated with prefrontal cortical
function.
Policy of full disclosure : Dr. Miyamoto has served as a consultant
for Dainippon Sumitomo Pharmaceutical. He has received advisory
board honoraria from Chugai Pharmaceutical. No other authors have
any conﬂicts of interest with any commercial or other associations in
connection with this study.
jP-08-092jCuprizone early deﬁcits accompanied by speciﬁc
glial activation implicate pathophysiological
changes in schizophrenia
T. Tezuka1, M. Tamura1, M. Kondo2, M. Sakaue1, K. Okada1,
K. Takemoto1, A. Fukunari1, H. Yasumatsu1, S.-I. Kano2, A. Sawa2,
Y. Kajii1. 1Mitsubishi Tanabe Pharma Corp., Yokohama, Japan ;
2Department of Psychiatry, Johns Hopkins University, Baltimore, USA
Objective : Despite an apparent lack of demyelination, a growing
body of clinical evidence suggests that abnormalities in white matter
are involved in pathophysiology of schizophrenia. A copper chelator,
cuprizone, is known to induce damage on rodent oligodendrocytes
when it is ingested with food for several weeks. Here we exposed
mice to cuprizone for only one week to model the mild glial damage
observed in schizophrenia.
Methods : C57BL/6J mice were given a diet containing 0.2%
cuprizone for one week and examined for behavioral and molecular
consequences. In addition to locomotor response to psychotomimetic,
Y-maze and novel object recognition tests were performed as behav-
ioral readouts. Expression levels of glial markers and cytokines were
investigated by immunohistochemical staining, in situ hybridization
and quantitative RT-PCR.
Results : Surprisingly, such short-term exposure to cuprizone was
enough to augment responsiveness to both methamphetamine and
MK-801, and also impaired memory function. In the cuprizone mice,
mRNA expression levels of astroglial (Glial ﬁbrillary acidic protein,
GFAP) and microglial (ionized calcium binding adaptor molecule 1,
Iba1) markers were elevated, while the one-week cuprizone treatment
substantially reduced mRNA expression of the oligodendrocyte mar-
ker (myelin basic protein, MBP) without any apparent change in MBP
immunohistochemical staining. Interestingly, a proinﬂammatory
cytokine, Interleukin 6 (IL6), was prominently induced in the hippo-
campus, and the induction was almost exclusively in astrocytes.
Conclusion : The behavioral deﬁcits elicited by short-term
cuprizone exposure showed similarities to schizophrenia and were
accompanied by speciﬁc glial activation predominantly in the hippo-
campus.
jP-08-093jMedication in schizophrenia with frequent relapses
C. Touloumis1, P. Ntounas1, C. Tsopelas1, D. Pappas1, M. Dimitraka1,
C. Mokas1, D. Dimitriadis1, P. Chatzimanolis1, A. Konsta2, E. Rizos3,
A. Douzenis3, S. Stamou4, S. Dimaki4, A. Vasiliou4,
A. Paraskevopoulou4, I. Gogolakis4, C. Marmarinou4, E. Siouti4.
1Psychiatric Hospital of Attica, Athens, Greece ; 21st Dept. of Psychiatry,
Aristotle University of Thessaloniki, Greece ; 32nd Dept. of Psychiatry,
National and Kapodistrian, Athens, Greece ; 4Psychiatric Hospital of
Attica, Athens, Greece
Objective : A signiﬁcant percentage of people with mental health
disorders need a long-standing care in psychiatric and social institu-
tions, or else they are relapsing and have increased number of hospital
admissions. Ten per cent of the patients with schizophrenia have fre-
quent relapses and long hospitalizations. The aim of the present work
was to study patients with a history of multiple hospitalizations,
to ﬁnd possible aggravating factors and to study the antipsychotic
therapy they received (monotherapy or polypharmacy).
Methods : The participants (305 patients) were randomly selected
among the hospitalized patients of the 9 acute admission departments
of PHA (Psyhiatric Hospital of Attica ). For the statistical analysis, the
program SPSS was used.
Results : The participants (305 patients) : average age of 44.3 years
old (SD=13.2), 68.2% men, 74.8% involuntary hospitalized, 7.9% on
ﬁrst episode, age onset of the disease 27.2 years old (SD=10.9), 18.7%
with illegal substance abuse, cessation of drug therapy before
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admission in 64.3%, and 89.8% showed thought disorder and only
54.8% perception disorder, 70.1% showed aggression, 25.2% were
administered more than one antipsychotic at admission with 7.2%
receiving long acting medications. After 3 weeks, 41.5% were on more
than one antipsychotic. There was no statistically signiﬁcant diﬀer-
ence regarding the use of multiple drugs in patients with multiple
admissions (over 5) compared to the rest of them.
Conclusion : Antipsychotic polypharmacy has been found to re-
duce the treatment compliance and to increase the relapses and the
mortality compared to antipsychotic monotherapy, but it remains a
usual practice which persists despite the doubtful clinical outcomes.
jP-08-094jThe eﬀect of antipsychotics on GABAergic
interneurogenesis in adult brain
W. Ukai1, H. Kaneta1, E. Hashimoto1, T. Igarashi1, T. Shirasaka1,
Y. Kigawa1, K. Watanabe1, T. Yoshinaga1, M. Tateno1, T. Ishii1,
T. Saito1. 1Sapporo Medical University, Japan
Objective : Patients with schizophrenia display cognitive, behavioral
disturbances and morphological abnormalities which might be
caused by the progressive neurodegeneration. Although the mech-
anism of neurodegeneration in schizophrenia is still unclear, one of
the current hypothesis focused on the relation to the altered GABA
neurotransmitter system and density of GABA interneurons. In the
previous study, we investigated the eﬀect of recently developed
atypical antipsychotics on the neural stem cell (NSC) function change
especially focusing on the neuronal diﬀerentiation prepared from
rat embryos. The atypical antipsychotics have shown the suppressive
eﬀects on the non competitive NMDA receptor antagonist MK-801-
induced inhibition of NSC diﬀerentiation to neurons, indicating that
atypical antipsychotic-induced alteration of neurogenesis could con-
tribute to the neural network repair impaired in the schizophrenic
brain.
Methods : In the present work, we examined the eﬀect of atypical
antipsychotics against MK-801/GABAA antagonist-induced impair-
ment of NSC diﬀerentiation to neurons those considered parallel ob-
servations in the pathophysiology of schizophrenia, using cultured
adult hippocampal and subventricular zone (SVZ)-derived NSCs, and
analyzed its diﬀerentiation of GABAergic interneuron subtypes, such
as somatostation, parvalbumin, and calretinin.
Results : Several antipsychotics suppressed the MK-801/GABAA
antagonist-induced inhibition of neuronal diﬀerentiation of adult
NSCs. Their promotions of each GABAergic subtype diﬀerentiation
was diﬀerent among tested antipsychotics.
Conclusion : The results suggested that the increase of adult inter-
neurogenesis by antipsychotic might be involved in the mechanism
of recovering of the neural network change in schizophrenia and the
diﬀerent proportion of each antipsychotic-induced cell phenotype
diﬀerentiation of NSCs might relate to its characteristic of clinical
eﬃcacy in the treatment of schizophrenia.
jP-08-095jAmineptine treatment of chronic catatonia :
A controlled study
G. Ungvari1, G. Gazdag2. 1Univ. of Notre Dame Australia, Perth,
Australia ; 2Consultation-Liaison Service, Szent Laszlo Hospital, Budapest,
Hungary
Objective : Data on the treatment response of catatonic phenomena
accompanying chronic schizophrenia are limited. The objective of this
study was to explore the therapeutic eﬀects of add-on amineptine, a
dopamine agonist antidepressant in chronic catatonic schizophrenia.
Methods : Fifteen subjects with DSM-IV schizophrenia with
persistent catatonic features underwent a 15-week, double-blind,
placebo-controlled cross-over trial ; 6 weeks each for amineptine and
placebo with a 3-week wash-out period in-between. The primary
outcome measure was the sum score of the Bush-Francis Catatonia
Rating Scale. Changes in psychopathology and extrapyramidal side
eﬀects (EPS) constituted the secondary outcome measures.
Results : Amineptine augmentation of pre-existing antipsychotic
treatment had no appreciable eﬀect on catatonia ratings. Apart form
a statistically signiﬁcant but clinically negligible improvement of
negative symptoms scores, there were no changes in the psychopath-
ology and EPS ratings.
Conclusion : The lack of therapeutic eﬀects of the dopamine agonist
amineptine on persistent catatonia suggests that the dopaminergic
system may not have a decisive role in the pathophysiology of cata-
tonic syndrome associated with chronic schizophrenia.
jP-08-096jSurvey of prescription for 2nd generation
antipsychotics in inpatients with schizophrenia in
Japan : A nationwide multiple-center survey on
prescriptions in 2010
J. Uno1, T. Kato2, T. Hasegawa3, M. Kurosawa4, K. Umeda5, T. Miwa6,
Y. Noda7, M. Tensho8, T. Yoshio9. 1Okehazama Hospital, Toyoake,
Aichi, Japan ; 2Tokorozawa Jikou Hospital, Tokorozawa, Saitama, Japan ;
3St. Mary Memorial Hospital, Narita, Chiba, Japan ; 4Seinan Hospital,
Hachinohe, Aomori, Japan ; 5Matsuyama Memorial Hospital, Matsuyama,
Ehime, Japan ; 6Yuge Hospital, Kumamoto, Kumamoto, Japan ; 7Meijo
University, Nagoya, Aichi, Japan ; 8Hokuto Clinic Hospital, Osaka, Osaka,
Japan ; 9Toho University, Funabashi, Chiba, Japan
Objective : Comprised mainly of pharmacists engaged in psychiatric
care in Japan, the Psychiatric Clinical Pharmacy Research Group
(PCP Research Group) has been conducting nationwide studies on
survey of prescription drugs on a continual basis since 2005, in order
to understand the current state of pharmaceutical therapy in in-
patients with schizophrenia. This article reports the study results of
2010 (n=25.346) from a view point of prescription 2nd generation
antipsychotics (SGAs).
Methods : Among the schizophrenic patients (ICD-10 : F20) hospi-
talized at one of the psychiatric clinics to which members of the PCP
Research Group belonged, the names of drugs and doses were studied
for the prescription given on the day of October in 2010, for the fol-
lowing types of drugs : antipsychotics, antiparkinsonians, anxiolytics/
hypnotics, and mood stabilizers.
Results : The mean number and dose of drugs prescribed per day
were 2.0 drugs at 802.8 mg/day (CP equivalents) for antipsychotics,
0.7 drugs and 1.9 mg/day (BP equivalents) for antiparkinsonians,
and 1.5 drugs at 15.0 mg/day (DAP equivalents) for anxiolytics/
hypnotics. The rates of prescriptions of 1st generation antipsychotics
(FGAs) were 58.2%, and that of SGAs were 84.0%, and the rates of
monotherapy of each were 6.1% and 30.4%, respectively. The rates
of concomitant therapy with SGAs were 33.7% for antiparkinsonians,
70.5% for anxiolytics/hypnotics, and 28.3% for mood stabilizers, re-
spectively.
Conclusion : While the rates of prescription of SGAs have reached
84.0% of all prescriptions, the rates of monotherapy are limited in
30.4% and they are often used in combination with FGAs. It is sug-
gested that pharmacists engaged in psychiatric care should actively
commit themselves as a professional of drugs to ensuring appropriate
prescriptions in order to get maximum merits of SGAs, and hence
improved adherence in patients.
jP-08-097jPharmacological treatment of schizophrenia and
schizoaﬀective disorder – focused on combinations
of antipsychotics
L. Ustohal1, R. Prikryl1, H. Prikrylova Kucerova1, M. Vrzalova2,
T. Kasparek1, E. Ceskova1, I. Stehnova2. 1CEITEC-MU, Faculty of
Medicine, Brno, Czech Republic ; 2Faculty of Medicine, Brno, Czech
Republic
Objective : Acute treatment of schizophrenia and schizoaﬀective
disorder is often carried out during hospitalization and its most
important role is based on psychopharmacs, especially antipsychotics
of the second generation. The most convenient is monotherapy but in
clinical practice it is sometimes not possible.
Methods : The aim of our retrospective study was to focuse on
pharmacotherapy, especially combinations of antipsychotics, in our
inpatients treated for schizophrenia or schizoaﬀective disorder during
one-year period. Data were collected from medical records of in-
patients treated for schizophrenia or schizoaﬀetive disorder at the
Department of Psychiatry in Brno, Czech Republic, during one-year
period. We focused on therapy before patients´discharge.
Results : During one-year period we treated 87 inpatients with
schizophrenia (F20 according to ICD-10) and 35 inpatients with
schizoaﬀective disorder (F25). One antipsychotic drug was used for
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the treatment of 58.6% patients with schizophrenia and 74.29%
patients with schizoaﬀective disorder. Two antipsychotic drugs were
used in the treatment of 36.78% patients with schizophrenia and
17.14% with schizoaﬀective disorder. Three antipsychotic drugs were
used in the treatment of 4.60% patients with schizophrenia nad
2.86% with schizoaﬀetive disorder. Remaining 5.71% patients with
schizoaﬀetive disorder were without antipsychotic medication, but no
patient with schizophrenia. The most often combinations were :
clozapine+amisulpride, clozapine+haloperidol and clozapine+
aripiprazole. Mood stabilizers were used in 13.79% patients with
schizophrenia and 45.71% patients with schizoaﬀective disorder.
Antidepressants were used in 4.60% patients with schizophrenia and
17.14% patients with schizoaﬀective disorder.
Conclusion : In our retrospective study we found out, that
most patients with schizophrenia and schizoaﬀective disorder are
treated with one antipsychotic. Combinations were especially used
in patients with treatment resistance, who are even resistant to
monotherapy with clozapine. Just clozapine was very often combined
with other antipsychotics, especially with amisulpride, haloperidol
or aripiprazole.
Policy of full disclosure : This work was supported by the project
‘‘CEITEC – Central European Institute of Technology’’ (CZ.1.05/
1.1.00/02.0068) from European Regional Development Fund.
jP-08-098jCognitive eﬀects of an anticholinergic challenge in
healthy volunteers and drug-free patients with
schizophrenia
T. Veselinovic1, I. Vernaleken1, H. Janouschek1, G. Gru¨nder1. 1RWTH
Aachen University, Germany
Objective : The importance of the cholinergic neurotransmission for
cognitive processes is very well established. However, its role in the
pathogenesis of schizophrenia is still not suﬃciently explored. The
purpose of this study was to investigate the eﬀects of an antic-
holinergic challenge on cognition and attention in unmedicated
patients with schizophrenia and healthy controls.
Methods : 12 medication-free patients with schizophrenia
(29.3¡8.8 years) and 12 healthy controls (29.8¡9.6 years) were in-
cluded. Psychopathology and cognitive performance were assessed
twice : at baseline and after administration of a single dose of the
subtype-nonselective acetylcholine receptor antagonist biperiden
(5 mg intravenously). The following scales/tests were used : PANSS,
Trail Making Test A and B (TMT-A/B), Regensburg Verbal Fluency
Task (RWT), Digit Span from the Wechsler Memory Scale, Letter-
Number Span, Digit-Symbol-Substitution Task and Continous
Performance Task- Identical Pairs version (CPT-IP).
Results : In almost all tests patients performed worse than controls
in both conditions. Biperiden impaired the performance in the ma-
jority of the tests in both groups. Using a repeated measures ANOVA
we found a statistically signiﬁcant time*group interaction concerning
the TMT-B (p=0.03), indicating a more pronounced impairment in
patients than in controls. Analyzing the parameters verbal and spatial
d-prime from the CPT-IP we found an eﬀect that did not achieved
statistical signiﬁcance (p=0.078 resp. p=0.074). These results point to
a slight improvement in attentional capacity in controls but not in
patients. In the RWT the number of generated words after biperiden
challenge increased in controls but not in patients (time*group inter-
action in phonemic category change : p=0.016). The score increase
showed a signiﬁcant positive correlation with the observed increase in
PANSS score in controls (r=0.688, p=0.019).
Conclusion : Our results indicate a complex inﬂuence of anti-
cholinergic intervention on diﬀerent cognitive domains. The diﬀer-
ences between controls and patients point to alternations in
cholinergic systems in schizophrenia.
Policy of full disclosure : Dr. Veselinovic has received grant sup-
port from Bristol-Myers Squibb. Dr. Vernaleken has served on
the speakers’ bureau of Bristol-Myers Squibb, Eli Lilly, and
GlaxoSmithKline. Dr. Gru¨nder has served as a consultant for
AstraZeneca, Bristol-Myers Squibb, Cheplapharm, Eli Lilly, Johnson
& Johnson, Lundbeck, Otsuka,and Servier. He has served on the
speakers’ bureau of Astra Zeneca,Bristol-Myers Squibb, Eli Lilly,
Janssen Cilag, Otsuka, Pﬁzer, Servier, and Wyeth. He has received
grant support from Alkermes, Bristol-Myers Squibb, Eli Lilly, and
Johnson & Johnson. He is co-founder of Pharma-Image – Molecular
Imaging Technologies GmbH, Du¨sseldorf, Germany. Dr. Janouschek
declares no conﬂicts of interest.
jP-08-099jNeeds and QoL in schizophrenic hospitalized
patients treated with risperidone or haloperidol
D. Vukic1, N. Djokic1. 1Special Hospital for Psychiatric Diseases, Gornja
Toponica Nish, Serbia
Objective :Objective of this research is a discovery of the diﬀerence in
most common needs and the QoL between groups of male paranoid
schizophrenic hospitalized patients treated with risperidone or halo-
peridol.
Methods : Patients are classiﬁed in accordance with the diagnostic
criteria of ICD X classiﬁcation. First group of 20 patients was treated
with risperidone in a dose of 2 mg to 6 mg. Second group of 20
patients was treated with haloperidol in a dose of 5 mg to 15 mg.
Sample of paranoid schizophrenic patients were evaluated with the
Camberwell Assessment of Need and the Lancashire Quality of
Life Proﬁle two months after admission to hospital treatment. Brief
Psychiatric Rating Scale was used to assess the strength of psycho-
pathological phenomena at the time of application of CAN and
LQOLP questionnaires. Research results obtained are processed using
standard statistical methods.
Results : Patients treated with risperidone showed signiﬁcantly
higher subjective and objective quality of life in section of leisure &
community participation and section of social relations. The same
group of patients showed not signiﬁcantly higher subjective quality
of life in section of religion and section of family relations. Most often
detected needs in the areas of accommodation, daytime activities,
company, intimate relationships and sexual expression. Patients
treated with haloperidol showed signiﬁcantly higher mean number of
unmet needs.
Conclusion : The results of this study indicate that risperidone may
contribute to the socialization of male paranoid schizophrenic patients
two months after admission to hospital treatment. Risperidone may
also contribute to reducing unmet needs.
jP-08-100jDaytime sleepiness and activity-rest rhythms in
patients with schizophrenia during treatment with
sedative and non-sedative antipsychotics
A. Wichniak1, A. Wierzbicka2, E. Waliniowska2, T. Jakubczyk2,
I. Musinska2, K. Czasak2, L. Wolkow2, W. Jernajczyk2, M. Jarema1.
1 Insitute of Psychiatry and Neurology, Third Department, Warsaw,
Poland ; 2 Institute of Psychiatry and Neurology, Department of Clinical
Neuroph., Warsaw, Poland
Objective : Antipsychotics have variable eﬀects on sleep and day-
time sleepiness. The study was aimed to assess daytime sleepi-
ness, sleep quality, and activity-rest rhythms in patients with
schizophrenia during treatment with sedative and non-sedative anti-
psychotics.
Methods : Hundred seventeen patients with paranoid schizo-
phrenia (67 males, 50 females, mean age 27.4¡6.9) were assessed with
the use of the wrist actigraphy (Cambridge Neurotechnology AW4)
throughout seven consecutive days. Daytime sleepiness was assessed
with Epworth Sleepiness Scale (ESS), Athens insomnia scale (AIS),
and sleep diaries were used for assessment of sleep quality. Analysis
of variance (ANOVA) was used to test the diﬀerences between the
patients and 40 healthy controls (HC) (20 males, 20 females, mean
age 28.5¡7.4) and between groups of patients with following mono-
therapy treatment options : aripiprazole n=13, olanzapine n=40,
risperidone n=20, sertindole n=17. As the groups were not matched
for gender the diﬀerences are reported separately for males and
females.
Results : Male patients had longer time in bed (TIB) (p<0.001),
longer total sleep time (TST) (p<0.001), lower average 24 h-activity
(p<0.005) and lower daytime activity (p<0.05) than male HC. Female
patients showed longer TIB (p<0.001), longer sleep latency (p<0.01),
longer TST (p<0.001), lower 24 h-activity (p<0.001), and lower day-
time activity (p<0.001) than female HC. Treatment with olanzapine
and risperidone was related to longer TIB, longer TST, and higher
sleep eﬃciency than treatment with aripiprazole and sertindole
(p<0.05). The kind of antipsychotic treatment did not have signiﬁcant
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eﬀects on average 24 h-activity and daytime activity. No signiﬁcant
diﬀerences were also found in AIS and ESS.
Conclusion : Patients with schizophrenia diﬀered from HC in nu-
merous parameters assessed with wrist actigraphy. The treatment
with sedative antipsychotics prolonged TIB and TST, but the physical
activity of the patients was low both during treatment with sedative
and non-sedative antipsychotics in comparison to the HC.
jP-08-101jValproic acid normalizes abnormal cellular
proliferation, transcriptional changes and
schizophrenia-related behaviors in Disc1 mutant
mice
A. Wong1, T. Lipina2, N. Haque1, A. McGirr2, L. Mesbah-Oskui2,
P. Boutros3, J. Roder4. 1CAMH, Toronto, Canada ; 2Samuel Lunenfeld
Research Inst, Mount Sinai Hospital, Toronto, Canada ; 3OICR, Toronto,
Canada ; 4CAMH, Samuel Lunenfeld Research Inst, Toronto, Canada
Objective : Disrupted-In-Schizophrenia-1 (DISC1) is an established
risk gene for schizophrenia. We sought to test potential preventative
treatments in Disc1-L100P mutant mice, an animal model with
schizophrenia-related behaviours.
Methods : We tested whether early valproate treatment would
prevent behavioral abnormalities in Disc1-L100P mutants by counter-
acting aberrant expression of some genes, thereby normalizing brain
development.
Results : Treatment with valproate before the onset of behavioral
impairments in Disc1-L100P mutants corrected hyperactivity, and
deﬁcits in prepulse inhibition and latent inhibition. Disc1-L100P mu-
tants also had increased glial cell proliferation in the subventricular
zone, which was normalized by valproate pre-treatment. Genome-
wide transcription proﬁling showed that the Disc1-L100P mutation
induced the largest changes in hippocampus, and some transcript
changes were reversed by valproate.
Conclusion : Valproate treatment in adolescence may represent
a type of preventative intervention for patients at risk for schizo-
phrenia.
jP-08-102jAssociation study of phencyclidine-responsive
synapse-associated protein 97 (SAP97) gene in
schizophrenia
N. Yamamoto1, A. Uezato1, J. Sato-Kimura1, E. Haramo1, D. Jitoku1,
M. Umino1, A. Umino1, A. Kurumaji1, Y. Iijima2, H. Kunugi2,
T. Nishikawa1. 1Tokyo Medical and Dental University, Japan ; 2National
Inst Neuroscience, NCNP, Kodaira, Japan
Objective : Disturbed neurotransmission via NMDA type glutamate
receptor is thought to be involved in some molecular mechanisms
of positive, negative and cognitive symptoms of schizophrenia. The
synapse-associated protein 97 (SAP97)/discs large (DLG1) gene
encodes the synaptic scaﬀolding PDZ protein, which interacts with
ionotropic glutamate receptors including the AMPA and NMDA re-
ceptors, and has been suggested to relate to the neural basis of the
puberty-associated onset of schizophrenia and the NMDA antagonist
psychosis : SAP97 mRNA expression is upregulated by phencyclidine
(PCP) in the neocortex only after a critical period for the development
of a PCP-induced animal model for these psychoses in the rat. Human
SAP97 gene is located in chromosome 3q29. In this study, we aimed to
investigate possible association between the SAP97 gene and schizo-
phrenia.
Methods : We genotyped total 23 SNPs capturing the known com-
mon haplotype variations of the SAP97 gene in the samples from
schizophrenic patients and healthy controls. The study was approved
by the ethics committees of the institutes. All participants gave in-
formed and written consent to participate in the study.
Results : In a single marker analysis, ten SNPs displayed nominally
signiﬁcant association with schizophrenia, although the p-values of
these SNPs were not signiﬁcant after the Bonferroni correction. We
also compared haplotype estimates based on case-control genotypes
and observed signiﬁcant association of eight two- and three- SNP
haplotypes with schizophrenia following permutation-based correc-
tion. Further examination of the above series of SNPs or haplotypes in
each gender revealed signiﬁcant associations between some of these
SNPs or haplotypes and the disorder only in males.
Conclusion : The present ﬁndings suggest that the SAP97 gene may
be a susceptibility factor in male schizophrenics. The modiﬁcation of
the glutamate receptors-SAP97 protein signaling and/or the receptor
traﬃcking might be involved in some of the etiology of schizophrenia
and other psychoses.
jP-08-103jThe satisfaction improved after switching to
pariperidone ER mono-therapy among Japanese
patients with schizophrenia
Y. Yamanouchi1, N. Iwata2. 1Fujita Health University Japan, Toyoake,
Aichi, Japan ; 2Fujita Health University Japan, Psychiatry, Toyoake, Aichi,
Japan
Objective : Medication adherence is an important thing for con-
tinuation of schizophrenia medical treatment. The patient itself has
satisfaction is important, in order to continue medical treatment and
prevent a recurrence. The Pariperidone ERwhich put on the market in
Japan in 2010 is expected stable blood concentration by OLOS system.
This may aﬀect to reduce the instability of symptoms or side eﬀects,
therefor may improve adherence. We investigated the patients’ satis-
faction by switching to Pariperidone ER mono therapy in Japanese
patients with schizophrenia.
Methods : Design : A 24-weeks, open trial. This study approved by
ethical committee in Fujita Health University. Setting : Inpatient
(N=34) and outpatient (N=87) at eleven hospitals in Japan.
Participants : Written informed consent patients with schizophrenia
(N=121) age 20–78. Investigations : Switching to Pariperidone ER
mono therapy and assessed GAF, CGI, side eﬀects and satisfaction
scale (POM) from patient and family in 0, 4, 12 and 24 week.
Results : Former antipsychotics were Risperidone (N=82),
Olanzapine (N=11), Aripiprazole (N=9) and others (N=19). 109
patients completed 24 weeks. The median of CGI score changed from
4 to 3, the average GAF score changed from 42.7 to 59.9 and the me-
dian of patients’ POM changed from ‘‘ little well ’’ to ‘‘well ’’. And the
EPS decreased among the study period.
Conclusion : We conﬁrmed the Pariperidone ER mono therapy
improved not only patients’ symptoms but also satisfaction. This
therapy expected to improve patients’ QOL and reduce the distress
among the life with schizophrenia.
Policy of full disclosure : Janssen Pharmaceutical K.K.
jP-08-104jCigarette smoking in male patients with chronic
schizophrenia in a chinese population : Prevalence
and relationship to clinical phenotypes
X. Zhang1, D. Chen1, M. Xiu1, T. Kosten2. 1Beijing HuiLongGuan
Hospital, China ; 2Baylor College of Medicine, Houston, USA
Objective : A signiﬁcantly high prevalence of smoking in schizo-
phrenia may be linked to reduced clinical symptoms and side eﬀects
in subjects of European background. The aims of the present study
were to examine the prevalence of smoking and its associations with
clinical phenotypes in Chinese patients with schizophrenia, who were
less well characterized than other populations.
Methods : The smoking prevalence and behaviors were evaluated
by clinician-administered questionnaires and the Fagerstrom Test for
Nicotine Dependence (FTND) in 776 male patients with schizophrenia
and 560 control subjects. Patients also were rated on the Positive and
Negative Symptom Scale (PANSS), the Simpson and Angus
Extrapyramidal Symptom Rating Scale (SAES), and the Abnormal
Involuntary Movement Scale (AIMS).
Results : Our results showed that compared to normal controls,
patients had higher lifetime incidence of smoking (79% vs. 63%), and
were more likely to be heavy smokers (61% vs. 31%), but had lower
smoking cessation rates (4% vs. 9%) (all p<0.0001). In schizophrenia
patients, the prevalence of smoking increased with age, with the par-
ticularly greater prevalence than controls in age cohorts of 55–75
years : 75% vs. 46% (p<0.0001). Of the smokers with schizophrenia,
73% started to smoke an average of 7.6 years before the onset of their
illness. Current smokers scored signiﬁcantly lower on the PANSS
negative symptom subscore (p<0.005), and on the SAES symptom
scale (p<0.04 ; Bonferroni corrected p>0.05), compared to non-
smokers in patients.
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Conclusion : These results suggest that male schizophrenia patients
of Chinese descent smoke more frequently than the general popu-
lation. Further, smokers with schizophrenia may display fewer nega-
tive symptoms and, possibly less parkinsonism than non-smokers
with schizophrenia.
jP-08-105jCognitive and serum BDNF correlates of BDNF
Val66Met gene polymorphism in patients with
schizophrenia and normal controls
X. Zhang1, D. Chen1, M. Xiu1, T. Kosten2. 1Beijing HuiLongGuan
Hospital, China ; 2Baylor College of Medicine, Houston, USA
Objective : Studies suggest that the functional polymorphism of
brain-derived neurotrophic factor gene (BDNF Val66Met) may
mediate hippocampal-dependent cognitive functions. Few studies
have reported its role in cognitive deﬁcits in schizophrenia and
whether peripheral BDNF levels may be useful to assess cognitive
measures in schizophrenia.
Methods : Six hundred and ﬁfty-seven schizophrenic inpatients and
445 healthy controls were included in this study. Performance on the
Repeatable Battery for the Assessment of Neuropsychological Status
(RBANS), presence of the BDNF Val66Met polymorphism and serum
BDNF levels were compared between groups. Patient psychopath-
ology was assessed using the Positive and Negative Syndrome Scale
(PANSS).
Results : Our results showed that visuospatial/constructional
abilities signiﬁcantly diﬀered by genotype but not genotyper
diagnosis, and the Val allele was associated with better visuospatial/
constructional performance in both schizophrenia patients and
healthy controls. On attention performance, there were signiﬁcant
genotype and genotype by diagnosis eﬀects. Met allele-associated
attention impairment was speciﬁc to schizophrenia patients but not
healthy controls. In patient group, partial correlation analysis showed
a signiﬁcantly positive correlation between serum BDNF and the
RBANS total score. Furthermore, BDNF levelsrgenotype interaction
on RBANS total score was statistically signiﬁcant.
Conclusion : Our ﬁndings demonstrate the association between the
BDNF Met variant and poor visuospatial/constructional perform-
ance. Furthermore, the BDNF Met variant may be speciﬁc to atten-
tional decrements in schizophrenic patients. The association between
decreased BDNF serum levels and cognitive impairment in schizo-
phrenia is dependent on the BDNF Val66Met polymorphism.
P-09. Antidepressants
jP-09-001jAntidepressant-like activity of water-soluble
curcumin formulations in behavioral paradigms
of despair
K. Akula1, J. Deshpande2, S. Kulkarni3. 1Legacy Research, Portland,
USA ; 2OmniActive Health Technologie, Thane, Mumbai, India ; 3Panjab
University, University Institute of Pharma, Chandigarh, India
Objective : Curcumin is the active principle of Curcuma longa, one
of the widely used components in traditional system of medicine
in India. Despite its eﬃcacy in experimental studies aiming
neuronal disorders like depression, curcumin’s poor water solubility
challenges its therapeutic formulations. This study investigates the
antidepressant-like activity of novel water soluble curcumin for-
mulations, dispensed in three diﬀerent concentration levels. Further,
the study comparatively evaluates St. John’s Wort (SJW), another
herbal preparation.
Methods : These compounds were evaluated in the forced swim-
ming test in mice and the corresponding changes in the neuro-
transmitter levels were measured.
Results : Three water soluble curcumin formulations, C-5, C-20,
C-50 (50–200 mg/kg, p.o.) decreased the immobility period, increased
serotonin and dopamine levels in the brain tissues. A sub-eﬀective
dose (50 mg/kg) of these formulations enhanced the antidepressant-
like eﬀect of various antidepressant drugs like desipramine (tricyclic
antidepressant), ﬂuoxetine (selective serotonin reuptake inhibitor
(SSRI)] or venlafaxine [dual (5-HT and NE) reuptake inhibitor
(SNRI)]. However, no signiﬁcant change in the anti-immobility eﬀect
with tranylcypromine (non-selective MAO inhibitor) was observed.
In addition, 25 mg/kg dose of SJW showed signiﬁcant antidepressant-
like eﬀect in all the behavioral studies and also signiﬁcantly increased
brain neurotransmitter levels, especially that of serotonin.
Conclusion : The eﬀects produced by C-5 were comparable with
that of SJW and ﬂuoxetine, respectively. Besides, in all these ob-
servations the water soluble formulation, C-5 showed signiﬁcant
antidepressant-like eﬀect, including enhancement of neurotransmitter
levels as compared to the similar dose of conventional curcumin
preparation. Thus, this formulation may be a novel treatment option
in the management of mental depression.
jP-09-002jTranscriptional modulation of serotonin transporter
as a new antidepressant strategy
F. Artigas1, A. Ferre´s-Coy2, F. Pilar-Cuellar3, R. Vidal4, R. Corte´s5,
M. Masana5, E. Valdiza´n4, A. Pazos4, A. Bortolozzi5. 1CSIC, Depart. of
Neurochemistry and, Barcelona, Spain ; 2 IIBBc-CSIS – IDIBAPS, Depart.
of Neurochemistry and, Barcelona, Spain ; 3University of Cantabria, Dept.
of Physiology and Pharmacology, Santander, Spain ; 4University of
Cantabria, Dept of Physiology and Pharma, Santander, Spain ;
5 IIBB – CSIC – IDIBAPS, Depart. of Neurochemistry, Barcelona, Spain
Objective : Identifying the factors contributing to the etiology of
anxiety and depression is critical for the development of more eﬃ-
cacious therapies. Serotonin (5-HT) is linked to both disorders.
Current antidepressants, which block the serotonin transporter
(SERT), show limited eﬃcacy and slow onset of action. Here, we used
a small interference RNA (siRNA) strategy to examine the biological
consequences of reducing SERT expression, as previously reported
for 5-HT1A-autoreceptors.
Methods : Adult mice were locally infused with vehicle, nonsense-
siRNA and SERT-siRNA into dorsal raphe nucleus (DR). The func-
tional eﬀects of SERT-siRNA knockdown were compared with those
produced by chronic ﬂuoxetine treatment.
Results : Local SERT-siRNA infusion for 4-days decreased SERT
expression in the DR (40%). This was accompanied by a widespread
reduction of SERT-binding sites throughout the brain. Moreover, a
4-day regimen with intra-DR SERT-siRNA modiﬁed brain variables
considered to be key markers of antidepressant action, such as :
(a) reduced expression and sensitivity of 5-HT1A-autoreceptors,
(b) augmented extracellular 5-HT in DR-projecting areas such as
striatum and hippocampus, (c) increased hippocampal neurogenesis,
and (d) increased expression of plasticity-associated genes (BDNF,
VEGF and ARC). In contrast, a 4-day regimen with ﬂuoxetine did not
alter any of these variables and only started to modify them after
15-day treatments.
Conclusion : These ﬁndings highlight the critical role of SERT in the
control of serotonergic function, including neural plasticity. They also
support the use of siRNA targeting serotonergic genes (SERT, 5-HT1A
autoreceptors) as a new generation of antidepressant therapies with a
potential greater eﬃcacy faster onset of action than current treat-
ments.
jP-09-003jPrevalence and pattern of sexual dysfunction in
females receiving antidepressants
A. Avasthi1, S. Grover1. 1PGIMER, Chandigarh, India
Objective : To study the prevalence and pattern of sexual dysfunction
in female patients receiving antidepressants.
Methods : Eighty married female patients with a diagnosis of de-
pressive disorder, currently in remission, and receiving a single anti-
depressant at least for 3 months, were assessed for sexual dysfunction
on Female Sexual Function Index (FSFI) scale.
Results : It was found that 95% of patients had decreased desire,
60% had decreased arousal, 37.5% had decreased lubrication, 63.8
had decreased orgasm, 55% had decreased satisfaction and 25% had
pain during sexual activity.
Conclusion : Sexual dysfunction is quite prevalent in married fe-
male patients receiving antidepressants and all the domains of sexual
functioning are impaired by antidepressants.
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jP-09-004jAntidepressant activity of curcumin : Involvement
of serotonin and dopamine system
M. Bishnoi1, B. Mohit2, S. Kulkarni2. 1NABI, Sas Nagar, India ;
2PU, Chandigarh, India
Objective : Curcumin is a major active principle of Curcuma longa,
one of the widely used preparations in the Indian system of medicine.
It is known for its diverse biological actions. The present study was
designed to investigate the involvement of monoaminergic system(s)
in the antidepressant activity of curcumin and the eﬀect of piperine, a
bioavailability enhancer, on the bioavailability and biological eﬀects
of curcumin.
Methods : Behavioral (forced swim test), biochemical (monoamine
oxidase (MAO) enzyme inhibitory activity), and neurochemical
(neurotransmitter levels estimation) tests were carried out.
Results : Curcumin (10–80 mg/kg, i.p.) dose dependently inhibited
the immobility period, increased serotonin (5-hydroxytryptamine,
5-HT) as well as dopamine levels (at higher doses), and inhibited
the monoamine oxidase enzymes (both MAO-A and MAO-B,
higher doses) in mice. Curcumin (20 mg/kg, i.p.) enhanced the anti-
immobility eﬀect of subthreshold doses of various antidepressant
drugs like ﬂuoxetine, venlafaxine, or bupropion. However, no sig-
niﬁcant change in the anti-immobility eﬀect of imipramine and desi-
pramine was observed. Furthermore, combination of subthreshold
dose of curcumin and various antidepressant drugs resulted in
synergistic increase in serotonin (5-HT) levels as compared to their
eﬀect per se. There was no change in the norepinephrine levels.
The co-administration of piperine (2.5 mg/kg, i.p.), a bioavailability
enhancing agent, with curcumin (20 and 40 mg/kg, i.p.) resulted
in potentiation of pharmacological, biochemical, and neurochemical
activities.
Conclusion : The study provides evidences for mechanism-based
antidepressant actions of curcumin. The co-administration of curcu-
min along with piperine may prove to be a useful and potent natural
antidepressant approach in the management of depression.
jP-09-005jAbuse antidepressant use
M. Blanco1, C. Bonilla Reyes1, C. Harkous Pen˜a1, E. Valdivia Baza´n1,
P. Sopelana Rodrı´guez1. 1Madrid, Spain
Objective : The number of antidepressants has grown exponentially
and its indication has been changing over time. Initially mainly used
as a treatment for mood disorders, while in recent decades, used to
treat anxiety, eating disorders, obsessive-compulsive disorder, sub-
stance abuse, personality disorders, schizoaﬀective disorder, chronic
neuropathic pain, etc. No conclusive data on long-term risks of these
drugs, but they continue to prescribe indiscriminately by the ﬁrm
belief of its safety. OBJECTIVE : Conduct a descriptive study to reﬂect
how many patients started antidepressant treatment on admission
to a Brief Hospitalization Unit (UHB) of Psychiatry during 2000. After
10 years of monitoring, evaluating the eﬀectiveness-ineﬀectiveness,
continuity-discontinuation of it.
Methods : Select medical records of patients who are discharged
with an antidepressant medication. Collect the following data : age,
sex, diagnosis and previous antidepressant treatments, family history
of antidepressant treatment, reason for admission and establishment
of antidepressant treatment, type of antidepressant, average stay,
discharge diagnosis, continuity of treatment/discontinued (reason
discontinuation), current clinical status.
Results : After 10 years found that 40% patients continue anti-
depressant treatment. $ Most did not have the diagnosis of Mood
Disorder.
Conclusion : $Antidepressants have a clear potential for abuse and
dependence that is attributed to its anticholinergic action. $ The rea-
sons for treatment discontinuation : clinical stability, abandonment,
powerlessness, turn, side eﬀects.
jP-09-006jLow-trapping NMDA channel blocker AZD6765
increases gamma-band EEG without dissociative
side-eﬀects : A comparison with ketamine in healthy
volunteers
P. Boeijinga1, P. Danjou1, A. Patroneva2, M.A. Smith2, M. Quirk2.
1FORENAP, Rouﬀach, France ; 2AstraZeneca, Wilmington, USA
Objective : Ketamine has demonstrated robust antidepressant activity
in small clinical trials. However, ketamine’s side-eﬀects may limit its
therapeutic utility. AZD6765, a low-trapping NMDA channel blocker
in development for major depression, is predicted to have an im-
proved tolerability proﬁle compared to ketamine. Preclinically,
NMDA channel blockers increase gamma-band EEG – a potential
therapeutic biomarker of cortical disinhibition. The object of this
study was to use quantitative EEG to determine whether AZD6765 in
humans causes electrophysiological changes comparable to ketamine
without the occurrence of dissociative side-eﬀects.
Methods : A four-way, placebo-controlled, crossover study in
healthy volunteers compared i.v. infusion of AZD6765 (75 and
150 mg) with an antidepressant dose of ketamine (0.5 mg/kg). Base-
line and post-drug EEGs were obtained under controlled conditions
and composite brain EEG maps were analyzed using Standard
Decision Tree methods. Changes in gamma (35–55 Hz) band power
served as the primary endpoint. Secondary endpoints included
Clinician Administered Dissociative Status Scale (CADSS), electro-
nystagmography, and pupil size.
Results : Signiﬁcant increases in gamma-band EEG were observed
at 1 hour for ketamine and AZD6765, and baseline-corrected gamma-
band EEG following AZD6765 150 mg was statistically indis-
tinguishable from that observed following ketamine. In contrast,
AZD6765 caused no dissociative symptoms, whereas ketamine pro-
duced a moderate yet signiﬁcant increase in CADSS and was as-
sociated with an increase in supine systolic blood pressure. No
signiﬁcant changes in nystagmus or pupil size were observed with
AZD6765.
Conclusion : Consistent with preclinical ﬁndings, this study sup-
ports the utility of gamma-band EEG as a biomarker for NMDA
channel blockade and provides evidence that diﬀerentiates ketamine
from AZD6765 across multiple tolerability endpoints including
cardiovascular and psychotomimetic liability. AZD6765 demon-
strated NMDA channel blockade and an improved tolerability proﬁle
compared to ketamine.
Policy of full disclosure : Author is employed by Forenap, the
CROI conducting the study on behalf of AstraZeneca.
jP-09-007jClinical predictors of antidepressant response and
remission in treatment resistant depression
R. Calati1, D. Souery2, I. Massat2, S. Kasper3, S. Montgomery4,
J. Zohar5, J. Mendlewicz2, A. Serretti1. 1Bologna University, Italy ;
2Brussels, Belgium ; 3Vienna, Austria ; 4London, United Kingdom ;
5Tel-Hashomer, Israel
Objective : Few studies investigated clinical predictors of anti-
depressant response-remission in treatment resistant depression
(TRD). The present has been performed in the context of a European
multicenter project. Its aim was to identify predictors of antide-
pressant response/remission in a sample of TRD prospectively
assessed patients and to compare results to ones obtained on another
sample of TRD patients retrospectively assessed.
Methods : 414 patients who failed to respond to a previous anti-
depressant were ﬁrstly included in a 6-week treatment with venla-
faxine ; secondly, those who failed to respond were treated for a
6-week treatment with escitalopram. MINI was administered at
baseline. HRSD, MADRS, CGI-S and CGI-I scales were administered
from baseline to week 12. Other information has been collected at
baseline.
Results : Completers have been included in the analyses. In the ﬁrst
phase, non responders and non remitters to venlafaxine reported
lower rate of inpatients, higher rate of psychiatric antecedents, lower
benzodiazepine use at baseline, higher rate of side eﬀects, higher CGI-
S and lower CGI-I scores, and higher treatment doses. Moreover, non
responders showed lower age and lower episode number while non
remitters showed higher current suicidal risk level. In the second
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phase, non responders and non remitters to escitalopram reported
higher duration of current episode, higher treatment dose, and higher
CGI-S and lower CGI-I scores. Moreover, non remitters showed
higher rate of current suicidal risk and higher current suicidal risk
level, higher rate of comorbid anxiety disorders, in particular panic
disorder and generalized anxiety disorder, and higher rate of ante-
cedents of second degree aﬀected by bipolar disorder.
Conclusion : Some clinical variables have been identiﬁed as as-
sociated with treatment non response/non remission in TRD.
Speciﬁcally, current suicidal risk and comorbid anxiety disorders,
in particular panic disorder, seem to be predictors of treatment non
remission/resistance in two sample of TRD patients. Further clariﬁ-
cation of the role of other clinical variables should be explored.
jP-09-008jEﬀects of pharmacodynamic properties of
antidepressants on central autonomic regulation
in young women with recurrent depression
J.S. Chang1, J.Y. Her2, S. Lee2, T.H. Ha2, K. Ha2. 1Seoul Nat´l Univ.,
Bundang Hosp, Seongnam, Republic of Korea ; 2Seoul Nat´l Univ. Bundang
Hosp, Seongnam, Republic of Korea
Objective : Recurrent depression is often associated with alterations
of central autonomic regulation. Pharmacodynamic properties of
antidepressants may cause changes in central autonomic function.
We examined the relationship between autonomic status of women
with recurrent depression and pharmacodynamic properties of anti-
depressants.
Methods : Resting RR intervals and respiratory signals were
simultaneously obtained from 38 euthymic women with recurrent
depression receiving escitalopram (n=19) or venlafaxine mono-
therapy (n=19) and 38 matched and healthy women. Linear measures
of heart rate variability were extracted to assess cardiac autonomic
control. Sample Entropy (SampEn) was computed to assess the com-
plexity of heart rate and respiratory signal, and Cross-SampEn were
calculated to measure a nonlinear interaction of both signals.
Results : Women with recurrent depression receiving venlafaxine
showed signiﬁcant decreases in cardiac vagal activity and interaction
between heart rate and respiration when compared to women with
recurrent depression receiving escitalopram or healthy controls. Eﬀect
sizes for these diﬀerences in autonomic control were large between
women receiving venlafaxine and healthy controls. Compared with
healthy controls, women with recurrent depression receiving escita-
lopram showed tendencies toward decreased cardiovagal tone and
reduced cardiorespiratory coupling. A signiﬁcant association between
cardiorespiratory decoupling and venlafaxine dose was observed.
Conclusion : In addition to a substantial link between depression
and autonomic dysregulation, the current study suggests that altered
autonomic modulation in euthymic women with recurrent depression
may be associated with pharmacological properties of anti-
depressants.
Policy of full disclosure : Prof. Kyooseob Ha has received grants,
research support, and/or honoraria from and has served on the
speaker/advisory board of Janssen, AstraZeneca, GlaxoSmithKline,
Pﬁzer, Eli Lilly, Otsuka, and Servier. The other authors declare that
they do not have any commercial associations that might pose a con-
ﬂict of interest in connection with this report.
jP-09-009jTianeptine in treatment of depression in cancer with
deep vein thrombosis on anticoagulant medication
A. Ciobanu1, A.A. Ciucu2, A. Surdu3, F. Ciobanu4. 1Univ. Med. &
Pharm. C. Davila, Bucharest, Romania ; 2University from Bucharest,
Romania ; 3Al. Obregia Hospital, Bucharest, Romania ; 4Cl. Emergency
Hospital Ilfov, Bucharest, Romania
Objective : Patients undergoing major abdominal surgery for malig-
nancy are at particularly high risk of developing deep vein thrombosis
(DVT). Studies show that half of all cancer patients have a psychiatric
disorder, usually a depression. The anticoagulant given to prevent
recurrent risk for DVT can cause bleeding but this adverse event was
reported also at more antidepressants classes like selective serotonin
reuptake inhibitors and serotonin-norepinephrine reuptake inhibitor.
The aim of this study was to investigate the tianeptine eﬀect, used
for treatment of depression, on overanticoagulation during the anti-
coagulant medication in patient with cancer and DVT.
Methods : We included 11 patients, 7 women and 3 men with
age between 30–42 years, with diagnosis of depression by DSM IV
criteria, who were suﬀered DVT o1 times during the last month
after a surgery intervention for cancer. All patients received anti-
coagulants daily with high intensity of international normalized ratio
(INR) settings (around 3.7–4.0 INR) and tianeptine 12.5 mg three times
on day. The combination of tianeptine with anticoagulants was
monitored by measurements of INR to avoid overanticoagulation.
For measurement the depressive symptoms we used Hamilton
Depression Rating Scale (HDRS)- 17 items. Period of study it was
3 month, with one visit per week in the ﬁrst month and at 2 weeks
to the endpoint.
Results : We didn’t found risk for overanticoagulation during anti-
coagulant treatment in combination with tianeptine. The patients tol-
erated very well the treatment and at the endpoint we obtained the
remission of depressive symptoms. It wasn’t necessary to adjustment
the doses of anticoagulant on the period of the study.
Conclusion : There was no increase in risk for overanticoagulation
in subjects treated with tianeptine and anticoagulants. This medi-
cation can be take in consideration in treatment of depression at
patients with recurrent DVT on anticoagulant medication.
jP-09-010jAntidepressant usage after bariatric surgery
M. Clark1, J. Cunningham1, D. McAlpine1, K. Somers1, M. Sarr1.
1Mayo Clinic, Rochester, USA
Objective : To examine antidepressant medication usage in a retro-
spective study of 439 patients who had Roux-en-Y gastric bypass
surgery for weight loss.
Methods : A retrospective chart review identiﬁed 170 patients on
antidepressant mediations presurgery and 180 patients not on anti-
depressant medications presurgery. Average age of the sample was
47 years old, most were female, and average BMI was 47.
Results : Of the 170 patients who were on antidepressant medi-
cations presurgery, 40% had no change in their antidepressant
medications, 23% had an increase in antidepressant medications,
18% changed antidepressants, and only 16% decreased or stopped
their antidepressant medications.
Conclusion : Many patients seeking to have bariatric surgery are
prescribed antidepressant medications, but there is little documen-
tation regarding antidepressant usage after having bariatric surgery.
In this retrospective medical chart review few patients were able
to reduce or discontinue their antidepressant medications after having
bariatric surgery. These results highlight the need for careful moni-
toring of mood after having bariatric surgery. These results have been
accepted for publication : Cunningham, JL, Merrell, CC, Sarr, MG,
Somers, KJ, McAlpine, D, Reese, M, Stevens, SR, & Clark, MM.
Investigation of Antidepressant Medication Usage after Bariatric
Surgery, Obesity Surgery, ‘‘ in press’’.
jP-09-011jAgomelatine treatment normalized anxiety
behaviour, Period 1 and Period 2 expression in a rat
model of posttraumatic stress disorder
H. Cohen1, J. Zohar2. 1Anxiety and Stress Unit, BeerSheva Mental
Health Center, Beer-Sheva, Israel ; 2Chaim Sheba Medical Center,
Department of Psychiatry, Tel Hashomer, Israel
Objective : Post-traumatic stress disorder (PTSD) is a chronic anxiety
disorder deﬁned by the co-existence of three clusters of symptoms : re-
experiencing (ﬂash-backs, recurrent and distressing recollections and
dreams, intense physiological reactivity after reminders exposure),
avoidance/numbing (persistent avoidance of trauma’s reminders)
and hyperarousal (anxiety, insomnia, concentration diﬃculties, exag-
gerated startle response, irritability). Moreover, abnormal circadian
rhythms are observed in PTSD patients. Agomelatine is a melatoner-
gic agonist (MT1/MT2) and 5HT2C antagonist with antidepressant,
anxiolytic and re-synchronizing eﬀects in animals and humans. Here,
we evaluated the eﬀect of agomelatine on behavior and clock genes
Period1 and Period2 expression in the predator scent stress (PSS) rat
PTSD model.
Methods :Adult male Sprague-Dawley rats were exposed to PSS for
10 min, and 1 h later treated for 3 days with vehicle or agomelatine
(50 mg/kg i.p.). Rats were assessed in the Elevated Plus Maze (EPM)
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and acoustic startle response (ASR) on Day8 and sacriﬁced 24 h after
(ZT19) for Per1 and Per2 immunohistochemistry evaluation.
Results : In the EPM, agomelatine antagonised (p<0.035) the time
spent in the open arms decrease observed in PPS vehicle-treated rats.
In the ASR, agomelatine (p<0.002) reversed the mean startle am-
plitude increase observed in PSS vehicle-treated rats. Moreover ago-
melatine induced decreases in the prevalence rates of individuals
displaying extreme behavioural responses (EBR) (PTSD-like). As re-
gards clock genes expression, agomelatine normalized Per1 increases
observed in the CA3 (p<0.05), DG (p<0.015) and SCN (p<0.0002)
of PPS rats. Agomelatine also normalized the Per2 increases observed
in the CA1 (p<0.00025), CA3 (p<0.0008), DG (p<0.05) and SCN
(p<0.0035) of PPS rats.
Conclusion : These results suggest that agomelatine normalized
anxiety behavior in this animal model of PTSD and normalized the
Per1 and Per2 clock genes expression changes observed in this model
suggesting that these clock genes are involved in the neurobiological
response to anxiety in this PTSD model.
jP-09-012jThe use of agomelatine in the current psychiatric
clinic : A naturalistic study
C.A. de Mednonc¸a Lima. Centro Hospitalar do Alto Ave, Guimara˜es,
Portugal
Objective : Agomelatine has been shown to be eﬀective and well-
tolerated in several Clinical Trials, under strict methodological limits,
for the treatment of Major Depression. Its use to treat depressive
symptoms in other mental disorders is less known. The present study
wass aimed to evaluate the clinical response to agomelatine and its
safety in an outpatient adult psychiatric facility.
Methods : 25 mg/day of agomelatine was prescribed according to
clinical judgment. MADRS assessed the intensity of symptoms before
(W0) and after at least 8 weeks of treatment (W8). CGI was used at W8
for self-assessment. Monotherapy or association with other psycho-
tropics were both used.
Results : 23 men (mean age=52.8 years, MADRS mean score at
W0=23.7) and 87 women (mean age=48.8 years, MADRS mean score
at W0=25.2) were included. The distribution of patient according to
ICD-10 was : F0=15 ; F1=2 ; F2=2 ; F3=71 ; F4=14 ; F5=3 ; F6=3).
105 patients completed the minimum 8 weeks of treatment (5 aban-
doned it). Cost (n=10) and side eﬀects (n=15) caused the interruption
of treatment at W8. Other 7 patients reported side eﬀects without
needing any further action. Mean MADRS scores were : W0=25.3 ;
W8=15.1 (p<0.001). 79% of patients were improved on W8 : 6% very
much improved, 46% much improved, 27% little improved
(p<0.001). The most signiﬁcant side eﬀects were nausea/vomiting
(n=9) and overall discomfort (n=8).
Conclusion : Agomelatine has demonstrated to be useful in current
psychiatric clinical practice with high response level in 8 weeks
of treatment. Side eﬀects can be related to the (i) possible drug inter-
actions, (ii) the context of the mental disorder, (iii) the intrinsic
pharmacological properties of the drug.
Policy of full disclosure : Servier suported the inscription and
travel fees to this congress.
jP-09-013jPharmacoMRI and cognitive eﬀects of the
low-trapping NMDA channel blocker AZD6765
compared with ketamine in untreated major
depressive disorder
B. Deakin1, S. Williams1, D. Downey1, S. McKie1, G. Goodwin2,
C. Harmer2, C. Dourish3, G. Dawson3, D.J. McCarthy4, M.A. Smith4.
1University of Manchester, Stopford Bldg, United Kingdom ; 2University
of Oxford, Department of Psychiatry, United Kingdom ; 3P1Vital,
Department of Psychiatry, Oxford, United Kingdom ; 4AstraZeneca,
Wilmington, DE, USA
Objective : To determine the immediate eﬀects of AZD6765 and
ketamine on neural activity in the subgenual cingulate cortex (SGC)
and its relationship with subsequent change in depressive symptoms
and emotion processing using pharmaco- and functional magnetic
resonance imaging (phMRI, fMRI).
Methods : Sixty treatment-naı¨ve males or females aged 18 to
45 years with major depressive disorder were randomly assigned to
three groups to receive (i.v.) ketamine, AZD6765, or placebo during a
60 min phMRI scan. Twenty-four hours later, behavioural and fMRI
responses to emotional stimuli were recorded. Baseline and follow-up
Montgomery-Asberg Depression Rating Scale (MADRS) scores were
recorded.
Results : Both AZD6765 and ketamine increased SGC BOLD signal
responses ; no decreases were seen in any brain region. The SGC re-
sponses correlated with improvement in MADRS scores 24 hours and
7 days post-infusion. Following administration of AZD6765, inter-
viewer-rated psychotic and dissociative symptoms were minimal and
not statistically signiﬁcant. In contrast, ketamine produced amoderate
statistically signiﬁcant increase in dissociative symptoms. Both drugs
reduced amygdala responses to fear and sadness in the emotional
faces task 24 hours post-infusion.
Conclusion : Activation of the SGC was seen following both drugs
and this eﬀect was associated with improvement in depressive
symptoms 24 hours and 7 days post-infusion. The results suggest
that AZ6765 and ketamine both have antidepressant-like eﬀects on
emotion processing in the brain and that diminished NMDA gluta-
mate neurotransmission in the SGC is a likely proximal mechanism.
Policy of full disclosure : Supported by funding from AstraZeneca.
jP-09-014jAntidepressant activity of 1-(7-methoxy-2-methyl-
1,2,3,4-tetrahydro-isoquinolin-4-YL)-cyclohexanol,
a b-substituted phenylethylamine in mice
A. Dhir1, S. Malik2, S. Kessar3, K. Singh4, S. Kulkarni5. 1UCDMC,
Sacramento, USA ; 2Department of Chemistry, UGC Centers of Advanced
Study, Chandigarh, India ; 3Panjab University, Chandigarh, Department of
Chemistry, India ; 4Panjab University, Chandigarh, Sector 14, India ;
5Panjab University, Chandigarh, Univ. Inst of Pharm. Sci., India
Objective : Trace amines are known to play an important role in the
pathophysiology of major depression. The present study is an attempt
to evaluate one of newly discovered putative trace amine modulator,
1-(7-methoxy-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-cyclo-
hexanol (NME), in animal models of depression.
Methods : Various behavioral and biochemical paradigms of de-
spair were used in the present study.
Results : The molecule (4–16 mg/kg., i.p.) dose-dependently in-
hibited the immobility period in mouse forced swim test, the eﬀect
comparable to venlafaxine. The ED50 values of this NME and venla-
faxine in mouse forced swim test were found to be 5.27 [4.38–6.35]
mg/kg., i.p. and 4.66 [3.48–6.25] mg/kg., i.p., respectively. Further,
NME at 4–16 mg/kg., i.p. reversed the immobility period in mouse
tail-suspension test. Additionally, the molecule at 8 mg/kg., i.p. re-
versed reserpine-induced behavioral despair in mouse forced swim
test. When administered simultaneously, it enhanced the anti-
depressant activity of sub-eﬀective doses of imipramine or ﬂuoxetine
in the mouse forced swim test. Neurochemical analysis revealed that
the molecule at 8 mg/kg., i.p. increased the levels of norepinephrine
(21% increase) without aﬀecting serotonin in the mouse brain.
However, at higher dose (16 mg/kg., i.p.), it increased the levels of
norepinephrine (13% increase), serotonin (37% increase), and dopa-
mine (42% increase). The molecule enhanced the locomotor activity in
mice only at higher doses. The molecule, unlike venlafaxine, which
potentiated barbiturate-induced hypnosis, was devoid of any sedative
activity.
Conclusion : In conclusion, the novel trace amine possess anti-
depressant-like activity in animal models of depression by modulat-
ing the neurotransmitter levels in the brain. Such an activity might
be due to the modulating action of this novel molecule on trace amine
receptors. Such a molecule may be the future drugs of choice for the
treatment of major depression.
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jP-09-015jSerotonergic antidepressants and hyponatraemia in
aged psychiatry
S. Dodd1, F. Giorlando2, J. Tester3, M. Udina4, M. Berk5. 1Deakin
University, School of Medicine, Geelong, Australia ; 2University of
Melbourne, Barwon Health, Geelong, Australia ; 3Barwon Health, Geelong,
Australia ; 4University of Barcelona, Hospital Clinic, Spain ; 5Deakin
University, Barwon Health, Geelong, Australia
Objective : To investigate the incidence and risk factors for anti-
depressant induced hyponatraemia in elderly people treated with
serotonergic antidepressants.
Methods : In a retrospective chart analysis depressed patients
aged>63 years were investigated for change in serum sodium levels
in two samples separated by a median period of 45.5 days and with
the ﬁrst specimen taken prior to treatment. Patients were grouped
into three cohorts ; treated with an SSRI or SNRI (n=77), treated with
an antidepressant other than an SSRI or SNRI (n=54) and not treated
with an antidepressant (n=128).
Results : For change in sodium level between measurements and
total number of patients with hyponatraemia, there was no signiﬁcant
diﬀerence between cohorts. However, the rate of reduction of serum
sodium levels between time points was signiﬁcantly greater for SSRI
and SNRI treated patients (p<0.001) and patients treated with other
antidepressants (p=0.03) compared to patients not treated with anti-
depressants. Moreover, the distribution of values of change in serum
sodium was skewed towards reduced serum sodium in patient
treated with SSRI or SNRIs (skew x0.43) and patients treated with
other antidepressants (skew x0.09) but not for patients not treated
with antidepressants (skew 0.25).
Conclusion : These data suggest that hyponatraemia is associated
with antidepressant treatment that eﬀects some individuals only.
Generalized linear modelling showed that the risk of hyponatraemia
increases with increased age, female gender, and particularly the
antidepressant agents sertraline and escitalopram. The ﬁndings are
of clinical signiﬁcance as they demonstrate that hyponatraemia can
occur rapidly in patients treated with these antidepressants.
Policy of full disclosure : Dr. Dodd has received grant support
from the Stanley Medical Research Institute, NHMRC, Beyond
Blue, ARHRF, Simons Foundation, Geelong Medical Research
Foundation, Eli Lilly, Glaxo SmithKline, Organon, Mayne Pharma
and Servier, speaker’s fees from Eli Lilly and conference travel sup-
port from Servier. Prof Berk has received Grant/Research Support
from Stanley Medical Research Foundation, MBF, NHMRC,
Beyond Blue, Geelong Medical Research Foundation, Australian
Rotary Health Research Fund, Bristol Myers Squibb, Eli Lilly,
GlaxoSmithKline, Organon, Novartis, Mayne Pharma and Servier,
has been a speaker for AstraZeneca, Bristol Myers Squibb, Eli
Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Pﬁzer, Sanoﬁ
Synthelabo, Servier, Solvay and Wyeth, and served as a consultant
to AstraZeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline,
Janssen Cilag, Lundbeck and Servier. Dr Giorlando has received re-
search funding from Pﬁzer. Dr Udina and Ms Teister have no conﬂicts
of interest.
jP-09-016jDiﬀerence between morning and evening
thyrotropin response (delta delta TSH) and
prediction of antidrepressant treatment outcome
in major depresion
F. Duval1, M.-C. Mokrani1, F. Gonzalez1, C. Alexa1, H. Rabia1,
K. Henry1, A. Erb1. 1Centre Hospitalier, Rouﬀach, France
Objective : About 50% of major depressed patients have inadequate
response to an individual antidepressant trial. Early predictors of re-
sponse are needed to improve eﬀectiveness of antidepressant treat-
ment. This study sought to determine whether the thyroid function
evaluation at baseline and after 2 weeks of treatment could predict
antidepressant response in hospitalized patients.
Methods : Serum levels of thyrotropin (TSH), free triiodothyronine
(FT3), free thyroxine (FT4) were measured before and after 08.00 h
and 23.00 h protirelin challenges (thyrotropin-releasing hormone
[TRH] ; 200 mg intravenously), on the same day, in 30 medication-free
DSM-IV euthyroid major depressed inpatients and 30 healthy hospi-
talized controls. After 2 weeks of antidepressant treatment (tianeptine,
n=15 ; extended-release venlafaxine, n=15) the same TRH tests were
repeated in all inpatients. Antidepressant response was evaluated
after 6 weeks of treatment.
Results : At baseline, serum 23.00 h-TSH basal values, 23.00 h
maximum increment in TSH level (delta TSH) and the diﬀerence be-
tween 11 PM-delta TSH and 8 AM-delta TSH (delta delta TSH) were
signiﬁcantly lower in patients compared to controls (p=0.03,
p=0.0001, and p<0.0001, respectively). Twenty patients showed re-
duced delta delta TSH values (i.e.f2.5 mIU/l ; sensitivity, 67% ;
speciﬁcity, 97%). Pretreatment thyroid function tests were not as-
sociated with clinical outcome (full response rate 57%). After 2 weeks
of treatment, patients with reduced delta delta TSH values (n=14
[47%]) showed poor clinical outcome, while those with normal delta
delta TSH values showed full response on day 42 (p<0.0006). A
logistic regression on delta delta TSH values on day 14 predicted
endpoint clinical response (odds ratio, 3.30 ; 95% conﬁdence interval,
1.35–8.08 ; p=0.009).
Conclusion : Our results suggest that the delta delta TSH test
performed early during antidepressant treatment could be used to
predict eventual outcome and guide treatment decision.
jP-09-017jPharmacodynamics of Org 26576, an AMPA positive
allosteric modulator, in patients with major
depression : an exploratory, randomized,
double-blind, placebo-controlled Phase 1b trial
L. Ereshefsky1, K. Nations2, L. Gertsik1, R. Bursi3, J. Schipper3,
S. Greenwald4, D. Zraket5, E. Kim1, S. Unabia, J. Johnstone6,
P. Dogterom3. 1PAREXEL, Glendale, USA ; 2Whitehouse Station, USA ;
3Oss, Netherlands ; 4Mansﬁeld, USA ; 5Covidien, Mansﬁeld, USA ;
6Q-Metrx, Burbank, USA
Objective : This study explored the safety, tolerability, pharmacoki-
netics, and pharmacodynamics(PD) of Org 26576 in depressed
patients ; PD included QEEG endpoints, cognition, and treatment re-
sponse on the MADRS.
Methods : Part I (N=24) evaluated maximum tolerated dose (MTD)
and optimal titration schedule using a 10 to 16-day multiple rising
dose paradigm in depressed subjects. Part II (N=30) followed a par-
allel-groups design, in which subjects received either 100 or 400 mg
BID of Org 26576 or placebo for 28 days. The QEEG-based endpoint
Antidepressant Treatment Response (ATR ; Covidien) was assessed at
baseline and Week 1. MADRS and a computerized cognitive battery
were administered at baseline and endpoint.
Results : Part I : The MTD study determined a safe starting dose of
200 mg BID with an MTD of 450 mg BID. Part II : Both doses of Org
26576 showed a small numeric advantage over placebo on the
MADRS at Day 28 [Change from baseline 100 mg BID : x15.40
(¡6.40) ; 400 mg BID :x14.78 (¡11.72) ; placebox12.67 (¡9.35) ; and
Org 26576 was associated with improvements on computerized tests
of executive functioning (Eﬀect size 100 mg BID vs. placebo : 1.01 ;
400 mg BID vs. placebo : 0.77) and speed of processing (Eﬀect size
100 mg BID vs. placebo : 0.88). The ATR at Week 1 was able to sig-
niﬁcantly predict symptomatic response at endpoint in the active
treatment group, as was early improvement in social acuity, as mea-
sured by a face emotion recognition task (POET ; CNS-Vital Signs).
Conclusion : Org 26576 was well tolerated in patients. Exploratory
pharmacodynamic endpoints suggested that it may show promise as
an antidepressant in future well-controlled, adequately powered
proof of concept trials. Further study is also warranted to assess the
use of markers such as ATR and social acuity as response surrogates
in small Phase I patient studies.
Policy of full disclosure : Ereshefsky, Gertsik, Kim, and Unabia are
employees of PAREXEL, recipient of grant support from Merck, USA.
Nations was an employee of Merck. Dogterom, Bursi, and Schipper
were employees of Merck Sharpe and Dohme, The Netherlands.
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jP-09-018jLymphoblastoid cell lines as models for
pharmacogenomics in psychopharmacology
E. Ersfeld1, K. Stiebel1, M. Ising2, J. Stingl1. 1Ulm, Germany ; 2Munich,
Germany
Objective : Epstein-Barr virus (EBV) immortalized human lympho-
blastoid cell lines (LCL) serve as models in personalized medicine to
understand the genetic variability underlying drug eﬀects. Diﬀerent
cohorts of LCLs are existing that so far have been mainly used to
study genomic inﬂuences on the phenotype of cytotoxic drug eﬀects
in cancer therapy. Recently, other than anticancer drugs have been
used to study transcriptomic variability in modulation of drug eﬀects.
We use this method to study the genetics of antidepressant drug
eﬀects and see if this method may serve as a surrogate parameter
for antidepressant drug response. The aim of this project was ﬁrst, to
study if the cell toxic eﬀects of diﬀerent antidepressant drugs are
speciﬁc to the drug class, and second, to correlate the ﬁndings of drug
induced cell-toxicity with clinical data.
Methods :We used LCLs from patients who have been treated with
antidepressant drugs and characterized for the clinical course of drug
response in the context of the Munich Antidepressant Response
Signature (MARS) study by the Max Planck Institute of Psychiatry.
We examined the eﬀects of mirtazapine, imipramine and paroxetine
in diﬀerent concentrations and epigallocatechin gallate (EGCG), the
main component of green tea that has known antiproliferative eﬀects
as a control for a diﬀerent antiproliferative substance class. The ex-
periments were repeated three-times in each cell line.
Results : The drug concentration that inhibited the cell growth
by 50% (IC50 : imipramine 80 mM, paroxetine 15 mM, mirtazapine
300 mM, EGCG 15 mM) correlated signiﬁcantly between the three anti-
depressant drugs (imipramine versus paroxetine r=0.55, p=0.017 ;
imipramine versus mirtazapine r=0.48, p=0.045). EGCG also in-
hibited cell growth but it did not correlate with the cell toxicity of
the antidepressant drugs (r=0.13, p=0.47 for imipramine, r=0.23,
p=0.23 for paroxetine, r=0.11, p=0.57 for mirtazapine).
Conclusion : Correlations between cell growth inhibition and clini-
cal antidepressant therapy outcome will then be tested in these patient
cohorts from Munich.
jP-09-019jDiﬀerential regulation of FADD protein content by
electroconvulsive seizure and classic antidepressants
in rat brain
M.J. Garcı´a Fuster1, J.A. Garcı´a Sevilla2. 1UIB/IUNICS, Palma, Spain ;
2University of Balearic Islands, Palma de Mallorca, Spain
Objective : Major depression has been linked with genetic ab-
normalities of Apaf1, suggesting a role for enhanced cell death or
apoptosis. Light deprivation in rats, a behavioral model of depression-
like behavior, was recently shown to increase apoptosis and apopto-
sis-related markers. Conversely, the antidepressant drugs desi-
pramine and tianeptine induced antiapoptotic eﬀects in an animal
model of depression. Fas-Associated protein with Death Domain
(FADD), the adaptor protein of the extrinsic apoptotic pathway, is
essential in Fas receptor-induced apoptosis. Moreover, FADD is a
unique regulator of cell life and death and plays a critical role in many
essential cellular processes. In fact, phosphorylated FADD (pSer191
FADD) mediates non-apoptotic actions such as cell growth and
diﬀerentiation.
Methods : The current study investigated the eﬀects of acute and
chronic electroconvulsive seizure (ECS) and classic antidepressant
treatments (desipramine and ﬂuoxetine) on total FADD and pFADD
protein contents in brain regions associated with depression in the rat.
Results :A single session of ECS (95 mA, 0.6 s, 0.6 ms, 100 pulses/s)
increased FADD in the hippocampus (22%, p<0.01) and cortex (30%,
p>0.05), without altering pFADD content. Repeated sessions of ECS
(5 days) were not associated with alterations in FADD (induction of
tolerance) or pFADD in the hippocampus and cortex. Contrarily, de-
sipramine (10–30 mg/kg, 2–4 h) and ﬂuoxetine (10 mg/kg, 2 h) de-
creased FADD in cortex (20–30%, p<0.05 ; 10–15%, p>0.05 ;
respectively), without altering pFADD content. Notably, two weeks
treatment with desipramine (10 mg/kg) or ﬂuoxetine (3 mg/kg) sti-
mulated pFADD in the cortex (desipramine : 23%, p<0.05 ; ﬂuox-
etine : 59%, p<0.01). These chronic treatments were not associated
with alterations in FADD content.
Conclusion : The results uncover novel diﬀerential eﬀects of diverse
antidepressant treatments over FADD protein in the rat brain. Future
experiments will aim at better understanding FADD-mediated cell
fate regulation, which might be relevant in the therapeutic context of
major depression.
Policy of full disclosure : Supported by SAF2011–29918
(MEC-FEDER, Spain) and RETICS RD06/001/003 (MSC, Spain).
MJGF is a ‘Ramo´n y Cajal’ Researcher (MEC-UIB, Spain).
jP-09-020jPotential beneﬁts of slow titration of paroxetine
treatment in elderly population
S. Gibiino1, S. Porcelli1, E. Mori1, D. De Ronchi1, A. Serretti1. 1 Institute
of Psychiatry, Bologna, Italy
Objective : Approximately 15% among over 65-years individuals
suﬀers from depression. Particularly in this population, SSRIs could
lead to an early exacerbation of anxiety and a very gradual titration is
usual in clinical practice. The aim of this study is to compare eﬃcacy
and tolerability of gradual versus rapid titration of paroxetine in the
elderly.
Methods : 50 non-demented elderly (o60 years old) outpatients
with Major Depression or Anxiety disorders (o13 total score at
Hamilton Depression Rating Scale – HAM-D – or Hamilton Anxiety
Rating Scale -HAM-A) were randomized to paroxetine 10 mg or to
gradual tapering (2.5 mg on alternate days up to 10 mg in 7 days).
Then dosage could be adjusted according to clinical response.
Results :During the ﬁrst 3 days of treatment a signiﬁcant worsening
in psychic anxiety was observed in patients treated abruptly with
10 mg of paroxetine (diﬀerence in HAM-D psychic anxiety subscale
from baseline : 110.61% vs. 89.38% with rapid and slow titration re-
spectively ; p=0.03). Overall a signiﬁcantly greater improvement in
depressive and anxious symptoms favored gradual titration (HAM-D
Core cluster and HAM-D psychic anxiety cluster respectively re-
peated misure ANOVA p=0.014 and p<0.001, also when controlling
for confounders). At 8th week slightly higher drop outs in patients
administered with abrupt dosage was observed (15.38% vs. 39.13%,
p=0.06 ; respectively for slow and rapid titration).
Conclusion : Our results suggest that a gradual titration of par-
oxetine could avoid the initial treatment anxiety worsening and
drop out at the beginning of the treatment. Open issues are poss-
ible concomitant somatic treatments and diﬀerence in long-term
tolerance.
Policy of full disclosure : This paper has received a research grant
from Italfarmaco.
jP-09-021jFluvoxamine boosts duloxetine plasma levels in
depressed patients
M. Gro¨zinger1, A. Finkelmeyer1, M. Paulzen1. 1University Clinic
Aachen, Germany
Objective : Duloxetine (DLX) is a serotonin-norepinephrine reuptake
inhibitor (SNRI) that is eﬀective for major depressive disorder and
generalized anxiety disorder (GAD). The drug is metabolized by
CYP1A2 and to a lesser extent by CYP2D6. Fluvoxamine (FLX) is a
serotonin reuptake inhibitor (SSRI) and known to be a potent inhibitor
of the cytochrome P450 isoenzyme CYP1A2. It should therefore not be
co-administered with DLX in the ﬁrst place. There are nevertheless
rare clinical situations when a combination might be advantageous,
for example in cases when plasma levels of DLX remain low despite
individuals taking high dosages.
Methods : In this study the plasma levels of DLX as well as the
clinical and adverse eﬀects were retrospectively analyzed in thirteen
patients treated with a combination of the two substances. Steady
state DLX levels were measured in patients before taking FLX and
under diﬀerent daily doses of FLX within the same subjects.
Results : Adding 25 mg of FLX per day to a steady-state treatment
with 30 mg of DLX in 8 patients led to an average increase of DLX
plasma levels that was 3-fold with a magnitude of 50–506%.
Conclusion : Our ﬁndings indicate that DLX plasma levels can
be boosted by the potent CYP1A2 inhibitor FLX. However, the co-
administration of duloxetine with potent CYP1A2 inhibitors should
not be used in clinical routine without extreme precaution and under
continuous control of plasma-levels.
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jP-09-022jProgesterone withdrawal-induced depression-like
behavior is diﬀerentially sensitive to the eﬀects of
direct serotonin receptor modulation in comparison
to selective serotonin reuptake inhibition
M. Gulinello1, K.F. Raaby2, Y. Li2, C. Sa´nchez Morillo2. 1Albert
Einstein Colleg of Med., Bronx, NY, USA ; 2Lundbeck Research USA,
Paramus, NJ, USA
Objective : Background : Long-term progesterone administration
followed by abrupt withdrawal induces depression-like and anxiety-
like behavior in female rats, similar to symptoms in women with
premenstrual dysphoric disorder (PMDD). However, few studies
have compared eﬃcacy of antidepressants with diﬀerent mechanisms
of action in women, or in animal models of hormonally induced
depression-like behavior. Objective : The progesterone withdrawal
(PWD) model was used to compare the eﬃcacy of an SSRI (ﬂuox-
etine), speciﬁc serotonin (5-HT) receptor modulators, and a novel
multimodal antidepressant, LuAA21004. LuAA21004 is a 5-HT3
and 5-HT7 receptor antagonist, a 5-HT1B receptor partial agonist, a
5-HT1A receptor agonist and an inhibitor of the 5-HT transporter in
vitro.
Methods : PWD was induced in a multiple withdrawal paradigm
by i.p. injection of progesterone in oil (30 mg/kg) for 3 weeks.
Depression-like behavior was assessed using forced swim test, and
brain 5-HT levels were measured using HPLC.
Results : Fluoxetine did not reduce depression-like behavior when
administered either chronically (2 weeks) or acutely (2 days). In con-
trast, LuAA21004 reduced depression-like behavior after both acute
and chronic administration. Acute administration of 5-HT3 receptor
antagonist ondansetron or 5-HT1A receptor agonist ﬂesinoxan also
reduced depression-like behavior. However, these eﬀects were not
additive in combination with ﬂuoxetine. Brain serotonin levels were
not altered after PWD.
Conclusion : These data indicate that antidepressants with 5-HT3
antagonist and/or 5-HT1A agonist activity are more eﬃcacious
than an SSRI after PWD in female rats. Furthermore, 5-HT receptor
modulation is not additive with SSRI administration, consistent with
data indicating no primary deﬁcit in serotonin levels in this model.
Policy of full disclosure : This project is supported by H Lundbeck
A/S and Takeda.
jP-09-023jEﬀect of the multimodal antidepressant LU AA21004
on rat hippocampal plasticity and recognition
memory
N. Haddjeri1, A. Etievant1, A. Pehrson2, C. Sa´nchez2, C. Betry1.
1University of Lyon, France ; 2Lundbeck Research USA, Paramus, USA
Objective : Many depressed patients have cognitive disturbances
[Gotlib IH, Joormann J. Annu Rev Clin Psychol 2010 ; 6 : 285–312.].
The multimodal antidepressant Lu AA21004 is a 5-HT3 and 5-HT7
receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor
agonist and 5-HT transporter inhibitor in vitro [Mørk A, et al.,
J Pharmacol Exp Ther 2011. jpet.111.189068.]. Here we report its pre-
clinical eﬀects on parameters involved in cognitive processing.
Methods : Field excitatory postsynaptic potentials were recorded in
the CA1 area of dorsal hippocampus before and after high frequency
stimulation (HFS) of the Schaﬀer’s collaterals in 5-HT-depleted rats
(with PCPA), stressed rats placed on an elevated platform, and con-
trols. The novel object recognition (NOR) test (24 h retention) in a
Y-maze was used to evaluate episodic memory. Hippocampal cell
proliferation was measured by immunohistochemistry.
Results : In controls, HFS provoked a stable long-term potentiation
(LTP) ofy30%. Lu AA21004 (10 mg/kg i.p.) reduced LTP toy10%.
Lu AA21004 pre-treatment prevented the suppressant eﬀect of stress,
but not of 5-HT depletion. In the NOR test, Lu AA21004 increased the
time spent exploring the novel object during the retention test (index
of recognition : y40% versus y10% for controls) ; this eﬀect was
partly prevented by the selective 5-HT3 receptor agonist SR57227 and
the selective 5-HT7 receptor agonist AS19. Finally, LuAA21004 in-
duced an increase in cell proliferation in the dentate gyrus after 1, 3
and 14 days of treatment.
Conclusion : Lu AA21004 produced an eﬀect on LTP similar to that
of serotonergic antidepressants, but prevented the suppressant eﬀect
of acute stress. Lu AA21004 also enhanced episodic memory, an eﬀect
mediated, at least partly, by its 5-HT3/7 receptor antagonism. Finally,
Lu AA21004 induced a surprisingly rapid increase of hippocampal
cell proliferation. Together, these preclinical data suggest that the
antidepressant, Lu AA21004, may have a beneﬁcial eﬀect on cognitive
processes.
Policy of full disclosure : Dr. Haddjeri has received research grants
from H. Lundbeck A/S. Drs. Pehrson and Sa´nchez are full time
employees of Lundbeck. The others authors declare no conﬂict of
interest.
jP-09-024jThe eﬃcacy of paroxetine in treating chronic
subjective dizziness
B. Han1, F. Deng2, X. Shan2, Q. Sun2, L. Ma2, N. Li2. 1The General
Hospital of CPAPF, Institute of Vertigo Disease, Peking, China ; 2The
General Hospital of CPAPF, Peking, China
Objective : To investigate the antidepressant paroxetine in the treat-
ment of chronic subjective dizziness eﬃcacy and indications.
Methods : 53 cases of chronic subjective dizziness were divided into
two groups, integrated treatment group received Paroxetine (Seroxat
20y40 mg/d), the control group received conventional medical
treatment (strong Dingxuan ﬁlms, etc.), both groups with supportive
psychotherapy, the treatment period of 4 weeks. Before treatment,
after Hamilton Depression Scale respectively (HAMD), Hamilton
Anxiety Scale (HAMA), 90 Symptom Checklist (SCL-90) and self-
vertigo symptom questionnaire score.
Results : 33 patients with chronic subjective dizziness with HAMD,
HAMA score and the SCL-90 part of the factor scores were signiﬁ-
cantly higher than the norm, the diﬀerence was signiﬁcant (P<0.05).
After 4 weeks of integrated group therapy HAMD, HAMA and SCL-
90 score was signiﬁcantly lower than the control group, the diﬀerence
was signiﬁcant (P<0.05). Patients with chronic subjective dizziness
antidepressants (paroxetine) reduce vertigo symptoms after treatment
was signiﬁcantly greater than the control sub-consolidated group, the
diﬀerence was signiﬁcant (P<0.05).
Conclusion : The prevalence of chronic subjective dizziness in
patients with emotional problems, antidepressants for the treatment
of patients with chronic subjective dizziness, vertigo can improve
symptoms but also improve mood symptoms. Keywords : chronic
subjective dizziness, anxiety, depression, paroxetine, treatment.
jP-09-025jEﬃcacy of agomelatine in elderly patients with
major depressive disorder (MDD). Arandomised,
double-blind study vs. placebo
R. Heun1, R.M. Corral2, A. Ahokas3, H. Nicolini4, J.M. Teixeira5,
P. Dehelean6. 1Derby City General Hospital, United Kingdom ; 2Buenos
Aires, Argentina ; 3Helsinki, Finland ; 4Mexico City, Mexico ; 5Porto,
Portugal ; 6Timis¸oara, Romania
Objective : This 8 weeks multiethnic international double-blind
randomized study evaluated the eﬃcacy of the antidepressant ago-
melatine, a MT1/MT2 receptor agonist and a 5HT2c receptor antag-
onist, in elderly patients suﬀering from MDD compared to placebo
using the Hamilton Depression Rating Scale 17 items (HAM-D-17).
Methods : 222 out-patients MDD aged of at least 65 years were
randomised to receive agomelatine 25–50 mg (151) or placebo (71) for
8 weeks.
Results : In the total population, the mean HAM-D total score sig-
niﬁcantly decreased from baseline to endpoint with agomelatine
(from 26.9¡2.8 to 13.4¡7.5) vs. placebo (from 26.8¡3.2 to 16.1¡7.6)
with a signiﬁcant diﬀerence in favor of agomelatine of 2.67 (SE=1.06),
p=0.013. In the more severe patients (HAM-D total score>=25 and
CGI-S>=5 at baseline), the clinical beneﬁt was reinforced with a
signiﬁcant diﬀerence in favor of agomelatine of 3.79 (SE=1.37),
p=0.007. The response rate to treatment (decrease in HAM-D total
score from baseline of at least 50%) was signiﬁcantly higher with
agomelatine than with placebo : 59.46% vs. 38.57% respectively in the
total population (p=0.004) and 64.95% vs. 36.59% respectively in the
more severe patients (p=0.002) The proportion of patients with at
least one Emergent Adverse Event (EAE) related to treatment was of
28.5% in the agomelatine group and 19.7% in the placebo group. A
similar proportion of patients discontinued the treatment due to EAE
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in the agomelatine group (7.9%) and in the placebo group (8.5%).
Most common reported adverse events and more frequent on ago-
melatine were somnolence, diarrhoea, dry mouth and constipation.
Conclusion : This study shows that agomelatine is an eﬃcient
antidepressant treatment in the elderly patients.
Policy of full disclosure : I received speaker honoraria from
AstraZeneka, Bayer, BMS, Eisai, Pﬁzer, Janssen-Cilag, Novartis and
Servier, and was international scientiﬁc coordinator of the study.
jP-09-026jThe combination of cognitive-behaviour therapy
and antidepressants in the treatment of depression
C. Istikoglou1, D. Foutsitzis2, F. Mouchourtis2, S.-Z. Marouda2,
N. Poloniﬁs2, P. Kanellos2. 1Nea Ionia, Athens, Greece ;
2Konstantopouleio Hospital, Psychiatric Department, Nea Ionia, Athens,
Greece
Objective : Cognitive Behavioral Psychotherapy constitutes a major
treatment for Depression. Nevertheless, there are forms of severe
depression that resist treatment, both with cognitive-behavioral
therapy in monotherapy, and with a combination of antidepressants.
Cognitive Behavioral anti-depression Treatment requires 20–25 ses-
sions and is mainly based on the principles of Collaborative
Empiricism, as well as on the doctrines of the ancient Greek philos-
opher Epictetus.
Methods : 15 patients (9 female, and 6 male) were studied. The
patients were selected among the patients treated in the inpatient
facility and the outpatient setting of the Psychiatric Department of
‘‘Konstatopouleio ’’ General Hospital, Nea Ionia, during the years
2009 and 2010. All patients, without exception, were taking a com-
bination of antidepressants. Furthermore, the above patients were
given the MADRS (Montgomery-Asberg Depression Rating Scale) for
Depression, and CGI-S (Clinical Global Impression of Severity) Scales.
The cut-oﬀ value for Depression in MADRS scale is 12. All 15 patients
were treated with a cognitive-behavioral treatment of 25–30 sessions,
along with medication treatment.
Results : From 15 patients, 2 (male) abandoned cognitive behavioral
treatment due to a lack of motivation, and free time. The 13 patients
(7 female, and 6 male) that remained in treatment received a com-
bination of antidepressant medication and cognitive behavioral
therapy, and showed a signiﬁcant improvement at their MADRS and
CGI-S scores, proving that their depressive symptomology improved.
It should be noted that all 15 patients suﬀered from moderate to
severe depression. Anyhow, all 13 patients submitted to Cognitive
Behavioral Therapy did not satisfactorily respond to the anti-
depressant medication combination.
Conclusion : Cognitive Behavioral Therapy, combined with anti-
depressant treatment, the latter being adequate in dosage and with a
low side-eﬀect proﬁle, helps to treat treatment-resisting Depression.
Research shall extend beyond the completion of Cognitive Behavioral
Therapy, with a follow-up of these particular patients every six
months, for a period of two years.
jP-09-027jEﬃcacy and tolerability of paroxetine, ﬂuvoxamine
and milnacipran in depression : A result of two
pooled open label randomized controlled trial
M. Kato1, M. Wakeno1, Y. Takekita1, G. Okugawa1, S. Sakai1,
T. Kinoshita1. 1Kansai Medical University, Moriguchi, Japan
Objective : To compare eﬃcacy and tolerability of paroxetine(PAX),
ﬂuvoxamine(FLV) and milnacipran(MIL) in Japanese patient with
major depressive disorder.
Methods : A total of 200 Japanese patients suﬀering from major
depression were allocated to ﬂexible dosage of PAX (n=100), FLV
(n=50) or MIL (n=50) in two randomized 6-week study. The clinical
response was evaluated using the Hamilton Rating Scale for
Depression (HAM-D) assessed at each visit. Tolerability was assessed
by dropout rate caused by side eﬀect. Involvement of anxious or de-
lusional depression in treatment eﬃcacy or tolerability was also
evaluated. A repeated measures analysis of variance, analysis of co-
variance and Cox regression analysis were applied.
Results :HAM-D percent change among three treatment group was
signiﬁcantly diﬀerent (p=0.005, endpoint HAM-D % changes ; PAX ;
63.8%, FLV ; 60.2% and Mil ; 44.6%) by LOCF procedure (n=168).
Subsequent analysis between two treatment groups showed signiﬁ-
cantly better improvement in PAX compare to MIL (p=0.004) and no
signiﬁcant diﬀerences were seen between PAX and FLV and also FLV
and MIL. While in per protocol analysis (n=143), PAX showed sig-
niﬁcantly better improvement than FLV (p=0.033) and MIL
(p=0.012). Cox regression analysis showed signiﬁcantly diﬀerence of
side eﬀect induced dropout rate among three antidepressants
(p=0.029, MIL ; 29.4%>PAX :18.8%, FLV ; 6.1%). In both anxious
depression and delusional depression subgroup, FLV showed sig-
niﬁcantly greater improvement than MIL. Anxious depression was
also associated with high side eﬀect-induced dropout rate (p=0.026).
Conclusion : PAX showed greater improvement than MIL and FLV
with moderate risk of drop out. FLV showed lower dropout risk
and subsequent favorable improvement only in LOCF procedure, in
which fewer side eﬀects medication tends to produce better result also
in treatment eﬃcacy. Grater eﬃcacy of FLV in anxious and delusional
depression might be related to its sigma1 receptor aﬃnity. Higher
anxiety should be also considered as the important factor of dropout.
Policy of full disclosure : This study was supported by Glaxo
SmithKline, Meiji Seika Kaisha Ltd., Asahi Kasei Pharma Corporation.
jP-09-028jAntidepressant selective gynecomastia
K. Kaufman1, D. Podolsky1, D. Greenman1, A. Nyisztor1, G. Tiu1,
S. Sostre1, A. Tobia1. 1UMDNJ-RWJMS, New Brunswick, USA
Objective : Selective serotonin reuptake inhibitors (SSRIs) and sero-
tonin norepinephrine reuptake inhibitors (SNRIs) indirectly result
in decreased dopamine neurotransmission. Adverse eﬀects (AE) as-
sociated with dopamine blocking agents have been reported with both
SSRIs and SNRIs, including movement disorders and galactorrhea.
Further, mammoplasia and gynecomastia have been reported which
may be associated with altered dopamine neurotransmission or per-
turbations in sexual hormones. Whereas movement disorders can be
objectively noted by the treating psychiatrist and galactorrhea is an
AE which the patient readily volunteers, increased breast mass is less
frequently directly reported by patients and rarely directly questioned
of patients receiving antidepressants. This case report addresses
selective gynecomastia in a patient having received multiple anti-
depressants.
Methods : Case analysis with literature review.
Results : A 67-year-old male with major depression, dysthymia,
obsessive-compulsive disorder, social anxiety, hypertension, diabetes,
and hyperlipidemia presented with new onset gynecomastia and
breast tenderness. Mammography revealed bilateral gynecomastia
without suspicious mass, cluster of calciﬁcation, or other abnormali-
ties. These new symptoms developed after sertraline was added to
his stable medication regimen (duloxetine, alprazolam, rosuvastatin,
metoprolol, hydrochlorothiazide, sitagliptin). When sertraline was
discontinued, gynecomastia and breast tenderness rapidly resolved.
Though the patient had been treated with multiple psychotropics
during 13 years (ﬂuoxetine, sertraline, paroxetine, ﬂuvoxamine,
citalopram, escitalopram, mirtazapine, duloxetine, desvenlafaxine,
bupropion, nortriptyline, alprazolam, buspirone, pregabalin and
modaﬁnil), gynecomastia and breast tenderness only occurred when
sertraline was combined with duloxetine.
Conclusion : Gynecomastia is an AE associated with antide-
pressants but is rarely addressed. Gynecomastia can be anti-
depressant selective. Clinicians are advised to question patients
regarding this potential AE.
jP-09-029jEﬀect of duloxetine on chronic tension-type
headache in patients with major depressive disorder
H. Kim1, K.J. Lee1. 1 Ilsan Paik Hospital Inje Univ., Goyang, Republic of
Korea
Objective : A wide variety of antidepressants have been used to treat
tension headache in patients with major depressive episode.
Alterations in noradrenergic and serotonergic neurotransmitter
systems have been implicated in the pathophysiology of major de-
pressive disorder and chronic pain. So the newer antidepressant,
duloxetine acting on both noradrenergic and serotonergic neuro-
transmitter systems is expected to be more eﬀective in pain manage-
ment in major depressive disorder than selective serotonin reuptake
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inhibitors(SSRIs) and tricyclic antidepressants(TCAs). The purpose
of this study was to investigate the clinical therapeutic eﬀects of
duloxetine treating tension-type headache in major depressive dis-
order patients.
Methods : 33 outpatients diagnosed with major depressive disorder
according to the Diagnostic and Statistical manual version IV
(DSM-IV) diagnostic criteria, complaining of tension-type headache
were included in this study. The duloxetine dose was adjusted when
required. The dose range was 30–60 mg/day. Simple self-rating
questionnaire about somatic pains including headache, Hamilton
Depression Rating Scale (HDRS), Mongomery-Asberg Depression
Rating Scale (MADRS), and Beck Depression Inventory (BDI) were
administerd at baseline and repeated after eight weeks of duloxetine
trial.
Results : 33 patients had fulﬁlled this clinical trials. 18 were female
and 15 subjects were male. Their mean age (¡SD) of this group was
37.50¡8.50. Mean duration of their current depressive episode (¡SD)
at baseline was 2.78¡1.42 months. After 8 weeks of duloxetine trial,
twenty seven patients (81.8%) reported that their daily headache was
absent or improved and twenty ﬁve patients (75.8%) remained free of
analgesics. All patients who reported improvement in headache, also
showed improvement in depressive symptoms. The remaining six
patients (18.2%) reported no improvement in headache. However,
two of them showed some improvement in mood states, both sub-
jectively and objectively.
Conclusion : These data suggest that duloxetine may be eﬀective in
reducing tension-type headache in patients with major depressive
disorder.
jP-09-030jMeasuring work productivity with depression
treatment : A novel methodology
R. Lam1, S. Parikh2, R. Ramasubbu3, E. Michalak1. 1University
of British Columbia, Vancouver, Canada ; 2University of Toronto, Canada ;
3University of Calgary, Canada
Objective : It is well recognized that major depressive disorder
(MDD) is associated with signiﬁcant impairment in occupational
functioning. However, there is still little information about gains in
work productivity with eﬀective treatment of MDD, in part because
the intensive nature of standard clinical trials makes it diﬃcult for
working patients to participate. In this study, we used a novel clinical
trials methodology (telephone raters, telephone administered
psychotherapy, on-line questionnaires) to examine work productivity
outcomes in treatment of MDD.
Methods : The WORKER Study was a 12-week randomized con-
trolled trial of escitalopram plus cognitive-behaviour therapy (CBT)
in employed patients with MDD. Patients were randomized to
open-label treatment with escitalopram 10–20 mg with 8 sessions of a
validated CBT program administered by trained therapists over the
telephone (Tel-CBT), or to escitalopram with adherence reminder
telephone calls. Outcome assessments included several work pro-
ductivity questionnaires (e.g., Lam Employment Absence and
Productivity Scale [LEAPS], Sheehan Disability Scale [SDS], Health
and Work Performance Questionnaire [HPQ]) completed on-line over
a secure web site.
Results : A total of 98 evaluable patients were randomized
to treatment. There were signiﬁcant gains for both conditions on all
work productivity measures after 12 weeks of treatment. However,
some measures showed greater sensitivity to change and larger eﬀect
sizes than others.
Conclusion : The novel methodology used in this study may pro-
vide better demonstration of productivity gains in clinical trials of
depression treatment. Sensitivity to improvement in productivity
varies by scale, so productivity scales must be validated in clinical
trials.
Policy of full disclosure : Funding for this study was provided by
an investigator-initiated trials grant from Lundbeck Canada. CTRN:
NCT00702598. Dr. Lam is on ad hoc Speaker/Advisory Boards for,
or has received research funds from : Aquaceutica, AstraZeneca,
Biovail, Bristol-Myers Squibb, Canadian Institutes of Health Research,
Canadian Network for Mood and Anxiety Treatments, Canadian
Psychiatric Association Foundation, Eli Lilly, Litebook Company,
Lundbeck, Lundbeck Institute, Pﬁzer, Servier, St. Jude’s Medical,
Takeda, and UBC Institute of Mental Health/Coast Capital Savings.
Dr. Parikh has received honoraria for speaking from AstraZeneca,
Lilly, Pﬁzer, and Bristol Myers-Squibb, the Canadian Psychiatric
Association, and the Canadian Network for Mood and Anxiety
Treatments ; has served as a consultant to AstraZeneca, Lilly, Pﬁzer,
Lundbeck, and Bristol Myers-Squibb ; and received educational or
research grants from AstraZeneca, Lilly, Pﬁzer, Lundbeck, and Bristol
Myers-Squibb.
jP-09-031jThe antidepressant eﬀectiveness of agomelatine in
severely depressed and depressed elderly patients :
Subgroups of the non-interventional study
VIVALDI
G. Laux1, C. Steinmann2. 1 Inn-Salzach-Klinikums GmbH, Wasserburg
a. Inn, Germany ; 2KBO-Inn-Salzach-Klinikum, Wasserburg Am Inn,
Germany
Objective : The antidepressant eﬃcacy of agomelatine, a melatonergic
agonist and 5-HT2C antagonist, has been demonstrated in clinical
trials. The aim of this non-interventional study was to evaluate the
eﬀectiveness of agomelatine on depressive symptoms, sleep-wake
rhythm and its acceptability in routine practice. Data of 2 subgroups,
severely depressed and elderly depressed patients, are presented.
Methods : Within the VIVALDI study 3317 outpatients with
MDD were treated by 665 German psychiatrists over 12 weeks.
Patients received 25 mg agomelatine once daily (od) at bedtime, with
possible dose increase to 50 mg od if needed. Antidepressant eﬀects
were evaluated by short-version MADRS (svMADRS) and CGI, the
eﬀects on sleep and daytime functioning by a patient questionnaire
(modiﬁed CircScreen). Adverse drug reactions (ADR) were docu-
mented at weeks 2, 6 and 12. Subgroups with severely depressed
(svMADRS o30 ; n=1882) and elderly patients o65 years (n=446)
were analysed.
Results : In the total population, svMADRS total score decreased
from 30.6 at baseline to 12.8 at ﬁnal visit, in severely depressed from
36.7 to 14.7, in elderly depressed patients from 29.0 to 12.2. In total
65.8% of patients could be classiﬁed as responders (o50% decrease in
svMADRS) and 54.8% as remitters (svMADRS f12). In the sub-
groups of severely depressed and elderly depressed patients 67.8%
and 65.0% were responders, 47.8% and 59.3% were in remission, re-
spectively. Daytime sleepiness was ameliorated in 78.2% of total
population, 80.6% of the severely ill and in 68.0% of the elderly de-
pressed patients. Agomelatine was well tolerated in all groups. ADR
were reported for 10.0%, 8.9% and 10.1% of patients in total popu-
lation, severely ill and elderly depressed patients, respectively.
Conclusion : In this study agomelatine demonstrated the anti-
depressant eﬀects, improvement of daytime functioning and good
tolerability in unselected depressed patients, including multimorbid
elderly and severely depressed patients in daily practice.
Policy of full disclosure : Georg Thieme Verlag, Springer Verlag
Heidelberg/Berlin, Springer Verlag Wien, Urban & Fischer/Elsevier
Mu¨nchen, Astra Zeneca, Bayer, Boehringer Ingelheim, Jannsen-
Cilag, Lilly, Lundbeck, Merz, Novartis, Organon, Pﬁzer, Servier,
Steigerwald, Teva, Wyeth.
jP-09-033j Investigating nitric oxide synthase as an up-stream
mediator of the antidepressant action of ketamine
N. Liebenberg1, H. Mu¨ller2, G. Wegener2. 1Aarhus University Hospital,
Aarhus N, Denmark ; 2Aarhus University Hospital, Denmark
Objective : Excessive glutamate transmission at N-methyl-D-aspar-
tate receptors (NMDA-R’s) may underlie a primary mechanism in the
physiology that leads to depression, and ketamine, an NMDA-R
antagonist, rapidly alleviates depression in humans. Several down-
stream mechanisms are suggested to mediate the antidepressant
action of ketamine, including the activation of extracellular-signal-
regulated kinases 1/2 (ERK1/2), protein kinase B (or Akt) and the
mammalian target of rapamycin (mTOR). However, the mechanism(s)
that are aﬀected immediately downstream of NMDA-R’s remain un-
clear. Neuronal nitric oxide synthase (nNOS) couples to and is acti-
vated by NMDA-R’s, and the uncoupling of the nNOS-NMDA-R
complex prevents NMDA-R-mediated excitotoxicity. Therefore, we
investigated whether the antidepressant mechanism of ketamine in-
volves the inhibition of nitric oxide (NO) signalling.
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Methods : We used a genetic rat model of depression, the Flinders
Sensitive Line (FSL) rats, and their control, the Flinders Resistant Line
(FRL) rats, to investigate whether l-arginine, a precursor of NO,
attenuates the behavioural antidepressant-like eﬀect of ketamine in
FSL rats in the forced swim test (FST), and whether l-arginine can
prevent the phosphorylation of ERK1/2, Akt and mTOR by ketamine
in the frontal cortex in these rats. We also measured the activity of
nNOS activity in this region. Four groups of FSL rats received vehicle
(saline, i.p.), ketamine (15 mg/kg, i.p.), l-arginine (250 mg/kg, i.p.) or
ketamine+l-arginine, and assessed in the FST 1 hour later, whereafter
their brains were dissected for molecular assays. One vehicle-treated
group of FRL rats was used as validation.
Results : Behavioural results showed that l-arginine signiﬁcantly
attenuated the antidepressant-like action of ketamine in the FST.
Western blotting and nNOS activity experiments are on going and
these results are imminent.
Conclusion : Results from the FST suggest that ketamine’s anti-
depressant activity may involve a reduction in NO signalling.
jP-09-034jRegulation of biological rhythms with agomelatine
in patients with major depression
I.I. Lieber1, A. Epelbaum2, D.M. Epelbaum2. 1Buenos Aires, Argentina ;
2Argentina
Objective : Dysruption of circadian function is a cause of neuro-
psychiatric disorder. Ageing and stress are also associatied with a
weakened responsiveness of the circadian clock to environmental
stimuli. Agomelatine shows chronobiotic eﬀects, it has resincroniza-
tion properties. Agomelatine is an agonist of MT1 and MT2 and
antagonist 5HT2c receptors, it desinhibits the release of noradrenalin
and dopamine in the prefrontal cortex via GABA interneurons.
Agomelatine promotes slow sleep wave, increases hippocampal
neurogenesis, cell survival, neurotrophic factors BDNF, neuro-
plasticity and cell survival. It decreases stress induced glutamate
release. Activates intracellular signaling involving kinases Erk, GSK3
beta, and Akt. The objective is to regulate the altered circadian
rhythms with Agomelatine and also to evaluate its eﬃcacy in the
treatment of depression.
Methods : We administered to 150 patients, with moderate major
depression, Agomelatine 25 mg, l hour before bedtime, during a
period of 6 months. We evaluated Ham-D score, HAD for anxiety,
Epworth for sleep.
Results : Experienced at least 50% reduction in HAM depression
score and improvement in the other parameters. There was decreased
depression, prevented relapse, adverse and discontinuation symp-
toms.
Conclusion : Agomelatine potentiates the eﬀects of melatonin. It
restores the circadian rhythm, resetting the suprachiasmatic nucleus,
starts a new reorganization of neurotransmitters and hormones. It
has the potencial to balance all the biological rhythms of hormones
producing an improvement in general health,because it helps to
reinstall the balance of the PNIE system. It demonstrated eﬃcacy
in the management of major depression, anxiety and in the re-
synchronization of circadian rhythms.
jP-09-035jBlood microRNA longitudinal changes in depressed
patients during antidepressant treatment
E. Maﬃoletti1, P. Bettinsoli2, C. Giovannini2, S. Bignotti2, D. Tardito3,
D. Corrada3, L. Milanesi3, M. Gennarelli2, L. Bocchio-Chiavetto2.
1 IRCCS S. Giovanni di Dio FBF, Brescia, Italy ; 2Brescia, Italy ; 3Milano,
Italy
Objective : Major depression (MD) is a severe mental disorder that
represents one of the major causes of disability worldwide. Less than
50% of all the patients treated with the currently available anti-
depressants (ADs) shows full remission. Recent eﬀorts to develop
novel ADs have been relatively unsuccessful, mainly because of deﬁ-
cits in basic knowledge about the pathogenesis of MD and the
mechanisms behind ADs eﬃcacy. Current research supports the hy-
pothesis that this disorder is driven by abnormalities in biological
pathways contributing to synaptic plasticity. MicroRNAs (miRNAs)
are potent modulators of protein expression that play key roles in
brain pathways regulating neurogenesis and synaptic plasticity.
These small RNAs may be critical for the pathophysiology of mental
disorders and may inﬂuence the eﬀectiveness of psychotropic drugs.
In this work, we wanted to investigate a possible involvement of
miRNAs in the mechanism of action of the AD escitalopram (SSRI).
Methods : We conducted a whole-miRNome quantitative analysis
with qRT-PCR of the changes in the blood of 10 depressed subjects
after 12 weeks of treatment with escitalopram. To get a global in-
terpretation of the possible biological functions of the modulated
miRNAs, we conducted a bioinformatic analysis of the 3’UTRs human
sequences for the prediction of target genes and a functional survey
of the KEGG pathways involved.
Results : Thirty miRNAs were signiﬁcantly diﬀerentially expressed
after the treatment : 28 were up-regulated and 2 were strongly down-
regulated. The analysis of target genes and related KEGG terms
showed a signiﬁcant enrichment in several pathways associated with
neuronal brain functions.
Conclusion : The results of this study represent the ﬁrst evidence in
the blood of MD patients of a possible involvement of miRNAs in AD
action. The 12 weeks treatment with escitalopram modiﬁed the
expression proﬁles of miRNAs that potentially target a multitude of
genes implicated in outstanding neuronal functions in the adult brain.
jP-09-036jA 6 month cross sectional study of antidepressants
use in the ﬁrst visits in our center for mental
health between July and December 2011
M. Malo Lopez1, A. Pe´rez Guitart2, E. Gorgues Queralt3, P. Bonet
i Dalmau4. 1Barcelona, Spain ; 2Althaia, Division of Mental Health,
Manresa (Barcelona), Spain ; 3Althaia, Division of Mental Health,
Barcelona, Spain ; 4Althaia, Division of Mental Health, Manresa, Spain
Objective : To evaluate the characteristics of the ﬁrst 150 new patients
and to determine the use of antidepressants in our Center for Mental
Health between July and December 2011 and to determine the
characteristics of the patients that were prescribed the use of anti-
depressants.
Methods : Subjects : The population study were one hundred and
ﬁfty patients that were ﬁrst time visited in ou Center for Mental
Health between July and December 2011. Procedure : This is a cross-
sectional study -Independent variable were sex and age. Patients were
diagnosed according to DSM’s criteria-IV of Unipolar disorder,
Bipolar aﬀective disorder/Psychotic disorders/Substance use dis-
order/or comorbidity among axis II.
Results : From the selected sample of 150 patients 58 were male and
92 were female. The 82%were treated with antidepressants in the ﬁrst
visit. The 59% of the selected sample were diagnosed of Unipolar
Depression disorder, the 21.3% of Anxiety disorders and only a 6% of
Psychotic disorder and 5.3% of substances abuse disorder. The mean
age of patients treated with antidepressants was 46 years old. The
18% of the patients that were treated with antidepressants had diag-
nosis of personality disorders. To be women aged between 24th-
55th years old were the main variables associated to be prescribed the
use of antidepressants ( p-value<0.005).
Conclusion : From our selected one hundred and ﬁfty patients
visited from the ﬁrst time in our Adults Center for Mental Health
123 were treated with antidepressant, the 70% of these patients were
diagnosed of unipolar depressive disorder (86 patients) and the 22%
of the patients treated with antidepressants were diagnosed of anxiety
disorders. Antidepressants were most frequently used in that time
period by people between 24 and 55 years old. The study shows that
80% of patients visited in our Cente between 24 and 55 years old take
antidepressants, more than in any other age-sex group.
jP-09-037jDysthymia treatment with agomelatine
V. Miguel1, A. Chinchilla1, M. Garcı´a1, C. Centelles1, C. Parro1,
G. Martinez1. 1Hospital Ramo´n y Cajal, Madrid, Spain
Objective : Use of agomelatine in patients with dysthymia (DSM-IV-
R), to evaluate eﬃcacy and tolerance.
Methods : In 21 patients with dysthymia (14 women and 7 men)
we have used for three months agomelatine as basic medication.
7 patients were treated with adjunctive benzodiazepines. We have
Assessed the eﬀectiveness of treatment by HAM-D (17 items) on days
0 and 90, also a complete haemathological analysis was performed on
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all patients, including liver enzymes, and recorded the presence of
side eﬀects when reported by patients. In 11 patients we tappered of
previous antidepressant treatment because of insuﬃcient therapeutic
response, and 10 were new patients, being agomelatine their ﬁrst
treatment.
Results : The mean baseline HAM-D was 14 points and decreased
at 3 months to 8 points, almost normal. There were no notable side
eﬀects, being Agomelatine well tolerated. The patients improvement
was quite rapid.
Conclusion : We believe that agomelatine due to its special mech-
anism of action (melatonergic receptor agonist MT1 and MT2, and
antagonist of 5HT2C receptors), and in the regulation of biological
clock, as well as depressed mood, should occupy a notable place in the
treatment of dystymic Depression.
jP-09-038jComparison of the eﬀects of agomelatine and
the 5ht2c antagonists sb242084 and s32006 on
suprachiasmatic nucleus cell ﬁring rates in vitro
E. Mocae¨r1, H. Zhao2, H.J. Jin2, B.L. Zhang2, B. Rusak3. 1 I.R.I.S.,
Suresnes, France ; 2 Jilin University, Norman Bethune College, Changchun,
China ; 3Dalhousie University, Psychology and Pharmacology, Halifax,
Canada
Objective : Agomelatine is a melatonergic agonist and a 5HT2C an-
tagonist with antidepressant activity in animal models and humans.
Several preclinical studies have demonstrated that its antidepressant
activity depends on synergy between its melatonergic agonist and
5HT2C antagonist properties. We previously showed that both
agomelatine and melatonin can cause dose-dependent suppressionof
ﬁring rates of suprachiasmatic nucleus (SCN) cells in Syrian hamsters
in vivo. The aim of this study was to investigate in vitro the mech-
anism by witch agomelatine decreases SCN neuronal activity by
comparing its eﬀects to those of two 5HT2C antagonists (SB242084,
a neutral antagonist, and S32006, an inverse agonist).
Methods : Coronal slices 500 mm thick containing the SCN were
prepared from male Wistar rats, and single-unit recordings of SCN
neurons were made using glass microelectrodes. After establishment
of baseline ﬁring rates, slices were perfused with vehicle (DMSO) or
agomelatine (3.75 mg/100 ml) in one study, or with vehicle (DMSO),
SB242084, or S32006 (0.3 mM) in another study.
Results : For agomelatine, 90% of SCN neurons showed>or=20%
suppression of ﬁring rates, with decreases averaging 37.3¡32.3%
(SEM) (n=23, p<0.001. For SB242084, 73.8% of neurons showed>
or=20% suppression of ﬁring rates, with average decreases of
32.1¡8.9% (n=45, p<0.01). For S32006, 66.7% showed>or=20%
suppression of ﬁring rates, with average decreases of 31.0¡8.0%
(n=26, p<0.01).
Conclusion : These results demonstrate that the two 5HT2C
antagonists decrease spontaneous ﬁring rates of SCN neurons in vitro
and that their eﬀects are somewhat weaker than those observed with
agomelatine. The ﬁndings suggest that the melatoninergic agonist
properties of agomelatine in synergy with its 5HT2C antagonist
properties could be involved in inmediating its eﬀects on SCN
neurons. Studies using a melatonergic antagonist (S22153) are on-
going to further clarify agomelatine’s mechanism of action.
jP-09-039jPioglitazone as an adjunct to citalopram for
moderate to severe major depressive disorder :
Randomized double blind placebo-controlled trial
A. Modabbernia1, K. Sepanjnia2, S. Akhondzadeh2. 1Tehran
University, Islamic Republic of Iran ; 2Tehran University, Department of
Psychiatry, Islamic Republic of Iran
Objective : Major depressive disorder (MDD) is associated with im-
mune and metabolic disturbances, neuroinﬂammation, and impaired
neuroprotection. Thiazolidinedions(including pioglitazone) have im-
portant immunoregulatory, neuroprotective, anti-excitotoxic, and
anti-neuroinﬂammatory properties. Moreover, these drugs have
shown antidepressant eﬀect in animal models of depression as well as
open-label human studies of concurrent MDD and metabolic syn-
drome. We aimed to evaluate the antidepressant eﬀect of add-on
pioglitazone in patients with MDD in the absence of metabolic syn-
drome and diabetes.
Methods : This was a randomized double-blind placebo-controlled
study (NCT01109030). Forty patients with MDD (DSM-IV-TR) who
had Hamilton depression rating scale-17 (Ham-D) scoreo22, were
randomized to pioglitazone (15 mg every 12 hours) (n=20) or placebo
(n=20) in addition to citalopram for six weeks. Evaluation was done
using Ham-D at baseline and, second, fourth and sixth weeks. Fisher’s
exact test was used for comparison of early improvement (o20%
score reduction by second week), treatment response (o50% score
reduction), and remission(scoref7) between the two groups. Two-
factor analysis of variance (ANOVA) with repeated measures, and
analysis of covariance were used for comparison of scores between
placebo and pioglitazone groups.
Results : More patients in pioglitazone group achieved early
improvement, response at sixth week, and remission than placebo
group. (95%,95%,45% in pioglitazone group versus 30%, 40%, 15%
in placebo group, P<0.001, <0.001, 0.04 respectively). Repeated
measure ANOVA showed signiﬁcantly better results in pioglitazone
than placebo group during the course of the study[F(1,38)=9.483,
p=0.004] [Figure 1]. Subjects in pioglitazone group showed signiﬁ-
cantly lower scores at all time-points(except baseline) than placebo
group (P<0.01). Frequency of side eﬀects was similar between the
two groups.
Conclusion : Pioglitazone is an eﬀective and safe add-on treatment
in patients with moderate to severe MDD, even when metabolic syn-
drome and diabetes are not present.
jP-09-040jRisk factors of drug interaction between warfarin
and antidepressant in a clinical setting
R.J. Na1, Y.-W. Shin1. 1Asan Medical Center, Seoul, Republic of Korea
Objective : Patients with cardiovascular or cerebrovascular diseases
are at increased risk of developing depression and when depression
develops, vascular risk is exacerbated further (Lett H., 2004 ; Frasure-
Smith N., 2009). Patients with treatment-resistant depression after an
acute coronary syndrome are at an even greater risk for cardiovascu-
lar accidents (Carney R., 2009). Treatment of depression in these pa-
tients should be emphasized not only to improve quality of life but
also to acquire a better prognosis of vascular disease. Information
concerning antidepressant use concurrently with warfarin is scarce. A
study evaluating the risk factors for INR change in respect with war-
farin and antidepressants would be very helpful.
Methods : In this study, we evaluated the risk factors for INR in-
crease after addition of an antidepressant in a total of 312 patients who
used warfarin. Patients’ sex, age, BMI, AST, ALT) creatinine, indi-
cation of warfarin use, dose of warfarin, type of added antidepressant
were assessed for investigating possible risk factors with INR increase
o15% after adding an antidepressant.
Results : Among 312 patients, 106 patients (34.0%) showed an
elevation of o15% after adding an antidepressant. We selected 12
antidepressants which were used in more than 5 patients. These
12 antidepressants were used in 300 patients. Univariate analysis
showed level of creatinine, indication of warfarin use, dose of war-
farin, type of used antidepressants are potential risk factors for INR
increase in respect to antidepressant and warfarin interaction.
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Among the antidepressants, imipramine showed statistically sig-
niﬁcant increase of INR in warfarin users.
Conclusion : The results of this study suggest that level of creati-
nine, indication of warfarin use, dose of warfarin, adding imipramine
are risk factors for INR increase with respect to the interaction of
antidepressant and warfarin. The small number of patients is a limi-
tation of this study. A large-scale study comparing multiple anti-
depressants will be needed.
jP-09-041jEﬀect of a single dose SSRI on serotonin levels in
the non-human and human primate brain
M. Nord1, S. Finnema1, C. Halldin1, L. Farde2. 1Karolinska Institutet,
Stockholm, Sweden ; 2Karolinska Institutet, AstraZeneca Pharmaceuticals
CN, Stockholm/So¨derta¨lje, Sweden
Objective : Despite widespread use of selective serotonin reuptake
inhibitors (SSRIs) for treatment of depression and anxiety disorders,
the exact mechanism underlying the clinical eﬀect remain unclear. We
previously demonstrated that the newly developed 5-HT1B-receptor
speciﬁc radioligand [11C]AZ10419369 is sensitive to changes in endo-
genous serotonin concentrations in monkey. The primary aim of
the present study was to examine whether a single dose of a SSRI
(escitalopram) aﬀects endogenous serotonin levels in serotonergic
projection areas.
Methods : The study was performed in 3 monkeys and 9 human
subjects. All subjects were examined with PET and [11C]AZ10419369
at baseline and post-dose conditions (monkey n=7, human n=9).
Escitalopram was administered intravenously (2 mg/kg) to monkeys
and per orally (20 mg) to humans. The binding potential (BPND)
of [11C]AZ10419369 in serotonergic projection areas (e.g. cortical re-
gions, caudate nucleus, putamen and thalamus) were deﬁned by
means of the simpliﬁed reference tissue model (SRTM) and an equi-
librium method (monkeys only). The diﬀerence in BPND between
pre- and post-dose PET measurements was the primary outcome.
Results : In monkeys the BPND decreased post-dose in all ex-
amined brain regions.The decrease reached statistical signiﬁcance
in occipital cortex, midbrain, dorsolateral prefrontal cortex and
thalamus (p<0.05). In humans, there was on the contrary no decrease
in BPND post-dose. Across examined areas there was rather a small
increase in BPND, which reached statistical signiﬁcance in occipital
cortex (5¡5% ; p<0.05).
Conclusion : A single dose of escitalopram generated a small, but
signiﬁcant, decrease in BPND in monkey, consistent with elevated
serotonin levels. In humans, no evident eﬀect was found at a 7-fold
lower dose level. The study does not support a major eﬀect on sero-
tonin levels after administration of a single dose escitalopram in
clinically relevant doses in either species.
Policy of full disclosure : The radioligand [11C]AZ10419369 has
been developed in a cooperation between Karolinska Institutet and
AstraZeneca. Lars Farde also holds a position as Chief Scientist, iMed
CNS/Pain, AstraZeneca, Sweden.
jP-09-042jChronic ﬂuoxetine treatment increases neurogenesis
in the cortex of adult mice
K. Ohira1, T. Miyakawa1. 1Fujita Health University, Toyoake, Japan
Objective : Adult neurogenesis in the hippocampal subgranular zone
(SGZ) and the anterior subventricular zone (SVZ) is regulated by
various factors including neurotransmitters, hormones, stress, aging,
voluntary exercise, environmental enrichment, learning, and is-
chemia. Chronic treatment with selective serotonin reuptake in-
hibitors (SSRIs) modulates adult neurogenesis in the SGZ, which is
hypothesized to mediate the antidepressant eﬀect of these substances.
Layer 1 inhibitory neuron progenitor cells (L1-INP cells) were recently
identiﬁed in the adult cortex, but it remains unclear what factors other
than ischemia aﬀect the neurogenesis of L1-INP cells.
Methods : FLX solution was intraperitoneally injected into mice at a
certain dose per day for 3 weeks. FLX concentrations were determined
for individual mice. For FLX pellet treatment, the mice were sub-
cutaneously administered either FLX or control pellets (Innovative
Research of America) in the dorsal interscapular region. To label L1-
INP cells and new neurons with the retrovirus vectors that express a
ﬂuorescence protein Venus under the enhanced synapsin I promoter,
the virus solution was stereotaxically injected into the cortical layer 1
of mice.
Results : Immunoﬂuorescence and genetic analyses revealed that
FLX treatments increased the number of L1-INP cells in all examined
cortical regions in a dose-dependent manner. The virus labeling
showed that Venus-expressing GABAergic interneurons were gener-
ated from retrovirus vector-labeled L1-INP cells.
Conclusion : This study indicates that FLX treatment can control the
production of GABAergic interneurons in the cortex. The cortical
neurogenesis of L1-INP cells would also account for some of the
therapeutic eﬀects of antidepressants.
jP-09-043jCompliance of depressed patients treated with
speciﬁc serotonin reuptake inhibitors (SSRIs) and
tricyclic antidepressants (TCAs)
C. Panzaru1, L. Tilea2. 1Obregia Hospital, Bucharest, Romania ;
2Psychiatric HospitalObregia, Bucharest, Romania
Objective : Current data conﬁrms previous estimates that depression
will become in the next years one of the most important causes
of social disability. Given the importance of the problem, patient
adherence to an antidepressant treatment that has clinical eﬃcacy,
tolerability and functional rehabilitation is essential in the manage-
ment of depression. The objective of this comparative study between
the two classes of antidepressants was to evaluate the dynamic pre-
dictors that might inﬂuence the therapeutic adherence.
Methods : As a working method we carefully selected two groups
of patients so that were no signiﬁcant diﬀerences in the demographic,
socio-professional, economic and family status. The study was de-
signed with six evaluation visits at signiﬁcant intervals, thus allowing
us to obtain statistically signiﬁcant data. Instruments used : MADRS to
assess the severity of depression, Sheehan Disability Scale (SDS) as a
global functionality scale, tolerability evaluation through direct inter-
view and by spontaneous reporting of adverse reactions.
Results : The dynamics in MADRS score for the two groups of
patients treated with two classes of antidepressants was comparable.
Both classes proved to be eﬀective as of 3 months and there were no
statistically signiﬁcant diﬀerences between the two classes in terms of
therapeutic remission. Patients in both groups showed improvement
in quality of life already noticeable at ﬁrst evaluation (probably due to
a lower acute depressive simptomatology), the patients treated with
SSRIs having a better socio-occupational functioning (p=0.001). There
was a signiﬁcant diﬀerence between the percentages of patients who
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abandoned the study because of side eﬀects, a signiﬁcantly higher
proportion of patients in the group treated with TCAs presenting side
eﬀects severe enough to warrant withdrawal from research.
Conclusion : Although part of diﬀerent generations of antide-
pressants, both SSRIs and TCAs are eﬀective and retain the long-term
eﬀectiveness, the only obvious diﬀerence being therapy discontinu-
ation due to adverse reactions.
jP-09-044jExperimental medicine model shows no
depressogenic eﬀects of varenicline
A. Pringle1, R. Mocking1, C. Pﬂanz1, L. Parsons1, S. McTavish1,
P. Cowen1, C. Harmer1. 1University of Oxford, United Kingdom
Objective : To assess the eﬀects of varenicline on emotional and non-
emotional cognition. Varenicline is a partial agonist at a4b2 nicotinic
acetylcholine receptors (nAChRs) and also binds at several other
nAChRs ; the drug is used clinically as an aid to smoking cessation.
Post marketing data suggested an association between varenicline
and depression and suicide, leading to a black box warning. By con-
trast, animal studies indicated a potential antidepressant eﬀect. There
is also evidence to suggest that varenicline may beneﬁt non-emotional
cognition, in particular working memory. Healthy volunteer models
of emotional processing have the potential to detect both anti-
depressant and depressogenic eﬀects of drugs (e.g. Horder et al.,
2012).
Methods : We randomized 41 non-smoking healthy volunteers to
receive varenicline (ﬁnal dose 1 mg) or placebo for seven days. On the
seventh day emotional processing (facial expression recognition,
emotional memory and dot probe) and non emotional cognition
(working and declarative memory) were assessed.
Results : 38 volunteers were included in the analysis. Varenicline
did not aﬀect subjective ratings of mood. There were no speciﬁc
eﬀects of the drug on facial expression recognition or the dot probe.
Varenicline did, however, speed responses (p=0.02) to positive
words in the emotional recognition memory test. Varenicline also
aﬀected non-emotional memory with positive eﬀects on recall mem-
ory (p=0.02) and working memory (p=0.03).
Conclusion : These results suggest that varenicline does not have
a depressogenic eﬀect in a healthy volunteer model, in fact the
emotional recognition memory ﬁnding is more in keeping with
the preclinical data in suggesting an antidepressant-like eﬀect of the
drug. These data also provide further evidence to support the in-
volvement of nAChRs in non-emotional memory. Horder et al. (2012)
J Psychopharm 26 : 125–32.
Policy of full disclosure : CJH has acted as a consultant for the
following companies : Servier, GSK, Astra-Zeneca. Lundbeck and
P1vital. She also holds shares in P1vital and is on the advisory board.
PJC has been a paid member of advisory boards of Eli Lilly, Lundbeck,
Servier and Wyeth and has been a paid lecturer for Eli Lilly, Servier,
and GlaxoSmithKline. He has received remuneration for scientiﬁc
advice given to legal representatives of GlaxoSmithKline AP, EP, RJM,
CPP and SFMcT report no conﬂicts of interest.
jP-09-045jEﬀects of low-trapping NMDA channel blocker
AZD6765 on gamma-band EEG and
psychotomimetic liability : A comparison to
ketamine in freely behaving rats
M. Quirk1, B. Ploeger1, N. Borg1, T. Piser1, J. Doherty1. 1AstraZeneca
Pharmaceuticals, Wilmington, USA
Objective : NMDA channel blockers increase gamma-band (y40 Hz)
EEG – a potential biomarker of cortical disinhibition. Cortical dis-
inhibition is believed to contribute to the antidepressant properties of
the NMDA antagonist, ketamine. However, changes in spontaneous
gamma-band EEG have been hypothetically linked to ketamine’s
psychotomimetic adverse eﬀects. Based on in vitro and behavioural
studies, AZD6765, a low-trapping NMDA channel blocker, in clinical
development for major depression, is predicted to have an improved
tolerability proﬁle compared with ketamine. The object of the current
study was to test the hypotheses that gamma-band EEG activity can be
separated from preclinical measures of psychotomimetic liability
and evaluate the adverse eﬀect proﬁle of AZD6765 relative to
ketamine.
Methods : EEG and behaviour were monitored simultaneously fol-
lowing administration of AZD6765 or ketamine to rats chronically
implanted with skull surface electrodes and trained to perform an
auditory detection task for food reward. Pharmacokinetic-pharmaco-
dynamic modeling related EEG power within the gamma-frequency
band (35–55 Hz) to free plasma and brain concentrations.
Results : Both ketamine and AZD6765 produced concentration-de-
pendent elevations in gamma-EEG. Based on free brain exposures, the
in vivo potency of AZD6765 (relative to in vitro MK-801 site-binding
aﬃnity) was greater than that of ketamine. At high plasma con-
centrations and high gamma-EEG, ketamine and AZD6765 produced
transient reductions in attention ; however, for comparable levels
of gamma-band EEG, AZD6765 produced signiﬁcantly less perform-
ance impairment and less hyper-locomotion than ketamine.
Conclusion : This study explored gamma-band EEG measurement
as a translational, pharmacodynamic biomarker of NMDA channel
blockade. Based on its ability to elevate gamma-band EEG without
producing the same degree of behavioural disruption as ketamine,
AZD6765 may deliver antidepressant beneﬁts comparable with keta-
mine but with reduced psychotomimetic liability.
Policy of full disclosure : Full-time employee of AstraZeneca.
jP-09-046jMode of action of agomelatine : Synergy between
melatonergic and 5-HT2C receptors
G. Racagni1, D. Tardito2, M.A. Riva2, R. Molteni2, A. Mallei2,
L. Musazzi2, F. Calabrese2, M. Popoli2. 1University of Milano, Italy ;
2University of Milano, Center of Neuropharmacology, Italy
Objective : Agomelatine is a novel and clinical eﬀective anti-
depressant drug with melatonergic (MT1/MT2) agonist and 5-HT2C
receptor antagonist properties. Both receptorial components are
widely expressed in the central nervous system and, although the role
of the diﬀerent receptor activities of agomelatine in relation to its
antidepressant action has not been fully elucidated, it seems that this
compound could act synergistically on both the melatonergic and the
5-HT2C receptors. Aim of this poster is to highlight the available
preclinical evidence suggesting that the molecular/cellular eﬀects of
agomelatine and, in turn its antidepressant activity, are the result of a
synergic action between its agonism at MT1/MT2 and antagonism at
5-HT2C receptors.
Results : Indeed, it was found that survival of newborn hippo-
campal cells is stimulated only when both receptorial actions of
agomelatine are present. In the same way, only agomelatine but not
the two individual components attenuated the circadian rhythm of
BDNF transcript in prefrontal cortex, resulting in signiﬁcantly higher
expression level in the morning, and increased Arc expression.
Moreover, agomelatine showed a typical eﬀect of antidepressants,
blockade of acute stress-induced increase of glutamate release in cor-
tical areas, which was not replicated by treatments with either mela-
tonin or a selective 5-HT2C receptor antagonist. This synergic action
was shown to be responsible for agomelatine eﬀects on neurogenesis,
BDNF, Arc and glutamate release. Even if traditional antidepressants
also modulate these parameters, this eﬀect is not optimized as in the
case of agomelatine, which is able to resynchronize these eﬀectors
at distinct circuital and intracellular levels.
Conclusion : Taken together, these ﬁndings strongly suggest that
agomelatine eﬀects at the cellular level result from a synergistic in-
teraction between its action on MT1/MT2 and 5-HT2C receptors. This
interaction underlies the eﬃcacy of agomelatine in terms of restoring
circadian rhythms and relieving depressive symptoms.
Policy of full disclosure : GR has scientiﬁc collaboration with
and is member of scientiﬁc board for Eli Lilly, Innova Pharma, and
Servier. MAR has received honoraria or research support from
AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma
Co. Ltd, Eli Lilly, Innova Pharma, Merck Sharp & Dohme, Servier
and Takeda. MP has received research support and/or has been con-
sultant for Abiogen, GlaxoSmith-Kline, MerckSharp & Dohme,
Servier and Fidia. The other Authors declare no conﬂict of interest.
All authors did not receive any support for this paper from Servier.
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jP-09-047jTreatment of major depressive disorder in epilepsy
B. Radmanovic1, S. Djukic Dejanovic1, D. Ravanic1, G. Mihajlovic1,
M. Pantovic2, V. Janjic1, M. Jovanovic1, O. Radmanovic3, M. Ilic3.
1Clinical Centre Kragujevac, Serbia ; 2Medical faculty Kragujevac, Serbia ;
3Medical Faculty Kragujevac, Serbia
Objective : In epileptic subjects oﬀten apperars Major depressive dis-
order. Clinically experience sugest that low doses of SSRI are much
beather than other antidepresants agents. In this study we conﬁrm the
ﬁndings in controlled design.
Methods : The total of 67 adult patients of both genders (28 females)
with Grand-mall epilepsy (clinically and EEG veriﬁed) and de-
pression was treated either with sertraline p.o. 50 mg qd (n=35) or
with psychotherapy, particularly supportive approach (n=32).
Diagnosis of epilepsy was conﬁrmed cllinicaly and by EEG. Diagnosis
of depression was established with DSM-IV criteria and severity of
illness was assessed with the use of HAM-D scale at baseline, after 2,
4, 6 and 8 weeks.
Results : The total HAM-D scores for sertraline group at baseline,
2, 4, 6, and 8 weeks were 22.36¡5.35, 16.89¡4.64, 13.97¡3.12,
11.99¡3.05 and 9.02¡1.64, respectively (p<0.05). The total HAM-D
scores for control group at baseline, 2, 4, 6, and 8 weeks were
22.96¡5.11, 19.65¡4.03, 19.12¡4.07, 17.81¡4.14 and 17.23¡4.76, re-
spectively (p<0.05). HAM-D scores of sertraline group was signiﬁ-
cantly lower than that ones in supportive psychotherapy group
(p<0.05). There were no diﬀerences in number of seizure episodes in
study groups (1 vs. 1, p>0.05).
Conclusion : Sertraline was signiﬁcantly eﬀective in ameliorating
of Major depressive episode in epilepsy, with no additional risk for
seizures.
jP-09-048jAripiprazole adjunctive pharmacotherapy in
depression : Probable drug-drug interaction
A. Rady1, O. Elkholy1, H. Abou El Wafa1. 1Alexandria, Egypt
Objective : Aripiprazole is a third generation antipsychotic with
partial dopaminergic activity. In addition to its proven antipsychotic
eﬀects, it has become more widely accepted at the clinical level. It is
FDA-approved as an adjunctive therapy for depression with or with-
out psychotic features. This case report concerns the development
of severe Parkinsonian features in a depressed psychotic patient fol-
lowing the addition of aripiprazole to his sertraline treatment.
Methods : Irrelevant (case report).
Results : Irrelevant (case report).
Conclusion : The occurrence of extrapyramidal side eﬀects of
aripiprazole in the case reported here is likely attributable to multiple
drug interaction. This may be explained by hepatic cytochrome P450-
dependent metabolism of aripiprazole, in particular the enzyme sub-
types 2D6 and 3A4, both of which have been shown to be inhibited
by sertraline. Sertraline-inhibited metabolism of aripiprazole would
cause serum aripiprazole levels to become elevated, resulting in
greater occupancy of striatal D2 receptors and producing the observed
extrapyramidal side eﬀects.
jP-09-049jAugmenting ssris with an alpha4beta2nachr partial
agonist : Lack of eﬃcay on major depressive
disorder with insuﬃcient response
T. Ramey. Pﬁzer Inc., Groton, USA
Objective :An a4b2nAChR Partial Agonist (PA) was tested in a proof-
of-concept study to investigate its eﬃcacy, safety, and tolerability in
the augmentation of SSRIs therapy in MDD with insuﬃcient clinical
response.
Methods : An OL 8 week SSRIs treatment was followed by a
6-week, DB phase where subjects were randomized to adjunctive
a4b2nAChR PA or placebo, while continuing on ADT. The primary
eﬃcacy endpoint was the change from DB baseline (week 8) in the
MADRS total score at week 14. Independent remote interviews were
utilized to conﬁrm eligibility at screening and at week 8.
Results : In the OL phase, 297 subjects were treated with SSRIs,
of whom 162 (54.5%) subjects were qualiﬁed to be randomized in the
DB phase. When 113 of 198 planned subjects in double-blind phase
(57%) either completed or discontinued the study, a Sponsor un-
blinded interim analysis for eﬃcacy and safety was conducted. The
stopping rule for futility was met and the study was terminated early.
In the ﬁnal analysis, the treatment diﬀerence presented in LS
mean¡S.E. of the b4b2nAChR PA vs. PBO was x1.30¡1.565 with
2-sided 80% conﬁdence interval (x3.32, 0.71), (2-sided p=0.4062).
Placebo response rate (MADRS change from DB baseline at Week 6 of
the DB phase ; LS mean¡S.E=x8.30¡1.088) was not a factor in
the lack of drug eﬀect. Exploratory post-hoc analyses are currently
ongoing.
Conclusion : The lack of a treatment eﬀect of a4b2 nAChR PA vs.
placebo was demonstrated. Interim analysis with a futility rule
allowed for early termination. Placebo response rate was not a factor
in the lack of drug eﬀect. The drug was safe and well tolerated in this
study.
Policy of full disclosure : Pﬁzer, Inc.
jP-09-050jCombined use of selective serotonin reuptake
inhibitor drugs with other CNS active drugs during
early pregnancy. Consequence on congenital
malformation risk
M. Reis1, B. Ka¨lle´n2. 1Linko¨ping University, Sweden ; 2Lund University,
Tornblad Institute, Lund, Sweden
Objective : Many studies have shown that pregnant women who
use selective serotonin receptor inhibitors (SSRI) also use several other
drugs in excess compared with other pregnant women. The present
study aimed to identify women with combined use of SSRIs and other
CNS-active drugs in early pregnancy and to study the possible impact
of such combinations on teratogenicity. It has been suggested that the
combined use of SSRI and benzodiazepines should represent a higher
teratogenic risk than either of the two drug categories.
Methods : Data from the Swedish Medical Birth Registry was used.
Women giving birth between July 1, 1995 and December 31, 2008
(n=1,290,672) were interviewed in early pregnancy by midwives. Use
of any CNS active drug was reported by 26,511 and 12,050 of them
reported the use of SSRI. Data was adjusted for year of birth, maternal
age, parity, smoking in early pregnancy, number of previous mis-
carriages, and body mass index. The teratogenicity risk analyzes were
performed in two steps : (1) for each single category of drugs : Opioids
(except dextropropoxyphene and codeine), Dextropropoxyphene or
codeine, Anticonvulsants, Antipsychotics (except lithium, dixyrasine
and proclorperazine), Lithium, Benzodiazepines, Hypnotic benzo-
diazepine receptor agonists, and Other sedatives or hypnotics, and
(2) for concomitant use of an SSRI and one or more of the listed drug
categories.
Results : Use of anticonvulsants, antipsychotics, or lithium alone
was associated with an increased risk for any relatively severe con-
genital malformation and the use of opioids with an increased risk
for a cardiovascular defect. The most common drug combination was
SSRI and a benzodiazepines ; n=509. No risk increase for any con-
genital malformation or for a cardiovascular defect was found.
Conclusion : The suggested synergistic action of SSRI drugs and
benzodiazepines with respect to teratogenesis could not be supported.
jP-09-051jEﬀect of antidepressants on serum sodium levels – a
prospective study
H. Shetty1, M.K2, S.B3, G. Sharma3, J. Mohan2, P. Rajashekaran4, P.S2.
1Quintiles India Pvt Ltd, Bangalore, India ; 2Department of Pharmacology,
Mahatma Gandhi Medical College, Pondicherry, India ; 3Department of
Psychiatry, Mahatma Gandhi Medical College, Pondicherry, India ;
4Department of Psychiatry, Kasturba Medical College, Mangalore, India
Objective : Antidepressants especially Selective Serotonin Reuptake
Inhibitors have been associated with hyponatremia, though literature
is mainly in the form of case reports. Considering paucity of literature
this study aims to establish the incidence, risk factors, time of detec-
tion of hyponatremia complicating treatment with antidepressant
therapy. Also, to objectively assess the causality, severity and pre-
ventability of hyponatremia.
Methods : A Prospective study with 74 patients in the Psychiatric
outpatient setting. All patients evaluated by Psychiatrist, initiated on
antidepressant therapy, with normal serum sodium concentration at
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baseline and meeting eligibility criteria were inducted into the study
with a follow up of more than 6 months.
Results : Overall incidence of hyponatremia [<135mEq/L] was
32.4% [24/72]. Time to detection of hyponatremia was 224.71¡117.79
days [Mean¡SD]. We found a moderately strong positive correlation
between the use of mirtazapine (p value of 0.089) and venlafaxine
(p value of 0.097) with hyponatremia. Though not statistically sig-
niﬁcant we identiﬁed 3 cases of hyponatremia with use of Milnacipran
which has not been reported so far. No risk factors could be isolated as
signiﬁcant on multivariate regression analysis. Of the cases 87.5%
were identiﬁed as ‘‘probable’’ with Naranjo’s Algorithm of causality
assessment, 91.7%were identiﬁed as ‘‘moderate severity – level 3’’ on
Hartwig and Siegel’s scale and all the cases were ‘‘probably prevent-
able’’ on Schumock and Thornton scale.
Conclusion : Hyponatremia is an under-recognized and potentially
serious complication of antidepressant therapy. There is a need for
awareness and routine monitoring especially during the initial weeks
of therapy and stratiﬁcation of patients based on risk factors such as
co morbid medical conditions and concomitant medications. Our
results provide the foundation of a model for prevention, early de-
tection and treatment of hyponatremia there by reducing the mor-
tality, morbidity and health care costs associated with preventable
adverse medical events.
jP-09-052jSimilarities in the biochemical modulation of
DARPP-32, CREB, CamKII and AMPA receptors by
lurasidone and ﬂuoxetine
T.L. Stan1, V. Sousa2, X. Zhang2, A. Alvarsson2, M. Ono3,
P. Svenningssson2. 1Karolinska Institute, Univ. Hospital L8:01,
Stockholm, Sweden ; 2Karolinska Institute, Stockholm, Sweden ;
3Dainippon Sumitomo Pharma Co., Osaka, Japan
Objective : Some atypical antipsychotics have antidepressant proper-
ties and are used as adjuvant therapies in depression. Lurasidone, a
novel atypical antipsychotic, acts as an antagonist at D2, 5-HT2A and
5-HT7 receptors, but agonist at 5-HT1A receptors, a binding proﬁle
indicative of antidepressant properties. This study therefore aimed at
comparing the biochemical actions of lurasidone with that of the
ﬂuoxetine, risperidone and the selective 5-HT7 receptor antagonist,
SB-258741.
Methods : Male adult C57Bl6 mice received daily oral gavage for
3 weeks with vehicle, lurasidone (3 mg/kg), ﬂuoxetine (20 mg/kg),
risperidone (1 mg/kg) or SB-258741 (10 mg/kg). One hour after the
last drug administration, mice were killed by decapitation and their
brains were rapidily snap frozen. Cortices, hippocampi and ventral
striata were processed for immunoblotting to measure the phosphor-
ylation states of proteins implicated in actions of antidepressants.
Results : Fluoxetine and lurasidone, but not risperidone and
SB-258741, shared the ability to decrease P-Ser845-GluR1 and
P-Ser133-CREB in hippocampus. Previous work has indicated that
ﬂuoxetine increases the phosphorylation states of GluR1 and CREB.
This discprepancy is likely due to diﬀerences in administration (oral
vs. subcutaneous or intraperitoneal) and/or treatment duration
between studies. Fluoxetine and lurasidone, but not risperidone
and SB-258741, also increased P-Thr286-CamKIIbeta in ventral stria-
tum. Finally, ﬂuoxetine and lurasidone decreased P-Thr34-DARPP-
32 in ventral striatum, an eﬀect shared with risperidone and
SB-258741.
Conclusion : These data demonstrate similarities in the biochemical
modulation of several important signaling molecules by lurasidone
and ﬂuoxetine. Future studies will evaluate whether co-adminstration
of lurasidone will augment biochemical eﬀects of ﬂuoxetine and study
behavioral paradigms of antidepressant eﬃcacy.
Policy of full disclosure : Dainippon Sumitumo.
jP-09-053jEnhanced memory for reward cues following acute
buprenorphine administration in humans
S. Syal1, J. Ipser1, D. Stein1, J. von Honk2. 1University of Cape Town,
South Africa ; 2University of Cape Town, Utrecht University, Netherland,
South Africa
Objective : The mu-opioid system has been implicated in the prefer-
ential processing of reward cues in rodents, but no such data are
available in humans. The happy facial expression is a pivotal reward
cue in humans, and it has been shown that impaired memory for facial
happiness is associated with self-reported and hormonal measures of
depression. We investigated whether a single 2 mg administration of
the mu-opioid agonist, buprenorphine, would change short-term
memory for happy, angry or fearful expressions relative to neutral
faces.
Methods : Healthy human subjects participated in a randomized
placebo-controlled within-subject design, in which they performed an
emotional face relocation task after administration of buprenorphine
and placebo.
Results : Compared to placebo, buprenorphine resulted in a sig-
niﬁcant enhancement of the memory for happy faces relative to
neutral faces.
Conclusion : Our data demonstrate, for the ﬁrst time in humans,
that acute up-regulation of the mu-opioid system increases the pro-
cessing of reward cues, and thus points at potential antidepressant
properties of mu-opioid agonists in humans.
jP-09-054jSERT and NET occupancy by serotonin and
norepinephrine reuptake inhibitors in non-human
primates in vivo
A. Takano1, C. Halldin1, L. Farde1. 1Karolinska Institutet, Stockholm,
Sweden
Objective : The monoamine systems are key targets for antidepressant
drugs. The combined serotonin and norepinephrine reuptake in-
hibitors (SNRIs), a subgroup of antidepressants, have been reported to
show a large variability in relative aﬃnity in vitro for the serotonin
transporter (SERT) and norepinephrine transporter (NET), respect-
ively. For instance, the calculated aﬃnity ratio is about 30 for venla-
faxine, and 1.6 for milnacipran. However, in vitro data do not
completely predict in vivo conditions. In this study in nonhuman
primates, the in vivo occupancy of SERT and NET of the two SNRIs,
venlafaxine and milnacipran was examined by PET.
Methods : PET measurements with [11C]MADAM, a PET radi-
oligand for SERT, and [18F]FMeNER-D2, a PET radioligand for NET,
were performed in two female cynomolgus monkeys using the
High Resolution Research Tomograph (HRRT) system at baseline
conditions and after intravenous administration of venlafaxine or
milnacipran, respectively. The relationship between dose, plasma
concentration and transporter occupancy was examined by using the
hyperbolic function developed for saturation analysis and a binding
aﬃnity (Kd) was expressed by the dose or plasma concentration cor-
responding to 50% occupancy of the transporter.
Results : After administration of venlafaxine and milnacipran SERT
and NET were occupied in a dose and plasma concentration depen-
dent manner. The aﬃnity ratio between SERT and NET was 1.9 for
venlafaxine and 0.6 for milnacipran.
Conclusion : In this PET study in nonhuman primates, the aﬃnity
in vivo was similar at SERT and NET after administration of any of the
two test-drugs venlafaxine and milnacipran. This observation is not
consistent with in vitro data in the literature and illustrates the need
for in vivo studies when characterizing antidepressants.
jP-09-055jAntidepressants as putative seizure-precipitating
factors in taylor’s dysplasia
E. Theochari1, D. Kontis2, K. Ouzonidou1, A. Retziou1, M. Fiste3,
E. Neroutsos1. 1General Hospital of Elefsina, Greece ; 2Psychiatric
Hospital of Attica, Dafni, Athens, Greece ; 3Psychiatric Hospital of Athens,
Dromokaitio, Greece
Objective : This is a case report of a patient with depressive symptoms
and a history of Taylor’s dysplasia (an epileptogenic cerebral cortical
dysplasia) who demonstrated late-onset epilepsy.
Methods : We reviewed the patient’s case notes and the literature
on Taylor’s dysplasia and the association of antidepressants with
epileptic seizures.
Results : The patient is a 42 year old Greek woman who presented
at the Emergency Department following a suicide attempt by drug
overdosing and coexisting depressive symptoms. The patient had a
history of Taylor’s dysplasia, which is associated with epilepsy, but
had not experienced seizures until 5 years ago. At that time she
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was ﬁrst prescribed mirtazapine for the treatment of anxiety and
depressive symptoms. Following mirtazapine administration she
developed focal seizures associated with aura. Thereafter, she ex-
perienced 5–6 seizures per year and was treated with oxcarbazepine.
Depressive symptoms proved resistant to mirtazapine and she se-
quentially received venlafaxine and several speciﬁc serotonin re-
uptake inhibitors with moderate results. Since the ﬁrst appearance of
seizures she has always been under treatment with antidepressants.
At psychiatric assessment she exhibited depressive mood, fatigue,
loss of energy, inability to cope with stress but was free from active
suicidal ideation. Her medication comprised Paroxetine 20 mg, ox-
carbazepine 600 mg and lorazepam 5 mg daily. Following admission
to psychiatric ward and due to the potential association of paroxetine
with seizures, paroxetine was discontinued and oxcarbazepine was
increased to 900 mg daily. Despite paroxetine discontinuation,
her psychiatric symptoms improved. After three months of follow up
she remains free of seizures and no longer demonstrates depressive
symptoms.
Conclusion : This case report suggests that antidepressants could
precipitate seizures in a patient with depressive symptoms and
Taylor’s dysplasia. We conclude that antidepressants should be used
with caution in patients suﬀering from brain disorders predisposing
to epilepsy.
jP-09-056jEﬃcacy of paroxetine compare to ﬂuoxetine in the
elderly patient with major depressive disorder
S. Tomori1, I. Braho2, F. Elezi2. 1QSUT, Tirana, Albania ; 2QSUT Nene
Tereza, Tirana, Albania
Objective : Depression is a common problem in older adults. The
symptoms of depression aﬀect every aspect of your life, including
energy, appetite, sleep, and interest in work, hobbies, and relation-
ships. There are many antidepressants for the eﬀective treatment of
depression in elderly people. To compare ﬂuoxetine vs. paroxetine in
terms of eﬃcacy and time of starting eﬀect.
Methods : The eﬃcacy of paroxetine and ﬂuoxetine and their eﬀects
on cognitive and behavioural function were compared in a 6 week,
randomized study of 60 elderly depressed patients (aged 61 to
75 years). Antidepressant eﬃcacy was assessed using the Hamilton
Depression Rating Scale (HAMD), Beck Depression Inventary and
Clinical Global Impression (CGI) scale. The Mini-Mental State
Examination (MMSE), and HAMD cognitive factor scores were used
to assess cognitive and behavioural function.
Results : Paroxetine demonstrated comparable eﬃcacy to ﬂuoxetine
in the treatment of elderly depressed patients, but at the end of treat-
ment, there was a signiﬁcantly higher proportion of responders to
paroxetine than to ﬂuoxetine. Both treatments produced improve-
ments in all measures of cognitive and behavioral function.
Conclusion : Paroxetine was signiﬁcantly superior to ﬂuoxetine
from Week 3, indicating a possible early eﬀect. There was no diﬀer-
ence between the two agents in either the tolerability or safety of
treatment.
jP-09-057jPolypharmacy in major depressive disorder
C. Touloumis1, P. Ntounas1, C. Tsopelas1, D. Pappas1, C. Mokas1,
A. Vasiliou1, M. Chronopoulou1, M. Dimitraka1, I. Gogolakis1,
C. Marmarinou1, A. Douzenis2, A. Paraskevopoulou3,
P. Chatzimanolis3, S. Stamou3, S. Dimaki3, D. Dimitriadis3, E. Siouti3,
A. Konsta4, E. Rizos4. 1Psychiatric Hospital of Attica, Athens, Greece ;
22nd Dept. of Psychiatry, National and Kapodistrian, Athens, Greece ;
3Psychiatric Hospital of Attica, Athens, Greece ; 4Papageorgiou General
Hospital, Thessaloniki, Greece
Objective : Major Depressive Disorder (MDD) is a disorder, that cau-
ses interpersonal disfunctioning. Although monotherapy is usually
recommended in the initial phase of treatment, the results of STAR*D
show, that <30% of the patients gain remission with monotherapy.
The goal of this study is to investigate the incidence of antidepressant
combination therapy against monotherapy between patients with
severe depression, who are hospitalized in acute treatment depart-
ments in the Psychiatric Hospital of Attica.
Methods : The participants (47 patients) were randomly selected
among the patients of the 9 acute treatment departments in
Psychiatric Hospital of Attica. Statistic program SPSS was used in the
analysis.
Results : The participants (47 patients) had average age of 51.3 years
(SD=13.7). 44.7% of them were men, 10.6% were in involuntarily
admitted in hospital, 66% had suicidal ideation or/and attempted
suicide, only 23.4% had their ﬁrst episode, 25.5% used also illegal
substances. The average age of onset for their disorder was 35.7 years
(SD=16.6). 34% of these patients were treated with only one anti-
depressant, while the rest of them were treated with a combination of
antipsychotics or/and mood stabilizers. After 3 weeks of treatment
23.4% of them were treated with only one antidepressant, when
combination therapy with more than 3 medications was more com-
plex and frequent. We were not able to ﬁnd any statistically signiﬁcant
diﬀerences between the beginning of involuntary admission and the
discharge in terms of combination treatment.
Conclusion : Due to development study of psychopharmacology
treatment for Major Depressive Disorder a new tendency has ap-
peared : increased polypharmacy – the concurrent use of many medi-
cations – for the treatment of depression.
jP-09-058jSelective serotonin reuptake inhibitors inhibit
glycoprotein vi-mediated platelet aggregation
through the inﬂuence of the interaction between
FCRY and syk
Y.-L. Tseng. China Medical University, Taichung, Taiwan
Objective : Platelets are recognized as a peripheral model for central
serotonergic neurons because thy share similarity in the reuptake,
storage and metabolism of serotonin. The antidepressants selective
serotonin reuptake inhibitors (SSRIs) block the reuptake of serotonin
through serotonin transporter in neurons as well as platelets.
We currently reported that an SSRI, citalopram, exerts an agonist-
dependent role in inhibiting the aggregation in response to collagen
and convulxin, indicating that the transport of serotonin regulates
the activation of glycoprotein (GP) VI-mediated pathways. Therefore,
we further clarify the mechanism of the inhibitory eﬀect of SSRIs on
GPVI-mediated pathway of platelet aggregation.
Methods : Blood from healthy donors was collected by venipunc-
ture into sodium citrate (9 : 1) and centrifuged to prepare platelet-rich
plasma. The antiplatelet eﬀect of SSRIs was determined by platelet
aggregometer. The expression of GPIIb/IIIa and P-selection on plate-
lets was examined by ﬂow cytometry. The inﬂuence of SSRIs on the
molecules of GPVI-dependent signal transduction pathways was de-
termined by Western immunoblot.
Results : SSRIs inhibited convulxin-induced platelet aggregation in
a concentration-dependent manner. SSRIs inhibited the expression of
GPIIb/IIIa and P-selection induced by convulxin. In addition, SSRIs
concentration-dependently inhibited the phosphorylation of signaling
molecules including Akt and Syk, but there was no inhibitory eﬀect on
the phosphorylation of FcRc, indicating that the target site of SSRIs in
the inhibition the GPVI dependent activation pathway is downstream
of FcRc and upstream of Syk. FcRd was co-immunoprecipitated with
Syk under the stimulation of convulxin. Pretreatment of platelets with
SSRIs reduced the amount of FcRc co-immunoprecipitated by Syk.
Conclusion : In platelets, the transport of serotonin through sero-
tonin transporter during GPVI stimulation regulated the interaction
or the recruitment of Syk to FcRc. This study partially explains the
mechanism of the antiplatelet eﬀect of SSRIs.
jP-09-059jComparative analysis of agomelatine and selective
serotoninergic reuptake inhibitors in major
depressive disorder with severe anxiety features
D. Vasile1, O. Vasiliu1, A.G. Mangalagiu1, M. Blandu1, A. Nanca1,
D.G. Ojog1. 1Military Emergency Hospital, Bucharest, Romania
Objective : To evaluate the comparative medium term eﬃcacy and
tolerability of agomelatine versus selective serotoninergic reuptake
inhibitors (SSRIs) in patients diagnosed with major depressive dis-
order and signiﬁcant anxiety symptoms.
Methods : We included in our study 42 patients, 28 female and
14 male, mean age 41.5, diagnosed with major depressive disorder,
according to DSM IV TR criteria, who also presented a Hamilton
Anxiety Rating Scale (HAMA) score of at least 25, corresponding to
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severe anxiety. Mean duration of hospitalization was 12.7 days
and both the depressive and anxiety symptoms were treated using
either agomelatine 25–50 mg daily, ﬂexible dose or an SSRI (ﬂuoxetine
20–40 mg daily, paroxetine 20–40 mg daily or escitalopram 10–20 mg
daily). Patients were monitored every 4 weeks for 6 months with
psychometric instruments- Hamilton Depression Rating Scale
(HAMD) 17 items, HAMA, Clinical Global Impressions- Severity/
Improvement (CGI-S/I), Global Assessment of Functioning (GAF).
Results : Depressive symptoms responded well to agomelatine
(mean endpoint HAMD value was 12.1) and SSRIs (mean endpoint
HAMD value 10.7), without signiﬁcant inter-group diﬀerence
(p=0.332) and both psychological and somatic components of the
anxiety decreased signiﬁcantly during the agomelatine administration
(overall HAMA decrease 77.6% – somatic 68.3% and psychological
86.9% at endpoint). Patients treated with SSRIs showed a similar
evolution, with a 78.9% overall HAMA decrease (somatic 77.1% and
psychological 80.7%). CGI-S/I and GAF decreased signiﬁcantly in
both groups, without signiﬁcant diﬀerences. Agomelatine was better
tolerated than SSRIs (6 mild and moderate adverse events reported
in the ﬁrst group versus 11 in the second group). No drop out was
recorded throughout the study due to adverse events.
Conclusion : Agomelatine has a similar eﬃcacy to the SSRIs in the
treatment of major depression associated with severe anxiety features.
Agomelatine was better tolerated than SSRIs during the 6 months of
this study.
jP-09-060jQuality of life assessment in ﬁbromyalgia during
duloxetine treatment
D. Vasile1, O. Vasiliu1, A.G. Mangalagiu1, M. Blandu1, A. Nanca1.
1Military Emergency Hospital, Bucharest, Romania
Objective : To assess the quality of life in patients diagnosed
with ﬁbromyalgia during medium-term treatment with duloxetine.
Methods : A group of 25 patients, 16 female and 9 male, mean
age 53.2, diagnosed with ﬁbromyalgia were evaluated for physical
symptoms severity, depressive and anxiety symptoms, daily
functioning and quality of life, using Hamilton Depression Rating
Scale-17 items (HAMD), Hamilton Anxiety Rating Scale (HAMA),
Fibromyalgia Impact Questionnaire (FIQ), Clinical Global
Impressions-Severity/Improvement (CGI-S/I) and Quality of Life
Inventory (QOLI). Patients included in this trail received duloxetine
60–90 mg daily, ﬂexible dose, for 24 weeks and were monitored
every 4 weeks. Inclusion criteria : age between 18 and 65, no personal
history of major depressive disorder. Exclusion criteria : other severe
organic diseases, comorbid axis I or II diagnosis, HAMD over 14,
HAM over 18.
Results : Patients responded well to duloxetine therapy, as the ﬁnal
normalized FIQ score decreased with 3.4 points (p<0.01). Also,
the HAMA scores improved signiﬁcantly (x71.3%, p<0.001), with
insomnia and psychological anxiety being more responsive than other
items (x82.2% and x75% at week 24). Reduction of insomnia cor-
related highly with improvement in life quality (.51), followed by
decreased lombar pain (.43) and overall HAMD score (.40). The CGI-I
scores improved, from mean baseline values of 4.8 to 2.1 at week 24.
The quality of life scales regarding health, family relations and social
relations from the QOLI registered signiﬁcant improvement com-
pared to baseline (+25.3%, +39.2% and +26.5% respectively,
p<0.01). Patients who had the higher response rate to the treatment
also had the higher rate of life quality improvement (r=0.63). There
were 4 drop-outs registered, due to adverse events (nausea, sedation,
n=2) or non-compliance (n=2).
Conclusion : Treatment of ﬁbromyalgia with duloxetine deter-
mined improvements in pain, anxiety and depressive symptoms and,
consequently, improved patients quality of life.
jP-09-061jSerotonin transporter gene-linked polymorphic
region inﬂuences discontinuation of
pharmacotherapy with paroxetine
T. Watanabe1, M. Ueda1, Y. Hayashi1, A. Aoki1, S. Ishiguro1,
K. Shimoda1. 1Dokkyo Medical University, Mibu, Japan
Objective : Discontinuation of antidepressant is critical for the out-
come of pharmacotherapy for depression and anxiety disorders,
however, factors aﬀecting discontinuation of antidepressants have
been unknown. We investigated the association between discontinu-
ation of selective serotonin reuptake inhibitor, paroxetine (PAX) and
genetic variants of serotonin (5-HT) transporter gene-linked poly-
morphic region (5-HTTLPR),x1019C/G promoter polymorphism of
the 5-HT1A receptor in Japanese patients with panic disorder.
Methods : Subjects were 65 patients who fulﬁlled DSM-IV-TR cri-
teria for a diagnosis of panic disorder. Subjects were administered
PAX 10 mg/day for 2 weeks. Plasma concentration of PAX after the
initiation of pharmacotherapy was determined by high performance
liquid chromatography, and the patients were identiﬁed as being non-
adherent for pharmacotherapy when their plasma levels were under
the lowest limit of detection (0.5 ng/ml). 5-HTTLPR and x1019C/G
5-HT1A genotypes were determined by polymerase chain reaction
techniques. A multiple logistic regression was performed to analyze
the relationships between gender, comorbid of agoraphobia,
comorbid major depressive disorder, comorbid physical illness,
smoking, habitual use of alcohol, use of drugs for internal medicine,
5-HTTLPR andx1019C/G gene variants (independent variables) and
total discontinuation rate, discontinuation rate due to non-adherence,
discontinuation rate due to adverse eﬀects (dependent variables).
Results : Multiple logistic regression revealed signiﬁcant relation-
ship between 5-HTTLPR genotype (L/L, L/S vs. S/S) and total
discontinuation rate (46.2% vs. 21.1%, p=0.034). There were not
signiﬁcant relationships between independent variables and discon-
tinuation rate due to non-adherence (26.9% vs. 10.5%), and due to
adverse eﬀects (19.2% vs. 10.5%). The odds ratio for L allele carrier
subjects who discontinued medication was 3.21 (95% conﬁdence in-
terval, 1.07 to 9.62).
Conclusion : L allele carrier of 5-HTTLPR might predict discon-
tinuation of pharmacotherapy with PAX.
jP-09-062jThe importance of rigor in post-baseline assessments
in CNS clinical trials
J. Williams1, D. Popp1, K.A. Kobak1, M.J. Detke1. 1MedAvante,
Hamilton, USA
Objective : Inappropriate subjects may be enrolled in a study when
enrollment pressures cause inﬂated baseline severity scores. An
increasing number of studies now include methods such as blinded
independent centralized ratings (CR) to ensure that appropriate sub-
jects are entered into the trial. Post-baseline factors such as functional
unblinding, expectation bias and rater drift can also aﬀect outcomes.
Independent raters, blind to study visit, can minimize functional
unblinding and expectation bias. Continuous calibration of CR can
minimize rater drift.
Methods : Studies with both site ratings (SR) and CR can be eval-
uated to determine how critical post-baseline blinding and continuous
calibration are. A trial of acute schizophrenia used CR for the PANSS
and SR for the BPRS on the same subjects. A Parkinson’s psychosis
study used CR in the US and SR ex-US to assess subjects using the
SAPS. A GAD trial used CR of subjects enrolled by SRs’ SIGH-A
evaluations.
Results : In the schizophrenia trial, CR separated the active
comparator and one of two test arms. SR separated the active com-
parator but neither test arm. In the Parkinson’s psychosis study,
pimavanserin showed greater separation with CR than SR. In the
GAD trial, CR had lower placebo response than SR, independent of
subject selection.
Conclusion : Data from several studies support the continued im-
portance of rater blinding and independence, post subject selection.
Results suggest that precision of ratings beyond baseline can increase
the sensitivity of ﬁndings in a clinical trial, decrease placebo response
rates and potentially eliminate Type II errors.
Policy of full disclosure : MedAvante, Inc.
jP-09-063jThe power of expectation bias
J. Williams1, D. Popp1, K.A. Kobak1, M.J. Detke2. 1MedAvante,
Hamilton, USA ; 2MedAvante, Inc., Hamilton, USA
Objective : Expectation bias occurs when an individual’s expectations
about an outcome inﬂuence perceptions of one’s own or others’ be-
havior. In clinical trials, both raters and subjects may enter trials with
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expectations. Rater expectation bias occurs when raters expect that
subjects will improve over the course of the trial. Subject expectation
bias occurs when subjects themselves expect to get better. Rater and
subject expectations can interact to create a therapeutic alliance. Any
or all of these may result in increased placebo response and decreased
drug-placebo separation. Double blind studies are designed to mini-
mize bias by blinding subjects and raters to randomization assign-
ment. However, other factors to which subjects and raters are
typically unblinded, such as inclusion/exclusion criteria, adverse
events and visit sequence may also aﬀect placebo response.
Methods : We reviewed eight published studies that illustrate the
problems of subject and rater expectation bias across several thera-
peutic areas including Major Depressive Disorder, Generalized
Anxiety Disorder, psychosis, Parkinson’s disease and dementia.
Results : Studies examining rater expectation bias suggest that rater
expectations can aﬀect diagnosis and decrease IRR when subjects do
not behave according to expectations. Studies of subject expectation
bias suggest subject expectations can increase placebo response and
aﬀect study outcome. Studies of the interaction of rater and subject
expectations ﬁnd placebo response increases linearly with number of
follow-up visits, and having a diﬀerent rater for baseline, endpoint,
and sequential visits may decrease placebo response.
Conclusion : Patient expectations, rater expectations, and rater-
patient relationships can increase placebo response and decrease sig-
nal detection. Blinding raters to protocol details, including entry cri-
teria and visit number, reduces expectations of improvement. Using
diﬀerent raters at baseline, endpoint and consecutive visits reduces
the possibility that relationship bias could inﬂuence ratings. Utilizing
remote, independent raters is one means to adequately blind and vary
raters.
Policy of full disclosure : MedAvante, Inc.
jP-09-064jEarly life stress prevents the antidepressant eﬀect
of carbamazepine in the rats
N. Wongwitdecha1, E. Threenet2. 1Mahidol University, Bangkok,
Thailand ; 2Faculty of Science, Maejo University, Chiangmai, Thailand
Objective : The present study was undertaken to investigate the
eﬀects of early life stress (social isolation rearing from weaning) on the
behavioral response produced by carbamazepine in the rat forced
swimming test.
Methods : Isolation and socially reared rats were compared for their
response in the two aversive situations, either without drug pretreat-
ment or following sub-chronic administration of carbamazepine or
vehicle (2% tween 80). Beginning at 21 days of age, male Wistar rats
were raised either in social isolation (one rat/cage) or in groups of ﬁve
or six rats/cage (social rearing) for six weeks before behavioral testing.
Results : The results demonstrated that untreated isolation reared
rats showed signiﬁcantly less immobility time and more struggling in
the forced swimming test than socially reared rats. Sub-chronic ad-
ministration of carbamzepine (10, 20 and 40 mg/kg i.p.) 24, 5 and 1 h
to socially reared rats signiﬁcantly induced the antidepressant eﬀects
(decreased immobility time and increased struggling time) compared
to vehicle (2% tween 80) treated rats. However, these eﬀects were not
observed in carbamazepine treated isolation reared rats.
Conclusion : These results indicate early life stress such as social
isolation rearing prevents the antidepressant eﬀects of carbamazepine
in the rat forced swimming test, but mechanisms of action remain
unknown.
jP-09-065jPotential antidepressant, but not antipsychotic,
activity of new 2,3-dichlorophenylpiperazines
containing quinoline- or isoquinoline-sulfonamide
moieties in behavioral models in mice
D. Wrobel1, M. Jastrzebska-Wiesek1, A. Partyka1, P. Zajdel1,
M. Pawlowski1, K. Marciniec2, A. Maslankiewicz2, A.J. Bojarski3,
G. Satala3, A. Wesolowska1. 1 Jagiellonian University, Medical College,
Krakow, Poland ; 2Medical University of Silesia, Sosnowiec, Poland ;
3 Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
Objective : Aﬀective disorders are highly debilitating diseases whose
treatment is still unsatisfactory because of poor eﬃciency and un-
wanted eﬀects of drugs. The most successful approaches in drug
development are those that demonstrate preclinical antidepressant
and/or antipsychotic activity and target the unmet clinical needs.
Methods : Continuing our research with long-chain arylpiperazines
as mixed ligands of serotonergic and dopaminergic receptors, a new
series of quinoline- and isoquinoline- sulfonamides with 2,3-di-
chlorophenylpiperazine moiety (PZ-380, PZ-381, PZ-387, PZ-394, PZ-
508, PZ-547, PZ-548, PZ-549, PZ-599) were synthesized and evaluated
in vitro for their aﬃnity for dopamine D2 and serotonin 5-HT1A, 5-
HT2A, 5-HT6, 5-HT7 receptors. Selected compounds with the most
promising receptor proﬁle, i.e. PZ-380, PZ-387, PZ-508, PZ-599, were
examined in in vivo models towards their potential antidepressant
and antipsychotic activity in mice.
Results :All compounds displayed high-to-moderate aﬃnity for D2
(Ki=8–54 nM), 5-HT1A (Ki=13–88 nM), 5-HT2A (Ki=57–200 nM)
and 5-HT7 (Ki=12–83 nM) and low aﬃnity for 5-HT6 receptors
(Ki=121–13310 nM). The four selected to study compounds produced
antidepressant-like eﬀects in the forced swim test in mice with eﬀec-
tive doses of 10 and/or 20 mg/kg. PZ-380 displayed antagonistic ac-
tivity toward D2 receptors examined in the apomorphine-induced
climbing model in mice. However, the remaining compounds proved
to be partial agonists of these sites. None of the tested compounds
attenuated locomotor hyperactivity induced by MK-801 in mice.
Conclusion : The obtained results indicate that new synthesized
compounds targeting the aforementioned receptor systems could
yield an eﬀective antidepressant action. Unfortunately, in contrary to
Aripiprazole containing 2,3-dichlorophenylpiperazine moiety, poten-
tial antipsychotic eﬀects of evaluated compounds have not been pro-
ven in the hyperlocomotion induced by MK-801 in mice. Study
supported by : MNiSW (No. N N405 378 437), Funds for Statutory
Activity (UJCM), Polish-Norwegian Research Fund (No. PNRF-103-
AI-1/07).
jP-09-066jKNT-127 produces antidepressant-like eﬀects in
mice though the delta opioid receptors, without
producing convulsions
M. Yamada1, A. Saitoh2, A. Sugiyama3, T. Nemoto4, H. Fujii4,
K. Wada5, J.-I. Oka3, H. Nagase4. 1NIMH, NCNP, Kodaira, Tokyo,
Japan ; 2NCNP, NIMH, Kodaira, Tokyo, Japan ; 3Tokyo Univ. Sci., Fac.
Pharm. Sci., Chiba, Japan ; 4Kitasato Univ., Sch. of Pharmacy., Tokyo,
Japan ; 5NCNP, NIN, Kodaira, Tokyo, Japan
Objective : We have previously reported that a delta opioid receptor
(DOP) agonist, SNC80, produces potent antidepressant-like eﬀect in
rodent. However, SNC80 also produced convulsions. Recently, we
succeeded in synthesizing a novel DOP agonist called KNT-127. In
this study, we have examined the antidepressant-like and the possible
convulsive eﬀects of KNT-127 in mice.
Methods : The forced swim test was performed using male ICR
mice weighing 30–40 g. KNT-127 (1 mg/kg, s.c.) or imipramine
(6 mg/kg, s.c.), a tricyclic antidepressant, was administered 30 min
before the test session. Naltrindole (1 mg/kg, sc), a selective DOP
antagonist, was administered 30 min before KNT-127 administration.
Convulsive eﬀects on mice were measured for 20 min after the drug
treatment.
Results : In mice subjected to the forced swim test, KNT-127 sig-
niﬁcantly decreased the duration of immobility and increased the
duration of swimming. These behavioral changes were similar to
that observed for imipramine. The antidepressant-like eﬀect of KNT-
127 in mice was antagonized by pretreatment with naltrindole. On the
other hand, KNT-127 produced no convulsions at doses of up to
100 mg/kg.
Conclusion : The present study demonstrated that a novel DOP
agonist, KNT-127, induces antidepressant-like eﬀects without pro-
ducing convulsions in mice. We propose that KNT-127 should be
considered as a candidate compound for the development of DOP-
based antidepressants that have fewer undesired side eﬀects.
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jP-09-067jNeuronal correlates of antidepressant eﬀect in the
forced swim test in mice
S. Yanagida1, K. Motomura1, A. Ohashi1, K. Hiraoka1, M. Hayashi1,
S. Kanba1. 1Kyushu University, Fukuoka City, Japan
Objective : The forced swim test (FST) has been widely used as a
behavior test to evaluate antidepressant eﬀects of drugs, while the
relevant neuronal pathways remain elusive.
Methods : BALB/c mice, pretreated with imipramine (IMP ; 10 mg/
kg, i.p.) or saline, were subjected to single session of the FST (10 min).
Mice were perfused 2 hours after onset of the FST, and the expression
of c-Fos, a marker of neuronal activation, was examined through
immunohistochemical method.
Results : Pretreatment with IMP signiﬁcantly decreased the dur-
ation of immobility in FST. IMP pretreatment increased expression of
c-Fos in a few subdivisions of the bed nucleus of the stria terminalis
(BNST) and the retrochiasmatic area of the hypothalamus. The den-
sities of the c-Fos immunoreactivity in some other regions showed
positive or negative correlations with the duration of immobility in
the FST.
Conclusion : The present result suggests that the BNST and hypo-
thalamus are involved in antidepressant eﬀect in the FST. Segregated
networks of the neurons might regulate active and passive stress-
coping behaviors.
P-10. Molecular Neurobiology/Pharmacology
jP-10-001jNeuroprotective eﬀect of novel low-molecular NGF
mimetic GK-2 was completely blocked via PI3K/Akt
pathways inhibition
T.A. Antipova1, S.V. Nikolaev1. 1FSBI Zakusov’s Institute of Pha,
Moscow, Russia
Objective : The neuroprotective action of nerve growth factor NGF
are mediated by tyrosine kinase receptor and phosphatidylinositide
3 kinase (PI3K)/Akt pathways. The dimeric linear dipeptide mimetic
of NGF loop 4, hexamethylenediamide bis-(N-succinyl-glutamyl-
lysine), named GK-2 was synthesized in Zakusov’s Institute of
Pharmacology RAMN. We have previously shown that GK-2 had
neuroprotective properties on cell models of oxidative stress, gluta-
mate toxicity and MPTP-induced injury of neurons. HT-22 cells were
pretreated with PI3 kinase inhibitor LY294002 in order to investigate
signaling pathway mediating the neuroprotective action of GK-2 on
model of oxidative stress.
Methods : Experiments were carried out on hippocampal cell cul-
ture line HT-22. Cells damages were provoked by 1.5 mM hydrogen
peroxide for 30 min. After that, medium was changed to original
medium without agents. HT-22 cells were pretreated with 100 mkM
LY294002 for 30 min prior to GK-2 stimulation. Cell viability was
measured by MTT-test.
Results : It was shown that LY294002 blocked the neuroprotective
eﬀects of GK-2 (10–5 and 10–8 M) and NGF (100 ng/ml) against
hydrogen peroxide-induced cell death in all experimental time points.
Conclusion : PI3K/Akt pathways were shown to be involved in the
neuroprotective eﬀect of GK-2 as well as that of NGF.
jP-10-002jCritical care in psychiatry
D. Bandyopadhyaya1, O.P. Singh2, G. Saha3. 1Manasij, Burdwan,
India ; 2 Institute of Psychiatry, Kolkata, India ; 3Brain Clinic, Barasat,
India
Objective : Psychiatric medications are frequently an essential com-
ponent of care for critically ill patients. Their use may lead to medical
complications, however, as a result of direct toxicity from psycho-
tropic medications, drug-drug interactions, or intoxication or with-
drawal states. These complications may be a nuisance (e.g., dry mouth
and nausea) or serious and life-threatening (e.g., neuroleptic malig-
nant syndrome [NMS] and cardiac arrhythmias). This symposium
addresses the most important medical complications of psychiatric
treatment, in critical care set up.
Methods : The use of psychiatric medications in critically ill patients
is an important component of comprehensive care. Many a times a
psychiatrist is consulted by ICU Internists for alteration in behaviour,
mood, thinking and perception of reality. Because the emergence of
psychiatric symptoms may be precipitated and exacerbated by vari-
ous medical conditions, proper evaluation and emergency manage-
ment is of utmost importance. Many psychotropic drugs are notorious
for causing sudden and life threatening physical complications
needing ICU management, like Neuroleptic Malignant Syndrome,
Serotonin Syndrome, Electrolyte imbalance, Cardiac Arrythmias etc.
Conclusion : Psychotropic drugs can cause toxicity, intoxication
and withdrawl states, severe drug reactions like rashes, S-J Syndrome,
drug interaction with several drugs used in general medical con-
ditions etc, which need to be evaluated and managed. In this regard, it
is essential to consider the potential complications of psychotropics
while balancing the important role they serve in treatment of the
medically ill.
jP-10-003jDopamine D2 and 5-hydroxytryptamine 5-HT2A
receptors assemble into functionally interacting
heteromers
D.O. Borroto Escuela1, W. Romero Fernandez1, A. Tarakanov2,
M. Perez Alea3, F. Ciruela4, L. Agnati5, K. Fuxe1. 1Karolinska Institutet,
Stockholm, Sweden ; 2Russian Academy of Sciences, Saint Petersburg,
Russia ; 3Aston University, Birmingham, United Kingdom ; 4Universitat
de Barcelona, Unitat de Farmacologia, Spain ; 5 IRCCS Lido Venice, Italy
Objective : In view of the co-distribution of dopamine D2LR and
5-hydroxytryptamine 5-HT2A receptors (D2LR and 5-HT2AR, re-
spectively) within inter alia regions of the dorsal and ventral striatum
and their role as a target of antipsychotic drugs ; in this study
we assessed the potential existence of D2LR-5-HT2AR heteromers
in living cells and the functional consequences of this interaction.
Methods : In the cellular and molecular work we have used BRET,
biochemical binding, dual luciferase reporter assay, ﬂuo-4 Non Wash
Calcium Assay and a bioinformatic approach based on a set of amino
acid triplet homologies.
Results : Bymeans of a proximity-based bioluminescence resonance
energy transfer (BRET) approach we demonstrated that the D2LR and
the 5-HT2AR form stable and speciﬁc heteromers when expressed in
HEK293T mammalian cells. Furthermore, when the D2LR-5-HT2AR
heteromeric signaling was analyzed we found that the 5-HT2AR-
mediated phospholipase C (PLC) activation was synergistically en-
hanced by the concomitant activation of the D2LR as shown in a
NFAT-luciferase reporter gene assay and a speciﬁc and signiﬁcant rise
of the intracellular calcium levels were observed when both receptors
were simultaneously activated. Conversely, when the D2LR-mediated
adenylyl cyclase (AC) inhibition was assayed we showed that costi-
mulation of D2LR and 5-HT2AR within the heteromer led to inhi-
bition of the D2LR functioning, thus suggesting the existence of a
5-HT2AR-mediated D2LR trans-inhibition phenomenon. Finally, a
bioinformatics study reveals that the triplet amino acid homologies
LLT (Leu-Leu-Thr) and AIS (Ala-Ile-Ser) in TM1 and TM3, res-
pectively of the D2R-5-HT2AR may be involved in the receptor
interface.
Conclusion : Overall, the presence of the D2LR-5-HT2AR hetero-
mer in discrete brain regions is postulated based on the existence of
D2LR-5-HT2A receptor–receptor interactions in living cells and their
codistribution inter alia in striatal regions. Possible novel therapeutic
strategies for treatment of schizophrenia should be explored by tar-
geting this heteromer.
jP-10-004jNot all dopamine D2 receptor antagonists were
created equal : Potential role of presynaptic versus
postsynaptic dopamine D2 receptor blockade in
early genes induction by antipsychotics
E.F. Buonaguro1, F. Marmo2, C. Tomasetti2, F. Iasevoli2, R. Rossi2,
A. de Bartolomeis2. 1Univ.di Napoli, Italy ; 2Univ. di Napoli Federico II,
Department of Neuroscience, Italy
Objective : Striatal dopamine D2 receptor (D2R) occupancy is related
to antipsychotics eﬃcacy and extra-pyramidal symptoms (EPS) oc-
currence. Low-dose amisulpride preferentially blocks presynaptic
dopamine autoreceptors, whereas higher doses block postsynaptic
D2Rs. Antipsychotics acting preferentially at presynaptic D2R appear
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to have low propensity to induce EPS, although the molecular ex-
planation is still elusive.
Methods : We investigated, using in situ hybridization, the
expression pattern of genes involved in neural activity (c-fos and
Zif-268) and synaptic rearrangements (Homer1a and Arc) after acute
treatment with low (10 mg/kg) and high (35 mg/kg) dose
Amisulpride (AMS10 and AMS35, respectively), Haloperidol
0.8 mg/kg (HAL), and vehicle (VEH), in rat forebrain regions relevant
for psychosis pathophysiology and treatment.
Results : c-fos expression was found increased by AMS10, AMS35
and HAL in dorsomedial caudate-putamen (CP) compared to VEH
and by HAL in lateral CP compared to other treatments (p<0.05). Zif-
268 expression was induced by AMS10 and AMS35 compared to VEH
in all CP subregions and by HAL in lateral CP compared to other
treatments and in medial CP and nucleus accumbens core compared
to VEH and AMS10 (p<0.05). Homer1a expression was increased by
HAL in dorsolateral CP compared to other treatments, in ventrolateral
CP compared to VEH and AMS35, and in dorsomedial CP compared
to VEH, (p<0.05). Arc expression was induced by HAL in lateral and
ventromedial CP compared to other treatments and in dorsomedial
CP compared to VEH and AMS10 (p<0.05).
Conclusion : Amisulpride induced gene expression in a region-
speciﬁc and dose-dependent manner. Despite haloperidol, that
induced prominent gene expression in lateral CP – putatively in-
volved in EPS occurrence, amisulpride preferentially modulated
gene expression in limbic regions. These results suggest that other
mechanisms behind D2R low-aﬃnity and multireceptorial-proﬁle
of the atypical antispychotics may account for their ‘‘atypicality’’,
probably involving a diﬀerential targeting of D2R antagonism in dis-
crete brain regions.
Policy of full disclosure : This study was partially supported by an
unrestricted grant of Sanoﬁ –Avensis Italia.
jP-10-005jEﬃcacy, tolerability and critical issues of switch
from quetiapine IR to XR in patients with aﬀective
disorders
B. Del’Osso1, B. Benatti2, C. Dobrea2, C. Arici2, S. Gianetti2, L. Lietti2,
M. Serati2, M. Cigliobianco2, D. Moliterno2, A.C. Altamura2.
1Fondazione IRCCS Ca` Granda, Milano, Italy ; 2Fondazione IRCCS Ca`
Granda, Ospedale Maggiore Policlinico, Milano, Italy
Objective : To date, few studies on the switch from Quetiapine
Immediate Release (IR) to XR, in terms of eﬃcacy, compliance, quality
of life and other critical aspects have been published. The aim of the
present study was to assess the aforementioned variables in patients
with Aﬀective Disorders.
Methods : Twenty-nine patients with Aﬀective Disorders (9 with
Major Depression, 20 with Bipolar Depression) switched from
Quetiapine IR to XR were recruited. HAM-D, HAM-A, MADRS,
YMRS, CGI, BARS, DISS were administered in order to assess eﬃcacy,
compliance and tolerability. Patients were assessed at T0 (switch),
T1 (1 week after the switch) and T2 (6 weeks after the switch).
Results : The sample (13=females, 16=males) had a mean age of
51¡14 years and a mean age of onset of 34¡14 years. Patients’
therapeutic regimen changed from a mean dose of 374¡255 mg of
Quetiapine IR to 376¡243 mg of Quetiapine XR. Statistical analyses
(paired t-test) showed a signiﬁcant reduction of the total scores from
T0 to T2 on HAM-D (t=2.03 ; p=0.05), HAM-A (t=2.9 ; p=0.009) and
on CGI-S (t=2.82 ; p=0.01). The switch was well tolerated by the
65.2% of patients. Most reported side eﬀects were early and central
insomnia with daily drowsiness (17.4%), increased weight and ap-
petite (4.3%), asthenia (4.3%) and constipation (4.3%). Seventy-one %
of the sample scored 100 at BARS (maximum compliance).
Conclusion : Present results seem to support the switch from
Quetiapine IR to XR in light of better outcome measures. However,
more than one-third of the sample reported side eﬀects that, in some
cases, led to the drop-out from the study. Strategies to relieve most
commonly reported side-eﬀects (including gradual cross-switch) can
facilitate the switch. Predictors of the above mentioned side eﬀects
need to be identiﬁed.
jP-10-006jModulating glutamate transmission in a rat model
of depression
T. Femenı´a Canto´1, S. Magara1, M. Go´mez-Gala´n1, M. Lindskog1.
1Karolinska Institutet, Stockholm, Sweden
Objective : Depression is a common disease characterized by cogni-
tive and emotional symptoms, with high rate of treatment resistance,
especially for cognitive symptoms. Depression has been linked to
alterations in glutamate neurotransmission. We explored the hippo-
campal glutamatergic system in a rat model of depression (Flinders
Sensitive line, FSL) to reveal mechanisms underlying the emotional
and cognitive aspects of the disease.
Methods : To carry out this aim we combine electrophysiological,
biochemical and behavioral approaches.
Results : We showed that FSL rats displayed hippocampal CA1
synaptic plasticity impairment and increased spontaneous excitatory
post-synaptic currents (sEPSCs) in CA1 pyramidal cells compared
to Sprague Dawley rats. Western blotting revealed hippocampal re-
duced levels of the glia glutamate transporter EAAT1 and the NMDA
receptor subunit NR2A. Moreover, FSL exhibited recognition memory
deﬁcits in the novel object recognition test (NOR). We have used
pharmacological treatments to target diﬀerent mechanisms of gluta-
mate regulation. D-serine bath application restored in vitro CA1-LTP
by acting on NMDA receptors, while acute systemic administration
restored the recognition memory deﬁcit. Bath application of the
mGlu2/3 receptor agonist LY354740 reduced CA1 sEPSCs and
LY354740 chronic treatment was able to partially restore in vitro CA1-
LTP (Go´mez-Gala´n et al., 2012). At present, we have assessed the
behavioral and physiological eﬀects of the H3-receptor antagonist
clobenpropit in FSL rats. Clobenpropit acutely restored memory im-
pairments (in NOR and passive avoidance test), and had an anti-
depressant-like eﬀect in the forced swim test. Clobenpropit bath
application did not aﬀect sEPSCs although acute systemic adminis-
tration increased NR2A protein expression levels in the hippocampus
of FSL rats.
Conclusion : Glutamatergic alterations associated to depression
might require selective targeted modulation to exert both anti-
depressant and pro-cognitive eﬀects. Understanding how to regulate
the glutamatergic system directly or through the modulatory eﬀect
of monoamines would help in the development of new therapies in
depression.
jP-10-007jFluvoxamine increased glutamate release by
activating both 5-HT3 and sigma-1 receptors
in prelimbic cortex of chronic restraint stress
C57BL/6 mice
Y. Fu1, S. Yu2, H. Li2, X. Guo1, Y. Dong3. 1Shanghai Mental Health
Center, China ; 2Shanghai Mental Health Center, Shanghai Jiao Tong
University, China ; 3State Key Laboratory of Medica, Neurobiology,
Shanghai Medical, China
Objective : Emerging evidence from therapeutic trials in humans
and animal models suggests that in the treatment of depression,
antidepressants play a role by targeting the glutamatergic system.
Fluvoxamine is one of a widely-used SSRIs which has been con-
sidered to target monoamine neurotransmitter reuptake mechanisms.
However, if ﬂuvoxamine has an eﬀect on the glutamate release is still
unclear. The present experiment studied the eﬀect of ﬂuvoxamine on
presynaptic glutamate release in prelimbic cortex, both in control
C57BL/6 mice and chronic restraint stress C57BL/6 mice, and further
investigated the mechanism underlying this eﬀect.
Methods : The present experiment studied by using patch clamp,
on-line ﬂuorimetry, pharmacological approaches combined with
other techniques.
Results : The results showed that ﬂuvoxamine increased the gluta-
mate release in the depression model mice but it had no eﬀect on the
glutamate release in the control mice. The mechanism underlying
these eﬀects in depression model mice was that, ﬂuvoxamine ﬁrstly
activated presynaptic 5-HT3 receptors, which transiently increased
the Ca2+ concentration. The increase of Ca2+ concentration via
5-HT3 receptors caused the activation of sigma-1 receptors, which
were activated by ﬂuvoxamine. The activation of sigma-1 receptors
increased the intrasynaptosomal Ca2+ concentration signiﬁcantly
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through the outﬂow of endoplasmic reticulum calcium and ﬁnally
activated PKC.
Conclusion : These results suggested that ﬂuvoxamine may have
a selective eﬀect and diﬀerent mechanism based on the condition of
animal.
Policy of full disclosure : This work was supported by Project
30800320, 30800317 of Foundation of National Natural Science of
China and National Key Project for IND, No. 2008ZX09312–003.
jP-10-008jThe cytochrome P450-mediated synthesis of
serotonin in the brain : An in vitro study
A. Haduch1, E. Bromek1, J. Wo´jcikowski1, W.A. Daniel1. 1 Institute of
Pharmacology PAS, Krakow, Poland
Objective : Brain cytochrome P450 (CYP) may be involved in the
local metabolism of drugs and endogenous substrates such as neuro-
steroids or monoaminergic neurotransmitters. The CYP2D-mediated
synthesis of dopamine and serotonin has been shown in vitro and
in vivo ; however, the formation of serotonin by this enzyme in the
brain has not been demonstrated as yet. Therefore the aim of
the present study was to demonstrate that the CYP2D-mediated
synthesis of serotonin from 5-methoxytryptamine took place in the
brain.
Methods : The experiment was carried out on male Wistar rats. The
ability of CYP2D isoforms to O-demethylate 5-methoxytryptamine
to serotonin was tested using rat recombinant CYP2D isoforms
(CYP2D1/2/4/18) and human CYP2D6. The obtained results were
compared with those concerning other CYP isoforms from the
subfamilies CYP2A, 2B, 2C and 3A. Then O-demethylation of 5-
methoxytryptamine was studied in brain microsomes in the absence
or presence of the CYP2D inhibitor quinine or ﬂuoxetine. Microsomes
were prepared from the whole brain or from diﬀerent brain
structures including the brain stem (containing serotonergic raphe
neurons) of control rats. The concentration of serotonin formed in vitro
was measured using HPLC.
Results : Of the rat CYP isoforms studied, CYP2D isoforms
(CYP2D2, CYP2D4 and CYP2D18) were the most eﬀective in catalyz-
ing the O-demethylation of 5-methoxytryptamine to serotonin ; how-
ever, human CYP2D6 was more active than rat CYP2D isoforms in
this respect. The formation of serotonin from 5-methoxytryptamine
was demonstrated in microsomes derived from diﬀerent brain struc-
tures. The reaction was inhibited by the two CYP2D inhibitors, quin-
ine and ﬂuoxetine.
Conclusion : In conclusion, brain CYP2D isoforms are able to cata-
lyze the formation of serotonin from 5-methoxytryptamine, which
may be of pharmacological importance to the treatment of psychiatric
diseases. (Grant DeMeTer no. POIG.01.01.02–12-004/09 (European
Union and the Ministry of Science and Higher Education, Warsaw,
Poland) and statutory funds from the Institute of Pharmacology,
PAS).
jP-10-009jDopaminergic signalling and associative learning
in the nematode caenorhabditis elegans
I. Hellwig1, W. Kaschka2, S. Hodgkinson2. 1University of UIm,
Ravensburg, Germany ; 2University of UIm, ZfP Su¨dwu¨rttemberg,
Ravensburg, Germany
Objective : Introduction : Defective dopaminergic signalling has been
implicated in the aetiology of a number of neuropsychiatric disorders.
However, although the molecular mechanisms involved in the
stimulus-reward pathway are relatively well characterised, their role
in behavioural plasticity remains unclear. We use the nematode
Caenorhabditis elegans (C.elegans) as a model to study behavioural
plasticity as it has a simple nervous system, comprising just 302
neurons, whilst at the same time exhibiting relatively complex behav-
ioural strategies.
Methods : Using a chemotaxis assay, we tested the role dopamine
signaling played in olfactory associative learning. We compared
olfactory chemotaxis in C. elegans wildtype (N2), the dopamine
negative mutant (cat-2-), and the serotonin negative mutant (tph-1-).
The Chemotaxis Index (CI), a measure of the strength of association
between food and a volatile odour (benzaldehyde) was determined
for each of the strains.
Results : As reported in previous work, the serotonin-deﬁcient
mutant tph-1- exhibited no olfactory chemotaxis. The dopamine-
deﬁcient mutant cat-2- exhibited a similar proﬁle to the wildtype ex-
cept for a raised CI 60 minutes after the end of the conditioning phase.
This increase in CI could be reduced by exposing cat-2- mutants to
exogenous dopamine.
Conclusion : The loss of the conditioning in the cat-2- mutants after
60 minutes and its reinstatement by exogenously applied dopamine
suggests a complex balance exists between dopamine and other
pathways involved in the maintenance of conditioning. One possible
mechanism would involve the repression of an ‘association signal ’ by
dopamine. In the cat-2- mutant the ‘association signal ’ is expressed
and, in the presence of food-odour stimuli, association gradually re-
turns reaching a maximum after 60 minutes. The subsequent decrease
in the CI after 60 minutes in the cat-2- mutant can be explained by
a negative feedback mechanism. We are working to identify this
signal and testing whether there is a dopamine dose eﬀect on this
mechanism.
jP-10-010jTemporal and spatial changes in tryptophan
hydroxylase expression are associated with
behaviour switching in caenorhabditis elegans
I. Hellwig1, S. Hodgkinson2, W. Kaschka2. 1University of UIm,
Ravensburg, Germany ; 2University of UIm, ZfP Su¨dwu¨rttemberg,
Ravensburg, Germany
Objective : Background : Tryptophan hydroxylase (tph) is a key en-
zyme in the biosynthesis of the neurotransmitter serotonin (5-HT).
During the adult stage of development and in response to particular
external conditions (presence of food), the nematode Caenorhabditis
elegans switches behavior from feeding to egg laying. This behavior
switching is controlled by serotonin but the mechanism remains un-
clear.
Methods : Wildtype C. elegans carrying a tph-1 promotor : :gfp
construct were live mounted on 5% agarose and changes in tph-gfp
was documented via ﬂuorescence microscopy as worms entered the
egg-laying phase of their life cycle.
Results : We show that wildtype worms entering the egg laying
phase upregulate tph expression in speciﬁc tissues including muscle
tissue adjacent to the vulva. This pattern of expression is not seen in
worms during the other stages of larval and adult development.
Conclusion : 5-HT has both a stimulatory (via a G protein-coupled
receptor) and inhibitory (via a 5-HT-gated Cl- channel) eﬀect on egg
laying. Long term exposure to 5-HT attenuates this inhibitory re-
sponse. The local actions of 5-HT include the stimulation of vulval
contractions. Taken together, the changes in tph expression we ob-
served are consistent with it playing a central role in egg laying be-
havior. We are now looking for potential candidates that might
regulate tph transcription consistent with the expression patterns
we observed.
jP-10-011jStress regulates the gene expression of neuronal PAS
domain 4 (Npas4), via glucocorticoid receptor
Y. Hibi1, J. Yun1, T. Nagai1, K. Yamada1. 1Nagoya University, Japan
Objective : The expression levels of neuronal PAS domain 4 (NPAS4)
mRNA are decreased in the hippocampus of socially-isolated or
chronically restricted mice, which is accompanied by impairments
of memory and emotional behavior with a reduced hippocampal
neurogenesis. The reduction of NPAS4 expression induced by
psychosocial stress may play a role in mental disorders, since NPAS4
has recently been shown to regulate the development of GABAergic
inhibitory neurons. In this study, to investigate the transcriptional
regulation of NPAS4 expression by stress, we focused on the eﬀect of
corticosterone (CS) on NPAS4 transcription.
Methods : Npas4 expression level in the hippocampus of ICR mice
were measured 2 hours after the CS (10 mg/kg) injection or 1 week
after the adrenalectomy. Eﬀect of CS on Npas4 expression in restraint
stressed mice was evaluated by using a glucocorticoid receptor (GR)
antagonist, RU486. The eﬀect of GR on the Npas4 promoter activity
in Neuro2a cells was determined by a luciferase assay. Interaction
of GR and Npas4 promoter was conﬁrmed by a chromatin im-
munoprecipitation assay.
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Results : Acute CS treatment signiﬁcantly decreased the expression
level of Npas4 mRNA in the hippocampus of mice, while the
expression level was increased by adrenalectomy. The GR antagonist
RU486 inhibited the reduction of NPAS4 expression induced by
restraint stress. Reduced NPAS4 expression was also observed in
CS-treated Neuro2a cells. Putative GREs were found at x2 kb to
x1 kb upstream of the transcription initiation site of Npas4 promoter.
The Npas4 promoter activity was increased by deletion of GREs rich
sequence or treatment with RU486. Moreover, chromatin immuno-
precipitation assay revealed the binding of ligand-bound GR to Npas4
promoter region.
Conclusion : These results suggest that psychosocial stress reduces
the Npas4 gene expression via the binding of CS/GR complex to
GREs located on the promoter region of the gene.
jP-10-012jPotentiation of nerve growth factor-induced neurite
outgrowth in PC12 cells by aripiprazole
T. Ishima1, M. Iyo1, K. Hashimoto1. 1Chiba University, Japan
Objective : Accumulating evidence suggests that neuronal plasticity
plays a role in the mechanisms of action of atypical antipsychotic
drugs. The atypical antipsychotic drug aripiprazole has been used as
treatment of psychiatric diseases such as schizophrenia, major de-
pression, bipolar disorder, and autism. In this study, we examined
whether aripiprazole could aﬀect nerve growth factor (NGF)-induced
neurite outgrowth in PC12 cells.
Methods : Twenty-four hours after plating, the medium was
replaced with DMEM containing 0.5% FBS, 1% penicillin and 1%
streptomycin with NGF (2.5 ng/ml), with or without aripiprazole,
WAY-100635 (5-HT1A receptor antagonist), xestospongin C, 2-APB
(IP3 receptor antagonists) or several speciﬁc inhibitors of cellular sig-
naling pathways (PLC-c, PI3K, Akt, p38 MAPK, and c-Jun N-terminal
kinase (JNK), and the Ras/Raf/ERK/MAPK). Four days after incu-
bation with NGF and test drugs, morphometric analysis on neurite
outgrowth in PC12 cells was performed.
Results : Aripiprazole signiﬁcantly potentiated NGF-induced
neurite outgrowth, in a concentration dependent manner. Potentiation
of NGF-induced neurite outgrowth mediated by aripiprazole was
signiﬁcantly antagonized by co-administration of the selective 5-
HT1A receptor antagonist WAY-100635, but not the dopamine
D2 receptor antagonist sulpiride. Furthermore, the potentiation of
NGF-induced neurite outgrowth by aripiprazole was signiﬁcantly
blocked by IP3 receptor antagonists (xestospongin C and 2-APB).
Moreover, selective inhibitors of several cellular signaling pathways
signiﬁcantly blocked the potentiation of NGF-induced neurite out-
growth by aripiprazole.
Conclusion : These ﬁndings suggest that aripiprazole could
potentiate NGF-induced neurite outgrowth in PC12 cells, and that
the beneﬁcial eﬀects of aripiprazole on neuronal plasticity may be in-
volved in the mechanisms of it’s action.
jP-10-013jPotentiation of nerve growth factor-induced neurite
outgrowth in PC12 cells by ifenprodil : The role of
sigma-1 and IP3 receptors
T. Ishima1, K. Hashimoto1. 1Chiba University, Japan
Objective : Ifenprodil (Cerocral1) has been used as a cerebral vaso-
dilator in a limited number of countries, including Japan and France.
In addition to both the b1 adrenergic receptor and N-methyl-D-
aspartate (NMDA) receptor antagonists, ifenprodil binds to the two
subtypes (1 and 2) of sigma receptor. In this study, we examined the
eﬀects of ifenprodil on nerve growth factor (NGF)-induced neurite
outgrowth in PC12 cells. Furthermore, we examine the role of these
receptors on the potentiation of NGF-induced neurite outgrowth by
ifenprodil.
Methods : Twenty-four hours after plating, the medium was re-
placed with DMEM containing 0.5% FBS, 1% penicillin and 1%
streptomycin with NGF (2.5 ng/ml), with or without ifenprodil,
prazosin (a1 adrenergic receptor antagonist), Ro 25–6981 (NMDA
receptor NR2B antagonist), NE-100 (sigma-1 receptor antagonist),
SM-21 (sigma-2 receptor antagonist), xestospongin C (inositol 1,4,5-
triphosphate (IP3) receptor antagonist) or 2-aminoethoxydiphenyl
borate (2-APB) (IP3 receptor antagonist). Four days after incubation
with NGF and test drugs, morphometric analysis on neurite out-
growth in PC12 cells was performed.
Results : Ifenprodil signiﬁcantly potentiated NGF-induced neurite
outgrowth, in a concentration-dependent manner. In contrast, prazo-
sin and Ro 25–6981 did not alter NGF-induced neurite outgrowth.
Potentiation of NGF-induced neurite outgrowth mediated by ifen-
prodil was signiﬁcantly antagonized by co-administration of the
selective sigma-1 receptor antagonist NE-100, but not the sigma-2
receptor antagonist SM-21. Furthermore, the potentiation of NGF-
induced neurite outgrowth by ifenprodil was signiﬁcantly blocked by
treatment with the IP3 receptor antagonists, xestospongin C or 2-APB.
Conclusion : These ﬁndings suggest that activation at sigma-1 re-
ceptor and subsequent interaction with IP3 receptor may mediate the
pharmacological eﬀects of ifenprodil on neurite outgrowth.
jP-10-014jModulation of the extracellular D-serine contents
by the a-amino-3-hydroxyl-5-methyl-4-isoxazole-
propionate type glutamate receptor in the rat medial
frontal cortex as revealed by in vivo microdialysis
S. Ishiwata1, T. Nishikawa1, A. Umino1, M. Umino1. 1TMDU, Tokyo,
Japan
Objective : It has been widely accepted that D-serine plays a pivotal
role in the control of the N-methyl-D-aspartate (NMDA) type gluta-
mate receptor as its endogenous co-agonist in the mammalian brain.
Abnormalities in the extracellular D-serine signal, which lead to the
NMDA receptor dysfunction, have been implicated in the patho-
physiology of a variety of neuropsychiatric disorders such as schizo-
phrenia. The exact mechanisms underlying regulation of extracellular
release of D-serine, however, await further elucidation. To get an in-
sight into this issue, we have characterized the eﬀects of agents acting
at the a-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA)
type glutamate receptor on the extracellular contents of cortical
D-serine in vivo, because in vitro experiments have suggested the
involvement of the AMPA receptor in the control over the extra-
cellular release of D-serine in the central nervous system although
there is so far no in vivo evidence to for this interaction.
Methods : The present animal studies have been approved by the
ethics committees of the Tokyo Medical and Dental University. We
used an in vivo microdialysis technique in combination with high-
performance liquid chromatography with ﬂuorometric detection.
Results :We have shown that intra-medial frontal cortex infusion of
the S-enantiomer of AMPA, an active enantiomer at the AMPA re-
ceptor causes a signiﬁcant reduction in the extracellular contents of
D-serine in the cortical area of the rat in a concentration-dependent, an
AMPA/kainate receptor antagonist NBQX- and a calcium permeable
AMPA receptor antagonist NASPM-reversible manner. The reducing
eﬀects of S-AMPA are augmented by co-infusion of an allosteric
modulator of the AMPA receptor, cyclothiazide, which prevents
AMPA receptor desensitization.
Conclusion : Our data support the view that the calcium permeable
subtype of the AMPA receptor might exert a phasic inhibitory inﬂu-
ence on the extracellular release of D-serine in the mammalian frontal
cortical area in vivo.
jP-10-016jAfobazole decrease menadione genotoxicity
I. Kadnikov1, M. Voronin1, S. Seredenin1. 1SF IPh RAMS, Moscow,
Russia
Objective :NRH quinone reductase 2 (NQO2) is a structural analog of
well known phase-II biotransformation enzyme NAD(P)H quinone
reductase 1 (NQO1). NQO2 catalyze two-electron reduction of o- and
p-quinones. However, because of speciﬁcs in the tertiary structure it is
capable for one-electron reduction of quinones, menadione for one,
and generation of reactive oxygen species. Overexpression of NQO2 is
associated with Alzheimer’s disease and idiopathic Parkinson’s dis-
ease, which pathogenesis is related to ROS generation due to products
of catecholamine self-oxidation, dopa-quinone ﬁrst of all. Our pre-
vious studies had revealed ligand properties of selective anxiolytic
with neuroprotective activity afobazole towards to MT3 receptor,
also known as regulatory site of NQO2 enzyme. In the next set
of experiments we established that afobazole is NQO2 inhibitor
with Ki=2.54r10–4 M (obtained for human recombinant NQO2).
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The purpose of present study was to determine the inﬂuence of afo-
bazole on NQO2-dependant quinone mediated genotoxicity as a
marker of oxidative stress in the model of menadione toxicity in vitro.
Methods :Materials and methods : We have used the single cell gel
electrophoresis assay (comet assay) as a marker of oxidative stress to
investigate the model quinone compound menadione genotoxic ef-
fects in mice bone marrow cells.
Results : Our experiments on menadione genotoxicity have shown
that incubation of mice bone marrow cells with dicoumarol in con-
centration of 10 mM, a potent selective NQO1 inhibitor, lead to 5,4-fold
increase in the amount of DNA-strand breaks contrary to control
group. Afobazole administration in concentration of 10 mM in same
conditions lead to 1,7-fold decreased toxicity.
Conclusion : Afobazole decrease NQO2 mediated menadione gen-
otoxicity. Obtained data assume one of the possible molecular
mechanisms of neuroprotective activity of afobazole. Thus the further
investigations are required.
jP-10-017jAntidepressants enhance hippocampal dendritic
outgrowth via mTOR signaling pathway
Y.-H. Kim1, J.-G. Lee2, S.-W. Park3, M.-K. Seo3, H. Cho3, C.-H. Lee3.
1Haeundae Paik Hospital, Busan, Republic of Korea ; 2Haeundae Paik
Hospital, Paik Institute for Clinical, Busan, Republic of Korea ; 3Paik
Institute for Clinical Research, Busan, Republic of Korea
Objective : A growing body of evidence has pointed to the rapid
antidepressant eﬀect of the subanesthetic dose of ketamine, N-methyl-
D-aspartate (NMDA) receptor antagonist, via mammalian target of
rapamycin (mTOR) signaling. mTOR signaling plays a fundamental
role in axonal and dendritic growth. However, the mechanisms
underlying this action of antidepressants have not been identiﬁed. We
examined whether certain antidepressants (escitalopram, ﬂuoxetine,
paroxetine, sertraline, imipramine and tranylcypromine) promote
neurite outgrowth via mTOR signaling in primary cultured hippo-
campal neurons.
Methods : Rat hippocampal cells were treated with ketamine or
antidepressants for 5 days. Rapamycin, mTOR inhibitor, was added
30 min before drugs treatment. Using neurite assays, we measured
changes in the dendritic morphology of hippocampal neurons.
Results : We found that ketamine (1–100 mM) and all anti-
depressants (1–50 mM escitalopram, 0.1–10 mM ﬂuoxetine, 0.05–1 mM
paroxetine, 0.05–1 mM sertraline, 0.1–10 mM imipramine and 1–50 mM
tranylcypromine) signiﬁcantly increased the total outgrowth of
hippocampal dendrites in dose-dependently (p<0.01). This eﬀect of
ketamine was blocked by mTOR inhibitor rapamycin (1 mM)
(p<0.01). The eﬀects of escitalpram, paroxetine and tranylcypromine
were also attenuated by rapamycin (p<0.05). In contrast, ﬂuoxetine,
sertraline and imipramine did not aﬀect this eﬀect.
Conclusion : This study presents novel in vitro evidence that some
antidepressants could promote neurite outgrowth through mTOR
signaling pathway. This ﬁnding may provide new target protein
for the mechanisms underlying neurotrophic properties of anti-
depressants.
jP-10-018jComparative study of hemantane and amantadine in
rats with experimental intracerebral posttraumatic
hematoma
V. Krayneva1, S. Kotelnikova2, I. Kokshenev2, E. Valdman2. 1Zakusov
Inst. of Pharmacology, Moscow, Russia ; 2Zakusov Inst. of Pharmacology,
RAMS, Moscow, Russia
Objective : Hemantane (H.) (N-2(adamantyl)hexamethylenimine hy-
drochloride) is novel antiparkinsonian drug with complex mechanism
of action including NMDA receptor antagonism and antiradical ac-
tivity which allows to suppose the neuroprotective eﬀect of H. The
aim of the study was to assess the eﬀects of H. in comparison with
amantadine (AMA) in rats with intracerebral posttraumatic haema-
toma (IPH) which could be considered as a model of haemorragic
stroke.
Methods : Sham-operated and rats with IPH were treated with sal-
ine (groups 1 and 2). H. (5 mg/kg, i.v.) or AMA (20 mg/kg, i.v.)
(groups 3 and 4). Saline and drugs were administered ﬁrst at 3,
5 hours after surgery and then for 4 consecutive days. On days 1, 3,
7 and 14 after surgery animals were placed in open ﬁeld, elevated
plus-maze, rotarod and passive avoidance tests.
Results : It was shown that both drugs signiﬁcantly decreased
mortality and improved motor activity and exploratory behavior in
open ﬁeld. AMA was little more eﬀective in improving motor activity
and exploratory behavior. In passive avoidance test no impairment
of hole reﬂex in all groups of rats was registered. Impaired acquisition
in animals with IPH was revealed in all retention trials. H. and AMA
prevented these alterations. H. 5 mg/kg i.v. demonstrated more pro-
nounced activity in restoring memory. There was no diﬀerence in re-
trieval testing between treated with H. and sham-operated animals
in all days of testing sessions, while termination of AMA treatment
caused decrease in retrieval of memory trace on day 7.
Conclusion : The results obtained testify for neuroprotective
properties of the novel antiparkinsonian drug hemantane.
jP-10-020jSerum pro-brain derived neurotrophic factor and
remission in depressed patients after selective
serotonin reuptake inhibitors treatment
S.-W. Lim1, H. Kang1, Y. Lee1, S.H. Kim1, J.H. Song1, S. Kim1,
J.S. Beck1, S.Y. Park1, D.K. Kim1. 1Samsung Medical Center, SBRI, Seoul,
Republic of Korea
Objective : The role of brain-derived neurotrophic factor (BDNF) has
been mainly known, implicating in the hippocampal neurogenesis
after antidepressant administration. It have been reported that serum
BDNF content is related to depression etiology and antidepressant
treatment, but they are controversial. Recent studies found that
proBDNF before processing is related to apoptosis by binding to
p75 NTR (neurotrophin receptor) and may facilitate long–term
depression. Our hypothesis is that the two forms of BDNF(pro- and
total-) are related to depression susceptibility and remission after
Selective Serotonin Reuptake Inhibitors(SSRI) treatment in elderly
depressed patients.
Methods : Twenty-nine elderly patients, diagnosed as major
depression according to criteria for depression of DSM-IV, entered a
6 week clinical trial with SSRIand documented the several clinical
variables and plasma drug concentrations. Remission was deﬁned
as=<7 score of HAM-D. Patients and 29 normal volunteers were
drawn venous blood between 9y12 a.m. Serum proBDNF immuno-
reactivity was determined by western blot and total BDNF(tBDNF)
content by BDNF Emax Immunoassay System. Comparison between
two groups was analyzed using t-test or Mann-Whitney test in SPSS
ver.10.1.
Results : No serum proBDNF immunoreactivity and total BDNF
contents was diﬀered between normal volunteer and depressed
patients. After 6 week of SSRI administration, proBDNF immuno-
reactivity was increased in remitted patients compared than in non-
remitted patients (p=0.041, by t test).
Conclusion : Our results suggest that serum proBDNF is possible
to be candidate marker for remission after SSRI treatment. Further
studies should elucidate the mechanism of the two types of BDNF in
serum related to SSRI action.
jP-10-021jComparative receptor binding proﬁle of lurasidone
and other ﬁrst and second generation antipsychotics
A. Loebel1, T. Ishiyama2, J. Cucchiaro1, T. Horisawa2, K. Tokuda2,
M. Ogasa2, P. Werner3, A. Pikalov1, T. Ishibashi4. 1Sunovion
Pharmaceuticals Inc, Fort Lee, USA ; 2Dainippon Sumitomo Pharma Co.,
Osaka, Japan ; 3Sunovion Pharmaceuticals Inc, Marlborough, USA ;
4Osaka, Japan
Objective : To characterize the receptor binding proﬁle of lurasidone
compared to other ﬁrst and second generation antipsychotics.
Methods : Binding aﬃnities for lurasidone and other antipsychotics
were determined in side-by-side assays using membrane preparations
from non-human CNS or cell lines expressing cloned human re-
ceptors.
Results : Lurasidone displayed potent binding and full antagonism
at dopamine D2 (Ki, 1.68 nM) and 5-HT7 (Ki, 0.49 nM) receptors ;
lurasidone had the highest aﬃnity for the dopamine D2 receptor
among antipsychotics tested, followed by risperidone and haloper-
idol. Lurasidone also showed full antagonism and high aﬃnity at
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serotonin 5-HT2A receptors (Ki, 2.03 nM). Lurasidone had nanomolar
aﬃnity (Ki=6.75 nM) for serotonin 5-HT1A receptors, behaving as a
weak-moderate partial agonist. Relative to dopamine D2 receptor
binding, lurasidone showed higher aﬃnity for 5-HT7, 5-HT2A, and
5-HT1A than the other antipsychotic agents tested. Lurasidone’s
binding to dopamine receptors was selective for dopamine D2 re-
ceptors : compared to its dopamine D2 receptor aﬃnity, its Ki for D1
receptors was 156-fold higher, for D316-fold higher, and 30-fold
higher for D4 receptors. Lurasidone had a favorable binding-proﬁle
at several receptors that are suspected of being associated with un-
desirable eﬀects, with minimal aﬃnity for 5-HT2C receptors (Ki,
415 nM), and no aﬃnity for histamine H1 (IC50>1000 nM) and mus-
carinic [cholinergic] M1 (IC50>1000 nM) receptors. Lurasidone also
displayed only moderate aﬃnity for a2C adrenoceptors (Ki, 10.8 nM),
and moderate-weak aﬃnity for a1 adrenoceptors (Ki, 48 nM).
Conclusion : Lurasidone has potent and selective antagonist
activity at the D2 receptor, coupled with equally potent antagonist
activity at both 5-HT7 and 5-HT2A receptors. This proﬁle is consistent
with the expected antipsychotic eﬃcacy, a moderate likelihood of EPS,
a low potential for weight gain and related metabolic consequences,
and the potential for beneﬁcial impact on mood and impaired cogni-
tive function.
Policy of full disclosure : Drs. Loebel, Cucchiaro, Werner and
Pikalov are full-time employees of Sunovion Pharmaceuticals Inc,
Fort Lee, NJ. Dr. Ishiyama, Horisawa, Tokuda, Ogasa and Ishibashi
are full-time employees of Dainippon Sumitomo Pharma, Osaka,
Japan.
jP-10-022jLow molecular weight dipeptide analogue of BDNF,
GSB-106, prevents the hyperexpression of HO-1
acting via the TrkB receptors
I. Logvinov1, T.A. Antipova1, A. Tarasiuk1, T.A. Gudasheva1,
S.B. Seredenin1. 1Zakusov Institute of Pharmacology, Moscow, Russia
Objective : Brain-derived neurotrophic factor (BDNF) deﬁciency
contributes a lot to the pathogenesis of most neurodegenerative dis-
eases. The cellular actions of BDNF are mediated through the acti-
vation of the Trk receptors. The novel dipeptide analogue of BDNF,
GSB-106, was synthesized in Zakusov Institute of Pharmacology
RAMS. We have previously shown that GSB-106 had neuroprotective
eﬀects in diﬀerent models of cell damages : oxidative stress, glutamate
or 6-hydroxydopamine-induced toxicity. This study was undertaking
in order to evaluate the possible mechanisms of this neuroprotective
eﬀect.
Methods : Experiments were performed on hippocampal neurons
in culture HT-22. Oxidative stress was modeled by addition of H2O2
(1.5 mM) into the cell medium. GSB-106 (10–8 M) was added after
damaging factor. BDNF (50 ng/ml) was added as a positive control.
Western blot analysis was used for the detection of phosphorylated
Trk-B level and synthesis of heme oxygenase-1 (HO-1).
Results : It is shown that GSB-106 caused a signiﬁcant increase in
phosphorylation of Trk-B ; this eﬀect appeared already in 30 sec in-
terval. These data alow to suggest that GSB-106 similar to BDNF acts
via the TrkB receptors. HO-1 is a stress-inducible enzyme involved in
protection cell from oxidative stress. However, limitation of HO-1
overexpression is an important component of neuroprotection. On the
next stage of this study we investigated the inﬂuence of GSB-106 on
the synthesis of HO-1 by oxidative stress. GSB-106, as well as BDNF
(50 ng/ml), limited the overexpression of the protein HO-1, induced
by oxidative stress.
Conclusion : (1) GSB-106 caused an increase of Trk-B phosphor-
ylation ; (2) the ability of GSB-106 to limit the hyperexpression of HO-1,
induced by oxidative stress, proposed to be one of the mechanisms of
its neuroprotective action ; (3) according to both these parameters
GSB-106 imitates the eﬀects of BDNF.
jP-10-023jExposure to enriched environments during
adolescence prevents abnormal behaviours
associated with histone deacetylation
inphencyclidine-treated mice
T. Nabeshima1, T. Koseki1, A. Mouri2, T. Mamiya1, T. Nagai3,
K. Toriumi1, Y. Aoyama1, T. Yamada1, S. Suzuki1, A. Nakajima1.
1Meijo University, Nagoya, Japan ; 2Nagoya University (Grobal COE),
Japan ; 3Nagoya University, Dept.of Neuropsychopharmacology, Japan
Objective : Enriched environments (EEs) during development have
been shown to inﬂuence adult behaviour. Environmental conditions
during childhood may contribute to the onset and/or pathology of
schizophrenia ; however, it remains unclear whether EE might pre-
vent the development of schizophrenia. Herein, we investigated the
eﬀects of EE during adolescence on phencyclidine (PCP)-induced ab-
normal behaviour, a proposed schizophrenic endophenotype.
Methods :Male ICR mice (3 wk old) were exposed to an EE for 4 wk
and then treated with PCP for 2 wk.To investigate whether the histone
modiﬁcation during adolescence might be critical for the eﬀect of EE,
3-wk-old mice were ﬁrst treated with sodium butyrate (SB ; an HDAC
inhibitor) for 4 wk and then treated with PCP for 2 wk.
Results : The EE potentiated the acute PCP treatment-induced
hyperlocomotion in the locomotor test and prevented chronic PCP
treatment-induced impairments of social behaviour and recognition
memory in the social interaction and novel object recognition tests.
It also prevented the PCP-induced decrease of acetylated Lys9 in
histone H3-positive cells and increase of the histone deacetylase
(HDAC)5 level in the prefrontal cortex. Chronic SB treatment during
adolescence mimicked the eﬀects of EE, including potentiation of
hyperlocomotion induced by acute PCP treatment and prevention
of social and cognitive impairments, decrease of acetylated Lys9 in
histone H3-positive cells and increase of the HDAC5 level in the pre-
frontal cortex associated with chronic PCP treatment.
Conclusion : Our results suggest that EEs prevent PCP-induced
abnormal behaviour associated with histone deacetylation. EEs dur-
ing childhood might prove to be a novel strategy for prophylaxis
against schizophrenia.
jP-10-024jUltrastructural study of the stressed-glutamatergic
synapse
N. Nava1, G. Wegener2, M. Popoli3, L. Musazzi3, J.R. Nyengaard4.
1Aarhus University, Risskov, Denmark ; 2Centre for Psychiatric Reasearch,
A˚rhus University, Risskov, Denmark ; 3Centre of Neuropharmacology,
Department of Pharmacological, Milan, Italy ; 4Stereology and Electron
Microscopy Laboratory, A˚rhus, Denmark
Objective : Dysfunction of the glutamatergic system has been asso-
ciated with the pathophysiology of many stress-related disorders.
Nevertheless, the mechanisms whereby stress and glucocorticoids
aﬀect the glutamatergic system are still unknown. In a previous study
acute Foot-shock (FS)-stress was found to induce a marked increase of
glutamate release from prefrontal and frontal cortex synaptosomes,
which was completely prevented by chronic antidepressant treatment
[1]. The aim of the present study was to evaluate if FS-stress induced
increase in glutamate release is correlated with an increase in the
number of vesicles anchored to the presynaptic membrane and ready
for release and to evaluate if chronic antidepressant treatment modu-
lates the eﬀects of FS-stress on docked vesicles.
Methods : Medial prefrontal cortex (mPFC) was isolated based on
its noticeable cytoarchitectural features. Asymmetric glutamatergic
synapses were identiﬁed through electron microscopy and vesicles
docked to the presynaptic membrane quantiﬁed.
Results : Overall vesicle redistribution after FS-stress and chronic
antidepressant treatment was evaluated. Volumetric modiﬁcations
within mPFC subareas were also investigated.
Conclusion : A better understanding of how behavioral stress and
current antidepressants aﬀect glutamatergic transmission will pro-
vide further knowledge in developing drugs directly targeting the
glutamatergic system.
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jP-10-025jSynergistic or independent relationships of MAO B
platelet avctivity, MAO B and COMT
polymorphisms to impulsivity, aggression and
novelty seeking?
P. Netter1, M.Y. Baars2, M. Reuter3, C. Montag3, J. Harro4, D. Eensoo4,
B. Gallhofer5. 1University of Giessen, Germany ; 2University of Zurich,
Department of Psychiatry, Switzerland ; 3University of Bonn, Germany ;
4University of Tartu, Estonia ; 5Department of Psychiatry, University of
Giessen, Germany
Objective : Low platelet MAO B activity and the COMT polymorph-
ism genotype MetMet would result in higher DA levels and have
been shown to be associated with Impulsivity, Novelty Seeking,
Aggression and alcoholism. So far it is not clear, how the A/G intron
13 polymorphism of the MAO B gene relates to MAO B activity
in platelets and personality traits, and if the three biomarkers act
synergistically or independently on personality traits. This was in-
vestigated in the present study.
Methods : 60 male abstinent alcoholics participated in a reaction
time task, ﬁlled in personality questionnaires and gave blood samples
for genetic analyses and MAO B activity in platelets.
Results : Although platelet MAO B activity and MAO B genotype
were not associated, interactions revealed that participants with low
MAO B activity among G allele carriers scored highest on Aggression,
A allele carriers in combination with the COMT ValVal genotype
highest on Attentional Impulsivity, and A allele carriers in the MetMet
group highest on Experience Seeking. Motor Impulsivity was only
related to high MAO B activity, not to genetics, and faster reaction
times were only observed in G allele carriers.
Conclusion : These results are compatible with the ﬁndings by
Balciuniene et al. (2002) that the G allele indicates lower MAO B ac-
tivity in brain than A, yielding higher DA levels and therefore perhaps
higher speed and aggression which adds to the lowMAO B activity in
platelets. Data also suggest that low DA resulting from the ValVal
genotype acts synergistically with the A allele in producing attention
deﬁcits. So the three biomarkers evidently diﬀerentially aﬀect im-
pulsivity, aggression, attention deﬁcits and novelty seeking : The
MAO B intron 13 A/G polymorphism is only one of several genetic
polymorphisms for MAO B activity, but does indicate relevance as a
behavioral marker.
jP-10-026jAntibody-capture scintillation proximity assay/
[35S]GTPyS binding to Gaq functionally coupled
with M1 acetylcholine receptors and 5-HT2A
receptors in rat brain membranes
Y. Odagaki1, R. Toyoshima2. 1Saitama Medical University, Moroyama-
Machi, Japan ; 2Saitama Medical University, Moroyama-Machi, Iruma-
Gun, Sai, Japan
Objective : To investigate receptor-mediated functional activation
of heterotrimeric G proteins other than Gi/o subtypes.
Methods : Immuno-capture of Ga subunits with anti-Ga antibodies
following [35S]GTPcS binding to rat brain membranes was combined
with scintillation proximity assay (SPA) technology.
Results : Preliminary experiments using a series of agonists and
commercially available anti-Ga antibodies indicated the increase in
speciﬁc [35S]GTPcS binding to Gaq determined with anti-Gaq (E-17)
(sc-393, Santa Cruz Biotechnology) evoked by carbamylcholine
chloride (CCh) was pharmacologically relevant. Under the optimized
conditions, CCh stimulated speciﬁc [35S]GTPcS binding to Gaq in
a concentration-dependent and saturable manner with an EC50 of
around 10 mM in all of the membranes prepared from rat hippocam-
pus, cerebral cortex, and striatum. The addition of MT-7, a snake toxin
with high selectivity for M1 over the other muscarinic acetylcholine
receptors (mAChRs) (M2-M5), almost completely extinguished CCh-
stimulated [35S]GTPcS binding to Gaq, even at a concentration as low
as 1 nM, indicative of the exclusive involvement of M1 receptors in
this response. The detailed pharmacological characterization was
further investigated by means of a series of muscarinic agonists, an-
tagonists, and allosteric modulators in hippocampal and cerebral
cortical membranes. Under the same condition, 5-HT also stimulated
speciﬁc [35S]GTPcS binding to Gaq in cortical membranes in a con-
centration-dependent manner. However, the stimulatory eﬀects of 5-
HT were not saturable and apparently biphasic. The inhibitory eﬀects
of ketanserin indicated that 5-HT2A receptor-mediated activation of
Gaq might be detectable when lower concentrations (up to 10 mM) of
5-HT were used.
Conclusion : Both receptors are implicated in pathophysiology of
several neuropsychiatric disorders as well as mechanisms of action of
psychotropic drugs. The assay developed in the present study will be
of help for the investigations in the ﬁeld of biological psychiatry as
well as drug discovery.
jP-10-027jChanges in vascular endothelial growth factor
(VEGF) induced by the morris water maze task
D.H. Oh1, M. Choi2, G. Lee2, H. Son2. 1Hanyang Univ. Medical Center,
Seoul, Republic of Korea ; 2Hanyang Univ., Seoul, Republic of Korea
Objective : The present study was undertaken to evaluate the eﬀects
on hippocampal vascular endothelial growth factor (VEGF) levels in
rats when they experience hippocampal-dependent spatial learning
via the Morris water maze (MWM) task.
Methods : After one day of intensive training, a highly sensitive
enzyme-linked immunosorbent assay (ELISA) was used to measure
VEGF protein levels in the hippocampus, cortex, and serum.
Results : Higher levels of VEGF were found in the trained group
compared to a naive control group. VEGF levels also increased in rats
that swam only for durations equal to the intensive training periods.
In contrast, rats trained under the weaker MWM paradigm for
ﬁve days showed a decrease in hippocampal VEGF protein level.
Mimicking increases in neuronal VEGF in the hippocampus by direct
infusion of VEGF into CA1 resulted in up-regulation of the phos-
phorylation of the cAMP response element-binding (CREB) protein
and the Ca2+/calmodulin-dependent protein kinases II (CaMKII).
Conclusion : These results suggest that VEGF may be a physio-
logical parameter involved in learning procedures that include
physical activity.
jP-10-028jComparison of neurite outgrowth induced
by erythropoietin (EPO) and carbamylated
erythropoietin (CEPO) in cultured hippocampal
neural progenitor cells
D.H. Oh1, I.Y. Lee2, S.H. Kim1, H. Son2. 1Hanyang Univ. Medical
Center, Seoul, Republic of Korea ; 2Hanyang Univ., Seoul, Republic of
Korea
Objective :A previous animal study has shown the eﬀects of EPO and
its non-erythropoietic carbamylated derivative (CEPO) on neuro-
genesis in the dentate gyrus. In the present study, we sought to in-
vestigate the eﬀect of EPO on adult hippocampal neurogenesis, and to
compare the ability of EPO and CEPO promoting dendrite elongation
in cultured hippocampal neural progenitor cells.
Methods : Two-month-old male BALB/c mice were given daily in-
jections of EPO (5 U/g) for seven days and were sacriﬁced 12 hours
after the ﬁnal injection. Proliferation assays demonstrated that EPO
treatment increased the density of bromodeoxyuridine (BrdU)-labeled
cells in the subgranular zone (SGZ) compared to that in vehicle-
treated controls (p<0.05).
Results : Functional diﬀerentiation studies using dissociated
hippocampal cultures revealed that EPO treatment also increased
the number of double-labeled BrdU/MAP2 (microtubule-associated
protein 2) neurons compared to those in vehicle-treated controls
(p<0.05). Both EPO and CEPO treatment signiﬁcantly increased the
length of neurites extending from MAP2(+) cell soma, with CEPO
(p<0.01) having a better eﬀect than EPO (p<0.05).
Conclusion : In summary, these results provide strong evidences
that EPO and CEPO promote adult hippocampal neurogenesis. We
speculate that EPO and CEPO could be a good candidate for treating
neuropsychiatric disorders such as depression and anxiety associated
with reduced hippocampal neurogenesis.
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jP-10-029jTianeptine treatment reverses increase on oxidative
damage and decrease of antioxidant defense
enzymes into the brain of rats submitted to the
chronic mild stress model
J. Quevedo1, G.Z. Re´us1, H.M. Abelaira1, K.F. Ribeiro1, F.P. Della1,
M.A.S. Bernardini1, A.V. Steckert1, L.S. Galant1, F. Dal-Pizzol1.
1UNESC, Criciuma, Brazil
Objective : A growing body of evidence has suggested that reactive
oxygen species may play an important role in the pathophysiology
and treatment of depression. The present study was aimed to evaluate
the eﬀects of tianeptine (an antidepressant, which enhances the
reuptake of serotonin) administration on the oxidative stress
parameters in the brain of rats exposed to chronic mild stress (CMS)
procedure.
Methods : To this aim, after 40 days of exposure to CMS Wistar rats
were treated with tianeptine (15 mg/kg) or saline for 7 days. Then, the
lipid and protein oxidation, and superoxide dismutase (SOD) and
catalase (CAT) activities were evaluated in the rat brain.
Results : Our ﬁndings demonstrated that lipid oxidation was
increased in stressed rats, and tianeptine reversed this eﬀect in the
prefrontal cortex and amygdala. In stressed rats there were an in-
crease on the protein oxidation in the hippocampus and amygdala,
but this eﬀect was reversed only in the amygdala by tianeptine ; in
the nucleus accumbens there was a reduced on the protein oxidation
in stressed rats treated with tianeptine, compared to stress group
treated with saline. The SOD activity was reduced in all brain areas
from stressed rats treated with saline, but treatment with tianeptine
reversed these eﬀects. The CAT activity decreased in stressed rats in
the prefrontal cortex and amygdala, and treatment with tianeptine
reversed these eﬀects ; in the hippocampus and nucleus accumbens
there were an increase in the CAT activity in stressed rats treated
with tianeptine, compared to control and stress group treated with
saline.
Conclusion : Our data indicate that stress produces oxidants and
impairment in the SOD and CAT activities, which could contributes to
depression. In addition, tianeptine antidepressant exerted positive
eﬀects on the oxidative stress parameters, decreasing lipid and protein
oxidation and increasing SOD and CAT activities in rats submitted
to CMS.
jP-10-030jThe dopamine stabilizers ACR16 and (x)-OSU6162
display nanomolar aﬃnities at the o-1 receptor
D. Marcellino1, K. Sahlholm2, P. A˚rhem2, K. Fuxe2. 1Karolinska
Institutet, Stockholm, Sweden ; 2Karolinska Institutet, Dept. of
Neuroscience, Stockholm, Sweden
Objective : Converging in vivo evidence has advanced the s-1 recep-
tor as a pharmacological target for the treatment of neurological and
psychiatric disorders such as L-DOPA-induced dyskinesia, schizo-
phrenia, drug addiction, and depression. Considering their close
structural resemblance to known s-1 receptor ligands we investigated
the ability of dopaminergic stabilizers, a new class of phenylpiper-
idine compounds, to bind s-1 receptors.
Methods : s-1 receptor ligand binding characteristics were deter-
mined by both saturation and competition assays using the speciﬁc
s-1 receptor agonist [3H](+)-pentazocine. Radioligand binding ex-
periments were performed in membranes prepared from HEK293
cells that were transiently transfected with the human s-1 receptor
and in rat striatal membranes.
Results : Our results reveal that the dopaminergic stabilizers,
(x)-OSU6162 and ACR16, display nanomolar aﬃnity for the human
s-1 receptor heterologously expressed in HEK293 cells, as well as
in rat striatal membranes. The aﬃnity of ACR16 appears to be in-
distinguishable from that of the structurally related compound (+)-3-
PPP ; a ligand which has been widely used to study s-1 receptors.
Conclusion : Dopaminergic stabilizers are a novel class of drug
candidates that have shown clinical promise in the treatment of
several severe neurological and neuropsychiatric disorders. While
their exact mechanism of action is still under investigation, our data
point to a previously overlooked aspect of their pharmacology. The
present ﬁndings warrant further exploration of the relevance of s-1
receptor binding for the in vivo actions of dopaminergic stabilizers.
jP-10-031jAnalysis of neuroadaptive changes following
co-treatment of lurasidone and valproic acid in rats
M. Riva1, F. Calabrese2, A. Luoni2, G. Guidotti2, G. Racagni2,
F. Fumagalli2. 1University of Milan, Department of Pharmacology, Italy ;
2University of Milan, Dept. of Pharmacol. Sciences, Italy
Objective : Combinatory therapy is widely used in psychiatry owing
to the possibility that drugs with diﬀerent mechanisms of action may
synergize in order to improve speciﬁc functions, which are deterio-
rated in schizophrenia, bipolar disorders and major depression. While
synaptic mechanisms may contribute to drug combination strategies,
it should also be considered that, on the long-term, two drugs may
‘cooperate’ in modulating neuronal plasticity, which represents a
downstream target crucial for functional recovery.
Methods : On this basis, in the present study we have investigated
neuroadaptive changes set in motion upon chronic concomitant
administration of the novel antipsychotic lurasidone (LUR) with the
mood stabilizer valproate (VPA). The two agents were given to rats
for 21 days and the animals were sacriﬁced 24 h after the last drug
administration for the molecular analyses. We investigated the ex-
pression of the neurotrophin BDNF that represents a key marker of
neuronal plasticity and cellular resiliency.
Results : The results emerging from these analyses suggest that
co-administration of LUR and VPA produces a larger increase of
BDNF expression in ventral hippocampus, through the regulation of
speciﬁc neurotrophin transcripts, compared to each drug alone. We
also found that the expression of HDAC-2 and DNMT1, two genes
involved in the epigenetic machinery, were also signiﬁcantly regu-
lated by the combination LUR+VPA, suggesting that some of the
transcriptional changes may be sustained by epigenetic mechanisms.
Other genes important for neuronal adaptation, such Arc (Activity-
regulated cytoskeletal associated protein), are signiﬁcantly regulated
by chronic treatment with LUR and VPA, although their combination
does not provide any advantage over the drugs employed alone.
Conclusion : Our results suggest that the beneﬁcial eﬀects as-
sociated with combinatory treatment between a second-generation
antipsychotic and a mood stabilizer could result from the ability to
modulate neuroplastic molecules such as BDNF, whose expression
and function is deteriorated in diﬀerent psychiatric conditions.
Policy of full disclosure : This work was supported by funding
from Sunovion Pharmaceuticals Inc.
jP-10-032jChronic lurasidone treatment restores functional and
neuroplastic deﬁcits in serotonin transporter
knockout rats, an animal model of depression
M. Riva1, A. Luoni2, G. Cazzaniga2, S. Hulsken3, G. Racagni2,
J. Homberg3. 1University of Milan, Department of Pharmacology, Italy ;
2University of Milan, Dept. of Pharmacol. Sciences, Italy ; 3Radboud
University Nijmegen, Dept.of Cognitive Neuroscience, Netherlands
Objective : Lurasidone is a novel antipsychotic drug characterized
by a multi-receptor signature. Some of these receptor mechanisms
have been associated with antidepressant activity, including blockade
of 5HT2a, 5HT7 as well as activation of 5HT1a. Furthermore, we have
recently shown that chronic administration of lurasidone can increase
the expression of BDNF, a marker of neuronal plasticity that has been
associated with clinical antidepressant properties.
Methods : In the present work we speciﬁcally addressed the
potential antidepressant activity of lurasidone by employing a genetic
model of the disease, namely serotonin transporter knockout (SERT
KO) rats, which are characterized by an anxious and depressive
phenotype. To this purpose we chronically administered lurasidone
to wild type or SERT KO rats and investigated behavioral and mol-
ecular changes produce by the drug.
Results : At behavioral level, we found that, chronic lurasidone
treatment signiﬁcantly increased fear extinction in SERT KO rats
(p<0.01), without aﬀecting wild-type animals. At molecular level,
lurasidone was able to normalize the reduced expression of the
neurotrophin BDNF in the prefrontal cortex SERT KO rats. Such eﬀect
occurred through the regulation of speciﬁc neurotrophin transcripts,
primarily of exon VI, and it was sustained by epigenetic mechanisms
as demonstrated by the signiﬁcant up-regulation of the DNA de-
methylating gene Gadd45c. We also found that, when given to SERT
KO rats, chronic lurasidone treatment was able to restore the reduced
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expression of diﬀerent GABAergic markers, including GAD67, par-
valbumin and somatostatin.
Conclusion : Our results show that lurasidone can improve de-
pression-related dysfunction of SERT KO rats, with a primary impact
on prefrontal cortex, also through the modulation of the neurotrophin
BDNF. The adaptive changes set in motion by repeated treatment
with lurasidone may contribute to the amelioration of functional
capacities, closely associated with neuronal plasticity, which are de-
teriorated in patients with schizophrenia, bipolar disease and major
depression.
Policy of full disclosure : This work was supported by funding
from Sunovion Pharmaceuticals Inc.
jP-10-033jAntagonist dissociation from dopamine D2
receptors – dopamine stabilizers unbind faster than
clozapine and quetiapine
K. Sahlholm1, S. Frisk2, D. Marcellino2, J. Nilsson2, K. Fuxe2,
P. A˚rhem3. 1Karolinska Institutet, Stockholm, Sweden ; 2Karolinska
Institutet, Dept. of Neuroscience, Stockholm, Sweden ; 3Stockholm, Sweden
Objective : Medication with dopamine D2 antagonists is often as-
sociated with extrapyramidal symptoms and increased serum pro-
lactin. The side-eﬀect liability of antipsychotics correlates inversely
with their rates of receptor dissociation. Recent studies indicate
that the novel D2 receptor ligands, ACR16 (pridopidine) and
(x)-OSU6162, initially described as ‘‘dopamine stabilizers, ’’ act as
antagonists with similarly high dissociation rates as clozapine and
quetiapine. Those studies measured ligand dissociation from mem-
brane preparations or used modiﬁed G proteins in functional assays.
We aimed to examine antagonist dissociation in living cells, using an
assay based on activation of G protein-coupled potassium (GIRK)
channels. This assay uses native G proteins and has higher temporal
resolution than previous studies.
Methods : GIRK current responses to dopamine receptor activation
were recorded using two-electrode voltage clamp in Xenopus oocytes
expressing dopamine D2L or D2S receptors, Regulator of G protein
Signaling-4, and GIRK1/4 channels. First, dopamine (100 nM) was
applied, eliciting a ‘‘baseline’’ response. Next, a maximally eﬀective
concentration of antagonist was washed in. After achieving steady-
state inhibition the antagonist was washed out, still in the presence of
dopamine. The time to half-maximal response recovery (T1/2) and
the response recovery amplitude relative to baseline were taken as
measures of antagonist dissociation.
Results : With clozapine and quetiapine, similar recovery time
courses were observed (T1/2=48¡5.5 s, and 60¡2.2 s, respectively).
About 50% response recovery was observed. The dopamine stabi-
lizers, ACR16 and (x)-OSU6162, lacked detectable eﬃcacy in our
assay. These compounds washed out faster than clozapine and que-
tiapine (T1/2=8.2¡1.8 s, and 6.1¡0.44 s, respectively) ; and near-
complete response recovery was observed.
Conclusion : The present data suggest that the ‘‘dopamine stabi-
lizers’’ ACR16 and (x)-OSU6162 dissociate faster than clozapine and
quetiapine. Such very rapid dissociation might be relevant to the low
incidence of side-eﬀects reported from clinical trials with these com-
pounds.
jP-10-034jMatrixmetalloproteinase-9 in schizophrenia and
depression – is this the link within the hierarchical
disease model?
R. Schennach-Wolﬀ1, B. Bondy1, M. Obermeier1, R. Musil1, M. Riedel1,
P. Zill1. 1Ludwig-Maximilians-Univeristy, Munich, Germany
Objective : Recently it has been reported that the protein expression of
the matrixmetalloproteinase-9 (MMP9), an extracellular protease, is
similarly increased in patients suﬀering from schizophrenia and de-
pression. Given the long discussed hypothesis that schizophrenia
and aﬀective disorder follow a hierarchical disease model and might
have overlapping pathophysiological dysfunction processes MMP9
might mirror a biological link between schizophrenia and aﬀective
disorder.
Methods : Therefore, within this pilot study the blood concen-
tration of MMP9 and its inhibitor TIMP1 (Tissue Inhibitors
of Metalloproteinases) was examined in 37 patients with a DSM-IV
diagnosis of a schizophrenia spectrum disorder, 78 patients with a
DSM.-IV diagnosis of a major depression and 38 healthy controls. The
Positive and Negative Syndrome Scale (PANSS) as well as the
Hamilton Depression Rating Scale (HAMD-17) were applied Blood
draws and clinical interviews were performed at baseline and every
two weeks within the six weeks study period. ANOVA and univariate
tests were calculated using the statistical program 2.11.1.
Results : The MMP9 concentration diﬀered signiﬁcantly between
the patients and healthy controls (schizophrenia 143¡101 ng/ml,
depression 135¡141 ng/ml, healthy controls 54¡48 ng/ml ; ANOVA
F=7.06, p=0.001). A signiﬁcant positive correlation was found be-
tween illness severity of the depressed patients via the HAMD and the
MMP9 concentration both at study entry (Pearson 0.234 ; p=0.040)
and also at endpoint (Pearson 0.302 ; p=0.0012). Also, in the schizo-
phrenia patients a signiﬁcant positive association was found in terms
of the severity of depressive symptoms measured via the depression
item (Pearson 0.50 ; p=0.0111) and the PANSS depression subscore
(Pearson 0.44 ; p=0.0289) at baseline.
Conclusion : These are the ﬁrst preliminary results of MMP9 in the
blood of patients with schizophrenia and depression. This suggests
that both diseases might share more biological underpinnings than
thought before. Future studies are warranted to replicate these ﬁrst
results.
jP-10-035jHigh-throughput screening for allosteric modulators
of the D2 dopamine receptor
D. Sibley1, R.B. Free2, N. Southall3, T. Doyle1, R. Roof2, J. Conroy2,
Y. Han4, J. Javitch5, M. Ferrer1. 1National Institutes of Health,
Bethesda, Maryland, USA ; 2National Institutes of Health,
NINDS, Bethesda, Maryland, USA ; 3National Institutes of Health,
NCGC, Bethesda, Maryland, USA ; 4Columbia University, Department of
Psychiatry, New York, NY, USA ; 5National Institutes of Health,
Department of Psychiatry, Bethesda, Maryland, USA
Objective : The D2 dopamine receptor (DAR) is central in the etiology
and/or therapy of many neuropsychiatric disorders, however, truly
speciﬁc drugs for this receptor have been diﬃcult to obtain. A novel
approach towards receptor-selective ligands is to identify allosteric
modulators that bind to less conserved sites on the receptor and have
the potential to be exquisitely selective. In order to identify allosteric
modulators of the D2 DAR, we developed a high throughput-
screening (HTS) platform to interrogate large chemical compound
libraries.
Methods : The primary HTS assay utilizes a cell line expressing
the D2 DAR coupled to a chimeric Gqi5 protein, thereby linking re-
ceptor activation to robust Ca2+ mobilization. Counter-screens
against other DAR subtypes and radioligand binding studies were
also carried out.
Results : Through the NIH Molecular Libraries Program, a
370,000+ small molecule library was screened to identify agonists
(allosteric or orthosteric), positive allosteric modulators, or antago-
nists (allosteric or orthosteric). From this primary screen, 2,288 com-
pounds with agonist activity, 1,408 compounds with potentiator
activity, and 2,294 compounds with antagonist activity were cherry-
picked. Upon further evaluation, none of the potentiators conﬁrmed
while 650 agonists and 858 antagonists did not conﬁrm. The remain-
ing conﬁrmed agonist and antagonist ligands were subjected to
orthogonal and counter-screening functional assays. On the basis of
these analyses, 745 agonist and 499 antagonist compounds were
evaluated using radioligand competition binding assays as a ﬁlter to
separate orthosteric and allosteric ligands. These experiments resulted
in the identiﬁcation of 47 agonists and 48 antagonists that had insig-
niﬁcant eﬀects on radioligand binding. These compounds would thus
appear to be allosteric agonists and negative allosteric modulators of
the D2 DAR.
Conclusion : We have conducted a high through-put screen of
the NIH Molecular Libraries Program small molecule repository.
Numerous lead compounds with agonist or antagonist activities were
identiﬁed that appear to exert their functional eﬀects via allosteric
mechanisms. The most promising of these ligands are undergoing
further characterization.
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jP-10-036jCompromising sigma-1 receptors at the ER renders
cytotoxicity to physiologically relevant
concentrations of dopamine in a NF-kB/Bcl-2-
dependent mechanism : Potential relevance to
Parkinson’s disease
T.P. Su1, T. Mori1, T. Hayashi1. 1 IRP NIDA NIH, Baltimore, USA
Objective : To examine if the endoplasmic reticulum (ER) chaperone
the sigma-1 receptor (Sig-1R) may play a role in Parkinsonism.
Methods : Dopamine (DA)-induced apoptosis was examined in
wild type CHO cells and in Sig-1R knockout CHO cells.
Results : DA in physiological concentrations (e.g., lower than
10 mM) does not cause apoptosis. However, the same concentrations
of DA cause apoptosis in Sig-1R knockdown CHO cells. In search for a
mechanistic explanation, we found that unfolded protein response is
not involved. Rather, the level of protective protein Bcl-2 is critically
involved in this DA/Sig-1R knockdown-induced apoptosis.
Speciﬁcally, the DA/Sig-1R knockdown causes a synergistic protea-
somal conversion of NF-kB p105 to the active form of p50 which is
known to downregulate the transcription of Bcl-2. Importantly, the
DA/Sig-1R knockdown-induced apoptosis is blocked by the over-
expression of Bcl-2.
Conclusion : Our results therefore indicate that DA is involved
in the activation of NF-kB and suggest that endogenous Sig-1Rs
are tonically inhibiting the proteasomal conversion/activation of
NF-kB caused by physiologically relevant concentrations of DAwhich
would otherwise cause apoptosis. Thus, Sig-1Rs and associated
ligands may represent new therapeutic targets for the treatment of
Parkinsonism.
jP-10-037jEﬀects of a single and repeated lectroconvulsive
seizure on hippocampal cell proliferation and
spontaneous behaviors in the rat
T. Suzuki1, K. Nakamura2, Y. Liu3, M. Ito3, H. Arai3, T. Seki4,
A. Baba5. 1 Juntendo University Faculty of Saitama, Japan ; 2 Juntendo
University Faculty of Shizuoka, Japan ; 3 Juntendo University Faculty of
Tokyo, Japan ; 4Tokyo Medical Collage, Japan ; 5Hino Hospital, Kanagawa,
Japan
Objective : Electroconvulsive therapy (ECT) is known as a successful
treatment for sever depression. However, the biological mechanism
underlying the beneﬁcial eﬀects of ECT remains largely unknown.
Thus, we investigated eﬀects of electroconvulsive seizure (ECS) on
hippocampal cell proliferation and behaviors in rats.
Methods : In this study, animals received a single or 10 repeated
applications of ECS, and then cell proliferation and diﬀerentiation of
new born cells (5-bromo-2-deoxyuridine (BrdU)-positive cells) in sub-
granular zone (SGZ) of the dentate gyrus were investigated. In ad-
dition, we investigated the eﬀect of ECS on behavioral changes
of animals by using a locomotor activity and spontaneous alteration
behavior in a Y-maze test on 3, 14 and 28 days after ECS treatments.
Results : On three days after ECS, both a single and 10 repeated
ECSs signiﬁcantly increased BrdU-positive cells in the SGZ by+84%
and +130% compared to each sham treatment, respectively. 10 On
14 days after the last ECS, both a single and 10 repeated ECSs
showed signiﬁcant decreases in cell proliferation by x52% and
x62%, respectively compared to sham treatment. On the other hand,
the locomotor activity and scores of spontatneous behavior of a
Y-maze test did not show signiﬁcant changes between the group with
a single or 10 repeated ECSs and sham group on neither 3, 14 nor
28 days, regardless of increase or decrease in cell proliferation or
diﬀerentiation of new born cells in SGZ after ECS.
Conclusion : These ﬁndings indicate that although ECT aﬀects
adult hippocampal neurogenesis, no obvious changes are observed in
certain behavioral tests. We need further investigation of how adult
hippocampal neurogenasis may involve in animal behavior after ECS
treatments.
jP-10-038jEﬀect of N-acetylcysteine on L-buthionine-
SR-sulfoximine-induced reduction of cell viability
in a-synuclein-transfected SH-SY5Y cells
K.-I. Tanaka1, K. Sonoda2, H. Ogo2, M. Asanuma3. 1Saitama
Prefectural University, Koshigaya, Japan ; 2Shujitsu University, School of
Pharmacy, Okayama, Japan ; 3Okayama University, Grad. Sch. Med., Dent
& Pharma, Japan
Objective : It is well known that a-synuclein (a-syn) plays an
important role in the pathogenesis of Parkinson’s disease (PD).
Moreover, oxidative stress is also thought to be an important factor in
PD due to dopaminergic neuronal cell death by free radicals and en-
hancement of a-syn ﬁbrillation by oxidized stress.
Methods : In the present study, we examined the eﬀects of L-
buthionine-SR-sulfoximine (BSO), a GSH synthase inhibitor, with or
without N-acetylcysteine (NAC), a source of GSH, on a-syn-induced
cell injury in human neuroblastoma SH-SY5Y cells, to clarify the role
of GSH, an intracellular antioxidant, on the molecular mechanism of
a-syn-induced cell injury.
Results : Treatment with BSO signiﬁcantly reduced cell viability
of both empty-vector- and a-syn-transfected SH-SY5Y cells in a dose-
dependent manner, although the ratio of a-syn-induced reduction
of cell viability in a-syn-transfected cells was much greater than
that in empty-vector-transfected cells. Moreover, BSO signiﬁcantly
reduced the intracellular total GSH level in both types of trans-
formant cells. However, NAC signiﬁcantly prevented BSO-induced
reduction of both cell viability and GSH level in the a-syn-transfected
cells.
Conclusion : Thus, these ﬁndings suggest that GSH plays an im-
portant role in a-syn-induced cell injury by reducing cell viability,
although further study is needed to clarify the molecular basis of
a-syn-induced cell injury.
jP-10-039jThe Sigma-1 receptor chaperone plays an essential
role in neural circuits
S.-Y. Tsai1, T. Hayashi2, T.-P. Su2. 1NIH, Baltimore, USA ; 2NIH,
Cellular Pathobiology Section, Baltimore, USA
Objective : The endoplasmic reticular protein sigma-1 receptor
(Sig-1R) is a novel chaperone and has been implicated in CNS diseases
such as Alzheimer’s disease, depression, and drug abuse. It is
known that Sig-1Rs are particularly enriched in the mitochondrial
associate ER membrane, MAM; however, little is known about
how Sig-1R regulate neuronal mitochondria. We previously showed
that Sig-1R promote the process of neuritogenesis and dendrito-
genesis in hippocampal neurons via the regulation of Rho GTP
signaling pathways. In this study, we further examined the eﬀects
of Sig-1R siRNA on axon elongation and synaptic mitochondrial ac-
tivities.
Methods : Neurons were transfected at DIV 1 and axon lengths
were measured on both DIV 3 and DIV 7 by using tau immuno-
staining. We also examined synaptosomal mitochondrial mass and
membrane potentials by using ﬂow cytometry analysis. Rhodamine
123 and 10-N-nonyl acridine orange (NAO) were used as membrane
potential- or mass- dependent ﬂuorescent dyes, respectively.
Results : Knocking down of Sig-1Rs impaired axon elongation sig-
niﬁcantly. The lengths of axon of the Sig-1R-knockdown neurons
were as short as 40% of the controls at DIV 3. The diﬀerence in axon
lengths became more noteworthy as neuron culture extended.
Although Sig-1R siRNA-transfected neurons were able to extend
axon gradually in time, they showed a slower extension rate.
Knocking down of Sig-1R caused aberrant axon extension was
also associated with hyperphosphoylation of tau as indicated by MC1
antibody that recognized an early conformational change in tau. Our
data showed that Sig-1R siRNA transduced neurons possessed sig-
niﬁcantly less mitochondrial mass and lower membrane potentials in
the synaptosome. Mitochondrial movement in the growth cone areas
was less active in Sig-1R siRNA neurons as well.
Conclusion : The observed changes in axon extension and synaptic
mitochondrial activities in Sig-1R knockdown neurons indicted the
importance of Sig-1R in maintaining synaptic functions and their sig-
niﬁcance in averting CNS diseases.
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jP-10-040jGABAergic regulation of extracellular
D-serine concentrations in the rat medial
frontal cortex of the rat as revealed by in vivo
microdialysis
A. Umino1, H. Iwama2, T. Nishikawa1. 1Tokyo Medical and Dental
Univ., Bunkyo, Japan ; 2Serigaya Hospital, Bunkyo, Japan
Objective : It has now been well accepted that D-serine may be
an intrinsic coagonist for the N-methyl-D-aspartate (NMDA) type
glutamate receptor in the mammalian brain. Thus, D-serine facilitates
various functions of the NMDA receptor by stereospeciﬁcally stimu-
lating its glycine site and is present in the tissue and extracellular
ﬂuid at high contents throughout life with a GRIN2B subunit-like
distribution. Moreover, selective elimination of D-serine by D-amino
acid oxidase or D-serine deaminase has been shown to reduce the
NMDA receptor functioning such as cGMP production and long-term
potentiation formation in the rat brain. Although these ﬁndings sug-
gest that the synaptic and/or extra-synaptic D-serine may play an
crucial role in the regulation of the NMDA receptors, the molecular
and cellular mechanisms of the physiological control of the extra-
cellular D-serine concentrations are still unclear.
Methods : Therefore, we have investigated by using an in vivo
microdialysis technique and a HPLC with ﬂuorometric detection
method the eﬀects of GABAergic agents on the extracellular contents
of D-serine in the medial frontal cortex of the freely moving rats. The
present animal experiments have been approved by the ethics com-
mittees of the Tokyo Medical and Dental University.
Results : We found that the local perfusion of a selective GABAA
receptor antagonist, bicuculline or picrotoxinin into the medial frontal
cortex lowered signiﬁcantly the cortical extracellular contents of
D-serine. The decreasing eﬀects of bicuculline was completely re-
versed by the local co-infusion of a selective GABAA receptor agonist
muscimol. Neither GABAB nor GABAC selective antagonist failed
to change the extracellular D-serine levels.
Conclusion : The present data are consistent with the seem the view
that the extracellular D-serine release may be under a tonic facilitatory
control by GABAergic transmission via the GABAA receptor at least
in the rat medial frontal cortex.
jP-10-041j Intravenous hemantane improves levodopa-induced
dyskinesias in in 6-hydroxydopamine-lesioned rats
E. Valdman1, I. Kokshenev2, I. Kapitsa2, E. Ivanova2, T. Voronina2.
1Zakusov Inst. of Pharmacology, Moscow, Russia ; 2Zakusov Inst. of
Pharmacology, RAMS, Moscow, Russia
Objective : Levodopa-induced dyskinesia (LID) becomes an
extremely common and debilitating problem. An overactive gluta-
mate transmission in the basal ganglia has been suggested to play a
key role in the pathophysiology of Parkinson’s disease (PD) and LID.
NMDA receptor antagonist amantadine (AMA) is widely used to
improve levodopa induced motor complications. Hemantane (H.)
(N-2(adamantyl)hexamethylenimine hydrochloride) is eﬀective in
animal models and in patients with early stages of PD. H. has complex
mechanism of action, including properties of uncompetitive, low-
aﬃnity NMDA receptor open-channel blocker. The aim of the study
was to assess the eﬀects of H. in parkinsonian rats with LID.
Methods : To induce parkinsonian syndrome 6-OHDA (12 mg)
was injected into the left medial forebrain bundle (MFB). Levodopa
(10 mg/kg) with benserazide (15 mg/kg) was administered
starting 3 weeks after lesion daily during next 4 weeks. The dyskinetic
eﬀects of levodopa were evaluated using a validated rat AIMs
scale, where axial, limb, orolingual and rotation AIMs represent
the rodent equivalent of peak-dose dyskinesia in PD. Rats with
LID were selected and divided in 2 groups. For 5 following days
levodopa administration was preceded by injection of H. (5 mg/kg,
i.v.) or AMA (20 mg/kg, i.v.). AIMs were registered 35 min after
evodopa administration 4 times during 140 min.
Results : Co-administration of levodopa with H. or AMA resulted
in signiﬁcantly less dyskinesia than levodopa alone. Eﬀects of acute
injection of H. were less pronounced than of AMA. After 5 days treat-
ment H. was more eﬀective in reducing orolingual and rotation LID.
Conclusion : Hemantane could be used as adjunctive therapy for
levodopa-induced dyskinesia.
jP-10-042jPre-analysis storage conditions inﬂuence measured
peripheral blood BDNF levels
N. Yasui-Furukori1, S. Tsuchimine1, N. Sugawara1, S. Kaneko1.
1Hirosaki, Japan
Objective : Brain-derived neurotrophic factor (BDNF) is a neuro-
trophin with a pivotal role in the regulation of neuronal function
throughout life and is regarded as a potential biomarker of mental
disorders. Previous studies suggest that plasma BDNF levels are more
variable than serum BDNF levels.
Methods :We determined the inﬂuence of time and temperature on
the measured peripheral blood BDNF levels. Blood samples were
aliquoted into 4 types of tubes : heparin, EDTA and citrate tubes for
plasma and anticoagulant-free tubes for serum. The samples were
stored at 4 xC or 25 xC for 0, 1, 2, 4, 6, 24 or 48 hours.
Results : The plasma and serum BDNF levels were measured by
ELISA. The measured plasma BDNF levels increased over time,
whereas the serum BDNF levels were unchanged. The BDNF levels
detected in heparin-plasma and EDTA-plasma samples stored at
4 xC were much higher than those in samples stored at 25 xC.
Conclusion : This study indicates that the measured plasma
BDNF levels are dependent on the time and the temperature of
storage after blood sampling.
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jP-11-001jPsychopathology in alzheime’s disease
M. Blanco1, C. Bonilla Reyes1, E. Valdivia Baza´n1, C. Harkous Pen˜a1,
P. Sopelana Rodriguez1. 1Madrid, Spain
Objective : In this review we analyze the psychopathological variants
found in this stereotype of patient and diagnostic diﬃculties.
Methods : It carries out a review about the data currently available
on this topic.
Results : Semiology psychic : depressive syndrome (20 to 40%),
psychotic symptoms (30 to 50%) are not correlated with the severity
of dementia, aggression and psychomotor agitation (20%)and sleep
disturbance (40 to 70%). They also appear frequently delirium, pro-
gressive deterioration in recent memory, disinhibited or socially in-
appropriate behavior, personality changes and emotional lability.
Somatic semiology : Table afas-apraxic-agnostic. It should also be no-
ted that the prognosis may overshadow the association with extra-
pyramidal signs, psychotic disorders and myoclonus.
Conclusion : We note that Alzheimer’s disease and psycho-
pathology are correlated. It hath in mind the existing diagnostic diﬁ-
vulatdes have to go deeper into these issues.
jP-11-002jDepressive disorders and medical conditions among
patients with alzheimer’s disease : A case-control
study of a national managed care database
R. Castilla-Puentes1, M. Habeych2. 1School of Pharmacy, Philadelphia,
USA ; 2Center for Clinical, Neurophysiology, Pittsburgh, USA
Objective : To compare the prevalence of depression and comorbid
medical conditions between patients with a diagnosis of Alzheimer’s
Disease (AD) (cases) in comparison with a matched control group of
patients without AD, in the National Managed Care Benchmark
Database (IHCIS).
Methods : The prevalence of depression and comorbid medical
conditions was compared between patients with AD (deﬁned by ICD-
9 codes) and controls using data from the IHCIS, a fully de-identiﬁed,
HIPAA compliant database made up of more than 35 Managed Care
health plans within the US and covering seven census regions.
Matched case-control method was used to compare depression and
medical comorbidity. Controls were matched to cases by type of
health plan and pharmacy beneﬁt on a 3 : 1 ratio.
Results : Among the 488,091 patients with full year of eligibility
during 2001, 2,947 were identiﬁed with a diagnosis of AD and 63.6%
were women. The prevalence of depressive disorders was much
higher in the AD group compared to a random selection of matched
non AD patients 12,880 (32.48% vs. 3.45%, p<0.001). AD patients had
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more comorbid medical conditions than patients without dementia.
In general, AD patients had more convulsions [odds ratio (OR)=6.16,
95% CI=3.3–11.5] ; hypotension (OR=2.90, 95% CI=2.0–4.2) ;
anemia (OR=2.31, 95% CI=1.4–3.8) ; heart failure (OR=2.21, 95%
CI=2.0–2.5) ; urinary system disorders (OR=1.73, 95% CI=1.4–2.7) ;
COPD (OR=1.53, 95% CI=1.2–1.8) ; gastrointestinal hemorraghe
(OR=1.46, 95% CI=1.2–1.9) ; and circulatory disease (OR=1.39, 95%
CI=1.0–1.9) ; compared with the controls.
Conclusion : The present study conﬁrms that depressive disorders
and medical comorbidities are complications of AD and physicians
should be alert to the presence of this clinically important diseases in
patients wit AD.
Policy of full disclosure : Dr. Castilla-Puentes is currently working
as Global Medical Safety Physician with Johnson & Johnson,
Pharmaceutical Research and Development.
jP-11-003jComparison of cognition measured by MMSE
between alzheimer’s disease and depression
S.M. Chang1, H.-D. Rim1, S. Jeong1, S.J. Lee1, S. Won1, T.Y. Choi2.
1Kyungpook National University, Daegu, Republic of Korea ; 2Catholic
University of Daegu, Republic of Korea
Objective : The Mini-Mental State Examination (MMSE) is the most
widely used screening measure for cognitive impairment. The aims
of this study are to compare the psychometric properties of the Mini-
Mental State Examination – Korean Version (MMSE-KC) between
Alzheimer’s disease and depression and to detect diﬀerential item
function (DIF).
Methods :Data were analyzed from a nationwide sample of Korean
elders, a total of 485 participants age 65 or older from cross-sectional
community-based study. All participants were assessed using Mini-
Mental State Examination by door-to-door home visit. Diagnostic
assessments of depression and dementia were administered using
the Korean version of the Consortium to Establish a Registry for
Alzheimer’s Disease Assessment Packet (CERAD-K) Clinical
Assessment Battery.
Results :All items of MMSE-KC ﬁt the model and together spanned
a range of threshold parameter (diﬃculty) from x3.86 (easier) to
1.15 (more diﬃcult) logits, and slope parameter (discrimination) from
0.55 to 8.6 logits. Depression group were more likely to have errors
like items about ‘recall of three words’ and ‘attention’ were the most
diﬃcult items. In contrast, dementia group had errors inmost of items.
Detecting DIF using IRTLRDIF, people with dementia showed DIF
such items as orientation to place, the last two items of ‘recall of three
words (car and cap)’, and The last two items of’ attention’, ’three stage
command’. People with depression showed DIF such items as ’time
orientation (week)’, ’repetition’, ’recall of three words (car)’.
Conclusion : The MMSE-KC can provide a reliable and valid
quantitative estimate of cognitive ability. However, some items have
DIF in case of people with depression or dementia.. Therefore, more
attention should be paid to items showing DIF.
jP-11-004jThe outcome of mild cognitive impairment after
administering treatment
P. Delia Marina1, C. Mila1. 1West Vasile Goldis University, Arad,
Romania
Objective : Mild cognitive impairment(MCI) is a frequent clinical en-
tity, considered today to be a prodromal stage of Alzheimer’s de-
mentia. The aim of this study is to determine the outcome of the
patients diagnosed with MCI treated with diﬀerent therapies and the
patients diagnosed with MCI and non-treated.
Methods : The study comprises a number of 157 patients (over
60 years) diagnosed with MCI. The patients were evaluated with
MMSE (Mini Mental State Evaluation) at the inclusion into the
study, after 6 months, after 1year and after 2years. The patients were
divided in : group Ax43 patients with MCI treated with Galantamine
(16 mg/day) group B x44 patients with MCI treated with Rhodiola-
rosea, 2capsules/day group C x41 patients with MCI treated with
Vitamin E, 800UI/day group Dx29 patients with MCI, which did not
received treatment.
Results : The average of MMSE scores at the inclusion into the study
was 23.62 points for group A, 24.36 for group B, 24,82 for group C and
25.0 for group D. After 1year, cognitive performance improves with
2.07 points for group A, with 2,04 for group B, 2,69 in group C ; in
group D we did not observed any improvement. After 2 years of
treatment cognitive performance improves with 3,14 points for group
A, 2,48 points for group B, 2,25 points for group C and in group D we
have observed an impairment of cognitive performance with 2,49
points.
Conclusion : Comparing the outcome of patients long time treat-
ment show a better improvement in group treated with cholinesterase
inhibitor (galantamine). The study prove the importance of early
treatment of MCI to improve the cognitive function and to delay the
progression to dementia.
jP-11-005jClozapine as mono-therapy in the management of
huntington’s chorea
D. Goel1, R. Butt1. 1Southland Hospital, Invercargill, New Zealand
Objective : Huntington’s Chorea, an autosomal dominant neuro-
degenerative disorder comprising movement disorder, cognitive
deﬁcits and distressing psychiatric symptoms, often poses a signiﬁ-
cant therapeutic and management challenge to clinicians and care-
givers alike. While a number of medication strategies, including
amantadine, tetrabenazine (the ﬁrst drug to receive speciﬁc US FDA
approval for the managing the choreiform component of the dis-
order), clonazepam and antipsychotics like haloperidol and risper-
idone, have been tried, none seems to produce sustained symptomatic
relief or signiﬁcantly reduced care-giving burden. Psychotic symp-
toms, irritability, aggression, depression, apathy and suicidality are
major contributors to the care-giver burden and, despite considerable
research, often remain unaddressed or inadequately managed.
Clozapine, with its demonstrated superior eﬃcacy and extremely low
risk of extra-pyramidal side-eﬀects (EPS) and tardive dyskinasia (TD),
would appear to be the ideal antipsychotic for the purpose and its
usefulness in this regard is supported by ﬁndings from several
studies. Unfortunately, however, it remains under-used in patients
with Huntington’ Chorea.
Methods : This naturalistic observational study describes an illus-
trative case. The patient, a 57 year old (European) male with the
diagnosis of Huntington’s Chorea and persisting paranoid delusions,
aggressive/disruptive/violent behaviour, aggravated movement dis-
order despite multiple medications (including risperidone 6 mg/day)
was referred for review as he had become unmanageable in the rest-
home where he had been assigned to live. He was transitioned un-
eventfully to clozapine 100 mg/day, with amelioration of psychotic
symptoms, as well as improvement in the movement disorder.
Results : Complete remission of psychotic symptoms, aggression,
disruptive and violent behaviour, along with signiﬁcant improvement
in the movement component.
Conclusion : Clozapine monotherapy is an eﬀective and safe
therapeutic option in patients with Huntington’ Chorea. Further re-
search is required to generate robust evidence in this area.
jP-11-006jEﬀects of intestinal endotoxemia (IETM) on learning
memory ability and brain levels of Ab, Tau protein
in rats with alzheimer’s disease
B. Han1, X. Shan2, Q. Sun2, L. Ma2, D. Han3. 1Shanxi Medical
University, The First Hospital, Taiyuan City, China ; 2The General
Hospital of CPAPF, Peking, China ; 3Shanxi Medical University, Taiyuan
City, China
Objective : To investigate the relationgship between intestinal endo-
toxemia (IETM) and learning memory ability, brain levels of
b-amyloid protein (Ab), Tau protein in rats with Alzheimer’s disease
(AD).
Methods : The AD model of wistar rats were produced by injecting
D-galactose and AlCl3 intraperitoneally for 90 days. Subsequently,
learning and memory ability of the rats were evaluated by
Morris water maze ; the level of lipopolysaccharide (LPS), tumor
necrosis factor-a (TNF-a), interleukin-1b(IL-1b) and Tau protein were
determined by ELISA ; the apoptotic neuron was detected by Flow
cytometry ; the expression levels of Abwas tested by
Immunohistochemical.
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Results : Compared with the normal control group, the model
group had longger latency (P<0.01) and more error times (P<0.05) in
Morris water maze test ; LPS, TNF-a, IL-1b and PD in AD rats were
increased (P<0.05) ; the expression levels of Aband Tau protein in
brain were increased (P<0.05).
Conclusion : The rat model of Alzheimer’s disease is accompanied
IETM and that may plays an important role in the development
of AD.
jP-11-007jEﬀects of intestinal endotoxemia (IETM) on learning
memory ability and cell apoptosis in rats with
alzheimer’s disease
B. Han1, F. Wu2, X. Li2, D. Han2. 1Shanxi Medical University, The First
Hospital, Taiyuan City, China ; 2Shanxi Medical University, Taiyuan City,
China
Objective : To investigate the relationship between intestinal en-
dotoxemia (IETM) and learning memory ability, cell apoptosis in rats
with Alzheimer’s disease (AD).
Methods : The AD model of wistar rats were produced by injecting
D-galactose and AlCl3 intraperitoneally for 90 days. Subsequently,
learning and memory ability of the rats were evaluated by Morris
water maze ; the level of lipopolysaccharide (LPS), tumor necrosis
factor-a (TNF-a) and interleukin-1b(IL-1b) were determined by
ELISA ; the apoptotic neuron was detected by TUNEL.
Results : Compared with the normal control group, the model
group had longger latency (P<0.01) and more error times (P<0.05) in
Morris water maze test ; LPS, TNF-a, IL-1band PD in AD rats were
increased (P<0.05).
Conclusion : The model of Alzheimer disease’s rats which
were established by D-galactose and AlCl3 is accompanied IETM
and that may plays an important role in the cell apoptotic of AD.
[Key words] Alzheimer’s disease (AD) ; Intestinal endotoxemia
(IETM) ; Lipopolysaccharide (LPS) ; Tumor necrosis factor-a (TNF-a) ;
Interleukin-1b(IL-1b) ; Apoptotic.
jP-11-008jEﬀects of intestinal endotoxemia (IETM) on learning
memory ability and hippocampal gene expression of
APP and PS1 in rats with alzheimer’s disease
B. Han1, X. Shan2, Q. Sun2, L. Ma2, D. Han3. 1Shanxi Medical
University, The First Hospital, Taiyuan City, China ; 2The General
Hospital of CPAPF, Peking, China ; 3Shanxi Medical University, Taiyuan
City, China
Objective : Alzheimer’s disease (AD) brains are characterized by
accumulation of amyloid b protein (Ab) and neuroin_ammation.
Deposition of Ab is the main component of the plaques, and the
neuroﬁbrillary tangles, cell loss, vascular damage, and dementia fol-
low as a direct result of this deposition. To investigate the eﬀect of
intestinal endotoxemia (IETM) on learning and memory ability in rats
with Alzheimer’s disease (AD) and its possible mechanisms.
Methods : The AD model of wistar rats were produced by injecting
D-galactose and AlCl3 intraperitoneally for 90 days. Subsequently,
learning and memory ability of the rats were evaluated by Morris
water maze ; the level of lipopolysaccharide (LPS) and tumor necrosis
factor-a (TNF-a) were determined by ELISA ; the apoptotic neuron
was detected by (TUNEL) ; hippocampal gene expression of amyloid
precursor protein (APP) and presenilin1 (PS1) was tested by RT-PCR.
Results : Compared with the normal control group, the model
group had longger latency (P<0.01) and more error times (P<0.05)
in Morris water maze test ; LPS, TNF-a and PD in AD rats were
increased (P<0.05) ; the expression of APP and PS1mRNA in hippo-
campus were increased (P<0.05).
Conclusion : The rat model of Alzheimer’s disease is accompanied
IETM and that may plays an important role in the development of
AD. [Key words] Alzheimer’s disease (AD) ; Intestinal endotoxemia
(IETM) ; Lipopolysaccharide (LPS) ; Tumor necrosis factor-a (TNF-a) ;
Amyloid beta-protein precursor (APP) ; Presenilin1 (PS1).
jP-11-009jThe study on the level of intestinal endotoxemia
(IETM) in alzheimer disease rats
B. Han1, F. Wu2, X. Li2, F. Wang2, D. Han2. 1Shanxi Medical University,
The First Hospital, Taiyuan City, China ; 2Shanxi Medical University,
Taiyuan City, China
Objective : The objective of the present study was to explore the level
of intestinal endotoxemia (IETM) in the model of Alzheimer disease’s
rats which were established by D-galactose and aluminum trichloride
(AlCl3).
Methods : Adult Wistar rats were subjected to 90 days of
intraperitoneal injection with D-galactose and AlCl3 to establish the
Alzheimer disease’s model. After the administration, the study and
memory ability of the Alzheimer disease’s rats were observed by
Morris water maze ; The level of Lipopolysaccharide (LPS) in the sera
of Alzheimer disease’s rats was determined by tachypleus amebocyte
lysate method ; The level of tumor necrosis factor-a (TNF-a) and
interleukin-1 (IL-1) in the sera of Alzheimer disease’s rats were
determined by radioimmunity method.
Results : Compared with the normal control, the level of LPS,
TNF-a and IL-1 in the sera of Alzheimer disease’s rats were markedly
increased (P<0.01).
Conclusion : The model of Alzheimer disease’s rats which were
established by D-galactose and AlCl3 is accompanied IETM. Key
words : intestinal endotoxemia ; lipopolysaccharide ; Alzheimer dis-
ease ; D-galactose ; aluminum trichloride ; model.
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jP-11-010jThe evaluation of anti-androgen therapy to dementia
patient with hyper sexuality using SPECT : A case
study
M. Inoue1, K. Kamino1, K. Kiuchi2, S. Kitamura2, T. Shinkai2,
A. Hattori1, T. Kishimoto2. 1Yamato Mental Medical Center, Nara,
Japan ; 2Nara Medical University, Japan
Objective : To investigate the changes in cerebral blood ﬂow in de-
mentia patient with hyper sexuality after anti-androgen therapy.
Methods : We performed 99mTc-ECD SPECT studies before and
after anti androgen therapy in a senile dementia patient with hyper
sexuality using statistical parametric mapping analysis.
Results : Statistical parametric mapping analysis showed that
increased cerebral blood ﬂow occurred in bilateral frontal gyri after
anti-androgen therapy. Furthermore, temporal gyri showed marked
increased cerebral blood ﬂow compared with baseline study. Patient
improved the sexual problem after the therapy, but cognitive function
did not change throughout the study.
Conclusion : Our ﬁndings indicate that the change of blood ﬂow in
frontal and temporal cortices may reﬂect the eﬀect of anti-androgen
therapy in patient with hyper sexuality. The patient with fronto-
temporal dementia sometimes shows abnormal behavior like hyper
sexuality. Our results might contribute to solving the problem.
jP-11-011jNeuropharmacological evidences of biochanin-A in
cognitive deﬁcit mice for the management of
alzheimer’s disease
H. Joshi1, S. Biradar2. 1Sarada Vilas College of Pharma, Mysore, India ;
2Sarada Vilas College of Pharma, Km Puram, Mysore, India
Objective : To evaluate the behavioural and neurochemical evidence
of Biochanin-A in cognitive deﬁcit mice for the management of
Alzheimer’s disease in scopolamine induced and naturally induced
amnesic models in young and aged mice.
Methods : Elevated Plus Maze, Passive Avoidance Shock were
used. Brain AchE, GSH and TBARS were analysed. Neurochemical
evidence was obtained by assay of brain Dopamine and Nor-
Adrenaline assay, brain tissue damage was analysed.
Results : BCA decreased in the Transfer Latency, increased Step
Through latency signiﬁcantly in Scopolamine treated and natural
aged mice in Elevated Plus Maze and Passive Shock Avoidance
Paradigm. A dose dependent (BCA 40, 20 & 10 mg/kg) signiﬁcant
(P<0.01) antioxidant (TBARS & GSH) and inhibition of acetyl-
cholinestease activity was observed as compared to Standard
Piracetam (400 mg/kg). BCA insigniﬁcantly (P<0.05) reduced
Dopamine and Nor-adrenalin content of young mice, where as in
scopolamine treated mice showed signiﬁcant (P<0.01) increase in the
content of Nor-adrenaline and insigniﬁcant (P<0.05) increase
in Dopamine, which is sign of dementia.
Conclusion : Further in histopathology of hippocampus of BCA
treated mice protected the formation of pyknotic black neurons com-
pare to Scopolamine. In the light of above, it may be worthwhile
to explore the potential of this Biochanin-A in the management of
Alzheimer’s disease.
jP-11-012jA comparison of clinical and neuropsychological
features in patients with alzheimer’s disease and
mixed dementia
H. Kang1, D. Kim1, S. Lim1, S. Kim1, Y. Lee1, J. Song1. 1Samsung
Medical Center, Seoul, Republic of Korea
Objective :We designed this study to diagnose Mixed dementia (MD)
using brain imaging data as well as clinical criteria, and compare the
clinical features and neuropsychological characteristics of AD
(Alzheimer’s disease) and MD.
Methods : A total of 1757 AD patients and 987 MD patients were
included from the Clinical Research Center for Dementia of South
Korea (CREDOS). All patients underwent comprehensive neuro-
psychological tests as follows : the Korean version of the Mini-Mental
State Examination (K-MMSE), the Clinical Dementia Rating (CDR)
scale, the Barthel Index for Daily Living Activities (Barthel-ADL),
the Seoul-Instrumental Activities of Daily Living (S-IADL), the
Korean-Neuropsychiatric Inventory (K-NPI), the 15-item Geriatric
Depression Scale (GDS), and the Dementia version of Seoul
Neuropsychological Screening Battery (SNSB-D).
Results : The results of a clinical features comparison revealed that
depressed mood and vascular factors such as hypertension, heart
disease, focal neurological symptoms and signs, and stroke were
present in MD patients more than in those with AD. With respect to
cognitive function, no signiﬁcant diﬀerence was found between AD
and MD patients in terms of SNSB-D scores except frontal/executive
function. Also, AD patients showed better performance than MD
patients with respect to activities of daily living.
Conclusion : This study reports that MD patients showed sig-
niﬁcantly diﬀerent clinical and neuropsychological features than AD
patients. These ﬁndings will be helpful in the development of pre-
vention and treatment strategies for MD.
Policy of full disclosure : This study was supported by a grant
of the Korea Health 21 R&D Project, Ministry of Health, Welfare, and
Family Aﬀairs, Republic of Korea (A050079) and of the Samsung
Biomedical Research Institute, #SBRI C-A9–205.
jP-11-013jComparative assessment of attention and clinical
eﬃcacy after treating galantamine between the
patients with pure alzheimer’s disease and mixed
dementia
H. Kang1, D. Kim1, S. Lim1, S. Kim1, Y. Lee1, J. Song1, J. Back1, Y. Noh1,
S. Shim1. 1Samsung Medical Center, Seoul, Republic of Korea
Objective : The purpose of this study was to compare the eﬃcacy of
galantamine treatment, especially attention ability between patients
with pure Alzheimer’s disease (AD) and Mixed dementia (MD) dur-
ing a 24-week trial.
Methods : A total of 40 patients were recruited for this 24-week
study. The eﬀect of galantamine on attention was measured using
Seoul Computerized NeuroCognitive Function Test (SCNT) and
frontal functions test of Seoul Neuropsychological Screening Battery
(SNSB). Patients’ activities of daily living using the Seoul-Activities of
Daily Living (S-ADL) and the Seoul-Instrumental Activities of Daily
Living (S-IADL) ; behavioral symptoms using the Korean version
Neuropsychiatric Inventory (K-NPI) were measured at baseline and
24-week.
Results : 17 pure AD patients and 23 MD patients were analyzed in
this study. Attention as measured by SCNT was not signiﬁcantly dif-
ferent from baseline after 24 weeks of treatment in both groups. There
was no signiﬁcant diﬀerence between two groups in mean change
from baseline in the SCNT, S-ADL, S-IADL and K-NPI scores at
24-week.
Conclusion : Galantamine showed a therapeutic eﬀect on cognition,
activities of daily living, neuropsychiatric symptoms in pure AD and
MD. Furthermore, Galantamine may speciﬁcally help to maintain
attention and it may have positive eﬀects on other cognitive and
functional abilities.
Policy of full disclosure : This study was supported by Janssen
Korea Ltd.
jP-11-015j Investigation of donepezil eﬀect to the prevention of
hippocamal volume loss in alzheimer’s disease
S. Kitamura1, K. Kiuchi1, T. Taoka1, M. Morikawa1, M. Inoue1,
J. Kosaka1, K. Hashimoto1, T. Nagashima1, K. Matsuoka1,
K. Kichikawa1, T. Kishimoto1. 1Nara Medical University, Kashihara,
Japan
Objective :Alzheimer disease (AD) is the most common disease in the
cognitive impairment diseases, and the AD patients have been in-
creasing in recent years. AD shows memory impairment, disturbance
of orientation and higher brain dysfunction such as visuospatial dis-
order and executive dysfunction with disease progression. In AD, the
hippocampal atrophy is progressively seen in disease course.
Meanwhile, it is suggested that donepezil has neuroprotective eﬀect
and prevents the disease progression. However, there are patients of
AD for whom donepezil is eﬀective or not. In this study, we followed
the AD patients who were medicated with donepezil and investigated
hippocampal volume change with each of the donepzil respeonder
and non-responder.
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Methods : Voxel-based morphometry analysis was perfomed in
13 AD patients who are prevented in cognitive decline with donepezil
treatment and 14 who are not. All participants were medicated with
donepezil. In the analysis. Voxel-based Speciﬁc Regional Analysis
System for Alzheimer’s disease (VSRAD : developed by Eisai Co., Ltd.
& Pﬁzer Japan) was used, and calculated hippocampal region atrophy
index deﬁned as Z score. The subjects were performed magnetic
resonance imaging scan at the baseline and the follow point, and cal-
culated the diﬀerence between the Z score at baseline and follow
point. Group analysis was performed using Mann-whitney U test.
Results : There was a signiﬁcant diﬀerence between donepezil
eﬀective and donepezil non-eﬀective patients in AD regarding the
severity of hippocampal region atrophy (p=0.038).
Conclusion : In this study, we found that the progression of the
hippocampal atrophy was more suppressed in AD patients who were
eﬀective with donepezil treatment than those who were non-eﬀective.
It is suggested that donepezil may play an important role in the sup-
pression of the neurodegeneration and help the neuronal protection,
and consequently delay the cognitive decline in AD patients.
jP-11-016jEﬀects of high-frequence transcranial magnetic
stimulation on cognition of elderly with cognitive
impairment no-dementia (CIND)
M.A. Marcolin1, H.L. Drumond Marra1, M.L. Myckowski1,
C.M. Memoria1, D. Arnaut1, O.V. Forlenza1. 1University of Sao Paulo,
Institute of Psychiatry, Sa˜o Paulo, Brazil
Objective : To verify the eﬀects of high-frequency rTMS to the left
dorsolateral prefrontal cortex (DLPFC) on global cognition of func-
tionally independent elderly with subjective complaints of memory
decline.
Methods : Clinical trial. Nineteen (8 male and 11 female) elderly,
aged between 60 and 74 years old (mean age=64.5¡3.8), independent
for instrumental activities of daily living (IADL) with subjective
memory complaints and evidence of some impairment in neuro-
psychological assessment, characterizing cognitive impairment
no-dementia (CIND). The MoCA test was used for screening. For each
patient, a brain magnetic resonance image excluded major causes of
cerebrovascular disease and white matter lesions, evidence of focal
atrophy or lacunes. Subjects were randomized into two groups :
(I) active rTMS (n=9) and (II) sham rTMS (n=10). A rapid magnetic
stimulator and a ﬁgure-of-eight cooled coil was used. We delivered
10 sessions of high-frequence rTMS (10 Hz) for 5 seconds to the left
DLPFC, with the parameters : 50 stimuli/train, 40 trains, 25 seconds
of intertrain interval, 2.000 pulses/session and intensity of 110%
of motor threshold. The placebo group used a sham coil. Follow-up
(‘oﬀ-line’’ paradigm) was obtained by detailed neuropsychological
assessment encompassing all cognitive domains including the
Rivermead Memory Behavioural Test (RMBT) and Stroop. Testing
was applied at baseline, after rTMS and one month later. All partici-
pants gave written informed consent.
Results : These preliminary results showed improvement higher
than 10% in the performance of RMBT and Stroop tests (ANOVA,
p=0.028 and p=0.038, respectively) after rTMS sessions. The im-
provement was sustained after one month on RMBT scores, but not on
STROOP test. (Updated results will be showed on the poster presen-
tation).
Conclusion : Although sample size is still statistically limiting, the
results suggest cognitive response in memory and attention to high-
frequency rTMS, and a sustained eﬀect in memory after one month.
jP-11-017jVascular risk factors and cognition in persons with
moderate cognitive impairment
A. Miljatovic1, J. Martinovic1, S. Drmanic2. 1Clinical Center Zvezdara,
Belgrade, Serbia ; 2Clinical Center of Serbia, Belgrade, Serbia
Objective : To investigate the impact of vascular diseases (assessed by
the number of vascular risk factors) on the cognition of persons with
amnestic moderate impairment. Persons with moderate cognitive
impairment are characteriyed by marked memory deﬁcits and show
brain atrophy in the mediotemporal areas of the brain.
Methods : This study included a total of 110 participants, including
52 persons with CI (cognitive impairment) and 58 healthy elderly
controls. Vascular risk factors (hypertension, hypotension, diabetes
mellitus) and vascular diseases (transient cerebral ischemia, carotid
stenosis, coronary artery disease) are clinically reported or recorded in
the individual charts of patients by their treating physican. All parti-
cipants were tested on a range of cognitive tests.
Results : A larger vascular burden among patients with cognitive
impairment is associated with lower performance in the executive
domain.There was no other signiﬁcant correlation in patients with
CI.There was no signiﬁcant correlationin the control group.
Conclusion : Our results show that vascular load is related to
executive dysfunctions in patients with CI similar to what has been
repeatedly reported in healthy older adults.In this study vascular load
was not associated with processing speed,episodic memory or overall
cognitive functioning.
jP-11-018jComparing frontotemporal dementia and
schizophrenia using EEG microstate analysis
K. Nishida1, T. Koenig1, T. Kinoshita2, T. Dierks3. 1University Hospital
of Psychiatry Bern, Switzerland ; 2Kansai Medical University, Department
of Neuropsychiatry, Osaka, Japan ; 3University Hospital, Bern, Switzerland
Objective : Recent study reveals electroencephalogram (EEG) micro-
state map D is correlated with frontal-parietal associated network :
linked to frontoparietal network or executive-control network, and
map C is correlated with salience network : hub of attention and con-
trols the other networks. To determine the relationship of resting stage
networks from EEG and mental disorders, microstate analysis was
performed in mild frontotemporal dementia (FTD) patients, which
has typical frontal lobe degeneration and hypoactivity in the salience
network, and compared with schizophrenia (SZ) patients whose
microstate abnormalities are well established.
Methods :We performed EEGMicrostate analysis in mild FTD, and
in SZ. Moreover, we collected a sample of age-matched normal con-
trols (NC) for each of the two study groups. Firstly, we compared the
duration of each Microstate map (A, B, C, and D) of the FTD and the
SZ group separately to the NC using a t-test. Next, we were interested
in the comparison of the standardized values of the durations of map
C and D between FTD and SZ.
Results : In FTD patients, the duration of the map C was signiﬁ-
cantly decreased compared to NC. However, in SZ patients, the dur-
ation of the maps A, B and D were signiﬁcantly decreasing in
comparison to NC. No group diﬀerence in the Map C was detected
between FTD and SZ, while the duration of the map D showed a
tendency towards a shorter duration in SZ than in FTD patients.
Conclusion : Previous results support the view that the duration
of various microstates (map A, B, D) in SZ were aﬀected, on the con-
trary, mild FTD demonstrates showed more limited pathological
changes (only Map C). We speculate that the decreasing duration in
the map C is speciﬁc for the FTD, while the diﬀerence in the duration
in schizophrenia may represent the wide range dysfunction in total
brain.
jP-11-019jThe eﬀect of 12-week open-label memantine
treatment on cognitive function and on alcohol
consumption in patients with alcohol dementia
G. Rubio1, R. Jurado1, I. Martı´nez-Gras1, G. Ponce1, A. Villarejo1.
1Hospital 12 de Octubre, Madrid, Spain
Objective : Alcohol dementia (AD) usually follows long-term alcohol
dependence. AD can occur in around 25% of alcohol dependent
patients. Despite its clinical relevance, few studies have been
published up to now on neuropsychiatric treatment of AD. The cen-
tral nervous glutamatergic system, with its N-methyl-D-aspartate
(NMDA) receptors, is suggested to be involved in toxic neuronal loss
due to alcohol withdrawal and may subsequently contribute to the
development of AD. Also, it was hypothesized that the low-aﬃnity
NMDA receptor antagonist memantine would improve the cognitive
function of patients with AD. The aim of this study was to evaluate the
eﬀect of memantine on the cognitive improvement and on alcohol
consumption of patients with AD.
Methods : The study was designed as a 12-wk open-label study
investigating the eﬃcacy of 20 mg memantine, a low-aﬃnity NMDA
receptor antagonist, as a treatment for cognitive and behavioural
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problems in 15 patients with probable AD according to the criteria for
ARD proposed by Oslin and colleagues. All participants were selected
from patients attended at the Alcoholism Programa in our hospital
(‘‘12 de octubre’’ University Hospital, Madrid, Spain). The CERAD-K
(Consortium to Establish a Registry for Alzheimer’s Disease – Spanish
version) and several clinical assessment scales were completed before
and after the 12-week memantine treatment period.
Results : Signiﬁcant improvements in the mean scores from baseline
to ﬁnal assessment were observed in the Global Deterioration Scale
(p<0.05), Brief Psychiatric Rating Scale (p<0.01) and Alcohol con-
sumption (p<0.05).
Conclusion : In this open-label study, patients with AD treated with
20 mg/d memantine for 12 weeks showed improvement on global
cognition, behavioural symptoms and alcohol consumption. The re-
sult of this study suggests the possible usefulness of memantine for
the treatment of AD.
jP-11-020jResponse to galantamine administration in patients
with alzheimer’s disease : Exploring subdomains of
cognitive function
J. Song1, I.S. Ahn1, H.S. Kang1, W. Myung1, Y. Lee1, S. Woo1,
D.K. Kim1. 1Samsung Medical Center, Seoul, Republic of Korea
Objective : To investigate galantamine’s eﬀect on cognitive sub-
domains, we examined the clinical response to galantamine in
patients with Alzheimer’s disease (AD) during a 12-month trial.
Methods : Sixty-six patients with mild to moderate AD were re-
cruited for this 52-week study. The eﬀect of galantamine on cognitive
function was measured using the Korean version of Alzheimer’s
Disease Assessment Scale-cognitive subscale (K-ADAS-cog). To assess
frontal/executive dysfunction, K-ADAS-cog included trail making
test-part A and B, digit span, and category ﬂuency. Patients’ activities
of daily living using the Seoul-Instrumental Activities of Daily Living
(S-IADL) and Seoul-Activities of Daily Living (S-ADL) ; and behav-
ioral symptoms using the Neuropsychiatric Inventory (NPI) were
measured at a given point of time. We deﬁned patients responsive to
galantamine as either those who have shown a cognitive improve-
ment or no change during the ﬁrst six-month clinical trial.
Results : Overall, patients administered with galantamine showed
less cognitive decline through a 52-week period than those with a
placebo, as predicted by the Stern equation. Based on the operational
criteria, 66.7% of patients were ascribed to treatment responders. The
responders showed eﬀects in the cognitive subdomains of memory
and language through a 26-week period. The responder group had an
average 2-point drop in the memory subdomain and a 1.18-point drop
in the language subdomain, while the non-responder group had rose
by 4.5 points on average in the memory subdomain and rose by 0.59
points on average in the language subdomain.
Conclusion : Approximately two-thirds of the patients responded
to galantamine, and they have shownmaintenance or improvement of
cognitive functions through 6 months of the clinical trial. The re-
sponders gained a cognitive improvement in memory and language
functions.
jP-11-021jComparative eﬃcacy of cholinesterase inhibitors in
dementia associated with Parkinson’s disease
D. Vasile1, O. Vasiliu1, A.G. Mangalagiu1, M. Blandu1, A. Nanca1.
1Military Emergency Hospital, Bucharest, Romania
Objective :All the cholinesterase inhibitors were investigated in PDD,
but there is a lack of head-to-head drug comparisons in this ﬁeld.
There are important reasons, both pharmaco-economic and clinical, to
investigate if cholinesterase inhibitors are equally eﬃcient in the
treatment of PDD.
Methods : In order to assess the comparative eﬃcacy of these
drugs we selected a group of 45 patients diagnosed with PDD, who
presented a documented history of PD for at least 3 years, and we
randomized them on single-blinded ﬂexible doses of galantamine
(mean daily dose 16 mg, dose range 8–24 mg/day, n=16), donepezil
(mean daily dose 7.5 mg, dose range 5–10 mg/day, n=15) or rivas-
tigmine (mean daily dose 9 mg, dose range 6–12 mg/day, n=14).
Patients were evaluated every 4 weeks for 6 months using Mini-
Mental State Examination (MMSE), Alzheimer Disease Assessment
Scale- Cognitive subscale (ADAS-Cog), Global Assessment of
Functioning (GAF) and Uniﬁed Parkinson Disease Rating Scale
(UPDRS).
Results : Patients diagnosed with dementia had a better evolution
under treatment with rivastigmine and galantamine, without sig-
niﬁcantly intergroup diﬀerences (+0.9¡0.7 points on MMSE,
+0.5¡0.3 points on ADAS-Cog and +4.1¡2.2 on GAF, p<0.05).
Donepezil had a positive impact over the mental clinical status,
but lesser than the other two cholinesterase inhibitors (+0.8¡1.0
MMSE and+2.1¡1.9 ADAS-Cog), although the intergroup diﬀerence
didn’t reach a level of signiﬁcance of 0.05. There was recorded no
drop out due to adverse events during the study. The UPDRS scores
didn’t vary signiﬁcantly, reported to baseline, in none of the three
groups.
Conclusion : Patients with PDD associated dementia responded
better to galantamine and rivastigmine, in the absence of signiﬁcant
impact over the basic neurologic disease symptoms. Donepezil was
also eﬃcient in PDD, with no clinical signiﬁcant negative interference
with Parkinson’s disease evolution.
jP-11-022jAn internet based instrument for cognitive function
assessment
K. Wesnes. Bracket Global, Goring On Thames, United Kingdom
Objective :Many large scale registry trials in normal and pathological
aging are being planned or conducted. In Alzheimer’s disease, interest
is turning to prevention studies which may be conducted in healthy
populations identiﬁed to be at risk of developing Alzheimer’s disease.
Methods : Four tests from a computer based cognitive method-
ology, the CDR System, were internet enabled. Participants logged on
to a website, entered their age and gender, and performed the tests on-
line. Their data were compared to normative data from the standard
administration of these CDR tests.
Results : A total of 52,237 individuals aged 18 or over performed
at least one of the tests. There were highly signiﬁcant declines
with increasing age on the measures of speed on all tasks, as well as
for the ability to correctly identify the pictures. Further, variability
in reaction times increased with age, as did cognitive reaction time
(the diﬀerence between choice and simple reaction time). The declines
from 18 to 25 years to successive ﬁve year age bandings (eg 26 to 30, 31
to 36 etc) were generally comparable between the internet based test-
ing and the standard administration. Also performance on a number
of measures was directly comparable between the two forms of
administration.
Conclusion : This study has shown that large cohorts can be
assessed using internet based cognitive tests, and that the general
performance on these tests is directly comparable to that from the
same tasks administered in the standard fashion. Notably, rates of
decline with aging were directly comparable, as were the patterns of
declines on various measures. These ﬁndings suggest that internet
based cognitive testing is a viable technique in large patient trials, and
should prove a useful and convenient means of longitudinally asses-
sing cognition in patient registry studies or large long-term clinical
trials.
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Policy of full disclosure : The CDR System is owned by Bracket
Global and is oﬀered as a sertvice in clinical trials. Keith Wesnes is
employed by Bracket and owns stock in the company.
jP-11-023jCognitive declines year by year in non-demented
elderly aged 70 to 90 years
K. Wesnes1, B. Saxby2, G. Ford3. 1Bracket Global, Goring On Thames,
United Kingdom ; 2 Institute for Ageing, Newcastle University, Newcastle
on Tyne, United Kingdom ; 3 Institute for Ageing, Campus for Ageing and
Vitality, Newcastle on Tyne, United Kingdom
Objective : The deﬁcits to cognitive function which occur in normal
ageing can potentially be treated with pharmaceutical and other pro-
ducts. Further, as criteria have now been proposed for pre-clinical
dementia, trials are now being planned with compounds designed to
prevent or reduce cognitive decline in groups of ‘healthy volunteers’
identiﬁed to be at risk of developing Alzheimer’s disease. However, in
order to conduct such trials, cognitive tests need to be employed
which can reliably assess such change.
Methods : The CDR System is a computerised set of 9 tests of
attention, working and episodic memory which has been widely used
in trials of potential cognition enhancers in healthy volunteers, age-
related cognitive decline, MCI and the dementias. 256 normotensive
volunteers (113 females), mean age 76 years (range 70 to 90),
mean MMSE 28.8 (range 23 to 30), were trained on the CDR System
before a baseline was established, and then retested yearly for up to
5 years.
Results : Composite factor scores were derived from the various test
measures. Performance was found to decline signiﬁcantly over the
study period on four of the ﬁve scores : power of attention (p<0.0001),
quality of episodic recognition memory (p<0.0002), quality of
working memory (p<0.015) and speed of retrieval of information
held in memory (p<0.0001). Power of attention showed signiﬁcant
deﬁcits from year one onwards, two other measures showed deﬁcits
by year one, and all showed signiﬁcant deﬁcits from year three
onwards.
Conclusion : This study has demonstrated that the use of validated
and sensitive tests of cognitive function can detect decline over a
5-year period in healthy elderly volunteers. Such testing is therefore
ﬁt for purpose for the evaluation of treatments aimed at preventing
or even reversing age-related declines in cognitive function, as well as
treatments which may delay the onset of Alzheimer’s disease in high
risk but otherwise healthy populations.
Policy of full disclosure : The CDR System is owned by Bracket
Global which oﬀer the use of this in clinical trials as a scientiﬁc service.
Keith Wesnes is an employee of Bracket Global and owns stock in the
company.
jP-11-024jDiﬀerential involvement of cathepsin B and NLRP3
inﬂammasome in chromogranin A- and amyloid
b-induced pathways for microglial production of IL-1b
Z. Wu1, H. Nakanishi1. 1Kyushu University, Fukuoka, Japan
Objective : It is well known that neuroninﬂammation is exacerbating
pathology in Alzheimer’s disease (AD). Chromogranin A (CGA), a
secretory 49 kDa glycoprotein, is localized in senile plaque dystrophic
neurites of AD brain. Besides amyloid b (Ab), CGA is also considered
to serve as a pro-inﬂammatory inducer of neuroinﬂammation in
AD, whereas little is known about diﬀerences between CGA and Ab
in microglial activation. In the current study, we have compared
the CGA- and Ab-induced microglial production pathway of IL-1b, a
key pro-inﬂammatory cytokine.
Methods : Electrophoresis and immunoblotting, immunohisto-
hemical stainings, NLRP3 konck-down with siRNA were conducted
in MG5 microglial cell line and AD brain sections.
Results : CGA alone could induce production and secretion of
mature IL-1b by cultured microglia. Furthermore, CGA alone acti-
vated both nuclear factor (NF)-kB and pro-caspase-1 through proteo-
lytic processing by cathepsin B (CB), a lysosomal cysteine protease.
However, NLRP3 was not involved in CGA-induced IL-1b production
pathway by microglia. On the other hand, ﬁbrillar Ab alone failed to
produce mature IL-1b, because ﬁbrillar Ab induced activation of pro-
caspase-1, but not NF-kB. It was noted that ﬁbrillar Ab-induced acti-
vation of pro-caspase-1 depended on both CB and NLRP3 inﬂamma-
some. Cytosolic leakage of CB in cultured microglia was observed
after treatment with Ab. Furthermore, in the frontal cortex and the
hippocampus of AD brain, CR3/43-positive microglia surrounded
and their processes inﬁltrated more frequently in CGA-positive than
Ab-positive plaques. Microglia surrounded CGA-positive plaques
were intensely expressed both CB and IL-1b.
Conclusion : These observations strongly suggest that CGA is more
potent microglial activator than Ab to produce mature IL-1b through
CB-dependent activation of pro-caspase-1. Therefore, it is considered
that CB inhibitors can be pharmacological interventions against AD.
jP-11-025jSerum brain-derived neurotrophic factor levels are
decreased in diﬀerent dementias
R. Zanardini1, M. Ventriglia2, C. Bonomini1, P. Pasqualetti2, S. Sartori1,
F. Lombardi1, O. Zanetti1, D. Volpe3, M. Gennarelli1, L. Bocchio
Chiavetto1. 1 IRCCS Centro S.Giovanni di Dio, Brescia, Italy ; 2Rome,
Italy ; 3Venice, Italy
Objective : There is a great need for a reliable early diagnosis of the
neurodegenerative diseases. New biochemical markers, obtained with
non invasive procedures, together with existing clinical, biological
and neuroimagingmarkers may add accuracy to diﬀerential diagnosis
and prognosis of dementias and movement disorders. The neuro-
trophin brain-derived neurotrophic factor (BDNF) plays a critical role
in neuronal survival, synaptic plasticity, and memory in the adult
brain. Altered functionality of BDNF in post mortem brains and ab-
normalities in the serum concentrations have been observed in dif-
ferent neurodegenerative diseases such as Alzheimer’s disease (AD),
Parkinson’s Disease (PD). Despite the numerous evidences about in-
volvement of BDNF in the neurological diseases, to date no study has
investigated the possible role of this neurotrophin as biochemical
marker for diﬀerential diagnosis of this neurological diseases. Starting
from these considerations, we compared serum BDNF in diﬀerent
dementias and movement disorders and in a group of healthy subjects
in order to evidence alterations across diﬀerent diagnoses.
Methods : The sample is composed by 631 subjects : 169 healthy
controls, 263 AD, 40 Lewy Body (LBD), 91 Vascular Dementia (VaD),
28 Fronto-Temporal Dementia (FTD) and 40 PD patients. Serum
BDNF levels were analyzed by the enzyme-linked immunosorbent
assay (ELISA) method.
Results : Decreased serum BDNF levels were observed for AD,
LBD, VSD and FTD patients when compared with the control group
(p=0.005, p=0.006, p=0.017 and p=0.003 respectively). No signiﬁ-
cant diﬀerences were observed for PD patients. Moreover, lower
BDNF levels were evidenced in patients taking benzodiazepines
(p=0.024) while increased concentrations were detected in PD
patients treated with L-DOPA (p=0.008).
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Conclusion : In conclusion our results support the hypothesis that
BDNF alterations are involved in the neurodegenerative mechanisms
and suggest the potential usefulness of the serum dosage as a marker
for diﬀerential diagnosis in dementias and movement disorders.
P-12. Childhood & Adolescent Disorders
jP-12-001jNeuroeducation : Neurocognitive enhancement of
the developing brain
E. Bonda. Bold Underlined, Paris, France
Objective : I report clinical evidence in children from 4 to 9 years
old that have been treated through neurocognitive enhancement
techniques. The objective of these studies has been to improve speciﬁc
cognitive functions targeted through diagnoses of cognitive and
emotional disturbances and assessed through neurocognitive analy-
ses and testing.
Methods : In response to speciﬁc disorders, for instance dyslexia,
dysgraphia or dyscalculia, speciﬁc neurocognitive training tasks
have been proposed and used on an individual basis to speciﬁcally
remediate the assessed condition-disorder. More speciﬁcally, the
treatment of a purely dysgraphic child, a severely disabling learning
condition resulting from diﬃculty in expressing thoughts in writing,
including litteracy and deduction impairments, requested selective
use of auditory tone discrimination tasks, auditory noise-background
discrimination, vowel or consonant word completion, visual scanning
ability and kinesthetic working memory tasks.
Results : Sessions of intensive and frequent neurocognitive training
resulted in massive reduction of the disability manifestations in
clinical assessment and school performance. In experimental post-
treatment measures, highly improved general processing speed
abilities and word visual and auditory recognition scores have been
obtained.
Conclusion : Our clinical results of neurocognitive enhancement
in children highly support straightforward improvement of speciﬁc
cognitive disturbances through selective training of their cognitive
sub-components. The eﬀects of this type of improvement seem ex-
hibiting a structural or long-lasting character, conserving however the
speciﬁcity of the cognitive abilities that have been endorsed.
jP-12-002jTeen depression prevention – an issue of great social
impact
A. Burlea1, I. Sacuiu1, V. Chirita1, R. Chirita1. 1University of Medicine,
Iasi, Romania
Objective : The number of depressive episodes in teenagers has
increased dramatically for the past two decades. Depression is a
common condition among teenagers, with prevalence between 3%
and 8%, becoming acknowledged as a public health problem. More
than 25% of teenagers of about 18 have had at least one depressive
episode.
Methods : This is a retrospective study, assessing suicide attempts
of adolescents registered for a period of three years (2006–2008) and
was carried out at the Iasi Children Hospital. The study group con-
sisted of 19 teenagers aged between 14 and 18 years. Only one of these
cases was diagnosed as depression and medication associated with
psychotherapy was prescribed. The other 18 cases are under the ob-
servation of family and family physicians.
Results : The conclusions state that males resorted more easily to
suicide methods, even compared to the girls-boys’ ratio of 1,5 : 1 for
the entire population. The teenagers living in rural areas represented
only 13% of the attempted suicide cases, because they are less fre-
quently subjected to the risk factors of depression and suicidal idea-
tion comparing to the teenagers living in the urban areas. An
accelerated increase in number from the groups of younger age to the
older ones is also to be noted.
Conclusion : The study is the ﬁrst published research comparing
the risks of suicide attempts before and after treatment. It shows that
suicide attempts are twice as common in teenagers than in adults
patients. Still, a time model is contained in both age groups : an at-
tempted suicide most likely occurs before treatment, the chances
decrease by 50% after starting the treatment, to almost disappear after
treatment.
jP-12-003jAsperger syndrome with recurrent psychosis in
adulthood
A. Ciobanu1, A. Surdu2, A.A. Ciucu3. 1Univ. Med. & Pharm. C. Davila,
Bucharest, Romania ; 2Al. Obregia Hospital, Bucharest, Romania ;
3University from Bucharest, Romania
Objective : Asperger syndrome (AS) is a pervasive developmental
disorder characterized by autistic social dysfunction and idiosyncratic
interests in the presence of normal intelligence. We try to analyze
the aspects of psychosis in two cases of Asperger syndrome and the
response at treatment.
Methods : Two male patients (18–20 years) diagnosis with AS were
hospitalized for psychotic symptoms. One of them was born prema-
turely and the other has family history of psychotic syndrome. Both
patients ﬁnished with diﬃculty the high school and presented ag-
gressivity and hostility ; the psychotic syndrome included ideas of
revenge about the colleagues. Behavioral and emotional disturbance
was characteristics. After hospitalization one patient was included in
cognitive- behavioral therapy (CBT). For measurement the psychotic
symptoms we used Brief Psychiatric Rating Scale (BPRS) and Clinical
Global Impressions-Severity (CGI-S). Functioning was evidenced on
Quality of Life Scale (QLS). Period of study 4 month with visits.
Results : The patients presented resistance at many antipsychotics
and the remission of symptoms was diﬃcult with long period of
hospitalization. In ﬁrst case the psychotic syndrome was resolved
with Quetiapine 600 mg/day and in the second case we use
Venlafaxine 225 mg/day and Risperidone 4 mg/day. Venlafazine was
necessary because one of the patients had a depressive symptoms
with suicidal ideation.
Conclusion : AS has comorbid psychiatric conditions with resist-
ance at therapy. CBT is important in a second period of recover. The
family involvement has a positive role in remission psychotic episode.
jP-12-004jClinical experience in Chile with clozapine in child
and adolescents under 18 years
E. Duran1, V. Boehme1. 1Universidad deCchile, Santiago, Chile
Objective : Increase in severe psychopathology in adolescents who
are resistant to common treatment creates a need to search new
alternatives in pharmacological treatment. Background : to describe
a sample 47 child and adolescent patients treated with clozapine be-
tween 1985 and 2010, indicating : age, gender, diagnoses, hospitaliza-
tion, electroconvulsive therapy, dosing, adverse eﬀects specially
hematological ones.
Methods : 47 patients between the ages of 10 and 18 were treated
with clozapine. Review of clinical charts, protocol investigation and
Excel statistic analysis.
Results : the sample consisted in : male : 40%, female : 60%, the
youngest was 10 and the oldest 17 years and 11 month old ; the most
frequent age was 15 years. The mean number of hospitalization was
1.5. Diagnosis axis-I, DSM-IV : aﬀective disorders 64%, schizophreni-
form disorder 23%. Electroconvulsive therapy : 57%.Treatment in-
dications : irreducible psychosis 23%. Suicidability : 33%. Average
dosing 200 mg. Adverse eﬀects : sedation : 76%, hypersalivation : 68%,
increase in weight : 66%. Neutropenia : not severe (more than 2000/
mm3) : 17% ; severe I : 15%, severe II : 2%, severe III : 2%.
Conclusion : Clozapine appears as an eﬀective drug, with moderate
but frequent adverse eﬀects. Hematologic adverse eﬀects where tran-
sient ; only one in 47 patients presented a severe neutropenia and re-
quire cancellation of treatment, which was reinstalled after three
month without mayor side eﬀects. There is a need for control studies
with larger population and a longer period of time.
jP-12-005jThe factors associated with metabolic syndrome in
Japanese patients with mental retardation
S. Hoshino1, K. Yamamoto2, S. Miyaji2, Y. Sakai3, H. Miyaoka2.
1Bunkyou-Ku, Japan ; 2Sagamihara-shi, Japan ; 3Hadano-shi, Japan
Objective : Mental retardation sometimes co-occur with psychiatric
and/or behavioral disorders, and those patients are usually treated
by psychotropic agents. Adverse eﬀects of antipsychotics are believed
to cause Metabolic Syndrome (MetS), signiﬁcantly contributing to the
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risk of death due to coronary artery diseases. As is the case in patients
with psychiatric disorders, patients with mental retardation may
have an increased risk of MetS. We conducted a study of the MetS in
patients with mental retardation to clarify the factors associated with
its prevalence and incidence.
Methods : A total of 199 patients with mental retardation were eli-
gible to participate in this study. All patients were engaged in ongoing
outpatient visits or were inpatients admitted to support facilities
for people with intellectual disabilities in Japan. We reviewed the
patients’ medications and prevalence of MetS at the two periods :
from October 2006 to March 2007 (term A), and from July 2011 to
August 2011 (term B). The MetS diagnostic criteria were based on
the consensus guidelines created by Japanese Society of Internal
Medicine.
Results : We divided the patients without a diagnosis of MetS
at term A into 2 groups : those diagnosed with MetS at term B (‘‘A-B+
group’’) and those without a diagnosis of MetS at term B (‘‘A-B-
group’’), and examined the clinical characteristics of both groups. At
term A, the ‘‘A-B+ group’’ showed a signiﬁcantly larger diameter
of waist circumference and a higher triglyceride compared to the
‘‘A-B- group.’’ These signiﬁcant diﬀerences were also observed in
logistic regression analyses. On the other hand, a signiﬁcant diﬀerence
between the two groups was not found in terms of the use of psy-
chotropic medications.
Conclusion : In the items of MetS diagnostic criteria, diameters of
waist circumference and triglyceride may be important predictive
factors for the future onset of MetS in patients with mental retar-
dation.
jP-12-006jAgreement and disagreement between parent and
teacher regarding child psychopathology :
Comparing SDQ with CBCL
H.K. Kim1, J.S. Ahn2, S.Y. Park2. 1Wonju Christian Hospital, Republic of
Korea ; 2Department of Psychiatry, Yonsei University, Wonju, Republic
of Korea
Objective : The assessment of childhood psychopathology requires
data frommultiple informants. Because children have a limited ability
to describe themselves and are often aﬀected by situations. And con-
fusions in the diagnosis in outpatient department are often caused by
the diﬀerence between parent’s and teacher’s perspectives about a
child’s behavior. In Korea, no systematic review of the inter-rater
disagreement has yet taken place. Considering SDQ is a brief screen-
ing questionnaire, this study was designed to evaluate the usefulness
of SDQ in clinical setting using information regarding the level of
parent-teacher agreement and symptoms with discordance.
Methods : K-CBCL and SDQ-Kr were completed by parents and
teachers in charge of 105 children (28 girls, 77 boys) aged 6–12 years
and the clinical diagnosis were made by a child and adolescent
psychiatrist. Spearman’s correlations were computed to assess as-
sociations between parent’s and teacher’s ratings in subscale
level. And we used Mann-Whitney U test to analyse the inﬂuence of
child’s age and sex on parent-teacher report. Finally, AUC values
were calculated to measure the diagnostic capacity of parent-teacher
ratings, and the diﬀerence between two AUCs was tested with the
z test.
Results : Correlations between parent- and teacher- reported SDQ
were high (range 0.362–0.545, p<0.01) in every scale except emotional
problems. Parents were more sensitive to emotional symptoms of girls
(p<0.01), while teachers seemed to be more sensitive to conduct
problems and inattention-hyperactivity of boys (p<0.05). Parents
were more sensitive to conduct problems of seniors, whereas teachers
seemed to be more sensitive to Inattention-hyperactivity of young
children (p<0.05). Teacher’s CBCL was shown to be most discrimi-
nating of conduct disorder/oppositional disorder and teacher’s SDQ
demonstrated the highest prediction of ADHD and Emotional dis-
order (p<0.05).
Conclusion : In situations where parents are unavailable or when
their reliability is low, teacher’s SDQ can be used instead of parent’s
report in identifying child psychopathology early.
jP-12-007jPrenatal lead and cadmium coexposure and infant
neurodevelopment at 6 months of age
Y. Kim1, E.-H. Ha2, H. Park2, M. Ha2, Y.-C. Hong2, B.-N. Kim2. 1Seoul
National Hospital, Republic of Korea ; 2Seoul, Republic of Korea
Objective : Little is known about the potential interactive eﬀect of
prenatal coexposure of lead (Pb) and cadmium (Cd) and cognitive
development of infants. The aims of this study were to investigate the
association of maternal blood concentration of Pb and Cd during
pregnancy with infant development at six months ; and also to explore
the potential interaction between prenatal Pb and Cd coexposure.
Methods : Between 2006 and 2010, Pb and Cd levels were measured
in blood samples of 889 mothers during ﬁrst and third trimester
pregnancy as part of Mothers’ and Children’s Environmental Health
Study. We examined the interaction between prenatal exposure to Pb
and Cd and the mental (MDI) and psychomotor (PDI) developmental
indices of the Bayley Scales of Infant Development at six months.
Results : The interaction between Pb and Cd status for the maternal
blood at ﬁrst trimester was signiﬁcant for MDI and PDI at 6 months. In
stratiﬁed linear model, the MDI at six months correlated signiﬁcantly
with the third trimester maternal blood Pb concentrations, for the
children with high Cd exposure. When maternal blood Pb and Cd
concentration were entered in a stepwise fashion to the linear model
for all subjects, the Cd concentration at ﬁrst trimester showed inverse
association with PDI at 6 months. In the third trimester, the Pb con-
centration showed inverse association with MDI at 6 months.
Conclusion : The results of this study shows that prenatal exposure
to Pb and Cd may be inversely associated with MDI and PDI of the
infant at 6 months. The present study also shows that there may be an
interaction between exposure to Pb and Cd during ﬁrst trimester on
the infant development at 6 months.
jP-12-008jPrevalence of mental disorders in Thailand : Results
from the epidemiology of mental disorders national
survey
T. Kongsuk1, W. Pangchuntr2, P. Kittirattanapaiboon2, W. Chutha2,
P. Boonyamarik2, S. Arunpongpaisan3, K. Kenbubpha1, S. Sukawaha1,
J. Leejongpermpoon1. 1Prasrimahabhodi Hospital, Ubonratchathanee,
Thailand ; 2Ministry of Public Health, Nonthaburi, Thailand ;
3Prasrimahabhodi Hospital, Faculty of Medical, Khon Kaen, Thailand
Objective : To estimate the prevalence rates of mood, anxiety, alcohol
and psychotic disorders in Thailand.
Methods : Nationally representative face-to-face household survey
based on a multistage area probability sample of non-institutionalized
people aged 15 to 59 years (n=17,100) and selected each stage by
means of random sampling. The data were conducted between June
and August 2008 using Mini International Neuropsychiatric Interview
(M.I.N.I.) by trained psychiatric professional. The data analyses were
calculated by means of adjust weighted with prevalence rate for gen-
eralized to Thai population.
Results : The participants of this survey were 17,140 people in 4
regions and the Bangkok accounted for 93% of response rate. The
results of weighted analysis for estimate the prevalence rate in Thais
population have shown any mental disorders about 7,348,902 people
(15.2%) which indicated approximately 14.3% of any current mental
disorders and 0.9% of any lifetime mental disorders. An alcohol de-
pendence current was the highest prevalence of mental disorders ac-
counted for 6.6% (SE=0.30) and the prevalence rate of an alcohol
abuse current was about 4.2% (SE=0.24). Furthermore, the preva-
lence rates of a major depressive episode current accounted for 2.2%
(SE=0.2) and recurrent represented about 0.7% (SE=0.1), while a
dysthymic disorder episode found 0.7% (SE=0.1).
Conclusion : The alcohol use disorders have shown the commonest
of mental disorders in Thais especially in male and the major de-
pressive episode has frequently found in female of Thailand. These
ﬁndings have signiﬁcantly been evidences for the establishment of
mental health care and prevention programs.
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jP-12-009jComorbidity in children and adolescents with
behavioral disorders
F. Oueriagli Nabih1, M. Touhami1, l. Abilkassem1. 1Military Hospital
Avicenne, Marrakech, Morocco
Objective : Behavioral disorders are frequents in children and ado-
lescents. This is a common symptom, often associated with other
psychiatric disorders. This comorbidity is a predictor of early onset of
other disruptive behavior, with a more rapid evolution and a bad
prognosis and many social problems. The interest of this study is to
assess psychiatric comorbidity between the behavioral disorders and
the other psychiatric disorders.
Methods :We conducted a retrospective study over a period of two
years with 120 children and teenagers showed in consultation for
behavioral disorder. The diagnosis of behavioral disorders and as-
sociated diseases was made according to the diagnostic criteria for
DSM IV-TR. Analysis of the results was made by epi-nfo10.
Results : The average age of patients is 7.34 years. 90% of our
patients are boys. The diagnosis of ADHD was found in 68% of cases,
conduct disorder in 17% of cases, the oppositional deﬁant disorder
in 25% of cases.The comorbidity of behavioral disorders is noted in
70%. 68, 7% of patients have at least 2 concomitants disorders. The
comorbidity with learning disorders is noted in 28.3%, with anxiety
disorders in 23% of cases, with mood disorders in 13.3% of cases,
with substance abuse in 15% of cases and with other medical dis-
orders in 10.8% of cases.
Conclusion : behavioral disorders is frequent in child psychiatry.
the comorbidity is multiple, the management is multidisciplinary and
depends on the type of behavioral disorder and associated disorders.
jP-12-010jSuicidality in autism : A review
S. Richa1, M. Fahed1, E. El Khoury1. 1Hotel-Dieu de France, Beirut,
Lebanon
Objective : This review focuses on suicide in patients with pervasive
developmental disorders as well as risk factors and comorbities seen
in patients who have attempted suicide.
Methods : Research in PubMed for articles dating from 1999 to 2011
on this subject. 25 articles were found.
Results : Suicide in autism is largely understudied. A higher
mortality in autistic patients is related to medical disorders like
epilepsy and accidents. Suicide occurs more frequently in high func-
tioning autism. Patients with PDD present with most of the risk
factors leading to suicide. Furthermore, a history of mood disorders
is frequently associated with suicide attempts as well as personal
vulnerabilities and other psychiatric comorbidities.
Conclusion : Patients with PDD present risk factors inherent to their
diagnosis, along with risk factors pertaining to the general population.
The inability of persons with PDD to express emotions and thoughts
makes the diagnosis of suicidal ideation diﬃcult. Therefore, more
studies are needed on the issue.
jP-12-011jFunctional restoration as an adjunct to
pharmacotherapy in treatment of postural orthostatic
tachycardia syndrome (POTS)
T. Rummans1, B. Bruce1, T. Harrison1. 1Mayo Clinic, Rochester, USA
Objective : Introduction : POTS is a clinical syndrome that has been
estimated to eﬀect up to 500,000 adults in the US and is being in-
creasingly recognized and identiﬁed in adolescents. POTS is deﬁned
by the presence of excessive tachycardia, (>30 beats per minute) on
the assumption of an upright posture. Associated symptoms can in-
clude lightheadedness, dizziness, palpitations, and sweating. The
functional disability observed in these patients can be severe and
can include incapacitation such as being bed or wheelchair bound.
The treatment of POTS to date has focused upon pharmacological
treatment and has included the use of beta blockers, midodrine, and
ﬂudrocortisones. No studies have examined the eﬀectiveness of a
functional restoration program in adolescents with POTS. The current
study examines the eﬃcacy of such a program as an adjunct to phar-
macotherapy for adolescents with POTS.
Methods : Patients, who were severely impaired despite adequate
pharmacotherapy, were referred to participate in a program designed
to restore their function.. In a group setting, patients and their parents
learn how to adaptively self-manage their chronic physical symptoms
through a structured, multidisciplinary intervention that utilized
medical, psychological, PT, and OT services. Functional status was
assessed with the Functional Disability Index.
Results : Thirty-three patients, ages 12–18, diagnosed with POTS,
were participants in this study. Seventy-four percent of patients with
a diagnosis of POTS were on one or more POTS medications upon
admission including beta blockers, Midodrine and ﬂudrocortisone
Pharmacotherapy initiated for the treatment of POTS was continued
during the program. After participation in the program, adolescents
with POTS demonstrated a signiﬁcant increase in overall functional
abilities (t=6.166, p<0.001).
Conclusion : A functional restoration program appears to be suc-
cessful as an adjunct to the pharmacotherapy currently used for the
treatment of POTS in adolescents.
jP-12-012jDevelopment of new diagnostic measure based on
integrated correlation analysis of behavior and
physiological parameters for socio-emotional
diﬃculties in Asperger’s disorders (AD)
A. Senoo1, G. Karino1, S. Obara1, H. Sekihara1, Y. Fukushima1,
S. Ozawa1, K. Yui2, S. Nakamura1, M. Koshiba1. 1Tokyo Univ. of Agri.
& Tech., Koganei-City, Tokyo, Japan2Ashiya Univ., Japan
Objective : Early diagnosis and intervention is crucial to improve
the quality of child life suﬀering developmental disorder like AD.
Brain imaging and genetics/epigenetic analyses which are two major
diagnostic tools are not fully applicable for developing child. Here we
developed another diagnostic measure based on non-contact or least
contact way of behavioral and physiological measurement, which
can be applicable at every-day clinic and non-clinical situations.
This algorithm that freely bridges over objective and subjective in-
formation was named as BOUQUET (Senoo et al., Koshiba et al.,
2011).
Methods : The study population comprised two groups, one diag-
nosed as asperger’s disorders (AD) (male 5, female 2, 6–13 years old)
according to DSM-IV and ADI-R and another, their healthy siblings
(Typically developed, TD) (male 1, female 4, 7–15 years old). They
were interviewed alternatively by unfamiliar lady, unfamiliar gentle-
man, their doctor in charge, and ﬁnally their mother for 2–5 min each.
As the default condition, they played TV game. We recorded them by
video-camera and infrared camera during the interview. We also re-
corded EEG (Fp1, Fp2, T3, T4, Cz, O1, 2) and ECG (Intercross 410).
Serum cortisol and prolactin were measured a month before the
interview and just after the interview. All the protocol was approved
by Sawa hospital, Osaka and internationally registered (NIH). The
correlation of behavioral and physiological parameters was analyzed
by BOUQUET based on principal component analysis.
Results : The diﬀerence between two groups was visualized in the
feature space reconstituted by two major principal components. The
parameters which contributed to the discrimination was high varia-
tions of EEG and head surface temperature in AD, head movement
velocity and gaze-frequency toward interviewer during self or family
episode consolidation in AD.
Conclusion : These results suggest the usefulness of the integrated
correlation analysis of behavior and physiological parameters by
BOUQUET to extract the feature of socio-emotional adaptability in
AD compared with TD child.
jP-12-013jViolence in adolescents : Gender diﬀerences
E. Serfaty1, A. Jorge2, A. Masautis2. 1 Instituto Investig-Sedronar, Buenos
Aires, Argentina ; 2 Instituto Investig, Academy of Medicine, Buenos Aires,
Argentina
Objective : Violence phenomenon in urban centres is undestood as a
social process including wide spectrum of forms of aggression having
an expansive and multiplying eﬀect not only on the victims but also
on the whole society ; I for this reason its increase is a source of con-
cern. Objetive : To determine some feature of violent adolescents and
their association with some personal, familial and environmental
characteristics in youngsters taken care by the National Council for
the Youngsters and the Family.
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Methods : Material and Methods : Violent adolescent was deﬁned
when having participating in fghts (physical aggression) during the
prceeding year. Population : 522 adolescents, both sexes, ages 10 to
21 years, assisted in the National Coucil for the Youngsters and the
Family. Survey Instrument : Two epidemiologic questionnaires (in-
cluding the Present State Examination) to register current pshychic
state as well as personal, familial and environmental history.
Results : With violent behaviour 21.3%. Males showed signiﬁcant
association with diagnosis of disocial behaviour and consume of
tobacco, marijuana, cocaine and sedatives. In women signiﬁcant as-
sociation was found with diagnoses of mild depression, deﬁan
behaviour, history of sexual harassment, and consume of alcohol.
Conclusion : The psychopharmacological treatment covers the
etiologic diagnosis insofar as it has been studied that the selective
serotonin reuptake inhibitors (SSRIs) not only have a therapeutic
eﬀect but also exert equilibrium on the serotonergic function. At ad-
equate doses, both neuroleptics as well as antireccurence agents de-
crease the violent behavior.
P-13. Psychoneuroimmunology
jP-13-001jAntidepressant eﬀects of macrophage migration
inhibitory factor gene deletion
C. Bay-Richter1, S. Janelidze1, R. Bucala2, T. Deierborg1, L. Brundin3.
1Lund University, Sweden ; 2Yale University, Rheumatology, New Haven,
USA ; 3Michigan State University, Grand Rapids, USA
Objective :Depression is a global health problem with high mortality.
Current treatment strategies only give suﬃcient symptom relief
to approximately half of the patients. It has been established that de-
pressed patients display immune alterations. Recently it was reported
that the cytokine macrophage migration inhibitory factor (MIF) cor-
relate positively with depression scores. It has also been shown that
depressed individuals show exaggeratedMIF levels following antigen
challenges. In the current study we wished to examine the causality
between MIF and depression. We therefore examined whether MIF
knockout (KO) mice would show altered depressive-like behaviour
compared to wildtype (WT) animals.
Methods : Male and female MIF KO mice and WT littermates were
tested for locomotor behaviour in the open ﬁeld, anhedonia in the
sucrose preference test (SPT), and despair in the forced swim test
(FST) and tail suspension test (TST). Brain mRNA expression of
the cytokines IL-1B and IL-6 was subsequently examined using RT
qPCR.
Results : Results showed that MIF KO mice had a slight decrease in
locomotor activity compared to WTs. In SPT a genotype/sex interac-
tion was found, with male KO animals showing increased sucrose
preference compared to control males. A similar interaction was
found for FST, where male KO mice showed decreased immobility. In
TST both male and female KOmice showed decreased immobility. No
genotype/gender eﬀects were found on IL-1B or IL-6 expression, but a
signiﬁcant positive correlation was found between IL-6 and stillness
in the TST.
Conclusion : Our results suggest that MIF gene deletion has clear
antidepressant eﬀects, possibly most pronounced in male animals.
Furthermore, a positive relationship between depressive-like behav-
iour in the TST and IL-6 was found, suggesting that IL-6 is involved in
this behaviour. These data supports the growing line of evidence for
an involvement of inﬂammatory factors in depression and further
suggests that MIF ligands have potential as antidepressant drugs.
jP-13-002jPlasma interleukin-6 as a biomarker in the treatment
of major depressive disorder
A. Halaris1, E. Meresh2, J. Fareed3, D. Hoppensteadt3, J. Sinacore4.
1Loyola University Medical Center, Maywood, USA ; 2Loyola University
Medical Center, Department of Psychiatry, Maywood, USA ; 3Loyola
University Medical Center, Department of Pathology, Maywood, USA ;
4Loyola University Medical Center, Department of Epedemiology,
Maywood, USA
Objective : 1. Conﬁrm that plasma IL-6 is higher in patients with
MDD than healthy controls 2. Examine the relationship between IL-6
and the severity of depression, anxiety, and perceived stress 3.
Evaluate whether IL-6 values normalized after monotherapy with ei-
ther escitalopram, or quetiapine. 4. Assess whether abnormal IL-6
speciﬁcally correlated with treatment resistant depression.
Methods :A cohort of 48 patients withMDD and 23 healthy subjects
were analyzed from two consecutively run studies of identical design.
Subjects met DSM-IV criteria for primaryMDD, with an index episode
of at least one month duration. Screening included structured psy-
chiatric interviews, physical exam, and laboratory studies. Subjects
with medical illness or co-morbid Axis-I diagnoses were excluded
from the study.
Results : Patients with MDD had signiﬁcantly higher baseline
plasma IL-6 than healthy controls (n=20) (p=0.05). IL-6 failed to
normalize with either escitalopram or quetiapine after treatment.
Treatment response (o50% reduction orf7 in HAM-D17 score) did
not correlate with the baseline level of IL-6. There was a signiﬁcant
correlation between baseline IL-6 level and depression severity as
measured by HAMD-7 (p=0.05). Additionally, there appeared to be a
trend for IL-6 to correlate with acute suicidality.
Conclusion :MDD patients had elevated IL-6 and this elevation did
not correlate with depression severity as measured by HAM-D7. This
scale emphasizes the core features of depression such as depressed
mood, guilt, and anhedonia. Patients in both studies experienced high
rates of treatment response, but neither escitalopram nor quetiapine
normalized IL-6 levels. Thus, inﬂammation persisted despite the
improvement in mood symptoms possibly because the length of
treatment may have been inadequate to reverse inﬂammation.
Antidepressants have been shown to inhibit the production and/or
release of pro-inﬂammatory cytokines and to stimulate production
of anti-inﬂammatory cytokines. Although current therapies may
attenuate inﬂammation, they may not suﬃciently resolve it.
jP-13-003j IL-1b induces TDO and provokes the release of
kynurenic acid from human astrocytes in vitro
M.E. Kegel1, C.I. Svensson2, S. Erhardt2. 1Karolinska Institutet,
Stockholm, Sweden ; 2Karolinska Institutet, Deptartment of Physiology,
Stockholm, Sweden
Objective : Kynurenic acid (KYNA) and interleukin-1b (IL-1b) are
elevated in the cerebrospinal ﬂuid (CSF) of patients with schizo-
phrenia. KYNA is an antagonist of the nicotinic a7* acetylcholine
receptor and the glycine site of the N-methyl D-aspartate (NMDA)
receptor and has been shown to modulate dopaminergic neuro-
transmission, implicating a role for KYNA in schizophrenia
pathology. Indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-
dioxygenase (TDO) are the rate limiting enzymes of the kynurenine
pathway, and it is known that other cytokines, in particular inter-
feron-c (IFN-c) induce IDO. This study was designed to investigate if
IL-1b induces the kynurenine pathway in human astrocytes, the main
KYNA producing cells of the brain.
Methods : Human astrocytes were cultured in AM medium sup-
plemented with 2% fetal bovine serum and a mix of growth factors.
Following 24 hours serum starvation cells were stimulated with IL-1b
(10 ng/ml) or vehicle. Cell culture supernatants were collected and
RNA and protein was extracted. RNA was reverse transcribed to
cDNA and real time quantitative PCR was performed. Protein levels
of IDO and TDO were analyzed using Western Blots. Levels of KYNA
in supernatants were analyzed using a high performance liquid
chromatography system.
Results : IL-1b increased levels of KYNA in the cell culture medium.
Stimulation with IL-1b also induced the expression of TDO mRNA
and protein. IDO was however only induced on the transcriptional
level.
Conclusion : This study shows that KYNA production increases
following IL-1b-induced upregulation of TDO. Interestingly, in-
creased TDO expression and activity have previously been reported
in patients with schizophrenia. Present results thus highlight the no-
tion that increased TDO expression and CSF KYNA levels observed in
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jP-13-004jCSF biomarkers in suicide
attempters – inﬂammation biomarkers
and monoamine metabolites
D. Lindqvist1, S. Janelidze1, S. Erhardt2, L. Tra¨skman-Bendz1,
G. Engstro¨m3, L. Brundin1. 1Psychoimmunology Unit, Lund, Sweden ;
2Karolinska Institutet, Stockholm, Sweden ; 3Malmo¨, Sweden
Objective : The objective of the present study was to identify biologi-
cal patterns (factors) among 20 cerebrospinal ﬂuid (CSF) biomarkers
in suicide attempters and subsequently analyse their association with
suicidal behaviour.
Methods : We measured kynurenic acid, orexin, homovanillic acid
(HVA), 5-hydroxyindoleacetic acid (5-HIAA), 3-methoxy-4- hydro-
xyphenylglycol, chemokines, matrix metalloproteases and cytokines
in the CSF of 124 drug-free suicide attempters. Patients were eval-
uated for suicidality and psychiatric symptoms using well-deﬁned
psychiatric rating scales and followed-up regarding future suicide.
We used principal component analysis to identify factors among the
biological substances.
Results : Four factors were extracted from the 20 biomarkers,
explaining 52.4% of the total variance. Factors 1 and 2 were charac-
terized by high loadings of chemokines and cytokines respectively.
They were both associated with severe depressive symptoms. Factor 2
was also associated with a high suicidal intent. Factor 4 was charac-
terized by strong loadings of the monoamine metabolites 5-HIAA
andHVA, as well as orexin and interleukin-6. High scores on this
factor were found in patients who performed a violent suicide attempt
and in patients who subsequently completed suicide.
Conclusion : Our results suggest that speciﬁc combinations of CSF
biomarkers may discriminate between types of suicidal behaviour
and indicate increased risk for future suicide.
jP-13-005jPsychoneuroimmunomodulation in treatment of
patients with schizophrenia
O. Lobacheva1, T. Vetlugina1, A. Semke1. 1Mental Health Research
Institute, Tomsk, Russia
Objective : To study dynamic of parameters of the immunity in group
of schizophrenic patients with diﬀerent eﬃcacy of treatment.
Methods : Dynamic of psychopathological symptoms in 388
schizophrenics was registered with ‘‘Clinical Global Impression’’
(CGI) in two points – at baseline and after 6 weeks of appropriate
for mental state treatment. According to results of clinical dynamic
patients were divided into 3 groups : group 1 (n=54) – with signiﬁ-
cant improvement of mental state ; group 2 (n=143) – with essential
improvement ; group 3 (n=191 s) – with insigniﬁcant improve-
ment and without changes of mental state. Immunological exam-
ination included identiﬁcation of phenotypes of surface receptors
of immunocompetent cells, immunoglobulins IgM, IgG, IgA, level
of circulating immune complexes (CIC) ; spontaneous and mitogen-
induced production of IFN-c, IL-4, TNFa by mononuclear leuko-
cytes of patients, serum concentration of cortisol and amino-
transferases.
Results : It has been shown that in the ﬁrst two groups as compared
with group 3 reliably higher values of T-helpers-inducers CD4+
(p=0.0001), cytotoxic T-lymphocytes CD8+ (p=0.0001), mitogen-
induced production of IFN-c (p=0.0001) and reliably low values
of production of TNF-a (p=0.0001), CD95¡lymphocytes, levels of
CIC, cortisol and amisnotransferases were high in all three
groups (p=0.0001 regarding to control in all groups). Study of
psychoneuroimmunomodulation under inﬂuence of psychotropic
therapy has shown that in the ﬁrst two groups high clinical eﬃcacy
was accompanied by normalization of most parameters of home-
ostasis : T-lymphocytes CD3+, CD4+, CD95¡lymphocytes, levels
of CIC, cortisol and aminotransferases, mitogeninduced production
of IFN-c and TNF-a. In group of absence of the eﬀect to the
therapy positive dynamic of immunobiological indices has not been
revealed.
Conclusion : Thus, it has been shown that favorable clinical dy-
namic in process of 6 weeks therapy of schizophrenic patients was
accompanied by positive dynamic of some indices of the immunity
what probably reﬂects optimization of mechanisms of psycho-
neuroimmune interaction.
jP-13-006jHuman CD8+ T cells and NK cells express and
secrete S100B upon stimulation
J. Steiner1, N. Marquardt2, I. Pauls2, K. Schiltz1, B. Bogerts1,
R.-E. Schmidt2, R. Jacobs2. 1University of Magdeburg, Germany ;
2Medical University of Hannover, Germany
Objective : Previous studies have demonstrated the utility of S100B as
a surrogate marker of brain-related pathologies, e.g. neuropsychiatric
disorders, and melanoma progression, which have an inﬂammatory
component.
Methods : This study addresses the relevance of S100B+ lympho-
cytes in mediating such responses. S100B expression was determined
in human peripheral blood leukocytes isolated from healthy volun-
teers using ﬂow cytometry. S100B+ lymphocytes were characterised
for phenotype, cytokine production and S100B secretion. In addition,
we investigated whether S100B activates monocytes and neutrophils.
Results : S100B+ cells comprised 2–4% of all lymphocytes and
the majority displayed a CD3+ CD8+ phenotype ; fewer cells were
CD3+ CD56+ NK lymphocytes. Comparison of S100B+ and
S100B+ CD3+ CD8+ cells revealed no diﬀerences in production of
interferon gamma (IFN-gamma) and interleukin-2 (IL-2). Stimulation
of S100B+ CD3+ CD8+ lymphocytes with anti-CD3 or phytohae-
magglutinin resulted in release of S100B. High concentrations of re-
combinant human S100B triggered upregulation of CD11b and
membrane shedding of CD62L in granulocytes and monocytes.
Conclusion : These ﬁndings set the stage for a new ﬁeld of research
addressing a S100B-mediated crosstalk between the innate and
adaptive immune systems if close proximity of eﬀector and responder
cells accomplishes suﬃcient local S100B levels. In various physio-
logical and pathological conditions S100B might function as an inter-
face to immunological processes, distinct from known cytokine- and
chemokine-mediated pathways.
jP-13-007jDecreased expression of S100B in a genetic rat model
of depression
N. Strenn1, P. Suchankova1, S. Nilsson2, C. Fischer3, G. Wegener3,
A. Mathe´4, A. Ekman1. 1Neuroscience and Physiology, Gothenburg,
Sweden ; 2Mathematical Sciences, Gothenburg, Sweden ; 3Centre for
Psychiatric Research, Risskov, Denmark ; 4Clinical Neuroscience,
Stockholm, Sweden
Objective : The glial-speciﬁc protein S100B has both neurotrophic and
apoptotic eﬀects, depending on its concentration. Elevated serum le-
vels of S100B have been shown in patients diagnosed with psychiatric
disorders. Genetic variability in the S100B gene has been associated
with schizophrenia and the personality trait self-directedness, which
is strongly correlated to general mental health. The aim was to study
S100B expression in brain and behaviour in a genetic model of de-
pression, the Flinders Sensitive line (FSL) and its control, the Flinders
Resistant line (FRL) both before and after lipopolysaccharid (LPS)-
induced peripheral immune activation.
Methods : Changes in behaviour were assessed using the forced
swim test (FST), an animal model to test for depressive-like behaviour.
S100B mRNA levels in amygdala, hippocampus, prefrontal cortex,
hypothalamus and striatum were measured using quantitative real
time PCR.
Results : S100B expression was signiﬁcantly lower in FSL compared
to controls in all investigated brain areas, both at baseline and after
peripheral immune stimulation. Immobility was larger in FSL com-
pared to FRL rats. Reduced S100B expression correlated signiﬁcantly
with increased immobility. Furthermore, LPS increased both the time
spent immobile and climbing in both lines.
Conclusion : The results in this study indicate the involvement of
S100B in behavioural diﬀerences of the FSL depression rat model. This
model may be useful in further studies regarding the inﬂuence of
S100B on mental functions.
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jP-13-008jMind-Body Interface : Polyunsaturated fatty acids
and somatic symptoms in major depressive disorder
K.-P. Su1, H.-T. Yang2, J.P.- Chen Chang3, C.-L. Huang4, C. Pariante5.
1China Medical Univ Taiwan, Taichung, Taiwan ; 2China Medical Univ
Taiwan, Department of Nutrition, Taichung, Taiwan ; 3China Medical
Univ Taiwan, Department of Psychiatry, Taichung, Taiwan ; 4China
Medical Unv Taiwan, Department of Psychiatry, Taichung, Taiwan ;
5 Institute of Psychiatry, King´s College London, United Kingdom
Objective : Lower n-3 polyunsaturated fatty acids (n-3 or omega-3
PUFAs) levels and genetic variations on their metabolic enzymes
of PUFA metabolic enzymes, phospholipase A2 (PLA2) and cyclo-
oxygenase-2 (COX2), have been found to be associated with the risk of
depression (1–4). In this study, we aimed to examine speciﬁc roles
of n-3 PUFAs, docosahexaenoic acid (DHA) and eicosapentaenoic
acid (EPA), and the polymorphisms on PLA2 and COX2 in diﬀerent
clusters of depressive symptoms.
Methods : Patients with major depressive disorders (n=122)
and their healthy controlled subjects (n=122) were assessed to
examine the eﬀects of PUFA levels and single nucleotide poly-
morphisms (SNPs) of PLA2 BanI and COX2 rs4648308 genes on the
development of major depression and on speciﬁc clusters of depress-
ive symptoms.
Results : Patients with major depressive disorders had a signiﬁcant
lower level of EPA (p=0.03) and a trend of lower level of DHA
(p=0.08). The COX2 rs4648308 AG genotype was associated with a
higher risk of major depression (p=0.006 ; odds ratio=2.36, 95%
CI=1.27–4.40), while the PLA2 BanI GG genotype had a border-
line eﬀect (p=0.06 ; odds ratio=1.81, 95% CI=0.87–3.79). The ‘‘at
risk’’ COX2 polymorphism was associated with more somatic symp-
toms (p=0.003) and lower DHA (p=0.002), and the ‘‘at risk’’ PLA2
polymorphism was associated with more somatic symptoms
(p=0.025). In addition, lower EPA and DHA levels were both sig-
niﬁcantly correlated with more somatic symptoms in patients with
depression.
Conclusion : Genetic variations in the COX2 and PLA2 genes have
eﬀects on depression and somatic features, possibly by aﬀecting the
levels of EPA and DHA. N-3 PUFAs may be a potential biomarker to
understand clinical subtypes of depression (1).
References
(1) Su KP. NeuroSignals 2009.
(2) Su KP et al. Biol Psychiatry 2010.
(3) Lin PY, Huang SY & Su KP. Biol Psychiatry 2010.
(4) Lin PY & Su KP. J Clin Psychiatry 2007.
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jP-14-001jRelation between unintended pregnancy among
teenagers and post-partum blues
A. Aghamohammadi Varnosfaderani1, M. Zafari1, A. Rajabi1. 1 Islamic
Azad Univers, Sari, Islamic Republic of Iran
Objective : Unintended pregnancy continue to many countries in the
world especially among teenagers. The aim of this study was to assess
the prevalence of post-partum blues in teenage mothers with unin-
tended pregnancy, compared with teenage mothers with planned
pregnancy.
Methods : 100 normal primiparous women with age less than 19
were studied and divided two groups who had unintended preg-
nancy and planned pregnancy. Maternity blues assessed in two
groups.
Results : There was postpartum blues in women with unwanted
pregnancies more than women with planned pregnancies in 3
and 10 days after delivery and this deferences are statistically sig-
niﬁcant.
Conclusion : unintended pregnancy may be a potential causal fac-
tor for maternity postpartum blues in teenagers.
jP-14-002jPersistent eﬀect of lead chronic toxicity on
depression and anxiety in male wistar rat
F.-Z. Azzaoui1, H. Hami2, A. Ahami1. 1Faculty of Science, Kenitra,
Morocco ; 2Faculty of Science, Department of Biology, Kenitra, Morocco
Objective : The objective of this study was to investigate the persistent
eﬀect of lead on depression and anxiety of adult male Wistar rats.
Methods : Male adult Wistar rats are submitted to chronic intoxi-
cation by lead nitrate (50 mg/L) diluted in tap water during six
months. After that, the intoxication was stopped for 4 months, and the
neurobehavioral tests were assessed. Depression was evaluated using
the Forced Swim Test (FST) by calculating the immobility time (IT).
Anxiety was measured by calculating the number of Entries in Open
Arm (EOA) and the time spent in the Open Arm (TOA), in the
Elevated Plus Maze Test (EPM).
Results : The results have shown that the IT was signiﬁcantly low in
intoxicated rats even the administration of toxic was stopped
(p<0.05), compared to control ones. However, no signiﬁcant diﬀer-
ence was registered in the intoxicated rats compared to the control in
the EOA and TOA.
Conclusion : Chronic lead toxicity had an antidepressant-like eﬀect
but had no eﬀect on anxiety in rats even after stopping the intoxi-
cation.
jP-14-003jThe galanin system in the human brain with focus
on locus coeruleus and the dorsal raphe nucleus
S. Barde1, E. Le Maitre1, M. Palkovits2, R. Diaz-Heijtz1, T. Hokfelt1.
1Karolinska Institutet, Stockholm, Sweden ; 2Semmelweis University and
Hungarian Academy of Budapest, Hungary
Objective : Major depressive disorder is a serious disease that
aﬀects about 10% of all men and 20% of women in their lifetime.
The noradrenaline (NA) neurons in the locus coeruleus (LC) and the
5-hydroxytryptamine (5-HT) neurons in the dorsal raphe nucleus
(DRN) are a central focus in research on depression. The neuropeptide
galanin, for which three receptors (GalR1–3) have been cloned is
of interest in relation to major depression (Branchek et al., 2000).
Galanin coexists with 5-HT in the DRN as well as with NA in LC
and has inhibitory actions on both NA and 5-HT neurons (Xu et al.,
2005).
Methods : In this study, we have used in situ hybridization to
visualize galanin and its receptors in LC and DRN of postmortem
human brains, and in addition, tryptophan hydroxylase (TH), nitric
oxide synthase (NOS) and vesicular glutamate transporters.
Results : Our results, when compared to rodent brains, show that
galanin is found in LC of all three species, but only in rat DRN. GalR1
was detected in rat LC, but in sharp contrast, GalR3 seems to be the
major galanin receptor in human LC and DRN. Thus in human, GalR3
is expressed in two nuclei of key importance for depression, that is LC
and DRN. In addition, VGLUT1 and x2 were strongly expressed in
the pontine nuclei, but could not be detected either in LC neurons or
5-HT neurons. Neither was NOS found in these regı´ons. Thus, con-
siderable species diﬀerences occur with regard to brain messenger
molecules, especially neuropeptides.
Conclusion : The present results, taken together with electro-
physiological experiments in rats, suggest that a small, blood-brain
barrier-penetrating GalR3 antagonist could have anxiolytic and/or
antidepressive activity. Such an antagonist has been developed and
shown to have anxiolytic/antidepressive-like eﬀects in animal models
of depression (Swanson et al., 2005).
jP-14-004jLevomilnacipran in the treatment of major depressive
disorder : Functional health and well-being eﬃcacy
results from a phase III clinical trial
S.I. Blum1, S. Tourkodimitris1, A. Ruth2, N. Hussainzada3. 1Forest
Research Institute, Jersey City, USA ; 2Prescott Medical, Communications
Group, Chicago, USA ; 3Forest Laboratories, Washington, USA
Objective : Levomilnacipran (1S, 2R-milnacipran) is a potent and
selective serotonin and norepinephrine reuptake inhibitor (SNRI)
with greater potency for norepinephrine than serotonin reuptake in-
hibition. Data from a positive Phase III trial (NCT00969709) were used
to evaluate the functional health and well being of patients with major
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depressive disorder (MDD) treated with sustained release (SR) levo-
milnacipran.
Methods : A double-blind, multicenter, parallel group, placebo-
controlled, ﬁxed-dose study was conducted in patients aged
18–65 years who met DSM-IV-TR criteria for MDD and Montgomery-
Asberg Depression Rating Scale-Clinician Rated (MADRS-CR) score
o30. The study comprised a 1-week single-blind, placebo lead-in,
8-week double-blind treatment, and 2-week double-blind down-
taper. Patients were randomized to placebo (n=175) or once-daily
levomilnacipran (n=529) 40 mg, 80 mg, or 120 mg (titrated-up from
an initial dose of 20 mg). Functional health and well being were
measured using change from baseline to Week 8 on the SF-36v2 acute
(1-week recall) health survey. Individual health dimensions, and
physical (PCS) and mental (MCS) component summary scores were
compared for levomilnacipran and placebo (ITT population) using an
ANCOVA model.
Results : Patients in both groups had deﬁcits in mental-health at
baseline (MCS scores : placebo, 17.2¡9.2 ; levomilnacipran, 18.2¡8.5) ;
in contrast, baseline PCS scores (PBO : 52.6¡11.1 ; LVM: 51.1¡11.1)
were slightly higher than the population norm. Following 8 weeks of
treatment, levomilnacipran patients versus placebo demonstrated
signiﬁcantly greater MCS improvement (LSMD=4.4¡1.36 ; P=.0013)
and on several individual dimensions (General Health [2.3¡0.69 ;
P=.0007], Vitality [2.4¡1.05, P=.0228], Social Functioning [3.1¡1.17 ;
P=.0086], Role Emotional [3.1¡1.20 ; P=.0097], and Mental Health
[4.3¡1.16 ; P=.0003]). Nonsigniﬁcant PCS [x0.2¡0.74 ; P=.8386] and
other dimension score changes were noted.
Conclusion : Levomilnacipran patients experienced statistically
signiﬁcant and clinically meaningful improvements in functional
health and well being as measured by SF-36 MCS and associated
individual dimensions. Changes in PCS and associated individual
dimensions were nonsigniﬁcant potentially due to limited physical
impairment at baseline.
Policy of full disclosure : Supported by funding from Forest
Laboratories, Inc.
jP-14-005jThe eﬃcacy and safety of levomilnacipran in the
treatment of major depressive disorder :
Results from a phase III clinical trial
A. Bose1, C. Chen1, C. Gommoll1, A. Ruth2, N. Hussainzada1. 1Forest
Research Institute, New Jersey, USA ; 2Prescott Medical, Communications
Group, Chicago, USA
Objective : Levomilnacipran (1S, 2R-milnacipran) is a potent and
selective serotonin and norepinephrine reuptake inhibitor (SNRI)
with greater potency for norepinephrine than serotonin reuptake in-
hibition. Eﬃcacy and safety were evaluated in a ﬁxed-dose Phase III
trial (NCT00969709).
Methods : A double-blind, multicenter, parallel-group, placebo-
controlled, ﬁxed-dose study with 1-week single-blind, placebo lead-
in, 8-week double-blind treatment, and 2-week double-blind down-
taper. Patients (18–65 years) who met DSM-IV-TR criteria for
MDD, with current major depressive episodeo8 weeks ando30 on
the Montgomery-Asberg Depression Rating Scale-Clinician Rated
(MADRS-CR) were randomized to placebo or once-daily levomilna-
cipran sustained release 40 mg, 80 mg, or 120 mg (20-mg initiation ; 7-
day titration to target dose). Primary eﬃcacy : MADRS-CR score
change from baseline to Week 8 (mixed-eﬀects model for repeated
measures [MMRM] ; intent-to-treat [ITT] population) ; secondary eﬃ-
cacy : Sheehan Disability Scale (SDS) ; safety : adverse events (AEs),
clinical laboratory measurements, vital signs, ECGs.
Results : Least squares mean diﬀerence for MADRS-CR total score
change from baseline was signiﬁcantly superior for all levomilnaci-
pran doses versus placebo : 40 mg (x3.23, P=.0186), 80 mg (x3.99,
P=.0038), and 120 mg (x4.86, P=.0005) ; results remained signiﬁcant
after Hochberg adjustment for multiple comparisons. Signiﬁcantly
greater improvement (P<0.05) was seen for levomilnacipran 80 mg
and 120 mg versus placebo on the SDS, HAMD17, SF-36, CGI-S, and
CGI-I assessments. AEs led to signiﬁcantly higher discontinuation of
levomilnacipran 40-mg (7% ; P=.0185), 80-mg (15% ; P<0.0001), and
120-mg patients (7% ; P=.0316) compared with placebo (2%).
Treatment-emergent AEs (TEAEs) occurred in 64%, 76%, 83%, and
77% of placebo and levomilnacipran 40-, 80-, and 120-mg patients,
respectively. Common TEAEs (o10% of any treatment group) were
headache, nausea, constipation, dry mouth, increased heart rate, and
hyperhidrosis.
Conclusion : Levomilnacipran SR 40 mg, 80 mg, and 120 mg dem-
onstrated signiﬁcant improvement in depressive symptoms versus
placebo. Levomilnacipran SR was generally well tolerated ; however,
signiﬁcantly more levomilnacipran SR patients discontinued due to
AEs.
Policy of full disclosure : Supported by funding from Forest
Laboratories, Inc.
jP-14-006jSide eﬀects and treatment discontinuance of
reboxetine ; treatment of depression in parkinson’s
disease : Three cases reports
M. Ak1, M.A. Cinar2, A. AKCA1, A. Ozsahin1, B. Hacio¨meroglu1,
L. Su¨tc¸igil1. 1Gulhane School of Medicine, Ankara, Turkey ; 2TAF
Rehabilitation Center, Ankara, Turkey
The eﬃcacy and tolerability of reboxetine, a norepinephrine reuptake
inhibitor, have been shown in patients with depression in Parkinson’s
patients (1,2). Depression in Parkinson’s disease occurs frequently
%25–40 (3), associated with greater involvement of dopaminergic and
non- dopaminergic system. Treatment options in depression of
Parkinson’s disease vary, including SSRI’s (commonly ﬁrst choice),
TCA, MAO inhibitors and new generation antidepressants (4). Main
criteria treating depression of Parkinson’s disease ; side eﬀect proﬁle
and eﬃcacy, because of antiparkinson treatment may cause many
side eﬀects including nausea, vomiting, orthostatic hypotension,
headache and also deterioration of cognitive and motor symptoms.
Antidepressant treatment in depression of Parkinson’s disease may
deteriorate the side eﬀects of antiparkinson treatment causing dis-
continuance of treatment. We report three cases that used reboxetine
treatment in depression at Parkinson’s disease. Three cases of our
group could not have tolerated the drug and stopped treatment due to
side eﬀects reboxetine. Contrary to our experiences and studies on
positive eﬀects and well tolerability of drug, we could say that if re-
boxetin is chosen for depression at Parkinson patients, giving infor-
mation to patients about side eﬀects and close follow up is necessary.
References
1. Burrows GD, Magure KP, Norman TR. Antidepressant Eﬃcacy
and Tolerability of The Selective Norepinephrine Reuptake
Inhibitor Reboxetine, A Review. J Clin Psychiatry. 1998 ; 59 4–7.
2. Lemke MR, Eﬀect or Reboxetine on Depression in Parkinson’s
Disease Patients. J Clin Psychiatry. 2002 ; 63 300–304.
3. Dooneief G, Mirabello E, Bell K, Marder K, Stern Y, Mayeux R. An
Estimate of Incidence of Depression in Idiopathic Parkinson’s
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jP-14-007jDesvenlafaxine naturalistic trial in outpatients
D. Dachesky1, M.B. Carpinetti1. 1School of Medicine, Rosario, Argentina
Objective : This trial evaluated the eﬃcacy and tolerability of des-
venlafaxine in the treatment of mayor depressive disorder.
Methods :Weworked during 6 months, in an open, naturalistic trial
with adult outpatients (24–70 years) with a primary diagnosis of
mayor depressive disorder (DSM IV criteria) rating outcome with
Clinical Global Impression, Hamilton Scale for Depression, and
Sheehan Disability Scale at baseline, 30, 90 and 180 days.
Results : All patients included could complete the trial, with side
eﬀects that did not require removal. The results were statistically sig-
niﬁcant for all variables studied, with a special point that just at ﬁrst
month them were observed.
Conclusion : Desvenlafaxine seems to be a useful therapeutic tool
and well tolerated in outpatients with major depression, considering
of course ; the limited study population and its characteristics.
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jP-14-008jSuicidal thoughts and reasons for living in
hospitalized patients with severe depression :
Post hoc analyses of a double-blind randomized
trial of duloxetine
K. Demyttenaere1, D. Desaiah2, J. Raskin3, V. Cairns4, S. Brecht5.
1Campus Gasthuisberg, Leuven, Belgium ; 2Eli Lilly and Company,
Indianapolis, USA ; 3Eli Lilly and Company, Toronto, Canada ;
4Boehringer Ingelheim GmbH, Germany ; 5Boehringer Ingelheim GmbH,
Ingelheim, Germany
Objective : To evaluate suicidal thoughts in relationship to depressive
symptom severity and to Reasons For Living (RFL) in patients hospi-
talized for severe major depressive disorder (MDD).
Methods : Post-hoc analyses of a duloxetine trial in adult inpatients
with MDD who met criteria of DSM-IV, showing a Montgomery-
A˚sberg Depression Rating Scale [MADRS] score o30 and a Clinical
Global Impression of Severity [CGI-S], o4. Suicidal thoughts
were assessed with MADRS item-10 (suicidal thoughts), depression
severity with the MADRS 6-item subscale and protective factors with
the patient-rated RFL questionnaire assessing ‘survival and coping
beliefs ’, ‘responsibility to family’, ‘child-related concerns’, ‘fear of
suicide’, ‘ fear of social disapproval ’ and ‘moral objectives ’.
Descriptive statistics and correlation analyses were performed.
Results : At baseline, patients (N=336) had varying severity
of suicidal thoughts on MADRS item-10 : 18% had a score of o4
(4 :‘‘Probably better oﬀ dead. Suicidal thoughts are common, and
suicide is considered as a possible solution, but without speciﬁc plans
or intention’’). The proportion of patients with a score o4 decreased
to 7% at Week-1 and 1% at Week-8 of treatment. RFL scores at base-
line were lower in patients with higher baseline suicidal thoughts ;
all RFL domain scores improved signiﬁcantly during treatment (all
P<0.01). Correlations between RFL domains and single depressive
symptoms were low and only negatively signiﬁcant for suicidal
thoughts (all P<0.05) and pessimistic thoughts (5 of 7 P<0.05).
Suicidal thoughts were signiﬁcantly, although poorly, positively cor-
related with depression severity (per MADRS 6-item core symptoms).
RFL scores were not signiﬁcantly correlated with the MADRS 6-item
core symptoms.
Conclusion : 18% of inpatients with severe depression had
explicit baseline suicidal thoughts scores, which decreased rapidly
with treatment. Protective RFL scores increased with decreasing de-
pression severity, suggesting that their protective power depends
on the aﬀective status. Depression severity, suicidal thoughts and
RFL are mainly independent dimensions since most correlations
were low.
jP-14-009jCerebrospinal ﬂuid biomarkers for major depression
conﬁrm relevance of associated pathophysiology
C. Ditzen1, N. Tang2, A. Jastorﬀ1, A. Yassouridis1, G. Maccarrone1, M.
Uhr1, T. Bronisch1, C. Miller2, F. Holsboer1, C.W. Turck3. 1Max-
Planck-Institute, Munich, Germany ; 2Agilent Technologies, Santa Clara,
CA, USA ; 3Max Planck Institute of Psychiatry, Mu¨nchen, Germany
Objective : Individual characteristics of pathophysiology and course
of depressive episodes are at present not considered in diagnostics.
There are no biological markers available that can assist in categoriz-
ing subtypes of depression and detecting molecular variances related
to disease causing mechanisms between depressed patients.
Identiﬁcation of such diﬀerences is important in order to create pa-
tient subgroups which will beneﬁt from medications that speciﬁcally
target the pathophysiology underlying their clinical condition.
Methods : In order to ﬁnd characteristic biological markers for ma-
jor depression we analyzed the cerebrospinal ﬂuid proteome of
twelve depressed versus twelve control persons using twodimen-
sional polyacrylamide gel electrophoresis and time-of-ﬂight mass
spectrometry peptide proﬁling. Proteins of interest were identiﬁed by
matrix assisted laser desorption ionization-time of ﬂight mass spec-
trometry (MALDI TOF/TOF). Validation of a subset of protein mar-
kers was performed by immuno-blotting.
Results : We found 11 cerebrospinal ﬂuid proteins and 144 peptide
features that diﬀered signiﬁcantly between depressed patients and
controls. In addition, we detected diﬀerences in the phosphorylation
pattern of several CSF proteins. A subset of the diﬀerentially ex-
pressed proteins implicated in brain metabolism or central nervous
system disease was validated by immunoblotting. The identiﬁed
proteins are involved in neuroprotection and neuronal development,
sleep regulation and amyloid plaque deposition in the aging brain.
Conclusion : This is one of the ﬁrst hypothesis-free studies that
identiﬁes characteristic protein expression diﬀerences in CSF of de-
pressed patients. Proteomic approaches represent a powerful tool for
the identiﬁcation of disease markers for subgroups of patients with
major depression.
jP-14-010jElectrophysiological eﬀects of long-term
administration of paroxetine and bupropion
on serotonin transmission in olfactory
bulbectomized rats
M. El Mansari1, S. Manta1, S. Shim1, P. Blier1. 1 Institute of Mental
Health Research, Ottawa, Canada
Objective : Olfactory bulbectomized (OB) rats generally manifest
many of the neurochemical, physiological, and behavioural features
of a depressive disorder in humans. Another interesting feature of this
model is that it responds to chronic but not acute antidepressant
treatments, including SSRIs. The purpose of the present study was
ﬁrst to characterize the ﬁring activity of dorsal raphe serotonin (5-HT)
neurons in OB rats and then examine the eﬀects of two anti-
depressants namely bupropion and paroxetine.
Methods : Olfactory bulbectomy was performed by aspirating
olfactory bulbs in anesthetized rats. Vehicle and drugs were delivered
for 2 and 14 days via subcutaneously implanted minipumps. In vivo
electrophysiological recordings were carried out in male anesthetized
Sprague-Dawley rats.
Results : Following ablation of olfactory bulbs, the ﬁring rate of
5-HT neurons was decreased by 33%. In OB rats, bupropion
(30 mg/kg/day) reversed ﬁring rate of 5-HT neurons to control
level following 2- and 14-day administration and also induced a dis-
inhibition of CA3 pyramidal neurons following i.v. injection of
WAY100635 ; paroxetine administration (10 mg/kg/day) did not
result in normalizing the decrease observed in OB rats. In the hippo-
campus, although to a lesser extent than bupropion, paroxetine ad-
ministration also resulted in disinhibition of pyramidal neurons.
Conclusion : The decrease in ﬁring of 5-HT neurons in OB rats is
consistent with the hypothesis of a decreased 5-HT neurotransmission
in depression. This supports the use of this model to test the action
of antidepressants on ﬁring activity of monoaminergic systems.
The present results also indicate that unlike paroxetine, bupropion
administration promptly normalized 5-HT neuronal activity and in-
creased tonic activation of the 5-HT1A receptors in hippocampus.
Policy of full disclosure :M. El Mansari, S. Manta and S. Shim have
no disclosures. P. Blier has received grants and/or honoraria from
Astra Zeneca, Biovail, Bristol Myers Squibb, Eli Lilly, Valeant, Janssen,
Labopharm, Lundbeck/Takeda, Schering-Plough/Merck, Sepracor,
Servier, and Wyeth.
jP-14-011jElectrophysiological eﬀects of the multimodal
antidepressant LU AA21004 on serotonin
transmission in the rat hippocampus
M. El Mansari1, M. Lecours1, P. Blier1. 1 Institute of Mental Health
Research, Ottawa, Canada
Objective : Newer classes of antidepressants with more than one
mode of action have the potential to increase remission rates.
LuAA21004 is a novel multimodal antidepressant that is a 5-HT3
and 5-HT7 receptor antagonist, a 5-HT1B receptor partial agonist, a
5-HT1A receptor agonist, and an inhibitor of the 5-HT transporter
in vitro.
Methods : In vivo electrophysiological recordings and stimulations
of the ascending 5-HT bundle originating from the raphe nuclei were
used to determine the eﬀects of LuAA21004 on CA3 hippocampal
pyramidal neurons in anesthetized male rats. LuAA21004 was in-
jected intravenously (2–6 mg/kg) or administered subcutaneously for
14 days, at a dose of 5 mg/kg/day via an osmotic minipump.
Results : The recovery time from complete inhibition of pyramidal
neurons after micro-iontophoretically applied 5-HT, an index of 5-HT
transporter activity, was increased after 14-day administration of
LuAA21004. In contrast, the inhibition of CA3 pyramidal neurons
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after micro-iontophoretically applied 5-HT was unchanged. Injection
of the 5-HT1A receptor antagonist WAY100635 increased CA3
pyramidal neuron ﬁring, indicating an enhanced tonic activation
of post-synaptic 5-HT1A receptors. Stimulation of the 5-HT bundle
produced a decreased inhibition of the ﬁring of CA3 pyramidal
neurons at 5 Hz compared to 1 Hz.
Conclusion : LuAA21004 blocks 5-HT transporters, but does not
dampen the sensitivity of postsynaptic 5-HT1A receptors. In addition,
LuAA21004 decreased the function of the terminal 5-HT1B auto-
receptor, thus showing that its partial agonism led to increased 5-HT
release. Long-term LuAA21004 administration increased the tonic
activation of the postsynaptic 5-HT1A receptor in the hippocampus,
an eﬀect common to all antidepressants.
Policy of full disclosure :Mostafa El Mansari and Maurice Lecours
have no disclosures. Pierre Blier has received grants and/or honoraria
from Astra Zeneca, Biovail, Bristol Myers Squibb, Valeant, Eli Lilly,
Janssen, Labopharm, Lundbeck/Takeda, Schering-Plough/Merck,
Sepracor, Servier, and Wyeth.
jP-14-012jChronic low-grade inﬂammation induces
depression-like behavior in rats
C. Fischer1, B. Elfving1, S. Lund2, G. Wegener1. 1Centre for Psychiatric
Research, Risskov, Denmark ; 2Medical Research Laboratory and Medical
Department M, Aarhus, Denmark
Objective : Depression has been associated with a low-grade
inﬂammation, as revealed by clinical studies showing elevated levels
of pro-inﬂammatory cytokines in depressed patients. These patients
are often treatment-resistant, and some studies show that elevated
markers of inﬂammation predict a poor response to treatment.
Furthermore, increasing evidences show that metabolic abnormalities
such as obesity and diabetes mellitus type 2 are associated with a low-
grade inﬂammation. The aim of this study is to investigate the eﬀects
of a systemic low-grade inﬂammation induced by lipopolysaccharide
(LPS) on Sprague-Dawley rats on depression-like and metabolic
parameters.
Methods : Chronic infusion of LPS (at a high, medium and low
dose) for 28 days was performed by using subcutaneously implanted
osmotic minipumps, administering LPS through a catheter into the
abdomen. Depression-like behavior was assessed in the forced swim
test (FST). Peripheral and central levels of pro-inﬂammatory cytokines
(TNF-alpha, IL-1, IL-6) together with the expression of enzymes
involved in the tryptophan-kynurenine pathway, will be analyzed
in speciﬁc brain regions using real-time qPCR. Body weight and food
intake was measured once a week, while fasting glucose and insulin
sensitivity was assessed after four weeks of LPS administration.
Results : Our results showed that a low dose of LPS increased
immobility in the FST relative to vehicle treatment, indicative of de-
pression-like behavior. We did not ﬁnd any diﬀerence in body weight,
fasting glucose and insulin values. However, a high dose of LPS
caused an increase in liver weight. Analysis of cytokine and mRNA
expression levels is currently being carried out and these results are
pending.
Conclusion : Our results indicate that a low dose of LPS can
produce depression-like behavior, without inducing metabolic dis-
turbances or sickness behavior. Thus, this model might help eluci-
dating some of the mechanisms underlying inﬂammation-associated
depression, in order to assist in developing more eﬀective treatment
strategies for this group of patients.
jP-14-013jLower frequency of early discontinuation of
mirtazapine in elderly Japanese patients with
depression
Y. Fujita1, Y. Iwasaki1, K. Bessyo1, H. Minagawa1, H. Yada1, T. Sato1,
G. Sato1. 1Kusatsu Hospital, Hiroshima, Japan
Objective : Mirtazapine is a noradrenergic and speciﬁc serotonergic
antidepressant (NaSSA), and has been approved in many counties
for the treatment of major depression. In Japan, it has been available
since 2009 and has been safely used for elderly patients. Treatment
continuation is an important measure of eﬀectiveness in patients
with depression, reﬂecting the eﬃcacy, safety, and tolerability.
This retrospective study examined whether there was association
between age of patients and the rate of early discontinuation of
mirtazapine.
Methods : A total of 89 patients with major depression, who were
on mirtazapine monotherapy, were surveyed. The rate of the patients
who discontinued mirtazapine within eight weeks from the initiation
was compared between elderly patients (65 years or older, n=33) and
non-elderly patients (n=56). In the patients who continued mirtaza-
pine, the ﬁnal dose, and its eﬃcacy assessed by Clinical Global
Impression – Improvement (CGI-I), were compared between the two
groups.
Results : The discontinuation rate of elderly patients within eight
weeks was signiﬁcantly lower than that of non-elderly patients (18%
vs. 63%, respectively, p<0.001). In the patients continuing mirtaza-
pine, there was no signiﬁcant diﬀerence in the ﬁnal dose between two
groups ( 26¡11 mg/day vs. 26¡11 mg/day). In addition, there was
no signiﬁcant diﬀerence in the eﬃcacy between two groups ; the
ratio of very much improved and much improved was 62% and 56%,
respectively. The most common reasons of discontinuation in non-
elderly patients were sedation (n=16) and increased appetite (n=4),
while there were only two patients who developed sedation in elderly
patients.
Conclusion : This study shows that the rate of early discontinuation
of mirtazapine is lower in elderly patients than non-elderly patients,
possibly due to lower incidence of side eﬀects. Therefore, mirtazapine
might be eﬀective, safe and tolerable agent especially for elderly
patients with depression.
jP-14-014jLevomilnacipran in the treatment of major
depressive disorder : An analysis of eﬃcacy and
safety data from two phase III studies
W. Greenberg1, C. Gommoll1, A. Bose1, H. Li1, A. Ruth2,
N. Hussainzada3. 1Forest Research Institute, New Jersey, USA ; 2Prescott
Medical, Communications Group, Chicago, USA ; 3Forest Laboratories,
Washington, USA
Objective : Levomilnacipran (1S, 2R-milnacipran) is a potent and
selective serotonin and norepinephrine reuptake inhibitor (SNRI)
with greater potency for norepinephrine than serotonin reuptake
inhibition. Data from Phase III trials (Study 1 : NCT00969709 ; Study 2 :
NCT00969150) were used to evaluate the eﬃcacy and safety of levo-
milnacipran sustained release in major depressive disorder (MDD).
Methods : Studies were double-blind, multicenter, randomized,
placebo-controlled with a 1week single-blind, placebo lead-in, 8-week
double-blind treatment, and 2-week double-blind down-taper.
Patients with Montgomery-Asberg Depression Rating Scale-Clinician
Rated (MADRS-CR) scores o30 with current major depressive epi-
sode o8 weeks (Study 1) or o4 weeks (Study 2) were randomized
to once-daily levomilnacipran 40, 80, or 120 mg (Study 1 ; ﬁxed-dose)
or levomilnacipran 40–120 mg/day (Study 2 ; ﬂex-dose) or placebo.
Primary and secondary eﬃcacy : MADRS-CR and SDS total score
change from baseline to end of Week 8, respectively ; safety : adverse
events (AEs), laboratory measures/vital signs. Data were pooled and
analyzed using a mixed-eﬀects model for repeated measures
(MMRM) ; statistical diﬀerence in primary eﬃcacy was seen in Study 1
only.
Results : Pooled baseline characteristics were similar for placebo
(n=358) and levomilnacipran (n=712) ; 80.2% of placebo and 70.6%
of levomilnacipran patients completed the studies. Signiﬁcant im-
provement was seen for levomilnacipran versus placebo on MADRS-
CR (LSMD=x2.73 ; P=.0009) and SDS (LSMD=x1.44 ; P=.0190).
Discontinuation due to AEs occurred in 2.0% of placebo and 9.1% of
levomilnacipran patients ; 63.1% of placebo and 78.8% of levomilna-
cipran patients reported treatment-emergent AEs (TEAEs) ; the
majority were transient and mild/moderate in intensity. The most
common (o10%) TEAEs (placebo vs. levomilnacipran) were head-
ache (12% vs. 17%), nausea (3% vs. 16%), and dry mouth (8% vs.
10%).
Conclusion : Pooled analyses showed that levomilnacipran-treated
patients achieved statistically signiﬁcant and clinically meaningful
improvement in depressive symptoms and functional impairment.
Higher placebo response in Study 2 may explain diﬀerent individual
study outcomes. Levomilnacipran was generally well tolerated.
Policy of full disclosure : Supported by funding from Forest
Laboratories, Inc.
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jP-14-015jTolerability of polypharmacotherapy in psychiatry
G. Hefner1, K.S. Hovland1, C. Hiemke1. 1University Medical Center,
Mainz, Germany
Objective : In this study we analyzed data from psychiatric inpatients
treated under naturalistic conditions and supervised by therapeutic
drug monitoring (TDM) to compare the occurrence of side eﬀects
under monotherapy and polypharmacy. Combination therapies were
screened for potential risks to reveal if combinations considered as
critical are associated with an increased risk of side eﬀects.
Methods :Data were collected from the request and reporting forms
of psychiatric inpatients for whom TDM of antipsychotic or anti-
depressant drugs was requested during a period of 6 months. All
drug combinations were checked by a drug-drug interaction program
(www.psiac.de) for potential risks.
Results : The study included data from 488 inpatients, most of them
with the diagnosis of either schizophrenia (46%) or major depression
(40%). The prefered antipsychotic drugs were olanzapine (n=139),
quetiapine (n=101), clozapine (n=90) and risperidone (n=85).
Antidepressant drugs included venlafaxine (n=145), mirtazapine
(n=96), sertraline (n=72), escitalopram (n=37) and citalopram
(n=32). Only 21% of the patients receiving antipsychotic drugs were
under monotherapy and under antidepressant medication, we ident-
iﬁed 23% of monotherapies. Side eﬀects were reported for 16% of
the patients under monotherapy and for 39% under polypharmacy
with antipsychotic drugs. Most frequent were sleepiness and extra-
pyramidal symptoms. Treatment with antidepressant drugs was
associated in 12% with side eﬀects under monotherapy and in 29%
under polypharmacy. Under combinations with antipsychotic drugs
for which a potential risk was identiﬁed by the computer program
side eﬀects were reported for 51% of the cases. For antidepressant
drugs, side eﬀects were reported in only 29% of the combinations
considered as critical.
Conclusion : Combination therapies with antipsychotic or anti-
depressant drugs is associated with reduced drug-tolerance.
Polypharmacy must therefore be considered as a risk for more side
eﬀects. Computerized analysis of drug combinations could be useful
to detect potential risks due to drug-drug interactions and thus im-
prove tolerability.
jP-14-016jAdjunctive acetaminophen therapy for major
depression : A preliminary report
J. Hirano1, S. Nakajima2, T. Suzuk3, H. Uchida4, H. Takeuchi4, S. Nio4,
M. Tada4, K. Watanabe4, M. Mimura4. 1Tokyo, Japan ; 2Toronto,
Canada ; 3Department of Neuropsychiatry, School of Medicine, Tokyo,
Japan ; 4Department of Neuropsychiatry, School of Medicine, Tokyo, Japan
Objective : To investigate the eﬃcacy of adjunctive acetaminophen in
the treatment of major depressive disorder.
Methods : In this preliminary open-label study, patients with major
depressive disorder (DSM-IV), who were aged between 20 and 80 and
failed to show a 20% reduction in the total score of Montgomery-
Asberg Depression Rating Scale (MADRS) from screening to baseline
were included. Exclusion criteria included presence of any psychotic
feature and/or suicidal thought and any past history of, or current
gastrointestinal ulceration, liver dysfunction, or allergic reactions
to acetaminophen. Acetaminophen was given at ﬁxed dose of
1500 mg/day for 4 weeks while other psychotropic medications,
including antidepressants, were kept constant during the study.
Assessment scales included the MADRS, the Quick Inventory of
Depressive Symptomatology self–report (QIDS-SR), and Visual
Analogue Scale (VAS) for pain at baseline and 1, 2, and 4 weeks.
Adverse eﬀects were monitored at every visit. Data were reported,
using a last-observation-carried-forward method.
Results : Seven patients entered this study. These patients had been
treated with their antidepressants for X¡Y weeks at the time
of baseline assessments. One patient showed an improvement during
the screening phase and was therefore excluded. Thus, six patients
proceeded to the augmentation stage and provided the data for
analyses. One patient prematurely withdrew from this study due to
abdominal discomfort and another due to deviation from the protocol.
As a result of 4-week acetaminophen augmentation, mean total
MADRS score was reduced from 21.7 to 12.2. Likewise, the mean total
QIDS-SR score improved from 15.2 to 9.8, and the VAS score from
4.7 to 3.2.
Conclusion : Although the data are still preliminary, the results
point to some possibility of acetaminophen as an augmentation
strategy for patients with treatment-refractory major depressive
disorder.
jP-14-017jPersonality dimensions in major depressive disorder
predict cortisol reactivity to the combined
dexamethasone/CRH test
H. Hori1, T. Teraishi1, D. Sasayama1, K. Hattori1, M. Hashikura1,
T. Higuchi2, H. Kunugi1. 1Natl. Inst. Neuroscience, NCNP, Tokyo,
Japan ; 2NCNP, Tokyo, Japan
Objective : It is generally acknowledged that depression is associated
with altered hypothalamic-pituitary-adrenal (HPA) axis function,
most notably hypercortisolism. However, ﬁndings on HPA axis
function in depression are not entirely unequivocal, such that
hypercortisolism has not been observed in some studies. Another line
of research has demonstrated that various psychiatric conditions,
including atypical depression, are associated with hypocortisolism.
Moreover, personality is shown to be associated with HPA axis
alteration. Taken together, diﬀerent personality pathology in de-
pression may play a role in the distinct HPA axis alteration.
Methods : Eighty outpatients with DSM-IV major depressive dis-
order were recruited. Personality was assessed by the Temperament
and Character Inventory (TCI). Depressive symptoms were assessed
by the Hamilton Rating Scale for Depression. HPA axis reactivity was
measured by the combined dexamethasone/corticotropin-releasing
hormone (CRH) test. According to previous studies, two subgroups
were considered based on their cortisol responses to the dex-
amethasone/CRH test : incomplete-suppressors whose cortisol re-
sponse was exaggerated and enhanced-suppressors whose cortisol
response was blunted.
Results : Of the seven TCI dimensions, cooperativeness was sig-
niﬁcantly positively correlated with cortisol levels after combined
dexamethasone/CRH challenge (p<0.001). Incomplete-suppressors
scored signiﬁcantly higher in cooperativeness than enhanced-
suppressors (p=0.003). A logistic regression analysis, controlling for
age, gender and symptom severity, was performed to predict the
cortisol suppression pattern (i.e., incomplete- vs. enhanced-
suppression) from TCI scores, which revealed that reward depen-
dence (p=0.04) and cooperativeness (p=0.003) were signiﬁcant
predictors for enhanced- and incomplete-suppression, respectively.
Conclusion : These ﬁndings can be viewed in light of the known
association of atypical depression with personality pathology and
hypocortisolism. Given the evidence that atypical depression and
melancholic depression could beneﬁt from diﬀerent treatment ap-
proaches, our ﬁndings would be of clinical importance as they suggest
the possibility of distinguishing these diﬀerent types of depression
based on the distinct directions of HPA axis alteration.
jP-14-018jDopamine transporter gene (DAT1) possible aﬀects
personality traits in early-onset patients with major
depressive disorder
C.-C. Huang1, S.-Y. Huang2, C.-H. Yen2. 1National Defense Medical,
Center, Taipei, Taiwan ; 2Taipei, Taiwan
Objective : Comorbid personality pathologies may aﬀect the out-
comes of patients with major depression (MD). The dopamine
transporter gene DAT1 (SLC6A3) has been suggested to play a role
in both depression and speciﬁc personality traits. The aim of this
study selected ﬁve polymorphisms of DAT1 to explore whether
this gene inﬂuences personality traits in patients with MD or its sub-
groups.
Methods : The DAT1 polymorphisms were analyzed in 463 un-
related Han Chinese MD patients. All patients were screened using
the same assessment tool and the diagnosis of MDwas made based on
a consensus opinion. The personality traits novelty seeking (NS) and
harm avoidance (HA) were examined using the Tridimensional
Personality Questionnaire. The patients were also divided into four
clinical subgroups based on diﬀerences in their sex (male or female)
and age at disease onset (early or late).
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Results : There was no association between DAT1 and either NS or
HA in the total MD patient sample. However, in a subgroup analysis,
male MD patients with the T/T genotype of rs2975226 had lower HA
scores than patients with the other genotypes (Pcorrected=0.015).
Furthermore, early-onset MD patients with the G/G genotype of
rs2550948 and the T/T genotype of rs2975226 had lower NS scores
than patients with other genotypes (Pcorrected=0.005 for rs2550948
and Pcorrected=0.0005 for rs2550948).
Conclusion : Our study suggests that DAT1 promoter variants
inﬂuence speciﬁc personality traits in male and early-onset subgroup
of depressed patients among Han Chinese population. Further pro-
spective cohort studies are required to verify our preliminary ﬁnding
and to conﬁrm the eﬀects of personality susceptibility on long-term
disease outcomes.
jP-14-019jDepressed patients with a mild inﬂammatory
phenotype display robust tryptophan depletion in
the absence of kynurenine pathway activation
M. Hughes1, A. Carballedo2, D. McLoughlin2, A. Harkin2, T. Frodl2,
T. Connor2. 1 Institute of Neuroscience, Dublin, Ireland ; 2 Institute of
Neuroscience, Dublin 2, Ireland
Objective : The kynurenine pathway (KP) and its rate-limiting
tryptophan degrading enzyme indolamine 2,3 dioxygenase (IDO),
have been implicated in the pathogenesis of major depression. IDO
expression is driven by the inﬂammatory cytokines IFN-c, IL-6 and
TNF-a, and it has been suggested that IDO induction and resultant KP
activation may be the link between inﬂammation and a decrease in
tryptophan availability, which could lead to a serotonergic deﬁcit
in depression.
Methods :Here we examined circulating concentrations of the acute
phase protein CRP, the inﬂammatory cytokines IFN-c, TNF-a and
IL-6, alongside plasma tryptophan and kynurenine concentrations
and whole blood IDO mRNA expression in a group of depressed
patients (average HAM-D score>25) (n=39) compared with healthy
age and sex-matched control subjects (n=39).
Results : Whilst no signiﬁcant change was observed in plasma
TNF-a, plasma concentrations of IFN-c, IL-6 and CRP were increased
in the depressed cohort relative to controls. Despite this inﬂammatory
phenotype, IDO mRNA expression or plasma kynurenine concentra-
tions were not signiﬁcantly diﬀerent between depressives and con-
trols, indicating that the KP was not activated. Nonetheless, a robust
depletion in tryptophan was evident in the depressed cohort relative
to controls.
Conclusion : These data support the idea that a mild inﬂammatory
signature is evident in depressed patients, and that this is accom-
panied by a depletion of tryptophan. However, we found no indi-
cation of KP activation in the depressed cohort suggesting that an
alternative mechanism/pathway mediates the depletion of trypto-
phan observed in depressed patients.
jP-14-020jQuality of living, depression and psychosomatic
diseases in medical doctors
N. Ilic1, V. Ilic1. 1Health Centar-Nis, Serbia
Objective : Material achieved from my four research works is used
for composing of this paper. This paper is related to one target
group – the medical doctors.
Methods : Thinking about doctor’s quality of living, from the aspect
of free-time, without free-of-charge professional engagement, we have
asked our colleagues speciﬁc questions (trought the anonymous
questionnaire). The questionnaire analysis of 50 polled doctors aged
30–55 y. gave the following results. Thirty polled doctors (60%) used
its own free-time for extra professional engagement. Seventeen polled
doctors (34%), partially managed to evade those activities, but only
three of them (6%) did not practice extra professional activities.
Results : As a research instrument, the scale for self-estimation of
depression (ZUNG) is used. Fifty two doctors of both sexes ﬁlled the
questionnaire out, 30–55 years aged. According to the scale recog-
nition key, the following results appeared. Depression – free were 8
of polled (15.38%), and 10 of them (19.23%) suﬀered depressivity in
remission. In category of depression with other disorders, belong
30 polled doctors (57.69%) and four (7.69%) of them need depression
treatment. Aim of the fourth examination is to show psychosomatic
diseases and related depres-sivity occurrence with general practice
medical doctors. We have used anonymous questionnaire on catching
psychosomatic diseases, and the self-estimating scale of depressivity
(ZUNG), as research instruments. Thirty six doctors and general
medicine specialists of both sexes, 30–55 year aged, were completed
those lists. In the polled group there is one third suﬀering from
psychosomatic diseases with doubled level of depressivity that needs
medical treatment, in relation with complete group (30.76% to
16.66%).
Conclusion : Depression is occurred considerably also in total
number of polled doctors. As the most important factors for de-
pression and psychosomatic diseases occurrence there are : stress
and overload at work, status in wide social environment and bad
economic situation.
jP-14-021jRecurrence of winter amenorrhea in aﬀective illness
F. Jacobsen1, L. Rodriguez-Roman2, L. Comas-Dı´az1. 1George
Washington University, School of Medicine, USA ; 2Universidad Central
del Caribe, School of Medicine, Bayamon, Puerto Rico
Objective : Aﬀective illness and endocrine dysfunction can worsen
perimenopausally. We described the phenomenon of winter amenor-
rhea in aﬀective illness (Jacobsen and Comas-Diaz, 2004). Our longi-
tudinal study now reveals that women suﬀering depressive illness
may experience recurrent amenorrhea during successive winters,
sometimes years before perimenopause.
Methods : Subjects were mood-stabilized female bipolar spectrum
or unipolar outpatients without previous amenorrhea (skipping three
consecutive periods) or recent steroid use. Naturalistic monitoring
included bimonthly evaluation of menstrual cycling, sleep, appetite/
weight, energy/activity, sexual function, cognition, and mood. Other
data analysed included menarche, parity, laterality, diurnality, head-
ache, neuroendocrinology, family genetic and treatment history.
Results : 26 women (17 bipolar, 9 unipolar) treated for
15.7¡5.9 years experienced 4.6¡1.9 months of fall/winter amenor-
rhea beginning age 48.8¡3.3 years. 17 (65%) had past fall/winter
depressions. – 7 of 26 (19%) had amenorrhea in 2+ successive win-
ters – depression ratings remained unchanged during amenorrheic
episodes. – 85% of winter amenorrheics (N=22) suﬀered migraine
(usually perimenstrual), which lessened in only 3 while amenor-
rheic. – 18 (69%) reported feeling menstrual cycle manifestations
while amenorrheic – two long-stabilized amenorrheic bipolars
abruptly menstruated and switched into mixed-mania following
7+ days mid-winter exposure to greatly increased environmental
sunlight+temperature – two unipolars experienced 7+ days of in-
somnia+racing thoughts coincident with abrupt resumption of men-
struation in spring.
Conclusion :Winter amenorrhea can be a recurrent phenomenon in
aﬀective illness. During winter amenorrhea mood appears stable
while physical feelings of menstrual cycling may recur, suggesting a
complex relationship between seasonally decreased serotonergic
function and perimenopausal estrogen decline. Sudden intense
light+heat exposure during winter may dramatically alter endocrine
and aﬀective symptomatology in perimenopausal women.
jP-14-022jEﬃcacy and clinical relevance of vilazodone in the
treatment of major depressive disorder : A pooled
analysis of phase III clinical trials
A. Khan1, W. Song2, A. Ruth3, J. Edwards4. 1Duke University, Bellevue,
USA ; 2Forest Research Institute, Jersey City, USA ; 3Prescott Medical,
Communications Group, Chicago, USA ; 4Forest Research Institute,
New Jersey, USA
Objective : Vilazodone, a serotonin reuptake inhibitor and 5-HT1A
receptor partial agonist, is FDA approved for treatment of major
depressive disorder (MDD) in adults. Data from Phase III trials, both
of which were positive, were analyzed to evaluate eﬃcacy across
depression symptoms (MADRS total and single items) and clinical
relevance of results (number needed to treat [NNT] and harm
[NNH]).
Methods : Data from 2 double-blind, 8-week, randomized, placebo-
controlled trials (NCT00285376, NCT00683592) were pooled. Patients
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(18–70 years) with DSM-IV-TR-deﬁned MDD and HAMD17 score
o22 received vilazodone (n=436) or placebo (n=433) ; trials com-
prised a 1-week screening and 8-week double-blind treatment.
Vilazodone was titrated to 40-mg (taken once daily with food) over a
2-week ﬁxed-dose titration period. Primary eﬃcacy outcome :
MADRS total score change from baseline to Week 8. Post hoc analyses
estimated treatment eﬀects of vilazodone versus placebo on MADRS
total and single items (using analysis of covariance and last obser-
vation carried forward approach), NNT for response (MADRSo50%
improvement) and remission (MADRSf10), NNH for adverse events
(AEs) and AE discontinuations.
Results : Vilazodone signiﬁcantly improved MADRS total scores
relative to placebo : least squares mean diﬀerence (LSMD), x2.79
(P<0.0001). Signiﬁcant improvement for vilazodone versus placebo
occurred on every MADRS single item (LSMD) : apparent sadness,
x0.24 ; reported sadness,x0.29 ; inner tension,x0.31 ; reduced sleep,
x0.30 ; reduced appetite, x0.20 ; concentration diﬃculties, x0.24 ;
lassitude,x0.27 ; inability to feel,x0.25 ; pessimistic thoughts,x0.35 ;
suicidal thoughts,x0.29 (P<0.01 for all). NNT (95% CI) for response
and remission : 8 (5, 17) and 12 (7, 37), respectively ; NNH (95% CI) for
AE discontinuations : 26 (15, 106).
Conclusion : Vilazodone showed broad eﬃcacy across depression
symptoms. An NNT f10 for response is generally regarded as evi-
dence for clinical relevance in depression treatment ; the NNT and
NNH analyses suggested a lower risk of AE discontinuation relative
to clinically meaningful improvement for vilazodone.
Policy of full disclosure : Supported by funding from Forest
Laboratories, Inc.
jP-14-023jHormones, cytokines, and adipokines in the course
of depression – potential biomarkers for treatment
response?
S. Kloiber1, J. Hennings1, M. Uhr1, S. Lucae1. 1Max-Planck-Institute,
Munich, Germany
Objective : A plethora of alterations in diﬀerent biological systems
such as hormonal axes, immune system, and metabolic pathways
have been described in major depression and gave rise to several
theories regarding pathophysiological mechanisms of depressive
disorders. This led us to investigate whether serum parameters
indicating status and changes of these biological systems are altered
among patients with major depression or could serve as potential
biomarkers for treatment response in depressed patients.
Methods : We analyzed hormones, cytokines, and adipokines (cor-
tisol, leptin, ghrelin, insulin, insulin like growth factor 1 (IGF-1),
sexual hormone binding globulin (SHBG), testosterone, C-reactive
protein (CRP), and interleukin 6 (IL6)) in healthy subjects and patients
with major depression from the Munich Antidepressant Response
Signature Project (MARS) at admission and after 6 weeks of anti-
depressant treatment.
Results : We observed signiﬁcantly elevated IGF-1 in depressed
patients compared to healthy controls. Additionally, IGF-1 was
signiﬁcantly decreased in patients responding to antidepressant
treatment at baseline and after 6 weeks in comparison with non-
responders. Furthermore, non-responders showed elevated inﬂam-
mation parameters (IL6 at baseline and CRP after 6 weeks) and
testosterone increased during antidepressant treatment in responders
compared to non-responders.
Conclusion : We conclude that easily accessible serum parameters
like IGF-1, CRP, IL6 or testosterone, could possibly serve as bio-
markers in antidepressant treatment. In particular, diﬀerences in
IGF-1 and IL6 levels between responders and non-responders were
already present at baseline. Further validations in prospective studies
as well as investigations particularly with regard to biological mech-
anisms in major depression are necessary to substantiate these
ﬁndings.
jP-14-024jThai women with depressive disorder : Explanatory
model
T. Kongsuk1, S. Rungreangkulkij2, S. Chirawatkul3, R. Yingyeun1,
J. Leejongpermpoon1. 1Prasrimahabhodi Hospital, Ubonratchathanee,
Thailand ; 2Faculty of Nursing, Khon Kaen, Thailand ; 3Khon Kaen,
Thailand
Objective : This qualitative study aims to describe an explan-
atory model of illness in Thai women with Major Depressive epi-
sode.
Methods : The study was conducted in a semi-rural area with 25
Thai women who were diagnosed with major depressive disorder.
These women were under a two-year project of the Thai Depression
Surveillance System. Semi-structure interviews based on Kleinman’s
explanatory framework were used. Data were collected by in-depth
interviews and focus groups. Content analysis was used to disclose
the relevant themes.
Results : Most participants called their illness as ‘‘stress ’’. Only
seven participants perceived it as depressive disorder. All expressed
that ‘‘ thinking a lot ’’, especially around family related issues was the
cause of their illness. The other common cause of their depression was
the inability to let go (Thum- jai) of the unwanted situation. Almost all
participants beneﬁted from the use of antidepressants. However, they
were not taken as prescribed. Some participants reported that listen-
ing to community broadcasting radio’s Dhrama was helpful. The
other method was self-agency. All women felt stigmatized from get-
ting treatment from a psychiatric hospital. They preferred to get
treatment from a community hospital instead. Almost all revealed
that they were more comfortable to receive treatment from a female
therapist.
Conclusion : The ﬁndings suggest that eﬀective psycho-education
program on depressive disorder is needed. Therapists have to listen to
and take patients’ perspectives into account. Mental illness treatment
should be integrated in a primary care setting and Buddhist teaching
should be employed.
jP-14-025jThe prevalence of major depressive disorders in
Thailand : National survey
T. Kongsuk1, W. Pengchuntr2, P. Kittirattanapaiboon2,
K. Kenbubpha1, S. Sukawaha1, S. Sukjai1, J. Leejongpermpoon1.
1Prasrimahabhodi Hospital, Ubonratchathanee, Thailand ; 2Ministry of
Public Health, Nonthaburi, Thailand
Objective : To present nationally representative data on prevalence of
major depressive disorder (MDD) and dysthymia in Thailand.
Methods : Nationally representative face-to-face household
survey based on a stratiﬁed three-stage cluster sampling of non-
institutionalized people aged 15 years and over (n=19.000) and
selected each stage by means of random sampling. The data were
conducted between June and August 2008 using Mini International
Neuropsychiatric Interview (M.I.N.I.) by trained psychiatric profes-
sionals. The data analysis were calculated by means adjust weight of
prevalence for generalized to Thai population.
Results : The number of participants of this the national survey
was 20,579 people of 15 and over years. The overall of prevalence
rates in major depressive episode current accounted for 2.40%
(SE=0.19) that could estimated the number of population about
1,311,797 in Thailand with 1.7% (SE=0.16) in male and 2.9%
(SE=0.32) in female, while all of major depressive episode recurrent
found approximately 386,712 in Thais with 0.7% (SE=0.13) of preva-
lence and 0.4% (SE=0.08) of male and 0.9% (SE=0.22) of
female. Also, the prevalence of dysthymia current found approxi-
mately 0.3% (SE=0.06) that could estimate the number of Thai about
181,809 with 0.2% (SE=0.04) in male and 0.5% (SE=0.09) in female.
Moreover, the age group among 80 years and older indicated the
prevalence rates of major depressive disorder about 5.0% (SE=2.32),
found in women rather than men with 1.71 : 1 sex ratio and shown the
highest in the region of capital of Thailand, Bangkok, account for 4.1%
(SE=0.51).
Conclusion :Major depressive disorder is a common disorder in the
general population of Thailand. These ﬁndings will establish the
programs for preventing and planning mental health services for
people who suﬀer from major depressive disorder or dysthymia es-
pecially in female and older person.
P-14. Depression 187
Downloaded from https://academic.oup.com/ijnp/article-abstract/15/Supplement_1/1/650920
by University of Groningen user
on 13 March 2018
jP-14-027jPsychopharmacological studies on atrovastatin and
its solvatomorphs in experimental paradigm
of depression
A. Kuhad1, S. Kishor2, R. Chadha2. 1University Institute of
Pharmaceutical Sciences, Chandigarh, India ; 2Panjab University,
Chandigarh, India
Objective : A complex relationship exists among stressful situations,
body’s reaction to stress, and the onset of clinical depression. Chronic
unpredictable stressors can produce a situation similar to clinical de-
pression and such animal models can be used for the pre-clinical
evaluation of antidepressants. There is a complex relationship
between lipid-lowering drug therapy and psychological well-being
and it remains an issue of debate for long. Atorvastatin’s poor bio-
availability and brain penetration limits its neuroprotective eﬃcacy.
Polymorphism could enhance the stability, solubility and bioavail-
ability of existing drugs. The present study was designed to inves-
tigate possible antidepressant potential of atorvastatin and its
solvatomorph in unpredictable chronic stress-induced depressive like
behavior.
Methods : Animals were subjected to diﬀerent stress paradigms
daily for a period of 21 days to induce depressive-like behavior. The
sucrose preference, immobility period, locomotor activity, memory
acquisition and retention were evaluated.
Results : Chronic treatment with atorvastatin and its solvatomorph
signiﬁcantly reversed the unpredictable chronic stress-induced beha-
vioral (increased immobility period, reduced sucrose preference),
biochemical (increased lipid peroxidation & nitrite levels ; decreased
glutathione levels, superoxide dismutase, catalase & MAO activities)
and inﬂammation surge (serum TNF-a) in stressed mice.
Conclusion : The study revealed that atorvastatin and its solvato-
morph exerted antidepressant-like eﬀects in behavioral despair
paradigm in chronically stressed mice, speciﬁcally by modulating
central oxidative-nitrosative stress, MAO activity and inﬂammation
independent of its lipid lowering eﬀect. However, solvatomorph
showed better antidepressant eﬃcacy as compared to atorvastatin.
jP-14-028jThe concentration of brain glucagon-like peptides
(GLP-1 and GLP-2) in an animal model of
depression
A. Kurek1, J. Detka1, K. Glombik1, M. Leskiewicz1, A. Basta-Kaim1,
M. Kubera1, W. Lason1, B. Budziszewska1. 1Pharmacology, PAS,
Krakow, Poland
Objective : Recent ﬁndings have shown that insulin resistance and,
in consequence, disturbed glucose metabolism in the brain might play
a role in the pathogenesis of depressive disorder. Insulin action and
metabolic processes are regulated by various hormones and proteins,
interactions of which have been thoroughly examined in peripheral
tissue, however, their role in brain tissues, especially in depression,
is weakly recognized, yet. Among compounds crucially involved
in insulin action, incretin hormones – glucagon-like peptides (GLP)
play an important role. The aim of the present study was to ﬁnd out
whether there are any changes in the amount of GLP-1 and GLP-2
in an animal model of depression.
Methods : Pregnant Sprague-Dawley rats were subjected to
stress from 14 to 21 days of pregnancy. After weaning, male rats
were housed for 3 months and next the forced swim test (Porsolt
test) was performed. Two days after the Porsolt test, the animals
were killed by rapid decapitation and the brain structures were dis-
sected. The concentrations of GLP-1 and GLP-2 were determined
by ELISA methods and glucose level was measured by ﬂuorometric
assay.
Results : It has been found that prenatally stressed rats had stat-
istically signiﬁcantly higher levels of immobility behavior in the
forced swimming test than control animals, i.e. they showed de-
pression-like behavior. A biochemical study demonstrated that pre-
natally stressed rats had about a 30% higher glucose concentration in
the frontal cortex, but the amount of GLP-1 and GLP-2 in frontal cor-
tex and hippocampus did not diﬀer from those observed in control
animals, however, a decreasing tendency was observed.
Conclusion : The obtained results indicated that prenatal stress
signiﬁcantly prolonged the immobility time in the Porsolt’s test,
i.e. evoked depression-like behavior, and enhanced glucose level in
the frontal cortex. However, these changes were not accompanied by a
signiﬁcant diﬀerence in the concentration of incretin hormones.
Policy of full disclosure : This work was supported by the
Operating Program of Innovative Economy 2007–2013, grant No.
POIG.01.01.02-12-004/09.
jP-14-029jContribution of socioeconomic conditions to
association studies of serotonin transporter gene-
linked promoter polymorphism and depressiveness
T. Kurrikoﬀ1, K. Hiio1, E. Kiive1, H.-M. Loit2, J. Ma¨estu1, J. Harro1.
1University of Tartu, Estonia ; 2Tallinn, Estonia
Objective : Environmental varieties aﬀect association between sero-
tonin transporter gene-linked promoter polymorphism (5-HTTLPR)
and depression [Karg et al., 2011, Arch Gen Psychiatry 68 : 444–454]. In
addition to the nature of stressful life events (SLE), other factors such
as ethnicity should be considered as modiﬁers because ethnic mino-
rities often experience socioeconomic disadvantages [Black et al.,
2006, Rev Econ Stud 88 : 300–313] and are therefore possibly more
exposed to stress compared to ethnic majorities.
Methods : The data of the ﬁrst and second follow-up of the older
cohort of the Estonian Children Personality, Behaviour and Health
Study [Harro et al., 2009, Biol Psychol 81 : 9–13] were used. Data were
collected in 2001 and 2008 when participants were 18 (n=454, 194
male and 260 female ; 356 Estonians, 98 Russians) and 25 years old
(n=540 ; 229 male and 311 female ; 423 Estonians, 117 Russians), re-
spectively. Symptoms of depression were measured with the self-
report version of the Montgomery-A˚sberg Depression Rating Scale
[Montgomery and Asberg 1979, Brit J Psychiat 134 : 382–389]. The
history of noninterpersonal SLE in the preceding year was self-
reported at age 25.
Results : The score of depressiveness, education level and income
were similar in Estonians and Russians. By age 25, Russians had
experienced more stressful life events. Eighteen years old Estonians
reported higher monthly income of both parents and better economic
conditions compared to Russians. Estonian males with the l’/l’ geno-
type of the 5-HTTLPR and more SLE had higher depressiveness. On
the contrary, in Russians, the s’-allele carriers who had experienced
higher level of SLE reported higher depressiveness. In females, the
5-HTTLPR x environment interaction eﬀect on depressiveness did not
diﬀer between Estonians and Russians.
Conclusion : In conclusion, association between the 5-HTTLPR
genotype and depressiveness qualitatively depends on demographic
variables and the impact of the latter can be gender-dependent.
jP-14-030jNeonatal tryptophan depletion and corticosterone
supplementation result in depressive-like
abnormalities in adult male mice
G. Laviola1, F. Zoratto1, M. Fiore2, S. Macrı`1. 1 Istituto Superiore di
Sanita`, Rome, Italy ; 2National Research Council, Rome, Italy
Objective : Current rodent models of human depression suﬀer
from limited construct and external validity whereby they disregard
the nature-nurture interactive origin of the disease and are normally
suited to inﬂexible conditions (e.g. single background strain). We de-
veloped a animal model reproducing several depressive-like features
(symptoms) through the combination of reduced serotonin and en-
vironmental stress during the early stages of postnatal life (aetiology).
We tested whether the adult mice thereon obtained exhibited beha-
vioral and neurochemical alterations isomorphic to symptoms of
human depression.
Methods : We administered, to outbred CD1 mouse dams, during
their ﬁrst week of lactation, a Ltryptophan deﬁcient diet (T) and cor-
ticosterone (C) via drinking water (80 mg/ml). Four groups of dams
(animal facility rearing, AFR ; T treated, T ; C treated, C ; T and C
treated, TC) and their oﬀspring were used in the study. Maternal care
was scored throughout treatment and adult male oﬀspring were
tested for : anhedonia (progressive ratio schedule) ; anxiety-related
behavior (approach-avoidance conﬂict paradigm) ; BDNF, dopamine
and serotonin concentrations in selected brain areas.
Results : Compared to AFR, T, C and TC treatments reduced
maternal care. Adult TC oﬀspring showed signiﬁcantly increased
anxiety- and anhedonia- related behaviors, reduced striatal and
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increased hypothalamic BDNF and reduced dopamine and serotonin
in the prefrontal cortex and their turnover in the hippocampus.
Conclusion : The present mouse model recapitulates both the
independent (aetiology) and the dependent (symptoms) variables
involved in human depression. Furthermore, the independent
variables used in this study are plausible to be translated to diﬀer-
ent mammalian species and ultimately allow externally valid test
strategies.
jP-14-031j Inﬂammation, cytokines and brain in psychiatric
disorders
I.I. Lieber1, A. Epelbaum2, D.M. Epelbaum2. 1Buenos Aires, Argentina ;
2Argentina, Argentina
Objective : There is evidence that in many psychiatric disorders,
like stress, depression, schizophrenia, and Alzheimer disease there
are involved inﬂammatory and immune processes. The objective
is to modulate them and reduce the symptoms. Psychoneuro-
immunendocrinology PNIE is concerned with the interaction between
the nervous, immune and endocrine system. The immune system
inﬂuences the brain and endocrine system by releasing cytokines
which also activate the central nervous and endocrine system, the
hypothalamus and the hypothalamic-pituitary-adrenal (HPA axis)
Cytokines can be synthetized and liberated in the brain by astrocytes
and microglia. In depression proinﬂammatory cytokines are in-
creased, IL1,IL6 TNF soluble receptors IL2 and IL6, there is a shift
to Th1 cytokines. Antiinﬂammatory cytokines IL4,IL10,IL13, inhibit
syntesis of cytokines. In schizophrenia there is a shift to the Th2 anti-
inﬂammatory cytokines and a reduction of IL2 and increment of IL6.
In Alzheimer disease there is an elevation of IL1,IL6, cytokines and
a reduction of IL2. and they favor synthesis of amyloid precursors
that produce senile plaques. Some cytokines like Interferon, TNF,
IL2 can alter neurotransmission, produce fatigue, depression, anxiety,
suicidal ideation cognitive, psychotic and somatic symptoms.
Methods : Omega 3 fatty acids are the precursors of antiin-
ﬂammatory prostaglandins, eicosanoids. In patients with moderate
depression, we administered polyunsaturated fatty acids omega 3, of
Chia capsules, 600 mg, 4 times a day, during 6 months. We evaluated
the ratio of TGL/HDL, that are an indirect marker for inﬂammation,
and with Beck depression scale.
Results : We obtained a lowering of the ratio TGL/HDL and an
improvement in Beck scale with stabilization of mood.
Conclusion : We suggest omega 3 fatty acids as an adjuvant to
modulate inﬂammatory and antiinﬂammatory eicosanoids and cyto-
kines. A disbalance could aﬀect the brain and modify the endocrine,
immunological, neurological, behavioural responses and the func-
tioning of the PNIE systems.
jP-14-032jEﬃcacy and safety of lisdexamfetamine dimesylate
in adults with executive dysfunction and partial or
full remission of major depressive disorder
M. Madhoo1, R.S.E. Keefe2, R.M. Roth3, A. Sambunaris4, J. Wu1,
M.H. Trivedi5, C.S. Anderson1, R. Lasser1. 1Shire Development, LLC,
Wayne, USA ; 2Duke University Medical Center, Durham, USA ;
3Dartmouth Medical School, Lebanon, USA ; 4Atlanta Institute of
Medicine & Research, USA ; 5University of Texas, Southwestern Medical
School, Dallas, USA
Objective : Evaluate lisdexamfetamine dimesylate (LDX) augmen-
tation of antidepressant monotherapy for executive dysfunction in
participants with major depressive disorder (MDD).
Methods : This randomized, placebo-controlled study enrolled par-
ticipants (18–55 y) with mild MDD (Montgomery-Asberg Depression
Rating Scale [MADRS] total score f18) and executive dysfunction
(Behavior Rating Inventory of Executive Function–Adult Version
[BRIEF-A] Global Executive Composite [GEC] T-scoreo60) on stable
antidepressant monotherapy for o8 weeks. After 2 weeks of screen-
ing, participants were randomized to 9 weeks of double-blind LDX
or placebo augmentation, followed by 2 weeks of single-blind
placebo. Double-blind treatment was initiated at 20 mg/day and
optimized over 6 weeks in 10-mg weekly increments (maximum dose,
70 mg/day) ; the optimized dose was maintained through week 9.
Eﬃcacy (change from baseline to endpoint in BRIEF-A GEC T-score
[primary outcome] and MADRS total score [secondary outcome]) was
analyzed using analysis of covariance with last observation carried
forward. Treatment-emergent adverse events (TEAEs) were recorded.
Results : Of 143 randomized participants (placebo, n=72 ; LDX,
n=71), 119 completed double-blind treatment (placebo, n=59 ;
LDX, n=60). Mean¡SD BRIEF-A GEC T-scores decreased from
baseline (placebo, 74.2¡8.88 ; LDX, 76.8¡9.66) to endpoint (placebo,
61.4¡14.61 ; LDX, 55.2¡16.15) ; the least squares (LS) mean (95% CI)
treatment diﬀerence signiﬁcantly favored LDX (x8.0 [x12.7, x3.3] ;
P=0.0009). Mean¡SD MADRS total scores decreased from baseline
(placebo, 11.8¡3.77 ; LDX, 12.7¡3.23) to endpoint (placebo, 8.9¡5.67 ;
LDX, 7.6¡6.28) ; the LS mean (95% CI) treatment diﬀerence signiﬁ-
cantly favored LDX (x1.9 [x3.7, 0.0] ; P=0.0465). Double-blind TEAE
rates were 73.6% with placebo and 78.9% with LDX and included
5 serious TEAEs (placebo, 3 ; LDX, 2).
Conclusion : LDX augmentation signiﬁcantly improved executive
dysfunction and depressive symptoms in participants with fully or
partially remitted MDD. The safety proﬁle was generally consistent
with published data.
Policy of full disclosure : Dr. Madhoo is an employee of Shire
Development, LLC and holds stock and/or stock options in Shire.
This study was funded by Shire Development, LLC.
jP-14-033jAgomelatine vs. venlafaxine in major depression :
Focus on anhedonia and tolerability
G. Martinotti1, D. Tedeschi2, F. Fiori3, L. Janiri1, M. Di Giannantonio2.
1Psychiatry, Rome, Italy ; 2Rome, Italy ; 3Psychiatry, Chieti, Italy
Objective : In this study we compared the eﬀects of agomelatine
and venlafaxine XR on anhedonia in patients with Major Depressive
Disorder. Secondary endpoints were to test the overall clinical con-
dition as to the evaluator (CGI) and the safety proﬁle.
Methods : Sixty patients were enrolled and randomly assigned
to two diﬀerent treatments : agomelatine (25–50 mg/day ; N=30
subjects) or venlafaxine XR (75–150 mg/day, N=30 subjects).
Psychopathological assessment was performed at baseline and after
eight weeks of treatment with the Snaith Hamilton Rating Scale
(SHAPS), the Hamilton Depression Rating Scale (HAM-D), and the
Clinical Global Impression (CGI). Safety parameters were monitored
with ECG, urinalysis, haematological and clinical chemical analyses
of blood samples at the start and end of the study. Self-reported
adverse events provided a measure of safety and tolerability.
Results : Both groups showed a signiﬁcant reduction in time for
SHAPS and HAM-D scores, with higer reduction in the agomelatine
group for anhedonia scores. Only patients treated with agomelatine
showed a statistically signiﬁcant improvement in CGI scores.
Common adverse events occurred in 1 (3.2%) patient of the AGO
group and in 11 (39.2%) patients of the VLX group. Nausea and
vomiting (n=6), dizziness (n=2) and hypotension (n=3) were
the most common eﬀects across the VLX group. Confusion (n=1) was
the adverse event that led to patient withdrawal from the study in the
AGO group.
Conclusion : In this study, agomelatine showed signiﬁcantly
greater eﬃcacy on anhedonia and similar antidepressant eﬃcacy to
the SNRI venlafaxine XR in patients with Major Depressive Disorder.
The subjective evaluation of the treatment eﬃcacy was in favor of
agomelatine as to CGI. Agomelatine’s safety proﬁle compared
favourably with that of venlafaxine XR. Fewer patients withdrew
and there were fewer withdrawals due to adverse events in the ago-
melatine group. In particular, agomelatine treatment was associated
with lower incidence of nausea, vomiting and dizziness.
jP-14-034jPainful syndromes as signs of masked depression
J. Martinovic1, A. Miljatovic1. 1Clinical Centre Zvezdara, Belgrade,
Serbia
Objective : Purpose of this paper is to show how primary painful
syndromes, among them mostly cervical and lumbar, are often being
unrecognized as depression symptoms.
Methods : 50 patients, diagnosed with cervical and lumbar syn-
dromes have been followed. Age of these patients was between
35–55 years. Appropriate RTG diagnostics have been performed
on these patients, in order to ﬁnd the source to their pain. These
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diagnostics excluded existence of serious diseases, which could ex-
plain intensity of pain at these patients. Patients have been treated for
several months with analgesics and have undergone rehab treatment.
After that, patients have been appointed to psychiatric examination.
After appropriate psychiatric tests have been conducted (MADRS,
HAM-D scales), scores conﬁrmed diagnosis of depression at 34
patients.
Results : All 34 patients received drug therapy (antidepressants)
and psychotherapy. 23 patients showed after three months signiﬁcant
improvement that was visible through decreasing of depressive
symptoms and minimized score on MADRS and HAM-D scales.
Conclusion : Patients with symptoms of lumbar and cervical
syndrome achieved signiﬁcant improvement after receiving anti-
depressive treatment. When patient complains of pain in the cervical
and lumbar area, it should be taken into consideration that this can be
a symptom of depression.
jP-14-035jA possible involvement of pro-BDNF processing
enzymes in antidepressive eﬀects of
electroconvulsive seizure
T. Matsumoto1, M. Segawa1, S. Morinobu1, M. Fuchikami1,
S. Yamawaki1. 1Hiroshima University, Japan
Objective : Electroconvulsive therapy (ECT) is the most eﬀective
treatment for antidepressant-resistant depression, though the mol-
ecular mechanisms remain to be fully elucidated. It was previously
shown that electroconvulsive seizure (ECS) strongly increased mRNA
levels of brain-derived neurotrophic factor (BDNF) in the rat hippo-
campus (Nibuya et al., 1995). Although mature BDNF (mBDNF), that
is produced through intracellular processing of biosynthetic precursor
BDNF (pro-BDNF) in central nervous system neurons (Matsumoto
et al., 2008), is antidepressive, recent studies demonstrate that pro-
BDNF has negative eﬀects on neurons if secreted. Here, we hypo-
thesized that 1) robust transcription of BDNF induced by ECS led
to excess production of pro-BDNF, 2) certain levels of pro-BDNF
might be secreted without undergoing intracellular processing, and
therefore 3) expression of prohormone convertase 1 (PC1) and tissue-
plasminogen activator (t-PA), those are involved in intra- or extra-
cellular processing of pro-BDNF respectively, might be regulated
by ECS.
Methods : Male Sprague-Dawley rats (250–300 g) received ECS
treatment as reported (Nibuya et al., 1995). Hippocampal levels of
pro-BDNF and mBDNF were determined by immunoprecipitation/
Western Blotting. PC1 and t-PA levels were determined by Western
Blotting or zymography respectively.
Results : Hippocampal pro-BDNF increased within 2 hours after
single administration of ECS. More rapidly, single ECS increased the
levels of not only PC1 but also t-PA. Interestingly, both pro-BDNF and
t-PA were transported to synaptic terminals within 4 hours after
ECS, suggesting that t-PA is secreted together with pro-BDNF.
Repeated ECS for 10 days increased mBDNF strongly. Finally, chronic
treatment with tricyclic antidepressant imipramine slightly increased
mBDNF, however, without changes in the levels of pro-BDNF, PC1
and t-PA.
Conclusion : These results suggest that ECS-induced increase in
hippocampal mBDNF levels is supported by the robust induction of
BDNF transcription and eﬃcient pro-BDNF processing. Such strong
increase in mBDNF levels may be important for antidepressive eﬀects
of ECT.
jP-14-036jDysregulated HPA-axis in major depression due to
FKBP5 polymorphism
A. Menke1, T. Klengel1, M. Rex-Haﬀner1, M. Uhr1, F. Holsboer1,
E. Binder1. 1Max Planck Institute, Munich, Germany
Objective : The FK 506 binding protein 51 or FKBP5 has been
implicated in the regulation of the glucocorticoid receptor (GR)
sensitivity, especially in major depression and posttraumatic stress
disorder. Since the dysregulation of the hypothalamic-pituitary-
adrenal (HPA-) axis is one of the most robust biological ﬁndings
in major depression, we wanted to characterize GR sensitivity in
healthy volunteers and depressed patients in dependence of pre-
viously identiﬁed functional FKBP5 SNPs.
Methods : FKBP5 mRNA expression (baseline and following
in vivo GR-stimulation with 1.5 mg dexamethasone p.o.) was
analyzed together with plasma cortisol, ACTH, dexamethasone
levels and FKBP5 polymorphism rs1360780 in 72 depressed
patients and 88 healthy controls. To further evaluate the function
of the HPA-axis, we employed the combined dexamethasone/
corticotropin-releasing hormone (dex/CRH) test in a subgroup
(n=64/45).
Results :While there were no baseline diﬀerences in FKBP5 mRNA
expression, patients showed less induction of FKBP5 mRNA ex-
pression following dexamethasone stimulation (p=0.04). We also
observe a signiﬁcant interaction between disease status and FKBP5
risk allele carriers status (minor allele T), p=0.007. Patients carrying
the risk T allele, but not patients carring the CC genotype showed a
reduced induction of FKBP5 mRNA. Cortisol and ACTH suppression
following dexamethasone was also diﬀerentially regulated between
T allele and the CC carriers with a reduced suppression only in
depressed patients carrying the T allele. These results remained sig-
niﬁcant when correction for diﬀerences in blood dexamethasone
concentrations.
Conclusion :Only depressed patients carrying the FKBP5 rs1360780
risk allele show signiﬁcant GR resistance compared to healthy con-
trols, as measured by dexamethasone-induced FKBP5 mRNA induc-
tion and suppression of cortisol and ACTH. This ﬁnding might
explain why endocrine alterations are not observed in all depressed
patients.
jP-14-037jDelivery of electroconvulsive therapy in Canada
R. Milev1, C. Gosselin2. 1Queen´s University, Kingston, ON, Canada ;
2University of British Columbia, Vancouver, BC, Canada
Objective : Electroconvulsive Therapy (ECT) continues to be used
widely in Canada, but no account of current practices exists. The need
for nationwide data about current practices was one of the motivating
factors for the Canadian ECT Survey.
Methods : An association of clinicians for Canadian ECT Survey
(CANECTS/ECANEC) was created. After ﬁrst identifying all sites
in Canada where ECT was delivered, we subsequently developed a
detailed questionnaire (13 pages ; 76 questions in 11 sections), trans-
lated it into French, piloted it at fourteen sites and then sent a ﬁnal
version to all 175 ECT centres.
Results : Thus we were able to gather wide ranging information
pertaining to the practice of ECT in Canada, including the ECT ap-
paratus used, the parameters of the electrical stimuli used to induce
seizures, and stimulating electrode placements.
Conclusion : Our ﬁndings conﬁrm that the practice of ECT in
Canada is generally consistent with contemporary guidelines. Sine
wave stimulation is rarely employed, and three placements of the
stimulating electrodes are commonly used : bitemporal, bifrontal and
right unilateral. Some practical suggestions are recommended to
address a few speciﬁc concerns.
jP-14-038jVascular endothelial growth factor (VEGF) serum :
Putative predictive biomarkers for the
electroconvulsive therapy (ECT) in depressed
patients
A. Minelli1, E. Maﬃoletti2, R. Zanardini2, M. Abate3, M. Bortolomasi3,
M. Gennarelli1, L. Bocchio-Chiavetto2. 1University of Brescia, Italy ;
2Fatebenefratelli, Brescia, Italy ; 3Hospital Villa S Chiara, Verona, Italy
Objective : Despite controversial issues, electroconvulsive therapy
(ECT) remains one of the most eligible therapies among patients
with treatment resistant depression (TRD). The Vascular endothelial
growth factor (VEGF) is an angiogenic cytokine able to induce vaso-
permeability in many types of tissues, including the Blood Brain
Barrier. Our group have demonstrated that serum VEGF levels in
major depressive disorder (MDD) patients were unaﬀected by escita-
lopram and that TRD patients have higher serum levels of VEGF fol-
lowing ECT. In addition, a correlation between the increase in VEGF
expression and the amelioration of symptoms after ECT was ob-
served. On these bases, the aim of the study was to investigate if VEGF
serum levels before treatment might be predictive of ECT response in
TRD patients.
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Methods : Sixty-four DSM-IV TRD patients were enrolled in the
study. Patients were maintained on the same pharmacological treat-
ment for at least 3 weeks before ECT and during the entire study
period. Illness severity and the outcome of ECT treatment were as-
sessed using the Montgomery and Asberg Depression Rating Scale
(MADRS), before the treatment (T0), and one month later the end
of ECT (T1). The Pearson coeﬃcient was used to evaluate bivariate
correlations. T-test was used to evaluate diﬀerences of means.
Results : The ECT treatment reduced symptomatology as measured
with MADRS (p<0.0001), and 73.4% of the patients were considered
responders (non responder if percentage MADRS reduction at T1 was
<50%). VEGF serum levels at baseline correlate signiﬁcantly with the
percentage reduction of symptomatology after ECT (p=0.004) and
were signiﬁcantly lower in patients non responder at follow-up
(p=0.002).
Conclusion : Our results suggested that VEGF serum levels might
play a role in the mechanism of response to ECT in TRD patients. The
dosage of serum VEGF may be helpful to identify patients who might
have a signiﬁcant beneﬁt from ECT supporting physicians in choosing
the better approach to treat TRD.
jP-14-039j Investigation to eﬀectiveness of neurofeedback on
treatment major depressive disorder in patients’
client of Qods hospital
S. Mohamadzade1, S. Mohamadzade1. 1Young Researchers Center,
Sanandaj, Islamic Republic of Iran
Objective : 20 patients that have received MDD diagnosis by psy-
chiatrists of Qods hospital contributed in research. patients were
divided to experimental and control group. 10 patients in exper-
imental group and 10 patients in control group. Hamilton rating scale
for depression scale (HDRS) was ﬁlled as pre test (before neurofeed-
back sessions) and post test (after neurofeedback sessions). In follow
up session after 3 month HDSR was ﬁlled for both experimental and
control group.
Methods : Technician of neurofeedback done neurofeedback ses-
sions. Per patient in experimental group had received 12 sessions of
neurofeedback therapy. Both groups have received psychiatric drugs.
Cut oﬀ point for depression diagnosis was 13. Because of ethical as-
pects of research control group after research process have received 1
session nurofeedback.
Results : Results show that experimental group has more signiﬁcant
improvement than control group (p>0/01). Results show 53% of
diﬀerences relate to group membership.
Conclusion : Neurofeedback treatments for depression appear
very promising not only in bringing relief from depression, but in
modifying the underlying biological predisposition for becoming de-
pressed. Neurofeedback focuses on retraining the brain, for example,
reversing the frontal brainwave asymmetry, with the goal of produc-
ing an enduring change that does not require people to remain on
medication indeﬁnitely.
Policy of full disclosure : This article is a section of admitted
research proposal that have received ﬁnancial support of young
researchers islamic azad university sanandaj, sanandaj branch.
jP-14-040jPrognostic implications of somatic symptoms
in patients with depression. Results from a
three-month, prospective, observational study
from Asia
D. Novick1, W. Montgomery2, A. Brnabic3, J. Aguado4, Z. Kadziola5,
X. Peng6, R. Brugnoli7, J.M. Haro8. 1Eli Lilly, Windlesham, United
Kingdom ; 2Eli Lilly Australia, Pty Ltd, West Ryde, Australia, Sydney,
Australia ; 3Eli Lilly, Pty Ltd, West Ryde, Australia, Sydney, Australia ;
4Parc Sanitari Sant Joan de De´u, Cibersam, Barcelona, Spain ; 5Eli Lilly
GmbH, Vienna, Austria ; 6Eli Lilly and Company, Indianapolis, USA ;
7Universita` di Roma Sapienza, Italy ; 8Parc Sanitari Sant Joan de De´u,
CIBERSAM, Barcelona, Spain
Objective : Patients with major depressive disorder (MDD) frequently
suﬀer from concomitant somatic symptoms. This study aims to in-
vestigate the existence of a group of patients depending on the pres-
ence of somatic symptoms and to understand the impact of these
symptoms on the course of depression.
Methods : Nine hundred and nine patients from Asia presenting
with a new or ﬁrst episode of MDD (DSM-IV/ICD-10) were enrolled
in this 3-month prospective observational study. Depressive symp-
toms (Hamilton Depression Scale-HAMD-17 and Clinical Global
Severity score – CGI-S) and somatic symptoms (Somatic Symptom
Inventory) were assessed. A cluster analysis was used to deﬁne pa-
tient groups based on the presence of somatic symptoms.
Conﬁrmatory factor analysis was used to classify somatic symptoms
in diﬀerent groups. Regression models were employed to assess the
relevance of somatic symptoms on outcomes.
Results : A three cluster solution was chosen based on the variance
explained. Cluster 1 patients (39%) had a low level of somatic symp-
toms. Cluster 2 patients (53%) had a signiﬁcant level of somatic
symptoms. Cluster 3 patients (8%) had severe somatic symptoms.
Patients with more somatic symptoms at baseline had more severe
depression (HAMD17 and CGI-S) and lower response and remission
rates. Response rates were 82% in cluster 1, 72% in cluster 2 and 55%
in cluster 3. Remission rates were 68%, 55% and 29% respectively.
Four groups of symptoms were validated with the conﬁrmatory factor
analysis : as Pain, Autonomic Symptoms, Energy and CNS symptoms.
A regression model showed patients with pain symptoms had a
lower response (OR=0.65 ; 95% CI 0.53–0.80) and remission rates
(OR=0.61 ; 95% CI 0.49–0.74).
Conclusion : Somatic symptoms are frequent in Asian patients with
MDD. Patients with more somatic symptoms have higher depression
severity and lower response and remission rates. Pain symptoms are
most associated with poorer outcomes.
Policy of full disclosure : Diego Novick, William Montgomery,
Alan Brnabic, Zbigniew Kadziola and Xiaomei Peng are full time Eli
Lilly & Co. employess Jordan Bertsch was a statistical consultant for
the SOHO and EMBLEM studies. He was working with the Fundacio
Sant Joan de Deu under a contract with Eli Lilly & Co. Josep Maria
Haro has acted as a consultant, received grants, or acted as a speaker
in activities sponsored by the following companies : Astra-Zeneca,
Eli Lilly, Glaxo-Smith-Kline, and Lundbeck Roberto Brugnoli has ac-
ted as a consultant, received grants, or acted as a speaker in activities
sponsored by the following companies : BMS, Eli Lilly, Innovapharma
and Sigma-Tau.
jP-14-041jDNA methylation proﬁles of the brain-derived
neurotrophic factor (BDNF) gene as a potent
diagnostic biomarker in psychiatric disorders
S. Okada1, S. Morinobu2, M. Fuchikami3, Y. Okamoto2, S. Yamawaki2,
N. Ozaki4, T. Inoue5, I. Kusumi5, T. Koyama5, K. Tsuchiyama6,
T. Terao7. 1Hiroshima University, Japan, Hiroshima-Shi, Japan ;
2Hiroshima University, Japan, Japan ; 3Yale University, USA, New Haven,
USA ; 4Nagoya University, Japan ; 5Hokkaido University, Japan, Sapporo,
Japan ; 6Oita, Japan ; 7Oita University, Japan, Japan
Objective : Psychiatric disorders, for example major depression or
schizophrenia, are diagnosed on the basis of clinical symptoms in
patients. The search for speciﬁc biological markers is of great im-
portance to advance the method of diagnosis for psychiatric disorders.
We examined the methylation proﬁles of the CpG islands at the pro-
moter of exon I of the brain-derived neurotrophic factor (BDNF) gene,
which is well known to be involved in the pathophysiology of
depression.
Methods : We analyzed genomic DNA from peripheral blood of 38
Japanese patients with major depression and 40 patients with schizo-
phrenia and 18 healthy subjects to identify an appropriate epigenetic
biomarker to aid in the establishment of an objective system for the
diagnosis of psychiatric disorders. Methylation rates at each CpG
unit was measured using a MassArray1 system (SEQUENOM), and
2-dimensional hierarchical clustering analyses were undertaken to
determine the validity of these methylation proﬁles as a diagnostic
biomarker.
Results : Analyses of the dendrogram from methylation proﬁles of
the CpG islands at the promoter of exon I of BDNF, demonstrated that
the classiﬁcation of healthy subjects and patients at the ﬁrst branch
completely matched the clinical diagnosis. At the next branch, classi-
ﬁcation of depression and schizophrenia by methylation proﬁles
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Conclusion : Despite the small number of subjects, our results
indicate that the classiﬁcation based on the DNA methylation proﬁles
of the CpG islands of the BDNF gene may be a valuable diagnostic
biomarker for psychiatric disorders.
jP-14-042jPrediction of antidepressant drug response of
patients with major depression by citalopram serum
concentrations on day 7 and clinical improvement
on day 14
E. Ostad Haji1, A. Tadic1, A. Dragicevic1, M.J. Mu¨ller2, K. Boland3,
M.L. Rao3, G. Laux4, C. Hiemke1. 1University Hospital Mainz,
Germany ; 2Vitos Klinik Gieben, Germany ; 3University Hospital Bonn,
Germany ; 4 Innsalzch Klinikum, Wasserburg, Germany
Objective : Clinical trials have shown that early improvement on the
Hamilton depression rating (HAMD) scale and citalopram serum
concentrations on day 7 are required to attain appropriate clinical re-
sponse. The aim of this study was to calculate cut oﬀ levels for serum
concentrations of citalopram and clinical improvement during the
early phase of treatment to predict later response and to analyse
the predictive power of the combined marker.
Methods : Data of 55 inpatients with a major depressive disorder
(MDD) according to ICD-10 who received citalopram were submitted
to the analyses. Psychopathology was assessed by the 17-item HAMD
rating scale and in parallel serum concentrations of citalopram were
measured in weekly intervals for ﬁve weeks.
Results : Receiver Operating Characteristics (ROC) analysis re-
vealed for citalopram a serum concentration of 53 ng/ml on day 7 and
clinical improvement on the HAMD scale by at least 24% on day 14
to predict response on day 35. The serum concentration of citalopram
on day 7 and early improvement on day 14 taken together, predicted
response on week 5 with 73% sensitivity and 85% speciﬁcity.
Conclusion : Our results show that treatment with citalopram
should be guided by symptom rating on day 14 and serum concen-
tration measurement on day 7 to guide antidepressant drug treatment
and minimize the risk of treatment failure in patients suﬀering from
major depression.
jP-14-043jDopamine and adenosine antagonism have opposite
eﬀects on the activational and the directional
components of sucrose-motivated behavior : Studies
in rats and mice
M. Pardo1, L. Lopez-Cruz2, N. San Miguel2, M. Ibarra2,
J.D. Salamone3, M. Correa1. 1Castellon, Spain ; 2Universitat Jaume I,
Psychobiology Area, Castellon, Spain ; 3University of Connecticut,
Department of Psychology, Storrs, USA
Objective : Functional interactions between adenosine and dopamine
(DA) receptors play an integral part in the regulation of striatal areas,
including nucleus accumbens (Nacb). Mesolimbic DA is a key com-
ponent of the brain circuitry regulating motivated behaviors, and
Nacb DA regulates behavioral activation and eﬀort-related processes.
Caﬀeine and theophylline are minor psychostimulants that act
as nonselective adenosine receptor antagonists. While adenosine
antagonists increase motor activities, DA antagonists reduce them.
However, because studies in the literature argued for a reduction
in the hedonic value of sucrose after DA antagonism, the present
experiments were undertaken to study the impact of adenosine and
DA antagonism on the activational and directional components of
motivated behaviors using sucrose as the reinforcer.
Results :Male CD-1 mice with one-hour access per day to a solution
containing 10% sucrose in the home cage consumed signiﬁcant
amounts of sucrose. A low dose of the DA D2 antagonist haloperidol
did not block sucrose consumption. A2A KO mice however, con-
sumed less sucrose than WT animals. A stimulus associated with
sucrose presentation in the home cage stimulated exploratory activity
in a novel environment. A low dose of haloperidol blocked this con-
ditioned behavioral activation. On a FR7/free access choice pro-
cedure, Sprague-Dawley rats press the lever to obtain 5% sucrose
and drink low quantities of free 0.3% sucrose. Haloperidol decreased
lever pressing for 5% sucrose but increased free 0.3% sucrose intake,
thus inducing a shift in the choice towards a less eﬀortful behavior.
Caﬀeine reduced lever pressing but also free access sucrose
consumption. These pharmacological manipulations in rats drinking
in the home cage under free access conditions do not change pre-
ference for the high concentration and do not reduce total sucrose
intake.
Conclusion : These results may have implications for understand-
ing phenomena related to motivation and energy-related disorders
such as psychomotor slowing or anergia in depression.
jP-14-044jMeta-analysis on cognitive function of depressive
patients compared with healthy controls
J.E. Park1, C. Han2. 1Keyo Hospital, Uiwang, Republic of Korea ; 2Korea
University, Ansan, Republic of Korea
Objective : Depression is a neurodegenerative disorder related with
chronic elevated corticosteroid level and decreased hippocampal size.
Functional decline in the cognitive functions including memory,
attention, and concentration often related with easy forgetfulness,
mild cognitive impairment, and dementia. However, the results about
the relationship of cognitive function and depression are often con-
troversial. Authors performed meta-analysis about the diﬀerence of
cognitive function between depressive patients and control.
Methods : Reports of Randomized controlled trials (RCTs) of anti-
depressants from 2000, in which they measure cognitive domains
were searched from PubMed and Cochrane library. Search terms
were ; (‘depression’ OR ‘major depression’, OR ‘depressive illness’,
OR ‘major depressive disorder ’, OR ‘depressed’) AND (‘cognitive
function’ OR ‘cognition’ OR ‘cognitive’ OR ‘neuropsychological ’ OR
‘neuropsychology’). Values of cognitive functions (mean, standard
deviation, and number of subjects) were recorded and the eﬀect
sizes, 95% conﬁdence intervals of each study were calculated using
Comprehensive Meta-Analysis Version 2.0 (Biostat Inc., Englewood,
NJ, USA).
Results :Among 4,140 papers, 27 RCT papers were ﬁnally analyzed.
Conclusion : Depressive patients showed signiﬁcant lowered
performance in the subsets of Digit Span, CPT, TMT A, Digit Symbol,
Stroop test, WCST, verbal ﬂuency, verbal memory immediate. We
might use these subsets to compare the cognitive change of depressive
patients during their course of illness.
jP-14-045jEﬃcacy and safety of lisdexamfetamine dimesylate
as augmentation therapy in adults with major
depressive disorder treated with an antidepressant
M.H. Trivedi1, A.A. Patkar2, A.J. Cutler3, C. Richards4, R. Lasser4,
B. Geibel4, J. Gao4, A. Sambunaris5. 1University of Texas, Southwestern
Medical School, Dallas, USA ; 2Duke University Medical Center, Durham,
USA ; 3Florida Clinical Research Center, Bradenton, USA ; 4Shire
Development LLC, Wayne, USA ; 5Atlanta Institute of Medicine, &
Research, USA
Objective : Evaluate the eﬃcacy and safety of lisdexamfetamine di-
mesylate (LDX) augmentation of antidepressant monotherapy in
participants with major depressive disorder (MDD).
Methods : This randomized, double-blind, placebo-controlled trial
enrolled participants (18–55 y) with nonpsychotic MDD. After 8 weeks
of open-label escitalopram (week 1 : 10 mg/d ; 20 mg/d thereafter),
participants with residual symptoms (Hamilton Rating Scale for
Depression 17-item scoreo4) were randomized to 6 weeks of double-
blind LDX (20, 30, or 50 mg/d) or placebo augmentation. The primary
endpoint, mean change in Montgomery-Asberg Depression Rating
Scale (MADRS) total score from augmentation baseline to study end-
point, was analyzed by analysis of covariance (prespeciﬁed a=0.10)
in nonremitters (i.e., participants with augmentation baseline MADRS
total scor >10) who had o1 randomized study drug dose and o1
postrandomization MADRS assessment. Safety assessments included
treatment-emergent adverse events (TEAEs).
Results : Of 246 enrolled participants, 173 (placebo, 85 ; LDX, 88)
received double-blind treatment and 157 (placebo, 79 ; LDX, 78) com-
pleted the study. For the 129 nonremitters (placebo, 64 ; LDX, 65) re-
ceiving randomized treatment, mean¡SD MADRS total scores
decreased from augmentation baseline (placebo, 20.8¡6.42 ; LDX,
20.3¡7.16) to study endpoint (placebo, 15.9¡9.17 ; LDX, 13.3¡8.77)
the LS mean (90% CI) treatment diﬀerence signiﬁcantly favored LDX
(x2.3 [x4.5, x0.1] ; P=0.0902]). During double-blind treatment,
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49.4% of participants receiving placebo and 60.2% receiving LDX had
a TEAE ; 1 serious TEAE occurred in a participant receiving placebo.
TEAEs occurring ino5% of participants with placebo and LDX were
dry mouth (0%, 11.4%, respectively), headache (4.7%, 11.4%),
decreased appetite (2.4%, 6.8%), nasopharyngitis (3.5%, 5.7%), and
insomnia (7.1%, 4.5%).
Conclusion : LDX augmentation of escitalopram monotherapy
in participants with residual MDD symptoms met prespeciﬁed signal
detection parameters. Further studies are needed. The safety proﬁle of
LDX was consistent with prior literature.
Policy of full disclosure : Dr. Patkar is a consultant for Avanir
Pharma, Gilead, and Dey Pharma ; is on the speakers bureau and
received honoraria from Alkermes, Bristol-Myers Squibb, Dey
Pharma, Merck, Sunovion, and Pﬁzer ; has received grant support
from National Institutes of Health (NIDA, NIAAA), SAMHSA,
AstraZeneca, Bristol-Myers Squibb, Cephalon, Forest, J & J, Jazz
Pharmaceuticals, Lundbeck, Merck, Organon, Pﬁzer, Sunovion,
Shire and Titan. He is not a major stockholder in or employed by
pharmaceutical companies, nor has he received other material sup-
port from pharmaceutical companies. This study was funded by
Shire Development LLC.
jP-14-046jMemory deﬁcits produced by serotonin depletion in
rats are reversed by the multimodal antidepressant
Lu AA21004, but not escitalopram
A. Pehrson1, K. Gaarn du Jardin1, J. Bornø Jensen1, C. Sanchez1.
1Lundbeck Research USA, Paramus, USA
Objective : To compare the ability of escitalopram and the multimodal
antidepressant LuAA21004 to reverse serotonin (5HT) depletion-
induced memory deﬁcits in rats.
Methods : General design : 5HT was depleted in female rats by
administering the irreversible tryptophan hydroxylase inhibitor
4-chloro-DL-phenylalanine methyl ester HCl (PCPA ; 100 mg/kg/
day, sc, 4 days). Memory performance was assessed in novel object
recognition (NOR) and spontaneous alternation (SA) tasks after
acute vehicle or drug administration. Experiment 1 : PCPA-treated
females were administered vehicle or 1 mg/kg carbidopa+50 mg/kg
of the 5-HT precursor 5-hydroxytryptophan (5HTP). Experiment 2 :
PCPA-treated females were administered vehicle, 10 mg/kg
LuAA21004 or 0.5 mg/kg escitalopram (s.c.) and compared to PCPA-
naı¨ve rats. Experiment 3 : A dose-response curve was generated
by administering vehicle, 0.1, 3, or 10 mg/kg LuAA21004 to PCPA-
treated animals.
Results : Experiment 1 : PCPA impaired memory performance
in NOR (F(2,22)=9.6, p<0.01) and SA tasks (F(2,19)=10.8, p<0.001).
Restoring central 5HT levels with acute 5HTP normalized memory
performance. Experiment 2 : PCPA-treated females were impaired in
NOR (F(3,28)=13.7, p<0.0001) and SA performance (F(3,27)=19.2,
p<0.0001). Treatment with LuAA21004 improved PCPA-induced
memory deﬁcits, while escitalopram had no eﬀect despite similar
5HT transporter occupancies. Experiment 3 : LuAA21004 dose-
dependently improved memory compared to vehicle in PCPA-treated
rats in NOR (F(4,45)=6.5, p<0.001) and SA (F(4,47)=4.8, p<0.01).
Conclusion : The current study demonstrates that PCPA-induced
5HT depletion leads to robust memory deﬁcits as assessed by NOR
and SA. Treatment with the 5HT precursor 5HTP or LuAA21004, but
not escitalopram, normalized memory deﬁcits. These data imply that
targets other than the 5HT transporter mediate the eﬀects of
Lu AA21004. The clinical implications of these ﬁndings remain to be
investigated.
Policy of full disclosure : This research was funded byH. Lundbeck
A/S, and Takeda Pharmaceutical Company, Ltd. All authors are
Lundbeck employees.
jP-14-047jPlatelet serotonin re-uptake velocity predicts
anterior cingulate activity
L. Pezawas1, U. Rabl1, C. Scharinger1, L. Bartova1, W. Huf1, A. Meyer-
Lindenberg1, S. Kasper1, M. Willeit1, R. Lanzenberger1, E. Moser1,
H. Sittte1. 1Medizinische Universita¨t Wien, Austria
Objective : Anterior cingulate cortex (ACC) activity has been related
to emotion and social stress processing and alterations of ACC
function have been implicated in depression. Although the serotonin
transporter (5-HTT) rich subgenual portion of the ACC (sACC)
has been demonstrated to be under signiﬁcant genetic control of the
serotonin transporter gene (SLC6A4), it remains unknown today
whether transmembrane 5-HTT function mediates sACC activity
under physiological conditions in adult humans.
Methods : Eight healthy male subjects were included in our
[11C]DASB PET study, 48 healthy subjects were enrolled in our MRI
study. During a block design fMRI task subjects underwent an
emotion-inducing paradigm. Platelet solution (50 ml) was incubated
using a dilution technique with unlabeled 5-HT to reveal Vmax and
Km values.
Results : Here we show a linkage between maximal serotonin
uptake velocity (Vmax) using a in vitro model system of neural 5-HTT
function in blood platelets and neural activity of the sACC assessed by
functional magnetic resonance imaging, a region also showing maxi-
mal 5-HTT availability within the cingulate cortex with positron
emission tomography. We further report that genetic variation within
SLC6A4 cannot suﬃciently explain this linkage, which contributes to
the understanding of the complex gene-protein-function relationship
of 5-HTT.
Conclusion : Our ﬁndings expand the knowledge of neuronal
consequences of altered 5-HTT protein function by relating in vitro
measures of 5-HTT function to in vivo human brain activity for the
ﬁrst time. While genetic studies investigating the 5-HTT gene have
provided insights about developmental eﬀects on brain wiring and
consecutive functional changes, this study among others underscores
the importance to investigate protein function in order to untangle the
complex gene-protein-function relationship in the context of mental
illness.
jP-14-048jMetabolic syndrom and C-reactive protein in
patients with depression disorder on antidepressive
medication
I. Popovic1, V. Popovic1, N. Djokic1, A. Stanojevic1. 1Specialized
Psychiatric Hospital, Gornja Toponica Nis, Serbia
Objective : The aim of this study was to investigate is there any dif-
ference in CRP levels in patients with Recurrent depressive disorder,
treated with antidepressants medication, compared to health control
group of subjects and if there is an association between increased
CRP levels and the presence of MetS in these two groups.
Methods : Sixty subjects entered the study, the experimental group
of patients (diagnosis of recurrent depressive disorder) included 35
subjects (18 male, 17 female), average age 47.85¡7.35 years. Healthy
control group of subjects (n=25), age 42.08¡4.93 years. The Metabolic
syndrome was deﬁned according to NCEP ATP III criteria. The cut-oﬀ
point for elevated CRP was set at 5 mg/L.
Results : There was no statistically signiﬁcant diﬀerence in the
prevalence of MetS and CRP values between the studied groups. As
an independent variables, Age, Waist circumpherence and Total
cholesterol levels were signiﬁcantly diﬀerent in favor of the exper-
imental group. In addition, patients that fulﬁlled the NCEP ATP III
criteria for MetS showed signiﬁcant diﬀerence for its constituting
variables Central obesity and Arterial hypertension, in a favor of ex-
perimental group, too. Elevated CRP levels were associated with in-
creased risk for the development of MetS in depressed patients, while
both CRP values and BMI were signiﬁcant predictors of MetS for the
control group. Smoking habit was a considerable predictor for high
CRP values (<5 mg/L) for depressed patients. Depression symptom
severity (measured by HAMD score), length of illness, such as lenght
of the antidepressant drug treatment didn’t show signiﬃcant impact
on both the MetS and CRP values.
Conclusion : Both the CRP levels and Metabolic risk proﬁle
screening may be beneﬁcial in order to obtain better assessment for
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jP-14-049jWhite matter integrity in major depressive disorder :
A comparison between distinct stages of the illness
M.J. Portella1, P. Pires2, J. de Diego-Adelin˜o3, Y. Vives-Gilabert2,
B. Go´mez-Anson4, D. Puigdemont3, E. Alvarez3, V. Perez3.
1 IIB-Hospital Sant Pau, Barcelona, Spain ; 2Port d’Informacio´ Cientı´ﬁca,
Campus UAB, Ediﬁci D, Bellaterra, Spain ; 3 IIB-Hospital Sant Pau,
Psychiatry, Barcelona, Spain ; 4 IIB-Hospital Sant Pau, Neuroradiology,
Barcelona, Spain
Objective : To study the white matter (WM) integrity in patients with
major depressive disorder (MDD) recruited in diﬀerent illness stages
as compared to healthy subjects, by means of diﬀusion tensor imaging
(DTI). We hypothesized that WM disruptions of the neuronal circuits
underlying the pathophysiology of MDD can be even worsened in
those patients with higher past illness burden.
Methods : Magnetic resonance imaging protocol (3T scanner) and
diﬀusion tensor images were acquired from a sample of forty-seven
right-handed adult patients with MDD (DSM-IV criteria) : 14 patients
suﬀering a ﬁrst episode (score >14 on the Hamilton Rating Scale for
Depression ; HRSD) ; 15 patients with more than two previous epi-
sodes and currently remitted in the last six months (HRSD<8) ; and
18 patients with a chronic depressive episode (HRS>17) ; and from 17
healthy subjects, comparable for age and years of schooling. DTI
analyses were performed with the FMRIB Software Library, FSL
v4.1.4 to obtain maps of fractional anisotropy (FA, WM integrity
measure) by means of Tract-based Spatial Statistics Package (TBSS)
using a general linear model (family wise error correction).
Results : Voxel-wise whole brain results revealed a generalized
signiﬁcant reduction of FA in chronic patients compared to healthy
controls (FWE p<0.05) aﬀecting bilateral inferior fronto-occipital
fasciculus, bilateral inferior longitudinal fasciculus, bilateral superior
longitudinal fasciculus, forceps major and forceps minor, body of
corpus callosum and bilateral cingulum (Fig. 1). Diﬀerences (FWE
p<0.05) also appeared between treatment-resistant chronic and ﬁrst
episode patients, aﬀecting body of corpus callosum, right inferior
fronto-occipital fasciculus, bilateral superior longitudinal fasciculus,
forceps minor, forceps major, bilateral cingulum, and bilateral inferior
longitudinal fasciculus.
Conclusion : The results revealed that decrements of FA are ob-
servable in the most severe illness stages of MDD as compared to
healthy controls, but also as compared to the earlier stages of the ill-
ness. Therefore, higher past illness burden entails greater white matter
disruptions in patients suﬀering MDD.
jP-14-050jPrevalence of depression among type II diabetes
mellitus in primary family health care centers
A. Rady1, A. Khairy1, O. Akl1, G. Orfali1. 1Alexandria, Egypt
Objective :Diabetes is one of the major world health problems. Recent
estimates from the World Health Organization (WHO) predict that if
current trends continue, the number of people with diabetes will be
more than double from 176 to 370 million people by 2030. In Egypt,
the total number of persons with diagnosed and undiagnosed
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Diabetes is expected to increase more than double from 3.80 million to
8.80 million by the year 2025. compared with the prevalence of de-
pression among normal subjects.) These reports indicate tha>25% of
patients with diabetes reach clinical criteria for depression, a rate far
higher than in the general population. The comorbidity of diabetes
and depression is associated with adverse diabetic outcomes, com-
pared with nondepressed diabetic patients. This work aim at de-
termining the prevalence of depression among type II diabetic
patients attending family health centers in Alexandria.
Methods : A sample size of approximately 303 adult diabetic cases
of type II in the age category of (20–60) years old based on a preva-
lence of 27% of depression in diabetics, degree of precision of 5% and
conﬁdence level of 95%, will be randomly selected from the attendees
of the studied family health facilities. Two days of the week will be
selected randomly to visit the studied primary health care facilities till
the allocated sample size is reached. An interview questionnaire will
be designed for depression assessment by using the Hamilton
Depression Rating Scale (HAM-D) among type II diabetic patients.
Results : 40.18% (n=135) of diabetic patients in our study showed
moderate to severe depression, 12.2% (n=41) showed mild de-
pression while 47.62% (n=160) showed normal values on HAM-D
scale. Moderate to severe depression was present in 39.1% and 40.7%
in males and females respectively.
Conclusion : Awareness campaigns against depression for primary
health physician is a major public halth issue.
jP-14-051jWCST Performance in schizophrenia and psychotic
depression
A. Rady1, A. Elsheshai1, O. Elkholy1, H. Abou El Wafa1. 1Alexandria,
Egypt
Objective : Diﬀerentiating between schizophrenia and major de-
pression with psychotic features often reveals diagnostic dilemma.
Both share psychotic features and severe impairment in occupational
functions. Severe psychomotor retardation, not uncommon in psy-
chotic depression, may simulate negative symptoms of schizophrenia.
Our work aims at utilizing Wisconsin Card Sorting Test (WCST) per-
formance as a potential diﬀerentiating neurocognitive tool.
Methods : 60 patients were recruited randomly from the outpatient
service at Alexandria University Hospital : 30 patients with schizo-
phrenia and 30 patients with chronic psychotic depression. They
were subjected to Clinical Global Impression for Severity (CGI-S) scale
and Wisconsin Card Sorting Test (WCST) 128 card computerized
version.
Results : Both groups were balanced in terms of gender distri-
bution, severity and duration of illness. The study compared all
parameters of WCST. Only perseverative errors showed mild signiﬁ-
cant diﬀerence (P<0.05) that disappeared when applying Bonferroni
adaptation, setting signiﬁcance level at 0.01 instead of 0.05.
Conclusion : Performance on WCST is similar in schizophrenia and
severe depression with psychotic features in most of the measured
parameters, hence WCST could not serve as a supplementary tool
diﬀerentiating between both diagnoses in our study.
jP-14-052jEﬃcacy and tolerability of vilazodone in patients
with moderate, moderately severe, and severe
depression-pooled analyses from 2 phase III trials
D. Robinson1, W. Song2, A. Ruth3, J. Edwards4. 1Worldwide Drug
Development, Burlington, USA ; 2Forest Research Institute, Jersey City,
USA ; 3Prescott Medical, Communications Group, Chicago, USA ; 4Forest
Research Institute, New Jersey, USA
Objective : Vilazodone, a serotonin reuptake inhibitor and 5-HT1A
receptor partial agonist, is approved for treatment of major depressive
disorder (MDD) in adults. Post hoc analyses of the Phase III trials
(NCT00285376, NCT00683592), both of which were positive, eval-
uated eﬃcacy and tolerability across baseline depression severity.
Methods :Data from 2, double-blind, 8-week, randomized, placebo-
controlled trials were pooled. Patients (18–70 years) with DSM-IV-TR-
deﬁned MDD and HAMD17 o22 were included ; trials comprised a
1-week screening and 8-week double-blind treatment. Vilazodone
was titrated to 40-mg (taken once daily with food) over a 2-week
ﬁxed-dose titration period. Primary eﬃcacy outcome : MADRS total
score change from baseline to Week 8 using an analysis of covariance
model based on the Intent-to-Treat [ITT] Population and last obser-
vation carried forward approach. Severity of baseline depression for
subgroup analyses was deﬁned by MADRS threshold scores : moder-
ate (MADR<30), moderately severe (30fMADR<35), and severe
(MADRSo35).
Results : Baseline depression severity was moderate in 31%
(placebo=143 ; vilazodone=130), moderately severe in 49%
(placebo=205 ; vilazodone=220), and severe in 20% (placebo=85 ;
vilazodone=86) of patients (Safety Population). Least squares mean
diﬀerence (LSMD) inMADRS total score change from baseline toweek
8 was signiﬁcantly greater for vilazodone versus placebo in each de-
pression subgroup : moderate (LSMD=x2.9 ; P=0.0056), moderately
severe (LSMD=x2.3 ; P=0.0314), and severe (LSMD=x4.1 ;
P=0.017) (ITT Population). Response rates (o50% MADRS im-
provement) for vilazodone and placebo were 41% versus 31% in the
moderate (P=0.0810), 41% versus 29% in the moderately severe
(P=0.0130) and 44% versus 26% in the severe depression (P=0.0124)
subgroups. Adverse event proﬁles were similar across severity
subgroups.
Conclusion : Vilazodone treatment versus placebo signiﬁcantly
improved MADRS scores in patients with moderate, moderately se-
vere, and severe depression with no obvious trend across severity of
illness ; treatment eﬀects (>2 point MADRS change from baseline)
were clinically signiﬁcant, with eﬃcacy and tolerability similar among
depression severity subgroups.
Policy of full disclosure : Supported by funding from Forest
Laboratories, Inc.
jP-14-053jElectroconvulsive stimulation alters levels of
BDNF-related microRNAs
K. Ryan1, S. O’Donovan2, D. McLoughlin2. 1Rm. 4.42, Dublin, Ireland ;
2Trinity College, Institute of Neuroscience, Dublin 2, Ireland
Objective : Electroconvulsive therapy (ECT) is one of the most eﬀec-
tive treatments for severe depression but its mechanism of action is
not yet fully understood. Electroconvulsive stimulation (ECS), an an-
imal model of ECT, is known to increase levels of the neurotrophin
brain derived neurotrophic factor (BDNF) within the brain, though
the precise means by which this occurs and how it contributes to the
antidepressant eﬀects of ECS are unknown. One possibility is that
such eﬀects involve a recently identiﬁed class of endogenous, small
RNA species termed microRNAs (miRNAs) since evidence suggests
that BDNF can both regulate and be regulated by miRNAs. We
therefore investigated the eﬀects the expression of BDNF-related
miRNA species in rat brain and blood following treatment with ECS.
Methods :Male Sprague-Dawley rats were randomised into groups
to receive either ‘‘sham’’ or ‘‘real ’’ ECS. ECS was administered either
acutely (r1) or chronically (r10) following a protocol which mimics
that of clinical ECT (100 pulses/s ; 0.5 ms ; 0.7 s ; 75 mA ; thrice weekly).
Total RNA was extracted from dentate gyrus, hippocampus, frontal
cortex, cerebellum and whole blood samples and TaqMan1 RT-PCR
was performed using stem-loop primers for BDNF-related miRNAs.
Results : Of the miRNAs examined, miR-212 levels were found to
be signiﬁcantly increased in dentate gyrus following both acute
(p<0.01) and chronic (p<0.05) ECS. miR-212 levels were also in-
creased in blood following chronic ECS. Notably, a positive corre-
lation was observed between miR-212 levels in dentate gyrus and in
blood (Pearson’s r=0.61, p<0.001).
Conclusion : Alterations in miRNA expression may be informative
about the mechanism of action of ECS/ECT and in turn may give
insight into the neurobiology of depression. Furthermore, examin-
ation of miRNAs in blood from severely depressed patients under-
going treatment with ECT will ascertain their potential to act as
clinical biomarkers for the treatment of depression.
jP-14-054j Impact of family history on drug placebo separation
in RCTS : Site rater and computer outcomes
G. Sachs1, D. DeBonis1. 1Bracket Global, Wayne, USA
Objective : High placebo response often hampers signal detection in
randomised clinical trials. We used data from 4 recent failed studies to
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Methods : We examined outcomes from 4 failed double blind
studies with 4 placebo groups and 7 active treatment groups that
collected outcomes independently from site-based raters (SBR) and
computer (Comp). Comparison groups were constructed based on
subject report of family history of mood disorder (FamHx) collected
by the computer. The studies were all powered to detect a drug-
placebo diﬀerence (Signal) of 3–4 points on the primary outcome
measure (change from baseline MADRS or HAMD). A priori, for
these exploratory analyses FamHx was deﬁned as Impactful if the
diﬀerence in signal for FamHx(x) vs. FamHx(+) was o1 (o25% of
the estimated eﬀect size).
Results : FamHx was impactful in all trials for all 7 comparisons
based on both SBR and Comp outcomes. A trend favouring active
treatment over placebo was found in all FamHx(+) subgroups. The
diﬀerence in signal detection for FamHx(+) vs. FamHx(x) sub-
groups was large ranging in magnitude from 1.9–13.4 for SBR and
5.7–13.1 for the Comp ratings. A contrary trend favouring placebo
over active treatment was found in 6 of the 7 FamHx(x) subgroups. In
three of the four trials examined the drug-placebo diﬀerence for
FamHx(+) reached statistical signiﬁcance based on MADRS-COMP
or HAMD-COMP. but not MADRS-SBR or HAMD-SBR.
Conclusion : The high rates of placebo response observed in sub-
jects reporting no family history of mood disorder likely contributed
to the failure of the clinical trials in this report. If this ﬁnding is re-
plicated further study is needed to clarify the correlates of the FHx(x)
subject status associated with high placebo response (e.g. diagnostic
validity or enrolment rate).
Policy of full disclosure :Dr. Sachs and Mr. DeBonis are employees
of Bracket Global.
jP-14-055jNeural correlates of remission in major depressive
disorder
C. Scharinger1, B. Hartinger1, K. Diers2, U. Rabl1, L. Bartova1, H. Sitte1,
C. Windischberger1, E. Moser1, B. Brocke2, S. Kasper1, L. Pezawas1.
1Medical University of Vienna, Austria ; 2Dresden University of
Technology, Germany
Objective :While overwhelming evidence points to alterations within
emotional brain circuitries including the amgydala and the subgenual
anterior cingulate cortex (sACC) in patients with concurrent major
depressive episodes and under antidepressant treatment, neural me-
chanisms underlying stable remission are largely unknown. Hence,
we aimed to investigate the neural dynamics between the amygdala
and sACC in remitted and untreated Major Depressive Disorder
(MDD) patients and healthy controls.
Methods :Within amulti-center, cross-sectional magnetic resonance
imaging study functional and structural local as well as brain systems
level measures of the amygdala-sACC circuitry have been compared
between thirty-eight adult, drug-free remitted MDD (rMDD) patients
and 38 healthy controls without any psychiatric life-time diagnosis.
Subjects underwent a functional block-design matching paradigm
comprising emotional stimuli, angry/fearful faces or fearful/threat-
ening scenes derived from the International Aﬀective Picture System
(IAPS). Based on our straight-forward a priori hypothesis, functional
and structural local (BOLD, gray matter volume) as well as brain sys-
tems level measures (functional connectivity, structural covariance)
have been analyzed restricted to the amygdalae and the cingulate
cortex using AFNI, SPM8 and the DARTEL extension of SPM8.
Results : Decreased amygdala (right : t=x3.83 ; left : t=x3.13) and
sACC (bilateral : t=x2.02) activation during conscious perception of
unpleasant visual stimuli was found in rMDD patients in comparison
to healthy controls. No structural diﬀerences could be found in both
structures between groups. On a brain systems level, rMDD patients
exhibited increased functional (t=3.03) and structural connectivity
(t=3.84) between the amygdala and sACC compared to controls. In
rMDD patients, functional coupling between amygdala and sACC
was related to means of illness duration (P=0.021).
Conclusion : This study demonstrates functional and morpho-
metric diﬀerences within the amygdala-sACC circuitry between drug-
free rMDD patients and healthy controls. Our ﬁndings suggest that
remission of MDD cannot simply be interpreted as a disease-free
condition from a neurobiological perspective.
jP-14-056jCharacteristics of the single event related [Oxy-Hb]
changes in patients with depressive disorder
Y. Shoji1, K. Morita2, H. Yanagimoto1, R. Fujiki1, Y. Ishii1,
N. Uchimura1. 1Kurume University, Kurume, Fukuoka, Japan ; 2Kurume
University, CMRIBD, Kurume, Fukuoka, Japan
Objective : The aim of this study was to examine characteristic of
single event related Oxy-hemoglobin (Oxy-Hb) changes in patients
with depressive disorder measured by multi-channel near-infrared
spectroscopy (NIRS) during word generation task, Japanese
‘Shiritori ’.
Methods : 26 patients with depression and 32 age and gender mat-
ched healthy subjects participated in the study. All the patients were
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right-handed and native Japanese speakers. Diagnosis of depression
was made for ICD-10 by two experienced psychiatrist. In all patients
psychiatric symptoms were evaluated using HAM-D (15.9¡5.3).
The ethical committee of the Kurume University approved this study.
All subjects gave written informed consent after a complete ex-
planation of the study. The 44-multi-channel NIRS machine (ETG-
4000, Hitachi) measures relative changes of [Oxy-Hb] and [deoxy-Hb].
The present study has segregated speciﬁc regions (ROI) in the pre-
frontal cortex associated with executive function (left 11Ch and
right 12Ch). As word generation tasks, standard shiritori, vertebrae
shirotori and word ﬂuency were used in this study. The cognitive
activation task induced a 12-s pre-task baseline and a single gener-
ation task of letter or word projected by TV monitor. The pre-tasks
and tasks were performed repeatedly 20 times and the data was
analyzed using average wave form.
Results : The changes of [Oxy-Hb] in patients with depressive
disorder were signiﬁcantly smaller than that of healthy subject during
all word generation task. In both left 11Ch and right 12Ch (ROI), the
changes of Oxy-Hb concentration in patients with depressive disorder
were smaller than that of healthy subjects during vertebrae shiritori
task, but there was not signiﬁcantly diﬀerence between two groups
during word ﬂuency task.
Conclusion : These data suggested that the examination using word
generation task measured by multi-channel NIRS were useful for a
psycho-physiological index of patient with major depressive disorder.
jP-14-057jMedication taking behavior and its correlates in
patients with comorbidity of depression and type 2
diabetes
Z. Stankovic1, M. Jasovic-Gasic2, M. Zamaklar3. 1Clinic for Psychiatry,
Belgrade, Serbia ; 2Clinic for Psychiatry, Faculty of Medicine, Belgrade,
Serbia ; 3 Institute for Endocrinology, Faculty of Medicine, Belgrade, Serbia
Objective : The objective of this study was to examine the diﬀerences
between depressed and non-depressed patients with diagnosis of
type 2 diabetes (T2DM) in sociodemographic, clinical characteristics,
metabolic control and medication taking behavior as well as corre-
lation between medication taking behavior and other examined
variables.
Methods : A group of depressed diabetic patients comprising those
with major depressive episode, ﬁrst or repeated (ICD-10) and endo-
crinologist-diagnosed T2DM, duration o5 years on oral, insulin
therapy or both (N=35) and non-depressed ones (N=32) (67 in total)
of both genders (<65 years) were included in this cross-sectional
study. The Mini international neuropsychiatric interview (MINI) were
used to establish diagnosis. The Beck Depression Inventory (BDI ; cut
oﬀ o16) for self-assessment of depression severity, The Medical
Adherence Questionnaire (MAQ) for self-assessment of medication
taking behavior and The Problem Areas in Diabetes (PAID) for self-
assessment of diabetes distress were also used. We performed
laboratory and non-laboratory measures to assess metabolic control
and the presence of metabolic syndrome. The exclusion criteria were
determined.
Results : Signiﬁcantly higher frequency of psychiatric heredity
and neuropathy in depressed diabetic patients in comparison to
non-depressed ones were found. Depressed diabetic patients had
signiﬁcantly higher MAQ (Mann-Whitney U test) and PAID score
(Student’s t test) in relation to non-depressed ones. MAQ score
signiﬁcantly positively correlated with PAID score and number of
metabolic components in depressed diabetic patients. In non-
depressed diabetic patients signiﬁcantly positive correlation between
MAQ score and frequency of patients on oral hypoglycemic therapy
and coronary artery diseases were found (Pearson’s Correlation).
Conclusion : Depressed diabetic patients had signiﬁcantly higher
frequency of diabetic neurological complications, signiﬁcantly
more problematic medication taking behavior and signiﬁcantly higher
level of diabetes distress in comparison with non-depressed ones.
Suboptimal medication adherence was signiﬁcantly associated with
elevated diabetes distress and metabolic risk in depressed diabetic
patients.
jP-14-058jSevere depression is associated with increased
microglial quinolinic acid in subregions of the
anterior cingulate gyrus : Evidence for an immune-
modulated glutamatergic neurotransmission?
J. Steiner1, M. Walter1, T. Gos1, H.-G. Bernstein1, K. Schiltz1,
L. Meyerzu Schwabedissen1, B. Bogerts1, A.-M. Myint2. 1University of
Magdeburg, Germany ; 2University of Munich, Germany
Objective : Immune dysfunction, including monocytosis and
increased blood levels of interleukin-1, interleukin-6 and tumour
necrosis factor a has been observed during acute episodes of major
depression. These peripheral immune processes may be accompanied
by microglial activation in subregions of the anterior cingulate
cortex where depression-associated alterations of glutamatergic neu-
rotransmission have been described.
Methods : Microglial immunoreactivity of the N-methyl-D-aspar-
tate (NMDA) glutamate receptor agonist quinolinic acid (QUIN) in
the subgenual anterior cingulate cortex (sACC), anterior midcingulate
cortex (aMCC) and pregenual anterior cingulate cortex (pACC) of 12
acutely depressed suicidal patients (major depressive disorder/MDD,
n=7 ; bipolar disorder/BD, n=5) was analyzed using immuno-
histochemistry and compared with its expression in 10 healthy control
subjects.
Results :Depressed patients had a signiﬁcantly increased density of
QUIN-positive cells in the sACC (P=0.003) and the aMCC (P=0.015)
compared to controls. In contrast, counts of QUIN-positive cells in the
pACC did not diﬀer between the groups (P=0.558). Post-hoc tests
showed that signiﬁcant ﬁndings were attributed to MDD and were
absent in BD.
Conclusion : These results add a novel link to the immune
hypothesis of depression by providing evidence for an upregulation
of microglial QUIN in brain regions known to be responsive to in-
fusion of NMDA antagonists such as ketamine. Further work in this
area could lead to a greater understanding of the pathophysiology of
depressive disorders and pave the way for novel NMDA receptor
therapies or immune-modulating strategies.
jP-14-059jThe association between sunshine duration and
paroxetine response time in patients with major
depressive disorder
T. Tomita1, N. Yasui-Furukori1, T. Nakagami2, A. Kaneda1,
S. Kaneko1. 1Hirosaki University, Hirosaki-Shi, Japan ; 2Hirosaki
University, Odate City General Hospital, Hirosaki-Shi, Japan
Objective : A recent study indicates that the serotonin transporter
function varies with the duration of monthly sunshine. This ﬁnding
may suggest that the eﬃcacy of serotonin selective reuptake inhibitors
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(SSRIs) is associated with the duration of monthly sunshine, but
information on this possible association is lacking.
Methods :Ninety-one Japanese subjects with depression completed
a 6-week treatment with paroxetine. Clinical evaluation was per-
formed using the Montgomery and Asberg Depression Rating Scale
(MADRS) before treatment and after 1, 2, 4 and 6 weeks of treatment.
Data on the duration of monthly sunshine were obtained from
the meteorological agency website. We divided the patients into
four groups : nonresponders (NRs), later responders (LRs), early
responders (ERs) and ultra-early responders (UERs).
Results : The responses to paroxetine treatment of the group that
began treatment in fall and winter and of the group that began treat-
ment in spring and summer did not diﬀer signiﬁcantly. The eﬀect of
the duration of monthly sunshine on paroxetine response time did not
diﬀer signiﬁcantly among the four groups, whereas the change in the
duration of monthly sunshine had a signiﬁcant eﬀect on paroxetine
response time.
Conclusion : The change in the duration of monthly sunshine is
associated with paroxetine response time.
jP-14-060jResistant depression in elderly
E.R. Valdivia Baza´n1, C.A. Harkous Pen˜a2, C. Bonilla Reyes2,
P. Sopelana Rodriguez2. 1Hospital Universitario Princip., Alcala´ de
Henares, Madrid, Spain ; 2HUPA, Alcala´ de Henares, Madrid, Spain
Objective : Knowing the most eﬀective therapeutic strategy used in
Brief Hospitalization Unit (UHB) for elderly patients with depression
who just entering after several treatments in the period between 2005
and 2010.
Methods : We performed a descriptive study using data based on
medical records of patients over 65 years with a diagnosis of de-
pression for those who have used therapeutic alternatives are not ef-
fective should be ﬁnally hospitalized in University Hospital Prince
UHBdeAsturias deAlcala´ deHenares (Madrid).We use the variables :
gender, age, socio-demographic data, previous antidepressant treat-
ments, comorbidities, length of stay, type of therapeutic strategy used.
Results :We have found that treatment strategies are used ECT and
augmentation with atypical antipsychotics.
Conclusion :We have found that treatment strategies are used ECT
and augmentation with atypical antipsychotics.
jP-14-061jBDNF, NTF3, NTF4 and GDNF neurotrophic factors
serum levels in drug-naı¨ve ﬁrst episode depression
during 8-weeks of treatment with sertraline or
venlafaxine
M. Skibinska1, A. Leszczynska-Rodziewicz1, J. Pawlak1, B. Budzinski2,
D. Zaremba2, J. Hauser1. 1University of Medical Sciences, Dept. of Adult
Psychiatry, Poznan, Poland ; 2University of Medical Sciences, Poznan,
Poland
Objective : Neurotrophic factors signalling disturbances have been
implicated in the etiopathogenesis of mood disorders. Antidepressant
treatment has been shown to inﬂuence neurotrophic factor expression
in diﬀerent brain areas. The aim of this study was to analyze
Brain-Derived Neurotrophic Factor (BDNF), Neurotrophin 3 (NTF3),
Neurotrophin 4 (NTF4) and Glial-Derived Neurotrohpic Factor
(GDNF) serum protein levels in ﬁrst-episode drug-naı¨ve depressed
women during 8-weeks treatment with sertraline or venlafaxine.
Correlations with clinical variables have been performed.
Methods : 30 drug-naı¨ve ﬁrst-episode women (mean age 38 years,
SD 10.5) with depression episode were recruited. Diagnosis was made
according to DSM IV criteria using Structured Clinical Interview for
DSM-IV SCID. Severity of depression was evaluated using 17-item
Hamilton Depression Rating Scale (HDRS) at the beginning of anti-
depressant therapy and after 8 weeks of treatment. Patients were
administered with sertraline (n=16) or venlafaxine (n=14). Control
group consisted of 30 healthy, age-matched women. BDNF, NTF3,
NTF4 and GDNF serum levels were measured using ELISA method.
Results : We have found lack of diﬀerences between BDNF, NTF3,
NTF4 and GDNF serum levels in ﬁrst-episode drug-naı¨ve women
compared to the control group. There were no changes in BDNF,
NTF3, NTF4 and GDNF serum levels during 8-week treatment with
sertraline or venlafaxine. No correlation have been found between
BDNF, NTF3, NTF4 and GDNF serum levels and depression severity
measured with Hamilton Depression Rating Scale as well as, age,
BMI, smoking status, family history of mental illness, psychosocial
stressor prior to onset and suicidal ideations. We have observed
strong positive correlation in NTF3, NTF4 and GDNF serum protein
levels in the studied group.
Conclusion : In our study we did not ﬁnd diﬀerences in serum
BDNF, NTF3, NTF4 and GDNF levels in ﬁrst-episode drug-naı¨ve de-
pressed women during treatment nor correlations with clinical vari-
ables. Limitation of the study was relatively small sample size.
Policy of full disclosure : This work was supported by Polish
Ministry of Science and Higher Education grant no NN402243635.
jP-14-062jPharmacological management of aﬀective symptoms
after primary hepatic tumor surgery
D. Vasile1, O. Vasiliu1, A.G. Mangalagiu1, A. Nanca1. 1Military
Emergency Hospital, Bucharest, Romania
Objective : Patients diagnosed with primary hepatic tumors could
develop aﬀective pathology, either during the evolution of the onco-
logic disease, or as a result of therapeutic interventions (radiotherapy,
surgery, chemotherapy). There are several factors involved in the pa-
tophysiology of aﬀective disorders in patients diagnosed with hepatic
tumors : psychological factors- due to the acknowledge of the diag-
nosis and prognosis, somatic factors- the side events of chemotherapy
and radiotherapy, the eﬀects of the tumor per se.
Methods : We selected a group of 18 patients who had surgery
for various stages of primary hepatic malignancies, diagnosed with
depressive episodes through DSM IV TR criteria in the ﬁrst month
post-intervention. These patients were evaluated using Hamilton
Depression Rating Scale (HAMD), Global Assessment of Functioning
(GAF) and Clinical Global Impressions – Severity and Improvement
(CGI-S/I) at baseline and every 4 weeks for 3 months. Patients re-
ceived psychopharmacological treatment with escitalopram (ﬂexible
daily dose 10–20 mg, n=10) or tianeptine (ﬂexible daily dose
25–37.5 mg, n=8). Intent-to-treat analysis and last observation carried
forward method were applied in this study.
Results : Patients responded well to the therapy, as the ﬁnal HAMD
(x16.2, p<0.01) and GAF (+22.3, p<0.01) scores reﬂected, with no
signiﬁcant inter-group diﬀerence (p=0.23). The CGI score improved
with 2.4 points at week 12 (p<0.01). Patients tolerated well both
drugs, with a similar rate of mild and moderate adverse events (6 re-
ports in the escitalopram group and 4 in the tianeptine group). No
drop out due to adverse events was recorded.
Conclusion : The treatment of post-surgery depression in oncologic
patients with primary hepatic tumors with escitalopram or tianeptine
eis associated with a high rate of response, while the tolerability of
both drugs was satisfactory.
jP-14-063jMagnesium deﬁciency induces anxiety- and
depression-like behavior and metabolic dysfunction
in C57Bl/6J mice
G. Winther1, T. Wang Nielsen2, G. Wegener3. 1Aarhus University,
Risskov, Denmark ; 2Aarhus University, Center for Bioscience, A˚rhus C,
Denmark ; 3Aarhus University, Center for Psychiatric Research, Risskov,
Denmark
Objective : There are indications that balance of magnesium (Mg) ions
may regulate mood. Magnesium deﬁciency is also linked with altered
glucose metabolism and an inﬂammatory response in the gut. In ad-
dition, mood disorders have been linked to a dysfunctional metab-
olism. In this study we investigated the involvement of Mg in
regulating depression- and anxiety-like behaviour and metabolism,
by using mice that have been deprived of dietary Mg and studying
several behavioral and metabolic markers.
Methods : We examined the behavioral eﬀects of Mg deﬁciency
(deprival of dietary Mg for 6 weeks) in mice through depression-
and anxiety phenotyping experiments, namely the forced swim test
and light-dark box respectively. We determined the behavioural
eﬀects 30 minutes after treatment with imipramine (20 mg . kg-1),
diazepam (2 mg . kg-1) and ketamine (3 mg . kg-1). The glucose toler-
ance test was used to assess metabolic function in Mg deﬁcient mice.
Results : We found that, compared to control (n=10), mice receiv-
ing Mg deﬁcient diet (n=10) (10% RDA), were more immobile in the
forced swim test (p<0.01), which suggested depression-like behavior
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which was signiﬁcantly attenuated by imipramine and ketamine
(p<0.0001 and p<0.001 respectively). Mg deﬁcient mice also dis-
played anxiety-like behavior in the light-dark box (p<0.01) compared
to control, although diazepam did not signiﬁcantly reverse this be-
haviour. The glucose tolerance test showed an elevation in glucose
response after 30 minutes in Mg-deﬁcient mice compared to the con-
trols (p<0.05).
Conclusion : Insuﬃcient dietary Mg may contribute to depressive
and/or anxiety symptoms, as well as metabolic dysfunction. This data
warrant further investigation into whether supplementation with Mg
may relieve these disorders.
jP-14-064jEﬀects of subanesthetic doses ketamine on the
serotonergic neuronal system in conscious
monkey brain
S. Yamamoto1, H. Ohba1, S. Nishiyama1, N. Harada1, T. Kakiuchi1,
E.F. Domino2, H. Tsukada1. 1Hamamatsu Photonics KK, Japan ;
2University of Michigan, USA
Objective : The antidepressant eﬀects of subanesthetic doses of keta-
mine, a noncompetitive N-methyl-D-aspartate (NMDA) glutamate
receptor antagonist, are well known. The serotonin transporter is a
target protein for many antidepressants. Hence, the aim of present
study was to determine the eﬀects of subanesthetic doses of ketamine
on serotonergic activity in the conscious monkey brain.
Methods : The brains of three young adult monkeys were scanned
using [11C]DASB for the serotonin transporter (SERT) and [18F]MPPF
for the serotonin 1A receptor (5-HT1AR). Ketamine hydrochloride
in doses of 0.5 and 1.5 mg/kg or vehicle was infused intravenously
over 40 min. PET scans were taken after the end of ketamine infusion.
Heart rate and blood pressure were monitored throughout the study.
Arterial blood sampling was conducted during the PET scan. Time-
activity curves (TAC) of metabolite-corrected arterial plasma were
used as the arterial input function. Logan plot analysis for each TAC
and each brain region was used for calculation of [11C]DASB and
[18F]MPPF binding to SERT and 5-HT1AR, respectively.
Results : No signiﬁcant changes in heart rate and blood pressure
were observed with either dose of ketamine. Furthermore, ketamine
infusion did not induce any substantial change in the plasma levels
and metabolism of each radioligand. With ketamine infusion, the
binding of [11C]DASB to SERT was reduced in a dose dependent
manner. The binding of [18F]MPPF to 5-HT1AR tended to reduce
compared with the control vehicle.
Conclusion : The present results from this conscious monkey PET
study suggest that one of the mechanisms for the antidepressant eﬃ-
cacy of subanesthetic doses of ketamine is via modulation of the brain
serotonergic neuronal system.
jP-14-065jComparison the eﬃcacy between paroxetine and
sertraline augmented with aripiprazole in patients
with refractory major depressive disorder
R. Yoshimura1, T. Kishi2, H. Hori3, A. Ikenouchi-Sugita3, W. Umene-
Nakano3, A. Katsuki3, K. Hayashi3, K. Atake1, N. Iwata4,
J. Nakamura1. 1Kitakyushu, Japan ; 2Fujita Health University, Toyoake,
Japan ; 3UOEH, Kitakyushu, Japan ; 4Toyoake, Japan
Objective : Only two-thirds of depressive patients respond to anti-
depressant treatment. Recently, addition of an atypical antipsychotic
drug to ongoing treatment with an antidepressant has been considered
eﬀective and well-tolerated. We have previously reported that the
augmentation of SSRI or SNRI therapy with an atypical antipsychotic
drug was eﬀective and well tolerated refractory depressed patients,
and its response is 42% (Yoshimura et al., 2010). In the present study,
we compared the eﬃcacy between paroxetine and sertraline aug-
mented with aripiprazole in patients with refractory major depression.
Methods : Twenty-four patients who met the DSM-IV criteria
for major depressive disorder who did not at least two diﬀerent classes
of antidepressants were enrolled in the study. Nine were male and 13
were female, and their ages ranged from 26 to 64 (mean¡SD=39¡17)
years. Patients were randomly prescribed paroxetine (n=11) or ser-
traline (n=13) for 4 weeks. The doses [mean¡SD] of paroxetine and
sertraline were 33¡8 mg/day and 88¡16 mg/day, respectively. The
dose of aripiprazole [mean¡SD] was 11¡7 mg/day. Paired t-test and
simple regression analysis were used for statistical analysis. The study
was approved by the Ethical Committee of the UOEH.
Results : Two patients with paroxetine group were dropped out
because of its side eﬀects. Those who their scores of 17-item of
Hamilton Rating Scale for Depression (HAMD17) decreased below
50% were added aripiprazole for 4 weeks after aripiprazole aug-
mentation. Reduction rates in paroxetine or sertraline at week 4 were
36.7% and 37.3%, respectively. No diﬀerence however was found
in HAMD17 scores between paroxetine plus aripiprazole group and
sertraline plus aripiprazole group.
Conclusion : Aripiprazole addition to paroxetine or sertraline is
both eﬀective and well tolerated in refractory depressed patients.
jP-14-066jEnhanced perception of negative emotion in
depression : A preliminary study
S. Youn1, Y. Choi2, Y.-W. Shin2. 1Asan Medical Center, Seoul, Republic
of Korea ; 2Asan Medical Center, University of Ulsan, Seoul, Republic
of Korea
Objective : It has been hypothesized that biases in the processing
of emotional stimuli may play an important role in interpersonal
diﬃculties in patients with depression. A good interpersonal re-
lationship requires capacity of context-based emotional processing.
However, previous studies investigating emotion perception in
patients with depression were mostly focused on perceiving facial or
bodily expressions without social context. In the present study, we
used movie scenes to examine context-based emotional processing
of patients with depression.
Methods : A set of movie clips lasting 10 to 20 seconds with various
emotional situations was presented to a total of 33 participants,
grouped by depression (N=7) or healthy non-psychiatric individuals
(N=16). The participants were asked to rate 5-point Likert scale,
ranging from 0 (never expressed) to 5 (very highly expressed), on
11 kinds of emotions including happy, love, humor, sympathy,
sorrow, fear, embarrassment, anxiety, anger, hatred, and greed.
The symptom severity of depression was measured by PHQ-9. The
degree of perception in each kind of emotion was compared between
two groups using independent samples t-test.
Results :While there was no group diﬀerence for positive emotions,
the patients with depression showed enhanced perception extensively
for negative emotions including fear (p<0.01), anxiety (p<0.05),
anger (p<0.05) and hatred (p=0.07) to the negative emotional scene.
Conclusion : The ﬁndings suggest that negatively biased emotional
processing is a salient feature, which can explain interpersonal
diﬃculties in depression.
P-15. Animal Models
jP-15-001jMorphological studies on the distribution and
expression of neuropeptide S and its receptor after
REM sleep deprivation in rat
C. Adori1, S. Barde1, S. Vas2, Z. To´th2, D. Pap2, G. Bagdy2,
R. Reinscheid3, T. Ho¨kfelt1. 1Karolinska Institute, Stockholm, Sweden ;
2Semmelweis University, Budapest, Hungary ; 3University of California,
Irvine, USA
Objective : The recently described 20 amino acid neuropeptide S (NPS)
is involved in the modulation of arousal. Here we describe a detailed
anatomical mapping of NPS expressing neurons in the rat brainstem,
examining the expression of NPS and NPSR1 after a 72-hour REM-
sleep deprivation and a subsequent 3-hour rebound sleep.
Methods : We applied the single platform-on-water (ﬂower pot)
method. NPS and NPSR1 expression was detected by quantitative in
situ hybridization. The NPS immunoreactivity (IR) was visualized by
immunohistochemistry and quantiﬁed by densitometry.
Results : The highest expression of NPS was found in the peri-
coerulear region and in a cell cluster close to the Ko¨lliker-Fuse nucleus
(KF cluster). A moderate expression level was detected in the lateral
parabrachial nucleus (LPN) and in occasional neurons in the medial
parabrachial nucleus and around the fourth ventricle. The NPS ex-
pression was signiﬁcantly increased in the peri-coerulear cluster but
not in the LPN or KF clusters after the deprivation. There was no such
signiﬁcant increase in the large pot (stress control) animals. The
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expression level in the peri-coerulear cluster returned close to control
levels after the 3-hour rebound sleep. The NPS IR ﬁber density was
signiﬁcantly decreased after the sleep deprivation in the preoptic
region of the hypothalamus. The expression of NPSR1 did not alter
signiﬁcantly in the preoptic region or in the rhomboid thalamic
nucleus.
Conclusion : Our results suggest a diﬀerential response of NPS
expressing neuron clusters after sleep deprivation and emphasize the
role of the peri-coerulear cluster in the modulation of arousal. This
modulation is, however, not associated with changes of NPSR1 ex-
pression. The decreased NPS ﬁber density suggests extensive release
of NPS in the preoptic region after sleep deprivation. As this is a sleep
promoting region, the release of NPS during the forced wakefulness
raises the possibility that NPS facilitates the arousal by an inhibitory
action here.
jP-15-002jModulation of biogenic amines, substance p and
neurotrophic factor produces chronic muscular pain
and tactile allodynia accompanied by depression-a
putative animal model of pain-depression dyad
V. Arora1, A. Kuhad1, K. Chopra1. 1Panjab University, Chandigarh,
India
Objective : The present study was designed to investigate the eﬀect of
para-chlorophenylalanine (PCPA) on modulation of biogenic amines,
Substance P and nerve growth factor on the pain-depression dyad to
establish a new rodent model and support the possibility of a re-
lationship and speciﬁcally address the neurogenic mechanism that
might be involved in this syndrome.
Methods : Pain and depression was induced by the intrperitoneal
administration of PCPA (350 mg/kg). The eﬀects of diﬀerent doses
of duloxetine (3–30 mg/kg ; p.o.), pregabalin (3–30 mg/kg ; p.o.)
and diclofenac (1–10 mg/kg ; p.o.) treatment was evaluated for beha-
vioural (pain and depression), neurochemical (dopamine, nor-
epinephrine, and 5-hydroxytryptamine) and molecular alterations
(Substance P and nerve growth factor) induced by PCPA.
Results : Administration of PCPA (350 mg/kg) led to a signiﬁcant
decrease in nociceptive threshold as evident from reduced paw
withdrawal threshold in Randall Sellitto and von-Frey hair test as
well as marked increase in immobility time in forced swim test.
This behavioural deﬁcit was integrated with decrease in biogenic
amines (dopamine, norepinephrine, and 5-hydroxytryptamine)
along with increased Substance P and nerve growth factor levels in
both brain and serum of the PCPA administered rats. Pregabalin and
duloxetine ameliorated the behavioural deﬁcits associated with pain
and depression by restoring behavioural, neurochemical and mol-
ecular alterations against PCPA-induced pain—depression dyad
in rats.
Conclusion : The validity of the use of this PCPA model is demon-
strated from three diﬀerent aspects, i.e., face validity (manifestation
of chronic pain and depression), construct validity (dysfunction of
biogenic amine Substance P and nerve growth factor-mediated CNS
pain control is involved), and predictive validity (similar responses to
treatments used in pain and depression).
jP-15-003jSubstance P1–7-amide – a peptide-derived molecule
with potential eﬀects on chronic pain and opioid
withdrawal
A. Carlsson1, Q. Zhou1, R. Fransson1, A. Sandstro¨m1, M. Hallberg1,
F. Nyberg1. 1Uppsala University, Sweden
Objective : The neuroactive peptide substance P (SP) is well
recognized for its critical role in the regulation of many processes in
the central nervous system. SP has received particular interest for its
involvement in pain processing and the development of opioid toler-
ance and dependence. Following neurokinin NK-1 receptor activation
SP is degraded into several fragments, some of which retain biological
activity. One of its major bioactive metabolites, the N-terminal frag-
ment SP1–7, is known to counteract several eﬀects of SP. For instance,
the heptapaptide opposes the SP-induced enhancement of pain
transmission and expression of opioid withdrawal. In order to ﬁnd
suitable drugs capable of relieving pain and attenuate opioid with-
drawal we have synthesized several analogues of SP1–7. One of these,
the SP1–7 amide, that exhibits higher aﬃnity for the SP1–7 speciﬁc
binding sites compared to the native heptapeptide, was investi-
gated for its eﬀects on chronic pain and opioid withdrawal using
experimental animal models.
Methods : Hypersensitivity to thermal stimuli was investigated
in streptozotocin (STZ)-induced diabetic mice. The expression of
naloxone-induced opioid withdrawal was evaluated using morphine-
tolerant rats.
Results : The results showed that the SP1–7 amide profoundly
alleviates signs of thermal hyperalgesia when injected intrathecally in
mice with STZ-induced diabetes. In addition, intracerebroventicular
administration of the amidated heptapeptide prior to naloxone ad-
ministration in rats reduced withdrawal signs in a dose-dependent
manner. In both cases the eﬀects surpassed those seen for native SP1–7.
Conclusion : To conclude, we have synthesized an analogue to the
bioactive N-terminal SP fragment SP1–7 that signiﬁcantly and more
potently than the native compound attenuates the expression of
opioid withdrawal and hyperalgesia in rodents through a mechanism
that does not involve any neurokinin or opioid receptor. This ﬁnding
opens for new possibilities to design and develop non-opioid and per-
haps also non-peptide mimetics as potential drugs for the treatment
of chronic pain and opioid dependence.
jP-15-004jStressful experience during peri-adolescent period
induces depression-like phenotype in adult mouse
V. Carola1, F. Visco Comandini2, S. Puglisi-Allegra3. 1EMBL, Mouse
Biology Programme, Santa Lucia Foundation, Rome, Italy ; 2Dept. of
Physiology and Pharmacology, Rome, Italy ; 3Dept. of Psychology,
University La Sapienza of Rome, Italy
Objective : Psychologists have long supposed that early life trauma
can increase risk for psychiatric disorders. The observation that dur-
ing early development individuals are susceptible to adverse en-
vironmental inﬂuences is conﬁrmed by mouse studies. During mouse
postnatal development, the third week (peri-adolescent age) re-
presents a critical stage for the maturation of several brain functions.
Moreover during this week it is possible to observe high levels of
forebrain synaptogenesis. In terms of behavioral development the ﬁrst
rudimentary elements of social play are observable during this week.
In spite of the relevance of this developmental period, there are no
studies investigating if exposure to stressful experience during this
week can induce long term changes on mouse behavior and brain
functionality.
Methods : We exposed mouse pups to an adverse experience, con-
sisting in social isolation in novel environment for 25 minutes per day
from postnatal day 14 to 21. These mice were tested in the Social
Interaction Test (SIT), Forced Swimming Test (FST), and Sucrose
Preference Test (SPT) in adulthood.
Results : Stressed mice showed a depression-like phenotype char-
acterized by increased social avoidance in SIT, behavioral despair in
FST, and absence of sucrose preference in SPT. Moreover inspired
by the hypothesis that environment has long term consequences on
behavior, acting through changes at level of epigenetic mechanisms in
the brain, we tried to protect the mouse pups from developing the
pathological phenotype injecting them with drugs acting on these
mechanisms. This pharmacological treatment was partially able to
rescue the depression-like phenotype observed.
Conclusion : Our ﬁndings conﬁrm that the peri-adolescent age is
a critical period for the development of adult mouse behavior and
exposure to stressful experiences during this period promotes de-
pression-like phenotype in adulthood through modiﬁcation of the
epigenetic machinery in the brain.
jP-15-005jMitochondria plasticity of the hippocampus in a
genetic rat depression model after antidepressant
treatment
F. Chen1, G. Wegener2, T. Madsen3, J.R. Nyengaard4. 1Aarhus
University, Risskov /Aarhus, Denmark ; 2Aarhus University, Centre for
Psych. Research, Denmark ; 3H. Lundbeck A/S, International Clinical Res.,
Valby, Denmark ; 4Aarhus University, Stereology and EM laboratory,
Denmark
Objective : A large body of data suggests that mitochondria may play
an important role in the pathophysiology of depressive disorders and
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eﬀects of antidepressant therapy. Here, we investigated whether
chronic antidepressant treatment of rats induced changes of the
mitochondrial number in hippocampus.
Methods : For this report, the eﬀects of the tricyclic antidepressant
imipramine were tested in two strains of rats ; the Sprague – Dawley
and the other strain from the Flinders sensitive line, which has been
bred to a phenotype with certain ‘‘depressive-like’’ phenotype.
Design-based stereological methods were used to estimate the num-
ber and the volume of mitochondria of mitochondria in CA1 stratum
radiatum (CA1SR) of the hippocampus.
Results : The results showed that the number of mitochondria in
CA1SR was signiﬁcantly smaller in the FSL saline group compared to
the FRL saline group. However, the mean volume of mitochondria
was signiﬁcantly larger in the FSL saline group compared to the FRL
saline group. Following treatment, the FSL imipramine group showed
a signiﬁcant increase in the number of mitochondria compared to the
FSL saline group. But treatment with imipramine did not induce sig-
niﬁcant diﬀerences in the number of CA1 mitochondria between the
SD saline group and SD imipramine group.
Conclusion : In conclusion, our results support the mitochondria
plasticity hypothesis that depressive disorders and the pharma-
cological treatment thereof may be related to impairments of
mitochondria plasticity in the hippocampus and that antidepressant
treatment may counteract the structural impairments.
jP-15-006jbCCT as well as ﬂumazenil prevent the diazepam
withdrawal-induced anxiety in the elevated plus
maze in rats
J. Divljakovic1, T. Timic1, M. Milinkovic1, B. Batinic1, M. Van Linn2,
J. Cook2, M. Savic1. 1Faculty of Pharmacy, Belgrade, Serbia ; 2University
of Wisconsin, Milwaukee, USA
Objective : Despite a half century of clinical use and the recognized
potential of benzodiazepine dependence, the mechanisms under-
lying benzodiazepine withdrawal remain insuﬃciently understood.
The aim of the present study was to assess the inﬂuence of the non-
selective antagonist (ﬂumazenil) and the preferential a1-subunit
selective antagonist (bCCt) on the anxiety level after diazepam with-
drawal.
Methods : The male Wistar rats were protractedly treated during
21 days with diazepam (2 mg/kg) or solvent. On the testing day,
24 hours after the last injection, animals from the diazepam-treated
groups received either antagonist (ﬂumazenil or bCCt) or solvent, and
animals from the solvent-treated groups received solvent or diaze-
pam. Twenty minutes after administration of treatment on the testing
day, single animals were placed in the elevated plus maze in order to
assess the level of anxiety.
Results : Two-way ANOVA revealed that animals withdrawn from
diazepam spent signiﬁcantly less time on the open arms than control
animals (p=0.023). One-way ANOVA, followed by post hoc test, re-
vealed that administration of ﬂumazenil (10 mg/kg) or bCCt (1.25,
5 or 20 mg/kg) reversed the diazepam withdrawal-induced anxiety
(percentage of open arm time : p=0.003, p=0.032, p=0.031 and
p=0.014 compared to the diazepam-withdrawn group, respectively).
Concomitant administration of antagonists (10 mg/kg ﬂumazenil,
or 1.25, 5 or 20 mg/kg bCCt) induced an anxiolytic eﬀect comparable
to that observed after acutely administrated diazepam (percentage of
open arm time : p=0.142, p=0.187, p=0.243 and p=0.290, respect-
ively).
Conclusion : The present study demonstrated that administration
of the a1-selective antagonist bCCt or non-selective antagonist
ﬂumazenil could prevent the withdrawal-induced anxiety and also
induce an anxiolytic-like eﬀect. Moreover, presented results have
suggested that mechanism of preventing the withdrawal-induced
anxiety involves the antagonism at a1-containing GABAA receptors.
jP-15-007jEﬀects of novel dopaminergic derivates on
depression-like behavior : A pilot study
J. Fedotova. Institute of Physiology, RASci, St. Petersburg, Russia
Objective : Recent evidences suggest that the dysfunction of the cen-
tral dopaminergic pathways may be a critical component of the
neurobiological basis of depression. The eﬀects of novel dopaminergic
substances, 3,4-dimethoxyphenylethylamine derivates, on exper-
imental model of depression were studied in male rats after acute or
chronic administration in comparison to those of the classical anti-
depressant, clomipramine.
Methods : The novel DA derivates, PK-2111, PK-2122, PK-2123, PK-
2126 (0,1, 1,0, 10,0 mg/kg, i.p.) and clomipramine (50.0 mg/kg) were
injected acutely (1 h prior to behavioral testing) or chronically (for 21
days, the last injection being made 1 h prior to behavioral testing) in
animals subjected to the forced swimming test (FST) and the loco-
motor activity test.
Results : In dose of 0.1 mg/kg PK-2122 exerted depressant-like
eﬀect, while in doses of 1.0 or 10.0 mg/kg PK-2122 exerted anti-
depressant-like eﬀect as compared with the control group. Chronic
treatment with PK-2123 or PK-2122 (0.1, 1.0 or 10.0 mg/kg) produced
antidepressant-like eﬀect which was signiﬁcant as compared with
control group and group treated with clomipramine. Also, chronic
treatment of PK-2122 in high dose of 10.0 mg/kg induces anti-
depressant-like eﬀect as compared with the control group, and this
eﬀect was less eﬀective than it in a doses of 0.1 and 1.0 mg/kg.
Conclusion : These results suggest that PK-2126 independently
from dose and PK-2122 in the middle and high doses may be eﬀective
in experimental model of depression in rats when administered
acutely, PK-2111, PK-2122 or PK-2123 may be eﬀective in experimen-
tal model of depression in rats when administered repeatedly.
jP-15-008jThe role of the 5-HT1A receptor in the murine
5-HT-syndrome
H. Fink1, R. Haberzettl1, B. Bert1, J. Brosda1. 1 Inst. PharmTox, Berlin,
Germany
Objective : In humans the incidence of the serotonin (5-HT)-syndrome
has increased over the last decade, likely due to a higher prescription
rate of serotonergic drugs. The 5-HT-syndrome can be evoked by
serotonergic drugs in high doses. It is characterized by severe auto-
nomic, neuromuscular and mental symptoms. It is also possible to
elicit a 5-HT-syndrome in mice, which has been linked to the occur-
rence of the Straub tail response. We revealed in male NMRI mice ﬁve
core responses that reliably occur and dose-dependently increase in
frequency and intensity after the treatment with ﬂuoxetine, 5-HTP,
and tranylcypromine as well as their combinations. Here, we in-
vestigated which signs of the 5-HT-syndrome are mediated by the 5-
HT1A-receptor.
Methods : We administered a full 5-HT1A-receptor agonist, 8-OH-
DPAT, and a partial 5-HT1A-receptor agonist, buspirone, in increas-
ing doses to male NMRI mice and assessed the occurrence and in-
tensity of 15 behavioral and physiological responses including body
temperature.
Results : Both agonists produced all ﬁve core responses (hindlimb
abduction, low body posture, tremor, piloerection, decrease of rear-
ing). Exclusively the 8-OH-DPAT induced the Straub tail, which was
not evoked by buspirone and any other tested serotonergic agonist.
Conclusion : 5-HT1A-receptor activation elicits the core responses
of the murine 5-HT-syndrome. However, the Straub tail response was
only provoked by the full agonist. Based on the presynaptic 5-HT1A-
receptor reserve and the higher intrinsic activity of the full agonist, the
Straub tail response seems to be associated to postsynaptic 5-HT1A-
receptor activation. Therefore, the Straub tail response is not a par-
ameter for describing the 5-HT-syndrome in mice.
jP-15-009jDiﬀerent contributions of nucleus accumbens
subregions to probabilistic reversal learning
S. Floresco1, G. Dalton1, C. Eades1, A. Phillips1. 1University of British
Columbia, Vancouver, Canada
Objective : Impairments in positive reinforcement mechanisms and
behavioural ﬂexibility are core features of clinical depression.
Cognitive deﬁcits associated with depression have been demonstrated
using a probabilistic decision-making task. Disruption in nucleus ac-
cumbens (NAc) functioning has been linked to motivational and
cognitive abnormalities associated with the disorder. Studies in ani-
mals have revealed dissociable roles for NAc subregions in diﬀerent
aspects of behavioural ﬂexibility. Interestingly, lesions in these
brain regions do not impair ﬂexible responding on simpler (ie : non-
probabilistic) reversals. However, contribution to more complex
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forms of cognitive ﬂexibility remains unexplored. Here, we in-
vestigated the contribution of the NAc core and shell to probabilistic
reversal learning, using an operant task developed for rats.
Methods :Over daily sessions of 200 discrete-choice trials, rats were
required to press one of two levers for food reward. One lever initially
designated ‘correct ’, delivered reward 80% of the time, and the other
‘ incorrect ’ lever delivered reinforcement on only 20% of trials. After
8 consecutive ‘correct ’ responses, reinforcement contingencies were
reversed, and this pattern continued throughout the daily session.
Aftery10 days of training, rats received counterbalanced microinfu-
sions of saline or GABA A/B agonists muscimol/baclofen into the
NAc core or shell on separate test days.
Results : Inactivation of the shell markedly impaired probabilistic
reversal performance, reducing the number of reversals completed
and increasing errors. These eﬀects were accompanied by a selective
decrease in win-stay strategy, indicating a reduced sensitivity to posi-
tive reinforcement. In contrast, inactivation of NAc core did not impair
reversal learning, but did increase the number of incomplete trials.
Conclusion : These results indicate that the NAc shell, but not
core, plays a key role in facilitating reward sensitivity and cognitive
ﬂexibility in situations of reward uncertainty. Furthermore, they raise
the possibility that impaired cognitive ﬂexibility associated with de-
pression may be due in part to abnormal function in the ventral
striatum.
jP-15-010jGrowth hormone treatment improves spatial
memory in rats
A. Gro¨nbladh1, J. Johansson2, F. Nyberg2, M. Hallberg2. 1Uppsala
University, Sweden ; 2Uppsala University, Pharmaceutical Biosciences,
Sweden
Objective : Growth hormone (GH) is a polypeptide with a wide range
of functions in the periphery and also in the brain. Replacement
therapy with recombinant human GH (rhGH) has been demonstrated
to alleviate cognitive deﬁciencies and improve memory in patients
with growth hormone deﬁciency. Furthermore, GH has been sug-
gested to be involved in neuroprotection and neuroregeneration and
has recently been shown to counteract opioid-induced apoptosis in
hippocampal cells. Anabolic androgenic steroids (AAS) have been
demonstrated to aﬀect several peripheral organs and also several
CNS-related behaviors such as aggression, anxiety, depression and
cognitive functions. In the present study, we investigated the eﬀects of
GH on rats treated with nandrolone decanoate.
Methods : Male Wistar rats received the steroid (15 mg/kg) or
peanut oil every third day for three weeks and were subsequently
treated with rhGH (1.0 IU/kg) or saline for ten consecutive days.
During the GH/saline treatment spatial learning and memory were
tested in the Morris water maze (MWM), where the rats had ﬁve
training days with four swims each day. Two days after the last
training session a probe trial was performed.
Results : The results demonstrated a signiﬁcant impact of GH on
spatial memory. In general, the behavior of the AAS animals was
unaﬀected by GH treatment suggesting that the underlying mechan-
isms does not seem to be directly coupled to the GH signaling system.
Both GH and AAS demonstrated important eﬀects on body weight
gain and GH was able to counteract the reduction of weight gain
induced by AAS.
Conclusion : To conclude, GH improved performance in the MWM,
suggesting an important impact of GH on memory functions.
jP-15-011jEﬀects of gastrodia elata blume on spatial memory
and choline acetyltransferase and
acetylcholinesterase levels in a rat model of
alzheimer’s disease
H. Guang-Biao1, T. Zhao1, S. Shrestha Muna1, Y.-C. Chung1. 1Chonbuk
National University, Jeonju, Republic of Korea
Objective : Gastrodia elata Blume (GEB) is a herb used in traditional
Chinese medicine to treat dizziness, paralysis, and epilepsy. Here, we
investigated the eﬀects of GEB on spatial memory in a rat model of
Alzheimer’s disease (AD) and on choline acetyltransferase (ChAT)
expression and acetylcholinesterase (AChE) activity in several regions
of the model rat brain.
Methods : A rat AD model was established by bilateral injection of
amyloid-beta peptide (Ab25 35) into the hippocampus. The ADmodel
rats were subsequently treated daily either with 0.5% cellulose (Ab25
35/cellulose group), with 500 mg/kg GEB (Ab25 35/GEB500 group),
or with 1000 mg/kg GEB (Ab25 35/GEB1000 group). Vehicle rats
received vehicle injections followed by daily treatment with 0.5%
cellulose. After 6 weeks, spatial memory was assessed using the
Morris water maze test, and ChAT expression and AChE activity
in the prefrontal cortex, medial septum, and hippocampus were
measured using Western blotting and a commercial AChE assay kit,
respectively.
Results : In the probe trial, signiﬁcant diﬀerences between the Ab25
35/cellulose group and the vehicle, Ab25 35/GEB500, and Ab25 35/
GEB1000 groups were observed in terms of both time spent and dis-
tance traveled in the target quadrant. The Ab25 35/cellulose rats also
had signiﬁcantly lower ChAT protein levels in the hippocampus and
higher AChE activity levels in the prefrontal cortex, medial septum,
and hippocampus than the other rats.
Conclusion : Intrahippocampal injection of Ab25 35 peptide im-
pairs spatial reference memory and has detrimental eﬀects on ChAT
expression and AChE activity in the brain. The long-term adminis-
tration of GEB acts to reverse these eﬀects, suggesting that it has
potential as a treatment for AD.
jP-15-012jThe impact of acute administration of escitalopram
on freezing behaviour in two diﬀerent strains of rats
S.M. Hagsa¨ter1, R. Pettersson1, J. Na¨slund1, E. Eriksson1. 1Gothenburg,
Sweden
Objective : Acute administration of selective serotonin reuptake in-
hibitors (SSRIs) may cause anxiety in susceptible subjects. Freezing
behaviour is a well-established measure of fear/anxiety in animal re-
search. In the current study, freezing was used in two diﬀerent
rat strains to assess the eﬀect of acute administration of an SSRI,
escitalopram, in a contextual conditioning model.
Methods : Wistar and Sprague-Dawley rats were investigated un-
der similar conditions. In both experiments, half of the rats received a
series of electric foot-shocks (‘‘ foot-shock’’) in the experimental
chamber the day before freezing was scored, whereas half of them
only habituated to the chamber (‘‘non foot-shock’’). These groups
were subsequently divided to receive escitalopram (10 mg/kg) or
vehicle. All animals received s.c. injections one hour before testing in
the experimental chamber. Freezing was scored during habituation
(ﬁrst 5 minutes in chamber) and in the presence of an aversive
stimulus (25 ms noise bursts, 30 sec interval).
Results : Non foot-shock group : In rats never exposed to foot-
shock, a signiﬁcant increase in freezing behaviour during habituation
(ﬁrst 5 minutes) was observed for the animals injected with escitalo-
pram compared to those treated with vehicle regardless of strain. This
eﬀect was however more pronounced in Sprague-Dawley rats. No
signiﬁcant eﬀect of the drug was obtained during the presence of the
aversive stimulus. Foot-shock group : Among rats exposed to foot-
shock the previous day, escitalopram did not enhance freezing during
the ﬁrst 5 min of habituation in any of the two strains. However,
a signiﬁcant increase in freezing behaviour was observed during the
presence of noise bursts (5–20 minutes) in Wistar rats only.
Conclusion : The results imply that acute administration of escita-
lopram causes an increase in freezing behaviour that tentatively may
correspond to the anxiogenic eﬀect of this substance in humans. The
eﬀect appears to be both context- and strain-dependent.
jP-15-013jPituitary adenylate cyclase-activating polypeptide
(PACAP) plays signiﬁcant roles in mental function
and neuronal development
A. Hayata1, K. Seiriki2, M. Tajiri2, K. Ogata2, N. Shintani2, A. Baba3,
H. Hashimoto4. 1Osaka University, United Grad. Sch. of Child Dev,
Japan ; 2Osaka University, Grad. Sch. of Pharmaceut. Sci., Japan ; 3Hyogo
Univ. of Health Sci., Sch. of Pharmacy, Japan ; 4Osaka University, Lab. of
Mol. Neuropharmacol., Japan
Objective : PACAP is a multifunctional neuropeptide acting as a
neurotransmitter and neuromodulator. Previously, we demonstrated
that PACAP-deﬁcient (PACAP-/-) mice display notable psychomotor
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abnormalities, most of which were reversed by atypical antipsychotic
drugs, and that PACAP gene SNPs were associated with schizo-
phrenia. These results suggest that PACAP might be a risk factor for
psychiatric disorders including schizophrenia, however, a pathogenic
pathway involving PACAP signaling remains unknown. Recent evi-
dence implicates abnormal spine morphology in the pathogenesis
of psychiatric disorders. In this study, we therefore examined if
PACAP-/- mice have such an abnormality. In addition, since sero-
tonin (5-HT)7 receptors have been implicated in psychiatric disorders
and as a promising novel target of antipsychotic drugs, we also ex-
amined if a similar feature of 5-HT7 antagonism is observed in
PACAP-/- mice to address predictive validity of the mutants as a
model for psychiatric disorders.
Methods : After Golgi staining, dendritic spine morphology was
analyzed in hippocampal CA1 neurons in PACAP-/- and wild-type
littermate mice. The number of postsynaptic density protein (PSD)-95-
immunolabeled synaptic puncta was determined in primary cultured
hippocampal neurons from both genotypes. For behavioral analyses,
mice were subjected to an open ﬁeld test, the Porsolt forced swimming
test, and a Y-maze working memory task.
Results : Golgi staining of hippocampal CA1 neurons revealed
dendritic spines are morphologically immature in PACAP-/- mice.
In primary cultured neurons from the mutant mice, the volume of
PSD-95-labeled synaptic puncta was decreased. SB-269970, a selective
5-HT7 antagonist, signiﬁcantly ameliorated the abnormal psycho-
motor behavior and impaired working memory performance in
PACAP-/- mice.
Conclusion : The present results implicate PACAP signaling in
synaptic pathology and provide predictive validity of PACAP-/- mice
in modeling psychiatric disorders. Taken together, it is suggested that
the PACAP signaling pathway may emerge as a potential therapeutic
target for psychiatric disorders.
jP-15-014jToxicity eﬀect of cisplatin-treatment on cerebellar
purkinje cells at during lactivorous in neonate mice
S. Hejazi. Tabriz branch, Islamic Azad University Iran, Islamic Republic
of Iran
Objective : Cisplatine is a Vina Alkaloid which is a cell-cycle-speciﬁc
agent and blocks. Cisplatin is a drug to treat certain types of cancer.
Although genital neoplasia can be supposed soon after cisplatin
treatment, its side eﬀects, although uncommon, may prevent the drug
from becoming a standard of therapy. At lactation period, it is not
known whether this drug is excreted in breast milk. In this research
we studied the eﬀect of cisplatin on Cerebellar Purkinje cells at During
Lactivorous in Neonate Mice.
Methods : 50 Female Mice at lactation period divided randomly to
control & experimental groups. Mices of experimental group were
injected by cisplatin (10 mg/kg IV for one dose on days 1th, 8th, 15th
of lactation period. One week after the inject, neonate brains (21days
old) ﬁxed with perfusion procedure & removed from skull. Then
cerebellum embedded in 10% formalin solution. The 5-micromiter
sections taken from cerebellum of neonate were stained by H&E &
Gold chloride. Density & volume of purkinje cells & distance of cells
from each other studied with light microscopy & digital camera. One
other way, T-test were used for analysis (P<0.05).
Results : The body weight in experimental group reduced in con-
trast to control group. The volume of purkinje cells in experimental
group were increased than the control group. The number of cells
were a few decreased and the distance of cells in experimental group a
few increased.
Conclusion : Cisplatin eﬀect on neonate purkinje cells is excreted in
breast milk with histopalothogic channges and decrease of number of
the purkinje cells.
jP-15-015jToxicity eﬀect of cisplatin-treatment on mice
cerebellum formation
S. Hejazi. Tabriz branch, Islamic Azad University Iran, Islamic Republic
of Iran
Objective : Cisplatin is an alkaloid that is administered to inhibit the
division of malignant tumor cells. Occurrence of malformation in
embryos has been proved in treated pregnant mothers. However,
there was no adequate information about its toxic eﬀect on cerebellar
structures of newborns. Considering the passage through the Blood
Brain Barrier and its cytotoxic eﬀect, the destructive eﬀects of cispla-
tine on the formation of cerebellum in newborns was demonstrated.
Methods : In this study 30 pregnant female mice were randomly
divided in two groups (control and experimental). The treated group
received 10 mg/kg at days 8 and 13 of pregnancy (I.P). At the end of
pregnancy, 60 newborns (control and experimental groups) were
selected for examination by H&E staining. T-test and SPSS software
were used to analyze data obtained from quantifying parameters.
Results : Morphologic observations showed signiﬁcant decrease in
weight, skull size and newborn growth (P<0.05) On microscopic ob-
servation, cerebellar white matter of cerebellum showed decreased
compaction of glial cells accompanied by deﬁciency in myelination of
nervous ﬁbers. Occurrence of apoptosis was seen in epithelial cells of
choroid plexus and in white matter glial cells.
Conclusion : Based on these results, we can conclude that the eﬀects
of anti-mitosis drugs can include inhibitory activity on the prolifer-
ation of cerebellar cortical cells. The results also show induction of
apoptosis in choroid plexus cells and cerebellum.
jP-15-016jProtective eﬀects of betaine on lipopolysaccharide-
induced memory impairment in mice and the
involvement of GABA transporter 2
M. Hiramatsu1, M. Miwa2, M. Tsuboi2, Y. Noguchi2, A. Enokishima2,
T. Nabeshima2. 1Meijo University, Faculty of Pharmacy, Nagoya, Japan ;
2Meijo University, Nagoya, Japan
Objective : Betaine (glycine betaine or trimethylglycine) plays im-
portant roles as an osmolyte and a methyl donor in animals. While
betaine is reported to suppress expression of proinﬂammatory mol-
ecules and reduce oxidative stress in aged rat kidney, the eﬀects of
betaine on the central nervous system are not well known. In this
study, we investigated the eﬀects of betaine on lipopolysaccharide
(LPS)-induced memory impairment and on mRNA expression levels
of proinﬂammatory molecules, glial markers, and GABA transporter 2
(GAT2), a betaine/GABA transporter.
Methods : Mice were continuously treated with betaine for 13 days
starting 1 day before they were injected with LPS, or received sub-
acute or acute administration of betaine shortly before or after LPS
injection. Then, their memory function was evaluated using Y-maze
and novel object recognition tests 7 and 10–12 days after LPS injection
(3 mg/mouse, i.c.v.), respectively. In addition, mRNA expression
levels in hippocampus were measured by real-time RT-PCR at
diﬀerent time points.
Results : Repeated administration of betaine (0.163 mmol/kg, s.c.)
prevented LPS-induced memory impairment. GAT2 mRNA levels
were signiﬁcantly increased in hippocampus 24 hr after LPS injection,
and administration of betaine blocked this increase. However, betaine
did not aﬀect LPS-induced increases in levels of mRNA related to
inﬂammatory responses. Both subacute administration (1 hr before,
and 1 and 24 hr after LPS injection) and acute administration (1 hr
after LPS injection) of betaine also prevented LPS-induced memory
impairment in the Y-maze test.
Conclusion : These data suggest that betaine has protective eﬀects
against LPS-induced memory impairment and that prevention of
LPS-induced changes in GAT2 mRNA expression is crucial to this
ameliorating eﬀect.
jP-15-017jBehavioral proﬁling for voluntary ethanol intake and
ethanol seeking in male outbreed rats
S. Holst1, I. Fredriksson1, P. Steensland1. 1Karolinska Institutet,
Stockholm, Sweden
Objective : The development of alcohol use disorder (AUD) is
dependent on the interaction between genetics and environment,
mirrored by the individual variation in voluntary ethanol intake and
seeking between, and within, outbreed rat strains. We used the Novel
Cage Test (NCT) to evaluate the emotional reactivity and stress coping
styles in relation to ethanol consumption in Rcc Wistar, Lister Hooded
and Long Evans rats.
Methods : The latency time, frequency and duration of locomotor,
explorative, risk assessment and anxiety-like behaviors were cal-
culated from 5 min of spontaneous behavior in a box. The rats were
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thereafter subjected to intermittent-access 20% ethanol two-bottle-
choice paradigm and operant self-administration of 20% ethanol.
The NCT results were correlated with voluntary ethanol intake and
ethanol seeking behavior through a pattern recognition analysis – the
prinicipal component analysis (PCA).
Results : The Wistar rats had the highest voluntary ethanol con-
sumption of the three strains and were cautious, proactive stress co-
pers, with high emotionality. However, nearly half of the Wistar rats
did not perform any ethanol seeking behavior. In contrast, Lister
Hooded that were very explorative with low emotionality, had the
lowest voluntary ethanol intake, but the highest level of ethanol
seeking behavior. The Long Evans rats were anxious, reactive stress
copers with high emotionality and had a low degree of both voluntary
ethanol consumption and seeking behavior.
Conclusion : In conclusion, the rats that had the highest ethanol
intake in a two-bottle-choice setting had a proactive stress coping style
and a higher level of emotionality compared to rats with a high level
of ethanol seeking behavior, which were more explorative. Being too
emotional or anxious in combination with a reactive stress coping
style decreased the initiative to voluntary ethanol consumatory
behavior signiﬁcantly. Behavioral proﬁling has potential to be a
valuable tool in the prediction of high or low individual responders in
preferred AUD models.
jP-15-018jEﬀect of hemantane on depressive-like behavior and
memory in rat model of parkinson’s disease
E. Ivanova1, I. Kapitsa1, A. Nepoklonov1, E. Valdman1, T. Voronina1.
1 Institute of Pharmacology, Moscow, Russia
Objective : Non-motor symptoms precede motor disturbances in
Parkinson’s disease. The aim of the study was to evaluate the eﬀects of
the novel antiparkinsonian drug Hemantane (N-2(adamantyl)hex-
amethylenimine hydrochloride) and Amantadine sulfate in methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned rats, a model of
the pre-motor stage of Parkinson’s disease.
Methods : Male white outbred rats were distributed into 4 groups :
1st – sham operated, 2nd – MPTP-lesioned, animals of the 3rd and 4th
groups were injected intraperitoneally with Hemantane (10 mg/kg)
or Amantadine (20 mg/kg) daily starting 5 days before the MPTP
infusion and throughout the study. MPTP (100 mg/1 ml) was infused
bilaterally into substantia nigra pars compacta (SNc). Three weeks
after surgery, rotarod, modiﬁed forced swimming and passive
avoidance tests were performed.
Results : No motor alterations were determined in the rotarod test
in animals of all groups. In the swimming test, animals of group 2
presented depressive-like behavior ; swimming activity was signiﬁ-
cantly reduced (38%), and immobility increased 10-fold compared to
group 1. Hemantane completely normalized immobility and swim-
ming duration. Amantadine signiﬁcantly decreased immobility. But
its eﬀect was 3 times less than that of Hemantane. In passive avoid-
ance test, impairment of the hole reﬂex was determined in 50% of
MPTP-lesioned rats, which did not enter the dark compartment at the
training session. The other group 2 animals demonstrated impaired
acquisition in retention trial. Hemantane and Amantadine prevented
these alterations.
Conclusion : Bilateral injection of MPTP into the SNc induced
depressive-like behavior and impaired learning and memory in rats.
Hemantane and Amantadine are able to prevent or reduce these
disturbances. The eﬀect of Hemantane was more pronounced than
that of Amantadine.
jP-15-019jPerinatal NMDA receptor blockade causes lasting
impairments to the synaptic and intrinsic physiology
of fast-spiking interneurons in a developmental
model of schizophrenia
K. Jones1, V. Gallo1, M. Huntsman1. 1Children´s National Medical CT,
Washington, USA
Objective : NMDA antagonists induce psychotic states that closely
resemble schizophrenic symptoms and are therefore widely used
to model schizophrenia (SZ). Neonatal mice sub-chronically treated
with NMDA antagonists incur long-lasting behavioral deﬁcits, and
repeated exposure decreases staining of biochemical markers of
inhibition. However, the impact on inhibitory physiology is less
clear. Thus, the aim of this study is to determine the impact of
perinatal NMDA receptor blockade on cortical inhibitory neuro-
transmission.
Methods : Whole-cell patch clamp electrophysiology was per-
formed on fast-spiking/parvalbumin-positive interneurons (FS cells)
from cortical brain slices of adult animals treated with the MK-801 as
neonates. Immunohistochemical analyses was also performed.
Results : Neonatal MK-801 treatment caused a four-fold reduction
in near-threshold spike latency of FS cells ; a 61% increase in mem-
brane resistance ; and a 23% increase in AP 1/2 width. The AP
threshold of FS cells from MK-801 treated animals was strongly
dependent on the amplitude of the depolarizing current, which did
not occur in vehicle treated animals. Consistent with these ﬁndings,
immunohistochemical analysis revealed dramatic reductions in the
somatic expression of the potassium channel, KV1.1. MK-801 treat-
ment also disrupted excitatory synaptic input to FS cells. We found
that thalmo-cortical synapses on FS cells were twice as likely to
express functional NMDA current in MK-801 treated animals (80%
MK-treated vs. 40% vehicle-treated), and immunohistochemical
analyses revealed a substantial increase in the expression of the NR2B
subunit in the soma of FS cells. Electrically evoked responses from the
thalamocortical synapses of MK-801-treated animals contained 300%
more NR2B-mediated current than vehicle-treated controls.
Conclusion : Together these data demonstrate that transient NMDA
receptor blockade during early development elicits changes in the
physiology of cortical FS cells that persist into adulthood, and may
provide a physiological basis for the behavioral deﬁcits observed in
this model.
jP-15-020jCognition improving and antioxidant eﬀects of
asparagus racemosus willd in mice
H. Joshi1, M. Parle2. 1Sarada Vilas College of Pharma, Mysore, India ;
2Sarada Vilas College of Pharma, Division of Pharmacology, Hisar, India
Objective : In the present study, nootropic activity of aqueous extract
of roots of A. racemosus (AR) was studied in mice.
Methods : Elevated plus maze and passive avoidance paradigm
were employed to evaluate learning and memory. Scopolamine
(0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.) were used to induce
amnesia in mice. AR (50 and 100 mg/kg, p.o.) signiﬁcantly attenuated
amnesic deﬁcits induced by scopolamine, diazepam and natural
aging. To delineate the possible mechanism through which A. race-
mosus elicits anti-amnesic activity, eﬀects on whole brain acet-
ylcholinesterase activity, brain lipid peroxide levels and antioxidant
enzymes activity were estimated.
Results : AR signiﬁcantly decreased acetylcholinesterase activity
and increased brain levels of thiobarbituric acid reactive substances
and gluthione peroxidase activity. These ﬁndings suggest that the
roots of A. racemosus exert a preventive eﬀect against cognitive
deﬁcits induced by scopolamine, diazepam and natural ageing.
Conclusion : The memory improving activity of A. racemosus may
be attributed to its antioxidant, neuroprotective, pro-cholinergic and
anti-acetylcholinesterase properties and can be of enormous use in
delaying the onset and reducing the severity of Alzheimer’s disease.
jP-15-021jBehavioral and neurochemical eﬀects of calcium salt
of N-(5-hydroxy-nicotinoyl)-L-glutamate in
accelerated aging male mice SAMP10
A. Kiselev1, S. Litvinova2, T. Garibova2, T. Voronina2, T. Kalinina2,
S. Stovbun1. 1NN Semenov Instuitute of Chemical Physics, Moscow,
Russia ; 2Zakusov Institute, of Pharmacology of Russian, Moscow, Russia
Objective : Senescence-accelerated mouse prone 10 (SAMP10)
strain is one of the models for study of neurodegeneration associated
with aging. It is known that SAMP10 mouse over 6 mo exhibits
behavioral disorders (memory deﬁciency, increased anxiety, de-
pressive-like responses) and shifts of neurotransmitter contents in
brain structures. Novel neuroprotective substance calcium salt of
N-(5-hydroxy-nicotinoyl)-L-glutamate (Ampassae1 (AMPS)) mod-
ulates an activity of the glutamate receptors AMPA-subtype and
possesses anti-hypoxic, anti-ischemic and anti-amnestic activities in
standard rodent’s tests.
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Methods : The aim of the study was to investigate AMPS
(5–20 mg/kg) eﬀects on behavior and neurotransmitter amino acids
contents in male SAMP10 of 9–16 mo. In behavioral experiments
memantine (2 mg/kg), a low-aﬃnity noncompetitive antagonist of
glutamate receptors NMDA-subtype, used as reference drug. The
substances were injected intraperitoneally once per day 30 min before
testing. Memory was studied in one-trail passive avoidance step-
through paradigm, anxiety – in elevated plus maze, depression-like
response – in the Porsolt’s forced swimming test. In the neurochem-
ical assay AMPS (5 mg/kg) was administered intraperitoneally for
5 days, the last injection x30 min before the animals were de-
capitated. The neurotransmitter amino acids glutamate, aspartate,
taurine, glycine and gamma-aminobutyric acid contents were deter-
mined in frontal cortex, hypothalamus, striatum, hippocampus by
HPLC/PD.
Results : AMPS (20 mg/kg) completely eliminated the memory
deﬁciency and anxiety and had no eﬀect on the animal’s depression-
like behavior. Memantine provided a greater corrective action on
emotion than on the memory in the mice. AMPS increased the level of
all recorded amino acids in striatum and glutamic acid and glycine
levels in hypothalamus.
Conclusion : Thus, AMPS decreases neurochemical shifts in the
animal brain, especially in striatum, one of the structures most prone
to atrophy in mice SAMP10, and the mechanism may at least partly
underlie its neuroprotective eﬀects in SAMP10.
jP-15-022jLocal GluN2B antagonism in responses to stress and
anxiety- and depression-related behavior
C. Kiselycznyk1, P. Svenningsson2, A. Holmes1. 1NIH, Rockville, USA ;
2Karolinska Institute, Stockholm, Sweden
Objective : Increasing evidence points to a role for N-methyl-D-
aspartate receptors (NMDARs) in the treatment of mood and anxiety
disorders. Systemic administration of drugs acting as antagonists
at the GluN2B subunit of the NMDAR has fast-acting clinical eﬃcacy
in depression, and reduces anxiety- and depression-related behaviors
in rodent preclinical assays. However, the speciﬁc brain regions
mediating these eﬀects remain to be determined. Prior studies have
shown that acute antidepressant-related eﬀects of systemically-
delivered GluN2B antagonists parallel synaptic changes in the medial
prefrontal cortex (mPFC) (Li et al., 2010), while gene deletion of
GluN2B in corticohippocampal principal neurons attenuates de-
pression-related responses to repeated swim stress (Kiselycznyk et al.,
2011). Here we examined the role of GluN2B localized in the mPFC
and basolateral amygdala (BLA) in mediating depression- and
anxiety-like behaviors.
Methods : Male C57BL/6J mice were cannulated to bilaterally
infuse the GluN2B-selective antagonist, Ro 25–6981, into either mPFC
or BLA prior to testing in the light/dark exploration test for anxiety-
like behavior or the forced swim test for depression-related behavior.
To compliment these pharmacological studies, mPFC GluN2B
expression was reduced via lentiviral-mediated knockdown and mice
were tested for depression-related responses to repeated swim stress.
Results : Results showed that Ro 25–6981 infused into mPFC, but
not BLA, reduced depression-related behavior. By contrast, there
were minimal eﬀects of Ro 25–6981 infused into mPFC or BLA on
anxiety-like behavior.
Conclusion : Collectively, these data are consistent with the mPFC
as a major eﬀect-locus for the antidepressant-like eﬀects of GluN2B
antagonists. This has implications for understanding the mechanisms
underlying the fact-acting antidepressant eﬀects of these drugs in
human patients.
jP-15-023jThe inﬂuence of selective serotonin
reuptake inhibitors (SSRI) and 3,4-
methylendioxymethamphetamine (MDMA) on
neurogenesis in the adult rat hippocampus
A. Kubesova1, T. Palenicek1, F. Tyls1, M. Fujakova1, V. Bubenikova-
Valesova1, J. Horacek1. 1Prague Psychiatric Center, Czech Republic
Objective : There are two regions of high density cell division in the
adult mammalian brain that produce new neurons throughout
adulthood : the subventricular zone of the lateral ventricle (SVZ) and
the subgranular zone of the dentate gyrus in the hippocampus (SGZ).
We examined the inﬂuence of two serotonin reuptake inhibitors
(SSRI – ﬂuoxetine, citalopram) and a serotonin releaser 3,4-methyl-
endioxymethamphetamine (MDMA) on proliferation and maturation
of neuronal cells in the hippocampus of adult rats.
Methods : Adult male Wistar rats were administered with the
tested substances (citalopram 10 mg/kg i.p., ﬂuoxetine 5 mg/kg i.p.,
MDMA 5 mg/kg i.p., saline) for 3 (proliferation) or 21 (maturation)
days. Newly generated cells were labeled with 5-bromo-2-deoxy-
uridine (BrdU ; 3r50 mg/kg s.c.) one day before (maturation) or
after (proliferation) drug treatment. Rat brains were perfused (4%
paraformaldehyde), sliced (40 mm) and every 6th section was im-
munohistochemically stained (rat anti-BrdU, Serotec OBT0030). The
number of BrdU positive cells was counted under a light microscope
(Zeiss Axio Imager Z1).
Results :Acute administration of SSRI and MDMA nonsigniﬁcantly
increased the number of BrdU positive cells in the dentate gyrus
compared to the controls. We detect no statistically signiﬁcant
diﬀerence in the number of BrdU positive cells after chronic drug
administration among the tested groups.
Conclusion : According to our result, proliferation of new hippo-
campal cells is not dependent on the way the serotonin system is
stimulated. However, it seems that maturation of neurons is not
inﬂuenced by the serotonin system, which is in conﬂict with various
studies. These data have an implication for neurogenesis in de-
pression as an underlying factor of antidepressant eﬀect. This
study was supported by the grants IGA MHCR NS 10374-3, NS
10375-3, MEYSCR 1M0517, MHCR MZ0PCP2005, VG2VS/200 and
VG2VS/271.
jP-15-025jModulation of ketamine-induced oxygen
amperometry signals in awake rats – a translational
imaging biomarker for novel antipsychotics?
J. Li. Eli Lilly, Centre for Cognitive Neuroscience, Windlesham, United
Kingdom
Objective : Human functional imaging has had a major impact
on cognitive neuroscience, linking brain structure to function. The
technique is translatable but rodent fMRI is limited to anaesthetised or
restrained animals. In-vivo oxygen amperometry is an alternative
approach that can measure oxygen changes related to behaviour since
it allows real time monitoring of extracellular tissue oxygen in freely-
moving animals. Neuroimaging techniques have previously been
used to determine the eﬀects of NMDA antagonists on brain acti-
vation in humans and animals ; these compounds have been
shown to be psychotropic and to induce cognitive disturbances.
Pharmacological reversal of the NMDA antagonist-induced imaging
response may represent antipsychotic activity, as previously seen
with mGlu2/3 agonists. Here, we compared the eﬀect of i.v. ketamine
challenge on neuroimaging signals in healthy volunteers and anaes-
thetised rats to the oxygen response in the medial prefrontal cortex
(mPFC) and dorsal hippocampus (dHPC) of freely-moving rats using
in vivo oxygen amperometry. The modulation of the oxygen am-
perometric ketamine response by the mGlu2/3 agonist LY379268 was
also assessed.
Methods : For the oxygen amperometry, rats were implanted with
oxygen sensors in the mPFC and dHPC and were given a 1 mg/kg i.v.
infusion of ketamine over 2 minutes. For the mGlu2/3 agonist
modulation studies, LY379268 (1, 3, and 10 mg/kg) was dosed i.p.
30 minutes before ketamine was administered.
Results : Our results show a translational response to i.v. ketamine
challenge, with the human fMRI, anaesthetised rat CBV imaging, and
freely-moving rat oxygen amperometry showing similar increases
in activation in the cingulate/mPFC. Pretreatment with LY379268
caused a dose-dependent reversal of the ketamine response in the
oxygen signal in freely moving rats.
Conclusion : We show that oxygen amperometry may be a good
translational surrogate for imaging studies in freely-moving animals,
and modulation of the oxygen ketamine response may provide a
translational neuropharmacological biomarker of antipsychotic
activity.
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jP-15-026jHypothalamic expression of Kiss1/Gpr54 and
GnIH/Gpr147 systems in adult male and female
rats exposed to early life stress and/or to juvenile
olanzapine administration
E.M. Marco1, C.E. Fraire2, A´. Llorente-Berzal3, J.M. Castellano4,
L. Pinilla4, M. Tena-Sempere4, M.-P. Viveros1. 1Complutense
University, Madrid, Spain ; 2University of Cordoba, Department of Cell
Biology, Co´rdoba, Spain ; 3Complutense University, Department of
Physiology, Madrid, Spain ; 4University of Cordoba, CIBERobn, ISCiii,
Co´rdoba, Spain
Objective : Hypothalamic circuitries responsible for the homeostatic
control of essential body functions can be permanently aﬀected by
the early-life environment. A single episode of maternal deprivation
(MD, 24 h on postnatal day, pnd, 9) compromises metabolic and
endocrine homeostasis, and provokes behavioral outcomes that re-
semble symptoms frequently observed in neuropsychiatric disorders.
In humans, the pharmacological management of such disorders
includes administration of atypical antipsychotics, i.e. olanzapine
(Olan), often prescribed to children and adolescents despite adverse
side-eﬀects. We aimed to investigate the long-lasting eﬀects of these
manipulations on hypothalamic key hormonal systems controlling
reproduction and energy balance, namely Kiss1/Gpr54 and GnIH/
Gpr147.
Methods : Male and female Wistar rats exposed to MD or left un-
disturbed were orally administered with Olan (7.5 mg/kg/day) or
vehicle (1 mM acetic acid) from pnd 28 to 49 and hypothalamic
mRNA expression of Kiss1/Gpr54 and GnIH/Gpr147 was analyzed
in adult animals.
Results : MD resulted in a persistent decrease in body weight
that extended to adolescence in males and to adulthood in females.
MD induced sex-dependent alterations in the kisspeptin system ; de-
creased Kiss1 levels in males and Gpr54 expression in females.
Olan only induced a subtle reduction in body weight gain among
females together with a reduction in Kiss1 levels in males that
was exacerbated by prior exposure to MD. Male animals exposed
to both MD and Olan exhibited the lowest levels of Gpr54 and
GnIH/Gpr147. In females, Olan reduced Gpr147 expression
whereas Kiss1/Gpr54 seemed not to be aﬀected. The combination of
both manipulations also diminished hypothalamic GnIH level among
females.
Conclusion : Present data indicate that MD critically interferes
with hypothalamic developmental programming in a sex-dependant
manner, mainly through modulation of the Kiss1/Gpr54 system.
Adolescence is also suggested as a sensitive period for pharmaco-
logical hypothalamic modulation. Further research on the long lasting
eﬀects of antipsychotic drugs and their interaction with early life
events is urgently needed.
Policy of full disclosure : This work was supported by grants from
Ministerio de Ciencia e Innovacio´n BFU2009-10109, BFU2008-00984
and Red de trastornos adictivos RD06/0001/1013.
jP-15-027jThe neuroprotective role of rivastigmine in the
treatment with haloperidol (animal model)
D. Marinescu1, L. Mogoanta2, T. Udristoiu2, I. Marinescu2,
I. Udristoiu2, D. Pirici2. 1UMPH of Craiova, Romania ; 2University of
Medicine and Pharmacy of Craiova, Romania
Objective : Evaluation of the neuroprotective role rivastigmine in
the treatment with haloperidol, noting the need to maintain balance
between neuron and glia.
Methods : Animal model study, on two lots consisting of 5 Winstar
rats each, male adults, weight 200–250 g, held during the study in
temperature, humidity, food and ambient stressless conditions. On
N1 lot, from day 1 to 14 has been administered saline solution through
stomach tube, and from day 15 to 28 has been administered haloper-
idol intraperioneally (equivalent to 0.20 mg/kg/day) and saline sol-
ution. On N2 lot, from day 1 to 14 has been administered rivastigmine
through stomach tube (equivalent to 0.5 mg/kg/day), and from day
15 to 28 has been administered haloperidol intraperioneally (equiva-
lent to 0.20 mg/kg/day) and rivastigmine (equivalent to 0.5 mg/kg/
day). In the day 29 the rats were sacriﬁced. The sample brain (frontal
cortex, hippocampus, striatum, Meynert nucleus, white matter) was
histopathologically processed : formalin (10%) and ethyl alcohol
(96%) ﬁxation and paraﬃn embeded. Microtome slices were stained
in hematoxyline-eosine, trichromicGS, PAS-hematoxyline, toluidine
blue, methylen blue for Nissle corpuscles and argentic impregnation
for neuroﬁbriles. The obtained slices were studied with optical
microscope.
Results : Haloperidol signiﬁcantly alter the neural structures and
white substance (neural apoptosis and vacuolisations). Rivastigmine
exercise neuroprotection on N2 lot by reducing neuronal loss in the
frontal cortex and hippocampus and reduction in neural changes
of striatum and Meynert nucleus. Rivastigmine ensures high protec-
tion for the white substance, with minimum number of vacuolisations.
Conclusion : Rivastigmine presents neuroprotective qualities, both
for the gray substance and white substance on brain structures
involved in the cognitive process (hippocampus, frontal cortex, stria-
tum, Meynert nucleus) under the treatment with haloperidol.
jP-15-028jEﬀects of BACE1 ablation on a phencyclidine-
induced model of schizophrenia
T. Melnikova1, D. Lee1, E. Cho1, A. Savonenko1. 1 Johns Hopkins
University, School of Medicine, Baltimore, USA
Objective : Genetic association studies have linked the neuregulin1
(NRG1) and its ErbB4 receptor to schizophrenia. Altered NRG1/
ErbB4 signaling has also been shown to result in hypofunction of
glutamatergic system. We hypothesized that NRG1/ErbB4 pathway
interacts with glutamatergic receptors pathways by homeostatic me-
chanisms in a way that the deﬁcits in one of the pathways could result
in adaptive changes in others.
Methods : To analyze primary changes in NRG1/ErbB4 pathway
we used knockout mice that lack beta-site APP cleavage enzyme 1
(BACE1). BACE1 participates in the proteolytic processing of NRG1
and its deletion results in multiple endophenotypes related to
schizophrenia as observed in BACE1ko mice. For analysis of second-
ary changes in NRG1/ErbB4 signaling we used sub-chronic phency-
clidine treatment (PCP), a non-competitive antagonist of the NMDA
receptors, on postnatal days (PND) 7, 9, and 11 (10 mg/kg, i.p). Wild
type (WT) and BACE1ko mice were behaviorally tested at PND 28–30.
Results : As expected, WT-PCP mice developed numerous schizo-
phrenia-like behavioral traits such as deﬁcits in prepulse inhibition,
spatial recognition memory, and increased sensitivity to MK-801.
BACE1ko mice demonstrated similar deﬁcits on the vehicle treatment.
Interestingly, PCP administration in BACE1ko mice resulted in the
amelioration of some of the deﬁcits. Western blot analyses showed
decreased levels of BACE1 protein in WT mice after PCP treatment.
The levels of two major substrates of BACE1, APP and NRG1, as well
as phosphorylation of NRG1 receptor, ErbB4, were modiﬁed. In ad-
dition, PCP treatment in WTmice resulted in reduced levels of myelin
basic protein (MBP), one of the down stream markers of NRG1/ErbB4
pathway activity. In contrast, PCP-treated BACE1ko mice showed
some recovery of low levels of MBP, a marker of central hypomyeli-
nation in these mice.
Conclusion : Results of this study indicate that the perinatal PCP
treatment modify activity of the BACE1/NRG1 pathway implicating
the interactions of these pathways during development.
jP-15-029jFunctional studies of altered Eaat3 expression in
obsessive-compulsive disorder
P. Moya1, M. Prochazkova2, E. Utreras2, A. Kulkarni2, D. Murphy3.
1NIMH, Bethesda, USA ; 2NIDCR, Bethesda, USA ; 3NIMH, Laboratory
of Clinical Science, Bethesda, USA
Objective : SLC1A1 gene (Eaat3) is an attractive candidate gene im-
plicated in Obsessive-Compulsive Disorder (OCD) : Eaat3 regulates
extracellular levels of glutamate in cortico-striato-thalamo-cortical
(CSTC) circuits consistently implicated in OCD. SLC1A1 is the most
evident ‘brain-related’ gene of interest located in the chromosomal
region 9p24. 3) In the ﬁrst case-control study of this gene in OCD we
found that SLC1A1 was associated with OCD. The strongest evidence
from this study indicated that a certain haplotype was almost
two times more frequent in OCD patients than controls (OR=1.89) ;
two of three SNPs of this haplotype were found to be expression
Quantitative-Trait Loci (eQTLs). These ﬁndings, plus earlier family
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studies point to to SLC1A1 as being the most solidly established gene
identiﬁed in OCD. This work aims to generate transgenic mouse
models for conditional Cre-recombinase-dependent Slc1a1 over-
expression and knockout.
Methods :We developed and fully characterized in vitro a construct
to achieve conditional, Cre-recombinase dependent Eaat3 ovex-
erpression. We performed transient expression of our construct in
N2A cells and evaluated the cre-mediated Eaat3 expression levels by
Western Blot. We also measured (3H)-glutamate uptake in N2A
cells, as well as glutamate-induced currents in HEK293 carrying the
construct.
Results : We show here that our construct allows for conditional,
Cre-mediated Eaat overexpression. We recenlty obtained the ﬁrst
generation of Eaat Tg mice mated with CamKII-Cre mice to achieve
Eaat3 overexpression restricted to forebrain.
Conclusion : Our animal model is expected to provide seminal in-
formation regarding the mechanism of SLC1A1 dysfunction at
the gene regulatory, neurochemical, and anatomical levels during
various stages of development. In addition, mice with conditional
Slc1a1 expression alterations may oﬀer exciting possibilities for gen-
erating new animal models of psychiatric and/or neurodegenerative
disorders and also help in the development of drugs that target glu-
tamate neurotransmitter system for eﬀective OCD treatment.
jP-15-030jExpression of serotonergic genes in the raphe nuclei
is associated with anxiety-related behaviour in rats
J. Na¨slund1, E. Studer2, L. Westberg2, E. Eriksson1. 1University of
Gothenburg, Sweden ; 2University of Gothenburg, Neuroscience and
Physiology, Sweden
Objective : Numerous genetic studies imply variation in brain ser-
otonergic neurotransmission as a determinant of diﬀerences in tem-
perament in humans. Since the biochemical underpinnings of such
associations are diﬃcult to study in man, it is of interest to explore if
similar associations are at hand also in experimental animals. To this
end, this study aimed at investigating (in rat) the possible association
between inter-individual diﬀerences in anxiety-like behaviour on the
one hand, and the expression of a number of genes important for
serotonergic transmission on the other.
Methods : 30 male Wistar rats were used. Inter-individual diﬀer-
ences in anxiety-like behaviour were assessed using the elevated plus-
maze. Three weeks later, the animals were sacriﬁced and the brains
extracted. Expression of serotonergic genes in the raphe nuclei was
determined using TLDA cards.
Results : Animals exhibiting high levels of anxiety-like behaviour
had signiﬁcantly higher mRNA levels for several of the genes nor-
mally expressed by serotonergic neurons, such as those encoding
tryptophan hydroxylase 2, amino acid decarboxylase and the sero-
tonin transporter.
Conclusion : The results suggest that the expression of serotonergic
genes in the raphe nuclei is associated with anxiety-like behaviour in
the rat, with animals exhibiting stronger such behaviour displaying
higher expression of a number of genetic markers of brain sero-
tonergic transmission.
jP-15-031jMemantine attenuates and reverses hyperthermia
induced by 3,4-methylenedioxymethamphetamine
(MDMA) in rats
K. Nishijima1, K. Shioda1, T. Yoshino1, S. Kato1. 1 Jichi Medical
University, Shimotuke, Japan
Objective : Life-threatening hyperthermia occurs in some individuals
consuming 3,4-methylenedioxymethamphetamine (MDMA). No ef-
fective pharmacological treatment for MDMA-induced hyperthermia
has yet been established. In the present study, we evaluated the
eﬀectiveness of memantine, a non-competitive NMDA receptor
antagonist and a-7 nicotinic Ach receptor antagonist, in treating
MDMA-induced hyperthermia. We also examined the pharmaco-
logical eﬀects of MDMA using in vivo microdialysis.
Methods : MDMA (10 mg/kg) was injected and the dopamine
and serotonin levels in rat hypothalamus were measured by the
microdialysis method. In the prior-administration experiment, saline,
memantine (10 mg/kg or 20 mg/kg), MK 801 (0.5 mg/kg), CGS 19755
(5 mg/kg), or methyllycaconitine (6 mg/kg) was injected intra-
peritoneally. MDMA (10 mg/kg) was then injected subcutaneously
30 minutes later. Rectal temperature was measured every 30 minutes.
In the post-administration experiment, MDMA was injected and then
memantine (10 mg/kg and 20 mg/kg) was injected intraperitoneally
30 minutes later.
Results : The extracellular concentrations of serotonin (5-HT) and
dopamine (DA) in rat anterior hypothalamus were increased 50- and
15-fold, respectively, compared with their respective pretreatment
levels after administration of MDMA. Pretreatment and post-
treatment with memantine each inhibited the peak increase in body
temperature. Although pretreatment with the NMDA receptor an-
tagonists MK-801 and CGS 19755 suppressed the increase in body
temperature induced by MDMA, pretreatment with methyllcaconi-
tine did not suppress the hyperthermia induced by MDMA. These
ﬁndings suggest that MDMA increases the concentrations of 5-HT
and DA in the hypothalamus, and that memantine suppresses
MDMA-induced hyperthermia via its NMDA receptor-antagonistic
eﬀect.
Conclusion : Our ﬁndings suggest that memantine may be an
oﬀ-label eﬀective drug for the treatment of MDMA-induced
hyperthermia in humans.
jP-15-032jProlonged activation of microglia induced by
systemic lipopolysaccharide administration in mice
A. Ohashi1, K. motomura1, S. Yanagida1, K. Hiraoka1, M. Hayashi1,
S. Kanba1. 1Kyushu University, Fukuoka, Japan
Objective : Peripheral lipopolysaccharide (LPS) administration in-
duces sickness behavior in experimental animals, and higher dose of
LPS may cause prolonged behavioral suppression. In the present
study, we assessed the systemic LPS-induced behavioral change and
time-course of microglial activation in mice brain.
Methods : BALB/c mice (male, 8–9 weeks old) were injected with
LPS (0.8 mg/kg, i.p.). Sickness behavior was measured at 23–24 h post
injection. Brain sections were obtained 2, 8, 24 and 48 h after LPS
injection, and distribution of microglia was visualized by immuno-
histochemical method with antibody against ionized calcium-binding
adaptor molecule 1 (Iba-1). Activation of microglia was estimated by
measuring the Iba-1-immunoreactive areas in digital images with
Image J software.
Results : Food and water consumption, body weight and locomotor
activity in a new cage were decreased after LPS injection. Iba-1 posi-
tive cells (microglia) showed time-dependent and region-speciﬁc
distribution. Activation of microglia was observed even 48 h after LPS
injection in some regions, including ventral hypothalamus and dorsal
medulla.
Conclusion : Our data suggested that prolonged microglial acti-
vation in speciﬁc brain regions may contribute to the lingering
behavioral suppression induced by considerable dose of LPS.
Policy of full disclosure : This work was ﬁnancially supported by
Grant-in-Aid for Scientiﬁc Research from MHLW (FAHK-200144).
jP-15-033jEﬀect of L-carnosine on repeated social defeat
stress-induced behavioral and neurochemical
changes in mice
M. Ohsawa1, Y. Fujisawa1, H. Katsu1, S. Yamamoto1, H. Ono1.
1Nagoya City University, Japan
Objective :Mood and anxiety disorders are two major mental illness,
and more than one-third people reported the symptoms of these dis-
orders in their life. Since current treatments are poorly eﬀective,
new curatives are greatly needed. Mice experiencing repeated social
defeat stress (SDS) develop a persisted aversion to social contact.
This aversion can be normalized by chronic treatment with anti-
depressants, which resemble depression in human. Previous studies
indicated that dipeptide L-carnosine produced many eﬀects in
nervous systems, such as antinociceptive and hypnotic actions. The
present study was, then, designed to investigate the antidepressive-
like activity of L-carnosine on repeated SDS model in mice.
Methods : Mice were subjected to daily social defeat, and then se-
parated from the aggressor behind a protective wire mesh barrier,
which allowed for sensory contact, for the remainder of the day.
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Mice were exposed to a diﬀerent aggressor each day for 10 days, and
were then examined for social behavior. Mice showed aversion to
social contact at 1 day after SDS was used. Imipramine or L-carnosine
treatment was started from 1 day after SDS for 10 days.
Results : Repeated social defeat stress-induced aversion to social
contact was attenuated by the repeated, but not acute, treatment with
imipramine or L-carnosine. We also examined the changes of the
glutamate receptors in anterior cingulate cortex (ACC) where mod-
ulates emotions responses. The expressions of NR2B NMDA receptor
subunit and GluA1 and GluA2 AMPA receptor subunits were in-
creased in the ACC of SDS mice. This increases were attenuated by
imipramine or L-carnosine treatment.
Conclusion : Our present results suggest that L-carnosine might be
eﬀective for long-lasting behavioral plasticity in response to aversive
social experience. We also hypothesized that enhanced glutamatergic
functions in ACC might be involved in the avoidance of social contact
after repeated SDS.
jP-15-034jThe eﬀects of mGlu2/3 agonist on neurochemical
and electrophysiological changes induced by
hallucinogen 4-bromo-2,5-dimethoxyphenetyhlamine
(2C-B)
T. Palenicek1, M. Fujakova1, F. Tyls1, A. Kubesova1, M. Brunovsky1,
L. Rambousek2, K. Syslova´2, P. Kacer2, V. Krajca3, J. Horacek1.
1Prague Psychiatric Center, Prague 8, Czech Republic ; 2 Institute of
Chemical Technology Prague, Prague 6, Czech Republic ; 3Faculty of
Biomedical Engineering, Czech Technical, Kladno, Czech Republic
Objective : Increases in the release of glutamate in the prefrontal
cortex (PFC) and disrupted functional connectivity induced by hallu-
cinogenic drugs have been proposed to be linked to hallucinogenesis
and psychotic symptoms. Therefore we examined whether inhibition
of this release by the metabotropic glutamate 2/3 (mGlu2/3) receptor
agonist (LY379268), will normalize the neurochemical and electro-
physiological eﬀects of the hallucinogen 4-bromo-2,5-dimethox-
yphenetyhlamine (2C-B). We concentrated on neurotransmission
in the prefrontal cortex (PFC) and cortical functional connectivity
(EEG spectra and coherence).
Methods : Male Wistar rats were used in all experiments.
Microdialysis of PFC was performed to measure levels of dopamine,
serotonin and their metabolites, and of glutamate and GABA. Cortical
EEG was recorded from 6 pairs of electrodes on each hemisphere
above the frontal, parietal and temporal cortex in freely moving rats.
EEG power spectra and coherence in EEG traces that correspond
to behavioral inactivity were subsequently analyzed in Neuroguide
Deluxe v.2.6 software.
Results : 2C-B increased the levels of dopamine, serotonin and
glutamate and decreased the levels of GABA in PFC. LY379268 nor-
malized the eﬀects of 2C-B on glutamatergic neurotransmission,
slightly potentiated the release of dopamine and serotonin and had no
eﬀect on GABA. 2C-B induced EEG power decreases except in theta
and alpha bands and globally decreased coherence. LY379268 nor-
malized 2C-B induced a power decrease in delta, potentiated the
decrease in all other bands and completely reversed decreased
coherence in the gamma band.
Conclusion :mGLU2/3 agonism selectively reversed changes in the
glutamate release in PFC and gamma coherence. However, the lack of
eﬀectiveness on most other parameters revealed that the glutamate
release induced by 2C-B only partially contributes to its psychedelic
potential. Our data have implications for serotonin-glutamate inter-
actions in psychoses and hallucinogenesis. This study was supported
by the grants IGAMHCR NS10374-3, NS 10375-3, MEYSCR1M0517,
MHCRMZ0PCP2005, MICR VG2VS/200 and VG2VS/271.
jP-15-035jLong-lasting memory abnormalities following
exposure to the mouse defense test battery
J. Philbert1, C. Belzung2, G. Griebel3. 1Sanoﬁ, Exploratory Unit, Chilly-
Mazarin, France ; 2 INSERM U-930, Universite´ Franc¸ois Rabelais, Tours,
France ; 3Sanoﬁ, Chilly-Mazarin, France
Objective : Memory dysfunctions are thought to play a crucial role
in development and maintenance of post-traumatic stress disorder
(PTSD). Patients persistently re-experience the traumatic event
particularly when exposed to trauma-related cues and display mem-
ory alterations (Morey et al., 2009 ; Chemtob et al., 1999). The objective
of the present study was to investigate potential long-term eﬀects of
predatory stress exposure on short-term episodic memory in mice by
evaluating their cognitive performance following or not trauma con-
text exposure.
Methods : Mice were exposed to the mouse defense test battery
(MDTB), a test designed to investigate defensive responses of mice
confronted with a rat (Griebel et al., 1995). Two weeks later, stressed
and control mice were placed in the MDTB apparatus. Locomotion
and escape attempts from the cage were measured. Two hours later,
their cognitive performances were evaluated using the object recog-
nition task.
Results : Mice exposed to the MDTB procedure displayed ﬂight,
avoidance, defensive and attack reactions, risk assessment behaviors
and increased escape attempts. When mice were exposed again to the
MDTB apparatus two weeks later, they displayed signiﬁcantly more
escape attempts than naive animals. Moreover, stressed mice not
exposed to the MDTB prior to memory testing displayed impaired
cognitive performance in the object recognition task. In contrast,
stressed mice exposed to the MDTB apparatus two hours prior to
the memory test, had similar cognitive performance than control
animals.
Conclusion : These ﬁndings demonstrate that MDTB exposure
causes long-lasting behavioral alterations. Interestingly, the stress-
induced cognitive deﬁcit can be alleviated by exposure to the trau-
matic environment in the absence of stressor. It can be hypothesized
that re-exposure to the context resulted in an increase of arousal or
vigilance, which subsequently led to an improvement in cognitive
performance. In conclusion, this procedure reproduces some of the
symptoms observed in patients suﬀering from PTSD and may thus be
of interest for studies on the complex interaction between emotion
and memory in PTSD.
jP-15-036jSexually dimorphic dopaminergic dysfunction
in a mouse model of Huntington’s disease
and depression
T. Renoir1, A. Argyropoulos1, A.J. Hannan1. 1Florey Neuroscience
Institutes, Parkville, Australia
Objective : Depression is the most common psychiatric disorder in
Huntington’s disease (HD) patients. There is yet to be a study of sex-
ual dimorphism in the development and presentation of depression
in HD patients. Interestingly, we have previously reported a female-
speciﬁc depression-like phenotype in the R6/1 transgenic mouse
model of HD associated with serotonergic system alterations. We now
extend these ﬁndings to include sex-dimorphic dopaminergic (DA)
dysfunction at an early pre-motor symptomatic disease stage.
Methods : In order to investigate whether transgenic HD mice dis-
play depressive-like endophenotypes associated with dopaminergic
impairments, we assessed the eﬀect of several dopaminergic ligands
(including the DA transporter inhibitor bupropion, as well as SKF-
81297 and ropinirole, respectively D1 and D2/D3 receptor agonists)
on the forced-swim test (FST) and on locomotor activity in 8–12-week-
old male and female HD mice.
Results : Overall we found that compared to female animals, males
were more sensitive to the locomotor stimulating eﬀects of bupropion
at both 8 and 12 weeks of age, which were successfully attenuated
with the selective D1 antagonist SCH-23390. In addition, 8-week-old
HD females but not males showed an impaired locomotor response to
bupropion. The HD mutation also resulted in a decrease of locomotor
response to the D1 agonist SKF-81297. In contrast, the selective D2/D3
agonist ropinirole signiﬁcantly reduced locomotor activity in all
animals. However, this eﬀect seemed dose–dependently reduced
in HD compared to WT mice. Finally, the depressive-like behavior
exhibited by female HD mice in the FST was rescued by acute bu-
propion, possibly through a mechanism involving D2/D3 receptor
signaling.
Conclusion : Our data suggest a crucial role for disrupted
dopaminergic signaling in mediating the sexually dimorphic de-
pression-like phenotype in HD mice and provide evidence suggest-
ing that bupropion could be explored as a potential antidepressant
in HD.
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jP-15-037jPharmacological characterization of the glycine
transporter-1 inhibitors RG1678 and SSR504734 in
rodent models for treatment of cognitive and
positive symptoms in schizophrenia
H. Rosenbrock1, R. Giovannini2, B. Schmid3, R. Arban3, C. Dorner-
Ciossek3. 1BI Pharma GmbH & Co. KG, Biberach, Germany ; 2BI Research
Italy, Milano, Italy ; 3BI Pharma GmbH & Co. KG, Biberach, Germany
Objective : Evidence from numerous clinical and preclinical studies
has led to the hypothesis that hypofunction of N-methyl-D-aspartate
(NMDA) receptors play an important role in the pathophysiology of
schizophrenia involving positive, negative and cognitive symptoms.
One approach to counteract NMDA receptor hypofunction is the
extracellular increase of the NMDA receptor co-agonist glycine by
glycine transporter-1 (GlyT1) inhibitors. Thus, by strengthening
glutamatergic neurotransmission, inhibiting GlyT1 has the potential
for treatment of positive and cognitive symptoms of schizophrenia,
besides the shown eﬃcacy on negative symptoms in a recent clinical
trial (Umbricht et al., 2011). In the present study, the GlyT1-inhibitors
RG1678 (Umbricht et al., 2011) and SSR504734 (Depoortere et al., 2005)
were evaluated in models of positive and cognitive symptoms in
rodents.
Methods : Adult male rats were administered with two diﬀerent
GlyT1-inhibitors, SSR504734 (as racemate) or RG1678, and the in-
crease of glycine in CSF was determined via LC/MS-MS analysis.
Regarding antipsychotic and memory enhancing eﬃcacy, both
compounds were tested for reversal of ketamine induced hyper-
locomotion in rats and for reversal of MK-801 induced memory
impairment in the mouse T-maze spontaneous alternation task.
Results : RG1678 and SSR504734 led to a dose-dependent increase
of glycine in rat CSF. Both compounds also showed antipsychotic-
like and pro-cognitiv eﬃcacy in the hyperlocomotion test and
T-maze task, respectively. However, the eﬃcacious dose/exposure
range in T-maze was 5–10-fold lower than in hyperlocomotion test.
Conclusion : The results of this study demonstrate preclinical
eﬃcacy of GlyT1-inhibitors in rodent models for positive and cog-
nitive symptoms of schizophrenia conﬁrming previous ﬁndings
(Depoortere et al., 2005). The marked diﬀerence of eﬃcacious
doses between antipsychotic and pro-cognitive activity might indicate
that diﬀerent levels of NMDA receptor potentiation via glycine
increase are needed for the treatment of positive or cognitive symp-
toms. Depoortere et al., (2005), Neuropsychopharmacology 30,
1963–1985. Umbricht et al., (2011), Schizophrenia Bulletin 37(Suppl.),
P324.
jP-15-038jBehavioral analysis of LRP1 mediated brain
adaptation
U. Schmitt1, M. Bednorz2, C. Pietrzik3. 1University Medical Center,
Mainz, Germany ; 2University Medical Center, Department of Psychi-
atry, Mainz, Germany ; 3University Medical Center, Institute of
Pathobiochemistry, Mainz, Germany
Objective : Several lines of evidence positioned the LDL receptor gene
family as one of the key players in homeostasis of neuronal signalling.
The Low Density Lipoprotein Receptor-Related Protein 1 (LRP1) is
well recognized as a receptor for amyloid b (Ab) and its modulation a
possibility in Alsheimer´s disease therapy. But recently, a new inter-
action between LRP1 and the NMDA receptor has been found. It was
demonstrated that knock-in mutations in the C-terminus of LRP1 di-
rectly inﬂuence NMDA receptor function. The in vivo relevance of
that mechanism is unknown.
Methods : To analyse the eﬀect of a perturbed LRP1 function on the
NMDA receptor due to the knock-in mutation in the LRP1 gene we
compared transgenic LRP1 KI mice to wild type littermates for a be-
havioural phenotype. Animals were tested with respect to activity
(open ﬁeld), anxiety (elevated plus maze, light dark chamber), learn-
ing and memory (object recognition, Morris Water maze) as well as
locomotion (Rotarod).
Results : The open ﬁeld paradigm revealed a tendency to hyper-
activity of the LRP1 KI mice. No diﬀerences between genotypes were
seen with respect to anxiety-related behaviours. Learning and mem-
ory related behaviours in the MWM test indicated that wild type mice
learned the position of the hidden platform faster and more accurately
compared to LRP1 KI mice. Similarly in a relearning paradigm and
with respect to emotional memory wildtype mice were superior.
However LRP1 KI mice outperformed wild type littermates on the
Rotarod task for locomotion.
Conclusion : Presently those behavioural alterations in form of
hyperactivity and altered spatial learning parallel eﬀects seen in con-
ditional knock out of LRP1 but also after antagonism of the NMDA
receptor giving a ﬁrst in vivo indication of a reduced LRP1 NMDA
receptor-related interaction in those transgenic mice. This opens
new possibilities for NMDA receptor modulation under pathological
conditions.
jP-15-039jRisperidone attenuated serotonin syndrome animal
model induced extracellular nitric oxide and
glutamate
K. Shioda1, K. Nisijima1, M. Kasai1, T. Yoshino1, S. Kato1. 1 Jichi
Medical University, Tochigi, Japan
Objective : As serotonergic agents prescription has increasing, sero-
tonin syndrome has been major and important health issue. Recently,
several studies reported that glutamate and nitric oxide (NO) play a
role in psychostimulant drugs-induced hyperthermia which related
to neurotoxicity. Therefore we hypothesized that serotonin animal
model can raise glutamate and NO concentration and those increasing
may be attenuated by risperidone (potent 5-HT2A and D1 rreceptor
antagonist) treatment. We therefore measured the changes in the le-
vels of glutamate and NO metabolites in the anterior hypothalamus
by using microdialysis method.
Methods : Male Wistar rats were used in this study. All the animal
procedures employed were approved by the Animal Investigation
Committee of our School and were in strict accordance with the NIH
Guide for the Care and Use of Laboratory Animals. Two diﬀerent
serotonin syndrome animal models were prepared. In the ﬁrst
model, tranylcypromine (3.5 mg/kg) and ﬂuoxetine (10 mg/kg)
were simultaneously intraperitoneally (i.p.) administered to rats.
We simultaneously administrated clorgyline (1.2 mg/kg) and 5-HTP
(80 mg/kg) i.p. to rats in the second model. The perfusate was col-
lected and injected into a HPLC unit by using an automatic injector
and the levels of glutamate and NO metabolites (NOx) were
immediately determined.
Results : In the both animal models induced NOx levels increasing
and each increasing were attenuated by risperidone (0.5 mg/kg)
pretreatment. Extracellular levels of glutamate were increased in
the ﬁrst animal model, but not second animal model, and risperiodne
pre-administration attenuated which increasing.
Conclusion : Previous studies have reported that D1 receptor
activation induces glutamate levels increasing and D1 and 5-HT2A
receptors activation increase the NOx synthesis, therefore risper-
idone’s D1 and 5-HT2A receptors antagonistic eﬀect were assumed to
suppress glutamate and NOx increasing.
jP-15-040jBlockade of the nmda-no pathway in the
ventromedial prefrontal cortex (vmpfc) induces
antidepressant-like eﬀects
V. Silva Pereira1, S.R.L. Joca1. 1University of Sa˜o Paulo, Ribeira˜o Preto,
Brazil
Objective : Stress exposition enhances glutamate and nitric oxide
(NO) levels into the central nervous system. Depressed individuals
show enhanced levels of glutamate and neuronal nitric oxide synthase
(nNOS) in limbic structures. Administration of antagonists of gluta-
mate NMDA receptors or inhibitors of NO synthesis induces anti-
depressant-like eﬀects. The aim of the present study was to evaluate
the participation of the glutamatergic and nitrergic systems of the
vmPFC over the behavioral consequences induced by forced swim-
ming (FS), an animal model of depression.
Methods : Male Wistar rats (230–260 g) with guide cannulas aimed
at the prelimbic (PL) region of vmPFC were submitted to a 15 min
session of FS and, 24 h later, they were submitted to a 5 min session
of the FS test when the immobility time was measured. Injection
of LY235959 (LY ; NMDA antagonist at 1, 3 and 10 nmol/0.2mL),
NPA (nNOS inhibitor at 0.01 nmol/0.2 mL), c-PTIO (NO scavenger
at 1.0 nmol/0.2 mL), ODQ (soluble guanylyl cyclase- sGC – inhibitor
at 1.0 nmol/0.2 mL) or vehicle was realized 5 min before the test
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session. All data were analyzed by ANOVA followed by Dunnet’s
post-hoc test.
Results : LY administration into vmPFC-PL reduced the immobility
time (Mean¡SEM : vehicle : 116.3¡21.17 ; LY 1 nmol : 164.4¡18.92 ;
LY 3 nmol : 28.71¡10.21* ; LY 10 nmol : 39.43¡7.99* ; *p<0.05 from
control group). NPA, c-PTIO and ODQ induced similar eﬀects
(Mean¡SEM: vehicle : 140.1¡15.23 ; NPA : 47.57¡10.42* ; c-PTIO :
56.86¡10.62* ; ODQ : 81.20¡15.99* ; *p<0.05 from control group).
Conclusion : These results show for the ﬁrst time that the blockade
of NMDA receptors, NO synthesis or sGC activity in the vmPFC-PL
induces antidepressant-like eﬀects. Therefore, the activation of the
NMDA-NO-cGMP pathway in the vmPFC in response to stress may
facilitate the development of its behavioral/emotional outcomes.
jP-15-041jThe role of dopamine signalling in the GABAergic
neuron development and motor behavior in
zebraﬁsh larvae
B. Souza1, V. Tropepe2, M. Romano-Silva1. 1UFMG, Belo Horizonte,
Brazil ; 2University of Toronto, Canada
Objective : An imbalance in dopamine-mediated neurotransmission
and neurodevelopmental abnormalities are features of schizophrenia.
The main target of antipsychotics, the dopamine D2 receptor, mod-
ulates the activity of Akt and DARPP-32, which are downregulated
in the brain of schizophrenic patients. To investigate if altered
D2-dependent signalling leads to abnormal neurodevelopment, we
ﬁrst evaluated if dopamine modulates Akt and DARPP-32 signalling
in the developing brain. Later, we investigated the role of dopamine in
the development of GABAergic neurons and the eﬀects in the motor
behavior.
Methods : Since the zebraﬁsh development is external, we used
zebraﬁsh as experimental model. We treated 3 days post fertilization
(dpf) and 5 dpf zebraﬁsh larvae with dopaminergic agonists and
antagonists to evaluate the dopaminergic intracellular pathways. In
order to investigate the role of dopamine in the neurodevelopment,
we examined dlx6 :gfp transgenic 3 dpf larvae, which express GFP
in several forebrain GABAergic neurons, chronically exposed to
dopamine. Ultimately, we recorded and analyzed the motor behavior
of the larvae.
Results : We observed dephosphorylation of Akt at threonine 308
(T308) and DARPP-32 at threonine 34 (T34) through D2 receptors.
Chronic exposure to dopamine resulted in region speciﬁc alterations
in the number of GABAergic neurons, but not the total number of
cells. Furthermore, we observed that dopamine aﬀects motor behav-
iour in 3–5 dpf larvae.
Conclusion : Together, our data suggest that dopamine signalling
represses Akt and DARPP-32 signalling in the developing brain and
leads to defects in GABAergic neuronal diﬀerentiation in the zebraﬁsh
larval brain. Furthermore, the alterations in forebrain GABAergic
neurons are correlated with altered context-dependent motor behav-
iour. Thus, with this model system, we could holistically assay the
biochemical, morphological, and behavioural consequences of altered
dopamine signalling during development. These results will help
shape our understanding of the role of dopamine in brain develop-
ment and provide new mechanistic insight for further assessing the
neurodevelopmental origin model of schizophrenia.
jP-15-042jNeonatal exposure to mk-801 impairs working
memory in adult rats that can be ameliorated by
galantamine
Y.-A. Su1, R.-H. Huang1, J.-T. Li1, T.-M. Si1. 1 Institute of Mental Health,
Beijing, China
Objective : The N-methyl-D-aspartate (NMDA) receptor plays a
crucial role in developmental plasticity. It has been shown that neo-
natal exposure to NMDA receptor antagonists impairs cognitive
function in adult rats. The aim of this study was to examine the eﬀects
of acetylcholinesterase inhibitors on working memory deﬁcits in adult
rats induced by neonatal MK-801 treatment.
Methods : Timed-pregnant Sprague-Dawley rats were obtained
from the Peking University Health Science Center. The day of birth
was considered postnatal day (PND) 0. From PND5-14, male pups
were injected subcutaneously with MK-801 or saline twice daily
beginning at 9:00 and 17:00, respectively. The animals were tested for
spatial working memory performed in Morris water maze task in
adulthood (PND 63–69). Rats were randomly assigned to treatment
with galantamine (1.0 mg/kg) or saline. Drug or saline was injected
each day 30 min before the animals were tested in the Morris
water maze. Twelve rats were used in each group : saline-saline,
MK-801-saline, saline-galantamine, MK-801-galantamine.
Results : Male MK-801-treated rats exhibited impaired working
memory during adulthood. This cognitive deﬁcit was ameliorated by
chronic treatment with galantamine.
Conclusion : These results suggest that a brief disruption of NMDA
receptors during a sensitive period of cortical development can
produce long lasting working memory deﬁcits in male rats that are
relevant to schizophrenia. In addition, AChE inhibitor galantamine
ameliorated memory deﬁcits produced by MK-801, which may have
relevance for the cognitive eﬀects of cholinomimetic drugs in patients
with schizophrenia.
Policy of full disclosure : This work was supported by the Natural
Science Foundation of China ( No :30770775 and 30800361).
jP-15-043jThe eﬀects of antipsychotics on amphetamine
induced recall impairments in a visuo-spatial paired
associates learning task using touchscreen equipped
operant boxes
J. Talpos1, N. Aerts1, L. Fellini1, T. Steckler1. 1 Janssen Pharmacutica,
Beerse, Belgium
Objective : The use of operant boxes equipped with touchsensitive
computer monitors for the testing of cognition in rodents is becoming
increasingly popular. However to date the majority of published work
has focused on task validation via lesions or direct administration
of compound to areas of interest. Little work has been done demon-
strating the pharmacological sensitivity of these assays, leaving there
utility for the drug discovery process largely unexplored. Here we
attempt to demonstrate that a touchscreen test of visuo-spatial paired
associates learning (PAL) can be selectively impaired by a pharmaco-
logical model of schizophrenia, and that this impairment can be
reversed.
Methods : Rats (male lister-hooded, Harlan) were trained in a PAL
task (Talpos et al., 2009, Psychopharmacology) performed in Med
Associates operant boxes run by K-Limbic software (Conclusive
Solutions). Once the task was acquired 0.5 mg/kg of amphetamine
given 60 minutes prior to testing, a dose known to selectively impair
accuracy, was used to disrupt recall. We then attempted to reverse
this disruption with common antipsychotics including risperidone
(0.04–0.16 mg/kg) and haloperidol (0.01–0.04 mg/kg) given 30 min
prior to behavioral testing.
Results : Haloperidol and risperidone were both shown to dose
dependently lessen the amphetamine induced impairment without
substantially altering response latencies.
Conclusion : A ‘‘low’’ dose of amphetamine consistently induced
a selective impairment in performance of an object-in-place PAL task.
This impairment was partially reversed by administration of common
antipsychotics risperidone and haloperidol. While additional work
will be required to see if this model has utility in exploring mech-
anisms beyond D2 receptor antagonism, these data demonstrate the
potential utility of this assay and challenge model for pharmacological
research. These results and additional data will be discussed, along
with the translational value of this approach.
Policy of full disclosure : All authors work for Janssen pharma-
ceutical companies of Johnson and Johnson, makers of risperidone
and haloperidol.
jP-15-044jSocial-cooperation is associated with increased
levels of hypothalamic nor-epinephrine and striatal
serotonin – evidence from a laboratory rat model
M. Tsoory1, M. Youdim2, R. Schuster3. 1Weizmann Institute of Science,
Rehovot, Israel ; 2The Technion, Haifa, Israel ; 3University of Haifa, Israel
Objective : Explanations and models of cooperation usually
focus on the ‘economics’ of individual’s ‘ invested eﬀorts ’ and ‘out-
comes’ while down-playing adjunct social dimensions of naturally
occurring cooperation. This study examined whether cooperative and
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individual behaviors diﬀer in monoaminergic function in a manner
that may explain the reported ‘bias for cooperation’ even in situations
where there is no immediate economic gain.
Methods : Cooperation, represented by pairs of rats reinforced
for coordinated shuttles within a shared chamber (COOP), was
compared with individual rats shuttling for reinforcements (IND),
and behaviorally naı¨ve rats (NAIVE). Following training, the hypo-
thalamus and striata were sampled and the activity pattern of the
noradrenergic, serotonergic and dopaminergic systems were assessed
using HPLC analyses.
Results : Since rates of shuttling and reinforcements were con-
trolled, COOP and IND rats did not diﬀer at the individual level
in either ‘ invested eﬀort ’ (shuttles) or ‘outcomes’ (reinforcements).
Nevertheless, diﬀerences were evident in monoaminergic functions.
COOP rats exhibited signiﬁcantly higher hypothalamic nor-
epinephrine levels than IND and NAIVE rats. Compared to IND rats,
COOP rats exhibited signiﬁcantly higher striatal serotonin levels.
Diﬀerences in levels of dopaminergic metabolites were restricted
to the right striatum ; compared to IND rats COOP rats exhibited sig-
niﬁcantly higher levels of HVA, whereas NAIVE rats exhibited
signiﬁcantly higher DOPAC levels.
Conclusion : These diﬀerences are dissociated from the ‘economics’
of ‘eﬀort ’ and ‘outcomes’ and thus highlight the importance of social
behaviors in the reported ‘bias for cooperation’ as they demonstrate a
relationship between social cooperation and a distinct activity pattern
in brain mechanisms that were related with arousal, goal directed
behaviors and motivation.
jP-15-045jA comparison of electroencephalographic activity in
serotonergic and gultamatergic models of psychosis
F. Tylsˇ1, T. Pa´lenı´cek1, M. Fuja´kova´1, A. Kubesˇova´1, M. Brunovsky´1,
J. Hora´cek1, V. Krajca1. 1Psychiatric Centre Prague, Czech Republic
Objective : We focused on the electrophysiological changes in the
two most reliable pharmacological models of psychosis, serotoner-
gic (indolamine (psilocin), ergoline (N,N-diethyllysergamid, LSD)
and phenylethylamine (mescaline) hallucinogens) and glutamatergic
(N-methyl-D-aspartate receptor (NMDA) antagonists ketamine and
dizocilpine (MK-801)). The objective of this study was to compare
these models from the aspect of functional connectivity using
quantitative EEG.
Methods : After stereotactical implantation and recovery, cortical
EEG was recorded from 6 pairs of electrodes on each hemisphere
above the frontal, parietal and temporal cortex in freely moving rats.
EEG power spectra (local synchronization) and coherence (long pro-
jections) were subsequently analyzed in Neuroguide Deluxe v.2.6.
In order to make a translational approach to human recordings only
EEG traces that correspond to behavioral inactivity (model of resting
EEG) were processed.
Results : In all serotonergic models a general decrease in EEG
spectral power as well as in EEG coherences was observed. Psilocin
and LSD caused a signiﬁcant power decrease in all frequency bands,
while the decrease after mescaline was signiﬁcant only in lower
frequencies. The most prominent decrease in EEG coherences was
observed in delta and theta bands after all serotonergic drugs. In
glutamatergic models ketamine and MK-801 increased power in the
gamma band ; a discrete decrease in theta and beta band after MK-801
was also observed. Both substances induced a signiﬁcant reduction of
EEG coherence across the whole spectrum with most prominent
changes in the delta and theta bands.
Conclusion : In conclusion, there was a clear disconnection of long
projections in the brain shared by both models. On the contrary there
were group speciﬁc eﬀects on local synchronization. Both eﬀects
were group-speciﬁc, indicating the validity of data. Our results will be
discussed in comparison with ﬁndings from schizophrenic patients.
This study was supported by the grants IGAMHCR NS10374-3,
NS 10375-3, MEYSCR1M0517, MHCRMZ0PCP2005, MICR VG2VS/
200 and VG2VS/271.
jP-15-046jEﬀect of transient blockade of N-methyl-D-aspartate
receptors at neonatal stage on stress-induced lactate
metabolism in the medial prefrontal cortex of adult
rats : Role of serotonin-1A receptor agonism
T. Uehara1, H. Itoh1, T. Matsuoka1, D. Rujescu2, J. Genius2, T. Seo1,
T. Sumiyoshi1. 1University of Toyama, Japan ; 2Ludwig-Maximilians
University, Munich, Germany
Objective : Decreased activity of the prefrontal cortex (PFC) has been
considered to provide a basis for the pathophysiology of schizo-
phrenia, an illness associated with a neurodevelopmental origin.
Evidence from preclinical and clinical studies indicates serotonin
(5-HT)1A receptors play a crucial role in energy metabolism of the
PFC. The present study was undertaken to determine 1) if transient
blockade of N-methyl-D-aspartate (NMDA) receptors during the
neonatal stage inhibit energy demands in response to stress, as
measured by extracellular lactate concentrations, in the medial PFC
(mPFC) at the young adult stage, and 2) if tandospirone, a 5-HT1A
partial agonist, reverses the eﬀect of the neonatal insult on energy
metabolism.
Methods : The procedures complied with the National Institutes of
Health Guideline for the care and use of Laboratory animals. All ex-
periments were reviewed and approved by the Committee of Animal
Research, University of Toyama. Male pups received MK-801
(0.20 mg/kg) on postnatal day (PD) 7 through 10. On PD 63, footshock
stress-induced lactate levels were measured using in vivo micro-
dialysis technique. Tandospirone (0.1, 1.0, 5.0 mg/kg) was adminis-
tered once daily for 14 days before the measurement of lactate levels.
Results : Neonatal MK-801 treatment suppressed footshock stress-
induced lactate production in the mPFC, but not caudate-putamen
(CPu), whereas basal lactate levels were not signiﬁcantly changed in
either brain region. The MK-801-induced suppression of footshock
stress-induced lactate production in the mPFC was attenuated by
tandospirone at 1.0 mg/kg/day, but not 0.1 or 5.0 mg/kg/day, an
eﬀect antagonized by co-administration of WAY-100635, a selective
5-HT1A antagonist.
Conclusion : These results suggest a role for impaired lactate
metabolism in negative symptoms and cognitive deﬁcits of schizo-
phrenia, and provide a novel insight into the ability of 5-HT1A
receptor agonists to treat these symptoms.
jP-15-047jPostnatal developmental changes in the gene
expression patterns induced by systemic
administration of methamphetamine in the
rat neocortex
M. Umino1, N. Yamamoto1, A. Umino1, A. Kurumaji1, T. Nishikawa1.
1Tokyo Medical and Dental Univ, Bunkyo, Japan
Objective : The onset of schizophrenia and the schizophrenomimetic
eﬀects of dopamine agonists and N-methyl-D-aspartate (NMDA)
receptor antagonists rarely occur during infancy and childhood, sug-
gesting that schizophrenia-related neuron circuits and molecules
in the brain could exhibit an age-dependent and a critical period-
associated response to these schizophrenomimetics.
Methods : To test this hypothesis to get an insight into the mol-
ecular basis of the onset of schizophrenia, we have explored in the
developing rat brain at postnatal days 8, 18, 25 and 50 the areas and
genes whose responses to a schizophrenomimetic dopamine agonist,
methamphetamine (MAP), are developmentally regulated by em-
ploying an activity mapping using c-fos gene expression, a DNA
microarray technique and a quantitative RT-PCRmethod. The present
animal experiments have been approved by the ethics committees of
the Tokyo Medical and Dental University.
Results : To test this hypothesis to get an insight into the molecular
basis of the onset of schizophrenia, we have explored in the de-
veloping rat brain at postnatal days 8, 18, 25 and 50 the areas and
genes whose responses to a schizophrenomimetic dopamine agonist,
methamphetamine (MAP), are developmentally regulated by em-
ploying an activity mapping using c-fos gene expression, a DNA
microarray technique and a quantitative RT-PCRmethod. The present
animal experiments have been approved by the ethics committees of
the Tokyo Medical and Dental University.
Conclusion : These data suggest that the neocortex and the
genes showing the critical period-related expressional changes could
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compose the neuron circuits and molecular cascades, respectively,
which might be involved in the pathophysiology of schizophrenia.
jP-15-048jEﬀects of chronic social defeat stress on behavior in
adult mice and expression on ChAT
T. Zhao1, G.B. Huang1, S. Shrestha Muna1, Y.-C. Chung1. 1Chonbuk
National University, Jeonju, Republic of Korea
Objective : Because social factors play a key role in human stress
precipitated brain disorders, social defeat stress is widely used in
biomedical research to model various psychiatric disorders in ani-
mals. The purpose of the present studies was to observe the behavior
of the adult mice and expression on choline acetyltransferase (ChAT)
after social defeat.
Methods : Male C57BL/6J mice were divided into two groups
(susceptible and unsusceptible groups) after 10 days of social de-
feat stress. Next, we measured spontaneous locomotion and social
interaction test, dark/light test, Morris water maze test, novel object
recognition test (NORT) and forced swimming test (FST). Choline
acetyltransferase (ChAT) expression was measured in the mouse
prefrontal cortex (PFC), amygdala and hippocampus using Western
blotting.
Results : There was no diﬀerence in locomotor activity between
control, susceptible and unsusceptible groups. In dark/light test, the
defeated mice spent much more time in the dark box than control
group and took longer to emerge from the dark box than control
group. However, between susceptible group and unsusceptible group,
there was no signiﬁcant diﬀerence. Susceptible group displayed sig-
niﬁcant impairment of memory for the novel object recognition and
decreased social sniﬃng compared with control group in NORT and
social interaction test, respectively. On the other hand, in Morris water
maze, there was no diﬀerence of escape latency and spent time in the
target quadrant between control and defeated groups. In FST, sus-
ceptible group displayed signiﬁcantly more immobility time com-
pared with control and unsusceptible groups. ChAT expression in the
PFC, amygdala and hippocampus was signiﬁcantly decreased in
susceptible group as compared to control.
Conclusion : Our results suggest that chronic social defeat stress in
mice produces signiﬁcant decrease of social interaction, impairment
of memory for novel object, increase of immobility and signiﬁcant
decreased expression of ChAT in the PFC and hippocampus. The
clinical implications of these ﬁndings should be discussed with regard
to environmental causes for mental disorders.
P-16. Imaging
jP-16-001jQuantitative immunohistochemical mapping of
neurochemicals in the human brain
K. Akiyama1, K. Yabe2, D. Sutoo2. 1University of Tsukuba, Japan ;
2University of Tsukuba, Institute of Medical Science, Japan
Objective : We developed a human brain mapping analyzer to
determine quantitative immunohistochemical distributions of neuro-
chemicals in a large tissue slice at the cellular or near-cellular level
(Sutoo et al., 1998). In this study, the distributions of choline acetyl-
transferase, tyrosine hydroxylase, dopamine-beta-hydroxylase,
glutamate decarboxylase, glutamate dehydrogenase, calmodulin
and substance P in the human brain were analyzed using this
analyzer.
Methods : The brains of three male adults (age range : 50–70) with
no history of neurological or psychiatric disorders were perfused with
ice-cold ﬁxative within 8 h following death. After ﬁxation, the right
hemisphere was sectioned at a thickness of 20 micron, and consecu-
tive coronal slices were stained ﬂuorescent immunohistochemically.
Each stained slice was divided into approximately 3 million micro-
areas at 50 micron intervals, and the ﬂuorescence intensities in the
microareas were measured quantitatively.
Results : Autoﬂuorescence in the brain slice was eliminated photo-
metrically, and pure immunohistochemical distribution was obtained
(Sutoo et al., 1998, 1999, 2000, 2001). Its quantitative linearity sur-
passes that of the image analyzers used with TV cameras, and the
sensitivity is greater than that of HPLC. Also, the measuring area is far
larger than that of laser confocal microscopes.
Conclusion : This method is a powerful technique for quantitative
and comparative analysis of the distributions of neurochemicals in the
whole brain slices, and we believe that it will facilitate the investi-
gation of the functions of the central nervous system and disorders
thereof in various diseases.
References
Sutoo D, Akiyama K, Yabe K (1998) Journal of Neuroscience Methods
85, 161–173.
Sutoo D, Yabe K, Akiyama K (1999) Neuroscience Research 35,
339–346.
Sutoo D, Akiyama K, Yabe K (2000) Human Brain Mapping 11,
93–103.
Sutoo D, Akiyama K, Yabe K (2001) Journal of Neuroscience Research
63, 369–376. URL for analyzer, http://www.yamato-net.co.jp/
english/products/bio/mapanalyzer.htm
jP-16-002jReduced hippocampal grey matter in depression :
Eﬀect of state and short-term antidepressant
treatment
I.M. Anderson1, D. Arnone2, S. McKie2, R. Elliott2, G. Juhasz2,
E. Thomas2, D. Downey2, S. Williams2, J.W. Deakin2. 1University
of Manchester, G. 907 Stopford, United Kingdom ; 2University of
Manchester, United Kingdom
Objective : Loss of grey matter volume in the hippocampus is one of
the most replicated structural changes in depression. Antidepressants
induce neuroplastic eﬀects in the hippocampus in animal but eﬀects of
antidepressants in this region have not been demonstrated in humans.
In this study we aimed to determine (1) whether grey matter loss in
the hippocampus in depression is a current state or trait abnormality
and (2) whether rapid change can be detected following anti-
depressant treatment and associated clinical improvement.
Methods : We recruited 64 medication free unipolar depressed
patients (39 currently depressed and 25 in remission) and 66 healthy
controls who underwent structural magnetic resonance imaging.
Thirty-two currently depressed participants were treated with the
antidepressant citalopram for 8 weeks. Adherence to treatment
was evaluated by measuring plasma citalopram concentration. We
measured regional variation of grey matter concentration by using
voxel-based morphometry (VBM-DARTEL).
Results : In the cross sectional study patients with current de-
pression had reduced grey matter concentration in the hippocampus
vs. healthy controls (L :x28,x16,x23 ; R : 28,x23,x24, both whole-
brain FWEc p<0.001) and vs. untreated patients in stable remission
(L : x29, x27, x22 ; FWEc p=0.01 and R : 34, x29, x24, whole
brain FWEc p=0.013). In the longitudinal analysis, after treatment,
there was bilateral hippocampal grey matter increase in currently
depressed participants (L : x24, x4, x25 ; R : 19, x13, x25, both
FWEc p=0.050) but not in healthy controls, although post-treatment
grey matter still remained lower than in controls.
Conclusion : Our results conﬁrm grey matter reduction in the
hippocampus in currently depressed patient that is not present in
those with long-term remission. Short-term, successful antidepressant
treatment partially reverses this abnormality suggesting that this may
be a state-marker for depression.
jP-16-003jGlobal decrease of serotonin-1A receptor binding
after electroconvulsive therapy in major depression
P. Baldinger1, R. Lanzenberger2, A. Hahn2, W. Wadsak3,
M. Mitterhauser3, Z. Micskei4, J. Ungersbo¨ck3, D. Winkler2, S. Kasper2,
R. Frey2. 1Medical University of Vienna, Austria, Austria ; 2Medical
University of Vienna, Psychiatry and Psychotherapy, Vienna, Austria ;
3Medical University of Vienna, Nuclear Medicine, Austria ; 4Medical
University of Vienna, Anaesthesiology, Austria
Objective : Electroconvulsive therapy (ECT) has been successfully
applied as ﬁrst-line approach for treatment-resistant depression.
However, the neurobiological mechanisms underlying its eﬀective-
ness remain unclear, although numerous preclinical studies point
towards a signiﬁcant involvement of the serotonergic system,
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particularly the serotonin-1A receptor (5-HT1A). Considering the
consistently reported 5-HT1A alterations in depression, this study
aims to investigate molecular mechanisms of ECT using positron
emission tomography (PET).
Methods : 12 subjects (8 female, mean age¡SD=47.83¡11.12
years) with severe unipolar depression (HAM-D17 scoreo23), par-
ticipated in this study. Patients underwent 3 PET scans using
[carbonyl-11C]WAY-100635, two before (test-retest reliability) and
one after completed ECT. ECT was carried out according to inter-
national standards, resulting in 10.08¡2.35 sessions. Medication re-
mained in steady-state during the investigation, drugs targeting the
5-HT1A receptor were discontinued prior inclusion. PET scans were
normalized to MNI-space (SPM8). Quantiﬁcation of 5-HT1A receptor
binding potential (BPND) was carried out in PMOD 3.3 using MRTM2
and the cerebellar grey as reference.
Results : Paired-samples t-test showed a signiﬁcant decrease
(t=9.16, p<0.001 ; mean=17.58¡6.65) of HAM-D values after ECT.
Voxel-wise repeated-measures ANOVA revealed a global decrease
of 5-HT1A BPND (p<0.05, FDR-corrected) comparing PET2/PET3,
corresponding to one interconnected cluster (436 cm3) with peak areas
in the anterior cingulate cortex (ACC : t=4.58, x/y/z=2/40/20 mm
MNI space), its subgenual part (sgACC : t=3.77, x/y/z=6/36/-8)
and the amygdala (t=3.91, x/y/z=x26/4/-26 mm). There was no
signiﬁcant diﬀerence comparing PET1/PET2.
Conclusion : Our results substantiate the eﬀectiveness of ECT
in depression. Furthermore, we showed a signiﬁcant decrease of
5-HT1A BPND in depressed patients after ECT aﬀecting virtually the
whole cortex. More precisely, these ﬁndings include brain regions,
consistently reported to present functional and morphological altera-
tions in subjects suﬀering from aﬀective disorders.
jP-16-004jFunctional abnormalities within the working
memory network in remitted major depressive
disorder
L. Bartova1, K. Diers2, C. Scharinger1, U. Rabl1, B. Meyer1, M. Kuhn1,
A. Popovic1, E. Moser1, S. Kasper1, B. Brocke3, L. Pezawas1. 1Medical
University Vienna, Austria ; 2Dresden University of Technology,
Germany ; 3Dresden, Germany
Objective : Highly variable severity and course as well as a hetero-
geneous clinical picture comprising emotional, vegetative, psycho-
motor and cognitive symptoms characterize Major Depressive
Disorder (MDD). Previous neuroimaging studies investigated pre-
dominantly MDD patients with a concurrent depressive episode
compared to healthy controls and repeatedly observed activation
increases within emotion as well as cognition brain circuits. While
limited evidence is available regarding neural alterations in cognition-
related circuits during symptomatic MDD, literally nothing is known
concerning the functionality of working memory (WM) networks
during stable remission.
Methods : Hence, we conducted a cross-sectional functional mag-
netic resonance imaging (fMRI) study with the goal to determine if
WM function and associated neural activation diﬀer between fully
remitted medication-free MDD patients (n=61) and healthy subjects
(N=84) without any previous psychiatric life-time diagnosis. We
employed the so-called n-back WM paradigm.
Results : While no signiﬁcant diﬀerences in task performance were
detected between the groups, activation increases in extended frontal,
parietal and cingulate areas, with punctum maximum in the frontal
gyrus, were identiﬁed in both, remitted MDD (rMDD) patients as well
as controls, during the 2-back versus 0-back condition. Moreover,
relative to controls, rMDD patients showed greater activation in the
left frontal cortex, including inferior and middle frontal gyrus as well
as adjacent areas such as the medial frontal and insular cortex,
with the peak of activation diﬀerences between the left inferior frontal
and precentral gyrus (Z=3.71, p<0.001, uncorrected ; x=x62,
y=12, z=12).
Conclusion :Our ﬁnding of increasedWM-related neural activation
in rMDD patients in comparison to controls in the absence of any
behavioral diﬀerences suggest, that rMDD patients have to compen-
sate underlying deﬁcits in cognitive networks by increasing neural
processing within the same neural circuits in order to maintain a
comparable level of WM performance. Moreover, our results point
towards persisting functional alterations in the cognitive networks
even after a full recovery of MDD.
jP-16-005j Impaired to P-down processing in schizophrenia in
the perception of a hollow mask revealed with
fMRT and event related potentials
W. Dillo1, H. Emrich1. 1Medical High School Hannover, Germany
Objective : Visual illusions can reveal mechanisms of perception that
try to make our world around us meaningful. In order to perceive our
environment around us as meaningful the interaction between bot-
tom-up and top-down processing has to be intact. In this study we use
the principles of the ‘hollow-mask illusion’ to investigate this inter-
action. The hollow-mask illusion occurs when a hollow mask is
perceived (incorrectly) as a normal face. It is understood to be a pro-
cess that involves the generation of hypotheses about the three-
dimensional shape of faces by interpreting the bottom-up signals re-
ceived from the eyes using conceptual and perceptual knowledge
(top-down processing). Healthy volunteers perceive a hollow mask
as a normal face, presumably due to the strength of constraining top-
down inﬂuences, while patients with schizophrenia do not. However
the neural mechanisms underpinning this eﬀect remain poorly
understood.
Methods : We used functional magnetic resonance imaging and
event related potentials to investigate the hollow-mask illusion in
schizophrenic patients and healthy controls. The primary aim of this
study was to use measures eﬀective connectivity arising from dy-
namic causal modelling (DCM).
Results : We identiﬁed diﬀerences between the two groups in ef-
fective connectivity. In particular, there was a strengthening of bot-
tom-up processes, and weakening of top-down ones, during the
presentation of ‘hollow’ faces for the patients. In contrast, the controls
exhibited a strengthening of top-down processes when perceiving the
same stimuli.
Conclusion : These ﬁndings suggest that schizophrenic patients
rely on stimulus-driven processing and are less able to employ con-
ceptually-driven top-down strategies during perception, where in-
coming sensory data are constrained with reference to a generative
model that entails stored information from past experience.
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jP-16-006jCombined in vivo PET-microdialysis studies of NA
release in minipig
D. Doudet1, A. Landau2, S. Jakobsen1, A.K. Alstrup1, A. Mork3,
J.C. Sorensen4, G. Wegener5. 1PET Center, Aarhus University,
Denmark ; 2CFIN, Aarhus University, PET Center, Denmark ;
3H Lundbeck A/S, Copenhagen-Valby, Denmark ; 4Dept. Neurosurgery,
Aarhus University, Denmark ; 5Dept. Biomedicine-Pharmacology, Aarhus
University, Denmark
Objective : To evaluate the hypothesis that [11C]yohimbine, a selec-
tive antagonist tracer of the alpha 2 receptors in tracer dose, may be
used to assess in vivo changes in synaptic noradrenaline (NA) during
acute pharmacological challenges.
Methods : Isoﬂuorane-anesthetized Gottingen minipigs were posi-
tioned in a stereotaxic headholder and a high resolution CT per-
formed in a Siemens PET/CT. Microdialysis probes (CMA70) were
placed stereotaxically in thalamus, striatum and cortex and perfused
with artiﬁcial CSF (2 mL/min). Samples were collected every 10 min
throughout the course of the experiment and immediately frozen
until assay. After a 2–3 hrs equilibrium period, three 90 min
[11C]Yohimbine ( 200–300 MBq in 10 mL, injected mass :<1 mg) scans
were acquired : the ﬁrst (baseline) scan was followed by a pharmaco-
logical intervention (amphetamine (1–10 mg/kg), a non speciﬁc
NA/DA releaser or nisoxetine (1 mg/kg), a speciﬁc NET inhibitor)
and scans at 30 and 150 min after challenge. Vital signs were mon-
itored throughout the course of the study. The animal was humanely
euthanized at the end of the experiment to verify probe integrity and
location. Samples were analyzed with HPLC for NA and DA and
their metabolites. Yohimbine total distribution volume (DVT) were
obtained from thalamus, striatum and several cortical regions as
previously described.
Results : Both pharmacological challenges induced a signiﬁcant
decrease in yohimbine binding, presumably from competition by the
endogenous ligand : cortical and thalamic regions showed the greatest
decrease (>20%) while the striatum had a more moderate decrease
(8–15%) consistent with reduced striatal NA innervation. Dialysis
samples revealed a signiﬁcant increase in NA extracellular con-
centrations after challenge. DA was also signiﬁcantly increased after
amphetamine challenge.
Conclusion : This data suggest that [11C]yohimbine may be a
potential tracer to evaluate acute variations in synaptic NA con-
centrations after pharmacological challenges.
jP-16-007j Imaging endophenotypic biomarkers for
schizophrenic and aﬀective psychoses in key
neural circuits
O. Gruber1, H. Vieker1, E.K. Diekhof1, S. Trost1, A. Fanelli1, K. Jakob1,
A. Petrovic1, K. Weber1, M. Keil1, D. Zilles1, P. Falkai1. 1University of
Goettingen, Germany
Objective : We conducted functional MRI studies in healthy subjects,
patients with schizophrenia and aﬀective disorders and in their
healthy ﬁrst-degree relatives. This combination of investigations per-
mits to identify pathophysiological abnormalities in brain circuits of
psychiatric patients, to test for their possible role as endophenotypes,
and to search the genome for genetic factors that may be involved in
the occurrence of these endophenotypic markers.
Methods : We applied a battery of recently established experi-
mental paradigms in order to systematically investigate diﬀerent core
pathophysiological processes and neurocognitive and neurophysio-
logical endophenotypes of schizophrenic and aﬀective psychoses.
These paradigms included diﬀerent versions of circuit-speciﬁc work-
ing memory tasks (Gruber & von Cramon 2003), a combined task-
switching, oddball and incongruency paradigm (Gruber et al., 2009),
and the ‘‘desire-reason dilemma’’ paradigm (Diekhof & Gruber,
2010), which assesses functional interactions between the reward
system and prefrontal control mechanisms. The functional integrity of
all of these neural mechanisms was investigated in groups of patients
with major psychoses and in their healthy ﬁrst-degree relatives.
Results : Results from a cohort of more than 300 subjects will be
presented. Patients with schizophrenia and patients with bipolar dis-
order, but not patients with unipolar depression revealed altered
brain activation in diﬀerent prefrontal and parietal brain areas during
working memory. In speciﬁc decision-making tasks, all patient groups
showed (in part diagnosis-speciﬁc) alterations in brain regions in-
volved in reward processing and other motivational processes. In
part, the same abnormalities in brain activation were also found in the
healthy ﬁrst-degree relatives, i.e. these pathophysiological changes
may qualify as endophenotypic biomarkers for the disorder. Genome-
wide association studies for these endophenotypic neuroimaging
markers are currently underway.
Conclusion : The endophenotypic approach in functional neuroi-
maging may help to identify genes involved in the pathogenesis of
psychiatric disorders and may provide important information for the
development of valid animal models for further research.
jP-16-008jReduced hippocampal volumes in bipolar disorders
are masked by exposure to lithium – meta-analysis
T. Hajek1, M. Kopecek2, C. Hoschl2, M. Alda1. 1Halifax, Canada ;
2Prague, Czech Republic
Objective : Smaller hippocampal volumes relative to controls are
among the most replicated neuroimaging ﬁndings in individuals with
unipolar but not bipolar depression. Preserved hippocampal volumes
in most studies of bipolar patients may reﬂect putative neuroprotec-
tive eﬀects of lithium (Li).
Methods : To investigate hippocampal volumes in bipolar disorders
(BD) while controlling for Li exposure, we performed a meta-analysis
of neuroimaging studies which subdivided BD patients based on the
presence or absence of current Li treatment. Hippocampal volumes
were compared by combining standardized diﬀerences in means
(Cohen’s d) from individual studies using random eﬀect models.
Results : Overall, we meta-analyzed data from 101 Li treated
BD subjects, 245 BD subjects not treated with Li (non-Li group) and
456 controls from 16 studies. Both the left and right hippocampal
volumes were signiﬁcantly larger in the Li treated BD subjects than in
controls (Cohen’s d=0.53, 95% CI=0.18 ; 0.88 ; Cohen’s d=0.51 ; 95%
CI=0.21 ; 0.81, respectively) or the non-Li group (Cohen’s d=0.93 ;
95% CI=0.56 ; 1.31 ; Cohen’s d=1.07, 95% CI=0.70 ; 1.45, respect-
ively), which had smaller bilateral hippocampal volumes than the
controls (Cohen’s d=x0.36, 95% CI=x0.55 ; x0.17 ; Cohen’s
d=x0.38 ; 95% CI=x0.63 ;x0.13, for the left and right hippocampal
volumes respectively). There was no evidence of publication bias.
Conclusion : Considering the opposite direction of ﬁndings in
subjects with versus without exposure to Li, the preserved hippo-
campal volumes among BD subjects in the majority of individual
studies and all previous meta-analyses, were most likely related to the
inclusion of Li-treated subjects. Our ﬁndings provide indirect support
for the neuroprotective eﬀects of Li and for the negative eﬀects of
bipolar disorders on hippocampal volumes.
jP-16-009jBrain network dysfunction as a model for
schizophrenia : Preliminary results using ketamine
and pharmacological magnetic resonance imaging
A. Ho¨ﬂich1, A. Hahn1, D. Winkler1, J. Tro¨stl1, P. Baldinger1,
T. Vanicek1, J. Losak1, C. Windischberger1, S. Kasper1, R.
Lanzenberger1. 1Medical University of Vienna, Austria
Objective : Alterations of functional brain networks have been fre-
quently demonstrated in schizophrenia, although the exact underly-
ing molecular mechanisms remain unrevealed. Ketamine is known to
exert its schizophrenia-like eﬀects through modulation of the gluta-
matergic system via the NMDA-receptor. Therefore, the aim of the
present study was to investigate the impact of this speciﬁc transmitter
system on resting state functional connectivity of the default-mode
network (DMN).
Methods : 10 healthy volunteers (23.2¡3.4 years, 6 males) under-
went resting state fMRI during esketamine hydrochloride (mean dose
15.12¡2.76 mg) intravenous maintenance infusion, lasting for 20
minutes. Functional MRI measurements were performed at 3 Tesla
using single-shot gradient-recalled EPI (TE=38 ms ; TR=1800 ms
matrix size 128r128 voxel ; 23 slices ; FoV 190r190 mm). Data sets
were normalized to MNI-space and analysed in SPM8. To avoid seed
selection bias, a recently developed approach for the computation of
functional connectivity was applied which allows for the deﬁnition of
the whole DMN as seed region. A repeated-measures ANOVA was
performed to assess diﬀerences between baseline connectivity values
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and each 5-minutes block beginning at the start of the ketamine in-
fusion (t=3.2 ; p<0.001 uncorrected voxel level).
Results : Functional connectivity analysis showed a consistent ke-
tamine-induced increase in the precuneus (0–5 min : t=3.95 ;
15–20 min : t=4.38 ; 30–35 min : t=4.6) and the posterior cingulate
cortex (PCC, 15–20 min : t=3.59 ; 30–35 min : t=3.44, see ﬁgure). For
the later time points (15–20 min and 30–35 min) the cluster in the
precuneus withstands correction for multiple comparisons (p<0.05
FWE-corrected cluster level).
Conclusion : The application of a subanaesthetic dose of ketamine
leads to a signiﬁcant increase of the functional connectivity of the
precuneus and the PCC, which represent key areas of the default-
mode network. These results are consistent with ﬁndings in schizo-
phrenic patients, which propose a hyperactivity of the DMN, pointing
toward a possible implication of the NMDA-receptor on resting-state
functional connectivity.
jP-16-010jAn initial baseline for machine learning classiﬁer
performance on resting state FMRI data
W. Huf1, K. Kalcher2, R. Boubela2, P. Filzmoser3, S. Kasper4,
E. Moser2, C. Windischberger2. 1Medical University of Vienna, Vienna,
Austria ; 2Medical University of Vienna, Center for Medical Physics,
Vienna, Austria ; 3Vienna University of Technology, Vienna, Austria ;
4Medical University of Vienna, Dept. of Psychiatry, Vienna, Austria
Objective : The classiﬁcation of disease states has long been an im-
portant goal of fMRI research in biological psychiatry. Real world
applications on other than severe cases, however, have been hindered
by the low signal-to-noise ratio of fMRI data. Multivariate statistical
methods can deal with this problem by taking into consideration the
covariance structure in addition to the marginal distributions of a
multivariate feature space. The goal of this study was to apply various
machine learning classiﬁers to features extracted from resting-state
fMRI data in order to classify subjects as male or female and thus
establish a baseline for what to expect employing naive features in
clinical samples.
Methods : Resting-state fMRI data of 84 healthy subjects (43 male)
from the 1000 Functional Connectomes Project database (Biswal et al.,
2010) was subjected to standard preprocessing (Weissenbacher et al.,
2009), features for subsequent classiﬁcation were extracted based on
the correlation of all pairs of voxel time series. Gaussian Naive Bayes,
k-Nearest-Neighbors, Support Vector Machine, and Random Forest
classiﬁers were trained on the raw features and their principal com-
ponents, classiﬁcation accuracy was assessed using leave-one-out
cross validation.
Results : Classiﬁcation accuracies for the classiﬁers were shown to
be highly dependent on sample size, with mean accuracies up to 60%
(SVM results see ﬁgure). Estimation on 20 principal components
yielded results comparable to classiﬁcation on the whole dataset for
most estimators.
Conclusion : On an empirical basis, we identiﬁed a classiﬁcation
accuracy of about 55 percent as a relatively stable result for our na-
ively selected features, in contrast to published classiﬁcation ac-
curacies of up to 80 percent using small sample sizes (around 40
subjects). Our results, however, show that those are prone to high
variability, warrantin caution when interpreting reliability in the
growing ﬁeld of machine learning in fMRI data analysis (Pereira et al.,
2009).
Policy of full disclosure : Siegfried Kasper has received grant/re-
search support from Eli Lilly, Lundbeck, Bristol-Myers Squibb,
GlaxoSmithKline, Organon, Sepracor, and Servier ; has served as a
consultant or on advisory boards for AstraZeneca, Bristol-Myers
Squibb, GlaxoSmithKline, Eli Lilly, Lundbeck, MSD, Pﬁzer, Organon,
Schwabe, Sepracor, Servier, Janssen, and Novartis ; and has served
on speakers’ bureaus for AstraZeneca, BMS, Angelini, Eli Lily,
Lundbeck, Schwabe, Sepracor, Servier, Pﬁzer, Pierre Fabre, and
Janssen.
jP-16-011jMetabotropic glutamate receptor 5 densities and free
glutamate concentrations in occasional and
dependent cocaine users
L. Hulka1, M. Scheidegger2, A. Henning2, K.H. Preller2, M. Vonmoos2,
S. Ametamey2, A. Buck2, E. Seifritz2, B.B. Quednow2. 1University of
Zurich, Switzerland ; 2Zurich, Switzerland
Objective : The primary focus of previous addiction research was on
the dopamine system, by which the rewarding and reinforcing eﬀects
of cocaine are mediated. However, over the past decade evidence
from preclinical studies emerged showing that cocaine use also leads
to long-lasting neuroadaptations in the corticostriatal glutamate sys-
tem, in which the dopamine axon terminals are embedded (Kalivas,
2009). Disruption of the glutamate homeostasis seems to be particu-
larly relevant for drug-seeking and relapse-related behaviors
(McFarland et al., 2003 ; Reissner and Kalivas, 2010). The metabotropic
glutamate receptor 5 (mGluR5) seems an interesting candidate to be
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investigated because mGluR5 null mutant mice did not self-adminis-
ter cocaine and mGluR5 anatagonists attenuated self-administration
and reinstatement of cocaine use in rodents (Backstrom and Hyytia,
2006 ; Chiamulera et al., 2001). Moreover, a human magnetic reson-
ance spectroscopy (MRS) study with chronic cocaine users found
lower glutamate levels in the ACC in comparison to controls (Yang et
al., 2009). Interestingly, years of cocaine use correlated positively with
glutamate levels possibly implying a compensatory neurobiological
mechanism over time. Therefore, achieving a more in-depth under-
standing of cocaine-related glutamatergic alterations in humans
may eventually lead to the development of novel drug treatment
approaches.
Methods : Sixteen male cocaine users either with an occasional
or chronic cocaine use pattern and 16 male controls will undergo
[11C]-ABP688 positron emission tomography (PET) and 1H MRS.
[11C]-ABP688 is a selective radioligand for the mGluR5, allowing to
investigate potential group diﬀerences in mGluR5 densities in selec-
ted regions of interest such as the DLPFC, OFC, ACC, MPFC, and the
striatum. Free in vivo glutamate concentrations of the perigenual
ACC and the DLPFC will be acquired in MRS by means of a 2D
JPRESS sequence and quantiﬁed by using ProFit. In addition, par-
ticipants will complete a comprehensive neuropsychological test
battery to relate putative neurobiological alterations to cognitive
impairment.
jP-16-012jRelationship between dose, plasma concentration
and a4b2 nicotinic receptor occupancy for AZD1446
(TC-6683)
A. Jucaite1, S. Nyberg1, A. Takano2, M. Ka˚gedahl1, P. Johnstro¨m1,
C. Halldin2, K.-G. Jostell1, E. Johnson1, L. Farde1. 1AstraZeneca,
So¨derta¨lje, Sweden ; 2Karolinska Institutet, SOLNA, Sweden
Objective : Neurodegeneration in Alzheimers disease (AD) involves
decreased cholinergic neurotransmission. Restoration of cholinergic
neurotransmission presently is limited to the use of inhibitors of the
enzyme acetylcholine esterase (AChE) increasing synaptic ACh levels.
A strategy, currently in exploratory phase is stimulation of post-
synaptic ACh receptors. Neuronal a4b2 nicotinic acetylcholine re-
ceptors (NNRs) are expressed in brain regions involved in cognition
and may be a target for symptomatic treatment of cognitive impair-
ment in AD. AZD1446 is a novel a4b2 NNR agonist in early clinical
development for symptomatic treatment of AD, with minimal de-
sensitization and high selectivity in vitro. AZD1446 has demonstrated
eﬃcacy in a broad range of preclinical models of cognition. Initial PET
studies in non-human primates showed that AZD1446 occupies a4b2
NNRs, and the plasma concentration at which 50% of receptors are
occupied, Kiplasma, was approximately 200 nmol/L. The main aim of
this PET study was to determine occupancy of AZD1446 at a4b2
NNRs using 2-[18F]-F-A85380, a radioligand which binds with high
aﬃnity and selectivity to a4b2 NNRS. The study serves as a transla-
tional step in understanding AZD1446 exposure at target, before
clinical studies in patients.
Methods : Nine healthy subjects were examined after adminis-
tration of 10–200 mg AZD1446. Receptor binding (VT ) was calculated
for brain regions of interest (ROIs) (frontal and temporal cortex,
thalamus, pons, cerebellum, caudate nucleus, putamen, hippo-
campus). Receptor occupancy was calculated using the population
PK/PD model.
Results : Dose-dependent, saturable binding of AZD1446 was
demonstrated, radioligand displacement approaching 100%. The
AZD1446 Kiplasma was estimated to 128 nmol/L (95% CI 51.8 to
309 nmol/L).
Conclusion : This study conﬁrmed the translatability of AZD1446
binding properties from non-human primate. The study identiﬁed a
dose range that can be tested in further clinical studies, and suggests
that AZD1446 is a suitable compound to explore the clinical beneﬁt of
a4b2 NNR agonist action.
Policy of full disclosure : The study is conducted by AstraZeneca.
jP-16-013jA volumetric study of hippocampus and amygdala
in major depression subtypes : Melancholic versus
psychotic depression
I. Michopoulos1, K. Vasilopoulou2, M. Papathanasiou3, F. Bouﬁdou4,
P. Oulis5, N. Kelekis3, E. Rizos2, C. Nikolaou4, C. Pantelis6,
D. Velakoulis6, L. Lykouras2. 1University of Athens, Medical, Greece ;
2University of Athens, Medical School, 2nd Department of Psy., Greece ;
3University of Athens, Medical School, 2nd Department of Radi.,
Greece ; 4University of Athens, Medical, School, Laboratory of Biopatho.,
Greece ; 5University of Athens, Medical, School, 1st Department of
Psy., Greece ; 6Melbourne Neuropsychiatry Cent, re, Department of
Psychiatry, Athens, Greece
Objective : The aim of the current study was to compare the volumes
of the hippocampus and amygdala in depression among patients
with melancholic depression, patients with psychotic depression and
normal controls.
Methods : Twenty two patients with melancholic major depression,
17 with psychotic major depression and 18 normal controls were in-
cluded in the study. Hippocampal (HV) and amygdala (AV) volumes
were measured on magnetic resonance volumetric images.
Results : There were no volumetric diﬀerences between patients
with melancholic and psychotic subtypes. We identiﬁed larger AVs in
both patient groups compared to controls, while there were no dif-
ferences in HVs across the 3 groups. AV bilaterally diﬀered between
early- and late-onset patient groups and between patients with and
without sleep disorder. Larger amygdalae bilaterally were signiﬁ-
cantly associated with smaller tail of the left hippocampus in patients,
but not in controls.
Conclusion : Larger AVs were identiﬁed in patients with major
depressive disorder compared to controls but no structural measures
distinguished between melancholic and psychotic subtypes. A poss-
ible inﬂuence of chronicity on AV is discussed, as well as a possible
explanation of amygdala enlargement by its role in sleep and wake-
fulness control, determined greatly by the hippocampus.
jP-16-014j In vivo measurement of ﬂuctuations in glutamate
levels : A positron emission tomography study using
[11C]ABP688 and N-acetylcysteine
N. Miyake1, M. Skinbjerg2, B. Easwaramoorthy2, D. Kumar3,
R. Girgis3, X. Xu2, M. Slifstein4, A. Abi-Dargham2. 1St Marianna Univ.
Sch. of Med., Kawasaki, Japan ; 2Columbia University, New York State
Psychiatric Ins, USA ; 3Columbia University, New York, USA ; 4Columbia
University, New York State Psychiatric Ins, New York, USA
Objective : An imaging method to probe glutamate levels in vivo
would allow the study of glutamate transmission in disease states and
in response to therapeutic interventions. Here we demonstrate the
feasibility of this approach for the ﬁrst time using positron emission
tomography (PET), and [11C]ABP688, a radiotracer for an allosteric
site on the metabotropic glutamate receptor 5.
Methods : We conducted two sets of experiments in anesthetized
baboons (n=3) : test and retest without pharmacological challenge,
and in combination with N-acetylcysteine (NAC), a promoter of the
cystine-glutamate antiporter that increases extrasynaptic glutamate
release. NAC 50 mg/kg was administered as constant infusion over
60 minutes. Scan durations were all 90 minutes. Data were acquired
on an HR+ scanner. PET data were coregistered to each animal’s
anatomical magnetic resonance imaging (MRI), regions of interest
were transferred from the MRIs to the PET, and time activity curves
for each region were generated. Data were analyzed by 2-tissue
compartment modeling with metabolite-corrected arterial input.
Cerebellum was included as a reference region. Outcome measures
were the binding potential relative to the nondisplaceable compart-
ment (BPND). The goal was to assess whether NAC-induced changes
in [11C]ABP688 binding potential, DBPND, could be detected above
the noise in the measurement.
Results : Linear mixed modeling comparing DBPND from test-ret-
est to DBPND from NAC challenge across all brain regions showed a
highly signiﬁcant eﬀect of treatment [F(1,40)=21.2, p<0.001]. DBPND
was signiﬁcantly diﬀerent from zero following NAC [F(1,20)=76.6,
p<0.001] but not after test-retest studies.
Conclusion : NAC induced decrease in [11C]ABP688 DBPND may
be the result of allosteric modulation, although other mechanisms
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may be at play. We outline steps needed to replicate and validate this
method as a new tool to measure in vivo glutamate transmission.
Policy of full disclosure : Dr. Girgis has received research support
from Janssen and Lilly through APIRE and a travel stipend from Lilly,
Forest, and Elsevier Science through the Society of Biological
Psychiatry. Dr. Slifstein has received research support from
Intracellular Therapies Inc and is a consultant of GlaxoSmitnKline and
Amgen, Inc. Dr. Abi-Dargham has received research support from
GlaxoSmithKline and is a consultant or a speaker for Bristol-Myers
Squibb, Otsuka, Sunovion, Lundbeck and Boehringer Ingelheim. The
other authors reported no biomedical ﬁnancial interests or potential
conﬂict of interest.
jP-16-015jAZD5213, a novel histamine H3 antagonist
permitting high daytime and low nocturnal H3
occupancy. A PET study in human subjects.
S. Nyberg1, E. Bostro¨m1, A. Jucaite1, A. Takano2, M. Ka˚gedal2,
C. Ahlgren1, E. Nordstro¨m1, C. Halldin2. 1AstraZeneca R&D,
So¨derta¨lje, Sweden ; 2Karolinska Institutet, Dept. of Clin. . Neuroscience,
Stockholm, Sweden
Objective : The histamine H3 receptor represents an appealing CNS
drug target due to its important role in the neurobiology of cognition
and sleep-wakefulness regulation. Several H3 speciﬁc compounds are
currently under development for a range of CNS indications with
cognitive impairment. Importantly, the therapeutic beneﬁt of this
mechanism may be hampered by disruption of sleep, and adverse
events related to sleep has been observed in human subjects at high
(>80%) H3 receptor occupancy (H3RO) during treatment with H3
antagonists. AZD5213 is a new highly selective H3 antagonist (in vitro
inverse agonist) developed to achieve a pharmacokinetic proﬁle per-
mitting circadian ﬂuctuations of H3RO. Eﬃcacy has been demon-
strated in rodent behavioural models of cognition, and in-vivo
microdialysis has shown release of histamine, acetylcholine, dopa-
mine and norepinephrine in the rodent brain. In human subjects,
AZD5213 was safe and well tolerated following repeated doses
(1–14 mg/d) and demonstrated a short (5–6 h) half-life.
Methods : In this PET study H3RO was measured using the radi-
oligand [11C]AZ12807110 ([11C]GSK189254) in 6 young male volun-
teers following single doses of AZD5213 (0.05 to 30 mg). H3RO was
calculated using the Lassen plot method. Population kinetic modeling
was used to predict H3RO time course.
Results : AZD5213 showed dose and concentration dependent
H3RO ranging from 16 to 90%. Modeling predicted that for most
subjects the dose range 0.5–6 mg given in the morning would achiev
>90% H3RO at peak while falling clearly below 80% during night.
Conclusion : This study conﬁrms that AZD5213 rapidly equilibrates
across the human blood-brain barrier. A dose range permitting high
daytime and low nocturnal H3 occupancy has been deﬁned. Such
circadian ﬂuctuation may be expected to reduce the risk of sleep dis-
ruption while maintaining daytime eﬃcacy. AZD5213 may thus be
an optimal compound to evaluate the clinical beneﬁt of selective H3
antagonism in cognitive disorders.
Policy of full disclosure : The study was funded by AstraZeneca
R&D.
jP-16-016jDiﬀusion tensor imaging in pathological skin
picking
B. Odlaug1, A. Hampshire2, S. Chamberlain3, L. Schreiber4, J. Grant4.
1University of Minnesota, Minneapolis, USA ; 2University of Western
Ontario, London, Canada ; 3University of Cambridge, Department of
Psychiatry, United Kingdom ; 4University of Minnesota, Department of
Psychiatry, Minneapolis, USA
Objective : Pathological skin picking (PSP) is a common psychiatric
condition associated with signiﬁcant psychosocial distress and func-
tional disability. Studies have identiﬁed dysconnectivity of white
matter tracts in related conditions such as trichotillomania and ob-
sessive-compulsive disorder (Szeszko et al., 2005), but neuroimaging
has yet to be applied in PSP. Further understanding the patho-
physiology of PSP may help in advancing treatments for this often
disabling disorder.
Methods : Diﬀusion tensor imaging was conducted in a sample of
patients with PSP and compared to a sample of healthy age- and
gender-matched controls with no lifetime or current psychiatric his-
tory using a 3T system at the University of Minnesota, USA. Diﬀusion-
weighted imaging data were acquired and pre-processed via pre-
viously validated methods (Chamberlain et al., 2010). The null
hypothesis of there being no signiﬁcant diﬀerence in fractional ani-
sotropy between the 2 groups was tested using two sample t-tests
at each voxel within the white matter mask in the SPM5 software
package.
Results : A total of 10 individuals with PSP (mean age 30.4¡9.8 ;
100% female) and 12 healthy controls underwent a full psychiatric
evaluation and DTI. Compared to controls, patients with PSP had
reduced fractional anisotropy within white matter tracts at several
locations including those connecting the left IFG (peak MNI co-
ordinatesx42 15 42 t=4.3 p<0.001 uncorrected).
Conclusion : These preliminary ﬁndings implicate disorganization
of white matter tracts involved in top-down cognitive control in PSP
and have implications for diagnostic classiﬁcation systems and future
research.
Policy of full disclosure : This research is supported in part by a
Center for Excellence in Gambling Research grant by the Institute for
Responsible Gaming and an American Recovery and Reinvestment
Act (ARRA) Grant from the National Institute on Drug Abuse
(1RC1DA028279-01) to Dr. Grant. Disclosures of interest include that
Mr. Odlaug has received honoraria from Oxford University Press.
Dr. Chamberlain has consulted for Cambridge Cognition, P1Vital, and
Shire Pharmaceuticals. Dr. Grant has received research grants from
Forest Pharmaceuticals and Psyadon Pharmaceuticals and receives
compensation as the Editor-in-Chief of the Journal of Gambling
Studies. Dr. Hampshire and Ms. Schreiber report no relevant conﬂicts
of interest.
jP-16-017jResidual cognitive impairment in patients aﬀected
by bipolar disorder during euthymia : An assessment
with functional magnetic resonance imaging (fMRI)
M.C. Palazzo1, M. Cristoﬀanini2, C. Dobrea3, C. Cinnante2,
S. Avignone2, C. Sina2, L. Cremaschi4, B. Penzo4, B. Dell’Osso4,
F. Triulzi2, A.C. Altamura4. 1Universita` Degli Studi Milano, Italy ;
2Fondazione IRCCS Ca’Granda, Ospedale Maggiore Policlinico,
Milano, Italy ; 3Universita` Degli Studi Milano, Department of Mental
Health, Italy ; 4Universita` Degli Studi Milano, Fondazione IRCCS
Ca’Granda, Italy
Objective : Bipolar Disorder (BD) is a chronic mood disorder with a
prevalence estimated around 1–2%. Bipolar patients may experience
social and working residual impairment even during euthymia.
Furthermore, speciﬁc cognitive deﬁcits, particularly involving work-
ing memory (WM), may persist during eythymia as well. To evaluate
the possible presence of cognitive and functional diﬀerences between
euthymic bipolar subjects vs. healthy controls during euthymia by
means of a WM task at fMRI associated with neuropsychological
evaluations.
Methods :A sample of 47 subjects aged between 20 and 55 years (12
with BD type I, 12 BD type II and 23 controls) underwent fMRI
examination at 3 Tesla with tasks of working memory (n-back). All
participants received a neuropsychological evaluation, inlcuding
Stroop Color-Word Interference test, Tower of London, Trail Making
test, Wisconsin Card Sorting Test and Verbal Fluency Test.
Comparison tests were performed using statistical software SPSS
and SPM5.
Results : The performance of the control group was signiﬁcantly
higher than both at the n-back task and at the neuropsychological
tests. The full-factorial analysis of fMRI data showed a hypoactivation
in bipolar patients in particular hippocampus and thalamus, asso-
ciated with increased involvement of areas not involved in the frontal-
parietal networks classically associated with WM.
Conclusion : The results seem to conﬁrm the existence of a residual
dysfunction during euthymia phase in BD, suggesting two distinct
patterns of activation in the two groups studied, both from a neuro-
psychological point of view and from a neuroimaging perspective.
P-16. Imaging 217
Downloaded from https://academic.oup.com/ijnp/article-abstract/15/Supplement_1/1/650920
by University of Groningen user
on 13 March 2018
jP-16-018jDepressive symptoms and apathy are associated
with psychomotor slowness and frontal activation
M. Sawa1, H. Yamashita2, K. Fujimaki3, G. Okada4, T. Takahashi1,
S. Yamawaki2. 1Mihara Hospital, Mihara-City, Japan ; 2Hiroshima
University, Hiroshima-City, Japan ; 3Prefectural University of Hiroshima,
Mihara-City, Japan ; 4University of Michigan, Ann Arbor, Armenia
Objective : Aﬀective symptoms, such as depression and apathy, and
cognitive dysfunction, such as psychomotor slowness, are known to
have negative impacts on the quality of life (QOL) of patients with
mental and physical diseases. However, the relationships among de-
pressive symptoms, apathy, psychomotor slowness, and QOL in a
non-clinical population are unclear. The aim of the present study
was to assess these relationships and examine the underlying cortical
mechanisms in a non-clinical population.
Methods : Fifty-two healthy male volunteers were assessed for de-
pressive symptoms using the Zung Self-rating Depression Scale
(SDS), for apathy measured using the Apathy Scale, and QOL using
the Short-Form 36 item questionnaire (SF36). The volunteers also
performed the Trail Making Test Part A (TMT-A) while undergoing
assessment of hemoglobin concentration changes in the frontal corti-
cal surface using 24-channel near-infrared spectroscopy (NIRS).
Results : The scores of the SDS and Apathy Scale showed signiﬁcant
negative correlations with the scores of most of subscales of the SF36.
In addition, the SDS score had a signiﬁcant positive correlation with
the time to complete the TMT-A. Further, activation of several frontal
cortical areas had a signiﬁcant positive correlation with the scores of
the SDS and Apathy Scale.
Conclusion : These results suggest that the degree of depressive
symptoms and apathy are associated with a lower QOL in a non-
clinical population, and that cortical hyperactivation during a psy-
chomotor task measured by NIRS may identify objectively
individuals with a high degree of depressive symptoms and apathy.
jP-16-019jPET imaging of serotoninergic system in monkeys :
Eﬀects of maternal separation, and chronic
ﬂuoxetine treatment during development
S. Shrestha. National Institutes of Health, Bethesda, USA
Objective : Major depressive disorder (MDD) is a serious disorder
that often begins following stress during adolescence. Selective sero-
tonin reuptake inhibitors (SSRIs) are a common treatment for both
adolescent and adult MDD. While MDD’s early onset and available
eﬃcacy data support use of SSRIs in adolescents, concerns about
safety have arisen, based on associations with suicidal behavior in
adolescents, coupled with minimal data on long-term eﬀects on the
developing brain. This study used rhesus monkeys as a model to
study the long term eﬀects of both early life stress and chronic anti-
depressant treatment on the central serotoninergic system in young
adult rhesus monkeys.
Methods : Thirty-two monkeys were randomly assigned to one of
four groups (8 monkeys/group). They were peer-reared (PR) vs. mo-
ther-reared (MR), and with or without ﬂuoxetine treatment. For PR,
monkeys were separated from mothers at birth and nursery-reared
until 6 months of age and thereafter housed with their peers. Chronic
ﬂuoxetine treatment began at 2-year of age for one year. One to two
years post-washout, monkeys (average age of 5) were scanned with
Positron Emission Tomography (PET) using three radioligands : 1)
[11C]CUMI, an agonist ; 2) [11C]RWAY, an antagonist, both for
5-HT1A receptor ; and 3) [11C]DASB for serotonin transporter (SERT).
Results : Preliminary data from 24 monkeys (6 in each group) show
1. A signiﬁcant global decrease in SERT binding in PR compared to
MR monkeys, 2. SERT binding is reversed in PR monkeys that re-
ceived ﬂuoxetine treatment, and 3. 5-HT1A receptor binding is de-
creased in PR compared to MR monkeys only in cortex and unlike
SERT, the binding was not reversed with ﬂuoxetine treatment.
Conclusion : Our study demonstrates serotoninergic alterations in
PR monkeys, and chronic ﬂouxetine treatment may reverse deﬁcits in
SERT density that is persistent more than one year after medication
discontinuation.
jP-16-021jDiﬀerential eﬀect of risperidone versus haloperidol
on brain activation in ﬁrstepisode schizophrenia
patients : A multicentre fMRI study
R. Thienel1, T. Kircher2, U. Habel3, T. Kellermann3, M. Reske4,
W. Woelwer5, I. Frommann6, E. Meisenzahl7, M. Wagner6,
F. Schneider3, W. Gaebel5. 1University of Newcastle, Waratah, Australia ;
2Philipps-University, Marburg, Germany ; 3RWTH, Aachen, Germany ;
4Forschungszentrum Juelich, Inst. of Neurosci & Med, Waratah, Germany ;
5University Clinic for Psychiatry & Psychotherapy, Duesseldorf,
Germany ; 6University of Bonn, Germany ; 7Klinikum der Uni Muenchen,
Germany
Objective : Neurocognitive impairments in schizophrenia are com-
mon and clinically relevant. The majority of people diagnosed with
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schizophrenia will experience a signiﬁcant decline in global, social
and occupational function levels in the course of their illness. This
disability is largely driven by cognitive impairment. Amongst the
diﬀerent cognitive domains, memory impairments in particular are
regarded as possible intermediate phenotypes of schizophrenia.
Whether haloperidol and risperidone two neuroleptic drugs with
diﬀerential receptor binding proﬁles show distinct impacts on func-
tional networks mediating working memory is subject of the current
study.
Methods : 36 ﬁrst episode schizophrenia patients (DSM IV)
were recruited as part of the German Research Network of schizo-
phrenia. Patients received either risperidone (N=17, mean daily
dose : 4.5¡1.7) or haloperidol (N=19, mean daily dose : 2.9¡1.5)
in a double blind treatment regime. The task during fMRI data ac-
quisition (1.5 Tesla scanner) consisted of an n-back paradigm
with a randomized sequence of 0-back and 2-back conditions
arranged in a block design. The data was analysed using a ﬂexible
factorial design (SPM8) including medication dose (in mg) and gender
as a covariate.
Results : Functional analysis revealed greater activations in the ris-
peridone group in a network comprising of superior parietal, orbito-
frontal, middle frontal, thalamic, temporal and occipital areas ;
p<0.05 at voxel level, Monte-Carlo-corrected p<0.05,o147 continu-
ous voxels.
Conclusion : Risperidone treated patients showed stronger activa-
tions in a cortical network that has previously been associated with
this kind of working memory task than patients treated with a com-
parably moderate dose of haloperidol. As the results were controlled
for dose, and neither side eﬀects nor co-treatment diﬀered between
the groups the results are not likely to be aﬀected by these con-
founding factors, but rather reﬂect the drugs diﬀerent receptor bind-
ing proﬁle. Risperidone binds much stronger to 5-HT2A and less
strong to D1- and D2-receptors, which might be responsible for the
diﬀerences in BOLD between the two medication groups.
jP-16-022jSpontaneous low-frequency oscillations during
resting state and personality traits measured by
the temperament and character inventory and NEO
Five-Factor inventory in healthy volunteers
S. Toki1, Y. Okamoto1, Y. Kunisato2, K. Onoda3, S. Yoshimura4,
G. Okada5, S. Yamawaki1. 1Hiroshima University, Japan ; 2Waseda
University, Tokorozawa, Japan ; 3Shimane University, Izumo, Japan ;
4 JSPS, Hiroshima, Japan ; 5University of Michigan, Ann Arbor, USA
Objective : Default mode network measured by resting state fMRI
(R-fMRI) has received a great deal of attention, because of its critical
role in ego function, such as attending to environmental stimuli,
reviewing the past and planning the future. Using R-fMRI, we ex-
amined the relationships between the amplitude of spontaneous low-
frequency oscillations (LFO) and the personality traits assessed by
two self-rating scales, Temperament and Character Inventory and
NEO Five-Factor Inventory in healthy subjects.
Methods : Twenty-four healthy right-handed subjects participated
in 5-min R-fMRI and completed the Temperament and Character
Inventory and NEO Five-Factor Inventory.
Results : We observed that Neuroticism correlated negatively with
regional activity of the middle frontal gyrus (MiFG) and precuneus ;
Extraversion correlated positively with regional activity of the
superior frontal gyrus (SFG), striatum, MiFG, subcallosal and
posterior cingulate cortex (PCC) ; Openness correlated positively
with the parahippocampal gyrus, and negatively with the SFG ;
Conscientiousness correlated positively with regional activity of the
MiFG and correlated negatively with the cerebellum. Additionally,
we observed that Harm avoidance correlated positively with regional
activity of the culmen, and negatively with regional activity of
the MiFG and insula ; Reward dependence correlated positively with
regional activity of the anterior cingulate, medial frontal and superior
temporal gyrus ; Cooperativeness correlated positively with the PCC ;
Self-transcendence correlated positively with regional activity of the
culmen, inferior frontal gyrus and thalamus, and correlated nega-
tively with the middle temporal and occipital gyrus.
Conclusion : Our results revealed the neural substrates of person-
ality traits in the amplitude of spontaneous LFO.
jP-16-023jEﬀects of ketamine infusion on brain activation
during an emotion discrimination task – a double-
blind placebo-controlled pharmaco-fMRI study
T. Vanicek1, A. Hahn2, D. Winkler2, J. Troestl3, J. Losak4, P.
Baldinger2, A. Hoeﬂich2, C. Windischberger3, S. Kasper2, R.
Lanzenberger2. 1Medical University of Vienna, Austria ; 2Medical
University of Vienna, Psychiatry and Psychotherapy, Austria ; 3Medical
University of Vienna, MR Center of Excellence, Austria ; 4Vienna, Austria
Objective : The application of low dose ketamine, a NMDA-receptor
antagonist, is used to modify the functional connectivity in brain
networks of healthy subjects as a model for schizophrenia associated
with altered glutamatergic connectivity. Altered connectivity changes
the processing of emotional and cognitive stimuli. Therefore we
assessed ketamine-induced changes in brain activation using an
emotion discrimination task (EDT).
Methods : 10 healthy volunteers underwent twice fMRI in a
double-blind, placebo-controlled study. During a 5 min run, sub-
jects performed EDT, before and after either ketamine (mean dose
15.12¡2.76 mg) or placebo (0.9% saline solution) intravenous main-
tenance infusion. FMRI was carried out at 3T with a single-shot
gradient-recalled EPI sequence (TR=1800 ms, TE=38 ms, 23 slices,
matrix=128r128 voxel). After spatial normalization to MNI-space,
individual activations were computed by contrasting EDT vs. ODT
(object discrimination task) in SPM8. Eﬀects of ketamine vs. placebo
were assessed by paired-samples t-test and random eﬀects analysis.
Results : According to previous fMRI-studies, task-speciﬁc acti-
vation before infusion was found in several regions, including the
amygdalae, fusiforme and dorsolateral prefrontal cortices (t>4.3,
p<0.001 uncorr.), when contrasting EDT vs. ODT. Direct comparison
between ketamine vs. placebo showed an increased activation in the
retrosplenial cortex (RSC) and precuneus (p<0.01 voxel level, p<0.05
FWE corr. cluster level). Subsequent analysis shows that diﬀerences of
ketamine vs. placebo emerge mainly from a reduced deactivation
during EDT in the RSC (t=8.22) and to a lesser extent in the pre-
cuneus (t=2.6).
Conclusion : While performing EDT, results revealed a reduced
deactivation in the RSC and precuneus, both representing essential
regions of the default-mode network (DMN) that is associated with
self-related processing. This ketamine-induced activity maintenance
in the DMN during goal-oriented tasks might be caused by alterations
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of NMDA receptor-modulated networks, suggesting an insuﬃcient
regulation of DMN in schizophrenia.
jP-16-024jThe impact of dopamine on behaviour during
an aggression provocation paradigm : An
18f FDOPA pet study
I. Vernaleken1, T. Schlu¨ter1, K. Dautzenberg1, S. Prinz1, K. Henkel1,
F. Mottaghy1, G. Gru¨nder1. 1RWTH Aachen University, Germany
Objective : Aggression is a multifarious type of (re-)action. Whereas
impulsivity could be well related to serotonergic deﬁciency, also
dopaminergic mechanisms were postulated in the modulation of ag-
gression. This investigation was performed to enlighten the inﬂuence
of striatal dopaminergic synthesis capacity on the vulnerability for
aggressive, defensive, or resilient behaviour during a standardized
aggressive provocation task (PSAP).
Methods : 18 healthy male subjects (24.7¡4.0 years)underwent
a single [18F]FDOPA-PET scan (124 min. ; 10 min. transmission
scan ; arterial blood sampling ; metabolite detection) without any
pharmacologic challenge except carbidopa pre-treatment. Directly
before the scan, the subjects underwent the Point Subtraction
Aggression Paradigm (PSAP). In short, this is an evaluated monetary
reward game against a putative adversary which habitually tries
to cheat. The proband can react by punishment (money subtraction),
by pressing a defensive button, or by continuing his money-making
behaviour (resilience). The PET-dynamics were analyzed according to
the ‘‘ inlet/outlet-model’’ of Kumakura et al. (2005) to obtain the net
uptake of [18F]FDOPA (K), the total distribution volume (VD) and
kloss in the striatum.
Results : The subjects showed mean K values of 0.025¡0.006, VD-
values of 4.7¡1.3, and kloss-values of 0.0059¡0.0022 (NC :
K=0.030¡0.007, VD : 3.3¡0.9, and kloss-values of 0.0078¡0.0037).
Correlation analyses to the PSAP-parameters revealed that the striatal
(especially left putamen) K and kloss parameters were negatively
correlated with combined defensive/aggressive behaviour (lePut-K :
r=x0.65, p=0.003) and positive correlated with the resilient money-
making behaviour (bilPut-K : r=0.52, p=0.028).
Conclusion : Apparently, lower presynaptic dopamine synthesis
capacity/turnover distract healthy subjects from reward-oriented
behaviour during aggressive provocation and let them shift to inter-
actional behaviour. The latter actions were dominated by defensive
strategies. This investigation suggests that the inﬂuence of dopamine
on aggression is not directly linked with harmful-behaviour but with
the distractibility from goal/reward-directed behaviour.
P-17. Attention Deﬁcit Disorder
jP-17-001jExecutive function in adult patients with
attention-deﬁcit/hyperactivity disorder during
treatment with atomoxetine in a randomized,
placebo-controlled withdrawal study
T. Goto1, L. Adler2, H. Upadhyaya1, P. Trzepacz1, Y. Tanaka1,
D. Williams3, A. Heinloth3, A. Allen1. 1Eli Lilly and Company,
Indianapolis, USA ; 2New York University, USA ; 3PharmaNet/i3, Ann
Arbor, USA
Objective : To assess executive function in adults with attention-
deﬁcit/hyperactivity disorder (ADHD) during longer-term treatment
with atomoxetine in a randomized withdrawal trial.
Methods : Responders to an open-label treatment period (12 weeks)
with atomoxetine (40–100 mg/day) entered a 37-week double-blind
maintenance period. Response criteria : o30% reduction from base-
line on Conners’ Adult Attention-Deﬁcit/Hyperactivity Disorder
Rating Scale-Investigator Rated :Screening Version (adult prompts)
and scoref3 on Clinical Global Impressions Scale-Attention-Deﬁcit/
Hyperactivity Disorder-Severity. Patients who maintained response
from Weeks 15 to 24 were randomized in 1 : 1 ratio to treatment with
atomoxetine (80 or 100 mg/day ; n=266) or placebo (n=258) for
25 weeks. Patients and investigators were blinded to response criteria
and timing of randomization. Change in executive function was as-
sessed using Behavior Rating Inventory of Executive Function–Adult
Version (BRIEF-A) Self-Report
TM
and Informant raw scores from
baseline (randomization) to last-observation-carried-forward (LOCF)
Week 13 post-randomization and to LOCF (after Week 17) Week 25
post-randomization.
Results : 2017 patients (mean age 33.2 years ; male 58.7%) enrolled ;
524 patients responded to treatment and were randomized. At Weeks
13 and 25 post-randomization, patients receiving atomoxetine showed
signiﬁcantly (Pf0.05) greater improvements versus placebo on the
following Self-Report
TM
and Informant subscales : behavioral regu-
lation, global executive composite, and metacognition indices and
inhibit, plan/organize, shift, and working memory section scores.
Signiﬁcantly (Pf0.05) improved for atomoxetine versus placebo at
Week 13 were initiate section score on both BRIEF-A scales and task
monitor section score on Self-Report
TM
; at Week 25, initiate section
score on Self-Report
TM
and task monitor section score on Informant ;
and at Weeks 13 and 25, emotional control and organization of mate-
rials section scores on Informant.
Conclusion : Treatment with atomoxetine resulted in signiﬁcantly
improved executive function compared with placebo in adults with
ADHD ; the observed improvement was maintained for at least
25 weeks.
Policy of full disclosure : This work was sponsored by Eli Lilly
and Company and/or any of its subsidiaries. Dr. Adler is a con-
sultant for Alcobra Pharmaceuticals, Otsuka Pharmaceuticals,
Shire Pharmacuticals, Theravance, and Major League Baseball ; he
is on the advisory boards of Alcobra Pharmaceuticals, Otsuka
Pharmaceuticals, and Shire Pharmacuticals ; he received research
support from Eli Lilly and Company, Bristol Myers Squibb, NIDA,
Shire Pharmaceuticals, Chelsea Therapeutics, and Theravance ; and he
receives royalty payments (as inventor) from NYU for license of adult
ADHD scales and training materials since 2004. Drs. Upadhyaya,
Goto, Trzepacz, Tanaka, and Allen are full-time employees and
minor stockholders of Eli Lilly and Company. Mr Williams and
Dr. Heinloth are full-time employees of PharmaNet/i3, an inVentiv
Health Company.
jP-17-002jValidity of conners’ adult attention-deﬁcit/
hyperactivity disorder rating scale–investigator
rated : Screening version in european patients with
attention-deﬁcit/hyperactivity disorder
T. Goto1, S. Kooij2, K. Conners3, Y. Tanaka1, D. Williams4, A. Allen1,
A. Heinloth4, H. Upadhyaya1. 1Eli Lilly and Company, Indianapolis,
USA ; 2PsyQ, Den Haag, Netherlands ; 3Duke University, Durham, USA ;
4PharmaNet/i3, Ann Arbor, USA
Objective : To validate Conners’ Adult Attention-Deﬁcit/Hyper-
activity Disorder (ADHD) Rating Scale–Investigator Rated :Screening
Version (CAARS-Inv :SV) in European patients.
Methods : We used data from adult patients with ADHD partici-
pating in the initial 12-week open-label treatment phase of a long-term
clinical trial to examine maintenance of response to atomoxetine
40–100 mg/day. We recruited patients from European countries
(E-patients) and from countries outside of Europe (OE-patients).
Primary eﬃcacy measures : CAARS-Inv :SV and Clinical Global
Impression-ADHD-Severity (CGI-ADHD-S). Internal consistency of
CAARS-Inv :SV total and subscales were assessed by Cronbach’s
alpha (a). Predictive validity of CAARS-Inv :SV total and subscale
baseline scores for 12-week scores were tested with an analysis of co-
variance model. Convergent validity was determined by Pearson’s
correlation coeﬃcients between the CAARS-Inv :SV total and subscale
scores and CGI-ADHD-S scores at baseline and at 12 weeks.
Results : A total of 2017 patients (1217 E-patients [57.7% male ;
mean age 33.0 years] and 800 OE-patients [60.3% male ; mean age 33.4
years]) were included in the analyses. In both patient populations,
CAARS-Inv :SV showed good internal consistency (E-patients :
Cronbach’s a=0.930 ; OE-patients : Cronbach’s a=0.938) and con-
vergent validity (Pearson’s correlation coeﬃcients : 0.65 to 0.82,
P<0.001) with the CGI-ADHD-S scale over 12-weeks of treatment.
Baseline scores on the CAARS-Inv :SV total, inattentive, and hyper-
active/impulsive subscales showed signiﬁcant predictive validity
(P<0.0001) for 12-week scores for E-patients and OE-patients.
Conclusion : The CAARS-Inv :SV was validated in adult patients
with ADHD in a pan-European population. No substantial diﬀerences
in scale validity were observed between patients from within and
outside of Europe. Based on these results, use of the CAARS-Inv :SV is
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appropriate for evaluation of adult ADHD, for clinical or research
purposes, in European patient populations.
Policy of full disclosure : This work was sponsored by Eli Lilly and
Company and/or any of its subsidiaries. Dr. Kooij has been a speaker
for Eli Lilly BV, Janssen-Cilag and Shire, and received unrestricted
research grants from Janssen-Cilag and Shire. Dr. Conners is the
author of the CAARS scale and receives loyalties from Multi-Health
Systems, the publisher of the scale. Drs. Goto, Tanaka, Allen, and
Upadhyaya are full-time employees and minor stockholders of
Eli Lilly and Company. Mr Williams and Dr. Heinloth are full-time
employees of PharmaNet/i3, an inVentiv Health Company.
jP-17-003jA microdialysis and behavioural comparison of
lisdexamfetamine dimesylate and methylphenidate
in freely-moving rats
D. Hackett1, H.L. Rowley2, R.S. Kulkarni2, D.J. Heal2. 1Shire,
Basingtsoke, United Kingdom ; 2Renasci Ltd, Biocity, Nottingham, United
Kingdom
Objective : The simultaneous collection of dual-probe microdialysis
samples and locomotor activity data in freely moving rats adminis-
tered lisdexamfetamine dimesylate (LDX ; Vyvanse1, Shire US Inc),
a d-amfetamine (d-AMF) prodrug, or immediate-release methyl-
phenidate (MPH).
Methods : The eﬀects of a range of comparable oral doses of LDX
(d-AMF base=0.5, 1.5, 4.5 mg/kg) and MPH (3, 10, 30 mg/kg) on
extracellular levels of norepinephrine (NA), dopamine (DA) and 5-HT
in the prefrontal cortex (PFC) and striatum (STR), and locomotor
activity, were determined using the Culex Bambino.
Results : In the PFC, LDX dose-dependently and signiﬁcantly (p<
0.05) increased eﬄux of NA (f529% of baseline), DA (f296%),
and, at the highest dose, 5-HT (f284%). MPH increased DA eﬄux
(f202%) at the low dose and both DA (f217% ; f343%) and
NA (f261% ; f289%) at mid and high doses ; it had no eﬀect on
5-HT. In the STR, LDX dose-dependently increased extracellular
DA (f364%) and, at the high dose, 5-HT (f359%). MPH (3.0 mg/kg)
did not increase DA or 5-HT in STR but DA increases were produced
at 10 mg/kg (f131%) and 30 mg/kg (f243%). MPH (30 mg/kg)
only increased 5-HT eﬄux at one time-point. The actions of LDX and
MPH in PFC and STR reached a plateau at 45–60 min, but LDX eﬀects
were larger and more sustained. LDX did not signiﬁcantly enhance
locomotor activity at 0.5 mg/kg or 1.5 mg/kg except at two time-
points. A small sustained increase (f3.6/15 min) was seen at 4.5 mg/
kg. All doses of MPH signiﬁcantly increased locomotor activity
(f4.7/15 min).
Conclusion : LDX had larger and more sustained enhancing eﬀects
on NA and DA neurotransmission in PFC and STR than IR-MPH. That
substantial increases in STR DA can be achieved without causing
unacceptable locomotor activation predict that LDX will have a
greater separation between eﬃcacy and stimulant adverse events
than MPH.
Policy of full disclosure : Studies funded by Shire Biosciences,
Basingstoke, UK.
jP-17-004jLisdexamfetamine dimesylate and d-
amfetamine – important diﬀerences for the
relationships between extracellular striatal
dopamine, locomotor activity and plasma drug
concentrations in freely-moving rats revealed by
hysteresis analysis
D. Hackett1, H.L. Rowley2, D.J. Heal2. 1Shire, Basingtsoke, United
Kingdom ; 2RenaSci Ltd, Nottingham, United Kingdom
Objective : Lisdexamfetamine dimesylate (LDX ; Vyvanse1, Shire US
Inc) is a prodrug of d-amfetamine (d-AMF) that is approved for the
treatment of ADHD.
Methods : The Culex Bambino automatically collects intracerebral
microdialysates, intravenous blood samples and simultaneously
measures locomotor behaviour in freely moving rats. The eﬀects of
immediate release (IR) d-AMF SO4 (d-AMF base=1.5 mg/kg ip) and
LDX (d-AMF base=1.5 and 5.0 mg/kg ip) on extracellular dopamine
levels ([DA]) in the striatum, locomotor activity and plasma d-AMF
concentrations ([d-AMF]) were compared over 8 hr.
Results : LDX dose-dependently increased striatal [DA]f300 min.
The eﬀect of LDX (1.5 mg/kg) on [DA] was gradual and sustained
with maximum increase of 854% @ 75 min. IR-AMF (1.5 mg/kg)
evoked a more rapid and substantial increase of [DA] (1291%
@ 30 min). LDX (1.5 mg/kg) produced a small increase in locomotor
activity, maximal between 90–120 min returning to pre-drug levels by
195 min. IR-AMF (1.5 mg/kg) evoked much more locomotor activity
with an earlier peak (30 min) and shorter duration of eﬀect. Three
hysteresis analyses were performed. The most interesting and im-
portant diﬀerence came from the relationship between the changes in
[DA] over time versus locomotor activity. The hysteresis was antic-
lockwise for LDX, but clockwise for IR-AMF (P<0.05). Thus, with
LDX the rats were less prone to activation as extracellular [DA]
was rising, but reduced activation was maintained for longer when
[DA] declined ; the opposite was found for IR-AMF.
Conclusion : The ﬁndings are clinically important because sub-
cortical DA is implicated in eﬃcacy and side-eﬀects of ADHD drugs.
The sustained increase in [DA] and reduced locomotor activation
predict that LDX will have an enlarged ‘‘therapeutic window’’ com-
pared with IR-AMF. Moreover, the maintenance of LDX’s pharmaco-
dynamic eﬀect when CNS [DA] was declining indicates the unusual
PK of LDX optimises the utilisation of its active metabolite, d-AMF.
Policy of full disclosure : Studies funded by Shire Biosciences,
Basingstoke, UK.
jP-17-005jEﬃcacy and safety of atomoxetine in Asian adults
with ADHD: A multinational 10-week randomized,
double-blind placebo-controlled Asian study
Y. Hirata1, T. Goto2, Y. Takita1, P. Trzepacz2, A. Allen2, D.-H. Song3,
S.S.-Fen Gau4, H. Ichikawa5, M. Takahashi1. 1Eli Lilly Japan KK, Kobe/
Hyogo, Japan ; 2Eli Lilly and Company, Indianapolis, USA ; 3Severance
Hospital Yonsei Univ, Seoul, Republic of Korea ; 4National Taiwan
University, Hospital & College of Medicine, Taipei, Taiwan ; 5Tokyo
Metropolitan, Children’s Medical Center, Japan
Objective : This study aims to demonstrate eﬃcacy and to assess the
safety proﬁle of atomoxetine compared with placebo in Asian adult
patients with ADHD.
Methods : This study was conducted in Asian countries including
Japan, Korea and Taiwan with approval of the ethical reviews
boards. The Conners’ Adult ADHD Diagnostic Interview for DSM-IV
(CAADID) was used for Adult ADHD diagnosis. After obtaining in-
formed consent, patients were randomly assigned to treatment with
atomoxetine or placebo for 10 weeks. Atomoxetine was initiated at
40 mg once daily and then titrated up to a maximum of 120 mg once
daily. The eﬃcacy of atomoxetine versus placebo was evaluated using
the mean change from baseline to endpoint in CAARS Inv : SV total
score. Safety was assessed by adverse events (AEs), vital-signs,
and ECGs.
Results : A total of 388 patients (atomoxetine, n=193 ; placebo,
n=195) were included in the eﬃcacy and safety analyses. The mean
age (mean¡SD) was 32.3¡8.0 years ; 52.3% of the patients were fe-
male. The study population consisted of patients from Japan (63.7%),
South Korea (18.8%), and Taiwan (17.5%). The mean changes
of CAARS-Inv : SV total score were x14.3 (atomoxetine) and x8.8
(placebo) (p<0.001 ; eﬀect size, 0.55). Statistically signiﬁcant re-
ductions in CAARS Inv :SV total scores following atomoxetine ad-
ministration versus placebo were observed from week 2 to week 10,
with a least-mean diﬀerence of 6.18 (p<0.001) at week 10. Treatment-
emergent adverse events were reported more frequently in the ato-
moxetine group (80.8%) than the placebo group (53.8%) (p<0.001).
Most AEs were mild or moderate in severity. Ten atomoxetine treated
patients and 3 placebo patients discontinued due to AEs.
Conclusion : This is the ﬁrst placebo-controlled clinical research for
adults with ADHD in Asia. Atomoxetine was shown to be superior to
placebo in reducing the symptoms of ADHD, and was well tolerated
in adult Asian patients with ADHD.
Policy of full disclosure : Yuko Hirata, Yasushi Takita and
Michihiro Takahashi are employees of Eli Lilly Japan KK. Taro Goto,
Paula T Trzepacz and Albert J Allen are employees of Eli Lilly and
Company. Hironobu Ichikawa is an advisor of Eli Lilly Japan and has
ever been invited as a speaker of Lilly-sponsored lecture meeting.
Dong-Ho Song is an advisor for Eli Lilly Korea and has ever been
invited as a chairperson/speaker of Lilly-sponsored lecture meeting.
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Susan Shur-Fen Gau is an advisor for Eli Lilly Taiwan and has ever
been invited as a chairperson/speaker of Lilly-sponsored lecture
meeting.
jP-17-006j Improvements of health-related QOL and executive
functions of atomoxetine in Asian adults with
ADHD: A multinational 10-week randomized,
double-blind placebo-controlled Asian study
Y. Hirata1, T. Goto2, Y. Takita1, P. Trzepacz2, A. Allen3, D.-H. Song4,
S.S.-Fen Gau5, H. Ichikawa6, M. Takahashi1. 1Eli Lilly Japan KK, Kobe/
Hyogo, Japan ; 2Eli Lilly and Company, Indianapolis, USA ; 3Eli Lilly and
Company, Indianapolis, USA ; 4Severance Hospital Yonsei Univ, Seoul,
Republic of Korea ; 5National Taiwan University, Hospital & College of
Medicine, Taipei, Taiwan ; 6Tokyo Metropolitan Children’s Medical
Center, Japan
Objective : The eﬃcacy and safety of atomoxetine in adult ADHD
patients were investigated in a double-blind placebo-controlled Asian
study. This study compared Health—related QOL and Executive
functions between atomoxetine-treated and placebo-treated patients
in Asia.
Methods : This study was conducted in Japan, Korea and Taiwan
with approval of the ethical reviews boards. The Conners’ Adult
ADHD Diagnostic Interview for DSM-IV (CAADID) was used for
Adult ADHD diagnosis. After obtaining informed consent, patients
were randomized treatment with atomoxetine or placebo for 10
weeks. Atomoxetine was initiated at 40 mg/day and then titrated up
to a maximum of 120 mg/day. Health—related QOL was measured
by Adult Attention-Deﬁcit/Hyperactivity Disorder Quality of Life
(AAQoL). Executive functions were assessed by Behavior Rating
Inventory of Executive Function-Adult Version(BRIEF-A) :Self Report
and Informant.
Results : A total of 388 patients (atomoxetine, n=193 ; placebo,
n=195) were included in the analyses. The mean age was 32.3
(SD=8.0) years ; 52.3% of the patients were female. The study popu-
lation consisted of patients from Japan (63.7%), South Korea (18.8%),
and Taiwan (17.5%). The mean changes of AAQoL were signiﬁcantly
greater in total score (p<0.001) and its components of life outlook
(p=0.049), life productivity (p<0.001) and relationships (p=0.007) in
the atomoxetine group than the placebo group. Atomoxetine showed
statistically signiﬁcant reductions in global executive composite
(p<0.001), behavioral regulation index (p=0.001) and metacognition
index (p<0.001) of the BRIEF-A self report, including all 9 compo-
nents. Though the group diﬀerences in BRIEF-A informant compo-
nents were not statistically signiﬁcant, tendency for improvement in
atomoxetine group were observed in behavioral regulation index,
emotional control and task monitor.
Conclusion : This is the ﬁrst placebo-control clinical research for
adults with ADHD in Asia. Atomoxetine was eﬀective in improving
the disease-speciﬁc functional impairments measured by AAQoL and
executive functions.
Policy of full disclosure : Yuko Hirata, Yasushi Takita and
Michihiro Takahashi are employees of Eli Lilly Japan KK. Taro Goto,
Paula T Trzepacz and Albert J Allen are employees of Eli Lilly and
Company. Hironobu Ichikawa is an advisor of Eli Lilly Japan and has
ever been invited as a speaker of Lilly-sponsored lecture meeting.
Dong-Ho Song is an advisor for Eli Lilly Korea and has ever been
invited as a chairperson/speaker of Lilly-sponsored lecture meeting.
Susan Shur-Fen Gau is an advisor for Eli Lilly Taiwan and has ever
been invited as a chairperson/speaker of Lilly-sponsored lecture
meeting.
jP-17-007jA neuropeptide S receptor gene variant and stressful
life events are associated with increased
hyperactivity and inattention in adolescents
E. Kiive1, K. Laas1, J. Deckert2, K.P. Lesch2, T. Veidebaum3, A. Reif2,
J. Harro1. 1University of Tartu, Estonia ; 2University of Wu¨rzburg,
Germany ; 3National Institute for Health, Tallinn, Estonia
Objective : Neuropeptide S and its receptor (NPSR) are involved in
regulation of activity, anxiety and fear [Reinscheid 2008, Results Probl
Cell Diﬀer 46 : 145–158]. We explored the association of the functional
NPSR1 gene A/T polymorphism (rs 324981) and stressful life events
(SLE) with inattentive/hyperactive behaviour in a population rep-
resentative sample of adolescents.
Methods : The data of the younger (n=593) and older cohort
(n=583) of the longitudinal Estonian Children Personality, Behaviour
and Health Study (ECPBHS, Tomson et al., 2011 [Prog Neuro-
Psychopharmacol Biol Psychiat 35 : 1857–1862]) was used. ADHD
symptoms were reported by teachers using the Hyperactivity Scale of
af Klinteberg (younger cohort at ages 9, 15 and 18 ; older cohort 15 and
18), and SNAP-IV (younger cohort at ages 15 and 18 ; older cohort
at 18 and ASRS self-report at 25). School grades and the history of
SLE were self-reported at ages 15 and 18. Analysis of variance and
multilevel modelling were used for statistical analysis with SAS 9.1.
Results : In both cohorts males with T/T genotype of the NPSR1
displayed signiﬁcantly more ADHD symptoms (p<0.05). No inter-
action eﬀect of genotype and age on hyperactivity measures was
found. In older cohort males with the T-allele were more aggressive
than females (p<0.001). In younger cohort the interaction eﬀect of
genotype and SLE on ADHD symptoms was found : both males and
females with high number of SLE and at least one T-allele exhibited
higher inattention (p<0.01) while the increase in motor restlessness
was observed only in males (p<0.05). Adolescents of the younger
cohort with T/T genotype reported lower school grades (p<0.05).
Conclusion : Our ﬁndings suggest that the T/T genotype of the
NPSR1 is associated with higher number of ADHD symptoms in
males. However, the T-allele in combination with high number of SLE
leads to increased hyperactive and inattentive behaviour in both
sexes.
jP-17-008jAdherence to OROS methylphenidate and
symptoms in children with attention deﬁcit
hyperactivity disorder
S.-H. Kim1, J. Yang2, M.-S. Lee1, S.-H. Joe1, I.-K. Jung1. 1Korea
University Guro Hospital, Seoul, Republic of Korea ; 2Korea University
Ansan Hospita, Seoul, Republic of Korea
Objective : The goal of this study was to examine medication
adherence to Osmotic-controlled Release Oral delivery System
methylphenidate using electronic measurements and other measures
of adherence in children with attention-deﬁcit hyperactivity disorder
(ADHD). The relationship between adherence and other clinical
factors was also analyzed.
Methods : Thirty-nine children diagnosed with ADHD were mon-
itored over the course of eight weeks. Medication adherence was as-
sessed using patient self-report, a clinician rating scale, pill counts,
and the Medication Event Monitoring System (MEMS), which is a
medication bottle cap with a microprocessor that records the time and
date every time the bottle is opened. Agreement among the adherence
measures and the relationships between adherence and other factors,
including ADHD rating scores of children and their parents, were
assessed.
Results : The rate of non-adherence measured by the MEMS was
found to be 46.2%, which was considerably higher than the clinician
scale (31.7%), patient self-report (17.9%), and pill count (12.8%) rates
of non-adherence. The rate of adherence measured by the MEMS was
not signiﬁcantly associated with baseline symptom severity or symp-
tom changes over a short-term period, though non-adherent group
experienced more severe symptoms in children with ADHD.
Conclusion : Adherence to OROS methylphenidate varied de-
pending on the method used to measure adherence. There was a dis-
crepancy between adherence measures according to clinician rating
and the MEMS. Further studies are needed to evaluate the variables
that may impact medication adherence in ADHD.
jP-17-009jD1 receptor hyperfunction in the nucleus accumbens
of SHR, a rat model of attention deﬁcit/hyperactivity
disorder
Y. Ohno1, M. Okana1, A. Masui1, Y. Mizuguchi1, J. Imaki1, M. Egawa1,
C. Yoshihara1, A. Tatara1, M. Sasa2, S. Shimizu1. 1Osaka Univ. Pharm.
Sci., Japan ; 2Nagisa Clinic, Osaka, Japan
Objective : Spontaneously hypertensive rats (SHR) are widely used as
a rat model of attention deﬁcit/hyperactivity disorder (ADHD). Here,
we conducted behavioral and immunohistochemical studies in SHR
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to clarify pathophysiological alterations in neurotransmission and
brain regions related to their behavioral abnormalities.
Methods : Juvenile (4–5 weeks old) Male SHR andWistar Kyoto rats
(WKY) were used. Spontaneous activity of animals were evaluated
with the open-ﬁeld test. Fos protein expression in various regions of
the brain was immunohistochemically stained using ABC-DAB
methods. In addition, the eﬀects of a selective D1 antagonist SCH-
23390 on open-ﬁeld behaviors and brain Fos expression in SHR were
also examined.
Results : In the open-ﬁeld test, juvenile SHR exhibited a signiﬁcant
increase in ambulation and rearing activity as compared with WKY.
Brain mapping analysis of Fos-immunoreactivity (IR) revealed that
SHR showed a marked increase in Fos expression in the core part
(AcC) of the nucleus accumbens (NAc). Small to moderate increases
were also observed in the shell part of the NAc and some regions of
the cerebral cortex (e.g., parietal association cortex). However, Fos-IR
levels in other brain regions including the limbic area, striatum and
diencephalon were unaltered. In addition, treatment of SHR with
SCH-23390 (0.2 mg/kg, i.p.) signiﬁcantly reduced behavioral hyper-
activity in SHR. Elevation of Fos expression in the AcC and cortices in
SHR was also reversed by SCH-23390.
Conclusion : The present study strongly suggests that D1 receptor-
mediated transmission in the AcC is region-speciﬁcally elevated in
SHR, which could be responsible for behavioral hyperactivity.
jP-17-010j Identiﬁcation and management of adult attention
deﬁcit disorder : Case discussions and brief
literature review
S. Pattanayak1, N. Bhimwal1. 1V.I.M.H.A.N.S., New Delhi, India
Objective : Introduction : Not all children with ADHD remit in ado-
lescence and many continue to manifest a host of behavioral and
lifestyle problems, and are often treated as ‘ lazy/disorganized’ by
family members. Adult ADD needs more clinical and research atten-
tion. Objective : To describe the case histories and management of
three patients diagnosed as Adult ADHD and present a brief review
of relevant literature.
Methods : The case details of three adult male patients (Mr A,
25 yrs ; Mr B 30 years and Mr C 34 years) presenting to the out-patient
psychiatric clinic of V.I.M.H.A.N.S., New Delhi are being presented.
All three patients reported long standing histories of diﬃculties ex-
perienced in organizing work or home aﬀairs, poor time manage-
ment/inability to keep appointments, at times not even making it on
time for examinations/interviews, tendency to delay/procrastinate
important things, frequent inattention towards the work at hand af-
fecting the academic/job performance, multiple changes of job, con-
sidered to be ‘chronically lazy’ and ‘inattentive’ by family members.
All three patients had childhood histories of ADHD.
Results :After a careful history and assessments, and ruling out any
other psychiatric/medical comorbidity, a diagnosis of Adult ADHD
was considered. They were initiated on stimulants and were carefully
monitored. Al the three patients responded well to Atomoxetine
15 mg, Methylphenidate 40 mg/day and Atomoxetine 58 mg/day
respectively, with a considerable improvement in symptoms of inat-
tention and improved socio-occupational performance. The ﬁndings
from the cases are being discussed in light of available literature.
Conclusion : The diagnosis of adult ADD should be considered in
all patients presenting with chronic histories of inattention. The
childhood history of ADHD should be enquired from family members
and if positive, these patients can be considered for an adequate trial
of stimulant-based pharmacotherapy.
jP-17-011jConversion of lisdexamfetamine dimesylate to
d-amfetamine : Low variability in exposure
to d-amfetamine after administration of
lisdexamfetamine dimesylate to children with
ADHD
M. Pennick1, J. Ermer2. 1Shire Pharmaceuticals, Basingstoke, United
Kingdom ; 2Shire Development LLC, Wayne, USA
Objective : Lisdexamfetamine dimesylate (LDX, Vyvanse1, Shire US
Inc) is a long-acting prodrug stimulant that requires hydrolytic
cleavage to generate active d-amfetamine. Preclinical studies indicate
that LDX is rapidly absorbed via active transport, and is a likely sub-
strate for PepT1 in the small intestine. Here, we describe the formation
of d-amfetamine from LDX in human tissues maintained in vitro, and
the low variability in d-amfetamine exposure in children with ADHD
treated with LDX.
Methods : Studies on LDX hydrolysis were performed in homo-
genized tissues and fractions of blood obtained from human donors.
Tissues were incubated (37 xC) with 1 mg/mL LDX, and samples were
collected for <4 hrs. Variability in systemic exposure of d-amfeta-
mine following administration of LDX 30 mg, 50 mg and 70 mg was
examined in a single-dose, randomized, crossover study in boys and
girls (6–12 years) with ADHD severe enough to require a treatment
change.
Results : Half-lives for the disappearance of LDX were 1.6 h, 2.3 h
and 9.7 h in whole blood, kidney and liver, respectively ; LDX was
stable in homogenates of upper and lower intestines, pancreas and
plasma. When incubated with red blood cells (RBC), the half-life for
the disappearance of LDX was 1.0 h ; and there was still substantial
conversion at 10–15% of normal haematocrit. In children with ADHD
(17 completed the study ; mean age 9.6 years), exposure (AUC0–1) of
d-amfetamine increased proportionally with increasing LDX dose
(mean [standard deviation] ng.h/mL : 30 mg, 844.6 [116.7] ; 50 mg,
1510.0 [241.6] ; 70 mg, 2157.0 [383.3]). The variability (percent coef-
ﬁcient of variation) in d-amfetamine AUC0–1 was below 20% for all
three doses of LDX (30 mg, 13.8% ; 50 mg, 16.0% ; 70 mg, 17.8%).
Conclusion : LDX was converted to d-amfetamine primarily in
RBC. In children with ADHD, exposure to d-amfetamine increased in
proportion to dose, and variability in exposure was low, within the
therapeutic dose range (30–70 mg).
Policy of full disclosure : Studies conducted by Shire
Pharmaceuticals Limited.
jP-17-012jDoes methylphenidate have an impact on ocular
motor system? A controlled study on children with
attention-deﬁcit/hyperactivity disorder
M. Seassau1, R. Carcangiu2, T. Weiss2, F. Duval2. 1 e(ye)BRAIN, Ivry-
Sur-Seine, France ; 2Centre Hospitalier, Unite´ Passerelle, Rouﬀach, France
Objective : Attention-Deﬁcit/hyperactivity disorder (ADHD) is char-
acterized by behavioral symptoms of inattention and may include
hyperactivity and impulsivity. The impulsivity and inattention sug-
gest deﬁcits in the voluntary control of behavior. Eye movements de-
pend on structures implicated in attention and in motor control, both
criteria areas of dysfunction in ADHD. In the present study, objective
was to evaluate the eﬀect of methylphenidate (MPH) on ocular motor
system in ADHD children.
Methods : Subjects were aged 7–12 years, with ADHD on and oﬀ
MPH (N=9), and control subjects (N=9). Saccade latencies, mean
velocity, precision, accuracy and percentage of anticipatory errors
were determined in visually-guided-saccades (automatic and volun-
tary attentional tasks) and antisaccades tasks.
Results : Signiﬁcant diﬀerences existed between ADHD on
MPH and ADHD oﬀ MPH, in latencies (p<0.02), precision (p<0.04),
accuracy (p<0.05) and percentage of anticipatory errors (p<0.05).
Compared to controls, ADHD on MPH had normalized perfor-
mances, in automatic task, while they still impaired in voluntary
attentional tasks.
Conclusion : MPH modiﬁed motor planning and response inhi-
bition in ADHD children. Beneﬁts depend of 1) the type of tasks
(automatic and voluntary attention) and 2) the analyzed variables
(motor control). These results suggest that eye movements could be a
good predictor response to MPH.
jP-17-013jPrevalence of adult attention deﬁcit hyperactivity
disorder in anxiety disorders sample
M. Van Ameringen1, B. Patterson2, W. Simpson3. 1McMaster
University/St.Josephs, Hamilton, Canada ; 2McMaster University,
Psychiatry/Behav.Neurosciences, Hamilton, Canada ; 3McMaster
University/St. Josephs, MiNDS Neuroscience Graduate Pg, Hamilton,
Canada
Objective :Adult Attention Deﬁcit Hyperactivity Disorder (ADHD) is
a life-long, chronic disorder, aﬀecting 8.1% of the US population.
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ADHD is highly comorbid with other psychiatric disorders, however
little is known about the prevalence of ADHD in anxiety disorder
clinical samples.
Methods : Consecutive adult patients (N=264) at an anxiety dis-
orders clinic in Hamilton Canada, completed the Adult ADHD self-
report scale and were assessed with a Structured Clinical Interview
for DSM-IV, and the ADHD module of the Mini International
Neuropsychiatric Interview (MINI).
Results : The rate of lifetime ADHD was 37.5% (48.5% male, 51.5%
female, p<0.05). Adult ADHD was signiﬁcantly associated with life-
time comorbid diagnoses of impulse control disorder and bipolar
disorder as well as a higher number of comorbid disorders. Symptom
severity measure scores on the Padua Inventory, Yale-Brown
Obsessive Compulsive Scale, Sheehan Disability Scale (SDS), Anxiety
Sensitivity Index (ASI), the QUIDS depression rating scale, the Penn
State Worry Questionnaire and the Davidson Trauma Scale were sig-
niﬁcantly higher in those with ADHD. Individuals with ADHD, plus
generalized anxiety disorder, and ADHD plus panic disorder with
agoraphobia had higher scores on a variety of symptom severity
measures than those without ADHD. Increased ADHD severity was
associated with a greater number of lifetime comorbid diagnoses, and
higher symptom severity scores. Males were more likely than females
to have received ADHD treatment in the past ; 76% with adult ADHD
had never received the diagnosis and 17.2% had received prior
ADHD treatment. Of the patients who had received previous ADHD
diagnoses, 25% were diagnosed in childhood.
Conclusion : The prevalence of lifetime ADHD was higher in our
anxiety disorders clinic sample than that found in the general popu-
lation. The presence of comorbid ADHD appears to have a signiﬁcant
impact on the severity and impact of comorbid anxiety disorders.
Policy of full disclosure : Financial Disclosure, Dr. Michael Van
Ameringen : Grant/Research Support : Janssen-Ortho Inc., NIH
(National Institutes of Health), Pﬁzer Inc. Speakers’ Bureau : Valiant,
GlaxoSmithKline, Lundbeck, Pﬁzer Inc. Advisory Boards : Valiant, Eli
Lilly, Janssen-Ortho Inc., Labo Pharm, Lundbeck, Pﬁzer Inc., Shire Ms.
Beth Patterson and Mr. William Simpson have no ﬁnancial interests to
disclose.
jP-17-014jAltered tryptophan and alanine transport in cultured
ﬁbroblast from boys with attention deﬁcit/
hyperactivity disorder (ADHD)
N. Venizelos1, J. Johansson2, M. Landgren3, E. Elisabeth4, R. Vumma1.
1 O¨rebro University, O¨rebro, Sweden ; 2 O¨rebro University, School of Health
& Medical Sc., O¨rebro, Sweden ; 3Skaraborg Hospital, Department of
Pediatrics, Mariestad, Sweden ; 4Sahlgrenska Academy, Gillberg
Neuoropsychiatry Center, Gothenburg, Sweden
Objective : The amino acid tyrosine and tryptophan are the pre-
cursors for the synthesis of the neurotransmitters dopamine, nor-
epinephrine and serotonin. These neurotransmitters are implicated in
the pathophysiology of Attention Deﬁcit/Hyperactivity Disorder
(ADHD). A disturbed transport of tyrosine, as well as other amino
acids, has been found in a number of other neuropsychiatric dis-
orders, such as autism, schizophrenia and bipolar disorder, when
using the ﬁbroblast cell model. Hence, the aim of this study was to
explore whether children with ADHDmay have disturbed amino acid
transport.
Methods : Materials and Methods : The precursor amino acid
transport was assessed in cultured ﬁbroblasts derived from biopsies
from 14 boys with ADHD diagnosis and 13 matching boys without a
diagnosis of a developmental disorder. The kinetic parameters,
maximal transport capacity (Vmax) and aﬃnity of the binding sites
(Km) for tyrosine, tryptophan and alanine were measured by using
the cluster tray method. Student’s unpaired t-test or the Mann
Whitney U test was used to analyze any diﬀerence between the two
groups.
Results : The tryptophan transport (Vmax) was signiﬁcantly de-
creased in the ADHD group in comparison to controls (p=0.039),
while the alanine transport (Vmax) was signiﬁcantly increased in the
ADHD group (p=0.031). There was no signiﬁcant diﬀerence regard-
ing the tyrosine transport between the two groups.
Conclusion : A decreased transport capacity of tryptophan implies
that less tryptophan is being transported across the BBB in the ADHD
group, since tryptophan uses the same transport systems in both
ﬁbroblasts and at the blood brain barrier (BBB). This could lead to
deﬁcient serotonin access in the brain that might cause disturbances in
both the serotonergic and the catecholaminergic neurotransmitter
systems, since these systems are highly interconnected. The physio-
logical importance of an elevated transport capacity of alanine to the
brain is not known to date.
jP-17-015jDecreased density of muscarinic acetylcholine
receptors in ﬁbroblast from boys with attention
deﬁcit/hyperactivity disorder (ADHD) : An in vitro
study
N. Venizelos1, J. Johansson1, M. Landgren2, E. Fernell3, T. Lewander4.
1 O¨rebro University, O¨rebro, Sweden ; 2Mariestad, Sweden ; 3Sahlgrenska
Academy, Gillberg Neuoropsychiatry Center, Gothenburg, Sweden ;
4Uppsala University, Sweden
Objective : Attention Deﬁcit/Hyperactivity Disorder (ADHD) is a
neurobehavioral disorder aﬀecting both children and adults world-
wide. It is speculated that the neurotransmitters, dopamine and nor-
epinephrine are involved in the pathophysiology of the
neurobehavioral disorder ADHD. Moreover, it is known that choli-
nergic activity can modulate dopaminergic activity in the brain. The
aim of this study was to measure the density and aﬃnity of muscari-
nic acetylcholine receptors (mAChRs) in children with ADHD, by
using the ﬁbroblast cell model.
Methods : Fibroblast cell homogenates from 11 boys with ADHD,
fulﬁlling the DSM-IV diagnostic criteria and from 9 matching controls
were used in the study. The maximal binding capacity (Bmax) and the
equilibrium dissociation constant (KD) of mAChRs were determined
by radioligand binding assay, using the mAChR antagonist 3H-QNB.
Due to non-normally distribution of the calculated data, three outliers
were identiﬁed by the MADE method (two in the ADHD group, both
with a non-hereditary ADHD and one in the comparison group),
and were therefore excluded from the statistical analyses (Student´s
unpaired t-test).
Results : A signiﬁcantly (p=0.01), lower Bmax for the binding of
the muscarinic antagonist 3H-QNB was observed in the ﬁbroblasts
from the ADHD children (n=9) with a hereditary family history
compared to controls (n=8), while the KD did not diﬀer between the
two groups (p=0.40).
Conclusion : The present results indicate a reduced density of
mAChR in ﬁbroblasts from children with a hereditary ADHD, which
might be a marker of the disorder. However, further studies are
needed to conﬁrm these observations.
P-18. Neurophysiology
jP-18-001jSimultaneous, but not separate activation of beta-1–
and beta-2–adrenoceptors in the nucleus accumbens
increases accumbal dopamine eﬄux in freely
moving rats
Y. Aono1, T. Saigusa2, T. Uchida3, N. Koshikawa2, A.R. Cools4.
1Nihon Univ Sch of Dent, Chiyoda-Ku Tokyo, Japan ; 2Nihon Univ Sch of
Dent, Department of Pharmacology, Chiyoda-Ku Tokyo, Japan ; 3Nihon
Univ Sch of Dent, Department of Anaesthesiology, Chiyoda-Ku Tokyo,
Japan ; 4Radboud Univ Nijmegen, Psychoneuropharmacology, Netherlands
Objective : Dopaminergic neurons, which arise in both the ventral
tegmental area and the substantia nigra pars compacta, terminate
among others in the nucleus accumbens (NAc). The NAc receives a
noradrenergic input from the locus coeruleus and the ventral med-
ulla. The NAc contains beta–adrenoceptors. There exists a close
beta–adrenoceptor mediated noradrenaline (NA) – dopamine (DA)
interaction within the NAc. We have already reported that endogen-
ous NA in the NAc activates accumbal beta–adrenoceptors that, in
turn, enhance accumbal DA release (Eur J Pharmacol, 2008, 601,
94–98). In the present study, the eﬀects of selective agonists of the
beta–adrenoceptor subtypes on the NA and DA eﬄux in the NAc of
freely moving rats were investigated, using in vivo microdialysis.
Methods :Male Sprague-Dawley rats were used. NA and DA levels
in accumbal dialysates taken every 20 min were measured by HPLC-
ECD system. Drugs were locally applied through the microdialysis
probe.
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Results : Neither beta-1– (dobutamine : 60 and 120 fmol) nor beta-
2–adrenoceptor agonist (salbutamol : 0.36 and 3.6 pmol) altered the
basal NA and DA eﬄux in the NAc. Co-administration of 60 fmol
of dobutamine with salbutamol (3.6 pmol) did not aﬀect the NA
levels, but it increased the DA eﬄux by approximately 120%. Co-
administration of 120 fmol of dobutamine with salbutamol (0.36 or
3.6 pmol) also increased DA eﬄux till approximately 120% without
aﬀecting NA levels. The non-selective beta–adrenoceptor antagonist
l-propranolol (1.2 nmol) which failed to alter the basal NA and DA
levels, suppressed the DA eﬄux, induced by co-administration of
dobutamine (120 fmol) and salbutamol (3.6 pmol).
Conclusion : The present study provides in vivo neurochemical
evidence that simultaneous, but not separate activation of accumbal
beta-1– and beta-2–adrenoceptors which are suggested to be located
on the dopaminergic nerve endings in the NAc, stimulates accumbal
DA release.
jP-18-002jThe role of the arcuate nucleus in the regulation of
cytochrome P450 in the liver
E. Bromek1, J. Wo´jcikowski1, W. Daniel1. 1 Institute of Pharmacology
PAS, Cracow, Poland
Objective : The neuroendocrine neurons of the arcuate nucleus (ARC)
produce and release growth hormone-releasing hormone. Growth
hormone released in the anterior pituitary regulates the expression
of cytochrome P450 (CYP), in particular of CYP2C11 – one the main
male rat isoforms. In our previous study we showed that the intra-
cerebroventricular injection of the noradrenergic neurotoxin DSP-4
led to a decrease in the expression of CYP2C11 and CYP3A in the
liver. The aim of present study was to estimate the role of nora-
drenergic innervation of the ARC in the regulation of cytochrome
P450 expression in the liver.
Methods : The experiment was carried out on male Wistar rats.
DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine) was injected
locally into the ARC. One week after the injection, the brains (and
livers) were rapidly removed, dissected into selected structures and
stored at x80 xC. The levels of noradrenaline, dopamine and sero-
tonin in the part of the hypothalamus containing ARC were deter-
mined (HPLC). Liver microsomes were prepared and the activity
of liver cytochrome P450 was measured as a rate of testosterone
hydroxylation (HPLC).
Results : A substantial decrease in the noradrenaline level was ob-
served after DSP-4 injection into the ARC. The levels of other neuro-
transmitters were unchanged. The activity of the CYP2C11 in the liver
of the lesioned rats was signiﬁcantly lower compared to the controls.
Conclusion : In conclusion, our study showed that destruction of
the noradrenaline terminals innervating ARC results in the decrease
of the activity of CYP2C11 in the liver. The ﬁnding seems to be of
physiological and pharmacological importance since CYP2C11 con-
stitutes the major part of male liver cytochrome P450 and is respon-
sible for the metabolism of testosterone and some drugs such as
lidocaine or antipyrine. (Grant no. NN405 304836 from theMinistry of
Science and Higher Education (Warsaw, Poland) and statutory funds
of the Institute of Pharmacology PAS).
jP-18-003jFirst and second generation antipsychotic diﬀerences
in 50 and 100 ms superior temporal gyrus paired-
click gating
J.M. Canive1, B.Y. Lu2, J.C. Edgar3, E. Epstein4, Y.-H. Chen4,
M.A. Hunter4, M. Huang5. 1NMVAHCS & Univ. of New Mexico,
Albuquerque, USA ; 2University of Hawaii, Department of Psychiatry,
Honolulu, USA ; 3University of Pennsylvania, Department of Radiology,
Philadelphia, USA ; 4University of New Mexico, Department of
Psychiatry, Albuquerque, USA ; 5Univ. California San Diego, Professor of
Radiology, USA
Objective : Introduction : Auditory gating deﬁcit continues to be a
widely studied schizophrenia endophenotype. Degre of gating is ty-
pically measured via a paired-click paradigm that generates two
evoked potentials (S1 and S2) at Cz. Individuals with schizophrenia
often exhibit a diminished S1 response and higher S2/S1 50 ms (P50)
and 100 ms (N100) ratio scores than controls. Previous studies suggest
that atypical antipsychotics, particularly clozapine, may be associated
with improved 50 ms Cz (P50) ratio scores. Whether such eﬀects are
detectable at the primary neuronal generators of the 50 and 100 ms
auditory response (superior temporal gyrus, STG) remains unstudied.
Methods :Methods/Hypotheses : Magnetoencephalography (MEG)
source localization provided measures of left and right STG paired-
click auditory S1 and S2 activity. As previous work demonstrates the
importance of prefrontal (PFC) dopamine in enhancing brain signal-
to-noise measures such as auditory responses, it was hypothesized
that (1) compared to ﬁrst generation antipsychotics, second generation
antipsychotics are associated with smaller ratio scores due to a smaller
degree of dopaminergic blockade, and (2) ‘normalization’ of gating is
greater at 100 ms (M100) than 50 ms (M50), due to greater involve-
ment of other cortices such as PFC modulating STG activity.
Results : In a sample of 74 healthy controls and 79 medicated
schizophrenia patients (ﬁrst to second generation ratio of 1 : 3), second
generation antipsychotics were associated with improved gating, with
S1 amplitude and ratio scores between healthy controls and patients
on ﬁrst generation Furthermore, these eﬀects were most pronounced
at left STG and for M100. No diﬀerences were detected among
the second generation antipsychotics, although a trend of a more
attenuated left S2 M100 response was seen with quetiapine and
olanzapine.
Conclusion : Present ﬁndings support the hypothesis that auditory
gating in schizophrenia is inﬂuenced by a left-dominant PFC-driven
dopaminergic signaling pathway, a network sensitive to diﬀerences
across antipsychotics in the degree of dopaminergic blockade.
jP-18-004jPrepulse inhibition deﬁcits in unmedicated patients
with Parkinson’s disease
I. Morales Mun˜oz1, J.A. Molina1, R. Jurado2, R. Rodrı´guez-Jime´nez2,
M. Jime´nez-Arriero2, G. Rubio2. 1Hospital 12 de Octubre, Madrid,
Spain ; 2Hospital 12 de Octubre, CIBERSAM, Madrid, Spain
Objective : Most patients with degenerative neurological diseases in-
volving the basal ganglia, such as Parkinson’s disease (PD), present
with functional abnormalities of brainstem reﬂexes. One method of
interest for the assessment of brainstem functions is prepulse inhi-
bition (PPI) of the startle reﬂex. PPI occurs because processing of
the prepulse transiently inhibits brainstem interneurons involved in
the generation of reﬂex blinks. In normal subjects, the response to the
second stimulus is smaller than the response to the ﬁrst stimulus,
whereas there is evidence suggesting diminished PPI in PD patients.
We aimed to determine whether PPI in PD is impaired at all intervals
or whether only some speciﬁc PPI levels are impaired.
Methods :We used a sample composed of 49 unmedicated patients
with PD and a control group of 37 healthy subjects. We used a com-
mercial human startle response monitoring system (CIBERTEC, S.A.)
to generate and deliver the startle stimuli, which were presented to
subjects binaurally through headphones. The startle measures used
were : prepulse inhibition percentages at 30, 60 and 120 milliseconds
(% PPI-30, % PPI-60 and % PPI-120, respectively), and habituation
percentage of the startle response. The SPSS statistical package
version 15 was used for the statistical analysis.
Results : ANOVA only demonstrated a signiﬁcant eﬀect of group x
intervals interactions at 120 ms (F(1,84)=14.35, p<0.001). Bonferroni
post-hoc analysis determined that PD patients exhibited lower PPI at
120 ms (p<0.001), whereas no diﬀerences were obtained regarding
PPI at 30 and 60 ms and habituation.
Conclusion : Our data suggest that within unmedicated patients
with PD, PPI is diminished at some levels compared to controls sub-
jects. Therefore, this examination with PPI can provide relevant in-
formation on functional abnormalities in PD. Furthermore, studies
with medicated patients with PD will be of interest, in order to
determine whether these deﬁcits still persist after being medicated.
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jP-18-005jAlpha-1–, but not alpha-2–adrenoceptor in the
nucleus accumbens exerts an inhibitory control upon
the accumbal noradrenaline and dopamine eﬄux in
freely moving rats
T. Saigusa1, Y. Aono1, N. Koshikawa1, A.R. Cools2. 1Nihon Univ.
School of Dent, Chiyoda-Ku, Tokyo, Japan ; 2Psychoneuropharmacology,
Dept. of Cognitive Neuroscience, Nijmegen, Netherlands
Objective : It is known that there exists a close alpha–adrenoceptor-
mediated noradrenaline (NA) – dopamine (DA) interaction within
the nucleus accumbens (NAc). We have shown that the alpha–
adrenoceptor antagonist phentolamine and the alpha–adrenoceptor
agonist phenylephrine increased and decreased accumbal NA eﬄux,
respectively (J Neural Transm, 2007, 114, 1135–1142). Both alpha–
adrenergic compounds increased accumbal DA eﬄux (Neuroscience,
2000, 99, 55–64). However, phentolamine and phenylephrine has
a limited selectivity in terms of aﬀecting alpha-1– and alpha-2–
adrenoceptors. Therefore, by using selective alpha-1– and alpha-
2–adrenoceptor ligands, we studied the role of alpha–adrenoceptor
subtypes in the regulation of accumbal NA and DA eﬄux of freely
moving rats.
Methods :Male Sprague-Dawley rats were used. NA and DA levels
in the accumbal perfusate samples taken every 20 min were measured
by HPLC-ECD system. Drugs were administered intracerebrally
through the microdialysis probe.
Results : Alpha-1–adrenoceptor antagonist prazosin (6 nmol) in-
creased the NA eﬄux by 207% and decreased the DA eﬄux by 43%,
respectively. Alpha-1–adrenoceptor agonist methoxamine (24 pmol)
that failed to alter the NA eﬄux reduced the DA eﬄux by 85%, and an
ineﬀective dose of prazosin (6 pmol) counteracted these eﬀects on DA
eﬄux. Neither the alpha-2–adrenoceptor antagonist RX821002
(6 nmol) nor the alpha-2–adrenoceptor agonists UK14304 and cloni-
dine (300 pmol) altered NA and DA eﬄux.
Conclusion : The present study shows that accumbal NA eﬄux is
under tonic inhibitory control of alpha-1–adrenoceptor that are sug-
gested to be presynaptically located on accumbal noradrenergic
nerve endings. This study also indicates that the accumbal alpha-
1–adrenoceptor that are suggested to be located on dopaminergic
terminals, play an inhibitory role on the regulation of DA eﬄux. The
present results imply that accumbal alpha-2–adrenoceptors play no
major role in the regulation of NA and DA eﬄux in the NAc.
jP-18-006jElectroconvulsive therapy parameters on parkinson’s
disease with poor response to levodopa treatment
R. Sanchez Gonzalez1, L. Pintor Pe´rez2, M. J. Jimenez Contreras1.
1Parc de Salut Mar – INAD, Sta. Coloma Gramenet, Spain ; 2 Institut de
Neurocie`ncies, Hospital Clı´nic i Provincial, Barcelona, Spain
Objective : The aim of this study is to determine the use parameters
and safety of ECT in patients diagnosed of advanced PD, levodopa
resistant and without psychiatric comorbidity.
Methods : 9 patients with PD diagnosis were assessed. The in-
clusion criteria were : a) PD stage III- IV of Hoehn and Yahr scale, b)
age between 45 and 80 years, c) ‘‘on-oﬀ’’ phenomena pharmacologi-
cally resistant, d) pharmacological optimized treatment without
changes in the last month and e) signed informed consent. ECT
Protocol : 8 sessions of bilateral electrode placement ECT were
performed twice a week, using a MECTA brief-pulse device. The
anesthetic drugs used in all cases were : atropine (0.5–0.8 mg),
succinilcoline (40–50 mg) and sodic tiopenthal (200–300 mg).
Results : 5 men and 4 women were recruited, with a mean age of 75
(SD=6, range 63–80) years old, with 14 (SD=9) years of disease, and
with 12 (SD=5) years of treatment with levodopa. Three patients did
not end the study. After the ECT treatment, the number of steps to
walk seven meters in ‘‘on phase’’ and the number of freezings in ‘‘on
phase’’ showed statistically signiﬁcant improvement. ECT parameters
are showed in a table.
Conclusion : ECT could be a safe and eﬀective therapeutic option in
levodopa resistant PD patients with predominantly axial ‘‘on’’
phenomena. Related with ECT parameters for PD patients without
psychiatric comorbidity found in the literature and with the para-
meters used by us, we proposed a guide for the safe and eﬀective
administration of ECT in this population : current intensity between
0.7 to 0.8 A ; frequency between 50 and 90 Hz ; bilateral electrode
placement with pulse width between 1.6 and 2 mSec (brief stimulus
technique), electrical stimulation time between 3 and 9 Sec, and a
motor and EEG seizure time target between 20 and 60 Sec.
jP-18-007jNeurophysiological hypotheses of electroconvulsive
therapy
R. Sanchez Gonzalez. Parc de Salut Mar – INAD, Sta. Coloma
Gramenet, Spain
Objective : Review the neurophysiological hypotheses associated
with the mechanism of action of ECT.
Methods : Bibliographic research : PubMed, EMBASE, ISI Web of
Knowledge.
Results : Anticonvulsant hypothesis : this hypothesis proposes that
the termination of the ECT-induced seizure is an active inhibitory
process essential for the eﬃcacy of the therapy. ECT has potent
anticonvulsant properties as demonstrated by 1) the progressive in-
crease of the seizure threshold and decrease of the seizure duration,
that we would designate as a tolerance phenomenon during the
treatment with ECT ; 2) the regional and/or global reductions of the
cerebral blood ﬂow and cerebral metabolic index ; 3) the induction of a
slow wave activity in the EEG and 4) the increase of the functional
activity of the neuropeptides and neurotransmitter inhibitors that
occurs with the ECT. Seizure generalization hypothesis : a more ex-
tensive ECT-induced brain seizure activity produces a better anti-
depressant clinical response. Prefrontal model : the magnitude of the
reductions in the cerebral blood ﬂow (CBF) in the speciﬁc prefrontal
regions is related with the eﬃcacy of ECT, and the responders to
this therapy have more likelihood of post-ictal suppression and of
developing slow wave activity on the EEG than the nonresponders.
Anatomico-ictal theory : iIs a uniﬁcation of the neurophysiological
hypotheses of ECT. Postulates that the seizure episodes precipitated
by ECT will have a better antidepressant clinical eﬀect if they are
initiated in the prefrontal regions of the brain and widely extend
towards the cortex and subcortex, involving the diencephalic
centers.
Conclusion : The diﬀerent neurobiological series cannot be con-
templated independently due to the complexity of the brain function
that involves the interaction of biochemical, hormonal and electro-
physiological systems. Having better knowledge about these me-
chanisms can achieve an improvement in the clinical practice and
provide a starting point to search for alternative treatments based on
the same physical bases.
jP-18-008jEarly prefrontal theta cordance changes anticipate
the antidepressant response to ketamine infusion in
patients with unipolar depressive disorder
P. Sos1, M. Klirova1, M. Brunovsky1, J. Horacek1, T. Novak1,
T. Palenicek1, B. Kohutova1, V. Krajca2. 1Prague Psychiatric Centre,
Czech Republic ; 2Faculty Hospital Na Bulovce, Department of Neurology,
Prague, Czech Republic
Objective : Antidepressant-like properties of glutamatergic agents
like ketamine were repetitively studied in animal models and de-
pressive patients (Berman et al., 2000 ; Zarate et al., 2006). Mechanisms
underlying the rapid (hours) and robust (days) antidepressant-like
eﬀect are widely studied. Quantitative electroencephalography
(QEEG) measure prefrontal theta cordance showed a relationship be-
tween changes in prefrontal brain activity in the ﬁrst week of treat-
ment and later clinical outcome for standard antidepressants (Cook
and Leuchter, 2001). Our study ﬁlls the gaps of missing evidence
about predictive value of prefrontal theta cordance in response to
single infusion of NMDA antagonist ketamine in patients with uni-
polar depressive disorder.
Methods : The study included in-patient with moderate and
severe unipolar depressive disorder (n=29) on stable antidepressant
medication. Antidepressant response was deﬁned as 50% decrease
of depressive symptoms evaluated by means of Montgomery-Asberg
Depression Rating Scale (MADRS). Single infusion of ketamine hy-
drochloride in subanesthetic dose (0.54 mg/kg) was administrated
with simultaneously recorded EEG. Prefrontal QEEG cordance in
theta frequency band was calculated according to UCLA algorithm
(Leuchter et al., 1994) before, at the end and day after the infusion.
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Results : Responders (n=11) to ketamine in compare to non-re-
sponders (n=18) showed signiﬁcant diﬀerence in cordance at the end
of ketamine infusion (Spearman test, p=0.039). The decrease of cor-
dance next day after ketamine infusion positively correlated with
antidepressant response fourth day after infusion (two-tailed Fisher’s
Exact test, df=1, pf0.0076 ; NPV 0.91 (95% CI 0.64–0.99) ; PPV 0.63
(95% CI 0.44–0.68)).
Conclusion : Our study conﬁrmed the capacity of early prefrontal
theta cordance changes to anticipate the ketamine induced anti-
depressant response in patients with unipolar depressive disorder.
More evidence is needed for utilizing predictive value of prefrontal
theta cordance in clinical practice. The results also support the hy-
pothesis about common antidepressant mechanisms underlying both
standard antidepressants and novel glutamatergic agents.
Policy of full disclosure : Supported by Ministry of Health of the
Czech Republic (IGA MZCR NS/10379-3). The study was assigned
the number 2009-010625-39 in the European Clinical Trials Database
(Eudra CT).
jP-18-009jDoes serotonin depletion augment or counteract the
aggression-provoking eﬀect of testosterone in mice?
E. Studer1, J. Na¨slund1, E. Andersson1, L. Westberg1, E. Eriksson1.
1Neuroscience and Physiology, Gothenburg, Sweden
Objective : While sex hormones increase aggression in most mam-
mals, the neurotransmitter serotonin has been reported to exert the
opposite eﬀect. Since testosterone inﬂuences various indices of sero-
tonergic transmission, one possibility would be that it exerts its pro-
aggressive inﬂuence by reducing a tonic anti-aggressive serotonergic
inﬂuence. Alternatively, however, the hormone and the transmitter
may inﬂuence aggression-regulating areas by parallel, independent
paths. Here, we sought to shed light on these possibilities by assessing
if testosterone is capable of enhancing aggression also in the absence
of serotonin, assuming that, in the case testosterone enhances ag-
gression by reducing serotonergic output, serotonin depletion would
be at least as eﬀective as testosterone in enhancing aggression, and
that no pro-aggressive eﬀect of testosterone above that induced by
serotonin depletion would be found.
Methods : Male C57Bl/6 mice were gonadectomised, implanted
with slow release testosterone or blank pellets and housed indivi-
dually after 3 weeks of recovery. Following 9 days of isolation,
during which territorial behaviour was established, baseline ag-
gression was assayed using the resident intruder paradigm. After
this, mice were treated with the serotonin synthesis inhibitor para-
chlorophenylalanine (pCPA) or saline for 3 days and re-tested
24 hours after the ﬁnal dose of pCPA.
Results : While both groups of testosterone-treated animals dis-
played enhanced aggression as compared to hormone-depleted ani-
mals, serotonin depletion did not enhance aggression in mice lacking
testosterone, and did hence also not diminish the diﬀerence between
testosterone-treated and hormone-depleted animals. On the other
hand, serotonin depletion did enhance aggression further in testos-
terone-treated mice (after omission of animals failing to display any
aggressive behaviour in spite of hormonal replacement).
Conclusion : Our result do not indicate that testosterone elicits ag-
gression by reducing serotonergic transmission, but suggests i) that
serotonin may exert a parallel dampening eﬀect on testosterone-
induced aggression, and ii) that presence of testosterone is an indis-
pensable prerequisite for serotonin depletion to enhance aggression.
jP-18-010jEvent related potentials in occasional and heavy
cannabis users while under the inﬂuence of
cannabis
E. Theunissen1, G. Kauert2, S. Toennes2, M. Moeller3, A. Sambeth1,
M. Blanchard4, J. Ramaekers1. 1Maastricht University, Netherlands ;
2Goethe University of Frankfurt, Germany ; 3Maastricht University,
Unikliniken des Saarlandes, Homburg, Germany ; 4Dalhousie University,
Halifax, Canada
Objective : Experienced cannabis users demonstrate tolerance to
some of the impairing acute eﬀects of cannabis. The present study
investigates whether event related potentials diﬀer between oc-
casional and heavy cannabis users after acute THC administration, as
a result of tolerance.
Methods : 12 occasional and 12 heavy cannabis users participated in
a double-blind, placebo controlled, cross-over study. On two separate
days they smoked a joint containing 0 or 500 mg/kg bodyweight THC.
Event related potentials were measured while subjects performed a
divided attention (DAT) and stop signal task (SST).
Results : In the DAT, THC signiﬁcantly decreased P100 amplitude
in occasional but not in heavy cannabis users. P300 amplitude in the
DAT was signiﬁcantly decreased by THC in both groups. The N200
peak in the SST was not aﬀected by treatment in neither of the groups.
Performance in the SST was impaired in both groups after THC
treatment whereas performance in the DAT was impaired by THC
only in the occasional group.
Conclusion : The present study conﬁrms that heavy cannabis users
develop tolerance to some of the impairing eﬀects of cannabis. This
tolerance was also evident in the underlying event related potentials,
suggesting that tolerance demonstrated on performance level is not
(completely) due to behavioral compensation.
jP-18-011jThe role of the dorsal noradrenergic pathway of the
brain (the locus coeruleus) in the regulation of liver
cytochrome P450 expression
D. Wladyslawa1, E. Bromek1, A. Sadakierska-Chudy1,
K. Golembiowska1, M. Kot1. 1Polish Academy of Sciences, Krakow,
Poland
Objective : Cytochrome P450 (CYP) expression is regulated by endo-
genous hormones and cytokines which remain under control of the
central nervous system. Our previous study indicated that in-
tracerebroventricular injection of the noradrenergic neurotoxin DSP-4
decreased noradrenaline concentration in the brain and the activity,
level and mRNA of liver CYP2C11 and CYP3A. The aim of the present
study was to investigate the role of the brain dorsal noradrenergic
pathway (the locus coeruleus) in the expression of liver cytochrome
P450.
Methods : The experiment was carried out on male Wistar rats. The
anesthetized animals were injected with 6-hydroxydopamine into the
locus coeruleus. One week after the neurotoxin injection, selected
brain structures (the cerebellum, hypothalamus, nucleus accumbens,
striatum, hippocampus, frontal cortex, rest of the cortex, anterior
and posterior brain stem) and a liver tissue were isolated. The levels
of neurotransmitters (noradrenaline, dopamine, serotonin) in those
brain structures and the activities of CYP isoforms in liver microsomes
(CYP1A: caﬀeine 8-hydroxylation and 3-N-demethylation ; CYP2A,
CYP2B, CYP2C11, CYP3A: testosterone hydroxylation) were deter-
mined by HPLC. CYP protein levels in liver microsomes were esti-
mated by the Western blot analysis.
Results : Local injection of 6-hydroxydopamine into the locus coer-
uleus selectively decreased noradrenaline level in the brain structures
tested (except for the hippocampus and cortex). However, in contrast
to the intracerebroventricular administration of DSP-4, the expression
of isoforms CYP2C11 and CYP3A was enhanced.
Conclusion : Since locus coeruleus ﬁbers innervate the periven-
tricular subnucleus (PeV) of the paraventricular nucleus (PVN) of the
hypothalamus, it is concluded that damage to the noradrenergic in-
nervation of the PeV (containing a growth hormone release- inhibiting
factor) may be responsible for the enhanced expression of isoforms
CYP2C11 and CYP3A, which is positively regulated by the growth
hormone. (Grant no. N N405 304836 from the Ministry of Science and
Higher Education (Warsaw, Poland) and statutory funds from the
Institute of Pharmacology, PAS).
jP-18-012jPharmaceutical choices in involuntarily admitted
patients of the psychiatric hospital of Attica
C. Touloumis1, P. Ntounas1, C. Tsopelas1, E. Rizos2, A. Konsta3,
D. Pappas1, P. Chatzimanolis1, S. Stamou1, D. Dimitriadis1,
A. Paraskevopoulou1, A. Douzenis2, E. Siouti1, A. Vasiliou1,
C. Mokas1, M. Chronopoulou1, M. Dimitraka1, I. Gogolakis1,
C. Marmarinou1. 1Psychiatric Hospital of Attica, Athens, Greece ; 22nd
Dept. of Psychiatry, National and Kapodistrian, Athens, Greece ; 31st Dept.
of Psychiatry, Aristotle University of Thessaloniki
Objective : Since most mentally ill patients who are involuntary ad-
mitted do not accept any kind of pharmaceutical therapies, mostly
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because of lack of insight the involuntary admission and hospitaliza-
tion of mentally ill patients implies the necessity to co-administer
medication. Our aim is to show pharmaceutical treatment choices in
the involuntarily hospitalized mentally ill patients of the psychiatric
hospital of Attica, which accepts the largest number of involuntarily
hospitalized patients per year.
Methods : Data were collected by random selection of 532 patients
who were involuntarily hospitalized in the psychiatric hospital of
Attica from 01/08/08 to 03/09/10. The statistical program SPSS was
used for the data analysis.
Results : Our sample consists of 532 patients, mean age 43.64 yrs
(SD=13.7), 64.3% male, 11.1% of which were having ﬁrst psychotic
episode and 61.8% being hospitalized for the ﬁrst time, 63.3% of
which diagnosed with the schizophrenic spectrum disorders, 10.8%
with bipolar disorder, 5.1% with depression and 24.1% with other
diagnoses. 72.4% of the patients stopped their medication. Typical
antipsychotics were administered in 32.7%, atypical antipsychotics
were used in 59.4% and combination of typical and atypical anti-
psychotics in 5.1%. 65.4% received benzodiazepines along with
their antipsychotic treatment, while 6.2% received antidepressants.
At the discharge 19.7% received typical antipsychotics, 61.8%
atypical, 15.8% combination of both typical and atypical, 54.7% ben-
zodiazepines, 10.5% antidepressants and 23.9% long acting and
psychotics.
Conclusion : Most of the patients of our sample were patients
having psychiatric disorders for more than 10 years and were in an
increased need for combination treatment, which was continued
during their involuntary hospitalization. The combination treatment
could be associated with the high percentage of treatment discon-
tinuation before their involuntary admission.
P-19. Suicide
jP-19-001jDepression and history of suicide attempts are risk
factors for pregnancy among adolescent girls
R. Castilla-Puentes1, R. Martinez Saravia2. 1Temple University,
Philadelphia, USA ; 2Maternal Infant Hospital, La Paz, Bolivia
Objective : To examine if depression and history of suicide attempts
are risk factors for pregnancy among adolescent girls.
Methods : A matched case-control study with cases and controls
identiﬁed within a community-based demographic and health survey
was conducted in La Paz Bolivia, from January 2010 to November
2011. A questionnaire was applied to 645 adolescent girls (9–19 years
of age). Depressive symptoms were measured by the Center for
Epidemiological Studies Depression Scale (CES-D), with score >16
indicative of elevated depressive symptoms. Conditional logistic
regression was used to adjust for potential confounders.
Results : Respondents included 99 cases and 546 controls. Through
multivariate analysis, depression [odds ratio (OR) 2.16, 95% conﬁ-
dence interval (CI) 1.24–3.77 ], the history of a prior suicide attempt
12 month and lifetime (OR 2.98, 95% CI 3.70–11.27 and OR 6.23, 95%
CI 1.12–64.90 respectively) were factors associated with increased risk
of adolescent pregnancies. As expected, another factors statistically
associated in the multivariate analysis were : physical and sexual
abuse during childhood-adolescence (OR 2.13, 95% CI 1.35–3.38 ;OR
2.07, 95% CI 0.95–4.49 respectively) ; being use of contraception (OR
5.31, 95% CI 2.92–9.65) ; history of anxiety disorders (OR 1.69, 95% CI
0.80–3.53) ; being less than 6 years in school at the time of the interview
(OR 2.71, 95% CI 0.82–8.93) ; and living in a very poor household (OR
7.67, 95% CI 3.81–15.47).
Conclusion : These ﬁndings suggest that depression (including
suicidality) may be a key mechanism accounting for pregnancy
among adolescents. The study found that in addition to depression
and lifetime and 12 month suicide attempts, having suﬀered from
physical and sexual abuse during childhood-adolescence, being use of
contraception, a reported history of anxiety disorders, lower edu-
cation and living in a very poor household were associated with
adolescent pregnancy in La Paz.
jP-19-002jAssociation between IL-8 and anxiety in suicidal
patients
S. Janelidze1, P. Suchankova2, A. Ekman2, S. Erhardt3, A˚. Westrin1,
L. Tra¨skman-Bendz1, L. Brundin4. 1Lund University, Sweden ;
2University of Gothenburg, Sweden ; 3Karolinska Institutet, Stockholm,
Sweden ; 4Lund, Sweden
Objective : IL-8 (CXCL8) is a chemokine that controls migration of
neutrophils. Emerging evidence suggests that IL-8 is also involved in
diverse physiological functions in the CNS. However, the role of IL-8
in psychiatric disorders remains to be deﬁned. The aim of this study
was to assess if IL-8 is altered in patient with suicidal behavior.
Methods : We measured CSF and plasma levels of IL-8, as well as
the genotype frequency of a single nucleotide polymorphism
(x251A/T, rs4073) in the promoter region of the IL-8 gene, in suicide
attempters compared to healthy controls. A total of 250 patients and
579 controls from several cohorts were included in the study. Plasma
and CSF levels of IL-8 were quantiﬁed using ultra-sensitive electro-
chemiluminescence-based immunoassay. Psychiatric symptoms were
rated with the Comprehensive Psychiatric Rating Scale with subscales
for anxiety and depression.
Results :We found negative correlation between plasma IL-8 levels
and anxiety scores in suicide attempters. In the CSF, low IL-8 was
associated with more severe symptoms of anxiety in females and de-
pression in males. Female suicide attempters had a signiﬁcantly lower
prevalence of the IL-8–251A allele. Moreover, the x251A allele was
coupled to higher plasma IL-8 and lower anxiety.
Conclusion : Taken together these ﬁndings implicate IL-8 in the
pathobiological mechanisms underlying symptoms of anxiety and
depression.
jP-19-003jThe suicidality in Thai population : A national
survey
T. Kongsuk1, W. Sriruenthong1, W. Pangchuntr2,
P. Kittirattanapaiboon3, K. Kenbubpha1, R. Yingyeun1, S. Sukawaha1,
J. Leejongpermpoon1. 1Prasrimahabhodi Hospital, Ubonratchathanee,
Thailand ; 2Ministry of Public Health, Nonthaburi, Thailand ; 3Mental
Health Department, Nonthaburi, Thailand
Objective : To study the rate of suicidality and factors related to the
Thai people.
Methods : Nationally representative face to face household survey
based on a stratiﬁed clustered sampling of people aging 15 to 59
(n=17.140). The data were conducted between June and August 2008
using Mini International Neuropsychiatric Interview (M.I.N.I.) mod-
ule C. Suicidality and general information questionnaire by trained
psychiatric professionals. The data analysis was determined by means
adjusted weight of rate generalized to Thai population and analyzed
with descriptive statistical methods by attaining percentage of mean,
proportions, standard errors, population estimation and probability
inference from the data.
Results : The overall national rate of suicidality accounted for 7.3%,
the severity risk of suicide was found mild 6.0%, moderate 0.6% and
severe 0.7%. The highest risk of suicide was found in the north (8.8%,
severe degree 1.3%) females (8.6%), age of 35 to 44 (8.1%), separated,
divorced or widowed (11.8%), being unemployed (13.8%), mood
disorders with psychotic features (87.9%), current manic episode
(64.3%).
Conclusion : For eﬀective surveillance and prevention of suicide
in Thailand’s population, the focus should be on the population of
Northern provinces, females, those in productive age, being unem-
ployed and those concurrently having mental disorders particulary,
mood disorders.
jP-19-004jThe role of anxiety and its correlates in suicide
re-attempters
J. Lopez-Castroman1, I. Jaussent1, C. Genty1, S. Guillaume1,
P. Courtet1. 1 Inserm U1061, Montpellier, France
Objective : Among the large population of suicide attempters, fre-
quent re-attempters present speciﬁc features. They are signiﬁcant
consumers of health care resources. An increasing severity of the at-
tempts could end to be lethal. They have also been associated with
228 Poster Sessions, Wednesday, 6 June 2012
Downloaded from https://academic.oup.com/ijnp/article-abstract/15/Supplement_1/1/650920
by University of Groningen user
on 13 March 2018
anxiety traits and diagnoses but the relationship of anxiousness and
frequent suicide attempts remains unclear.
Methods : We examine a large sample of suicide attempters that
were assessed at a specialized unit of the Montpellier University
Hospital. Only subjects with one-time lifetime suicide attempt
(n=477 ; one-time attempters) and subjects with more than two life-
time suicide attempts (n=411 ; frequent attempters) were included in
the analyses. These two populations were compared with regards to
demographic, diagnostic and suicidal features, including character-
istics of the ﬁrst suicide attempt (Suicide Intent Scale, Scale of Suicide
Ideation, age at ﬁrst attempt). Trait anxiety scores of the State-Trait
Anxiety Inventory (STAI) were also examined in a subsample of
patients.
Results : Frequent attempters were more often females with family
history of suicide behavior. Several lifetime diagnoses were associated
with frequent attempters : aﬀective disorders, eating disorders,
alcohol and substance use disorders. Lifetime diagnoses of anxiety
disorders diﬀered signiﬁcantly between one-time attempters and fre-
quent attempters (p=0.0008). Frequent attempters were also younger
at their ﬁrst attempt and presented higher suicide ideation scores.
However, no diﬀerence was found in trait anxiety scores according
to the STAI between subjects with and without lifetime anxiety
diagnoses or one-time attempters and frequent attempters.
Conclusion : Anxiety diagnoses may be independently associated
with frequent attempters when compared to one-time attempters.
However, the negative ﬁnding of an association between anxiety
traits, as measured by the STAI, and frequent suicide attempters limits
the possibility of determining a cut-oﬀ level of anxiety to distinguish
frequent attempters from one-time attempters. The lack of association
between anxiety traits and diagnoses in suicide attempters warrants
further investigation.
jP-19-005jEpidemiological overview on pattern of suicide in
the district of Tirana in Albania, over the period
2001–2010
P. Maksuti1, V. Kola2, A. Simaku3. 1University Hospital Centre, Tirana,
Albania ; 2University Hospital Centre, Psychiatric Service, Tirana,
Albania ; 3 Institute of Public Health, Tirana, Albania
Objective : Introduction : Suicide is an increasing phenomenon in
Albania. Despite recent investments in mental health by authorities
there is a widespread culture of shame surrounding mental illness.
Aim : To present an epidemiological overview on the pattern of
suicide in the district of Tirana over the period 2001–2010.
Methods : A retrospective study with a homogenous cohort. Data
were collected from the records of the Prosecution Oﬃce of Tirana
district. Medical data and the statements of the witnesses were
studied.
Results :A total of 254 people have committed suicide in the district
of Tirana from 2001 to 2010. The prevalence of suicide was found
0.04% (95%CI 0.035–0.045). Suicide is most frequent among males 163
(64%) and in individuals with a low socio-economical level. The mean
age of the victims is 38.5 (16 SD) years old. Suicides are more common
during autumn 72 (28%) or during the months of April 35 (13.8%) and
September 36 (14.2%). In rural areas is 1.6 times more prevalent than
in urban ones. The prevalence among married 132 (52%) is signiﬁ-
cantly higher compared to single individuals 103 (41%). As regards
profession, most aﬀected were workers 64 (25%) followed by house-
wives 40 (16%) and farmers 26 (10%). The most frequent method was
poisoning in 100 (39.4%) cases, followed by hanging in 51 (20%) cases.
165 (65%) cases were previously diagnosed with mental illnesses.
129 (78%) out of them were diagnosed with depression, while only
74 (45%) were treated before the suicide.
Conclusion : For a large number of victims there were no data they
suﬀered from an illness. It means that a relatively large number of
the victims have had psychiatric disturbances, but they have not
sought medical help. A small number of cases were treated before
the suicide.
jP-19-006jPharmaceutical choices in patients with self/hetero
aggression
C. Touloumis1, P. Ntounas1, C. Tsopelas1, A. Vasiliou1, S. Stamou1,
S. Dimaki1, C. Mokas1, D. Dimitriadis1, A. Paraskevopoulou1,
C. Marmarinou1, A. Douzenis2, D. Pappas1, M. Chronopoulou1,
I. Gogolakis1, P. Chatzimanolis1, M. Dimitraka1, E. Siouti1, A. Konsta1,
E. Rizos1. 1Psychiatric Hospital of Attica, Athens, Greece ; 22nd Dept. of
Psychiatry, National and Kapodistrian, Athens, Greece
Objective : The suicide risk in patients with schizophrenia is 20 to 50
times higher than the general population. Recent data show increased
association between schizophrenia and self-destruction or/and viol-
ence against others. Purpose of this study is to investigate pharma-
ceutical choice in patients with severe mental illness exhibiting
suicidal and violent behaviour issues during their examination at the
emergency department of Psychiatric Hospital of Attica.
Methods : The participants (423 patients) were selected randomly
from the inpatients of the acute treatment departments of the
Psychiatric Hospital of Attica. The statistical program SPSS has been
used for the data analysis.
Results : 423 patients participate in the study. The mean age was
45.9% years and 60.8% were men. 63.7% were involuntary hospita-
lized and the mean age of the ﬁrst episode was 28.4 years. The main
diagnosis were schizophrenic disorders 72.1%, with the rest having
bipolar disorders 16.8%, depression 11.1% and drug abuse 18.7%.
The main reasons of admission were disease relapse 46.1%, discon-
tinuation of medication 27% and aggression 24.3%. The presenting
symptoms at the emergency department were : agression against
others 30.8%, self distractive behavior 17.5%, verbal aggression
14.5%, aggression against objects 5.5%. At the admission 25.6% were
administered with more than one antipsychotic drug and the second
medication used was benzodiazepine at 53.7%, antidepressant at
19.1% and mood stabilizer at 16.8%.
Conclusion : Suicide is the most common cause of premature death
among psychiatric patients suﬀering from both depression or schizo-
phrenia. Several factors have been historically associated with suicidal
behaviour such as alcohol or drug abuse. These have been repeatedly
indentiﬁed as the most important factors for attempted or successful
suicide and demand immediate care most eﬃciently with combi-
nation treatment.
jP-19-007jAnalysis of polymorphism in the gene for alpha-1
subunit of a voltage-dependent calcium channel in
suicide victims
A. Videtic Paska1, V. Sˇtorgel1, T. Zupanc1, R. Komel1. 1University of
Ljubljana, Faculty of Medicine, Slovenia
Objective : Suicide is complex, multifactorial phenomenon, and is
an outcome of interplay of environmental, genetic, and epigenetic
factors. Slovenia belongs to the group of countries with the highest
suicide rate in the world ; in the year 2011 ranked 7th with suicide rate
of 30.9 suicide victims per 100.000. In the present study we in-
vestigated association between suicide and gene for alpha-1 subunit
of a voltage-dependent calcium channel (CACNA1C). Gene for
CACNA1C is localised on chromosome12, and has 55 known exons,
whereas 19 follow alternative splicing, consequently leading to nu-
merous diﬀerent combinations. Eﬃciencies of alternative splicing,
having eﬀects on alternations of neural transmission, have been as-
sociated with suicide. In gene for CACNA1C more than 2000 single
nucleotide polymorphisms (SNPs) have been identiﬁed, but very few
have been studied. The most often investigated SNP was rs1006737
in the 3rd intron. In meta-analysis this SNP has been implicated in
suicide in depressed, bipolar, and schizophrenic patients.
Methods :We analyzed polymorphism rs1006737 with quantitative
real-time PCR using LNA probes in 599 subjects (384 suicide victims,
215 controls) of Slovenian nationality. We determined the impact of
polymorphism on suicide, by comparing the distribution of genotypes
and alleles between the groups of suicide victims and controls. For
detailed analysis additional subgroups were formed (e.g. male, fe-
male, violent and non-violent suicide, alcoholics).
Results : Genetic analysis of polymorphism in suicide victims did
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Conclusion : Nevertheless our results are representative and could
be important for future studies, because our research was conducted
on a population with extremely high suicide rate. Calcium channel
gene is still an important candidate gene for further investigation in
suicide behaviour.
jP-19-009jCNR1 gene polymorphism and psychological
functioning in persons who have attempted suicide
P. Wierzbinski1, M. Talarowska2. 1Medical University of Lodz, Poland ;
2Medical University of Lodz, Department of Adult Psychiatry, Poland
Objective : An analysis of the psychological functioning of patients
after their suicide attempts when compared to the comparative group
and a description of the link between the occurrence of the poly-
morphism CNR1 – 1359 G/A (SNP rs1049353) and suicide attempts
made by patients of psychiatric units. The work also aims at providing
the answer to the question about whether there is a link between
genotype 1359 G/A and a higher risk of suicide attempts.
Methods : 78 patients have made psychological tests. 1359G/A
CNR1 polimorphism was made in all patients by RFLP method. Allel
frequencies were compared between control subjects and patient after
suicide attempt. We analysed association between 1359G/A CNR1
polimorphism and suicide attempt.
Results : Allel frequencies did not diﬀered signiﬁcantly between
two groups of subjects. There is signiﬃcant diﬀerence between Indivi-
duals attempting suicide and the control group in their psychological
functioning. There is no evidence for association between SNP rs
1049353 and suicide attempt.
Conclusion : The genetic research and analysis of psychological
tests reveal that a 1359 G/A polymorphism does not lead to so drastic
a change in the functioning of the endocannabinoid system that this
change would have any eﬀect whatsoever on the functioning of other
systems of neurotransmitters in the central nervous system and thus
on leading to an increased incidence of suicide attempts in persons
with this particular polymorphism.
P-20. Anxiolytics
jP-20-001jSome psychotropic eﬀects of kolanut (cola nitida)
extract on adult wistar rats
B. Banjoko1, A. Ayoka1, Y. Ogunleye1, S. Babalola1. 1Obafemi Awolowo
University, Ile-Ife, Nigeria
Objective : Kola nut (Cola nitida) is a widely consumed snack in the
western part of Africa, and observed eﬀects on consumers indicate it
possesses some pharmacological properties. Caﬀeine is the most ac-
tive ingredient in the fruit and the potential of its interaction with
prescribed medication underscores the necessity for investigations of
its pharmacological properties.
Methods : This study investigated the eﬀects of aqueous extract of
Kola Nut (C. nitida) on novelty-induced behaviours, weight and food
consumption patterns of adult wistar rats. Twenty rats (mean weight
of 150.6 g) were divided randomly into two groups (Test and Control)
of ten rats each. Each group was subjected to the same environment of
experiments. The test group was fed with the aqueous extract of kola
nut in addition to normal feeds, while the control group had normal
feed plus clean water.
Results : Test rats on kola nuts extract exhibited increased novelty-
induced rearing (NIR), (novelty-induced grooming (NIG) and open
ﬁeld locomotion (OFL) at the ﬁrst two days of oral administration
in rats (P<0.05) but prolonged ingestion of the extract caused de-
creased eﬀects (P<0.05). They also exhibited anxiolytic behaviour
as measured by elevated plus maze on the ﬁrst day (P<0.05) and
anxiogenic behaviour after prolonged feeding with the kola nuts ex-
tract (P<0.05). The test group compared to the control group had
signiﬁcant weight loss (P<0.05) and progressive decrease in food
consumption even when feeding with the kola nut extract was
discontinued.
Conclusion : Kola nuts extract possesses anxiogenic, anxiolytic and
anorectic properties. These properties could be exploited in designing
weight reducing therapies since no toxicity has been associated with
human consumption.
jP-20-002jAmygdala response to SSRIs in social anxiety
disorder
J. Engman1, V. Faria1, L. Appel2, F. A˚hs3, C. Linnman4, M. Bani5,
K. Wahlstedt6, M. Fredrikson1, T. Furmark1. 1Uppsala University,
Sweden ; 2Uppsala University Hospital, Sweden ; 3Duke University,
Durham, NC, USA ; 4Harvard Medical School, Belmont, MA, USA ;
5GlaxoSmithKline, Verona, Italy ; 6Quintiles AB, Uppsala, Sweden
Objective : Selective serotonin reuptake inhibitors (SSRIs) are com-
monly accepted as the ﬁrst line pharmacological therapy for anxiety
disorders and depression. However, there is a high percentage of
patients that fail to achieve satisfactory response with SSRI treat-
ments. The neural mechanisms underlying eﬀective and ineﬀective
outcome with SSRIs are not well characterized. The amygdala
has dense serotonergic innervation, and studies have suggested the
amygdala to be a crucial brain target for SSRI treatment. This study
aimed at investigating diﬀerences in amygdala responsivity between
responders and nonresponders to SSRI treatments in patients with
social anxiety disorder (SAD).
Methods : Stress-related regional cerebral blood ﬂow (rCBF) was
measured in SAD patients (n=35) with [15O]-water positron emission
tomography (PET) during public speaking before and after 6–8 weeks
of treatment with citalopram or paroxetine. Response rate was deter-
mined by the Clinical Global Impression-Improvement scale.
Results : Within-group comparisons revealed reduced rCBF re-
sponse bilaterally in the amygdala in responders (n=20) as well as in
nonresponders (n=15). Between-group contrasts revealed a greater
amygdala attenuation in responders (>nonresponders) in the
left basolateral/basomedial (x-16, y-6, z-14, Z=1.66, P[uncorr]=
0.024) and right ventrolateral subregions (x26, y-4, z-26, Z=2.12,
P[uncorr]=0.009). However, greater rCBF attenuation in non-
responders (>responders) was observed in the left lateral amygdala
(x-28, y-6, z-14, Z=2.38, P[uncorr]=0.005).
Conclusion : Lowered amygdala responsivity does not seem
to be exclusively related to clinical improvement in anxiety patients.
In accordance with animal literature, our data suggest that amyg-
dala subregions are functionally heterogeneous with regards to
anxiolysis.
Policy of full disclosure : This work was supported by
GlaxoSmithKline and the Swedish Research Council.
jP-20-003jRapid anti-anxiety eﬀects in women of picogram
quantities of a 19-carbon steroid
B. Grosser1, L. Monti-Bloch2, C. Jennings-White3. 1University of Utah,
Salt Lake City, USA ; 2University of Utah, Pherin Pharmaceutical, Salt
Lake City, USA ; 3Pherin Pharmaceutical, Los Altos, USA
Objective : Picogram (pg) quantities of androstadienone (ADO), a
naturally occurring non-hormonal steroid in male skin, induces in
vitro, robust inward currents in isolated patch recorded human nasal
chemosensory neurons (Monti-Bloch, 1995). When administered in-
tranasally to healthy women, ADO rapidly decreases tension, ner-
vousness, and other negative feeling states (Grosser et al., 2000).
Similar observations subsequently, have been shown by others (Jacob
et al., 2001). Because of these ﬁndings, we studied the eﬀects of an-
drostadienol (ADOL), an odorless 19-carbon steroid and analog of
ADO, administered intranasally to women with generalized anxiety
disorder (GAD).
Methods : Nineteen women with GAD and a Hamilton Anxiety
Scale (HAM-A)>18, selected after placebo run-in, were randomized
for double blind treatment with 200 pg ADOL (N=11) or placebo
(N=8) administered in a one second aerosol pulse directly to nasal
chemoreceptors. HAM-A, Covi Anxiety Scale (COVI), and clinical
electrophysiological measures (respiratory and cardiac frequency,
electromyogram, skin conductance, electroencephalogram, body
temperature) were administered at randomization and 30 and
60 min later.
Results : Thirty min after administration of ADOL, there was a
signiﬁcant reduction in the HAM-A (p<0.03) and COVI (p<0.02).
Seven of the 11 subjects administered ADOL exhibited decreases in
the HAM-A of 50% or more whereas two of the eight controls had
similar reductions. After 60 min, all signiﬁcant improvements had
disappeared. Electrophysiological readings were concordant with the
reduction in anxiety.
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Conclusion : 1. Nasal chemoreceptors appear to be a portal of entry
for substances aﬀecting feeling states. 2. The rapid and temporary
eﬀect in GAD suggests that ADOL may be useful in rapid-onset
and short-lived psychiatric conditions. FDA approved clinical trials of
ADOL in social anxiety disorder are currently in progress.
Policy of full disclosure : Supported by funding from Pherin
Pharmaceuticals.
jP-20-004jThe inﬂuence of an a5GABAA selective agonist
XLi356 on rats’ performance in morris water maze
M. Milinkovic1, T. Timic2, J. Divljakovic2, S. Joksimovic2, S. Rallapalli3,
J. Cook3, M. Savic2. 1Faculty of Pharmacy, Belgrade, Serbia ; 2Department
of Pharmacology, Faculty of Pharmacy, Belgrade, Serbia ; 3Milwaukee,
USA
Objective : The impairing eﬀects of diazepam in Morris water maze
(MWM) could be partially antagonized with co-administration of an
a5 subunit selective antagonist XLi093 (Savic´ et al., 2009). In order
to further assess the role of the a5GABAA receptors population
in mediating amnesic eﬀects in rats, the present study examined
eﬀects of an a5GABAA selective agonist XLi356 on the MWM
performance.
Methods : Male Wistar rats were given vehicle or 5, 10 and 20 mg/
kg of XLI356 intraperitoneally 20 minutes before the testing. A single-
day water maze task had three swimming blocks, each consisting of
4 trials, lasting a maximum time of 60 s each. Afterwards, a probe trial
was given and a number of standard parameters was calculated.
Additionally, rats were tested in spontaneous locomotor activity
(SLA) and elevated plus maze (EPM) tests, where the sedative and
anxiolytic eﬀects were assessed.
Results : Results were analyzed using one-way ANOVA with post
hoc Student-Newman-Keuls test where applicable. XLi356 signiﬁ-
cantly increased latency to platform (F(3,444)=3.1287, p=0.026) ; post
hoc test revealed that the dose of 20 mg/kg was signiﬁcantly diﬀerent
from vehicle. The same dose of XLi356 signiﬁcantly increased cumu-
lative distance from the platform zone (p=0.028) and the time spent
in the periphery ring (p=0.009), while the path eﬃciency was on the
control level. On the other hand, XLi356 did not show behavioral
activity in SLA and EPM tests at either of three doses tested.
Conclusion : The present results suggest that ligands with ap-
preciable agonist activity at GABAA receptors containing a5 subunits
may impair memory acquisition in Morris water maze task, without
discernible eﬀects on general behavior. Thus the activity of the ben-
zodiazepine type drugs at a5GABAA receptors should be decreased if
the amnesic eﬀects are to avoid.
jP-20-005jThe investigation of 2-mercaptobenzimidazole
derivatives interaction with sigma-1 receptors in mice
E. Ryaskina1, M. Voronin2, S. Seredenin2. 1Zakysov’s IPh RAMS,
Moscow, Russia ; 2FSBI Zakusov Institute of Pharmacology, Russian
Academy, Moscow, Russia
Objective : At present sigma-1 (s1) receptor is considered to be pro-
spective target for neuroprotective and anxiolytic drugs. In ‘‘Zakusov
Institute of Pharmacology’’ RAMS neuroprotector and anxiolytic
afobazole (5-ethoxy-2-[2-(morpholino)-ethylthio] benzimidazole di-
hydrochloride) was developed. In vitro afobazol revealed ligand
properties towards MT1, MT3, s1 receptors and MAOA with
IC50=2.7r10x5 M, 9.9r10x7 M, 7.1r10x6 M, 6.2r10x6 M
correspondingly (Seredenin et al., 2009). The main metabolite of
afobazole (2-[2-(3-oxomorpholine-4-yl)-ethylthio]-5-ethoxy benzimi-
dazole hydrochloride) interacted only with MT3 receptors with Ki=
9.7r10x7 M. The aim of the research is to study the interaction of
afobazole and its main metabolite with s1 receptors versus prototype
s1 ligands of diﬀerent pharmacological groups on mice ex vivo.
Methods : Binding experiments were carried out in P2 fraction ob-
tained from brain of male CD-1 mice according Entrena et al. with
slight modiﬁcations (Entrena et al., 2006).The radioligand used in the
assays was [Ring-1,3–3H]-(+)-Pentazocine in ﬁnal concentration of
1 nM. The cold ligands of diﬀerent pharmacological groups were used
with a concentration range of 10x3–10x12 M.
Results : In ex vivo experiments the displacement curves of [Ring-
1,3–3H]-(+)-Pentazocine by afobazole versus ligands of diﬀerent
pharmacological groups were obtained. IC50 obtained for afobazole
was 2,67*10x5 M. The value is close to compounds, considered as
endogenous ligands DHEA and progesterone. IC50 for afobazol main
metabolite was in the millimolar range. The results of research on
male CD-1 mice conﬁrmed the previously established ligand proper-
ties of afobazole and its main metabolite in regard to s1 receptors in
vitro experiments.
Conclusion : Binding experiment with afobazole versus prototype
s1 ligands on CD-1 mice was carried out. Due to the results obtained
from the binding experiments afobazol can be regarded as a novel s1
ligand.
jP-20-006jNon-selective and a5 subunit-selective negative
modulators of GABAA receptors in a single-day
morris water maze task in rats
T. Timic1, J. Divljakovic1, M. Milinkovic1, S. Rallapalli2, J.M. Cook2,
M.M. Savic1. 1Faculty of Pharmacy, Belgrade, Serbia ; 2University of
Wisconsin, Milwaukee, USA
Objective : It is well known that benzodiazepine binding site ligands
inﬂuence learning and memory and that the a5 subunit is signiﬁcantly
involved in cognition enhancement mediated by the negative modu-
lation of GABAA receptor function. PWZ-029, a moderately selective
a5GABAA receptor inverse agonist, improved learning in passive but
not in active avoidance test, without eﬀects on anxiety or muscle tone.
The aim of this study was to investigate eﬀects of PWZ-029 and
DMCM, a non-selective inverse agonist, on learning ability and short-
term memory in Morris water-maze (MWM) test.
Methods : MWM test was conducted 20 minutes after in-
traperitoneal administration of treatments (solvent, 5, 15 or 30 mg/kg
PWZ-029 or 2 mg/kg DMCM) to male Wistar rats. The single-day
MWM task consisted of 3 consecutive blocks of 4 trials lasting maxi-
mally 60 s each and a probe trial. During spatial learning the platform
was hidden in the middle of the NE quadrant.
Results : Two-way ANOVAwith one repeated measure (block) and
animals nested in treatment has shown that latency to ﬁnd the plat-
form, path eﬃciency and total distance travelled were on the control
level for DMCM and all doses of PWZ-029. Factors block and treat-
ment were signiﬁcant only for latency to ﬁrst entry to the NE quadrant
[block eﬀect : F(2,386)=10.50, p<0.001, treatment eﬀect : F(4,31)=3.10,
p<0.05]. Tukey’s post-hoc test revealed that animals treated with
DMCM and 5 mg/kg of PWZ-029 had longer latency to ﬁrst entry
to the target quadrant than those treated with solvent (p=0.001,
p<0.001, respectively). Probe trial performance did not diﬀer signiﬁ-
cantly between treatments.
Conclusion : These results suggest that neither non-selective nor b5
subunit-selective negative modulation of GABAA receptors is suf-
ﬁcient to enhance learning and short-term memory in the single-day
MWM spatial task.
jP-20-007jRiluzole produces distinct anxiolytic-like eﬀects in
rat innate anxiety models
M. Yamada1, A. Sugiyama2, A. Saitoh3, T. Iwai3, K. Takahashi3,
S. Sasaki-Hamada2, J.-I. Oka2, M. Inagaki3. 1NIMH, NCNP, Kodaira,
Tokyo, Japan ; 2Tokyo Univ. Sci., Fac. Pharm. Sci., Chiba, Japan ; 3NCNP,
NIMH, Kodaira, Tokyo, Japan
Objective : Growing evidence suggests that sodium channel blockers,
such as riluzole and lamotrigine, are eﬀective as non-benzodiazepine
treatments of anxiety disorders. In the present study, we ﬁrst in-
vestigated the anxiolytic-like eﬀect of riluzole using innate anxiety
models in rats.
Methods : Male Wistar rats were used for experiments. We used
three diﬀerent innate anxiety models, such as the elevated plus-maze,
the light/dark and the open-ﬁeld tests. A benzodiazepine, diazepam,
was used as a positive control anxiolytic drug. To clarify the involve-
ment of sodium channels in the anxiolytic-like eﬀects of riluzole,
we examined the eﬀect of co-administration of the sodium channel
activator, veratrine.
Results : In the elevated plus-maze test, riluzole (3 mg/kg) signiﬁ-
cantly increased the time spent in, and entries into, the open arm after
60 min administration. This ﬁnding was supported by results ob-
tained from the light/dark and the open-ﬁeld tests. The magnitude of
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the anxiolytic-like eﬀects of riluzole in each of the behavioral models
was similar to those produced by diazepam (1 mg/kg). Interestingly,
the anxiolytic-like action of riluzole was diminished by the co-
administration of veratrine (0.1 mg/kg) in the elevated plus-maze,
the light/dark and the open-ﬁeld tests. In contrast, veratrine had no
signiﬁcant eﬀect on the anxiolytic eﬀects of diazepam in these tests.
Conclusion : In this study, riluzole produced robust anxiolytic-like
eﬀects in rats. In addition, it is also suggested that the anxiolytic
mechanism of riluzole is clearly distinct from that of diazepam. The
voltage-activated sodium channels may play some important roles
in these anxiolytic-like eﬀects of riluzole. We propose that riluzole
would be considered as a candidate compound for the development
of anxiolytics with novel class of actions.
P-21. Pharmacoeconomics
jP-21-001jAntidepressant treatment optimization with
BrainChip test : Eﬀectiveness and costs
C. Crespo1, M. Blanca-Tamayo2, A. Villacampa3, S. Lobo4. 1Barcelona,
Spain ; 2Department of Psychiatry, Badalona Serveis Assistencials,
Barcelona, Spain ; 3Oblikue Consulting, Barcelona, Spain ;
4BRAINcoBiopharma S.L., Bilbao, Spain
Objective : BrainChip is a genetic biomarker test that determines
CYP450 isoenzyme polymorphisms, making possible response pre-
diction to pharmacological treatment of patients suﬀering from major
depression disorder (MDD). The objective of this study was to assess
the eﬃciency and the budget impact of BrainChip test addition after
failure to a ﬁrst line antidepressant treatment in Spain.
Methods :AMarkov model was developed per each treatment after
simulating regimen therapy changes derived from BrainChip test
addition. Clinical parameters were collected from literature reviews,
and health resource use and costs were calculated to the Spanish
context. Budget impact results were analyzed during 3 years after
BrainChip additionand the eﬃciency was studied after 1, 3, 5, 7 and
10 years. Both analysis were builtunder the National Health System
(NHS) perspective andit wasconsidered a 3% discount for eﬀects and
costs (euro 2011).
Results : BrainChip improves patient remission around
9.5%–11.7% and patient response 5.5%–10.2%, reaching after 10 years
a total response rate of 72%. Patients with MDD and BrainChip im-
prove their quality of life between 0.04 and 0.25 in terms of quality
adjusted life years. BrainChip cost will be compensated after 2 years,
being always a cost-eﬀectiveness alternative in a short term and
dominant from the third year.24,308 out of 64,713 patients could re-
ceive an alternative therapy based on the results of BrainChip infor-
mation. BrainChip can reach after 3 years cumulative savings of more
than 13.6 million euros (6.8% of budget) taking into account direct
costs, and 194.4 million euros in terms of total costs (direct and
indirect).
Conclusion : BrainChip incorporation allows less risk on pharmaco-
logical prescription and health care cost reductions in MDD for the
NHS, being a dominant option.
Policy of full disclosure : This study was funded by
BRAINcoBiopharma, the manufacturer of BrainChip. Dr. Blanca-
Tamayo M receive consulting fees from BRAINcoBiopharma. Crespo
C and Villacampa A worked in an independent consultant company
and they got funds from BRAINcoBiopharma. Lobo S is an employee
of BRAINcoBiopharma.
jP-21-002j Is pharmaceutical industry inﬂuence distorting
psychiatric practice?
D. Goel. Southland Hospital, Invercargill, New Zealand
Objective : To examine the impact of pharmaceutical industry on
psychiatric practice.
Methods : Interogation of relevant information and data available
in the public domain to construct the evidence base for evidence-
based evaluation of the ways in which pharmaceutical industry
related interests inﬂuence psychiatric practice.
Results : Pharmaceutical companies are amongst the most proﬁt-
able in the corporate world and the margins are rising even as
the pill for every ill culture penetrates the emerging economies. The
oft-repeated argument that these high proﬁt margins are justiﬁed by
the high costs of research and development (R &D) of new drugs does
not bear scrutiny. These companies spend thrice as much on market-
ing and advertisements, increasingly supplemented with aggressive
direct to patient approaches, as on R & D. This in itself could perhaps
be condoned as mildly laissez faire free-market capitalism, but what
cannot be glossed over is the lack of transparency in the relationship
between the industry and the medical profession. Doctoring research
evidence by suppressing negative ﬁndings (‘‘ failed studies’’), sub-
verting the integrity of peer-reviewed medical journals through
questionable tactics like ghost writing and passing oﬀ hired guns as
independent experts are some of the shady tactics which threaten to
distort clinical practice at the cost of good patient care. Disease-mon-
gering is an even more worrying phenomenon and the extensive ﬁ-
nancial linkages of the experts drafting diagnostic systems like the
DSM-V with the pharmaceutical industry have resulted in lowered
thresholds of caseness and the manufacture of new disorders on an
industrial scale. The implications, medical as well as economic, of
these pernicious trends are wide and far-reaching.
Conclusion : The proposed presentation aims to examine the evi-
dence in this regard, contextualizing the evidence within practices in
the developed and developing world, evaluate possible remedial
strategies, and suggest the way forwards.
jP-21-003jHealthcare costs before and after diagnosis of
depression in patients with unexplained pain :
A retrospective cohort study using the United
Kingdom general practice research database
J. Hong1, C. Reed2, D. Novick2, A. Lenox-Smith3, M. Happich4. 1Eli
Lilly and Company, Surrey, United Kingdom ; 2Eli Lilly and Company,
Windlesham, United Kingdom ; 3Eli Lilly UK, Basingstoke, United
Kingdom ; 4Lilly Deutschland GmbH, Bad Homburg, Germany
Objective : To assess the impact of pain severity and time to diagnosis
of depression on healthcare costs for primary care patients with pre-
existing unexplained pain who subsequently received a diagnosis of
depression.
Methods : In this retrospective cohort study, 4000 adults (aged
o18 years) with unexplained pain (deﬁned as painful physical
symptoms [PPS] without any probable organic cause) and a sub-
sequent diagnosis of depression, identiﬁed from the UK General
Practice Research Database using diagnostic codes, were analysed.
Patients were categorised into four groups based on pain severity
(milder or more severe based on pain-relief prescriptions with or
without opioid use) and time to diagnosis of depression (f1 year or
>1 year, respectively, from PPS index date). Health care costs were
calculated (2009 values) and included GP consultations, secondary
care referrals and prescriptions for pain-relief medication for the 12
months before depression diagnosis and in the subsequent two years.
Multivariate models were adjusted for age, gender and co-morbid
conditions.
Results : Total annual healthcare costs before and after diagnosis of
depression for the four groups of patients were higher for the two
groups with more severe pain (£819–£988 vs. £565–£628 ; p<0.001 for
all pair-wise comparisons) and highest for the group with more severe
pain and longer time to depression diagnosis in the years subsequent
to diagnosis (p<0.05). Total GP costs were highest in the group with
more severe pain and longer time to depression diagnosis both before
and after depression diagnosis (p<0.05). In the second year following
depression diagnosis, this group also had the highest secondary re-
ferral costs (p<0.01). The highest drug costs were in the two groups
with more severe pain (p<0.001), although costs within each group
were similar before and after depression diagnosis.
Conclusion : Co-existing pain and late depression diagnosis con-
tribute to higher costs for the UK healthcare system.
Policy of full disclosure : Funded by Eli Lilly and Company. All
authors are employees of Lilly and (excluding Jiyhung Hong) minor
shareholders.
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jP-21-004jFactors determining eﬃcacy of specialized
psychiatric help under conditions of primary
care unit
V. Lebedeva1, V. Semke1. 1Mental Health Research Institute, Tomsk,
Russia
Objective : Using clinical diagnostic criteria of course and outcome of
mental disorders co-morbid with somatic pathology to distinguish
basic treatment programs and to assess their eﬃcacy.
Methods : Clinical-diagnostic, clinical-follow-up ‘‘scale of eﬃcacy
of therapy of patients with borderline states ’’, SF-36, correlation
and factor analyses. Material : 680 patients with mental disorders co-
morbid with somatic pathology needing systematic therapy and
dynamic observation by a psychiatrist.
Results : We have developed six rehabilitative programs with their
gradual realization for patients with neurotic and somatoform
disorders, organic mental disorders, personality disorders, aﬀective
mood disorders, alcohol dependence, for elderly. Basic therapeutic
stages : initial, basic therapy and maintenance therapy. Basic and im-
portant method of therapy at all stages of treatment was medication.
Most eﬀective and used preparations were tranquilizers (sonval,
radedorm, nozepam, phenazepam, grandaxin, sibazon, relanium) ;
neuroleptics (sonapax, chlorprotixen, haloperidol, eglonil) ; anti-
depressants (amitriptiline, ﬂuoxetin, azafen, pirazidol, anafranil).
Conducted by us investigations during 25 years allowed distinguish-
ing basic and obligatory principles of therapy providing its quality
and eﬃcacy, gradual character, complexity (treatment of somatic
and mental pathology), suﬃciency (necessary volume of therapy with
minimum side-eﬀects), individual-diﬀerentiated approach (along
with other factors, account for ﬁnancial possibilities), accessibility (not
only territorial but also psychological), continuity (collaboration of
psychiatrist and physicians at all stages of therapy), cooperativeness
(possibility of concomitant curing by doctors of various specialties).
According to data of follow-up and assessment of eﬃcacy of treat-
ment programs, recovery has been achieved in 46.2% of cases, stable
clinical improvement – 44.1%. Temporary disability decreased in
patients with somatoform disorders as many as 1.8 times and number
of not grounded seeking for help and examinations per 1 patient
during the year as many as 2.3 times.
Conclusion : Integrative approach to medical help rendering as well
as all-sided diﬀerentiated and grounded medication were enough
eﬀective according not only on clinical but also economic indices.
jP-21-005j Investigations of the accessible drugs used for
central nervous system in Bangladesh :
An explorative survey among medical-staﬀs
and patients
A.H. Mollik. Power Foundation Bangladesh, Bogra Sadar, Bangladesh
Objective : Drugs are usually distinguished from endogenous bio-
chemicals by being introduced from outside the organism. Drugs
acting on the central nervous system (CNS) inﬂuence the lives of
everyone almost every-day. Drugs aﬀecting the CNS are important
therapeutically because they may relieve pains, fevers, suppress dis-
orders of movement, induce sleep, reduce the desire to eat, inhibit
motion sickness, and schizophrenia etc. Generally CNS patients are
not found in the willing for operation. In that cases the CNS drugs
play important roles.
Methods : Interviews were conducted of the medical-staﬀs and pa-
tients with the help of a semi-structured questionnaire. Patients’ ad-
herence or compliance with the prescribed medication schedule has
been a source of concern to the physician, and pharmacist. Specially
designed medication containers are useful in assisting to adhere to
their medication schedule.
Results : As far as the pharmaceutical market of Bangladesh is
concerned it is self dependent. It has a huge collection of the locally
produced CNS products at reasonable price. Simply the market of
CNS products of Bangladesh is saturated by its own products. It is
also an important exporter of CNS products to the 1st and 2nd world
countries in addition to the 3rd world countries.
Conclusion : There should be a well coordination of CNS related
information to the medical practitioners, pharmacist, and ﬁnally the
patients for the proper achievement of the great endeavor spent in the
ﬁeld of CNS products in Bangladesh. The CNS products can also be
proved as a key factor for the earning of foreign currency through its
export.
jP-21-006jThe brain-derived neurotrophic factor (BDNF)
polymorphism Val66Met is associated with neither
serum BDNF level nor response to paroxetine and
sertraline in depressed Japanese patients
W. Nakano1, R. Yoshimura1, T. Kishi2, A. Suzuki3, A. Ikenouchi-
Sugita1, H. Hori1, K. Otani3, N. Iwata2, J. Nakamura1. 1UOEH,
Kitakyushu, Japan ; 2Fujita Health University, Toyoake, Japan ; 3Yamagata
University, Japan
Objective : We investigated the relationship between the brain-
derived neurotrophic factor (BDNF) polymorphism (Val66Met) and
the clinical response of patients with major depressive disorder to
selective serotonin reuptake inhibitors (SSRIs ; here, paroxetine and
sertraline). In addition, serum BDNF levels in these patients were
considered together with the clinical response.
Methods : A total of 132 patients who met the DSM-IV criteria for
major depressive disorder were enrolled in the study. Of these pa-
tients, 54 were male and 78 were female (age range, 20–74 years ;
mean¡S.D., 51¡15). The patients’ clinical improvement was eval-
uated using the 17-item of Hamilton Ra ting Scale for Depression
(HAMD-17) at before (T0), and at 8 weeks after, the administration
of SSRI treatment (T8). Patients with at least a 50% decrease in the
HAMD-17 score were classiﬁed as responders.
Results : No correlation was observed between BDNF Val66Met
polymorphism and response to SSRIs or between BDNF Val66Met
polymorphism and serum BDNF levels at T0. An inverse correlation
was found between serum BDNF levels and HAMD-17 scores at T0.
Conclusion : These results suggest that the BDNF Val66Met poly-
morphism is independent of both the response to SSRI treatment and
serum BDNF levels. The ﬁnding in the present study reconﬁrms that
serum BDNF level is a stat e biomarker for depression.
jP-21-007jA cost-consequence analysis of long-acting
injectable risperidone in schizophrenia : A one-year
mirror image study with national claim-based
database in Taiwan
K.-P. Su1, H.-C. Chang2, C.-H. Tang2. 1China Medical Univ Taiwan,
Taichung, Taiwan ; 2School of Health Care Administ, Taipei Medical Univ
Taiwan, Taiwan
Objective : The development of long-acting, injectable, second-gen-
eration antipsychotics (SGA) has provided a new treatment paradigm
to improve treatment outcome of schizophrenia. Recent studies have
demonstrated that risperidone long-acting injection (RLAI) treatment
was associated with signiﬁcant reductions in relapses and hospital
service utilization. This study was designed to assess the change of
service utilization and costs for schizophrenia before and after treat-
ing patients with RLAI in Taiwanese national database.
Methods : This 1-year mirror-image study was conducted with
national claimed-data. Comparison was made for service sectors and
cost components (outpatient, inpatient, emergency, medication and
non-medication costs).
Results : Service uses reduced in the post-RLAI period, with sig-
niﬁcant reductions of inpatient service costs. However, overall psy-
chiatric service costs went up by 26%, with increases of 190% on total
outpatient service costs and 177% on medication costs.
Conclusion : With signiﬁcant reductions of inpatient service uses,
overall psychiatric service costs were compromised by costs incurred
from increased outpatient service and RLAI medication costs.
jP-21-008j Improving somatic health for outpatients with severe
mental illness ; the development of an intervention
F. van Hasselt1, A. Loonen2. 1University of Groningen, Dordrecht,
Netherlands ; 2University of Groningen, Pharmacotherapy and
Pharmaceut., Netherlands
Objective : Patients with severe mental illness (SMI) suﬀer from
more somatic illness than the general population. Possible causes are
side eﬀects of neuropsychiatric medication, genetic vulnerability,
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insuﬃcient health care and lifestyle. This co-morbidity is potentially
reversible and augments the costs for health care and diminishes
quality of life. Screening on symptoms and risks of somatic diseases
and coordination of care are proposed to improve SMI-patients’
somatic health status.
Methods : A clinical facility was started to improve the somatic
health status of patients in an outpatient centre in southern
Netherlands. This outpatient centre was added to the specialized care
for severe and enduring SMI. The intervention consisted of the in-
ventarisation of side-eﬀects and the detection of gaps in health care
provision for 72 patients. This was based on interviewing the patients,
laboratory screening, collecting information from their general prac-
titioner and pharmacy. A list was compiled of possible diagnosis and
health risks, and a plan of action was made for the treatment.
Healthcare consumption, quality of life and general functioning were
assessed to analyze cost-eﬀectiveness. Evaluations were performed
with the psychiatric care team on the process.
Results : Mean annual cost of GP’s and medical specialist’s con-
sultations were E492. There existed a negative relation between EQ5D
VAS and the number of self reported chronic diseases.
Conclusion : The authors conclude that the procedure is well fea-
sible, but should be set up in close collaboration with all health
care professionals of these patients to make tailor made solutions
possible.
P-22. Brain Stimulation/Deep Brain
Stimulation
jP-22-001jPsychiatric side eﬀects of bilateral monopolar
high frequency stimulation or stimulation at the
ventro-medial part of the subthalamic nucleus in
patients with parkinson’s disease
O. Abulseoud1, S. Stead1, K. Lee1, S. Tye2, B. Klassen1, J. Fields1,
S. Sampson1, J. Richardson1, J. Matsumoto1, M. Frye1. 1Mayo Clinic,
Rochester, USA ; 2Deakin University, Melbourne, Australia
Objective : To investigated the relationship between contact location
within the subthalamic nucleus (STN) or stimulation parameters
during programming and the occurrence of psychiatric side eﬀect in
patients with parkinson’s disease (PD).
Methods : Fifty consecutive patients with PD with bilateral STN
DBS were enrolled in a 6-months follow up study. Patients’ spon-
taneous utterances or behaviors were systematically identiﬁed during
DBS parameter optimization. The location of each of the stimulating
electrode contacts within the STN was veriﬁed post-operatively.
stimulation parameters (polarity, voltage, pulse width, and frequency)
were recorded at each follow up visit.
Results : Within 6 months of follow-up period, there were 29 in-
stances (in 15 patients) of emotional or behavioral induction [EBI (+)]
at time of adjustment of stimulation parameters to obtain better con-
trol of tremors. The majority (86% : 13/15 patients) of experienced EBI
occurred during stimulation of ventro-medial contact. The frequency
of EBI (+) instances was signiﬁcantly higher (Fisher’s Exact
p-value=0.042) in subjects who received bilateral monopolar stimu-
lation compared to subjects who received non-monopolar stimulation
on at least one side. The presence of EBI was associated with lack of
improvement in depressive symptoms and quality of life.
Conclusion : We found signiﬁcant association between bilateral
monopolar stimulation or stimulation at the ventro-medial contact
and the EBI (+) status. The neurobiological underpinnings of this
relationship remain to be investigated.
jP-22-002jRegulation of dopaminergic brain functions by
exercise or music
K. Akiyama1, D. Sutoo2. 1University of Tsukuba, Japan ; 2University of
Tsukuba, Institute of Medical Science, Japan
Objective : Our previous studies suggested that the convulsions in
epileptic mice rectify the decrease in dopamine synthesis in the brain
through the calcium/calmodulin-dependent system and subsequently
improve abnormal physiology. These studies led to the hypothesis
that neurologic disorders that involve dopamine dysfunction require
intense movement to improve the principal disorder. On the other
hand, we suggested that music also enhances this pathway. In this
study, the eﬀect of daily activities such as exercise and music on brain
functions was investigated.
Methods : Spontaneously hypertensive rats (SHR) were used to
conﬁrm this hypothesis. A decrease in calcium-dependent dopamine
synthesis results in hypertension in SHR.
Results : Exercise or exposure to music increased serum calcium
levels, and the calcium was transported to the brain and in turn en-
hanced dopamine synthesis. The subsequent increase in dopamine
rectiﬁed hypertension and various other disorders.
Conclusion : Our animal experiments indicate that exercise and
music rectify dopaminergic functions and related disorders. We sug-
gest that the activities of daily life such as participating in exercise and
listening to music might regulate and/or aﬀect various brain func-
tions through dopaminergic neurotransmission. These daily life ex-
periences therefore might lead to the amelioration of symptoms of
various diseases, such as hypertension, Parkinson’s disease, dementia
with Lewy bodies, epilepsy, and attention-deﬁcit/hyperactivity dis-
order. Also, it is possible that abnormal movements in neurologic
disorders, such as tremor in Parkinson’s disease, wandering around
and fugue in senile dementia, and movement in attention-deﬁcit/
hyperactivity disorder, in addition to convulsions in epilepsy, play a
role in improving the principal disorder.
References
Sutoo D, Akiyama K (2003) Neurobiology of Disease 13, 1–14.
Sutoo D, Akiyama K (2004) Brain Research 1016, 255–262.
Akiyama K, Sutoo D (2010) Clinical Psychopharmacology and
Neuroscience 8, 156–159.
Akiyama K, Sutoo D (2011) Neuroscience Letters 487, 58–60.
jP-22-003j In vivo alpha2 adrenoceptor binding demonstrates a
prolonged eﬀect of electroconvulsive therapy on
noradrenergic function in Gottingen minipigs
A.M. Landau1, G. Wegener2, A. K. Olsen Alstrup3, S. Jakobsen3,
H. Audrain3, A. Moeller1, M. Simonsen3, A. Gjedde4, P. Videbech2,
D. Doudet5. 1Aarhus University, Denmark ; 2Aarhus University, Risskov,
Denmark ; 3Aarhus University Hospital, Denmark ; 4University of
Copenhagen, Denmark ; 5University of British Columbia, Vancouver,
Canada
Objective :Major depression is one of the leading causes of disability,
aﬀecting 121 million individuals worldwide. Approximately one third
of depressed patients are unresponsive to antidepressant drugs. Brain
stimulation therapies, such as electroconvulsive therapy (ECT) are
potential alternatives for drug refractory patients. The noradrenaline
(NA) hypothesis of depression posits a deﬁciency in cortico-limbic
NA circuitry. It is supported by the increased presence of NA re-
ceptors in the cortex of depressed suicide victims and the eﬀective
antidepressant actions of NA reuptake inhibitors. Our objective is
to investigate the longitudinal eﬀect of ECT, a highly eﬀective
non-pharmacological antidepressant, on NA neurotransmission.
Methods : Here we use positron emission tomography and the
alpha 2 adrenoceptor antagonist tracer [11C]yohimbine to study the
eﬀect of ECT on NA receptor binding in cortical (frontal, temporal and
occipital cortices) and limbic (hippocampus and amygdala) regions in
Gottingen minipigs. Seven female adult minipigs were anesthetized
with isoﬂurane and scanned prior to the onset of a clinical course of
ECT (baseline), and at 24–48 hours and 8–10 days after the end of ECT
(10 ECT sessions in anesthetized animals over a 3.5 week period).
Results : The volume of distribution of yohimbine binding to alpha
2 adrenoceptors was decreased after ECT treatment in all the cortical
and limbic regions considered by 15–22% at 24–48 hours after ECT,
and by 12–16% 8–10 days post-ECT. Binding data from 3 animals that
were scanned at 6–8 weeks after the end of the ECT treatment showed
either return to baseline, increased compared to baseline or continued
decrease, reminiscent of the wide variability in length of eﬃcacy of the
antidepressant eﬀect of ECT observed in the clinic.
Conclusion : The decrease in alpha2 adrenoceptor binding after
ECT treatment may suggest increased NA release and/or receptor
downregulation. Potential increased NA neurotransmission in the
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cortical and limbic regions suggested by our results may contribute to
the therapeutic eﬀects of ECT in depression.
jP-22-004jThe brain stimulation by pulsed low-intensity
electromagnetic ﬁelds (PLEF) in acute ischemic
stroke (AIS) patients with psycho-vegetative
disorders, within 24 hours of symptom onset
G. Markarov1, I. Kalenova2, A. Howe2. 1Clinical Hospital 1, Moscow,
Russia ; 2Clinical Hospital 1, Presidental Administration, Moscow, Russia
Objective : To study the possibility of the usage the PLEF brain
stimulation within the ﬁrst 24 hours of acute ischemic stroke onset. To
research the psycho-vegetative and neuro-hemodynamics indices
changes, under transcerebral PLEF eﬀect in AIS patients.
Methods : The randomized, double-blind, placebo-controlled study
of PLEF brain stimulation had been done in 60 AIS patients. The main
group (30 patients) had received the drug therapy and the PLEF
treatment, which had begun within the ﬁrst 24 hours of acute ischemic
stroke onset. PLEF (2 mV/cm, 30 Hz) brain stimulation was carried
out through optical-vegetative system. It was applied 3 minutes
per day, 12 days. The 1-st control (15 patients) applied electric
ﬁeld-placebo (device not included) and drugs. In the 2nd control
(15 patients) were used only drugs. In all groups of patients used
comparable drug therapy.
Results : In the main group after the treatment course it was
showed the positive dynamics of clinical symptoms : reducing of
psycho-somatic changes, improved locomotion. The increase per-
centage slow waves (electroencefalography data) correlated with de-
crease sadness. It had been estimated the control glycine blood level,
reduction of cortizol, what correlated with decrease anxiety. In the
main group had been indicated the improve cerebral blood circulation
by doppler sonography computed tomography, IMR data. It was
indicated a more pronounced dynamics of clinical and laboratory
indices eﬀectiveness of the treatment in the main group compared
to controls.
Conclusion : It had been stated the improving psycho-somatic,
neurohemodynamic indices by the early pulsed low-intensity electro-
magnetic ﬁelds brain stimulation in the examined patients.
jP-22-006jThe role of transcranial magnetic stimulation in
cognitive processes and treatment psychiatrc
disorders
S. Mohamadzade1. 1Young Researchers Center, Sanandaj, Islamic
Republic of Iran
Objective : Transcranial magnetic stimulation (TMS) is a neuro-
stimulation and neuromodulation technique, based on the principle of
electromagnetic induction of an electric ﬁeld in the brain. This ﬁeld
can be of suﬃcient magnitude and density to depolarize neurons, and
when TMS pulses are applied repetitively they can modulate cortical
excitability, decreasing or increasing it, depending on the parameters
of stimulation, even beyond the duration of the train of stimulation.
This has behavioral consequences and therapeutic potential. Due to its
easy use and relatively fair side eﬀects, nowadays transcranial mag-
netic stimulation is widely used in neurosciences and medicine.
Methods : The method of research in this paper is review of litera-
ture in that researches that applied TMS for treatment and investi-
gation goals. 104 paper relative to the subject were studied and results
gathered here.
Results : TMS through induce the electric ﬁeld is a useful instru-
ment to visualize regional activities in response to stimulation. the
mechanism of eﬀect of TMS is induce depolarization of neurons that
in turn activate other neurons and produces behavioral and cognitive
outcomes, depends on the stimulated area and its function. for ex-
ample some of the observable TMS-induced eﬀects are induce phos-
phene in stimulation occipital cortex or interrupt working memory
and speech processes due to stimulate frontal lobe or improving ver-
bal memory in major depressive disorders through modulating eﬀects
on dopamine system. TMS has eﬀects on neurochemical and synaptic
processes in neurons. depression, mania, schizophrenia, pain dis-
order, hallucination, catatonia, post traumatic stress disorders, ob-
sessive- compulsive disorder, Parkinson’s disease, and epilepsy were
improved by TMS procedure.
Conclusion : Current published studies and meta-analyses have
evaluated the eﬃcacy of rTMS as given in treatment paradigms that
are almost certainly suboptimal (e.g. of two weeks’ duration) TMS is a
safe and tolerable intervention. These ﬁndings raises the possibility
of using TMS as a therapeutic device in psychiatric disorders and
neuroscience researches.
jP-22-007jA double-blind crossover study of subcallosal
cingulate gyrus deep brain stimulation in treatment-
resistant depression
M.J. Portella1, D. Puigdemont2, R. Pe´rez-Egea3, A. Martı´n-Blanco2,
J. Molet3, A. Gironell3, E. Alvarez2, V. Pe´rez2. 1 IIB-Hospital Sant Pau,
Barcelona, Spain ; 2Hospital de Sant Pau, IIB-Sant Pau, Barcelona, Spain ;
3Hospital de Sant Pau, Barcelona, Spain
Objective :Major depression is one of the leading causes of disability
worldwide since it is often accompanied by high rates of resistance to
treatment. Poor eﬃcacy of drugs for treatment-resistant depression
(TRD) has prompted investigation of alternative treatment strategies.
Deep Brain Stimulation (DBS) involves high-frequency electrical
stimulation of stereotaxically implanted electrodes. Several studies
have evaluated various areas of the brain that may be susceptible
to modulation of the cortico-limbic circuits through DBS. Results
published to date are encouraging, mainly for the subcallosal cingu-
late gyrus (SCG) We previously reported ﬁndings from the pre-
randomisation period for this clinical trial, with response rates of
87.5% (7 of 8 patients) and 62.5% (5 of 8) at 6 months and 1 year
respectively.
Methods : Here we report the ﬁndings of the double-blind cross-
over phase of the clinical trial. Five patients (those who responded
after one year of chronic DBS) were included, and randomized to 2
trial arms : on-stimulation or oﬀ-stimulation for a period of three
months. Subsequently, patients were crossed over to the other arm for
three additional months for a total of 6 months.
Results : Three patients completed the 6-month trial, without any
evidence of clinical changes in that period, regardless of treatment
arm. The other two patients relapsed during the oﬀ-stimulation arm,
as can be observed in Figure 1.
Conclusion :We cannot make any deﬁnitive conclusions regarding
the eﬀects of turning on or oﬀ the stimulator due to the limited num-
ber of subjects, but it is important to note that no patient relapsed
during the on-stimulation phase, whereas 2 out of 5 (40%) in the oﬀ-
stimulation arm experienced a relapse.
jP-22-008jDiﬀerential biasing of risk-based decision-making
by outcome-contingent stimulation of the lateral
habenula
C. Stopper1, S. Floresco2. 1University of British Columbia, Vancouver,
Canada ; 2Vancouver, Canada
Objective : Ventral tegmental area (VTA) dopamine (DA) neurons
encode reward prediction errors which facilitate making decisions
about uncertain outcomes. The lateral habenula (LHb) is a key input
to the VTA that provides indirect inhibition to DA neurons. Firing
of LHb cells is reduced in response to rewards, and these neurons
show phasic increases following reward omission. Likewise, LHb
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stimulation inhibits DA neural activity, resembling phasic ‘‘dips’’
associated with reward prediction errors. What is unclear is how
phasic suppression of DA neural ﬁring may modulate choice in cost/
beneﬁt decision scenarios. Accordingly, the present study examined
the eﬀects of temporally-discrete stimulation of the LHb on probabil-
istic decision-making.
Methods : Rats were trained on a discounting task entailing choice
between a small/certain (1-pellet) and a large/uncertain reward
(4-pellets). The odds of obtaining the larger reward decreased sys-
tematically over a session (50–12.5%). Following extended training,
electrical stimulation of the LHb (20–80 pulses, 100 Hz, 200 uA) was
delivered following or prior to certain outcomes/actions (ie ; im-
mediately after a large/risky ‘‘win’’, after smaller/certain reward
delivery, prior to a choice, during the inter-trial interval).
Results : Phasic manipulation of LHb activity inﬂuenced prob-
abilistic choice. Speciﬁcally, stimulation of the LHb only after risky
‘‘wins’’ decreased choice of the large/uncertain option. Conversely,
stimulation only after receipt of the small/certain reward had the
opposite eﬀect, increasing risky choice. Similar eﬀects were observed
on non-stimulation probe trials, when the large or small reward was
never delivered, which decreased/increased risky choice, respect-
ively. Importantly, LHb stimulation did not aﬀect preference for
larger vs. smaller reward when both were delivered with 100% cer-
tainty. Ongoing experiments are investigating the eﬀects of LHb
inactivation on risky choice.
Conclusion : These results suggest that phasic activation of the LHb
(and presumably, inhibition of DA neurons) provides an important
‘‘reward omission’’ signal that can bias decision making in situations
involving reward uncertainty.
P-23. Miscellaneous
jP-23-001jThe neurosteroid dehydroepiandrosterone sulfate
suppresses neurovirulence produced by human and
feline immunodeﬁciency viruses
G. Baker1, F. Maingat1, M. Polyak1, A. Paul1, P. Vivithanaporn1,
F. Noorbakhsh1, S. Ahboucha2, K. Pearson1, C. Power1. 1University of
Alberta, Edmonton, Canada ; 2Universite Cadi Ayyad, Marrakech, Morocco
Objective : Neurosteroids, cholesterol-derived molecules synthesized
within the brain, can exert trophic and protective actions. Infection
by human (HIV) and feline (FIV) immunodeﬁciency viruses causes
neuroinﬂammation and neurodegeneration. The objective of the study
reported here was to investigate interactions between neurosteroids
and lentivirus infection outcomes.
Methods : Human brain tissue was obtained from a brain bank
in the Division of Neurology at the University of Alberta. In the
FIV studies, cats were infected with FIV-Ch29 at day 1 postnatal.
Behavioural tests included gait analysis, a modiﬁed T maze (to test
spatial memory, cognitive learning capacity and performance speed)
and an object memory test.
Results : Analyses of postmortem brain tissue from HIV-infected
and uninfected persons disclosed a reduction in expression of 5a-re-
ductase, P450scc and 3bHSD, enzymes involved in the synthesis of
neurosteroids, in neurons of HIV-infected samples. Neurons exposed
to supernatants from HIV-infected macrophages exhibited sup-
pressed 5a-reductase and 3b-HSD expression (p<0.05) without re-
duced cellular viability. We then focused on dehydroepandrosterone
sulfate (DHEA-S) and found that HIV-infected macrophages treatead
with this neurosteroid showed suppression of inﬂammatory gene
(IL-1b, IL-6, TNFa) expression (p<0.05). Treatment of FIV-infected
cats with DHEA-S resulted in a reduction of inﬂammatory gene
transcripts (IL-1b, TNF-a, CD3e, GFAP) in brain (p<0.05), and blood
CD4+ T-cell levels were increased in DHEA-S-treated FIV-infected
animals (p<0.05). DHEA-S treatment also markedly reduced neuro-
behavioral deﬁcits and neuronal loss among FIV-infected animals
(p<0.05).
Conclusion : Thus, reduced neuronal neurosteroid-related
enzyme expression accompanied lentivirus infections but treatment
with DHEA-S limited inﬂammation and neurobehavioral deﬁcits.
Neurosteroid-derived therapies might be eﬀective in the treatment
of virus- or inﬂammation-mediated neurodegeneration. (Funded
by CIHR, AHFMR, the Canada Research Chairs program and the
University of Alberta).
jP-23-002jCerebral ischemia in mice : Neuroprotection by
progesterone and curcumin
A. Chakrabarti1, D. Hota2, V. Dhawan3, A. Prakash2. 1Pgimer,
Chandigarh, India ; 2Pgimer, Department of Pharmacology, Chandigarh,
India ; 3Pgimer, Department of Experimental Med., Chandigarh, India
Objective : Ischemic damage to brain leads to morbidities like sei-
zures, motor functional loss, memory impairment and others. The
study was designed to evaluate the eﬀects of progesterone and cur-
cumin on sub-acute phase changes induced by partial global cerebral
ischemia in male, Swiss strain mice.
Methods : Animals were randomized into four groups (6 ani-
mals per group) : Sham- operated and Saline-, Progesterone- and
Curcumin – treated surgically operated groups. Cerebral ischemia
was produced by bilateral common carotid artery occlusion with an-
eurismal clips for 10 min followed by reperfusion in anaesthetized
animals. On post- ischemic day 15, the animals were subjected to :
Behavioral studies on elevated plus maze, rota rod, hole- board and
kainic acid (20 mg/kg intraperitoneal) – induced seizure susceptibility
tests ; Biochemical studies for estimation of whole brain tissue
malondialdehyde (MDA), catalase, super oxide dismutase (SOD),
glutathione peroxidase (GPx) and TNF1 ; Histopathological study of
brain. The protocol was approved by Institutional Animal Ethics
Committee.
Results : Compared to the Sham- operated group, the Saline-
treated surgically operated group showed signiﬁcant decrease in the
exploratory behavior in hole- board, retention time on rota rod and
entry into the open arm of the plus maze while there was signiﬁcant
increase in the closed-arm entry in plus maze and seizure suscepti-
bility to kainic acid ; brain levels for MDA and TNF1 were increased
while that for SOD, catalase and GPx were reduced signiﬁcantly fol-
lowing ischemia ; ischemia caused signiﬁcant increase in the histo-
pathological score. Intraperitoneal administration of progesterone
(15 mg/kg) and curcumin (300 mg/kg), once-a-day, for post-ischemic
14 days, showed signiﬁcant reversal of the data for all the para-
meters compared to the Saline- treated surgically operated group of
animals.
Conclusion : The study showed the ant oxidative and neuro-
protective eﬀects of progesterone, a neurosteroid and curcumin, a
phytophenolic compound against cerebral ischemic injury during the
sub-acute phase in the mice model.
jP-23-003jAlterations in gene expression of FGF2 in HIV and
major depressive disorder
I. Everall1, T. Nguyen2, T. Money3, G. Chana3, E. Tatro4, B. Hult4,
J.H. Atkinson4, D. Moore4, C. Achim4, E. Masliah5. 1University of
Melborne, Melbourne, Australia ; 2Department of Psychiatry, University of
Melborne, Melbourne, Australia ; 3Department of Psychiatry, University
of Melbourne, Australia ; 4Department of Psychiatry, University of
California, San Diego, USA ; 5Departments of Neurosciences and
Pathology, University of, San Diego, USA
Objective : Altered expression of neurotrophic factors has been im-
plicated in both the pathology of human immunodeﬁciency virus
(HIV) infection and major depressive disorder (MDD) in the brain
and may be linked to the higher incidence of MDD in the HIV+
population.
Methods : This current investigation assessed gene expression
changes of ﬁbroblast growth factor 2 (FGF2), microtubule-associate
protein 2 (MAP2), growth arrest and DNA-damage-inducible protein
45 beta (GADD45b), somatostatin (SST), and serum/glucocorticoid
regulated kinase 1 (SGK1), previously implicated in neurodegenera-
tive and mood disorders, in the frontal cortex of a novel brain cohort
from patients with documented HIV, MDD, or HIV with MDD (HIV/
MDD) by qRT-PCR. We further assessed the contributing eﬀects of
HIV and cortisol, known to be elevated in MDD, in primary human
neuronal-glial in vitro cultures exposed to 6000 pg/ml HIV (BaL)
and/or 500 nM cortisol after 6 and 24 hours.
Results : Post-mortem FGF2 was increased in both HIV and HIV/
MDD compared to controls (p<0.01) but was signiﬁcantly lower in
HIV/MDD compared to HIV alone (p<0.01). Additionally, MAP2
was signiﬁcantly decreased in HIV and HIV/MDD (p<0.05) and was
signiﬁcantly correlated with FGF2 in the post-mortem HIV group
(p=0.02). Increased GADD45b and decreased SST were detected in
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post-mortem HIV and HIV/MDD groups (p<0.05). With the excep-
tion of SST, expression changes corroborated with directional changes
in vitro.
Conclusion : Whilst we did not detect signiﬁcant changes speciﬁc
to MDD or cortisol alone, upregulated FGF2 in the brains of HIV pa-
tients may reﬂect a neuroprotective mechanism which is diminished
in patients with comorbid MDD and associated reduction in MAP2.
Our overall ﬁndings indicate that HIV is associated with compensa-
tory gene expression changes of several neurotrophic and mood-
related genes in the brain.
jP-23-004jProtein changes in cholinergic neurons of nucleus
basalis in progression of alzheimer’s disease
D. Getova1, S. Perez2, E. Mufson2. 1Medical University, Plovdiv,
Bulgaria ; 2Rush University, Neuroscience Division, Chicago, USA
Objective : The cell cycle protein Rac1 plays a crucial role in the
neuronal death during the progression of Alzheimer’s disease (AD).
Rac1 activates the apoptotic machinery of the low aﬃnity p75NTR
and the cytoskeletal abnormalities in nucleus basalis (NB) cholinergic
neurons in AD.
Methods : Sections containing cholinergic neurons of the NB were
obtained from autopsy cases from people who died with a clinical
diagnosis of no cognitive impairment (NCI), mild cognitive impair-
ment (MCI) or AD. Rac1b was visualized within NB neurons by dual
immunostaining using a monoclonal p75NTR and a polyclonal Rac1b-
speciﬁc antibody visualized by with the chromogens DAB with or
without nickel intensiﬁcation. Additional sections were double or tri-
ple immunoﬂuorescence labeled using antibodies directed against
Rac1b, choline acetyltransferease (ChAT), the early conformational
tau antibody Alz50 and the phosphorylation antibodies AT180 and
AT8. Sections were analyzed using light and confocal microscopy.
Results : 1. Dual immunostaining revealed that not all p75NTR NB
neurons contain Rac1b and virtually all Rac1b were p75NTR
immunoreactive in all clinical groups. 2. The greatest number of
p75NTR/Rac1b NB positive neurons occurs in AD compared to MCI
and NCI. 3. Many Rac1b positive NB neurons were dual labeled with
antibodies for early conformational tau isoform Alz50 and the tau
phosphorylational epitopes, AT180 and AT8 in AD. 4. Many more
ChAT positive neurons were triple labeled for Alz50 and AT8 in AD
compared to NCI or MCI.
Conclusion : 1. Rac1b is co-expressed in a subpopulation of
p75NTR NB neurons. 2. Rac1b is found in many more p75NTR NB
neurons in AD compared to NCI and MCI. 3. Rac1b is co-expressed
in a subpopulation of p75NTR NB neurons, which contain tau con-
formation (Alz50) and phosphorylation (AT180 and AT8) epitopes to
a greater extend in AD compared to NCI and MCI. 4. Rac1b activation
induces cytoskeletal reorganization inducing neuroﬁbrillary tangle
formation in p75NTR NB neurons. 5. p75NTR activates Rac1b, which
induces apoptosis.
Policy of full disclosure : Supported by Fulbright Grant for
Dr. D. Getova.
jP-23-005jThe relationship between cognitive outcome and
microinfarctions after coiling of asymptomatic
unruptured intracranial aneurysm : A prospective
study
S.J. Lee1, D.H. Kang1, Y. Hwang1, H.-D. Rim1, S. Jeong1, S.M. Chang1,
Y.W. Park1. 1Daegu, Republic of Korea
Objective : The aim of this study was to prospectively investigate the
possible cognitive impairment in patients undergoing coil emboliza-
tion for the treatment of asymptomatic unruptured intracranial an-
eurysm (UAI) under the hypothesis that clinically negligible multiple
micorinfarctions would cause higher cortical dysfunction.
Methods : Twenty-nine patients were evaluated preoperatively
and postoperatively at 1 and 4 weeks later with a battery of neuro-
psychometric tests. The results were analyzed by both event-rate and
group-rate analyses. For event-rate analysis, a cognitive deﬁcit was
deﬁned as a decrease of 1 standard deviation in the postoperative
score compared with the preoperative score for each test for individ-
ual patients. A patient with deﬁcits in at least one test score was
considered to have postoperative cognitive impairment.
Results : Group-rate analysis found that no tests except PAL
showed signiﬁcant impairments from baseline at Week 4. In event-
rate analysis, 13(45%) patients had no cognitive deﬁcit or superior
performances whereas 16(55%) patients still had cognitive deﬁcits
from baseline with 0.68¡0.69 of the mean number of cognitive deﬁcit
variables at Week 4. Pearson’s correlation analysis found no correla-
tions between the number of mircoinfarctions and the cognitive sum
z-score at both Week 1 and Week 4 (r=x.18, p=0.35 ; r=0.06,
p=0.79). No correlation was also found between the number of
microinfarctions and any individual test score.
Conclusion : Neuropsychometric evaluation of patients under-
going coil embolization for UIAs demonstrates recovery or im-
provements after one month in general. However, we failed to
prove any relationships between cognitive changes and microinfarct
lesions.
jP-23-006jOlig 1-immunoreactive oligodendrocytes are
elevated in the white matter of the anterior cingulate
gyrus in patients with major depression
J. Mosebach1, H. Dobrowolny1, B. Bogerts1, J. Steiner1. 1University of
Magdeburg, Germany
Objective : Alterations in oligodendrocyte cell density, thickness of
myelin sheaths and expression of myelin-associated genes have been
described in patients with aﬀective disorders and schizophrenia. This
may indicate impaired myelinisation, leading to disturbed connec-
tivity of brain regions which are relevant for the pathogenesis of af-
fective disorders and schizophrenia. In this context, the transcription
factor Olig 1 is of particular interest, because it is expressed by oligo-
dendrocytes and is involved in myelin-repair.
Methods : In this postmortem study, the cell density of Olig 1-im-
munoreactive oligodendrocytes was analyzed in the pregenual an-
terior cingulate (pACC, Brodmann Area 24/32) and dorsolateral
prefrontal (DLPFC, Brodmann Area 9) cortices, including a separate
analysis of the adjacent white matter in 8 patients with major de-
pression, 8 patients with bipolar depression, 13 patients with schizo-
phrenia and 12 matched control subjects. Statistical analyses were
performed with analysis of variance (ANOVA) followed by Post-hoc
Tukey-HSD Tests.
Results : A signiﬁcantly increased density of Olig 1-im-
munoreactive oligodendrocytes was observed in patients with major
depression in the adjacent white matter of the pACC in both hemi-
spheres (p<0.001), as well as in the left DLPFC (p=0.029). Olig
1-immunoreactive cell counts were not correlated with potential
confounds like age, gender, duration of disease, autolysis or ﬁxation
time, and medication dosage.
Conclusion : This study reveals an increased expression of Olig 1
in patients with major depression compared to healthy controls,
particularly in the white matter of the pACC. These ﬁndings could
indicate a regenerative attempt in order to reestablish connectivity
between the pACC and other brain regions, such as the limbic system
or the mediodorsal thalamic nucleus in subjects with major de-
pression. Impairment of pACC-connectivity with these brain regions
has been shown by various MRI-studies (Liu S. et al., 2011, Anand
et al., 2009).
jP-23-007jPerceptual disturbance in schizophrenia is related to
diﬀerential EGFR mRNA expression in cortical
layers in post mortem brain
V. Swaminathan1, A. Pereira2, C. Shannon-Weickert3, S. Sundram1.
1MHRI, The University Of Melbourne, Australia ; 2MHRI, Kenneth Myer
Building, The University of Melbourne, Australia ; 3SRL/SRI, NeuRA,
Randwick, Australia
Objective : There is emerging evidence for dysregulation of the
Epidermal Growth Factor (EGF) system in schizophrenia (SCZ).
Previously we have shown that the antipsychotic drug clozapine
transactivates the EGF receptor (EGFR) which may relate to its eﬀec-
tiveness in treatment resistant SCZ. We hypothesised therefore that
EGFR changes in schizophrenia may be related to the clinical charac-
teristics of the disorder and examined EGFR mRNA expression in the
DLPFC (Dorso Lateral Pre Frontal Cortex) (BA46) of post mortem
tissue from people with SCZ and healthy controls.
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Methods : Messenger RNA expression was measured using in-situ
hybridization in a cohort of 37 patients with SCZ and 37 controls
matched for age, sex, post-mortem interval and pH. All samples were
obtained from the NSW Tissue Resource Centre (University of
Sydney). Relevant parametric statistical analyses with post hoc tests
and correlation coeﬃcients were computed.
Results : In schizophrenia, people without auditory hallucinations
(AH) had signiﬁcantly higher EGFR mRNA expression in layer VIa
compared to those with AH (AH negative 0.071¡0.008 mCi/g
mean¡sem vs. AH positive 0.054¡0.002 mCi/g ; p=0.043, t=2.11,
df=35) and this tended to signiﬁcance in layer VI (AH negative
0.069¡0.01 mCi/g vs. AH positive 0.052¡0.002 mCi/g ; p=0.057,
t=1.97, df=35). In schizophrenia with visual hallucinations (VH)
EGFR mRNA expression was signiﬁcantly higher in layers II (VH
positive 0.063¡0.008 mCi/g vs. VH negative 0.044¡0.002 mCi/g ;
p=0.006, t=2.96, df=35) and III (VH positive 0.067¡0.007 mCi/g vs.
VH negative 0.050¡0.002 mCi/g ; p=0.01, t=2.65, df=35). There
were no main eﬀect diﬀerences between schizophrenia and control
groups and no other diﬀerences within the schizophrenia group with
regards other symptoms or clinical parameters.
Conclusion : EGFR mRNA dysregulation may be implicated in the
pathology of perceptual disturbances within schizophrenia, and this
varies between auditory and visual perceptual modalities.
jP-23-008j Individual scores on harm avoidance are
diﬀerentially related to dorsolateral prefrontal
cortical and hippocampal serotonin 2A receptor
binding indices
C. Baeken1, R. De Raedt1, A. Bossuyt2. 1UGent, Ghent, Belgium ;
2UZBrussel, Brussels, Belgium
Objective :Although the serotonergic system has been documented to
be implicated in healthy as well as in pathological emotional states,
knowledge about its involvement in personality is limited. Former
research on this topic suggests that post-synaptic 5-HT2A receptors
could be involved in particular in fronto-limbic areas.
Methods : In drug-naı¨ve healthy subjects we examined the role
of these 5-HT2A receptors with 123I-5-I-R91150 SPECT using the
temperament dimension Harm Avoidance (HA), a personality feature
closely related to stress and anxiety proneness, thought to be medi-
ated by the serotonergic system. Frequently reported to be implicated
in aﬀective disorders, we focused on the dorsolateral prefrontal cor-
tices (DLPFC) and the hippocampus. All analyses were corrected for
age and gender.
Results : We found a relationship between DLPFC and hippo-
campal 5-HT2A receptor binding indices (BI) associated with indi-
vidual HA scores : HA was positively related with DLPFC and
negative related to hippocampal 5-HT2A receptor BI. Further, our
results suggest that in particular those individuals with a tendency to
worry or to ruminate display signiﬁcantly higher 5-HT2A receptor
BI in the left DLPFC. Participants scoring higher on HA had
lower hippocampal 5-HT2A receptor BI with preponderance to the
right, possibly reﬂecting an enhanced sensitivity for stress-related
responses.
Conclusion : Our results give support to the hypothesis that
5-HT2A receptors might exert diﬀerent functions depending as to
where they are located in the brain. Although we only examined
psychologically healthy individuals, the inverse relationship of
5-HT2A receptor binding indices between the two anatomical regions
suggests that a possible serotonergic vulnerability for aﬀective dis-
orders, in line with other studies.
jP-23-009jTherapeutic management of borderline personality
disorder in emergencies
B. Garcia Delgar1, J.M. Gine´s1, D. Co´rcoles1, A´. Malago´n1, J.M.
Arcega1, M. Martin1, M.T. Nascimento1, A. Sabate´1, A. Bulbena1. 1Parc
de Salut Mar, Barcelona, Spain
Objective : To describe demographic and clinical factors of BPD pa-
tients that visit PES and their association with psychotropic drugs and
hospitalization indication.
Methods : Socio-demographic, clinical, severity and treatment
variables are collected from visits attended at PES during a 4 years
period. Logistic regression model is used to analyze which factors are
related to pharmacotherapy and hospitalization.
Results : A sample of 11.578 patients was obtained. 1032 (8.9%) re-
ceived BPD diagnosis and were mostly women (n=653) with a mean
age of 31¡9. Psychiatric and substance abuse history were more
common in BPD group (p<0.001). They showed more severe symp-
toms, frequently related to behavior disorders (27%) or anxiety
(21.5%). Anxiety was the condition more frequently related to ben-
zodiazepines prescription for BPD patients (OR 3.77, IC 95%
2.52–5.66). Female gender (OR 0.52, IC 95% 0.35–0.76), substance
abuse (OR 0.58, IC 95% 0.38–0.88), improper self-care (OR 0.61, IC
95% 0.42–0.88) and lack of family support (OR 0.49, IC 95% 0.27–0.87)
decrease likelihood of receiving benzodiazepines. Psychotic symp-
toms (OR 6.88, IC 95% 1.64–28.90) and danger to others (OR 2.07, IC
95% 1.39–3.06) increase probability to prescribe antipsychotics. BPD
patients were less hospitalized (p<0.001). High risk of suicide (OR
10.33, IC 95% 6.38–16.71), opposition to treatment (OR 4.50, IC 95%
1.89–10.69) or danger to others (OR 2.55, IC 95%1.59–4.11) were
variables related to hospitalization.
Conclusion : Although clinical presentation was more severe
in BPD patients, hospitalization was less indicated. The use of psy-
chotropic drugs was more common in BPD patients with an atypical
socio-medical proﬁle.
jP-23-010jPersonality traits of diﬀerent professional groups
and their impact on coping with stress and job
satisfaction
K. Krysta1, A. Gojowy2, A. Janoska2, A. Krasnodebska2, M. Masnica2,
M. Janas Kozik3, I. Krupka-Matuszczyk2. 1Medical University of
Silesia, Katowice, Poland ; 2Medical University of Silesia, Psychiatry and
Psychotherapy, Katowice, Poland ; 3Medical University of Silesia, Child/
Adolescents Psychiatry, Katowice, Poland
Objective : Temperament is the most stable dimension of personality.
According to the recently validated questionnaire TEMPS-A, there are
ﬁve distinguishable types of temperament, including depressive
temperament, cyclothymic, hiperthymic, irritable, and anxiety tem-
perament. All of the above except for the hiperthymic temperament
predispose to psychiatric disorders. With the help of this test one may
also predict propensity for addiction. The aim of this study was to
evaluate the temperament of diﬀerent social groups. The study looked
at seven diﬀerent groups. The survey examined ways of coping with
stress and the level of job satisfaction.
Methods : The examined group included 77 people, including
30 men and 47 women aged from 21 to 60 years. Mental illness
was ruled out in all participants, all of them agreed to participate
in the study. We used the TEMPS-A questionnaire to assess tem-
perament, while Minnesotta’s questionnaire was used to assess
the level of job satisfaction and the COPE questionnaire was used
to assess the style of coping. The results were analyzed using
Statistica 9.0.
Results : Among the interviewees there was 35 people (45.5%) with
no speciﬁc temperament, 19 (24.6%) with mixed temperament and
23 (26.9%) people with a determined temperament. Among those of
determined temperament, hiperthymics dominated (65%).We ob-
served signiﬁcant diﬀerences in the various study groups and found
that there is a correlation between temperament and the level of
job satisfaction, but found no clear correlation between the type of
temperament and the strategies used to cope with stress.
Conclusion : It may be imprtant to evaluate the personality traits of
people working in diﬀerent professions in oreder to achieve a better
job satisfaction. The problem of coping with stress seems to be a more
complex phenomenon and needs further ivestigation.
jP-23-011jCourse and stability of personality disorders in the
elderly : A review
S. Richa1, C. Ibrahim1. 1Hotel-Dieu de France, Beirut, Lebanon
Objective : Personality disorders in the elderly have received little
serious attention. They are quite diﬀerent from younger adult popu-
lations in matters of prevalence, symptoms and clinical presentation.
The purpose of this article is to provide a comprehensive review about
the course and stability of personality disorders across the lifespan.
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Methods : 22 cross sectional and longitudinal studies were
reviewed.
Results : Older subjects most frequently presented with avoidant
and dependent PDs followed by schizoid PDs. Borderline personality
disorder become less impulsive but relationship instability persists.
Extraversion, Agreeableness, Conscientiousness, and Intellect de-
clined signiﬁcantly in old age. Neuroticism declined up to the age 70.
There was great a variability in stability of PDs diagnostic criteria.
25% of DSM criteria contained poor face validity for use with older
adults.
Conclusion : Some personality disorders are being diagnosed more
frequently because of the bias created by some DSM criteria for PD
diagnosis. It seems that a dimensional approach might eliminate this
bias, thus allowing for a better diagnosis and management of
personality disorders in the elderly.
jP-23-012jChildhood trauma, telomere length and hiv-
associated neurocognitive impairments in women
S. Seedat1, S. Malan2, S. Hemmings2, G. Spies2, M. Kidd3, I. Grant4,
C. Fennema-Notestine5, S. Archibald6. 1University of Stellenbosch, Cape
Town, South Africa ; 2Department of Psychiatry, Stellenbosch University,
Tygerberg, South Africa ; 3Centre for Statistical Consultation, Stellenbosch
University, South Africa ; 4HIV Neurobehavioral Research Center,
University of California, San Diego, USA ; 5Departments of Psychiatry
and Radiology, San Diego, USA ; 6Laboratory of Cognitive Imaging,
University of California, San Diego, USA
Objective : The neuropathogenesis of the human immunodeﬁciency
virus (HIV) may manifest as various neurocognitive impairments
(NCI). HIV-positive individuals also have signiﬁcantly shorter telo-
mere length (TL) in peripheral blood mononuclear cells (PBMCs) and
CD8+ T cells compared to HIV-negative individuals. Additionally,
reduced TL has been found to be associated with chronic psycho-
logical stress. This study focused on the eﬀects of chronic stress asso-
ciated with childhood trauma and HIV status on telomere length and
investigated whether leukocyte TL (LTL) in particular represents a
risk factor for NCI.
Methods : 83 HIV-positive and 45 HIV-negative women were
assessed for childhood trauma and were subjected to detailed neuro-
cognitive testing. Blood from each participant was used to extract
DNA. Relative LTL were determined by performing real time quan-
titative PCR reactions as described by Cawthon et al. (2002).
Results : As expected, relative LTL in the HIV-positive individuals
was signiﬁcantly shorter than that of HIV-negative individuals.
Notably, in HIV-positive participants a signiﬁcant positive correlation
was evident between relative LTL and learning performance. Within
the HIV-positive group, there also was a signiﬁcant diﬀerence be-
tween trauma groups, with a negative correlation between relative
LTL and verbal ﬂuency within the trauma group.
Conclusion : Our results suggest that reduced LTL negatively in-
ﬂuences the learning process in HIV-positive individuals, indicating
that TL could act as a susceptibility factor in increasing neurocognitive
decline in HIV-infected individuals.
jP-23-013jThe dopamine D2 receptor (DRD2)x141C Ins/Del
polymorphism aﬀects the personality traits of
healthy Japanese participants
S. Tsuchimine1, N. Yasui-Furukori2, K. Sasaki2, A. Kaneda2,
N. Sugawara2, S. Yoshida3, S. Kaneko2. 1Hirosaki University, Japan ;
2Hirosaki University, Graduate School of Medicine, Japan ; 3Hamamatsu
University, School of Medicine, Japan
Objective : Dopamine neurotransmitter systems have been associated
with reward-related and novelty-seeking personality traits. We in-
vestigated the possible relationship between the personality traits
measured by the Temperament and Character Inventory (TCI) and the
TaqI A and x141C Ins/Del polymorphisms in the dopamine D2
receptor gene (DRD2).
Methods : The sample consisted of 1084 healthy Japanese medical
students and medical staﬀ (age=29.0¡9.7 years), each of whom
completed the TCI. Their genomic DNA was isolated from whole
blood and genotyped using the TaqMan allele-speciﬁc assay method.
The associations between gene polymorphisms and the scores for TCI
were statistically analyzed by one-way analysis of covariance
(ANCOVA) adjusting age. Males and females were analyzed separ-
ately. Epstatis was assesses using two-way ANCOVA between the
DRD2 and ANKK1 genes.
Results : Men with the Ins/Del genotype of the x141C Ins/Del
polymorphism had signiﬁcantly higher self-directedness scores than
those with the Ins/Ins genotype (p=0.021). None of the TCI scores
diﬀered among women with regard to the three genotype groups
of the x141C Ins/Del polymorphism. The DRD2/ANKK1 Taq1 A
polymorphism did not aﬀect any TCI factor for either men or women.
An epistatic analysis did not reveal main eﬀects of the two genes with
regard to TCI scores, but an ANKK1r DRD2 interaction signiﬁcantly
predicted TCI scores.
Conclusion : These ﬁndings suggest the possibility that thex141C
Ins/Del polymorphism and the DRD2/ANKK1 Taq1 A polymorph-
ism are not strongly linked to personality traits directly, but inﬂuences
them under the interaction between the DRD2 and ANKK1 genes.
jP-23-014jExercising autonomy
E.M. Ciorabai. University, Constanta, Romania
Objective : The concept of autonomy occupies a central role in both
the legal and ethical frameworks governing clinical practice. In the
latter half of the twentieth century this new ethical principle has
emerged, resulting in many changing in patient centered models of
care, shared decision making processes and stricter requirements for
consent processes. One important change is from long term inpatient,
to daycare patient to outpatient, the balance between individual and
public interests.
Methods : Participants were patients with diagnosis of severe
mental disorders treated in psychiatric clinic in Constantza by a psy-
chiatrist at list six months, with good compliance to treatment, with
good therapeutic alliance and good improvement on CGI scale.
During a period of four years clinical, demographic and routinely
collected outcome data was obtained from clinical case notes for
people who were patients with diagnosis of severe mental disorders.
They received letters from psychiatrists to their family doctors, and
they where asked to change the visit from psychiatrist to family doc-
tor. Outcome and engagement data were collected on 79 service-users
who were included in the study.
Results : Data was collected over three distinct time periods, ﬁrst
contact until transfer, time under the care of family doctor, and time
under the care of psychiatrist or in-patient, during a period of four
years. Findings suggested that some factors were associated with less
admittance and less bed days, for example treatment compliance
determined by perception of usefulness of treatment, quality of
therapeutic interactions and openness.
Conclusion : Clinical and demographic variables associated with
good outcome were single service users, longer than three years and
those who did not use substances and who were well engaged in
change. Better engaged clients might more easily accept the need for
early or even voluntarily admission, which in turn has been shown to
reduce length of hospitalization. The engagement once developed
is fairly stable over several years and collaboration with treatment
increases over time.
jP-23-015jThe eﬀects of modaﬁnil on ‘cold’ cognition,
creativity, and motivation in healthy volunteers
A.D. Mohamed. University of Cambridge, Department of Psychiatry,
United Kingdom
Objective : The aim of this study was to investigate the eﬀects
of modaﬁnil on cognition, motivation and creativity in healthy
volunteers.
Methods : A double-blind placebo-controlled parallel design study
evaluated the eﬀects of 200 mg of modaﬁnil (n=32) or placebo (n=32)
in non-sleep deprived healthy volunteers. Reliable tests of divergent
and convergent thinking were used to measure creativity. The diﬃcult
versions of the CANTAB tasks were used to measure executive
function. Finally, subjective eﬀects were measured using a novel
motivational salience task.
Results : For the CANTAB tasks, signiﬁcant improvements with
modaﬁnil were seen on a load dependent manner (p<0.05). On a test
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of creativity, the Remote Associates Task, modaﬁnil improved sub-
jects who were low in trait creativity (p<0.05) but impaired those
who were high in trait creativity. In the high trait creativity group, a
trend towards improvement was found in placebo subjects relative
to those on modaﬁnil (p=0.08). Modaﬁnil induced signiﬁcant in-
crease in salience of pleasure as the total ratings were signiﬁcantly
greater for the modaﬁnil group relative to the placebo group
(p<0.05).
Conclusion : This is the ﬁrst study investigating the eﬀects of
modaﬁnil on objective measures of creativity and motivation. We
demonstrated improvements in creativity by modaﬁnil but only in
subjects who had low trait creativity at baseline. We also found im-
provements on tasks of ‘cold’ cognition. It was especially noticeable
that when CANTAB SWM was made more diﬃcult, performance
improved under modaﬁnil. Due to ceiling eﬀects, this improvement
was not seen in a previous study with an earlier version of this task.
Importantly and strikingly, subjective ratings of task pleasure were
greater in the modaﬁnil group, suggesting that the drug increases
salience of pleasure independent of the performance of all tasks.
These results have important implications for cognitive enhancement
practices among healthy individuals and they inform the ongoing
neuroethical debate.
jP-23-016jPharmacotherapy in pregnancy and breastfeeding :
Clinical database
P. Mohr1, D. Hnidek1, J. Hanka1, T. Melicher1. 1Prague Psychiatric
Center, Praha 8, Czech Republic
Objective : Decision on drug treatment of mental disorders in preg-
nancy and breastfeeding poses a clinical problem. Psychiatrists have
to weigh the potential risks of drugs for the fetus and infant versus
known risks of untreated disorder. Treatment discontinuation during
pregnancy frequently results in a relapse of mental illness. Controlled
clinical trials provide little guidance ; females of fertile age are rarely
included in the early phases of clinical testing, the Phase IIb and III
trials have a standard provision to use a reliable contraception.
Pregnancy during drug trial is considered as a ‘serious adverse event’
with subsequent study discontinuation. The available information on
teratogenic eﬀects, neonatal toxicity, withdrawal symptoms, or long-
term neurobehavioral eﬀects of drugs on fetus and infant is based
mostly on anecdotal case vignettes, case series, drug registries, and
epidemiological studies.
Methods : In the Prague Psychiatric Center, a specialized outpatient
clinic for treatment of mental disorders in pregnancy and lactation
was established in 2005. The Clinic provides treatment, counseling,
and consultation services. We present an overview of our clinical
experience and summarize treatment recommendations.
Results : Our clinical database currently includes 148 patients (54%
diagnosed with anxiety disorders, 24% psychotic, 9% depressive,
7% bipolar, 5% personality disorders, and 1% behavioral syndromes.
Approximately 20% pregnant patients were without drug treatment.
Clinical complications were observed in 14% cases. Experience
with administration of psychotropic drugs and the most frequent ad-
verse outcomes are reviewed, including the use of alternative non-
pharmacological interventions (psychotherapy, ECT, rTMS).
Conclusion : In general, monotherapy is recommended, changes in
prescription should be avoided. Preferred are drugs with low number
of metabolites, higher protein binding aﬃnity and low potential for
drug-drug interactions. Our results support the notion that the cau-
tious use of psychotropic drugs in pregnancy and breastfeeding may
be associated with a low number of drug-induced complications.
Supported by the research project MZ0PCP2005.
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jP-23-017jComparison of pharmaceutical treatment in patients
hospitalised in diﬀerent acute departments of
psychiatric hospital of Attica
C. Touloumis1, P. Ntounas1, C. Tsopelas1, C. Marmarinou1,
S. Dimaki1, I. Gogolakis1, M. Chronopoulou1, M. Dimitraka1,
S. Stamou1, A. Konsta2, A. Douzenis3, E. Rizos1, D. Pappas1,
C. Mokas1, A. Paraskevopoulou1, P. Chatzimanolis1, A. Vasiliou1,
E. Siouti1. 1Psychiatric Hospital of Attica, Athens, Greece ; 21st Dept. of
Psychiatry, Aristotle University of Thessaloniki, Greece ; 32nd Dept. of
Psychiatry, National and Kapodistrian, Athens, Greece
Objective : Despite the constant recommendations for avoiding anti-
psychotic polypharmacy and the absence of a convincing reasoning in
such pharmaceutical treatment, the combination of antipsychotic
drugs remain a common and widespread practice. The aim of this
audit is calculating the prevalence of polypharmacy in hospitalized
patients, and ﬁnding out if there are any diﬀerences concerning
medication options among the 9 acute departments of Psychiatric
Hospital of Attica.
Methods : Participants (423 inpatients) were selected randomly
among the 9 acute departments of Psychiatric Hospital of Attica. The
statistical program SPSS was used in the analysis.
Results : Participants (423 inpatients) had the following character-
istics : Age of 45.9 years on average (SD=13.1), 60.8% males, 63.7%
involuntarily hospitalized, onset age of disease 28.4 years (SD=12.1),
with a diagnosis of schizophrenic disorder in 72.1%, bipolar disorder
in 16.8%, and depression in 11.1%. Use of illegal substances in 18.7%
with cause of hospitalization : destructive or self-destructive behav-
iour in 24.3%, disease recurrence in 46.1%, and discontinuation of
drug treatment in 27%. During their hospital admission, their ag-
gressiveness decreased to 22.9% with verbal aggression estimated to
be the main type (14.4%). 41.9% of patient treatment involved more
than one antipsychotic. Despite the similar proﬁles of patients hospi-
talized in diﬀerent acute departments of the Psychiatric Hospital of
Attica revealed great diﬀerences concerning the treatment options
and the use of multiple concomitant formulations.
Conclusion : There is a concern about the balance between the risks
and the beneﬁts of polypharmacy in psychiatry. The combination of
several drugs should be the last option for treatment of resistant
psychiatric disorders. In future, prospective observational studies on
this issue should be conducted among the diﬀerent acute departments
of the Psychiatric Hospital of Attica in order to decide about the best
practices for the treatment of mentally ill patients.
jP-23-018jMedication used in aggression in a sample of
involuntarily hospitalized patients at the psychiatric
hospital of Attica
C. Touloumis1, P. Ntounas1, C. Tsopelas1, D. Pappas1, S. Stamou1,
P. Chatzimanolis1, A. Konsta2, E. Rizos3, A. Paraskevopoulou1,
S. Dimaki1, A. Douzenis3, A. Vasiliou1, C. Mokas1, M. Dimitraka1,
D. Dimitriadis1, M. Chronopoulou1, I. Gogolakis1, C. Marmarinou1,
E. Siouti1. 1Psychiatric Hospital of Attica, Athens, Greece ; 21st Dept. of
Psychiatry, Aristotle University of Thessaloniki, Greece ; 32nd Dept. of
Psychiatry, National and Kapodistrian, Athens, Greece
Objective : Violent behavior and psychiatric disorder such as schizo-
phrenia seem to be strongly associated with the involuntary hospita-
lization in the mind of people outside the mental health system. The
aim of the present research is to study the choice of pharmaceutical
drugs in patients who were involuntarily hospitalized in the psychi-
atric hospital of Attica and have exhibited aggression or/and violent
behavior while either arriving to the emergency department of the
hospital or throughout their hospitalization.
Methods : Data collection was made by randomly selected 532
patients who were involuntarily hospitalized in the psychiatric hos-
pital of Attica from 01/08/08 to 03/09/10. The statistical program
SPSS was used for the data analysis.
Results : Our sample consists of 532 patients, mean age 43.64 yrs
(SD=13.7), 64.3% male, 63.3% of which diagnosed with the schizo-
phrenic spectrum disorders, 10.8% with bipolar disorder, 5.1% with
depression and 24.1% with other diagnoses. Our research showed
that 92.7% of the patients were escorted by the police, while 1.1% was
escorted by an ambulance, and 6.2% by relatives. That wasn’t justiﬁed
by the absence of any kind of aggression in 46.4% of them, as 12.6%
were in need to be placed under protective restrain. In 32.7% of them
typical antipsychotics were administered, in 59.4% of them atypical
antipsychotics were used and in 5.1% of the patients a combination of
both typical and atypical antipsychotics. There was a need to admin-
ister intramuscular antipsychotics in 34.4% of our sample.
Conclusion : In patients who are hospitalized involuntarily, have
no capacity to decide for their self and show increased aggression, the
need for intramuscular antipsychotic drug treatment and protective
restrain is decreased after their involuntary admission in the hospital.
jP-23-019jTinnitus co-morbid with insomnia : A signiﬁcant
interrelationship and implications
G. Asnis1, K. Majeed2, M. Henderson1, R. De La Garza3. 1Monteﬁore
Medical Center, Bronx, USA ; 2Temple University Hospital, Philadelphia,
USA ; 3Baylor College of Medicine, Bronx, USA
Objective : Tinnitus is a prevalent medical disorder (10–20%), fre-
quently resulting in compromised daily-life functioning and insomnia
(Langguth, 2010). We hypothesized that tinnitus and co-morbid in-
somnia (symptom and diagnosis) negatively eﬀect each other leading
to added distress. Our paper will review the tinnitus co-morbid
literature and present our prospective tinnitus study evaluating this
co-morbidity.
Methods : 14 studies evaluating insomnia in tinnitus were reviewed
addressing the criteria of insomnia used (symptom vs. diagnosis), the
questionnaire utilized, etc. In addition, we screened 72 prospective
patients responding to an advertisement for a tinnitus treatment
study. We used a semi-structured questionnaire addressing issues of
tinnitus (e.g. constant vs. intermittent), speciﬁc sleep disturbances,
daytime functioning, and total sleep time. Diagnosing insomnia fol-
lowed ICSD-2 and DSM-IV-TR criteria.
Results : 14 studies were reviewed examining co-morbid insomnia ;
unfortunately, only the prevalence of insomnia symptoms (versus a
diagnosis) was presented (19%–79%). Most only asked whether tin-
nitus disturbed a patients’ sleep while a few assessed a full range of
sleep disturbances. Our tinnitus sample consisted of 72 subjects ;
69.4% endorsed at least 1 insomnia symptom (See Tables 1 and 2 for
demographics and speciﬁc sleep disturbances). 59.7% had a diagnosis
of insomnia secondary to tinnitus. Tinnitus patients with co-morbid
insomnia had a more severe illness, e.g., bilateral vs. unilateral
tinnitus.
Conclusion : Although previous studies found that insomnia was
frequently co-morbid with tinnitus (19–79%), they were inadequate
asking as few as 1–3 insomnia questions. They only identiﬁed in-
somnia as a symptom and did not clarify whether insomnia as a
diagnostic category existed. Our current study provided for a more
in-depth evaluation of insomnia. Our data conﬁrmed that not only is
insomnia a prevalent co-morbid symptom-70%- but is also a preva-
lent co-morbid diagnosis in approximately 60% of tinnitus patients.
Furthermore, co-morbid insomnia was associated with more severe
tinnitus. Implications of this possible bidirectional interrelationship
will be discussed.
Policy of full disclosure : Consultant, Bristol-Myers Squibb
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jP-23-020jExploding head syndrome – case study and
therapeutic approaches
B. Buda1, G. To´th2. 1Private Practice for Neurology, Szombathely,
Hungary ; 2University of West Hungary, Savaria Campus, Szombathely,
Hungary
Objective : Exploding head syndrome (EHS) is a relatively rare type
of parasomnias characterised by a sense of an explosive loud banging
noise in the head usually in the twilight stage of sleep. The sudden
awakening due to this loud noise shortly after falling asleep is oc-
casionally accompanied by the sensation of a ﬂash light. Abrupt
electroencephalographic and electromyographic changes during
polysomnography indicate suddenly increasing alertness in stage
N1 or stage N2 sleep at the time of the attacks. Although EHS attacks
are usually quite painless, however, they may precede migraines in
certain cases.
Methods : The authors present the case of a 47-year-old female
patient suﬀering for EHS attacks for 4 years. The painless attacks were
characterised by auditory sensations as if noisy lorries would quickly
pass by. In roughly one third of the cases sparking ﬂash light was
simultaneously perceived. After a sudden awakening palpitation
and excessive sweating was often reported by the patient. However,
migraine or other type of headache has never been related to the
attacks.
Results : EHS patients are mostly reported to require getting re-
assured about the benign nature of the rush. Beyond that, treatment
with clomipramine is suggested by some authors. Thus, in our case
75 mg clomipramine has been administered as a ﬁrst therapeutic ap-
proach. Due to disturbing adverse eﬀects (blurred vision, drowsiness,
and constipation), however, clomipramine medication had to be
ceased and topiramate therapy (50 mg in the evening) has been
gradually launched. From the third week of the treatment on, no EHS
attacks could have been observed any more.
Conclusion : The aetiology of EHS is still unclear. A detailed
analysis of polysomnographic data could probably help in under-
standing the underlying pathophysiology. The plausible link to mi-
graine may encourage clinicians to choose new therapeutic strategies,
administering for example topiramate or some other second- or third-
generation antiepileptic drugs.
jP-23-021jElevated levels of serum plasminogen activator
inhibitor-1 are associated with moderate to very
severe sleep disturbances in individuals with a
history of elevated depressive symptoms
S. Lehto1, A.-P. Elomaa2, L. Niskanen2, H. Koivumaa-Honkanen2,
K. Honkalampi2, M. Valkonen-Korhonen2, K.-H. Herzig3,
H. Viinama¨ki2. 1Kuopio University Hospital, Finland ; 2Kuopio, Finland ;
3Oulu, Finland
Objective : Plasminogen activator inhibitor type 1 (PAI-1) is an acute-
phase reactant and an inhibitor of intravascular ﬁbrinolysis, and its
increased levels lead to pathological intravascular ﬁbrin deposition
(Aso, 2007). Elevated PAI-1 levels have been reported to associate
with sleep-disordered breathing, but not with self-reported sleep
quality (Matthews et al., 2010). Furthermore, depressive symptoms
also modulate PAI-1 levels (Lahlou-Laforet et al., 2006). We sought
to examine the association between sleep disturbance and the serum
levels of PAI-1 in a population-based sample with a history of elev-
ated depressive symptoms.
Methods :A total of 136 general population study participants, who
reported elevated depressive symptoms (Beck Depression Inventory
(BDI)<9 ; Beck et al., 1961) at least once during the earlier study
phases (1998, 1999, or 2001), participated the clinical part of the study
in 2005. They rated their sleep disturbances as none or mild and oc-
casional (n=90) vs. moderate to very severe (n=46), and provided
data on socioeconomic status and lifestyle. They were also examined
to diagnose metabolic syndrome. Circulating PAI-1 levels were ana-
lysed with a human serum adipokine LincoPlex kit using a Bio-Plex
Suspension Array System.
Results : Individuals with moderate to very severe sleep disturb-
ance had elevated levels of PAI-1, and each 1 standard deviation in-
crease in the level of PAI-1 was associated with an almost doubled
likelihood of belonging to the disturbed sleep group (OR 1.91, 95% CI
1.22–2.98, p=0.004) in a logistic regression model adjusted for age,
gender, BDI scores and metabolic syndrome. No diﬀerences between
the sleep disturbance groups were observed with regard to socio-
economic or lifestyle variables.
Conclusion : Elevated circulating levels of PAI-1 were indepen-
dently associated with disturbed sleep, which may lead to increased
vulnerability to adverse vascular events in this group.
jP-23-022jEﬀect of valerian on sleep quality in menopausal
women : A randomized placebo-controlled
clinical trial
S. Taavoni1, N. Nazem Ekbatani1, H. Haghani1. 1Tehran University of
Medical S., Islamic Republic of Iran
Objective : Sleep problems, can lead to low quality of life in
Menopausal women. There are a wide variety of pharmacologic and
non- pharmacologic methods for solving it. Some of Herbal Medicine,
which have low side eﬀect, may be useful for management of sleep
disturbance during this time. Aim : To evaluate eﬀects of valerian ex-
tract on improvement of sleep quality in menopause women.
Methods :Material and Methods : In this randomized, triple- blind,
controlled trials 100 volunteer menopause women with age 50–60,
who had insomnia and selected from 250 volunteers, had been visited
in Public clinics of West of Tehran. Instrument includes demographic
form and Pittsburg sleep quality index (PSQI). Samples randomly
divided to two groups. Each group received twice a day for four
weeks 530 mg of concentrated Valerian extract or 50 mg Starch as
placebo in capsules.
Results : Equality of personal characteristics and sleep quality be-
fore intervention were checked and there were no diﬀerences in
two groups. Valerian led to signiﬁcant decrease in average of PSQI
in compared to placebo (Valerian before intervention : 9.8¡3.6, after
one month intervention : 6.02¡2.6) (Placebo before intervention :
11.14¡4.3, after one month intervention : 9.4¡3.9) (p=0.000). Also
30% of valerian group and 4% of placebo group had important im-
provement in sleep quality, which was decreasing of 5 score of PSQI.
There were signiﬁcant diﬀerence between two groups (p=0.00).
Conclusion : Findings from this study add to the scientiﬁc evidence
that support use of valerian in the clinical management of insomnia
especially in menopausal women.
Policy of full disclosure : Acknowledgments : This study is sup-
ported by Vice Chancellor for Research of Tehran University of
Medical Sciences, Year 2010–2011.
jP-23-023j Insomnia and ADHD self-reported symptomatology :
A comparison in adult ADHD and chronic insomnia
likely individuals
B.I. Voinescu1, A. Szentagotai1, J. Thome2. 1Babes Bolyai University,
Cluj-Napoca, Romania ; 2Rostock University, Germany
Objective : To compare self-reported sleep parameters and quality in
individuals likely to suﬀer from adult attention deﬁcit hyperactivity
disorder (ADHD) and insomnia disorder.
Methods : We conducted a web-based survey with a battery of
tests consisted in Sleep Condition Indicator (SCI), Sleep Disorders
Questionnaire (SDQ), Sleep Timing Questionnaire (STQ), Adult
ADHD Self-Reporting Scale (ASRS) and Barkley Adult ADHD Self-
Reporting Scale (BAARS-IV). About six hundred participants were
recruited from psychology students (in two cities) and from general
population across Romania via adverts in mass media. We identiﬁed
46 participants likely to suﬀer from ADHD (mean age 27¡10.32) and
60 individuals likely to suﬀer from insomnia disorder (without co-
morbid ADHD, average age 32.35¡13.52). Less than 30% were men.
Results : ADHD likely reported signiﬁcant later going to bed and
going out of bed times (particularly in a rest day), as well as shorter
sleep durations (n.s.) Insomnia likely reported signiﬁcantly more fre-
quently needing more than 45 minutes for falling asleep and being
awake for more than 45 minutes per night. Ten ADHD likely (21.7%)
met the criteria for comorbid insomnia disorder, too. Higher scores in
impulsivity (rho=x.410) and inattention (rho=0.488) were signiﬁ-
cantly linked with poor sleep in ADHD group only.
Conclusion : While not as severe, insomnia is common in ADHD
likely and appears to be linked positively with inattention and nega-
tively with impulsivity.
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jP-23-024jREM-sleep behavior disorder in psychiatry- a case
control study
Y.K. Wing1, S.P. Lam1, J. Zhang1, S.X. Li1, J. Tsoh1, C.K. Wah Ho1,
V. Mok1, A.Y. Chan1. 1Chinese University of Hong Kong, Hong Kong
SAR, China
Objective : REM sleep behavior disorder (RBD) is a sleep disorder
characterized by loss of normal REM-related muscle atonia with en-
actment of violent dreams and sleep-related injury. In recent years,
RBD variants have been reported in young population, women and
psychiatric population. While early case reports suggested that RBD
symptoms in psychiatric patients were secondary to antidepressant
treatment, we found that the lifetime prevalence of RBD symptoms in
psychiatric out-patients was 5.8% and the risk of developing RBD
symptoms among those taking selective serotonin reuptake inhibitor
(SSRI) was only 1 out of 20.
Methods : This is a case-control study, aimed at establishing
the clinical and polysomnographic features of RBD in psychiatric
populations. Two age-, sex-matched control groups were selected :
1) one from psychiatric clinic (also psychiatric diagnosis matched)
and 2) healthy control from general population. All cases and con-
trol subjects undergo standard measurements, including self-
reported questionnaires, structural clinical interviews, overnight
polysomnography, neuro-cognitive tests and neurological exam-
inations.
Results : 40 subjects were recruited for each arm. (Total number of
subjects : 120). Results showed that patients with RBD reported more
core features of RBD, including nightmares, dream enactment and
resultant sleep-related injury. They also scored higher marks in anxi-
ety scale (p<0.05) when comparing with the controls. For the PSG
features, the cases had a higher REM-related muscle activities and loss
of REM related muscle atonia (p<0.05). Despite there was no signiﬁ-
cant diﬀerence over the use and dosage of antidepressants between
the cases and psychiatric control group, the cases still had a signiﬁcant
higher degree of loss of REM atonia. (p<0.01).
Conclusion : This study suggested that RBD exists in psychiatric
populations and antidepressant per se could not fully account for the
clinical and polysomnographic features.
jP-23-025jAlcohol use among Indigenous group in Gombak,
Malaysia
R. Abd Rashid1, M. Munir1, W.A. Irnee Wan husin1, U.A. Silim2, H.
Habil3, A.K. Abdul Razak1, A. Jazaeri1. 1University of Malaya,
Selangor, Malaysia ; 2Ministry of Health, Selangor, Malaysia ; 3University
of Malaya, UMCAS, Selangor, Malaysia
Objective : To investigate the pattern of alcohol use and psychiatric
orbidity among the indiginous people in Malaysia and their psycho-
social correlates.
Methods : The cross sectional study conducted among 18 years
and above of 201 Orang Asli settlement in Tekala river village of
Gombak district, Malaysia in year 2010. We interviewed every third
house after house mapping procedures based on previous studies
using systematic sampling. The study was approved by the ethic
committee board of the University hospital. The alcohol use were
measured using ASSIST-BI and psychiatric comorbidity using MINI
Ver 5.0.
Results : The study population consist of 201 respondents from 76
households. The respondent mean age is 37.3 years, almost three
quaters are married, more than half are females and 84.1% are em-
ployed at the time of study. We found the lifetime and current
prevalence of alcohol use are 14.4% and 13.4% respectively. The
number of respondents fulﬁlled at least one psychiatric diagnosis is
4.0%. There was signiﬁcance negative correlation between Islamic
religion and alcohol use even after adjusted with gender and marital
status. However, there was no signiﬁcance correlation found between
psychiatric morbidity and alcohol use in this study.
Conclusion : The prevalence of alcohol use among orang
asli Gombak is higher as compared to the general population group
in Malaysia. Islamic religion seems to have protective factors
against alcohol use. There is a need for further study to proove the
causal relationship of Islamic religion and alcohol use in this popu-
lation.
jP-23-026jMass psychogenic illness-temporal spread and
containment- a south east Asian story
D. Bandyopadhyaya1, O. Prakash Singh2, G. Saha3. 1Manasij,
Burdwan, India ; 2 Institute of Psychiatry, Kolkata, India ; 3Brain Clinic,
Barasat, India
Objective : Mass hysteria, also known as mass psychogenic illness
(MPI), has been reported for hundreds of years in diﬀerent socio-
cultural settings. MPI has been characterized by a group of symptoms
that usually mimic an organic disease, but without any identiﬁed
cause, and occurs in those who share a common belief that those
symptoms constitute a deﬁnite illness.
Methods : Few months back in a wedding party in Jharkhand,
India, a lady had a sudden death and among the guests it spread that
the death was caused due to henna or mehendi poisoning. Henna is
used to colour the hands of the bride and other women during wed-
ding in India. This news spread more through mobile and sms service
than through mass media and a particular brand of henna was dis-
cussed as the cause. For the next 2 weeks more than 500 young women
were admitted in various hospitals and nursing homes across
Jharkhand and West Bengal with conversion symptoms similar to
poisoning.
Results : Recently in October 2010, there was an epidemic of Koro in
West Bengal which spread to Assam, Mumbai and Delhi which is an
area of more than 1500 km of epidemic like spread in temporal fash-
ion. The name Koro means ‘‘shrinking penis’’. Other local languages
in South-East Asia also have similar names for the condition. The
classic syndrome in South-East Asia is culture-bound and is char-
acterized by the belief that the penis is shrinking ; it will disappear
into the abdomen and it will cause death. These beliefs are ac-
companied by an intense fear and by preventive manoeuvres such as
tying, clamping or grasping the penis.
Conclusion : This poster addresses the issues on factors
aﬀecting the origin and spread of Mass Psychogenic Illness and its
containment.
jP-23-027jCaﬀeine counteracts impairments in task-oriented
psychomotor performance induced by
chlorpheniramine : A double-blind placebo-
controlled crossover study
J.-E. Jang1, S.-W. Kim1, K.-Y. Bae1, J.-M. Kim1, I.-S. Shin1, S.-H. Kim1,
B.-O. Jeong1, H.-J. Kang1, J.-S. Yoon1. 1Chonnam National University,
Gwangju, Republic of Korea
Objective : The combined eﬀects of chlorpheniramine and caﬀeine on
task-oriented psychomotor function have not been systematically
evaluated. This study aimed to evaluate the eﬀects of chlorphenir-
amine on psychomotor performance and the counteracting eﬀects of
caﬀeine on those sedative antihistamine actions.
Methods : Sixteen healthy young men participated in this study.
Using a double-blind placebo-controlled crossover design, each sub-
ject was administered one of the following conditions in a random
order with a 1-week interval : ‘placebo-placebo’, ‘chlorpheniramine-
placebo’, ‘placebo-caﬀeine’, or ‘chlorpheniramine-caﬀeine’. Before
and after the treatments, psychomotor functions were assessed using
a battery of tests. Additionally, subjective responses were assessed
using a visual analogue scale (VAS).
Results : Psychomotor performance changed over time in diﬀerent
ways according to the combination of study medications. In the
‘chlorpheniramine-placebo’ condition, reaction times of the com-
pensatory tracking task were signiﬁcantly impaired compared with
the other three conditions. In addition, the number of omission errors
of the continuous performance test were signiﬁcantly greater com-
pared with the ‘placebo-caﬀeine’ condition. However, the response
pattern of the ‘chlorpheniramine-caﬀeine’ condition was not signiﬁ-
cantly diﬀerent from that of the ‘placebo-placebo’ condition. Changes
of VAS for sleepiness were signiﬁcantly greater in the ‘chlorphenir-
amine-placebo’ condition compared with the other three conditions.
Blood pressures signiﬁcantly increased in conditions that included
caﬀeine compared with the conditions that did not.
Conclusion : Chlorpheniramine signiﬁcantly increases subjective
sleepiness and objectively impairs psychomotor reactions to a
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stimulus. However, caﬀeine counteracts these sedative eﬀects and
psychomotor impairments.
jP-23-028jPlants used in popular medicine for treatment of
atherosclerosis : The experience of Dhaka city
in Bangladesh
A.H. Mollik. Power Foundation Bangladesh, Bogra Sadar, Bangladesh
Objective : Today a person is very much preoccupied. Modern life-
style has contributed to serious increases in killer diseases like
atherosclerosis. Currently, most medications or therapies for treat-
ment of atherosclerosis have serious side-eﬀects, which sometimes
can be more life-threatening than the diseases itself. It is important,
therefore, to turn to plant sources for discovery of novel yet safe
compounds, which has less or no side-eﬀects to treat atherosclerosis.
We accordingly conducted a survey of several areas within Dhaka city
of Bangladesh to learn more about plants used by the traditional
medicinal practitioners to treat atherosclerosis.
Methods : Interviews were conducted with the help of a semi-
structured questionnaire and plant specimens as pointed by the
traditional medicinal practitioners were collected, deposited, and
identiﬁed at the Bangladesh National Herbarium.
Results : The plant names obtained in our survey included Morus
alba L., Coccinia grandis (L.) Voigt, Saccharum oﬃcinarum L., Bacopa
monnieri (L.) Pennell, Arachis hypogaea L., Terminalia arjuna (Roxb.
ex DC.) Wight & Arn., Abrus precatorius L., Withania somnifera (L.)
Dunal, Maranta arundinacea L., Allium sativum L., Zea mays L.,
Psidium guajava L., Sorghum bicolor (L.) Moench, Cicer arietinum L.,
Hemidesmus indicus (L.) R. Br., Swertia chirata (Wall.) C. B. Clarke,
Nigella sativa L., Ocimum tenuiﬂorum L., Carica papaya L., Aloe vera
(L.) Burm F., Euphorbia thymifolia L., Citrullus vulgaris Schrad.
ex Eckl. & Zeyh., Cocos nucifera L., Prunus communis (L.) Arcang.,
Olea europaea L., Strychnos nux-vomica L., Aegle marmelos (L.)
Correˆa, Ficus racemosa L., Rosa achburensis Chrshan., Punica grana-
tum L., Vitis vinifera L., Sterculia foetida L., and Cinnamomum verum
J. Presl.
Conclusion : Since the Dhaka city patients appeared to be generally
satisﬁed with the treatment oﬀered through these plants, it is im-
portant to conduct proper scientiﬁc studies towards discovery of
compounds of interest in these plants, which can be used as safe and
eﬀective medicines.
jP-23-029jManic episode after malaria prophylaxis with
meﬂoquine : Case report
F. Oueriagli Nabih1, M. Touhami1, l. Abilkassem1. 1Military Hospital
Avicenne, Marrakech, Morocco
Objective : Meﬂoquine (Lariam) is the drug of choice as malaria
prophylaxis for travel to countries with chloroquine-resistant malaria.
Severe Neuropsychiatric side eﬀects are rare. We report a clinical case
of mood disorders : manic episode with psychotic characteristics in a
patient with meﬂoquine antimalarial prophylaxis.
Methods : A 31 years old man has taken Meﬂoquine at a rate of
250 mg /week as malaria prophylaxis for his mission in Democratic
Republic of Congo. He developed mania with psychotic symptoms
after taking 5 tablets of 250 mg of Meﬂoquine. He was very unstable ;
he exhibited an elevated mood and also developed delusions of
grandeur, reference and persecution, with auditory hallucinations.
The physical examination and the blood laboratory tests were
normal. The patient was treated with atypical neuroleptic (olanzapine
20 mg/d) giving a complete resolution of symptomatology at the end
of 3 weeks.
Results : Meﬂoquine is widely accepted as a safe and eﬀective
treatment and a prophylactic agent for cholorquine- resistant malaria.
Common Neuropsychiatric sequelae of meﬂoquine can occur in up to
40% of patients. Other more serious adverse reactions are rare. they
are represented primarily by attacks of panics, acute psychosis, sui-
cidal ideation, disorders of mood : major depressive episode and the
excitation maniac. The incidence of such neuropsychiatric eﬀects is 1/
10 000 to 1/15 000 during the prophylactic treatment. The causal
mechanism for the side eﬀects is not known. Several risk factors in-
creasing the neurotoxicity of meﬂoquine can be identiﬁed, the patient
with personal or familial antecedents of psychiatric disorders are
more frequently concerned. Alcohol and the association with other
drugs (like quinine ) are two other risk factors.
Conclusion : It is pertinent for medical practitioners to be aware of
the severe neuropsychiatric side eﬀects of meﬂoquine as malaria
prophylaxis. It requires to investigate the risk factors such personnal
or familial history of psychiatric disorders.
jP-23-030jCriminal poisoning with scopolamine and
psychiatric symptoms
K. Parra1, G. Oviedo1, F. Mun˜oz1, J. Vengoechea1. 1Clı´nica Nuestra
Sra de la Paz, Bogota, Colombia
Objective : In Colombia and other Latin American countries, in-
toxications with delictive intention are common in the emergency
room of general and psychiatric hospitals and scopolamine is a sub-
stance frequently used. The present work aims to identify psychiatric
symptoms secondary to criminal anticholinergic poisoning in exposed
patients victims of theft.
Methods : Analysis of two cases and literature review.
Results : The ﬁrst patient was evaluated in the emergency depart-
ment during the ﬁrst 24 hours of intoxication and the second one was
evaluated two months later, in both cases we applied the Minimental
State Examination (MMSE), Hamilton Rating Scale For Anxiety and
the Hamilton Rating Scale for Depression as well as a narrative
description taken from several interviews. These patients had no
previous psychiatric history. The ﬁrst case showed a severe cognitive
impairment in Minimental test scoring 18/30, additional identiﬁ-
cation of depressive and anxiety symptoms was found on the scales.
The second case was evaluated two months later and we found simi-
lar scores in the Minimental (MMSE) and in the scales for anxiety and
depression.
Conclusion : Scopolamine- induced deﬁcits in cognitive and motor
processes have been widely demonstrated in animals and humans,
although the role of acetylcholine in working memory is not well
understood. There is little information in the current literature about
psychiatric symptoms related to criminal anticholingergic poisoning
that can occur with scopolamine, antihistamines, tricyclic anti-
depressants, antiparkinsonian agents and fenotiazines among others.
From the neuropsychiatric point of view, descriptions of changes are
evident at the level of memory besides aﬀective symptoms, therefore
protocols for collaborative care that include an integrative approach
are required for patients aﬀected with delictive intoxication.
jP-23-031jThe lithium archives project : The role of lithium in
the protection of neurodegenerative and
cardiovascular disease
R. Fieve1, M. Gilbert2, B. Orlowski3, M. Oliva4. 1Columbia University,
New York, USA ; 2Foundation for Mood Disorders, New York, USA ;
3New York Medical College, USA ; 4New York University, USA
Objective : Since the 1950’s Lithium has been used in the successful
treatment of bipolar disorder. Advancements in neuroscience suggest
that Lithium increases gray matter volume and therefore may also
have neuro-protective properties. Lithium has also been shown to
have a low incidence of suicide attempts when compared to other
medications but little exists in the literature showing any relationship
between lithium and cardiovascular disease. The Lithium Archives
Project is based on systematic chart reviews of over 8,000 patients
treated at the New York State Psychiatric Institute, Columbia
University and the Foundation for Depression and Manic Depression
over the past 40 years. This is a retrospective naturalistic study which
includes over 100 variables that can be analyzed collectively or
autonomously.
Methods : The Lithium Archives Project is a retrospective, random
electronic chart review conducted by a research scientist. Patient
charts are examined for over 100 variables including neurological and
cardiovascular diseases, eye disorders, medication history, side ef-
fects, demographics and patient histories. The current sample of over
800 charts was analyzed by a statistician using standard SPSS stat-
istical software. Mean, standard deviation and signiﬁcance of cere-
brovascular disease, myocardial infarction, brain tumors, stroke, and
seizures of patients treated with lithium and patients treated without
lithium were compared and analyzed. Multivariate analysis was
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performed to analyze group (lithium/no lithium) and incidence of
disease. The means of disease incidence in the lithium versus non-
lithium groups were then charted.
Results : Analysis of the current data shows that group is a signiﬁ-
cant variable in the incidence of diseases analyzed (Pillai’s Trace
F=2.926, df=11.416, p=0.004). The patients treated with lithium
show less incidence of myocardial infarction (p=0.014), seizures
(p=0.091, stroke (p=0.014) and brain tumors (p=0.072).
Conclusion : The current analysis indicates that in this patient
population, lithium may have played a role in protection from de-
veloping both cardiovascular and neurodegenerative diseases.
jP-23-032j In utero exposure to lithium, fetal biometry and
neonatal outcomes
M.L. Imaz1, A. Gonzalez2, G. Marin3, G. Espanyol3, D. Hidalgo2,
M. Garcia2, E. Roda2, C. Herna´ndez4, A. Torres5, L. Garcia-Esteve2.
1Hospital Clı´nic, Barcelona, Spain ; 2Hospital Clı´nic, Department of
Psychiatry, Barcelona, Spain ; 3Consorci Sanitari Terrassa, Department of
Psychiatry, Spain ; 4Hospital Parc Taulı´, Parc Taulı´ 1, Sabadell, Spain ;
5Hospital Clı´nic, Department of Psychology, Barcelona, Spain
Objective : To determine the eﬀect of in-utero exposure to lithium on
fetal biometry and neonatal outcomes.
Methods : Prospective observational study including 18 pregnant
women on maintenance treatment with lithium alone (n=13) or
polytherapy (n=5) during late pregnancy, which were treated at the
Perinatal Psychiatry Program CLI´NIC between 2007 and 2011. We
evaluated sociodemographic data, lithium plasma concentrations
in maternal blood and umbilical cord, fetal biometry and neonatal
outcomes.
Results : Women did not fulﬁll diabetes or obesity criteria pre-
pregnancy and during pregnancy. Mean maternal age (SD) 32.71
(4.02), 66% primiparaes, 95% Caucasian and 100% married or with
partner. Tetuses exposed to lithium had a mean (SD) waist circum-
ference of 291.84 mm (18.1), which was lower than those exposed to
polytherapy [317.8 mm (27.93)]. Statistical signiﬁcant diﬀerences were
not found (p=0.055) ; fetuses exposed to lithium had a mean femur
length of 62.69 mm (3,82) compared to polytherapy that had a femur
length of 69 mm (5.15), which was statistical signiﬁcant (p=0.018).
Estimated fetal weight by percentile, adjusted for sex and gestational
age, was higher in the polytheraphy group compared to lithium
monotherapy [61.62 (32.16) vs. 78.00 (27,94)], but it did not have
clinical signiﬁcance. Infant exposed to polytherapy had on average a
higher birth weight (3773.3 vs. 3079.6), but not in terms of percentile.
They had higher gestational age (40 vs. 38.29 weeks), were longer
(51.8 vs. 48, 89 cm), had increased head circumference (35.6 vs. 33.43).
There not were diﬀerences in umbilical cord/maternal plasma lithium
levels in both groups (0.95 vs. 0.98).
Conclusion : Lithium crosses the placental barrier almost com-
pletely. The fetuses that were exposed to lithium had a lower waist
circumference and femur length, lower weigth, gestational age and
head circunference compared to polytherapy group. Foetal growth
surveillance is recommended in pregnancy.
jP-23-033jThe relationship between temperament and the
eﬃcacy of lamotrigine augmentation therapy for
refractory depression
S. Kagawa1, K. Nemoto1, T. Suzuki1, G. Nagai1, A. Nakamura1,
K. Mihara1, T. Kondo1. 1University of the Ryukyus, Okinawa, Japan
Objective : We showed that lamotrigine (LTG) augmentation
was eﬀective for the treatment of treatment-resistant mood
disorder (TRMD). The combined model of the brief version of the
Temperament Evaluation of Memphis, Pisa, Paris and San Diego-
autoquestionnaire (TEMPS-A), which assesses 5 aﬀective tempera-
ments (depressive, cyclothymic, irritable, hyperthymic and anxious)
and the Munich Personality Test (MPT), which examines other 2 per-
sonality traits (schizoid and melancholic), is suggested to be an useful
pretreatment tool for the screening of baseline temperaments without
a time-consuming interview process. This study investigated the
relationship between therapeutic response to LTG augmentation treat-
ment and the patients’ temperamental features assessed by TEMPS-
A/MPT in TRMD.
Methods : The subjects were 39 depressive patients who had
already shown insuﬃcient response to at least 3 antidepressants or
mood stabilizers despite enough therapeutic doses and durations.
LTGwas added to the ongoing antidepressants or mood stabilizers for
8 weeks. The daily dose of LTGwas titrated by the clinician’s decision.
Treatment response was assessed by MADRS before and after the
8-week treatment. Responders were deﬁned as 50% or more symptom
reduction from baseline, and complete remitters were deﬁned as less
than 4 of MADRS score for more than 2 weeks. The TEMPS-A/MPT
was administered to the subjects.
Results : Twenty (51%) patients were responders, and 5 (13%) of
them were complete remitters. 19 (49%) were non-responders. There
were no signiﬁcant diﬀerences in the 7 temperaments between re-
sponders and non-responders.
Conclusion : The present result suggests that therapeutic response
to LTG augmentation in TRMD cannot be predicted by the patients’
temperaments by using the TEMPS-A/MPT.
jP-23-034jThe eﬀect of valproic acid on excessive dopamine
release in the amygdala in response to conditioned
fear stress : An in vivo microdialysis study in
methamphetamine-sensitized rats
M. Kawano1, K. Inada2, H. Muraoka2, T. Kawano2, H. Oshibuchi2,
J. Miyagi2, A. Kasai2, J. Ishigooka2. 1TWMU, Shinjuku-Ku Tokyo,
Japan ; 2TWMU, Department of Psychiatry, Shinjuku-Ku Tokyo, Japan
Objective : Emotional hypersensitivity in handling the event may
play a role in patients with schizophrenia, therefore, it is meaningful
to study dopamine dynamics in the amygdala. In our series of studies,
we have found that dopamine release in amygdala was increased
signiﬁcantly higher in the methamphetamine (MAP)-sensitized rats
than in un-sensitized ones under conditioned fear stress application.
The hypersensitivity of dopamine release was considered to be a
biochemical marker of vulnerability to psychosis. We also demon-
strated this excessive dopamine release was inhibited by anti-
psychotics (Oshibuchi et al., 2009). Meanwhile, valproic acid (VPA) is
used for augmentation therapy, in the treatment of schizophrenia and
other emotional disorders. But there is no biochemical evidence of
the diﬀerence of pharmacological eﬀect on psychological stress.
Therefore, in order to examine the diﬀerential eﬀect between VPA and
antipsychotic agents on fear response, the eﬀect of VPA on the basal
dopamine release and on dopamine response to the conditioned stress
in amygdala in this model rats was measured.
Methods : Male Sprague-Dawley rats were used. Rats were
administrated 2 mg/kg/day of MAP for 10 days to develop MAP-
sensitization. The fear conditioning was conducted to develop
psychological stress. Dopamine changes to conditioned fear stress
in amygdale were measured by microdialysis and high-performance
liquid chromatography (HPLC).
Results :As a result, VPA showed similar eﬀect to antipsychotics on
dopamine dynamics in amygdala.
Conclusion : Our results exhibit the partial mechanism of VPA in
dopamine change in amygdala of emotional disorders.
jP-23-035jPrescription of mood stabilizers : Lithium vs.
valproate – what clinicians expect for them
T. Owashi1, H. Tanaka1, M. Hida2, G. Minegishi1, T. Tamura1,
S. Yokoyama2, I. Kudo1. 1Showa Univ. Fujigaoka Hospital, Yokohama,
Japan ; 2Showa Univ. Northern Yokohama, Japan
Objective : Although both lithium and valproate are used as classical
mood stabilizer, the real world prescriptive condition is not well
known. Our study aimed to explore how common the use of lithium
and valproate in psychiatric conditions of Japanese outpatients and to
describe the diﬀerence of characteristics of the patients. Because
Japanese Society of Mood Disorders described the guideline for bi-
polar disorder in 2011, we surveyed the patients before 2011 to ex-
clude the inﬂuence of the guideline.
Methods : We investigated prescriptions for lithium and for
valproate given for psychiatric conditions to the ﬁrst visit from 2005
till 2010 in Showa University Fujigaoka Hospital, Japan. Psychiatrist
who sees new outpatients changed depending on the day of the week.
DSM-IV and ICD-10 were used for diagnosis of psychiatric disorders.
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Clinical records were assessed retrospectively. As valproate is also
used as antiepileptic drug, subjects with diagnosis of epilepsy were
excluded from the analysis.
Results : The numbers of the patients with prescription of lithium
and valproate at the date of the ﬁrst visit were 39 and 48, respectively.
2 patients were prescribed both lithium and valproate. There was no
signiﬁcant diﬀerence of age and sex between the groups. Patients with
lithium prescription showed signiﬁcantly more frequency of diag-
nosis of bipolar disorder (rate of bipolar disorder : lithium 71.8% ;
valproate 31.3%, p<0.001). Among bipolar subjects, patients pre-
scribed lithium were signiﬁcantly younger compared with those
prescribed valproate (50.08¡16.82 years old vs. 63.62¡12.63 years
old, p=0.020).
Conclusion : Lithium appears to be more expected as mood stabi-
lizer for bipolar disorder rather than valproate in clinical practice.
jP-23-036jThe transcultural concept of epilepsy in beliefs
M. Darghal. Medical Center Diour Jemaa, Rabat, Morocco
Objective : The prevalence of epilepsy is 1.1%. But despite the high
number of patients, epilepsy is still unknown and care is lacking.
The point about this disease too long remained mysterious.
Methods : Traditional beliefs reinforce the public on the idea that
epilepsy is a disease caused by evil spirits. Besides the names we give
this evil in language Moroccan dialect are revealing : jnoun, maskoun,
krina, msalmin, ladam, riah. Unfortunately these beliefs are behind
the delay in diagnosing the disease and hence the bad disease and
poor social integration of the patient. This is very expensive. The
stigma associated with epilepsy are very numerous. Sometimes
patients suﬀer much more than their disease. Sometimes it is claimed
that epilepsy is contagious, that patients with epilepsy are ‘‘abnor-
mal’’, dangerous or having mental retardation and even doors
misfortune.
Results : All these ideas are false and exacerbate the isolation
of patients with epilepsy. Epilepsy aﬀects people of all ages but
especially children and adolescents, and because of the weight of
prejudice and delay diagnosis, these patients outside the circuit of the
school, vocational training, and social life (marriage…) and are com-
pletely marginalized. The scientiﬁc advances in recent years, it is now
possible to improve the plight of epilepsy. The anxiety generated by
the onset of the crisis, can lead to emotional dependency relationships
with parents and inhibit the acquisition of emotional or intellectual
autonomy of a child or young person.
Conclusion : These diﬃculties autonomy may themselves be a
source of pain or symptoms (emotional immaturity, self disorders,
disturbances, aggressiveness) The loss of self-control during the crisis,
dependence with regard to others cause an injury which in turn,
aﬀects self-conﬁdence. Thus, the real trauma of the disease in addition
to the psychological trauma that deserves to be considered.
jP-23-037jSafety and eﬃcacy of sustained release lamotrigine
as monotherapy/add on therapy in the treatment of
epilepsy
V. Dixit. M.A. Medical College, New Delhi, India
Objective : Our aim was to determine the safety and eﬃcacy of the
LTG(SR) in Indian patients of epilepsy.
Methods : Total 20 patients were enrolled. All patients completed
the full (12 weeks) duration of the study. Patients in the age range
of 16–70 years with diagnosis of Epilepsy, as deﬁned in ICES were
selected. Patient-categories included were : Category-I : Newly diag-
nosed patients (h/o>2 seizures in last 3 months), Category-II :
Patients who did not achieve adequate seizure control (>4 seizures in
last six weeks) with other AED. Category-III : Patients who were
on Lamotrigine Conventional release (IR) formulation, followed by
exclusion criteria.
Results : LTGSR treatment reduced seizure frequency in all patient-
categories. Statistically signiﬁcant reduction in seizure frequency (per
4 weeks) was seen in patient-Category – II. QOLIE-31 total score also
signiﬁcantly improved, in each patient-category. No serious adverse
event (AE) was reported during the study.
Conclusion : It can be concluded that the LTGSR is safe and eﬀec-
tive in the Indian patients of Epilepsy. It oﬀers the advantage of a
better tolerability proﬁle as compared to conventional LTG. It also
oﬀers a safe switchablility from conventional preparation at the same
molar dose.
jP-23-038j Involvement of the nicotinic acetylcholine system in
the cognitive impairment induced by
electroconvulsive seizures in rats
N. Hidaka1, K. Suemaru1, H. Araki1. 1Ehime University Hospital,
Toon, Japan
Objective : Epilepsy is a chronic neurological condition characterized
by recurrent seizures. The seizures are frequently comorbid with
psychiatric disorders, including cognitive disorders. We recently re-
ported that seven consecutive electroconvulsive shock (ECS)-induced
seizures markedly impaired spontaneous alternation behavior in a
Y-maze test, indicating impairments in short-term working memory.
The involvement of the nicotinic acetylcholine system in these ECS-
induced behavioral impairments remains incompletely understood.
Methods : Wistar rats were administered ECS (100 V, 50 mA,
0.2 sec, 60 Hz) once daily for 7 days. The Y-maze test was conducted
24 h after the last ECS administration. Physostigmine, cholinesterase
inhibitor, 0.5 and 1 mg/kg ; anabasine, a7 nicotinic acetylcholine re-
ceptor (nAChR) agonist, 0.3 and 3 mg/kg ; and ABT-418, a4b2 nAChR
agonist, 0.1 and 0.5 mg/kg, were administered i.p. to ECS-treated rats
30 min before the test. For immunohistochemical analysis, a4 nicotinic
acetylcholine receptor-positive cells were quantiﬁed 24 h after the last
administration of ECS.
Results : ECS reduced spontaneous alternation behavior in the
Y-maze test as reported previously. Increasing acetylcholine levels
with physostigmine (0.5 and 1 mg/kg) prevented this impairment,
whereas a7 receptor activation by anabasine treatment had no sig-
niﬁcant eﬀect. The impairment of spontaneous alternation behavior
was signiﬁcantly improved by the a4b2 nAChR agonist ABT-418
(0.5 mg/kg). In addition, the ECS administration caused a reduction
in the number of a4 nicotinic acetylcholine receptor-positive cells in
the prefrontal prelimbic cortex and the hippocampal areas CA1 and
CA3, compared with the sham group.
Conclusion : These results suggest that impairment of the a4b2
nAChR underlies cognitive impairments induced by seizures, and
that the positive eﬀect of a4b2 nAChR activation on spontaneous
alternation behavior may be linked to the medial prefrontal cortex or
hippocampus.
jP-23-039jAssessement of comorbidity in post-neurosurgical
patients with epilepsy
D. Marazziti1, A. Caserta1, S. Baroni1, C. Nisita1. 1University of Pisa,
Italy
Objective : The depressive comorbidity in epileptic patients is more
frequent than in the general population and other chronic diseases.
In this cross-sectional study, we investigated the prevalence and
clinical features of interictal depressive symptomatology in a cohort of
neurosurgical patients.
Methods : The study was carried out in 54 post-neurosurgical epi-
lepsy patients (PNS), 53 with ‘no-postneurochirurgical ’ epilepsy
(NPNS) and 52 healthy control subjects. The majority of patients were
receiving antiepileptic monotherapy, and had no prior history of
mood disorders. Screening for depressive disorder (DD) was con-
ducted by means of a self-assessment scale, the CES-D (Center for
Epidemiologic Studies-Depression Scale), as validated in Italian, and
already used in similar studies.
Results : In the group of PNS the total score for the individual CES-
D scale value (mean+SD) was 12.15¡9.42. The 45.40% of patients
had a scor >16, indicative of DD. The total score on the individual
CES-D was 13.98¡8.90. The 54.55% of patients had a scor >16, in-
dicative of DD. In control subjects the total score on the individual
CES-D was 9.11¡5.3, with scores indicative of DD in 17.30% of cases.
A further stratiﬁcation of patients with satisfactorily controlled fre-
quency of seizures or less did not show any relationship with the
presence of DD.
Conclusion : The results of the study showed no diﬀerences in the
prevalence of comorbid interictal depression in neurosurgical
patients, according to the type of epilepsy. However, the prevalence of
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depression ranged between 45.40% and 54.55% of cases and suggest
the need for careful assessment of this comorbid condition in patients
with epilepsy.
jP-23-040jEnhancement of morphine-induced antinociception
by electroconvulsive shock
K. Iwata1, H. Yamamoto2, E. Kamegaya2, Y. Takamatsu2, N. Doi3,
K. Ikeda2. 1Tokyo Metropolitan Hiroo Hosp., Shibuyaku, Tokyo, Japan ;
2Tokyo Metropolitan Institute of Medical Science, Setagayaku, Tokyo,
Japan ; 3 Ibaraki Prefectural Medical Center of Psychiatry, Tomobe, Ibaragi,
Japan
Objective : Electroconvulsive therapy (ECT) is a widely used method
for treating drug-resistant depression and schizophrenia, and
reportedly has a positive eﬀect on neuropathic pain. Interestingly,
some studies have reported that an amount of opioid to relieve pain is
reduced after a series of ECT. In the present study, we administered
electro-convulsive shocks (ECS) to mice, since mice are supposed to
have a similar response pattern to ECS as humans have to ECT,
in order to clarify the eﬀect of ECT on morphine-induced anti-
nociception and to elucidate its mechanism.
Methods : Hot plate tests were performed to study morphine-
induced antinociception in mice that were treated with ECS 24 hours
before the administration of morphine.
Results : Results demonstrated that the dose-response curve for
morphine-antinociception in ECS-pretreated mice was shifted left and
the EC50 of morphine in ECS-pretreated mice was 30% decreased
compared to it in mice which were not pretreated with ECS.
Additionally, we administrated morphine twice with 24 hours inter-
val to develop an acute tolerance to clarify the eﬀect of ECS on the
tolerance. Mice pretreated with ECS 21, 23, and 25 hours before the
second administration of morphine did not develop acute morphine
tolerance, while those pretreated with ECT 1 to 6 hours before did.
Western blotting was performed with a speciﬁc antibody to detect
mu-opioid receptors in the thalamus. The expression level of
mu-opioid receptors was signiﬁcantly higher in the thalamus of the
morphine- and ECS-treated mice compared to that of the mice only
treated with morphine.
Conclusion : These results indicate that ECS may facilitate the
antinociceptive eﬀects of morphine and counteract the develop-
ment of a tolerance to morphine, possibly due to increased ex-
pression of mu-opioid receptors, suggesting that similar mechanisms
may underlie the eﬀect of ECT on opioid-induced analgesia in
humans.
jP-23-041jComparative characterization of ADX71653 and
ADX71943, novel CNS- and peripherally-targeted
GABAB receptor positive allosteric modulators
M. Kalinichev1, L. Tang1, I. Royer-Urios1, M. Schneider1, F. Girard1,
A. Bessif1, E. Riguet1, B. Bonnet1, S. Poli1. 1Addex Pharmaceuticals,
Geneva, Switzerland
Objective : There is evidence that the orthosteric GABAB agonist
baclofen has anxiolytic- and analgesic- like proﬁle, albeit showing
narrow therapeutic window, rapid onset of side-eﬀects, with signs of
tolerance, withdrawal and rebound. Here we compared eﬃcacy and
side-eﬀect proﬁles of a CNS-targeted GABAB positive allosteric
modulator (PAM) ADX71653 to that of a peripherally-targeted PAM
ADX71943.
Methods : Eﬃcacy of ADX71653 was evaluated in the mouse marble
burying (MB) test of anxiety while eﬃcacy of ADX71943 was eval-
uated in the mouse MB and in the acetic acid writhing (AAW) test of
visceral pain. Side-eﬀect proﬁle of each compound was assessed in
the mouse locomotor activity (LMA), rotarod and body temperature
(BT) tests.
Results : ADX71653 reduced numbers of buried marbles (MED
3 mg/kg), indicative of its anxiolytic-like eﬀect. However, it also re-
duced LMA, body temperature and impaired rotarod activity from
10 mg/kg. ADX71943 reduced the number of acetic acid-induced
writhes (MED 3 mg/kg), indicative of antinociceptive-like eﬃcacy.
However, it failed to have an eﬀect in MB when tested at up to
100 mg/kg. ADX71943 had no eﬀect in the mouse LMA, rotarod and
BT tests when tested at up to 100 mg/kg.
Conclusion : Thus, peripherally-targeted GABABR PAMs oﬀer a
wide therapeutic margin when evaluating indications with peripheral
mechanisms, while being inactive in centrally-mediated conditions.
However, centrally-targeted PAMs oﬀer a narrow margin, similar to
that seen with baclofen. Therefore, GABABR PAMs with a balanced
central/peripheral proﬁle may oﬀer the potential for development
of novel non-opioid alternative for chronic osteoarthritis (OA) pain
and a non-muscarinic alternative for overactive bladder (OAB) with
a wider therapeutic margin. Recently we develop a novel, orally-
bioavailable GABABR PAM with a balanced central/peripheral pro-
ﬁle which oﬀers eﬃcacy in models of anxiety, OAB and pain, with
ameliorated side-eﬀect liability. It is currently advancing toward
the IND.
jP-23-042jVitamin D in pediatric patients with chronic
non-malignant pain
T. Rummans1, T. Harrisoin1, B. Bruce1. 1Mayo Clinic, Rochester, USA
Objective : Vitamin D deﬁciency (25[OH]D<20 ng/mL)has been
found to contribute to both medical and psychiatric conditions. The
association with chronic pain has been noted in adult patients with
chronic non-malignant pain (Turner 2008), with a 26% prevalence of
hypovitaminosis D. Antiel et al., (2011) studied a group of adolescent
patients with postural orthostatic tachycardia syndrome (POTS)
and found that 22% of those patients met the criteria of Vitamin D
deﬁciency with serum 25[OH]D<20 ng/mL. To date there has been
no report of the prevalence of Vitamin D deﬁciency in a population of
adolescents with chronic non-malignant pain which is the purpose of
this study.
Methods : This study reviewed the records of 333 adolescent
and young adult (ages 11–21 years old) patients with chronic non-
malignant pain who participated in a three week outpatient Pediatric
Pain Rehabilitation Program. As part of the standard admission
process, serum 25[OH]D level was measured in all patients at the
start of the program. Supplementation of vitamin D is provided
to those patients who are vitamin D deﬁcient as part of the rehabili-
tation.
Results : In this group of pediatric patients with chronic non-
malignant pain, we found a prevalence of 21.6% (72/333 patients)
with Vitamin D deﬁciency. Of those with Vitamin D insuﬃciency/
deﬁciency, mean serum 25[OH]D was 28 ng/mL. Female patients
(n=250) had a 25[OH]D level of 30.7 ng/mL ; male patients (n=83)
had a mean of 20 ng/mL. Of the African American patients (n=5),
mean serum 25[OH]D level was 17 ; Asian patients (n=5) demon-
strated a mean level of 28 ng/mL. The remainder were Caucasian
patients (n=323) with a mean level of 28.2 ng/mL.
Conclusion : Supplementation of vitamin D may help improve
pain and physical functioning in adolescent populations with chronic
non-malignant pain.
jP-23-043jSadness enhances the experience of pain and aﬀects
brain regions associated with pain
A. Yoshino1, Y. Okamoto1, S. Yoshimura1, S. Toki1, K. Shishida1,
S. Yamawaki1. 1Hiroshima University, Japan
Objective : Pain is a multidimensional experience. Human pain per-
ception can be modulated by subjective emotional responses. We ex-
amined this association by using functional magnetic resonance
imaging (fMRI) (15 healthy subjects) and magnetoencephalography
(MEG) (19 healthy subjects).
Methods : Pain-inducing stimuli were presented during diﬀerent
emotional contexts, which were induced via the continuous presen-
tation (5 s) of sad, happy or neutral pictures of faces. Subjects also
rated their subjective pain intensity.
Results : We found : 1) The intensity of subjective pain ratings in-
creased in the sad emotional context, 2) pain-related activation in the
anterior cingulate cortex (ACC) was more pronounced in the sad
context, and we demonstrated amygdala to ACC connections during
the experience of pain in the sad context, and 3) event-related desyn-
chronization (ERD) of lower beta bands in the right hemisphere after
pain stimuli was larger in the sad emotional condition.
Conclusion : These results show that sadness can modulate
neural responses to pain stimuli, and that it may be relevant to
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understanding the broader relationship between somatic complaints
and negative emotion. We also consider that further research is
needed to understand this relationship from the clinical viewpoint
including the psychiatric treatment.
jP-23-044jAssociation between smoking and plasma brain-
derived neurotrophic factor (BDNF) levels in healthy
workers
H.-I. Chen1, R. Yoshimura2, T. Shinkai2, K. Utsunomiya2, K. Yamada2,
J. Nakamura2. 1UOEH, Kitakyushu, Japan ; 2UOEH, Department of
Psychiatry, Kitakyushu, Japan
Objective : Brain-derived neurotrophic factor (BDNF) had been
reported to play an important role in the development of nicotine
dependence (ND). Chronic nicotine intake increased BDNF mRNA
expression in rat hippocampus. In addition, human plasma BDNF
level was found signiﬁcantly increased after nicotine abstinence, but
same result cannot be reconﬁrmed in another study using serum
sample. In other words, the issue is controversial. In the present study,
we investigate the plasma BDNF concentration between smoker and
non-smoker using health samples from industrial workers.
Methods : 85 never smokers and 220 current smokers from a major
industrial company were enrolled in this study. Plasma was quickly
separated in a centrifuge and stored at x80 degrees Celsius until it
was used for assay. Plasma BDNF levels were assayed using ELISA
methods following to the manufacturer’s instructions. All the stat-
istics were performed using SPSS v16.0 Japanese version.
Results : The mean plasma BDNF concentration in smokers is
1636.31 (SD=1250.33) pg/mL and, it is 1601.17 (SD=1699.06) pg/mL
in never smoker. We found a signiﬁcant diﬀerence in the Log-
transferred BDNF concentration between smokers and never smokers
(p=0.035). After adjusting age, the smoking behavior still increase the
plasma BDNF concentration (p=0.029).
Conclusion : Our results suggested that the plasma BDNF
concentration in smoker is higher than that in non-smoker which
is in line with a research in male schizophrenia patients. However,
it was inconsistent with other human researches which revealed the
lower BDNF concentration in smokers. The inconsistency between
our and other human studies might due to diﬀerent settings of par-
ticipant fs background. Unfortunately, we still had some limitations
in this study, such as BMI, excise and disease information of the
workers. Association between smoking and the plasma BDNF level
remains controversial. Further studies are needed to draw a ﬁrm
conclusion.
jP-23-045jSmoking cessation in patients with chronic
schizophrenia
C. Cheng1, C.-H. Chan1, T.-H. Lan1. 1VGHTC, Taichung, Taiwan
Objective : To examine whether smoking cessation is associated
with psychotic symptom severity and antipsychotics side eﬀects in
smoking patients with chronic schizophrenia.
Methods : A total of 100 smoking patients with chronic schizo-
phrenia were recruited at a Taiwan chronic mental hospital for the
8-week smoking secession program using nicotine patch replacement
therapy (NRT). Medication adjustment was allowed during the NRT.
All subjects were evaluated for the clinical psychotic symptoms
and antipsychotic side eﬀects at baseline and after the NRT. Psychotic
symptom severity and antipsychotic side eﬀects were measured by
the Positive and Negative Syndrome Scale (PANSS) and the Udvalg
for Kliniske Undersøgelser (UKU) Side Eﬀect Rating Scale, re-
spectivelly. The diﬀerences before and after the NRT were analyzed
by multiple logistic regression analysis.
Results :After adjusting for age and hospitalization day, the clinical
psychotic symptoms signiﬁantly improved after the NRT (PANSS
score at baseline and after the NRT : 63.77¡1.72 ; 60.85¡1.55), es-
pecially in general and positive subdivisions. The antipsychotic side
eﬀects, however, were not signiﬁcantly diﬀerent (UKU Side Eﬀect
Rating Scale at baseline and after the NRT : 5.46¡0.38 ; 5.09¡0.39) ;
items including fatigue, rigidity, and constipation signiﬁcantly im-
proved after the NRT, while blurred vision and drooling signiﬁcantly
worsened (p-value<0.05).
Conclusion : Smoking cessation is beneﬁcial for smoking patients
with chronic schizophrenia in reduction of clinical psychotic symp-
toms and certain side eﬀects of antipsychotics.
jP-23-046jGenome-wide association study identiﬁed
susceptibility loci associated with nicotine
dependence in a Japanese population
D. Nishizawa1, S. Kasai1, J. Hasegawa1, N. Sato, F. Tanioka2,
H. Sugimura3, K. Ikeda1. 1Tokyo Metro. Inst. Med. Sci., Japan ; 2 Japan ;
3Hamamatsu Univ. School of Med., Japan
Objective : Many genetic and environmental factors can be involved
in the etiology of nicotine dependence. To date, several candidate
genetic variations have been identiﬁed to be associated with
smoking behaviors and vulnerability to nicotine dependence. These
were found mostly by investigating single nucleotide polymorphisms
(SNPs) on each gene related to phenotypes of concern or by genome-
wide association studies (GWAS), which treat genetic markers in the
whole genome, conducted for subjects with European ancestry.
However, genetic factors have not been reportedly investigated
for Japanese population utilizing whole-genome genotyping arrays.
We comprehensively explored genetic contributors to nicotine
dependence by GWAS in Japanese.
Methods : Subjects were 300 patients who visited Iwata City
Hospital. A number of participants involved in this study had various
smoking habits and ﬁlled in a questionnaire leaﬂet containing various
questions. Whole-genome genotyping was performed with iScan
System (Illumina K.K.) and the BeadChip HumanCytoSNP-12.
Results : In association study between over 200,000 marker SNPs
and scores of the Fagerstro¨m Test for Nicotine Dependence (FTND),
a test that yields a continuous measure of nicotine dependence, the
Tobacco Dependence Screener (TDS), consisting of 10 questions, and
the numbers of cigarettes smoked per day (CPD), none of the SNPs
were found to reach the genome-wide signiﬁcant level and the
P-values were no less than 10–6 in all analyses. However, several
potent SNPs were found in loci that have not been highlighted, as well
as in loci that include known candidate genes resulted from previous
GWAS. Among them was CSMD1, CUB and Sushi multiple domains
1, which appeared in top ranks of our GWAS results for all the three
phenotypes examined.
Conclusion : Although future studies with larger sample size
is required, these results will serve to discover genetic factors con-
tributing to nicotine dependence and smoking behavior speciﬁc
to Japanese population in addition to those common to other popu-
lations.
jP-23-047jEﬀects of smoking cessation on reward processing
L. Rademacher1, K.N. Spreckelmeyer1, S. Prinz1, I. Vernaleken1,
G. Gru¨nder1. 1Aachen University Hospital, Germany
Objective : Research on nicotine addiction indicates greater ventral
striatal activity in smokers compared to non-smokers in response to
smoking-associated cues but blunted reactivity to non-drug rewards
(David et al., Biol Psychiatry 2005, 58 : 488–494 ; Martin-Soelch et al.,
Eur J Neurosci 2003, 18 : 680–688). However, it is still unclear how
reward processing changes after smoking cessation. The aim of the
present study was to examine eﬀects of long term smoking abstinence
on neural correlates of reward anticipation and cue reactivity.
Methods : Thirty-three smokers and 30 non-smokers performed
two paradigms on a 1.5 T scanner : Monetary and social reward
anticipation were investigated using the Monetary and Social
Incentive Delay task (Knutson et al., Neuroimage 2000, 12 : 20–27 ;
Spreckelmeyer et al., SCAN 2009, 4 : 158–165). The second paradigm
examined cue reactivity by presenting blocks of smoking-related,
neutral or sexually arousing pictures. All smokers took part in a
smoking cessation course. Fifteen smokers who succeeded in staying
abstinent for three months underwent a second fMRI scan with the
same paradigms.
Results : During both monetary and social reward anticipation
smokers showed weaker striatal activity compared to non-smokers.
However, in response to smoking-associated pictures stronger neural
responses were found in the caudate nucleus. For both reward
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anticipation and cue reactivity no eﬀect of smoking cessation could be
detected.
Conclusion : The data implies that striatal activation during anti-
cipation of non-smoking rewards is decreased in smokers while re-
activity is increased for smoking-associated pictures. The ﬁndings
further suggest that neural activation during reward processing
is not aﬀected by smoking abstinence. The data points towards a
general dysfunction of the reward system in nicotine-dependent
smokers. A subsample of 22 smokers and 12 nonsmokers in this
study underwent [18F]FDOPA PET scans parallel to the fMRI scans.
These data is currently being analyzed and will be available at
the meeting.
jP-23-048jThe amnesic eﬀects of benzodiazepines : A science
or media concern?
E. Bacon. Inserm u 666, Strasbourg Cedex, France
Objective : This study highlights the history and logic of the discovery
and study of the amnesic eﬀect of benzodiazepines, and how infor-
mation about it is relayed in diﬀerent sources, from research journals
to the medical and lay media. Benzodiazepines are the most-
prescribed drugs worldwide, thanks to their eﬀects on anxiety and
insomnia, but in some circumstances trigger amnesic episodes.
Almost 20 years elapsed (at least in France) between when these
eﬀects were discovered and when general practitioners and users
were told about them.
Methods : The written media are important for disseminating
information about drugs. Unlike information relating to other ﬁelds
of research, however, information about drugs has many diﬀerent
written sources (research and medical journals, rules and regulations,
magazines and lay media). This study explored how information
about them was relayed in the written media, and why it took so long
to reach those who prescribe or use them.
Results : The amnesic properties of benzodiazepines were dis-
covered by anaesthetists, who considered them useful, and the rel-
evant information was ﬁrst conﬁned to anaesthesia journals.
The molecules were later used by fundamental cognitive researchers
to investigate memory processes and again considered useful
tools. Gradually, however, medical and lay journals began to describe
benzodiazepine-induced amnesic episodes, for the most part drug-
induced aggressive disinhibition behaviour accompanied by amnesia.
Since then, benzodiazepines have become unpopular with other seg-
ments of the population, namely the general practitioners who
prescribe them, and users who take them to alleviate anxiety or
insomnia.
Conclusion : This study demonstrates why physicians remained in
the dark for such a long time, and how a beneﬁcial eﬀect became an
undesirable eﬀect, partly due to media coverage of a trial.
jP-23-049jDevelopment of a short questionnaire for the
assessment of the onset and latency to treatments in
psychiatric disorders
B. Dell’Osso1, M. Palazzo1, C. Arici1, B. Penzo1, C. Dobrea1, L. Oldani1,
G. Camuri1, B. Benatti1, M. Serati1, L. Lietti1, A.C. Altamura1.
1Fondazione IRCCS Ca` Granda, Milano, Italy
Objective : Psychiatric disorders are prevalent and disabling condi-
tions often undiagnosed and untreated for several years [1,2]. To date,
little is known about causal mechanisms that determine diﬀerent
latency to treatments [3], given that few questionnaires focused on the
onset and latency to treatments are available. From this perspective,
our Department of Mental Health has recently developed a brief
questionnaire on the topic : the psychopathological onset and latency
to treatment questionnaire (POL-Q).
Methods : 316 patients with any psychiatric diagnosis were
required to complete the questionnaire. Statistical analyses were per-
formed using SPSS.
Results : The sample showed the following demographic variables
in terms of age (47.58 years ¡14.7), occupation (56% unemployed)
and family history for psychiatric disorders (48.1%). Clinical variables
included : age at onset (30.6 years ¡14.6), age at ﬁrst diagnosis
(35.5 years ¡18.7), age at ﬁrst drug treatment (34.6 years¡14.6) and
duration of untreated illness (47.2 months ¡95.9), showing that, on
average, patients received the ﬁrst pharmacological treatment before
having received a speciﬁc diagnosis. The most common symptoms at
onset were related to anxiety spectrum (29.4%), depression (19.9%)
or both (28.5%) then to psychotic spectrum (13.6%). Most frequent
primary diagnoses were major depressive disorder (25.3%), bipolar
disorder (13.3%) and generalized anxiety disorder (11.7%). Mean
latency to the ﬁrst visit was 31.4 months. In the 45.6% of the sample
the ﬁrst contact was with a psychiatrist, in the 27% with the general
physician and in the 13% with a psychologist. The 76.9% of the
sample was treated with drugs as ﬁrst treatment, while 11.4% with
psychotherapy.
Conclusion : In a ﬁrst group of 316 patients aﬀected by diﬀerent
psychiatric disorders, the POL-Q resulted to be a useful and reliable
instrument in order to collect information on the psychopathological
onset and latency to treatments.
jP-23-050jConduction abnormalities and associated factors in
Korean patients with eating disorders
Y.-R. Kim1, S.-B. Bae1, J.H. Doh2. 1 Inje Univ. Seoul Paik Hosp., Republic
of Korea ; 2 Inje Univ. Ilsan-Paik Hosp., Int. Medicine, Goyang, Republic
of Korea
Objective : QT interval prolongation and dispersion known as the in-
dicators of an increased risk for ventricular arrhythmias and sudden
death, have been reported to be prolonged in patients with anorexia
nervosa. The aims of this study were to compare conduction ab-
normalities in Korean patients with anorexia nervosa and bulimia
nervosa, and to examine its relation with clinical and laboratory
factors.
Methods : We retrospectively examined 45 women with anorexia
nervosa and 75 women with bulimia nervosa who were assessed
12-lead electrocardiogram as a baseline assessment. Conduction ab-
normalities were measured as QT interval and corrected QT interval,
QT dispersion of the diﬀerence between the longest and shortest QT
intervals, and abnormal U wave.
Results : QT interval was signiﬁcantly longer in patients with an-
orexia nervosa compared with patients with bulimia nervosa. There
were no diﬀerences in QTc, QTd and abnormal U wave between
patients with anorexia nervosa and patients with bulimia nervosa.
QTd was signiﬁcantly correlated with the lowest ever lifetime body
mass index (kg/m2) as well as the serum amylase level in patients
with anorexia nervosa.
Conclusion : These results suggest some conduction abnormalities
reported in patients with anorexia nervosa are also found in patients
with bulimia nervosa. It appears severity of weight loss and purging
behavior could aﬀect on the cardiac arrhythmia in patients with eating
disorders. Appropriate attention should be paid to cardiac involve-
ment in patients with eating disorders.
Policy of full disclosure : This work was supported by a 2010 Inje
University research grant.
jP-23-051jAdverse eﬀects of zolpidem and lorazepam in
three-week treatment of primary insomnia
V. Janjic1, B. Radmanovic1, D. Milovanovic1, Z. Bukumiric2,
D. Ravanic1, G. Mihajlovic1, S. Djukic Dejanovic1. 1Clinical Center,
Kragujevac, Serbia ; 2Medical Faculty Pristina, Kosovska Mitrovica, Serbia
Objective : Objective of this work was to establish diﬀerences in
adverse eﬀects of zolpidem and lorazepam during the three-week
treatment of primary insomnia.
Methods : Forthy one patients with primary insomnia were in-
cluded in double-blind randomized research, out of which 21
were treated with 10 mg/d of zolpidem and 20 mg/d of lorazepam
during three weeks. Examinees received the medication each
night during the ﬁrst week, 5 times a week during the second week,
and during the third week they received one of the investigated
drugs 3 times a week. The most common adverse eﬀects were re-
corded in patients at the beginning, then after the ﬁrst, the second
and the third week of treatment by using the list of adverse eﬀects
(AECL), and their intensity was estimated with visual analogue
scale (VAS).
Results : Our results show that the examinees on zolpidem had total
statistically signiﬁcantly less adverse eﬀects than examinees on
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lorazepam (U=82 ; p=0.001), and that they also had less total intensity
of adverse eﬀects (U=58.5 ; p<0.002) and intensity by individual ad-
verse event (U=45 ; p<0.008). In both groups of examinees there is
statistically signiﬁcant diﬀerence in time, that is, both examinees on
zolpidem and lorazepam had decrease of adverse events and by
number (F=29,805 ; p<0.001 ; F=24,968 ; p<0.001) and by intensity
(F=27,335 ; p<0.001 ; F=28.423 ; p<0.001), during the course of
treatment.
Conclusion : Based on results obtained, we can conclude that from
the point of adverse events, zolpidem is safer drug than lorazepam, as
well as that during the time there is a decrease of number and inten-
sity of adverse events in both drugs.
250 Poster Sessions, Wednesday, 6 June 2012
Downloaded from https://academic.oup.com/ijnp/article-abstract/15/Supplement_1/1/650920
by University of Groningen user
on 13 March 2018
Satellite Symposia
Monday 4 June 2012
SA-01. Managing depression: Agomelatine a
landmark treatment supported by an
educational grant from Servier
jSA-01-001jCircadian rhythm dysfunction and severity of
depression
G. Hajak. Clinic of Pychiatry, Psychosomatic & Psychotherapy,
Regensburg, Germany
Circadian rhythms control many biological, physiological, and beha-
vioral parameters such as variations in the daily pattern of mood,
body temperature, and secretion of various hormones. Animal as well
as human data support the assumption that dysfunction of the circa-
dian system may underlie the pathophysiology of depression as well
as other psychiatric diseases. Disruption of circadian rhythms aﬀect
mood, day-time functioning, concentration, energy, sleep-wake cycle,
and cognition, and predispose individuals to a wide range of mood
disorders including depression, mania, and impulsivity. Recent data
established the correlation of circadian misalignment and depression
symptom severity, indicating that the clinical expression of some core
symptoms of depression reveal circadian rhythm deregulation and
pointing out therefore the importance of a chronobiological approach
to depression treatment. Among the established strategies such as
sleep deprivation, circadian phase advance, entrainment by light
therapy, and social rhythms, the development of drugs that target the
circadian system appears to be the most promising approach. The
novel antidepressant agomelatine acts as an agonist of MT1/MT2 re-
ceptors, as well as an antagonist of 5-HT2C receptors, and has been
shown to resynchronize altered circadian rhythms in both animal
models and humans. Agomelatine was shown to increase the ﬂat-
tened amplitude and to phase advance the circadian timing of several
psychological parameters in healthy volunteers and depressives and
to resynchronize the impaired circadian system in depressed patients.
In particular, agomelatine rapidly improves daytime functioning,
quality of sleep, and as a critical measure of circadian functioning the
circadian rest-activity cycle. Its antidepressant eﬃcacy has been
demonstrated in a great number of clinical trials versus placebo and
comparator drugs. Its robust antidepressant eﬃcacy in severe de-
pression, versus placebo and comparators, suggests that agomelatine
can reduce unmet therapeutic needs in the treatment of depressed
patients, thanks to the resynchronization of disturbed circadian
rhythms in these patients.
jSA-01-002jSynergistic mechanisms involved in the
antidepressant eﬀects of agomelatine
G. Racagni. University of Milano, Italy
Major depression is considered as a complex disorder resulting from
interactions between genetic, physiological, psychological, and en-
vironmental factors. The clinical manifestations of depression include
aﬀective, cognitive, somatic, and behavioral symptoms. Despite their
variety, current antidepressants still have limitations in terms of eﬃ-
cacy, onset of action, and tolerability. In particular, none of them can
alleviate all the symptoms of depression. Since the core symptoms of
depression reveal disturbance of circadian rhythms in their clinical
expression, an antidepressant with resynchronizing eﬀects would
be of value. The new antidepressant agomelatine is an agonist of
melatonergic MT1/MT2 receptors as well as an antagonist of ser-
otonergic 5-HT2C receptors. Both properties contribute to agomela-
tine’s antidepressant activity, which has been proven in several
animal models of depression and in patients with major depressive
disorder. Moreover, agomelatine was shown to resynchronize
disturbed circadian rhythms in several animal models and in patients.
Given the action of agomelatine through these receptors, it was im-
portant to investigate how agomelatine really works : through a
modulation or a synergistic interaction between MT1/MT2 and 5-
HT2C receptors. Recent data on the cellular processes involved in the
mechanisms of antidepressants have demonstrated that agomelatine
increases the expression of brain-derived neurotrophic factor in the
prefrontal cortex and hippocampus, as well as the expression of ac-
tivity-regulated cytoskeleton-associated protein (arc) in the prefrontal
cortex. Moreover, chronic agomelatine therapy increases neurogen-
esis in the hippocampus, via enhancement of neuronal cell survival,
and attenuates stress-induced glutamate release in the cortex. 5-HT2C
antagonists or melatonin alone fail to reproduce these eﬀects. These
data suggest therefore that agomelatine acts through a synergistic
action on MT1/MT2 and 5-HT2C receptors. This novel pharmaco-
logical proﬁle translates into a distinctive antidepressant eﬃcacy
demonstrated in depressed patients.
jSA-01-003jAgomelatine : A new insight into antidepressant
eﬃcacy
G.M. Goodwin. Warneford Hospital, University Dep. of Psychiatry,
Oxford, United Kingdom
Several clinical challenges associated with the management of major
depressive disorder contribute to the poor performance of established
antidepressant treatments : delayed onset of perceived improvement,
side eﬀects, and residual symptoms. Agomelatine is diﬀerentiated
from conventional antidepressants by its pharmacology MT1,
MT2 receptor agonism and 5-HT2C receptor antagonism which
modulates circadian function and has no action on serotonergic brain
levels, unlike most other antidepressants. In double-blind, rando-
mized clinical trials versus placebo and comparators, there was
promise of early eﬃcacy. Thus in one 8-week study versus placebo,
agomelatine reduced HAM-D scores signiﬁcantly from the ﬁrst
week of treatment, remaining statistically signiﬁcant until week 8,
and in a head-to-head comparison with sertraline, the HAM-D re-
sponse rate was signiﬁcantly higher (20% versus 10.9%, P=0.027)
at the ﬁrst (2-week) assessment visit. In comparison with venlafaxine,
agomelatine improved alertness and daytime functioning at
week 1. Clinical experience with agomelatine has conﬁrmed early
beneﬁts, beyond reduced side eﬀect burden, also evident in double-
blind trials. In experimental studies of healthy volunteers, agomela-
tine improved positive aﬀective memory and decreased recognition of
sad facial expressions more selective eﬀects on the processing
of emotional information than conventional antidepressants such
as citalopram or reboxetine. Our hypothesis, that this could lead
to less blunting of emotional experience in depressed patients,
has also received preliminary conﬁrmation : in comparison with
escitalopram, agomelatine improved some items of blunted
emotional reactivity from week 2 to week 24. Taken together, these
results conﬁrm that, in responding patients, agomelatine’s novel
mode of action leads to early improvement of the core symptoms of
depression and potentially to less blunting of ordinary emotional
experience.
jSA-01-004jAgomelatine in real life : practical experience with
agomelatine
P. Gorwood. Sainte-Anne Hospital, INSERM Unit 675, Paris, France
Agomelatine is an innovative antidepressant, an MT1, MT2 receptor
agonist and a 5-HT2C antagonist, which is being investigated in
noninterventional studies to assess its eﬃcacy and tolerability in daily
practice. The French D-CHANGE trial assessed in daily practice the
eﬃcacy of agomelatine in depressed patients who were either not
treated before for this episode (naı¨ve population) or previously
treated with another antidepressant (switch population). In this
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6-week prospective study, more than 2700 depressed patients re-
ceived agomelatine (25–50 mg) once daily at bedtime. In order to de-
tect early clinical markers predictive of clinical response after 6 weeks,
assessments were performed at day 0, week 2, and week 6 : severity of
symptoms using the Quick Inventory of Depressive Symptomatology
by Clinicians (QIDS-C) and the Clinical Global Improvement Severity
(CGI-S) scale, the level of mood with a VAS, sleep complaints with the
Leeds Sleep Evaluation Questionnaire (LSEQ), social functioning
(SDS), and emotional state (MATHYS). The balance between sensi-
tivity and speciﬁcity for each parameter was assessed using ROC
curves. The early improvement at week 2 with agomelatine, perceived
by both clinicians (QIDS and CGI-EI) and patients (VAS), was the
criterion most predictive of response later (week 6). The severity of
symptoms was similarly reduced after just 2 weeks in the total
population and both subpopulations, conﬁrming the clinical beneﬁt of
agomelatine in the naı¨ve and switch populations. All noninterven-
tional trials conducted in real daily practice conditions, ie, represent-
ing the heterogeneous depressed population with severe symptoms
and symptoms of anxiety, conﬁrmed the antidepressant eﬃcacy and
good tolerability proﬁle of agomelatine. Taken together, the converg-
ing data observed in both randomized clinical trials and prospective
trials make agomelatine a treatment of choice for a large spectrum of
depressed patients.
SA-02. Asenapine, a multifunctional
antipsychotic. Beyond symptom control
in schizophrenia and bipolar disorder
supported by an educational grant
from Lundbeck
jSA-02-001j Improving patient outcomes in schizophrenia and
bipolar I disorder
A. Gonzales-Pinto. Spain
Psychiatric disorders are frequently misdiagnosed due to overlapping
symptomatology and comorbidities. Early and accurate diagnosis is
essential to ensure that the correct treatment is received at the earliest
opportunity and that the beneﬁts are maintained over the long-term.
There is also a need for diagnostic markers that may allow earlier,
accurate diagnosis. Despite important advances in pharmacotherapy
for bipolar I disorder, a substantial number of individuals do not
achieve full remission, experiencing treatment-resistant symptoms,
frequent relapse, and poor functioning. There remains a need for more
eﬀective, and better tolerated, antipsychotic, antidepressant, and
mood-stabilising therapies with faster onset of action, including im-
proved treatment of comorbid psychiatric and medical disorders, and
of cognitive deﬁcits. Successful management of bipolar I disorder may
be further hindered by poor treatment adherence due to intrinsic
disease symptoms (e.g., poor insight), problems with intolerable side
eﬀects, use of numerous concomitant medications, and poor social
support systems. Non-adherence to treatment regimens is generally
reported to range from 40 to 60%. An ideal treatment for bipolar I
disorder should be able to rapidly control symptoms and achieve
clinical, as well as functional, remission.
jSA-02-002jAsenapine, a multifunctional antipsychotic
F. Tarazi. Harvard Medical School, Belmont, USA
Asenapine is a new treatment option with some speciﬁcproperties.
It is derived from a tetracyclic chemical class that is diﬀerent from
other antipsychotics, and has a unique sublingual mode of adminis-
tration. Asenapine has a unique multi-functional human receptor
pharmacology with three distinctive components. It is a potent
D2-receptor antagonist and, like other antipsychotics, has a high
5-HT2A/D2 binding aﬃnity ratio – a key driver for antimanic and
antipsychotic eﬃcacy. Additionally, asenapine has ‘untypical ’ recep-
tor properties, such as the combination of potent 5-HT2A/b2 and
5-HT7/5-HT6 receptor antagonism, when compared to ﬁrst- and
second-generation antipsychotics, at therapeutic doses. This triple
action multi-functional pharmacology has driven hypotheses for po-
tential additional therapeutic beneﬁts of asenapine. For example,
5-HT2A/b2 receptor blockade may contribute towards alleviating
depressive symptoms. Furthermore, the preclinical pharmacology
of asenapine provides a rationale for enhancing cognition. Unlike
the tricyclic antipsychotics, asenapine does not have excessive anti-
histaminic or appreciable antimuscarinic activity, which are linked
with development of metabolic dysfunction and anticholinergic
eﬀects, respectively. Eﬃcacy of asenapine has been demonstrated in
the management of bipolar disorder, but translation of asenapine’s
unique pharmacology into additional therapeutic beneﬁts should be
determined in patients. The pre-clinical proﬁle provides rationale for
study in depressive symptoms.
jSA-02-003jEﬀective remission with asenapine for patients
with bipolar I disorder
H. Grunze. Newcastle University, Institute of Neuroscience, United
Kingdom
Asenapine is a novel, tetracyclic antipsychotic medication delivered
in a fast-dissolving sublingual tablet. In two 3-week, double-blind,
randomised, placebo-controlled studies in patients with bipolar I
disorder experiencing manic or mixed episodes, asenapine-treated
patients showed a signiﬁcantly greater reduction than placebo-treated
patients in the Young Mania Rating Scale (YMRS) total score, as early
as Day 2. A subsequent 9-week, double-blind, head-to-head, non-
inferiority extension study demonstrated that over 12 weeks of
treatment asenapine maintained eﬃcacy and was comparable to
olanzapine in terms of improving YMRS total score, and in rates of
response and remission. A further 40-week, double-blind, extension
study showed that the eﬃcacy of asenapine treatment (secondary
endpoint) was maintained up to 1 year. A post-hoc analysis was
performed to assess the eﬀect of asenapine on depressive symptoms
experienced by patients during an acute manic phase. In patients with
signiﬁcant depressive symptoms (baseline MADRS total scoreo20) a
highly signiﬁcant improvement in MADRS total score with asenapine
treatment relative to placebo was observed ; an eﬀect that was not
shown in patients in the olanzapine group. Asenapine oﬀers a new
treatment option for patients with bipolar I disorder. The strong
clinical eﬃcacy of asenapine has been demonstrated in acute
manic and mixed episodes. Asenapine eﬃcacy is comparable to
olanzapine over 12 weeks and is maintained up to 1 year.
Furthermore, reduction of depressive symptoms was shown in a
post-hoc analysis.
Wednesday 6 June 2012
SA-04. Designing new antidepressants:
A focus on multimodality supported by
an educational grant from Lundbeck
jSA-04-001jWhat is the rationale for designing multimodal
antidepressants?
J. A. Den Boer. University Medical Center, Department of Psychiatry,
Groningen, Netherlands
Major depressive disorder (MDD) is characterised by aberrations in
many intertwined pathways : monoaminergic dysfunctions ; inﬂam-
matory pathways (increased levels of proinﬂammatory cytokines) ;
hypothalamic-pituitary-adrenal (HPA) axis abnormalities ; impair-
ments in neuroplasticity markers ; and disturbances in circadian
rhythmicity. Monoaminergic dysfunctions have dominated clinical
development of antidepressant drugs, as witnessed by the role of
selective serotonin reuptake inhibitors (SSRIs) and dual-action anti-
depressants during recent decades [1]. However, treatments with
improved response and tolerability are needed. Several attempts have
been undertaken to develop antidepressants based on pathogenetic
principles related to hyperactivity of the HPA axis, such as CRH1,
glucocorticoid and vasopressin1B receptor antagonists [2]. So far,
these developments have been disappointing. Candidate targets have
been identiﬁed that reduce the increased signs of neuroinﬂammation
in MDD [3]. Based on this, new targets could include cytokine
antagonists, Cox-2 inhibitors, acetylsalicylic acid, ketamine and
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antioxidants. Clinical evidence for these candidate compounds is,
however, still circumstantial. In clinical practice, recent studies have
shown that augmentation of SSRIs with atypical antipsychotics leads
to enhanced antidepressant response [4]. There is increasing clinical
evidence for the augmentation strategy involving combination of
an SSRI and mirtazapine [5, 6]. This response could be explained by
assuming a synergistic eﬀect between inhibiting reuptake of 5-HT and
adding an antidepressant that is a 5-HT2A/2C and 5-HT3 receptor
antagonist. From preclinical studies, there is evidence for the eﬃcacy
of multi-target serotonergic compounds, such as combination of an
SSRI with 5-HT1A agonism, 5-HT2C antagonism, 5-HT3 antagonism,
5-HT6 agonism and 5-HT7 antagonism in diﬀerent varieties [7]. When
studied in isolation, 5-HT1A agonists may have modest anti-
depressant eﬀects, as may 5-HT2C and 5-HT3 antagonists. There is a
rationale for combining these two pharmacological modes of action
into one molecule, constituting a multimodal drug. This may lead to
synergistic eﬀects and a strong antidepressant response.
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jSA-04-002jOptimising receptor activity and
reuptake inhibition in multimodal
antidepressants – examining the evidence to date
C. Sanchez. USA
The new multimodal compounds vilazodone and Lu AA21004 are
thought to work via a combination of both receptor activity and re-
uptake inhibition. Vilazodone combines serotonin (5-HT) transporter
(SERT) inhibition and 5-HT1A receptor partial agonism, increases
extracellular 5-HT in vivo in the rat frontal cortex and ventral hippo-
campus, and is active in preclinical models of anxiety and depression
[1]. Lu AA21004 functions as a 5-HT3 and 5-HT7 receptor antagonist,
5-HT1B receptor partial agonist, 5-HT1A receptor agonist and inhibi-
tor of the SERT in vitro [2]. In vivo non-clinical studies have demon-
strated that Lu AA21004 dose-dependently occupies these targets [2]
and enhances extracellular levels of 5-HT, noradrenaline, dopamine,
acetylcholine and histamine in the prefrontal cortex [3, 4]. In a rat
progesterone-withdrawal model, Lu AA21004 produced an anti-
depressant-like response, whereas ﬂuoxetine was inactive at corre-
sponding SERT occupancies [5]. Lu AA21004 is eﬀective in animal
models of cognitive function, enhancing episodic memory in the rat
novel object recognition (NOR) test and contextual memory in the rat
fear conditioning test [4]. In contrast to the selective serotonin re-
uptake inhibitor (SSRI) escitalopram, Lu AA21004 normalises deﬁcits
in episodic and spatial memory induced in rats by 5-HT depletion, as
measured in the NOR test and spontaneous alteration test, respect-
ively [6]. Thus, Lu AA21004 exerts both its antidepressant-like activity
and memory-enhancing eﬀects via mechanisms beyond SERT inhi-
bition [5,6]. Overall target occupancies, neurotransmitter levels and
behavioural models, as well as quantitative EEG analyses [7], point
towards a unique preclinical proﬁle for Lu AA21004 compared to both
vilazodone and current SSRIs.
Policy of full disclosure : The studies were jointly sponsored by
H Lundbeck A/S and the Takeda Pharmaceutical Company.
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jSA-04-003jPotential clinical beneﬁts of Multimodals in
depression
D. Nutt. London, United Kingdom
The ability of the new multimodal compounds vilazodone and Lu
AA21004 to target receptors and enhance neurotransmitters in speciﬁc
brain areas is expected to have particular clinical beneﬁts, including
fewer side eﬀects than are associated with serotonin-noradrenaline
reuptake inhibitors. It is anticipated that the multimodal eﬀects of
Lu AA21004 could reduce treatment-emergent sexual dysfunction
(TESD) (via 5-HT3 antagonism and 5-HT1A agonism) and improve
cognitive function (via 5-HT3 and 5-HT7 antagonism) [1–4].
Vilazodone is an eﬀective treatment for adults with MDD, as shown
by signiﬁcant improvements compared with placebo in the MADRS
and HAM-D-17 in two pivotal, 8-week, randomised, double-blind,
Phase III studies [5, 6]. Vilazodone was generally well tolerated, with
diarrhoea and nausea being the most common treatment-emergent
AEs, and had minimal impact on sexual functioning. In a proof-of-
concept study, Lu AA21004 was comparable to a high-dose venla-
faxine in improving depressive symptoms (MADRS and CGI-S/I at 6
weeks) [7]. Lu AA21004 also signiﬁcantly reduced the risk of relapse
compared with placebo in a long-term study in patients with MDD
(24–64 weeks) [8]. In elderly patients (o65 years) with MDD, Lu
AA21004 signiﬁcantly improved depressive symptoms (HAM-D-24)
and cognitive performance (DSST and RAVLT) compared with pla-
cebo at 8 weeks [9]. Lu AA21004 was well tolerated in the short-term
and maintenance studies [7, 8], with placebo-level TESD [7]. In elderly
patients, the AE proﬁle was similar to placebo for Lu AA21004, with
nausea being the only AE that was signiﬁcantly higher [9]. Several
AEs were signiﬁcantly higher than placebo with the active comparator
duloxetine. To date, vilazodone and Lu AA21004 have shown evi-
dence of eﬃcacy in improving depressive symptoms, together with a
lack of serotonin-related AEs such as TESD. Ongoing clinical trials
will further assess the potential beneﬁts of their multimodal pharma-
cological proﬁles.
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